PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Douwes, J; Le Gros, G; Gibson, P; Pearce, N				Douwes, J; Le Gros, G; Gibson, P; Pearce, N			Can bacterial endotoxin exposure reverse atopy and atopic disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; allergies; endotoxin; protection; hygiene hypothesis	HOUSE-DUST ENDOTOXIN; CD14 GENE; PROMOTER POLYMORPHISM; ALLERGIC DISEASE; SOLUBLE CD14; ASTHMA; RESPONSES; SENSITIZATION; PREVALENCE; CHILDREN	Studies have shown that endotoxin exposure in childhood is associated with a reduced risk of atopy and atopic asthma. It is commonly assumed that these effects only occur in early life. However, recent epidemiologic studies suggest that immune deviation might take place throughout life. Assuming that the immune system is not fixed after the first years of life, we hypothesize that endotoxin exposure might not only inhibit the development of atopic sensitization and disease at any time throughout life but might also reverse this process. This novel extension of the hygiene hypothesis is primarily based on the indirect evidence of several epidemiologic observations showing a reduction in atopy in adults highly exposed to endotoxin that is unlikely to be explained by protective effects alone. In addition, some animal studies demonstrated the potential of endotoxin to downregulate pre-existing airway eosinophilia and hyperreactivity. However, there is currently little direct evidence that endotoxin might reverse atopy and allergic diseases. Observational studies and randomized trials to test this hypothesis could ultimately lead to the development of novel treatments for atopic diseases, such as allergic asthma, hay fever, and eczema.	Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Victoria Univ Wellington, Malaghan Inst Med Res, Wellington, New Zealand; John Hunter Hosp, Airway Res Ctr, Newcastle, NSW, Australia	Massey University; Malaghan Institute; Victoria University Wellington; John Hunter Hospital	Douwes, J (corresponding author), Massey Univ, Ctr Publ Hlth Res, Wellington Campus,Private Box 756, Wellington, New Zealand.	j.douwes@massey.ac.nz	Le Gros, Graham/C-6725-2011; gibson, peter/G-6194-2014	Le Gros, Graham/0000-0002-5721-0442; gibson, peter/0000-0001-5865-489X; Douwes, Jeroen/0000-0003-3599-4036; Pearce, Neil/0000-0002-9938-7852				Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Beasley R, 2002, CLIN EXP ALLERGY, V32, P1128, DOI 10.1046/j.1365-2745.2002.01485.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Kemp A, 2003, PEDIAT ALLERG IMM-UK, V14, P74, DOI 10.1034/j.1399-3038.2003.00017.x; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Liu Andrew H, 2004, Paediatr Respir Rev, V5 Suppl A, pS65, DOI 10.1016/S1526-0542(04)90013-9; Lundy SK, 2003, AM J PATHOL, V163, P1961, DOI 10.1016/S0002-9440(10)63554-7; Marsland BJ, 2004, P NATL ACAD SCI USA, V101, P6116, DOI 10.1073/pnas.0401582101; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; MATSON SC, 1983, J ALLERGY CLIN IMMUN, V72, P299, DOI 10.1016/0091-6749(83)90035-0; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2000, ALLERGY, V55, P219, DOI 10.1034/j.1398-9995.2000.00461.x; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	44	46	46	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1051	1054		10.1016/j.jaci.2004.08.004	http://dx.doi.org/10.1016/j.jaci.2004.08.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536409	Bronze			2022-12-18	WOS:000225047800009
J	Hsu, CH; Lin, SS; Liu, FL; Su, WC; Yeh, SD				Hsu, CH; Lin, SS; Liu, FL; Su, WC; Yeh, SD			Oral administration of a mite allergen expressed by zucchini yellow mosaic virus in cucurbit species downregulates allergen-induced airway inflammation and IgE synthesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic asthma; zucchini yellow mosaic virus; allergen; oral tolerance	HOUSE-DUST MITE; IN-VIVO; SUBLINGUAL IMMUNOTHERAPY; BETA-GLUCURONIDASE; GENE-EXPRESSION; TOLERANCE; POTYVIRUS; ANTIGEN; POLYPROTEIN; REACTIVITY	Background: Sublingual-swallow immunotherapy in house dust mite-related asthma has a good safety profile and improves respiratory function and bronchial hyperreactivity. Zucchini yellow mosaic virus (ZYMV) is envisaged as a promising viral vector for expressing large quantity of foreign proteins in cucurbit species. Objective: We sought to investigate whether oral feeding of dust mite allergen expressed by ZYMV in a cucurbit species can suppress allergen-induced inflammation and IgE synthesis. Methods: An infectious plant virus clone, p35SZYMV2-26, that contains the full-length cDNA to the genomic RNA of a Taiwan isolate of ZYMV, driven by the cauliflower mosaic virus 35S promoter, was engineered as an in vivo viral vector to express Dermatophagoides pteronyssinus group 5 allergen (Der p 5) in cucurbit species. Female BALB/c mice were intraperitoneally sensitized with Escherichia coli bacteria-expressed Der p 5 and orally treated with the virus-expressed Der p 5 (vDer p 5) extracted from the recombinant virus-infected squash plants. Der p 5-specific immunoglobulins were measured by ELISA, and bronchoalveolar lavage assays were used to measure airway inflammation. Results: Infectivity assays and immunoblotting revealed that large quantities of free-form vDer p 5 are produced in the recombinant virus-infected squash plants. The recombinant virus carried and expressed the Der p 5 allergen in squash plants for at least 1 year after numerous passages. In animal tests, squash extract containing vDer p 5 inhibited Der p 5-specific IgE synthesis and airway inflammation. Conclusion: Our results suggest that oral feeding with allergen produced by the plant viral vector provides a novel approach for the therapy of allergic asthma.	Natl Chung Hsing Univ, Ctr Biotechnol, Taichung 402, Taiwan; China Med Univ, Div Pediat, Allergy Immunol & Rheumatol Dept, Taichung, Taiwan; Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 402, Taiwan; Taimont Biotech, Tainan, Taiwan	National Chung Hsing University; China Medical University Taiwan; National Chung Hsing University	Yeh, SD (corresponding author), Natl Chung Hsing Univ, Ctr Biotechnol, Taichung 402, Taiwan.	sdyeh@nchu.edu.tw	Lin, Shih-Shun/HCH-9241-2022	LIN, SHIH-SHUN/0000-0002-7295-5004				Arazi T, 2001, J BIOTECHNOL, V87, P67, DOI 10.1016/S0168-1656(01)00229-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Desbiez C, 1997, PLANT PATHOL, V46, P809, DOI 10.1046/j.1365-3059.1997.d01-87.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DOLJA VV, 1992, P NATL ACAD SCI USA, V89, P10208, DOI 10.1073/pnas.89.21.10208; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; German-Retana S, 2000, MOL PLANT MICROBE IN, V13, P316, DOI 10.1094/MPMI.2000.13.3.316; Guo HS, 1998, VIRUS RES, V57, P183, DOI 10.1016/S0168-1702(98)00100-2; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Kuo IC, 2003, J ALLERGY CLIN IMMUN, V111, P603, DOI 10.1067/mai.2003.167; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; Lin SS, 2002, BOT BULL ACAD SINICA, V43, P261; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Marth T, 1996, J IMMUNOL, V157, P2348; Masuta C, 2000, PLANT J, V23, P539, DOI 10.1046/j.1365-313x.2000.00795.x; Nelson Harold S., 2003, Journal of Allergy and Clinical Immunology, V111, pS793, DOI 10.1067/mai.2003.150; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Spall VE, 1997, SEMIN VIROL, V8, P15, DOI 10.1006/smvy.1997.0102; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0	26	46	48	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1079	1085		10.1016/j.jaci.2004.02.047	http://dx.doi.org/10.1016/j.jaci.2004.02.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208588				2022-12-18	WOS:000222091000012
J	Boehlecke, B; Hazucha, M; Alexis, NE; Jacobs, R; Reist, P; Bromberg, PA; Peden, DB				Boehlecke, B; Hazucha, M; Alexis, NE; Jacobs, R; Reist, P; Bromberg, PA; Peden, DB			Low-dose airborne endotoxin exposure enhances bronchial responsiveness to inhaled allergen in atopic asthmatics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									UNC, Sch Med, Dept Med, Chapel Hill, NC 27514 USA; UNC, Sch Med, Dept Pediat, Chapel Hill, NC USA; UNC, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; UNC, Sch Publ Hlth, Chapel Hill, NC USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Eastern Virginia Medical School	Boehlecke, B (corresponding author), UNC, Sch Med, Dept Med, Chapel Hill, NC 27514 USA.			Peden, David/0000-0003-4526-4627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62624-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339	6	46	48	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1241	1243		10.1016/j.jaci.2003.08.052	http://dx.doi.org/10.1016/j.jaci.2003.08.052			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657891	Bronze			2022-12-18	WOS:000187154200034
J	Roche, N; Stirling, RG; Lim, S; Oliver, BG; Oates, T; Jazrawi, E; Caramori, G; Chung, KF				Roche, N; Stirling, RG; Lim, S; Oliver, BG; Oates, T; Jazrawi, E; Caramori, G; Chung, KF			Effect of acute and chronic inflammatory stimuli on expression of proteaseactivated receptors 1 and 2 in alveolar macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						protease-activated receptors; chronic airways disease; asthma; alveolar macrophages	PROTEASE-ACTIVATED RECEPTOR-2; THROMBIN RECEPTOR; ENDOTHELIAL-CELLS; AIRWAYS; RELEASE; ASTHMA; PERMEABILITY; EPITHELIUM; AGONIST; ALPHA	Background: Protease-activated receptors 1 and 2 (PAR-1 and PAR-2) are 7-transmembrane G protein-coupled receptors activated by serine proteases in many cell types, including monocytes-macrophages, leading to the production of pro-inflammatory mediators, cytokines, and growth factors. Objective: We determined the influence of chronic smoking and asthma on the expression of PAR-1 and PAR-2 receptors on alveolar macrophages (AMs). Methods: We used RT-PCR and immunocytochemistry with confocal microscopy to determine mRNA and protein expression of PAR-1 and PAR-2 in AMs obtained from healthy smokers, asthmatic patients, and healthy subjects. In addition, we examined the effect of IL-1beta and LPS. Results: PAR1 mRNA was decreased, whereas PAR2 mRNA was increased in 24-hour cultured AMs from smokers when compared with values in AMs from healthy subjects. Paradoxically, there was a higher degree of PAR-1 protein staining in AMs from smokers, whereas PAR-2 staining was similar in smokers and healthy subjects. PAR-1 and PAR-2 mRNA and protein expression were similar in asthmatic patients and control subjects. IL-1beta and LPS had no effect on PAR1 and PAR2 gene expression by AMs. Conclusions: There is a dissociation between gene and protein expression of PAR-1 and PAR-2. PAR-1 protein overexpression in AMs from smokers might be important in the pathophysiology of chronic airways disease.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Chung, KF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.		Chung, Kian Fan/I-8456-2019; Oliver, Brian/E-7939-2010; Roche, Nicolas/AAP-4445-2021; stirling, rob/AAY-7125-2020; Roche, Nicolas/AAE-9206-2021; Chung, Kian Fan/B-1872-2012; Caramori, Gaetano/AAS-8611-2020	Chung, Kian Fan/0000-0001-7101-1426; Oliver, Brian/0000-0002-7122-9262; stirling, rob/0000-0001-9877-5450; Chung, Kian Fan/0000-0001-7101-1426; Caramori, Gaetano/0000-0002-9807-327X; roche, nicolas/0000-0002-3162-5033				Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; ALTIERI DC, 1990, J IMMUNOL, V145, P246; Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871; Cicala C, 1999, BRIT J PHARMACOL, V126, P478, DOI 10.1038/sj.bjp.0702303; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Hamilton JR, 1999, BRIT J PHARMACOL, V127, P617, DOI 10.1038/sj.bjp.0702583; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Hou L, 1998, J PERIODONTAL RES, V33, P205, DOI 10.1111/j.1600-0765.1998.tb02192.x; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jeffery PK, 1998, THORAX, V53, P129, DOI 10.1136/thx.53.2.129; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Kranzhofer R, 1996, CIRC RES, V79, P286, DOI 10.1161/01.RES.79.2.286; LANE SJ, 1994, ALLERGY, V49, P201, DOI 10.1111/j.1398-9995.1994.tb02650.x; LUNDGREN JD, 1994, RESP MED, V88, P511, DOI 10.1016/S0954-6111(05)80333-6; Miike S, 2001, J IMMUNOL, V167, P6615, DOI 10.4049/jimmunol.167.11.6615; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Naldini A, 1998, J CELL PHYSIOL, V177, P76, DOI 10.1002/(SICI)1097-4652(199810)177:1<76::AID-JCP8>3.0.CO;2-B; *NAT HEART LUNG BL, 1995, 953659 NHLBIWHO; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29, DOI 10.1164/ajrccm.160.supplement_1.9; Tittelbach V, 1998, BIOCHEM PHARMACOL, V56, P967, DOI 10.1016/S0006-2952(98)00231-7; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Yan W, 1996, J CELL PHYSIOL, V166, P561, DOI 10.1002/(SICI)1097-4652(199603)166:3<561::AID-JCP10>3.3.CO;2-Q	30	46	50	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					367	373		10.1067/mai.2003.6	http://dx.doi.org/10.1067/mai.2003.6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589358	Bronze			2022-12-18	WOS:000180942700022
J	Kumagai, N; Yamamoto, K; Fukuda, K; Nakamura, Y; Fujitsu, Y; Nuno, Y; Nishida, T				Kumagai, N; Yamamoto, K; Fukuda, K; Nakamura, Y; Fujitsu, Y; Nuno, Y; Nishida, T			Active matrix metalloproteinases in the tear fluid of individuals with vernal keratoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vernal keratoconjunctivitis; tear fluid; matrix metalloproteinases	CORNEA; EXPRESSION; COLLAGEN	Corneal epithelial lesions distinguish vernal keratoconjunctivitis (VKC) from other ocular allergic diseases. Such lesions result from degradation of the corneal epithelial basement membrane, which comprises mostly type IV collagen and laminin. Matrix metalloproteinase 2 (MMP-2) and MMP-9 catalyze the degradation of these 2 extracellular matrix proteins. The possible role of MMP-2 and MMP-9 in the pathogenesis of corneal lesions associated with VKC was investigated by assaying tear fluid for the presence of these enzymes. Tear fluid was collected from 6 eyes of 6 patients with active VKC, 14 eyes of 14 patients with active allergic conjunctivitis, and 6 eyes of 6 nonallergic healthy volunteers. Gelatin zymography revealed that the tear fluid of healthy volunteers contained inactive proforms of both MMP-2 and MMP-9 but not the active forms of these enzymes. Active forms of MMP2 or MMP-9 were detected in a minority of patients with allergic conjunctivitis. However, with the exception of one individual for whom active MMP-9 was not detected, tear fluid from all patients with VKC contained both proforms and active forms of MMP-2 and MMP-9. These results implicate MMP-2 and MMP-9 in the pathogenesis of corneal epithelial disorders associated with VKC.	Yamaguchi Univ, Sch Med, Dept Biomol Recognit & Ophthalmol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Ocular Pathophysiol, Ube, Yamaguchi 755, Japan	Yamaguchi University; Yamaguchi University	Kumagai, N (corresponding author), Yamaguchi Univ, Sch Med, Dept Biomol Recognit & Ophthalmol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.		Fukuda, Ken/A-3076-2011	Fukuda, Ken/0000-0003-4990-6308				Abu El-Asrar AM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1505; CAMERON JA, 1995, OPHTHALMOLOGY, V102, P985, DOI 10.1016/S0161-6420(95)30925-6; FINI ME, 1990, INVEST OPHTH VIS SCI, V31, P1779; Fini ME, 1996, AM J PATHOL, V149, P1287; Fukuda K, 1999, CORNEA, V18, P73, DOI 10.1097/00003226-199901000-00013; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Nagano T, 2001, INVEST OPHTH VIS SCI, V42, P1247; Tanaka H, 2000, J ALLERGY CLIN IMMUN, V105, P900, DOI 10.1067/mai.2000.105316	10	46	48	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					489	491		10.1067/mai.2002.126379	http://dx.doi.org/10.1067/mai.2002.126379			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209100				2022-12-18	WOS:000177936900023
J	Szefler, SJ; Eigen, H				Szefler, SJ; Eigen, H			Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; budesonide; budesonide inhalation; suspension; efficacy; inhaled corticosteroid; pediatric; Pulmicort Respules; safety	LONG-TERM TREATMENT; YOUNG-CHILDREN; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; DOUBLE-BLIND; INFANTS; EFFICACY; PHARMACOKINETICS; STEROIDS	Guidelines for managing asthma in pediatric patients published by the American Academy of Allergy, Asthma, and Immunology and the American Academy of Pediatrics recommend the use of inhaled corticosteroids for the management of persistent asthma in infants and young children. When these guidelines were published, pressurized metered-dose inhalers and dry-powder inhalers were the only delivery devices available for inhaled corticesteroids in the United States. These devices can be difficult for young children to use correctly. Furthermore, no inhaled corticosteroid was approved in the United States for the treatment of children younger than 4 years. Budesonide inhalation suspension (Pulmicort Respules; AstraZeneca LP, Wilmington, Del) v as developed to meet the medication delivery, needs of infants and young children with persistent asthma. Pulmicort Respules is the first inhaled corticosteroid approved for administration by means of a nebulizer and the only inhaled corticosteroid approved in the United States for infants as young as 12 months. Budesonide has been studied extensively worldwide. In the United States the tolerability and efficacy of budesonide inhalation suspension were confirmed in 3 placebo-controlled multicenter trials. These studies demonstrated that both once- and twice-daily dosing of budesonide inhalation suspension (0.25-1 mg) improved pulmonary function and ameliorated asthma symptoms in infants and young children with persistent asthma. Budesonide inhalation suspension was well tolerated, and the incidences of reported adverse events were similar among patients in the budesonide, placebo, and conventional asthma therapy groups. This article reviews the results of these studies, as well as the pharmacokinetics, pharmacodynamics, and clinical use of budesonide inhalation suspension.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA	National Jewish Health; James Whitcomb Riley Hospital Children	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,Rm B121, Denver, CO 80206 USA.							Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; Agertoft L, 1999, ARCH DIS CHILD, V80, P241, DOI 10.1136/adc.80.3.241; Agertoft L, 1998, ACTA PAEDIATR, V87, P842, DOI 10.1080/080352598750013608; *AM AC ALL ASTHM I, 1999, PED ASTHM PROM BEST; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; [Anonymous], PUBL NIH; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Barnes PJ, 1997, PULM PHARMACOL THER, V10, P3, DOI 10.1006/pupt.1997.0074; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Barry PW, 1997, THORAX, V52, pS78, DOI 10.1136/thx.52.2008.S78; Barry PW, 1999, J ALLERGY CLIN IMMUN, V104, P1168, DOI 10.1016/S0091-6749(99)70009-6; BESSMERTNY O, 2001, J PEDIAT PHARM THER, V6, P212; BISGAARD H, 1994, EUR RESPIR J, V7, P740, DOI 10.1183/09031936.94.07040740; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P263; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; Burke C. M., 1994, European Respiratory Journal, V7, p421S; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Chedevergne F, 2000, ARCH DIS CHILD, V82, pS6; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Crim C, 2001, CLIN THER, V23, P1339, DOI 10.1016/S0149-2918(01)80113-2; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; Daley-Yates PT, 2001, BRIT J CLIN PHARMACO, V51, P400, DOI 10.1046/j.0306-5251.2001.01374.x; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; EDSBACKER S, 1987, DRUG METAB DISPOS, V15, P403; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; Foucard T, 1996, ALLERGY, V51, P367, DOI 10.1111/j.1398-9995.1996.tb04631.x; Friday GA, 1997, ANN ALLERG ASTHMA IM, V78, P221, DOI 10.1016/S1081-1206(10)63391-1; Georgitis John W., 2001, Pediatric Asthma Allergy and Immunology, V15, P3, DOI 10.1089/088318701750314527; GOREN A, 1994, PEDIATR PULM, V18, P77, DOI 10.1002/ppul.1950180204; Grimfeld A., 1994, European Respiratory Journal, V7, p27S; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; HANSEN OR, 1989, EUR RESPIR J, V2, P637; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; Hvizdos KM, 2000, DRUGS, V60, P1141, DOI 10.2165/00003495-200060050-00010; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; JONSSON G, 1995, DRUG METAB DISPOS, V23, P137; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Kemper K J, 1996, Pediatr Rev, V17, P111, DOI 10.1542/pir.17-4-111; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Laitinen LA, 2000, J ALLERGY CLIN IMMUN, V105, pS582, DOI 10.1016/S0091-6749(00)90062-9; LEBOURGEOIS M, 1999, EUR RESPIR J, V14, P171; LOWENTHAL D, 1992, PEDIATR PULM, V14, P192, DOI 10.1002/ppul.1950140309; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Mellon M, 2000, AM J RESP CRIT CARE, V162, P593, DOI 10.1164/ajrccm.162.2.9909030; MENDELSON L, 2002, IN PRESS J ASTHMA; Miller-Larsson A, 2000, AM J RESP CRIT CARE, V162, P1455, DOI 10.1164/ajrccm.162.4.9806112; Miller-Larsson A, 1998, DRUG METAB DISPOS, V26, P623; Moller C, 1999, DRUGS, V58, P35; *NAT HEART LUNG BL, 1995, NIH PUBL; Nikander K, 1999, J AEROSOL MED, V12, P47, DOI 10.1089/jam.1999.12.47; PEDERSEN S, 1990, ARCH DIS CHILD, V65, P308, DOI 10.1136/adc.65.3.308; PEDERSEN S, 1986, ALLERGY, V41, P118, DOI 10.1111/j.1398-9995.1986.tb00287.x; Petersen H, 2000, J ALLERGY CLIN IMMUN, V105, pS202, DOI 10.1016/S0091-6749(00)91033-9; Scott MB, 1999, J ALLERGY CLIN IMMUN, V104, pS200, DOI 10.1016/S0091-6749(99)70062-X; Scott MB, 2001, ANN ALLERG ASTHMA IM, V87, P488, DOI 10.1016/S1081-1206(10)62262-4; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, P259, DOI 10.1016/S0091-6749(00)90074-5; Smaldone GC, 1998, J AEROSOL MED, V11, P113, DOI 10.1089/jam.1998.11.113; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V104, pS162, DOI 10.1016/S0091-6749(99)70057-6; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V104, pS175, DOI 10.1016/S0091-6749(99)70059-X; Szefler SJ, 2001, AM J RESP CRIT CARE, V163, pA589; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; Tunek A, 1997, DRUG METAB DISPOS, V25, P1311; von Mutius E, 2000, ARCH DIS CHILD, V82, pS2; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x; 2000, PULMICORT RESPULES B	75	46	52	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					730	742		10.1067/mai.2002.122712	http://dx.doi.org/10.1067/mai.2002.122712			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941331				2022-12-18	WOS:000175132600031
J	Wedi, B; Wieczorek, D; Stunkel, T; Breuer, K; Kapp, A				Wedi, B; Wieczorek, D; Stunkel, T; Breuer, K; Kapp, A			Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; apoptosis; superantigens; staphylococcal exotoxins; surface markers; respiratory burst	SHOCK-SYNDROME TOXIN-1; MOLECULE-1 ICAM-1 EXPRESSION; ATOPIC-DERMATITIS; ENTEROTOXIN-B; RESPIRATORY BURST; IGE ANTIBODIES; CROSS-LINKING; UP-REGULATION; IN-VITRO; AUREUS	Background: Staphylococcus aureus colonization of the skin represents a potent trigger factor of atopic dermatitis. Our previous studies demonstrated that in atopic dermatitis eosinophil apoptosis is significantly delayed. Objective: We sought to investigate the effect of staphylococcal exotoxins (SETs) on eosinophil apoptosis and functional activities. Methods: Apoptotic eosinophils were investigated by determining their hypodiploid DNA peak. Eosinophil surface-antigen expression and intracellular production of hydrogen peroxide were assessed by means of flow cytometric analysis and respiratory burst by lucigenin-dependent chemiluminescence. Results: The SETs SEA, SEB, SEC, and toxic shock syndrome toxin I significantly inhibited eosinophil apoptosis in a manner comparable with that of high concentrations of IL-3. The LPS inhibitor polymyxin B was found to significantly inhibit LPS-mediated, but not SET-mediated, inhibition of apoptosis. Neither SETs nor LPS was able to modulate eosinophil surface expression of CD9, CD11a, CD16, CD40, CD44, or CD63. However, 24- and 48-hour incubation with all SETs, but not with LPS, significantly upregulated expression of CD11b and CD45 in a manner similar to that of IL-3, whereas dexamethasone induced a downregulation. Moreover, all SETs resulted in a significant upregulation of CD54 after 24 hours but not after 48 hours. Interestingly, CD69 was upregulated by means of IL-3 and SEB only. Neither direct stimulation of eosinophils nor 24-hour incubation with SETs or stimulation with SETs after a 24-hour prestimulation with IL-3, IL-5, or GM-CSF resulted in a significant extracellular production of reactive oxygen species or in a significant production of intracellular hydrogen peroxide. However, SEB and toxic shock syndrome toxin 1 were able to enhance cytokine-induced respiratory burst. Conclusion: Taken together, our data demonstrate that SETs may modulate the course of the allergic inflammatory response through modulation of potent eosinophil effector functions. This may be of particular importance in atopic dermatitis, in which the skin is regularly colonized with SET-producing S aureus.	Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany	Hannover Medical School	Wedi, B (corresponding author), Hannover Med Sch, Dept Dermatol & Allergol, Ricklinger Str 5, D-30449 Hannover, Germany.		Wedi, Bettina/ABE-3636-2021	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276				Akiyama H, 1996, ARCH DERMATOL RES, V288, P418, DOI 10.1007/BF02507115; Blaylock MG, 1999, J ALLERGY CLIN IMMUN, V104, P1244, DOI 10.1016/S0091-6749(99)70020-5; Boguniewicz M, 1999, J ALLERGY CLIN IMMUN, V103, pS178; Bratton DL, 1999, J ALLERGY CLIN IMMUN, V103, P895, DOI 10.1016/S0091-6749(99)70435-5; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Chihara J, 2000, J ALLERGY CLIN IMMUN, V106, pS99, DOI 10.1067/mai.2000.106884; CZECH W, 1993, J INVEST DERMATOL, V100, P417, DOI 10.1111/1523-1747.ep12472082; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; ELSNER J, 1994, BLOOD, V83, P3324; Fernvik E, 1995, APMIS, V103, P699, DOI 10.1111/j.1699-0463.1995.tb01426.x; Foresi A, 2000, ANN ALLERG ASTHMA IM, V84, P411, DOI 10.1016/S1081-1206(10)62274-0; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; Hofer MF, 1996, P NATL ACAD SCI USA, V93, P5425, DOI 10.1073/pnas.93.11.5425; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; LILES WC, 1995, J IMMUNOL, V155, P2175; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; Luttmann W, 1996, J IMMUNOL, V157, P1678; MALY FE, 1988, ANAL BIOCHEM, V168, P462, DOI 10.1016/0003-2697(88)90344-2; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; Matsumoto K, 1998, INT ARCH ALLERGY IMM, V117, P34, DOI 10.1159/000053568; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; McLeod JD, 1998, J IMMUNOL, V160, P2072; Morishita Y, 1999, CLIN EXP ALLERGY, V29, P1110; Moulding DA, 1999, INFECT IMMUN, V67, P2312, DOI 10.1128/IAI.67.5.2312-2318.1999; OLENICK JG, 1991, J HISTOCHEM CYTOCHEM, V39, P373, DOI 10.1177/39.3.1993831; Plotz SG, 2001, BLOOD, V97, P235, DOI 10.1182/blood.V97.1.235; RODER BL, 1995, J MED MICROBIOL, V42, P43; Rudikoff D, 1998, LANCET, V351, P1715, DOI 10.1016/S0140-6736(97)12082-7; Saloga J, 1996, J INVEST DERMATOL, V106, P982, DOI 10.1111/1523-1747.ep12338479; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; THORNE KJI, 1990, J IMMUNOL METHODS, V133, P47, DOI 10.1016/0022-1759(90)90317-O; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wedi B, 1999, INT ARCH ALLERGY IMM, V118, P234, DOI 10.1159/000024083; Wedi B, 1998, J ALLERGY CLIN IMMUN, V102, P1013, DOI 10.1016/S0091-6749(98)70340-9; Wedi B, 1996, ALLERGY, V51, P676; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Wedi B, 1999, BLOOD, V94, P2365, DOI 10.1182/blood.V94.7.2365.419k08_2365_2373; Yamada H, 1999, INT ARCH ALLERGY IMM, V120, P100, DOI 10.1159/000053605	49	46	51	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					477	484		10.1067/mai.2002.121702	http://dx.doi.org/10.1067/mai.2002.121702			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897995				2022-12-18	WOS:000174586400015
J	Dempsey, OJ; Kennedy, G; Lipworth, BJ				Dempsey, OJ; Kennedy, G; Lipworth, BJ			Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotriene antagonist; corticosteroid; asthma; triamcinolone acetonide; montelukast; methacholine; adenosine monophosphate; inflammation	EOSINOPHIL CATIONIC PROTEIN; BRONCHIAL BIOPSY SPECIMENS; FLUTICASONE PROPIONATE; RECEPTOR ANTAGONIST; MONTELUKAST; HYPERRESPONSIVENESS; BECLOMETHASONE; INFLAMMATION; ZAFIRLUKAST; SEVERITY	Background: Current guidelines advocate the, use of preventative anti-inflammatory therapy for mild persistent asthma. Objective: We compared the efficacy and anti-inflammatory profiles of a leukotriene receptor antagonist and a low dose of inhaled corticosteroid in patients with mild persistent asthma. Methods. Twenty-one adult Patients with mild asthma received 4 weeks of either once-daily inhaled hydrofluoroalkane triamcinolone acetonide (450 mug/day ex-actuator dose) or oral mon- telukast (10 mg/day) in a randomized, placebo-controlled, single-blinded crossover study. Measurements were made before and after 2 and 4 weeks of each treatment. Results: At the endpoint (after 4 weeks), triamcinolone and montelukast had improved the primary outcome (provocative dose of methacholine required to produce a 20 % fall in FEV1) in comparison with placebo (P <.05), there being no difference between the treatments (1.09-fold; 95% CI 0.73 to 1.63). Triamcinolone was better than placebo or montelukast for effects on all other surrogate inflammatory markers (P <.05), including exhaled nitric oxide, blood eosinophils, serum eosinophil cationic protein, plasma intracellular circulating adhesion molecule 1, and plasma E-selectin. Both treatments improved (P <.05) morning and evening peak flow, nighttime. beta2-agonist use, and symptoms in comparison with placebo, though triamcinolone was better than montelukast (P <.05) with regard to peak flow. Triamcinolone produced suppression (P <.05), of overnight urinary cortisol/creatinine and serum osteocalcin. Conclusion: Once-daily inhaled corticosteroid and leukotriene antagonist improved the primary outcome variable of bronchial hyperresponsiveness to a similar degree.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.			Kennedy, Gwen/0000-0002-9856-3236				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227, DOI 10.1164/ajrccm.160.4.9903004; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Hoshino M, 1997, INT ARCH ALLERGY IMM, V112, P59, DOI 10.1159/000237432; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Pearson MG, 1997, THORAX, V52, pS1; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Westbroek J, 2000, RESP MED, V94, P112, DOI 10.1053/rmed.1999.0618; WEVER AMJ, 1994, RESP MED, V88, P613, DOI 10.1016/S0954-6111(05)80010-1; 1997, NATL ASTHMA ED PREVE	24	46	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					68	74		10.1067/mai.2002.120559	http://dx.doi.org/10.1067/mai.2002.120559			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799368				2022-12-18	WOS:000173739300011
J	Higashi, N; Gesser, B; Kawana, S; Thestrup-Pedersen, K				Higashi, N; Gesser, B; Kawana, S; Thestrup-Pedersen, K			Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; CD14; IL-1 beta; IL-8; IL-10; IL-18; IL-1 beta-converting enzyme; LPS; monocyte; PBMC; prostaglandin E-2	GAMMA-INDUCING FACTOR; BLOOD MONONUCLEAR-CELLS; CD4(+) T-CELLS; IFN-GAMMA; INTERFERON-GAMMA; MESSENGER-RNA; CYTOKINE PRODUCTION; SERUM IGE; IN-VIVO; INTERLEUKIN-18	Background: IL-18 has been found to be an IFN-gamma -inducing factor that plays an important role in T(H)1 cell activation. Recently, IL-18 has also been found to enhance a T(H)2 cellular response in a specific setting. Objective: The aim of this study was to elucidate the role of monocytes and soluble factors, with special focus on IL-18, in the pathogenesis of atopic dermatitis (AD). Methods: The release of cytokines front PBMCs and purified monocytes was measured through use of ELISA; mRNA expression was evaluated by RT-PCR. The results from patients with AD were compared with those from healthy controls. Results: IL-18 secretion was reduced in both unstimulated and lipopolysaccharide-stimulated monocytes from patients with AD. The mRNA expression of IL-18 and IL-lp-converting enzyme was significantly reduced in unstimulated monocytes from patients with AD (P <.03 and P <.01, respectively). Patients with AD had an elevated secretion of prostaglandin E-2 (PGE(2)) from unstimulated PBMCs (P <.001). The anti-PGE(2) antibody reversed the suppressive effect of PGE(2) on IL-18 secretion in unstimulated PBMCs from patients with AD. Conclusions: Decreased IL-18 production, together with a significantly reduced IL-18 and ICE mRNA expression in unstimulated monocytes and elevated PGE(2) secretion from PBMCs, was associated with the pathogenesis of AD.	Nippon Med Coll, Dept Dermatol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Aarhus, Marselisborg Hosp, Dept Dermatol, Aarhus, Denmark	Nippon Medical School; Aarhus University	Higashi, N (corresponding author), Nippon Med Coll, Dept Dermatol, Bunkyo Ku, 1-1-3 Sendagi, Tokyo 1138602, Japan.							CHAN SC, 1993, J IMMUNOL, V151, P3345; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Conti B, 1997, J BIOL CHEM, V272, P2035; Gesser B, 1997, P NATL ACAD SCI USA, V94, P14620, DOI 10.1073/pnas.94.26.14620; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Habu Y, 2001, J IMMUNOL, V166, P5439, DOI 10.4049/jimmunol.166.9.5439; HANIFIN JM, 1995, J INVEST DERMATOL, V105, pS84, DOI 10.1111/1523-1747.ep12316116; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hatano Y, 1999, CLIN EXP IMMUNOL, V117, P237; Higashi N, 2001, ACTA DERM-VENEREOL, V81, P3, DOI 10.1080/000155501750208092; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hoshino T, 1999, J IMMUNOL, V162, P5070; Hoshino T, 2000, EUR J IMMUNOL, V30, P1998, DOI 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U; JAKOB T, 1990, CLIN EXP IMMUNOL, V79, P380; JAKOB T, 1995, BRIT J DERMATOL, V132, P384, DOI 10.1111/j.1365-2133.1995.tb08671.x; Jung T, 1999, CLIN EXP ALLERGY, V29, P207; Junghans V, 1998, J INVEST DERMATOL, V111, P1184, DOI 10.1046/j.1523-1747.1998.00409.x; KAPP A, 1989, ACTA DERM-VENEREOL, P97; KIMATA H, 1994, ARCH DIS CHILD, V70, P119, DOI 10.1136/adc.70.2.119; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; Kohno K, 1997, J IMMUNOL, V158, P1541; Kumano K, 1999, AM J RESP CRIT CARE, V160, P873, DOI 10.1164/ajrccm.160.3.9805026; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1998, ENV DERMATOL S2, V5, P107; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Ohkusu K, 2000, INFECT IMMUN, V68, P2449, DOI 10.1128/IAI.68.5.2449-2456.2000; OHMEN JD, 1995, J IMMUNOL, V154, P1956; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; PALUDAN K, 1992, J INVEST DERMATOL, V99, P830, DOI 10.1111/1523-1747.ep12614794; RASANEN L, 1987, ARCH DERMATOL RES, V279, P215, DOI 10.1007/BF00417317; Reznikov LL, 2000, P NATL ACAD SCI USA, V97, P2174, DOI 10.1073/pnas.040582597; RUZICKA T, 1987, ACTA DERM-VENEREOL, V67, P469; SIMON HU, 1995, INT ARCH ALLERGY IMM, V107, P124, DOI 10.1159/000236950; Snijders A, 1998, CLIN EXP IMMUNOL, V111, P472; Stoll S, 1997, J IMMUNOL, V159, P298; Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q; Takeuchi M, 1997, CELL TISSUE RES, V289, P499, DOI 10.1007/s004410050895; Tanaka H, 2001, J ALLERGY CLIN IMMUN, V107, P331, DOI 10.1067/mai.2001.112275; THESTRUPPEDERSEN K, 1990, ACTA DERM-VENEREOL, V70, P395; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; YOSHIZAWA Y, 2001, IN PRESS CLIN EXP DE	45	46	47	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					607	614		10.1067/mai.2001.118601	http://dx.doi.org/10.1067/mai.2001.118601			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590389				2022-12-18	WOS:000171760300022
J	Jacobsen, HP; Herskind, AM; Nielsen, BW; Husby, S				Jacobsen, HP; Herskind, AM; Nielsen, BW; Husby, S			IgE in unselected like-sexed monozygotic and dizygotic twins at birth and at 6 to 9 years of age: High but dissimilar genetic influence on IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						twins; IgE; cord blood; children; heritability; maximum likelihood analysis	SERUM IMMUNOGLOBULIN-E; INTERLEUKIN-4 RECEPTOR; SIGNAL-TRANSDUCTION; LINKAGE ANALYSIS; ASTHMA; ASSOCIATION; RESPONSES; ATOPY; CORD; RESPONSIVENESS	Background: IgE is a major determinant of allergic disease. Twin analysis of serum levels of IgE has been carried out previously in children and adults with heritability estimates of 30% to 70% on the basis of ANOVA. Objective: This study included the analysis of serum IgE in a population of 126 twins, 27 monozygotic pairs and 36 dizygotic pairs, studied at birth (cord blood [CB] IgE) and consecutively at the age of 6 to 9 years of age (serum IgE). Methods: IgE was determined by means of RIA. ANOVA, correlation analysis, and structural equation modeling by maximal likelihood analysis was used for genetic analysis. Results: Structural equation modeling by maximal likelihood analysis showed the best-fitting model to be the AE model (A For additive genetic variance and E for environmental variance) both at birth and later in childhood. The estimated heritability was 0.92 (95% CI, 0.84-0.95) for CB IgE and 0.78 (95% CI, 0.60-0.87) for serum IgE. The correlation between CB IgE and serum IgE was 0.04. Conclusions: The study demonstrated a higher genetic dependency of serum IgE than previously recognized, The low correlation between the IgE levels at birth and later in childhood suggested that different effector mechanisms may be operating at different ages.	Odense Univ Hosp, Dept Pediat, DK-5000 Odense C, Denmark; Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus, Denmark	University of Southern Denmark; Odense University Hospital; Aarhus University	Husby, S (corresponding author), Odense Univ Hosp, Dept Pediat, DK-5000 Odense C, Denmark.			Husby, Steffen/0000-0002-6286-2496				Amelung PJ, 1998, CLIN EXP ALLERGY, V28, P397; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; COOKSON WOCM, 1989, LANCET, V1, P1292; Cox HE, 1998, BRIT J DERMATOL, V138, P182; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Eichenbaum HB, 1998, HIPPOCAMPUS, V8, P1; Falconer D.S., 1961, INTRO QUANTITATIVE G; Falconer D.S., 1960, INTRO QUANTITATIVE G; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; HANSEN LG, 1992, ALLERGY, V47, P391, DOI 10.1111/j.1398-9995.1992.tb02078.x; HANSON B, 1991, AM J HUM GENET, V48, P873; HAZIOT A, 1988, J IMMUNOL, V141, P547; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Husby S, 1996, CLIN GENET, V50, P332; Izuhara K, 1999, INT J MOL MED, V3, P3; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; Kruse S, 1999, IMMUNOLOGY, V96, P365; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; LALUTA MO, 2000, J EXP MED, V191, P1807; Mao XQ, 1998, CLIN GENET, V53, P54, DOI 10.1034/j.1399-0004.1998.531530111.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moffatt MF, 1999, CURR OPIN IMMUNOL, V11, P606, DOI 10.1016/S0952-7915(99)00024-2; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; Mutitts E, 1994, AM J RESP CRIT CARE, V149, P358; Neale M.C.C.L., 2013, METHODOLOGY GENETIC, V67, DOI DOI 10.1007/978-94-015-8018-2; NEALE MC, 1994, MX STAT MODELING; PEARCE N, 1993, EUR RESPIR J, V6, P1455; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Prescott SL, 1998, J IMMUNOL, V160, P4730; SEARS MR, 1991, NEW ENGL J MED, V325, P454; SPARHOLT SH, 1994, HUM IMMUNOL, V39, P76, DOI 10.1016/0198-8859(94)90104-X; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; Stephan V, 1999, CLIN EXP ALLERGY, V29, P1049, DOI 10.1046/j.1365-2222.1999.00610.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	44	46	47	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					659	663						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295655				2022-12-18	WOS:000168190100018
J	Inui, N; Chida, K; Suda, T; Nakamura, H				Inui, N; Chida, K; Suda, T; Nakamura, H			T(H)1/T(H)2 and T(C)1/T(C)2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1; T(H)2; T(C)1; T(C)2; sarcoidosis; bronchoalveolar lavage	HUMAN T-CELLS; FLOW-CYTOMETRY; CYTOKINE PRODUCTION; FUNCTIONAL SUBSETS; INTERFERON-GAMMA; IFN-GAMMA; HUMAN TH1; TYPE-1; HELPER; EXPRESSION	Background: Sarcoidosis is thought to be a type-1 cytokine-mediated disorder. However, few data are available on the profiles of cytokine expression by TH cells at the single-cell level, as assessed by intracellular cytokine now cytometry. Additionally, it remains to be determined whether the balance of T(C)1 and T(C)2 cells can be altered in sarcoidosis. Objective: The aim of this study was to evaluate the T(H)1/T(H)2 and T(C)1/T(C)2 balances in sarcoidosis. Methods: Using triple-color flow cytometry and phorbol 12-myristate acetate/ionomycin stimulation, we measured the production of the intracellular cytokines IFN-gamma and IL-4 in CD4(+) and CD8(+) T cells separately, which were obtained from peripheral blood and bronchoalveolar lavage fluid (BALF) of 20 patients with sarcoidosis, and compared their cytokine expressions with those of 10 normal subjects. Results: Under unstimulated conditions, there were no significant differences in the proportion of cytokine-producing CD4(+) or CD8(+) T cells in peripheral blood or BALF between patients with sarcoidosis and normal control subjects. On stimulation with phorbol 12-myristate acetate/ionomycin for 4 hours, in BALF of the patients, but not in peripheral blood, we found a significant increase in the percentage of IFN-gamma -producing CD4(+) T cells and a decrease in the percentage of IL-4-producing CD4(+) T cells, resulting in a 3.5-fold higher ratio of IFN-gamma /IL-4-producing CD4(+) T cells compared with that found in normal subjects. In contrast, no difference was found in the proportions of cytokine-producing CD8(+) T cells or the ratio of IFN-gamma /IL-4-producing CD8(+) T cells in either the peripheral blood or BALF between the patients and normal subjects. Conclusions: These findings suggest that the prominent shift toward a type-1 phenotype may occur in CD4(+) T-cell populations but not in CD8(+) T-cell populations in the affected organs of sarcoidosis.	Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Shizuoka, Japan	Hamamatsu University School of Medicine	Suda, T (corresponding author), 3600 Handa Cho, Shizuoka 4313192, Japan.							ANDERSON SJ, 1993, J IMMUNOL, V151, P5123; ANDERSSON U, 1988, J IMMUNOL METHODS, V112, P139, DOI 10.1016/0022-1759(88)90044-0; ANDERSSON U, 1990, EUR J IMMUNOL, V20, P1591, DOI 10.1002/eji.1830200727; Baumer I, 1997, AM J RESP CELL MOL, V16, P171; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; Carter LL, 1996, CURR OPIN IMMUNOL, V8, P336, DOI 10.1016/S0952-7915(96)80122-1; CASSEL D, 1994, J EXP MED, V180, P1251; Cerwenka A, 1999, J EXP MED, V189, P423, DOI 10.1084/jem.189.2.423; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1991, IMMUNOL REV, V123, P189, DOI 10.1111/j.1600-065X.1991.tb00611.x; DECARLI M, 1994, AUTOIMMUNITY, V18, P301; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; ELSON LH, 1995, J IMMUNOL, V154, P4294; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; GARLEPP MJ, 1994, THORAX, V49, P577, DOI 10.1136/thx.49.6.577; Harada Y, 1996, J ALLERGY CLIN IMMUN, V98, pS161, DOI 10.1016/S0091-6749(96)70063-5; Ito N, 1999, CANCER, V85, P2359, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2359::AID-CNCR10>3.3.CO;2-1; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; Krouwels FH, 1997, J IMMUNOL METHODS, V203, P89, DOI 10.1016/S0022-1759(97)00016-1; LUMINITA AS, 1997, J ALLERGY CLIN IMMUN, V100, P373; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; MITCHELL DN, 1974, AM REV RESPIR DIS, V110, P774; Moller DR, 1996, J IMMUNOL, V156, P4952; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1994, AM J RESP CRIT CARE, V149, P989, DOI 10.1164/ajrccm.149.4.8143065; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SUDA T, 1995, CHEST, V107, P711, DOI 10.1378/chest.107.3.711; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WIERENGA EA, 1991, J IMMUNOL, V147, P2942	35	46	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					337	344		10.1067/mai.2001.112273	http://dx.doi.org/10.1067/mai.2001.112273			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174202				2022-12-18	WOS:000167071400022
J	Volovitz, B; Tabachnik, E; Nussinovitch, M; Shtaif, B; Blau, H; Gil-Ad, I; Weizman, A; Varsano, I				Volovitz, B; Tabachnik, E; Nussinovitch, M; Shtaif, B; Blau, H; Gil-Ad, I; Weizman, A; Varsano, I			Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotrienes; nasal washes; asthma; children; montelukast; leukotriene modifiers	ARACHIDONIC-ACID METABOLITES; DOUBLE-BLIND TRIAL; BRONCHOALVEOLAR LAVAGE; PEPTIDE LEUKOTRIENE; ALLERGEN CHALLENGE; ANTIGEN CHALLENGE; URINARY-EXCRETION; HUMAN EOSINOPHILS; AIRWAY RESPONSES; BRONCHIAL-ASTHMA	Background: Leukotrienes are bronchoactive mediators secreted by inflammatory cells in the respiratory mucosa on exposure to asthma triggers. Objective: We investigated the effect of montelukast, a leukotriene receptor antagonist, on the release of leukotrienes in the respiratory mucosa of children with persistent asthma Method: Twenty-three children aged 6 to 11 gears with moderately severe asthma were treated in a cross-over design starting after a 2-week run in period, with either montelukast (n = 12) or cromolyn (n = 11) for 4 weeks with a 2-week washout period between treatments, Twelve of them were then treated with either montelukast or beclomethasone for 6 months. The use of beta(2)-agonists was recorded on a diary card. The concentration of leukotriene C-4 (LTC4) was measured by HPLC in nasal cashes obtained before and at the end of each treatment period. Eosinophilic cationic protein (ECP) was measured in the nasal washes by RIA Results: The LTC4 concentration significantly decreased in the children treated for the first 4 weeks with montelokast, from 5.03 +/- 1.17 to 1.42 +/- 033 ng/mL (P < .005), and a nonsignificant increase was noted in children treated with cromolyn, from 3.37 +/- 1.11 to 5.88 +/- 2.17 ng/mL (P = .71). ECP concentration also decreased in the children receiving montelukast (P = .12). The concentration of LTC4 remained low after 3 and 6 months of treatment with montelukast (0.8 +/- 0.7 and 1.0 +/- 0.3 mu g/mL) and was lower than with beclomethasone. Children treated with montelukast required significantly fewer beta(2)-agonists (P < .04), Conclusion: Montelukast reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma parallel to reduction in ECP and clinical improvement This effect was not observed when the same children were treated with cromolyn.	Schneider Childrens Med Ctr Israel, Dept Pediat C, IL-49202 Petah Tiqwa, Israel; Felsensten Res Lab, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Kaplan Hosp, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center	Volovitz, B (corresponding author), Schneider Childrens Med Ctr Israel, Dept Pediat C, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.		Weizman, Abraham/AAK-6450-2020	Weizman, Abraham/0000-0002-9765-8938				BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BRODSKY L, 1991, ANN OTO RHINOL LARYN, V100, P589; Chavis C, 1997, ALLERGY, V52, P589, DOI 10.1111/j.1398-9995.1997.tb02606.x; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Dixon W.J, 1990, BMDP STAT SOFTWARE; DRAZEN JM, 1991, AM REV RESPIR DIS, V144, P743, DOI 10.1164/ajrccm/144.4.743; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; IWASAKI E, 1989, Acta Paediatrica Japonica, V31, P286; KIKAWA Y, 1991, PEDIATR RES, V29, P455, DOI 10.1203/00006450-199105010-00009; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; KUMLIN M, 1990, BIOCHIM BIOPHYS ACTA, V1044, P201, DOI 10.1016/0005-2760(90)90304-G; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P587; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; OWEN WF, 1987, J IMMUNOL, V138, P532; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; RAMIS I, 1991, PROSTAG OTH LIPID M, V42, P411, DOI 10.1016/0090-6980(91)90032-B; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; SCHWARTZBERG SB, 1987, PROSTAG LEUKOTR ESS, V26, P143, DOI 10.1016/0262-1746(87)90109-0; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SHINDO K, 1994, CHEST, V105, P1033; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; VOLOVITZ B, 1988, PEDIATR RES, V24, P504, DOI 10.1203/00006450-198810000-00018; VOLOVITZ B, 1988, J PEDIATR-US, V112, P218, DOI 10.1016/S0022-3476(88)80058-1; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; VOLOVITZ B, 1988, INT ARCH ALLER A IMM, V86, P420, DOI 10.1159/000234628; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322	34	46	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1162	1167		10.1016/S0091-6749(99)70008-4	http://dx.doi.org/10.1016/S0091-6749(99)70008-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588996	Bronze			2022-12-18	WOS:000084289200007
J	Wagner, B; Krebitz, M; Buck, D; Niggemann, B; Yeang, HY; Han, KH; Scheiner, O; Breiteneder, H				Wagner, B; Krebitz, M; Buck, D; Niggemann, B; Yeang, HY; Han, KH; Scheiner, O; Breiteneder, H			Cloning, expression, and characterization of recombinant Hev b 3, a Hevea brasiliensis protein associated with latex allergy in patients with spina bifida	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; spina bifida; recombinant Hev b 3; complementary DNA cloning; immunoblots; inhibition studies; cross-reactivity	RUBBER ELONGATION-FACTOR; MAJOR ALLERGEN; RISK-FACTORS; CHILDREN; IGE; HYPERSENSITIVITY	Background: Two natural rubber later proteins, Hev b I and Hev b 3, have been described in spina bifida (SB)-associated later allergy. Objective: The aim of this study was to clone and express Kev b 3 and to obtain the immunologic active and soluble recombinant allergen for diagnosis of SE-associated later allergy. Methods: A complementary DNA (cDNA) coding for Hev b 3 was amplified from RNA of fresh later collected from Malaysian rubber trees (Hevea brasiliensis). PCR primers were designed according to sequences of internal peptide fragments of natural (n) Hev b 3. The 5'-end sequence was obtained by specific amplification of cDNA ends. The recombinant (r) Hev b 3 was produced in Escherichia coli as a 6xHis tagged protein. Immunoblotting and inhibition assays were performed to characterize the recombinant allergen. Results: An Hev b 3 cDNA clone of 922 bp encoding a protein of 204 amino acid residues corresponding to a molecular weight of 22.3 kd aas obtained. In immunoblots 29/35, latex-allergic patients with SB revealed IgE binding to rHev b 3, as did 4 of 15 of the later-sensitized group. The presence of all IgE epitopes on rHev b 3 was shown by its ability to abolish all IgE binding to nHev b 3, Hev b 3 is related to Hev b 1 by a sequence identity of 47%. Cross-reactivity between these 2 rater allergens nas illustrated by the large extent of inhibition of IgE binding to nHev b I by rHev b 3. Conclusion: rHev b 3 constitutes a suitable in vitro reagent for the diagnosis of latex allergy in patients with SE. The determination of the full sequence of Hev b 3 and the production of the recombinant allergen will allow the epitope mapping and improve diagnostic reagents for later allergy.	Univ Vienna, Dept Gen & Expt Pathol, A-1090 Vienna, Austria; Childrens Hosp, Virchow Clin, Berlin, Germany; Rubber Res Inst Malaysia, Biotechnol & Strateg Res Div, Kuala Lumpur, Malaysia; Kumho Life & environm Sci Lab, Kwangju, South Korea	University of Vienna; Institute Penyelidikan Getah Malaysia	Breiteneder, H (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH-EBO-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Han, Kyung-Hwan/G-6141-2012	Han, Kyung-Hwan/0000-0001-9481-4643				ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; AXEN R, 1998, N ENGL REG ALLERGY P, V9, P503; Baur X, 1997, ALLERGY, V52, P661, DOI 10.1111/j.1398-9995.1997.tb01046.x; Burrow GH, 1998, AUST NZ J SURG, V68, P183, DOI 10.1111/j.1445-2197.1998.tb04741.x; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; Cremer R, 1998, EUR J PEDIATR, V157, P13, DOI 10.1007/s004310050758; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; Jensen-Jarolim E, 1998, INT ARCH ALLERGY IMM, V116, P103, DOI 10.1159/000023932; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245, DOI 10.1007/BF02668748; LU LJ, 1995, J IMMUNOL, V155, P2721; Michael T, 1996, CLIN EXP ALLERGY, V26, P934; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; Niggemann B, 1998, J ALLERGY CLIN IMMUN, V102, P665, DOI 10.1016/S0091-6749(98)70285-4; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; SLATER JE, 1997, ALLERGY ALLERGIC DIS, V2, P981; SOEDJANAATMADJA UMS, 1995, FEBS LETT, V363, P211, DOI 10.1016/0014-5793(95)00309-W; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Yeang HY, 1998, ALLERGY, V53, P513, DOI 10.1111/j.1398-9995.1998.tb04089.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	26	46	51	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1084	1092		10.1016/S0091-6749(99)70093-X	http://dx.doi.org/10.1016/S0091-6749(99)70093-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550757	Bronze			2022-12-18	WOS:000083778400036
J	Handley, D				Handley, D			The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchodilation; anti-inflammatory; (R)-albuterol; levalbuterol; (S)-albuterol; safety	PARADOXICAL BRONCHOCONSTRICTION; CHIRAL DRUGS; SALMETEROL; SALBUTAMOL; ALBUTEROL; BRONCHOSPASM; PHARMACOKINETICS; ENANTIOMERS; BUDESONIDE; INHALATION	beta(2) agonists were designed to emulate the bronchodilation and mast cell suppression effects of human adrenaline, an endogenous neuomediator. Endogenous adrenaline is produced exclusively as the single enantiomer or Isomer, (R)-adrenaline, although all selective beta(2) agonists are marketed as racemic drugs, composed of a precise 50:50 mixture of R and S isomers, Isomers are compounds that are nonsuperimposable mirror images. The R isomers of beta agonists, essentially all congeners of (R)-adrenaline, exhibit the observed bronchodilation and clinical benefit of the racemate. The S isomers of the racemic beta agonists are devoid of clinical benefit, are assumed to be benign, and have not been studied until recently. In contradistinction to their assumed benign status, extensive studies with (S)-albuterol have shown that it opposes the bronchodilation effects of (R)-albuterol (levalbuterol), may be proinflammatory, and exhibits the potential to exacerbate airway reactivity to a variety of spasmogens by enhancing contractile responses. Clinically, (S)-albuterol can increase airway reactivity and, because of its slow metabolism, exists in higher and prolonged plasma concentrations than levalbuterol, The sustained presence of (S)-albuterol may help to explain why racemic beta agonists have not demonstrated a significant clinical anti-inflammatory potential. Furthermore, the adverse effects (S)albuterol may contribute to paradoxic bronchospasm and the occurrence of severe reagenic-like reactions seen with racemic albuterol, These adverse effects of (S)-albuterol are completely avoided with single isomer version of (R)-albuterol (levalbuterol), The removal of (S)-albuterol increased the clinical potency of levalbuterol, such that bronchodilator efficacy is achieved at one-fourth the dose of racemic albuterol, but with marked reduction in side effects. Levalbuterol, a third generation beta agonist, retains the clinical benefit of racemic albuterol without the proinflammatory and potentially detrimental effects of (S)-albuterol.	Sepracor Inc, Marlborough, MA 01752 USA	Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.	Handley, D (corresponding author), Sepracor Inc, 111 Locke Dr, Marlborough, MA 01752 USA.							Alvarez-Cuesta E, 1999, J ALLERGY CLIN IMMUN, V103, pS65; [Anonymous], 1992, CHIRALITY, V4, P338; ARIENS EJ, 1993, TRENDS PHARMACOL SCI, V14, P68, DOI 10.1016/0165-6147(93)90033-G; Asmus MJ, 1999, J ALLERGY CLIN IMMUN, V104, pS53, DOI 10.1016/S0091-6749(99)70274-5; Bailey J, 1998, SCIENCE, V281, P672, DOI 10.1126/science.281.5377.672; Barnes PJ, 1997, CHEST, V111, pS17, DOI 10.1378/chest.111.2_Supplement.17S; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; Boulton DW, 1997, CLIN PHARMACOL THER, V62, P138, DOI 10.1016/S0009-9236(97)90061-8; Braun JJ, 1999, J ALLERGY CLIN IMMUN, V103, pS33; BRODDE OE, 1989, RECEPTOR PHARM FUNCT, P222; BROGDEN RN, 1991, DRUGS, V42, P895, DOI 10.2165/00003495-199142050-00010; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; Chung K, 1999, J ALLERGY CLIN IMMUN, V103, pS52; COCCHETTO DM, 1991, J ASTHMA, V28, P49, DOI 10.3109/02770909109073370; DAVIES BH, 1992, BRIT MED J, V305, P1161, DOI 10.1136/bmj.305.6862.1161; Eaton EA, 1996, BRIT J CLIN PHARMACO, V41, P201, DOI 10.1111/j.1365-2125.1996.tb00183.x; Edelman JM, 1999, J ALLERGY CLIN IMMUN, V103, pS134; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FINNERTY JP, 1993, AM REV RESPIR DIS, V148, P512, DOI 10.1164/ajrccm/148.2.512; Fried KM, 1998, CHIRALITY, V10, P484, DOI 10.1002/(SICI)1520-636X(1998)10:5<484::AID-CHIR11>3.0.CO;2-W; Galgiani JV, 1939, J AMER MED ASSOC, V112, P1929, DOI 10.1001/jama.1939.02800190043011; Handley D A, 1998, Expert Opin Investig Drugs, V7, P2027, DOI 10.1517/13543784.7.12.2027; Jeppsson A B, 1989, Pulm Pharmacol, V2, P81, DOI 10.1016/0952-0600(89)90028-8; JOHNSON M, 1995, MED RES REV, V15, P225, DOI 10.1002/med.2610150303; JOHNSON M, 1993, LIFE SCI, V52, P2131, DOI 10.1016/0024-3205(93)90728-L; JOHNSON M, 1995, ANN ALLERG ASTHMA IM, V75, P177; Kalberg CJ, 1999, J ALLERGY CLIN IMMUN, V103, pS229; Knowles SR, 1999, J ALLERGY CLIN IMMUN, V103, pS64; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; Liggett SB, 1999, J ALLERGY CLIN IMMUN, V104, pS42, DOI 10.1016/S0091-6749(99)70272-1; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; *MED EC CO, 1996, PHYS DESK REF, P1198; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; MORGAN DJ, 1990, CLIN PHARMACOKINET, V18, P270, DOI 10.2165/00003088-199018040-00002; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; OOSTERHUIS B, 1991, J ASTHMA, V43, P126; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; RHODES DG, 1992, MOL PHARMACOL, V42, P596; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHINDO H, 1995, CHIRALITY, V7, P349, DOI 10.1002/chir.530070507; Skalky CS, 1999, J ALLERGY CLIN IMMUN, V103, pS228; Spiegel WA, 1998, J ALLERGY CLIN IMMUN, V101, pS62; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STILES GL, 1983, LIFE SCI, V33, P467, DOI 10.1016/0024-3205(83)90796-8; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; Trujillo MJ, 1999, J ALLERGY CLIN IMMUN, V103, pS35; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1988, American Review of Respiratory Disease, V137, P32; VIAU C, 1999, IN PRESS AM COLL ALL; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; WANG ZL, 1994, AM J RESP CRIT CARE, V149, P960, DOI 10.1164/ajrccm.149.4.8143062; WANNER A, 1995, AM J RESP CRIT CARE, V151, P597; WILKINSON JRW, 1992, BRIT MED J, V305, P931, DOI 10.1136/bmj.305.6859.931	59	46	48	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S69	S76		10.1016/S0091-6749(99)70276-9	http://dx.doi.org/10.1016/S0091-6749(99)70276-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452791	Bronze			2022-12-18	WOS:000082419400009
J	Beezhold, DH; Hickey, VL; Slater, JE; Sussman, GL				Beezhold, DH; Hickey, VL; Slater, JE; Sussman, GL			Human IgE-binding epitopes of the latex allergen Hev b 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hev b 5; latex allergy; antigens; IgE antibodies; recombinant allergens	NATURAL-RUBBER LATEX; ACIDIC ALLERGEN; CELL EPITOPES; HEV-B-5; IDENTIFICATION; PEPTIDES; CLONING	Background: Hev b 5 is an acidic protein (isoelectric point, 3.5) rich in glutamic acid with 9 repeated amino acid (AA) sequences of XEEX or XEEEX, Although its function in Hevea brasiliensis unknown, Hev b 5 has been identified as a major latex allergen. Immunoblot inhibition studies suggest Hev b 5 exists as multiple isoforms or contains a common epitope found in several other proteins. Objective: The purpose of this study was to further characterize Hev b 5 and to identify linear IgE-binding epitopes. Methods: Octapeptides spanning the entire Hev b 5 protein were synthesized on a derivatized cellulose membrane, The membrane was reacted with sera pooled from health care workers allergic to latex or rabbits immunized with latex proteins. B-cell epitopes were identified by subsequent incubations with the appropriate secondary antibodies and detected by using chemifluorescence. Results: Sera from patients allergic to latex recognized 6 IgE-binding regions located throughout the molecule. Two epitopes (2 and 4) had the common AA sequence of KTEEP. Epitopes 3 and 5 bad a similar AA sequence of EEXXA, where X was P, T, or K. Epitopes 1 and 6 appeared to be unrelated to the other epitopes, Database analysis could not identify other proteins with similar sequences. Neither of the XEEEX sequences bound IgE. Control sera failed to react to any peptides. Conclusions: Hev b 5 exists as multiple isoforms, but only small amounts are present in the nonammoniated latex preparations, such as those used for diagnostic tests, and this may help to explain the relatively poor sensitivity of some in vitro tests.	Guthrie Res Inst, Immunobiol Lab, Sayre, PA 18840 USA; US FDA, Lab Immunobiochem, Washington, DC 20204 USA; Univ Toronto, Div Clin Immunol & Allergy, Toronto, ON, Canada	US Food & Drug Administration (FDA); University of Toronto	Beezhold, DH (corresponding author), Guthrie Res Inst, Immunobiol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.			Beezhold, Donald/0000-0001-5543-5747				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; Banerjee B, 1997, J IMMUNOL, V159, P5724; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; Beezhold D H, 1994, AORN J, V59, P605, DOI 10.1016/S0001-2092(07)69975-X; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; Breiteneder H, 1998, INT ARCH ALLERGY IMM, V116, P83, DOI 10.1159/000023930; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; Hsieh LS, 1997, J ALLERGY CLIN IMMUN, V99, P1395; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; OWNBY DR, 1995, IMMUNOL ALLERGY CLIN, V15, P31; PAUPORE E, 1998, J ALLERGY CLIN IMMUN, V101, pS852; Rasmussen H B, 1993, APMIS Suppl, V39, P1; Raulf-Heimsoth M, 1998, CLIN EXP ALLERGY, V28, P339; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; Shi Q., 1990, GEL ELECTROPHORESIS; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; Slater JE, 1997, J ALLERGY CLIN IMMUN, V99, P2037; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; VANDENPLAS O, 1995, EUR RESPIR J, V8, P1957, DOI 10.1183/09031936.95.08111957	24	46	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1166	1172		10.1016/S0091-6749(99)70194-6	http://dx.doi.org/10.1016/S0091-6749(99)70194-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359901				2022-12-18	WOS:000080929500028
J	Chung, HL; Hwang, JB; Kwon, YD; Park, MH; Shin, WJ; Park, JB				Chung, HL; Hwang, JB; Kwon, YD; Park, MH; Shin, WJ; Park, JB			Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the mucosa of the small intestine in infants with cow's milk-sensitive enteropathy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk-sensitive enteropathy; chronic diarrhea; major basic protein; vascular cell adhesion molecule-1; intercellular adhesion molecule-1	INFLAMMATORY BOWEL-DISEASE; BRONCHIAL-ASTHMA; IMMUNE-RESPONSE; ALLERGY; CHALLENGE; CHILDHOOD; CHILDREN; TIME	Background: Cow's milk-sensitive enteropathy (CMSE) is an important cause of chronic diarrhea and failure to thrive in infancy. The immunopathology of the mucosal lesion associated with CMSE has not yet been described. Objectives: This study investigated the eosinophil activation and the role of adhesion molecules in the pathogenesis of intestinal mucosal damage associated with CMSE. Methods: Twenty-one patients with chronic diarrhea and abnormal mucosa on duodenal biopsy specimens were included. The patients had negative responses to skin prick tests and RASTs with milk. Fourteen patients were diagnosed with CMSE by milk challenge test and were designated as the CMSE group. Seven patients with no milk intolerance were defined as the non-CMSE group. Four infants with frequent vomiting and no mucosal abnormalities were also studied as the control group. Immunohistochemical stains for eosinophil major basic protein (MBP), vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 on endoscopic duodenal biopsy specimens were performed. Results: The degree of eosinophil degranulation, as evidenced by localization of extracellular MBP, was significantly greater in the CMSE group compared with the non-CMSE and control groups (P < .05). Expression of VCAM-1 on mononuclear cells was higher in the CMSE group compared with the non-CMSE and control groups (P < .05). The severity of villous atrophy was positively correlated with the deposition of MBP (r = 0.79, P < .001). Conclusion: These results strongly suggest eosinophils and VCAM-1 are implicated in the pathogenesis of mucosal damage associated with CMSE.	Catholic Univ Taegu Hyosung, Sch Med, Dept Pediat, Taegu 705034, South Korea; Catholic Univ Taegu Hyosung, Sch Med, Dept Pathol, Taegu 705034, South Korea	Catholic University of Daegu; Catholic University of Daegu	Chung, HL (corresponding author), Catholic Univ Taegu Hyosung, Sch Med, Dept Pediat, 3056-6 Taemyung 4 Dong Nam Gu, Taegu 705034, South Korea.							Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; ENSARI A, 1993, CLIN EXP IMMUNOL, V92, P303; FILLEY WV, 1982, LANCET, V2, P11; FIRER MA, 1987, INT ARCH ALLER A IMM, V84, P173, DOI 10.1159/000234419; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; ISOLAURI E, 1990, PEDIATR RES, V28, P582, DOI 10.1203/00006450-199012000-00006; KOIZUMI M, 1992, GASTROENTEROLOGY, V103, P840, DOI 10.1016/0016-5085(92)90015-Q; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; MALIZIA G, 1991, GASTROENTEROLOGY, V100, P150, DOI 10.1016/0016-5085(91)90595-C; MANUEL PD, 1979, GUT, V20, P211, DOI 10.1136/gut.20.3.211; NAGATA S, 1995, J PEDIATR GASTR NUTR, V20, P44, DOI 10.1097/00005176-199501000-00008; NAKAMURA S, 1993, LAB INVEST, V69, P77; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PETERS MS, 1986, LAB INVEST, V54, P656; SAVILAHTI E, 1992, J PEDIATR GASTR NUTR, V14, P108, DOI 10.1097/00005176-199201000-00022; SUOMALAINEN H, 1994, ANN MED, V26, P289, DOI 10.3109/07853899409147904; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; Walker-Smith John, 1994, Acta Paediatrica Japonica, V36, P545; WALKERSMITH J, 1978, ARCH DIS CHILD, V53, P375, DOI 10.1136/adc.53.5.375; WALKERSMITH JA, 1983, J PEDIAT, V121, pS111; WHITEHEAD R, 1971, J CLIN PATHOL, V24, P108	25	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1195	1201		10.1016/S0091-6749(99)70199-5	http://dx.doi.org/10.1016/S0091-6749(99)70199-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359906				2022-12-18	WOS:000080929500033
J	Vally, H; Carr, A; El-Saleh, J; Thompson, P				Vally, H; Carr, A; El-Saleh, J; Thompson, P			Wine-induced asthma: A placebo-controlled assessment of its pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sulfite; wine	SODIUM METABISULFITE; BRONCHIAL REACTIVITY; PROVOCATION TEST; SULFUR-DIOXIDE; SENSITIVITY; CHALLENGE; HISTAMINE; BRONCHOCONSTRICTION; RESPONSIVENESS	Background: The sulfite family of food additives has been implicated in the pathogenesis of wine-induced asthma, However, the evidence supporting this is weak, and because wines have many hundreds of components, nonsulfite-associated mechanisms may also play a role, Objectives: The aim of the study was to assess the potential sensitivity of persons with asthma to nonsulfite components in wine by using low-sulfite wine challenges. Methods: Sixteen adults with a strong history of sine-induced asthma were challenged with both low-sulfite red and white wines and wine-placebo drinks. Challenges were performed double blind, using a Latin square design, with lung function being assessed before the challenge and at 5, 10, 15, 30, and 60 minutes after the challenge. Subsequently, single-blind challenges with high-sulfite white wine were also completed in 10 individuals whose lack of reactivity to low-sulfite white sine suggested possible reactivity to sulfite additives. Results: The mean FEV1; forced expiratory pow, mid-expiratory phase; and peak expiratory flow of subjects to low-sulfite red and white wines and red and white placebo mines were not significantly different. Furthermore, with a predetermined criterion of a fall in FEV1 of more than 15% representing a positive challenge, only one individual exhibited a positive reaction in the presence of a negative response to placebo. Only 2 of the 10 test individuals who were challenged with a high-sulfite wine demonstrated a marked and rapid fall in FEV1, Reactivity to low-sulfite wines appears to occur only in a small number of individuals who report sensitivity to wines, suggesting that the sulfite additives may be the major cause of wine-induced asthmatic reactions. However, direct challenge with high-sulfite wine revealed only 2 clear reactions in this asthma cohort. Conclusion: Wine-induced asthma appears to be a complex phenomenon and may involve several mechanisms that are codependent.	Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, Asthma & Allergy Res Unit, Nedlands, WA 6009, Australia	University of Western Australia	Thompson, P (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, Asthma & Allergy Res Unit, Nedlands, WA 6009, Australia.		Vally, Hassan/AAG-1307-2022; Vally, Hassan/AFK-2936-2022	Vally, Hassan/0000-0001-5281-7459; Vally, Hassan/0000-0001-5281-7459				AYRES JG, 1983, BRIT J DIS CHEST, V77, P370, DOI 10.1016/0007-0971(83)90072-4; BUSH RK, 1986, AM J MED, V81, P816, DOI 10.1016/0002-9343(86)90351-7; CORDER EH, 1995, J CLIN EPIDEMIOL, V48, P1269, DOI 10.1016/0895-4356(95)00017-X; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; DELOHERY J, 1984, AM REV RESPIR DIS, V130, P1027; Evans DJ, 1996, THORAX, V51, P1185, DOI 10.1136/thx.51.12.1185; FIELD PI, 1994, THORAX, V49, P250, DOI 10.1136/thx.49.3.250; GERSHWIN ME, 1985, J ALLERGY CLIN IMMUN, V75, P411, DOI 10.1016/0091-6749(85)90080-6; HALPERN GM, 1985, ANN ALLERGY, V55, P686; HARIPARSAD D, 1984, CLIN ALLERGY, V14, P81, DOI 10.1111/j.1365-2222.1984.tb02194.x; RANKINE B, 1962, AUST WINE BREW SPIRI, V80, P14; ROMANO NP, 1992, WINE MICROBIOLOGY BI, P373; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; WANTKE F, 1994, ALLERGY PROC, V15, P27, DOI 10.2500/108854194778816599; Wantke F, 1996, INT ARCH ALLERGY IMM, V110, P397, DOI 10.1159/000237333; WILSON N, 1982, BRIT MED J, V284, P1226, DOI 10.1136/bmj.284.6324.1226; WILSON NM, 1985, EUR J RESPIR DIS, V66, P25; WRIGHT W, 1990, AM REV RESPIR DIS, V141, P1400, DOI 10.1164/ajrccm/141.6.1400; Zuskin E, 1997, AM J IND MED, V31, P250, DOI 10.1002/(SICI)1097-0274(199702)31:2<250::AID-AJIM15>3.0.CO;2-0	19	46	47	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				41	46		10.1016/S0091-6749(99)70523-3	http://dx.doi.org/10.1016/S0091-6749(99)70523-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893183				2022-12-18	WOS:000078112300007
J	Jenmalm, MC; Bjorksten, B				Jenmalm, MC; Bjorksten, B			Exposure to cow's milk during the first 3 months of life is associated with increased levels of IgG subclass antibodies to beta-lactoglobulin to 8 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk; children; atopy; oral tolerance; IgG subclass antibodies	ATOPIC-DERMATITIS; IMMUNE-RESPONSES; IFN-GAMMA; DERMATOPHAGOIDES-PTERONYSSINUS; INHALANT ALLERGENS; INDUCED TOLERANCE; INTERFERON-GAMMA; SERUM LEVELS; 1ST YEAR; CHILDREN	Background: Exposure to allergens early in Life influences the development of allergen-specific immune responses. In animal models, the development of tolerance to proteins delivered to the gastrointestinal and the respiratory mucosa is influenced by age and genetic background. Late introduction of cow's milk in infants is associated with slower increase and lower peak IgG antibody responses to milk during early childhood, but the long-term effects have not been investigated, nor is the relation to atopic disease later in Life clear. Objective: The purpose of this study was to investigate the development of Ige subclass antibodies to beta-Lactoglobulin in relation to early exposure to cow's milk, atopic heredity, and the development of atopic disease. Methods: Ige subclass antibodies to beta-lactoglobulin were analyzed by ELISA at birth, at 6 and 18 months, and at 8 years in 96 children followed prospectively. Results: The levels of IgG subclass antibodies to beta-Lactoglobulin peaked in early childhood and then declined up to 8 years of age. Exposure to cow's milk during the first 3 months of Life was associated with high IgG subclass antibody levels to beta-lactoglobulin up to 8 years, particularly in children with maternal atopy, Children with atopic symptoms and sensitivity to allergens often had high levels of IgG(4) antibodies to beta-lactoglobulin at 8 years of age, even if they were not exposed to cow's milk during the first 3 months of life, Furthermore, atopic dermatitis was associated with high levels of IgG subclass antibodies to beta-lactoglobulin in early childhood. Conclusions: IgG subclass antibody levels to milk peak during early infancy, with particularly high Levels in children with atopic dermatitis, and decline thereafter. Exposure to cow's milk during early infancy has long-lasting effects on the humoral antigen-specific responses, indicating less effective tolerance-inducing mechanisms in the intestinal mucosa during the first months of life.	Linkoping Univ, Fac Hlth, Dept Hlth & Environm, Div Paediat, Linkoping, Sweden; Linkoping Univ, Fac Hlth, Clin Res Ctr, Linkoping, Sweden	Linkoping University; Linkoping University	Jenmalm, MC (corresponding author), Linkoping Univ Hosp, Div Paediat, S-58185 Linkoping, Sweden.		Jenmalm, Maria C/C-9679-2009	Jenmalm, Maria C/0000-0002-2117-5366				AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; BARNES RMR, 1993, CLIN EXP DERMATOL, V18, P211, DOI 10.1111/j.1365-2230.1993.tb02173.x; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BORRES MP, 1995, CLIN EXP ALLERGY, V25, P543, DOI 10.1111/j.1365-2222.1995.tb01092.x; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; DELPRETE GF, 1991, J EXP MED, V174, P809, DOI 10.1084/jem.174.4.809; FALLSTROM SP, 1984, INT ARCH ALLER A IMM, V75, P87, DOI 10.1159/000233595; FALTHMAGNUSSON K, 1988, J ALLERGY CLIN IMMUN, V81, P743, DOI 10.1016/0091-6749(88)91048-2; GERMANO P, 1993, INT J CLIN LAB RES, V23, P206, DOI 10.1007/BF02592310; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANSON DG, 1981, J IMMUNOL, V127, P1518; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Holter W, 1996, PEDIAT ALLERG IMM-UK, V7, P75, DOI 10.1111/j.1399-3038.1996.tb00110.x; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; JEFFERIS R, 1985, IMMUNOL LETT, V10, P223, DOI 10.1016/0165-2478(85)90082-3; Jenmalm MC, 1997, INT ARCH ALLERGY IMM, V114, P175, DOI 10.1159/000237664; Kawano Y, 1996, IMMUNOLOGY, V88, P40, DOI 10.1046/j.1365-2567.1996.d01-634.x; KAWANO Y, 1994, J IMMUNOL, V153, P4948; KEMENY DM, 1991, J ALLERGY CLIN IMMUN, V87, P920, DOI 10.1016/0091-6749(91)90413-I; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P667, DOI 10.1159/000230448; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P656, DOI 10.1159/000230447; MARIANI F, 1992, CLIN EXP ALLERGY, V22, P29, DOI 10.1111/j.1365-2222.1992.tb00111.x; MATSUMOTO T, 1991, CLIN EXP IMMUNOL, V85, P288; NELSON D, 1991, PEDIATR ALLERGY IMMU, V4, P170; Noma T, 1996, CLIN EXP ALLERGY, V26, P1298, DOI 10.1111/j.1365-2222.1996.tb00527.x; OKAHATA H, 1990, CLIN EXP ALLERGY, V20, P39, DOI 10.1111/j.1365-2222.1990.tb02773.x; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; RUIZ RGG, 1992, ARCH DIS CHILD, V67, P1023, DOI 10.1136/adc.67.8.1023; SEDGWICK JD, 1984, EUR J IMMUNOL, V14, P893, DOI 10.1002/eji.1830141006; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TAINIO VM, 1988, ACTA PAEDIATR SCAND, V77, P807, DOI 10.1111/j.1651-2227.1988.tb10760.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6	38	46	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				671	678		10.1016/S0091-6749(98)70286-6	http://dx.doi.org/10.1016/S0091-6749(98)70286-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802378				2022-12-18	WOS:000076600400020
J	Yamada, T; Sun, QY; Zeibecoglou, K; Bungre, J; North, J; Kay, AB; Lopez, AF; Robinson, DS				Yamada, T; Sun, QY; Zeibecoglou, K; Bungre, J; North, J; Kay, AB; Lopez, AF; Robinson, DS			IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-3 receptor; IL-5 receptor; GM-CSF receptor; basophils; eosinophils; monocytes; neutrophils,; T lymphocytes	HUMAN HEMATOPOIETIC-CELLS; FC-EPSILON-RI; HUMAN INTERLEUKIN-3; CYTOKINE RECEPTORS; HUMAN EOSINOPHILS; AFFINITY BINDING; MESSENGER-RNA; ACTIVATION; BASOPHILS; AGONISTS	Background: IL-3, IL-5, and granulocyte-macrophage colony stimulating factor (GM-CSF) receptors consist of cytokine-specific alpha-subunits, which associate with a shared signalling common beta-subunit (beta c) to form a high affinity complex. The expression of IL-3, IL-5, and GM-CSF is upregulated in atopic inflammation, and these cytokines are thought to contribute to pathology through mechanisms that include eosinophil activation. Objective: We sought to examine the distribution of receptor expression between cells relevant to allergic inflammation from individual subjects and to compare atopic and nonatopic individuals. Methods: Peripheral blood was obtained from atopic and nonatopic volunteers. Cytokine-receptor expression was examined by bow cytometry with monoclonal antibodies specific for alpha-subunits and beta c in combination with phenotypic markers for eosinophils, basophils, neutrophils, dendritic cells, monocytes, and T cells. Results: Using a ligand-independent system,,ve confirmed the cellular distribution of IL-5R alpha, IL-3R alpha, and GM-CSFR alpha. IL-3R alpha and GM-CSFR alpha were detected on high-affinity IgE receptor blood dendritic cells, beta c expression was detected on basophils, eosinophils, neutrophils, and, at low levels, on monocytes and dendritic cells. There was intense staining of basophils for IL-3R alpha relative to IL-5R alpha, GM-CSFR alpha, and beta c, whereas eosinophil-staining intensity was similar for IL-3P alpha, IL-5R alpha, GM-CSFR alpha, and beta c. There were no significant differences between atopic and nonatopic subjects in cytokine-receptor staining. Conclusion: IL-3R alpha and GM-CSR alpha are shown on a newly defined population of Fc epsilon RI-high dendritic cells. The intense staining of basophils for IL-3R alpha, relative to that of IL-5R alpha and GM-CSFR alpha, is in contrast to eosinophils from the same subjects and may explain the higher sensitivity of basophils to IL-3 compared with IL-5 and GM-CSF. We found no evidence for downregulation of receptor expression in atopic compared with nonatopic subjects, suggesting that these receptors remain accessible as potential targets for therapeutic intervention in atopic allergic disease.	Natl Heart & Lung Inst, Imperial Coll, Sch Med, London SW3 6LY, England; Hanson Ctr Canc Res, Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA, Australia	Imperial College London; Institute Medical & Veterinary Science Australia	Robinson, DS (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dovehouse St, London SW3 6LY, England.		Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135				BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BURGI B, 1994, EUR J IMMUNOL, V24, P1583, DOI 10.1002/eji.1830240720; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Huston MM, 1996, J IMMUNOL, V156, P1392; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IVERSEN PO, 1997, IN PRESS AM J RESP R; Jansen HM, 1996, ALLERGY, V51, P279, DOI 10.1111/j.1398-9995.1996.tb04611.x; KAMPGEN E, 1994, J EXP MED, V179, P1767, DOI 10.1084/jem.179.6.1767; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Larregina A, 1996, IMMUNOLOGY, V87, P317, DOI 10.1046/j.1365-2567.1996.451513.x; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Macardle PJ, 1996, CELL IMMUNOL, V168, P59, DOI 10.1006/cimm.1996.0049; Maurer D, 1996, J IMMUNOL, V157, P607; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; OGAWA M, 1993, BLOOD, V81, P2844; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SATO N, 1993, BLOOD, V82, P752; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SMITH WB, 1995, BLOOD, V86, P3938, DOI 10.1182/blood.V86.10.3938.bloodjournal86103938; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun QY, 1996, BLOOD, V87, P83; TAKAGI M, 1995, J EXP MED, V181, P889, DOI 10.1084/jem.181.3.889; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YUO A, 1992, BLOOD, V79, P1553	37	46	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					677	682		10.1016/S0091-6749(98)70177-0	http://dx.doi.org/10.1016/S0091-6749(98)70177-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600506				2022-12-18	WOS:000073697400017
J	Kemp, JP; Cook, DA; Incaudo, GA; Corren, J; Kalberg, C; Emmett, A; Cox, FM; Rickard, K				Kemp, JP; Cook, DA; Incaudo, GA; Corren, J; Kalberg, C; Emmett, A; Cox, FM; Rickard, K		Salmeterol Quality Life Study Grp	Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						salmeterol; asthma; quality of life; pharmacoeconomics	OF-LIFE; SALBUTAMOL; ALBUTEROL; DISEASE	Background: Traditional clinical outcomes have demonstrated that salmeterol improves pulmonary function and reduces asthma symptoms. However, they do not evaluate how patients perceive the effect of therapeutic intervention on day-to-day functioning and well-being. Objective: We sought to evaluate the impact of salmeterol on disease-specific quality of life with the Asthma Quality-of-Life Questionnaire, as well as the efficacy and safety of salmeterol in patients with stable asthma who were symptomatic despite daily use of inhaled corticosteroids. Methods: This was a randomized, double-blind, placebo-controlled, parallel-group study of 506 patients. Patients were treated with 42 mu g salmeterol or placebo twice daily for 12 weeks delivered through a metered dose inhaler. Results: Mean change from baseline in asthma quality-of-life scores was significantly greater (p less than or equal to 0.006) after 12 weeks of treatment with salmeterol compared with placebo ("as-needed" albuterol) in global scores (1.08 vs 0.61) and individual domains (activity limitations, 0.91 vs 0.54; asthma symptoms, 1.28 vs 0.71; emotional function, 1.17 vs 0.65; and environmental exposure, 0.84 vs 0.47). Patients treated with salmeterol experienced significantly greater improvements from baseline to week 12 compared with placebo in FEV1 (0.42 L vs 0.15 L, p < 0.001), morning peak expiratory flow (47 L/min vs 14 L/min, p < 0.001), evening peak expiratory flow (29 L/min vs 11 L/min, p < 0.001), and asthma symptom scores (daytime scores reduced by 0.55 vs 0.30, p < 0.001). Patients treated with salmeterol used significantly less supplemental albuterol (reduced by 3 puffs/day vs 1 puff/day, p < 0.001). Conclusion: Salmeterol provided significantly greater improvement in quality-of-life outcomes in patients whose asthma symptoms are not well controlled with inhaled corticosteroids. These results demonstrate that the benefits of salmeterol are not limited to conventional clinical measures of efficacy.	Allergy & Asthma Med Grp & Res Ctr, APC, San Diego, CA 92123 USA; Allergy & Asthma Med Grp Diablo Valley Inc, Walnut Creek & Clin Res Div, Danville, PA USA; Allergy Associates, Chico, CA USA; Allergy Res Fdn, Los Angeles, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Kemp, JP (corresponding author), Allergy & Asthma Med Grp & Res Ctr, APC, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CHARPIN D, 1992, EUR RESP J S15, V15, pS12; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; FJELLBIRKELAND L, 1994, RESP MED, V88, P599, DOI 10.1016/S0954-6111(05)80008-3; GARDNER RM, 1988, ANN INTERN MED, V108, P217, DOI 10.7326/0003-4819-108-2-217; *GLOB IN ASTHM, 1995, NIH NAT HEART LUNG B; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HERMANSSON BA, 1992, EUR RESP J S15, V5, P3665; HOLGATE S, 1992, ALLERGY          S12, V47, P348; HYLAND ME, 1994, QUAL LIFE RES, V3, P121, DOI 10.1007/BF00435255; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; NATHAN RA, 1995, ANN ALLERG ASTHMA IM, V75, P243; PAGGIARO PL, 1992, ALLERGY, V47, P348; PALMER JBD, 1991, EUR RESPIR REV, V1, P301; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Polgar G, 1971, PULMONARY FUNCTION T, P170; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; Selby C, 1997, AM J RESP CRIT CARE, V155, P104, DOI 10.1164/ajrccm.155.1.9001297; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; WISNIEWSKI M, 1997, AM J RESP CRIT CARE, V155, pA721; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	25	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				188	195		10.1016/S0091-6749(98)70383-5	http://dx.doi.org/10.1016/S0091-6749(98)70383-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500751	Bronze			2022-12-18	WOS:000072244800007
J	Condemi, JJ; Chervinsky, P; Goldstein, MF; Ford, LB; Berger, WE; Ayars, GH; Rogenes, PR; Edwards, L; Pepsin, PJ				Condemi, JJ; Chervinsky, P; Goldstein, MF; Ford, LB; Berger, WE; Ayars, GH; Rogenes, PR; Edwards, L; Pepsin, PJ			Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	International Conference of the American-Thoracic-Society	MAY 10-22, 1996	NEW ORLEANS, LA	Amer Thorac Soc		inhaled corticosteroid; asthma; fluticasone propionate; triamcinolone acetonide; randomized controlled trial	TO-MODERATE ASTHMA; BECLOMETHASONE DIPROPIONATE; FLUNISOLIDE AEROSOL; UNITED-STATES; MULTI-CENTER; EFFICACY; CORTICOSTEROIDS; BUDESONIDE; PREDNISONE	Background: Attempts to delineate efficacy and safety differences among inhaled corticosteroids have been difficult because of the lack of well-controlled, comparative studies re ported in the medical literature. Methods: A randomized, double-blind, double-dummy study was conducted in 24 outpatient centers. A total of 291 male and female patients at least 12 years of age with asthma (FEV, between 50% and 80% of predicted value), who had previously received maintenance therapy with beclomethasone dipropionate or triamcinolone acetonide, were switched to treatment with fluticasone propionate powder (250 mu g twice daily), triamcinolone acetonide aerosol (200 mu g four times daily), or placebo for 24 weeks. Results: Mean increase in FEV, from baseline to end point was significantly (p = 0.009) greater in patients switched to treatment with fluticasone compared with patients switched to treatment with triamcinolone (0.27 L and 0.07 L, respectively). At end point, mean increase in morning peak expiratory flow from baseline was 21 L/min with fluticasone compared with mean decreases of 6 L/min and 28 L/min with triamcinolone and placebo, respectively (p < 0.001 vs triamcinolone and placebo). Supplemental rescue albuterol use decreased by 30% from baseline with fluticasone (p < 0.05 vs triamcinolone and placebo) compared,vith triamcinolone (6%) or placebo (increased by 50%). The percentage of patients withdrawn from the study because they met predefined lack-of-efficacy criteria was higher with placebo (60%) and triamcinolone (27%) than with fluticasone (17%), Incidence of adverse events and low morning plasma cortisol concentrations were similar across treatment groups except for oral candidiasis (p = 0.035, fluticasone vs placebo). Conclusion: Fluticasone propionate powder twice daily (500 mu g/day) was superior in efficacy to triamcinolone acetonide aerosol four times daily (800 mu g/day) in patients with persistent asthma.	NEW ENGLAND RES CTR INC, N DARTMOUTH, MA USA; ASTHMA CTR, FORKED RIVER, NJ USA; CTR ASTHMA & ALLERGY, PAPILLION, NE USA; SO CALIF RES CTR, MISSION VIEJO, CA USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline	Condemi, JJ (corresponding author), ALLERGY ASTHMA IMMUNOL ROCHESTER, 919 WESTFALL RD, BLDG B, ROCHESTER, NY 14618 USA.			Edwards, Lisa/0000-0002-4867-2151				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BERNSTEIN IL, 1982, CHEST, V81, P20, DOI 10.1378/chest.81.1.20; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; Bray GA, 1999, DIABETES CARE, V22, P623; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; BROGDEN RN, 1975, DRUGS, V10, P166, DOI 10.2165/00003495-197510030-00002; BURNEY PGJ, 1993, ASTHMA, P3; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CRESCENZI KL, 1996, ANN ALLERG ASTHMA IM, V74, P64; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FULLER R, 1995, RESP MED, V89, P3, DOI 10.1016/0954-6111(95)90259-7; GRIECO MH, 1978, ARCH INTERN MED, V138, P1337, DOI 10.1001/archinte.138.9.1337; GROSS G, 1996, FLUTICASONE PROPIONA; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; KAMADA AK, 1994, ANN PHARMACOTHER, V28, P904, DOI 10.1177/106002809402800716; LEE ET, 1980, STATISTICAL METHODS; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; MCCUBBIN MM, 1995, CLIN PHARMACOL THER, V57, P455, DOI 10.1016/0009-9236(95)90216-3; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P608, DOI 10.1001/archderm.1962.01590110044005; MELTZER EO, 1982, PEDIATRICS, V69, P340; *NAT ASTHM ED PROG, 1991, NIH PUBL; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Pearlman DS, 1997, ANN ALLERG ASTHMA IM, V78, P356, DOI 10.1016/S1081-1206(10)63196-1; Polgar G, 1971, PULMONARY FUNCTION T; RAFFERTY P, 1985, BRIT J DIS CHEST, V79, P244; ROSENHALL L, 1982, EUR J RESPIR DI S122, V63, P62; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P379, DOI 10.1016/0091-6749(80)90117-7; SLY RM, 1994, ANN ALLERGY, V73, P259; Terr AI, 1996, ANN ALLERG ASTHMA IM, V76, P273, DOI 10.1016/S1081-1206(10)63441-2; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; 1995, MMWR-MORBID MORTAL W, V43, P952	39	46	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					467	474		10.1016/S0091-6749(97)70137-4	http://dx.doi.org/10.1016/S0091-6749(97)70137-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	YA529	9338539	hybrid			2022-12-18	WOS:A1997YA52900007
J	Storms, W; Meltzer, EO; Nathan, RA; Selner, JC				Storms, W; Meltzer, EO; Nathan, RA; Selner, JC			Allergic rhinitis: The patient's perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal symptoms; environmental triggers; self-medication; nationwide survey		A self-administered screening questionnaire was sent to 15,000 households randomly selected from a nationwide panel of approximately 200,000 households. This questionnaire was used to select a balanced sample of 1450 persons with greater than or equal to 7 days of nasal/ocular symptoms in the previous 12 months. These persons received a second questionnaire that contained detailed questions regarding symptoms, triggers, patient attitudes, and medical treatment. Of the 1065 people who responded to the second questionnaire, 481 were identified as having self-reported seasonal or perennial allergic rhinitis. Our major findings regarding the attitudes toward their disease expressed by these 481 respondents are as follows. Although 53% of our study population regarded their symptoms as mild, 47% reported onset before age 17, suggesting that many have become accustomed to their symptoms. The level of allergen avoidance was generally low; only 38% took any allergen avoidance measures in the home. The level of self-medication was high; 92% reported self-medication with prescription and nonprescription drugs. Finally, 26% believed that their symptoms were ''well controlled'' or ''completely controlled,'' and 52% believed that effective treatments were available. Our findings suggest the need for a greater effort on the part of health care providers to identify patients with allergic rhinitis and to educate them about their disease.	ASTHMA & ALLERGY ASSOCIATES, COLORADO SPRINGS, CO USA; ALLERGY & ASTHMA MED GRP & RES CTR, SAN DIEGO, CA USA; ALLERGY RESP INST COLORADO, DENVER, CO USA									BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	5	46	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	2	S			S825	S828		10.1016/S0091-6749(97)80043-7	http://dx.doi.org/10.1016/S0091-6749(97)80043-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ363					2022-12-18	WOS:A1997XJ36300005
J	Bressler, RB; Lesko, J; Jones, ML; Wasserman, M; Dickason, RR; Huston, MM; Cook, SW; Huston, DP				Bressler, RB; Lesko, J; Jones, ML; Wasserman, M; Dickason, RR; Huston, MM; Cook, SW; Huston, DP			Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-5 MESSENGER-RNA; LATE-PHASE REACTION; RECOMBINANT HUMAN; EOSINOPHIL CHEMOTAXIS; BRONCHIAL BIOPSIES; MILD ASTHMA; BONE-MARROW; KIT-LIGAND; T-CELLS; CYTOKINES	Background: The late-phase allergic reaction is an eosinophilic inflammatory response that begins several hours after allergen exposure, may persist for 24 hours, and is an important pathogenic mechanism in allergic disease. Objective: Cultured naive human mast cells were used to investigate whether mast cells are a direct source of the eosinophil-promoting cytokines IL-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Methods: Naive human mast cells were derived from bone marrow mononuclear cells cultured in the presence of stem-cell factor. Cytokine message and protein production in response to high-affinity IgE receptor ligation of cultured mast cells were measured by semiquantitative polymerase chain reaction and ELISA, respectively. Results: IL-5, IL-3, and GM-CSF messenger RNA increased within 2 hours of mast cell activation, with IL-5 and GM-CSF message remaining elevated for 24 hours, whereas IL-3 mRNA rapidly declined. IL-S and GM-CSF protein were measurable 4 to 6 hours after stimulation and peaked by 24 and 12 hours, respectively. IL-3 protein was not detectable. Conclusion: These findings demonstrate that naive mast cells do not constitutively produce IL-5 or GM-CSF protein but are a major source of these eosinophilotropic cytokines on high-affinity IgE receptor Ligation.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Huston, David/0000-0002-2332-0010	NIAID NIH HHS [AI36936, AI27881] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036936, R29AI027881] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRESSLER RB, 1989, J IMMUNOL, V143, P135; BRESSLER RB, 1992, CLIN RES, V40, P343; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FUKUDA T, 1994, J ALLERGY CLIN IMMUN, V94, P584, DOI 10.1016/0091-6749(94)90134-1; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIROHATA S, 1989, J IMMUNOL, V142, P2597; IRANI AMA, 1992, BLOOD, V80, P3009; JAFFE JS, 1995, AM J RESP CELL MOL, V13, P665, DOI 10.1165/ajrcmb.13.6.7576704; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; LEMANSKE RF, 1994, ALLERGY PRINCIPLES P, P320; MASSEY W, 1993, J IMMUNOL, V150, P1084; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; TILL S, 1995, EUR J IMMUNOL, V25, P2727, DOI 10.1002/eji.1830251002; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; VALENT P, 1992, BLOOD, V80, P2237; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, BLOOD, V79, P1836; WILLHEIM M, 1995, J IMMUNOL METHODS, V182, P115, DOI 10.1016/0022-1759(95)00034-8; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	42	46	46	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					508	514		10.1016/S0091-6749(97)70078-2	http://dx.doi.org/10.1016/S0091-6749(97)70078-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111496				2022-12-18	WOS:A1997WU27400014
J	Hakansson, L; Heinrich, C; Rak, S; Venge, P				Hakansson, L; Heinrich, C; Rak, S; Venge, P			Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: Effect of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; neutrophil; adhesion; pollen season; immunotherapy; vascular cell adhesion molecule-1; intercellular adhesion molecule-1; very late activation antigen; macrophage antigen-1	MESSENGER-RNA EXPRESSION; VASCULAR ENDOTHELIAL-CELLS; CD4+ T-CELLS; ASTHMATIC-PATIENTS; BRONCHIAL BIOPSIES; E-SELECTIN; BRONCHOALVEOLAR LAVAGE; CHEMOTACTIC ACTIVITY; CATIONIC PROTEIN; CYTOKINE	The adhesion of eosinophil granulocytes to E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) was investigated before and during birch pollen season in 24 patients allergic to birch pollen who had rhinoconjunctivitis and, in half of the cases, asthma during season, Half of the patients were undergoing specific immunotherapy for birch pollen allergy, Increased adhesion to VCAM-1 and ICAM-1 (p < 0.05) during season as compared with before season was demonstrated by eosinophils of patients in the control group and by eosinophils of the patients without asthma treated with immunotherapy, but not by eosinophils from the immunotherapy-treated patients with asthma, Eosinophils from the control group of patients demonstrated increased cell surface expression of CD18 and CD49d (p < 0.05 and p < 0.01, respectively) during season as compared with before season, and eosinophils from the immunotherapy-treated patients showed increased cell surface expression of CD49d (p < 0.01) during season. Simultaneous measurement of neutrophil adhesion revealed increased adhesion to E-selectin and ICAM-1 (p < 0.01) during season compared with before season in the immunotherapy-treated group of patients, Neutrophils from the control subjects without asthma showed increased adhesion to E-selectin (p < 0.05) during season, In conclusion, eosinophils from patients allergic to birch pollen demonstrated priming of the adhesion to VCAM-1 and ICAM-I during birch pollen season, Immunotherapy treatment prevented the priming of eosinophil adhesion during pollen season in the patients allergic to birch pollen who had asthma, but not in those without asthma. In contrast, neutrophils from the immunotherapy-treated patients, both with and without asthma, demonstrated priming of the adhesion to E-selectin and ICAM-1 during season. The latter results indicate that immunotherapy, in case of the patients allergic to birch pollen with asthma induced a shift from the production of primarily eosinophil priming agents to primarily neutrophil I,riming agents, which may be caused by a shift from Th2 to Th1 lymphocytes.	UNIV UPPSALA HOSP, ASTHMA RES CTR, S-75185 UPPSALA, SWEDEN; CENT HOSP VASTERAS, DEPT OTOLARYNGOL, VASTERAS, SWEDEN; SAHLGRENS UNIV HOSP, DEPT LUNG MED, GOTHENBURG, SWEDEN	Uppsala University; Uppsala University Hospital; Vasteras Central Hospital; Sahlgrenska University Hospital	Hakansson, L (corresponding author), UNIV UPPSALA HOSP, DEPT CLIN CHEM, INFLAMMAT RES LAB, S-75185 UPPSALA, SWEDEN.							ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BJORNSSON E, 1994, ALLERGY, V49, P730, DOI 10.1111/j.1398-9995.1994.tb02095.x; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388, DOI 10.1164/ajrccm.152.1.7599853; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; CARLOS TM, 1994, BLOOD, V84, P2068; CARLSON M, 1992, J ALLERGY CLIN IMMUN, V89, P131, DOI 10.1016/S0091-6749(05)80050-8; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; EBISAWA M, 1994, J IMMUNOL, V153, P2153; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FUKUDA T, 1994, J ALLERGY CLIN IMMUN, V94, P584, DOI 10.1016/0091-6749(94)90134-1; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GOSSET P, 1995, INT ARCH ALLERGY IMM, V106, P69, DOI 10.1159/000236892; GOSSET P, 1994, ANN NY ACAD SCI, V725, P163, DOI 10.1111/j.1749-6632.1994.tb00276.x; HAKANSSON L, 1994, J IMMUNOL METHODS, V176, P53, DOI 10.1016/0022-1759(94)90350-6; HAKANSSON L, 1990, J ALLERGY CLIN IMMUN, V85, P743, DOI 10.1016/0091-6749(90)90193-8; Hakansson L, 1995, J ALLERGY CLIN IMMUN, V96, P941, DOI 10.1016/S0091-6749(95)70232-6; HAMID Q, 1991, INT ARCH ALLER A IMM, V94, P169, DOI 10.1159/000235353; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MOQBEL R, 1994, ANN NY ACAD SCI, V725, P223, DOI 10.1111/j.1749-6632.1994.tb39805.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; Ogden EC, 1974, MANUAL SAMPLING AIRB; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; RICCI M, 1993, CLIN EXP ALLERGY, V23, P360, DOI 10.1111/j.1365-2222.1993.tb00340.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SAITO H, 1986, BLOOD, V67, P50; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TANIZAKI Y, 1993, J ASTHMA, V30, P257, DOI 10.3109/02770909309054525; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P757, DOI 10.1016/0091-6749(92)90099-N; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586	55	46	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					551	562		10.1016/S0091-6749(97)70084-8	http://dx.doi.org/10.1016/S0091-6749(97)70084-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111502				2022-12-18	WOS:A1997WU27400020
J	Essayan, DM; Han, WF; Li, XM; Xiao, HQ; KleineTebbe, J; Huang, SK				Essayan, DM; Han, WF; Li, XM; Xiao, HQ; KleineTebbe, J; Huang, SK			Clonal diversity of IL-4 and IL-13 expression in human allergen-specific T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-specific T cell; IL-4; IL-13; IFN-gamma	HUMAN B-CELLS; CYTOKINE PRODUCTION; IGE SYNTHESIS; IFN-GAMMA; INTERLEUKIN-13; PROLIFERATION; RESPONSES; INDIVIDUALS; MODULATION; MONOCYTES	The expression of IL-4 and IL-13 was analyzed in a panel of short ragweed allergen (Amb a 1)-specific T-cell clones from an allergic subject and a nonallergic individual. The T cells from the allergic subject showed a predominantly T-H0 phenotype. The T cells from the nonallergic individual produced undetectable levels of IL-4 and high levels of interferon-gamma, suggesting a T-H1 cytokine profile. However; all T-cell clones showed significantly higher levels of IL-13 secretion than IL-4 secretion, and no quantitative correlation could be found between the levels of IL-4 and IL-13 in the clones tested Furthermore, both cytokines showed similar kinetics of expression in antigen-induced steady-state messenger RNA. Finally both cytokines were induced by stimulation of the cells with either ionomycin alone or with a combination of ionomycin and phorbol myristate acetate. These results demonstrate that there is a significant clonal diversity and quantitative difference in the levels of IL-4 and IL-13 expression in allergen-specific human T cells.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine			Huang, Shau-Ku/F-5509-2010	Kleine-Tebbe, Joerg/0000-0002-2862-7353	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRINKMANN V, 1995, J IMMUNOL, V154, P3078; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; EBNER C, 1995, J IMMUNOL, V154, P1932; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; HUANG SK, 1995, J IMMUNOL, V155, P2688; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JOHNSTON SL, 1990, CURR OPIN IMMUNOL, V2, P513, DOI 10.1016/0952-7915(90)90004-Z; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SHANAFELT MC, 1995, J IMMUNOL, V154, P1684; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YSSEL H, 1992, J IMMUNOL, V148, P738; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	29	46	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1035	1044		10.1016/S0091-6749(96)80188-6	http://dx.doi.org/10.1016/S0091-6749(96)80188-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977502	hybrid			2022-12-18	WOS:A1996WB37800006
J	Rennard, SI				Rennard, SI			Repair mechanisms in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; epithelial repair mechanisms	BRONCHIAL EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; HUMAN NEUTROPHIL ELASTASE; RAT TRACHEAL EPITHELIUM; AIRWAY INFLAMMATION; LUNG-FUNCTION; FIBRONECTIN PRODUCTION; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; BASEMENT-MEMBRANE	Asthma is classically defined in terms of reversible airflow obstruction. It is now recognized that histologic abnormalities, including inflammation, are a regular feature of asthma. In addition, alterations of the structural elements of the airway wall occur regularly in asthma. These alterations include a thickened basal lamina comprised of interstitial collagens as well as alterations in the mesenchymal cell population with an accumulation of myofibroblasts. It seems likely that these connective tissue alterations in the airway wall contribute to the physiologic abnormalities of asthma. While controversial, the long-term physiologic sequela of asthma may depend in large part on these changes. The biochemical and cellular basis that leads to these changes is, as yet, unknown, but recent studies suggest that a variety of cells in the airway, including inflammatory cells and the cells of the airway epithelium, may participate in regulating this response.			Rennard, SI (corresponding author), UNIV NEBRASKA,MED CTR,PULM & CRIT CARE MED SECT,600 S 42ND ST,OMAHA,NE 68198, USA.							Adachi Y, 1996, J LAB CLIN MED, V127, P448, DOI 10.1016/S0022-2143(96)90062-1; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; BITTERMAN PB, 1986, J CLIN INVEST, V77, P700, DOI 10.1172/JCI112364; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; BREUER R, 1985, J LAB CLIN MED, V105, P635; BREUER R, 1987, AM REV RESPIR DIS, V136, P698, DOI 10.1164/ajrccm/136.3.698; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BURKE C, 1992, EUR RESPIR J, V5, P73; CAMBREY AD, 1995, CLIN SCI, V89, P611, DOI 10.1042/cs0890611; CHRISTENSEN TG, 1988, ENVIRON RES, V45, P78, DOI 10.1016/S0013-9351(88)80010-0; CHRISTENSEN TG, 1977, J CLIN INVEST, V59, P397, DOI 10.1172/JCI108652; CHRISTENSEN TG, 1987, EXP LUNG RES, V13, P279, DOI 10.3109/01902148709069594; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; CRYSTAL RG, 1991, LUNG, V1, P527; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EHRLICH HP, 1983, J CELL PHYSIOL, V116, P345, DOI 10.1002/jcp.1041160312; ERTL RF, 1992, AM REV RESPIR DIS, V145, P19; EVANS MJ, 1988, AM REV RESPIR DIS, V138, P481, DOI 10.1164/ajrccm/138.2.481; FERRIOLA PC, 1992, J CELL PHYSIOL, V152, P302, DOI 10.1002/jcp.1041520211; FINE A, 1989, J BIOL CHEM, V264, P16988; FLETCHER C, 1976, NATURAL HIST CHRONIC, P1; GLYNN A, 1960, THORAX, V15, P132; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; ISLIKER H, 1981, IMMUNE SYSTEM, V2, P231; ITO H, 1993, AM REV RESPIR DIS, V147, pA46; ITO H, IN PRESS J LAB CLIN; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JOHNSON NF, 1990, AM J RESP CELL MOL, V3, P579, DOI 10.1165/ajrcmb/3.6.579; KAWAMOTO M, 1995, AM J RESP CELL MOL, V12, P425, DOI 10.1165/ajrcmb.12.4.7695922; KEENAN KP, 1982, VIRCHOWS ARCH B, V41, P193, DOI 10.1007/BF02890281; KRZYZANOWSKI M, 1990, CHEST, V98, P62, DOI 10.1378/chest.98.1.62; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LAITINEN A, 1994, AM J RESP CRIT CARE, V149, P942; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LANE BP, 1974, P SOC EXP BIOL MED, V145, P1139; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; LEIKAUF GD, 1988, AM REV RESPIR DIS, V137, P435, DOI 10.1164/ajrccm/137.2.435; LIU JY, 1994, AM J PHYSIOL, V266, pL296, DOI 10.1152/ajplung.1994.266.3.L296; MATSUBA K, 1989, EUR RESPIR J, V2, P834; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MIO T, 1995, AM J RESP CRIT CARE, V151, P561; MYERS JL, 1993, CLIN CHEST MED, V14, P611; NAKAMURA Y, 1995, AM J PHYSIOL-LUNG C, V269, pL377, DOI 10.1152/ajplung.1995.269.3.L377; NAYLOR B, 1964, J CLIN PATHOL, V17, P84, DOI 10.1136/jcp.17.1.84; NIEWOEHNER DE, 1993, TXB PULMONARY DIS, V2, P973; NOGAMI M, 1994, AM J PHYSIOL, V266, pL187, DOI 10.1152/ajplung.1994.266.2.L187; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; RENNARD SI, 1994, BASOPHILS MAST CELLS, P229; RENNARD SI, IN PRESS PULMONARY D; RENNARD SI, 1990, LUNG, P157; RICKARD KA, 1993, AM J RESP CELL MOL, V8, P63, DOI 10.1165/ajrcmb/8.1.63; ROCHE WR, 1962, THORAX, V17, P69; ROMAN J, 1991, LUNG SCI F, V1, P399; ROMBERGER DJ, 1992, AM J RESP CELL MOL, V7, P149, DOI 10.1165/ajrcmb/7.2.149; ROMBERGER DJ, 1995, AM J PHYSIOL-LUNG C, V268, pL230, DOI 10.1152/ajplung.1995.268.2.L230; ROMBERGER DJ, 1991, AM REV RESPIR DIS, V143, P532; SACCO O, 1992, J CLIN INVEST, V90, P1379, DOI 10.1172/JCI116004; SANERKIN NG, 1965, J PATHOL BACTERIOL, V89, P535, DOI 10.1002/path.1700890211; SCHNEEBERGER EE, 1990, LUNG SCI FDN, P157; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SHELHAMER JH, 1995, ANN INTERN MED, V123, P288, DOI 10.7326/0003-4819-123-4-199508150-00008; SHERMAN CB, 1992, AM REV RESPIR DIS, V146, P855, DOI 10.1164/ajrccm/146.4.855; SHIMIZU T, 1994, AM J RESP CELL MOL, V11, P85, DOI 10.1165/ajrcmb.11.1.7517145; SHOJI S, 1990, AM REV RESPIR DIS, V141, P218, DOI 10.1164/ajrccm/141.1.218; SHOJI S, 1990, AM REV RESPIR DIS, V141, P433, DOI 10.1164/ajrccm/141.2.433; SHOJI S, 1990, AM J RESP CELL MOL, V2, P553, DOI 10.1165/ajrcmb/2.6.553; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; Snider G, 1994, RESP MED, V2nd, P1331; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SOBONYA RE, 1994, TXB PULMONARY DIS, V2, P955; SPENCER H, 1968, PATHOLOGY LUNG, P715; TAKIZAWA H, 1990, AM J RESP CELL MOL, V2, P245, DOI 10.1165/ajrcmb/2.3.245; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331, DOI 10.1164/arrd.1971.104.3.331; THOMPSON AB, 1995, EUR RESPIR J, V8, P127, DOI 10.1183/09031936.95.08010127; THURLBECK WM, 1970, MEDICINE, V49, P81, DOI 10.1097/00005792-197003000-00001; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WANG A, 1991, J BIOL CHEM, V266, P15598; WOOLCOCK AJ, 1994, TXB RESP MED, V2, P1288	84	46	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S278	S286		10.1016/S0091-6749(96)70076-3	http://dx.doi.org/10.1016/S0091-6749(96)70076-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977537				2022-12-18	WOS:A1996WC44700014
J	SVENSSON, C; GRONNEBERG, R; ANDERSSON, M; ALKNER, U; ANDERSSON, O; BILLING, B; GILLJAM, H; GREIFF, L; PERSSON, CGA				SVENSSON, C; GRONNEBERG, R; ANDERSSON, M; ALKNER, U; ANDERSSON, O; BILLING, B; GILLJAM, H; GREIFF, L; PERSSON, CGA			ALLERGEN CHALLENGE-INDUCED ENTRY OF ALPHA(2)-MACROGLOBULIN AND TRYPTASE INTO HUMAN NASAL AND BRONCHIAL AIRWAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE; ALBUMIN; ALPHA(2)-MACROGLOBULIN; TRYPTASE	PLASMA EXUDATION; HYDROSTATIC-PRESSURE; ANTIGEN CHALLENGE; MUCOSA; HISTAMINE; ABSORPTION; ASTHMA; REACTIVITY; INCREASE; RHINITIS	Background: Microvascular-epithelial exudation of bulk plasma may characterize inflammatory airway diseases. This study compares the acute allergen challenge-induced mast cell and exudative responses in nasal nad bronchial airways. The focus is on alpha(2)-macroglobulin as an index of luminal entry of plasma exudates. Methods: Separate nasal and bronchial allergen challenges were carried out outside the pollen season in eight patients with pollen-induced seasonal allergic rhinitis. The levels of different-sized plasma proteins (albumin molecular weight, 66,000 d and alpha(2)-macroglobulin molecular weight, 725,000 d) and tryptase were determined in pre- and postchallenge nasal lavage and bronchoalveolar lavage (BAL) fluids. Diluent and increasing doses of allergen were sprayed into the right nasal cavity, and each challenge was followed by a nasal lavage (volume, 15 ml) with a ''nasal pool'' device (recovery, >80%). Endobronchial allergen challenge (individual doses) and BAL (volume, 2 x 25 ml) were performed in a lobe bronchus through a fiberoptic bronchoscope (recovery, 30%). Saline challenge and BAL were carried out in the contralateral lung as control. Results: The levels of albumin, alpha(2)-macroglobulin, and tryptase increased dose-dependently in postchallenge and nasal lavage fluids (p < 0.05) and correlated to nasal symptoms. In particular, albumin and alpha(2)-macroglobulin correlated (r = 0.98, p < 0.001). Both alpha(2)-macroglobulin and tryptase, but not albumin, were increased in BAL fluids from the allergen-challenged side (p < 0.05). Conclusion: Local allergen challenge causes luminal entry of tryptase and alpha(2)-macroglobulin in the nose and bronchi of patients with allergy. We suggest that mass cell and plasma exudation responses may be similar in human nasal and bronchial airways and that albumin levels (in BAL fluids) may not well reflect the exudation process in bronchial airways	UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,S-22185 LUND,SWEDEN; HUDDINGE UNIV HOSP,DEPT RESP & ALLERG DIS,S-14186 HUDDINGE,SWEDEN; ASTRO DRACO AB,DEPT BIOANAL,LUND,SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Karolinska Institutet								ALKNER U, 1991, Journal of Allergy and Clinical Immunology, V87, P217, DOI 10.1016/0091-6749(91)91595-K; Atkinson TP, 1995, ASTHMA RHINITIS, P777; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ERJEFALT I, 1991, CLIN EXP ALLERGY, V21, P217, DOI 10.1111/j.1365-2222.1991.tb00833.x; Erjefalt I, 1989, Pulm Pharmacol, V2, P93, DOI 10.1016/0952-0600(89)90030-6; ERJEFALT I, 1993, J APPL PHYSIOL, V74, P817, DOI 10.1152/jappl.1993.74.2.817; ERJEFALT JS, 1995, CLIN EXP ALLERGY, V25, P187, DOI 10.1111/j.1365-2222.1995.tb01025.x; ERJEFALT JS, 1994, MICROVASC RES, V48, P161, DOI 10.1006/mvre.1994.1047; GREIFF L, 1991, THORAX, V46, P700, DOI 10.1136/thx.46.10.700; GREIFF L, 1991, THORAX, V46, P630, DOI 10.1136/thx.46.9.630; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; GREIFF L, 1994, ALLERGY CLIN IMMUNOL, V2, P165; GUSTAFSSON BG, 1991, CLIN EXP ALLERGY, V21, P121, DOI 10.1111/j.1365-2222.1991.tb00813.x; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; LUTS A, 1990, INT ARCH ALLER A IMM, V91, P385, DOI 10.1159/000235146; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V126, P615, DOI 10.1111/j.1748-1716.1986.tb07863.x; PERSSON CGA, 1988, LUNG, V166, P1, DOI 10.1007/BF02714025; PERSSON CGA, 1992, THORAX, V47, P993, DOI 10.1136/thx.47.12.993; PERSSON CGA, 1990, INT ARCH ALLER A IMM, V92, P148, DOI 10.1159/000235206; PERSSON CGA, 1986, LANCET, V2, P1126; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535, DOI 10.1164/ajrccm/146.6.1535; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; SVENSSON C, 1994, EUR J CLIN PHARMACOL, V46, P59; SVENSSON C, 1995, IN PRESS CLIN EXP AL; 1991, J ALLERGY CLIN IMMUN, V88, P808	30	46	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					239	246		10.1016/S0091-6749(95)70013-7	http://dx.doi.org/10.1016/S0091-6749(95)70013-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7543503	Bronze			2022-12-18	WOS:A1995RQ00100013
J	PETERSEN, A; SCHRAMM, G; BUFE, A; SCHLAAK, M; BECKER, WM				PETERSEN, A; SCHRAMM, G; BUFE, A; SCHLAAK, M; BECKER, WM			STRUCTURAL INVESTIGATIONS OF THE MAJOR ALLERGEN PHL P I ON THE COMPLEMENTARY-DNA AND PROTEIN LEVEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COMPLEMENTARY DNA CLONING; GRASS POLLEN ALLERGEN; IGE BINDING; IMMUNOBLOTTING; 2-DIMENSIONAL GEL ELECTROPHORESIS	GRASS-POLLEN; MONOCLONAL-ANTIBODIES; CROSS-REACTIVITY; V-ALLERGENS; NITROCELLULOSE; DETERMINANTS; CLONING	Until now investigations of group I grass allergens have mainly been performed on ryegrass allergen (Lol p I). We studied this major allergen grass group with timothy grass pollen (Phl p I), a very common and important cause of type I allergy, to determine intraspecific and interspecific variations among different grass species. By immunoscreening a timothy grass pollen complementary DNA library we obtained three full-length clones. They revealed identical nucleotide sequences in the coding regions consisting of 262 amino acids, including a leader sequence of 23 amino acid residues. The comparison of our data with the amino acid sequences deduced from Lol p I and Hol 1 I clones showed sequence identities of greater than 85% and homologies of greater than 90%, indicating a high degree of sequence conservation. Despite the high degree of homology, amino acid differences were in immunodominant positions, which may be responsible for the differing immune response to group I allergens of different grass species.			PETERSEN, A (corresponding author), FORSCHUNGSINST BORSTEL,DIV ALLERGOL,PK ALLEE 22,D-23845 BORSTEL,GERMANY.			Bufe, Albrecht/0000-0001-7335-9362				BALDO BA, 1982, PROG ALLERGY, V30, P1; BECKER WM, 1988, BIOCH ENG, P440; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; ESCH RE, 1989, J IMMUNOL, V142, P179; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1995, IMMUNOCHEMISTRY, V3, P101; JOHNSONP, 1965, IMMUNOCHEMISTRY, V3, P91; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1992, ALLERGY S, V47, P31; MOURAD W, 1988, J IMMUNOL, V141, P3486; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1993, J ALLERGY CLIN IMMUN, V92, P789, DOI 10.1016/0091-6749(93)90055-K; PETERSEN A, 1991, Applied and Theoretical Electrophoresis, V2, P129; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAMM G, 1993, ALLERGY, V48, P127; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SUPHIOGLU C, 1993, INT ARCH ALLERGY IMM, V102, P144, DOI 10.1159/000236565; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; WEBER RW, 1981, ANN ALLERGY, V46, P208; 1987, 220 PHARM DEV TECHN	33	46	50	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				987	994		10.1016/S0091-6749(95)70099-4	http://dx.doi.org/10.1016/S0091-6749(95)70099-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751520				2022-12-18	WOS:A1995QY91700010
J	FERNANDEZRIVAS, M; CARRAL, CP; CUEVAS, M; MARTI, C; MORAL, A; SENENT, CJ				FERNANDEZRIVAS, M; CARRAL, CP; CUEVAS, M; MARTI, C; MORAL, A; SENENT, CJ			SELECTIVE ALLERGIC REACTIONS TO CLAVULANIC ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGEN VALLE HOSP,DEPT PHARMACEUT,TOLEDO,SPAIN; HOSP RAMON Y CAJAL,DEPT IMMUNOL,MADRID,SPAIN	Hospital Universitario Ramon y Cajal	FERNANDEZRIVAS, M (corresponding author), HOSP VIRGEN VALLE,ALLERGY SECT,CARRETERA COBISA S-N,E-45071 TOLEDO,SPAIN.							DEHAAN P, 1985, INT ARCH ALLER A IMM, V76, P42, DOI 10.1159/000233659; EDWARDS RG, 1988, INT ARCH ALLER A IMM, V85, P184, DOI 10.1159/000234500; HAGINAKA J, 1985, CHEM PHARM BULL, V33, P218, DOI 10.1248/cpb.33.218; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603	5	46	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					748	750		10.1016/S0091-6749(95)70181-8	http://dx.doi.org/10.1016/S0091-6749(95)70181-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897159				2022-12-18	WOS:A1995QM01700016
J	KALISH, RS; LAPORTE, A; WOOD, JA; JOHNSON, KL				KALISH, RS; LAPORTE, A; WOOD, JA; JOHNSON, KL			SULFONAMIDE-REACTIVE LYMPHOCYTES DETECTED AT VERY-LOW FREQUENCY IN THE PERIPHERAL-BLOOD OF PATIENTS WITH DRUG-INDUCED ERUPTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DRUG ERUPTION; DRUG HYPERSENSITIVITY; LYMPHOCYTE; INTERLEUKIN-2 SULFAMETHOXAZOLE; FUROSEMIDE; LYMPHOCYTE TRANSFORMATION TEST	TOXIC EPIDERMAL NECROLYSIS; HYDROXYLAMINE METABOLITES; HYPERSENSITIVITY REACTIONS; IDIOSYNCRATIC TOXICITY; CUTANEOUS REACTIONS; TRANSFORMATION TEST; T-LYMPHOCYTES; CELLS; HUMANS; SULFAMETHOXAZOLE	Background: The role of T lymphocytes in mediating drug eruptions is uncertain. Methods: Twenty-four patients with eruptions induced by sulfonamide-related drugs were studied to detect lymphocyte reactivity to drugs. Both the lymphocyte transformation test and limiting dilution analysis were used as assays for drug-reactive lymphocytes. Peripheral blood lymphocytes were expanded in interleukin-2 and tested for reactivity to sulfamethoxazole and furosemide. Results: The lymphocyte transformation test results to sulfamethoxazole, sulfisoxazole, and furosemide were found to be generally unreliable with a high rate of false-negative and false-positive results. However, as determined by limiting dilution analysis, sulfamethoxazole-reactive lymphocytes were detected in the peripheral blood of one patient at a frequency of 1/172,000. This is within the lower range of frequencies of urushiol-reactive T cells in the peripheral blood of patients with allergic contact dermatitis to urushiol (poison ivy). Two sulfonamide-reactive lymphocyte lines were cultured from two patients. Both lines proliferated in response to sulfamethoxazole but not in response to furosemide, suggesting that furosemide does not cross-react with the sulfonamides. Conclusions: Lymphocytes reactive to sulfamethoxazole were detected at low frequencies in the peripheral blood of three patients with drug eruptions secondary to administration of sulfamethoxazole.			KALISH, RS (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DEPT DERMATOL, T-16 RM 60, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026580] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26580] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSEM ESK, 1974, IMMUNOLOGY, V27, P255; BIGBY M, 1986, Journal of the American Medical Association, V256, P3358, DOI 10.1001/jama.256.24.3358; BOECKER C, 1993, J INVEST DERMATOL, V100, P540; CRIBB AE, 1990, MOL PHARMACOL, V38, P744; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1991, J PHARMACOL EXP THER, V259, P1241; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; DOBOZY A, 1981, CLIN EXP DERMATOL, V6, P367, DOI 10.1111/j.1365-2230.1981.tb02319.x; DVORAK HF, 1977, J IMMUNOL, V118, P1549; GIMENEZCAMARASA JM, 1975, NEW ENGL J MED, V292, P819, DOI 10.1056/NEJM197504172921601; GUILLAUME JC, 1987, ARCH DERMATOL, V123, P1166, DOI 10.1001/archderm.123.9.1166; HALEVY S, 1990, ARCH DERMATOL, V126, P48, DOI 10.1001/archderm.126.1.48; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; KALISH RS, 1989, J INVEST DERMATOL, V92, P46, DOI 10.1111/1523-1747.ep13070998; KALISH RS, 1990, J IMMUNOL, V145, P3706; KALISH RS, 1988, CELL IMMUNOL, V111, P379, DOI 10.1016/0008-8749(88)90101-3; KALISH RS, 1992, ARCH DERMATOL, V128, P1072, DOI 10.1001/archderm.128.8.1072; KATZ SI, 1978, J INVEST DERMATOL, V71, P70, DOI 10.1111/1523-1747.ep12544415; KHAN IU, 1992, DRUG METAB DISPOS, V20, P620; MIHAS AA, 1978, JAMA-J AM MED ASSOC, V239, P2590, DOI 10.1001/jama.239.24.2590; PARKER CW, 1962, J EXP MED, V115, P803, DOI 10.1084/jem.115.4.803; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; ROUJEAU JC, 1985, INT ARCH ALLER A IMM, V78, P22, DOI 10.1159/000233856; SARKANY I, 1981, INT J DERMATOL, V8, P544; SCHMID DS, 1988, J IMMUNOL, V140, P3610; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SHEAR NH, 1985, BR J DERMATOL S113, V28, P112; SPIELBERG SP, 1984, FED PROC, V43, P2308; STEJSKAL VDM, 1987, INT ARCH ALLER A IMM, V82, P461, DOI 10.1159/000234254; TASWELL C, 1981, J IMMUNOL, V126, P1614; THESTRUP PK, 1987, DAN MED B, V34, P3; ZAKRZEWSKA JM, 1988, J ALLERGY CLIN IMMUN, V82, P110, DOI 10.1016/0091-6749(88)90059-0	34	46	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				465	472		10.1016/0091-6749(94)90202-X	http://dx.doi.org/10.1016/0091-6749(94)90202-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083451	Bronze			2022-12-18	WOS:A1994PG90700005
J	BEASLEY, R; BURGESS, C; CRANE, J; PEARCE, N; ROCHE, W				BEASLEY, R; BURGESS, C; CRANE, J; PEARCE, N; ROCHE, W			PATHOLOGY OF ASTHMA AND ITS CLINICAL IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHOALVEOLAR LAVAGE; BRONCHIAL HYPERREACTIVITY; BETA-AGONISTS; MILD ASTHMA; NEW-ZEALAND; MAST-CELLS; RESPONSIVENESS; TERBUTALINE; FENOTEROL; CHILDREN	Although detailed histopathologic studies have described the inflammatory processes present in fatal asthma, until recently the pathology of less severe forms of the disease has been less well understood. Now a series of important studies has extended our understanding of the pathophysiology of mild asthma. Studies that examine sputum or fluid obtained by bronchoalveolar lavage from mildly asthmatic subjects revealed findings consistent with an active inflammatory process within the airways. The histopathologic examination of endobronchial biopsy specimens from stable asthmatic patients has shown that inflammatory cell infiltration of the mucosa is a distinctive feature of mildly asthmatic subjects requiring only intermittent inhaled beta-agonist therapy. These studies have also shown that marked tissue disruption may occur early in the natural history of mild asthma. These investigations have demonstrated that asthma is a disease characterized by acute and chronic inflammatory changes within the airways and that in many respects the histopathologic features of mild allergic asthma are similar to those observed in fatal asthma. The therapeutic implications of these findings are that management of mild asthma should be directed toward resolving this inflammatory process. There is now sufficient evidence to suggest that anti-inflammatory drugs such as cromolyn sodium, inhaled corticosteroids, and nedocromil sodium be used earlier in the course of the disease and that the use of these therapeutic agents should not be limited to patients with severe forms of asthma. This may be particularly important in view of the increasing awareness of the potential problems associated with the overreliance on beta-agonist therapy in patients with asthma.	UNIV SOUTHAMPTON, DEPT PATHOL, SOUTHAMPTON SO9 5NH, HANTS, ENGLAND	University of Southampton	BEASLEY, R (corresponding author), WELLINGTON SCH MED, DEPT MED, POB 7343, WELLINGTON, NEW ZEALAND.			Beasley, Richard/0000-0003-0337-406X; Pearce, Neil/0000-0002-9938-7852				ANDERSON HR, 1980, BRIT MED J, V281, P1191, DOI 10.1136/bmj.281.6249.1191; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEASLEY R, 1990, MED J AUSTRALIA, V152, P570, DOI 10.5694/j.1326-5377.1990.tb125385.x; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; CRANE J, 1972, LANCET, V105, P833; CURSCHMANN H, 1883, DTSCH ARCH KLIN MED, V32, P1; DAWSON KP, 1987, NEW ZEAL MED J, V100, P520; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GLYNN A. A., 1960, THORAX, V15, P142, DOI 10.1136/thx.15.2.142; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; INMAN WHW, 1969, LANCET, V2, P279; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KELLY CA, 1988, AM REV RESPIR DIS, V138, P81, DOI 10.1164/ajrccm/138.1.81; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LUNDGREN R, 1977, SCAND J RESPIR DIS, P179; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; NOWAK J, 1969, ACTA MED POL, V2, P153; PALMER KNV, 1967, LANCET, V2, P383; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE NE, 1990, MED J AUST NZ S1, V20, P515; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; ROCHE WR, 1989, LANCET, V1, P520; SALVATO G, 1968, THORAX, V23, P168, DOI 10.1136/thx.23.2.168; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TREMBATH PW, 1979, J ALLERGY CLIN IMMUN, V63, P395, DOI 10.1016/0091-6749(79)90212-4; VATHENEN AS, 1988, LANCET, V1, P554; von Leyden E.V, 1872, ARCH PATHOL ANAT PHY, V54, P324, DOI [10.1007/BF01997025, DOI 10.1007/BF01997025]; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WILSON JD, 1981, LANCET, V1, P1235	45	46	47	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				148	154		10.1016/0091-6749(93)90097-Y	http://dx.doi.org/10.1016/0091-6749(93)90097-Y			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	8335862				2022-12-18	WOS:A1993LQ35400003
J	JAMES, JM; KAGEYSOBOTKA, A; SAMPSON, HA				JAMES, JM; KAGEYSOBOTKA, A; SAMPSON, HA			PATIENTS WITH SEVERE ATOPIC-DERMATITIS HAVE ACTIVATED CIRCULATING BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; FOOD HYPERSENSITIVITY; BASOPHIL RELEASIBILITY; HISTAMINE; LEUKOTRIENE C4; D2O; HISTAMINE-RELEASING FACTOR; ANTI-IGE; C5A; BASOPHIL ACTIVATION	HIGH SPONTANEOUS RELEASE; HISTAMINE-RELEASE; INVITRO; RELEASABILITY; LEUKOCYTES; SKIN; FOOD	Background: The purpose of this study was to define the potential role of the basophil in the pathogenesis of atopic dermatitis by comparing basophil releasibility in patients with food allergy and either mild or severe atopic dermatitis. Methods: A clinical scoring system was used to differentiate patients into either a low clinical score (LCS) group, 10 patients, or a high clinical score (HCS) group, 14 patients. Basophil histamine release was measured with a radioenzymatic assay, and leukotriene C4 (LTC4) was determined with a radioimmunoassay. Histamine and LTC4 released from basophils spontaneously or after incubation with deuterium oxide, an IgE-dependent histamine-releasing factor, anti-IgE, and C5a were measured Results: Basophils from the HCS group released more histamine than those from the LCS group when stimulated with deuterium oxide (median percent total release: 85% vs 68%, p < 0.05), with 10 and 100 ng/ml of anti-IgE (58% vs 26% and 62.5% vs 37%, both p < 0.05) and 5 and 50 ng/ml of C5a (50.5% vs 11.5, p < 0.05; 49% vs 11%, p < 0.01, respectively). The spontaneous release of LTC4 from basophils was greater in the HCS group (median release: 34 vs 3.5 pg/0.1 ml, p < 0.05). Basophils stimulated with deuterium oxide, with 100 ng/ml anti-IgE; and 50 ng/ml C5a released more LTC4 in the HCS group (111.5 vs 39 pg/0.1 ml, p < 0.05; 64.5 vs 10 pg.0.1 ml, p < 0.01; 80 vs 1 pg/0.1 ml, p < 0. 05, respectively). Conclusions: These data indicate that patients with more severe atopic dermatitis have ''activated'' circulating basophils in vivo and increased basophil releasibility in particular in response to C5a. These studies may serve as markers for more severe atopic dermatitis.	JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI07290, AI24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DVORAK AM, 1981, J IMMUNOL, V126, P523; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GILBERT HS, 1975, BLOOD, V46, P279; GILLESPIE E, 1972, P SOC EXP BIOL MED, V140, P1228; GRANT JA, 1976, J IMMUNOL, V117, P450; HANIFIN JM, 1981, COMPREHENSIVE IMMUNO, V7, P301; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAYES EC, 1983, J IMMUNOL, V131, P429; HOOK WA, 1975, J IMMUNOL, V114, P1185; HOOK WA, 1977, J IMMUNOL, V118, P679; KAPLAN AP, 1987, JAMA-J AM MED ASSOC, V258, P2900, DOI 10.1001/jama.258.20.2900; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACGILBERT HS, 1990, J LEUKOCYTE BIOL, V49, P29; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MARONE G, 1986, J ALLERGY CLIN IMMUN, V77, P377, DOI 10.1016/S0091-6749(86)80121-X; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHMIED C, 1991, HDB ATOPIC ECZEMA, P9; SEBAHOUN G, 1978, J CLIN PATHOL, V31, P749, DOI 10.1136/jcp.31.8.749; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; TUNG R, 1982, J IMMUNOL, V128, P2067; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3	25	46	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1155	1162		10.1016/0091-6749(93)90318-A	http://dx.doi.org/10.1016/0091-6749(93)90318-A			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	7685363				2022-12-18	WOS:A1993LG74000007
J	SIMONS, FER; SONI, NR; WATSON, WTA; BECKER, AB				SIMONS, FER; SONI, NR; WATSON, WTA; BECKER, AB			BRONCHODILATOR AND BRONCHOPROTECTIVE EFFECTS OF SALMETEROL IN YOUNG-PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; SALMETEROL; SALBUTAMOL; METHACHOLINE; BRONCHODILATION; BRONCHOPROTECTION; CHILDREN	BRONCHIAL RESPONSIVENESS; DOUBLE-BLIND; SALBUTAMOL; AGONIST; REACTIVITY; CHILDREN; PHARMACOKINETICS; METHACHOLINE; TERBUTALINE; SYMPTOMS	Background: In adults with asthma, the selective beta2-adrenergic agonist salmeterol has a prolonged bronchodilator and bronchoprotective effect. To date, there are few published studies of salmeterol in children. Methods: We compared the bronchodilator and bronchoprotective effects of salmeterol, 25 and 50 mug, with salbutamol, 200 mug, and with placebo, administered via metered-dose inhaler, in a randomized, double-blind, within-patient, four-way crossover, single-dose study in 20 children. Results: Mean baseline forced expiratory volume in 1 second (FEV1) and PC20 methacholine were not significantly different (p > 0.05) on the 4 study days, and did not change significantly after placebo. FEV, increased significantly from 5 to 30 minutes after salbutamol, and from 5 minutes to 12 hours after 25 mug or 50 mug salmeterol, compared with placebo. After 25 mug or 50 mug salmeterol, FEV1 was significantly lower than after salbutamol at 5 and 10 minutes, did not differ from salbutamol at 30 minutes, and was significantly greater than after salbutamol from 3 to 12 hours. No significant difference occurred between the effect of 25 mug salmeterol and the effect of 50 mug salmeterol on FEV1. After salbutamol, there was a significant increase in PC20 only at 30 minutes. After 25 mug or 50 mug salmeterol, PC20 increased significantly from 30 minutes to 12 hours. Salmeterol, 25 mug and 50 mug provided significantly greater bronchoprotection than salburamol from 3 to 12 hours and from 30 minutes to 12 hours, respectively. Salmeterol, 50 mug, provided significantly better bronchoprotection than 25 mug salmeterol from 30 minutes to 12 hours. The amount of change in PC20 accounted for by change in FEV1 varied from 14% to 28%, indicating that protection against bronchoconstriction was not entirely dependent on bronchodilation. Conclusions: Salmeterol is a potent, long-acting bronchodilator, with a slower onset Of bronchodilation than salbutamol. It provides significantly greater and longer-lasting protection against bronchoconstriction than salbutamol.	UNIV MANITOBA,FAC MED,ALLERGY & CLIN IMMUNOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BECKER AB, 1989, J ALLERGY CLIN IMMUN, V84, P891, DOI 10.1016/0091-6749(89)90385-0; BECKER AB, 1984, NEW ENGL J MED, V310, P743, DOI 10.1056/NEJM198403223101202; BOYD G, 1990, American Review of Respiratory Disease, V141, pA206; BRITTAIN RT, 1990, LUNG, V168, P111, DOI 10.1007/BF02718122; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; CLOUGH JB, 1991, ARCH DIS CHILD, V66, P579, DOI 10.1136/adc.66.5.579; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DAHL R, 1989, EUR RESPIR J S8, V2, pS677; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; EGGLESTON PA, 1981, CLIN PHARMACOL THER, V29, P505, DOI 10.1038/clpt.1981.70; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; GONGORA HC, 1991, AM REV RESPIR DIS, V144, P626, DOI 10.1164/ajrccm/144.3_Pt_1.626; GREEN CP, 1992, ARCH DIS CHILD, V67, P1014, DOI 10.1136/adc.67.8.1014; JACK D, 1991, BRIT J CLIN PHARMACO, V31, P501, DOI 10.1111/j.1365-2125.1991.tb05571.x; JOHNSON M, 1990, LUNG, V168, P115, DOI 10.1007/BF02718123; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LOFDAHL CG, 1991, EUR RESPIR J, V4, P218; MACONOCHIE JG, 1988, BRIT J CLIN PHARMACO, V25, pP115; PALMER JBD, 1989, AM REV RESPIR DIS, V2, pS676; SANDSTROM T, 1990, AM REV RESPIR DIS, V139, pS64; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SIMONS FER, 1985, J ALLERGY CLIN IMMUN, V76, P703, DOI 10.1016/0091-6749(85)90674-8; SOUSQUET J, 1991, EUR RESPIR J S14, V4, pS399; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Steel R.G.D., 1980, PRINCIPLES STAT; THIRINGER G, 1975, SCAND J RESPIR DIS, V56, P93; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; VERBEME AAPH, 1991, EUR RESP J S14, V4, pS403	36	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					840	846		10.1016/0091-6749(92)90110-N	http://dx.doi.org/10.1016/0091-6749(92)90110-N			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1358932	Bronze			2022-12-18	WOS:A1992JZ31900016
J	THIVIERGE, M; ROLAPLESZCZYNSKI, M				THIVIERGE, M; ROLAPLESZCZYNSKI, M			PLATELET-ACTIVATING-FACTOR ENHANCES INTERLEUKIN-6 PRODUCTION BY ALVEOLAR MACROPHAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYTOKINES; PAF; LIPID MEDIATORS; LIPOXYGENASE PRODUCTS; INFLAMMATION; LTB4; IL-6; IMMUNE REGULATION; ALVEOLAR MACROPHAGES; RECEPTOR ANTAGONISTS; 5 LIPOXYGENASE ACTIVATING PROTEIN	TUMOR-NECROSIS-FACTOR; ARACHIDONIC-ACID METABOLISM; HUMAN-MONOCYTES; PAF-ACETHER; INTERFERON-GAMMA; GROWTH-FACTOR; CELLS; LIPOPOLYSACCHARIDE; ASTHMA; STIMULATION	The production of the cytokine interleukin-6 (IL-6) by rat alveolar macrophages (AMs) was analyzed after their stimulation with muramyl dipeptide (1 mug/ml), in the presence of graded concentrations of platelet-activating factor (PAF). Significantly enhanced production of IL-6 was observed at 10(-10) to 10(-8) mol/L PAF, with peak effect at 10(-10) mol/L. This enhancement was blocked by three structurally unrelated specific PAF receptor antagonists BN 52021, WEB 2170, and CV 3988. The biologically inactive PAF precursor/metabolite, lyso-PAF, and the enantiomer enantio-PAF failed to induce significant enhancement in IL-6 production. In parallel, addition of PAF to AM triggered leukotriene B4 (LTB4) release. Inhibition of 5-lipoxygenase pathway by AA-861 or MK 886 inhibited the PAF-induced augmentation of both IL-6 and LTB4 production, suggesting an implication of endogenous leukotrienes in this mechanism. Furthermore, addition of exogenous LTB4 to AMs could augment their IL-6 production, with peak activity at 10(-12) mol/L LTB4, and reverse the inhibitory effects of 5-lipoxygenase inhibitors. Taken together, these observations suggest that PAF can modulate lung immune and inflammatory responses by enhancing IL-6 production and that this activity may be dependent on secondary 5-lipoxygenase metabolites. This may have clinical relevance in PAF-mediated events in the lung, such as the cellular components of late-phase asthma.	UNIV SHERBROOKE,FAC MED,DIV IMMUNOL,3001 N 12TH AVE,SHERBROOKE J1H 5N4,QUEBEC,CANADA	University of Sherbrooke								AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ADERKA D, 1989, J IMMUNOL, V143, P3517; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P152, DOI 10.1016/0091-6749(88)90234-5; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CAMUSSI G, 1990, CLIN IMMUNOL IMMUNOP, V57, P331, DOI 10.1016/0090-1229(90)90108-3; CAMUSSI G, 1983, AM J PATHOL, V112, P75; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CUSS FM, 1986, LANCET, V2, P189; DUBOIS C, 1989, J IMMUNOL, V143, P964; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; HAMASAKI Y, 1984, AM REV RESPIR DIS, V129, P742, DOI 10.1164/arrd.1984.129.5.742; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; JOUVINMARCHE E, 1984, J IMMUNOL, V133, P892; LESLIE CC, 1986, BIOCHEM J, V236, P251, DOI 10.1042/bj2360251; MAY LT, 1988, J BIOL CHEM, V263, P7760; MOHRI M, 1990, J IMMUNOL, V144, P2678; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PEPLOW PV, 1990, PROSTAG LEUKOTR ESS, V41, P71, DOI 10.1016/0952-3278(90)90057-R; PIGNOL B, 1990, J IMMUNOL, V145, P980; POUBELLE PE, 1991, IMMUNOLOGY, V72, P181; PRETOLANI M, 1989, BIOCHEM PHARMACOL, V38, P1373, DOI 10.1016/0006-2952(89)90175-5; ROLAPLESZCZYNSKI M, 1985, J IMMUNOL, V135, P3958; ROLAPLESZCZYNSKI M, 1990, J LIPID MEDIATOR, V2, pS77; ROLAPLESZCZYNSKI M, 1987, J IMMUNOL, V139, P513; ROLAPLESZCZYNSKI M, 1986, PROSTAG LEUKOTR ESS, V23, P207, DOI 10.1016/0262-1746(86)90187-3; ROLAPLEZCZYNSKI M, 1992, IN PRESS BLOOD; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SCHINDLER R, 1990, BLOOD, V75, P40; SMITH LJ, 1988, AM REV RESPIR DIS, V137, P1015, DOI 10.1164/ajrccm/137.5.1015; STENSON WF, 1980, J IMMUNOL, V125, P1; TAYLOR IK, 1991, J APPL PHYSIOL, V71, P1396, DOI 10.1152/jappl.1991.71.4.1396; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TOWNLEY RG, 1989, J ALLERGY CLIN IMMUN, V83, P997, DOI 10.1016/0091-6749(89)90437-5; ULICH TR, 1991, AM J PATHOL, V138, P1097; VALONE FH, 1991, J ALLERGY CLIN IMMUN, V87, P715, DOI 10.1016/0091-6749(91)90394-4; VALONE FH, 1988, J IMMUNOL, V141, P3945; WARD SG, 1988, NEW TRENDS LIPID MED, P6; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	47	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					796	802		10.1016/0091-6749(92)90104-A	http://dx.doi.org/10.1016/0091-6749(92)90104-A			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1331218	Bronze			2022-12-18	WOS:A1992JZ31900010
J	ALRAYES, H; PACHAS, W; MIRZA, N; AHERN, DJ; GEHA, RS; VERCELLI, D				ALRAYES, H; PACHAS, W; MIRZA, N; AHERN, DJ; GEHA, RS; VERCELLI, D			IGE REGULATION AND LYMPHOKINE PATTERNS IN AGING HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; AGING; LYMPHOKINES; IL-4; IFN-GAMMA; CALCIUM FLUXES	T-CELL CLONES; COMMUNITY POPULATION-SAMPLE; SKIN-TEST REACTIVITY; AGE-RELATED-CHANGES; HUMAN B-CELLS; HUMAN CD4+; FUNCTIONAL SUBSETS; HUMAN-LYMPHOCYTES; INTERFERON-GAMMA; SENIEUR PROTOCOL	IgE production declines with age, and allergic symptoms tend to improve. Aging therefore represents an in vivo model to study IgE regulation. We compared IgE production in older (greater-than-or-equal-to 60 years old) and young (15 to 30 years old) nonatopic individuals. Addition of exogenous interleukin-4 (IL-4) to mononuclear cells from older and young subjects induced equivalent amounts of IgE, indicating that IL-4 responsiveness is preserved in aging. After surface receptor stimulation with concanavalin A, IL-4 production by mononuclear cells from older subjects was approximately 50% as compared with the young, whereas interferon-gamma (IFN-gamma) production was reduced threefold (p = 0.008). By contrast, stimulation with phorbol esters and ionophore, which bypass surface receptor signaling, induced comparable amounts of IL-4 and IFN-gamma in older and young subjects. These data point to an impairment in T-cell membrane signal transduction in older individuals. This hypothesis was directly confirmed by showing that Ca+2 fluxes after CD3 crosslinking were significantly (p = 0.014) decreased in the older population. Our findings altogether suggest that an age-dependent T-cell activation defect may result in decreased availability of IL-4 and in the waning of IgE responses.	CHILDRENS HOSP MED CTR, DIV IMMUNOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; SPAULDING REHABIL HOSP, DIV RHEUMATOL, BOSTON, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Spaulding Rehabilitation Hospital					NIA NIH HHS [P01AG04727] Funding Source: Medline; PHS HHS [R01A122058] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG004727] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; CHILSON OP, 1989, EUR J IMMUNOL, V19, P389, DOI 10.1002/eji.1830190225; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DEPAOLI P, 1988, CLIN IMMUNOL IMMUNOP, V48, P290, DOI 10.1016/0090-1229(88)90022-0; DERYCKX S, 1992, J IMMUNOL, V148, P1465; ERNST DN, 1990, J IMMUNOL, V145, P1295; FLURKEY K, 1992, EUR J IMMUNOL, V22, P931, DOI 10.1002/eji.1830220408; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GAUCHAT JF, 1992, J IMMUNOL, V148, P2291; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; LERNER A, 1989, EUR J IMMUNOL, V19, P977, DOI 10.1002/eji.1830190604; LEWIS DB, 1988, P NATL ACAD SCI USA, V85, P9743, DOI 10.1073/pnas.85.24.9743; LIGTHART GJ, 1990, MECH AGEING DEV, V55, P89, DOI 10.1016/0047-6374(90)90108-R; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MILLER RA, 1989, J GERONTOL, V44, pB4, DOI 10.1093/geronj/44.1.B4; MILLER RA, 1991, CLIN IMMUNOL IMMUNOP, V58, P305, DOI 10.1016/0090-1229(91)90122-Q; MILLER RA, 1986, J IMMUNOL, V137, P805; MILLER RA, 1987, J CELL PHYSIOL, V132, P337, DOI 10.1002/jcp.1041320220; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALIARD X, 1988, J IMMUNOL, V141, P849; PARRONCHI P, 1990, J IMMUNOL, V144, P2102; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PHILOSOPHE B, 1989, EUR J IMMUNOL, V19, P695, DOI 10.1002/eji.1830190419; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RABINOVITCH PS, 1990, FLOW CYTOMETRY SORTI, P651; RAYNAL MC, 1989, P NATL ACAD SCI USA, V86, P8024, DOI 10.1073/pnas.86.20.8024; ROPER RL, 1990, J IMMUNOL, V145, P2644; SALMON M, 1989, J IMMUNOL, V143, P907; SCHNEIDER LC, 1991, BLOOD, V78, P3076; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; THOMAN ML, 1989, ADV IMMUNOL, V46, P221, DOI 10.1016/S0065-2776(08)60655-0; UMETSU DT, 1988, J IMMUNOL, V140, P4211; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WALKER C, 1990, AGING IMMUNOL INFECT, P31; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	48	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				630	636		10.1016/0091-6749(92)90136-P	http://dx.doi.org/10.1016/0091-6749(92)90136-P			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1328343	Bronze			2022-12-18	WOS:A1992JT99500009
J	JACQUES, P; LAVOIE, A; BEDARD, PM; BRUNET, C; HEBERT, J				JACQUES, P; LAVOIE, A; BEDARD, PM; BRUNET, C; HEBERT, J			CHRONIC IDIOPATHIC URTICARIA - PROFILES OF SKIN MAST-CELL HISTAMINE-RELEASE DURING ACTIVE DISEASE AND REMISSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						URTICARIA; REMISSION; SKIN; CHRONIC; HISTAMINE; COMPOUND 48/80; MAST CELL	NONLESIONAL SKIN; MEDIATOR	Chronic idiopathic urticaria (CIU) is characterized by the increased releasability of histamine by mast cells in normal-appearing skin. In active CIU, this abnormality is consistently present, To determine if this finding subsides when the disease goes into remission phase, we analyzed the histamine secretion in patients with CIU in remission (CIUR) compared with that of patients with CIU and in normal control (NC) subjects, with the skin-chamber technique. The profiles of histamine release in sites challenged with compound 48/80 were significantly different in the groups with CIU and CIUR. Furthermore, patients with CIUR did not differ from NC subjects in terms of histamine releasability under compound 48/80 stimulation (p > 0.1). These data suggest that the state of excessive skin mast cell sensitivity is a reversible and transient phenomenon in CIU disease.	CHU LAVAL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,SUITE 9800,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University								ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BRUNET C, 1988, J ALLERGY CLIN IMMUN, V82, P398, DOI 10.1016/0091-6749(88)90011-5; BRUNET C, 1990, J ALLERGY CLIN IMMUN, V86, P787, DOI 10.1016/S0091-6749(05)80184-8; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KRAUSE LB, 1985, BRIT J CLIN PHARMACO, V20, P486, DOI 10.1111/j.1365-2125.1985.tb05103.x; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; QUARANTA JH, 1989, ANN ALLERGY, V62, P421; ROSENSTREICH DL, 1986, J ALLERGY CLIN IMMUN, V78, P1099, DOI 10.1016/0091-6749(86)90256-3	15	46	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1139	1143		10.1016/0091-6749(92)90297-F	http://dx.doi.org/10.1016/0091-6749(92)90297-F			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1376735				2022-12-18	WOS:A1992HZ74800008
J	REID, MJ; NISH, WA; WHISMAN, BA; GOETZ, DW; HYLANDER, RD; PARKER, WA; FREEMAN, TM				REID, MJ; NISH, WA; WHISMAN, BA; GOETZ, DW; HYLANDER, RD; PARKER, WA; FREEMAN, TM			HLA-DR4-ASSOCIATED NONRESPONSIVENESS TO MOUNTAIN-CEDAR ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MOUNTAIN-CEDAR POLLENOSIS; HLA-ASSOCIATED PROTECTION; HLA-DR4	MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN IMMUNE-RESPONSE; HLA-D REGION; CROSS-REACTIVITY; GENETIC-MARKER; T-CELL; POLLEN; IMMUNOTHERAPY; SEQUENCE; HLA-DW2	We did human lymphocyte antigen (HLA)-DR and DQ typing on 37 subjects with mountain-cedar (MC) pollinosis as defined by history and a positive skin test. Of these 37 subjects, 31 were subdivided into 18 subjects with a single positive skin test (SPST) and 13 subjects with multiple positive skin tests (MPSTs). We also typed 51 subjects without MC sensitivity or atopy as defined by history and negative skin tests to a battery of aeroallergens. We also typed 116 subjects in whom MC sensitivity had not been determined. Total IgE, MC-specific immunoglobulin E (sIgE), and MC-sIgE binding bands by immunoblot were also determined on the subjects with SPSTs and MPSTs. No significant differences were found between the subjects with SPSTs and MPSTs for HLA type, total IgE, MC sIgE, or bands bound by MC sIgE by immunoblot. There was a strong negative relationship between HLA-DR4 and subjects with MC pollinosis; chi-square, 14.857; p = 0.0096; and odds ratio, 0.139. These findings suggest that there is no difference in genetic immunoregulation between subjects with SPSTs and MPSTs but that the presence of the DR4 gene product is associated with a decreased risk of an IgE response to MC and protection from MC pollenosis.	WILFORD HALL USAF MED CTR,DIV MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force	REID, MJ (corresponding author), ALLERGY & IMMUNOL CLIN SAN FRANCISCO,220 MONTGOMERY ST,SUITE 577,SAN FRANCISCO,CA 94104, USA.							[Anonymous], 1984, HISTOCOMPATIBILITY T; BACH FH, 1985, IMMUNOL TODAY, V6, P89, DOI 10.1016/0167-5699(85)90023-4; FEIN BT, 1962, J ALLERGY, V33, P141; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; FRENCH SW, 1930, J ALLERGY, V1, P286; GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642; HARDY DA, 1986, NATURE, V323, P453, DOI 10.1038/323453a0; Kahn IS, 1924, J AMER MED ASSOC, V82, P871, DOI 10.1001/jama.1924.02650370039013; KOBORI JA, 1986, SCIENCE, V234, P173, DOI 10.1126/science.3018929; KORMAN AJ, 1985, IMMUNOL REV, V85, P45, DOI 10.1111/j.1600-065X.1985.tb01130.x; LOWRY RP, 1978, TRANSPL P, V10, P833; LYMPANY P, 1990, J ALLERGY CLIN IMMUN, V86, P160, DOI 10.1016/S0091-6749(05)80061-2; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; ROEBBERM, 1984, J IMMUNOL, V134, P3062; ROLLINI P, 1985, P NATL ACAD SCI USA, V82, P7197, DOI 10.1073/pnas.82.21.7197; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SASAZUKI T, 1984, IMMUNOGENETICS ITS A, P21; SCHWIETZ LA, 1989, J ALLERGY CLIN IMMUN, V83, P253; SCHWIETZ LA, 1987, J ALLERGY CLIN IMMUN, V79, P216; TIEBER VL, 1986, J BIOL CHEM, V261, P2738; TROWSDALE J, 1985, IMMUNOL REV, V85, P5, DOI 10.1111/j.1600-065X.1985.tb01129.x; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	28	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					593	598		10.1016/0091-6749(92)90327-X	http://dx.doi.org/10.1016/0091-6749(92)90327-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740588				2022-12-18	WOS:A1992HD75300012
J	MALO, JL; CARTIER, A; LARCHEVEQUE, J; GHEZZO, H; SOUCY, F; SOMERS, J; DOLOVICH, J				MALO, JL; CARTIER, A; LARCHEVEQUE, J; GHEZZO, H; SOUCY, F; SOMERS, J; DOLOVICH, J			PREVALENCE OF OCCUPATIONAL ASTHMA AND IMMUNOLOGICAL SENSITIZATION TO GUAR GUM AMONG EMPLOYEES AT A CARPET-MANUFACTURING PLANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CLOUTIER Y, 1989, EUR RESPIR J, V2, P769; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; KANERVA L, 1988, CLIN ALLERGY, V18, P245, DOI 10.1111/j.1365-2222.1988.tb02866.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LACHANCE P, 1988, J ALLERGY CLIN IMMUN, V81, P385, DOI 10.1016/0091-6749(88)90906-2; LAGIER F, 1990, J ALLERGY CLIN IMMUN, V85, P785, DOI 10.1016/0091-6749(90)90199-E; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; Montgomery R., 1959, CHEM PLANT GUMS MUCI; NEWMAN J M, 1984, Journal of Nutrition for the Elderly, V4, P3, DOI 10.1300/J052v04n02_02; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PRICE JA, 1989, J ALLERGY CLIN IMMUN, V84, P520, DOI 10.1016/0091-6749(89)90366-7; SLOVAK AJM, 1987, BRIT J IND MED, V44, P129	21	46	46	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				562	569		10.1016/S0091-6749(05)80213-1	http://dx.doi.org/10.1016/S0091-6749(05)80213-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229815				2022-12-18	WOS:A1990EG45400017
J	MELTZER, EO				MELTZER, EO			PERFORMANCE EFFECTS OF ANTIHISTAMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM					UNIV CALIF SAN DIEGO,DIV ALLERGY & IMMUNOL,SAN DIEGO,CA 92103; ALLERGY & ASTHMA MED GRP,SAN DIEGO,CA	University of California System; University of California San Diego								ASO T, 1989, ANN ALLERGY, V62, P250; ASO T, 1988, JPN J CLIN PHARM THE, V19, P681; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; FRIEDMAN HM, 1987, AM J RHINOL, V1, P95; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GENGO FM, 1987, ANN ALLERGY S, V59, P1; HESS A, 1985, 41ST ANN M AM AC ALL; HINDMARCH I, 1987, INT CLIN PSYCHOPHARM, V2, P117, DOI 10.1097/00004850-198704000-00004; KEMP JP, 1985, ANN ALLERGY, V54, P502; KING G, 1965, ELECTROEN CLIN NEURO, V18, P503, DOI 10.1016/0013-4694(65)90132-X; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; KULSHRESTHA VK, 1978, BRIT J CLIN PHARMACO, V6, P25, DOI 10.1111/j.1365-2125.1978.tb01677.x; LESSON GA, 1982, ARZNEIMITTEL-FORSCH, V32, P1173; MCNAIR DM, 1970, MANUAL PROFILE MOOD; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V14, P683, DOI 10.1111/j.1365-2125.1982.tb04957.x; NICHOLSON AN, 1985, AVIAT SPACE ENVIR MD, V56, P293; RICHARDSON GS, 1978, ELECTROEN CLIN NEURO, V45, P621, DOI 10.1016/0013-4694(78)90162-1; RIEDEL WJ, 1987, THESIS U LIMBURG NET; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; THACH BT, 1975, NEW ENGL J MED, V293, P486, DOI 10.1056/NEJM197509042931008; VOLLMER R, 1983, NEUROPSYCHOBIOLOGY, V10, P249, DOI 10.1159/000118019; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; YOUNG P, 1980, US DEP HLTH HUMAN SE, P14	27	46	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			613	619		10.1016/S0091-6749(05)80225-8	http://dx.doi.org/10.1016/S0091-6749(05)80225-8			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229823				2022-12-18	WOS:A1990EH09300006
J	GOLDENHERSH, MJ; RACHELEFSKY, GS; DUDLEY, J; BRILL, J; KATZ, RM; ROHR, AS; SPECTOR, SL; SIEGEL, SC; SUMMANEN, P; BARON, EJ; FINEGOLD, S				GOLDENHERSH, MJ; RACHELEFSKY, GS; DUDLEY, J; BRILL, J; KATZ, RM; ROHR, AS; SPECTOR, SL; SIEGEL, SC; SUMMANEN, P; BARON, EJ; FINEGOLD, S			THE MICROBIOLOGY OF CHRONIC SINUS DISEASE IN CHILDREN WITH RESPIRATORY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT HEAD & NECK SURG,LOS ANGELES,CA 90024; VET ADM WADSWORTH MED CTR,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; BJORKWALL T, 1950, ACTA OTOLAR, V83, P35; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; BROOK I, 1985, AM J DIS CHILD, V139, P280, DOI 10.1001/archpedi.1985.02140050074026; BROOK I, 1981, ANN OTO RHINOL LARYN, V90, P261, DOI 10.1177/000348948109000313; BROOK I, 1987, J CLIN MICROBIOL, V25, P2020, DOI 10.1128/JCM.25.10.2020-2022.1987; BROOK I, 1984, ARCH OTOLARYNGOL, V110, P803; BROOK I, 1988, IMMUNOL ALLERGY PRAC, P25; Chen J. -S., 1977, ANAEROBE LAB MANUAL, VFourth; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Finegold S.M., 1986, BAILEY SCOTTS DIAGNO, V7th; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; HOFFMANN S, 1983, ACTA PATH MICRO IM B, V91, P23; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1919, DOI 10.1128/JCM.26.10.1919-1925.1988; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1926, DOI 10.1128/JCM.26.10.1926-1933.1988; MENA E, 1978, J CLIN MICROBIOL, V8, P28; NYLEN O, 1972, Scandinavian Journal of Infectious Diseases, V4, P43; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1982, CURRENT PROBLEMS PED, V12; SLOTS J, 1982, J CLIN MICROBIOL, V15, P606, DOI 10.1128/JCM.15.4.606-609.1982; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; WALD ER, 1989, J PEDIATR-US, V115, P28, DOI 10.1016/S0022-3476(89)80324-5; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; 1987, M100S2 NAT COMM CLIN, V7; [No title captured]; 1984, M2A3 NAT COMM CLIN L, V4; [No title captured]	28	46	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1030	1039		10.1016/0091-6749(90)90047-8	http://dx.doi.org/10.1016/0091-6749(90)90047-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2355153	Bronze			2022-12-18	WOS:A1990DK50900008
J	LOZEWICZ, S; GOMEZ, E; CLAGUE, J; GATLAND, D; DAVIES, RJ				LOZEWICZ, S; GOMEZ, E; CLAGUE, J; GATLAND, D; DAVIES, RJ			ALLERGEN-INDUCED CHANGES IN THE NASAL MUCOUS-MEMBRANE IN SEASONAL ALLERGIC RHINITIS - EFFECT OF NEDOCROMIL SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP, ST BARTHOLOMEWS CTR CLIN RES, DEPT RESP MED, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London								BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CORRADO OJ, 1987, J ALLERGY CLIN IMMUN, V80, P218, DOI 10.1016/0091-6749(87)90132-1; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUNNILL MS, 1987, PULMONARY PATHOLOGY, P61; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; EADY RP, 1986, EUR J RESPIR DIS, V69, P112; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1987, ALLERGIC VASOMOTOR R, P121; FREI W, 1987, REV ESP ALLERGOL IMM, V2, P322; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GOMEZ E, 1987, INT ARCH ALLER A IMM, V83, P52, DOI 10.1159/000234330; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; IHLE JN, 1983, J IMMUNOL, V131, P282; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LOZEWICZ S, 1989, IN PRESS ASTHMA RHIN; LOZEWICZ S, 1989, CLIN SCI         S20, V76, pP22; MACKAY JA, 1985, THORAX, V40, P719; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V77, P247; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V81, P172, DOI 10.1016/0091-6749(88)90251-5; PLATZER E, 1986, IMMUNOL TODAY, V7, P185, DOI 10.1016/0167-5699(86)90093-9; RUHNO J, 1988, J ALLERGY CLIN IMMUN, V81, P557, DOI 10.1016/0091-6749(88)90196-0; SANDERSON IR, 1985, J CLIN PATHOL, V38, P771, DOI 10.1136/jcp.38.7.771; SCHWARTZ HJ, 1987, J ALLERGY CLIN IMMUN, V79, P186; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SIPILA P, 1987, CLIN OTOLARYNGOL, V12, P365, DOI 10.1111/j.1365-2273.1987.tb00218.x; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; WONG E, 1982, ACTA DERM-VENEREOL, V62, P431	34	46	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				125	131		10.1016/0091-6749(90)90233-T	http://dx.doi.org/10.1016/0091-6749(90)90233-T			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2153719	Bronze			2022-12-18	WOS:A1990CM37800021
J	COYLE, AJ; PAGE, CP; ATKINSON, L; SJOERDSMA, K; TOUVAY, C; METZGER, WJ				COYLE, AJ; PAGE, CP; ATKINSON, L; SJOERDSMA, K; TOUVAY, C; METZGER, WJ			MODIFICATION OF ALLERGEN-INDUCED AIRWAY-OBSTRUCTION AND AIRWAY HYPERRESPONSIVENESS IN AN ALLERGIC RABBIT MODEL BY THE SELECTIVE PLATELET-ACTIVATING FACTOR ANTAGONIST, BN-52021	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									E CAROLINA UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,GREENVILLE,NC 27858; IHB LABS,LES ULIS,FRANCE; UNIV LONDON KINGS COLL,DEPT PHARMACOL,LONDON WC2R 2LS,ENGLAND	University of North Carolina; East Carolina University; University of London; King's College London					NHLBI NIH HHS [5R01 HL37741-3] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM WM, 1989, J APPL PHYSIOL, V66, P2351, DOI 10.1152/jappl.1989.66.5.2351; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BARNES PJ, 1987, BRIT J PHARMACOL, V90, P709, DOI 10.1111/j.1476-5381.1987.tb11224.x; BRAQUET P, 1987, Drugs of the Future, V12, P643; BRAQUET P, 1985, LANCET, V1, P1501; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CHRISTMAN BW, 1987, AM REV RESPIR DIS, V135, P1267; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1987, LANCET, V1, P248; COYLE AJ, 1988, EUR J PHARMACOL, V148, P51, DOI 10.1016/0014-2999(88)90453-0; CUSS FM, 1986, LANCET, V2, P189; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; EVANS TJ, 1987, J APPL PHYSIOL, V63, P469; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GILES RE, 1971, ARCH INT PHARMACOD T, V194, P213; HALONEN M, 1980, AM REV RESPIR DIS, V122, P915; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HELLEWELL PG, 1989, BRIT J PHARMACOL, V97, P171, DOI 10.1111/j.1476-5381.1989.tb11939.x; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HOUSFORD D, 1988, PHYTO THER RES, V2, P1; HUTSON PA, 1987, BRIT J PHARMACOL, V95, P770; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MAZZONI L, 1985, J PHYSIOL-LONDON, V365, pP107; MCMANUS LM, 1987, NEW HORIZONS PLATELE; METZER WJ, 1985, CHEST, V88, P369, DOI 10.1378/chest.88.3.369; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P431; METZGER WJ, 1982, AM REV RESPIR DIS, V125, pA62; METZGER WJ, IN PRESS LATE ASTHMA; MICHEL L, 1988, LANCET, V2, P404; NAKAMURA T, 1987, INT ARCH ALLER A IMM, V82, P57, DOI 10.1159/000234290; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PAGE CP, 1985, AGENTS ACTIONS, V16, P30, DOI 10.1007/BF01999636; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PINCKARD RN, 1972, J ALLERGY CLIN IMMUN, V49, P301; RICHERSON HB, 1986, ASTHMA CLIN PHARM TH, P23; ROBERTS NM, 1988, J ALLERGY CLIN IMMUN, V82, P236, DOI 10.1016/0091-6749(88)91005-6; ROBERTSON DN, 1987, BRIT J PHARMACOL, V92, P105, DOI 10.1111/j.1476-5381.1987.tb11301.x; ROBERTSON DN, 1988, AM REV RESPIR DIS, V137, P1317, DOI 10.1164/ajrccm/137.6.1317; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; SMITH HR, 1988, AM REV RESPIR DIS, V137, pA283; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	49	46	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				960	967		10.1016/0091-6749(89)90395-3	http://dx.doi.org/10.1016/0091-6749(89)90395-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600327	Bronze			2022-12-18	WOS:A1989CG29300016
J	NACLERIO, RM				NACLERIO, RM			THE PATHO-PHYSIOLOGY OF ALLERGIC RHINITIS - IMPACT OF THERAPEUTIC INTERVENTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NACLERIO, RM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DIV PEDIAT OTOLARYNGOL, BALTIMORE, MD 21205 USA.							BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; LAVKER RM, 1985, J IMMUNOL, V135, P2368; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127	8	46	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			927	934						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	3057045				2022-12-18	WOS:A1988R235300006
J	KIVITY, S; SNEH, E; GREIF, J; TOPILSKY, M; MEKORI, YA				KIVITY, S; SNEH, E; GREIF, J; TOPILSKY, M; MEKORI, YA			THE EFFECT OF FOOD AND EXERCISE ON THE SKIN-RESPONSE TO COMPOUND 48-80 IN PATIENTS WITH FOOD-ASSOCIATED EXERCISE-INDUCED URTICARIA-ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ICHILOV MED CTR, INST PULM & ALLERG DIS, TEL AVIV, ISRAEL; MEIR HOSP, ALLERGY IMMUNOL UNIT, KFAR SABA, ISRAEL; SACKLER SCH MED, TEL AVIV, ISRAEL	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine								BENYON RC, 1987, J IMMUNOL, V138, P861; DAVIS KC, 1986, J ALLERGY CLIN IMMUN, V77, P566, DOI 10.1016/0091-6749(86)90346-5; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ERRINGTON GW, 1985, J ALLERGY CLIN IMMUN, V75, P193, DOI 10.1016/0091-6749(85)90490-7; GENTON C, 1985, J ALLERGY CLIN IMMUN, V76, P40, DOI 10.1016/0091-6749(85)90802-4; GRANT A, 1982, J ALLERGY CLIN IMMUN, V69, P103; HORNER FA, 1968, ANN ALLERGY, V26, P107; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KIDD J, 1982, Journal of Allergy and Clinical Immunology, V69, P103; LONGLEY S, 1982, Journal of Allergy and Clinical Immunology, V69, P103; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; SHATIN H, 1962, ARCH DERMATOL, V85, P794; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SMITH JA, 1983, ANN ALLERGY, V51, P30; SOLOMON LM, 1966, ARCH DERMATOL, V94, P156, DOI 10.1001/archderm.94.2.156; SOUHRADA JT, 1983, EXERCISE TESTING PRO, V2, P75; SUSSMAN GL, 1982, ANN ALLERGY, V48, P75	19	46	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1155	1158		10.1016/0091-6749(88)90884-6	http://dx.doi.org/10.1016/0091-6749(88)90884-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379228				2022-12-18	WOS:A1988P002300014
J	MEURS, H; KAUFFMAN, HF; KOETER, GH; TIMMERMANS, A; DEVRIES, K				MEURS, H; KAUFFMAN, HF; KOETER, GH; TIMMERMANS, A; DEVRIES, K			REGULATION OF THE BETA-RECEPTOR-ADENYLATE CYCLASE SYSTEM IN LYMPHOCYTES OF ALLERGIC PATIENTS WITH ASTHMA - POSSIBLE ROLE FOR PROTEIN-KINASE-C IN ALLERGEN-INDUCED NONSPECIFIC REFRACTORINESS OF ADENYLATE-CYCLASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	MEURS, H (corresponding author), STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BOOYNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BRUYNZEEL PLB, 1979, ANN ALLERGY, V43, P105; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CUNDELL DR, 1985, J ALLERGY CLIN IMMUN, V75, P109, DOI 10.1016/0091-6749(85)90153-8; DAVIS C, 1980, BRIT J CLIN PHARMACO, V10, P425, DOI 10.1111/j.1365-2125.1980.tb01783.x; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DIAZ R, 1985, ANN ALLERGY, V55, P258; DYER EL, 1986, J ALLERGY CLIN IMMUN, V78, P44, DOI 10.1016/0091-6749(86)90113-2; FARFEL Z, 1984, CLIN RES, V32, pA428; FELDMAN RD, 1983, J CLIN INVEST, V72, P164, DOI 10.1172/JCI110954; FRASER J, 1981, J CLIN INVEST, V67, P1777, DOI 10.1172/JCI110217; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GALANT SP, 1984, J LAB CLIN MED, V103, P322; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GOFFSTEIN BJ, 1980, J LAB CLIN MED, V96, P1002; HAMBERGER B, 1980, LIFE SCI, V26, P1465, DOI 10.1016/0024-3205(80)90267-2; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KENT RS, 1980, MOL PHARMACOL, V17, P14; Koeter G H, 1983, Agents Actions Suppl, V13, P259; KOETER GH, 1982, EUR J RESPIR DIS, V63, P72; KRALL JF, 1980, J PHARMACOL EXP THER, V214, P554; KRALL JF, 1982, BIOCHEM PHARMACOL, V31, P117, DOI 10.1016/0006-2952(82)90248-9; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINO S, 1985, ANN ALLERGY, V55, P339; MEURS H, 1980, CLIN CHIM ACTA, V106, P91, DOI 10.1016/0009-8981(80)90378-2; MEURS H, 1986, BIOCHEM PHARMACOL, V35, P4217, DOI 10.1016/0006-2952(86)90698-2; MEURS H, 1985, INT ARCH ALLER A IMM, V76, P256, DOI 10.1159/000233701; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MEURS H, 1982, EUR J PHARMACOL, V85, P185, DOI 10.1016/0014-2999(82)90464-2; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; MUKHOPADHYAY AK, 1985, FEBS LETT, V187, P56, DOI 10.1016/0014-5793(85)81213-8; NISHIZUKA Y, 1984, RECENT PROG HORM RES, V40, P301; NOVOGRODSKY A, 1982, BIOCHEM BIOPH RES CO, V104, P389, DOI 10.1016/0006-291X(82)90649-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PATERSON JW, PERSPECTIVES ASTHMA, V1; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Rodbell M, 1975, Adv Cyclic Nucleotide Res, V5, P3; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHER R, 1983, CLIN EXP IMMUNOL, V51, P525; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SU YF, 1980, J BIOL CHEM, V255, P7410; Szentivanyi A, 1979, Triangle, V18, P109; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TITINCHI S, 1984, CLIN SCI, V66, P323, DOI 10.1042/cs0660323; TUCK ML, 1980, J CLIN ENDOCR METAB, V51, P1; VANDENBERG W, 1982, J ALLERGY CLIN IMMUN, V69, P410, DOI 10.1016/0091-6749(82)90115-4; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254	64	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				326	339		10.1016/0091-6749(87)90039-X	http://dx.doi.org/10.1016/0091-6749(87)90039-X			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3040837				2022-12-18	WOS:A1987K103600015
J	SPECTOR, SL; PERHACH, JL; ROHR, AS; RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC				SPECTOR, SL; PERHACH, JL; ROHR, AS; RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC			PHARMACODYNAMIC EVALUATION OF AZELASTINE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; WALLACE LABS,CRANBURY,NJ 08512	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAND N, 1985, ANN ALLERGY, V55, P393; CONNELL JT, 1985, ANN ALLERGY 2, V52, P392; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; KEMP JP, 1986, J ALLERGY CLIN IMMUN, V77, P249; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; PERHACH J, 1984, Journal of Allergy and Clinical Immunology, V73, P144; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; WEILER JM, 1986, J ALLERGY CLIN IMMUN, V77, P180	9	46	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					75	80		10.1016/S0091-6749(87)80194-X	http://dx.doi.org/10.1016/S0091-6749(87)80194-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3298379				2022-12-18	WOS:A1987J219400012
J	MALO, JL; CARTIER, A; PINEAU, L; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR				MALO, JL; CARTIER, A; PINEAU, L; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR			LACK OF ACUTE EFFECTS OF ASCORBIC-ACID ON SPIROMETRY AND AIRWAY RESPONSIVENESS TO HISTAMINE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							ANAH CO, 1980, TROP GEOGR MED, V32, P132; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DAWSON W, 1965, J PHARM PHARMACOL, V17, P595, DOI 10.1111/j.2042-7158.1965.tb07729.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Hunt HB, 1938, BMJ-BRIT MED J, V1938, P726; KERSHNER RP, 1981, J AM STAT ASSOC, V76, P612, DOI 10.2307/2287519; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KORDANSKY DW, 1979, J ALLERGY CLIN IMMUN, V63, P61, DOI 10.1016/0091-6749(79)90163-5; KRATZING CC, 1980, CHEM-BIOL INTERACT, V30, P53, DOI 10.1016/0009-2797(80)90113-1; KREISMAN H, 1977, LUNG, V154, P223; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; LEUNG HW, 1981, RES COMMUN CHEM PATH, V31, P111; MCCARTHY DS, 1975, AM REV RESPIR DIS, V112, P407; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MIHOUD MC, 1982, B EUR PHYSIOPATHOL R, V18, P609; MOHSENIN V, 1983, AM REV RESPIR DIS, V127, P143; OGILVY CS, 1981, J ALLERGY CLIN IMMUN, V67, P363, DOI 10.1016/0091-6749(81)90081-6; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SPANNHAKE EW, 1983, AM REV RESPIR DIS, V127, P139; ZUSKIN E, 1973, J ALLERGY CLIN IMMUN, V51, P218, DOI 10.1016/0091-6749(73)90141-3	27	46	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1153	1158		10.1016/0091-6749(86)90265-4	http://dx.doi.org/10.1016/0091-6749(86)90265-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782678				2022-12-18	WOS:A1986F302600011
J	BOCK, SA				BOCK, SA			A CRITICAL-EVALUATION OF CLINICAL-TRIALS IN ADVERSE REACTIONS TO FOODS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,NATL ASTHMA CTR,DENVER,CO 80206; UNIV COLORADO,SCH MED,DENVER,CO 80202	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; AMENT ME, 1972, GASTROENTEROLOGY, V62, P227; ANDERSON JA, 1974, J PEDIATR-US, V84, P59, DOI 10.1016/S0022-3476(74)80554-8; BEHAR D, 1984, Nutrition and Behavior, V1, P277; BOAT TF, 1975, J PEDIATR-US, V87, P23, DOI 10.1016/S0022-3476(75)80062-X; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1983, J ALLERGY CLIN IMMUN, V72, P262, DOI 10.1016/0091-6749(83)90030-1; BOCK SA, 1983, ALLERGY PRINCIPLES P, P1415; DANNAEUS A, 1977, CLIN ALLERGY, V7, P109, DOI 10.1111/j.1365-2222.1977.tb01431.x; DAVIDSON GP, 1976, MED J AUST, V19, P945; EGGER J, 1983, LANCET, V2, P865; FALCHUK ZM, 1978, SCAND J GASTROENTERO, V13, P839, DOI 10.3109/00365527809182200; FALCHUK ZM, 1974, GUT, V15, P947, DOI 10.1136/gut.15.12.947; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; FORD RPK, 1980, ARCH DIS CHILD, V55, P608, DOI 10.1136/adc.55.8.608; FREIER S, 1969, J PEDIATR-US, V75, P623, DOI 10.1016/S0022-3476(69)80458-0; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HARLEY JP, 1978, PEDIATRICS, V62, P975; HARLEY JP, 1978, PEDIATRICS, V61, P818; HARRIS MJ, 1977, AUST PAEDIATR J, V13, P276; HEINER DC, 1962, AM J DIS CHILD, V103, P40; HILL DJ, 1984, CLIN REV ALLERG, V2, P125; HILL DJ, 1979, ACTA PAEDIATR SCAND, V68, P847; HOLLAND NH, 1962, J PEDIATR, V61, P81; IYNGKARAN N, 1978, ARCH DIS CHILD, V53, P150, DOI 10.1136/adc.53.2.150; IYNGKARAN N, 1978, ARCH DIS CHILD, V53, P20, DOI 10.1136/adc.53.1.20; JAKOBSSON I, 1983, PEDIATRICS, V71, P268; JOS J, 1979, SCAND J IMMUNOL, V9, P441, DOI 10.1111/j.1365-3083.1979.tb03066.x; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; KATZ AJ, 1977, GASTROENTEROLOGY, V73, P705; KATZ AJ, 1984, J ALLERGY CLIN IMMUN, V74, P72, DOI 10.1016/0091-6749(84)90090-3; KOCOSHIS S, 1979, JAMA-J AM MED ASSOC, V242, P1169; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; LESSOF MH, 1980, Q J MED, V195, P259; LOTHE L, 1982, PEDIATRICS, V70, P7; LOVELESS MH, 1950, J ALLERGY, V21, P489, DOI 10.1016/0021-8707(50)90097-9; LUNDSTROM U, 1983, ARCH DIS CHILD, V58, P438, DOI 10.1136/adc.58.6.438; MANSFIELD LE, 1985, ANN ALLERGY, V55, P126; Maslansky L, 1971, Conn Med, V35, P5; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MINFORD AMB, 1982, ARCH DIS CHILD, V57, P742, DOI 10.1136/adc.57.10.742; PERKKIO M, 1981, EUR J PEDIATR, V137, P63, DOI 10.1007/BF00441172; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAVILAHTI E, 1973, GUT, V14, P491, DOI 10.1136/gut.14.6.491; SELBEKK BH, 1979, ALLERGY, V34, P283; STINTZING G, 1979, ACTA PAEDIATR SCAND, V68, P383, DOI 10.1111/j.1651-2227.1979.tb05024.x; STROBER W, 1975, ANN INTERN MED, V83, P242, DOI 10.7326/0003-4819-83-2-242; STRUNK RC, 1978, CLIN ALLERGY, V8, P51, DOI 10.1111/j.1365-2222.1978.tb00447.x; VANMETRE TE, 1968, J ALLERGY, V41, P195, DOI 10.1016/0021-8707(68)90042-7; VAZ GA, 1978, LANCET, V1, P1066; VITORIA JC, 1982, ARCH DIS CHILD, V57, P44; WILSON JF, 1974, J PEDIATR-US, V84, P335, DOI 10.1016/S0022-3476(74)80713-4; WILSON JF, 1962, J PEDIATR-US, V60, P787, DOI 10.1016/S0022-3476(62)80105-X; WOODRUFF CW, 1972, AM J DIS CHILD, V124, P18, DOI 10.1001/archpedi.1972.02110130020003; WOODRUFF CW, 1972, AM J DIS CHILD, V124, P26, DOI 10.1001/archpedi.1972.02110130028004	57	46	46	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			165	174		10.1016/0091-6749(86)90009-6	http://dx.doi.org/10.1016/0091-6749(86)90009-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722644				2022-12-18	WOS:A1986D299700009
J	GOLDEN, DBK; JOHNSON, K; ADDISON, BI; VALENTINE, MD; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				GOLDEN, DBK; JOHNSON, K; ADDISON, BI; VALENTINE, MD; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			CLINICAL AND IMMUNOLOGICAL OBSERVATIONS IN PATIENTS WHO STOP VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				PHS HHS [A108270] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLAAUW PJ, 1983, FOLIA ALLERGOL IMMUN, V30, P141; DVORIN D, 1984, Journal of Allergy and Clinical Immunology, V73, P188; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GOLDEN DBK, 1982, CECIL TXB MED, P1805; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; GRAFT DF, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90331-7; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P791; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; SCHUBERTH KC, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90332-9; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x	18	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					435	442		10.1016/0091-6749(86)90177-6	http://dx.doi.org/10.1016/0091-6749(86)90177-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3950251				2022-12-18	WOS:A1986A536700006
J	MARONE, G; POTO, S; DIMARTINO, L; CONDORELLI, M				MARONE, G; POTO, S; DIMARTINO, L; CONDORELLI, M			HUMAN BASOPHIL RELEASABILITY .1. AGE-RELATED-CHANGES IN BASOPHIL RELEASABILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV NAPLES 2,SCH MED,DEPT PEDIAT,I-80131 NAPOLI,ITALY	Universita della Campania Vanvitelli	MARONE, G (corresponding author), UNIV NAPLES 2,SCH MED,FAC MED,CLIN MED 1,DEPT MED,VIA S PANSINI,I-80131 NAPOLI,ITALY.							AUSTEN KF, 1965, P SOC EXP BIOL MED, V120, P542; CONROY MC, 1982, FED PROC, V41, P376; CONROY MC, 1977, J IMMUNOL, V118, P1317; CONROY MC, 1979, ALLERGY, V14, P307; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLEISCH JH, 1978, BIOCHEM PHARMACOL, V27, P2119, DOI 10.1016/0006-2952(78)90283-6; GREENBERG LJ, 1978, FED PROC, V37, P1258; KAY MMB, 1978, FED PROC, V37, P1241; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; Lichtenstein LM., 1979, MAST CELL ITS ROLE H, P83; MAKINODAN T, 1975, FED PROC, V34, P153; MARONE G, 1980, J IMMUNOL, V125, P2277; MARONE G, 1981, J PHARMACOL EXP THER, V217, P292; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; MARONE G, 1978, J IMMUNOL, V121, P2153; MARONE G, 1984, J IMMUNOL, V133, P1542; MARONE G, 1983, ADV CLIN IMMUNOLOGY, P139; MARONE G, 1983, 12TH P C EUR AC ALL, P293; MARONE G, 1981, CLIN IMMUNOL IMMUNOP, V20, P1292; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MENDOZA GR, 1982, PEDIATRICS, V69, P188; ORIDA N, 1982, FED PROC, V41, P822; PLAUT M, 1973, J IMMUNOL, V111, P389; PLAUT M, 1983, J IMMUNOL, V131, P2945; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; ROCKLIN RE, 1981, J CLIN IMMUNOL, V1, P73, DOI 10.1007/BF00915479; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P167; SCHEFLER WC, 1984, STATISTICS HLTH PROF, P249; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TUNG R, 1982, J IMMUNOL, V128, P2067; WANG SR, 1978, CELL IMMUNOL, V36, P28, DOI 10.1016/0008-8749(78)90247-2	34	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					377	383		10.1016/S0091-6749(86)80121-X	http://dx.doi.org/10.1016/S0091-6749(86)80121-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	2418093	Bronze			2022-12-18	WOS:A1986A089900019
J	SIEGEL, SC				SIEGEL, SC			OVERVIEW OF CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BHAGAT RG, 1984, PEDIATRICS, V73, P626; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; CHRISTY NP, 1984, HOSP PRACTICE, V17, P77; COLLINS JV, 1975, Q J MED, V44, P259; DWYER J, 1967, AUSTRALAS ANN MED, V16, P297; ELLULMICALLEF R, 1980, BRIT J CLIN PHARMACO, V9, P479, DOI 10.1111/j.1365-2125.1980.tb05843.x; FALLIERS CJ, 1965, ARCH DIS CHILD, V40, P593, DOI 10.1136/adc.40.214.593; FANTA CH, 1983, AM J MED, V74, P485; FINKEL KC, 1975, PEDIATRICS, V28, P436; FREY FJ, 1983, J LAB CLIN MED, V101, P593; GAMBERTOGLIO JG, 1980, J PHARMACOKINET BIOP, V8, P1, DOI 10.1007/BF01059447; HARFI H, 1978, PEDIATRICS, V61, P829; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; HOLGATE ST, 1977, LANCET, V2, P375; JUSKO WJ, 1980, THER DRUG MONIT, V2, P169, DOI 10.1097/00007691-198004000-00011; KATTAN M, 1980, J PEDIATR-US, V96, P596, DOI 10.1016/S0022-3476(80)80872-9; KERSHNAR H, 1978, PEDIATRICS, V62, P189; LANGE K, 1953, P SOC EXP BIOL MED, V82, P315; LUKSZA AR, 1982, BRIT J DIS CHEST, V76, P15, DOI 10.1016/0007-0971(82)90003-1; MCFADDEN ER, 1976, AM J MED, V60, P52, DOI 10.1016/0002-9343(76)90533-7; PIERSON WE, 1974, PEDIATRICS, V54, P282; PLUMPTON FS, 1969, ANAESTHESIA, V24, P3, DOI 10.1111/j.1365-2044.1969.tb02798.x; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; ROSE JQ, 1980, J ALLERGY CLIN IMMUN, V66, P366, DOI 10.1016/0091-6749(80)90115-3; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; SCHATZ M, 1975, JAMA-J AM MED ASSOC, V233, P804, DOI 10.1001/jama.233.7.804; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SIEGEL SC, 1959, PEDIATRICS, V24, P434; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; TANAKA RM, 1982, CHEST, V82, P438, DOI 10.1378/chest.82.4.438; TANNER AR, 1979, BRIT J CLIN PHARMACO, V7, P397, DOI 10.1111/j.1365-2125.1979.tb00952.x; TEMBO AV, 1976, J CLIN PHARMACOL, V16, P620, DOI 10.1002/j.1552-4604.1976.tb01500.x; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P321; URIBE M, 1976, GASTROENTEROLOGY, V71, P362; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; WEBB J, 1981, THORAX, V36, P18, DOI 10.1136/thx.36.1.18; WEINBERGER M, 1982, EUR J RESPIR DIS, V63, P243	40	46	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					312	320		10.1016/0091-6749(85)90647-5	http://dx.doi.org/10.1016/0091-6749(85)90647-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019959				2022-12-18	WOS:A1985APE8900011
J	TOGIAS, AG; BURNETT, JW; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				TOGIAS, AG; BURNETT, JW; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			ANAPHYLAXIS AFTER CONTACT WITH A JELLYFISH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239; UNIV MARYLAND,SCH MED,DIV DERMATOL,BALTIMORE,MD 21201	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NIADDK NIH HHS [AM-19766] Funding Source: Medline; NIAID NIH HHS [AI-07290, AI-08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURNETT JW, 1971, P SOC EXP BIOL MED, V138, P759, DOI 10.3181/00379727-138-35983; BURNETT JW, 1977, TOXICON, V15, P177, DOI 10.1016/0041-0101(77)90044-7; Endean R., 1981, P46; FLOWERS AL, 1981, BIOCHEM BIOPH RES CO, V103, P1083, DOI 10.1016/0006-291X(81)90919-0; GILLESPIE E, 1972, P SOC EXP BIOL MED, V140, P1228; HALSTEAD BW, 1965, POISONOUS VENOMOUS M, V1, P297; HARTMAN KR, 1980, INT ARCH ALLER A IMM, V61, P389, DOI 10.1159/000232466; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MJORNDAL TO, 1983, J ALLERGY CLIN IMMUN, V71, P62, DOI 10.1016/0091-6749(83)90548-1; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; PRUZANSKY J, 1983, J ALLERGY CLIN IMMUN, V71, P93, DOI 10.1016/0091-6749(83)90142-2; RUSSO AJ, 1983, TOXICON, V21, P475, DOI 10.1016/0041-0101(83)90125-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; UVNAS B, 1960, ANN NY ACAD SCI, V90, P751, DOI 10.1111/j.1749-6632.1960.tb26419.x	15	46	50	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					672	675		10.1016/0091-6749(85)90092-2	http://dx.doi.org/10.1016/0091-6749(85)90092-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	2409122				2022-12-18	WOS:A1985ALA8400007
J	GRAMMER, LC; SHAUGHNESSY, MA; SUSZKO, IM; SHAUGHNESSY, JJ; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; SUSZKO, IM; SHAUGHNESSY, JJ; PATTERSON, R			PERSISTENCE OF EFFICACY AFTER A BRIEF COURSE OF POLYMERIZED RAGWEED ALLERGEN - A CONTROLLED-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOPE COLL,HOLLAND,MI 49423	Hope College	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P160, DOI 10.1016/0091-6749(83)90524-9; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1981, J ALLERGY CLIN IMMUN, V67, P124, DOI 10.1016/0091-6749(81)90007-5; LEVY DA, 1980, REGULATORY CONTROL S, P179; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; WISE PJ, 1979, J ALLERGY CLIN IMMUN, V63, P216; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V62, P83, DOI 10.1016/0091-6749(78)90083-0	15	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					484	489		10.1016/0091-6749(84)90359-2	http://dx.doi.org/10.1016/0091-6749(84)90359-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6707391				2022-12-18	WOS:A1984SM08900010
J	TALBOT, SF; ATKINS, PC; VALENZANO, M; ZWEIMAN, B				TALBOT, SF; ATKINS, PC; VALENZANO, M; ZWEIMAN, B			CORRELATIONS OF INVIVO MEDIATOR RELEASE WITH LATE CUTANEOUS ALLERGIC RESPONSES IN HUMANS .1. KINETICS OF HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania					NIAID NIH HHS [R01 AI14332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BASRAN, 1982, AM REV RESPIR DI 2 S, V125, P52; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DORSCH W, 1983, J ALLERGY CLIN IMMUN, V72, P168, DOI 10.1016/0091-6749(83)90525-0; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X	19	46	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					819	826		10.1016/0091-6749(84)90185-4	http://dx.doi.org/10.1016/0091-6749(84)90185-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6209324				2022-12-18	WOS:A1984TW41800010
J	VANDERHOEK, JY; EKBORG, SL; BAILEY, JM				VANDERHOEK, JY; EKBORG, SL; BAILEY, JM			NONSTEROIDAL ANTI-INFLAMMATORY DRUGS STIMULATE 15-LIPOXYGENASE LEUKOTRIENE PATHWAY IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VANDERHOEK, JY (corresponding author), GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT BIOCHEM,WASHINGTON,DC 20037, USA.			Vanderhoek, Jack/0000-0002-2051-2236				BORGEAT P, 1982, LIPIDS, V17, P676, DOI 10.1007/BF02534650; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; FERRANTE A, 1978, J IMMUNOL METHODS, V24, P389, DOI 10.1016/0022-1759(78)90143-6; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; KUHN H, 1983, FEBS LETT, V153, P353, DOI 10.1016/0014-5793(83)80641-3; MAAS RL, 1981, P NATL ACAD SCI-BIOL, V78, P5523, DOI 10.1073/pnas.78.9.5523; MILLS RFN, 1973, XENOBIOTICA, V3, P589, DOI 10.3109/00498257309151547; MYERS RF, 1983, BIOCHEM BIOPH RES CO, V112, P586, DOI 10.1016/0006-291X(83)91504-8; PORTER NA, 1979, J ORG CHEM, V44, P3177, DOI 10.1021/jo01332a017; RANDALL RW, 1980, AGENTS ACTIONS, V10, P553, DOI 10.1007/BF02024164; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SIEGEL MI, 1980, BIOCHEM BIOPH RES CO, V92, P688, DOI 10.1016/0006-291X(80)90388-5; VANDERHOEK JY, 1980, J BIOL CHEM, V255; VANDERHOEK JY, 1982, J BIOL CHEM, V257; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6	17	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					412	417		10.1016/0091-6749(84)90140-4	http://dx.doi.org/10.1016/0091-6749(84)90140-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432882	Bronze			2022-12-18	WOS:A1984TQ63300020
J	KALINER, MA				KALINER, MA			IS A MAST-CELL A MAST-CELL A MAST-CELL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KALINER, MA (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205, USA.							BEFUS AD, 1979, MAST CELL ITS ROLE H, P702; BENDITT EP, 1964, PROG ALLERGY, V8, P195, DOI 10.1159/000320507; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; COMBS JW, 1965, J CELL BIOL, V25, P577, DOI 10.1083/jcb.25.3.577; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1974, CELL TISSUE RES, V150, P95; FAWCETT DW, 1955, ANAT REC, V121, P29, DOI 10.1002/ar.1091210104; GINSBURG H, 1967, J CELL BIOL, V35, P685, DOI 10.1083/jcb.35.3.685; GINSBURG H, 1962, J NATL CANCER I, V31, P1; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; HEATLEY RV, 1979, MAST CELL ITS ROLE H, P716; ISHIZAKA T, J ALLERGY CLIN IMMUN; KALINER M, 1977, J CLIN INVEST, V60, P951, DOI 10.1172/JCI108850; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KALINER M, 1976, BRONCHIAL ASTHMA MEC, P163; KALINER M, AIRWAY REACTIVITY; KENNERLY DA, 1979, J IMMUNOL, V123, P1519; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; LAZARUS SC, 1979, J APPL PHYSIOL, V46, P919, DOI 10.1152/jappl.1979.46.5.919; LOVE LD, 1979, HISTOCHEMISTRY, V62, P221, DOI 10.1007/BF00493322; MARTIN GL, J ALLERGY CLIN IMMUN; MAYRHOFER G, 1976, EUR J IMMUNOL, V6, P537, DOI 10.1002/eji.1830060803; MICHELS NICHOLAS A., 1963, ANN NEW YORK ACAD SCI, V103, P232; MILLER HRP, 1971, IMMUNOLOGY, V20, P277; ORR T S C, 1977, Acta Allergologica Supplementum, V32, P9; PRETLOW TG, 1970, AM J PATHOL, V61, P323; SCHUMACHER NJ, 1980, J ALLERGY CLIN IMMUN, V66, P33; SHELDON JM, 1951, ANN ALLERGY, V41, P45; TUFT L, 1936, J ALLERGY, V7, P278; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77; [No title captured]	33	46	45	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					1	4		10.1016/0091-6749(80)90131-1	http://dx.doi.org/10.1016/0091-6749(80)90131-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6247378				2022-12-18	WOS:A1980JZ54100001
J	PARRILLO, JE; LAWLEY, TJ; FRANK, MM; KAPLAN, AP; FAUCI, AS				PARRILLO, JE; LAWLEY, TJ; FRANK, MM; KAPLAN, AP; FAUCI, AS			IMMUNOLOGICAL REACTIVITY IN THE HYPEREOSINOPHILIC SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, CLIN INVEST LAB, CLIN PHYSIOL SECT, BETHESDA, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAEHNER RL, 1971, BRIT J HAEMATOL, V20, P277, DOI 10.1111/j.1365-2141.1971.tb07038.x; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BASTEN A, 1970, J EXP MED, V131, P1271, DOI 10.1084/jem.131.6.1271; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BENVENISTI DS, 1969, ANN INTERN MED, V71, P731, DOI 10.7326/0003-4819-71-4-731; BIANCO C, 1970, J EXP MED, V132, P702, DOI 10.1084/jem.132.4.702; BOYER MH, 1970, BLOOD-J HEMATOL, V36, P458, DOI 10.1182/blood.V36.4.458.458; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRINK AJ, 1963, AM J MED, V34, P52, DOI 10.1016/0002-9343(63)90038-X; BUTTERWORTH AE, 1977, J EXP MED, V145, P136, DOI 10.1084/jem.145.1.136; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; CLINE MJ, 1968, BLOOD, V32, P922, DOI 10.1182/blood.V32.6.922.922; COHEN S, 1971, J EXP MED, V133, P133, DOI 10.1084/jem.133.1.133; COLLEY DG, 1973, J IMMUNOL, V110, P1419; DAVIES JNP, 1960, AM HEART J, V59, P600, DOI 10.1016/0002-8703(60)90464-6; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FAUCI AS, 1975, J CLIN INVEST, V56, P98, DOI 10.1172/JCI108085; GAITHER TA, 1974, J IMMUNOL, V113, P574; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; IVE FA, 1967, Q J MED, V36, P495; JOHNY KV, 1965, AM HEART J, V69, P591, DOI 10.1016/0002-8703(65)90239-5; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; KAPLAN AP, J ALLERGY CLIN IMMUN; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KEDAR E, 1974, J IMMUNOL, V112, P37; KELLGREN JH, 1951, BRIT MED J, V2, P1183, DOI 10.1136/bmj.2.4741.1183; KENNEDY BJ, 1972, CANCER-AM CANCER SOC, V29, P1052, DOI 10.1002/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7; LITT M, 1964, J CELL BIOL, V23, P355, DOI 10.1083/jcb.23.2.355; MACDONALD HR, 1975, SCAND J IMMUNOL, V4, P487, DOI 10.1111/j.1365-3083.1975.tb02654.x; MAHMOUD AAF, 1975, J EXP MED, V142, P805, DOI 10.1084/jem.142.4.805; MAHMOUD AAF, 1975, J EXP MED, V142, P560, DOI 10.1084/jem.142.3.560; MICKENBERG ID, 1972, BLOOD-J HEMATOL, V39, P67, DOI 10.1182/blood.V39.1.67.67; NEVA FA, 1975, J ALLERGY CLIN IMMUN, V55, P422, DOI 10.1016/0091-6749(75)90081-0; PARRILLO JE, 1978, BLOOD, V51, P457; PARRILLO JE, 1978, SCAND J IMMUNOL, V8, P99, DOI 10.1111/j.1365-3083.1978.tb00501.x; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; PARRILLO JE, 1978, CLIN EXP IMMUNOL, V31, P116; RESNICK M, 1971, AM J MED, V51, P560, DOI 10.1016/0002-9343(71)90262-2; ROBERTS WC, 1969, AM J MED, V46, P28, DOI 10.1016/0002-9343(69)90055-2; SABESIN SM, 1963, P SOC EXP BIOL MED, V112, P667, DOI 10.3181/00379727-112-28134; SCHRIBER RA, 1975, J IMMUNOL, V114, P1348; SOLLEY GO, 1976, MAYO CLIN PROC, V51, P697; VAKIL RJ, 1961, BRIT HEART J, V23, P578; WALLS RS, 1976, S AFR MED J, V50, P1313; WARD PA, 1969, AM J PATHOL, V54, P121; WILLIAMS CA, 1971, METHODS IMMUNOLOGY I, V3, P173; YARBRO JW, 1968, CANCER RES, V28, P1082; ZEIJLEMAKER WP, 1975, EUR J IMMUNOL, V5, P579, DOI 10.1002/eji.1830050815; ZUBLER RH, 1976, J IMMUNOL, V116, P232; Zucker-Franklin D, 1974, Adv Intern Med, V19, P1	52	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					113	121		10.1016/0091-6749(79)90044-7	http://dx.doi.org/10.1016/0091-6749(79)90044-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	313411				2022-12-18	WOS:A1979HG42600004
J	TARLO, SM; BELL, B; SRINIVASAN, J; DOLOVICH, J; HARGREAVE, FE				TARLO, SM; BELL, B; SRINIVASAN, J; DOLOVICH, J; HARGREAVE, FE			HUMAN SENSITIZATION TO GANODERMA ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON L8N 1Y4,ONTARIO,CANADA; ST JOSEPHS HOSP,REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McGill University; McMaster University; McMaster University				Tarlo, Susan/0000-0002-4746-5310				ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; BARLOW HS, 1963, ANN ALLERGY, V21, P569; BRUCE RA, 1963, INT ARCH ALLER A IMM, V22, P294, DOI 10.1159/000229372; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; COLLINSWILLIAMS C, 1973, ANN ALLERGY, V31, P69; COLLINSWILLIAMS C, 1955, J ALLERGY, V26, P468, DOI 10.1016/0021-8707(55)90038-1; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HERXHEIMER H, 1969, LANCET, V2, P131; HYDE H A, 1972, Clinical Allergy, V2, P153, DOI 10.1111/j.1365-2222.1972.tb01280.x; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; PEPYS J, 1975, CLIN ASPECTS IMMUNOL, P58	16	46	48	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					43	49		10.1016/0091-6749(79)90082-4	http://dx.doi.org/10.1016/0091-6749(79)90082-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447950				2022-12-18	WOS:A1979HC42400010
J	PATTERSON, R; SUSZKO, IM; ZEISS, R; PRUZANSKY, JJ; BACAL, E				PATTERSON, R; SUSZKO, IM; ZEISS, R; PRUZANSKY, JJ; BACAL, E			COMPARISON OF IMMUNE REACTIVITY TO POLYVALENT MONOMERIC AND POLYMERIC RAGWEED ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HUSSAIN R, 1977, AM C ALLERGY IMMUNOL; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PRUZANSK.JJ, 1965, J IMMUNOL, V95, P48; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	14	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					28	35		10.1016/0091-6749(78)90470-0	http://dx.doi.org/10.1016/0091-6749(78)90470-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618944				2022-12-18	WOS:A1978EH11200005
J	HANDELMAN, NI; FRIDAY, GA; SCHWARTZ, HJ; KUHN, FS; LINDSAY, DE; KOORS, PG; MOYER, RP; SMITH, CS; KEMPER, CF; NAGEL, JR; ROSCH, J; MURPHEY, S; MILLER, DL				HANDELMAN, NI; FRIDAY, GA; SCHWARTZ, HJ; KUHN, FS; LINDSAY, DE; KOORS, PG; MOYER, RP; SMITH, CS; KEMPER, CF; NAGEL, JR; ROSCH, J; MURPHEY, S; MILLER, DL			CROMOLYN SODIUM NASAL SOLUTION IN PROPHYLACTIC TREATMENT OF POLLEN-INDUCED SEASONAL ALLERGIC RHINITIS - TRI-CITY STUDY OF EFFICACY AND SAFETY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; BLAIR H, 1973, Clinical Allergy, V3, P283, DOI 10.1111/j.1365-2222.1973.tb01335.x; CAPEL LH, 1971, LANCET, V1, P575; CHAMPION RH, 1971, LANCET, V1, P187; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; Cox J S, 1970, Adv Drug Res, V5, P115; ENGSTROM L, 1971, ANN ALLERGY, V29, P505; FAGERBERG E, 1975, ACTA ALLERGOL, V30, P63, DOI 10.1111/j.1398-9995.1975.tb01329.x; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P83; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HOLOPAINEN E, 1971, LANCET, V1, P187; Hopper I, 1972, J Laryngol Otol, V86, P725; KNIGHT A, 1976, J ALLERGY CLIN IMMUN, V58, P278, DOI 10.1016/0091-6749(76)90132-9; LEIFERMAN KM, 1975, J ALLERGY CLIN IMMUN, V56, P481, DOI 10.1016/0091-6749(75)90066-4; ORIE NGM, 1969, DISODIUM CROMOGLYCAT, P33; PELIKAN Z, 1970, ANN ALLERGY, V28, P548; PEPYS J, 1968, LANCET, V2, P134; SMITH JM, 1971, LANCET, V1, P295; SOMAZZI S, 1972, SCHWEIZ MED WSCHR, V102, P776; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; THORNE MG, 1972, ACTA ALLERGOL, V27, P307, DOI 10.1111/j.1398-9995.1972.tb01430.x; TUFFIASH WA, 1975, J ALLERGY CLIN IMMUN, V55, P116; WELSH PD, TO BE PUBLISHED; WINER BJ, 1971, STATISTICAL PRINCIPL, P796	24	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					237	242		10.1016/0091-6749(77)90156-7	http://dx.doi.org/10.1016/0091-6749(77)90156-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	402406				2022-12-18	WOS:A1977CZ24900009
J	SHEFFER, AL; FEARON, DT; AUSTEN, KF; ROSEN, FS				SHEFFER, AL; FEARON, DT; AUSTEN, KF; ROSEN, FS			TRANEXAMIC ACID - PREOPERATIVE PROPHYLACTIC THERAPY FOR PATIENTS WITH HEREDITARY ANGIONEUROTIC-EDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROBERT B BRIGHAM HOSP,DEPT MED,BOSTON,MA 02120; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital								AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; Crowder JR, 1917, ARCH INTERN MED, V20, P840; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; DONALDSON VH, CLINICAL ASPECTS COM; Dunlap HF, 1929, AM J MED SCI, V177, P259, DOI 10.1097/00000441-192902000-00012; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; PENCE HL, 1974, J ALLERGY CLIN IMMUN, V53, P298, DOI 10.1016/0091-6749(74)90109-2; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Rosse W F, 1976, Trans Assoc Am Physicians, V89, P122; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SHEFFER AL, 1977, AM C ALLERGY IMMUNOL; SPAULDING W B, 1955, Can Med Assoc J, V73, P181	17	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					38	40		10.1016/0091-6749(77)90080-X	http://dx.doi.org/10.1016/0091-6749(77)90080-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	874207				2022-12-18	WOS:A1977DN22400005
J	BLAYLOCK, WK				BLAYLOCK, WK			ATOPIC-DERMATITIS - DIAGNOSIS AND PATHOBIOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGINIA COMM UNIV,MED COLL,DEPT DERMATOL,RICHMOND,VA 23298	Virginia Commonwealth University								BLAYLOCK WK, 1966, CANCER-AM CANCER SOC, V19, P233, DOI 10.1002/1097-0142(196602)19:2<233::AID-CNCR2820190215>3.0.CO;2-3; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; CARR RH, 1973, J ALLERGY CLIN IMMUN, V51, P255, DOI 10.1016/0091-6749(73)90127-9; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; CORMANE RH, 1973, BRIT J DERMATOL, V88, P307, DOI 10.1111/j.1365-2133.1973.tb07554.x; DAVIS MJ, 1958, J INVEST DERMATOL, V30, P127, DOI 10.1038/jid.1958.24; EDELSON RL, 1973, J INVEST DERMATOL, V61, P82, DOI 10.1111/1523-1747.ep12675403; ERICKSON L, 1970, J INVEST DERMATOL, V54, P11, DOI 10.1111/1523-1747.ep12551480; GOTTLIEB BR, 1974, CLIN RES, V12, pA159; GOTTLIEB BR, 1974, CLIN RES, V22, pA159; HILL HR, 1974, LANCET, V1; HINRICHS WL, 1966, J INVEST DERMATOL, V46, P189, DOI 10.1038/jid.1966.28; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JONES HE, 1973, ARCH DERMATOL, V108, P61, DOI 10.1001/archderm.108.1.61; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JUHLIN L, 1969, ARCH DERMATOL, V100, P13; KALZ F, 1960, J INVEST DERMATOL, V35, P135, DOI 10.1038/jid.1960.97; KRAIN LS, 1973, LANCET, V1, P1059; LEE TP, 1974, J ALLERGY CLIN IMMUN, V53, P99; LEGUIT P, 1973, INT ARCH ALLER A IMM, V44, P101; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LOBITZ WC, 1956, JAMA-J AM MED ASSOC, V161, P1226, DOI 10.1001/jama.1956.02970130014004; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; LORINCZ AL, 1965, J PEDIATR, V66, P207; LOUIE JS, 1972, CLIN EXP IMMUNOL, V11, P469; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MCGEADY S, 1974, J ALLERGY CLIN IMMUN, V53, P73; MCGEADY SJ, 1974, J ALLERGY CLIN IMMUN, V53, P72; MIER PD, 1970, BRIT J DERMATOL, V83, P359, DOI 10.1111/j.1365-2133.1970.tb15716.x; MOLLER H, 1959, Acta Derm Venereol, V39, P212; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OKUMURA K, 1971, J IMMUNOL, V107, P6; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PALACIOS J, 1966, J INVEST DERMATOL, V47, P5; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PASS F, 1966, ANN ALLERGY, V24, P426; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; SOLOMON LM, 1964, J INVEST DERMATOL, V43, P193, DOI 10.1038/jid.1964.142; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; SULZBERGER MB, 1955, ATOPIC DERMATITIS, P13; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAYLOR, 1973, LANCET, V2, P111	44	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					62	79		10.1016/0091-6749(76)90080-4	http://dx.doi.org/10.1016/0091-6749(76)90080-4			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	1107396				2022-12-18	WOS:A1976BC14100008
J	KAPLAN, AP; AUSTEN, KF				KAPLAN, AP; AUSTEN, KF			ACTIVATION AND CONTROL MECHANISMS OF HAGEMAN FACTOR-DEPENDENT PATHWAYS OF COAGULATION, FIBRINOLYSIS, AND KININ GENERATION AND THEIR CONTRIBUTION TO INFLAMMATORY RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,LAB CLIN INVEST,BETHESDA,MD 20014; HARVARD UNIV,MED SCH,DEPT MED,BOSTON,MA 02138; ROBERT B BRIGHAM HOSP,DEPT MED,PARKER HILL AVE,BOSTON,MA 02120	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School								ABILDGAARD U, 1969, SCAND J CLIN LAB INV, V24, P23, DOI 10.3109/00365516909080127; ABILDGAARD U, 1967, SCAND J CLIN LAB INV, V19, P190, DOI 10.3109/00365516709093501; ASTRUP T, 1974, THROMB RES, V4, P609, DOI 10.1016/0049-3848(74)90235-7; BARLOW GH, 1969, J BIOL CHEM, V244, P1138; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; BROCKLEHURST WE, 1966, BRIT J PHARM CHEMOTH, V27, P256, DOI 10.1111/j.1476-5381.1966.tb01661.x; COCHRANE CG, 1972, J CLIN INVEST, V51, P2736, DOI 10.1172/JCI107093; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COCHRANE CG, 1971, J EXP MED, V134, P986, DOI 10.1084/jem.134.4.986; COCHRANE CG, 1972, INFLAMMATION MECHANI, P119; COCHRANE CG, 1970, 6TH INT S IMM, P220; COLMAN R W, 1970, British Journal of Haematology, V19, P675, DOI 10.1111/j.1365-2141.1970.tb07012.x; COLMAN RF, IN PRESS; COLMAN RW, 1969, J CLIN INVEST, V48, P23, DOI 10.1172/JCI105971; COLMAN RW, KALLIKREIN KININ SYS; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIES GE, 1962, INT ARCH ALLER A IMM, V20, P235, DOI 10.1159/000229263; DERENZO EC, 1967, J BIOL CHEM, V242, P2428; EISEN V, 1970, BRIT J EXP PATHOL, V51, P328; EPSTEIN WV, 1969, ANN NY ACAD SCI, V168, P173, DOI 10.1111/j.1749-6632.1969.tb43106.x; ERDOS EG, 1962, BIOCHEM PHARMACOL, V11, P585, DOI 10.1016/0006-2952(62)90119-3; ERDOS EG, 1967, NATURE, V215, P1402; FORBES CD, 1970, J LAB CLIN MED, V76, P809; GALLIN JI, 1974, J IMMUNOL, V113, P1928; GIGLI I, 1970, J IMMUNOL, V104, P574; GIGLI I, 1971, J EXP MED, V134, P1466, DOI 10.1084/jem.134.6.1466; GLADNER JA, 1963, ANN NY ACAD SCI, V104, P47, DOI 10.1111/j.1749-6632.1963.tb17651.x; GOETZL EJ, 1974, J CLIN INVEST, V53, P591, DOI 10.1172/JCI107594; GOETZL EJ, 1974, ANTIBIOTICS CHEMOTHE, P218; GOTZE O, 1971, J EXP MED          2, V134, P90; HABAL FM, 1974, FED PROC, V33, P641; HARPEL PC, 1970, J EXP MED, V132, P329, DOI 10.1084/jem.132.2.329; HARPEL PC, 1973, J CLIN INVEST, V52, P2175, DOI 10.1172/JCI107402; HATHAWAY WE, 1970, BRIT J HAEMATOL, V18, P161, DOI 10.1111/j.1365-2141.1970.tb01431.x; HATHAWAY WE, 1965, BLOOD-J HEMATOL, V26, P521, DOI 10.1182/blood.V26.5.521.521; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; HIGHSMITH RF, 1974, J BIOL CHEM, V249, P4335; HOUGIE C, 1973, LANCET, V1, P616; JACOBSEN S, 1967, BRIT J PHARM CHEMOTH, V29, P25, DOI 10.1111/j.1476-5381.1967.tb01935.x; JOHNSTON AR, 1974, J IMMUNOL, V113, P103; KAGEN LJ, 1963, NATURE, V197, P693, DOI 10.1038/197693a0; KAGEN LJ, 1964, BRIT J EXP PATHOL, V45, P604; KAPLAN AP, 1972, J EXP MED, V136, P1378, DOI 10.1084/jem.136.6.1378; KAPLAN AP, 1973, J CLIN INVEST, V52, P2591, DOI 10.1172/JCI107451; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; KAPLAN AP, 1970, J IMMUNOL, V105, P802; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; KAPLAN AP, UNPUBLISHED OBSERVAT; KAPLAN AP, 1971, BIOCHEMISTRY ACUTE A, P280; KATO H, 1967, J BIOCHEM, V62, P591, DOI 10.1093/oxfordjournals.jbchem.a128709; KATO H, 1968, BIOCHEM BIOPH RES CO, V32, P800, DOI 10.1016/0006-291X(68)90311-2; KAY AB, 1973, NATURE-NEW BIOL, V243, P56; KELLERMEYER RW, 1965, J LAB CLIN MED, V65, P307; KRAHN J, 1973, BIOCHEMISTRY-US, V12, P1330, DOI 10.1021/bi00731a600; LAAKE K, 1974, THROMB RES, V4, P285, DOI 10.1016/0049-3848(74)90093-0; LAHIRI B, 1974, FED PROC, V33, P642; LAWRENCE T G, 1970, Federation Proceedings, V29, P576; LORAND L, 1962, FED PROC, V21, P62; MACKAY ME, 1953, NATURE, V172, P714, DOI 10.1038/172714b0; MAGOON EH, 1974, CLIN EXP IMMUNOL, V17, P345; MARCINIAK E, 1973, BRIT J HAEMATOL, V24, P391, DOI 10.1111/j.1365-2141.1973.tb01662.x; MARCUS AJ, 1964, BLOOD, V23, P389, DOI 10.1182/blood.V23.3.389.389; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MOVAT HZ, 1969, J IMMUNOL, V103, P875; MOVAT HZ, 1971, INT ARCH ALLER A IMM, V40, P89, DOI 10.1159/000230397; MULLEREBERHARD HJ, 1972, J EXP MED, V135, P1003, DOI 10.1084/jem.135.4.1003; NAGASAWA S, 1966, J BIOCHEM, V60, P643, DOI 10.1093/oxfordjournals.jbchem.a128490; Niewiarowski S, 1965, Thromb Diath Haemorrh, V14, P387; NILSSON IM, 1957, ACTA MED SCAND, V159, P35; OSTERUD B, 1970, BIOCHEMISTRY-US, V9, P1854; OWEN WG, 1972, THROMB DIATH HAEMOST, V27, P502, DOI 10.1055/s-0038-1649389; OZAWA K, 1966, J BIOL CHEM, V241, P3955; PIERCE JV, 1968, FED PROC, V27, P52; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; QUICK AJ, 1952, SCIENCE, V112, P558; RAPAPORT SI, 1963, BLOOD, V21, P221, DOI 10.1182/blood.V21.2.221.221; RATNOFF OD, 1967, J EXP MED, V125, P337, DOI 10.1084/jem.125.2.337; RATNOFF OD, 1961, J CLIN INVEST, V40, P803, DOI 10.1172/JCI104314; RATNOFF OD, 1968, SCIENCE, V29, P1007; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1973, BIOCHEM BIOPH RES CO, V51, P672, DOI 10.1016/0006-291X(73)91367-3; RIMON A, 1966, J BIOL CHEM, V241, P5102; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROBBINS KC, 1966, IMMUNOCHEMISTRY, V3, P29, DOI 10.1016/0019-2791(66)90279-5; ROCHAESILVA M, 1972, 5TH P INT C PHARM BA, V5, P250; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SAITO H, 1974, J LAB CLIN MED, V84, P62; SAITO H, 1975, J CLIN INVEST, V55, P1082, DOI 10.1172/JCI108009; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1394, DOI 10.1172/JCI107312; SCHREIBER AS, 1974, CLIN EXP IMMUNOL, V17, P603; SOLTAY MJ, 1972, P SOC EXP BIOL, V138, P952; SOTER NA, 1974, J INVEST DERMATOL, V63, P219, DOI 10.1111/1523-1747.ep12679439; SPRAGG J, 1971, J IMMUNOL, V107, P1512; SPRAGG J, 1974, BIOCHEM PHARMACOL, V23, P781, DOI 10.1016/0006-2952(74)90208-1; SPRAGG J, 1973, ANN NY ACAD SCI, V209, P372, DOI 10.1111/j.1749-6632.1973.tb47541.x; STEWART PB, 1957, BRIT J EXP PATHOL, V38, P462; SUMMARIA L, 1972, J BIOL CHEM, V247, P4691; SUMMARIA L, 1968, J BIOL CHEM, V243, P144; TAKAHASHI H, 1972, FEBS LETT, V24, P98, DOI 10.1016/0014-5793(72)80835-4; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; TAYLOR FB, 1970, J CLIN INVEST, V49, P2068, DOI 10.1172/JCI106425; TREOLAR MP, 1970, FED P, V29, P576; WARD PA, 1967, J EXP MED, V126, P189, DOI 10.1084/jem.126.2.189; WEBSTER ME, 1961, NATURE, V192, P180, DOI 10.1038/192180a0; WEBSTER ME, 1969, CELLULAR HUMORAL MEC, P207; WEBSTER ME, 1963, ANN NY ACAD SCI, V104, P41; WEISS AS, 1974, J CLIN INVEST, V53, P622, DOI 10.1172/JCI107597; WEISS HJ, 1972, THROMB DIATH HAEMOST, V27, P212, DOI 10.1055/s-0038-1649358; WEISS HJ, 1973, SCIENCE, V182, P1149, DOI 10.1126/science.182.4117.1149; WILNER GD, 1968, J CLIN INVEST, V47, P2608, DOI 10.1172/JCI105943; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x; WIMAN B, 1963, EUR J BIOCHEM, V39, P1; WUEPPER KD, 1973, J EXP MED, V138, P1345, DOI 10.1084/jem.138.6.1345; WUEPPER KD, 1975, FED PROC, V34, P859; WUEPPER KD, 1970, J IMMUNOL, V105, P1307; WUEPPER KD, 1972, J EXP MED, V135, P1, DOI 10.1084/jem.135.1.1; WUEPPER KD, 1972, INFLAMMATION MECHANI; WUEPPER KD, 1971, BIOCHEMISTRY ACUTE A, P299; YANO M, 1967, J BIOCHEM-TOKYO, V62, P504, DOI 10.1093/oxfordjournals.jbchem.a128698; YANS M, 1970, BIOCHEM BIOPHYS RES, V40, P914; YIN ET, 1971, J BIOL CHEM, V246, P3712; YONEMASU K, 1971, BIOCHEM BIOPH RES CO, V43, P1388, DOI 10.1016/S0006-291X(71)80028-1; ZIMMERMAN TS, 1973, J EXP MED, V138, P1015, DOI 10.1084/jem.138.4.1015	125	46	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	6					491	506		10.1016/0091-6749(75)90067-6	http://dx.doi.org/10.1016/0091-6749(75)90067-6			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ301	1107395				2022-12-18	WOS:A1975AZ30100008
J	KUMAR, L; HORNBROOK, M; NEWCOMB, RW				KUMAR, L; HORNBROOK, M; NEWCOMB, RW			YEAR-ROUND STUDY OF SERUM IGE LEVELS IN ASTHMATIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; GLEICH GJ, 1970, J ALLERGY, V45, P108; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KUMAR L, 1971, PEDIATRICS, V47, P848; LEVY DA, 1967, J IMMUNOL, V99, P1068; MCNEMAR O, 1962, PSYCHOLOGICAL STATIS, P109; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; TADA T, IN PRESS; YUNGINGER JW, 1971, J ALLERGY, V47, P87	14	46	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	5					305	+		10.1016/0091-6749(71)90032-7	http://dx.doi.org/10.1016/0091-6749(71)90032-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K7978	5285781				2022-12-18	WOS:A1971K797800008
J	Kelsen, SG; Agache, IO; Soong, W; Israel, E; Chupp, GL; Cheung, DS; Theess, W; Yang, XY; Staton, TL; Choy, DF; Fong, A; Dash, A; Dolton, M; Pappu, R; Brightling, CE				Kelsen, Steven G.; Agache, Ioana O.; Soong, Weily; Israel, Elliot; Chupp, Geoffrey L.; Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying; Staton, Tracy L.; Choy, David F.; Fong, Alice; Dash, Ajit; Dolton, Michael; Pappu, Rajita; Brightling, Christopher E.			Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; ST2; severe asthma; asthma exacerbations; eosinophils	AIRWAY SMOOTH-MUSCLE; EOSINOPHILIC ASTHMA; ALLERGIC-ASTHMA; IL-33; OMALIZUMAB; PLACEBO; EXACERBATIONS; BENRALIZUMAB; INFLAMMATION; MEPOLIZUMAB	Background: The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived "alarmin."Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils (type 2-high), but limited options are available for patients with low blood eosinophils (type 2-low). Inhibiting IL-33 signaling may target pathogenic pathways in a wider spectrum of asthmatics. Objectives: This study evaluated astegolimab efficacy and safety in patients with severe asthma. Methods: This double-blind, placebo-controlled, dose-ranging study (ZENYATTA [A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma]) randomized 502 adults with severe asthma to subcutaneous placebo or 70-mg, 210-mg, or 490-mg doses of astegolimab every 4 weeks. The primary endpoint was the annualized asthma exacerbation rate (AER) at week 54. Enrollment caps ensured similar to 30 patients who were eosinophil-high (>= 300 cells/mu L) and similar to 95 patients who were eosinophil-low (<300 cells/mu L) per arm. Results: Overall, adjusted AER reductions relative to placebo were 43% (P = .005), 22% (P = .18), and 37% (P = .01) for 490 mg, 210-mg, and 70-mg doses of astegolimab, respectively. Adjusted AER reductions for patients who were eosinophil-low were comparable to reductions in the overall population: 54% (P = .002), 14% (P = .48), and 35% (P = .05) for 490-mg, 210 mg, and 70-mg doses of astegolimab. Adverse events were similar in astegolimab-and placebo-treated groups. Conclusions: Astegolimab reduced AER in a broad population of patients, including those who were eosinophil-low, with inadequately controlled, severe asthma. Astegolimab was safe and well tolerated.	[Kelsen, Steven G.] Temple Univ, Dept Thorac Med & Surg, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Agache, Ioana O.] Transylvania Univ, Allergy & Clin Immunol, Fac Med, Brasov, Romania; [Soong, Weily] Alabama Allergy & Asthma Ctr, Birmingham, AL USA; [Soong, Weily] Clin Res Ctr Alabama, Birmingham, AL USA; [Israel, Elliot] Brigham & Womens Hosp, Div Pulm & Crit Care Med & Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA; [Israel, Elliot] Harvard Med Sch, Boston, MA 02115 USA; [Chupp, Geoffrey L.] Yale Sch Med, Div Pulm & Crit Care & Sleep Med, New Haven, CT USA; [Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying; Staton, Tracy L.; Choy, David F.; Fong, Alice; Dash, Ajit; Dolton, Michael; Pappu, Rajita] Genentech Inc, San Francisco, CA USA; [Brightling, Christopher E.] Univ Leicester, Dept Resp Sci, Leicester LE3 9QP, Leics, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Transylvania University of Brasov; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University; Roche Holding; Genentech; University of Leicester	Brightling, CE (corresponding author), Univ Leicester, Dept Resp Sci, Leicester LE3 9QP, Leics, England.	ceb17@leicester.ac.uk		brightling, chris/0000-0002-9345-4903	Genentech, Inc.	Genentech, Inc.(Roche HoldingGenentech)	This work was supported by Genentech, Inc. Genentech, Inc, participated in the study design, the collection, analysis, and interpretation of data, the writing of the report, and in the decision to submit the report for publication.	Agache I, 2021, ALLERGY, V76, P14, DOI 10.1111/all.14425; Agache I, 2020, ALLERGY, V75, P1043, DOI 10.1111/all.14235; Agache I, 2019, J CLIN INVEST, V129, P1493, DOI 10.1172/JCI124611; [Anonymous], 2007, EXPERT PANEL REPORT; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Casale TB, 2018, ALLERGY, V73, P490, DOI 10.1111/all.13302; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Choy DF, 2020, EXPERT OPIN THER TAR, V24, P463, DOI 10.1080/14728222.2020.1744567; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Drake LY, 2017, IMMUNOL REV, V278, P173, DOI 10.1111/imr.12552; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fuhlbrigge AL, 2017, LANCET RESP MED, V5, P577, DOI 10.1016/S2213-2600(17)30218-7; Global strategy for asthma management and prevention, 2020, GLOBAL INITIATIVE AS; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Johansson K, 2019, PEDIAT ALLERG IMM-UK, V30, P503, DOI 10.1111/pai.13040; Johnston LK, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00051; Johnston LK, 2016, J IMMUNOL, V197, P3445, DOI 10.4049/jimmunol.1600611; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kaur D, 2015, ALLERGY, V70, P556, DOI 10.1111/all.12593; Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Le Goffic R, 2011, AM J RESP CELL MOL, V45, P1125, DOI 10.1165/rcmb.2010-0516OC; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peters SP, 2006, RESP MED, V100, P1139, DOI 10.1016/j.rmed.2006.03.031; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Ramirez-Carrozzi V, 2017, J ALLERGY CLIN IMMUN, V139, P705, DOI 10.1016/j.jaci.2016.08.026; Ravanetti L, 2019, J ALLERGY CLIN IMMUN, V143, P1355, DOI 10.1016/j.jaci.2018.08.051; Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; SIGNORINI DF, 1991, BIOMETRIKA, V78, P446; Smith D, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006659; Spahn JD, 2016, J ALLERGY CLIN IMMUN, V138, P1296, DOI 10.1016/j.jaci.2016.09.002; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Vannella KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1938; Zervas E, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00125-2017	45	45	45	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					790	798		10.1016/j.jaci.2021.03.044	http://dx.doi.org/10.1016/j.jaci.2021.03.044		SEP 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	33872652	hybrid			2022-12-18	WOS:000695242900028
J	Renert-Yuval, Y; Thyssen, JP; Bissonnette, R; Bieber, T; Kabashima, K; Hijnen, D; Guttman-Yassky, E				Renert-Yuval, Yael; Thyssen, Jacob P.; Bissonnette, Robert; Bieber, Thomas; Kabashima, Kenji; Hijnen, DirkJan; Guttman-Yassky, Emma			Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; biomarker; International Eczema Council; CCL17/TARC; IgE; eosinophils; CCL22/MDC; CCL26/eotaxin-3; CCL27/CTACK; CCL18/pulmoncuy and activation-regulated chemokine; IL-13; IL-22	ACTIVATION-REGULATED CHEMOKINE; MACROPHAGE-DERIVED CHEMOKINE; EOSINOPHIL CATIONIC PROTEIN; SOLUBLE E-SELECTIN; MESSENGER-RNA EXPRESSION; T-CELL SUBSETS; DISEASE-ACTIVITY; SERUM THYMUS; STRATUM-CORNEUM; IFN-GAMMA	Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management. Herein, we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases, or therapeutic response, and current practice of biomarkers in AD. We found that chemokine C-C motif ligand 17/thymus and activation-regulated chemokine, a chemoattractant of T(H)2 cells, has currently the greatest evidence for robust correlation with AD clinical severity, at both baseline and during therapy, by using the recommendations, assessment, development, and evaluation approach. Although the potential of biomarkers in AD is yet to be fully elucidated, due to the complexity of the disease, a comprehensive approach taking into account both clinical and reliable, AD-specific biomarker evaluations would further facilitate AD research and improve patient management.	[Renert-Yuval, Yael] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA; [Thyssen, Jacob P.] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark; [Bissonnette, Robert] Innovaderm Res, Dept Dermatol, Montreal, PQ, Canada; [Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Christine Kuhne Ctr Allergy Res & Educ, Bonn, Germany; [Kabashima, Kenji] Kyoto Univ, Dept Dermatol, Sch Med, Kyoto, Japan; [Hijnen, DirkJan] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY USA	Rockefeller University; University of Copenhagen; Bispebjerg Hospital; Innovaderm Research Inc.; University of Bonn; Kyoto University; Erasmus University Rotterdam; Erasmus MC; Icahn School of Medicine at Mount Sinai	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Hijnen, DirkJan/L-1387-2015; Renert-Yuval, Yael/AAP-5414-2020	Hijnen, DirkJan/0000-0003-3379-3425; 	National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University [UL1TR001866]	National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University	Y.R.-Y. was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University (grant no. UL1TR001866).	Ahrens B, 2015, PEDIAT ALLERG IMM-UK, V26, P634, DOI 10.1111/pai.12431; Angelova-Fischer I, 2006, BRIT J DERMATOL, V154, P1112, DOI 10.1111/j.1365-2133.2006.07201.x; Aral M, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/73098; Ariens LFM, 2020, ALLERGY, V75, P116, DOI 10.1111/all.14080; Aronson Jeffrey K, 2017, Curr Protoc Pharmacol, V76, DOI 10.1002/cpph.19; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Berdyshev E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98006; Berin MC, 2002, DRUG NEWS PERSPECT, V15, P10, DOI 10.1358/dnp.2002.15.1.660501; Bieber T, 2020, ALLERGY, V75, P2936, DOI 10.1111/all.14194; Bissonnette R, 2019, BRIT J DERMATOL, V181, P733, DOI 10.1111/bjd.17932; Bissonnette R, 2019, J ALLERGY CLIN IMMUN, V144, P1274, DOI 10.1016/j.jaci.2019.06.047; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Bogaczewicz J, 2016, INT J DERMATOL, V55, P856, DOI 10.1111/ijd.12992; Brunner PM, 2017, ALLERGY, V72, P2017, DOI 10.1111/all.13223; Brunner PM, 2019, J AM ACAD DERMATOL, V81, P510, DOI 10.1016/j.jaad.2019.04.036; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Chan TC, 2018, J ALLERGY CLIN IMMUN, V142, P1013, DOI 10.1016/j.jaci.2018.06.016; Chaoimh CN, 2020, ANN ALLERG ASTHMA IM, V124, P500, DOI 10.1016/j.anai.2020.01.022; Chen YL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2945; Clausen ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20204-8; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Cuccaro A, 2016, CANCER MED-US, V5, P398, DOI 10.1002/cam4.585; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; Dallos T, 2010, ARTHRITIS RHEUM-US, V62, P3496, DOI 10.1002/art.27678; Dominguez-Huttinger E, 2017, J ALLERGY CLIN IMMUN, V139, P1861, DOI 10.1016/j.jaci.2016.10.026; Dyjack N, 2018, J ALLERGY CLIN IMMUN, V141, P1298, DOI 10.1016/j.jaci.2017.10.046; Ellis KL, 2004, PEDIATR DERMATOL, V21, P619, DOI 10.1111/j.0736-8046.2004.21600.x; Emson C, 2018, IMMUNOL ALLERGY CLIN, V38, P611, DOI 10.1016/j.iac.2018.06.004; Engebretsen KA, 2018, J EUR ACAD DERMATOL, V32, P796, DOI 10.1111/jdv.14801; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Fujisawa T, 2009, PEDIATR ALLERGY IMMU, V20, P633, DOI 10.1111/j.1399-3038.2009.00851.x; Furue M, 2012, J DERMATOL SCI, V66, P60, DOI 10.1016/j.jdermsci.2012.01.011; Furukawa H, 2004, J DERMATOL SCI, V36, P165, DOI 10.1016/j.jdermsci.2004.09.001; Garzorz-Stark N, 2016, EXP DERMATOL, V25, P767, DOI 10.1111/exd.13077; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Glatz M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192443; Glatz M, 2015, ACTA DERM-VENEREOL, V95, P191, DOI 10.2340/00015555-1864; Glickman JW, 2020, J ALLER CL IMM-PRACT, V8, P3622, DOI 10.1016/j.jaip.2020.07.015; Glickman JW, 2021, J AM ACAD DERMATOL, V84, P370, DOI 10.1016/j.jaad.2020.04.138; Gohar Maha K, 2017, Egypt J Immunol, V24, P9; Gu CY, 2015, INT J DERMATOL, V54, pE261, DOI 10.1111/ijd.12830; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Guttman-Yassky E, 2019, JAMA DERMATOL, V155, P1358, DOI 10.1001/jamadermatol.2019.2983; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.03.017, 10.1016/j.jclinepi.2011.06.004]; Halmerbauer G, 1997, ALLERGY, V52, P765, DOI 10.1111/j.1398-9995.1997.tb01236.x; Hamilton JD, 2015, IMMUNOTHERAPY-UK, V7, P1043, DOI 10.2217/imt.15.69; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Han Y, 2017, J ALLERGY CLIN IMMUN, V140, P888, DOI 10.1016/j.jaci.2017.04.015; Hashimoto S, 2006, J DERMATOL SCI, V44, P93, DOI 10.1016/j.jdermsci.2006.08.004; He H, 2021, J ALLERGY CLIN IMMUN, V147, P1369, DOI 10.1016/j.jaci.2020.08.041; He H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01768; He HE, 2021, J ALLERGY CLIN IMMUN, V147, P199, DOI 10.1016/j.jaci.2020.05.048; He H, 2020, ANN ALLERG ASTHMA IM, V124, P70, DOI 10.1016/j.anai.2019.10.013; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Holm JG, 2017, INT J DERMATOL, V56, P18, DOI 10.1111/ijd.13353; Hon KL, 2011, PEDIAT ALLERG IMM-UK, V22, P704, DOI 10.1111/j.1399-3038.2011.01174.x; Hon KLE, 2004, CLIN EXP DERMATOL, V29, P293, DOI 10.1111/j.1365-2230.2004.01501.x; Horikawa T, 2002, INT IMMUNOL, V14, P767, DOI 10.1093/intimm/dxf044; Horimukai K, 2016, ALLERGOL INT, V65, P103, DOI 10.1016/j.alit.2015.09.004; Hulshof L, 2019, BRIT J DERMATOL, V180, P621, DOI 10.1111/bjd.16994; Hulshof L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00630; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Inoue Y, 2011, BRIT J DERMATOL, V164, P560, DOI 10.1111/j.1365-2133.2010.10145.x; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kagami S, 2003, CLIN EXP IMMUNOL, V134, P309, DOI 10.1046/j.1365-2249.2003.02273.x; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kakinuma T, 2002, CLIN EXP IMMUNOL, V127, P270, DOI 10.1046/j.1365-2249.2002.01727.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Kataoka Y, 2014, J DERMATOL, V41, P221, DOI 10.1111/1346-8138.12440; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2019, J INVEST DERMATOL, V139, P2387, DOI 10.1016/j.jid.2019.03.1160; Koning H, 1997, CYTOKINE, V9, P416, DOI 10.1006/cyto.1996.0184; Konrad RJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41609-z; Koppes SA, 2016, INT ARCH ALLERGY IMM, V170, P187, DOI 10.1159/000448400; Kou K, 2014, BRIT J DERMATOL, V171, P283, DOI 10.1111/bjd.12943; Kou KZ, 2012, ARCH DERMATOL RES, V304, P305, DOI 10.1007/s00403-011-1198-9; Kwon YS, 2010, EXP DERMATOL, V19, P246, DOI 10.1111/j.1600-0625.2009.00971.x; Kyoya M, 2014, J DERMATOL SCI, V75, P204, DOI 10.1016/j.jdermsci.2014.06.001; Landheer J, 2014, J AM ACAD DERMATOL, V71, P1160, DOI 10.1016/j.jaad.2014.07.031; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Laske N, 2004, PEDIAT ALLERG IMM-UK, V15, P86, DOI 10.1046/j.0905-6157.2003.00106.x; Lauffer F, 2021, ALLERGY, V76, P1158, DOI 10.1111/all.14557; Leung DYM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav2685; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P296, DOI 10.1034/j.1399-3038.2003.00052.x; Machura E, 2012, PEDIAT ALLERG IMM-UK, V23, P278, DOI 10.1111/j.1399-3038.2011.01225.x; McAleer MA, 2019, BRIT J DERMATOL, V180, P586, DOI 10.1111/bjd.17088; Miyahara H, 2011, CLIN EXP ALLERGY, V41, P186, DOI 10.1111/j.1365-2222.2010.03634.x; Mizawa M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/138027; Morishima Y, 2010, PEDIATR INT, V52, P171, DOI 10.1111/j.1442-200X.2009.02908.x; Morita E, 2010, ALLERGY, V65, P1166, DOI 10.1111/j.1398-9995.2010.02361.x; MORITA H, 1995, J DERMATOL SCI, V10, P145, DOI 10.1016/0923-1811(95)96802-T; Motegi S, 2014, ACTA DERM-VENEREOL, V94, P112, DOI 10.2340/00015555-1623; MUKAI H, 1990, Journal of Dermatology (Tokyo), V17, P477; Murayama T, 2015, INT J DERMATOL, V54, P1071, DOI 10.1111/ijd.12281; Nakazato J, 2008, PEDIAT ALLERG IMM-UK, V19, P605, DOI 10.1111/j.1399-3038.2007.00692.x; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Neuber K, 2000, BRIT J DERMATOL, V143, P385, DOI 10.1046/j.1365-2133.2000.03667.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nygaard U, 2016, J EUR ACAD DERMATOL, V30, P1930, DOI 10.1111/jdv.13679; Oka T, 2017, ACTA DERM-VENEREOL, V97, P1172, DOI 10.2340/00015555-2723; Olesen AB, 2005, ACTA DERM-VENEREOL, V85, P240, DOI 10.1080/00015550510026352; Olesen CM, 2019, J EUR ACAD DERMATOL, V33, P1562, DOI 10.1111/jdv.15609; Ozceker D, 2018, ALLERGOL IMMUNOPATH, V46, P322, DOI 10.1016/j.aller.2017.10.005; Park DS, 2007, KOREAN J LAB MED, V27, P128, DOI 10.3343/kjlm.2007.27.2.128; Patel N, 2017, ADV EXP MED BIOL, V1027, P139, DOI 10.1007/978-3-319-64804-0_12; Pavel AB, 2021, ALLERGY, V76, P314, DOI 10.1111/all.14490; Pavel AB, 2020, J AM ACAD DERMATOL, V82, P690, DOI 10.1016/j.jaad.2019.10.039; Pavel AB, 2019, J ALLERGY CLIN IMMUN, V144, P1011, DOI 10.1016/j.jaci.2019.07.013; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Raap U, 2012, PEDIAT ALLERG IMM-UK, V23, P285, DOI 10.1111/j.1399-3038.2011.01241.x; Renert-Yuval Y, 2019, DERMATOL CLIN, V37, P205, DOI 10.1016/j.det.2018.12.007; Roekevisch E, 2020, J EUR ACAD DERMATOL, V34, P1545, DOI 10.1111/jdv.16164; Rosinska-Wieckowicz A, 2016, POSTEP DERM ALERGOL, V33, P211, DOI 10.5114/ada.2016.60614; Saeki H, 2006, J DERMATOL SCI, V43, P75, DOI 10.1016/j.jdermsci.2006.06.002; Salomon J, 2008, J EUR ACAD DERMATOL, V22, P223, DOI 10.1111/j.1468-3083.2007.02399.x; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Shaheen Maha A, 2011, Indian J Dermatol, V56, P673, DOI 10.4103/0019-5154.91827; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2018, J INVEST DERMATOL, V138, P2224, DOI 10.1016/j.jid.2018.03.1517; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Song TW, 2006, CLIN EXP ALLERGY, V36, P346, DOI 10.1111/j.1365-2222.2006.02430.x; Strickland I, 2017, J ALLERGY CLIN IMMUN, V140, P1703, DOI 10.1016/j.jaci.2017.06.046; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sung M, 2017, PEDIAT ALLERG IMM-UK, V28, P543, DOI 10.1111/pai.12744; Suwarsa O, 2017, ASIAN PAC J ALLERGY, V35, P54, DOI 10.12932/AP0787; Szegedi K, 2015, J EUR ACAD DERMATOL, V29, P2136, DOI 10.1111/jdv.13160; Takeuchi H, 2005, J INVEST ALLERG CLIN, V15, P172; Tham EH, 2019, ALLERGY ASTHMA IMMUN, V11, P4, DOI 10.4168/aair.2019.11.1.4; Thijs JL, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0132-9; Thijs J, 2015, CURR OPIN ALLERGY CL, V15, P453, DOI 10.1097/ACI.0000000000000198; Thyssen JP, 2018, ALLERGY, V73, P1741, DOI 10.1111/all.13457; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tsuboi H, 1998, BRIT J DERMATOL, V138, P1033; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Uysal P, 2017, CLIN LAB, V63, P1071, DOI 10.7754/Clin.Lab.2017.161107; van Velsen SGA, 2010, PEDIATR DERMATOL, V27, P470, DOI 10.1111/j.1525-1470.2010.01285.x; Vekaria Anjali S, 2017, F1000Res, V6, P1712, DOI 10.12688/f1000research.12422.1; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Wen HC, 2018, J ALLERGY CLIN IMMUN, V142, P324, DOI 10.1016/j.jaci.2018.02.047; Wen HJ, 2011, PEDIAT ALLERG IMM-UK, V22, P695, DOI 10.1111/j.1399-3038.2011.01177.x; Wolkerstorfer A, 2003, PEDIAT ALLERG IMM-UK, V14, P302, DOI 10.1034/j.1399-3038.2003.00057.x; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Wu KG, 2011, INT J IMMUNOPATH PH, V24, P15, DOI 10.1177/039463201102400103; Yamashita N, 1997, J ALLERGY CLIN IMMUN, V99, P410, DOI 10.1016/S0091-6749(97)70060-5; Yasukochi Y, 2014, ASIAN PAC J ALLERGY, V32, P240, DOI 10.12932/AP0419.32.3.2014; Yoshizawa Y, 2002, CLIN EXP DERMATOL, V27, P225, DOI 10.1046/j.1365-2230.2002.00987.x; Zedan K, 2015, J CLIN DIAGN RES, V9, pWC1, DOI 10.7860/JCDR/2015/12261.5742; Zheng XY, 2003, J DERMATOL, V30, P26; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	170	45	46	7	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1174	+		10.1016/j.jaci.2021.01.013	http://dx.doi.org/10.1016/j.jaci.2021.01.013		APR 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33516871	Green Published, hybrid			2022-12-18	WOS:000637368900006
J	Tsoi, LC; Rodriguez, E; Stolzl, D; Wehkamp, U; Sun, JR; Gerdes, S; Sarkar, MK; Hubenthal, M; Zeng, C; Uppala, R; Xing, XY; Thielking, F; Billi, AC; Swindell, WR; Shefler, A; Chen, JH; Patrick, MT; Harms, PW; Kahlenberg, JM; White, BEP; Maverakis, E; Gudjonsson, JE; Weidinger, S				Tsoi, Lam C.; Rodriguez, Elke; Stoelzl, Dora; Wehkamp, Ulrike; Sun, Jingru; Gerdes, Sascha; Sarkar, Mrinal K.; Huebenthal, Matthias; Zeng, Chang; Uppala, Ranjitha; Xing, Xianying; Thielking, Frederieke; Billi, Allison C.; Swindell, William R.; Shefler, Alanna; Chen, Jiahan; Patrick, Matthew T.; Harms, Paul W.; Kahlenberg, J. Michelle; White, Bethany E. Perez; Maverakis, Emanual; Gudjonsson, Johann E.; Weidinger, Stephan			Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; RNA-sequencing; nonlesional; chronic AD; acute AD	CELLS; ACTIVATION; EXPRESSION; PROTEINS; PATHWAY; INDUCE	Background: Although multiple studies have assessed molecular changes in chronic atopic dermatitis (AD) lesions, little is known about the transition from acute to chronic disease stages, and the factors and mechanisms that shape chronic inflammatory activity. Objectives: We sought to assess the global transcriptome changes that characterize the progression from acute to chronic stages of AD. Methods: We analyzed transcriptome changes in paired nonlesional skin, acute and chronic AD lesions from 11 patients and 38 healthy controls by RNA-sequencing, and conducted in vivo and histological assays to evaluate findings. Results: Our data demonstrate that approximately 74% of the genes dysregulated in acute lesions remain or are further dysregulated in chronic lesions, whereas only 34% of the genes dysregulated in chronic lesions are altered already in the acute stage. Nonlesional AD skin exhibited enrichment of TNF, T(H)1, T(H)2, and T(H)17 response genes. Acute lesions showed marked dendritic-cell signatures and a prominent enrichment of T(H)1, T(H)2, and T(H)17 responses, along with increased IL-36 and thymic stromal lymphopoietin expression, which were further heightened in chronic lesions. In addition, genes involved in skin barrier repair, keratinocyte proliferation, wound healing, and negative regulation of T-cell activation showed a significant dysregulation in the chronic versus acute comparison. Furthermore, our data show progressive changes in vasculature and maturation of dendritic-cell subsets with chronicity, with FOXK1 acting as immune regulator. Conclusions: Our results show that the changes accompanying the transition from nonlesional to acute to chronic inflammation in AD are quantitative rather than qualitative, with chronic AD having heightened T(H)2, T(H)1, T(H)17, and IL36 responses and skin barrier repair mechanisms. These findings provide novel insights and highlight underappreciated pathways in AD pathogenesis that may be amenable to therapeutic targeting.	[Tsoi, Lam C.; Sun, Jingru; Sarkar, Mrinal K.; Zeng, Chang; Uppala, Ranjitha; Xing, Xianying; Billi, Allison C.; Shefler, Alanna; Patrick, Matthew T.; Harms, Paul W.; Gudjonsson, Johann E.] Univ Michigan, Med Sch, Dept Dermatol, Ann Arbor, MI 48109 USA; [Tsoi, Lam C.] Univ Michigan, Med Sch, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Tsoi, Lam C.; Chen, Jiahan] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA; [Rodriguez, Elke; Stoelzl, Dora; Wehkamp, Ulrike; Gerdes, Sascha; Huebenthal, Matthias; Thielking, Frederieke; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Campus Kiel, Kiel, Germany; [Uppala, Ranjitha] Univ Michigan, Med Sch, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Swindell, William R.] Ohio Univ, Heritage Coll Osteopath Med, Athens, OH 45701 USA; [Swindell, William R.] Jewish Hosp, Dept Internal Med, Cincinnati, OH USA; [Harms, Paul W.] Univ Michigan, Med Sch, Dept Pathol, Ann Arbor, MI 48109 USA; [Kahlenberg, J. Michelle] Univ Michigan, Med Sch, Div Rheumatol, Internal Med, Ann Arbor, MI 48109 USA; [White, Bethany E. Perez] Northwestern Univ, Dept Dermatol, Chicago, IL USA; [Maverakis, Emanual] UC Davis Med Ctr, Sch Med, Dept Dermatol, Sacramento, CA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Kiel; Schleswig Holstein University Hospital; University of Michigan System; University of Michigan; University System of Ohio; Ohio University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northwestern University; University of California System; University of California Davis	Gudjonsson, JE (corresponding author), 6427C Med Sci 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	johanng@med.umich.edu	White, Bethany E. Perez/AAF-7256-2020; Billi, Allison/AAP-1684-2021; Gerdes, Sascha/J-4308-2017; Hubenthal, Matthias/M-8149-2015	Gerdes, Sascha/0000-0002-6667-7757; Sarkar, Mrinal/0000-0001-8505-4259; Tsoi, Lam Cheung/0000-0003-1627-5722; Perez White, Bethany/0000-0002-5594-0599; Rodriguez, Elke/0000-0003-3692-3950; Hubenthal, Matthias/0000-0002-5956-3006	BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking [821511]; European Union; EFPIA; Babcock Endowment Fund; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01-AR060802, P30-AR075043, K01AR072129]; National Institute of Allergy and Infectious Diseases [R01-AR069071]; A. Alfred Taubman Medical Research Institute; Kenneth and Frances Eisenberg Emerging Scholar Award; Dermatology Foundation; Arthritis National Research Foundation; National Psoriasis Foundation; DFG Cluster of Excellence ``Precision Medicine in Inflammation'' [EXC2167]	BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking; European Union(European Commission); EFPIA; Babcock Endowment Fund; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); A. Alfred Taubman Medical Research Institute; Kenneth and Frances Eisenberg Emerging Scholar Award; Dermatology Foundation; Arthritis National Research Foundation(National Research Foundation of Korea); National Psoriasis Foundation; DFG Cluster of Excellence ``Precision Medicine in Inflammation''(German Research Foundation (DFG))	This work was supported by BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. It further received support from the Babcock Endowment Fund (L.C.T., M.K.S., J.E.G.), the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award numbers R01-AR060802 (J.E.G.), P30-AR075043 (J.E.G.), and K01AR072129 (L.C.T.), and the National Institute of Allergy and Infectious Diseases under award number R01-AR069071 (J.E.G.), the A. Alfred Taubman Medical Research Institute (J.E.G. and J.M.K.), and the Kenneth and Frances Eisenberg Emerging Scholar Award (J.E.G.). L.C.T. is supported by the Dermatology Foundation, the Arthritis National Research Foundation, and the National Psoriasis Foundation. Infrastructure support was provided through the DFG Cluster of Excellence ``Precision Medicine in Inflammation'' (grant no. EXC2167).	Abuabara K, 2018, ALLERGY, V73, P696, DOI 10.1111/all.13320; Abuabara K, 2019, J ALLERGY CLIN IMMUN, V144, P710, DOI 10.1016/j.jaci.2019.05.040; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bachelez H, 2019, NEW ENGL J MED, V380, P981, DOI 10.1056/NEJMc1811317; Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; de Koning HD, 2012, BRIT J DERMATOL, V166, P1245, DOI 10.1111/j.1365-2133.2012.10885.x; Ding Z, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.03.010; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Fischer M, 2006, J CLIN INVEST, V116, P2748, DOI 10.1172/JCI24274; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Gahr N, 2011, BRIT J DERMATOL, V164, P586, DOI 10.1111/j.1365-2133.2010.10112.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Harden JL, 2016, J ALLERGY CLIN IMMUN, V137, P1830, DOI 10.1016/j.jaci.2015.09.055; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Johnston A, 2011, J IMMUNOL, V186, P2613, DOI 10.4049/jimmunol.1003162; Lau D, 2018, J BIOL CHEM, V293, P203, DOI 10.1074/jbc.M117.818930; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lloyd-Lavery A, 2019, CLIN EXP DERMATOL, V44, P370, DOI 10.1111/ced.13853; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakatsumi H, 2017, CELL REP, V21, P2471, DOI 10.1016/j.celrep.2017.11.014; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Rahrig S, 2019, ALLERGY, V74, P1327, DOI 10.1111/all.13756; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766; Simpson EL, 2019, J AM ACAD DERMATOL, V80, P1013, DOI 10.1016/j.jaad.2018.11.059; SOTER NA, 1980, ACTA DERM-VENEREOL, P11; Steinhoff M, 2006, J ALLERGY CLIN IMMUN, V118, P190, DOI 10.1016/j.jaci.2006.04.025; Takaishi M, 2005, J BIOL CHEM, V280, P4696, DOI 10.1074/jbc.M409026200; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Yang Xiao-Feng, 2009, Front Biosci (Schol Ed), V1, P420, DOI 10.2741/s35; Yoshihara Y, 2019, J INVEST DERMATOL, V139, P475, DOI 10.1016/j.jid.2018.08.016	42	45	48	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1406	1415		10.1016/j.jaci.2019.11.047	http://dx.doi.org/10.1016/j.jaci.2019.11.047			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	31891686	Green Accepted, Bronze			2022-12-18	WOS:000531063400013
J	Winkler, C; Hochdorfer, T; Israelsson, E; Hasselberg, A; Cavallin, A; Thorn, K; Muthas, D; Shojaee, S; Luer, K; Muller, M; Mjosberg, J; Vaarala, O; Hohlfeld, J; Pardali, K				Winkler, Carla; Hochdoerfer, Thomas; Israelsson, Elisabeth; Hasselberg, Annemarie; Cavallin, Anders; Thoern, Kristofer; Muthas, Daniel; Shojaee, Shervin; Lueer, Katrin; Mueller, Meike; Mjoesberg, Jenny; Vaarala, Outi; Hohlfeld, Jens; Pardali, Katerina			Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; allergic asthma; allergen challenge; migration; gene expression	TYPE-2 IMMUNE-RESPONSE; CUTTING EDGE; INFLAMMATION; TRAFFICKING; HOMEOSTASIS; EXPRESSION; INDUCTION; PROMOTES; READS	Background: Group 2 innate lymphoid cells (ILC2s) are effective producers of IL-5 and IL-13 during allergic inflammation and bridge the innate and adaptive immune responses. ILC2 numbers are increased in asthmatic patients compared with healthy control subjects. Thus far, human data describing their phenotype during acute allergic inflammation in the lung are incomplete. Objectives: This study aims to characterize and compare blood and lung-derived ILC2s before and after segmental allergen challenge in patients with mild-to-moderate asthma with high blood eosinophil counts (>= 300 cells/mu L). Methods: ILC2s were isolated from blood and bronchoalveolar lavage (BAL) fluid before and after segmental allergen challenge. Cells were sorted by means of flow cytometry, cultured and analyzed for cytokine release or migration, and sequenced for RNA expression. Results: ILC2s were nearly absent in the alveolar space under baseline conditions, but numbers increased significantly after allergen challenge (P < .05), whereas at the same time, ILC2 numbers in blood were reduced (P < .05). Prostaglandin D2 and CXCL12 levels in BAL fluid correlated with decreased ILC2 numbers in blood (P = .004, respective P = .024). After allergen challenge, several genes promoting type 2 inflammation were expressed at greater levels in BAL fluid compared with blood ILC2s, whereas blood ILC2s remain unactivated. Conclusion: ILC2s accumulate at the site of allergic inflammation and are recruited from the blood. Their transcriptional and functional activation pattern promotes type 2 inflammation.	[Winkler, Carla; Hochdoerfer, Thomas; Israelsson, Elisabeth; Hasselberg, Annemarie; Cavallin, Anders; Thoern, Kristofer; Muthas, Daniel; Vaarala, Outi; Pardali, Katerina] AstraZeneca, Biotech IMED Unit, Resp Inflammat & Autoimmun, Gothenburg, Sweden; [Shojaee, Shervin] AstraZeneca, Biotech IMED Unit, Discovery Sci, Gothenburg, Sweden; [Lueer, Katrin; Mueller, Meike; Hohlfeld, Jens] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Mjoesberg, Jenny] Karolinska Inst, Ctr Infect Dis, Stockholm, Sweden; [Mjoesberg, Jenny] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Hohlfeld, Jens] German Ctr Lung Res BREATH, Hannover, Germany; [Hohlfeld, Jens] Hannover Med Sch, Dept Resp Med, Hannover, Germany	AstraZeneca; AstraZeneca; Fraunhofer Gesellschaft; Karolinska Institutet; Linkoping University; Hannover Medical School	Winkler, C (corresponding author), AstraZeneca, Biotech IMED Unit, Resp Inflammat & Autoimmun, Gothenburg, Sweden.; Winkler, C (corresponding author), Pepparedsleden 1, SE-43183 Molndal, Sweden.	carla.winkler@astrazeneca.com			AstraZeneca, Sweden; Fraunhofer ITEM, Germany	AstraZeneca, Sweden(AstraZeneca); Fraunhofer ITEM, Germany	Supported by AstraZeneca, Sweden and Fraunhofer ITEM, Germany.	Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Atochina-Vasserman EN, 2011, AM J RESP CRIT CARE, V183, P856, DOI 10.1164/rccm.201004-0654OC; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Califano D, 2015, IMMUNITY, V43, P354, DOI 10.1016/j.immuni.2015.07.005; Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI 10.1164/rccm.201612-2427OC; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Cosmi L, 2017, AM J RESP CRIT CARE, V196, P656, DOI 10.1164/rccm.201704-0799ED; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Drake LY, 2016, J IMMUNOL, V197, P1335, DOI 10.4049/jimmunol.1502669; Eastman JJ, 2017, J ALLERGY CLIN IMMUN, V140, P101, DOI 10.1016/j.jaci.2016.11.023; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Foronjy RF, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0041-4; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Janssen O, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-19; Karta MR, 2018, J ALLERGY CLIN IMMUN, V141, P329, DOI 10.1016/j.jaci.2017.03.010; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Li SY, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01909; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu SC, 2018, J ALLERGY CLIN IMMUN, V141, P257, DOI 10.1016/j.jaci.2017.03.032; Liu T, 2015, RESP MED, V109, P1391, DOI 10.1016/j.rmed.2015.09.016; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Mariani M, 2004, EUR J IMMUNOL, V34, P231, DOI 10.1002/eji.200324429; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Patro R, 2014, NAT BIOTECHNOL, V32, P462, DOI 10.1038/nbt.2862; Quinton LJ, 2012, J IMMUNOL, V188, P6300, DOI 10.4049/jimmunol.1200256; Rauber S, 2017, NAT MED, V23, P938, DOI 10.1038/nm.4373; Seehus CR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02023-z; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421	42	45	46	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					61	+		10.1016/j.jaci.2019.01.027	http://dx.doi.org/10.1016/j.jaci.2019.01.027			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30731124	Bronze			2022-12-18	WOS:000473432800010
J	Yao, Y; Wang, ZC; Wang, N; Zhou, PC; Chen, CL; Song, J; Pan, L; Liao, B; Zhang, XH; Yang, YS; Xu, XY; Zhu, RF; Yu, D; Liu, Z				Yao, Yin; Wang, Zhi-Chao; Wang, Nan; Zhou, Peng-Cheng; Chen, Cai-Ling; Song, Jia; Pan, Li; Liao, Bo; Zhang, Xin-Hao; Yang, Yong-Shi; Xu, Xiao-Yan; Zhu, Rong-Fei; Yu, Di; Liu, Zheng			Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; follicular regulatory T cells; IgE; allergen immunotherapy	HELPER-CELL; RESPONSES; TFH; INTERLEUKIN-2; MECHANISMS	Background: The function of follicular regulatory T (T-FR) cells, especially in regulating IgE production in patients with allergic diseases, is poorly understood. Objective: We sought to investigate the phenotype, function, and clinical relevance of T-FR cells in patients with allergic rhinitis (AR). Methods: The phenotype and frequency of tonsillar and circulating T-FR cells were characterized by using flow cytometry. T-FR cell function was examined in an assay by coculturing with follicular helper T cells and B cells. The associations between T-FR cells and the clinical features in patients with AR before and after allergen immunotherapy (AIT) were analyzed. Results: T-FR cells were detected in germinal centers of tonsils, but compared with subjects without AR, the frequencies decreased in patients with AR who were allergic to house dust mites. Circulating T-FR cells in blood were phenotypically and numerically correlated with tonsillar T-FR cells, and a reduction of circulating T-FR cells but not total or CXCR5(-) regulatory T cells was noted in patients with AR compared with healthy control subjects. Moreover, circulating T-FR cells in patients with AR showed a specific defect in suppressing IgE production but were capable of suppressing production of other immunoglobulin types. We identified negative associations of circulating T-FR cell frequencies and function with antigen-specific IgE levels or disease severity in patients with AR. After AIT, the frequencies and function of circulating T-FR cells were improved, which positively associated with disease remission. Conclusion: Impairment in T-FR cells might contribute to aberrant IgE production in patients with AR, and AIT improves defective T-FR cell function. T-FR cells might serve as a potential biomarker to monitor clinical response to AIT.	[Yao, Yin; Wang, Zhi-Chao; Wang, Nan; Chen, Cai-Ling; Song, Jia; Pan, Li; Liao, Bo; Zhang, Xin-Hao; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Yang, Yong-Shi; Zhu, Rong-Fei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Allergy, Wuhan, Hubei, Peoples R China; [Zhou, Peng-Cheng; Yu, Di] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia; [Xu, Xiao-Yan] China Resources & Wisco Gen Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Australian National University; John Curtin School of Medical Research; China Resources Group	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Yu, D (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia.	di.yu@anu.edu.au; zhengliuent@hotmail.com	Zhu, Rongfei/AAC-5570-2022; Yu, Di/C-2163-2009; Zhou, Pengcheng/GRR-4171-2022; Zhou, Pengcheng/AAQ-1320-2020; Yang, Yongshi/GYJ-0367-2022	Zhu, Rongfei/0000-0003-2103-3381; Yu, Di/0000-0003-1721-8922; Zhou, Pengcheng/0000-0002-7736-2902; Zhou, Pengcheng/0000-0002-7736-2902; Yin, Yao/0000-0002-5833-5263	National Natural Science Foundation of China (NSFC) [81570899, 81630024, 81325006, 81470677, 81429003]; Natural Science Foundation of Hubei Province of China [2017CFA016]; "Ten thousand plan''-National High Level Talents Special Support Plan; Australian National Health and Medical Research Council (NHMRC) [GNT1085509]; Bellberry-Viertel Senior Medical Research fellowship; China Scholarship Council [201706160045]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province of China(Natural Science Foundation of Hubei Province); "Ten thousand plan''-National High Level Talents Special Support Plan; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Bellberry-Viertel Senior Medical Research fellowship; China Scholarship Council(China Scholarship Council)	Supported by National Natural Science Foundation of China (NSFC) grants 81570899, 81630024, and 81325006 (to Z.L.), 81470677 (to X.H.Z.) and 81429003 (to D.Y.); the Natural Science Foundation of Hubei Province of China grant 2017CFA016 (to Z.L.); the "Ten thousand plan''-National High Level Talents Special Support Plan (to Z.L.); Australian National Health and Medical Research Council (NHMRC) fellowship GNT1085509 and the Bellberry-Viertel Senior Medical Research fellowship (to D.Y.); and a China Scholarship Council scholarship 201706160045 (to Y.Y.).	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Botta D, 2017, NAT IMMUNOL, V18, P1249, DOI 10.1038/ni.3837; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BUTTERWOM, 1967, NATURE, V214, P1224, DOI DOI 10.1038/2141224A0; Chen W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01625-3; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Ciebiada M, 2013, CLIN EXP ALLERGY, V43, P752, DOI 10.1111/cea.12124; Ciprandi G, 2016, RHINOLOGY, V54, P231, DOI 10.4193/Rhino15.300; Debock I, 2013, J IMMUNOL, V191, P1231, DOI 10.4049/jimmunol.1203288; Dhaeze T, 2015, J IMMUNOL, V195, P832, DOI 10.4049/jimmunol.1500759; Fonseca VR, 2018, ARTHRITIS RHEUMATOL, V70, P774, DOI 10.1002/art.40424; Fonseca VR, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan1487; Gomez E, 2015, CLIN EXP ALLERGY, V45, P1542, DOI 10.1111/cea.12578; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Pandiyan P, 2015, CYTOKINE, V76, P13, DOI 10.1016/j.cyto.2015.07.005; Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P639, DOI 10.1016/j.jaci.2016.06.003; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sage PT, 2014, J CLIN INVEST, V124, P5191, DOI 10.1172/JCI76861; Schulten V, 2018, J ALLERGY CLIN IMMUN, V141, P775, DOI 10.1016/j.jaci.2017.04.032; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Song J, 2018, J ALLERGY CLIN IMMUN, V141, P927, DOI 10.1016/j.jaci.2017.10.014; Stavnezer J, 2009, J IMMUNOL, V182, P5, DOI 10.4049/jimmunol.182.1.5; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wei YB, 2015, METHODS MOL BIOL, V1291, P199, DOI 10.1007/978-1-4939-2498-1_17; Wheatley LM, 2015, NEW ENGL J MED, V372, P456, DOI 10.1056/NEJMcp1412282; Xu BH, 2017, CLIN IMMUNOL, V183, P46, DOI 10.1016/j.clim.2017.07.004; Yao Y, 2018, J ALLERGY CLIN IMMUN, V142, P321, DOI 10.1016/j.jaci.2018.03.008; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	39	45	50	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					118	128		10.1016/j.jaci.2019.02.008	http://dx.doi.org/10.1016/j.jaci.2019.02.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30796979	Bronze			2022-12-18	WOS:000473432800015
J	Lee, J; Aoki, T; Thumkeo, D; Siriwach, R; Yao, CC; Narumiya, S				Lee, Jinju; Aoki, Tomohiro; Thumkeo, Dean; Siriwach, Ratklao; Yao, Chengcan; Narumiya, Shuh			T cell-intrinsic prostaglandin E-2-EP2/EP4 signaling is critical in pathogenic T(H)17 cell-driven inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; pathogenic T(H)17 cells; IL-23 receptor; prostaglandin E-2; prostaglandin E receptor EP2; prostaglandin E receptor EP4; signal transducer and activator of transcription 3; cAMP-responsive element binding protein 1; nuclear factor kappa light chain enhancer of activated B cells	INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; ANTIGEN-SPECIFIC TH17; DOUBLE-BLIND; PSORIATIC-ARTHRITIS; TGF-BETA; DIFFERENTIATION; RECEPTOR; IL-23; INDUCTION; EFFICACY	Background: IL-23 is the key cytokine for generation of pathogenic IL-17-producing helper T (T(H)17) cells, which contribute critically to autoimmune diseases. However, how IL-23 generates pathogenic T(H)d17 cells remains to be elucidated. Objectives: We sought to examine the involvement, molecular mechanisms, and clinical implications of prostaglandin ( PG) E-2-EP2/EP4 signaling in induction of IL-23-driven pathogenic T(H)17 cells. Methods: The role of PGE(2) in induction of pathogenic T(H)17 cells was investigated in mouse TH17 cells in culture in vitro and in an IL-23-induced psoriasis mouse model in vivo. Clinical relevance of the findings in mice was examined by using gene expression profiling of IL-23 and PGE(2)-EP2/EP4 signaling in psoriatic skin from patients. Results: IL-23 induces Ptgs2, encoding COX2 in T(H)17 cells, and produces PGE(2), which acts back on the PGE receptors EP2 and EP4 in these cells and enhances IL-23-induced expression of an IL-23 receptor subunit gene, Il23r, by activating signal transducer and activator of transcription (STAT) 3, cAMP-responsive element binding protein 1, and nuclear factor kappa light chain enhancer of activated B cells (NF-kappa B) through cyclic AMP-protein kinase A signaling. This PGE(2) signaling also induces expression of various inflammation-related genes, which possibly function in T(H)17 cell-mediated pathology. Combined deletion of EP2 and EP4 selectively in T cells suppressed accumulation of IL-17A(+) and IL-17A(+)IFN-gamma(+) pathogenic Th17 cells and abolished skin inflammation in an IL-23-induced psoriasis mouse model. Analysis of human psoriatic skin biopsy specimens shows positive correlation between PGE(2) signaling and the IL-23/T(H)17 pathway. Conclusions: T cell-intrinsic EP2/EP4 signaling is critical in IL-23-driven generation of pathogenic T(H)17 cells and consequent pathogenesis in the skin.	[Lee, Jinju; Aoki, Tomohiro; Thumkeo, Dean; Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, CREST, Kyoto, Japan; [Lee, Jinju] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto, Japan; [Aoki, Tomohiro; Thumkeo, Dean; Siriwach, Ratklao; Narumiya, Shuh] Kyoto Univ, Grad Sch Biostudies, Kyoto, Japan; [Yao, Chengcan] Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland	Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; University of Edinburgh	Yao, CC (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.; Narumiya, S (corresponding author), Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Sakyo Ku, 53 Shogoin Kawaharacho, Kyoto 6068507, Japan.	Chengcan.Yao@ed.ac.uk; snaru@mfour.med.kyoto-u.ac.jp		Narumiya, Shuh/0000-0001-8062-6529; Siriwach, Ratklao/0000-0001-9191-8711	Core Research for Evolutional Science and Technology Program on Chronic Inflammation from the Japan Agency for Medical Research and Development [15gm0410006h0006]; Japanese Ministry for Education, Culture, Sports, Science and Technology (MEXT); Astellas Pharma; Medical Research Council UK [MR/R008167/1]; Cancer Research UK [C63480/A25246]; Wellcome Trust Institutional Strategic Support Fund; Ono Pharmaceuticals; MRC [MR/R008167/1] Funding Source: UKRI	Core Research for Evolutional Science and Technology Program on Chronic Inflammation from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Japanese Ministry for Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Astellas Pharma(Astellas Pharmaceuticals); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Wellcome Trust Institutional Strategic Support Fund(Wellcome Trust); Ono Pharmaceuticals; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported in part by the Core Research for Evolutional Science and Technology Program on Chronic Inflammation (15gm0410006h0006) from the Japan Agency for Medical Research and Development (to S.N.); a Coordination Fund from the Japanese Ministry for Education, Culture, Sports, Science and Technology (MEXT) and Astellas Pharma to Kyoto University (to S.N.); a collaborative grant to Kyoto University from Ono Pharmaceuticals (to S.N.); and Medical Research Council UK (MR/R008167/1 to C.Y.), Cancer Research UK (C63480/A25246 to C.Y.), and Wellcome Trust Institutional Strategic Support Fund (to C.Y.).	Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Aoki T, 2011, BRIT J PHARMACOL, V163, P1237, DOI 10.1111/j.1476-5381.2011.01358.x; Aoki T, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah6037; Aoki T, 2012, TRENDS PHARMACOL SCI, V33, P304, DOI 10.1016/j.tips.2012.02.004; Best JL, 2004, P NATL ACAD SCI USA, V101, P17622, DOI 10.1073/pnas.0406374101; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Boyman O, 2014, NAT REV RHEUMATOL, V10, P612, DOI 10.1038/nrrheum.2014.123; Burkett PR, 2015, J CLIN INVEST, V125, P2211, DOI 10.1172/JCI78085; Chen HY, 2009, PROSTAG LEUKOTR ESS, V80, P195, DOI 10.1016/j.plefa.2009.01.006; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Duhen R, 2013, J IMMUNOL, V190, P4478, DOI 10.4049/jimmunol.1203172; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Hernandez JB, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8489, 10.1038/ncomms8216]; Hirata T, 2012, ADV IMMUNOL, V116, P143, DOI 10.1016/B978-0-12-394300-2.00005-3; Hirata T, 2011, CHEM REV, V111, P6209, DOI 10.1021/cr200010h; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994; Kofler DM, 2014, J CLIN INVEST, V124, P2513, DOI 10.1172/JCI72973; Kopp T, 2015, NATURE, V521, P222, DOI 10.1038/nature14175; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Korn T, 2008, P NATL ACAD SCI USA, V105, P18460, DOI 10.1073/pnas.0809850105; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Lee W, 2015, IMMUNOL CELL BIOL, V93, P472, DOI 10.1038/icb.2014.104; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li CR, 2014, J IMMUNOL, V192, P1425, DOI 10.4049/jimmunol.1301742; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Ma XJ, 2016, CELL MOL IMMUNOL, V13, P240, DOI 10.1038/cmi.2015.70; Ma XJ, 2015, CANCER RES, V75, P2822, DOI 10.1158/0008-5472.CAN-15-0125; Maseda D, 2018, J IMMUNOL, V200, P725, DOI 10.4049/jimmunol.1601808; Mat NFC, 2011, J INTERF CYTOK RES, V31, P363, DOI 10.1089/jir.2010.0083; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Menter A, 2008, J AM ACAD DERMATOL, V58, P826, DOI 10.1016/j.jaad.2008.02.039; Morishima N, 2009, BIOCHEM BIOPH RES CO, V386, P105, DOI 10.1016/j.bbrc.2009.05.140; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nakamura Mio, 2016, F1000Res, V5, DOI 10.12688/f1000research.8846.1; Napolitani G, 2009, EUR J IMMUNOL, V39, P1301, DOI 10.1002/eji.200838969; Nishimoto S, 2013, J IMMUNOL, V191, P3065, DOI 10.4049/jimmunol.1300348; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Reilly DM, 2000, ACTA DERM-VENEREOL, V80, P171; Rizzo HL, 2011, J IMMUNOL, V186, P1495, DOI 10.4049/jimmunol.1001001; Sakata D, 2010, J PHARMACOL SCI, V112, P1, DOI 10.1254/jphs.09R03CP; Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168; Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Soontrapa K, 2011, P NATL ACAD SCI USA, V108, P6668, DOI 10.1073/pnas.1018625108; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Stuart PE, 2015, AM J HUM GENET, V97, P816, DOI 10.1016/j.ajhg.2015.10.019; Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895; Torchinsky MB, 2010, CELL MOL LIFE SCI, V67, P1407, DOI 10.1007/s00018-009-0248-3; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yao CC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2684; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x; zu Horste GM, 2016, CELL REP, V16, P392, DOI 10.1016/j.celrep.2016.05.088	73	45	46	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					631	643		10.1016/j.jaci.2018.05.036	http://dx.doi.org/10.1016/j.jaci.2018.05.036			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29935220	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000457718700022
J	Chang, YS; Chiang, BL				Chang, Yung-Sen; Chiang, Bor-Luen			Sleep disorders and atopic dermatitis: A 2-way street?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sleep disturbance; atopic dermatitis; eczema; melatonin; sleep disorder	QUALITY-OF-LIFE; CIRCADIAN-RHYTHM; CHILDREN; ECZEMA; DISTURBANCE; MELATONIN; DISEASE; MINDFULNESS; MANAGEMENT; PATTERNS	Sleep disturbance is very common in patients with atopic dermatitis (AD) and is a major factor leading to impaired quality of life. Sleep disturbance is often viewed as one of the symptoms of AD and one of the measures of disease severity. In this review we describe a variety of sleep disorders associated with AD and a wide range of effect that sleep disorders have on patients with AD. We also discuss our current understanding of the mechanism of sleep disturbance in patients with AD. The relationship between sleep disorders and AD might be bidirectional and could form a vicious cycle. Therefore we suggest viewing sleep disorders as a comorbidity of AD for which regular screening and bidirectional management strategies are indicated, with equal focus on maintaining disease control and implementing specific strategies to improve sleep.	[Chang, Yung-Sen] Taipei City Hosp, Dept Pediat, Renai Branch, Taipei, Taiwan; [Chang, Yung-Sen; Chiang, Bor-Luen] Natl Taiwan Univ Hosp, Dept Pediat, Taipei, Taiwan; [Chang, Yung-Sen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chiang, Bor-Luen] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan	Taipei City Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; National Taiwan University	Chiang, BL (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan South Rd, Taipei 100, Taiwan.	gicmbor@ntu.edu.tw		CHIANG, BOR-LUEN/0000-0002-6705-0286				Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2; Bae BG, 2012, ACTA DERM-VENEREOL, V92, P57, DOI 10.2340/00015555-1189; Barilla S, 2017, ADV EXP MED BIOL, V1027, P71, DOI 10.1007/978-3-319-64804-0_7; Bartlet LB, 1997, ACTA DERM-VENEREOL, V77, P446; Beattie PE, 2006, BRIT J DERMATOL, V155, P145, DOI 10.1111/j.1365-2133.2006.07185.x; Bender BG, 2008, J AM ACAD DERMATOL, V58, P415, DOI 10.1016/j.jaad.2007.10.010; Benjamin K, 2004, J AM ACAD DERMATOL, V50, P33, DOI 10.1016/S0190-9622(03)02480-0; Besedovsky L, 2012, PFLUG ARCH EUR J PHY, V463, P121, DOI 10.1007/s00424-011-1044-0; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blake M, 2016, J CONSULT CLIN PSYCH, V84, P1039, DOI 10.1037/ccp0000142; Bollinger T, 2009, CLIN EXP IMMUNOL, V155, P231, DOI 10.1111/j.1365-2249.2008.03822.x; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Camfferman D, 2010, J CLIN SLEEP MED, V6, P581; Camfferman D, 2010, SLEEP MED REV, V14, P359, DOI 10.1016/j.smrv.2010.01.004; Chamlin SL, 2005, ARCH PEDIAT ADOL MED, V159, P745, DOI 10.1001/archpedi.159.8.745; Chang YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040462; Chang YS, 2016, JAMA PEDIATR, V170, P35, DOI 10.1001/jamapediatrics.2015.3092; Chang YS, 2014, PEDIATRICS, V134, pE397, DOI 10.1542/peds.2014-0376; Chng SY, 2004, PEDIATR PULM, V38, P210, DOI 10.1002/ppul.20075; Cicek D, 2012, CLIN EXP DERMATOL, V37, P469, DOI 10.1111/j.1365-2230.2012.04356.x; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; Dogan DG, 2017, POSTEP DERM ALERGOL, V34, P143, DOI 10.5114/ada.2017.67080; Doss N, 2010, PEDIAT ALLERG IMM-UK, V21, P321, DOI 10.1111/j.1399-3038.2009.00895.x; Fishbein AB, 2015, J ALLERGY CLIN IMMUN, V136, P1170, DOI 10.1016/j.jaci.2015.08.028; Foster EL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022029; Franca K, 2017, DERMATOL THER, V30; Geiger SS, 2015, IMMUNOLOGY, V146, P349, DOI 10.1111/imm.12525; Gong H, 2016, J PSYCHOSOM RES, V89, P1, DOI 10.1016/j.jpsychores.2016.07.016; Gupta MA, 2017, CLIN DERMATOL, V35, P319, DOI 10.1016/j.clindermatol.2017.01.004; He A, 2018, J AM ACAD DERMATOL, V79, P92, DOI 10.1016/j.jaad.2017.12.077; Hirotsu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051183; Hon KLE, 2008, CLIN EXP DERMATOL, V33, P705, DOI 10.1111/j.1365-2230.2008.02853.x; Hon KLE, 2007, BRIT J DERMATOL, V157, P922, DOI 10.1111/j.1365-2133.2007.08149.x; Hon KLE, 2007, ADV THER, V24, P23, DOI 10.1007/BF02849989; Hon KLE, 2006, BRIT J DERMATOL, V154, P629, DOI 10.1111/j.1365-2133.2006.07213.x; Hon KLE, 2005, J DERMATOL TREAT, V16, P22, DOI 10.1080/09546630410020145; Hu JM, 2018, PEDIAT ALLERG IMM-UK, V29, P260, DOI 10.1111/pai.12853; Jeon C, 2017, DERMATOLOGY THER, V7, P349, DOI 10.1007/s13555-017-0192-3; Kelsay K, 2006, J ALLERGY CLIN IMMUN, V118, P198, DOI 10.1016/j.jaci.2006.04.038; Lange T, 2010, ANN NY ACAD SCI, V1193, P48, DOI 10.1111/j.1749-6632.2009.05300.x; Lawson V, 1998, BRIT J DERMATOL, V138, P107; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Lewis-Jones MS, 2001, BRIT J DERMATOL, V144, P104, DOI 10.1046/j.1365-2133.2001.03960.x; Lewis-Jones S, 2006, INT J CLIN PRACT, V60, P984, DOI 10.1111/j.1742-1241.2006.01047.x; Lin YT, 2000, ALLERGY, V55, P641, DOI 10.1034/j.1398-9995.2000.00523.x; Marseglia L, 2014, INT J MOL SCI, V15, P13482, DOI 10.3390/ijms150813482; Meltzer LJ, 2008, J PEDIATR PSYCHOL, V33, P279, DOI 10.1093/jpepsy/jsm118; Mindell JA, 2010, CLIN GUIDE PEDIAT SL; Misery L, 2011, CLIN REV ALLERG IMMU, V41, P259, DOI 10.1007/s12016-010-8225-z; Montgomery K, 2016, BRIT J DERMATOL, V175, P930, DOI 10.1111/bjd.14719; MONTI JM, 1989, SLEEP, V12, P309, DOI 10.1093/sleep/12.4.309; Moore K, 2006, BRIT J DERMATOL, V154, P514, DOI 10.1111/j.1365-2133.2005.07082.x; Mullington JM, 2010, BEST PRACT RES CL EN, V24, P775, DOI 10.1016/j.beem.2010.08.014; Opp MR, 2005, SLEEP MED REV, V9, P355, DOI 10.1016/j.smrv.2005.01.002; Parekh PJ, 2015, AM J GASTROENTEROL, V110, P484, DOI 10.1038/ajg.2014.247; Patel D, 2018, PEDIATR DERMATOL, V35, P428, DOI 10.1111/pde.13444; REID P, 1995, CLIN EXP DERMATOL, V20, P38, DOI 10.1111/j.1365-2230.1995.tb01280.x; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Ricci G, 2007, PEDIATR ALLERGY IMMU, V18, P245, DOI 10.1111/j.1399-3038.2006.00502.x; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Romanos M, 2010, J EPIDEMIOL COMMUN H, V64, P269, DOI 10.1136/jech.2009.093534; Sadeh A, 2002, CHILD DEV, V73, P405, DOI 10.1111/1467-8624.00414; Sadeh A, 2009, J SLEEP RES, V18, P60, DOI 10.1111/j.1365-2869.2008.00699.x; Sakami S, 2002, NEUROIMMUNOMODULAT, V10, P337, DOI 10.1159/000071474; Schmitt J, 2011, ALLERGY, V66, P404, DOI 10.1111/j.1398-9995.2010.02487.x; SCHWARZ W, 1988, ACTA DERM-VENEREOL, V68, P224; Silverberg JI, 2015, JAMA DERMATOL, V151, P401, DOI 10.1001/jamadermatol.2014.3432; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Simpson EL, 2016, J AM ACAD DERMATOL, V75, P506, DOI 10.1016/j.jaad.2016.04.054; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stores G, 1998, PEDIATR DERMATOL, V15, P264, DOI 10.1046/j.1525-1470.1998.1998015264.x; Talbott W, 2015, AM J CLIN DERMATOL, V16, P147, DOI 10.1007/s40257-015-0128-6; Tien KJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089656; Touchette E, 2007, SLEEP, V30, P1213, DOI 10.1093/sleep/30.9.1213; Trier AM, 2018, CURR OPIN IMMUNOL, V54, P7, DOI 10.1016/j.coi.2018.05.005; Urrutia-Pereira M, 2017, ALLERGOL IMMUNOPATH, V45, P276, DOI 10.1016/j.aller.2016.08.014; Vaughn AR, 2018, PEDIATR DERMATOL, V35, P152, DOI 10.1111/pde.13364; Yamaguchi J, 2009, J DERMATOL SCI, V53, P48, DOI 10.1016/j.jdermsci.2008.08.011; Yen CH, 2008, ANN ALLERG ASTHMA IM, V100, P66, DOI 10.1016/S1081-1206(10)60407-3; Yosipovitch G, 2004, J INVEST DERMATOL, V122, P824, DOI 10.1111/j.0022-202X.2004.22313.x	81	45	47	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1033	1040		10.1016/j.jaci.2018.08.005	http://dx.doi.org/10.1016/j.jaci.2018.08.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	GV7RG	30144472	Bronze			2022-12-18	WOS:000446327300002
J	Lian, J; Cuk, M; Kahlfuss, S; Kozhaya, L; Vaeth, M; Rieux-Laucat, F; Picard, C; Benson, MJ; Jakovcevic, A; Bilic, K; Martinac, I; Stathopulos, P; Kacskovics, I; Vraetz, T; Speckmann, C; Ehl, S; Issekutz, T; Unutmaz, D; Feske, S				Lian, Jayson; Cuk, Mario; Kahlfuss, Sascha; Kozhaya, Lina; Vaeth, Martin; Rieux-Laucat, Frederic; Picard, Capucine; Benson, Melina J.; Jakovcevic, Antonia; Bilic, Karmen; Martinac, Iva; Stathopulos, Peter; Kacskovics, Imre; Vraetz, Thomas; Speckmann, Carsten; Ehl, Stephan; Issekutz, Thomas; Unutmaz, Derya; Feske, Stefan			ORAI1 mutations abolishing store-operated Ca2+ entry cause anhidrotic ectodermal dysplasia with immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ca2+ release-activated Ca2+ channel; store-operated Ca2+ entry; calcium; ORAI1; T cells; regulatory T cells; invariant natural killer T cells; immunodeficiency; combined immunodeficiency; anhidrotic ectodermal dysplasia	T-CELL-RECEPTOR; TUBULAR AGGREGATE MYOPATHY; CALCIUM-ENTRY; CRAC CHANNEL; IMMUNE-DEFICIENCY; EFFECTOR FUNCTION; NK CELLS; STIM1; ACTIVATION; INFLUX	Background: Store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ channels is an essential signaling pathway in many cell types. Ca2+ release-activated Ca2+ channels are formed by ORAI1, ORAI2, and ORAI3 proteins and activated by stromal interaction molecule (STIM) 1 and STIM2. Mutations in the ORAI1 and STIM1 genes that abolish SOCE cause a combined immunodeficiency (CID) syndrome that is accompanied by autoimmunity and nonimmunologic symptoms. Objective: We performed molecular and immunologic analysis of patients with CID, anhidrosis, and ectodermal dysplasia of unknown etiology. Methods: We performed DNA sequencing of the ORAI1 gene, modeling of mutations on ORAI1 crystal structure, analysis of ORAI1 mRNA and protein expression, SOCE measurements, immunologic analysis of peripheral blood lymphocyte populations by using flow cytometry, and histologic and ultrastructural analysis of patient tissues. Results: We identified 3 novel autosomal recessive mutations in ORAI1 in unrelated kindreds with CID, autoimmunity, ectodermal dysplasia with anhidrosis, and muscular dysplasia. The patients were homozygous for p.V181SfsX8, p.L194P, and p.G98R mutations in the ORAI1 gene that suppressed ORAI1 protein expression and SOCE in the patients' lymphocytes and fibroblasts. In addition to impaired T-cell cytokine production, ORAI1 mutations were associated with strongly reduced numbers of invariant natural killer T and regulatory T (Treg) cells and altered composition of gamma delta T-cell and natural killer cell subsets. Conclusion: ORAI1 null mutations are associated with reduced numbers of invariant natural killer T and Treg cells that likely contribute to the patients' immunodeficiency and autoimmunity. ORAI1-deficient patients have dental enamel defects and anhidrosis, representing a new form of anhidrotic ectodermal dysplasia with immunodeficiency that is distinct from previously reported patients with anhidrotic ectodermal dysplasia with immunodeficiency caused by mutations in the nuclear factor kappa B signaling pathway (IKBKG and NFKBIA).	[Lian, Jayson; Kahlfuss, Sascha; Vaeth, Martin; Benson, Melina J.; Feske, Stefan] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Cuk, Mario; Martinac, Iva] Univ Zagreb, Sch Med, Univ Hosp Ctr Zagreb, Dept Pediat, Zagreb, Croatia; [Kozhaya, Lina; Unutmaz, Derya] Jackson Lab Genom Med, Farmington, CT USA; [Rieux-Laucat, Frederic] INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmune Dis, Paris, France; [Rieux-Laucat, Frederic; Picard, Capucine] Paris Descartes Sorbonne Paris Cite Univ, INSERM, Imagine Inst, UMR1163, Paris, France; [Picard, Capucine] Necker Enfants Malad Hosp, AP HP, Necker Med Sch, Study Ctr Primary Immunodeficiencies, Paris, France; [Jakovcevic, Antonia] Univ Hosp Ctr Zagreb, Dept Pathol & Cytol, Zagreb, Croatia; [Bilic, Karmen] Univ Hosp Ctr Zagreb, Dept Lab Diagnost, Zagreb, Croatia; [Stathopulos, Peter] Western Univ, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada; [Kacskovics, Imre] ImmunoGenes, Budapest, Hungary; [Vraetz, Thomas; Speckmann, Carsten; Ehl, Stephan] Univ Freiburg, Fac Med, Med Ctr, Dept Pediat Hematol & Oncol,Ctr Pediat, Freiburg, Germany; [Speckmann, Carsten; Ehl, Stephan] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Issekutz, Thomas] Dalhousie Univ, Dept Pediat, Div Immunol, Halifax, NS, Canada	New York University; University of Zagreb; Jackson Laboratory; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Zagreb; University of Zagreb; Western University (University of Western Ontario); University of Freiburg; University of Freiburg; Dalhousie University	Feske, S (corresponding author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.	feskes01@nyumc.org	Feske, stefan/ABB-3554-2021; Rieux-Laucat, Frédéric/A-7916-2017; Ehl, Stephan/AAM-6006-2020	Feske, stefan/0000-0001-5431-8178; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Speckmann, Carsten/0000-0002-6217-1556; Stathopulos, Peter B./0000-0002-0536-6656; Ehl, Stephan/0000-0002-9265-2721; Issekutz, Thomas/0000-0001-5486-9463; Vaeth, Martin/0000-0001-8974-7052; Kahlfuss, Sascha/0000-0001-8813-1061	National Institutes of Health [AI097302, AI065303]; German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) [KA 4514/1-1, VA882/1-1]; BMBF by German Federal Ministry of Education and Research [01 EO0803]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065303, R01AI097302] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)(German Research Foundation (DFG)); BMBF by German Federal Ministry of Education and Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI097302 (to S.F.), and AI065303 (to D.U.), postdoctoral fellowships KA 4514/1-1 (to S.K.) and VA882/1-1 (to M.V.) by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), and BMBF grant 01 EO0803 by the German Federal Ministry of Education and Research (to S.E. and C.S.).	Badran YR, 2016, CLIN IMMUNOL, V166, P100, DOI 10.1016/j.clim.2016.03.012; Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003; Bohm J, 2017, HUM MUTAT, V38, P426, DOI 10.1002/humu.23172; Boisson B, 2017, J CLIN IMMUNOL, V37, P397, DOI 10.1007/s10875-017-0400-z; Byun M, 2010, J EXP MED, V207, P2307, DOI 10.1084/jem.20101597; Chou J, 2015, J ALLERGY CLIN IMMUN, V136, P479, DOI 10.1016/j.jaci.2015.03.050; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; Concepcion AR, 2016, J CLIN INVEST, V126, P4303, DOI 10.1172/JCI89056; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Crosby CM, 2016, IMMUNOGENETICS, V68, P639, DOI 10.1007/s00251-016-0933-y; Dahmane R, 2005, J BIOMECH, V38, P2451, DOI 10.1016/j.jbiomech.2004.10.020; Das H, 2004, J IMMUNOL, V172, P6578, DOI 10.4049/jimmunol.172.11.6578; Desvignes L, 2015, J CLIN INVEST, V125, P2347, DOI 10.1172/JCI80273; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Eckstein M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91166; Elling R, 2016, J ALLERGY CLIN IMMUN, V137, P1587, DOI 10.1016/j.jaci.2015.09.047; Endo Y, 2015, HUM MOL GENET, V24, P637, DOI 10.1093/hmg/ddu477; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Feske S, 1996, EUR J IMMUNOL, V26, P2119, DOI 10.1002/eji.1830260924; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Feske S, 2011, ANN NY ACAD SCI, V1238, P74, DOI 10.1111/j.1749-6632.2011.06240.x; Feske S, 2010, PFLUG ARCH EUR J PHY, V460, P417, DOI 10.1007/s00424-009-0777-5; Fuchs S, 2012, J IMMUNOL, V188, P1523, DOI 10.4049/jimmunol.1102507; Furukawa Y, 2017, J DENT RES, V96, P1422, DOI 10.1177/0022034517719872; Gwack Y, 2008, MOL CELL BIOL, V28, P5209, DOI 10.1128/MCB.00360-08; Hou XW, 2012, SCIENCE, V338, P1308, DOI 10.1126/science.1228757; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jorgensen SE, 2016, J ALLERGY CLIN IMMUN, V138, P1706, DOI 10.1016/j.jaci.2016.05.030; Kawai T, 2012, ALLERGOL INT, V61, P207, DOI 10.2332/allergolint.12-RAI-0446; Kim KD, 2011, J IMMUNOL, V187, P3620, DOI 10.4049/jimmunol.1100847; Klemann C, 2017, J ALLERGY CLIN IMMUN, V140, P1721, DOI 10.1016/j.jaci.2017.05.039; Lacruz RS, 2015, ANN NY ACAD SCI, V1356, P45, DOI 10.1111/nyas.12938; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lin FF, 2013, J PHARMACOL EXP THER, V345, P225, DOI 10.1124/jpet.112.202788; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Maul-Pavicic A, 2011, P NATL ACAD SCI USA, V108, P3324, DOI 10.1073/pnas.1013285108; Maus M, 2017, CELL METAB, V25, P698, DOI 10.1016/j.cmet.2016.12.021; Maus M, 2015, P NATL ACAD SCI USA, V112, P6206, DOI 10.1073/pnas.1418852112; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; McCarl CA, 2009, J ALLERGY CLIN IMMUN, V124, P1311, DOI 10.1016/j.jaci.2009.10.007; McNally BA, 2012, NATURE, V482, P241, DOI 10.1038/nature10752; McNally BA, 2009, P NATL ACAD SCI USA, V106, P22516, DOI 10.1073/pnas.0909574106; Nurbaeva MK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15803; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Oh-hora M, 2013, IMMUNITY, V38, P881, DOI 10.1016/j.immuni.2013.02.008; Parry DA, 2016, J ALLERGY CLIN IMMUN, V137, P955, DOI 10.1016/j.jaci.2015.08.051; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Pitard V, 2008, BLOOD, V112, P1317, DOI 10.1182/blood-2008-01-136713; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Schaballie H, 2015, J ALLERGY CLIN IMMUN, V136, P816, DOI 10.1016/j.jaci.2015.03.009; Vaeth M, 2017, IMMUNITY, V47, P664, DOI 10.1016/j.immuni.2017.09.003; Vaeth M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14714; Vaeth M, 2016, IMMUNITY, V44, P1350, DOI 10.1016/j.immuni.2016.04.013; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wang S, 2014, J DENT RES, V93, P94, DOI 10.1177/0022034514527971; Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1; Yamashita M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14512; Yen M, 2016, BIOPHYS J, V111, P1897, DOI 10.1016/j.bpj.2016.09.020; Yokobori N, 2009, CLIN EXP IMMUNOL, V157, P385, DOI 10.1111/j.1365-2249.2009.03974.x; Yu N, 2012, INFLAMMATION, V35, P1773, DOI 10.1007/s10753-012-9496-8; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2011, P NATL ACAD SCI USA, V108, P17838, DOI 10.1073/pnas.1114821108; Zheng L, 2015, DEV DYNAM, V244, P1249, DOI 10.1002/dvdy.24307; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	70	45	47	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1297	+		10.1016/j.jaci.2017.10.031	http://dx.doi.org/10.1016/j.jaci.2017.10.031			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29155098	Bronze, Green Accepted			2022-12-18	WOS:000446327300027
J	Chan, TC; Sanyal, RD; Pavel, AB; Glickman, J; Zheng, XZ; Xu, H; Cho, YT; Tsai, TF; Wen, HC; Peng, XY; Cueto, I; Krueger, JG; Guttman-Yassky, E				Chan, Tom C.; Sanyal, Riana D.; Pavel, Ana B.; Glickman, Jacob; Zheng, Xiuzhong; Xu, Hui; Cho, Yung-Tsu; Tsai, Tsen-Feng; Wen, Huei-Chi; Peng, Xiangyu; Cueto, Inna; Krueger, James G.; Guttman-Yassky, Emma			Atopic dermatitis in Chinese patients shows T(H)2/T(H)17 skewing with psoriasiform features	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CYTOKINES; ALPHA		[Chan, Tom C.; Cho, Yung-Tsu; Tsai, Tsen-Feng] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; [Chan, Tom C.; Cho, Yung-Tsu; Tsai, Tsen-Feng] Coll Med, Taipei, Taiwan; [Chan, Tom C.; Sanyal, Riana D.; Pavel, Ana B.; Glickman, Jacob; Xu, Hui; Wen, Huei-Chi; Peng, Xiangyu; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, Dept Dermatol, New York, NY 10029 USA; [Chan, Tom C.; Zheng, Xiuzhong; Cueto, Inna; Krueger, James G.] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA	National Taiwan University; National Taiwan University Hospital; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, Dept Dermatol, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Cho, Yung-Tsu/AAX-7031-2021; Wen, Huei-Chi/ABD-7417-2021	Cho, Yung-Tsu/0000-0002-5297-8997; Sanyal, Riana/0000-0002-6638-9026; TSAI, TSEN-FANG/0000-0002-1498-1474	National Center for Advancing Translational Sciences, National Institutes of Health [TR001434]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001434] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	R.D.S. was supported by TL1 grant number TR001434 from the National Center for Advancing Translational Sciences, National Institutes of Health.	Baliwag J, 2015, CYTOKINE, V73, P342, DOI 10.1016/j.cyto.2014.12.014; Breiman L., 1983, CLASSIFICATION REGRE, V1st, DOI 10.1201/9781315139470; Cortina-Borja Mario, 2009, BMC Res Notes, V2, P105, DOI 10.1186/1756-0500-2-105; Danso MO, 2014, J INVEST DERMATOL, V134, P1941, DOI 10.1038/jid.2014.83; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963; Gaspar K, 2013, J DERMATOL SCI, V71, P12, DOI 10.1016/j.jdermsci.2013.04.011; Lee CH, 2012, BRIT J DERMATOL, V167, P794, DOI 10.1111/j.1365-2133.2012.11047.x; Li Jiawen, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P294; Ma L, 2012, J DERMATOL SCI, V68, P66, DOI 10.1016/j.jdermsci.2012.07.009; MORGAN JN, 1963, J AM STAT ASSOC, V58, P415, DOI 10.2307/2283276; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Ohtsuki M, 2017, J DERMATOL, V44, P873, DOI 10.1111/1346-8138.13829; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; SAHA N, 1992, AM J PHYS ANTHROPOL, V88, P27, DOI 10.1002/ajpa.1330880104; Schofield C, 2016, BIOANALYSIS, V8, P2317, DOI 10.4155/bio-2016-0207; Shukla R, 2013, J IMMUNOL METHODS, V390, P30, DOI 10.1016/j.jim.2013.01.002; Slinker BK, 1998, J MOL CELL CARDIOL, V30, P723, DOI 10.1006/jmcc.1998.0655; Todd J, 2013, CYTOKINE, V64, P660, DOI 10.1016/j.cyto.2013.09.018; Wang X, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006317	19	45	47	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					1013	+		10.1016/j.jaci.2018.06.016	http://dx.doi.org/10.1016/j.jaci.2018.06.016			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29964056	Bronze			2022-12-18	WOS:000443726500043
J	Knudsen, TM; Rezwan, FI; Jiang, Y; Karmaus, W; Svanes, C; Holloway, JW				Knudsen, Torii Morkve; Rezwan, Faisal I.; Jiang, Yu; Karmaus, Wilfried; Svanes, Cecilie; Holloway, John W.			Transgenerational and intergenerational epigenetic inheritance in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transgenerational; intergenerational; multigenerational; parental; epigenetics; DNA methylation; asthma; allergy; environment	GRANDMATERNAL SMOKING PATTERNS; GENE-ENVIRONMENT INTERACTIONS; DNA METHYLATION; CHILDHOOD ASTHMA; AIRWAY INFLAMMATION; PRENATAL EXPOSURE; ATOPIC ECZEMA; LUNG-FUNCTION; PHASE-III; RISK	It has become clear that early life (including in utero exposures) is a key window of vulnerability during which environmental exposures can alter developmental trajectories and initiate allergic disease development. However, recent evidence suggests that there might be additional windows of vulnerability to environmental exposures in the parental generation before conception or even in previous generations. There is evidence suggesting that information of prior exposures can be transferred across generations, and experimental animal models suggest that such transmission can be conveyed through epigenetic mechanisms. Although the molecular mechanisms of intergenerational and transgenerationational epigenetic transmission have yet to be determined, the realization that environment before conception can alter the risks of allergic diseases has profound implications for the development of public health interventions to prevent disease. Future research in both experimental models and in multigenerational human cohorts is needed to better understand the role of intergenerational and transgenerational effects in patients with asthma and allergic disease. This will provide the knowledge basis for a new approach to efficient intervention strategies aimed at reducing the major public health challenge of these conditions.	[Knudsen, Torii Morkve] Univ Bergen, Dept Clin Med, Bergen, Norway; [Svanes, Cecilie] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway; [Rezwan, Faisal I.; Holloway, John W.] Univ Southampton, Fac Med, Human Dev & Hlth, Southampton, Hants, England; [Jiang, Yu; Karmaus, Wilfried] Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA; [Svanes, Cecilie] Haukeland Hosp, Dept Occupat Med, Bergen, Norway	University of Bergen; University of Bergen; University of Southampton; University of Memphis; University of Bergen; Haukeland University Hospital	Holloway, JW (corresponding author), Univ Hosp Southampton, Human Genet & Genom Med, Duthie Bldg,MP808, Southampton SO16 6YD, Hants, England.	j.w.holloway@soton.ac.uk	Holloway, John W/B-5424-2009; Svanes, Cecilie/N-7556-2017; Rezwan, Faisal I/E-8905-2017	Holloway, John W/0000-0001-9998-0464; Svanes, Cecilie/0000-0001-8512-5192; Rezwan, Faisal I/0000-0001-9921-222X	National Institutes of Health [R01AI091905, R01HL132321, R01AI121226]; Western Norway Health Authorities grant [912011]; European Union (Horizon 2020) [GA-633212]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL132321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091905, R01AI121226] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Western Norway Health Authorities grant; European Union (Horizon 2020); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health grants R01AI091905 and R01HL132321 (PI: Karmaus) and R01AI121226 (MPI: Zhang and Holloway), the Western Norway Health Authorities grant 912011, and the European Union (Horizon 2020, GA-633212) Ageing Lungs in European Cohorts study.	Accordini S, 2018, INT J EPIDEMIOL; Accordini S, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA1178; Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479; Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/epi.11.22, 10.2217/EPI.11.22]; Angulo M, 2012, ARCH BRONCONEUMOL, V48, P325, DOI 10.1016/j.arbres.2012.04.011; Arshad SH, 2017, J ALLERGY CLIN IMMUN, V139, P415, DOI 10.1016/j.jaci.2016.12.002; Arshad SH, 2012, J ALLERGY CLIN IMMUN, V130, P427, DOI 10.1016/j.jaci.2012.03.042; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9; Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Beck IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069115; Bertelsen RJ, 2017, CLIN EXP ALLERGY, V47, P627, DOI 10.1111/cea.12906; Bertelsen RJ, 2013, ALLERGY, V68, P84, DOI 10.1111/all.12058; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blacquiere MJ, 2009, EUR RESPIR J, V33, P1133, DOI 10.1183/09031936.00129608; Blewitt M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017939; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braback L, 2018, PEDIAT ALLERG IMM-UK, V29, P361, DOI 10.1111/pai.12883; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brugha R, 2017, ACTA PAEDIATR, V106, P2011, DOI 10.1111/apa.14027; Buckley BA, 2012, NATURE, V489, P447, DOI 10.1038/nature11352; Buescher JL, 2013, DIS MODEL MECH, V6, P1123, DOI 10.1242/dmm.011924; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Clifford RL, 2012, J IMMUNOL, V189, P819, DOI 10.4049/jimmunol.1103641; Cullati S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0151-1; Daxinger L, 2012, NAT REV GENET, V13, P153, DOI 10.1038/nrg3188; Day K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165488; Dolinoy DC, 2007, PEDIATR RES, V61, p30R, DOI 10.1203/pdr.0b013e31804575f7; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Duijts L, 2016, THORAX, V71, P1071, DOI 10.1136/thoraxjnl-2016-209061; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Everson TM, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0213-8; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Fedulov AV, 2011, AM J RESP CELL MOL, V44, P285, DOI 10.1165/rcmb.2009-0400OC; Feinberg AP, 2018, NEW ENGL J MED, V378, P1323, DOI [10.1056/NEJMra1402513, 10.1056/nejmra1402513]; Gapp K, 2014, NAT NEUROSCI, V17, P667, DOI 10.1038/nn.3695; Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228; Greer EL, 2011, NATURE, V479, P365, DOI 10.1038/nature10572; Gregory DJ, 2017, AM J PHYSIOL-LUNG C, V313, pL395, DOI 10.1152/ajplung.00035.2017; Guerrero-Bosagna C, 2012, REPROD TOXICOL, V34, P694, DOI 10.1016/j.reprotox.2012.09.005; Haahtela T, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-3; Han ST, 2015, ANN APPL STAT, V9, P2052, DOI 10.1214/15-AOAS865; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Harb H, 2015, J ALLERGY CLIN IMMUN, V135, P15, DOI 10.1016/j.jaci.2014.11.009; Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045; Heckerman D, 2016, P NATL ACAD SCI USA, V113, P7377, DOI 10.1073/pnas.1510497113; Herz U, 2000, AM J RESP CRIT CARE, V162, pS62, DOI 10.1164/ajrccm.162.supplement_2.ras-1; Hirvonen A, 2009, MUTAT RES-FUND MOL M, V667, P132, DOI 10.1016/j.mrfmmm.2008.12.013; Jahreis S, 2018, J ALLERGY CLIN IMMUN, V141, P741, DOI 10.1016/j.jaci.2017.03.017; Jogi NO, 2018, CLIN EXP ALLERGY, V48, P66, DOI 10.1111/cea.13055; Johannessen A, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA2615; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832; Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730; Knecht AL, 2017, TOXICOL APPL PHARM, V329, P148, DOI 10.1016/j.taap.2017.05.033; Knudsen TM, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.OA2948; Kothari PH, 2018, J ALLERGY CLIN IMMUN, V141, P2282, DOI 10.1016/j.jaci.2017.11.057; Langie SAS, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0484-1; Larcombe AN, 2011, EUR RESPIR J, V38, P932, DOI 10.1183/09031936.00156910; Lee-Sarwar K, 2018, J ALLER CL IMM-PRACT, V6, P711, DOI 10.1016/j.jaip.2018.01.026; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lim R, 2014, AM J PHYSIOL-LUNG C, V307, pL141, DOI 10.1152/ajplung.00250.2013; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Lockett GA, 2015, PEDIAT ALLERG IMM-UK, V26, P394, DOI 10.1111/pai.12408; Lodge CJ, 2018, CLIN EXP ALLERGY, V48, P167, DOI 10.1111/cea.13031; Loke YJ, 2013, TWIN RES HUM GENET, V16, P13, DOI 10.1017/thg.2012.114; Lovinsky-Desir S, 2012, CURR ALLERGY ASTHM R, V12, P211, DOI 10.1007/s11882-012-0257-4; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Magnus MC, 2015, THORAX, V70, P237, DOI 10.1136/thoraxjnl-2014-206438; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Manoli SE, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-42; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Matzkin LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059530; McArdle JJ, 2005, BEHAV GENET, V35, P631, DOI 10.1007/s10519-005-2868-1; McRae AF, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r73; Mendell MJ, 2018, INDOOR AIR, V28, P488, DOI 10.1111/ina.12464; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Miller LL, 2014, CHEST, V145, P1213, DOI 10.1378/chest.13-1371; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Niedzwiecki M, 2012, ALLERGY, V67, P904, DOI 10.1111/j.1398-9995.2012.02841.x; Norback D, 2013, OCCUP ENVIRON MED, V70, P325, DOI 10.1136/oemed-2012-100963; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Ollikainen M, 2010, HUM MOL GENET, V19, P4176, DOI 10.1093/hmg/ddq336; Patel S, 2009, ALLERGY, V64, P1766, DOI 10.1111/j.1398-9995.2009.02099.x; Pawankar R, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-12; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pembrey M, 2014, J MED GENET, V51, P563, DOI 10.1136/jmedgenet-2014-102577; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Rechavi O, 2014, CELL, V158, P277, DOI 10.1016/j.cell.2014.06.020; Rehan VK, 2013, AM J PHYSIOL-LUNG C, V305, pL501, DOI 10.1152/ajplung.00078.2013; Rehan VK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-129; Reid PA, 2013, J ROY COLL PHYS EDIN, V43, P44, DOI 10.4997/JRCPE.2013.111; Rothstein Mark A, 2009, Health matrix, V19, P1; Rowlatt A, 2016, HUM MOL GENET, V25, P2600, DOI 10.1093/hmg/ddw072; Royce SG, 2012, J ASTHMA, V49, P121, DOI 10.3109/02770903.2011.648298; Sales VM, 2017, CELL METAB, V25, P559, DOI 10.1016/j.cmet.2017.02.016; Schwartz DA, 2009, PEDIATRICS, V123, pS151, DOI 10.1542/peds.2008-2233E; Shoemaker R, 2010, GENOME RES, V20, P883, DOI 10.1101/gr.104695.109; Somineni HK, 2016, J ALLERGY CLIN IMMUN, V137, P797, DOI 10.1016/j.jaci.2015.10.021; Song Y, 2014, J ALLERGY CLIN IMMUN, V134, P1339, DOI 10.1016/j.jaci.2014.08.034; Su WY, 2010, BIOCHEM BIOPH RES CO, V396, P177, DOI 10.1016/j.bbrc.2010.04.147; Suderman M, 2016, J STEROID BIOCHEM, V159, P102, DOI 10.1016/j.jsbmb.2016.03.005; Svanes C, 2004, THORAX, V59, P295, DOI 10.1136/thx.2003.009746; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Svanes C, 2017, INT J EPIDEMIOL, V46, P235, DOI 10.1093/ije/dyw151; Svanes O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131959; Thurston GD, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00419-2016; Triebner K, 2016, J ALLERGY CLIN IMMUN, V137, P50, DOI 10.1016/j.jaci.2015.08.019; Uddin MJ, 2016, INT J CLIN PHARM-NET, V38, P714, DOI 10.1007/s11096-016-0299-0; Van Baak TE, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1374-0; van Dijk SJ, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0281-7; Veenendaal MVE, 2013, BJOG-INT J OBSTET GY, V120, P548, DOI 10.1111/1471-0528.12136; Victor JR, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-11; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Wongtrakool C, 2012, AM J RESP CELL MOL, V46, P695, DOI 10.1165/rcmb.2011-0028OC; Wu Haotian, 2015, Curr Environ Health Rep, V2, P356, DOI 10.1007/s40572-015-0067-7; Xu CJ, 2018, LANCET RESP MED, V6, P379, DOI 10.1016/S2213-2600(18)30052-3; Yang IV, 2017, J ALLERGY CLIN IMMUN, V140, P14, DOI 10.1016/j.jaci.2017.05.011; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yang IV, 2011, AM J RESP CRIT CARE, V183, P1295, DOI 10.1164/rccm.201010-1579PP	133	45	45	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					765	772		10.1016/j.jaci..2018.07.007	http://dx.doi.org/10.1016/j.jaci..2018.07.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	30040975				2022-12-18	WOS:000443726500006
J	Santos, AF; Couto-Francisco, N; Becares, N; Kwok, M; Bahnson, HT; Lack, G				Santos, Alexandra F.; Couto-Francisco, Natalia; Becares, Natalia; Kwok, Matthew; Bahnson, Henry T.; Lack, Gideon			A novel human mast cell activation test for peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BASOPHIL ACTIVATION; OXIDATIVE STRESS; METABOLOMICS; URINE; PATHWAYS; ASTHMA; TOLERANCE; DIAGNOSIS; INFANTS; DISEASE		[Santos, Alexandra F.; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Sch Life Course Sci, London, England; [Santos, Alexandra F.; Lack, Gideon] Guys & St Thomas Hosp NHS Fdn Trust, London, England; [Santos, Alexandra F.; Couto-Francisco, Natalia; Becares, Natalia; Kwok, Matthew; Lack, Gideon] Kings Coll London, Peter Gorer Dept Immunobiol, Sch Immunol & Microbial Sci, London, England; [Santos, Alexandra F.; Couto-Francisco, Natalia; Becares, Natalia; Kwok, Matthew; Lack, Gideon] MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Bahnson, Henry T.] Benaroya Res Inst, Immune Tolerance Network, Seattle, WA USA	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Benaroya Research Institute; Immune Tolerance Network	Santos, AF (corresponding author), Kings Coll London, Dept Pediat Allergy, Sch Life Course Sci, London, England.; Santos, AF (corresponding author), Guys & St Thomas Hosp NHS Fdn Trust, London, England.; Santos, AF (corresponding author), Kings Coll London, Peter Gorer Dept Immunobiol, Sch Immunol & Microbial Sci, London, England.; Santos, AF (corresponding author), MRC & Asthma UK Ctr Allerg Mech Asthma, London, England.	alexandra.santos@kcl.ac.uk		Lack, Gideon/0000-0001-7350-4021; Santos, Alexandra/0000-0002-7805-1436	Medical Research Council [MR/M008517/1]; Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; National Institute of Allergy and Infectious Diseases/National Institutes of Health [UM1AI109565]; MRC [MR/M008517/1, G0902018] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI109565, N01AI015416] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London(General Electric); King's College Hospital NHS Foundation Trust; National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Medical Research Council (MRC Clinician Scientist Fellowship MR/M008517/1 and MRC Centenary Early Career Award awarded to A.F.S) and the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. H.T.B. received support (salary) from the National Institute of Allergy and Infectious Diseases/National Institutes of Health through UM1AI109565 for the statistical analyses and manuscript development.	Adamko DJ, 2015, J ALLERGY CLIN IMMUN, V136, P571, DOI 10.1016/j.jaci.2015.05.022; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Assfalg M, 2012, BRIT J DERMATOL, V166, P1123, DOI 10.1111/j.1365-2133.2011.10711.x; Banoei MM, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1672-7; Biedron R, 2008, ARCH IMMUNOL THER EX, V56, P127, DOI 10.1007/s00005-008-0009-2; Callejon-Leblic B, 2016, J PROTEOMICS, V145, P197, DOI 10.1016/j.jprot.2016.05.030; Carrola J, 2011, J PROTEOME RES, V10, P221, DOI 10.1021/pr100899x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dawiskiba T, 2014, WORLD J GASTROENTERO, V20, P163, DOI 10.3748/wjg.v20.i1.163; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Fukuhara K, 2013, J CLIN BIOCHEM NUTR, V52, P133, DOI 10.3164/jcbn.12-118; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Hori S, 2011, LUNG CANCER, V74, P284, DOI 10.1016/j.lungcan.2011.02.008; Jung J, 2013, CLIN EXP ALLERGY, V43, P425, DOI 10.1111/cea.12089; Keshteli AH, 2017, WORLD J GASTROENTERO, V23, P3890, DOI 10.3748/wjg.v23.i21.3890; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lenz EM, 2004, J PHARMACEUT BIOMED, V36, P841, DOI 10.1016/j.jpba.2004.08.002; Marzetti E, 2013, INT J BIOCHEM CELL B, V45, P2288, DOI 10.1016/j.biocel.2013.06.024; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Robert C, 2003, FEMS MICROBIOL ECOL, V46, P81, DOI 10.1016/S0168-6496(03)00207-1; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Saude EJ, 2007, METABOLOMICS, V3, P439, DOI 10.1007/s11306-007-0091-1; Saude EJ, 2007, METABOLOMICS, V3, P19, DOI 10.1007/s11306-006-0042-2; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Schicho R, 2012, J PROTEOME RES, V11, P3344, DOI 10.1021/pr300139q; Ubhi BK, 2012, MOL BIOSYST, V8, P3125, DOI 10.1039/c2mb25194a; Wetmore DR, 2010, J BIOL CHEM, V285, P30516, DOI 10.1074/jbc.M110.140806; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Xu FG, 2013, J CLIN ENDOCR METAB, V98, pE1060, DOI 10.1210/jc.2012-4132; YOUNG VR, 1973, METABOLISM, V22, P1429, DOI 10.1016/0026-0495(73)90257-6	35	45	46	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					689	691		10.1016/j.jaci.2018.03.011	http://dx.doi.org/10.1016/j.jaci.2018.03.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29731128	Green Published, hybrid			2022-12-18	WOS:000440664400040
J	Leas, BF; D'Anci, KE; Apter, AJ; Bryant-Stephens, T; Lynch, MP; Kaczmarek, JL; Umscheid, CA				Leas, Brian F.; D'Anci, Kristen E.; Apter, Andrea J.; Bryant-Stephens, Tyra; Lynch, Marcus P.; Kaczmarek, Janice L.; Umscheid, Craig A.			Effectiveness of indoor allergen reduction in asthma management: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; allergens; environmental; house dust mites; carpet; pests; pets; air purification; high-efficiency particulate air filtration vacuums; mattress covers	HOUSE-DUST-MITE; RANDOMIZED CONTROLLED-TRIAL; HEALTH WORKER INTERVENTION; IMPERMEABLE BED COVERS; SENSITIVE ADULT ASTHMA; INNER-CITY CHILDREN; DOUBLE-BLIND TRIAL; ENVIRONMENTAL INTERVENTION; AVOIDANCE MEASURES; CHILDHOOD ASTHMA	Background: This review will inform updated National Asthma Education and Prevention Program clinical practice guidelines. Objective: We sought to evaluate the effectiveness of allergen reduction interventions on asthma outcomes. Methods: We systematically searched the "gray literature'' and 5 bibliographic databases. Eligible studies included systematic reviews, randomized controlled trials, and nonrandomized interventional studies. Risk of bias was assessed by using the Cochrane Risk of Bias instrument and the Newcastle-Ottawa scale. The evidence base was assessed by using the approach of the Agency for Healthcare Research and Quality's Evidence-based Practice Center program. Results: Fifty-nine randomized and 8 nonrandomized trials addressed 8 interventions: acaricide, air purification, carpet removal, high-efficiency particulate air filtration (HEPA) vacuums, mattress covers, mold removal, pest control, and pet removal. Thirty-seven studies evaluated single-component interventions, and 30 studies assessed multicomponent interventions. Heterogeneity precluded meta-analysis. For most interventions and outcomes, the evidence base was inconclusive or showed no effect. No interventions were associated with improvement in validated asthma control measures or pulmonary physiology. Exacerbations were diminished in multicomponent studies that included HEPA vacuums or pest control (moderate strength of evidence [SOE] for both). Quality of life improved in studies of air purifiers (SOE: low) and in multicomponent studies that included HEPA vacuums (SOE: moderate) or pest control (SOE: low). Conclusions: Single interventions were generally not associated with improvement in asthma measures, with most strategies showing inconclusive results or no effect. Multicomponent interventions improved various outcomes, but no combination of specific interventions appears to be more effective. The evidence was often inconclusive because of a lack of studies. Further research is needed comparing the effect of indoor allergen reduction interventions on validated asthma measures, with sufficient population sizes to detect clinically meaningful differences.	[Leas, Brian F.; Umscheid, Craig A.] Univ Penn Hlth Syst, Ctr Evidence Based Practice, 3535 Market St,Suite 50, Philadelphia, PA 19104 USA; [D'Anci, Kristen E.; Lynch, Marcus P.; Kaczmarek, Janice L.] Univ Penn, ECRI Inst Plymouth Meeting, Perelman Sch Med, Philadelphia, PA 19104 USA; [Apter, Andrea J.; Umscheid, Craig A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Leas, BF (corresponding author), Univ Penn Hlth Syst, Ctr Evidence Based Practice, 3535 Market St,Suite 50, Philadelphia, PA 19104 USA.	brian.leas@uphs.upenn.edu		Leas, Brian/0000-0003-2450-8434; Umscheid, Craig/0000-0003-1853-1013	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [290-2015-00005-I]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported under contract no. 290-2015-00005-I from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services. The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the AHRQ or the US Department of Health and Human Services. AHRQ retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of the agency's contract with the author. This topic was nominated by the National Heart, Lung, and Blood Institute (NHLBI) and selected by the AHRQ for systematic review by an Evidence-based Practice Center. A representative from AHRQ served as a Contracting Officer's Technical Representative and provide technical assistance during the conduct of the full evidence report and provided comments on draft versions of the full evidence report. AHRQ did not directly participate in the literature search, determination of study eligibility criteria, data analysis or interpretation, or preparation, review, or approval of the manuscript for publication.	[Anonymous], 2014, AHRQ PUBLICATION, V10(14)-EHC063-EF; [Anonymous], 3 NAT HEART LUNG BLO; Bahir A, 1997, ANN ALLERG ASTHMA IM, V78, P506, DOI 10.1016/S1081-1206(10)63239-5; Breysse J, 2014, AM J PUBLIC HEALTH, V104, pE57, DOI 10.2105/AJPH.2013.301402; Bryant-Stephens T, 2009, AM J PUBLIC HEALTH, V99, pS657, DOI [DOI 10.2105/AJPH.2009.165423, 10.2105/AJPH.2009.165423]; Bryant-Stephens T, 2008, J NATL MED ASSOC, V100, P306, DOI 10.1016/S0027-9684(15)31243-8; Burr ML, 2007, THORAX, V62, P767, DOI 10.1136/thx.2006.070847; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1976, LANCET, V1, P333; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Chang JH, 1996, ANN ALLERG ASTHMA IM, V77, P187, DOI 10.1016/S1081-1206(10)63253-X; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; de Vries MP, 2007, BRIT J GEN PRACT, V57, P184; Dharmage S, 2006, INT ARCH ALLERGY IMM, V139, P132, DOI 10.1159/000090388; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DiMango E, 2016, J ALLER CL IMM-PRACT, V4, P671, DOI 10.1016/j.jaip.2016.01.016; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; El-Ghitany Engy M., 2012, Environmental Health and Preventive Medicine, V17, P377, DOI 10.1007/s12199-011-0263-5; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Francis H, 2003, CLIN EXP ALLERGY, V33, P101, DOI 10.1046/j.1365-2222.2003.01570.x; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Geller-Bernstein C, 1995, Allerg Immunol (Paris), V27, P147; Glasgow NJ, 2011, ARCH DIS CHILD, V96, P541, DOI 10.1136/adc.2010.189696; Gotzsche P. C., 2008, COCHRANE DB SYST REV, V2; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Hayden ML, 1997, ANN ALLERG ASTHMA IM, V79, P437, DOI 10.1016/S1081-1206(10)63040-2; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kahwati L, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0256-y; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Kilburn S., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002989, DOI 10.1002/14651858.CD002989]; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; Krieger J, 2010, J PUBLIC HEALTH MAN, V16, pS11, DOI 10.1097/PHH.0b013e3181ddcbd9; Krieger J, 2009, ARCH PEDIAT ADOL MED, V163, P141, DOI 10.1001/archpediatrics.2008.532; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Lee IS, 2003, YONSEI MED J, V44, P313, DOI 10.3349/ymj.2003.44.2.313; Levy JI, 2006, SOC SCI MED, V63, P2191, DOI 10.1016/j.socscimed.2006.05.006; Luczynska C, 2003, CLIN EXP ALLERGY, V33, P1648, DOI 10.1111/j.1365-2222.2003.01729.x; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; MITCHELL EA, 1980, LANCET, V2, P559; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nambu Mitsuhiko, 2008, Pediatric Asthma Allergy & Immunology, V21, P137, DOI 10.1089/pai.2008.0002; National Heart Lung and Blood Advisory Council Asthma Expert Working Group, 2007, 3 NAT HEART LUNG BLO; Parker EA, 2008, HEALTH EDUC BEHAV, V35, P376, DOI 10.1177/1090198106290622; Pedroletti C, 2009, RESP MED, V103, P1313, DOI 10.1016/j.rmed.2009.03.020; Popplewell EJ, 2000, PEDIATR ALLERGY IMMU, V11, P142, DOI 10.1034/j.1399-3038.2000.00058.x; Rabito FA, 2017, J ALLERGY CLIN IMMUN, V140, P565, DOI [10.1016/j.jaci.2016.10.019, 10.1016/j.jaci.2016.12.221]; REISER J, 1990, CLIN EXP ALLERGY, V20, P561, DOI 10.1111/j.1365-2222.1990.tb03150.x; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; SETTE L, 1994, PEDIATR PULM, V18, P218, DOI 10.1002/ppul.1950180405; Shani Z, 2015, HEALTH PROMOT PRACT, V16, P291, DOI 10.1177/1524839914529593; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Sheikh Aziz, 2002, BMC Fam Pract, V3, P12, DOI 10.1186/1471-2296-3-12; SHETH JS, 2017, AM J RESP CRIT CARE, V195; Shirai T, 2005, CHEST, V127, P1565, DOI 10.1378/chest.127.5.1565; Sulser C, 2009, INT ARCH ALLERGY IMM, V148, P23, DOI 10.1159/000151502; Sweet LL, 2014, PUBLIC HEALTH NURS, V31, P243, DOI 10.1111/phn.12071; Takaro TK, 2011, AM J PUBLIC HEALTH, V101, P55, DOI 10.2105/AJPH.2010.300008; Tsurikisawa N, 2016, J ASTHMA, V53, P843, DOI 10.3109/02770903.2016.1155218; Tsurikisawa N, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-44; Turcotte DA, 2014, AM J PUBLIC HEALTH, V104, P665, DOI 10.2105/AJPH.2013.301695; van den Bemt L, 2004, J ALLERGY CLIN IMMUN, V114, P858, DOI 10.1016/j.jaci.2004.05.069; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; WALSHAW MJ, 1986, Q J MED, V58, P199; WARNER JA, 1993, THORAX, V48, P330, DOI 10.1136/thx.48.4.330; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Wells GA, NEWCASTLE OTTAWA SCA; Williams SG, 2006, J NATL MED ASSOC, V98, P249; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright GR, 2009, ALLERGY, V64, P1671, DOI 10.1111/j.1398-9995.2009.02098.x; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	79	45	48	3	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1854	1869		10.1016/j.jaci.2018.02.001	http://dx.doi.org/10.1016/j.jaci.2018.02.001			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	GF7KX	29452202	Bronze			2022-12-18	WOS:000432148200030
J	Tian, BP; Xia, LX; Bao, ZQ; Zhang, H; Xu, ZW; Mao, YY; Cao, C; Che, LQ; Liu, JK; Li, W; Chen, ZH; Ying, SM; Shen, HH				Tian, Bao-ping; Xia, Li-xia; Bao, Zheng-qiang; Zhang, Hao; Xu, Zhi-wei; Mao, Yuan-yuan; Cao, Chao; Che, Luan-qing; Liu, Jin-kai; Li, Wen; Chen, Zhi-hua; Ying, Songmin; Shen, Hua-hao			Bcl-2 inhibitors reduce steroid-insensitive airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; eosinophil; neutrophil; apoptosis; Bcl-2; steroid insensitive	GLUCOCORTICOID RESISTANCE; MOLECULAR-MECHANISMS; CELL-DEATH; ASTHMA; FAMILY; EOSINOPHIL; MANAGEMENT; APOPTOSIS; SURVIVAL; SPUTUM	Background: Asthmatic inflammation is dominated by accumulation of either eosinophils, neutrophils, or both in the airways. Disposal of these inflammatory cells is the key to disease control. Eosinophilic airway inflammation is responsive to corticosteroid treatment, whereas neutrophilic inflammation is resistant and increases the burden of global health care. Corticosteroid-resistant neutrophilic asthma remains mechanistically poorly understood and requires novel effective therapeutic strategies. Objective: We sought to explore the underlying mechanisms of airway inflammation persistence, as well as corticosteroid resistance, and to investigate a new strategy of effective treatment against corticosteroid-insensitive neutrophilic asthma. Methods: Mouse models of either eosinophil-dominated or neutrophil-dominated airway inflammation were used in this study to test corticosteroid sensitivity in vivo and in vitro. We also used vav-Bcl-2 transgenic mice to confirm the importance of granulocytes apoptosis in the clearance of airway inflammation. Finally, the Bcl-2 inhibitors ABT-737 or ABT-199 were tested for their therapeutic effects against eosinophilic or neutrophilic airway inflammation and airway hyperresponsiveness. Results: Overexpression of Bcl-2 protein was found to be responsible for persistence of granulocytes in bronchoalveolar lavage fluid after allergic challenge. This was important because allergen-induced airway inflammation aggravated and persisted in vav-Bcl-2 transgenic mice, in which nucleated hematopoietic cells were overexpressed with Bcl-2 and resistant to apoptosis. The Bcl-2 inhibitors ABT-737 or ABT-199 play efficient roles in alleviation of either eosinophilic or corticosteroid-resistant neutrophilic airway inflammation by inducing apoptosis of immune cells, such as eosinophils, neutrophils, TH2 cells, T(H)17 cells, and dendritic cells. Moreover, these inhibitors were found to be more efficient than steroids to induce granulocyte apoptosis ex vivo from patients with severe asthma. Conclusion: Apoptosis of inflammatory cells is essential for clearance of allergen-induced airway inflammation. The Bcl-2 inhibitors ABT-737 or ABT-199 might be promising drugs for the treatment of airway inflammation, especially for corticosteroid-insensitive neutrophilic airway inflammation.	[Tian, Bao-ping; Xia, Li-xia; Bao, Zheng-qiang; Zhang, Hao; Xu, Zhi-wei; Mao, Yuan-yuan; Cao, Chao; Che, Luan-qing; Liu, Jin-kai; Li, Wen; Chen, Zhi-hua; Ying, Songmin; Shen, Hua-hao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China; [Bao, Zheng-qiang; Ying, Songmin] Zhejiang Univ, Sch Med, Dept Pharmacol, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China; [Tian, Bao-ping; Xia, Li-xia; Bao, Zheng-qiang; Zhang, Hao; Xu, Zhi-wei; Mao, Yuan-yuan; Cao, Chao; Che, Luan-qing; Liu, Jin-kai; Li, Wen; Chen, Zhi-hua; Ying, Songmin; Shen, Hua-hao] Key Site Natl Clin Res Ctr Resp Dis, Hangzhou, Zhejiang, Peoples R China; [Xu, Zhi-wei] Ningbo Univ, Lihuili Hosp, Dept Crit Care Med, Ningbo Med Ctr, Ningbo, Zhejiang, Peoples R China; [Shen, Hua-hao] State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China	Zhejiang University; Zhejiang University; Ningbo University; State Key Laboratory of Respiratory Disease	Shen, HH (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.; Ying, SM (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	yings@zju.edu.cn; huahaoshen@163.com		Xu, Zhiwei/0000-0002-5732-4618	National Natural Science Foundation of China [81130001, 91542000, 31370901, 81422031, 81370126]; State Key Laboratory of Respiratory Disease [SKLRD2016OP002]; National Key Technologies RD Program [2012BAI05B01]; Key Science Technology Innovation Team of Zhejiang Province [2011R50016]; Fundamental Research Funds for the Central Universities [2015XZZX004-16]; National 1000 Talents Program for Young Scholars	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Respiratory Disease; National Key Technologies RD Program(National Key Technology R&D Program); Key Science Technology Innovation Team of Zhejiang Province; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National 1000 Talents Program for Young Scholars	Supported by the National Natural Science Foundation of China (to H.-h.S. [81130001 and 91542000], to S.Y. [31370901 and 81422031], and to W.L. [81370126]), Open Project of State Key Laboratory of Respiratory Disease (SKLRD2016OP002), the National Key Technologies R&D Program for the 12th Five-year Plan (2012BAI05B01), the Key Science Technology Innovation Team of Zhejiang Province (2011R50016), the Fundamental Research Funds for the Central Universities (2015XZZX004-16 to S.Y.), and the National 1000 Talents Program for Young Scholars (to S.Y.).	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; [Anonymous], 2016, DRUGS; Banuelos J, 2016, ALLERGY, V71, P640, DOI 10.1111/all.12840; Bardwell PD, 2009, J IMMUNOL, V182, P7482, DOI 10.4049/jimmunol.0802813; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bittar HET, 2015, ANNU REV PATHOL-MECH, V10, P511, DOI 10.1146/annurev-pathol-012414-040343; Bogaert P, 2011, AM J PHYSIOL-LUNG C, V300, pL679, DOI 10.1152/ajplung.00202.2010; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Gauvreau GM, 2015, EUR RESPIR J, V46, DOI [10.1183/13993003.congress-2015.PA5091, 10.1183/13993003.00536-2015]; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Hirsch G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044606; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018; Ierodiakonou D, 2011, EUR RESPIR J, V38, P1044, DOI 10.1183/09031936.00194710; Kim do H, 2015, PLOS ONE, V10; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Liang ZK, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-72; Maazi H, 2013, ALLERGY, V68, P695, DOI 10.1111/all.12166; Manni ML, 2016, J IMMUNOL, V196, P963, DOI 10.4049/jimmunol.1501531; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Olin JT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5517; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ottina E, 2015, J IMMUNOL, V194, P1316, DOI 10.4049/jimmunol.1400637; Park YM, 2010, ALLERGY ASTHMA IMMUN, V2, P87, DOI 10.4168/aair.2010.2.2.87; Saffar AS, 2011, CURR DRUG TARGETS, V12, P556; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; Simon HU, 2001, IMMUNOL REV, V179, P156, DOI 10.1034/j.1600-065X.2001.790115.x; Thomson NC, 2016, THER ADV RESPIR DIS, V10, P211, DOI 10.1177/1753465816632638; Tian BP, 2015, AM J RESP CELL MOL, V52, P459, DOI 10.1165/rcmb.2014-0097OC; Tian BP, 2014, MICROBES INFECT, V16, P811, DOI 10.1016/j.micinf.2014.07.004; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Wright DB, 2014, TRENDS PHARMACOL SCI, V35, P23, DOI 10.1016/j.tips.2014.09.006; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773	44	45	48	5	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					418	430		10.1016/j.jaci.2016.11.027	http://dx.doi.org/10.1016/j.jaci.2016.11.027			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28043871				2022-12-18	WOS:000406855500014
J	Belgrave, D; Henderson, J; Simpson, A; Buchan, I; Bishop, C; Custovic, A				Belgrave, Danielle; Henderson, John; Simpson, Angela; Buchan, Iain; Bishop, Christopher; Custovic, Adnan			Disaggregating asthma: Big investigation versus big data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; endotypes; machine learning; big data; birth cohorts	1ST 6 YEARS; GENE-ENVIRONMENT INTERACTIONS; GENOME-WIDE ASSOCIATION; WHEEZE PHENOTYPES; LUNG-FUNCTION; CHILDHOOD ASTHMA; IGE RESPONSES; RISK-FACTORS; ATOPY; LIFE	We are facing a major challenge in bridging the gap between identifying subtypes of asthma to understand causal mechanisms and translating this knowledge into personalized prevention and management strategies. In recent years, '' big data'' has been sold as a panacea for generating hypotheses and driving new frontiers of health care; the idea that the data must and will speak for themselves is fast becoming a new dogma. One of the dangers of ready accessibility of health care data and computational tools for data analysis is that the process of data mining can become uncoupled from the scientific process of clinical interpretation, understanding the provenance of the data, and external validation. Although advances in computational methods can be valuable for using unexpected structure in data to generate hypotheses, there remains a need for testing hypotheses and interpreting results with scientific rigor. We argue for combining data- and hypothesis-driven methods in a careful synergy, and the importance of carefully characterized birth and patient cohorts with genetic, phenotypic, biological, and molecular data in this process cannot be overemphasized. The main challenge on the road ahead is to harness bigger health care data in ways that produce meaningful clinical interpretation and to translate this into better diagnoses and properly personalized prevention and treatment plans. There is a pressing need for cross-disciplinary research with an integrative approach to data science, whereby basic scientists, clinicians, data analysts, and epidemiologists work together to understand the heterogeneity of asthma.	[Belgrave, Danielle; Custovic, Adnan] Imperial Coll, Dept Paediat, London, England; [Henderson, John] Univ Bristol, Fac Hlth Sci, Sch Social & Community Med, Bristol, Avon, England; [Simpson, Angela] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Buchan, Iain] Univ Manchester, Fac Biol Med & Hlth, Hlth Informat, Manchester, Lancs, England; [Bishop, Christopher; Custovic, Adnan] Microsoft Res, Cambridge, England	Imperial College London; University of Bristol; University of Manchester; University of Manchester; Microsoft	Custovic, A (corresponding author), Imperial Coll London, Sch Med, Dept Paediat, St Marys Campus, London W2 1PG, England.	a.custovic@imperial.ac.uk	Custovic, Adnan/A-2435-2012; Buchan, Iain E/H-5767-2013	Custovic, Adnan/0000-0001-5218-7071; Buchan, Iain E/0000-0003-3392-1650; Simpson, Angela/0000-0003-2733-6666	Medical Research Council Career Development Fellowship [MR/M015181/1]; Medical Research Council grant [MR/K002449/1]; Medical Research Council [G1000758B, MR/K002449/1, MR/M015181/1, MR/K006665/1, MC_PC_13042, MR/K002449/2, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [MR/K006665/1, G0601361, MR/K002449/1, MR/K002449/2, MR/M015181/1] Funding Source: UKRI	Medical Research Council Career Development Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	D.B. is supported by Medical Research Council Career Development Fellowship MR/M015181/1. The STELAR consortium is funded by Medical Research Council grant MR/K002449/1.	Agusti A, 2015, AM J RESP CRIT CARE, V191, P391, DOI 10.1164/rccm.201410-1935PP; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 2001, SPRINGE SER STAT N; Bach F, 2012, FOUND TRENDS MACH LE, V4, P1, DOI 10.1561/2200000015; Bechhofer S, 2013, FUTURE GENER COMP SY, V29, P599, DOI 10.1016/j.future.2011.08.004; Belgrave D, 2014, AM J RESP CRIT CARE, V189, P121, DOI 10.1164/rccm.201312-2206ED; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Belgrave DCM, 2013, EXPERT REV CLIN IMMU, V9, P921, DOI 10.1586/1744666X.2013.836450; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Bentler P M, 1992, Stat Methods Med Res, V1, P159, DOI 10.1177/096228029200100203; Berger J, 2006, BAYESIAN ANAL, V1, P385, DOI 10.1214/06-BA115; Berry A, 2016, J ALLERGY CLIN IMMUN, V137, P1317, DOI 10.1016/j.jaci.2016.03.009; Bishop, 1995, NEURAL NETWORKS PATT; Bishop C. M., 2006, MACH LEARN, V128; Bishop CM, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0222; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Collins SA, 2013, PEDIATR PULM, V48, P683, DOI 10.1002/ppul.22766; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Curtin JA, 2013, CLIN EXP ALLERGY, V43, P304, DOI 10.1111/cea.12046; Custovic A, 2004, THORAX, V59, P825, DOI 10.1136/thx.2004.027334; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, pe1, DOI DOI 10.1016/HACI.2010.10.050; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Custovic A, 2015, THORAX, V70, P799, DOI 10.1136/thoraxjnl-2015-206781; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; Custovic A, 2012, EXPERT REV RESP MED, V6, P301, DOI [10.1586/ERS.12.24, 10.1586/ers.12.24]; Deliu Matea, 2016, Pulm Ther, V2, P19; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Dunson DB, 2001, AM J EPIDEMIOL, V153, P1222, DOI 10.1093/aje/153.12.1222; Garden FL, 2016, EUR RESPIR J, V47, P499, DOI 10.1183/13993003.00284-2015; Gardy J, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0726-x; Gelman A., 2021, BAYESIAN DATA ANAL; Gelman A, 2013, BRIT J MATH STAT PSY, V66, P8, DOI 10.1111/j.2044-8317.2011.02037.x; Gibbs MN, 2000, IEEE T NEURAL NETWOR, V11, P1458, DOI 10.1109/72.883477; Gilboa I, 2016, AMBIGUITY BAYESIAN P, P385; Glass TA, 2013, ANNU REV PUBL HEALTH, V34, P61, DOI 10.1146/annurev-publhealth-031811-124606; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Granell R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048359; Han M, 2016, AM THORAC SOC, V193, pA3509; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hofmann T, 2001, MACH LEARN, V42, P177, DOI 10.1023/A:1007617005950; Howard R, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0542-0; Ic-Jusufagic AS, 2014, LANCET RESP MED, V2, P621, DOI 10.1016/S2213-2600(14)70096-7; Jordan MI, 2009, ARE YOU BAYESIAN FRE; Katz LB, 2015, INT DIABETES NURS, V12, P27, DOI DOI 10.1179/2057332415Y.0000000001; Kerkhof M, 2014, J ALLERGY CLIN IMMUN, V133, P68, DOI 10.1016/j.jaci.2013.06.004; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Laprise C, 2013, CURR OPIN ALLERGY CL, V13, P461, DOI 10.1097/ACI.0b013e328364ebc3; Lawrence ND, 2004, ADV NEUR IN, V16, P329; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Lodge CJ, 2014, J PEDIATR-US, V164, P289, DOI 10.1016/j.jpeds.2013.09.056; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MATTHYSSE S, 1986, J PSYCHIAT RES, V20, P57, DOI 10.1016/0022-3956(86)90023-3; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Muthen BO., 2002, BEHAVIORMETRIKA, V29, P81, DOI [DOI 10.2333/BHMK.29.81, 10.2333/bhmk.29.81]; Olson DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003256; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Prosperi MCF, 2013, AM J RESP CRIT CARE, V188, P1303, DOI 10.1164/rccm.201304-0694OC; Saria S, 2015, IEEE INTELL SYST, V30, P70, DOI 10.1109/MIS.2015.60; Schneeweiss S, 2014, NEW ENGL J MED, V370, P2161, DOI 10.1056/NEJMp1401111; Simpson A, 2010, CLIN EXP ALLERGY, V40, P209, DOI 10.1111/j.1365-2222.2009.03391.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Skrondal A., 2004, GEN LATENT VARIABLE; Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88; Sordillo JE, 2015, J ALLERGY CLIN IMMUN, V136, P885, DOI 10.1016/j.jaci.2015.02.035; Spycher B, 2016, EUR RESPIR J, V47, P362, DOI 10.1183/13993003.02011-2015; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; van Staa TP, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3636; Velasquez G, 2013, SPE MIDDLE EAST INTE; Velikova M, 2014, INT J APPROX REASON, V55, P59, DOI 10.1016/j.ijar.2013.03.016; West M, 2003, BAYESIAN STATISTICS 7, P733; Williams CKI, 1998, IEEE T PATTERN ANAL, V20, P1342, DOI 10.1109/34.735807; Williams SM, 2013, BIODATA MIN, V6, DOI 10.1186/1756-0381-6-22; Wjst M, 2013, CURR OPIN ALLERGY CL, V13, P112, DOI 10.1097/ACI.0b013e32835c1674; Woodcock A, 1998, THORAX, V53, pS47, DOI 10.1136/thx.53.2008.S47	86	45	45	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					400	407		10.1016/j.jaci.2016.11.003	http://dx.doi.org/10.1016/j.jaci.2016.11.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27871876	Green Published, hybrid			2022-12-18	WOS:000397002400003
J	Hall, SL; Baker, T; Lajoie, S; Richgels, PK; Yang, YF; McAlees, JW; van Lier, A; Wills-Karp, M; Sivaprasad, U; Acciani, TH; LeCras, TD; Myers, JB; Kovacic, MB; Lewkowich, IP				Hall, Sara L.; Baker, Theresa; Lajoie, Stephane; Richgels, Phoebe K.; Yang, Yanfen; McAlees, Jaclyn W.; van Lier, Adelaide; Wills-Karp, Marsha; Sivaprasad, Umasundari; Acciani, Thomas H.; LeCras, Timothy D.; Myers, Jocelyn Biagini; Kovacic, Melinda Butsch; Lewkowich, Ian P.			IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL-13; IL-17A; signal transducer and activator of transcription 6; cytokines; signal transduction	ALLERGIC AIRWAY INFLAMMATION; INTERLEUKIN (IL)-13 RESPONSES; MESSENGER-RNA STABILIZATION; GENE-EXPRESSION PROFILES; COMPLEMENT COMPONENT C3; DELTA-T-CELLS; RECEPTOR ALPHA-2; SMOOTH-MUSCLE; SEVERE ASTHMA; NEGATIVE REGULATOR	Background: Increased IL-17A production has been associated with more severe asthma; however, the mechanisms whereby IL-17A can contribute to IL-13-driven pathology in asthmatic patients remain unclear. Objective: We sought to gain mechanistic insight into how IL-17A can influence IL-13-driven responses. Methods: The effect of IL-17A on IL-13-induced airway hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assessed by using in vivo models of IL-13-induced lung pathology and in vitro culture of murine fibroblast cell lines and primary fibroblasts and human epithelial cell lines or primary human epithelial cells exposed to IL-13, IL-17A, or both. Results: Compared with mice given intratracheal IL-13 alone, those exposed to IL-13 and IL-17A had augmented airway hyperresponsiveness, mucus production, airway inflammation, and IL-13-induced gene expression. In vitro, IL-17A enhanced IL-13-induced gene expression in asthma-relevant murine and human cells. In contrast to the exacerbating influence of IL-17A on IL-13-induced responses, coexposure to IL-13 inhibited IL-17A-driven antimicrobial gene expression in vivo and in vitro. Mechanistically, in both primary human and murine cells, the IL-17A-driven increase in IL-13-induced gene expression was associated with enhanced IL-13-driven signal transducer and activator of transcription 6 activation. Conclusions: Our data suggest that IL-17A contributes to asthma pathophysiology by increasing the capacity of IL-13 to activate intracellular signaling pathways, such as signal transducer and activator of transcription 6. These data represent the first mechanistic explanation of how IL-17A can directly contribute to the pathogenesis of IL-13-driven pathology.	[Hall, Sara L.; Richgels, Phoebe K.; Yang, Yanfen; McAlees, Jaclyn W.; van Lier, Adelaide; Lewkowich, Ian P.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Baker, Theresa; Sivaprasad, Umasundari; Myers, Jocelyn Biagini; Kovacic, Melinda Butsch] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Acciani, Thomas H.; LeCras, Timothy D.] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; [Lajoie, Stephane; Wills-Karp, Marsha] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lewkowich, IP (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Ian.Lewkowich@cchmc.org		Lajoie, Stephane/0000-0002-0514-1801; Le Cras, Timothy/0000-0001-8538-2703; Baker, Theresa/0000-0002-2068-5989	National Heart, Lung, and Blood Institute [R01 HL122300]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122300] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grant R01 HL122300 (to I.P.L.).	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Allen HB, 2014, JAMA DERMATOL, V150, P260, DOI 10.1001/jamadermatol.2013.8627; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chen HC, 2010, J IMMUNOL, V185, P64, DOI 10.4049/jimmunol.0903323; Chen WG, 2013, J ALLERGY CLIN IMMUN, V132, P951, DOI 10.1016/j.jaci.2013.04.016; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Clausen ML, 2016, EXP DERMATOL, V25, P3, DOI 10.1111/exd.12831; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Gray MJ, 2005, GENE, V353, P98, DOI 10.1016/j.gene.2005.04.004; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135; Hartupee J, 2009, J IMMUNOL, V182, P1660, DOI 10.4049/jimmunol.182.3.1660; Hebenstreit D, 2005, MOL IMMUNOL, V42, P295, DOI 10.1016/j.molimm.2004.09.004; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kinyanjui MW, 2013, J IMMUNOL, V190, P3859, DOI 10.4049/jimmunol.1200506; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Lu XQ, 2008, BLOOD, V112, P4098, DOI 10.1182/blood-2008-03-148726; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moon MR, 1999, J SURG RES, V82, P48, DOI 10.1006/jsre.1998.5503; Murdoch JR, 2010, AM J RESP CRIT CARE, V182, P464, DOI 10.1164/rccm.200911-1775OC; Newcomb DC, 2012, J IMMUNOL, V188, P1027, DOI 10.4049/jimmunol.1102216; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Newcomb DC, 2013, THORAX, V68, P717, DOI 10.1136/thoraxjnl-2012-202404; Perkins C, 2011, J EXP MED, V208, P853, DOI 10.1084/jem.20100023; Persson H, 2015, J ALLERGY CLIN IMMUN, V136, P638, DOI 10.1016/j.jaci.2015.02.026; Qiao GL, 2014, CELL REP, V6, P709, DOI 10.1016/j.celrep.2014.01.012; Sahoo A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5732; Sozzani P, 1998, BIOCHEM BIOPH RES CO, V244, P665, DOI 10.1006/bbrc.1998.8314; Tao B, 2014, J IMMUNOL, V193, P2801, DOI 10.4049/jimmunol.1303463; Umeshita-Suyama R, 2000, INT IMMUNOL, V12, P1499, DOI 10.1093/intimm/12.11.1499; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wands JM, 2005, J LEUKOCYTE BIOL, V78, P1086, DOI 10.1189/jlb.0505244; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wei Q, 2014, AM J RESP CRIT CARE, V189, P16, DOI 10.1164/rccm.201305-0874OC; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson MS, 2011, GASTROENTEROLOGY, V140, P254, DOI 10.1053/j.gastro.2010.09.047; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	66	45	46	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					462	+		10.1016/j.jaci.2016.04.037	http://dx.doi.org/10.1016/j.jaci.2016.04.037			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27417023	Green Accepted, Bronze			2022-12-18	WOS:000397002400012
J	De Grove, KC; Provoost, S; Hendriks, RW; McKenzie, ANJ; Seys, LJM; Kumar, S; Maes, T; Brusselle, GG; Joos, GF				De Grove, Katrien C.; Provoost, Sharen; Hendriks, Rudi W.; McKenzie, Andrew N. J.; Seys, Leen J. M.; Kumar, Smitha; Maes, Tania; Brusselle, Guy G.; Joos, Guy F.			Dysregulation of type 2 innate lymphoid cells and T(H)2 cells impairs pollutant-induced allergic airway responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diesel exhaust particles; house dust mite; type 2 innate lymphoid cell; T(H)2 response; asthma	DIESEL EXHAUST PARTICLES; T-CELLS; INFLAMMATION; ASTHMA; IL-25; EXPRESSION; IL-33; LUNG; SENSITIZATION; ASSOCIATION	Background: Although the prominent role of T(H)2 cells in type 2 immune responses is well established, the newly identified type 2 innate lymphoid cells (ILC2s) can also contribute to orchestration of allergic responses. Several experimental and epidemiologic studies have provided evidence that allergen-induced airway responses can be further enhanced on exposure to environmental pollutants, such as diesel exhaust particles (DEPs). However, the components and pathways responsible remain incompletely known. Objective: We sought to investigate the relative contribution of ILC2 and adaptive T(H)2 cell responses in a murine model of DEP-enhanced allergic airway inflammation. Methods: Wild-type, Gata-3 (+/ nlslacZ) (Gata-3-haploinsufficient), RAR-related orphan receptor alpha(ROR alpha) (fl/ fl) IL7R (Cre) (ILC2-deficient), and recombination-activating gene (Rag) 2 (-/ -) mice were challenged with saline, DEPs, or house dust mite (HDM) or DEP+HDM. Airway hyperresponsiveness, as well as inflammation, and intracellular cytokine expression in ILC2s and T(H)2 cells in the bronchoalveolar lavage fluid and lung tissue were assessed. Results: Concomitant DEP+HDM exposure significantly enhanced allergic airway inflammation, as characterized by increased airway eosinophilia, goblet cell metaplasia, accumulation of ILC2s and T(H)2 cells, type 2 cytokine production, and airway hyperresponsiveness compared with sole DEPs or HDM. Reduced Gata-3 expression decreased the number of functional ILC2s and T(H)2 cells in DEP+HDM exposed mice, resulting in an impaired DEP-enhanced allergic airway inflammation. Interestingly, although the DEP-enhanced allergic inflammation was marginally reduced in ILC2-deficient mice that received combined DEP+HDM, it was abolished in DEP+HDM-exposed Rag2(-/ -) mice. Conclusion: These data indicate that dysregulation of ILC2s and T(H)2 cells attenuates DEP-enhanced allergic airway inflammation. In addition, a crucial role for the adaptive immune system was shown on concomitant DEP+HDM exposure.	[De Grove, Katrien C.; Provoost, Sharen; Seys, Leen J. M.; Kumar, Smitha; Maes, Tania; Brusselle, Guy G.; Joos, Guy F.] Ghent Univ Hosp, Dept Resp Med, Lab Translat Res Obstruct Pulm Dis, Ghent, Belgium; [Hendriks, Rudi W.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands; [McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Francis Crick Ave, Cambridge, England	Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC; MRC Laboratory Molecular Biology	Provoost, S (corresponding author), Ghent Univ Hosp, Dept Resp Med, Med Res Bldg MRB 2,2nd Floor,De Pintelaan 185, B-9000 Ghent, Belgium.	sharen.provoost@UGent.be	Maes, Tania/M-8675-2016	Maes, Tania/0000-0002-3037-6928; Brusselle, Guy/0000-0001-7021-8505; Joos, Guy/0000-0002-3149-9444	Interuniversity Attraction Poles Programme (IUAP), Belgian state; Belgian Science Policy [P7/30]; Concerted Research Action of the Ghent University [BOF/GOA 01G02714]; Fund for Scientific Research-Flanders; Lung Foundation Netherlands; Medical Research Council [MC_U105178805] Funding Source: researchfish; MRC [MC_U105178805] Funding Source: UKRI	Interuniversity Attraction Poles Programme (IUAP), Belgian state; Belgian Science Policy(Belgian Federal Science Policy Office); Concerted Research Action of the Ghent University; Fund for Scientific Research-Flanders(FWO); Lung Foundation Netherlands; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Interuniversity Attraction Poles Programme (IUAP), Belgian state; Belgian Science Policy (P7/30), Concerted Research Action of the Ghent University (BOF/GOA 01G02714); Fund for Scientific Research-Flanders (FWO-Vlaanderen); and Lung Foundation Netherlands (to R.W.H.). S.P. is a postdoctoral researcher of the Fund for Scientific Research-Flanders.	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Bleck B, 2008, J CLIN IMMUNOL, V28, P147, DOI 10.1007/s10875-007-9149-0; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fujimaki H, 2001, INT ARCH ALLERGY IMM, V124, P485, DOI 10.1159/000053784; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; KleinJan A, 2014, J IMMUNOL, V192, P1385, DOI 10.4049/jimmunol.1301888; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Provoost S, 2012, J ALLERGY CLIN IMMUN, V129, P483, DOI 10.1016/j.jaci.2011.07.051; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Shadie AM, 2014, CLIN EXP IMMUNOL, V177, P491, DOI 10.1111/cei.12348; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Takahashi G, 2010, J PHARMACOL SCI, V112, P192, DOI 10.1254/jphs.09276FP; Tindemans I, 2014, IMMUNITY, V41, P191, DOI 10.1016/j.immuni.2014.06.006; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Walker JA, 2013, CURR OPIN IMMUNOL, V25, P148, DOI 10.1016/j.coi.2013.02.010; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Wolterink RGJK, 2013, CURR ALLERGY ASTHM R, V13, P271, DOI 10.1007/s11882-013-0346-z; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yang Q, 2016, J ALLERGY CLIN IMMUN, V137, P571, DOI 10.1016/j.jaci.2015.06.037; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	47	45	45	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					246	+		10.1016/j.jaci.2016.03.044	http://dx.doi.org/10.1016/j.jaci.2016.03.044			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27315767	hybrid, Green Published			2022-12-18	WOS:000393996800026
J	Yu, H; Zhang, VW; Stray-Pedersen, A; Hanson, IC; Forbes, LR; de la Morena, MT; Chinn, IK; Gorman, E; Mendelsohn, NJ; Pozos, T; Wiszniewski, W; Nicholas, SK; Yates, AB; Moore, LE; Berge, KE; Sorte, H; Bayer, DK; ALZahrani, D; Geha, RS; Feng, YM; Wang, GL; Orange, JS; Lupski, JR; Wang, J; Wong, LJ				Yu, Hui; Zhang, Victor Wei; Stray-Pedersen, Asbjorg; Hanson, Imelda Celine; Forbes, Lisa R.; de la Morena, M. Teresa; Chinn, Ivan K.; Gorman, Elizabeth; Mendelsohn, Nancy J.; Pozos, Tamara; Wiszniewski, Wojciech; Nicholas, Sarah K.; Yates, Anne B.; Moore, Lindsey E.; Berge, Knut Erik; Sorte, Hanne; Bayer, Diana K.; ALZahrani, Daifulah; Geha, Raif S.; Feng, Yanming; Wang, Guoli; Orange, Jordan S.; Lupski, James R.; Wang, Jing; Wong, Lee-Jun			Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; severe combined immunodeficiency newborn screening; next-generation sequencing; molecular diagnostics	TBX1 HAPLOINSUFFICIENCY; THYMUS TRANSPLANTATION; OMENN SYNDROME; MUTATIONS; DEFECTS; DISEASE; INFECTIONS; EXPERIENCE; DELETIONS; ARTEMIS	Background: Primary immunodeficiency diseases (PIDDs) are inherited disorders of the immune system. The most severe form, severe combined immunodeficiency (SCID), presents with profound deficiencies of T cells, B cells, or both at birth. If not treated promptly, affected patients usually do not live beyond infancy because of infections. Genetic heterogeneity of SCID frequently delays the diagnosis; a specific diagnosis is crucial for life-saving treatment and optimal management. Objective: We developed a next-generation sequencing (NGS)-based multigene-targeted panel for SCID and other severe PIDDs requiring rapid therapeutic actions in a clinical laboratory setting. Methods: The target gene capture/NGS assay provides an average read depth of approximately 10003. The deep coverage facilitates simultaneous detection of single nucleotide variants and exonic copy number variants in one comprehensive assessment. Exons with insufficient coverage (<20 x read depth) or high sequence homology (pseudogenes) are complemented by amplicon-based sequencing with specific primers to ensure 100% coverage of all targeted regions. Results: Analysis of 20 patient samples with low T-cell receptor excision circle numbers on newborn screening or a positive family history or clinical suspicion of SCID or other severe PIDD identified deleterious mutations in 14 of them. Identified pathogenic variants included both single nucleotide variants and exonic copy number variants, such as hemizygous nonsense, frameshift, and missense changes in IL2RG; compound heterozygous changes in ATM, RAG1, and CIITA; homozygous changes in DCLRE1C and IL7R; and a heterozygous nonsense mutation in CHD7. Conclusion: High-throughput deep sequencing analysis with complete clinical validation greatly increases the diagnostic yield of severe primary immunodeficiency. Establishing a molecular diagnosis enables early immune reconstitution through prompt therapeutic intervention and guides management for improved long-term quality of life.	[Yu, Hui; Gorman, Elizabeth; Feng, Yanming; Wang, Guoli] Baylor Genet, Houston, TX USA; [Zhang, Victor Wei; Lupski, James R.; Wang, Jing; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg; Hanson, Imelda Celine; Forbes, Lisa R.; Chinn, Ivan K.; Nicholas, Sarah K.; Orange, Jordan S.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg; Hanson, Imelda Celine; Forbes, Lisa R.; Chinn, Ivan K.; Nicholas, Sarah K.; Orange, Jordan S.; Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg; Hanson, Imelda Celine; Forbes, Lisa R.; Chinn, Ivan K.; Nicholas, Sarah K.; Orange, Jordan S.] Texas Childrens Hosp, Feigin Ctr, Ctr Human Immunobiol Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg; Wiszniewski, Wojciech; Lupski, James R.] Baylor Coll Med, Baylor Hopkins Ctr Mendelian Genom, Dept Mol & Human Genet, Houston, TX 77030 USA; [Stray-Pedersen, Asbjorg] Oslo Univ Hosp, Norwegian Natl Unit Newborn Screening, Oslo, Norway; [Berge, Knut Erik; Sorte, Hanne] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway; [de la Morena, M. Teresa] Univ Texas Southwestern Med Ctr Dallas, Div Allergy & Immunol, Childrens Med Ctr, Dallas, TX 75390 USA; [Mendelsohn, Nancy J.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Pozos, Tamara] Childrens Hosp & Clin Minnesota, Pediat Infect Dis & Immunol, St Paul, MN USA; [Yates, Anne B.; Moore, Lindsey E.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Bayer, Diana K.] Univ Iowa, Dept Pediat, Div Pediat Allergy Immunol & Pulmonol, Carver Coll Med, Iowa City, IA 52242 USA; [ALZahrani, Daifulah] King Saud Bin Abdulaziz Univ Hlth Sci, Dept Pediat, Jeddah, Saudi Arabia; [Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Oslo; University of Oslo; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Hospitals & Clinics of Minnesota; Children's Hospitals & Clinics of Minnesota; University of Mississippi; University of Mississippi Medical Center; University of Iowa; King Saud Bin Abdulaziz University for Health Sciences; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Baylor College of Medicine	Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA.	ljwong@bcm.edu		Hanson, Imelda/0000-0001-9457-0757; Bayer, Diana/0000-0001-7181-7446; orange, jordan/0000-0001-7117-7725; Chinn, Ivan/0000-0001-5684-5457; Pozos, Tamara/0000-0003-0763-8763	Baylor College of Medicine; Horizon Investigator initiated restricted Award; Horizon; Jeffery Model Foundation; Clinical Immunology Society; National Institutes of Health; Jeffrey Modell Foundation; Baylor Genetics; Regeneron Pharmaceuticals; National Institute of Neurological Disorders and Stroke [R01 NS058529]; National Human Genome Research Institute/National Heart Lung and Blood Institute [U54 HG006542]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG006542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS058529] Funding Source: NIH RePORTER	Baylor College of Medicine; Horizon Investigator initiated restricted Award; Horizon; Jeffery Model Foundation; Clinical Immunology Society; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; Baylor Genetics; Regeneron Pharmaceuticals(Regeneron); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Human Genome Research Institute/National Heart Lung and Blood Institute; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	H. Yu is an employee of Baylor Genetics (Baylor College of Medicine and Miraca Holdings Inc have formed a joint venture with shared ownership and governance of the Baylor Genetics). L. R. Forbes serves on the board for Baxaltal, receives grant support from Baylor College of Medicine and Horizon Investigator initiated restricted Award, receives payments for lectures from Horizon, and received travel support from the Jeffery Model Foundation and the Clinical Immunology Society. M. T. de la Morena serves on the board for the Atlantic Research group. I. K. Chinn receives grants from the National Institutes of Health and the Jeffrey Modell Foundation. E. Gorman is an employee of Baylor Genetics. J. S. Orange serves as a consultant for Baxalta, CSL Behring, and Grifols; holds patents with the Children's Hospital of Philadelphia; and receives royalties from UpToDate. J. R. Lupski is an employee of Baylor College of Medicine and derives support through a professional services agreement with Baylor Genetics; serves on the Scientific Advisory Board of Baylor Genetics; has stock ownership in 23andMe; is a paid consultant for Regeneron Pharmaceuticals; has stock options in Lasergen, Inc and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases and bacterial genomic fingerprinting; and receives funding in part by grants R01 NS058529 (JRL) from the National Institute of Neurological Disorders and Stroke and U54 HG006542 (JRL) from the National Human Genome Research Institute/National Heart Lung and Blood Institute to the Baylor Hopkins Center for Mendelian Genomics. L.-J. Wong is an employee of Baylor Genetics. The rest of the authors declare that they have no relevant conflicts of interest.	Adams SP, 2014, J CLIN IMMUNOL, V34, P323, DOI 10.1007/s10875-014-0007-6; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Alsmadi O, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-116; Audrain M, 2014, CLIN IMMUNOL, V150, P137, DOI 10.1016/j.clim.2013.11.012; Bayer DK, 2014, CLIN EXP IMMUNOL, V178, P459, DOI 10.1111/cei.12421; Bontron S, 1997, HUM GENET, V99, P541, DOI 10.1007/s004390050403; Boone PM, 2013, GENOME RES, V23, P1383, DOI 10.1101/gr.156075.113; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Campbell IM, 2015, TRENDS GENET, V31, P382, DOI 10.1016/j.tig.2015.03.013; Chan A, 2011, CLIN IMMUNOL, V138, P3, DOI 10.1016/j.clim.2010.09.010; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; De P, 2004, IMMUNOL REV, V200, P70, DOI 10.1111/j.0105-2896.2004.00154.x; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Feng YM, 2015, GENET MED, V17, P99, DOI 10.1038/gim.2014.80; Gennery AR, 2012, CELL MOL LIFE SCI, V69, P17, DOI 10.1007/s00018-011-0842-z; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Grazioli S, 2014, CLIN IMMUNOL, V153, P209, DOI 10.1016/j.clim.2014.04.015; Hernandez-Trujillo V, 2014, CLIN REV ALLERG IMMU, V46, P145, DOI 10.1007/s12016-013-8380-0; Jilkina O, 2014, MOLEC GENET METAB RE, V1, P324, DOI 10.1016/j.ymgmr.2014.07.003; Kavadas FD, 2008, J ALLERGY CLIN IMMUN, V122, P1178, DOI 10.1016/j.jaci.2008.07.036; Kuo CY, 2013, J ALLERGY CLIN IMMUN, V131, P1693, DOI 10.1016/j.jaci.2013.01.019; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Leuzzi V, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000098; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lupski JR, 2015, ENVIRON MOL MUTAGEN, V56, P419, DOI 10.1002/em.21943; Mallott J, 2013, J CLIN IMMUNOL, V33, P540, DOI 10.1007/s10875-012-9846-1; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Markert ML, 2011, BLOOD, V117, P688, DOI 10.1182/blood-2010-06-292490; Martin-Santiago A, 2013, PEDIATR DERMATOL, V30, pE221, DOI 10.1111/pde.12126; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Ogata T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091598; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Pannicke U, 2010, HUM MUTAT, V31, P197, DOI 10.1002/humu.21168; Paylor R, 2006, P NATL ACAD SCI USA, V103, P7729, DOI 10.1073/pnas.0600206103; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; Puck JM, 1997, BLOOD, V89, P1968; Ram G, 2011, CLIN EXP IMMUNOL, V164, P9, DOI 10.1111/j.1365-2249.2011.04335.x; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; Schuetz C, 2010, AUTOIMMUN REV, V9, P477, DOI 10.1016/j.autrev.2010.02.005; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; Su DM, 2003, NAT IMMUNOL, V4, P1128, DOI 10.1038/ni983; Tsuda M, 2010, J AUTOIMMUN, V35, P265, DOI 10.1016/j.jaut.2010.06.017; van Zelm MC, 2008, AM J HUM GENET, V82, P320, DOI 10.1016/j.ajhg.2007.10.011; Verbsky J, 2014, CLIN PERINATOL, V41, P1001, DOI 10.1016/j.clp.2014.08.017; Verbsky JW, 2012, J CLIN IMMUNOL, V32, P82, DOI 10.1007/s10875-011-9609-4; Vogel BH, 2014, J CLIN IMMUNOL, V34, P289, DOI 10.1007/s10875-014-0006-7; Wang J, 2014, INVEST OPHTH VIS SCI, V55, P6213, DOI 10.1167/iovs.14-14936; Wang J, 2012, GENET MED, V14, P620, DOI 10.1038/gim.2012.4; Wong MTY, 2015, EUR J HUM GENET, V23, P1451, DOI 10.1038/ejhg.2015.7; Yagi H, 2003, LANCET, V362, P1366, DOI 10.1016/S0140-6736(03)14632-6	63	45	46	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1142	+		10.1016/j.jaci.2016.05.035	http://dx.doi.org/10.1016/j.jaci.2016.05.035			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27484032				2022-12-18	WOS:000385499400020
J	Hoffman, HM; Broderick, L				Hoffman, Hal M.; Broderick, Lori			The role of the inflammasome in patients with autoinflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoinflammation; inflammasome; innate immunity	FAMILIAL MEDITERRANEAN FEVER; NLRP3 INFLAMMASOME; COLCHICINE-RESISTANT; SUSTAINED RESPONSE; NALP3 INFLAMMASOME; SOMATIC MOSAICISM; CIAS1 MUTATIONS; PERIODIC FEVER; TNF RECEPTOR; PYRIN DOMAIN	Autoinflammatory diseases are disorders of the innate immune system, characterized by systemic inflammation often driven by inflammasomes, and independent of infection and autoreactive antibodies or antigen-specific T cells. These diseases are increasingly recognized as disorders of immune dysregulation, presenting with a constellation of fevers, rashes, and mucosal symptoms in many cases, which suggests that the allergist/immunologist is the appropriate specialist for these patients. However, many practicing physicians are unaware of these disorders in their pediatric and adult patient populations, leading to substantial delays in diagnosis. Recognizing autoinflammatory disease symptom patterns, performing appropriate diagnostic tests, and instituting early effective therapy are essential to reduce morbidity and mortality in these patients. This review will focus on understanding the molecular basis of inflammasomes, recognizing the distinguishing features of the classic autoinflammatory disorders, and appreciating the treatment modalities available.	Univ Calif San Diego, Div Pediat Allergy Immunol & Rheumatol, La Jolla, CA 92093 USA; Rady Childrens Hosp San Diego, San Diego, CA USA	University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Hoffman, HM (corresponding author), Univ Calif San Diego, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	hahoffman@ucsd.edu			Burroughs Wellcome; SOBI; Novartis; National Institutes of Health; Arthritis National Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD075830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052430] Funding Source: NIH RePORTER	Burroughs Wellcome(Burroughs Wellcome Fund); SOBI; Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arthritis National Research Foundation(National Research Foundation of Korea); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H. M. Hoffman has received research support from Burroughs Wellcome; has received consultancy fees from SOBI and Novartis; has received travel support from SOBI, Novartis, and Regeneron; and has received lecture fees from Novartis. L. Broderick has received research support from the National Institutes of Health and the Arthritis National Research Foundation; has received consultancy fees from SOBI and Novartis; and has received travel support from Regeneron.	Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 1997, CELL, V90, P797; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Ayres JS, 2013, CELL HOST MICROBE, V14, P491, DOI 10.1016/j.chom.2013.10.013; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Braun-Falco M, 2012, J AM ACAD DERMATOL, V66, P409, DOI 10.1016/j.jaad.2010.12.025; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Brydges SD, 2013, J CLIN INVEST, V123, P4695, DOI 10.1172/JCI71543; Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Cailliez M, 2006, J INHERIT METAB DIS, V29, P763, DOI 10.1007/s10545-006-0408-7; Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Curtis CD, 2015, J ALLER CL IMM-PRACT, V3, P817, DOI 10.1016/j.jaip.2015.05.020; de Koning HD, 2015, J ALLERGY CLIN IMMUN, V135, P561, DOI 10.1016/j.jaci.2014.07.050; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; Drewe E, 2003, RHEUMATOLOGY, V42, P235, DOI 10.1093/rheumatology/keg070; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Eroglu FK, 2015, RHEUMATOL INT, V35, P1733, DOI 10.1007/s00296-015-3293-2; Federici S, 2012, ANN RHEUM DIS, V71, P1961, DOI 10.1136/annrheumdis-2011-200977; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Galon J, 2000, CURR OPIN IMMUNOL, V12, P479, DOI 10.1016/S0952-7915(00)00124-2; Garcia-Carbonero R, 2013, LANCET ONCOL, V14, pE358, DOI 10.1016/S1470-2045(13)70169-4; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; Grimwood C, 2015, RHEUMATOLOGY, V54, P1749, DOI 10.1093/rheumatology/kev111; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Haneklaus M, 2015, IMMUNOL REV, V265, P53, DOI 10.1111/imr.12285; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hashkes PJ, 2012, ANN INTERN MED, V157, P533, DOI 10.7326/0003-4819-157-8-201210160-00003; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hoffman HM, 2008, ARTHRITIS RHEUM, V58, P2443, DOI 10.1002/art.23687; Hoffman HM, 2009, J ALLERGY CLIN IMMUN, V124, P1129, DOI 10.1016/j.jaci.2009.11.001; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Holzinger D, 2015, J ALLERGY CLIN IMMUN, V136, P1337, DOI 10.1016/j.jaci.2015.04.016; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Kim ML, 2015, J EXP MED, V212, P927, DOI 10.1084/jem.20142384; Kitamura A, 2014, J EXP MED, V211, P2385, DOI 10.1084/jem.20141091; La Torre F, 2015, RHEUMATOL INT, V35, P1943, DOI 10.1007/s00296-015-3305-2; Lamkanfi M, 2009, J BIOL CHEM, V284, P20574, DOI 10.1074/jbc.M109.023689; Lehman HK, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0553-x; Leslie KS, 2006, ARCH DERMATOL, V142, P1591, DOI 10.1001/archderm.142.12.1591; Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Liu Y, 2012, ARTHRITIS RHEUM-US, V64, P895, DOI 10.1002/art.33368; Marchetti C, 2015, J CARDIOVASC PHARM, V66, P1, DOI 10.1097/FJC.0000000000000247; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Nakagawa K, 2015, ANN RHEUM DIS, V74, P603, DOI 10.1136/annrheumdis-2013-204361; Netea MG, 2011, CURR OPIN PHARMACOL, V11, P412, DOI 10.1016/j.coph.2011.03.003; Nigrovic PA, 2001, CLIN EXP RHEUMATOL, V19, P484; Rieber N, 2015, CLIN IMMUNOL, V157, P56, DOI 10.1016/j.clim.2015.01.003; Romberg N, 2014, NAT GENET, V46, P1135, DOI 10.1038/ng.3066; Rosengren S, 2007, J ALLERGY CLIN IMMUN, V119, P991, DOI 10.1016/j.jaci.2006.12.649; Ross JB, 2008, J CUTAN MED SURG, V12, P8, DOI 10.2310/7750.2008.07050; Schett G, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2015-000046; Sibley CH, 2015, ANN RHEUM DIS, V74, P1714, DOI 10.1136/annrheumdis-2013-204877; Sibley CH, 2012, ARTHRITIS RHEUM-US, V64, P2375, DOI 10.1002/art.34409; Simon A, 2010, P NATL ACAD SCI USA, V107, P9801, DOI 10.1073/pnas.0914118107; Smith EJ, 2010, CURR GENOMICS, V11, P519, DOI 10.2174/138920210793175921; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Tricarico PM, 2014, INT J MOL SCI, V15, P6843, DOI 10.3390/ijms15046843; van der Burgh R, 2014, J BIOL CHEM, V289, P27757, DOI 10.1074/jbc.M114.571810; Wree A, 2013, NAT REV GASTRO HEPAT, V10, P627, DOI 10.1038/nrgastro.2013.149; Xu H, 2014, NATURE, V513, P237, DOI 10.1038/nature13449; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yu JW, 2007, MOL CELL, V28, P214, DOI 10.1016/j.molcel.2007.08.029; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zhou Q, 2015, ARTHRITIS RHEUMATOL, V67, P2482, DOI 10.1002/art.39190	84	45	47	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					3	15		10.1016/j.jaci.2016.05.001	http://dx.doi.org/10.1016/j.jaci.2016.05.001			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27373321	Bronze			2022-12-18	WOS:000379659100001
J	Weinhold, M; Shimabukuro-Vornhagen, A; Franke, A; Theurich, S; Wahl, P; Hallek, M; Schmidt, A; Schinkothe, T; Mester, J; von Bergwelt-Baildon, M; Bloch, W				Weinhold, Max; Shimabukuro-Vornhagen, Alexander; Franke, Axel; Theurich, Sebastian; Wahl, Patrick; Hallek, Michael; Schmidt, Annette; Schinkoethe, Timo; Mester, Joachim; von Bergwelt-Baildon, Michael; Bloch, Wilhelm			Physical exercise modulates the homeostasis of human regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BRONCHIAL RESPONSIVENESS; AUTOIMMUNITY; MECHANISMS; HISTAMINE; DISEASES; LIFE		[Weinhold, Max; Bloch, Wilhelm] German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Dept Mol & Cellular Sport Med, Cologne, Germany; [Weinhold, Max] German Olymp Hockey Team 2012, Monchengladbach, Germany; [Shimabukuro-Vornhagen, Alexander; Theurich, Sebastian; Hallek, Michael; von Bergwelt-Baildon, Michael] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne Intervent Immunol, D-50931 Cologne, Germany; [Franke, Axel] German Armed Forces, Cent Hosp, Koblenz, Germany; [Wahl, Patrick; Mester, Joachim; Bloch, Wilhelm] German Sport Univ Cologne, Inst Training Sci & Sport Informat, Cologne, Germany; [Wahl, Patrick; Mester, Joachim] German Sport Univ Cologne, German Res Ctr Elite Sport, Cologne, Germany; [Schmidt, Annette] German Armed Forces, Inst Pharmacol & Toxicol, Munich, Germany; [Schinkoethe, Timo] Inst Innovat & Med GmbH, Munich, Germany	German Sport University Cologne; University of Cologne; German Sport University Cologne; German Sport University Cologne	Bloch, W (corresponding author), German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Dept Mol & Cellular Sport Med, Cologne, Germany.; Bloch, W (corresponding author), German Sport Univ Cologne, Inst Training Sci & Sport Informat, Cologne, Germany.	W.Bloch@dsh-koeln.de	Theurich, Sebastian/AAB-2855-2022; Shimabukuro-Vornhagen, Alexander/AAM-8900-2020; Theurich, Sebastian/C-9995-2018; Hallek, Michael/Y-3191-2019; Wahl, Patrick/GRX-9246-2022	Theurich, Sebastian/0000-0001-5706-8258; Hallek, Michael/0000-0002-7425-4455; Wahl, Patrick/0000-0001-8682-5916; Shimabukuro-Vornhagen, Alexander/0000-0002-2351-7294				Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 2013, ASCIA SKIN PRICK TES; EATON SB, 1988, AM J MED, V84, P739, DOI 10.1016/0002-9343(88)90113-1; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; Kolte L, 2011, BLOOD, V117, P1861, DOI 10.1182/blood-2010-07-298992; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338, DOI 10.1164/ajrccm/144.2.338; PEPYS J, 1972, P ROY SOC MED, V65, P271, DOI 10.1177/003591577206500320; Sly PD, 2000, EUR RESPIR J, V16, P741, DOI 10.1034/j.1399-3003.2000.16d29.x; STICK SM, 1990, AM REV RESPIR DIS, V142, P1143, DOI 10.1164/ajrccm/142.5.1143; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P6; Wan YY, 2008, J CLIN IMMUNOL, V28, P647, DOI 10.1007/s10875-008-9251-y; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	19	45	46	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1607	1610		10.1016/j.jaci.2015.10.035	http://dx.doi.org/10.1016/j.jaci.2015.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26774657	Bronze			2022-12-18	WOS:000376180200043
J	Alvarez-Twose, I; Jara-Acevedo, M; Morgado, JM; Garcia-Montero, A; Sanchez-Munoz, L; Teodosio, C; Matito, A; Mayado, A; Caldas, C; Mollejo, M; Orfao, A; Escribano, L				Alvarez-Twose, Ivan; Jara-Acevedo, Maria; Mario Morgado, Jose; Garcia-Montero, Andres; Sanchez-Munoz, Laura; Teodosio, Cristina; Matito, Almudena; Mayado, Andrea; Caldas, Carolina; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis			Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; mastocytosis; well differentiated; KIT; imatinib	MARROW MAST-CELLS; DIAGNOSTIC-CRITERIA; SPANISH NETWORK; KIT MUTATION; WILD-TYPE; CLASSIFICATION; IMATINIB; BIOLOGY; STI571	Background: Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined. Objective: We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM. Methods: Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied. Results: Our cohort of patients showed female predominance (female/male ratio, 4:1) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KIT D816V (n = 5), K509I (n 5 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM. Conclusions: WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.	[Alvarez-Twose, Ivan; Mario Morgado, Jose; Sanchez-Munoz, Laura; Matito, Almudena] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo 45071, Spain; [Alvarez-Twose, Ivan; Jara-Acevedo, Maria; Mario Morgado, Jose; Garcia-Montero, Andres; Sanchez-Munoz, Laura; Teodosio, Cristina; Matito, Almudena; Mayado, Andrea; Caldas, Carolina; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis] Spanish Network Mastocytosis REMA, Toledo, Spain; [Alvarez-Twose, Ivan; Jara-Acevedo, Maria; Mario Morgado, Jose; Garcia-Montero, Andres; Sanchez-Munoz, Laura; Teodosio, Cristina; Matito, Almudena; Mayado, Andrea; Caldas, Carolina; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis] Spanish Network Mastocytosis REMA, Salamanca, Spain; [Jara-Acevedo, Maria; Garcia-Montero, Andres; Teodosio, Cristina; Mayado, Andrea; Caldas, Carolina; Orfao, Alberto] Univ Salamanca, Ctr Invest Canc IBMCC USAL CSIC, Toledo, Spain; [Jara-Acevedo, Maria; Garcia-Montero, Andres; Teodosio, Cristina; Mayado, Andrea; Caldas, Carolina; Orfao, Alberto] Univ Salamanca, IBSAL, Dept Med, Toledo, Spain; [Jara-Acevedo, Maria; Garcia-Montero, Andres; Teodosio, Cristina; Mayado, Andrea; Caldas, Carolina; Orfao, Alberto] Univ Salamanca, Serv Gen Citometria NUCLEUS, Toledo, Spain; [Mollejo, Manuela] Hosp Virgen de la Salud, Dept Pathol, Toledo, Spain	Complejo Hospitalario de Toledo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; Complejo Hospitalario de Toledo	Alvarez-Twose, I (corresponding author), Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Carretera Cobisa S-N, Toledo 45071, Spain.	ivana@sescam.jccm.es	Garcia-Montero, Andres C/B-6558-2017; Montero, Andres/HGA-9093-2022; Orfao, Alberto/B-5801-2017	Garcia-Montero, Andres C/0000-0003-4360-1386; Caldas, Carolina/0000-0003-3967-6211; Mollejo, Manuela/0000-0001-5658-0532; Jara-Acevedo, Maria/0000-0001-7965-7512; Alvarez-Twose, Ivan/0000-0002-1190-4473; Matito, Almudena/0000-0002-9547-4844; Teodosio, Cristina/0000-0002-2097-7199; Sanchez-Munoz, Laura/0000-0003-1757-7255	Asociacion Espanola de Mastocitosis, Madrid, Spain [AEDM 2014]; Instituto de Salud Carlos III, FEDER, Ministry of Economy and Competitivity, Madrid, Spain [PI11/02399]; Fundacion Ramon Areces, Madrid, Spain [CIVP16A1806]; Novartis Farmaceutica, S.A., Spain	Asociacion Espanola de Mastocitosis, Madrid, Spain; Instituto de Salud Carlos III, FEDER, Ministry of Economy and Competitivity, Madrid, Spain; Fundacion Ramon Areces, Madrid, Spain; Novartis Farmaceutica, S.A., Spain	Supported by grants from Asociacion Espanola de Mastocitosis, Madrid, Spain (grant AEDM 2014); Instituto de Salud Carlos III, FEDER, Ministry of Economy and Competitivity, Madrid, Spain (grant PI11/02399); Fundacion Ramon Areces, Madrid, Spain (grant CIVP16A1806); and Novartis Farmaceutica, S.A., Spain.	Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C., 2004, Journal of Allergy and Clinical Immunology, V113, pS327, DOI 10.1016/j.jaci.2004.01.683; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Akin C, 2014, IMMUNOL ALLERGY CLIN, V34, P207, DOI 10.1016/j.iac.2014.02.003; Alvarez-Twose I, 2012, INT J LAB HEMATOL, V34, P445, DOI 10.1111/j.1751-553X.2012.01427.x; Alvarez-Twose I, 2014, J ALLERGY CLIN IMMUN, V133, P520, DOI 10.1016/j.jaci.2013.06.020; Alvarez-Twose I, 2012, J CLIN ONCOL, V30, pE126, DOI 10.1200/JCO.2011.38.9973; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Chan EC, 2014, J ALLERGY CLIN IMMUN, V134, P178, DOI 10.1016/j.jaci.2013.12.1090; Campos PD, 2014, LEUKEMIA RES, V38, P1245, DOI 10.1016/j.leukres.2014.07.010; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Escribano L, 2012, LAB HEMATOLOGY PRACT, P388; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Hartmann K, 2002, LEUKEMIA RES, V26, P483, DOI 10.1016/S0145-2126(01)00157-6; Horny HP, 2006, J CLIN PATHOL, V59, P298, DOI 10.1136/jcp.2005.028738; Horny HP, 2008, WHO CLASSIFICATION T, P54; Jara-Acevedo M, 2008, HAEMATOL-HEMATOL J, V93, P91; Kopp P, 1997, MOL CELL PROBE, V11, P217, DOI 10.1006/mcpr.1997.0099; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Morgado JM, 2013, HISTOPATHOLOGY, V63, P780, DOI 10.1111/his.12221; Morgado JMT, 2012, MODERN PATHOL, V25, P516, DOI 10.1038/modpathol.2011.192; Pardanani A, 2003, LANCET, V362, P535, DOI 10.1016/S0140-6736(03)14115-3; PARKER RI, 1991, J INVEST DERMATOL, V96, pS47, DOI 10.1111/1523-1747.ep12469034; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84; Sanchez-Munoz L, 2011, METHOD CELL BIOL, V103, P333, DOI 10.1016/B978-0-12-385493-3.00014-0; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Teodosio C, 2012, LEUKEMIA, V26, P951, DOI 10.1038/leu.2011.293; Teodosio C, 2010, J ALLERGY CLIN IMMUN, V125, P719, DOI 10.1016/j.jaci.2009.10.020; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2014, ANN ONCOL, V25, P1691, DOI 10.1093/annonc/mdu047; Valent P, 2014, ALLERGY, V69, P1267, DOI 10.1111/all.12436; Valent P, 2001, LEUKEMIA RES, V25, P595, DOI 10.1016/S0145-2126(01)00040-6; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Wu Y, 2003, FERTIL STERIL, V79, P710, DOI 10.1016/S0015-0282(02)04821-5; Zhang LY, 2006, LEUKEMIA RES, V30, P373, DOI 10.1016/j.leukres.2005.08.015	37	45	48	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					168	+		10.1016/j.jaci.2015.05.008	http://dx.doi.org/10.1016/j.jaci.2015.05.008			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26100086				2022-12-18	WOS:000367724300007
J	Sander, I; Rihs, HP; Doekes, G; Quirce, S; Krop, E; Rozynek, P; van Kampen, V; Merget, R; Meurer, U; Bruning, T; Raulf, M				Sander, Ingrid; Rihs, Hans-Peter; Doekes, Gert; Quirce, Santiago; Krop, Esmeralda; Rozynek, Peter; van Kampen, Vera; Merget, Rolf; Meurer, Ursula; Bruening, Thomas; Raulf, Monika			Component-resolved diagnosis of baker's allergy based on specific IgE to recombinant wheat flour proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Baker's asthma; Triticum aestivum; recombinant allergens; alpha-amylase inhibitor; cross-reactivity; grass pollen; rye flour; wheat allergy; specific IgE; component-resolved diagnosis	SKIN PRICK TEST; EXERCISE-INDUCED ANAPHYLAXIS; MOLECULAR-WEIGHT-GLUTENIN; LIPID TRANSFER PROTEIN; IMMUNOLOGICAL CHARACTERIZATION; FOOD ALLERGY; BD 27K; ASTHMA; TRI; SENSITIZATION	Background: Sensitization to wheat flour plays an important role in the development and diagnosis of baker's asthma. Objectives: We evaluated wheat allergen components as sensitizers for bakers with work-related complaints, with consideration of cross-reactivity to grass pollen. Methods: Nineteen recombinant wheat flour proteins and 2 cross-reactive carbohydrate determinants were tested by using CAP-FEIA in sera of 101 bakers with wheat flour allergy (40 German, 37 Dutch, and 24 Spanish) and 29 pollen-sensitized control subjects with wheat-specific IgE but without occupational exposure. IgE binding to the single components was inhibited with wheat flour, rye flour, and grass pollen. The diagnostic efficiencies of IgE tests with single allergens and combinations were evaluated by assessing their ability to discriminate between patients with baker's allergy and control subjects based on receiver operating characteristic analyses. Results: Eighty percent of bakers had specific IgE levels of 0.35 kU(A)/L or greater and 91% had specific IgE levels of 0.1 kU(A)/L or greater to at least one of the 21 allergens. The highest frequencies of IgE binding were found for thiol reductase (Tri a 27) and the wheat dimeric a-amylase inhibitor 0.19 (Tri a 28). Cross-reactivity to grass pollen was proved for 9 components, and cross-reactivity to rye flour was proved for 18 components. A combination of IgE tests to 5 components, Tri a 27, Tri a 28, tetrameric a-amylase inhibitor CM2 (Tri a 29.02), serine protease inhibitor like allergen (Tri a 39), and 1-cys-peroxiredoxin (Tri a 32), produced the maximal area under the curve (AUC = 0.84) in receiver operating characteristic analyses, but this was still lower than the AUC for wheat- or rye flour specific IgE (AUC = 0.89 or 0.88, respectively). Conclusions: Component-resolved diagnostics help to distinguish between sensitization caused by occupational flour exposure and wheat seropositivity based on cross-reactivity to grass pollen. For routine diagnosis of baker's allergy, however, allergen-specific IgE tests with whole wheat and rye flour extracts remain mandatory because of superior diagnostic sensitivity.	[Sander, Ingrid; Rihs, Hans-Peter; Rozynek, Peter; van Kampen, Vera; Merget, Rolf; Meurer, Ursula; Bruening, Thomas; Raulf, Monika] Ruhr Univ Bochum IPA, Inst Prevent & Occupat Med, German Social Accid Insurance, Bochum, Germany; [Doekes, Gert; Krop, Esmeralda] Univ Utrecht, IRAS, NL-3508 TC Utrecht, Netherlands; [Quirce, Santiago] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain; [Quirce, Santiago] CIBER Resp Dis CIBERES, Madrid, Spain	Ruhr University Bochum; Utrecht University; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Sander, I (corresponding author), Inst Ruhr Univ Bochum IPA, Dept Allergol Immunol, Forschungsinst Pravent & Arbeitsmed Deutschen Ges, Burkle Camp Pl 1, D-44789 Bochum, Germany.	Sander@ipa-dguv.de	s, q/AAD-7171-2020; van Kampen, Vera/AAH-3657-2019; Brüning, Thomas/G-8120-2015; Sander, Ingrid/R-8940-2017	Brüning, Thomas/0000-0001-9560-5464; Sander, Ingrid/0000-0002-5014-4112; Krop, Esmeralda/0000-0002-6009-1181	DGUV (German Social Accident Insurance)	DGUV (German Social Accident Insurance)	Supported by the DGUV (German Social Accident Insurance).	Baar A, 2014, J ALLERGY CLIN IMMUN, V133, P585, DOI 10.1016/j.jaci.2013.10.044; Baar A, 2012, J IMMUNOL, V189, P3018, DOI 10.4049/jimmunol.1200438; BARBER D, 1986, BIOCHIM BIOPHYS ACTA, V869, P115, DOI 10.1016/0167-4838(86)90318-3; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Constantin C, 2008, J IMMUNOL, V180, P7451, DOI 10.4049/jimmunol.180.11.7451; GarciaCasado G, 1996, CLIN EXP ALLERGY, V26, P428, DOI 10.1046/j.1365-2222.1996.d01-326.x; Gomez-Casado C, 2014, J ALLERGY CLIN IMMUN, V134, P480, DOI 10.1016/j.jaci.2014.03.016; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Heederik D, 2001, ANN OCCUP HYG, V45, P175, DOI 10.1016/S0003-4878(00)00044-2; Hiemori M, 2010, BIOSCI BIOTECH BIOCH, V74, P199, DOI 10.1271/bbb.90634; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499, DOI 10.1164/ajrccm.158.5.9803055; Jacobs JH, 2008, ALLERGY, V63, P1597, DOI 10.1111/j.1398-9995.2008.01698.x; Kimoto M, 2009, BIOSCI BIOTECH BIOCH, V73, P85, DOI 10.1271/bbb.80485; Langen U, 2012, BUNDESGESUNDHEITSBLA, V55, P318, DOI 10.1007/s00103-011-1440-9; Mameri H, 2012, MOL NUTR FOOD RES, V56, P1874, DOI 10.1002/mnfr.201200244; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Merget R, 2011, INT ARCH OCC ENV HEA, V84, P753, DOI 10.1007/s00420-011-0617-8; Mittag D, 2004, MOL NUTR FOOD RES, V48, P380, DOI 10.1002/mnfr.200400016; Nam YH, 2013, J KOREAN MED SCI, V28, P1697, DOI 10.3346/jkms.2013.28.11.1697; Olivieri M, 2013, OCCUP ENVIRON MED, V70, P617, DOI 10.1136/oemed-2012-101112; Pahr S, 2012, CLIN EXP ALLERGY, V42, P597, DOI 10.1111/j.1365-2222.2012.03961.x; Pahr S, 2013, J ALLERGY CLIN IMMUN, V132, P1000, DOI 10.1016/j.jaci.2013.05.016; Palacin A, 2009, CLIN EXP ALLERGY, V39, P1267, DOI 10.1111/j.1365-2222.2009.03280.x; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; POSCH A, 1995, ELECTROPHORESIS, V16, P1115, DOI 10.1002/elps.11501601188; Rozynek P, 2002, ALLERGY, V57, P463, DOI 10.1034/j.1398-9995.2002.23638.x; Salcedo G, 2011, J INVEST ALLERG CLIN, V21, P81; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sander I, 2005, INT ARCH ALLERGY IMM, V136, P39, DOI 10.1159/000082583; Sander I, 2011, ALLERGY, V66, P1208, DOI 10.1111/j.1398-9995.2011.02636.x; Sander I, 2004, ALLERGY, V59, P95, DOI 10.1046/j.1398-9995.2003.00349.x; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sander I, 1997, INT ARCH ALLERGY IMM, V112, P378, DOI 10.1159/000237483; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; Schmitz R, 2013, INT ARCH ALLERGY IMM, V162, P263, DOI 10.1159/000353344; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; Takahashi H, 2012, CLIN EXP ALLERGY, V42, P1293, DOI 10.1111/j.1365-2222.2012.04039.x; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Tatham AS, 2008, CLIN EXP ALLERGY, V38, P1712, DOI 10.1111/j.1365-2222.2008.03101.x; van Kampen V, 2008, ALLERGY, V63, P448; van Kampen V, 2013, ALLERGY, V68, P651, DOI 10.1111/all.12116; van Kampen V, 2009, CLIN EXP ALLERGY, V39, P1896, DOI 10.1111/j.1365-2222.2009.03342.x; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040	44	45	47	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1529	1537		10.1016/j.jaci.2014.11.021	http://dx.doi.org/10.1016/j.jaci.2014.11.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25576081				2022-12-18	WOS:000355933400016
J	Rosner-Friese, K; Kaul, S; Vieths, S; Pfaar, O				Roesner-Friese, Karen; Kaul, Susanne; Vieths, Stefan; Pfaar, Oliver			Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Environmental exposure chamber; allergen immunotherapy; clinical validation; pivotal studies	VIENNA CHALLENGE CHAMBER; NASAL AIR-FLOW; GRASS-POLLEN; DOUBLE-BLIND; OUTCOME MEASURES; RAGWEED POLLEN; 120 MG; EFFICACY; PLACEBO; ONSET	As required by the European Medicines Agency and the US Food and Drug Administration for pivotal trials involving allergen immunotherapy (AIT) products, clinical efficacy assessment is currently based on double-blind, placebo-controlled field studies with natural allergen exposure during the allergen season. However, this study design is associated with several drawbacks, such as the high variability of allergen exposure in different trial sites or seasons and the presence of confounding environmental factors. On the contrary, environmental exposure chambers (EECs) aim to operate with a stable and reproducible allergen exposure under highly standardized environmental conditions. Technical validation parameters for different EECs worldwide have been published by several groups. However, full clinical validation of EEC study outcomes is required for their classification as an appropriate alternative to natural allergen exposure for AIT product efficacy assessment. Some clinical validation parameters have already been addressed for EEC units. The reliability of provoked symptoms in repeated EEC sessions is high, but the predictive power of EEC settings for the clinical response on natural exposure and the impact of seasonal priming on test results still have to be validated systematically, as does the inter-EEC variability. Thus the authors recommend a continued in-depth validation of EECs to exploit the potential of this technology for future AIT product development.	[Roesner-Friese, Karen; Kaul, Susanne; Vieths, Stefan] Fed Inst Vaccines & Biomed, Paul Ehrlich Inst, Div Allergol, D-63225 Langen, Germany; [Pfaar, Oliver] Ctr Rhinol & Allergol Wiesbaden, Mannheim, Germany; [Pfaar, Oliver] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryn Head & Neck Surg, Mannheim, Germany	Paul Ehrlich Institute; Ruprecht Karls University Heidelberg	Kaul, S (corresponding author), Fed Inst Vaccines & Biomed, Paul Ehrlich Inst, Div Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	Susanne.Kaul@pei.de; oliver.pfaar@allergiezentrum.org			Monsanto Company; Deutsche Dermatologische Gesellschaft; Spanish Society of Allergy; Clinical Immunology; Schattauer Allergologie Handbuch; Elsevier Nahrungscmittelaller-gien und Intoleranzen; German Research Foundation; Federal Institute for Risk Assessment; Austrian Society for Allergology and Immunology; European Directorate for the Quality of Medicines and Health Care; European Academy of Allergy and Clinical Immunology; World Allergy Organization; Association Monegasque pour le Perfectionnement des Connaissances des Medicins; Federal Office of Consumer Protection and Food Safety; German Chemical Society (GDCh); Austrian Society for Dermatology and Venerology; AKM Allergiekongress; Austrian Food Chemical Society; Allergopharma; Bencard/Allergy Therapeutics; HAL-Allergy; Novartis/LETI; MEDA; ALK-Abello; Biotech Tools s.a.; GfK Bridgehead; NAVIGANT consulting; Sanofi; Guidepoint Global Advisors,; Thermo Fisher; Stallergenes; European Union [FP7-HEALTH]; MEDA-Pharma GmbH; Roxall; Paul-Ehrlich-Institut; GEKA mbH; Bencard; Novartis	Monsanto Company; Deutsche Dermatologische Gesellschaft; Spanish Society of Allergy; Clinical Immunology; Schattauer Allergologie Handbuch; Elsevier Nahrungscmittelaller-gien und Intoleranzen; German Research Foundation(German Research Foundation (DFG)); Federal Institute for Risk Assessment; Austrian Society for Allergology and Immunology; European Directorate for the Quality of Medicines and Health Care; European Academy of Allergy and Clinical Immunology; World Allergy Organization; Association Monegasque pour le Perfectionnement des Connaissances des Medicins; Federal Office of Consumer Protection and Food Safety; German Chemical Society (GDCh); Austrian Society for Dermatology and Venerology; AKM Allergiekongress; Austrian Food Chemical Society; Allergopharma; Bencard/Allergy Therapeutics; HAL-Allergy; Novartis/LETI; MEDA; ALK-Abello; Biotech Tools s.a.; GfK Bridgehead; NAVIGANT consulting; Sanofi; Guidepoint Global Advisors,; Thermo Fisher; Stallergenes; European Union(European Commission); MEDA-Pharma GmbH; Roxall; Paul-Ehrlich-Institut; GEKA mbH; Bencard; Novartis(Novartis)	K. Rosner-Friese is employed by the Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut. S. Kaul is employed by Paul-Ehrlich-Institut. S. Vieths has provided consultancy to the Food Allergy Resource and Research Program; has provided expert testimony for the Medical University of Vienna; has received research support from Monsanto Company; has received payment for lectures from Deutsche Dermatologische Gesellschaft, the Spanish Society of Allergy and Clinical Immunology, Westdeutsche Arbeitsgemeinschaft fur padiatrische Pneumologie und Allergologie e.V., Gesellschaft fur padiatrische Allergologie and Umweltmedizin, Arzteverband Deutscher Allergologen, and the American Academy of Allergy, Asthma & Immunology; has received royalties from Schattauer Allergologie Handbuch and Elsevier Nahrungscmittelaller-gien und Intoleranzen; and has received travel support from the German Research Foundation, the Federal Institute for Risk Assessment, the Austrian Society for Allergology and Immunology, the European Directorate for the Quality of Medicines and Health Care, the European Academy of Allergy and Clinical Immunology, the World Allergy Organization, Association Monegasque pour le Perfectionnement des Connaissances des Medicins, the Federal Office of Consumer Protection and Food Safety, the German Chemical Society (GDCh), the Austrian Society for Dermatology and Venerology, AKM Allergiekongress, and the Austrian Food Chemical Society. O. Pfaar is current chairman of the Immunotherapy Interest Group (IT IG) of the European Academy of Allergy and Clinical Immunology; is current Secretary of Section ENT of Deutsche Gesellschaft fur Allergologie und Klinische Immunologie; has received consultancy fees from Allergopharma, Bencard/Allergy Therapeutics, HAL-Allergy, Novartis/LETI, MEDA, ALK-Abello, Biotech Tools s.a., GfK Bridgehead, NAVIGANT consulting, Sanofi, Guidepoint Global Advisors, Thermo Fisher, and Stallergenes; is Scientific Board Member of Mobile Chamber Experts (MCX), a GA<SUP>2</SUP>LEN Partner; is employed by the Department of Otorhinolaryngology, Head and Neck Surgery, Universitats medizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; his institution has received research grants from Allergopharma, ALK-Abello, Stallergenes, HAL-Allergy, Artu Biologicals, Allergy Therapeutics/Bencard, Hartington, Lofarma, Novartis/Leti, GlaxoSmithKline, EssexPharma, Cytos, Curalogic, Roxall, Biomay, Thermo Fisher, Circassia, Biotech Tools s.s., European Union (FP7-HEALTH. 2013-Innovation 1), and MEDA-Pharma GmbH. He has received grants for the "Spezifische Immuntherapie''-award 2014 and the "Nachwuchsforderpreis''-award 2010 of the Deutsche Gesellschaft fur Allergologie und klinische Immunologie; has received lecture fees from ALK-Abello, Allergopharma, Stallergenes, HAL-Allergy, Allergy Therapeutics/Bencard, Hartington, Lofarma, Novartis/Leti, GlaxoSmithKline, Roxall, Paul-Ehrlich-Institut, GEKA mbH, Thermo Fisher, and MEDA-Pharma GmbH; is co-editor and an author of the textbook Allergien bei Kindern und Jugendlichen (publisher: Schattauer-Verlag, Germany); is author of different chapters of Allergologie-Handbuch (publisher: Schattauer-Verlag, Germany); has received payment for development of educational presentations from GlaxoSmithKline, Bencard, and Novartis; and has received travel support from HAL-Allergy and Allergopharma.	Badorrek P, 2011, ANN ALLERG ASTHMA IM, V106, P336, DOI 10.1016/j.anai.2010.12.018; Barchuk WT, 2013, J ALLERGY CLIN IMMUN, V132, P838, DOI 10.1016/j.jaci.2013.05.001; Baron-Bodo V, 2013, CLIN EXP ALLERGY, V43, P1362, DOI 10.1111/cea.12187; Berkowitz RB, 2002, ANN ALLERG ASTHMA IM, V89, P38, DOI 10.1016/S1081-1206(10)61909-6; Bernstein JA, 2012, J ALLERGY CLIN IMMUN, V130, P128, DOI 10.1016/j.jaci.2012.05.032; Bonvalet M, 2012, CLIN EXP ALLERGY, V42, P1745, DOI 10.1111/cea.12015; Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMA), 2008, GUID CLIN DEV PROD S; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Day JH, 1999, ANN ALLERG ASTHMA IM, V83, P83, DOI 10.1016/S1081-1206(10)62616-6; Day JH, 2000, J ALLERGY CLIN IMMUN, V105, P489, DOI 10.1067/mai.2000.104550; Day JH, 2006, ANN ALLERG ASTHMA IM, V96, P263, DOI 10.1016/S1081-1206(10)61235-5; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163, DOI 10.1016/S1081-1206(10)63104-3; Day JH, 2004, ALLERGY ASTHMA PROC, V25, P59; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638, DOI 10.1016/S0091-6749(98)70172-1; Day JH, 2001, ANN ALLERG ASTHMA IM, V87, P474, DOI 10.1016/S1081-1206(10)62260-0; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; Ellis AK, 2010, ANN ALLERG ASTHMA IM, V104, P293, DOI 10.1016/j.anai.2010.01.012; Enomoto T, 2007, J INVEST ALLERG CLIN, V17, P173; Hashiguchi K, 2009, INT ARCH ALLERGY IMM, V149, P141, DOI 10.1159/000189197; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; HORAK F, 1994, AGENTS ACTIONS, V41, pC124, DOI 10.1007/BF02007795; Horak F, 1996, ARZNEIMITTEL-FORSCH, V46, P1077; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Horak F, 2003, ALLERGY, V58, P481, DOI 10.1034/j.1398-9995.2003.00148.x; Horak F, 2003, CLIN DRUG INVEST, V23, P329, DOI 10.2165/00044011-200323050-00003; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; Horak F, 2010, ARZNEIMITTEL-FORSCH, V60, P249; Horak F, 2010, INFLAMM RES, V59, P391, DOI 10.1007/s00011-009-0117-4; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Ito K, 2010, AURIS NASUS LARYNX, V37, P694, DOI 10.1016/j.anl.2010.04.001; Jacobs RL, 2012, J ALLERGY CLIN IMMUN, V130, P122, DOI 10.1016/j.jaci.2012.03.031; Jacobs RL, 2011, ANN ALLERG ASTHMA IM, V107, P133, DOI 10.1016/j.anai.2011.04.009; Krug N, 2005, ALLERGY, V60, P354, DOI 10.1111/j.1398-9995.2005.00703.x; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Makatsori M, 2013, CURR ALLERGY ASTHM R, V13, P371, DOI 10.1007/s11882-013-0359-7; Meyer W, 2013, ALLERGY, V68, P724, DOI 10.1111/all.12148; Patel P, 2007, AM J RHINOL, V21, P499, DOI 10.2500/ajr.2007.21.3058; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; Radcliffe MJ, 2006, CLIN EXP ALLERGY, V36, P1488, DOI 10.1111/j.1365-2222.2006.02594.x; Ronborg SM, 1996, ALLERGY, V51, P82, DOI 10.1111/j.1398-9995.1996.tb00039.x; Ronborg SM, 1997, ALLERGY, V52, P821, DOI 10.1111/j.1398-9995.1997.tb02153.x; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; Stuebner P, 2006, ANN ALLERG ASTHMA IM, V96, P37, DOI 10.1016/S1081-1206(10)61038-1; Toth J, 1998, ALLERGY, V53, P1172, DOI 10.1111/j.1398-9995.1998.tb03837.x; US Food and Drug Administration- Center for Drug Evaluation and Research, 2000, DRAFT GUID; Van Overtvelt L, 2011, ALLERGY, V66, P1530, DOI 10.1111/j.1398-9995.2011.02696.x; Yuki Ayumi, 2011, Allergology International, V60, P533, DOI 10.2332/allergolint.10-OA-0264; Zieglmayer PU, 2013, CURR OPIN ALLERGY CL, V13, P244, DOI 10.1097/ACI.0b013e328360c7b6; Zimmer A, 2012, J ALLERGY CLIN IMMUN, V129, P1020, DOI 10.1016/j.jaci.2012.02.014	56	45	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					636	643		10.1016/j.jaci.2014.10.045	http://dx.doi.org/10.1016/j.jaci.2014.10.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25528360				2022-12-18	WOS:000351065000006
J	Wang, Q; Du, JG; Zhu, JJ; Yang, XW; Zhou, BH				Wang, Qun; Du, Jianguang; Zhu, Jingjing; Yang, Xiaowei; Zhou, Baohua			Thymic stromal lymphopoietin signaling in CD4(+) T cells is required for T(H)2 memory	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; T(H)2 memory; memory recall; allergic airway inflammation; eosinophilia	ALLERGIC AIRWAY INFLAMMATION; GENOME-WIDE ASSOCIATION; ATOPIC-DERMATITIS; DENDRITIC CELLS; TH2 MEMORY; IN-VIVO; ASTHMA; TSLP; GENERATION; EXPRESSION	Background: Thymic stromal lymphopoietin (TSLP) is a key factor in the development of allergic asthma. Numbers of T(H)2 memory cells gradually increase in allergic patients with the progression of disease and persist in the lungs during remission, although the mechanism is not clear. Objective: We sought to define the role of TSLP in T(H)2 memory cell generation and maintenance in vivo. Methods: Adoptive transfer of wild-type and thymic stromal lymphopoietin receptor (TSLPR)-deficient ovalbumin-specific CD4(+) T cells before T(H)2 sensitization was used to define T cellspecific TSLP effects. Atopic dermatitis and increased serum TSLP concentrations were induced by topical application of the vitamin D3 analog MC903. Memory cells in peripheral blood were monitored weekly with flow cytometry. Memory recall was tested after intranasal ovalbumin challenge. Results: TSLP signaling in CD4(+) T cells is required for the generation/maintenance of memory cells after in vivo priming. TSLPR-deficient CD4(+) T cells have no defects in proliferation but do not survive 1 week after sensitization, and increased TSLP expression during sensitization significantly increased the frequency of memory cells. Although in vitro-differentiated TSLPR-deficient T(H)2 cells develop into memory cells with equal efficiency to wild-type cells, the recall response to airway antigen challenge is impaired. Moreover, after antigen challenge of mice with established T(H)2 memory, TSLP signaling in CD4(+) T cells significantly affects memory cell generation/maintenance from secondary effector cells. Conclusion: TSLP signaling in CD4(+) T cells is required for not only T(H)2 memory cell formation in vivo but also the recall response of the memory cells to local antigen challenge.	[Wang, Qun; Du, Jianguang; Zhu, Jingjing; Zhou, Baohua] Indiana Univ Sch Med, Dept Pediat, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Zhou, Baohua] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Yang, Xiaowei] Southwest Univ Rongchang, Dept Vet Med, Chongqing, Peoples R China	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Zhou, BH (corresponding author), Indiana Univ Sch Med, Dept Microbiol & Immunol, HB Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA.	zhoub@iu.edu			National Institutes of Health [AI085046]; HB Wells Center part from the Riley Children's Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085046] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HB Wells Center part from the Riley Children's Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (grant AI085046 to B.Z.). Support was provided by the HB Wells Center was in part from the Riley Children's Foundation.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Blair DA, 2007, P NATL ACAD SCI USA, V104, P15045, DOI 10.1073/pnas.0703767104; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Diebold SS, 2008, IMMUNOL CELL BIOL, V86, P389, DOI 10.1038/icb.2008.26; Dooms H, 2006, IMMUNOL REV, V211, P23, DOI 10.1111/j.0105-2896.2006.00387.x; Epstein MM, 2006, PHARMACOL THERAPEUT, V109, P107, DOI 10.1016/j.pharmthera.2005.06.006; Guo ZY, 2010, IMMUNOL LETT, V128, P116, DOI 10.1016/j.imlet.2009.12.019; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Iwamura C, 2012, P NATL ACAD SCI USA, V109, P16992, DOI 10.1073/pnas.1203494109; Jang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056433; Kim BS, 2010, P NATL ACAD SCI USA, V107, P8742, DOI 10.1073/pnas.0911756107; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kurashima K, 2006, RESPIROLOGY, V11, P152, DOI 10.1111/j.1440-1843.2006.00822.x; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lei LY, 2011, J IMMUNOL, V186, P2254, DOI 10.4049/jimmunol.1002503; Li JC, 2003, J EXP MED, V198, P1807, DOI 10.1084/jem.20030725; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Li M, 2009, J INVEST DERMATOL, V129, P498, DOI 10.1038/jid.2008.232; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; McKinstry KK, 2010, IMMUNOLOGY, V130, P1, DOI 10.1111/j.1365-2567.2010.03259.x; Mojtabavi N, 2002, J IMMUNOL, V169, P4788, DOI 10.4049/jimmunol.169.9.4788; Nakatani T, 2001, J ALLERGY CLIN IMMUN, V107, P353, DOI 10.1067/mai.2001.112601; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Salek-Ardakani S, 2006, VACCINE, V24, P872, DOI 10.1016/j.vaccine.2005.07.108; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Yang N, 2013, PHYTOTHER RES, V27, P1381, DOI 10.1002/ptr.4862; Yao WG, 2013, IMMUNITY, V38, P360, DOI 10.1016/j.immuni.2013.01.007; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yurovsky VV, 1998, AM J RESP CELL MOL, V18, P370, DOI 10.1165/ajrcmb.18.3.2935; Zhang YL, 2012, EUR J IMMUNOL, V42, P1735, DOI 10.1002/eji.201142123; Zhang YL, 2012, IMMUNOL RES, V52, P211, DOI 10.1007/s12026-012-8264-z; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	49	45	47	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					781	U313		10.1016/j.jaci.2014.09.015	http://dx.doi.org/10.1016/j.jaci.2014.09.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25441291	Green Accepted			2022-12-18	WOS:000351065000026
J	Lemiere, C; NGuyen, S; Sava, F; D'Alpaos, V; Huaux, F; Vandenplas, O				Lemiere, Catherine; NGuyen, Sebastien; Sava, Francesco; D'Alpaos, Vinciane; Huaux, Francois; Vandenplas, Olivier			Occupational asthma phenotypes identified by increased fractional exhaled nitric oxide after exposure to causal agents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchial provocation tests; eosinophils; exhaled nitric oxide; occupational diseases; sputum	SPUTUM CELL COUNTS; AIRWAY INFLAMMATION; BRONCHIAL RESPONSE; EARLY MARKER; CHALLENGE; TESTS; DIAGNOSIS	Background: The added value of fractional exhaled nitric oxide (FENO) remains controversial in the investigation of occupational asthma (OA). Objective: We sought to assess whether or not the increase of FENO levels following positive specific inhalation challenge (SIC) was restricted to phenotypes of subjects sharing common clinical characteristics by using a statistical cluster analysis. Methods: Subjects were investigated for possible OA in a tertiary center using SICs from 2006 to 2012. FENO levels and sputum eosinophil counts were assessed at baseline and 24 hours after SIC. We performed a 2-step cluster analysis of the subgroup of subjects with OA. A multivariate logistic regression was performed in order to identify the variables associated with an increase in FENO in subjects with OA. Results: One hundred and seventy-eight subjects underwent SIC; 98 had a positive test. The cluster analysis performed in the OA subgroup identified 3 clusters. Despite a positive SIC, there was no increase in the FENO levels after exposure to occupational agents in Cluster 3, in which subjects were only exposed to low-molecular-weight (LMW) agents. The molecular weight of the agent (high molecular weight vs LMW) was the only factor associated with an increase in FENO (OR: 4.2 [1.1-16.8]) in subjects with a positive SIC. Conclusion: An increase in FENO after exposure to agents causing OA seems to occur more consistently in subjects with OA caused by high molecular weight than in those with OA due to LMW.	[Lemiere, Catherine; NGuyen, Sebastien; Sava, Francesco] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ H3C 3J7, Canada; [D'Alpaos, Vinciane; Vandenplas, Olivier] Catholic Univ Louvain, Ctr Hosp Univ Mt Godinne, Dept Chest Med, Yvoir, Belgium; [Vandenplas, Olivier] Fonds Malad Prof, Brussels, Belgium; [Huaux, Francois] Catholic Univ Louvain, Ind Toxicol & Occupat Med Unit, B-1200 Brussels, Belgium	Universite de Montreal; Universite Catholique Louvain; Universite Catholique Louvain	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin West, Montreal, PQ H4J 1C5, Canada.	catherine.lemiere@umontreal.ca			Actions de Recherche Concertees de la Communaute Francaise de Belgique, Belgium	Actions de Recherche Concertees de la Communaute Francaise de Belgique, Belgium	This work was supported by a grant from the Actions de Recherche Concertees de la Communaute Francaise de Belgique, Belgium.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Banovcin P, 2009, EUR J MED RES, V14, P9, DOI 10.1186/2047-783X-14-S4-9; Barbinova L, 2006, INT ARCH OCC ENV HEA, V79, P387, DOI 10.1007/s00420-005-0051-x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; D'Alpaos V, 2013, RESP MED, V107, P739, DOI 10.1016/j.rmed.2013.01.008; Dahgam S, 2012, J MED GENET, V49, P200, DOI 10.1136/jmedgenet-2011-100584; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; European Community for Coal and Steel, 1983, B EUR PHYSIOPATHO S5, V19, P45; Ferrazzoni S, 2009, CHEST, V136, P155, DOI 10.1378/chest.08-2338; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Jang WN, 2013, ALLERGY ASTHMA IMMUN, V5, P155, DOI 10.4168/aair.2013.5.3.155; Lemiere C, 2010, CHEST, V137, P617, DOI 10.1378/chest.09-2081; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Pedrosa M, 2012, LUNG, V190, P209, DOI 10.1007/s00408-011-9358-4; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; Piipari R, 2002, EUR RESPIR J, V20, P1532, DOI 10.1183/09031936.02.00041802; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Quirce S, 2010, ALLERGY, V65, P445, DOI 10.1111/j.1398-9995.2009.02274.x; Schleich FN, 2010, THORAX, V65, P1039, DOI 10.1136/thx.2009.124925; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; Vandenplas O, 2003, EUR RESPIR J, V22, P689, DOI 10.1183/09031936.03.00053203; Vandenplas O, 2009, ALLERGY, V64, P754, DOI 10.1111/j.1398-9995.2008.01896.x; Vandenplas O, 2014, EUR RESPIR J, V43, P1573, DOI 10.1183/09031936.00180313; Vandenplas O, 2013, CHEST, V143, P1261, DOI 10.1378/chest.12-1983	26	45	45	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1063	1067		10.1016/j.jaci.2014.08.017	http://dx.doi.org/10.1016/j.jaci.2014.08.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25262466	Bronze			2022-12-18	WOS:000344938900010
J	Newby, C; Agbetile, J; Hargadon, B; Monteiro, W; Green, R; Pavord, I; Brightling, C; Siddiqui, S				Newby, Christopher; Agbetile, Joshua; Hargadon, Beverley; Monteiro, Will; Green, Ruth; Pavord, Ian; Brightling, Christopher; Siddiqui, Salman			Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; airway inflammation; lung function decline; eosinophilia; induced sputum	EOSINOPHILIC ASTHMA; CONTROLLED TRIAL; EXACERBATIONS; SPUTUM; MEPOLIZUMAB; MULTICENTER; SMOKING; COUNTS; HEALTH; ADULTS	Background: Eosinophilic airway inflammation measured by using induced sputum is an important treatment stratification tool in patients with severe asthma. In addition, sputum eosinophilia has been shown to be associated with severe exacerbations and airflow limitation. Objectives: We sought to identify whether eosinophilic inflammation in sputum is associated with FEV1 decrease in patients with severe asthma and whether we could identify subgroups of decrease behavior based on the variation of eosinophilic airway inflammation over time. Methods: Ninety-seven patients with severe asthma from the Glenfield Asthma Cohort were followed up with scheduled 3-month visits; the median duration of follow-up and number of visits was 6 years (interquartile range, 5.6-7.6 years) and 2.7 visits per year. Induced sputum was analyzed for eosinophilic inflammation at scheduled visits. Linear mixed-effects models were used to identify variables associated with lung function and overall decrease. In addition, using individual patients' mean and SD sputum eosinophil percentages over time, a 2-step cluster analysis was performed to identify patient clusters with different rates of decrease. Results: FEV1 decrease was -25.7 mL/y in the overall population. Postbronchodilator FEV1 was also dependent on exacerbations, age of onset, height, age, sex, and log(10) sputum eosinophil percentages (P < .001). Three decrease patient clusters were identified: (1) noneosinophilic with low variation (mean decrease, -14.0 mL/y), (2) eosinophilic with high variation (mean decrease, -40.9 mL/y), and (3) hypereosinophilic with low variation (mean decrease in lung function, -19.2 mL/y). Conclusion: The amplitude of sputum eosinophilia was associated with postbronchodilator FEV1 in asthmatic patients. In contrast, high variability rather than the amplitude at baseline or over time of sputum eosinophils was associated with accelerated FEV1 decrease.	[Newby, Christopher] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England; [Agbetile, Joshua; Hargadon, Beverley; Monteiro, Will; Green, Ruth; Brightling, Christopher; Siddiqui, Salman] Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Pavord, Ian] Univ Oxford, Oxford Univ Hosp, Oxford OX1 2JD, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Oxford	Siddiqui, S (corresponding author), Univ Hosp Leicester, Inst Lung Hlth, Resp Biomed Res Unit, Leicester LE3 9QP, Leics, England.	salman95@yahoo.com		brightling, chris/0000-0002-9345-4903; Siddiqui, Salman/0000-0003-3770-7870; Pavord, Ian/0000-0002-4288-5973	National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; National Institute for Health Research (NIHR); Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM) project [270194]; Wellcome Senior Fellowship; National Institute for Health Research [CL-2008-11-005, NF-SI-0510-10157, NF-SI-0512-10018] Funding Source: researchfish	National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM) project; Wellcome Senior Fellowship; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit. This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Additional funding was received from the Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through Seventh Framework Programme FP7/2007-2013 under grant agreement no. 270194) and from a Wellcome Senior Fellowship (to C.B.).	Agbetile J, 2012, CLIN EXP ALLERGY, V42, P782, DOI 10.1111/j.1365-2222.2012.03987.x; Anees W, 2006, THORAX, V61, P751, DOI 10.1136/thx.2005.054080; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Broekema M, 2010, RESP MED, V104, P1254, DOI 10.1016/j.rmed.2010.03.030; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Contoli M, 2010, J ALLERGY CLIN IMMUN, V125, P830, DOI 10.1016/j.jaci.2010.01.003; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Edwards LJ, 2000, PEDIATR PULM, V30, P330, DOI 10.1002/1099-0496(200010)30:4<330::AID-PPUL10>3.0.CO;2-D; ENGELHARD D, 1983, P NATL ACAD SCI-BIOL, V80, P5734, DOI 10.1073/pnas.80.18.5734; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lindsay JT, 2013, EXPERT REV RESP MED, V7, P607, DOI 10.1586/17476348.2013.842129; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Sennels HP, 2011, SCAND J CLIN LAB INV, V71, P532, DOI 10.3109/00365513.2011.602422; Siddiqui S, 2009, ALLERGY, V64, P951, DOI 10.1111/j.1398-9995.2009.01951.x; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; SPSS, 2004, 2 STEP CLUST AN; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; van der Valk RJP, 2012, ALLERGY, V67, P265, DOI 10.1111/j.1398-9995.2011.02734.x; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC	36	45	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					287	+	294.e5	10.1016/j.jaci.2014.04.005	http://dx.doi.org/10.1016/j.jaci.2014.04.005			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24928647				2022-12-18	WOS:000341370800006
J	Chen, YYK; Khoury, P; Ware, JM; Holland-Thomas, NC; Stoddard, JL; Gurprasad, S; Waldner, AJ; Klion, AD				Chen, Yun-Yun K.; Khoury, Paneez; Ware, JeanAnne M.; Holland-Thomas, Nicole C.; Stoddard, Jennifer L.; Gurprasad, Shakuntala; Waldner, Amy J.; Klion, Amy D.			Marked and persistent eosinophilia in the absence of clinical manifestations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; hypereosinophilic syndrome; cytokine; pathogenesis	HYPEREOSINOPHILIC SYNDROME; CLASSIFICATION; VARIANT	Background: Although most patients with hypereosinophilic syndromes (HES) present with clinical signs and symptoms attributable to eosinophilic tissue infiltration, some untreated patients remain asymptomatic or have signs and symptoms, such as allergic rhinitis, for which the relationship to peripheral eosinophilia is unclear (hypereosinophilia of unknown significance [HEUS]). Objective: To identify and characterize subjects with HEUS of 5 years duration or more as compared to untreated patients with symptomatic HES and healthy normal volunteers. Methods: All subjects with eosinophilia underwent yearly evaluation, including a standardized clinical evaluation, whole blood flow cytometry to assess lymphocyte subsets and eosinophil activation, and serum collection. Peripheral blood mononuclear cells were cultured overnight with and without phorbol 12-myristate 13-acetate/ionomycin. Cytokines and chemokines were measured in serum and cell supernatants, and mRNA expression was assessed by using quantitative real-time PCR. Results: Eight of the 210 subjects referred for the evaluation of eosinophilia (absolute eosinophil count [AEC] > 1500/mu L) met the criteria for HEUS of 5 years duration or more (range, 7-29 years). Peak eosinophil count and surface expression of eosinophil activation markers were similar in subjects with HEUS and in untreated subjects with platelet-derived growth factor alpha-negative HES (n 5 28). Aberrant or clonal T-cell populations were identified in 50% of the subjects with HEUS as compared to 29% of the subjects with HES (P = .12). Increased levels of IL-5, GM-CSF, IL-9, and IL-17A were also comparable in subjects with HEUS and HES. Serum levels of IgE and IL-13 were significantly increased only in subjects with HES. Conclusions: A small number of patients with persistent peripheral eosinophilia (AEC > 1500/mu L) appear to have clinically benign disease.	[Chen, Yun-Yun K.; Khoury, Paneez; Ware, JeanAnne M.; Waldner, Amy J.; Klion, Amy D.] NIAID, Eosinophil Pathol Unit, Parasit Dis Lab, Frederick, MD USA; [Holland-Thomas, Nicole C.] SAIC Frederick Inc, Natl Lab Canc Res, Parasit Dis Lab, Clin Res Directorate CMRP, Frederick, MD USA; [Stoddard, Jennifer L.; Gurprasad, Shakuntala] NIH, Dept Lab Med, Warren Magnusson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA	Klion, AD (corresponding author), NIH, Parasit Dis Lab, Bldg 4,Rm B1-28,4 Mem Dr, Bethesda, MD 20892 USA.	aklion@nih.gov	Khoury, Paneez/ABH-1951-2020	Khoury, Paneez/0000-0003-1800-0079; Klion, Amy/0000-0002-4986-5326; Ware, JeanAnne/0000-0003-0331-3195	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) [NCT00001406, NCT00090662]; National Cancer Institute, NIH [HHSN2610080001E]; NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH; Clinical Trials NCT00001406 and NCT00090662). This project has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under contract no. HHSN2610080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. This research was supported in part by the NIAID.	Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bochner BS, 2012, J ALLERGY CLIN IMMUN, V130, P587, DOI 10.1016/j.jaci.2012.07.024; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Crane MM, 2010, J ALLERGY CLIN IMMUN, V126, P179, DOI 10.1016/j.jaci.2010.03.035; de Lavareille A, 2002, J ALLERGY CLIN IMMUN, V110, P476, DOI 10.1067/mai.2002.127003; Helbig G, 2009, HAEMATOL-HEMATOL J, V94, P1236, DOI 10.3324/haematol.2008.005447; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; PRIN L, 1991, BLOOD, V78, P2626; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Wilson TM, 2011, J ALLERGY CLIN IMMUN, V128, P1086, DOI 10.1016/j.jaci.2011.05.032	15	45	47	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1195	+		10.1016/j.jaci.2013.06.037	http://dx.doi.org/10.1016/j.jaci.2013.06.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	23987798	Green Accepted, Bronze			2022-12-18	WOS:000333531700031
J	Yu, XM; Almeida, JR; Darko, S; van der Burg, M; DeRavin, SS; Malech, H; Gennery, A; Chinn, I; Markert, ML; Douek, DC; Milner, JD				Yu, Xiaomin; Almeida, Jorge R.; Darko, Sam; van der Burg, Mirjam; DeRavin, Suk See; Malech, Harry; Gennery, Andrew; Chinn, Ivan; Markert, Mary Louise; Douek, Daniel C.; Milner, Joshua D.			Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell receptor; recombination activating gene; Omenn syndrome; T-cell receptor sequencing	OMENN-SYNDROME; V(D)J RECOMBINATION; THYMUS TRANSPLANTATION; DIGEORGE-SYNDROME; IMMUNE FUNCTION; RAG MUTATIONS; DIVERSITY; LYMPHOCYTES	Background: Human immunodeficiencies characterized by hypomorphic mutations in critical developmental and signaling pathway genes allow for the dissection of the role of these genes in the development of the T-cell receptor (TCR) repertoire and the correlation of alterations of the TCR repertoire with diverse clinical phenotypes. Objective: The presence of T cells in patients with Omenn syndrome (OS) and patients with atypical presentations of severe combined immunodeficiency gene mutations presents an opportunity to study the effects of the causal genes on TCR repertoires and provides a window into the clinical heterogeneity observed. Methods: We performed deep sequencing of TCR beta complementarity-determining region 3 (CDR3) regions in subjects with a series of immune dysregulatory conditions caused by mutations in recombination activating gene 1/2 (RAG 1/2), IL-2 receptor gamma (IL2RG), and zeta chain-associated protein kinase 70 (ZAP70); a patient with atypical DiGeorge syndrome; and healthy control subjects. Results: We found that patients with OS had marked reductions in TCRb diversity compared with control subjects, as expected. Patients with atypical presentations of RAG or IL2RG mutations associated with autoimmunity and granulomatous disease did not have altered overall diversity but instead had skewed V-J pairing and skewed CDR3 amino acid use. Although germline TCRs were more abundant and clonally expanded in patients with OS, nongermline sequences were expanded as well. TCRb from patients with RAG mutations had less junctional diversity and smaller CDR3s than patients with OS caused by other gene mutations and healthy control subjects but relatively similar CDR3 amino acid use. Conclusions: High-throughput TCR sequencing of rare immune disorders has demonstrated that quantitative TCR diversity can appear normal despite qualitative changes in repertoire and strongly suggests that in human subjects RAG enzymatic function might be necessary for normal CDR3 junctional diversity.	[Yu, Xiaomin; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Almeida, Jorge R.; Darko, Sam; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; [DeRavin, Suk See; Malech, Harry] NIAID, Lab Host Defenses, NIH, Bethesda, MD 20892 USA; [van der Burg, Mirjam] Univ Med Ctr Rotterdam, Dept Immunol, Erasmus MC, Rotterdam, Netherlands; [Gennery, Andrew] Newcastle Univ, Dept Pediat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Gennery, Andrew] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Chinn, Ivan; Markert, Mary Louise] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Markert, Mary Louise] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Erasmus University Rotterdam; Erasmus MC; Newcastle University - UK; Newcastle University - UK; Duke University; Duke University	Douek, DC (corresponding author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Rm 3504,40 Convent Dr, Bethesda, MD 20892 USA.	ddouek@mail.nih.gov; jdmilner@niaid.nih.gov		De Ravin, Suk See/0000-0002-9800-774X; Chinn, Ivan/0000-0001-5684-5457; Ramos de Almeida, Jorge/0000-0002-5009-8478; Malech, Harry/0000-0001-5874-5775	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; ZonMW; National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001099, ZIAAI001098, ZIAAI000645, ZIAAI000644, ZIAAI000988, ZIAAI001183] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ZonMW(Netherlands Organization for Health Research and Development); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.; M. van der Burg has received research support from ZonMW. I. Chinn has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; Bourgeois C, 2006, IMMUNOL LETT, V107, P89, DOI 10.1016/j.imlet.2006.08.001; Chinen J, 2007, BLOOD, V110, P67, DOI 10.1182/blood-2006-11-058933; Chinn IK, 2013, CLIN EXP IMMUNOL, V173, P140, DOI 10.1111/cei.12088; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; De Ravin SS, 2009, IMMUNOL RES, V43, P223, DOI 10.1007/s12026-008-8073-6; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Khiong K, 2007, J CLIN INVEST, V117, P1270, DOI 10.1172/JCI30513; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Markert ML, 2004, BLOOD, V104, P2574, DOI 10.1182/blood-2003-08-2984; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Marrella V, 2011, CURR OPIN ALLERGY CL, V11, P525, DOI 10.1097/ACI.0b013e32834c311a; Naumova EN, 2009, J IMMUNOL, V183, P2851, DOI 10.4049/jimmunol.0900162; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Quigley M.F., 2011, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735.im1033s94, DOI 10.1002/0471142735.IM1033S94]; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Turul T, 2009, EUR J PEDIATR, V168, P87, DOI 10.1007/s00431-008-0718-x; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wada T, 2000, CLIN EXP IMMUNOL, V119, P148, DOI 10.1046/j.1365-2249.2000.01101.x; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0	24	45	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1109	+		10.1016/j.jaci.2013.11.018	http://dx.doi.org/10.1016/j.jaci.2013.11.018			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24406074	Green Accepted			2022-12-18	WOS:000333531700022
J	MacGlashan, DW; Saini, SS				MacGlashan, Donald W., Jr.; Saini, Sarbjit S.			Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; basophil; allergy; Fc receptors	FC-EPSILON-RI; ALLERGEN THRESHOLD-SENSITIVITY; HISTAMINE-RELEASE; CD-SENS; DIAGNOSTIC-TESTS; DOWN-REGULATION; SYK EXPRESSION; RELEASABILITY; IL-3; DESENSITIZATION	Background: Treatment of allergic patients with omalizumab results in a paradoxical increase in their basophil histamine release (HR) response ex vivo to cross-linking anti-IgE antibody. It is not known whether this change in response is associated with an increase in intrinsic cellular sensitivity, which would be a paradoxical response. Objective: We sought to determine whether the increase in response to anti-IgE antibody is a reflection of an increased cellular sensitivity expressed as molecules of antigen-specific IgE per basophil required to produce 50% of the maximal response. Methods: Patients were treated with omalizumab or placebo for 12 weeks (NCT01003301 at ClinicalTrials. gov), and the metric of basophil sensitivity was assessed at 4 time points: baseline, 6 to 8 weeks, 12 weeks (after which treatment stopped), and 24 weeks (12 weeks after the end of treatment). Results: As observed previously, treatment with omalizumab resulted in a marked increase in the maximal HR induced by cross-linking anti-IgE antibody. This change was accompanied by a marked shift in intrinsic basophil sensitivity, ranging from 2.5- to 125-fold, with an average of 6-fold at the midpoint of the treatment to 12-fold after 12 weeks. The magnitude of the increase in cellular sensitivity was inversely related to the starting sensitivity or the starting maximum HR. The increased cellular sensitivity also occurred when using leukotriene C-4 secretion as a metric of the basophil response. Twelve weeks after the end of treatment, cellular sensitivity was found to shift toward the baseline value, although the return to baseline was not yet complete at this time point. Conclusions: Treatment with omalizumab results in a markedly increased sensitivity of basophils to IgE-mediated stimulation in terms of the number of IgE molecules required to produce a given response. These results provide a better quantitative sense of the phenotypic change that occurs in basophils during omalizumab treatment, which has both mechanistic and clinical implications.	[MacGlashan, Donald W., Jr.; Saini, Sarbjit S.] Johns Hopkins Univ, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, DW (corresponding author), Johns Hopkins Univ, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Unit Off 3, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			National Institutes of Health [AI070345]; Novartis; Genentech; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070345] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Genentech(Roche HoldingGenentech); UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant AI070345.; Disclosure of potential conflict of interest: D. W. MacGlashan, Jr, has been supported by one or more grants from the National Institutes of Health. S. S. Saini has been supported by one or more grants from and has received one or more consulting fees or honoraria from Novartis and Genentech and has received royalties from UpToDate.	Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; Dahlen B, 2011, CLIN EXP ALLERGY, V41, P1091, DOI 10.1111/j.1365-2222.2011.03763.x; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Gomez G, 2007, J IMMUNOL, V179, P1353, DOI 10.4049/jimmunol.179.2.1353; Ishmael SS, 2010, J LEUKOCYTE BIOL, V87, P291, DOI 10.1189/jlb.0509336; Johansson SGO, 2009, ALLERGY, V64, P1472, DOI 10.1111/j.1398-9995.2009.02051.x; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; MacGlashan D, 2003, J IMMUNOL, V170, P4914, DOI 10.4049/jimmunol.170.10.4914; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan D, 2012, CLIN EXP ALLERGY, V42, P1060, DOI 10.1111/j.1365-2222.2012.04013.x; MacGlashan D, 2006, J IMMUNOL, V177, P1040, DOI 10.4049/jimmunol.177.2.1040; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Miura K, 2000, J IMMUNOL, V164, P3026, DOI 10.4049/jimmunol.164.6.3026; Miura K, 2001, J IMMUNOL, V167, P2282, DOI 10.4049/jimmunol.167.4.2282; Miura K, 2001, J IMMUNOL, V167, P7027, DOI 10.4049/jimmunol.167.12.7027; Nag A, 2010, IET SYST BIOL, V4, P334, DOI 10.1049/iet-syb.2010.0006; Noga O, 2008, INT ARCH ALLERGY IMM, V146, P66, DOI 10.1159/000112504; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; Paterniti M, 2011, CLIN EXP ALLERGY, V41, P963, DOI 10.1111/j.1365-2222.2011.03719.x; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Saini SS, 1999, J IMMUNOL, V162, P5624; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Vilarino N, 2005, J IMMUNOL, V175, P3006, DOI 10.4049/jimmunol.175.5.3006; Vilarino N, 2004, J LEUKOCYTE BIOL, V75, P928, DOI 10.1189/jlb.0903431; Youssef LA, 2007, J IMMUNOL, V178, P4584, DOI 10.4049/jimmunol.178.7.4584; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996	39	45	45	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					906	+		10.1016/j.jaci.2013.04.056	http://dx.doi.org/10.1016/j.jaci.2013.04.056			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23791510	Bronze, Green Accepted			2022-12-18	WOS:000325096500018
J	Junttila, IS; Watson, C; Kummola, L; Chen, X; Hu-Li, J; Guo, LY; Yagi, R; Paul, WE				Junttila, Ilkka S.; Watson, Cynthia; Kummola, Laura; Chen, Xi; Hu-Li, Jane; Guo, Liying; Yagi, Ryoji; Paul, William E.			Efficient cytokine-induced IL-13 production by mast cells requires both IL-33 and IL-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; basophils; allergic inflammation; cytokines; signal transducer and activator of transcription 5; tyrosine phosphorylation; BAC transgenic mouse; DsRed fluorochrome	EXPRESSION; LIPOPOLYSACCHARIDE	Background: IL-13 is a critical effector cytokine for allergic inflammation. It is produced by several cell types, including mast cells, basophils, and T(H)2 cells. In mast cells and basophils its induction can be stimulated by cross-linkage of immunoglobulin receptors or cytokines. The IL-1 family members IL-33 and IL-18 have been linked to induction of IL-13 production by mast cells and basophils. In CD4 T(H)2 cells IL-33-mediated production of IL-13 requires simultaneous signal transducer and activator of transcription (STAT) 5 activation. Objective: Here we have addressed whether cytokine-induced IL-13 production in mast cells and basophils follows the same logic as in T(H)2 cells: requirement of 2 separate signals. Methods: By generating a bacterial artificial chromosome (BAC) transgenic IL-13 reporter mouse, we measured IL-13 production in mast cells and basophils. Results: In mast cells harvested from peritoneal cavities, 2 cytokine signals are required for IL-13 production: IL-33 and IL-3. In bone marrow mast cells IL-13 production requires IL-33, but the requirement for a STAT5 inducer is difficult to evaluate because these cells require the continuous presence of IL-3 (a STAT5 activator) for survival. Poorer STAT5 inducers in culture (IL-4 or stem cell factor) result in less IL-13 production on IL-33 challenge, but the addition of exogenous IL-3 enhances IL-13 production. This implies that bone marrow-derived mast cells, like peritoneal mast cells and T(H)2 cells, require stimulation both by an IL-1 family member and a STAT5 inducer to secrete IL-13. Basophils follow the same rule; splenic basophils produce IL-13 in response to IL-18 or IL-33 plus IL-3. Conclusion: Optimal IL-13 production from mast cells and basophils requires 2 cytokine signals.	[Junttila, Ilkka S.; Watson, Cynthia; Chen, Xi; Hu-Li, Jane; Guo, Liying; Yagi, Ryoji; Paul, William E.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; [Junttila, Ilkka S.; Kummola, Laura] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Junttila, Ilkka S.] Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tampere University; Pirkanmaa Hospital District	Junttila, IS (corresponding author), Biokatu 4,Rm C-306, Tampere 33520, Finland.	ilkka.junttila@uta.fi; wpaul@niaid.nih.gov		Junttila, Ilkka/0000-0002-9830-0823	National Institute of Allergy and Infectious Diseases Intramural Program; Finnish Medical Foundation; Competitive Research Funding of the Tampere University Hospital [9N018]; Sigrid Juselius Foundation; Fimlab laboratories [X51409]; Competitive Research Funding of Tampere University Hospital; Fimlab Laboratories; Sigrig Juselius Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000493] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases Intramural Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Finnish Medical Foundation; Competitive Research Funding of the Tampere University Hospital; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Fimlab laboratories; Competitive Research Funding of Tampere University Hospital; Fimlab Laboratories; Sigrig Juselius Foundation(Sigrid Juselius Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases Intramural Program (to I.S.J., C.W., X.C., J.H.-L., L.G., R.Y., and W.E.P.), the Finnish Medical Foundation (to I.S.J.), Competitive Research Funding of the Tampere University Hospital (grant 9N018, to I.S.J.), the Sigrid Juselius Foundation (to I.S.J. and L.K.), and Fimlab laboratories (grant X51409, to I.S.J.).; I. S. Junttila has been supported by one or more grants from Competitive Research Funding of Tampere University Hospital, Fimlab Laboratories, and the Sigrid Juselius Foundation. L. Kummola has been supported by one or more grants from the Sigrig Juselius Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Espinassous Q, 2009, J IMMUNOL, V183, P1446, DOI 10.4049/jimmunol.0803067; Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105-2896.2004.00192.x; Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Hueber AJ, 2011, EUR J IMMUNOL, V41, P2229, DOI 10.1002/eji.201041360; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kroeger KM, 2009, J LEUKOCYTE BIOL, V86, P769, DOI 10.1189/jlb.0708452; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	22	45	46	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					704	+		10.1016/j.jaci.2013.03.033	http://dx.doi.org/10.1016/j.jaci.2013.03.033			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23683462	Green Accepted, Bronze			2022-12-18	WOS:000323612000023
J	Beigelman, A; King, TS; Mauger, D; Zeiger, RS; Strunk, RC; Kelly, HW; Martinez, FD; Lemanske, RF; Rivera-Spoljaric, K; Jackson, DJ; Guilbert, T; Covar, R; Bacharier, LB				Beigelman, Avraham; King, Tonya S.; Mauger, David; Zeiger, Robert S.; Strunk, Robert C.; Kelly, H. William; Martinez, Fernando D.; Lemanske, Robert F., Jr.; Rivera-Spoljaric, Katherine; Jackson, Daniel J.; Guilbert, Theresa; Covar, Ronina; Bacharier, Leonard B.		Natl Heart Lung Blood Inst	Do oral corticosteroids reduce the severity of acute lower respiratory tract illnesses in preschool children with recurrent wheezing?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral corticosteroids; episodic wheezing; preschool children	PROPENSITY SCORE METHODS; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; DOUBLE-BLIND; PREDNISOLONE; THERAPY; INTERLEUKIN-8; EFFICACY; INFANTS; RISK	Background: Oral corticosteroids (OCSs) are recommended for severe wheezing episodes in children. However, limited evidence supports this intervention in preschool children with outpatient wheezing illnesses. Objective: We sought to investigate whether OCSs reduce symptom scores during acute lower respiratory tract illnesses (LRTIs) in preschool children with recurrent wheeze. Methods: We performed post hoc and replication analyses in 2 outpatient cohorts of children aged 1 to 5 years with episodic wheezing participating in clinical trials. We compared symptom scores during LRTIs that were or were not treated with OCSs, adjusting for differences in disease and episode severity covariates. We stratified episodes by severity by using a propensity model. The primary outcome was the area under the curve (AUC) of total symptom scores among the more severe episodes. Results: Two hundred fifteen participants from the Acute Intervention Management Strategies trial experienced 798 acute LRTIs, 112 of which were defined as severe based on propensity scores. The AUCs of total symptom scores did not differ between the episodes that were (n = 70) and were not (n = 42) treated with OCSs (P = .46) nor was there an OCS treatment effect on individual symptom scores. Similar analyses of the Maintenance Versus Intermittent Inhaled Corticosteroids in Wheezing Toddlers trial, involving 278 participants with 133 severe LRTIs, confirmed the above findings (P = .46 for AUC of total symptoms score comparison). Conclusion: In 2 separate cohorts of preschool children with episodic wheezing, OCS treatment during clinically significant LRTIs did not reduce symptom severity during acute LRTIs, despite asthma controller medication use during most episodes. These findings need to be confirmed in a prospective randomized controlled trial.	[Beigelman, Avraham; Strunk, Robert C.; Rivera-Spoljaric, Katherine; Bacharier, Leonard B.] Washington Univ, Dept Pediat, St Louis, MO 63110 USA; [Beigelman, Avraham; Strunk, Robert C.; Rivera-Spoljaric, Katherine; Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [King, Tonya S.; Mauger, David] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.] Univ Calif La Jolla, Dept Pediat, La Jolla, CA USA; [Kelly, H. William] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Sch Pharm, Dept Med, Madison, WI 53706 USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Sch Pharm, Dept Pediat, Madison, WI 53706 USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Sch Publ Hlth, Dept Med, Madison, WI 53706 USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Sch Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Guilbert, Theresa] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; [Covar, Ronina] Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO USA; [Covar, Ronina] Dept Pediat, Div Allergy & Immunol, Denver, CO USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Kaiser Permanente; University of California System; University of California San Diego; University of New Mexico; University of Arizona; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Beigelman, A (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, 660 S Euclid Ave,Campus Box 8116, St Louis, MO 63110 USA.	beigelman_a@kids.wustl.edu		Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences [UL1 TR000448, KL2 TR000450]; Colorado CTSA from the National Center for Research Resources (NCRR)/National Institutes of Health (NIH) [1 UL1RR025780]; General Clinical Research Center at Washington University School of Medicine [M01 RR00036]; General Clinical Research Center at National Jewish Health [M01 RR00051]; General Clinical Research Center at University of New Mexico [5M01 RR00997]; National Heart, Lung, and Blood Institute (NHLBI)/Washington University School of Medicine; American College of Allergy, Asthma & Immunology (ACAAI); KL2 Award; Washington University's ICTS award; NHLBI; GlaxoSmithKline; Sunovion; AstraZeneca; Genentech; MedImmune; Schering-Plough; Novartis; NHLBI/Penn State; Merck; Aerocrine; National Institutes of Health (NIH); Abbott; NIH; Sepracor; SA Boney and Associates; American Institute of Research; Double Helix Development; Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital; American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians; American Academy of Allergy, Asthma & Immunology (AAAAI); National Institutes of Health; AAAAI/GlaxoSmithKline; Gilead; Teva; MAP Pharmaceuticals; Centers for Disease Control and Prevention (CDC); US Department of Health and Human Services (DHHS); Altus Pharmaceuticals; Inspire Pharmaceuticals; UW Medical and Education Research Committee; Abbott Laboratories; Array Biopharma; Mylan; Forest Research Institute; Hoffman-LaRoche; GlaxoSmithKline and Development Limited; Merck/Schering-Plough; United Biosource; NHLBI/NIH Childhood Asthma Research and Education Network; Genentech/Novartis; Schering; Cephalon; NATIONAL CANCER INSTITUTE [KM1CA156708] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000450, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997, UL1RR025780, M01RR000036, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064288, U10HL064287, U10HL064313, U10HL064305, U10HL064295, U10HL064307] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences; Colorado CTSA from the National Center for Research Resources (NCRR)/National Institutes of Health (NIH); General Clinical Research Center at Washington University School of Medicine; General Clinical Research Center at National Jewish Health; General Clinical Research Center at University of New Mexico; National Heart, Lung, and Blood Institute (NHLBI)/Washington University School of Medicine; American College of Allergy, Asthma & Immunology (ACAAI); KL2 Award; Washington University's ICTS award; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Sunovion; AstraZeneca(AstraZeneca); Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Schering-Plough(Merck & CompanySchering Plough Corporation); Novartis(Novartis); NHLBI/Penn State; Merck(Merck & Company); Aerocrine; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abbott(Abbott Laboratories); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sepracor; SA Boney and Associates; American Institute of Research; Double Helix Development; Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital(General Electric); American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians(General Electric); American Academy of Allergy, Asthma & Immunology (AAAAI); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AAAAI/GlaxoSmithKline(GlaxoSmithKline); Gilead(Gilead Sciences); Teva(Teva Pharmaceutical Industries); MAP Pharmaceuticals; Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Department of Health and Human Services (DHHS); Altus Pharmaceuticals; Inspire Pharmaceuticals; UW Medical and Education Research Committee; Abbott Laboratories(Abbott Laboratories); Array Biopharma(Pfizer); Mylan; Forest Research Institute; Hoffman-LaRoche; GlaxoSmithKline and Development Limited; Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); United Biosource; NHLBI/NIH Childhood Asthma Research and Education Network; Genentech/Novartis(Roche HoldingGenentech); Schering; Cephalon; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. Supported in part by Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences subaward KL2 TR000450 and by Colorado CTSA grant 1 UL1RR025780 from the National Center for Research Resources (NCRR)/National Institutes of Health (NIH). This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), at National Jewish Health (M01 RR00051), and at the University of New Mexico (5M01 RR00997).; Disclosure of potential conflict of interest: A. Beigelman has received research support from the National Heart, Lung, and Blood Institute (NHLBI)/Washington University School of Medicine, an American College of Allergy, Asthma & Immunology (ACAAI) Young Investigator Award, a KL2 Award, and Washington University's ICTS award and is employed by Washington University School of Medicine. T. S. King has received research support from the NHLBI. D. Mauger has received consultancy fees from GlaxoSmithKline and Sunovion. R. S. Zeiger has received research and travel support from the NHLBI; is on the GlaxoSmithKline pediatric steering committee; has received consultancy fees from AstraZeneca, Genentech, Sunovion, GlaxoSmithKline, MedImmune, Schering-Plough, Novartis, and NHLBI/Penn State; and has received research support from Genentech, GlaxoSmithKline, Merck, Aerocrine, and MedImmune. R. C. Strunk has received research support from the NHLBI and has received consultancy fees from GlaxoSmithKline, Novartis, Merck, and AstraZeneca for work on various steering committees. H. W. Kelly has received research support from the NHLBI and has received consultancy fees from Novartis, Merck, GlaxoSmithKline, and AstraZeneca. F. D. Martinez has received consultancy fees from MedImmune; has received research support from the National Institutes of Health (NIH); and has received lecture fees and travel support from Abbott and Merck. R. F. Lemanske has received travel support and fees for participation in review activities from the NIH; has received consultancy fees from Merck, Sepracor, SA Boney and Associates, GlaxoSmithKline, the American Institute of Research, Genentech, and Double Helix Development; is employed by the University of Wisconsin School of Medicine and Public Health; has received research support from the NHLBI and Pharmaxis; has received lecture fees from the Michigan Public Health Institute, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health Systems, California Chapter 4 AAP, the Colorado Allergy Society, the Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, and the American College of Chest Physicians; has received payment for manuscript preparation from the American Academy of Allergy, Asthma & Immunology (AAAAI); and receives royalties from Elsevier and UpToDate. D. J. Jackson has received research support from the National Institutes of Health, AAAAI/GlaxoSmithKline, and Pharmaxis and has received consultancy fees from Gilead. T. Guilbert has received research and travel support as well as fees for review activities from the NIH; is on the American Board of Pediatrics Pediatric Pulmonary Subboard; has received consultancy fees from MedImmune, Teva, MAP Pharmaceuticals, and GlaxoSmithKline; has received research support from the Centers for Disease Control and Prevention (CDC), the US Department of Health and Human Services (DHHS), Altus Pharmaceuticals, Inspire Pharmaceuticals, the NIH, UW Medical and Education Research Committee, Abbott Laboratories, Array Biopharma, Teva, Mylan, Forest Research Institute, Hoffman-LaRoche, GlaxoSmithKline and Development Limited, and MedImmune; has received lecture fees from Merck/Schering-Plough; receives royalties from UpToDate; and has received payment for the development of educational presentations from Teva. R. Covar has received consultancy fees from United Biosource and Merck and has received research support from GlaxoSmithKline. L. B.; Bacharier has received research support from the NHLBI/NIH Childhood Asthma Research and Education Network; has received consultancy fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, and Cephalon; and has received lecture fees from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Schering-Plough. K. Rivera-Spoljaric declares that she has no relevant conflicts of interest.	Akinbami Lara, 2006, Adv Data, P1; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; Csonka P, 2003, J PEDIATR-US, V143, P725, DOI 10.1067/S0022-3476(03)00498-0; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; GRANT CC, 1995, PEDIATRICS, V96, P224; Grigg J, 2010, ARCH DIS CHILD, V95, P491, DOI 10.1136/adc.2009.160994; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hulley SB, 2007, DESIGNING CLIN RES, P139; Knirsch CA, 2012, NEW ENGL J MED, V367, P772, DOI [10.1056/NEJMoa1003833, 10.1056/NEJMc1207269]; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Rachelefsky G, 2003, PEDIATRICS, V112, P382, DOI 10.1542/peds.112.2.382; Rowe BH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000195.pub2; Rowe BH, 2004, RESP MED, V98, P275, DOI 10.1016/j.rmed.2003.11.016; Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002178; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TAL A, 1990, PEDIATRICS, V86, P350; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	34	45	46	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1518	+		10.1016/j.jaci.2013.01.034	http://dx.doi.org/10.1016/j.jaci.2013.01.034			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23498594	Green Accepted			2022-12-18	WOS:000320532800008
J	Han, JY; Dakhama, A; Jia, Y; Wang, MQ; Zeng, WJ; Takeda, K; Shiraishi, Y; Okamoto, M; Ziegler, SF; Gelfand, EW				Han, Junyan; Dakhama, Azzeddine; Jia, Yi; Wang, Meiqin; Zeng, Wanjiang; Takeda, Katsuyuki; Shiraishi, Yoshiki; Okamoto, Masakazu; Ziegler, Steven F.; Gelfand, Erwin W.			Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory syncytial virus; OX40 ligand; thymic stromal lymphopoietin	PLASMACYTOID DENDRITIC CELLS; IN-VIVO BLOCKADE; T-CELLS; AIRWAY HYPERRESPONSIVENESS; ALLERGIC INFLAMMATION; VIRAL BRONCHIOLITIS; THERAPEUTIC TARGET; TH2 RESPONSES; MURINE MODEL; INFECTION	Background: Recent studies revealed a critical role for thymic stromal lymphopoietin (TSLP) released from epithelial cells and OX40 ligand (OX40L) expressed on dendritic cells (DCs) in T(H)2 priming and polarization. Objectives: We sought to determine the importance of the TSLP-OX40L axis in neonatal respiratory syncytial virus (RSV) infection. Methods: Mice were initially infected with RSV as neonates or adults and reinfected 5 weeks later. Anti-OX40L or anti-TSLP were administered during primary or secondary infection. Outcomes included assessment of airway function and inflammation and expression of OX40L, TSLP, and IL-12. Results: OX40L was expressed mainly on CD11c(+) MHC class II (MHCII)(+)CD11b(+) DCs but not CD103(+) DCs. Treatment of neonates with OX40L antibody during primary RSV infection prevented the subsequent enhancement of airway hyperresponsiveness and the development of airway eosinophilia and mucus hyperproduction on reinfection. Administration of anti-TSLP before neonatal RSV infection reduced the accumulation of lung DCs, decreased OX40L expression on lung DCs, and attenuated the enhancement of airway responses after reinfection. Conclusions: In mice initially infected as neonates, TSLP expression induced by RSV infection is an important upstream event that controls OX40L expression, lung DC migration, and TH2 polarization, accounting for the enhanced response on reinfection. (J Allergy Clin Immunol 2012;130:1175-87.)	[Han, Junyan; Dakhama, Azzeddine; Jia, Yi; Wang, Meiqin; Zeng, Wanjiang; Takeda, Katsuyuki; Shiraishi, Yoshiki; Okamoto, Masakazu; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Ziegler, Steven F.] Benaroya Res Inst, Seattle, WA USA	National Jewish Health; Benaroya Research Institute	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Shiraishi, Yoshiki/Q-3914-2019	Shiraishi, Yoshiki/0000-0001-5275-6318	National Institutes of Health (NIH) [AI-77609, HL-36577, HL-61005]; National Institutes of Health (NIH); American Academy of Allergy, Asthma Immunology; NIH; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, R56AI077609] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) grants AI-77609, HL-36577, and HL-61005. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the NIH.; Disclosure of potential conflict of interest: S. F. Ziegler has received research support from the National Institutes of Health (NIH), has received lecture fees from the American Academy of Allergy, Asthma & Immunology, and has received travel expenses from the Federation of Clinical Immunology Societies. E. W. Gelfand has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4; Beyer M, 2004, J ALLERGY CLIN IMMUN, V113, P127, DOI 10.1016/j.jaci.2003.10.057; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Collins PL, 2008, J VIROL, V82, P2040, DOI 10.1128/JVI.01625-07; Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243; Croft M, 2009, IMMUNOL REV, V229, P173, DOI 10.1111/j.1600-065X.2009.00766.x; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Dakhama A, 2009, J ALLERGY CLIN IMMUN, V123, P138, DOI 10.1016/j.jaci.2008.10.012; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Flynn S, 1998, J EXP MED, V188, P297, DOI 10.1084/jem.188.2.297; Han J, 2010, J ALLERGY CLIN IMMUN, V125, pAB62, DOI 10.1016/j.jaci.2009.12.966; Han J, 2011, PULM MED, V2011, DOI 10.1155/2011/748038; Han JY, 2010, AM J RESP CRIT CARE, V182, P455, DOI 10.1164/rccm.200912-1811OC; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351; Huston DP, 2006, CURR ALLERGY ASTHM R, V6, P372, DOI 10.1007/s11882-996-0006-7; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jakubzick C, 2010, METHODS MOL BIOL, V595, P371, DOI 10.1007/978-1-60761-421-0_24; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Jessup HK, 2008, J IMMUNOL, V181, P4311, DOI 10.4049/jimmunol.181.6.4311; Kristjansson S, 2005, J ALLERGY CLIN IMMUN, V116, P805, DOI 10.1016/j.jaci.2005.07.012; Lee YM, 2008, AM J RESP CRIT CARE, V177, P208, DOI 10.1164/rccm.200612-1890OC; Lukens MV, 2009, J VIROL, V83, P7235, DOI 10.1128/JVI.00452-09; McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314; Ohshima Y, 1998, BLOOD, V92, P3338, DOI 10.1182/blood.V92.9.3338.421k19_3338_3345; Qiao JO, 2011, IMMUNOL CELL BIOL, V89, P231, DOI 10.1038/icb.2010.85; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Schwarze J, 2008, PEDIATR INFECT DIS J, V27, pS89, DOI 10.1097/INF.0b013e318168b6f0; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Smit JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001720; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; So T, 2006, P NATL ACAD SCI USA, V103, P3740, DOI 10.1073/pnas.0600205103; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tregoning JS, 2008, J VIROL, V82, P4115, DOI 10.1128/JVI.02313-07; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; Wang HW, 2006, J IMMUNOL, V177, P2536, DOI 10.4049/jimmunol.177.4.2536; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2007, J CLIN INVEST, V117, P3655, DOI 10.1172/JCI34182; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2008, J IMMUNOL, V181, P6557, DOI 10.4049/jimmunol.181.9.6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	54	45	46	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1175	+		10.1016/j.jaci.2012.08.033	http://dx.doi.org/10.1016/j.jaci.2012.08.033			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23036746	Green Accepted			2022-12-18	WOS:000310571400020
J	Marodi, L; Cypowyj, S; Toth, B; Chernyshova, L; Puel, A; Casanova, JL				Marodi, Laszlo; Cypowyj, Sophie; Toth, Beata; Chernyshova, Liudmyla; Puel, Anne; Casanova, Jean-Laurent			Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Primary immunodeficiency diseases; signal transducer and activator of transcription; signal transducer and activator of transcription 1 and 3; IL-17; Candida species; Staphylococcus species	HYPER-IGE SYNDROME; X-LINKED AGAMMAGLOBULINEMIA; HOST-DEFENSE MECHANISMS; SYNDROME TYPE-I; INBORN-ERRORS; FUNGAL-INFECTIONS; STAT3 MUTATIONS; PRIMARY IMMUNODEFICIENCIES; CELL-DIFFERENTIATION; SIGNAL TRANSDUCER	Signal transducer and activator of transcription (STAT) proteins are key components of the innate and adaptive immune responses to pathogenic microorganisms. Recent research on primary immunodeficiency disorders and the identification of patients carrying germline mutations in STAT1, STAT3, and STAT5B have highlighted the role of human STATs in host defense against various viruses, bacteria, and fungi. Mutations in STAT1 and STAT3 disrupt various cytokine pathways that control mucocutaneous immunity against Candida species, especially Candida albicans, and Staphylococcus species, especially Staphylococcus aureus. Here we consider inborn errors of immunity arising from mutations in either STAT1 or STAT3 that affect mucocutaneous immunity to Candida and Staphylococcus species. (J Allergy Clin Immunol 2012;130:1019-27.)	[Marodi, Laszlo; Toth, Beata] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infect & Pediat Immunol, H-4032 Debrecen, Hungary; [Cypowyj, Sophie; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Univ Hosp, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Chernyshova, Liudmyla] Natl Med Acad Postgrad Educ, Dept Pediat Infect Dis & Immunol, Kiev, Ukraine; [Puel, Anne; Casanova, Jean-Laurent] INSERM, U980, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Puel, Anne; Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Paris Sorbonne Cite, Paris, France	University of Debrecen; Rockefeller University; Shupyk National Healthcare University of Ukraine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Marodi, L (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Infect & Pediat Immunol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	lmarodi@dote.hu	Casanova, Jean-Laurent/I-3418-2017; Marodi, Laszlo/AAU-9915-2020; Puel, Anne/H-7305-2017; Chernyshova, Liudmyla/E-9457-2019	Puel, Anne/0000-0003-2603-0323; Casanova, Jean-Laurent/0000-0002-7782-4169; Chernyshova, Liudmyla/0000-0002-9980-250X; Cernysova, Ludmila/0000-0002-6989-612X	Axa Fellowship; National Center for Research Resources; National Center for Advancing Sciences (National Institutes of Health); St Giles Foundation; Pfizer; GlaxoSmithKline; NovImmune; Merck; Sanofi; TAMOP [4.2.1./B-09/1/KONV-2010-0007]; National Center for Research Resources [8UL1TR000043]; National Center for Advancing Sciences (NCATS), National Institutes of Health; ANR [GENCMCD 11-BSV3-005-01]; AXA Research Fund	Axa Fellowship(AXA Research Fund); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Sciences (National Institutes of Health); St Giles Foundation; Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); NovImmune; Merck(Merck & Company); Sanofi; TAMOP; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Sciences (NCATS), National Institutes of Health; ANR(French National Research Agency (ANR)); AXA Research Fund(AXA Research Fund)	S. Cypowyj has received research support from the Axa Fellowship. J.-L. Casanova has received research support from the National Center for Research Resources and the National Center for Advancing Sciences (National Institutes of Health) and the St Giles Foundation and has received consultancy fees from Pfizer, GlaxoSmithKline, NovImmune, Merck, and Sanofi. The rest of the authors declare that they have no relevant conflicts of interest.; Supported by TAMOP 4.2.1./B-09/1/KONV-2010-0007 to L.M. The Laboratory of Human Genetics of Infectious Diseases is supported in part by grants from the St Giles Foundation and Rockefeller University grant no. 8UL1TR000043 from the National Center for Research Resources and the National Center for Advancing Sciences (NCATS), National Institutes of Health, and the ANR (grant no. GENCMCD 11-BSV3-005-01). S.C. is supported by the AXA Research Fund.	Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Alcais A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/j.1749-6632.2010.05834.x; Averbuch D, 2011, PEDIATR INFECT DIS J, V30, P352, DOI 10.1097/INF.0b013e3181fdff4a; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Casanova JL, 2005, J EXP MED, V202, P197, DOI 10.1084/jem.20050854; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Cheng MH, 2012, ANNU REV IMMUNOL, V30, P393, DOI 10.1146/annurev-immunol-020711-074953; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Conti HR, 2010, MICROBES INFECT, V12, P518, DOI 10.1016/j.micinf.2010.03.013; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Husebye ES, 2009, J INTERN MED, V265, P514, DOI 10.1111/j.1365-2796.2009.02090.x; Jiao H, 2008, MOL IMMUNOL, V46, P202, DOI 10.1016/j.molimm.2008.07.001; Kilic SS, 2012, J PEDIATR-US, V160, P1055, DOI 10.1016/j.jpeds.2012.01.056; Kisand K, 2011, EUR J IMMUNOL, V41, P1517, DOI 10.1002/eji.201041253; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MacLennan C, 2004, J INFECT DIS, V190, P1755, DOI 10.1086/425021; MARODI L, 1983, J IMMUNOL METHODS, V57, P353, DOI 10.1016/0022-1759(83)90095-9; MARODI L, 1991, J IMMUNOL, V146, P2783; Marodi L, 1998, INFECT IMMUN, V66, P2750; MARODI L, 1995, PEDIATR INFECT DIS J, V14, P632, DOI 10.1097/00006454-199507000-00020; MARODI L, 1984, PEDIATR RES, V18, P1127, DOI 10.1203/00006450-198411000-00014; Marodi L, 1997, PEDIATR INFECT DIS J, V16, P795, DOI 10.1097/00006454-199708000-00012; Marodi L, 2010, NEW ENGL J MED, V362, P7; Marodi L, 2007, CURR OPIN PEDIATR, V19, P693, DOI 10.1097/MOP.0b013e3282f1dde9; Marodi L, 2007, NAT REV IMMUNOL, V7, P851, DOI 10.1038/nri2195; McDonald DR, 2012, J ALLERGY CLIN IMMUN, V129, P1429, DOI 10.1016/j.jaci.2012.03.034; Mehes L, 2012, J MED MICROBIOL, V61, P198, DOI 10.1099/jmm.0.029421-0; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Milner JD, 2011, CURR OPIN IMMUNOL, V23, P784, DOI 10.1016/j.coi.2011.09.006; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; Neofytos D, 2010, TRANSPL INFECT DIS, V12, P220, DOI 10.1111/j.1399-3062.2010.00492.x; Netea MG, 2011, NEW ENGL J MED, V364, P60, DOI 10.1056/NEJMra1001976; Netea MG, 2010, TRENDS IMMUNOL, V31, P346, DOI 10.1016/j.it.2010.06.007; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; O'Shea JJ, 2011, NAT REV IMMUNOL, V11, P239, DOI 10.1038/nri2958; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; Paulson ML, 2008, CURR OPIN ALLERGY CL, V8, P527, DOI 10.1097/ACI.0b013e3283184210; Pfaller MA, 2010, CRIT REV MICROBIOL, V36, P1, DOI 10.3109/10408410903241444; Prando C, 2012, MEDICINE BA IN PRESS; Puel A, 2008, J IMMUNOL, V180, P647, DOI 10.4049/jimmunol.180.1.647; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sancho-Shimizu V, 2011, CURR OPIN VIROL, V1, P487, DOI 10.1016/j.coviro.2011.10.016; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Shui JW, 2012, NATURE, V488, P222, DOI 10.1038/nature11242; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Szekely A, 2012, PEDIATR BLOOD CANCER, V58, P828, DOI 10.1002/pbc.23362; Toth B, 2012, LANCET, V380, P806; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; Toth B, 2010, CLIN ENDOCRINOL, V72, P641, DOI 10.1111/j.1365-2265.2009.03740.x; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059	71	45	45	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1019	1027		10.1016/j.jaci.2012.09.011	http://dx.doi.org/10.1016/j.jaci.2012.09.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23040277	Green Accepted			2022-12-18	WOS:000310571400001
J	Schroeder, S; Fleischer, DM; Masterson, JC; Gelfand, E; Furuta, GT; Atkins, D				Schroeder, Shauna; Fleischer, David M.; Masterson, Joanne C.; Gelfand, Erwin; Furuta, Glenn T.; Atkins, Dan			Successful treatment of eosinophilic esophagitis with ciclesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ONCE-DAILY CICLESONIDE; BUDESONIDE; CHILDREN		[Schroeder, Shauna; Fleischer, David M.; Masterson, Joanne C.; Furuta, Glenn T.; Atkins, Dan] Childrens Hosp Colorado, Gastrointestinal Eosinophil Dis Program, Dept Pediat, Mucosal Inflammat Program,Digest Hlth Inst, Aurora, CO USA; [Fleischer, David M.; Gelfand, Erwin; Furuta, Glenn T.; Atkins, Dan] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO USA; [Schroeder, Shauna; Fleischer, David M.; Masterson, Joanne C.; Gelfand, Erwin; Furuta, Glenn T.; Atkins, Dan] Univ Colorado, Denver Sch Med, Aurora, CO USA	Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Schroeder, S (corresponding author), Childrens Hosp Colorado, Gastrointestinal Eosinophil Dis Program, Dept Pediat, Mucosal Inflammat Program,Digest Hlth Inst, Aurora, CO USA.	Glenn.Furuta@childrenscolorado.org			NIDDK NIH HHS [T32 DK067009] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067009] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aceves SS, 2007, AM J GASTROENTEROL, V102, P2271, DOI 10.1111/j.1572-0241.2007.01379.x; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; Gelfand EW, 2006, J PEDIATR-US, V148, P377, DOI 10.1016/j.jpeds.2005.10.028; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; MUTCH E, 2003, EUR RESP J S45, V22, pS267; Pearlman DS, 2005, J ALLERGY CLIN IMMUN, V116, P1206, DOI 10.1016/j.jaci.2005.08.037; Richter K, 2005, J CLIN PHARMACOL, V45, P146, DOI 10.1177/0091270004271094; Rohatagi S, 2003, J CLIN PHARMACOL, V43, P365, DOI 10.1177/0091270002250998; Stoeck M, 2004, J PHARMACOL EXP THER, V309, P249, DOI 10.1124/jpet.103.059592; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048	10	45	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1419	1421		10.1016/j.jaci.2012.03.007	http://dx.doi.org/10.1016/j.jaci.2012.03.007			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22480537	Green Accepted			2022-12-18	WOS:000303418000040
J	Hilger, C; Swiontek, K; Arumugam, K; Lehners, C; Hentges, F				Hilger, Christiane; Swiontek, Kyra; Arumugam, Karthik; Lehners, Christiane; Hentges, Francois			Identification of a new major dog allergen highly cross-reactive with Fel d 4 in a population of cat- and dog-sensitized patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPOCALIN ALLERGEN		[Hilger, Christiane; Swiontek, Kyra; Hentges, Francois] CRP Sante, Lab Immunogenet & Allergol, Luxembourg, Luxembourg; [Arumugam, Karthik] CRP Sante, Lab Retrovirol, Luxembourg, Luxembourg; [Lehners, Christiane; Hentges, Francois] Ctr Hosp Luxembourg, Natl Unit Immunol Allergol, Luxembourg, Luxembourg	Luxembourg Institute of Health; Luxembourg Institute of Health; Luxembourg Hospital Center	Hilger, C (corresponding author), CRP Sante, Lab Immunogenet & Allergol, Luxembourg, Luxembourg.	christiane.hilger@crp-sante.lu		Hilger, Christiane/0000-0001-9455-5442				Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Madhurantakam C, 2010, J MOL BIOL, V401, P68, DOI 10.1016/j.jmb.2010.05.043; Reininger R, 2007, CLIN EXP ALLERGY, V37, P116, DOI 10.1111/j.1365-2222.2006.02611.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Smith W, 2011, INT ARCH ALLERGY IMM, V156, P159, DOI 10.1159/000322879; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)70306-3; Virtanen Tuomas, 2008, Clin Allergy Immunol, V21, P201	9	45	47	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1149	1151		10.1016/j.jaci.2011.10.017	http://dx.doi.org/10.1016/j.jaci.2011.10.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22104604				2022-12-18	WOS:000302144600034
J	Kapoor, S; Patel, SA; Kartan, S; Axelrod, D; Capitle, E; Rameshwar, P				Kapoor, Simi; Patel, Shyam A.; Kartan, Saritha; Axelrod, David; Capitle, Eugenio; Rameshwar, Pranela			Tolerance-like mediated suppression by mesenchymal stem cells in patients with dust mite allergy-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mesenchymal stem cells; proliferation; T cells; dust mite; allergic asthma; dendritic cells	T-CELL; STROMAL CELLS; AIRWAY INFLAMMATION; DENDRITIC CELLS; INTERFERON-GAMMA; PROLIFERATION; INHIBITION; DIFFERENTIATION; TRANSPLANTATION; GENERATION	Background: Mesenchymal stem cells (MSCs) can suppress and enhance immune functions. MSCs show promise as off-the-shelf cellular therapy for several disorders, including inflammation. Objective: We investigated the effects of MSCs on the proliferation of PBMCs to allergic subjects (dust mite [DM]), allergic asthmatic subjects, or both. Methods: Proliferation was studied by using tritiated thymidine uptake with or without MSCs. The refractoriness of PBMCs to DM was examined after preconditioning with MSCs and after repeated challenge with low-dose DM. Flow cytometry was used to study regulatory T cells and dendritic cells (DCs), and ELISA was used to study cytokine production. Results: Seven subjects with allergic asthma met the inclusion/exclusion criteria. MSCs significantly (P < .05) reduced the proliferation of 6 subjects with allergic asthma but not those with allergy alone. The effect was specific to the allergen because MSCs did not affect challenges to tetanus toxoid. There was no change in CD4/CD25/forkhead box protein 3-positive cells, although there were decreased IFN-gamma and increased IL-10 levels. Numbers of mature DCs were increased 6-fold. Refractoriness to DM was achieved by means of repeated exposure to low-dose DM and MSCs and also MSC-preconditioned MSC. Conclusion: MSCs suppressed the proliferation of DMchallenged PBMCs from allergic asthmatic subjects but not from allergic subjects without asthma. MSCs blunted the maturation of DCs but not regulatory T cells. Repeated exposure to low-dose DM and MSCs, as well as preconditioning of PBMCs with MSCs, caused refractoriness to DM. These findings have implications for the use of MSCs in attenuation of the inflammatory responses to allergic triggers in asthmatic patients with off-the-shelf MSCs. (J Allergy Clin Immunol 2012; 129:1094-101.)	[Kapoor, Simi; Patel, Shyam A.; Kartan, Saritha; Axelrod, David; Capitle, Eugenio; Rameshwar, Pranela] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rameshwar, P (corresponding author), UMDNJ New Jersey Med Sch, 185 S Orange Ave,MSB,Room E-579, Newark, NJ 07103 USA.	rameshwa@umdnj.edu			F. M. Kirby Foundation; American College of Allergy, Asthma Immunology	F. M. Kirby Foundation; American College of Allergy, Asthma Immunology	Supported by the F. M. Kirby Foundation.; S. Kapoor received the 2nd place Clemons Von Pirquet Award from the American College of Allergy, Asthma & Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Benvenuto F, 2007, STEM CELLS, V25, P1753, DOI 10.1634/stemcells.2007-0068; Bullens Dominique M. A., 2007, Inflammation & Allergy Drug Targets, V6, P81; Busse D, 2010, P NATL ACAD SCI USA, V107, P3058, DOI 10.1073/pnas.0812851107; Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood-2006-01-0057; Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007; Francois M, 2009, BLOOD, V114, P2632, DOI 10.1182/blood-2009-02-207795; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-005-0052-6; Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood-2004-09-3696; Gonzalez-Rey E, 2010, ANN RHEUM DIS, V69, P241, DOI 10.1136/ard.2008.101881; Helmy KY, 2010, THER DELIV, V1, P693, DOI [10.4155/tde.10.57, 10.4155/TDE.10.57]; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; Leech MD, 2007, J IMMUNOL, V179, P7050, DOI 10.4049/jimmunol.179.10.7050; Li YP, 2008, J IMMUNOL, V180, P1598, DOI 10.4049/jimmunol.180.3.1598; Liang J, 2010, NAT REV RHEUMATOL, V6, P486, DOI 10.1038/nrrheum.2010.80; Luckey U, 2011, J CLIN INVEST, V121, P3860, DOI 10.1172/JCI45963; Lun SWM, 2009, J CLIN IMMUNOL, V29, P330, DOI 10.1007/s10875-008-9269-1; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Nouri-Aria Kayhan T., 2008, Inflammation & Allergy Drug Targets, V7, P237, DOI 10.2174/187152808786848405; Parekkadan B, 2008, STEM CELLS, V26, P1913, DOI 10.1634/stemcells.2007-0790; Park HK, 2010, STEM CELLS DEV, V19, P1811, DOI 10.1089/scd.2009.0513; Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143; Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426; Prockop DJ, 2010, J CELL MOL MED, V14, P2190, DOI 10.1111/j.1582-4934.2010.01151.x; Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54; Rasmusson I, 2006, EXP CELL RES, V312, P2169, DOI 10.1016/j.yexcr.2006.03.019; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ringden O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14; Ryan JM, 2007, CLIN EXP IMMUNOL, V149, P353, DOI 10.1111/j.1365-2249.2007.03422.x; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Tyndall A, 2009, NAT MED, V15, P18, DOI 10.1038/nm0109-18; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Zhang QZ, 2010, J IMMUNOL, V184, P1656, DOI 10.4049/jimmunol.0990118; Zheng ZH, 2008, RHEUMATOLOGY, V47, P22, DOI 10.1093/rheumatology/kem284	44	45	50	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1094	1101		10.1016/j.jaci.2011.10.048	http://dx.doi.org/10.1016/j.jaci.2011.10.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22196773				2022-12-18	WOS:000302144600026
J	Stokes, JR; Romero, FA; Allan, RJ; Phillips, PG; Hackman, F; Misfeldt, J; Casale, TB				Stokes, Jeffrey R.; Romero, Francisco A., Jr.; Allan, Richard J.; Phillips, Peter G.; Hackman, Frances; Misfeldt, Janie; Casale, Thomas B.			The effects of an H-3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-3 receptor antagonist; nasal congestion; decongestant; allergic rhinitis	NASAL; ACTIVATION	Background: Nasal H-3 receptors might have a role in mediating the effects of histamine in patients with allergic rhinitis. Objective: This study explored the effect of the potent oral H-3 receptor antagonist PF-03654746 in combination with an oral H-1 receptor antagonist on the objective (acoustic rhinometry) and subjective (symptoms) responses to nasal allergen challenge. Methods: Twenty patients with out-of-season allergic rhinitis displaying a 30% or greater decrease in minimum nasal cross-sectional area (A(min)) after bolus (ragweed) complete nasal allergen challenge at screening were studied by using a randomized, double-blind, single-dose, 4-way crossover design. Treatments included 10 mg of PF-03654746 plus 60 mg of fexofenadine (group 1), 1 mg of PF-03654746 plus 60 mg of fexofenadine (group 2), 60 mg of fexofenadine/120 mg of pseudoephedrine (group 3), and placebo (group 4). After dosing, subjects underwent complete nasal allergen challenge. Nasal symptom scores (no. of sneezes and 0- to 5-point scores for severity of congestion, itching, and rhinorrhea), A(min) (in square centimeters), and nasal volume (in cubic centimeters) were recorded 15, 30, 45, and 60 minutes after allergen. There was a minimum 10-day washout between periods. Results: The following symptom scores were significantly (P <= .05) reduced by active treatments versus placebo: group 1, congestion of -0.7 (SE, 0.3), itching of -1.0 (SE, 0.3), rhinorrhea of -1.3 (SE, 0.3), and sneeze of -8.8 (SE, 1.5); group 2, itching of -0.6 (SE, 0.3), rhinorrhea of -0.8 (SE, 0.3), and sneeze of -9.1 (SE, 1.5); and group 3, rhinorrhea of -0.7 (SE, 0.3) and sneeze of -7.0 (SE, 1.5). There was no significant effect of any treatment on mean A(min) proportion or nasal volume proportion after nasal allergen challenge. Conclusions: In combination with fexofenadine, single doses of PF-03654746 caused a reduction in allergen-induced nasal symptoms. H3 receptor antagonism might be a novel therapeutic strategy to further explore in patients with allergic rhinitis. (J Allergy Clin Immunol 2012;129:409-12.)	[Stokes, Jeffrey R.; Romero, Francisco A., Jr.; Misfeldt, Janie; Casale, Thomas B.] Creighton Univ, Dept Med, Div Allergy Immunol, Sch Med, Omaha, NE 68131 USA; [Allan, Richard J.; Phillips, Peter G.; Hackman, Frances] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England	Creighton University; Pfizer	Casale, TB (corresponding author), Creighton Univ, Dept Med, Div Allergy Immunol, Sch Med, 601 N 30th St,Suite 5850, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Allan, Richard/0000-0003-3205-3572	Pfizer Pharmaceuticals; Pfizer	Pfizer Pharmaceuticals(Pfizer); Pfizer(Pfizer)	Supported by Pfizer Pharmaceuticals.; R. J. Allan is employed by Pfizer. P. G. Phillips was employed by Pfizer Ltd and is currently employed by Novartis Pharmaceuticals UK Ltd. F. Hackman is employed by Pfizer Ltd. T. B. Casale receives research support from Pfizer and is Executive Vice President of the American Academy of Allergy, Asthma & Immunology.	Baraniuk James N, 2011, Proc Am Thorac Soc, V8, P62, DOI 10.1513/pats.201006-042RN; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; HAMILTON JW, 1995, ACTA OTO-LARYNGOL, V115, P811, DOI 10.3109/00016489509139406; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Markham A, 1998, DRUGS, V55, P269, DOI 10.2165/00003495-199855020-00012; McLeod RL, 1999, AM J RHINOL, V13, P391, DOI 10.2500/105065899781367483; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Romero FA, 2008, J ALLERGY CLIN IMMUN, V121, pS277, DOI 10.1016/j.jaci.2007.12.1095; Simons FER, 2002, AM J MED, V113, p38S; Taylor-Clark T, 2005, BRIT J PHARMACOL, V144, P867, DOI 10.1038/sj.bjp.0706118; Varty LM, 2004, EUR J PHARMACOL, V484, P83, DOI 10.1016/j.ejphar.2003.10.051; Varty LM, 2002, EUR J PHARMACOL, V452, P339, DOI 10.1016/S0014-2999(02)02336-1	13	45	49	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					409	U204		10.1016/j.jaci.2011.11.026	http://dx.doi.org/10.1016/j.jaci.2011.11.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22196768				2022-12-18	WOS:000299951700017
J	Lieberman, JA; Cox, AL; Vitale, M; Sampson, HA				Lieberman, Jay A.; Cox, Amanda L.; Vitale, Michelle; Sampson, Hugh A.			Outcomes of office-based, open food challenges in the management of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Lieberman, Jay A.; Cox, Amanda L.; Vitale, Michelle; Sampson, Hugh A.] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Lieberman, JA (corresponding author), Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY USA.	Jay.lieberman@mssm.edu			NIAID NIH HHS [U19 AI044236, P01 AI044236-06, P01 AI044236, AI-044236] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236, U19AI044236] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47, DOI 10.1016/S1081-1206(10)62195-3; Mankad VS, 2008, ANN ALLERG ASTHMA IM, V100, P469, DOI 10.1016/S1081-1206(10)60473-5; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Venter C, 2007, J HUM NUTR DIET, V20, P565, DOI 10.1111/j.1365-277X.2007.00828.x	7	45	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1120	1122		10.1016/j.jaci.2011.07.012	http://dx.doi.org/10.1016/j.jaci.2011.07.012			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21835446	Bronze, Green Accepted			2022-12-18	WOS:000296578200033
J	Moore, WC; Evans, MD; Bleecker, ER; Busse, WW; Calhoun, WJ; Castro, M; Chung, KF; Erzurum, SC; Curran-Everett, D; Dweik, RA; Gaston, B; Hew, M; Israel, E; Mayse, ML; Pascual, RM; Peters, SP; Silveira, L; Wenzel, SE; Jarjour, NN				Moore, Wendy C.; Evans, Michael D.; Bleecker, Eugene R.; Busse, William W.; Calhoun, William J.; Castro, Mario; Chung, Kian Fan; Erzurum, Serpil C.; Curran-Everett, Douglas; Dweik, Raed A.; Gaston, Benjamin; Hew, Mark; Israel, Elliot; Mayse, Martin L.; Pascual, Rodolfo M.; Peters, Stephen P.; Silveira, Lori; Wenzel, Sally E.; Jarjour, Nizar N.		Natl Heart Lung Blood Inst	Safety of investigative bronchoscopy in the Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Investigative bronchoscopy; safety; severe asthma; exacerbation	BRONCHOALVEOLAR LAVAGE; FIBEROPTIC BRONCHOSCOPY; BIOPSY; LUNG	Background: Investigative bronchoscopy was performed in a subset of participants in the Severe Asthma Research Program to gain insights into the pathobiology of severe disease. We evaluated the safety aspects of this procedure in this cohort with specific focus on patients with severe asthma. Objective: To evaluate prospectively changes in lung function and the frequency of adverse events related to investigative bronchoscopy. Methods: Bronchoscopy was performed by using a common manual of procedures. A subset of very severe asthma was defined by severe airflow obstruction, chronic oral corticosteroid use, and recent asthma exacerbations. Subjects were monitored for changes in lung function and contacted by telephone for 3 days after the procedure. Results: A total of 436 subjects underwent bronchoscopy (97 normal, 196 not severe, 102 severe, and 41 very severe asthma). Nine subjects were evaluated in hospital settings after bronchoscopy; 7 of these were respiratory-related events. Recent emergency department visits, chronic oral corticosteroid use, and a history of pneumonia were more frequent in subjects who had asthma exacerbations after bronchoscopy. The fall in FEV1 after bronchoscopy was similar in the severe and milder asthma groups. Prebronchodilator FEV1 was the strongest predictor of change in FEV1 after bronchoscopy with larger decreases observed in subjects with better lung function. Conclusion: Bronchoscopy in subjects with severe asthma was well tolerated. Asthma exacerbations were rare, and reduction in pulmonary function after the procedure was similar to that in subjects with less severe asthma. With proper precautions, investigative bronchoscopy can be performed safely in severe asthma. (J Allergy Clin Immunol 2011;128:328-36.)	[Moore, Wendy C.; Bleecker, Eugene R.; Pascual, Rodolfo M.; Peters, Stephen P.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med Res, Winston Salem, NC 27157 USA; [Moore, Wendy C.; Bleecker, Eugene R.; Pascual, Rodolfo M.; Peters, Stephen P.] Wake Forest Univ, Bowman Gray Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA; [Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; [Moore, Wendy C.; Bleecker, Eugene R.; Busse, William W.; Calhoun, William J.; Castro, Mario; Chung, Kian Fan; Erzurum, Serpil C.; Curran-Everett, Douglas; Dweik, Raed A.; Gaston, Benjamin; Hew, Mark; Israel, Elliot; Mayse, Martin L.; Pascual, Rodolfo M.; Peters, Stephen P.; Silveira, Lori; Wenzel, Sally E.; Jarjour, Nizar N.] Severe Asthma Res Program, Bethesda, MD USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Wisconsin System; University of Wisconsin Madison	Moore, WC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	wmoore@wfubmc.edu	Chung, Kian Fan/B-1872-2012; Fain, Sean B./K-4260-2016; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Fain, Sean B./0000-0001-5461-0646; Chung, Kian Fan/0000-0001-7101-1426; Calhoun, William/0000-0001-7075-712X; Curran-Everett, Douglas/0000-0001-5992-4839; Evans, Michael/0000-0001-7449-3993	NHLBI; National Institutes of Health (NIH)/NHLBI; NIH-NIAID; Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception; Asthmatx; Amgen; Genentech; Merck; NIH; Elsevier; state of Ohio; Aerovance; Ception Therapeutics; Icagen;  [HL69116];  [HL69130];  [HL69155];  [HL69167];  [HL69170];  [HL69174];  [HL69349];  [HL091762];  [M01 RR03186];  [M01 RR007122-14];  [1UL1RR024992];  [1UL1RR024989];  [1UL1RR025011]; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005, UL1TR000454, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, UL1RR024992, UL1RR024989, M01RR007122, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069174, R01HL069155, R01HL069167, R01HL069349, R01HL069116, R01HL069130, R01HL069170, R01HL091762] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; Asthmatx; Amgen(Amgen); Genentech(Roche HoldingGenentech); Merck(Merck & Company); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Elsevier; state of Ohio; Aerovance; Ception Therapeutics; Icagen; ; ; ; ; ; ; ; ; ; ; ; ; ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, HL091762, M01 RR03186, M01 RR007122-14, 1UL1RR024992, 1UL1RR024989, and 1UL1RR025011.; W. C. Moore receives research support from the NHLBI Severe Asthma Research Program. E. R. Bleecker receives research support from the National Institutes of Health (NIH)/NHLBI/Severe Asthma Research Program. W. W. Busse is on advisory boards for Centocor and Merck; has consultant arrangements with AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, GlaxoSmithKline, Amgen, Prizer, MedImmune, and Genentech; and receives research support from the NIH-NIAID, NIH-NHLBI, Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. M. Castro has consultant arrangements with Electrocore, NKTT, Schering, Asthmatx, and Cephalon; is on the advisory board for Genentech; is a speaker for AstraZeneca, Boerhinger-Ingelheim, Pfizer, Merck, and GlaxoSmithKline; receives research support from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the NIH, and GlaxoSmithKline; and receives royalties from Elsevier. K. F. Chung receives research support from the NIH. S. C. Erzurum receives research support from Asthmatx. R. A. Dweik receives research support from the NIH and the state of Ohio. B. Gaston is a primary shareholder in Respiratory Research, Inc, and receives research support from the NIH. E. Israel has consultant arrangements with Abbott, Amgen, Cowen & Co, GlaxoSmithKline, Icagen, MedImmune, Merck, NewMentor, NKT Therapeutics, Ono Pharmaceuticals US, Pulmatrix, Schering Plough, and Teva Specialty Pharmaceuticals and receives research support from Aerovance, Amgen, Ception Therapeutics, Genentech, Icagen, MedImmune, the NIH, and Novartis. M. L. Mayse has consultant arrangements with Asthmatx. S. P. Peters receives research support from the NIH/NHLBI/Severe Asthma Research Program. N. N. Jarjour has consultant arrangements with Asthmatx and Genentech and receives research support from GlaxoSmithKline, Merck, and MedImmune. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Busse WW, 2005, AM J RESP CRIT CARE, V172, P807, DOI 10.1164/rccm.200407-966WS; CHETTA A, 1992, CHEST, V101, P1563, DOI 10.1378/chest.101.6.1563; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; Elston WJ, 2004, EUR RESPIR J, V24, P375, DOI 10.1183/09031936.04.00063003; GOLDSTEIN RA, 1985, J ALLERGY CLIN IMMUN, V76, P145; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Humbert M, 1996, THORAX, V51, P664, DOI 10.1136/thx.51.7.664; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Julius P, 2008, J ALLERGY CLIN IMMUN, V121, P712, DOI 10.1016/j.jaci.2007.08.058; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116, DOI 10.1164/ajrccm/146.1.116	15	45	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					328	U339		10.1016/j.jaci.2011.02.042	http://dx.doi.org/10.1016/j.jaci.2011.02.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21496892	Green Accepted			2022-12-18	WOS:000293280800012
J	Fitzpatrick, AM; Stephenson, ST; Hadley, GR; Burwell, L; Penugonda, M; Simon, DM; Hansen, J; Jones, DP; Brown, LAS				Fitzpatrick, Anne M.; Stephenson, Susan T.; Hadley, Graham R.; Burwell, Leandrea; Penugonda, Madhuri; Simon, Dawn M.; Hansen, Jason; Jones, Dean P.; Brown, Lou Ann S.			Thiol redox disturbances in children with severe asthma are associated with posttranslational modification of the transcription factor nuclear factor (erythroid-derived 2)-like 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; oxidative stress; inflammation; glutathione; cysteine; nuclear factor (erythroid-derived 2)-like 2 (Nrf2)	NF-E2-RELATED FACTOR-2; OXIDATIVE STRESS; FACTOR NRF2; GLUTATHIONE; PROTEIN; POLYMORPHISMS; PHENOTYPES; GENES; KEAP1; LUNG	Background: Airway thiol redox disturbances, including depletion of the antioxidant, glutathione, are differentiating features of severe asthma in children. Objectives: Given the role of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in maintaining glutathione homeostasis and antioxidant defense, we quantified expression and activity of Nrf2 and its downstream targets in the airways and systemic circulation of children with asthma. We hypothesized that Nrf2 activation and function would be impaired in severe asthma, resulting in depletion of thiol pools and insufficient glutathione synthesis and conjugation. Methods: PBMCs and airway lavage cells were collected from children 6 to 17 years with severe (n = 51) and mild-to-moderate asthma (n = 38). The thiols glutathione and cysteine were quantified, and expression and activity of Nrf2 and its downstream targets were assessed. Results: Children with severe asthma had greater oxidation and lower concentrations of glutathione and cysteine in the plasma and airway lavage. Although Nrf2 mRNA and protein increased in severe asthma as a function of increased thiol oxidation, the Nrf2 expressed was highly dysfunctional. Nrf2 activation and downstream targets of Nrf2 binding, including glutathione-dependent enzymes, were not different between groups. The duration of asthma was a key factor associated with Nrf2 dysfunction in severe asthma. Conclusion: Children with severe asthma have a global disruption of thiol redox signaling and control in both the airways and systemic circulation that is associated with posttranslational modification of Nrf2. We conclude that the Nrf2 pathway is disrupted in severe asthma as a function of chronic oxidative stress, which ultimately inhibits glutathione synthesis and antioxidant defense. (J Allergy Clin Immunol 2011;127:1604-11.)	[Fitzpatrick, Anne M.; Stephenson, Susan T.; Hadley, Graham R.; Burwell, Leandrea; Penugonda, Madhuri; Simon, Dawn M.; Hansen, Jason; Brown, Lou Ann S.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Jones, Dean P.] Emory Univ, Dept Med, Atlanta, GA 30322 USA; [Fitzpatrick, Anne M.; Brown, Lou Ann S.] Childrens Healthcare Atlanta Ctr Dev Lung Biol, Atlanta, GA USA	Emory University; Emory University; Children's Healthcare of Atlanta (CHOA)	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	NIH [RO1 NR012021]; National Institutes of Health, National Center for Research Resources [UL1RR025008]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported by NIH RO1 NR012021 and in part by PHS Grant UL1RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources.	Adenuga D, 2010, BIOCHEM BIOPH RES CO, V403, P452, DOI 10.1016/j.bbrc.2010.11.054; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC; Comhair SAA, 2010, ANTIOXID REDOX SIGN, V12, P93, DOI 10.1089/ARS.2008.2425; Ercan H, 2006, J ALLERGY CLIN IMMUN, V118, P1097, DOI 10.1016/j.jaci.2006.08.012; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P282, DOI 10.1016/j.jaci.2010.10.036; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V124, P990, DOI 10.1016/j.jaci.2009.08.039; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Goven D, 2008, THORAX, V63, P916, DOI 10.1136/thx.2007.091181; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Hubner RH, 2009, MOL MED, V15, P203, DOI 10.2119/molmed.2008.00130; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Minelli C, 2010, INT J EPIDEMIOL, V39, P539, DOI 10.1093/ije/dyp337; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Reddy NM, 2007, PHYSIOL GENOMICS, V32, P74, DOI 10.1152/physiolgenomics.00126.2007; Reddy NM, 2009, J IMMUNOL, V183, P4601, DOI 10.4049/jimmunol.0901754; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Siedlinski M, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-73; Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670; Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08; Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang XL, 2005, EUR J IMMUNOL, V35, P3258, DOI 10.1002/eji.200526116	44	45	47	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1604	1611		10.1016/j.jaci.2011.03.031	http://dx.doi.org/10.1016/j.jaci.2011.03.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21514635	Green Accepted			2022-12-18	WOS:000291048500043
J	Goussetis, E; Peristeri, I; Kitra, V; Traeger-Synodinos, J; Theodosaki, M; Psarra, K; Kanariou, M; Tzortzatou-Stathopoulou, F; Petrakou, E; Fylaktou, I; Kanavakis, E; Graphakos, S				Goussetis, Evgenios; Peristeri, Ioulia; Kitra, Vasiliki; Traeger-Synodinos, Joanne; Theodosaki, Maria; Psarra, Katerina; Kanariou, Maria; Tzortzatou-Stathopoulou, Fotini; Petrakou, Eftichia; Fylaktou, Irene; Kanavakis, Emmanuel; Graphakos, Stelios			Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; STAT3		[Goussetis, Evgenios; Peristeri, Ioulia; Kitra, Vasiliki; Theodosaki, Maria; Petrakou, Eftichia; Graphakos, Stelios] Aghia Sophia Childrens Hosp, Stem Cell Transplant Unit, Athens, Greece; [Kanariou, Maria] Aghia Sophia Childrens Hosp, Dept Immunol & Histocompatibil, Athens, Greece; [Traeger-Synodinos, Joanne; Fylaktou, Irene; Kanavakis, Emmanuel] Univ Athens, Dept Med Genet, Aghia Sophia Childrens Hosp, Athens, Greece; [Psarra, Katerina] Evangelismos Med Ctr, Dept Immunol & Histocompatibil, Athens, Greece; [Tzortzatou-Stathopoulou, Fotini] Univ Athens, Sch Med, Aghia Sophia Childrens Hosp, Pediat Clin 1, GR-11527 Athens, Greece	The Aghia Sophia Children's Hospital; The Aghia Sophia Children's Hospital; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital; Evangelismos Hospital; Athens Medical School; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital	Goussetis, E (corresponding author), Aghia Sophia Childrens Hosp, Stem Cell Transplant Unit, Athens, Greece.	evgoussetis@gmail.com	Traeger-Synodinos, J/E-4283-2010	Traeger-Synodinos, J/0000-0002-1860-5628				Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Freeman AF, 2008, IMMUNOL ALLERGY CLIN, V28, P277, DOI 10.1016/j.iac.2008.01.005; Freeman AF, 2007, J ALLERGY CLIN IMMUN, V119, P1234, DOI 10.1016/j.jaci.2006.12.666; Gennery AR, 2000, BONE MARROW TRANSPL, V25, P1303, DOI 10.1038/sj.bmt.1702446; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Nester TA, 1998, AM J MED, V105, P162, DOI 10.1016/S0002-9343(98)00200-9; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059	9	45	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.005	http://dx.doi.org/10.1016/j.jaci.2010.05.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20584545				2022-12-18	WOS:000281203800029
J	Mukhopadhyay, S; Sypek, J; Tavendale, R; Gartner, U; Winter, J; Li, W; Page, K; Fleming, M; Brady, J; O'Toole, M; Macgregor, DF; Goldman, S; Tam, S; Abraham, W; Williams, C; Miller, DK; Palmer, CNA				Mukhopadhyay, Somnath; Sypek, Joseph; Tavendale, Roger; Gartner, Ulrike; Winter, John; Li, Wei; Page, Karen; Fleming, Margaret; Brady, Jeff; O'Toole, Margot; Macgregor, Donald F.; Goldman, Samuel; Tam, Steve; Abraham, William; Williams, Cara; Miller, Douglas K.; Palmer, Colin N. A.			Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; chronic obstructive pulmonary disease; metalloproteinase; genetics; exacerbation; polymorphism; animal studies	FILAGGRIN NULL MUTATIONS; COPD; METALLOELASTASE; EXACERBATIONS; POLYMORPHISMS; INFLAMMATION; EXPRESSION; PROTEINS; MMP12; RISK	Background: Matrix metalloproteinase (MMP)-12-mediated pathologic degradation of the extracellular matrix and the subsequent repair cycles influence the airway changes in patients with asthma and chronic obstructive pulmonary disease (COPD). The common serine variant at codon 357 of the MMP12 gene (rs652438) is associated with clinical manifestations consistent with more aggressive matrix degradation in other tissues. Objective: We sought to explore the hypothesis that MMP12 represents a novel therapeutic target in asthma. Methods: The role of the rs652438 variant on clinical phenotype was explored in young asthmatic patients and patients with COPD. Candidate MMP-12 inhibitors were identified on the basis of potency and selectivity against a panel of other MMPs. The role of MMP-12 specific inhibition was tested in vitro, as well as in animal models of allergic airway inflammation. Results: The odds ratio for having greater asthma severity was 2.00 (95% CI, 1.24-3.24; P = .004) when comparing asthmatic patients with at least 1 copy of the serine variant with those with none. The carrier frequency for the variant increased in line with asthma treatment step (P = .000). The presence of the variant nearly doubled the odds in favor of asthmatic exacerbations (odds ratio, 1.90; 95% CI, 1.19-3.04; P = .008) over the previous 6 months. The serine variant was also associated with increased disease severity in patients with COPD (P = .016). Prior administration of an MMP-12 specific inhibitor attenuated the early airway response and completely blocked the late airway response with subsequent Ascaris suum challenge in sheep. Conclusion: Studies on human participants with asthma and COPD show that the risk MMP12 gene variant is associated with disease severity. In allergen-sensitized sheep pharmacologic inhibition of MMP12 downregulates both early and late airway responses in response to allergic stimuli. (J Allergy Clin Immunol 2010;126:70-6.)	[Mukhopadhyay, Somnath] Royal Alexandra Childrens Hosp, Brighton & Sussex Med Sch, Acad Unit level 10C, Chair Paediat,Dept Pediat, Brighton BN2 5BE, E Sussex, England; [Sypek, Joseph; Page, Karen; Fleming, Margaret; Goldman, Samuel; Williams, Cara] Pfizer Res, Inflammat & Immunol, Cambridge, MA 02140 USA; [Tavendale, Roger; Gartner, Ulrike; Winter, John; Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Inst, Populat Pharmacogenet Grp, Dundee DD1 9SY, Scotland; [Li, Wei; Tam, Steve] Pfizer Res, Chem & Screening Sci, Cambridge, MA 02140 USA; [Brady, Jeff] Univ Dundee, TMRC Lab, Dundee DD1 4HN, Scotland; [O'Toole, Margot] Pfizer Res, Biol Therapeut, Global Biotherapeut Technol, Cambridge, MA 02140 USA; [Macgregor, Donald F.] Ninewells Hosp, NHS Tayside, Directorate Paediat, Dundee DD1 9SY, Scotland; [Abraham, William] Univ Miami, Mt Sinai Med Ctr, Dept Res, Miami Beach, FL 33140 USA; [Miller, Douglas K.] Pfizer Res, Discovery Translat Med, Collegeville, PA USA	University of Brighton; University of Sussex; Pfizer; University of Dundee; Pfizer; University of Dundee; Pfizer; University of Dundee; Mount Sinai Medical Center; University of Miami; Pfizer	Mukhopadhyay, S (corresponding author), Royal Alexandra Childrens Hosp, Brighton & Sussex Med Sch, Acad Unit level 10C, Chair Paediat,Dept Pediat, Eastern Rd, Brighton BN2 5BE, E Sussex, England.	s.mukhopadhyay@bsms.ac.uk; jsypek@wyeth.com	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	Translational Medicine Research Collaboration [INF-DU-031]; Wyeth Research; Scottish Enterprise Tayside; Gannochy Trust (Perth); Perth and Kinross City Council; MSD; Wyeth; National Institute of Environmental Health Sciences; Parion; JSJ Pharmaceuticals; Novartis; Wyeth Pharma	Translational Medicine Research Collaboration; Wyeth Research(Wyeth); Scottish Enterprise Tayside; Gannochy Trust (Perth); Perth and Kinross City Council; MSD; Wyeth(Wyeth); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Parion; JSJ Pharmaceuticals; Novartis(Novartis); Wyeth Pharma(Wyeth)	Supported by the Translational Medicine Research Collaboration (INF-DU-031) and, Wyeth Research. The BREATHE study of asthma in children was funded by Scottish Enterprise Tayside, the Gannochy Trust (Perth), and the Perth and Kinross City Council.; S. Mukhopadhyay receives research support from MSD UK and Wyeth plc and has provided legal consultation/expert witness testimony in cases related to cystic fibrosis. J. Winter provides personal injury reports per annum income @ 20k pound. J. Sypek, W. Li, K. Page, M. Fleming, J. Brady, M. O'Toole, S. Goldman, S. Tam, C. Williams, and D. K. Miller are employed by Pfizer Research. D. F. Macgregor receives research support from MSD and has provided legal consultation/expert witness testimony in cases related to pediatric respiratory illness and child protection issues. W. Abraham receives research support from Wyeth, the National Institute of Environmental Health Sciences, Parion, JSJ Pharmaceuticals, and Novartis. C. N. A. Palmer receives research support from Wyeth Pharma. The rest of the authors have declared that they have no conflict of interest.	Abraham WM, 2008, PULM PHARMACOL THER, V21, P743, DOI 10.1016/j.pupt.2008.01.010; AGRAWAL DK, 1990, CRC PRESS SERIES PHA; Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; Chandler S, 1996, BIOCHEM BIOPH RES CO, V228, P421, DOI 10.1006/bbrc.1996.1677; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; Jormsjo S, 2000, CIRC RES, V86, P998, DOI 10.1161/01.RES.86.9.998; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lavigne MC, 2004, BIOCHEM BIOPH RES CO, V324, P534, DOI 10.1016/j.bbrc.2004.09.080; LI W, 2008, Patent No. 2008057254; Li W, 2009, J MED CHEM, V52, P1799, DOI 10.1021/jm900093d; Molnar J., 1993, In Vivo (Athens), V7, P431; Palmer CNA, 2007, CLIN PHARMACOL THER, V81, P713, DOI 10.1038/sj.clpt.6100119; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Pouladi MA, 2004, AM J RESP CELL MOL, V30, P84, DOI 10.1165/rcmb.2003-0051OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Shin AS, 2005, BREAST CANCER RES, V7, pR506, DOI 10.1186/bcr1033; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Warner RL, 2004, AM J PATHOL, V165, P1921, DOI 10.1016/S0002-9440(10)63244-0; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1	24	45	63	4	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					70	76		10.1016/j.jaci.2010.03.027	http://dx.doi.org/10.1016/j.jaci.2010.03.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20546881				2022-12-18	WOS:000280061800013
J	Schouten, B; van Esch, BCAM; van Thuijl, AOJ; Blokhuis, BRJ; Kormelink, TG; Hofman, GA; Moro, GE; Boehm, G; Arslanoglu, S; Sprikkelman, AB; Willemsen, LEM; Knippels, LMJ; Redegeld, FA; Garssen, J				Schouten, Bastiaan; van Esch, Betty C. A. M.; van Thuijl, Anders O. J.; Blokhuis, Bart R. J.; Kormelink, Tom Groot; Hofman, Gerard A.; Moro, Guido E.; Boehm, Gunther; Arslanoglu, Sertac; Sprikkelman, Aline B.; Willemsen, Linette E. M.; Knippels, Leon M. J.; Redegeld, Frank A.; Garssen, Johan			Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow's milk proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunoglobulin free light chains; IgE; cow's milk allergy; food allergy; casein; whey; atopic dermatitis	ATOPIC-DERMATITIS; MAST-CELLS; FOOD; CHILDREN; CASEIN; HYPERSENSITIVITY; RESPONSES; INFANTS; SERUM; WHEY	Background: Cow's milk allergy (CMA) affects 2.5% of young infants. In previous murine studies it was observed that allergic sensitization to the major cow's milk allergens casein and whey led, respectively, to IgE-independent and IgE-dependent clinical responses. Objectives: In this study the involvement of immunoglobulin free light chains (Ig-fLCs) in the hypersensitivity response to cow's milk proteins was explored in mice, and Ig-fLC serum levels were determined in children affected by CMA or atopic dermatitis (AD). Methods: Mice were orally sham, casein, or whey sensitized. Acute allergen-specific skin responses were determined, and serum immunoglobulin and Ig-fLC concentrations were measured. Ig-fLC dependency was validated by using the Ig-fLC blocker F991 in actively and passively sensitized mice. Ig-fLC serum concentrations were measured in a cohort of infants with CMA and infants with AD. Results: After sensitization, no specific IgE was detectable in sera of casein-sensitized mice, whereas specific IgE levels were enhanced in whey-sensitized mice. Instead, Ig-fLC levels were increased in sera from casein-sensitized mice. Furthermore, blocking Ig-fLCs strongly diminished the allergic skin responses not only in casein-sensitized mice but also in mice transferred with splenocyte supernatants of casein-sensitized mice. In both patients with CMA and patients with AD, serum Ig-fLC concentrations were significantly enhanced. Conclusions: This study indicates that sensitization with cow's milk proteins can lead to both IgE-dependent and Ig-fLC dependent allergic hypersensitivity responses. Also, in children affected with CMA or AD, serum Ig-fLC concentrations were increased, implying the relevance of Ig-fLC measurements in the diagnoses of human allergic disease. (J Allergy Clin Immunol 2010;125:1308-14.)	[Schouten, Bastiaan; van Esch, Betty C. A. M.; Blokhuis, Bart R. J.; Kormelink, Tom Groot; Hofman, Gerard A.; Willemsen, Linette E. M.; Redegeld, Frank A.; Garssen, Johan] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol & Pathophysiol, NL-3584 CA Utrecht, Netherlands; [Schouten, Bastiaan; van Esch, Betty C. A. M.; Knippels, Leon M. J.; Garssen, Johan] Danone Res Ctr Specialised Nutr, Wageningen, Netherlands; [van Thuijl, Anders O. J.; Sprikkelman, Aline B.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Resp Med & Allergy, NL-1105 AZ Amsterdam, Netherlands; [Moro, Guido E.; Arslanoglu, Sertac] Macedonio Melloni Matern Hosp, Ctr Infant Nutr, Milan, Italy; [Boehm, Gunther] Erasmus Univ, Sophia Childrens Hosp, Rotterdam, Netherlands	Utrecht University; Danone Nutricia; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	Willemsen, LEM (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol & Pathophysiol, Sorbonnelaan 16, NL-3584 CA Utrecht, Netherlands.	l.e.m.willemsen@uu.nl	Arslanoglu, Sertac/ABE-8915-2021; garssen, johan/I-7159-2016; Willemsen, Linette/K-9397-2016; Redegeld, Frank A/O-6534-2016	Willemsen, Linette/0000-0001-9882-5331; Redegeld, Frank A/0000-0001-8830-7960; van Esch, Betty/0000-0001-9961-750X				Abe M, 1998, CLIN EXP IMMUNOL, V111, P457; Bahna SL, 2002, ANN ALLERG ASTHMA IM, V89, P56, DOI 10.1016/S1081-1206(10)62124-2; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Calbet JAL, 2004, EUR J NUTR, V43, P127, DOI 10.1007/s00394-004-0448-4; Chehade M, 2007, CURR OPIN ALLERGY CL, V7, P264, DOI 10.1097/ACI.0b013e32814a5607; Chen YY, 2005, ELECTROPHORESIS, V26, P2117, DOI 10.1002/elps.200410381; COOPER A, 1968, ANN RHEUM DIS, V27, P537, DOI 10.1136/ard.27.6.537; Crittenden RG, 2005, J AM COLL NUTR, V24, p582S, DOI 10.1080/07315724.2005.10719507; Dangin M, 2002, J NUTR, V132, p3228S, DOI 10.1093/jn/131.10.3228S; Eigenmann PA, 2007, PEDIAT ALLERG IMM-UK, V18, P265, DOI 10.1111/j.1399-3038.2006.00528.x; Fiocchi A, 2003, PEDIATRICS, V112, P359, DOI 10.1542/peds.112.2.359; Gabriele C, 2008, PEDIAT ALLERG IMM-UK, V19, P420, DOI 10.1111/j.1399-3038.2007.00673.x; Gottenberg JE, 2007, ANN RHEUM DIS, V66, P23, DOI 10.1136/ard.2006.052159; Hall WL, 2003, BRIT J NUTR, V89, P239, DOI 10.1079/BJN2002760; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hauk PJ, 2008, CURR ALLERGY ASTHM R, V8, P188, DOI 10.1007/s11882-008-0032-8; HOPPER JE, 1989, J CLIN IMMUNOL, V9, P338, DOI 10.1007/BF00918666; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Huang ZQ, 1997, J CLIN INVEST, V99, P732, DOI 10.1172/JCI119218; Kraneveld AD, 2005, P NATL ACAD SCI USA, V102, P1578, DOI 10.1073/pnas.0406808102; Lara-Villoslada F, 2005, J DAIRY SCI, V88, P1654, DOI 10.3168/jds.S0022-0302(05)72837-X; Lied GA, 2007, TURK J GASTROENTEROL, V18, P5; Monaci L, 2006, EUR FOOD RES TECHNOL, V223, P149, DOI 10.1007/s00217-005-0178-8; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Oranje AP, 2007, BRIT J DERMATOL, V157, P645, DOI 10.1111/j.1365-2133.2007.08112.x; Ozol D, 2008, CURR OPIN PULM MED, V14, P9, DOI 10.1097/MCP.0b013e3282f1981c; Peng HJ, 2005, J PEDIATR GASTR NUTR, V41, P438, DOI 10.1097/01.mpg.0000177309.79285.c9; Pourpak Z, 2004, IMMUNOL INVEST, V33, P69, DOI 10.1081/IMM-120027686; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, P139, DOI 10.1016/j.jaci.2009.07.025; Redegeld FA, 2003, TRENDS IMMUNOL, V24, P181, DOI 10.1016/S1471-4906(03)00059-0; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Rijnierse A, 2007, PHARMACOL THERAPEUT, V116, P207, DOI 10.1016/j.pharmthera.2007.06.008; Rinker John R 2nd, 2006, Neurology, V67, P1288, DOI 10.1212/01.wnl.0000238107.31364.21; Sabra A, 2003, ANN ALLERG ASTHMA IM, V90, P71, DOI 10.1016/S1081-1206(10)61664-X; Schouten B, 2008, INT ARCH ALLERGY IMM, V147, P125, DOI 10.1159/000135699; Sediva A, 2008, ALLERGY, V63, P157; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Sletten GBG, 2006, PEDIATR ALLERGY IMMU, V17, P435, DOI 10.1111/j.1399-3038.2006.00408.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Thio M, 2008, TRENDS PHARMACOL SCI, V29, P170, DOI 10.1016/j.tips.2008.01.004; Toden S, 2007, BRIT J NUTR, V97, P535, DOI 10.1017/S0007114507336817; van der Heijden M, 2006, EUR J PHARMACOL, V533, P319, DOI 10.1016/j.ejphar.2005.12.065; van Hoffen E, 2009, ALLERGY, V64, P484, DOI 10.1111/j.1398-9995.2008.01765.x; van Houwelingen AH, 2007, CLIN EXP ALLERGY, V37, P270, DOI 10.1111/j.1365-2222.2007.02655.x; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Werfel T, 2004, CURR OPIN ALLERGY CL, V4, P379, DOI 10.1097/00130832-200410000-00009	47	45	47	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1308	1314		10.1016/j.jaci.2010.02.039	http://dx.doi.org/10.1016/j.jaci.2010.02.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20434201				2022-12-18	WOS:000278831000019
J	Sternthal, MJ; Enlow, MB; Cohen, S; Canner, MJ; Staudenmayer, J; Tsang, K; Wright, RJ				Sternthal, Michelle Judith; Enlow, Michelle Bosquet; Cohen, Sheldon; Canner, Marina Jacobson; Staudenmayer, John; Tsang, Kathy; Wright, Rosalind J.			Maternal interpersonal trauma and cord blood IgE levels in an inner-city cohort: A life-course perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Interpersonal trauma; life course; pregnancy; cord blood IgE; urban asthma	CHILDHOOD SOCIOECONOMIC-STATUS; INTIMATE PARTNER VIOLENCE; SERUM IGE; STRESS; ASTHMA; BIRTH; RISK; RELIABILITY; SYMPTOMS; HEALTH	Background: Prenatal stress affects immunocompetence in offspring, although the underlying mechanisms are not well understood. Objective: We sought to examine associations between maternal lifetime interpersonal trauma (IPT) and cord blood total IgE levels in a sample of urban newborns (n = 478). Methods: Maternal IPT during childhood and adolescence (birth to 17 years), adulthood (18 years to index pregnancy), and the index pregnancy were ascertained by using the Revised Conflict Tactics Scale at 28.4 +/- 7.9 weeks' gestation. Cord blood IgE levels were derived by using a fluoroenzyme immunoassay. We examined effects of maternal IPT on increased cord blood IgE levels (upper quartile, 1.08 IU/mL) by using logistic regression, adjusting for confounders and mediating variables. Results: Maternal trauma was categorized as unexposed (n = 285 [60%]), early (childhood and/or teenage years only, n = 107 [22%]), late (adulthood and/or index pregnancy only, n = 29 [6%]), and chronic (early and late, n = 57 [12%]) exposure. Relative to no IPT, early (odds ratio [OR], 1.78; 95% CI, 1.05-3.00) and chronic maternal IPT (OR, 2.25; 95% CI, 1.19-4.24) were independently associated with increased IgE levels in unadjusted analyses. When adjusting for standard controls, including maternal age and race, season of birth, child's sex, and childhood and current socioeconomic status, early effects became nonsignificant (OR, 1.48; 95% CI, 0.85-2.58). Chronic exposure remained significant in fully adjusted models, including standard controls, current negative life events, allergen exposure, and potential pathway variables (maternal atopy, prenatal smoking, and birth weight; OR, 2.18; 95% CI, 1.06-4.50). Conclusion: These data link chronic trauma over the mother's life course with increased IgE levels in infants at birth. Research examining associations between maternal trauma and indicators of offspring's atopic risk might be particularly relevant in inner-city high-risk populations. (J Allergy Clin Immunol 2009;124:954-60.)	[Sternthal, Michelle Judith; Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Environm & Occupat Med & Epidemiol, Boston, MA 02215 USA; [Enlow, Michelle Bosquet] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Enlow, Michelle Bosquet] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Cohen, Sheldon] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; [Canner, Marina Jacobson; Tsang, Kathy; Wright, Rosalind J.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02215 USA; [Staudenmayer, John] Univ Massachusetts, Dept Math & Stat, Amherst, MA 01003 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Carnegie Mellon University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Massachusetts System; University of Massachusetts Amherst	Sternthal, MJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm & Occupat Med & Epidemiol, 401 Pk Dr, Boston, MA 02215 USA.	msternth@hsph.harvard.edu		Cohen, Sheldon/0000-0003-2248-4600; Bosquet Enlow, Michelle/0000-0003-2598-3894	Leaves of Grass Foundation;  [R01ES10932];  [U01HL072494];  [R01HL080674];  [T32-ES07069-29]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080674, U01HL072494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010932, T32ES007069] Funding Source: NIH RePORTER	Leaves of Grass Foundation; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The Asthma Coalition on Community, Environment, and Social Stress study was funded by grants R01ES10932, U01HL072494, and R01HL080674. M. S. is supported by grant T32-ES07069-29 and the Leaves of Grass Foundation.	Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Berry CA, 2006, PSYCHOL REP, V98, P123, DOI 10.2466/PRO.98.1.123-132; Beydoun H, 2008, PAEDIATR PERINAT EP, V22, P438, DOI 10.1111/j.1365-3016.2008.00951.x; BRAVEMAN P, 2008, MATERN CHILD HLTH J; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; BREWIN CR, 1993, PSYCHOL BULL, V113, P82, DOI 10.1037/0033-2909.113.1.82; Brown J, 1998, CHILD ABUSE NEGLECT, V22, P1065, DOI 10.1016/S0145-2134(98)00087-8; Brown RA, 1998, PSYCHOL ADDICT BEHAV, V12, P101, DOI 10.1037/0893-164X.12.2.101; CANTANI A, 2008, PEDIAT ALLERGY ASTHM, P269; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Chida Y, 2008, PSYCHOSOM MED, V70, P102, DOI 10.1097/PSY.0b013e31815c1b71; Cohen S, 2004, PSYCHOSOM MED, V66, P553, DOI 10.1097/01.psy.0000126200.05189.d3; COHEN S, ANN NEW YOR IN PRESS; de Weerth C, 2005, NEUROSCI BIOBEHAV R, V29, P295, DOI 10.1016/j.neubiorev.2004.10.005; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; Ford JD, 2006, J INTERPERS VIOLENCE, V21, P1399, DOI 10.1177/0886260506292992; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; Hansen L G, 1993, Pediatr Allergy Immunol, V4, P34, DOI 10.1111/j.1399-3038.1993.tb00063.x; Holland P, 2000, SOC SCI MED, V50, P1285, DOI 10.1016/S0277-9536(99)00375-5; Jackson B, 2004, INT J EPIDEMIOL, V33, P271, DOI 10.1093/ije/dyh003; Jun HJ, 2008, AM J PUBLIC HEALTH, V98, P527, DOI 10.2105/AJPH.2003.037663; KESSLER RC, 1994, J HEALTH SOC BEHAV, V35, P13, DOI 10.2307/2137332; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miller G, 2007, PSYCHOSOM MED, V69, P402, DOI 10.1097/PSY.0b013e318068fcf9; Monroe SM, 2005, PSYCHOL REV, V112, P417, DOI 10.1037/0033-295X.112.2.417; Neggers Y, 2004, ACTA OBSTET GYN SCAN, V83, P455, DOI 10.1111/j.0001-6349.2004.00458.x; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Power C, 1997, BRIT MED BULL, V53, P210; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Rick S, 2007, J PSYCHOSOC NURS, V45, P47, DOI 10.3928/02793695-20070401-10; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Straus Murray A, 2004, Violence Vict, V19, P507; Suglia SF, 2009, ARCH PEDIAT ADOL MED, V163, P244, DOI 10.1001/archpediatrics.2008.555; VARONIER HS, 1991, EUR J PEDIATR, V150, P844, DOI 10.1007/BF01955005; WRIGHT RJ, 2008, CIENCIA SAUDE COLETI, V43, P55; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2008, EXPERT REV CLIN IMMU, V4, P535, DOI 10.1586/1744666X.4.5.535; Yehuda R, 2007, PROG BRAIN RES, V167, P121, DOI 10.1016/S0079-6123(07)67009-5	49	45	47	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					954	960		10.1016/j.jaci.2009.07.030	http://dx.doi.org/10.1016/j.jaci.2009.07.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	523XI	19748657	Green Published, Green Accepted			2022-12-18	WOS:000272108000012
J	Stanke-Labesque, F; Back, M; Lefebvre, B; Tamisier, R; Baguet, JP; Arnol, N; Levy, P; Pepin, JL				Stanke-Labesque, Francoise; Back, Magnus; Lefebvre, Blandine; Tamisier, Renaud; Baguet, Jean-Philippe; Arnol, Nathalie; Levy, Patrick; Pepin, Jean-Louis			Increased urinary leukotriene E-4 excretion in obstructive sleep apnea: Effects of obesity and hypoxia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leukotriene E-4; obstructive sleep apnea syndrome; nocturnal oxygen desaturation; obesity	C-REACTIVE PROTEIN; RISK-FACTOR; ATHEROSCLEROSIS; CHILDREN; INFLAMMATION; RECEPTORS; 5-LIPOXYGENASE; ACTIVATION; MECHANISMS; DISEASE	Background: Low-grade inflammation may potentially explain the relationship between obstructive sleep apnea syndrome (OSA) and cardiovascular events. However, the respective contribution of intermittent hypoxia and confounders, such as obesity, is still debated. Objectives: To monitor urinary leukotriene E-4 (U-LTE4), a validated marker of proinflammatory cysteinyl leukotriene production, in OSA; to determine the influence of obesity and other confounders on U-LTE4 concentrations; to examine the mechanisms involved through transcriptional profiling of the leukotriene pathway in peripheral blood mononuclear cells (PBMCs); and to investigate the effect of continuous positive air pressure (CPAP) on U-LTE4 concentrations. Methods: We measured U-LTE4 by liquid chromatographytandem mass spectrometry. Results: The U-LTE4 concentrations were increased (P =.019) in 40 nonobese patients with OSA carefully matched for age, sex, and body mass index (BMI) to 25 control subjects, and correlated (r = 0.0312; P =.017) to the percentage of time spent with mean oxygen saturation (SaO(2)) less than 90%. In a larger cohort of patients with OSA (n = 72), U-LTE4 increased as a function of BMI (r = 0.445; P =.0002). In those patients, the expression levels of 5-lipoxygenase activating protein mRNA in mononuclear cells exhibited a similar pattern. A stepwise multiple linear regression analysis performed in this cohort identified BMI (P =.001; regression coefficient, 3.33) and percentage of time spent with SaO(2) <90% (P =.001; regression coefficient, 1.01) as independent predictors of U-LTE4 concentrations. Compared with baseline, CPAP reduced by 22% (P =.006) U-LTE4 concentrations only in patients with OSA with normal BMI. Conclusion: Obesity, and to a lesser extent hypoxia severity, are determinant of U-LTE4 production in patients with OSA. (J Allergy Clin Immunol 2009;124:364-70.)	[Stanke-Labesque, Francoise; Lefebvre, Blandine; Tamisier, Renaud; Arnol, Nathalie; Levy, Patrick; Pepin, Jean-Louis] INSERM, Grenoble, France; [Stanke-Labesque, Francoise; Lefebvre, Blandine; Tamisier, Renaud; Arnol, Nathalie; Levy, Patrick; Pepin, Jean-Louis] Univ Grenoble 1, Fac Med, F-38041 Grenoble, France; [Stanke-Labesque, Francoise] Hop A Michallon, CHU, Pharmacol Lab, Grenoble, France; [Tamisier, Renaud; Arnol, Nathalie; Levy, Patrick; Pepin, Jean-Louis] Hop A Michallon, CHU, Lab EFCR, Grenoble, France; [Back, Magnus] Karolinska Inst, Dept Cardiol, Stockholm, Sweden; [Back, Magnus] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Back, Magnus] St Gorans Univ Hosp, S-11281 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; CHU Grenoble Alpes; Karolinska Institutet; Karolinska Institutet; Saint Goran's Hospital	Stanke-Labesque, F (corresponding author), Grenoble Univ Hosp, Pharmacol Lab, BP 217, F-38043 Grenoble 9, France.	FStanke@chu-grenoble.fr	Stanke, Francoise/M-7142-2014; Baguet, Jean-Philippe/M-5536-2014; Lévy, Patrick/M-6903-2014; LEVY, Patrick/AAX-2802-2020; Back, Magnus/E-4879-2011; PEPIN, Jean-Louis/M-6549-2014; Tamisier, Renaud/M-6858-2014	Stanke, Francoise/0000-0002-4643-6323; Lévy, Patrick/0000-0003-3632-1327; LEVY, Patrick/0000-0003-3174-7935; Back, Magnus/0000-0003-0853-5141; Tamisier, Renaud/0000-0003-1128-6529; Pepin, Jean Louis/0000-0003-3832-2358	"Delegation Regionale a la Recherche Clinique" du CHU de Grenoble; the French-Swedish Foundation; Swedish Heart and Lung Foundation	"Delegation Regionale a la Recherche Clinique" du CHU de Grenoble; the French-Swedish Foundation; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation)	Supported by a grant from the "Delegation Regionale a la Recherche Clinique" du CHU de Grenoble, the French-Swedish Foundation, and the Swedish Heart and Lung Foundation.	ALLEN SP, 1993, CORONARY ARTERY DIS, V4, P899, DOI 10.1097/00019501-199310000-00009; Back M, 2007, CIRC RES, V100, P946, DOI 10.1161/01.RES.0000264498.60702.0d; Back M, 2006, ANN MED, V38, P493, DOI 10.1080/07853890600982737; CARRY M, 1992, CIRCULATION, V85, P230, DOI 10.1161/01.CIR.85.1.230; Coughlin SR, 2007, EUR RESPIR J, V29, P720, DOI 10.1183/09031936.00043306; Davi G, 2002, JAMA-J AM MED ASSOC, V288, P2008, DOI 10.1001/jama.288.16.2008; Dayyat E, 2009, CHEST, V135, P1142, DOI 10.1378/chest.08-2102; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Goldbart AD, 2006, CHEST, V130, P143, DOI 10.1378/chest.130.1.143; Hardy G, 2005, PROSTAG OTH LIPID M, V78, P291, DOI 10.1016/j.prostaglandins.2005.10.001; Hosselet JJ, 2001, AM J RESP CRIT CARE, V163, P398, DOI 10.1164/ajrccm.163.2.9808132; Jelic S, 2008, CIRCULATION, V117, P2270, DOI 10.1161/CIRCULATIONAHA.107.741512; Kaditis AG, 2008, CHEST, V134, P324, DOI 10.1378/chest.07-2746; Kaditis AG, 2009, CHEST, V135, P1496, DOI 10.1378/chest.08-2295; Kim ND, 2007, THESCIENTIFICWORLDJO, V7, P1307, DOI 10.1100/tsw.2007.181; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Lefebvre B, 2008, EUR RESPIR J, V32, P113, DOI 10.1183/09031936.00137107; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; McNicholas WT, 2007, EUR RESPIR J, V29, P156, DOI 10.1183/09031936.00027406; Mehra R, 2008, J ALLERGY CLIN IMMUN, V121, P1096, DOI 10.1016/j.jaci.2008.04.002; Mehrabian M, 2003, CURR OPIN LIPIDOL, V14, P447, DOI 10.1097/00041433-200310000-00005; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Piliar G, 2008, DIABETES CARE, V31, pS303, DOI 10.2337/dc08-s272; Ridker PM, 2004, CIRCULATION, V109, P6, DOI 10.1161/01.CIR.0000133444.17867.56; Robinson GV, 2004, THORAX, V59, P777, DOI 10.1136/thx.2003.018739; Schwartz Alan R, 2008, Proc Am Thorac Soc, V5, P185, DOI 10.1513/pats.200708-137MG; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; Spanbroek R, 2003, DRUG NEWS PERSPECT, V16, P485, DOI 10.1358/dnp.2003.16.8.829345; STEADMAN R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P264, DOI 10.1016/0167-4889(90)90220-8; Taheri S, 2007, SLEEP, V30, P991, DOI 10.1093/sleep/30.8.991; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104	31	45	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					364	370		10.1016/j.jaci.2009.05.033	http://dx.doi.org/10.1016/j.jaci.2009.05.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19596146				2022-12-18	WOS:000268860400026
J	Joseph, K; Tholanikunnel, BG; Kaplan, AP				Joseph, Kusumam; Tholanikunnel, Baby G.; Kaplan, Allen P.			Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Factor XII; prekallikrein; kininogen; C1 inhibitor; angioedema	HUMAN HAGEMAN-FACTOR; HEREDITARY ANGIOEDEMA PLASMA; VEIN ENDOTHELIAL-CELLS; CONTACT ACTIVATION; BINDING-SITE; CORN SEEDS; KALLIKREIN; BRADYKININ; GENERATION; PLATELETS	Background: Bradykinin formation typically requires interaction of Factor XII, prekallikrein (PK), and high-molecular-weight kininogen (HK) with negatively charged exogenous initiators or cell-surface proteins. Approximately 85% of plasma PK circulates as a complex with HK. Nonenzymatic cell-derived initiators, such as heat shock protein 90, can activate the HK-PK complex to generate kallikrein, bradykinin, and cleaved HK, even in the absence of Factor XII. Objective: We sought to determine whether PK, without activation to kallikrein, can digest HK to release bradykinin. Methods: Kallikrein was measured by using a chromogenic assay, and bradykinin levels were determined by ELISA. Cleavage of PK and HK were assessed by SDS-PAGE and Western blot analysis. Results: Cleavage of HK by PK is demonstrated without any conversion of PK to kallikrein. HK cleavage by PK is distinguished from that of kallikrein by the following: (1) stoichiometric activation of HK by PK with release of bradykinin proportional to the PK input; (2) inhibition of PK cleavage of HK by corn trypsin inhibitor, which has no effect on kallikrein; and (3) inhibition of PK cleavage of HK by a peptide derived from HK, which inhibits binding of PK to HK. The same peptide has no effect on kallikrein activation of HK. C1 inhibitor (C1INH), the major control protein of the plasma bradykinin-forming cascade, inhibits PK cleavage of HK. Conclusion: PK is an enzyme that can cleave HK to release bradykinin, and this reaction is inhibited by C1INH. This might account, in part, for circulating bradykinin levels and initiation of kinin formation in C1INH deficiency. (J Allergy Clin Immunol 2009;124:143-9.)	[Joseph, Kusumam] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA; [Joseph, Kusumam; Tholanikunnel, Baby G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Joseph, K (corresponding author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 171 Ashley Ave, Charleston, SC 29425 USA.	josephk@musc.edu						CARRETERO OA, 1989, KALLIKREINKANIN SYST, P63; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COLE TC, 1989, BIOCHIM BIOPHYS ACTA, V990, P254, DOI 10.1016/S0304-4165(89)80042-X; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; Imamura T, 1996, LAB INVEST, V74, P861; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Joseph K, 2001, THROMB HAEMOSTASIS, V85, P119; Joseph K, 2008, ANN ALLERG ASTHMA IM, V101, P279, DOI 10.1016/S1081-1206(10)60493-0; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MANDLE RJ, 1979, BLOOD, V54, P850; MELONI FJ, 1992, BLOOD, V79, P1233; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; RATNOFF OD, 1981, P SOC EXP BIOL MED, V166, P297; REDDIGARI S, 1988, BLOOD, V71, P1334; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; REDDIGARI SR, 1989, BLOOD, V74, P695; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SCHREIBER AD, 1973, J CLIN INVEST, V52, P1402, DOI 10.1172/JCI107313; SCICLI AG, 1982, J LAB CLIN MED, V100, P81; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; SHIBAYAMA Y, 1994, BRAZ J MED BIOL RES, V27, P1817; Shibayama Y, 1996, IMMUNOPHARMACOLOGY, V32, P24, DOI 10.1016/0162-3109(96)00004-5; SHIMAMOTO K, 1982, ENDOCRINOL JAPON, V29, P487; SILVERBERG M, 1980, J BIOL CHEM, V255, P7281; SWARTZ MJ, 1977, J BIOL CHEM, V252, P8105; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; WEISS R, 1986, BLOOD, V68, P239; WIGGINS RC, 1983, J BIOL CHEM, V258, P8963	43	45	48	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					143	149		10.1016/j.jaci.2009.02.006	http://dx.doi.org/10.1016/j.jaci.2009.02.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19342086				2022-12-18	WOS:000267909700018
J	Wittmann, M; Zeitvogel, J; Wang, D; Werfel, T				Wittmann, Miriam; Zeitvogel, Jana; Wang, Dong; Werfel, Thomas			IL-27 is expressed in chronic human eczematous skin lesions and stimulates human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human primary keratinocytes; eczema; inflammation; IL-6/IL-12 family; chemokines	CD4(+) T-CELLS; PROINFLAMMATORY CYTOKINE PRODUCTION; TH1 DIFFERENTIATION; DENDRITIC CELLS; ATOPIC-DERMATITIS; INDUCED GENE-3; CHAIN WSX-1; RECEPTOR; INDUCTION; INFLAMMATION	Background: IL-27 is produced by antigen-presenting cells early during immune responses. IL-27 has been described to support T-cell polarization along the T(H)1 lineage but also to exert important anti-inflammatory responses in later phases of inflammation in murine models. Objective: It was the aim of this study to analyze the potential role of IL-27 in epidermal inflammatory skin responses in human subjects. Methods: Surface receptor expression and apoptosis of human primary keratinocytes were analyzed by means of flow cytometry. Supernatants of stimulated keratinocytes were either analyzed by means of ELISA or submitted to chemotaxis assays. RT-PCR from lesional skin and phospho-specific Western blotting were performed. Results: Both subunits of IL-27 were expressed in chronic lesional allergic eczematous skin, whereas the IL-27 subunit EBV-induced gene 3 was not detectable in the acute phase of eczema. Human primary keratinocytes responded to IL-27. Stimulation of keratinocytes with IL-27 resulted in activation of the signal transducer and activator of transcription 1 and 3 pathways. Major effects found for IL-27 include CXCL10 production and MHC class I upregulation. Importantly, we could demonstrate that IL-27 acts as a priming signal on keratinocytes able to amplify chemokine production and surface molecule expression when used before a second signal, such as TNF-alpha. The effects of IL-27 could not be mimicked by IL-6, IL-12, or IL-23. Conclusion: These results support the notion that IL-27 might act in an inflammatory, disease-maintaining manner in the epidermal compartment of patients with eczema. (J Allergy Clin Immunol 2009;124:81-9.)	[Wittmann, Miriam; Zeitvogel, Jana; Wang, Dong; Werfel, Thomas] Hannover Med Sch, Dept Immunodermatol & Allergy Res, D-3000 Hannover, Germany	Hannover Medical School	Wittmann, M (corresponding author), Univ Leeds, Inst Mol & Cell Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.	M.Wittmann@leeds.ac.uk	Wittmann, Miriam/F-9006-2010; Zeitvogel, Jana/G-1712-2013; Werfel, Thomas/B-6921-2012	Wittmann, Miriam/0000-0003-2328-4926	DFG [Wi1822/5-1, GRK1441]	DFG(German Research Foundation (DFG))	Supported by DFG grant Wi1822/5-1, GRK1441, and SFB 566, A6.	Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Batten M, 2007, J MOL MED-JMM, V85, P661, DOI 10.1007/s00109-007-0164-7; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Chen Q, 2000, NATURE, V407, P916, DOI 10.1038/35038103; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Hamano S, 2003, IMMUNITY, V19, P657, DOI 10.1016/S1074-7613(03)00298-X; Hibbert L, 2003, J INTERF CYTOK RES, V23, P513, DOI 10.1089/10799900360708632; Holscher C, 2005, J IMMUNOL, V174, P3534, DOI 10.4049/jimmunol.174.6.3534; Kamiya S, 2004, J IMMUNOL, V173, P3871, DOI 10.4049/jimmunol.173.6.3871; Kanda N, 2008, EUR J IMMUNOL, V38, P1287, DOI 10.1002/eji.200738051; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Larousserie F, 2004, J PATHOL, V202, P164, DOI 10.1002/path.1508; Larousserie F, 2006, J IMMUNOL, V176, P5890, DOI 10.4049/jimmunol.176.10.5890; Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100; Maaser C, 2004, IMMUNOLOGY, V112, P437, DOI 10.1111/j.1365-2567.2004.01895.x; Owaki T, 2005, J IMMUNOL, V175, P2191, DOI 10.4049/jimmunol.175.4.2191; Owaki T, 2006, J IMMUNOL, V176, P2773, DOI 10.4049/jimmunol.176.5.2773; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Purwar R, 2008, J INVEST DERMATOL, V128, P59, DOI 10.1038/sj.jid.5700940; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; Purwar R, 2006, J IMMUNOL, V177, P4444, DOI 10.4049/jimmunol.177.7.4444; Ruckerl D, 2006, IMMUNOBIOLOGY, V211, P427, DOI 10.1016/j.imbio.2006.05.008; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Shimizu M, 2006, J IMMUNOL, V176, P7317, DOI 10.4049/jimmunol.176.12.7317; Smits HH, 2004, EUR J IMMUNOL, V34, P1371, DOI 10.1002/eji.200324815; Sonoda KH, 2007, INT IMMUNOL, V19, P93, DOI 10.1093/intimm/dxl125; Sturt Jackie, 2006, BMC Fam Pract, V7, P45, DOI 10.1186/1471-2296-7-45; Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; Villarino A, 2003, IMMUNITY, V19, P645, DOI 10.1016/S1074-7613(03)00300-5; Villarino AV, 2006, J IMMUNOL, V176, P237, DOI 10.4049/jimmunol.176.1.237; Villarino AV, 2005, J IMMUNOL, V174, P7684, DOI 10.4049/jimmunol.174.12.7684; Werfel Thomas, 2008, V94, P101, DOI 10.1159/000154935; Wirtz S, 2005, J IMMUNOL, V174, P2814, DOI 10.4049/jimmunol.174.5.2814; Wittmann M, 2005, J INVEST DERMATOL, V124, P1225, DOI 10.1111/j.0022-202X.2005.23715.x; Wittmann M, 2004, J ALLERGY CLIN IMMUN, V114, P965, DOI 10.1016/j.jaci.2004.06.033; Wittmann M, 2006, CURR OPIN ALLERGY CL, V6, P329, DOI 10.1097/01.all.0000244792.95615.3a; Yoshimoto T, 2004, J IMMUNOL, V173, P2479, DOI 10.4049/jimmunol.173.4.2479; Yoshimoto T, 2007, J IMMUNOL, V179, P4415, DOI 10.4049/jimmunol.179.7.4415; Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377	41	45	48	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					81	89		10.1016/j.jaci.2009.04.026	http://dx.doi.org/10.1016/j.jaci.2009.04.026			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19523673				2022-12-18	WOS:000267909700010
J	Nguyen, KD; Vanichsarn, C; Fohner, A; Nadeau, KC				Nguyen, Khoa D.; Vanichsarn, Christopher; Fohner, Alison; Nadeau, Kari C.			Selective deregulation in chemokine signaling pathways of CD4(+)CD25(hi)CD127(lo/-) regulatory T cells in human allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; regulatory T cells; cell trafficking; cell signaling; CCL1; CCR8; AKT	AIRWAY HYPERRESPONSIVENESS; ATOPIC ASTHMATICS; PHOSPHOINOSITIDE 3-KINASES; DEPENDENT PATHWAY; CHILDHOOD ASTHMA; RECEPTOR CCR4; DISEASE; EXPRESSION; INFLAMMATION; ACTIVATION	Background: CD4(+)CD25(hi)CD127(lo/-) regulatory T cells have been suggested to be critical regulators of inflammatory processes in allergic asthma. Recent studies reported a selective decrease in the frequency of regulatory T cells in the bronchoalveollar lavage fluid of allergic asthmatic (AA) subjects, prompting the possibility of defective recruitment of these cells to the airway in response to chemokines produced during asthmatic inflammation. Objectives: This study aimed to characterize the chemotactic profile of circulating regulatory T cells in AA subjects in response to chemokines abundantly produced in airway inflammation, such as CCL1, CCL17, and CCL22. Methods: The study was performed in a cohort of 26 AA, 16 healthy control, and 16 non-AA subjects. We used chemotaxis assays to evaluate cell migration, flow cytometry to examine chemokine receptor expression, and phospho-ELISA to study consequent signaling pathways in regulatory T cells. Results: Regulatory T cells, but not CD4(+)CD25(-)T cells, from AA subjects showed decreased chemotactic responses, specifically to CCL1, in comparison with their healthy control and non-AA counterparts. Decreased CCL1-mediated chemotaxis in AA regulatory T cells was associated with decreased phosphorylation of protein kinase B (AKT), a protein involved in chemokine intracellular signaling. Furthermore, the decreased chemotactic response to CCL1 in AA regulatory T cells significantly correlated with asthma severity and decreased pulmonary function in AA subjects. Conclusions: These results provide the first evidence of dysfunction in the chemokine signaling pathway in AA regulatory T cells. (J Allergy Clin Immunol 2009;123:933-9.)	[Nadeau, Kari C.] Stanford Univ, Pulm Ctr Excellence, Dept Pediat, Stanford, CA 94305 USA	Stanford University	Nadeau, KC (corresponding author), Stanford Univ, Pulm Ctr Excellence, Dept Pediat, Stanford, CA 94305 USA.	knadeau@stanford.edu		Nguyen, Khoa/0000-0002-6720-2470	Mary Hewitt Loveless Foundation; Parker B. Francis Foundation; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES022153] Funding Source: NIH RePORTER	Mary Hewitt Loveless Foundation; Parker B. Francis Foundation; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the Mary Hewitt Loveless Foundation, the Parker B. Francis Foundation, and the American Academy of Allergy, Asthma & Immunology.	Averbeck Marco, 2007, J Dtsch Dermatol Ges, V5, P1015, DOI 10.1111/j.1610-0387.2007.06538.x; Baecher-Allan C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/j.smim.2003.12.005; Buckland KF, 2007, J ALLERGY CLIN IMMUN, V119, P997, DOI 10.1016/j.jaci.2006.12.660; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gernez Y, 2007, J ALLERGY CLIN IMMUN, V120, P1441, DOI 10.1016/j.jaci.2007.08.012; Gonzalo JA, 2007, J IMMUNOL, V179, P1740, DOI 10.4049/jimmunol.179.3.1740; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hoshino M, 2005, ALLERGY, V60, P317, DOI 10.1111/j.1398-9995.2005.00694.x; JOHANSSON SG, 1970, CLIN EXP IMMUNOL, V6, P43; Jousilahti P, 2002, ANN ALLERG ASTHMA IM, V89, P381, DOI 10.1016/S1081-1206(10)62039-X; Lai ST, 2008, PEDIATR INT, V50, P99, DOI 10.1111/j.1442-200X.2007.02533.x; LEE TH, 1987, AM REV RESPIR DIS, V135, pS14; LELLEM A, 2001, J EXP MED, V194, P847; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; MATSUMOTO T, 1991, CLIN EXP IMMUNOL, V85, P288; Medoff BD, 2005, ANN NY ACAD SCI, V1062, P220, DOI 10.1196/annals.1358.026; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Mira E, 2008, J IMMUNOL, V181, P3524, DOI 10.4049/jimmunol.181.5.3524; Montes-Vizuet R, 2006, EUR RESPIR J, V28, P59, DOI 10.1183/09031936.06.00134304; Nakamura ES, 2006, CLIN EXP METASTAS, V23, P9, DOI 10.1007/s10585-006-9006-1; Nguyen KD, 2008, EUR J IMMUNOL, V38, P2034, DOI 10.1002/eji.200738082; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; OBYRNE PM, 1988, J ALLERGY CLIN IMMUN, V81, P119, DOI 10.1016/0091-6749(88)90230-8; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Pilette C, 2004, EUR RESPIR J, V23, P876, DOI 10.1183/09031936.04.00102504; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2005, CURR ALLERGY ASTHM R, V5, P136, DOI 10.1007/s11882-005-0087-8; Sasaki AT, 2006, EUR J CELL BIOL, V85, P873, DOI 10.1016/j.ejcb.2006.04.007; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Soler D, 2006, J IMMUNOL, V177, P6940, DOI 10.4049/jimmunol.177.10.6940; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; Ward SG, 2004, TRENDS IMMUNOL, V25, P67, DOI 10.1016/j.it.2003.12.003; Wei S, 2006, BLOOD, V108, P426, DOI 10.1182/blood-2006-01-0177; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790	49	45	47	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					933	939		10.1016/j.jaci.2008.11.037	http://dx.doi.org/10.1016/j.jaci.2008.11.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19152963	Green Accepted			2022-12-18	WOS:000265058600023
J	Kirino, M; Kirino, Y; Takeno, M; Nagashima, Y; Takahashi, K; Kobayashi, M; Murakami, S; Hirasawa, T; Ueda, A; Aihara, M; Ikezawa, Z; Ishigatsubo, Y				Kirino, Mio; Kirino, Yohei; Takeno, Mitsuhiro; Nagashima, Yoji; Takahashi, Kazuo; Kobayashi, Masayoshi; Murakami, Shuji; Hirasawa, Tsutomu; Ueda, Atsuhisa; Aihara, Michiko; Ikezawa, Zenro; Ishigatsubo, Yoshiaki			Heme oxygenase 1 attenuates the development of atopic dermatitis-like lesions in mice: Implications for human disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; heme oxygenase 1; allergy; inflammation	ONSET STILLS-DISEASE; DS-NH MICE; HEME OXYGENASE-1; OXIDATIVE STRESS; AIRWAY INFLAMMATION; LUNG INJURY; EXPRESSION; CELLS; INDUCTION; IL-10	Background: Oxidative stress has been implicated in the exacerbation of atopic dermatitis (AD). Objective: We sought to investigate the pathophysiologic roles of inducible antioxidant heme oxygenase (HO) 1 in the development of AD. Methods: Serum HO-1 levels of patients with AD (n = 100) and age-matched healthy control subjects (n = 72) were determined by means of ELISA. The relationships between serum 140-1 levels and clinical severities, laboratory parameters, and cytokines/chemokines were assessed. Skin lesions of patients with AD and psoriasis were analyzed by means of immunohistochemistry. A murine AD model, DS-Nh, was used to further investigate localization and function of HO-1. Evaluation of symptoms, serum IgE and IL-18 levels, immunoblotting results, and histologic analyses of skin were performed. The effect of intraperitoneally administered hemin, a potent HO-1 inducer, or zinc protoporphyrin IX, an inhibitor of HO, was monitored. Results: Serum HO-1 levels were significantly increased in patients with AD compared with those seen in healthy control subjects and were associated with AD disease severity. Serum HO-1 levels correlated with serum IgE, lactate dehydrogenase, IL-18, and thymus and activation-regulated chemokine levels. HO-1-expressing cells were accumulated in skin lesions of patients with AD and DS-Nh mice. Immunofluorescence of mouse skin lesions revealed that HO-1-positive cells were macrophages and dendritic cells. Treatment with hemin, but not with zinc protoporphyrin IX, attenuated the development of the skin lesions in DS-Nh mice and reduced serum IL-18 levels. Conclusion: HO-1 levels were increased in sera and skin lesions of patients with AD. Enhancement of HO-1 attenuated the development of skin lesions in mice, suggesting that HO-1 induction offers a promising therapeutic strategy for AD.	[Kirino, Mio; Kirino, Yohei; Takeno, Mitsuhiro; Kobayashi, Masayoshi; Murakami, Shuji; Ueda, Atsuhisa; Ishigatsubo, Yoshiaki] Yokohama City Univ, Dept Internal Med & Clin Immunol, Grad Sch Med, Yokohama, Kanagawa 232, Japan; [Kirino, Mio; Takahashi, Kazuo; Aihara, Michiko; Ikezawa, Zenro] Yokohama City Univ, Dept Environm Immunodermatol, Grad Sch Med, Yokohama, Kanagawa 232, Japan; [Nagashima, Yoji] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Yokohama, Kanagawa 232, Japan; [Hirasawa, Tsutomu] Shionogi & Co Ltd, Discovery Res Labs, Osaka, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Shionogi & Company Limited	Ishigatsubo, Y (corresponding author), 3-9 Fukuura,Kanazawa Ku, Kanagawa 2360004, Japan.	ishigats@med.yokohama-cu.ac.jp	Nagashima, Yoji/AAA-2591-2021; Kirino, Yohei/B-3701-2009	Kirino, Yohei/0000-0002-9488-661X				Allanson M, 2004, J INVEST DERMATOL, V122, P1030, DOI 10.1111/j.0022-202X.2004.22421.x; Almolki A, 2004, AM J PHYSIOL-LUNG C, V287, pL26, DOI 10.1152/ajplung.00237.2003; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Chaitidis P, 2005, CYTOKINE, V30, P366, DOI 10.1016/j.cyto.2005.02.004; Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494; Fernandez P, 2003, BIOCHEM PHARMACOL, V66, P2049, DOI 10.1016/S0006-2952(03)00543-4; Fuchs J, 2001, FREE RADICAL BIO MED, V30, P337, DOI 10.1016/S0891-5849(00)00482-2; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Haraguchi M, 1997, EXP ANIM TOKYO, V46, P225, DOI 10.1538/expanim.46.225; Hikita I, 2002, J DERMATOL SCI, V30, P142, DOI 10.1016/S0923-1811(02)00070-1; Horvath I, 1998, THORAX, V53, P668, DOI 10.1136/thx.53.8.668; Inoue S, 2001, HUM GENE THER, V12, P967, DOI 10.1089/104303401750195926; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; Jung M, 2004, EUR J IMMUNOL, V34, P481, DOI 10.1002/eji.200324323; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kawashima M, 2001, ARTHRITIS RHEUM-US, V44, P550, DOI 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5; Kirino Y, 2005, ARTHRITIS RES THER, V7, pR616, DOI 10.1186/ar1721; Kirino Y, 2007, ARTHRITIS RHEUM-US, V56, P464, DOI 10.1002/art.22370; Kobayashi H, 2006, ARTHRITIS RHEUM-US, V54, P1132, DOI 10.1002/art.21754; Kubo M, 2005, FREE RADICAL RES, V39, P719, DOI 10.1080/10715760500139260; Lee BS, 2007, J DERMATOL SCI, V46, P31, DOI 10.1016/j.jdermsci.2007.01.001; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; LESTER MR, 1995, J IMMUNOL, V154, P6174; Listopad J, 2007, EXP DERMATOL, V16, P661, DOI 10.1111/j.1600-0625.2007.00581.x; Masutaka F, 2005, ALLERGOL INT, V54, P45; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; MUKAI H, 1990, Journal of Dermatology (Tokyo), V17, P477; Nakamichi I, 2005, J CLIN INVEST, V115, P3007, DOI 10.1172/JCI24912; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Ndisang JF, 2003, BLOOD, V101, P3893, DOI 10.1182/blood-2002-08-2608; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Rowe A, 1997, BRIT J DERMATOL, V136, P18, DOI 10.1046/j.1365-2133.1997.d01-1136.x; Sato T, 2006, AM J RESP CRIT CARE, V174, P906, DOI 10.1164/rccm.200508-1237OC; Schipper HM, 2000, NEUROLOGY, V54, P1297, DOI 10.1212/WNL.54.6.1297; Takeda Y, 2004, CLIN EXP IMMUNOL, V138, P237, DOI 10.1111/j.1365-2249.2004.02594.x; Tsukahara H, 2003, LIFE SCI, V72, P2509, DOI 10.1016/S0024-3205(03)00145-0; Tsutsui H, 2004, IMMUNOL REV, V202, P115, DOI 10.1111/j.0105-2896.2004.00205.x; Udono-Fujimori R, 2004, EUR J BIOCHEM, V271, P3076, DOI 10.1111/j.1432-1033.2004.04241.x; Wagener FADTG, 2003, BLOOD, V102, P521, DOI 10.1182/blood-2002-07-2248; Wojas-Pelc A, 2007, INT J EXP PATHOL, V88, P95, DOI 10.1111/j.1365-2613.2006.00505.x; Xia ZW, 2006, J IMMUNOL, V177, P5936, DOI 10.4049/jimmunol.177.9.5936; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05-4278fje	46	45	48	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					290	297		10.1016/j.jaci.2008.05.031	http://dx.doi.org/10.1016/j.jaci.2008.05.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18582925				2022-12-18	WOS:000258426300012
J	Simon, D; Wittwer, J; Kostylina, G; Buettiker, U; Simon, HU; Yawalkar, N				Simon, Dagmar; Wittwer, Jennifer; Kostylina, Ganna; Buettiker, Urs; Simon, Hans-Uwe; Yawalkar, Nikhil			Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC PLAQUE PSORIASIS; T-CELLS		[Simon, Dagmar; Buettiker, Urs; Yawalkar, Nikhil] Inselspital Bern, Dept Dermatol, CH-3010 Bern, Switzerland; [Wittwer, Jennifer; Kostylina, Ganna; Simon, Hans-Uwe] Inselspital Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Simon, D (corresponding author), Inselspital Bern, Dept Dermatol, CH-3010 Bern, Switzerland.	nikhil.yawalkar@insel.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Akdis CA, 1999, INT ARCH ALLERGY IMM, V118, P140, DOI 10.1159/000024051; Cooper JC, 2003, EUR J IMMUNOL, V33, P666, DOI 10.1002/eji.200323586; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; JOHNSON JG, 1993, IMMUNOL RES, V12, P48, DOI 10.1007/BF02918368; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; Perlmutter A, 2008, J AM ACAD DERMATOL, V58, P116, DOI 10.1016/j.jaad.2007.09.030; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016	7	45	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					423	424		10.1016/j.jaci.2008.06.010	http://dx.doi.org/10.1016/j.jaci.2008.06.010			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18602679				2022-12-18	WOS:000258426300037
J	Chatterjee, R; Batra, J; Das, S; Sharma, SK; Ghosh, B				Chatterjee, Rajshekhar; Batra, Jyotsna; Das, Sudipta; Sharma, Surendra Kumar; Ghosh, Balaram			Genetic association of acidic mammalian chitinase with atopic asthma and serum total IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHIA; SNPs; promoter IgE; atopic asthma	IMMUNOGLOBULIN-E; INFLAMMATION; POLYMORPHISMS; HAPLOTYPES; TISSUE	Background: In view of the hygiene hypothesis and the involvement of acidic mammalian chitinase (CHIA) in the effector responses of IL-13 with asthma, CHIA (GeneID-27159) is a potential asthma candidate gene. Objective: To investigate the association of CHIA polymorphisms with atopic asthma and serum total IgE levels. Methods: Twenty-one single nucleotide polymorphisms were identified by sequencing DNA of 60 individuals. On the basis of linkage disequilibrium, 6 polymorphisms were selected and genotyped in unrelated atopic patients with asthma (N = 270) and controls (N = 292) and an independent pediatric cohort (patients, 150; controls, 101). Electrophoretic mobility shift assay and reporter gene assays were also performed. Results: The rs3806448G/A promoter polymorphism showed significant association with atopic asthma (P-adult = .00001 and P-pediatric = .0002) and serum total IgE (P <.05). Also rs2282290G/A was associated with atopic asthma (P-adult = 00009 and P-pediatric = .00003), whereas the rs10494132C/T polymorphism was associated with serum total IgE in the patients (P <.05). We also showed that the promoter single nucleotide polymorphisms altered the transcriptional activity of CHIA promoter and the C to T substitution at rs10494132 abrogated the Octamer transcription factor-1 (Oct-1) binding site. Conclusion: Our results establish a significant association of CHIA with atopic asthma and serum total IgE levels in the Indian population.	[Chatterjee, Rajshekhar; Batra, Jyotsna; Das, Sudipta; Ghosh, Balaram] Inst Genom & Integrat Biol, Immunogenet Mol Lab, Delhi 11007, India; [Sharma, Surendra Kumar] All India Inst Med Sci, Dept Med, Div Pulm & Crit Care Med, New Delhi 110029, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); All India Institute of Medical Sciences (AIIMS) New Delhi	Ghosh, B (corresponding author), Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 11007, India.	bghosh@igib.res.in	Ghosh, Balaram/G-1248-2010; Batra, Jyotsna/B-4130-2011	batra, Jyotsna/0000-0003-4646-6247; Das, Sudipta/0000-0001-9380-2907				ARAUJO ACG, 1993, J HISTOCHEM CYTOCHEM, V41, P571, DOI 10.1177/41.4.8450196; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Batra J, 2007, THORAX, V62, P16, DOI 10.1136/thx.2006.057935; Bierbaum S, 2005, AM J RESP CRIT CARE, V172, P1505, DOI 10.1164/rccm.200506-890OC; Boot RG, 2005, J HISTOCHEM CYTOCHEM, V53, P1283, DOI 10.1369/jhc.4A6547.2005; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; CALENOFF E, 1993, ARCH OTOLARYNGOL, V119, P830; Chatterjee R, 2005, CLIN EXP ALLERGY, V35, P914, DOI 10.1111/j.1365-2222.2005.02273.x; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; Elias JA, 2005, J ALLERGY CLIN IMMUN, V116, P497, DOI 10.1016/j.jaci.2005.06.028; FUHRMAN JA, 1985, MOL BIOCHEM PARASIT, V17, P93, DOI 10.1016/0166-6851(85)90130-6; Homer RJ, 2006, AM J PHYSIOL-LUNG C, V291, pL502, DOI 10.1152/ajplung.00364.2005; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nagpal K, 2005, J ALLERGY CLIN IMMUN, V115, P527, DOI 10.1016/j.jaci.2004.11.048; NEVILLE AC, 1976, J CELL SCI, V21, P73; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; SHAHABUDDIN M, 1994, EXP PARASITOL, V79, P85, DOI 10.1006/expr.1994.1066; SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x; Sharma S, 2006, CLIN EXP ALLERGY, V36, P1019, DOI 10.1111/j.1365-2222.2006.02525.x; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; VOLLER A, 1975, TROPENMED PARASITOL, V26, P247; Zhao J, 2005, PROTEOMICS, V5, P2799, DOI 10.1002/pmic.200401169; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	27	45	49	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					202	208		10.1016/j.jaci.2008.04.030	http://dx.doi.org/10.1016/j.jaci.2008.04.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602573				2022-12-18	WOS:000257605100032
J	Gamboa, P; Sanchez-Monge, R; Sanz, ML; Palacin, A; Salcedo, G; Diaz-Perales, A				Gamboa, Pedro; Sanchez-Monge, Rosa; Sanz, M. Luisa; Palacin, Arantxa; Salcedo, Gabriel; Diaz-Perales, Araceli			Sensitization to Cannabis sativa caused by a novel allergenic lipid transfer protein, Can s 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; FOOD		[Gamboa, Pedro] Hosp Basurto, Serv Alergia, Bilbao, Spain; [Sanchez-Monge, Rosa; Palacin, Arantxa; Salcedo, Gabriel; Diaz-Perales, Araceli] Univ Politecn Madrid, Dept Biotechnol, Unidad Bioquim, Escuela Tech Superior Ingenieros Agmomos, Madrid, Spain; [Sanz, M. Luisa] Univ Navarra, Univ Navarra Clin, Dept Alergol, Pamplona, Spain	Basurto Hospital; Universidad Politecnica de Madrid; University of Navarra	Gamboa, P (corresponding author), Hosp Basurto, Serv Alergia, Bilbao, Spain.	araceli.diaz@upm.es	Díaz-Perales, Araceli/D-8433-2016	Díaz-Perales, Araceli/0000-0002-1093-3627				Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P926, DOI 10.1016/j.jaci.2005.05.041; Garcia BE, 2004, CLIN EXP ALLERGY, V34, P291, DOI 10.1111/j.1365-2222.2004.01871.x; HERNANDODELARRAMENDI C, 2007, J ALLERGY CLIN IMM S, V119, pS196; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Perez JA, 2000, J EMERG MED, V18, P260, DOI 10.1016/S0736-4679(99)00209-7; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; Stadtmauer G, 2003, J ALLERGY CLIN IMMUN, V112, P216, DOI 10.1067/mai.2003.1591; Stockli Simone Schwarzenbach, 2007, J Dtsch Dermatol Ges, V5, P303, DOI 10.1111/j.1610-0387.2007.06270.x; Tanaka H, 1998, FORENSIC SCI INT, V97, P139, DOI 10.1016/S0379-0738(98)00152-2; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	11	45	47	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1459	1460		10.1016/j.jaci.2007.07.052	http://dx.doi.org/10.1016/j.jaci.2007.07.052			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17881043				2022-12-18	WOS:000251653800032
J	Ueta, M; Sotozono, C; Inatomi, T; Kojima, K; Hamuro, J; Kinoshita, S				Ueta, Mayumi; Sotozono, Chie; Inatomi, Tsutomu; Kojima, Kentaro; Hamuro, Junji; Kinoshita, Shigeru			Association of IL4R polymorphisms with Stevens-Johnson syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR-ALPHA-CHAIN; ASTHMA		[Ueta, Mayumi; Sotozono, Chie; Inatomi, Tsutomu; Kojima, Kentaro; Hamuro, Junji; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan	Kyoto Prefectural University of Medicine	Ueta, M (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.	mueta@ophth.kpu-m.ac.jp		Kojima, Kentaro/0000-0003-2347-4789				CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Dabbagh K, 1999, J IMMUNOL, V162, P6233; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; OHJI M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1686; Oiso N, 2000, BRIT J DERMATOL, V142, P1003, DOI 10.1046/j.1365-2133.2000.03485.x; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; YETIV JZ, 1980, SOUTH MED J, V73, P599, DOI 10.1097/00007611-198005000-00015	9	45	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1457	1459		10.1016/j.jaci.2007.07.048	http://dx.doi.org/10.1016/j.jaci.2007.07.048			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17900677				2022-12-18	WOS:000251653800031
J	Finkelman, FD; Vercelli, D				Finkelman, Fred D.; Vercelli, Donata			Advances in asthma, allergy mechanisms, and genetics in 2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; mechanisms; mouse models; genetics; single nucleotide polymorphisms; association studies; linkage studies	SERUM IGE LEVELS; AIRWAY INFLAMMATION; GROWTH-FACTOR; MURINE MODEL; RESPONSES; ASSOCIATION; HYPERRESPONSIVENESS; POLYMORPHISMS; IL-13; ATOPY	This review discusses the main advances in animal models of allergic airway disease and genetics of asthma and allergy published in the Journal in 2006. This work highlighted and extended what has become the central dogma of allergic pathogenesis by highlighting the mechanisms involved in inducing a T(H)2 response and in determining how T(H)2 cytokines induce the allergic airway disease phenotype. By so doing, they have identified a considerable number of potential therapeutic targets. Genetic analyses, on the other hand, revealed novel, potentially important candidate genes, confirmed known ones, and refined our understanding of the putative role played by others, sometimes positively, sometimes negatively. These data reiterate allergic inflammation is a classic complex genetic disease-that is, a disorder in which multiple and distinct genetic determinants variously interact with one another and with relevant environmental exposures to result in clinical phenotypes that, although superficially similar, involve distinct genetic pathways and represent the outcome of distinct pathogenetic mechanisms.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Cincinnati, Div Immunol, Cincinnati, OH 45221 USA	University of Arizona; University of Arizona Health Sciences; University System of Ohio; University of Cincinnati	Vercelli, D (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, 1501 N Campbell Ave,Suite 2349, Tucson, AZ 85724 USA.	donata@arc.arizona.edu						Akei HS, 2006, J ALLERGY CLIN IMMUN, V118, P62, DOI 10.1016/j.jaci.2006.04.046; BAMES KC, 2006, J ALLERGY CLIN IMMUN, V118, P70; Blumchen K, 2006, J ALLERGY CLIN IMMUN, V118, P615, DOI 10.1016/j.jaci.2006.04.054; Blumenthal MN, 2006, J ALLERGY CLIN IMMUN, V117, P79, DOI 10.1016/j.jaci.2005.09.038; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; Chen CL, 2006, J ALLERGY CLIN IMMUN, V118, P105, DOI 10.1016/j.jaci.2006.02.047; Cho JY, 2006, J ALLERGY CLIN IMMUN, V117, P618, DOI 10.1016/j.jaci.2005.12.1324; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Ferrara TJ, 2006, J ALLERGY CLIN IMMUN, V117, P780, DOI 10.1016/j.jaci.2005.12.1330; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Keller AC, 2006, J ALLERGY CLIN IMMUN, V117, P283, DOI 10.1016/j.jaci.2005.10.019; Kendall M, 2006, J ALLERGY CLIN IMMUN, V117, P275, DOI 10.1016/j.jaci.2005.09.049; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P403, DOI 10.1016/j.jaci.2006.04.041; Lee SY, 2006, J ALLERGY CLIN IMMUN, V117, P597, DOI 10.1016/j.jaci.2005.11.008; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Li HL, 2006, J ALLERGY CLIN IMMUN, V117, P119, DOI 10.1016/j.jaci.2005.09.026; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; Mak JCW, 2006, J ALLERGY CLIN IMMUN, V117, P92, DOI 10.1016/j.jaci.2005.08.049; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Miyahara S, 2006, J ALLERGY CLIN IMMUN, V118, P1110, DOI 10.1016/j.jaci.2006.06.014; Munitz A, 2006, J ALLERGY CLIN IMMUN, V118, P1082, DOI 10.1016/j.jaci.2006.07.041; Nassenstein C, 2006, J ALLERGY CLIN IMMUN, V118, P597, DOI 10.1016/j.jaci.2006.04.052; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Park HW, 2006, J ALLERGY CLIN IMMUN, V117, P774, DOI 10.1016/j.jaci.2005.12.1328; Perkins C, 2006, J ALLERGY CLIN IMMUN, V118, P410, DOI 10.1016/j.jaci.2006.06.004; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Tsai YJ, 2006, J ALLERGY CLIN IMMUN, V118, P1242, DOI 10.1016/j.jaci.2006.07.045; Vercelli D, 2005, J ALLERGY CLIN IMMUN, V116, P60, DOI 10.1016/j.jaci.2005.04.031; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Yamashita N, 2006, J ALLERGY CLIN IMMUN, V117, P1040, DOI 10.1016/j.jaci.2006.01.009; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	44	45	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					544	550		10.1016/j.jaci.2007.05.025	http://dx.doi.org/10.1016/j.jaci.2007.05.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17610942				2022-12-18	WOS:000249505400011
J	Williams, AN; Simon, RA; Woessner, KM; Stevenson, DD				Williams, Adam N.; Simon, Ronald A.; Woessner, Katharine M.; Stevenson, Donald D.			The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol		aspirin; nonsteroidal anti-inflammatory drugs; leukotrienes; leukotriene modifier drugs; asthma; aspirin-exacerbated respiratory disease; aspirin challenge; aspirin desensitization; nasal polyposis; chronic rhinosinusitis	LEUKOTRIENE-MODIFIER DRUGS; NASAL SECRETIONS; DESENSITIZATION; SENSITIVITY	Background: Historical aspirin- or nonsteroidal anti-inflammatory drug (NSAID)-induced reactions might provide predictive information about the severity of reactions in patients with aspirin-exacerbated respiratory disease (AERD) undergoing oral aspirin challenge (OAC). Objective: We sought to assess the relationship between historical aspirin- or NSAID-induced bronchial reactions and the severity of bronchial reactions during OAC in patients with AERD. Methods: Data regarding the provoking doses, treatments, and treatment settings of historical aspirin/NSAID-induced reactions were recorded, analyzed, and compared with the provoking doses, maintenance regimens, and observed decreases in FEV1 that occurred during OAC in 210 consecutive patients referred with suspected AERD. Results: Of 147 patients who reported seeking acute medical care for their historical aspirin/NSAID-induced asthma attacks, 101 (69%) were treated in an emergency department and released, and 46 (31%) required hospitalization. During OAC in these 147 subjects, 23 (16%) had a 20% to 29% decrease and 14 (10%) had a 30% or greater decrease in FEV1 values from baseline. Of the 46 patients previously hospitalized for aspirin/NSAID-induced asthma attacks, 9 (20%) had a 20% to 29% decrease and 6 (13%) had a 30% or greater decrease in FEV1 during OAC. By contrast, of the 63 patients who treated their prior aspirin/NSAID-induced reactions at home, 5 (8%) had a 20% to 29% decrease and 5 (8%) had a 30% or greater decrease in FEV1 during OAC (P = not significant for both). Conclusion: The severity of the historical aspirin/NSAID-induced asthma attack was not predictive of asthma severity during OAC. Clinical implications: These data provide further reassurance regarding the safety of outpatient aspirin desensitization.	Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA	Scripps Research Institute	Williams, AN (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr,S99, San Diego, CA 92130 USA.	a.williams33@yahoo.com						Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; KOWALSKI ML, 1993, J ALLERGY CLIN IMMUN, V91, P580, DOI 10.1016/0091-6749(93)90264-G; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2003, MIDDLETONS ALLERGY P, P1695; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5	21	45	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					273	277		10.1016/j.jaci.2007.03.020	http://dx.doi.org/10.1016/j.jaci.2007.03.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	198VF	17481713				2022-12-18	WOS:000248654900007
J	Gieras, A; Focke-Tejkl, M; Ball, T; Verdino, P; Hartl, A; Thalhamer, J; Valenta, R				Gieras, Anna; Focke-Tejkl, Margarete; Ball, Tanja; Verdino, Petra; Hartl, Arnulf; Thalhamer, Josef; Valenta, Rudolf			Molecular determinants of allergen-induced effector cell degranulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergen; epitope; effector cell degranulation	GRASS-POLLEN ALLERGEN; HISTAMINE-RELEASE; HUMAN BASOPHILS; ANTIGEN-E; IGE; SENSITIVITY; EXPRESSION; ANTIBODIES; EPITOPES; FRAGMENT	Background: Allergen-induced effector cell degranulation is a key event in allergic inflammation and leads to early-phase symptoms, such as allergic rhinitis, conjunctivitis, urticaria, or bronchial asthma. Objective: We sought to study molecular determinants of effector cell degranulation using a monoclonal IgE antibody specific for a peptide epitope of one of the most important respiratory allergens, the major grass pollen allergen Phi p 1, as a model system. Methods: A hybridoma cell line producing a monoclonal IgE antibody against a Phi p 1-derived peptide, P1, was established by means of immunization of mice and used to sensitize rat basophil leukemia cells, which were exposed to P1 monomer, P1 dimer, and P1 polymer. Results: It is demonstrated that the number of IgE epitopes on an allergen molecule and the concentration of allergen-specific IgE antibodies determine the extent of degranulation. The P1 monomer did not cause mediator release and prevented degranulation induced by polymeric P1. Conclusion: Our results suggest that the number of IgE epitopes on an allergen molecule determines its allergenic activity and explains why increases of allergen-specific IgE levels make patients more sensitive to allergens. Allergen-derived monomeric structures isolated by means of combinatorial chemistry might be used to develop new therapeutic strategies for allergy. Clinical implications: Our study reveals molecular factors that determine the immediate allergenic activity of allergens and hence influence clinical sensitivity to these allergens.	Med Univ Vienna, Div Immunopathol, Dept Pathophysiol,Ctr Physiol & Pathophysiol, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria; Scripps Res Inst, Dept Mol Biol, Wilson Lab, La Jolla, CA USA; Paracelsus Private Med Univ Salzburg, Inst Physiol & Pathophysiol, Salzburg, Austria; Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria	Medical University of Vienna; Scripps Research Institute; Paracelsus Private Medical University; Salzburg University	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol,Vienna Gen Hosp,AKH, Waehringer Guertel 18, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	Gieras, Anna/S-8345-2019; Thalhamer, Josef/E-5787-2011	Thalhamer, Josef/0000-0003-2285-6400; Gieras, Anna/0000-0002-5147-2281; Hartl, Arnulf/0000-0001-9626-6425; Valenta, Rudolf/0000-0001-5944-3365				Ball T, 2005, FEBS J, V272, P217, DOI 10.1111/j.1432-1033.2004.04403.x; BALL T, 1994, J BIOL CHEM, V269, P28323; Davies JM, 2000, J ALLERGY CLIN IMMUN, V105, P1085, DOI 10.1067/mai.2000.107040; DEMBO M, 1978, J IMMUNOL, V121, P354; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; FEDOROV AA, 2003, RCSB PROTEIN DATA BA; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Irving MB, 2001, CURR OPIN CHEM BIOL, V5, P314, DOI 10.1016/S1367-5931(00)00208-8; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENSTEIN LM, 1971, J ALLERGY, V47, P103; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MALLEY A, 1969, J ALLERGY, V43, P59, DOI 10.1016/0021-8707(69)90126-9; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; Nadler M J, 2000, Adv Immunol, V76, P325; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684	30	45	46	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					384	390		10.1016/j.jaci.2006.09.034	http://dx.doi.org/10.1016/j.jaci.2006.09.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291855				2022-12-18	WOS:000244327900016
J	Nakazawa, T; Satinover, SM; Naccara, L; Goddard, L; Dragulev, BP; Peters, E; Platts-Mills, TAE				Nakazawa, Takuya; Satinover, Shama M.; Naccara, Lisa; Goddard, Lucy; Dragulev, Bojan P.; Peters, Edward; Platts-Mills, Thomas A. E.			Asian ladybugs (Harmonia axyridis): A new seasonal indoor allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; ladybugs; streptavidin CAP; insect; cross reactivity; winter indoor allergy	IGE ANTIBODIES; HYPERSENSITIVITY; ASTHMA; TROPOMYOSIN; RESIDENTS; KENTUCKY; CHILDREN; BEETLE	Background: Harmonia axyridis, the Asian ladybug (ALB), was repeatedly introduced between 1916 and 1990. These beetles are intolerant to cold and move indoors during the winter. Objective: To investigate sensitization to ALB. Methods: Proteins in ALB extracts were purified by gel filtration and ion exchange chromatography. Purified fractions were screened for IgE antibody using the streptavidin CAP technique in sera from 20 patients with allergy living in ALB-infested houses. Two proteins were fully purified. Serum antibodies were also assessed in sera from 68 adult patients with asthma. Results: Fifteen of the 20 sera had measurable IgE antibody, 7 with high titers, > 10 IU/ml, to ALB extract. The 2 proteins, Har a 1, 10 kd, and Har a 2, 55 kd, bound IgE antibody in 65% and 75% of the sera, respectively. Sequencing revealed a novel N-terminal sequence for Har a 1. Sequencing of Har a 2 demonstrated homology to a dehydrogenase from the red Hour beetle. Although sera from 18 of the patients with asthma were positive for IgE antibody to ALB, they were also positive to Blatella germanica. These subjects did not report exposure to H axyridis, and inhibition studies with B germanica blocked >= 95% of ALB IgE antibody binding. Conclusion: Two proteins of ALB have been purified and used to demonstrate that patients exposed to this beetle can develop high-titer TgE antibody. Cross-reactivity with B germanica was found but was significant only among patients primarily exposed to cockroaches. Clinical implications: Asian ladybug has become an important seasonal indoor allergen in the United States.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Asthma & Allergy Consultants, Austin, TX USA	University of Virginia; University of Virginia	Nakazawa, T (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tn4d@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-20565, AI-50989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, P01AI050989, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albright DD, 2006, ANN ALLERG ASTHMA IM, V97, P521, DOI 10.1016/S1081-1206(10)60944-1; Asturias JA, 1999, J IMMUNOL, V162, P4342; BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278, DOI 10.1159/000234518; Brown SJ, 2003, GENET RES, V82, P155, DOI 10.1017/S0016672303006451; Davis RS, 2006, ANN ALLERG ASTHMA IM, V97, P440, DOI 10.1016/S1081-1206(10)60930-1; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; Goetz DW, 2006, J ALLERGY CLIN IMMUN, V117, pS29, DOI 10.1016/j.jaci.2005.12.121; KAGEN SL, 2000, ANN ALLERG ASTHMA IM, V84, P146; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Magnan EM, 2002, J ALLERGY CLIN IMMUN, V109, pS80, DOI 10.1016/S0091-6749(02)81341-0; MUTHIAH R, 2003, ANN ALLERG ASTHMA IM, V90, P100; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Peters EJ, 2003, ANN ALLERG ASTHMA IM, V90, P316, DOI 10.1016/S1081-1206(10)61800-5; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Sharma K, 2006, J ALLERGY CLIN IMMUN, V117, pS30, DOI 10.1016/j.jaci.2005.12.123; Sharma K, 2006, ANN ALLERG ASTHMA IM, V97, P528, DOI 10.1016/S1081-1206(10)60945-3; Throne JE, 2003, PEST MANAG SCI, V59, P619, DOI 10.1002/ps.690; *USDA AGR RES SERV, 2000, MULT AS LAD BEETL; Yarbrough JA, 1999, J ALLERGY CLIN IMMUN, V104, P704, DOI 10.1016/S0091-6749(99)70347-7	21	45	48	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					421	427		10.1016/j.jaci.2006.11.633	http://dx.doi.org/10.1016/j.jaci.2006.11.633			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291858				2022-12-18	WOS:000244327900021
J	Ciprandi, G; Cirillo, I				Ciprandi, Giorgio; Cirillo, Ignazio			The lower airway pathology of rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; airflow; bronchial obstruction; eosinophils; bronchial hyperreactivity	SEASONAL ALLERGIC RHINITIS; BRONCHIAL HYPERREACTIVITY; SPIROMETRIC IMPAIRMENT; ASTHMA; SYMPTOMS; NASAL; INFLAMMATION	There is a close link between allergic rhinitis (AR) and lower airways disorders, and this concept has been clarified and confirmed in several studies. AR constitutes a main risk factor for new-onset asthma. Furthermore, numerous epidemiologic surveys indicate that AR is very frequently associated with asthma. Bronchial hyperreactivity, a component of asthma, has often been reported to be present in patients with AR. Bronchial hyperreactivity in AR might represent a prognostic factor for further progress to asthma. In this regard forced expiratory flow at 25% and 75% of pulmonary volume has been proposed as an early marker of bronchial involvement in patients with AR who perceive only nasal symptoms. A close structural and functional relationship between the upper and lower airways has been recently demonstrated. Finally, adequate treatment of AR might positively affect the course of asthma. Taking these facts into consideration, a new diagnostic approach should be considered in managing patients with AR: a possible bronchial involvement must be sought in each patient.	Azienda Osped Univ San Martino, Genoa, Italy		Ciprandi, G (corresponding author), Osped San Martino Genova, Dipartimento Patol Testa Collo, Allergol UO ORL, Padiglione Specialita Piano Terzo, Largo R Benzi 10, I-16132 Genoa, Italy.	gio.cip@libero.it	Ciprandi, Giorgio/G-7462-2012	Ciprandi, Giorgio/0000-0001-7016-8421				Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x; Ciprandi G, 2004, RESP MED, V98, P826, DOI 10.1016/j.rmed.2004.02.021; Ciprandi G, 2005, RESP MED, V99, P1606, DOI 10.1016/j.rmed.2005.03.030; Ciprandi G, 2005, ALLERGY, V60, P882, DOI 10.1111/j.1398-9995.2005.00602.x; Ciprandi G, 2005, INT ARCH ALLERGY IMM, V136, P266, DOI 10.1159/000083953; Ciprandi G, 2004, ANN ALLERG ASTHMA IM, V93, P575, DOI 10.1016/S1081-1206(10)61266-5; Ciprandi G, 2004, CLIN EXP ALLERGY, V34, P891, DOI 10.1111/j.1365-2222.2004.01970.x; Ciprandi G, 2004, INT ARCH ALLERGY IMM, V133, P14, DOI 10.1159/000075249; CIPRANDI G, IN PRESS AM J RHINOL; Downie SR, 2004, ALLERGY, V59, P320, DOI 10.1111/j.1398-9995.2003.00419.x; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5	17	45	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1105	1109		10.1016/j.jaci.2006.05.010	http://dx.doi.org/10.1016/j.jaci.2006.05.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088136	Bronze			2022-12-18	WOS:000244282300016
J	Torrent, M; Sunyer, J; Munoz, L; Cullinan, P; Iturriaga, MV; Figueroa, C; Vall, O; Taylor, AN; Anto, JM				Torrent, Matias; Sunyer, Jordi; Munoz, Laura; Cullinan, Paul; Iturriaga, Maria Victoria; Figueroa, Cecilia; Vall, Oriol; Taylor, Anthony Newman; Anto, Josep Maria			Early-life domestic aeroallergen exposure and IgE sensitization at age 4 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; aeroallergens; Der p 1; Fel d 1; specific IgE	HOUSE-DUST MITE; MODIFIED TH2 RESPONSE; ALLERGEN EXPOSURE; ATOPIC SENSITIZATION; CHILDHOOD ASTHMA; CAT; CHILDREN; INFANCY; RISK; PETS	Background: Although it is widely assumed that childhood sensitization to common aeroallergens is directly related to allergen exposure in early life, few longitudinal studies have investigated this issue, and available data are scarce and mainly limited to high-risk groups. Objective: We sought to assess the role of early exposure to 2 major household aeroallergens; (Der p 1 and Fel d 1) in sensitization at the age of 4 years. Methods: Pregnant women and their children were recruited for the Asthma Multicenter Infant Cohort Study. Three cohorts (Ashford in the United Kingdom and Menorca and Barcelona in Spain) followed the same research protocol. A total of 1611 newborn children were initially included in the cohort, from whose homes we collected dust samples at 3 months of age for 1474; Der p I and Fel d 1 levels were measured. Of these children, we obtained blood for specific IgE determination in 1019. Results: The risk of Fel d 1 sensitization increased with exposure in a nonlinear manner. No association was found between specific IgE to Der p 1 and aeroallergen levels of exposure at early life in 2 centers, but a positive association was observed in the third. Conclusions: The dose-response relationships between allergen exposure and sensitization differ between allergens and might vary between different locales. The hypothesis that sensitization to house dust mite is directly related to levels of allergen exposure might not apply to the general population or to different ranges of exposure. Clinical implications: Aeroallergen avoidance might not have any important effect on the incidence of sensitization.	Area Salut Menorca, Mao 07703, Menorca, Spain; Inst Municipal Invest Med, Environm Epidemiol Res Ctr, E-08003 Barcelona, Spain; Pompeu Fabra Univ, Barcelona, Spain; Imperial Coll Sch Med, Dept Occupat & Environm Med, London, England; Univ Autonoma Barcelona, Environm & Pediat Res Unit URIE, Serv Pediat, Hosp Mar, E-08193 Barcelona, Spain	Atencio Primaria de Menorca; Pompeu Fabra University; Imperial College London; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Torrent, M (corresponding author), Area Salut Menorca, C Barcelona 3, Mao 07703, Menorca, Spain.	mtorrent@smen.es	Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014; vall, oriol/G-2980-2010	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; 				Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Anto JM, 2004, ALLERGY, V59, P121, DOI 10.1111/j.1398-9995.2003.00480.x; Atkinson W, 1999, EUR RESPIR J, V13, P583, DOI 10.1183/09031936.99.13358599; Basagana X, 2002, PEDIAT ALLERG IMM-UK, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, CURR OPIN ALLERGY CL, V1, P133; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Gore C, 2004, ALLERGY, V59, P151, DOI 10.1046/j.1398-9995.2003.00358.x; Heinrich J, 2003, J EXPO ANAL ENV EPID, V13, P152, DOI 10.1038/sj.jea.7500267; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Murray CS, 2001, CURR OPIN ALLERGY CL, V1, P407, DOI 10.1097/00130832-200110000-00005; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2003, CURR OPIN ALLERGY CL, V3, P517, DOI 10.1097/01.all.0000104444.09202.ae; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Ponsonby AL, 2003, PEDIAT ALLERG IMM-UK, V14, P81, DOI 10.1034/j.1399-3038.2003.00023.x; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Umetsu DT, 2005, LANCET, V365, P98, DOI 10.1016/S0140-6736(05)17714-9; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wahn U, 1997, PEDIAT ALLERG IMM-UK, V8, P16; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x	36	45	48	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					742	748		10.1016/j.jaci.2006.04.059	http://dx.doi.org/10.1016/j.jaci.2006.04.059			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950296				2022-12-18	WOS:000240649000032
J	Fiset, PO; Leung, DYM; Hamid, Q				Fiset, Pierre-Olivier; Leung, Donald Y. M.; Hamid, Qutayba			Immunopathology of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							IN-VIVO EXPRESSION; GENE-EXPRESSION; IL-16		McGill Univ, Meakins Christie Labs, Dept Pathol & Lab Med, Montreal, PQ H2X 2P2, Canada; Univ Colorado, Hlth Sci Ctr, Div Pediat Allergy Immunol, Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	McGill University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, Dept Pathol & Lab Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Reich K, 2002, J ALLERGY CLIN IMMUN, V109, P681, DOI 10.1067/mai.2002.122234; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414	9	45	49	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					287	290		10.1016/j.jaci.2006.03.046	http://dx.doi.org/10.1016/j.jaci.2006.03.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815171				2022-12-18	WOS:000239184800039
J	Park, EJ; Kim, B; Eo, H; Park, K; Kim, Y; Lee, HJ; Son, M; Chang, YS; Cho, SH; Kim, S; Jin, M				Park, EJ; Kim, B; Eo, H; Park, K; Kim, Y; Lee, HJ; Son, M; Chang, YS; Cho, SH; Kim, S; Jin, M			Control of IgE and selective T(H)1 and T(H)2 cytokines by PG102 isolated from Actinidia arguta	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Actinidia arguta; PG102T; PG102E; T(H)1/T(H)2 cytokines; IgE; GATA-3; T-bet; NFATc2	INDUCED AIRWAY HYPERRESPONSIVENESS; T-BET; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; EOSINOPHILIA; EXPRESSION; INHIBITION; RESPONSES; GATA-3	Background: Various allergic responses are thought to result from the unbalanced development of T(H)1 and T(H)2 pathways and, subsequently, the overproduction of IgE. Therefore the modulation of T(H)1 and T(H)2 responses is a rational strategy for the treatment of allergic diseases. Objective: The present study was performed to investigate the immune-modulating activities of PG102 preparations from Actinidia arguta in ovalbumin-sensitized murine models. Methods: Two preparations from A arguta, PG102T and PG102E, were chosen for animal experimentation on the basis of their ability to regulate the production of IgE in U266B1 cells. The changes in splenic levels of cytokines and plasma levels of immunoglobulin isotypes were examined. The effects of PG102 on subcellular composition (CD4(+)IL-4(+) or CD19(+)IgE(+) cells), IgE production in B cells, and selective transcription factors were analyzed. Results: Oral administration of PG102T and PG102E significantly decreased the level of selective T(H)2 cytokines, whereas it increased the level of T(H)1 cytokines. The differential effects of PG102T and PG102E on T(H)1 and T(H)2 cytokines were accompanied by a decrease in the plasma levels of IgE and IgG1 and by an increase in the plasma level of IgG2a. The percentages of both IL-4-producing T cells and IgE-producing B cells were decreased. The concentration of IgE produced within B cells also appeared to be reduced. Finally, PG102T and PG102E clownregulated the level of GATA-binding protein 3, while inducing that of T-box transcription factor and nuclear factor of activated T cells c2. Conclusion: PG102T and PG102E have great potential as orally active immune modulators for the therapy of various allergic diseases.	Seoul Natl Univ, Inst Mol Biol & Genet 105306, Seoul 151742, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; PanGenom Co Ltd, Biotechnol Incubating Ctr, Seoul, South Korea; Kyunghee Vincent Oriental Hosp, Suwon, South Korea; Dong A Co Ltd, R&D Ctr, Yongin, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Samsung; Seoul National University (SNU)	Kim, S (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet 105306, San 56-1,Shillim Dong, Seoul 151742, South Korea.	sunyoung@plaza.snu.ac.kr	Chang, Yoon-Seok/J-5628-2012; Cho, Sang Heon/J-2793-2012	Chang, Yoon-Seok/0000-0003-3157-0447; 				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; COFFMAN RL, 1986, J IMMUNOL, V136, P949; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerth AJ, 2003, INT IMMUNOL, V15, P937, DOI 10.1093/intimm/dxg093; HIRANO T, 1989, J IMMUNOL METHODS, V119, P145, DOI 10.1016/0022-1759(89)90391-8; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Kang HW, 2002, BIOL PHARM BULL, V25, P102, DOI 10.1248/bpb.25.102; Kato Y, 1999, J IMMUNOL, V162, P7470; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Kim HM, 2001, PHYTOTHER RES, V15, P572, DOI 10.1002/ptr.749; KYOKO K, 2002, J DERMATOL SCI, V29, P19; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Semper AE, 2003, J ALLERGY CLIN IMMUN, V112, P411, DOI 10.1067/mai.2003.1626; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Vercelli D, 2001, CURR OPIN ALLERGY CL, V1, P61, DOI 10.1097/01.all.0000010986.58020.8d	20	45	46	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1151	1157		10.1016/j.jaci.2005.07.024	http://dx.doi.org/10.1016/j.jaci.2005.07.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275390	Bronze			2022-12-18	WOS:000235686700031
J	Santillan, AA; Camargo, CA; Ramirez-Rivera, A; Delgado-Enciso, I; Rojas-Martinez, A; Cantu-Diaz, F; Barrera-Saldana, HA				Santillan, AA; Camargo, CA; Ramirez-Rivera, A; Delgado-Enciso, I; Rojas-Martinez, A; Cantu-Diaz, F; Barrera-Saldana, HA			Association between beta(2)-adrenoceptor polymorphisms and asthma diagnosis among Mexican adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alleles; asthma; beta 2-adrenoceptor polymorphism; case-control studies; genetics; genotype; phenotype	BETA-2-ADRENERGIC RECEPTOR; GENETIC POLYMORPHISMS; ADRENOCEPTOR; HYPERRESPONSIVENESS; HAPLOTYPES; PROMOTER; REGION	Background: Recent studies demonstrate that genetic variations in the human beta(2)-adrenergic receptor (beta(2)AR) structure at codons 16 and 27 alter receptor function in vitro and are associated with asthma severity and airway hyperresponsiveness but have not been linked to asthma diagnosis. The nature of the relation in a more homogeneous population is uncertain. Objective: We determined frequencies of these polymorphisms to explore the association between beta(2)AR haplotypes and asthma diagnosis and phenotype. Methods: This is a population-based, case-control study that involves a total sample of 907 unrelated Mexican Mestizos. Genotyping at beta(2)AR was identified by polymerase chain reaction-restriction fragment length polymorphism analysis. Multivariate logistic regression analysis was used to estimate the odds ratio (OR) of the association between beta(2)AR haplotype status and asthma diagnosis. Results: A significant inverse association was found between subjects with Glu27 allele (OR, 0.5; 95% CI, 0.4 to 0.7) and Gly16-Glu27 alleles (OR, 0.5; 95% CI, 0.3 to 0.8) and asthma. Sex differences in this association were explored, given the complex relation between sex and asthma. Among men, a positive association was present between the "Gly16 allele without Glu27" (OR, 2.9; 95% CI, 1.26 to 6.8) and asthma. In contrast, a lower risk of asthma was found among women Gly16-Glu27 alleles (OR, 0.3; 95% CI, 0.2 to 0.6). Nocturnal asthma was associated with the Gly16 allele (OR, 1.8; 95% CI, 1.3 to 2.6). Conclusions: Variation in the beta(2)AR gene is associated in the pathogenesis of asthma and acts as a disease modifier in nocturnal asthma.	Univ Autonoma Nuevo Leon, Dept Bioquim, Fac Med, Monterrey, Mexico; Hosp Enfermedades Cardiovasc & Torax, Lab Fisiol Pulmonar, Ctr Med Nacl Norte, IMSS, Monterrey, Mexico; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Universidad Autonoma de Nuevo Leon; Harvard University; Brigham & Women's Hospital	Camargo, CA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St,Clin Bldg 397, Boston, MA 02114 USA.		Delgado-Enciso, Ivan/B-1743-2018; Camargo, Carlos A./C-2145-2008; ROJAS-MARTINEZ, AUGUSTO/D-1710-2011; ROJAS-MARTINEZ, AUGUSTO/Z-3585-2019	Delgado-Enciso, Ivan/0000-0001-9848-862X; Camargo, Carlos A./0000-0002-5071-7654; ROJAS-MARTINEZ, AUGUSTO/0000-0003-3765-6778; Barrera Saldana, Hugo A./0000-0003-1587-4571	NHLBI NIH HHS [HL-03533] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barr RG, 2001, CHEST, V120, P1474, DOI 10.1378/chest.120.5.1474; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Emala CW, 2002, CHEST, V121, P722, DOI 10.1378/chest.121.3.722; Gorodezky C, 2001, HUM IMMUNOL, V62, P979, DOI 10.1016/S0198-8859(01)00296-8; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hopes E, 1998, BRIT MED J, V316, P664, DOI 10.1136/bmj.316.7132.664; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Large V, 1997, J CLIN INVEST, V100, P3005, DOI 10.1172/JCI119854; Liggett SB, 2000, J ALLERGY CLIN IMMUN, V105, pS487, DOI 10.1016/S0091-6749(00)90048-4; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Meirhaeghe A, 1999, LANCET, V353, P896, DOI 10.1016/S0140-6736(99)00251-2; Ramsay CE, 1999, CLIN EXP ALLERGY, V29, P1195; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Scott MGH, 1999, BRIT J PHARMACOL, V126, P841, DOI 10.1038/sj.bjp.0702385; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; Summerhill E, 2000, AM J RESP CRIT CARE, V162, P599, DOI 10.1164/ajrccm.162.2.9910108; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Ulbrecht M, 2000, AM J RESP CRIT CARE, V161, P469, DOI 10.1164/ajrccm.161.2.9902072; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Xie HG, 1999, PHARMACOGENETICS, V9, P511	30	45	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1095	1100		10.1016/j.jaci.2003.09.029	http://dx.doi.org/10.1016/j.jaci.2003.09.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657864				2022-12-18	WOS:000187154200010
J	Nance, CL; Shearer, WT				Nance, CL; Shearer, WT			Is green tea good for HIV-1 infection?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						green tea; catechins; CD4 molecule; CD4 HIV-1 binding domain; electron density map; CD4 pocket for EGCG; conformational fit; protein databank; competitive inhibition	EPIGALLOCATECHIN GALLATE; CD4; (-)-EPIGALLOCATECHIN-3-GALLATE; POLYPHENOLS; BINDING; COMPLEX		Texas Childrens Hosp, Sect Allergy & Immunol, Dept Allergy & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Nance, CL (corresponding author), Texas Childrens Hosp, Sect Allergy & Immunol, Dept Allergy & Immunol, MC FC330 01,6621 Fannin, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR-02250] Funding Source: Medline; NHLBI NIH HHS [HL-72705] Funding Source: Medline; NIAID NIH HHS [AI-27551, AI-36211] Funding Source: Medline; NICHD NIH HHS [HD-41983] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027551, P30AI036211] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; Charlton AJ, 2002, J AM CHEM SOC, V124, P9899, DOI 10.1021/ja0126374; Chinen J, 2002, J ALLERGY CLIN IMMUN, V110, P189, DOI 10.1067/mai.2002.126226; CHINEN J, 2003, MED MANAGEMENT AIDS, P139; Chow HHS, 2001, CANCER EPIDEM BIOMAR, V10, P53; Fassina G, 2002, AIDS, V16, P939, DOI 10.1097/00002030-200204120-00020; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Kohlmeier L, 1997, NUTR CANCER, V27, P1, DOI 10.1080/01635589709514494; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Maeda-Yamamoto M, 1999, J AGR FOOD CHEM, V47, P2350, DOI 10.1021/jf9811525; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; Nakane H, 1989, Nucleic Acids Symp Ser, P115; *NCI DCPC, 1996, J CELL BIOCHEM, V26, pS236; OKUBO S, 1997, J JPN ASS INFECT DIS, V72, P211; Pisters KMW, 2001, J CLIN ONCOL, V19, P1830, DOI 10.1200/JCO.2001.19.6.1830; Sartippour MR, 2002, J NUTR, V132, P2307, DOI 10.1093/jn/132.8.2307; Sleasman John W., 2003, Journal of Allergy and Clinical Immunology, V111, pS582; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; ZAVERI N, 2000, EGCG ORGANIC LETT, V3, P843	23	45	53	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					851	853		10.1016/j.jaci.2003.08.048	http://dx.doi.org/10.1016/j.jaci.2003.08.048			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610469	Bronze			2022-12-18	WOS:000186553300004
J	Sandrini, A; Ferreira, IM; Jardim, JR; Zamel, N; Chapman, KR				Sandrini, A; Ferreira, IM; Jardim, JR; Zamel, N; Chapman, KR			Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breath tests; triamcinolone; airways; inflammation; asthma; rhinitis	EXHALED NITRIC-OXIDE; INDEPENDENT RISK-FACTOR; HYDROGEN-PEROXIDE; EXPIRED BREATH; POLLEN SEASON; ASTHMA; ATOPY; SENSITIZATION; CHILDREN; RESPONSIVENESS	Background: Allergic rhinitis (AR) and asthma are commonly associated, and similar underlying inflammatory processes link both diseases. AR, even in the absence of asthma, is associated with increased levels of exhaled nitric oxide (ENO) and hydrogen peroxide (H2O2) in exhaled breath condensate, 2 noninvasive markers of lower airway inflammation. Objective: We sought to evaluate the effect of treatment with the nasal steroid triamcinolone acetonide on ENO and exhaled H2O2 in subjects with AR. Methods: We allocated 23 subjects in a randomized, double-blind, parallel-controlled fashion to 4-week treatment with triamcinolone acetonide (220 mug/d) or matching placebo. Results: ENO levels were greater in the subgroup with concomitant asthma (16/23 subjects) and decreased significantly with triamcinolone acetonide treatment in this subgroup of patients in comparison with patients receiving placebo. Breath condensate levels Of H2O2 were higher in. patients with AR without asthma than in those with asthma but decreased significantly with triamcinolone acetonide treatment in both subgroups. No changes were observed in bronchial hyperresponsiveness, nasal and asthma symptoms, or peak expiratory flow with active treatment or placebo. Conclusion: We conclude that treatment of AR with triamcinolone acetonide results in decrease of 2 noninvasive markers of lower airway inflammation, ENO and H2O2] supporting that upper and lower airway inflammation should be seen as a continuum in subjects with AR with and without asthma. ENO might be a more specific marker of the lower airway inflammation present in asthma. (J Allergy Clin Immunol 2003;111:313-20.).	Univ Toronto,Hlth Network, Toronto Western Hosp, Asthma & Airway Ctr, Div Resp Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chapman, KR (corresponding author), Univ Hlth Network, Asthma & Airway Ctr, Suite 4-011 ECW,399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Jardim, Jose R/E-3205-2016					[Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Antczak A, 2000, RESP MED, V94, P416, DOI 10.1053/rmed.1999.0801; BALDWIN SR, 1986, LANCET, V1, P11; Baraldi E, 1998, RESP MED, V92, P558, DOI 10.1016/S0954-6111(98)90308-0; Barreto M, 2001, PEDIATR ALLERGY IMMU, V12, P247, DOI 10.1034/j.1399-3038.2001.00041.x; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Donnelly LE, 2002, AM J RESP CELL MOL, V26, P144, DOI 10.1165/ajrcmb.26.1.4477; Effros RM, 2002, AM J RESP CRIT CARE, V165, P663, DOI 10.1164/ajrccm.165.5.2101018; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Ferreira IM, 2001, AM J RESP CRIT CARE, V164, P1012, DOI 10.1164/ajrccm.164.6.2012139; Foresi A, 2000, ANN ALLERG ASTHMA IM, V84, P411, DOI 10.1016/S1081-1206(10)62274-0; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032, DOI 10.1164/ajrccm.158.4.9707143; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; GALLATI H, 1985, J CLIN CHEM CLIN BIO, V23, P453; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; Gratziou C, 2001, CLIN EXP ALLERGY, V31, P409, DOI 10.1046/j.1365-2222.2001.01001.x; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hazari Mehdi S., 2000, Chest, V118, p153S; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Ho LP, 2000, CHEST, V118, P1327, DOI 10.1378/chest.118.5.1327; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042, DOI 10.1164/ajrccm.158.4.9710091; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Loukides S, 2002, CHEST, V121, P338, DOI 10.1378/chest.121.2.338; Ludviksdottir D, 1999, RESP MED, V93, P552, DOI 10.1016/S0954-6111(99)90154-3; Moody A, 2000, J ALLERGY CLIN IMMUN, V105, P895, DOI 10.1067/mai.2000.105318; OGASAWARA H, 1991, Auris Nasus Larynx, V18, P133; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1034/j.1399-3003.2000.15a07.x; Schleiss MB, 2000, EUR RESPIR J, V16, P1115, DOI 10.1034/j.1399-3003.2000.16f16.x; Silvestri M, 1999, EUR RESPIR J, V13, P321, DOI 10.1034/j.1399-3003.1999.13b17.x; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; YEMELYANOV A, 2001, EUR RESP J S33, V18, pS166	38	45	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					313	320		10.1067/mai.2003.64	http://dx.doi.org/10.1067/mai.2003.64			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589351				2022-12-18	WOS:000180942700015
J	Jaakkola, JJK; Jaakkola, N; Piipari, R; Jaakkola, MS				Jaakkola, JJK; Jaakkola, N; Piipari, R; Jaakkola, MS			Pets, parental atopy, and asthma in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						parental atopy; pets; gene-by-environment interaction; asthma; adults	HAY-FEVER; EXPOSURE; CHILDREN; ALLERGY; FARM; RISK; CAT	Background: Studies of exposure to pets and the risk of asthma have provided conflicting results. Objective: We conducted a population-based incident case-control study to assess the relationship of current and previous pet keeping with the risk of adult-onset asthma. We also investigated whether genetic propensity as a result of parental atopy modifies these relations. Methods: From the source population of 441,000 inhabitants of a geographically defined area in South Finland, we systematically recruited, during a 2.5-year period, all new cases of asthma in 21- to 63-year-old adults and randomly selected control subjects. The clinically diagnosed case series consisted of 521 adults with newly diagnosed asthma and a control series of 932 control subjects. Information on current and past exposure to hairy pets was collected by using a self-administered questionnaire. Results: In logistic regression analysis the risk of asthma was lower among subjects with pets during the past 12 months (adjusted odds ratio [OR], 0.74; 95% confidence interval [0], 0.57-0.96) but higher among subjects with pets more than 12 months previously (adjusted OR, 1.39; 95% CI, 1.05-1.84). Parental atopy increased the risk of asthma (OR, 1.88; 95% CI, 1.47-2.41), but there was no interaction between parental atopy and pet exposure. Conclusions: The present results are consistent with the hypothesis that both keeping furry pets and parental atopy increase the risk of asthma development in adulthood. Parental atopy does not modify the effects of pet exposure. The negative association between current pets and the risk of asthma is consistent with selective avoidance of these pets by symptomatic individuals.	Nord Sch Publ Hlth, Environm Hlth Program, SE-40242 Gothenburg, Sweden; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, Helsinki, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland	University of Helsinki; Finnish Institute of Occupational Health	Jaakkola, JJK (corresponding author), Nord Sch Publ Hlth, Environm Hlth Program, Box 12133, SE-40242 Gothenburg, Sweden.		Jaakkola, Jouni J.K./G-4314-2012	Jaakkola, Jouni/0000-0003-4168-4683; Jaakkola, Maritta S./0000-0003-1373-7784				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; JAAKKOLA MS, 2002, IN PRESS ENV HLTH PE; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Mutitts E, 1994, AM J RESP CRIT CARE, V149, P358; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Siracusa A, 1997, Monaldi Arch Chest Dis, V52, P434; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x	21	45	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					784	788		10.1067/mai.2002.123870	http://dx.doi.org/10.1067/mai.2002.123870			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994700	Bronze			2022-12-18	WOS:000175687800006
J	Hoek, KL; Cassell, GH; Duffy, LB; Atkinson, TP				Hoek, KL; Cassell, GH; Duffy, LB; Atkinson, TP			Mycoplasma pneumoniae-induced activation and cytokine production in rodent mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycoplasma pneumoniae; asthma; mast cells; cytokines	BASOPHILIC LEUKEMIA-CELLS; IL-5 MESSENGER-RNA; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL BIOPSIES; NONATOPIC ASTHMA; MICE; INFLAMMATION; INFECTIONS; MODEL; IGE	Background: Mycoplasma pneumoniae is a respiratory tract pathogen that has been associated with severe exacerbations in patients with chronic asthma. Murine models of infection have recently been established, with disease manifestations similar to those observed in human subjects. Previous studies have suggested that this organism is capable of producing activation of a wide range of immunologic cell types. Objective: We sought to determine whether M pneumoniae can induce mast cell activation in the rodent mast cell line RBL-2H3. Results: After 4 hours of coculture, morphologic changes indicative of activation were observed by means of electron microscopy, and M pneumoniae was identified, by means of immunoelectron microscopy, adhering to mast cell membranes. Coculture of rat basophilie leukemia cells with viable M pneumoniae for 4 hours resulted in net release of beta-hexosaminidase and serotonin into the supernatant. Live, but not heat-killed, organisms induced the release of IL-4 protein into the culture supernatant, with a peak at 4 hours. During coculture with M pneumoniae, production of mRNA for IL-4, IL-6, and TNF-alpha was upregulated after 2 hours and had returned to near baseline by 24 hours after infection. Conclusions: We conclude that viable M pneumoniae induces activation of mast cells with release of granule contents, as well as cytokine production.	Univ Alabama, Dept Pediat & Microbiol, Div Dev & Clin Immunol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Atkinson, TP (corresponding author), Univ Alabama, Wallace Tumor Inst 378, 1824 6th Ave S, Birmingham, AL 35294 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ P, 1987, J INFECT DIS, V155, P482, DOI 10.1093/infdis/155.3.482; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BASEMAN JB, 1982, INFECT IMMUN, V38, P389, DOI 10.1128/IAI.38.1.389-391.1982; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; BIBERFELD G, 1977, SCAND J IMMUNOL, V6, P1145; BIBERFELD G, 1976, NATURE, V261, P238, DOI 10.1038/261238a0; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Cassell G. H., 1994, P491; CASSELL GH, 2000, 40 INT C ANT AG CHEM, P61; CHAN BMC, 1986, EUR J IMMUNOL, V16, P1319, DOI 10.1002/eji.1830161102; CHAN BMC, 1987, EUR J IMMUNOL, V17, P637, DOI 10.1002/eji.1830170509; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; DAVIS CP, 1988, ARCH INTERN MED, V148, P969, DOI 10.1001/archinte.148.4.969; DUFFY LB, 2000, 40 INT C ANT AG CHEM, P61; FEWTRELL C, 1980, J IMMUNOL, V125, P701; GIL JC, 1993, ANN ALLERGY, V70, P23; GOULET M, 1995, J CLIN MICROBIOL, V33, P2823, DOI 10.1128/JCM.33.11.2823-2825.1995; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haier J, 1999, RHEUMATOLOGY, V38, P504, DOI 10.1093/rheumatology/38.6.504; Hardy RD, 2001, INFECT IMMUN, V69, P3869, DOI 10.1128/IAI.69.6.3869-3876.2001; HUHTI E, 1974, ANN ALLERGY, V33, P145; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; KASAHARA I, 1985, J INFECT DIS, V152, P823, DOI 10.1093/infdis/152.4.823; KITA M, 1992, MICROBIOL IMMUNOL, V36, P507, DOI 10.1111/j.1348-0421.1992.tb02048.x; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Kotsimbos TC, 1998, J ALLERGY CLIN IMMUN, V102, P859, DOI 10.1016/S0091-6749(98)70029-6; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; KULCZYCKI A, 1976, J IMMUNOL, V117, P661; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LACROIX EL, 1993, MOL IMMUNOL, V30, P321, DOI 10.1016/0161-5890(93)90060-O; LEVY M, 1991, CLIN PEDIATR, V30, P42, DOI 10.1177/000992289103000107; LOVELESS RW, 1989, INFECT IMMUN, V57, P1285, DOI 10.1128/IAI.57.4.1285-1289.1989; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; Micillo E, 2000, ALLERGY, V55, P42; Nasralla M, 1999, EUR J CLIN MICROBIOL, V18, P859, DOI 10.1007/s100960050420; PETROVSKY T, 1990, MED J AUSTRALIA, V152, P391, DOI 10.5694/j.1326-5377.1990.tb125255.x; RAZIN S, 1992, J GEN MICROBIOL, V138, P407, DOI 10.1099/00221287-138-3-407; SABATO AR, 1984, ARCH DIS CHILD, V59, P1034, DOI 10.1136/adc.59.11.1034; Schaffner E, 1998, MICROB PATHOGENESIS, V24, P257, DOI 10.1006/mpat.1997.0196; Seggev JS, 1996, ANN ALLERG ASTHMA IM, V77, P67, DOI 10.1016/S1081-1206(10)63482-5; SEGGEV JS, 1986, ANN ALLERGY, V57, P263; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; Wasiela Malgorzata, 2000, Medycyna Doswiadczalna i Mikrobiologia, V52, P389; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wubbel L, 1998, J INFECT DIS, V178, P1526, DOI 10.1086/314439; YANO T, 1994, AM J RESP CRIT CARE, V149, P1348, DOI 10.1164/ajrccm.149.5.8173777; Ying S, 1997, J IMMUNOL, V158, P3539	54	45	51	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					470	476		10.1067/mai.2002.121951	http://dx.doi.org/10.1067/mai.2002.121951			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897994				2022-12-18	WOS:000174586400014
J	Rizzo, CA; Yang, R; Greenfeder, S; Egan, RW; Pauwels, RA; Hey, JA				Rizzo, CA; Yang, R; Greenfeder, S; Egan, RW; Pauwels, RA; Hey, JA			The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; acetylcholine; contractility; ainvay hyperreactivity; asthma; human bronchus; human saphenous vein; human jejunum; TRFK-5; anti-human IL-5R alpha antibody	AIRWAY SMOOTH-MUSCLE; MONOCLONAL-ANTIBODY; CRYOPRESERVATION; INFLAMMATION	Background: The role of IL-5-induced eosinophilia in airway hyperresponsiveness has been questioned. In addition, h eosinophil-independent IL-5-induced airway hyperresponsiveness has been demonstrated in animals. Objective: In this study, IL-5 was investigated for direct effects on human bronchial responsiveness. Methods: Human muscle preparations were isolated from organ donor and surgical tissue. Bronchus, jejunum, and saphenous vein were incubated for 24 hours in vitro with recombinant human (rh) IL-5. Contractility to acetylcholine (bronchus, jejunum) and phenylephrine (saphenous vein) was then investigated. RT-PCR was used to evaluate IL-5 receptor alpha (IL-5Ralpha) expression in various tissues and to assess bronchus and saphenous vein eosinophils through use of CCR3 expression. Results: rhIL-5 primed bronchus for an exaggerated contraction to acetylcholine. The acetylcholine concentration that produced 50% of the control maximum response was reduced 17-to 20-fold in bronchus treated with I and 10 nmol/L rhIL-5. The lower concentration of 0.1 nmol/L rhIL-5 had no effect. The rhIL-5 effect on bronchial contractility was attenuated by antibodies to IL-5 (TRFK-5; 100 nmol/L) and human IL-5Ralpha (100 nmol/L). rhIL-5 (10 nmol/L) did not enhance contractility of saphenous vein or jejunum. When RT-PCR was used, IL-5Ralpha expression was strong in bronchus muscle, weak in trachealis, saphenous vein, and atrial muscle, and undetectable in jejunum, urinary bladder, and pulmonary and renal artery muscle. Comparable weak expression of CCR3 was identified in bronchus and saphenous vein. Conclusion: The findings are consistent with an airway tissuelective expression of the IL-5 receptor that mediates IL-5-induced airway hyperresponsiveness independent of eosinophils. In asthma, in which IL-5 expression is elevated, IL-5 might directly induce bronchial hyperresponsiveness.	Schering Plough Res Inst, Kenilworth, NJ 07033 USA; State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Merck & Company; Schering-Plough Research Institute; Ghent University; Ghent University Hospital	Rizzo, CA (corresponding author), Schering Plough Res Inst, K-15-1-1600,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.							Amrani Y, 1998, THORAX, V53, P713, DOI 10.1136/thx.53.8.713; Billington CK, 1999, AM J RESP CELL MOL, V21, P597, DOI 10.1165/ajrcmb.21.5.3759; Cosmi L, 2001, INT ARCH ALLERGY IMM, V125, P273, DOI 10.1159/000053827; Croci T, 1998, BRIT J PHARMACOL, V125, P1393, DOI 10.1038/sj.bjp.0702190; Egan RW, 1999, ARZNEIMITTEL-FORSCH, V49, P779; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248, DOI 10.1165/ajrcmb.20.2.3327; Garlisi CG, 1999, PULM PHARMACOL THER, V12, P81, DOI 10.1006/pupt.1999.0192; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Greenfeder S, 2001, RESP RES, V2, P71, DOI 10.1186/rr41; HAKONARSON H, 1995, AM J PHYSIOL-LUNG C, V269, pL645, DOI 10.1152/ajplung.1995.269.5.L645; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; HAYASHI S, 1986, SCAND J GASTROENTERO, V21, P9, DOI 10.3109/00365528609034614; Kips JC, 2000, AM J RESP CRIT CARE, V161, pA505; Lazaar AL, 1997, AM J RESP CELL MOL, V16, P38, DOI 10.1165/ajrcmb.16.1.8998077; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Nagase H, 2001, INT ARCH ALLERGY IMM, V125, P29, DOI 10.1159/000053849; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; Rizzo CA, 2001, EUR J PHARMACOL, V413, P263, DOI 10.1016/S0014-2999(01)00772-5; Sakai Tetsuya, 1995, Kobe Journal of Medical Sciences, V41, P33; Sanderson C J, 2000, Curr Opin Investig Drugs, V1, P435; SARRIA B, 1995, BRIT J PHARMACOL, V116, P2569, DOI 10.1111/j.1476-5381.1995.tb17209.x; SCHILLING A, 1995, CRYOBIOLOGY, V32, P109, DOI 10.1006/cryo.1995.1010; Tahara K, 2001, J PEDIATR SURG, V36, P602, DOI 10.1053/jpsu.2001.22295; Tournoy KG, 2001, J IMMUNOL, V166, P6982, DOI 10.4049/jimmunol.166.11.6982; Virchow JC, 1996, J ALLERGY CLIN IMMUN, V98, pS27; WHITNEY B, 1965, J PHARM PHARMACOL, V17, P465, DOI 10.1111/j.2042-7158.1965.tb07706.x	26	45	48	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					404	409		10.1067/mai.2002.122459	http://dx.doi.org/10.1067/mai.2002.122459			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897983				2022-12-18	WOS:000174586400004
J	Lockey, RF				Lockey, RF			"ARIA": Global guidelines and new forms of allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; EFFICACY; RHINITIS; ASTHMA; MITE		Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33620 USA; James A Haley Vet Adm Hosp, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Lockey, RF (corresponding author), Vet Adm Med Ctr, 13000 Bruce B Downs Blvd,111D, Tampa, FL 33612 USA.							Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BOUSQUET J, 2001, IN PRESS J ALLERGY C; Brown JL, 2001, CLIN EXP ALLERGY, V31, P8, DOI 10.1046/j.1365-2222.2001.01009.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Committee on the Safety of Medicines (CSM), 1986, BMJ-BRIT MED J, V293, P948; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Lima MT, 2001, J ALLERGY CLIN IMMUN, V107, pS256; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; 2001, MERRIAM WEBSTERS COL	14	45	52	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					497	499						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590370				2022-12-18	WOS:000171760300003
J	Boushey, HA				Boushey, HA			Experiences with monoclonal antibody therapy for allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; anti-IgE; amalizumab; allergic disease; atopy	IGE ANTIBODY; SERUM IGE; AIRWAY RESPONSIVENESS; AFFINITY RECEPTOR; COMPLEX-FORMATION; RESPONSES; E25	Identification of the central role IgE plays in the pathogenesis of allergic diseases made it a key target for therapy. The first selective anti-I-E therapy, a unique humanized monoclonal anti-IgE antibody (omalizumab), binds with high affinity to the Fc epsilon RI receptor binding site on IgE, thereby reducing the amount of free IgE available to bind to Fc epsilon RI receptors on mast calls, basophils, and other cells. In addition, administration of omalizumab indirectly reduces Fc epsilon RI receptor density on cells involved in allergic responses. In two bronchoprovocation trials involving patients with mild allergic asthma, omalizumab attenuated both early- and late-phase allergic responses. Omalizumab was subsequently evaluated as a treatment for asthma in large, multicenter, randomized, double-blind phase II and III trials involving patients with moderate to severe asthma who required corticosteroid therapy. When added to treatment with oral or inhaled corticosteroids, omalizumab reduced symptoms and exacerbations, improved lung function and quality of life, and reduced the need for rescue medications. These benefits persisted even in the "corticosteroid reduction" phase of these trials, when omalizumab treatment was shown to allow patients to reduce or discontinue their inhaled and/or oral corticosteroids. These effects of omalizumab in improving asthma control, as NN ell as its excel I ent safety profile, may ultimately make this agent a useful addition to the physician's armamentarium of treatments for asthma.	Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Boushey, HA (corresponding author), Univ Calif San Francisco, Sch Med, 505 Paranassus Ave,Box 0130, San Francisco, CA 94143 USA.							Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023, DOI 10.1164/ajrccm.160.3.9810012; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; Frew AJ, 1998, THORAX, V53, pS52, DOI 10.1136/thx.53.2008.S52; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1967, J ALLERGY, V39, P254, DOI 10.1016/0021-8707(67)90019-6; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SOLER M, 2001, IN PRESS EUR RESP J; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3	19	45	46	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2		S			S77	S83		10.1067/mai.2001.116434	http://dx.doi.org/10.1067/mai.2001.116434			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	466VB	11498677				2022-12-18	WOS:000170665900003
J	Eggleston, PA; Bush, RK				Eggleston, PA; Bush, RK			Environmental allergen avoidance: An overview	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, Madison, WI 53705 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; Johns Hopkins University	Bush, RK (corresponding author), Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.								0	45	52	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S403	S405						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	418KR	11242600	Bronze			2022-12-18	WOS:000167891800001
J	Frew, AJ; Smith, HE				Frew, AJ; Smith, HE			Sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; rhinitis; safety; efficacy; sublingual	HOUSE-DUST-MITE; PLACEBO-CONTROLLED EVALUATION; STANDARDIZED 5-GRASS-POLLEN EXTRACT; GRASS-POLLEN IMMUNOTHERAPY; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; CONTROLLED TRIAL; DERMATOPHAGOIDES-PTERONYSSINUS; ALLERGIC RHINOCONJUNCTIVITIS; CLINICAL EFFICACY	Recent claims have been made that sublingual immunotherapy (SLIT) may be a viable alternative to injection immunotherapy (SIT). Animal studies show that when allergens are administered topically, they are handled differently, and IgE responses can be reduced. Most published studies of human SLIT have been small but show fairly consistent benefits on symptom scores, with few systemic side effects. Objective measures of allergen reactivity usually do not change. Relatively few subjects have been treated in SLIT trials compared with the numbers that would be required to validate new drug therapies. On the plus side, SLIT appears to work in adults and in children; it offers some logistic advantages and seems to be safe. Giving allergen by mouth rather than by injection should decrease the costs of immunotherapy, but the cumulative dose of allergen used in SLIT has been between 20 to 375 times the dose given in conventional SIT. Further cost-benefit analysis is needed. On the other hand, standard SIT is effective and is supported by better clinical and experimental evidence. The balance sheet for SLIT is improving, but on the current evidence, SLIT requires further evaluation before it could be recommended for use in routine clinical practice.	Univ Southampton, Sch Med, Dept Med Specialties, Southampton, Hants, England; Univ Southampton, Sch Med, Dept Primary Med Care, Southampton, Hants, England	University of Southampton; University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Mailpoint 810, Southampton SO16 6YD, Hants, England.		Smith, Helen E/M-2449-2016; Kelly, Frank J/C-6125-2009	Smith, Helen E/0000-0003-1883-6124; Kelly, Frank J/0000-0003-2558-8392				Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Black JH, 1927, J LAB CLIN MED, V12, P1156; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Chanez P, 1996, ALLERGY, V51, P850; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feinberg SM, 1940, J AMER MED ASSOC, V115, P23; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HASSEUS B, 1995, J ORAL PATHOL MED, V24, P56, DOI 10.1111/j.1600-0714.1995.tb01139.x; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Holt PG, 1989, CLIN EXP ALLERGY, V19, P55; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOFKVIST T, 1994, ALLERGY, V49, P100, DOI 10.1111/j.1398-9995.1994.tb00808.x; MACATINIA SE, 1993, J EXP MED, V177, P1199; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; REILLY DT, 1986, LANCET, V2, P881; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	49	45	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					441	444		10.1067/mai.2001.113525	http://dx.doi.org/10.1067/mai.2001.113525			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240942				2022-12-18	WOS:000167793300003
J	Lemiere, C; Chaboilliez, S; Trudeau, C; Taha, R; Maghni, K; Martin, JG; Hamid, Q				Lemiere, C; Chaboilliez, S; Trudeau, C; Taha, R; Maghni, K; Martin, JG; Hamid, Q			Characterization of airway inflammation after repeated exposures to occupational agents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; induced sputum eosinophils; IL-5; eotaxin; provocation challenges	INDUCED SPUTUM; TOLUENE DIISOCYANATE; ASTHMATIC RESPONSES; ALLERGEN CHALLENGE; MESSENGER-RNA; HYPERRESPONSIVENESS; INTERLEUKIN-5; EXPRESSION; CELLS; IL-5	Background: Little is known about the comparative kinetics of eosinophil recruitment after exposure to low- and high-molecular-weight sensitizers in subjects with occupational asthma (OA). Objectives: The aims of the study were to investigate the kinetics of changes in inflammatory mediators associated with eosinophil infiltration (IL-5 and eotaxin) and to examine the nature of the airway inflammation induced in response to different types of occupational agents. Methods: We investigated 15 subjects with OA caused by high- and low-molecular-weight agents. The subjects were exposed to increasing doses of the relevant occupational agent over 3 to 4 days until a 20% fall in FEV1 occurred. Methacholine challenge and sputum induction were performed at the end of each day of exposure, Sputum samples were assessed for differential cell counts, including eosinophils, IL-5, and eotaxin messenger RNA. Results: There was an increase in sputum eosinophils, eotaxin, and IL-5 on the day preceding the occurrence of asthmatic reaction, although there was no change in functional parameters (FEV1 and PC20). Increase in sputum eosinophils was more prominent in subjects exposed to low-molecular-weight agents than to high-molecular-weight agents. Conclusion: Changes in eosinophils, IL-5, and eotaxin precede functional changes after exposure to occupational agents in subjects with OA, Eosinophil inflammation is a feature of exposure to both high- and low-molecular-weight agents. Induced sputum may be a useful tool in the early diagnosis of OA.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; Meakins Christie Labs, Montreal, PQ, Canada	Universite de Montreal	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 W Gouin, Montreal, PQ H4J 1C5, Canada.			Martin, James/0000-0001-7574-5363				AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; Boulet L P, 1999, Can Respir J, V6, P231; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; Cartier Andre, 1993, P215; CLOUTIER Y, 1992, CHEST, V102, P402, DOI 10.1378/chest.102.2.402; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P543, DOI 10.1164/ajrccm.161.2.9812083; Kelly MM, 2000, J ALLERGY CLIN IMMUN, V105, P1162, DOI 10.1067/mai.2000.106375; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; PEDERSEN D, 1999, EUR RESPIR J, V8, pS50; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1991, AM REV RESPIR DIS, V145, P582; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; Wong AG, 1996, EUR RESPIR J, V9, P2174, DOI 10.1183/09031936.96.09102174; Ying S, 1999, J IMMUNOL, V163, P6321; Zeibecoglou K, 1999, ALLERGY, V54, P730, DOI 10.1034/j.1398-9995.1999.00058.x	33	45	47	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1163	1170						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112901				2022-12-18	WOS:000165930300020
J	Nakayama, T; Aizawa, C				Nakayama, T; Aizawa, C			Change in gelatin content of vaccines associated with reduction in reports of allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gelatin allergy; DTaP	IGE; MEASLES; MUMPS		Kitasato Inst, Dept Virol, Minato Ku, Tokyo 1088642, Japan		Nakayama, T (corresponding author), Kitasato Inst, Dept Virol, Minato Ku, Shirokane 5-9-1, Tokyo 1088642, Japan.							KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8	4	45	47	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					591	592						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984383	Bronze			2022-12-18	WOS:000089471900026
J	Davenpeck, KL; Berens, KL; Dixon, RAF; Dupre, B; Bochner, BS				Davenpeck, KL; Berens, KL; Dixon, RAF; Dupre, B; Bochner, BS			Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis(x) antagonist TBC1269: Preferential activity against neutrophil adhesion in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; neutrophils; adhesion; P-selectin; PSGL-1; antagonist; glycomimetic; sialyl Lewis(x)	GLYCOPROTEIN LIGAND; SMALL-MOLECULE; LEUKOCYTE; OLIGOSACCHARIDE; ENDOTHELIUM; EXPRESSION	Background: Leukocyte rolling on vascular endothelium is mediated by selectins and their carbohydrate-containing counterligands. The tetrasaccharide sialyl Lewis(x) (sLe(x)) binds to all 3 selectins, so compounds that mimic sLe(x) are potential antagonists. Objective: Our purpose was to examine the ability of the sLe(x) mimetic TBC1269 to inhibit binding of human neutrophils and eosinophils to P-selectin. Methods: Expression of the primary P-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-1), was examined on neutrophils and eosinophils, and their adhesion to immobilized P-selectin was examined under both static and dynamic conditions in the presence and absence of TBC1269. Results: Neutrophils and eosinophils expressed PSGL-1, with eosinophils expressing about twice as much as neutrophils, Tn the absence of TBC1269, both cell types adhered avidly to P-selectin under static and dynamic conditions. For neutrophils, preincubation of P-selectin-coated plates with TBC1269 (1 to 1000 mu g/mL) resulted in concentration-dependent decreases in neutrophil adhesion, with significant inhibition seen at concentrations greater than or equal to 100 mu g/mL. Eosinophil adhesion to P-selectin was more refractory to inhibition by TBC1269 and was only partially inhibited at the highest concentration tested (1000 mu g/mL). Two structurally related control compounds, TBC1900 and TBC746, had no effect when tested at similar concentrations. Conclusion: These data indicate that an sLe(x) mimetic can exhibit fell type-specific differences in potencies with respect to antagonism of P-selectin adhesion. Although this may in part be the result of differences in PSGL-1 expression, the discrepancy in potencies may also be due to other differences, including carbohydrate composition and binding affinity of PSGL-1.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; Texas Biotechnol Corp, Houston, TX USA	Johns Hopkins University	Davenpeck, KL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA.							Abraham WM, 1999, AM J RESP CRIT CARE, V159, P1205, DOI 10.1164/ajrccm.159.4.9806002; Bochner B. S., 1997, ADHESION MOL ALLERGI; BOCHNER BS, 1994, J IMMUNOL, V152, P774; Bochner BS, 1997, J ALLERGY CLIN IMMUN, V100, P581, DOI 10.1016/S0091-6749(97)70158-1; BOCHNER BS, 1998, ALLERGY PRINCIPLES P, P94; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; KAVANAUGH A, 1997, CELL ADHESION MOL AL, P1; Kilgore KS, 1998, J PHARMACOL EXP THER, V284, P427; Kim MK, 1998, AM J RESP CELL MOL, V19, P836, DOI 10.1165/ajrcmb.19.5.3032; Kogan TP, 1998, J MED CHEM, V41, P1099, DOI 10.1021/jm9704917; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1998, IMMUNOLOGIST, V6, P61; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; PalmaVargas JM, 1997, J AM COLL SURGEONS, V185, P365; Patel KD, 1997, J IMMUNOL, V159, P4555; RAO BNN, 1994, J BIOL CHEM, V269, P19663; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; Symon FA, 1996, J IMMUNOL, V157, P1711; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WEIN M, 1995, AM J RESP CELL MOL, V12, P315, DOI 10.1165/ajrcmb.12.3.7532979	32	45	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					769	775		10.1067/mai.2000.105121	http://dx.doi.org/10.1067/mai.2000.105121			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756228				2022-12-18	WOS:000086604100016
J	Jen, A; Baroody, F; deTineo, M; Haney, L; Blair, C; Naclerio, R				Jen, A; Baroody, F; deTineo, M; Haney, L; Blair, C; Naclerio, R			As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; fluticasone propionate nasal spray; eosinophils; eosinophil cationic protein		Background: The daily use of intranasal corticosteroids is approved for the treatment of seasonal allergic rhinitis, Objective: Our objective was to test the effectiveness of as-needed use of intranasal corticosteroids in the treatment of seasonal allergic rhinitis. Methods: A double-blind, placebo-controlled, randomized, parallel-group study of the as-needed usage of fluticasone propionate nasal spray in the management of seasonal allergic rhinitis was performed. Outcome measures were symptom score, Rhinitis Quality of Life Questionnaire (RQLQ), and the number of eosinophils and the level of eosinophilic cationic protein (ECP) in nasal lavage. Results: Twenty-six subjects in each group completed the 4-week study. The median symptom score over the duration of the study In the placebo group was 8.5 versus 4.5 in the active group. The active group had significant improvement on the interim visit in the sleep, non-nose/eye, activities, nasal, practical, and overall domains (P < .05) of the RQLQ and on the final visit in the nasal symptom domain. The number of eosinophils was significantly lower in the active than in the placebo group at the final visit. Changes in ECP were not significant. Conclusion: As-needed fluticasone propionate nasal spray is efficacious in the treatment of seasonal allergic rhinitis.	Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	University of Chicago	Naclerio, R (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC 1035, Chicago, IL 60637 USA.				NIAID NIH HHS [AI 45583] Funding Source: Medline; NIDCD NIH HHS [DC 02742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045583] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; BAVEL J, 1994, ARCH INTERN MED, V154, P2699; BENDE M, 1983, ALLERGY, V38, P461, DOI 10.1111/j.1398-9995.1983.tb02354.x; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; LAFORCE CF, 1994, J FAM PRACTICE, V38, P145; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; MAJCHEL AM, 1993, J ALLERGY CLIN IMMUN, V92, P767, DOI 10.1016/0091-6749(93)90021-7; MYGIND N, 1998, RHINITIS MECH MANAGE, P221; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; Noon JP, 1996, BRIT J DERMATOL, V134, P837	13	45	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					732	738		10.1067/mai.2000.105225	http://dx.doi.org/10.1067/mai.2000.105225			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756223				2022-12-18	WOS:000086604100011
J	Magone, MT; Whitcup, SM; Fukushima, A; Chan, CC; Silver, PB; Rizzo, LV				Magone, MT; Whitcup, SM; Fukushima, A; Chan, CC; Silver, PB; Rizzo, LV			The role of IL-12 in the induction of late-phase cellular infiltration in a murine model of allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-12; IFN-gamma; allergic conjunctivitis; cytokine-deficient mice; IL-4	INDUCED AIRWAY HYPERRESPONSIVENESS; EXPERIMENTAL AUTOIMMUNE UVEITIS; INDUCED EOSINOPHIL INFILTRATION; COLONY-STIMULATING FACTOR; IFN-GAMMA; DEFICIENT MICE; INTERLEUKIN-4-DEFICIENT MICE; INTERFERON-GAMMA; IL-12-DEFICIENT MICE; OCULAR ALLERGY	Background: The applied murine model of allergic conjunctivitis mimics human disease, and an immediate hypersensitivity reaction (LHR) and a late-phase cellular reaction typically develop in sensitized mice after topical challenge with the allergen. Objective: We investigated the role of IL-4, IFN-gamma, and IL-12 in the early and late phases of ocular allergy with use of cytokine knockout (KO) mice and neutralizing antibodies. Methods: Ragweed-sensitized wild-type or IL-4KO, IL-12KO, IFN-gamma KO, anti-IL-12 mAb-treated, recombinant murine IL-12-treated, and anti-IFN-gamma mAb-treated mice were challenged with the allergen 10 days after the immunization, IHR, cellular infiltration, lymphoproliferative response, and cytokine production from draining lymph nodes were recorded and compared among groups. Results: We show that IL-12KO mice and anti-IL-12 antibody-treated wild-type animals failed to have a cellular infiltration into the conjunctiva. Treatment with recombinant murine IL-12 also reduced the number of infiltrating PMNs but increased the percentage of mononuclear cells in the conjunctiva compared with controls, IFN-gamma KO mice had a significantly stronger MR and prolonged infiltration into the conjunctiva after challenge with ragweed than controls. Conclusion: Our data suggest that the presence of IL-12, although better known as a T(H)1-inducing cytokine, is important for the development and the regulation of the late-phase pathologic features in ocular allergy. Furthermore, IFN-gamma is a limiting factor in the late phase of allergy and thus may be important in preventing chronic allergic disease.	NEI, NIH, Bethesda, MD 20892 USA; Kochi Med Sch, Kochi, Japan; Univ Sao Paulo, Sao Paulo, Brazil	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Kochi University; Universidade de Sao Paulo	Magone, MT (corresponding author), NEI, NIH, Bldg 10,Rm 10N208, Bethesda, MD 20892 USA.		Rizzo, Luiz Vicente/B-4458-2009	Magone, M. Teresa/0000-0001-6370-6295				ABELSON MB, 1983, ARCH OPHTHALMOL-CHIC, V101, P631; Aebischer I, 1996, ADV IMMUNOL, V61, P341, DOI 10.1016/S0065-2776(08)60871-8; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; Belser RB, 1996, OTOLARYNG HEAD NECK, V114, P418, DOI 10.1016/S0194-5998(96)70212-7; Bliss J, 1996, J IMMUNOL, V156, P887; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; Broide D, 1998, J IMMUNOL, V161, P7054; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Coligan JKA, 1991, CURRENT PROTOCOLS IM; EHLERS W H, 1992, CLAO Journal, V18, P117; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FOSTER CS, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb04250.x; GALLI SJ, 1998, FUNDAMENTAL IMMUNOLO, P1123; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hingorani M, 1998, J ALLERGY CLIN IMMUN, V102, P821, DOI 10.1016/S0091-6749(98)70023-5; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hoshino T, 1999, J IMMUNOL, V162, P5070; Jones LS, 1997, J IMMUNOL, V158, P5997; Keane-Myers A, 1998, J IMMUNOL, V161, P919; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Krouwels FH, 1998, AM J RESP CELL MOL, V18, P721, DOI 10.1165/ajrcmb.18.5.2909; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Lack G, 1996, J IMMUNOL, V157, P1432; Levi-Schaffer F, 1998, J IMMUNOL, V160, P5554; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MAKINO S, 1995, ALLERGY PROC, V16, P13, DOI 10.2500/108854195778690110; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; NAKAJIMA H, 1993, AM REV RESPIR DIS, V148, P1102, DOI 10.1164/ajrccm/148.4_Pt_1.1102; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; REISS J, 1996, OCULAR INFECT IMMUNI, P345; Rizzo L V, 1998, Dev Immunol, V6, P325, DOI 10.1155/1998/47168; RIZZO LV, 1992, BRAZ J MED BIOL RES, V25, P509; RIZZO LV, 1994, J CLIN INVEST, V94, P1668, DOI 10.1172/JCI117511; RIZZO LV, 1995, EUR J IMMUNOL, V25, P708, DOI 10.1002/eji.1830250312; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Ruede E., 1998, ENCY IMMUNOLOGY, V3, P1483; Sato J, 1999, INT ARCH ALLERGY IMM, V119, P197, DOI 10.1159/000024195; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Shi HZ, 1996, CHINESE MED J-PEKING, V109, P215; Sur S, 1996, J IMMUNOL, V157, P4173; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tarrant TK, 1998, J IMMUNOL, V161, P122; Tomoe S, 1992, Arerugi, V41, P699; TROCME SD, 1992, MAYO CLIN PROC, V67, P557, DOI 10.1016/S0025-6196(12)60464-9; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; Vezzio N, 1996, INT IMMUNOL, V8, P1963, DOI 10.1093/intimm/8.12.1963; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; Wakeham J, 1998, J IMMUNOL, V160, P6101; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WU CY, 1994, J IMMUNOL, V152, P1141; XU H, 1995, J IMMUNOL METHODS, V181, P245, DOI 10.1016/0022-1759(95)00008-X; Yokoi H, 1997, EUR J IMMUNOL, V27, P641, DOI 10.1002/eji.1830270310	63	45	45	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				299	308		10.1016/S0091-6749(00)90080-0	http://dx.doi.org/10.1016/S0091-6749(00)90080-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669851				2022-12-18	WOS:000085402200015
J	Romano, A; Quaratino, D; Venemalm, L; Torres, MJ; Venuto, A; Blanca, M				Romano, A; Quaratino, D; Venemalm, L; Torres, MJ; Venuto, A; Blanca, M			A case of IgE-mediated hypersensitivity to ceftriaxone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Cattolica Sacro Cuore, Dept Internal Med & Geriatr, Allergy Unit, Rome, Italy; Ist Ricovero & Cura Carattere Sci Oasi Maria SS, Troina, Italy; Pharmacia & Upjohn Inc, Uppsala, Sweden; Carios Haya Hosp, Res Unit Allerg Dis, Malaga, Spain	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Oasi Maria SS; Pfizer; Pharmacia Corporation	Romano, A (corresponding author), Unita Allergol, Complesso Integrato Columbus,Via G Moscati 31, I-00168 Rome, Italy.		Romano, Antonino/D-3102-2017; Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017	Romano, Antonino/0000-0001-9742-9898; Torres, María José/0000-0001-5228-471X				BLANCA M, 1994, CLIN EXP ALLERGY, V24, P405; FEINBERG JG, 1968, APPL IMMUNOL, V33, P439; GRABOWSKI EJJ, 1985, J AM CHEM SOC, V107, P267, DOI 10.1021/ja00287a057; MOSKOVITZ BL, 1984, AM J MED, V77, P84; NEWTON GGF, 1967, POSTGRAD MED J, VS 43, P10	5	45	45	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1113	1114		10.1016/S0091-6749(99)70100-4	http://dx.doi.org/10.1016/S0091-6749(99)70100-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550764				2022-12-18	WOS:000083778400043
J	Scott, MB; Skoner, DP				Scott, MB; Skoner, DP			Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		budesonide; budesonide inhalation suspension; asthma; inhaled corticosteroid; pediatric; safety; growth	INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; CHILDHOOD ASTHMA; GROWTH; BECLOMETHASONE	This article reviews the short-term and long-term safety profile of budesonide inhalation suspension (BIS) for nebulization in infants and young children with persistent asthma. Shortterm safety (12 weeks) was assessed by pooling the results from the 3 randomized, double-blind, placebo-controlled, multicenter studies (studies A, B, and C) on the efficacy and safety of once- and twice-daily BIS. Long-term safety of BIS and conventional asthma therapy (CAT) was assessed in 52-week extension studies of the 12-week double-blind trials. CAT consisted of any available therapy for asthma; in 2 studies, CAT could have included treatment,with inhaled glucocortico-steroids. Safety was assessed by monitoring adverse events (AEs), physical examinations, and basal and ACTH-stimulated plasma cortisol levels tin a subset of subjects). In the 52-week open-label extensions, the effects of BIS on growth velocity and skeletal age also were determined. In the 12-week studies, a total of 1017 subjects was evaluated for safety; totals of 231, 185, 229, 327, and 45 subjects were randomized to receive placebo or BLS at total daily doses of 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg, respectively. Subject demographics and baseline asthma characteristics were similar across treatment groups, except that age, weight, height, and duration of asthma appeared higher in the 2.0-mg daily dose group. For BIS groups, mean age was 58.9 months; mean weight was 20.3 kg; mean height was 108.9 cm, and mean duration of asthma was 3.2 years. There were no differences in the incidence, severity, or types of AEs reported among the BIS and placebo groups. There were no significant differences between placebo and BIS treatment groups in basal or ACTH-stimulated cortisol levels, physical examinations, clinical laboratory values, or fungal cultures. A total of 670 subjects completed the 52-week extension studies; 223 subjects received CBT and 447 received BIS. Median total daily doses of BIS ranged from 0.50 mg to 1.0 mg in the 3 studies, and the mean duration of treatment exposure was 304 +/- 119 days and 342 +/- 83 days in CAT and BIS groups, respectively. During the 52-week treatment period, the incidences of reported AEs were comparable between treatment groups and were mild-to-moderate in intensity; no new AEs occurred during the 52-week studies compared with 12-week studies. No significant differences were observed between BIS and CAT in basal or A(ACTH-stimulated cortisol levels, physical examinations, clinical laboratory values, or fungal cultures. There was a small but statistically significant reduction in growth velocity (a difference of 0.8 cm) in the BIS-treated group compared with the CAT group in study A. In studies B and C, growth velocity: was not different between BIS and CAT groups. In pooled analyses, no statistically significant differences in growth velocity, standard median heights, or skeletal age were observed between BIS and CAT groups. Shortterm and long-term treatment with BIS, over a nide range of doses, was well tolerated for the treatment of persistent asthma in infants and young children.	Fairfield Cty Allergy Asthma & Immunol Associates, PC, Norwalk, CT 06851 USA; Childrens Hosp, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Scott, MB (corresponding author), Fairfield Cty Allergy Asthma & Immunol Associates, PC, 148 East Ave,Suite 3G, Norwalk, CT 06851 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; *DEP HLTH ED WELF, 1997, VIT STAT, V2, P1; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; *MED EC CO, 1999, PHYS DESK REF, P587; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Reid A, 1996, ACTA PAEDIATR, V85, P421, DOI 10.1111/j.1651-2227.1996.tb14053.x; Roche AF., 1988, ASSESSING SKELETAL M; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305	27	45	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	2	S			S200	S209		10.1016/S0091-6749(99)70062-X	http://dx.doi.org/10.1016/S0091-6749(99)70062-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	249RH					2022-12-18	WOS:000083345700007
J	De Lucca, SD; Taylor, DJM; O'Meara, TJ; Jones, AS; Tovey, ER				De Lucca, SD; Taylor, DJM; O'Meara, TJ; Jones, AS; Tovey, ER			Measurement and characterization of cockroach allergens detected during normal domestic activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergy; aeroallergen; Bla g 1; immunostaining	INNER-CITY CHILDREN; INDOOR ALLERGENS; CAT ALLERGEN; RISK-FACTORS; EXPOSURE; DUST; ASTHMA; MITE; HYPERSENSITIVITY; QUANTITATION	Background: Cockroach allergen is recognized as a causal factor for asthma. However, airborne cockroach allergen has not been detected in undisturbed conditions, and therefore the behavior and properties of airborne cockroach allergen have been poorly characterized. A new aeroallergen sampling method and sensitive system of immunoassay have been used to examine cockroach allergen exposure. Objective: Our purpose was to measure and characterize airborne cockroach allergens during normal domestic exposure in the homes of Sydney, Australia. Methods: Air sampling with Institute of Occupational Medicine, Edinburgh (IOM) samplers was performed in the living rooms of 10 houses during low- and no-disturbance environments, In addition, inhaled particles were collected by each home occupant during low domestic exposure with use of intra-nasal samplers that impact particles onto an adhesive surface. The particles collected on the IOMs and the intranasal samplers were immunostained with Bla g 1 monoclonal antibodies. Particle size, morphologic characteristics, and the relative Bla g 1 content of particles were estimated. Reservoir dust samples from the kitchen, living room, and bedroom were assayed by an ELISA. Two forms of repeatability of IOM air sampling were examined, The first measure tested the repeatability of 2 IOM samples collected simultaneously in the same room during low- and no-disturbance activities. The second measure examined the repeatability of IOM;I sampling over time on 10 consecutive days. Results: Bla g 1 was detected in reservoir dust samples taken from all homes (geometric mean 1.5 U/g, range 0.2-9.4 U/g), Inhaled particles containing Bla g 1 were detected during 1 hour of intra-nasal sampling in 8 of 10 homes during low disturbance. Cockroach particles were detected on all of the IOM samples collected for both 4-hour low-disturbance and overnight no-disturbance sampling environments. Particles containing Bla g 1 collected with the IOM samplers during low disturbance ranged in size from 3 to 350 mu m. These particles are amorphous and irregular in shape, and a majority of the large particles were described as flakes (flat, transparent particles) and fibers (threadlike). A relationship was demonstrated between the allergen content of cockroach particles and their particle size. The larger particles elute more Bla g 1, The coefficient of repeatability for measurements made during low and no disturbance was 3.62 and 2.09, respectively. For measurements repeated over time at the same site, the coefficient of repeatability was 2.61. This represents the fold range within which 95% of pairs of measurements made at an interval of 1 day would be expected to lie. Conclusions: Airborne cockroach allergen is present in both undisturbed and low-disturbance environments in homes with relatively low reservoir levels of Bla g 1. In agreement with previous reports, airborne particles containing cockroach allergen (Bla g 1) are mainly associated with particles >10 mu m. These particles are amorphous and irregular in shape and can be described as flakes and fibers.	Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia	University of Sydney	Tovey, ER (corresponding author), Univ Sydney, Inst Resp Med, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHINN S, 1991, THORAX, V46, P454, DOI 10.1136/thx.46.6.454; CHOOVIVATHANAVANICH P, 1970, LANCET, V2, P1362; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; De Lucca S, 1999, J ALLERGY CLIN IMMUN, V103, P174, DOI 10.1016/S0091-6749(99)70543-9; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GELBER L, 1991, Journal of Allergy and Clinical Immunology, V87, P233, DOI 10.1016/0091-6749(91)91659-H; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1040, DOI 10.1016/S0091-6749(96)70255-5; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sercombe JK, 1998, J ALLERGY CLIN IMMUN, V101, pS80; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TANDON N, 1990, ANN ALLERGY, V64, P155; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; ZWICK H, 1991, J ALLERGY CLIN IMMUN, V87, P626, DOI 10.1016/0091-6749(91)90380-7	27	45	47	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				672	680		10.1016/S0091-6749(99)70341-6	http://dx.doi.org/10.1016/S0091-6749(99)70341-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482845				2022-12-18	WOS:000082870000033
J	Shimizu, T; Abe, R; Ohkawara, A; Nishihira, J				Shimizu, T; Abe, R; Ohkawara, A; Nishihira, J			Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; chronic urticaria; cytokine; concanavalin A; macrophage migration inhibitory factor; PBMCs	MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; REGULATORY ROLE; CYTOKINE; HYPERSENSITIVITY; QUANTIFICATION; ACTIVATION; INFILTRATE; ECZEMA	Background: Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disorder. The underlying cause of AD is multifactorial, and several cytokines are considered to be involved in this severe inflammatory skin disease. Macrophage migration inhibitory factor (MIF) is an immunoregulatory cytokine essential for T-cell activation and delayed-type hypersensitivity. Recently we demonstrated that serum MIF content was significantly elevated in patients with AD, Consistent with this, expression of MLF messenger RNA in keratinocytes of the eczematous skin lesion was up-regulated. Objective and Method: Although keratinocytes are considered to be a potential source of increased serum MIF content in AD, precise evaluation has not been carried out in other tissues. NIP is ubiquitously expressed in various cells, including T cells and macrophages. In this study we examined MIF production and its messenger RNA level of PBMCs from patients with AD to investigate the contribution of these cells to elevated serum MIF content and to its pathologic characteristics. Results: Consistent with our previous findings, the serum MIF content of patients with AD was significantly elevated compared with nonatopic healthy control subjects and patients with chronic urticaria without eczema. As for the MIF productivity of unstimulated PBMCs, the MIF content in the culture medium of PBMCs obtained from patients with AD (40.4 +/- 8.4 ng/mL) (mean +/- SEM) was significantly increased compared with that from healthy control subjects (6.6 +/- 1.1 ng/mL) and patients with chronic urticaria (8.5 +/- 1.4 ng/ml) (P < .0001). When PBMCs were stimulated by concanavalin A, MIF production by PBMCs of patients with AD was more enhanced than in control subjects or patients with chronic urticaria, The increased ratio of MIF production by PBMCs in response to concanavalin A was significantly correlated with the severity of clinical features of AD. Supporting these results, the level of MIF mRNA in PMBCs of patients with AD was significantly higher than in nonatopic healthy control subjects. Conclusions: The current results showed that PBMCs should be an important source of increased serum MIF in AD. Because MIF has the potential to induce local and systemic inflammatory and immune responses, it is conceivable that MIF produced by PBMCs may affect Local and systemic pathologic features in AD.	Hokkaido Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Sch Med, Cent Res Inst, Kita Ku, Sapporo, Hokkaido 060, Japan	Hokkaido University; Hokkaido University	Nishihira, J (corresponding author), Hokkaido Univ, Sch Med, Cent Res Inst, Kita Ku, Sapporo, Hokkaido 060, Japan.			Shimizu, Tadamichi/0000-0002-3231-0279				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bacher M, 1997, AM J PATHOL, V150, P235; BAHMER FA, 1991, ARCH DERMATOL, V127, P1239, DOI 10.1001/archderm.127.8.1239; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; GOODYEAR HM, 1993, CLIN EXP DERMATOL, V18, P300, DOI 10.1111/j.1365-2230.1993.tb02202.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; HOLDEN CA, 1993, CLIN EXP DERMATOL, V18, P201, DOI 10.1111/j.1365-2230.1993.tb02171.x; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; LEUNG DYM, 1986, CLIN REV ALLERG, V4, P67; LEVER R, 1987, J INVEST DERMATOL, V89, P4, DOI 10.1111/1523-1747.ep12579727; Nishihira J, 1998, INT J MOL MED, V2, P17; OHMEN J, 1996, J IMMUNOL, V154, P1956; RAJKA G, 1989, ESSENTIAL ASPECTS AT; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; SAKAI M, 1994, BIOCHEM MOL BIOL INT, V33, P439; Shimizu T, 1999, J INVEST DERMATOL, V112, P210, DOI 10.1046/j.1523-1747.1999.00486.x; Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633; SHIMIZU T, 1996, FEBS LETT, V381, P188; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; THESTRUPPEDERSE.K, 1997, SKIN IMMUNE SYSTEM C, P497; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x	33	45	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				659	664		10.1016/S0091-6749(99)70339-8	http://dx.doi.org/10.1016/S0091-6749(99)70339-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482843				2022-12-18	WOS:000082870000031
J	Agarwal, S; Viola, JPB; Rao, A				Agarwal, S; Viola, JPB; Rao, A			Chromatin-based regulatory mechanisms governing cytokine gene transcription	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chromatin remodeling; DNA methylation; T-cell differentiation; T-cell activation; IL-4	T-CELL SUBSETS; HELPER TYPE-1 CELLS; IFN-GAMMA; REPRESS TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; TH1; METHYLATION; ACTIVATION; REGION	On initial contact with antigen, naive T cells differentiate and acquire effector characteristics, including the ability to transcribe specific cytokine genes rapidly and at high levels on subsequent exposure to antigen. Several effector T-cell subsets showing distinct patterns of cytokine gene transcription have been described. The patterns of cytokine expression in response to pathogenic challenges have a significant impact on the outcome of immune and inflammatory reactions. Here we review recent studies suggesting that the ability of naive T cells to differentiate into specific cytokine-expressing cells is regulated by epigenetic changes in the accessibility and chromatin structure of cytokine genetic loci. Antigen and cytokine stimulation of naive T cells activates diverse intracellular signaling pathways, which result in chromatin remodeling and demethylation of cytokine genes. These changes are likely to increase, in a stable and heritable fashion, the accessibility of these genes to the basal transcriptional machinery. Chromatin-based regulatory mechanisms may explain several features of cytokine gene expression in effector versus naive T cells, including their monoallelic expression, coordinate regulation, and stable maintenance in memory T cells. The hypothesis of epigenetic changes occurring during T-cell differentiation provides a framework for a comprehensive understanding of cytokine expression by T cells.	Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, Boston, MA 02115 USA; INCA, Inst Nacl Canc, Ctr Pesquisa Basica, Program Med Expt, Rio De Janeiro, Brazil	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; National Cancer Institute (Inca)	Rao, A (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Viola, Joao P.B./AAP-4125-2020	Viola, Joao P.B./0000-0002-0698-3146				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; BUCY RP, 1995, P NATL ACAD SCI USA, V92, P7565, DOI 10.1073/pnas.92.16.7565; Carter LL, 1996, CURR OPIN IMMUNOL, V8, P336, DOI 10.1016/S0952-7915(96)80122-1; CROFT M, 1995, J IMMUNOL, V154, P4269; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; Gorham JD, 1996, P NATL ACAD SCI USA, V93, P12467, DOI 10.1073/pnas.93.22.12467; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; Huang H, 1998, J EXP MED, V187, P1305, DOI 10.1084/jem.187.8.1305; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; Kaplan MH, 1998, J EXP MED, V188, P1191, DOI 10.1084/jem.188.6.1191; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KoyanoNakagawa N, 1996, J ALLERGY CLIN IMMUN, V98, pS174, DOI 10.1016/S0091-6749(96)70064-7; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lalani I, 1997, ANN ALLERG ASTHMA IM, V79, P469, DOI 10.1016/S1081-1206(10)63052-9; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSTOSLAVSKY R, 1997, BIOCHIM BIOPHYS ACTA, V1, P29; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; Nakamura T, 1997, J IMMUNOL, V158, P1085; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Garra A, 1997, CURR OPIN IMMUNOL, V9, P872, DOI 10.1016/S0952-7915(97)80192-6; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, CURR BIOL, V7, pR729, DOI 10.1016/S0960-9822(06)00368-X; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WEISS MJ, 1995, EXP HEMATOL, V23, P99; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	45	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					990	999		10.1016/S0091-6749(99)70168-5	http://dx.doi.org/10.1016/S0091-6749(99)70168-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359875				2022-12-18	WOS:000080929500002
J	Taha, RA; Leung, DYM; Ghaffar, O; Boguniewicz, M; Hamid, Q				Taha, RA; Leung, DYM; Ghaffar, O; Boguniewicz, M; Hamid, Q			In vivo expression of cytokine receptor mRNA in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; skin; allergy; cytokine receptors	INTERFERON-GAMMA; MESSENGER-RNA; IGE SYNTHESIS; T-CELLS; B-CELLS; EOSINOPHIL FUNCTION; ALPHA-CHAIN; GM-CSF; IL-4; INTERLEUKIN-13	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with immunopathologic features that vary depending on the duration of the lesion. Acute lesions are associated with a T-cell infiltrate and a high expression of IL-4 mRNA compared with chronic lesions, uninvolved AD skin, or skin from normal control subjects. Chronic lesions are rich in eosinophils and monocyte/macrophages and contain a greater number of IL-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-12 (p40) mRNA-positive cells. Objectives: In this study, we investigated the mRNA expression of the IL-4 receptor (IL-4R alpha), IL-5R alpha, GM-CSFR alpha, and IL-12R beta(2) in biopsy specimens from acute and chronic AD lesions, uninvolved AD skin, normal skin, and psoriatic skin lesions. Methods: Cytokine receptor mRNA was examined in paraformaldehyde-fixed biopsy specimens with in situ hybridization with specific antisense riboprobes. Results: Acute and chronic skin lesions exhibited a significant increase in numbers of IL-5R alpha and GM-CSFR alpha mRNA-positive cells compared with uninvolved AD skin and normal skin (P <.001). Chronic skin lesions had a significantly greater number of IL-5R alpha and GM-CSFR alpha mRNA-positive cells when compared with acute AD skin (P <.001), In contrast, IL-4R alpha mRNA expression was increased in acute but not chronic AD lesions compared with uninvolved and normal skin (P <.001). No significant differences were observed in numbers of IL-12R beta(2) mRNA-positive cells when comparing acute AD, chronic AD, uninvolved AD, and normal skin. In psoriatic skin, the numbers of GM-CSFR alpha and IL-12R beta(2) mRNA-positive cells were significantly increased compared with acute AD lesions, uninvolved skin, and normal control skin (P <.01). Conclusions: These results demonstrate that acute AD is associated with a high expression of IL-4R alpha, whereas IL-5R alpha and GM-CSFR alpha mRNA are predominantly increased in chronic AD and to lesser extent in acute lesions. These findings support the biphasic role of IL-4, IL-5, and GM-CSF in the pathophysiology of AD.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA	McGill University; National Jewish Health	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.				NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; Barata LT, 1997, EUR J IMMUNOL, V27, P1236, DOI 10.1002/eji.1830270527; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOLTZNITULESCU G, 1995, J LEUKOCYTE BIOL, V58, P256, DOI 10.1002/jlb.58.2.256; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; COFFMAN RL, 1991, RES IMMUNOL, V142, P7, DOI 10.1016/0923-2494(91)90002-Z; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196, DOI 10.1159/000237545; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; KOTSIMBOS TC, IN PRESS J ALLERGY C; KOTSIMBOS TC, 1997, J ALLERGY CLIN IMMUN, V99, P666; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1995, ATOPIC DERMATITIS PA, P111; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; METCALF D, 1986, BLOOD, V67, P257; MOZO L, 1993, J IMMUNOL, V150, P4261; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Stoll S, 1997, J IMMUNOL, V159, P298; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; YASRUEL Z, 1997, AM J RESP CRIT CARE, V155, P413; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	40	45	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					245	250		10.1016/S0091-6749(98)70093-4	http://dx.doi.org/10.1016/S0091-6749(98)70093-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723668	Bronze			2022-12-18	WOS:000075537100016
J	Juniper, EF				Juniper, EF			Quality of life questionnaires: Does statistically significant = clinically important?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada	McMaster University	Juniper, EF (corresponding author), McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Fac Hlth Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; JONES PW, 1994, AM J RESP CRIT CARE, V149, pA211; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, QUALITY LIFE PHARMAC, V2nd; JUNIPER EF, 1997, EUR RESPIR REV, V49, P333; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Ware Jr JE, 1996, QUALITY LIFE PHARMAC, P445; WELLS GA, 1993, J RHEUMATOL, V20, P557	10	45	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					16	17		10.1016/S0091-6749(98)70048-X	http://dx.doi.org/10.1016/S0091-6749(98)70048-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679842	Bronze			2022-12-18	WOS:000074909500003
J	Wu, CH; Wang, NM; Lee, MF; Kao, CYY; Luo, SF				Wu, CH; Wang, NM; Lee, MF; Kao, CYY; Luo, SF			Cloning of the American cockroach Cr-PII allergens: Evidence for the existence of cross-reactive allergens between species	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						American cockroach; Cr-PII allergen; cDNA cloning; cross-reactive allergen	GERMAN BLATTELLA-GERMANICA; MONOCLONAL-ANTIBODIES; PERIPLANETA-AMERICANA; BRONCHIAL-ASTHMA; MAJOR ALLERGENS; FECAL EXTRACTS; WHOLE-BODY; HYPERSENSITIVITY; IDENTIFICATION; PURIFICATION	Background: previously, we have identified the 28 and 32 kd proteins as additional important allergens from the American cockroach (Periplaneta americana) Cr PII allergenic fraction. Objective: The aim of this study was the cloning of P. americana Cr-PII allergens. Methods: A lambda gt22A cDNA library constructed from P. americana mRNA was packaged into Escherichia call Y1090 (r(-)), and clones recognized by murine anti-Cr-PII monoclonal antibodies and human IgE antibodies were isolated, sequenced, and subcloned into pET 21 and expressed in E. call BL21(DE3). Results: Six Cr-PII-positive clones recognized by human IgE antibodies were isolated. Two clones, C6 and C17, were sequenced, and we found encoding proteins of 228 and 274 amino acids with no cysteine or any potential N-glycosylation site, with predicted masses of 25.8 and 31.14 kd, respectively. Both molecules contain internal repeated sequences with a 94% identity between them. C6 and C17 showed 59% and 77.3% skin reactivities, respectively, on 22 cockroach-sensitive atopic patients. Both clones were found to have 28.9% to 31,8% identities to ANG12 protein, a precursor of the African malaria mosquito (Anopheles gambiae) and 82.7% to 85.1% identity to a nucleotide sequence of the German cockroach (Blattella germanica) Bla g Bd90K allergen. The anti-C6 and anti-C17 antibodies were able to recognize Cr PII, recombinant proteins, five commercial American extracts, and two German cockroach extracts. Moreover, the binding of anti-C6 and anti C17 antibodies to recombinant protein can be inhibited by B. germanica crude extract. Furthermore, Northern blot analyses have shown that B. germanica mRNAs could be detected by both cDNA probes. Conclusion: Our findings provide the first evidence of antigenic cross-reactivity between P. americana and B. germanica allergens on molecular levels. The results will be a great aid in facilitating the epitope mapping and improving diagnostic and therapeutic reagents for both cockroach species.	Taichung Vet Gen Hosp, Dept Med Res, Taichung 407, Taiwan; Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan; Chang Gung Mem Hosp, Dept Med, Sect Rheumatol Allergy & Immunol, Taipei 10591, Taiwan	Taichung Veterans General Hospital; National Chung Hsing University; Chang Gung Memorial Hospital	Wu, CH (corresponding author), Taichung Vet Gen Hosp, Dept Med Res, 160 Chung Kang Rd,Sect 3, Taichung 407, Taiwan.							Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; CHOOVIVATHANANI.S, 1970, LANCET, V2, P362; FRASER BN, 1979, S AFR MED J, V55, P637; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; HULETT AC, 1979, ANN ALLERGY, V42, P160; Jeng KCG, 1996, CLIN EXP ALLERGY, V26, P349, DOI 10.1111/j.1365-2222.1996.tb00102.x; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; MAHANA W, 1993, J IMMUNOL METHODS, V161, P187, DOI 10.1016/0022-1759(93)90294-H; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENON P, 1991, ANN ALLERGY, V67, P573; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; Sakaguchi Masahiro, 1994, Japanese Journal of Allergology, V43, P1309; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; THONG Y H, 1976, SMJ Singapore Medical Journal, V17, P90; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Wu CH, 1996, ANN ALLERG ASTHMA IM, V76, P195, DOI 10.1016/S1081-1206(10)63422-9; Wu CH, 1997, MOL IMMUNOL, V34, P1, DOI 10.1016/S0161-5890(97)00009-6; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4; WU CH, 1993, CLIN EXP ALLERGY, V23, P493, DOI 10.1111/j.1365-2222.1993.tb03236.x; Wu CH, 1997, ALLERGY, V52, P411, DOI 10.1111/j.1398-9995.1997.tb01020.x; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x	41	45	47	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				832	840		10.1016/S0091-6749(98)70312-4	http://dx.doi.org/10.1016/S0091-6749(98)70312-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648712				2022-12-18	WOS:000074414200019
J	Aaronson, D; Kaiser, H; Dockhorn, R; Findlay, S; Korenblat, P; Thorsson, L; Kallen, A				Aaronson, D; Kaiser, H; Dockhorn, R; Findlay, S; Korenblat, P; Thorsson, L; Kallen, A			Effects of budesonide by means of the turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: A dose-response study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; budesonide; turbuhaler; HPA axis; corticosteroids	INHALED BUDESONIDE; BRONCHIAL-ASTHMA; PREDNISONE	Background: As a general phenomenon, corticosteroids may suppress the activity in the hypothalamic-pituitary-adrenal (HPA) axis. The adrenal stimulation test is a commonly used method to assess the relative risk of exogenous corticosteroids to induce systemic side effects. Objectives: This clinical trial was performed to assess the effects of budesonide on the HPA axis (at 800, 1600, or 3200 mu g/day, given as a twice daily regimen, administered by means of the Turbuhaler) in adult patients with mild, non-steroid-dependent asthma. Methods: Sixty-four asthmatic patients received budesonide or placebo by inhalation or 10 mg/day oral prednisone once daily as a positive control in a double-blind, double-dummy, randomized, placebo-controlled, parallel-group, multicenter study. Plasma cortisol concentration was measured to assess the effect on the HPA axis before and during a 6-hour infusion of synthetic adrenocorticotropic hormone (ACTH), cosyntropin. Results: After 6 weeks of treatment, plasma cortisol concentrations after adrenal stimulation by cosyntropin infusion had fallen by 4% in the placebo group; by 13%, 11%, and 27% in the budesonide groups (800, 1600, and 3200 mu g/day respectively); and by 35% in the prednisone group. The decrease was significant only in the 3200 mu g/day budesonide (p = 0.03) and prednisone (p = 0.005) groups. Over the same time period, decreases in basal plasma cortisol concentrations were 1% in the placebo group; 19%, 19%, and 34% in the three budesonide groups; and 37% in the prednisone group. Only in the prednisone group nas the decrease significant (p = 0.03 vs placebo). Conclusions: In this study budesonide inhaled by means of the Turbuhaler, al doses recommended for clinical use (800 or 1600 mu g/day), did not produce any statistically significant suppression of the HPA axis compared with placebo.	Aaronson Asthma & Allergy Associates, Des Plaines, IL 60016 USA; Asthma & Allergy Specialists, Clin Study Ctr, Minneapolis, MN 55440 USA; Int Med Tech Consultants Inc, Lenexa, KS 66285 USA; HealthQuest Res, Austin, TX 78767 USA; Barnes Jewish W Cty Hosp, Asthma Ctr, St Louis, MO 63110 USA; Astro Draco AB, Lund, Sweden	Barnes-Jewish Hospital	Aaronson, D (corresponding author), Aaronson Asthma & Allergy Associates, 9301 Golf Rd, Des Plaines, IL 60016 USA.							Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; BRAATSAND R, 1991, ASTHMA ITS PATHOLOGY, P667; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BUSSE W, 1998, IN PRESS J ALLERGY C; CORREN J, 1996, CHEST S, V110, P83; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; EBDEN P, 1986, THORAX, V41, P869, DOI 10.1136/thx.41.11.869; EDSBACKER S, 1983, DRUG METAB DISPOS, V11, P590; ELLULMICALLEF R, 1983, BRIT J CLIN PHARMACO, V15, P419, DOI 10.1111/j.1365-2125.1983.tb01524.x; ELLULMICALLEF R, 1980, EUR J RESPIR DIS, V61, P167; FEISS G, 1992, J ALLERGY CLIN IMMUN, V89, P1151, DOI 10.1016/0091-6749(92)90299-H; Grahnen A, 1997, EUR J CLIN PHARMACOL, V52, P261, DOI 10.1007/s002280050287; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KELLERMAN D, 1996, EUR RESP J S23, V9, P162; LAFORCE C, 1996, EUR RESP J S23, V9, P163; LAURSEN LC, 1986, EUR J RESPIR DIS, V68, P19; NELSON H, 1998, IN PRESS CHEST; PADFIELD PL, 1993, EUR RESPIR REV, V3, P494; REED CE, 1991, NEW ENGL J MED, V325, P425, DOI 10.1056/NEJM199108083250610; SORKNESS C, 1996, EUR RESP J S23, V9, P163; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; VANDENBERG JHM, 1977, CLIN CHIM ACTA, V78, P165, DOI 10.1016/0009-8981(77)90303-5	27	45	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					312	319		10.1016/S0091-6749(98)70241-6	http://dx.doi.org/10.1016/S0091-6749(98)70241-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525445				2022-12-18	WOS:000072593900006
J	Chihara, J; Yasuba, H; Tsuda, A; Urayama, O; Saito, N; Honda, K; Kayaba, H; Yamashita, T; Kurimoto, F; Yamada, H				Chihara, J; Yasuba, H; Tsuda, A; Urayama, O; Saito, N; Honda, K; Kayaba, H; Yamashita, T; Kurimoto, F; Yamada, H			Elevation of the plasma level of RANTES during asthma attacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology	JUL   06, 1996	TOKYO, JAPAN	Novartis Pharma KK, Tokyo, Japan		bronchial asthma; chemokine; eosinophils; platelets; RANTES; platelet factor 4; beta-thromboglobulin	HUMAN EOSINOPHILS; CYTOKINE RANTES; CELLS; PLATELETS; RECEPTOR; ACTIVATION; EXPRESSION; PRODUCTS	Background: RANTES is considered to play an important role in various immune and allergic disorders since it is a potent chemoattractant for inflammatory cells such as eosinophils, memory T cells, and monocytes. Objective: To investigate the possible role of RANTES in the pathogenesis of bronchial asthma. Methods: The plasma level of RANTES was measured in 12 asthma patients and 15 normal controls by a sandwich enzyme-linked immunosorbent assay. Results: In the patients with asthma, the plasma RANTES level was significantly elevated during acute attacks compared to that in the controls. In addition, it was higher than that during the asymptomatic state in the same patients. Plasma beta-thromboglobulin levels were also elevated in asthma patients during acute attacks and showed a correlation with the RANTES level. Conclusion: These findings suggest a role for IL RANTES in the pathogenesis of asthma and a possible role for platelets in RANTES release in asthma.	Akita Univ, Sch Med, Dept Clin Lab & Med, Akita 010, Japan; Takautsuki Red Cross Hosp, Dept Internal Med, Takatsuki, Osaka, Japan; Kinki Univ, Sch Med, Dept Internal Med 4, Higashiosaka, Osaka 577, Japan; Kinki Univ, Sch Med, Dept Dermatol, Higashiosaka, Osaka 577, Japan	Akita University; Kindai University (Kinki University); Kindai University (Kinki University)	Chihara, J (corresponding author), Akita Univ, Sch Med, Dept Clin Lab & Med, Akita 010, Japan.							ALAM R, 1993, J IMMUNOL, V150, P3442; *AM THOR SOC, 1975, CHEST, V67, P583; BECK LA, 1994, J ALLERGY CLIN IMMUN, V94, P234; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CHIHARA J, 1989, ALLERGY PROC, V10, P27, DOI 10.2500/108854189778968515; CHIHARA J, 1994, INT ARCH ALLERGY IMM, V104, P52, DOI 10.1159/000236752; CHIHARA J, 1995, INT ARCH ALLERGY IMM, V106, P428, DOI 10.1159/000236878; CHIHARA J, 1991, ALLERGY CLIN IMMUN S, V1, P144; CHIHARA J, 1989, EOSINOPHILS ASTHMA, P151; CHIHARA J, 1990, CELLS ASTHMA, P123; Chihara Junichi, 1993, Biotechnology Therapeutics, V4, P271; DEVALIA JL, 1994, CLIN EXP ALLERGY, V24, P922; GLEICH GJ, 1986, ADV IMMUNOL, V39, P77; GRESELE P, 1982, NEW ENGL J MED, V306, P549; HENSON PM, 1981, PLATELETS BIOL PATHO, P265; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; MCLEAN A, 1994, LANCET, V343, P189, DOI 10.1016/S0140-6736(94)90985-7; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; PAGE CP, 1989, IMMUNOPHARMACOLOGY, V17, P51, DOI 10.1016/0162-3109(89)90008-8; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; STELLATO C, 1994, FASEB J, V8, pA225; YASUBA H, 1991, J LIPID MEDIATOR, V4, P5	24	45	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	2	S			S52	S55		10.1016/S0091-6749(97)70005-8	http://dx.doi.org/10.1016/S0091-6749(97)70005-8			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR026	9440545				2022-12-18	WOS:000071449600005
J	Kidney, JC; Boulet, LP; Hargreave, FE; Deschesnes, F; Swystun, VA; OByrne, PM; Choudry, N; Morris, MM; Jennings, B; Andersson, N; Andreasson, A; Cockcroft, DW				Kidney, JC; Boulet, LP; Hargreave, FE; Deschesnes, F; Swystun, VA; OByrne, PM; Choudry, N; Morris, MM; Jennings, B; Andersson, N; Andreasson, A; Cockcroft, DW			Evaluation of single dose inhaled corticosteroid activity with an allergen challenge model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-induced late response; inhaled corticosteroid; budesonide	LATE ASTHMATIC RESPONSES; BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; HISTAMINE; BECLOMETHASONE; REACTIVITY; BUDESONIDE	Background: Inhaled corticosteroids are the most;commonly used antiinflammatory agents for asthma. There is no simple may to compare objectively the relative potency of inhaled corticosteroids. The allergen-induced lute asthmatic response (LAR) can be suppressed by a single dose of inhaled corticosteroid. Objective: This study was undertaken to evaluate LAR as a model for the determination of the relative potency of single doses of inhaled corticosteroids. Methods: We compared doses of 200 and 800 mu g of a highly active inhaled corticosteroid (budesonide) with placebo and a marginally active investigational inhaled corticosteroid (D5159). Ten atopic patients with asthma completed a randomized, double-blind, double-dummy, multicenter, four-way, crossover trial, A standardized allergen challenge with the identical dose of allergen was performed 10 minutes after each of four blinded, single-dose treatments: 200 mu g of budesonide, 800 mu g of budesonide, 8 mg of D5159, and placebo, all administered from Turbuhaler. The LAR was recorded as the maximum percent fall in FEV1 between 4 and 7 hours, and the allergen-induced increase in methacholine airway responsiveness at 24 hours was recorded as the Delta log PC20 from the day before to the day after allergen challenge. Results: There were no significant differences in the early asthmatic responses during the 4 days; the mean maximum percent in FEV1 fall ranged between 19.5% and 22%. D5159 produced a slight inhibition of the LAR with maximum percent fall in FEV1 recorded as 28.8% +/- 5.0% for D5159 versus 34.1% +/- 4.8% for placebo (p < 0.05). There was a greater reduction recorded after administration of the two doses of budesonide. The mean LAR was 15.1% +/- 3.8% for 200 mu g of budesonide and 11.2% +/- 2.3% for 800 mu g of budesonide (p < 0.01 compared with placebo and D5159). The two doses of budesonide were not statistically different. Airway responsiveness to methacholine increased by 1.07 doubling doses 24 hours after allergen challenge. This increased airway responsiveness was slightly, but not significantly, reduced by the three active treatments (0.6 to 0.91 doubling doses). Conclusion: The allergen-induced LAR model was able to differentiate a single dose of an active inhaled corticosteroid from placebo and a highly potent inhaled corticosteroid from a weak inhaled corticosteroid. The model did not differentiate between 2 fourfold doses of the highly active inhaled corticosteroid (at the doses used in this study), neither for the fall in FEV1 nor for the increase in airway hyperresponsiveness.	MCMASTER UNIV, ASTHMA RES GRP, HAMILTON, ON, CANADA; UNIV LAVAL, QUEBEC CITY, PQ, CANADA; UNIV SASKATCHEWAN, SASKATOON, SK, CANADA; ASTRA PHARMA INC, MISSISSAUGA, ON, CANADA; ASTRO DRACO AB, LUND, SWEDEN	McMaster University; Laval University; University of Saskatchewan			Andersson, Neil/G-2248-2011	O'Byrne, Paul/0000-0003-0979-281X				[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; DAHL R, 1982, EUR J RESPIR DIS, V63, P167; De Marzo N, 1988, Pulm Pharmacol, V1, P15, DOI 10.1016/0952-0600(88)90005-1; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Juniper E, 1994, HISTAMINE METHACHOLI; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; Marshik PL, 1996, J ALLERGY CLIN IMMUN, V97, P534; MCCUBBIN MM, 1995, CLIN PHARMACOL THER, V57, P455, DOI 10.1016/0009-9236(95)90216-3; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; Swystun VA, 1996, J ALLERGY CLIN IMMUN, V97, P274; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156; WONG BJO, 1993, J ALLERGY CLIN IMMUN, V92, P373, DOI 10.1016/0091-6749(93)90115-V	22	45	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					65	70		10.1016/S0091-6749(97)70196-9	http://dx.doi.org/10.1016/S0091-6749(97)70196-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257789	Bronze			2022-12-18	WOS:A1997XP42800011
J	Zweiman, B; Kaplan, AP; Tong, LJ; Moskovitz, AR				Zweiman, B; Kaplan, AP; Tong, LJ; Moskovitz, AR			Cytokine levels and inflammatory responses in developing late-phase allergic reactions in the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						late phase; skin; chamber; allergic; cytokines; chemokines; inflammation	HISTAMINE-RELEASING FACTORS; COLONY-STIMULATING FACTOR; INTERLEUKIN-3 IL-3; MESSENGER-RNA; APPEARANCE; EXPRESSION; CHALLENGE; MEDIATORS; RECEPTOR; IGE	Background: Cytokines could play roles in the attraction of leukocytes into sites of IgE-mediated late-phase reactions (LPR) or in the activation of such cells at the sites, Previous studies found increased release of IL-6, IL-1, and granulocyte-macrophage colony-stimulating factor into skin chambers overlying allergen-challenged sites, mainly after 6 hours when LPR are already well-developed. Objective: To compare levels of several cytokines with inflammatory responses in skin chambers overlying developing LPRs. Methods: Skin chambers were appended to denuded blister bases in 15 sensitive subjects, then challenged over a 5-hour period with pollen allergens (Ag) or buffer control (B), Levels of several chemotactic cytokines, eosinophil cationic product (released from eosinophils), and lactoferrin (released from neutrophils) were measured and leukocyte accumulation was assessed. Results: Levels of the chemokines IL-8, RANTES, and monocyte chemotactic protein-1 (but not IL-1, IL-6, or granulocyte-macrophage colony-stimulating factor) were significantly higher at Ag-challenge sites than at B-challenge sites, IL-5 was not detected, In individual chamber fluids at Ag-challenge sites, (1) IL-8 levels correlated strongly with levels of lactoferrin but not with eosinophil cationic protein levels; (2) RANTES levels correlated with numbers of eosinophils hut not with eosinophil cationic protein levels; and (3) levels of monocyte chemotactic protein-1 correlated weakly with histamine released after the first hour. Conclusions: During LPRs developing during the first 5 hours of Ag challenge, there is increased local release of several chemokines, which could play roles in the observed attraction and subsequent activation of leukocytes and continued histamine release observed at such sites.	SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zweiman, B (corresponding author), UNIV PENN,SCH MED,ALLERGY & IMMUNOL DIV,DEPT MED,512 JOHNSON PAVIL,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [R01 AI4332] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; KAPLAN AP, 1994, ALLERGY, V49, P495, DOI 10.1111/j.1398-9995.1994.tb01119.x; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; KUNA P, 1993, J IMMUNOL, V150, P1932; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MASSEY W, 1993, J IMMUNOL, V150, P1084; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V50, P41; SHUTE J, 1994, CLIN EXP ALLERGY, V24, P203, DOI 10.1111/j.1365-2222.1994.tb00220.x; SIM TC, 1994, AM J RESP CRIT CARE, V150, P1038; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; VOWELS BR, 1995, J ALLERGY CLIN IMMUN, V96, P92, DOI 10.1016/S0091-6749(95)70037-4; ZHANG L, 1994, CLIN EXP ALLERGY, V24, P899, DOI 10.1111/j.1365-2222.1994.tb02720.x; ZWEIMAN B, 1993, CURR OPIN IMMUNOL, V5, P950, DOI 10.1016/0952-7915(93)90111-5; ZWEIMAN B, 1991, J ALLERGY CLIN IMMUN, V87, P984, DOI 10.1016/0091-6749(91)90421-J; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953; ZWEIMAN B, 1988, CLIN ALLERGY, V18, P419, DOI 10.1111/j.1365-2222.1988.tb02892.x	24	45	49	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					104	109		10.1016/S0091-6749(97)70201-X	http://dx.doi.org/10.1016/S0091-6749(97)70201-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257794	hybrid			2022-12-18	WOS:A1997XP42800016
J	KleinJan, A; Godthelp, T; vanToornenenbergen, AW; Fokkens, WJ				KleinJan, A; Godthelp, T; vanToornenenbergen, AW; Fokkens, WJ			Allergen binding to specific IgE in the nasal mucosa of allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal mucosa; specific IgE; allergen	FC-EPSILON-RI; SKIN PRICK TEST; MHC CLASS-II; MAST-CELLS; LANGERHANS CELLS; IMMUNOGLOBULIN-E; RECEPTOR	Background: Until now, it has not been possible to identify specific IgE locally in the airway mucosa. In this study we investigated the possibility of determining specific allergen binding locally in the nasal mucosa. Methods: Nasal mucosal biopsy specimens were taken from 11 patients with symptoms of an isolated grass pollen allergy, 10 patients with symptoms of perennial allergic rhinitis in response to house dust mite allergen, and 10 nonallergic control subjects, Sections of these biopsy specimens were stained by using commercially available biotinylated allergens (AlaSTAT, Diagnostic Products Corp.). Results: Staining with biotinylated grass pollen (GP1) demonstrated positive cells only in patients with grass pollen allergy. Biotinylated Dermatophagoides pteronyssinus (D1) only stained cells in patients with perennial allergy. Specific binding of allergen to cells of patients with allergy and the blocking experiments proved the method to be highly specific. Allergen-positive cells stained double with IgE, the high-affinity receptor for IgE (Fc epsilon RI), CD1, HLA-DR, tryptase, and chymase. Most allergen-positive cells proved to be mast cells. Conclusion: This immunohistochemical study shows the presence of specific IgE against grass pollen and house dust mite allergens locally on cells in the airway mucosa.	UNIV HOSP DIJKZIGT,DEPT OTORHINOLARYNGOL,DIJKZIGT,NETHERLANDS; UNIV HOSP DIJKZIGT,DEPT CLIN CHEM,LAB ALLERGOL,DIJKZIGT,NETHERLANDS		KleinJan, A (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT OTORHINOLARYNGOL,ROOM EE1655,DR MOLEWATERPLEIN 50,NL-3015 GD ROTTERDAM,NETHERLANDS.		Fokkens, Wytske WJ/ABF-2185-2020					AALBERSE RC, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P103; BIEBER T, 1994, IMMUNOL TODAY, V15, P52, DOI 10.1016/0167-5699(94)90132-5; BOUSQUET J, 1989, PROVOCATIVE CHALLENG, P85; Capron A, 1989, Ann Ital Med Int, V4, P79; COOKSON WOCM, 1988, LANCET, V1, P86; ELSHAMI AS, 1989, ADV BIOSCI, V74, P191; *EX COMM AM AC ALL, 1992, J ALLERGY CLIN IMMUN, V90, P263; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 1990, CLIN EXP ALLERGY, V20, P627, DOI 10.1111/j.1365-2222.1990.tb02701.x; FRANDJI P, 1993, J IMMUNOL, V151, P6318; KINET JP, 1991, INT ARCH ALLER A IMM, V94, P51, DOI 10.1159/000235323; KleinJan A, 1996, ALLERGY, V51, P614, DOI 10.1111/j.1398-9995.1996.tb02295.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MYGIND N, 1986, ESSENTIAL ALLERGY; NELSON H, 1989, PROVOCATIVE CHALLENG, P639; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; SHIMOJO N, 1992, INT ARCH ALLERGY IMM, V98, P135, DOI 10.1159/000236176; VANHOUTE AJ, 1992, EUR J CLIN CHEM CLIN, V30, P101; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WARBRICK EV, 1995, CELL IMMUNOL, V163, P222, DOI 10.1006/cimm.1995.1120; Warner JA, 1990, PAED ALLERGY IMMUNOL, V1, P34; WIDE L, 1967, LANCET, V2, P1105	24	45	47	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					515	521		10.1016/S0091-6749(97)70079-4	http://dx.doi.org/10.1016/S0091-6749(97)70079-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111497				2022-12-18	WOS:A1997WU27400015
J	Puerta, L; Caraballo, L; FernandezCaldas, E; Avjioglu, A; Marsh, DG; Lockey, RF; Dao, ML				Puerta, L; Caraballo, L; FernandezCaldas, E; Avjioglu, A; Marsh, DG; Lockey, RF; Dao, ML			Nucleotide sequence analysis of a complementary DNA coding for a Blomia tropicalis allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blomia tropicalis; recombinant allergens; cDNA sequence mite allergens	DUST MITES; IDENTIFICATION; SENSITIZATION; RECOGNITION; PEPTIDES; PROTEIN; SITE; IGE	Blomia tropicalis is a mite of allergenic importance in tropical and subtropical areas. A clone (Bt11a) from a B. tropicalis complementary DNA library was expressed in lambda phage and analyzed by plaque radioimmunoassay. The recombinant allergen produced by this clone was bound by IgE in 16 of 32 sera from individuals with asthma with a positive RAST response and none of 3 control sera from healthy individuals with negative RAST response to B. tropicalis. The cDNA insert was amplified by polymerase chain reaction with use of universal primers. A 582-base-pair (bp) fragment was cloned into a pCR II vector. The complete sequence of both strands was determined by using T7, SP6, and internal primers. The sequence shows a 432 bp reading frame with a 34 bp 5' untranslated region and a 116 bp 3' untranslated region with a poly A tail. Analysis of the sequence suggests that it encodes a putative signal peptide of 20 residues and a 124-residue mature protein allergen of 14,206 Da. The nucleotide and the inferred amino acid sequences did not show homology to any known sequence. No potential N-linked glycosylation site was found. The recombinant protein appears to represent a major allergen of the mite B. tropicalis.	UNIV CARTAGENA, IMMUNOL RES INST, CARTAGENA, COLOMBIA; UNIV S FLORIDA, COLL MED, TAMPA, FL USA; JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD USA	Universidad de Cartagena; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI19727] Funding Source: Medline; NIDCR NIH HHS [DEO7836] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R55AI019727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007836] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; BRONSWIJK JEM, 1973, ACAROLOGIA, V15, P477; CARABALLO L, 1994, CLIN EXP ALLERGY, V24, P1056, DOI 10.1111/j.1365-2222.1994.tb02743.x; CARABALLO L, IN PRESS J ALLERGY C; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; GABRIEL M, 1982, CLIN ALLERGY, V12, P157, DOI 10.1111/j.1365-2222.1982.tb01635.x; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HURTADO I, 1987, ANN ALLERGY, V59, P128; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PUERTA L, 1995, ALLERGY S, V50, P734; Sambrook J, 1989, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN HD, 1995, CLIN EXP ALLERGY, V25, P416, DOI 10.1111/j.1365-2222.1995.tb01072.x; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; [No title captured]	29	45	50	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				932	937		10.1016/S0091-6749(96)80009-1	http://dx.doi.org/10.1016/S0091-6749(96)80009-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939156	Bronze			2022-12-18	WOS:A1996VU76400009
J	Christiansen, SC; Martin, SB; Schleicher, NC; Koziol, JA; Hamilton, RG; Zuraw, BL				Christiansen, SC; Martin, SB; Schleicher, NC; Koziol, JA; Hamilton, RG; Zuraw, BL			Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; Hispanic; socioeconomic; environmental; mite; sensitization	HOUSEHOLD-DUST SAMPLES; UNITED-STATES; CHANGING PATTERNS; CHILDHOOD ASTHMA; MITES; HOSPITALIZATION; HYPERREACTIVITY; INFLAMMATION; MORTALITY; INFECTION	Background: Environmental living conditions co-sorting with economic status may influence the disease morbidity rate of childhood asthma in ethnic minority urban poor populations. Objectives: This study was carried out to assess exposure and sensitization to environmental allergens in southeast San Diego children with current asthma-related symptoms and to determine the utility of environmental control measures. Methods: Children, 9 to 12 years old, with current asthma-related symptoms were identified and enrolled at four school sites. Skin prick testing with aeroallergens was performed, and allergen in collected dust (from mattresses, pillows, and bedroom carpets) was quantified by enzyme immunoassay. Environmental control instruction and products were provided. Results: Of 41 subjects who underwent skin testing, 51.2% were reactive to environmental allergens (39% to mite, 22% to cockroach, and 9.8% to cat). Mean allergen levels for sensitized subjects were: Der p I (11 subjects), 18,722 ng/gm dust; Der f 1 (8 subjects), 5345 ng/gm dust; Fel d 1 (3 subjects), 214 ng/gm dust; Bla 1 (8 subjects), 7.15 U/gm dust; and Bla 2 (3 subjects) 7.13 U/gm dust. Environmental allergen exposure levels were not significantly different between sensitized and nonsensitized subjects. Environmental control measures for mite exposure were completed in six homes of sensitized subjects. One month after treatment, allergen levels fell 91.2% for Der p 1, 98.9% for Der f 1, and 88.2% for Fel d 1. One year after treatment, mite and cat allergen levels remained low. Environmental control had no consistent impact on cockroach allergen levels. Conclusion: Environmental allergen sensitization and exposure may be cofactors contributing to increased disease severity in urban poor populations.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA USA; JOHNS HOPKINS UNIV, CTR ASTHMA & ALLERGY, BALTIMORE, MD 21224 USA	Scripps Research Institute; Johns Hopkins University				Zuraw, Bruce/0000-0003-0640-6768	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32834] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHAPMAN MD, 1993, INSIGHTS ALLERGY, V8, P1; Christiansen SC, 1996, J ASTHMA, V33, P17, DOI 10.3109/02770909609077759; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EMPRY DW, 1976, AM REV RESPIR DIS, V113, P131; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823, DOI 10.1164/ajrccm/146.4.823; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Hamilton RG, 1992, IMMUNOL ALLERGY PRAC, V14, P9; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WILLIESJACOBO LJ, 1993, J ALLERGY CLIN IMMUN, V92, P630, DOI 10.1016/0091-6749(93)90090-3; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7; 1991, 913042 NIH	35	45	45	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					288	294		10.1016/S0091-6749(96)70152-5	http://dx.doi.org/10.1016/S0091-6749(96)70152-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757205				2022-12-18	WOS:A1996VC99500007
J	Tomassini, M; Magrini, L; DePetrillo, G; Adriani, E; Bonini, S; Balsano, F; Bonini, S				Tomassini, M; Magrini, L; DePetrillo, G; Adriani, E; Bonini, S; Balsano, F; Bonini, S			Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil cationic protein; allergic inflammation; eosinophils; perennial and seasonal allergens	CYTOKINE GENE-CLUSTER; BLOOD EOSINOPHILS; BRONCHIAL-ASTHMA; INDUCED INCREASE; ECP; HYPERRESPONSIVENESS; ACTIVATION; SECRETION; MUCOSA; FLUID	Background: Eosinophil cationic protein (ECP) is a cytotoxic preformed mediator stored in eosinophil granules and released under various in vitro and in vivo conditions. Objective: This study was carried out to evaluate the clinical value of ECP as a marker of allergic inflammation. Methods: ECP was measured by a competitive radioimmunoassay in serum samples from 265 patients and 45 matched control subjects and related to the type of allergic disease (asthma, rhinitis, conjunctivitis) and to the type of allergic sensitization. Results: All the patient groups studied showed significantly higher levels of serum ECP than control groups (p < 0.001). The type of sensitization was shown to be the only variable influencing ECP serum levels. In fact subjects sensitized to perennial allergens had significantly higher ECP values than subjects with seasonal allergy (p < 0.001), whereas in patients with seasonal allergy ECP levels were significantly increased only during the pollen season. Differences in ECP values between various allergic diseases ol age groups were only due to a nonhomogeneous distribution of the type of sensitization or to time of sera collection. Conclusions: Results obtained indicate that persistent natural exposure to a sensitizing allergen is responsible for a measurable increase in serum ECP levels in patients with allergy.	UNIV ROMA LA SAPIENZA, IST CLIN MED 1, I-00161 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT OPHTHALMOL, ROME, ITALY; UNIV NAPLES 2, DEPT CLIN IMMUNOL & ALLERGOL, NAPLES, ITALY	Sapienza University Rome; University of Rome Tor Vergata; Universita della Campania Vanvitelli			Bonini, Sergio/T-6594-2019; Bonini, Stefano/A-2250-2012	Bonini, Sergio/0000-0003-0079-3031; Bonini, Stefano/0000-0002-7787-2144				ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; ARAI K, 1992, ACI NEWS, V4, P113; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BONINI S, 1994, ALLERGY, V49, P6, DOI 10.1111/j.1398-9995.1994.tb04232.x; BOUSQUET J, 1991, INT ARCH ALLER A IMM, V94, P227, DOI 10.1159/000235367; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; CAPRON M, 1985, J IMMUNOL, V134, P3013; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; DAHL R, 1981, ALLERGY, V36, P129, DOI 10.1111/j.1398-9995.1981.tb04107.x; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DAHL R, 1989, EUR RESPIR J, V2, pS430; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; DVORAK AM, 1990, BLOOD CELL BIOCH, V2, P237; FUKUDA T, 1989, J ALLERGY CLIN IMMUN, V83, P369, DOI 10.1016/0091-6749(89)90120-6; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HALLGREN R, 1991, CLIN IMPACT MONITORI, P119; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REIMERT CM, 1991, J IMMUNOL METHODS, V138, P285, DOI 10.1016/0022-1759(91)90177-H; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; VENGE P, 1977, LANCET, V2, P373; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VENGE P, 1993, CLIN EXP ALLERGY, V23, P3, DOI 10.1111/j.1365-2222.1993.tb00372.x; VENGE P, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P175; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WINQVIST I, 1981, ALLERGY, V36, P419, DOI 10.1111/j.1398-9995.1981.tb01848.x; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	39	45	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1350	1355		10.1016/S0091-6749(96)70204-X	http://dx.doi.org/10.1016/S0091-6749(96)70204-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648032				2022-12-18	WOS:A1996VD60700024
J	CARRILLO, T; BLANCO, C; QUIRALTE, J; CASTILLO, R; CUEVAS, M; RODRIGUEZ, F				CARRILLO, T; BLANCO, C; QUIRALTE, J; CASTILLO, R; CUEVAS, M; RODRIGUEZ, F			PREVALENCE OF LATEX ALLERGY AMONG GREENHOUSE WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									HOSP RAMON Y CAJAL,SERV IMMUNOL,MADRID,SPAIN; HOSP INSULAR,SERV INMUNOL,LAS PALMAS,SPAIN; HOSP INSULAR,FAC CIENCIAS SALUD,SERV NEUMOL,LAS PALMAS,SPAIN	Hospital Universitario Ramon y Cajal	CARRILLO, T (corresponding author), HOSP UNIV NTRA SRA PINO,SECC ALERGIA,C ANGEL GUIMERA 93,E-35005 LAS PALMAS,SPAIN.		Blanco, Carlos/B-3895-2012; IBIS, ALERGICAS/C-1733-2016	Blanco, Carlos/0000-0002-2893-6594; 				BLANCO C, 1994, ANN ALLERGY, V73, P309; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V90, P279, DOI 10.1016/S0091-6749(05)80003-X; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0	5	45	45	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				699	701		10.1016/S0091-6749(95)70273-3	http://dx.doi.org/10.1016/S0091-6749(95)70273-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499691				2022-12-18	WOS:A1995TG52800020
J	PAGANELLI, R; SCALA, E; MEZZAROMA, I; PINTER, E; DOFFIZI, G; FANALESBELASIO, E; ROSSO, RM; ANSOTEGUI, IJ; PANDOLFI, F; AIUTI, F				PAGANELLI, R; SCALA, E; MEZZAROMA, I; PINTER, E; DOFFIZI, G; FANALESBELASIO, E; ROSSO, RM; ANSOTEGUI, IJ; PANDOLFI, F; AIUTI, F			IMMUNOLOGICAL ASPECTS OF HYPERIMMUNOGLOBULINEMIA E-LIKE SYNDROME IN PATIENTS WITH AIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIDS; HYPER-IGE; EOSINOPHILS; CD4; EOSINOPHIL CATIONIC PROTEIN; SOLUBLE CD23	VIRUS HIV INFECTION; T-CELL CLONES; ACQUIRED IMMUNODEFICIENCY SYNDROME; EOSINOPHIL CATIONIC PROTEIN; IMMUNE-DEFICIENCY SYNDROME; HUMAN B-CELLS; IGE SYNTHESIS; INTERFERON-GAMMA; SERUM IGE; HUMAN-LYMPHOCYTES	In this study we describe a series of nine patients affected by acquired immunodeficiency syndrome (AIDS) or AIDS-related complex who had hypereosinophilia and hyperimmunoglobulinemia E (hyper-IgE) with chronic dermatitis and recurrent staphylococcal infections. These patients had features similar to those present in hyper-IgE syndrome, a primary immunodeficiency disease. In addition, immunologic characterization of these patients with human immunodeficiency virus (HIV) infection, compared with 51 HIV-positive patients without hyper-IgE, both atopic and nonatopic, and three patients affected by the primary hyper-IgE syndrome also revealed art increase in IgA and a severe decrease in B and CD4+ lymphocytes. Spontaneous in vitro synthesis of IgE by peripheral blood mononuclear cells was confirmed in both hyper-IgE conditions together with increased levels of circulating eosinophil cationic protein. Serum-soluble CD23, usually increased in atopic conditions and hyper-IgE, was similar to that of normal control subjects in the HIV-positive patients with hyper-IgE. On the basis of our findings, we conclude that a hyper-Ige-like syndrome represents a distinct aspect of the clinical manifestations associated with HIV infection and that the immunologic mechanisms in this condition seem to differ from those known in primary hyper-IgE syndrome, because. CD4+ T-H2 type cells, which are currently believed to have a role in IgE production, are severely depleted in HN-positive patients.	UNIV ROMA LA SAPIENZA, DEPT ALLERGY & CLIN IMMUNOL, I-00185 ROME, ITALY; CATHOLIC UNIV ROME, DEPT SEMEIOT & METODOL MED, ROME, ITALY	Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			BELASIO, EMANUELE FANALES/C-7718-2016; Paganelli, Roberto/AAF-5712-2020; Pandolfi, Franco/D-3025-2011; Scala, Enrico/H-6997-2012	BELASIO, EMANUELE FANALES/0000-0003-2369-9996; Scala, Enrico/0000-0002-9391-9168; Pandolfi, Franco/0000-0003-3516-3961				AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; FREEDMAN AR, 1991, J EXP MED, V174, P1661, DOI 10.1084/jem.174.6.1661; GASCAN H, 1991, J IMMUNOL, V147, P8; Geha R S, 1989, Immunodefic Rev, V1, P155; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIN RY, 1988, ACTA DERM-VENEREOL, V68, P486; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MACCHIA D, 1991, J IMMUNOL, V146, P3413; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; PAGANELLI R, 1991, J ALLERGY CLIN IMMUN, V88, P416, DOI 10.1016/0091-6749(91)90107-Y; PAGANELLI R, 1991, CLIN EXP IMMUNOL, V84, P28; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REDDY MM, 1992, ANN ALLERGY, V69, P131; RICHARDS ML, 1991, CRIT REV IMMUNOL, V11, P65; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; WELLER PF, 1992, CURR OPIN IMMUNOL, V4, P782, DOI 10.1016/0952-7915(92)90062-J; WELLER PF, 1994, CURR OPIN IMMUNOL, V6, P85, DOI 10.1016/0952-7915(94)90038-8; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; 1986, MMWR-MORBID MORTAL W, V35, pN19	32	45	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				995	1003		10.1016/S0091-6749(95)70100-1	http://dx.doi.org/10.1016/S0091-6749(95)70100-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751521				2022-12-18	WOS:A1995QY91700011
J	PELUCCHI, A; CHIAPPARINO, A; MASTROPASQUA, B; MARAZZINI, L; HERNANDEZ, A; FORESI, A				PELUCCHI, A; CHIAPPARINO, A; MASTROPASQUA, B; MARAZZINI, L; HERNANDEZ, A; FORESI, A			EFFECT OF INTRANASAL AZELASTINE AND BECLOMETHASONE DIPROPIONATE ON NASAL SYMPTOMS, NASAL CYTOLOGY, AND BRONCHIAL RESPONSIVENESS TO METHACHOLINE IN ALLERGIC RHINITIS IN RESPONSE TO GRASS POLLENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEASONAL RHINITIS; AZELASTINE; BECLOMETHASONE DIPROPIONATE; NASAL LAVAGE; BRONCHIAL RESPONSIVENESS	HISTAMINE-RELEASE; SEASONAL INCREASE; DOUBLE-BLIND; HAY-FEVER; ASTHMA; EOSINOPHILS; INHIBITION; EXPOSURE; AEROSOL; MUCOSA	Background: We compared the effect of nasal azelastine (0.56 mg/day), nasal beclomethasone dipropionate (BDP, 200 mu g/day) and matched placebo on seasonal symptoms, nasal cytology, and the increase in bronchial responsiveness occurring during pollen season in a group of subjects with history of allergic rhinitis to grass pollens only. Methods: The study was completed by nine subjects in the azelastine group, 13 subjects in the BDP group, and 13 subjects in the placebo group. Treatments were randomly administered for 6 weeks. Each subject recorded daily nasal, eye and chest symptoms and additional treatment requirement for the entire pollen season. Each subject performed nasal lavage 4 weeks into the pollen season. Bronchial responsiveness to methacholine was measured before and 4 weeks into the pollen season. Response was expressed as provocative dose causing a 20% fall in forced expiratory volume in 1 second in micromoles. Results: Azelastine-treated subjects had significantly fewer nasal symptoms during week 4 (p < 0.05), and BDP-treated subjects had fewer nasal symptoms during week 4 (p < 0.05) and week 5 (p < 0.05) compared with subjects given placebo. Both treatments significantly reduced the need for additional medications. BDP, but not azelastine, treatment significantly reduced the percent of eosinophils recovered in nasal lavage (p < 0.05). Neither azelastine nor BDP protected against the increase in bronchial responsiveness to methacholine occurring during the pollen season. Conclusion: We demonstrated that both azelastine and BDP are effective treatments for nasal symptoms of seasonal allergic rhinitis after 4 weeks of therapy. However, we were not able to demonstrate an antiinflammatory activity of nasally administered azelastine. Nasal therapy with azelastine and BDP did not block the increase in bronchial responsiveness to methacholine caused by seasonal allergen exposure.	OSPED CITTA SESTO SAN GIOVANNI,SERV FISIOPATOL RESP G CAMPARI,I-20099 SESTO SAN GIOVANN,ITALY									ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911, DOI 10.1164/ajrccm/139.4.911; BALZANO G, 1992, CLIN EXP ALLERGY, V22, P371, DOI 10.1111/j.1365-2222.1992.tb03098.x; BOULET LP, 1989, ANN ALLERGY, V63, P114; BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; CARLSON M, 1992, J ALLERGY CLIN IMMUN, V89, P131, DOI 10.1016/S0091-6749(05)80050-8; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1989, INT ARCH ALLER A IMM, V90, P67, DOI 10.1159/000235002; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HONDA M, 1982, ALLERGY, V37, P41, DOI 10.1111/j.1398-9995.1982.tb04115.x; JOHNSON HG, 1992, AM REV RESPIR DIS, V146, P621, DOI 10.1164/ajrccm/146.3.621; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; LITTLE MM, 1989, AGENTS ACTIONS, V28, P16, DOI 10.1007/BF02022975; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MELTZER EO, 1987, ANN ALLERGY, V58, P281; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PELUCCHI A, 1992, EUR RESPIR J S15, V5, pS133; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123, DOI 10.1159/000234410; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; SIEGEL SC, 1982, J ALLERGY CLIN IMMUN, V69, P345, DOI 10.1016/0091-6749(82)90144-0; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; THOMAS KE, 1992, CLIN EXP ALLERGY, V22, P642, DOI 10.1111/j.1365-2222.1992.tb00182.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; 1989, ALLERGY S10, V444, P22	36	45	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					515	523		10.1016/S0091-6749(95)70313-6	http://dx.doi.org/10.1016/S0091-6749(95)70313-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852667				2022-12-18	WOS:A1995QH69700003
J	MELTZER, EO; ORGEL, HA; ROGENES, PR; FIELD, EA				MELTZER, EO; ORGEL, HA; ROGENES, PR; FIELD, EA			NASAL CYTOLOGY IN PATIENTS WITH ALLERGIC RHINITIS - EFFECTS OF INTRANASAL FLUTICASONE PROPIONATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; INTRANASAL CORTICOSTEROIDS; FLUTICASONE PROPIONATE; NASAL CYTOLOGY	BECLOMETHASONE DIPROPIONATE; MEDIATOR RELEASE; MAST-CELLS; SPRAY; CHALLENGE; EOSINOPHILIA; PRETREATMENT; SECRETIONS; SYMPTOMS; MUCOSA	Background: Nasal cytograms of patients with allergic rhinitis contain increased numbers of eosinophils and basophilic cells. Neutrophils are also more numerous in cytograms of allergic persons. Topical intranasal corticosteroid therapy for allergic rhinitis has been shown to decrease the numbers of some inflammatory cell types. Fluticasone propionate aqueous nasal spray, a potent synthetic corticosteroid preparation, is effective therapy for seasonal and perennial allergic rhinitis. Methods: Nasal mucosal scrapings were obtained with a Rhinoprobe (Apotex Scientific Inc. Arlington, Texas) before and after therapy with fluticasone propionate aqueous nasal spray at several doses in patients with either seasonal allergic rhinitis (2 to 4 weeks' therapy) or perennial allergic rhinitis (24 weeks' therapy). More than 1000 paired nasal cytograms obtained from patients participating in five multicenter studies were evaluated. Results: The percentage of patients with nasal eosinophils (p < 0.01, most studies) and basophilic cells (p < 0.05, most studies) decreased significantly after treatment with fluticasone propionate compared with placebo-treated patients. Similar findings were observed with beclomethasone dipropionate in one study. The number of neutrophils remained relatively unchanged after treatment with the intranasal corticosteroids or placebo. Conclusions: These findings suggest that the therapeutic benefits of topical intranasal fluticasone propionate and beclomethasone dipropionate for the therapy of seasonal and perennial allergic rhinitis are reflected by the decrease in inflammatory cells in the nasal mucosa.	GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	GlaxoSmithKline	MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR, 9610 GRANITE RIDGE DR, SUITE B, SAN DIEGO, CA 92123 USA.							ARBESMAN C, 1983, J ALLERGY CLIN IMMUN, V71, P597, DOI 10.1016/0091-6749(83)90442-6; BANOV C, IN PRESS ANN ALLERGY; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BROWN HM, 1977, BRIT J CLIN PHARMACO, V4, pS283, DOI 10.1111/j.1365-2125.1977.tb04522.x; CONNELL JT, 1983, ANN ALLERGY, V50, P227; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOCKHORN RJ, 1993, AM J RHINOL, V7, P77, DOI 10.2500/105065893781976519; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; HANSEL FK, 1966, ANN ALLERGY, V24, P564; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; JALOWAYSKI A A, 1991, Annals of Allergy, V66, P86; JALOWAYSKI AA, 1983, J ALLERGY CLIN IMMUN, V71, P89, DOI 10.1016/0091-6749(83)90125-2; KALINER MA, 1987, HOSP PRACT, V22, P73; KAPP JF, 1982, N ENGL SOC ALLERGY P, V3, P482; KAY AB, 1989, ALLERGY ASTHMA NEW T, P151; LANG DM, 1988, ANN ALLERGY, V60, P176; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MYGIND N, 1982, CLIN OTOLARYNGOL, V7, P343, DOI 10.1111/j.1365-2273.1982.tb01918.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NATHAN RA, 1991, ANN ALLERGY, V67, P332; OKUDA M, 1977, ARCH OTORHINOLARYNGO, V214, P253; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PELIKAN Z, 1983, J ALLERGY CLIN IMMUN, V72, P657, DOI 10.1016/0091-6749(83)90625-5; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; VANAS A, 1991, ANN ALLERGY, V67, P156; WELCH M J, 1991, Journal of Allergy and Clinical Immunology, V87, P144, DOI 10.1016/0091-6749(91)91306-E	40	45	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					708	715		10.1016/0091-6749(94)90178-3	http://dx.doi.org/10.1016/0091-6749(94)90178-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930304	Bronze			2022-12-18	WOS:A1994PM27300009
J	DIFELICE, G; CAIAFFA, MF; BARILETTO, G; AFFERNI, C; DIPAOLA, R; MARI, A; PALUMBO, S; TINGHINO, R; SALLUSTO, F; TURSI, A; MACCHIA, L; PINI, C				DIFELICE, G; CAIAFFA, MF; BARILETTO, G; AFFERNI, C; DIPAOLA, R; MARI, A; PALUMBO, S; TINGHINO, R; SALLUSTO, F; TURSI, A; MACCHIA, L; PINI, C			ALLERGENS OF ARIZONA CYPRESS (CUPRESSUS-ARIZONICA) POLLEN - CHARACTERIZATION OF THE POLLEN EXTRACT AND IDENTIFICATION OF THE ALLERGENIC COMPONENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CUPRESSUS ARIZONICA; ALLERGENS; CHARACTERIZATION; DIAGNOSIS; IGE; IGG; LECTINS; ELISA	CRYPTOMERIA-JAPONICA POLLEN; JAPANESE CEDAR POLLEN; CRY-J-I; CROSS-REACTIVITY; IGE ANTIBODIES; MAJOR ALLERGEN; MEDITERRANEAN AREA; INHALANT ALLERGENS; IGG4 ANTIBODIES; SEMPERVIRENS	Species of the Cupressaceae family are an important cause of respiratory allergies in countries with a Mediterranean climate. An allergenic extract from Cupressus arizonica pollen was prepared with two extraction steps followed by ammonium sulfate precipitation, giving a protein yield of about 3%. Cupressus arizonica pollen extract was also characterized by means of sodium dodecylsulfate-polyacrylamide gel electrophoresis, followed by IgE and IgG immunoblotting and lectin blotting. IgE reactivity was restricted to sir components, whereas IgG binding showed a more complex pattern. A 43 kd component, predominant both in ifs intensity and frequency of recognition by human IgE antibodies, was identified as the major allergen of C arizonica Four of the six IgE-binding components, including the major allergen, seem to be glycoproteins, as confirmed by the lectin blotting analysis. The extract produced inhouse was used to set up an immunoenzymatic test to evaluate the specific IgE binding in a panel of sera from 33 immunotherapy-free subjects who were monosensitized to cypress pollen. The percent of positivity obtained was much higher than that repelled in the literature for commercial immunoassays.	UNIV BARI,DEPT CLIN IMMUNOL & ALLEROGOL,BARI,ITALY	Universita degli Studi di Bari Aldo Moro	DIFELICE, G (corresponding author), IST SUPER SANITA,DEPT IMMUNOL,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		AFFERNI, CLAUDIA/B-9978-2016; Di Felice, Gabriella/B-9985-2016	AFFERNI, CLAUDIA/0000-0002-8567-7365; Di Felice, Gabriella/0000-0001-7387-9683; Macchia, Luigi/0000-0002-5896-086X				ANSARI AA, 1987, J IMMUNOL, V139, P4034; AUTERI P, 1989, MODERN TRENDS IMMUNO, P388; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIAFFA MF, 1993, ANN ALLERGY, V71, P45; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CALKHOVEN PG, 1991, CLIN EXP ALLERGY, V21, P91, DOI 10.1111/j.1365-2222.1991.tb00809.x; CALKHOVEN PG, 1991, CLIN EXP ALLERGY, V21, P99, DOI 10.1111/j.1365-2222.1991.tb00810.x; CORBI AL, 1985, INT ARCH ALLER A IMM, V77, P377, DOI 10.1159/000233812; DE CESARE F, 1993, ALLERGY, V48, P248; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GROSS GN, 1978, SCAND J IMMUNOL, V8, P437, DOI 10.1111/j.1365-3083.1978.tb00539.x; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUCCI N, 1992, ALLERGY, V47, P424, DOI 10.1111/j.1398-9995.1992.tb02083.x; ORDMAN D, 1945, S AFR MED J, V19, P142; PALUMBO S, 1994, ALLERGY, V49, P222, DOI 10.1111/j.1398-9995.1994.tb02653.x; PANZANI R, 1986, ANN ALLERGY, V56, P460; PANZANI R, 1986, ANN ALLERGY, V57, P26; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TANIAI M, 1988, FEBS LETT, V239, P329, DOI 10.1016/0014-5793(88)80945-1; TAS J, 1965, ACTA ALLERGOL, V20, P405, DOI 10.1111/j.1398-9995.1965.tb03073.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YOO TJ, 1975, ANN ALLERGY, V34, P87	31	45	45	4	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				547	555		10.1016/0091-6749(94)90212-7	http://dx.doi.org/10.1016/0091-6749(94)90212-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083460				2022-12-18	WOS:A1994PG90700015
J	PLATT, MS; YUNGINGER, JW; SEKULAPERLMAN, A; IRANI, AMA; SMIALEK, J; MIRCHANDANI, HG; SCHWARTZ, LB				PLATT, MS; YUNGINGER, JW; SEKULAPERLMAN, A; IRANI, AMA; SMIALEK, J; MIRCHANDANI, HG; SCHWARTZ, LB			INVOLVEMENT OF MAST-CELLS IN SUDDEN-INFANT-DEATH-SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SIDS; MAST CELL; TRYPTASE; ANAPHYLAXIS	MATERNAL SMOKING; GASTROESOPHAGEAL REFLUX; ANAPHYLAXIS; RISK; TRYPTASE; ANTIBODIES; IGE; POPULATION; ACTIVATION; CHILDREN	The pathogenesis of sudden infant death syndrome (SIDS) is elusive and probably multifactorial. The occurrence of mast cell activation in SIDS was assessed in this study by measuring concentrations of tryptase, a neutral protease produced mainly by mast cells, in postmortem sera from term infants with SIDS and from age-matched control infants who died unexpectedly at home from a known-cause. Tryptase levels were significantly higher in the 50 infants with SIDS than in the 15 control infants (p = 0.0004). Forty percent of the infants with SIDS and none of the control infants had a tryptase level greater than 10 ng/ml, the threshold chosen to indicate premortem mast cell activation. An infant with SIDS had a 20-fold higher chance of having an elevated tryptase level compared with a control infant. The postmortem interval did not influence these results. Thus mast cell-mediated anaphylaxis is likely to be the pathogenetic mechanism involved in some but not all SIDS cases. Recognition of this pathway as operative in SIDS should facilitate a more precise identification of the allergens involved, the processes leading to mast cell activation, and procedures to identify those infants at risk for anaphylaxis, and should, in time, lead to better therapeutic interventions aimed at preventing this specific cause of SIDS.	VIRGINIA COMMONWEALTH UNIV, DEPT PEDIAT, RICHMOND, VA 23298 USA; OFF CHIEF MED EXAMINER MARYLAND, BALTIMORE, MD USA; MAYO MED CTR, DEPT PEDIAT, ROCHESTER, MN USA; PHILADELPHIA MED EXAMINERS OFF, PHILADELPHIA, PA USA; VIRGINIA COMMONWEALTH UNIV, DEPT MED, RICHMOND, VA USA	Virginia Commonwealth University; Mayo Clinic; Virginia Commonwealth University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R01AI020487, R21AI020487] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20487, AI-0176] Funding Source: Medline; NICHD NIH HHS [HD-13138] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKER LE, 1990, CAN J NEUROL SCI, V17, P361, DOI 10.1017/S0317167100030894; BERNARD F, 1990, CLIN REV ALLERG, V8, P403; CLARK JW, 1979, J PEDIATR-US, V95, P85, DOI 10.1016/S0022-3476(79)80094-3; COOMBS RRA, 1990, CLIN EXP ALLERGY, V20, P359, DOI 10.1111/j.1365-2222.1990.tb02794.x; DELAGE C, 1972, Journal of Forensic Sciences, V17, P525; EMERY JL, 1974, P FE CAMPS INT S SUD, P7; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; GAULTIER CL, 1990, CLIN REV ALLERG, V8, P395; GILLETTE PC, 1992, CIRCULATION, V85, P64; GUNTHEROTH WG, 1989, J AM COLL CARDIOL, V14, P443, DOI 10.1016/0735-1097(89)90200-3; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; KINNEY HC, 1992, J NEUROPATH EXP NEUR, V51, P115, DOI 10.1097/00005072-199203000-00001; LUCET V, 1992, PRESSE MED, V21, P1896; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MARTINEZ FD, 1991, PEDIATRICS, V87, P190; MATTHEWS TG, 1992, ARCH DIS CHILD, V67, P654, DOI 10.1136/adc.67.5.654; MIRCHANDANI HG, 1984, J FORENSIC SCI, V29, P425; PARISH WE, 1964, INT ARCH ALLER A IMM, V24, P215, DOI 10.1159/000229462; PARISH WE, 1960, LANCET, V2, P1106; ROCHE WR, 1992, J CLIN PATHOL, V45, P46; ROGNUM TO, 1991, PEDIATRICS, V87, P306; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; VALDESDAPENA M, 1992, PATHOL ANNU, V27, P133; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; WILLINGER M, 1991, Pediatric Pathology, V11, P677; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678; ZEIGER RS, 1988, ALLERGY PRINCIPLES P, P930	37	45	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					250	256		10.1016/0091-6749(94)90047-7	http://dx.doi.org/10.1016/0091-6749(94)90047-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064077				2022-12-18	WOS:A1994PC92600016
J	PIERSON, WE; KOENIG, JQ				PIERSON, WE; KOENIG, JQ			RESPIRATORY EFFECTS OF AIR-POLLUTION ON ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DIOXIDE-INDUCED BRONCHOCONSTRICTION; SULFURIC-ACID AEROSOLS; WOOD-BURNING STOVES; PULMONARY-FUNCTION; ASTHMATIC SUBJECTS; NITROGEN-DIOXIDE; LUNG-FUNCTION; SHORT-TERM; BRONCHIAL RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE		UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIEHS NIH HHS [1 R01 ES 02366] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; AVOL EL, 1988, AM IND HYG ASSOC J, V49, P143, DOI 10.1202/0002-8894(1988)049<0143:LSOAVE>2.0.CO;2; AVOL EL, 1990, AM REV RESPIR DIS, V142, P343, DOI 10.1164/ajrccm/142.2.343; BARDANA EJ, 1991, ANN ALLERGY, V66, P441; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; BECKETT WS, 1985, J APPL PHYSIOL, V59, P1879, DOI 10.1152/jappl.1985.59.6.1879; BECKETT WS, 1991, YALE J BIOL MED, V64, P167; BENNETT R, 1990, THESIS U WASHINGTON; BETHEL RA, 1984, J APPL PHYSIOL, V57, P419, DOI 10.1152/jappl.1984.57.2.419; BUTTERFIELD P, 1989, J ENVIRON HEALTH, V52, P172; BYLIN G, 1985, EUR J RESPIR DIS, V66, P205; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CRAPO RO, 1987, AM REV RESPIR DIS, V135, P1221; CULLEN MR, 1990, NEW ENGL J MED, V322, P594, DOI 10.1056/NEJM199003013220905; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223, DOI 10.1080/00022470.1986.10466168; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937, DOI 10.1080/00022470.1982.10465494; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; DOCKERY DW, 1988, LUNG BIOL HLTH DIS, V43, P201; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; ESCHENBACHER WL, 1989, ATMOSPHERIC OZONE RE, P493; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; GERRITY TR, 1988, J APPL PHYSIOL, V65, P393, DOI 10.1152/jappl.1988.65.1.393; GONG H, 1988, ARCH ENVIRON HEALTH, V43, P46, DOI 10.1080/00039896.1988.9934373; GRAHAM D, 1988, ARCH ENVIRON HEALTH, V43, P228, DOI 10.1080/00039896.1988.9934938; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152, DOI 10.1164/ajrccm/142.1.152; HACKNEY JD, 1989, ATMOSPHERIC OZONE RE, P311; HANLEY QS, 1992, AM REV RESPIR DIS, V145, P326, DOI 10.1164/ajrccm/145.2_Pt_1.326; HAZUCHA MJ, 1989, J APPL PHYSIOL, V67, P1535, DOI 10.1152/jappl.1989.67.4.1535; HAZUCHA MJ, 1983, J APPL PHYSIOL, V54, P730, DOI 10.1152/jappl.1983.54.3.730; HENDERSON RF, 1989, CONCEPTS INHALATION, P415; HENDERSON WR, 1991, AM REV RESPIR DIS, V143, pS86, DOI 10.1164/ajrccm/143.5_Pt_2.S86; HIGHSMITH R, 1987, 1987 EPA APCA S MEAS; HILDEBRANDT J, 1989, TXB PHYSL, V2, P1002; HONICKY RE, 1985, PEDIATRICS, V75, P587; Horstman D. H., 1989, SUSCEPTIBILITY INHAL; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158, DOI 10.1164/ajrccm/142.5.1158; HULKA BA, 1986, ENV TABACCO SMOKE; HYNES B, 1988, ARCH ENVIRON HEALTH, V43, P357, DOI 10.1080/00039896.1988.9934949; Johnson K., 1990, J OFF STAT, V5, P391; KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124; KINNEY PL, 1989, AM REV RESPIR DIS, V139, P56, DOI 10.1164/ajrccm/139.1.56; KLEINMAN MT, 1983, J TOXICOL ENV HEALTH, V12, P815, DOI 10.1080/15287398309530472; KOENIG JQ, 1983, AM REV RESPIR DIS, V128, P221; KOENIG JQ, 1989, ENVIRON HEALTH PERSP, V79, P173, DOI 10.2307/3430546; KOENIG JQ, 1987, J ALLERGY CLIN IMMUN, V79, P54, DOI 10.1016/S0091-6749(87)80016-7; KOENIG JQ, 1992, J ALLERGY CLIN IMMUN, V89, P789, DOI 10.1016/0091-6749(92)90432-2; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; KOENIG JQ, 1991, J TOXICOL-CLIN TOXIC, V29, P401, DOI 10.3109/15563659109000366; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P897, DOI 10.1016/0091-6749(88)90947-5; KOENIG JQ, 1988, PEDIATR ASTHMA ALLER, V2, P199; KOENIG JQ, 1989, PEDIATR ASTHMA ALLER, V3, P147; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; LARSON TV, 1989, ENVIRON HEALTH PERSP, V79, P7, DOI 10.2307/3430525; LARSON TV, 1982, AM REV RESPIR DIS, V125, P502, DOI 10.1164/arrd.1982.125.5.502; LARSON TV, IN PRESS ADV CONTROL; LEWIS CW, 1988, ENVIRON SCI TECHNOL, V22, P968, DOI 10.1021/es00173a017; LEWTAS J, 1987, EPA APCA S MEASUREME; LINN WS, 1988, ARCH ENVIRON HEALTH, V43, P399, DOI 10.1080/00039896.1988.9935858; LIOY PJ, 1985, JAPCA J AIR WASTE MA, V35, P1068, DOI 10.1080/00022470.1985.10466008; LIPPMANN M, 1989, JAPCA J AIR WASTE MA, V39, P672, DOI 10.1080/08940630.1989.10466554; MCBRIDE DE, 1991, THESIS U WASHINGTON; MCDONNELL WF, 1991, EUR RESPIR J, V4, P279; MCMANUS MS, 1989, J ALLERGY CLIN IMMUN, V83, P619, DOI 10.1016/0091-6749(89)90074-2; MOHSENIN V, 1987, J TOXICOL ENV HEALTH, V22, P371, DOI 10.1080/15287398709531080; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MORGAN MS, 1986, J OCCUP ENVIRON MED, V28, P415, DOI 10.1097/00043764-198606000-00007; MORRIS K, 1990, AM J DIS CHILD, V144, P105, DOI 10.1001/archpedi.1990.02150250117047; MORROW PE, 1992, AM REV RESPIR DIS, V145, P291, DOI 10.1164/ajrccm/145.2_Pt_1.291; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1989, PEDIATRICS, V84, P451; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PERRY GB, 1983, AM J PUBLIC HEALTH, V73, P50, DOI 10.2105/AJPH.73.1.50; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SANDSTROM T, 1989, AM REV RESPIR DIS, V140, P1828, DOI 10.1164/ajrccm/140.6.1828; SCHWARTZ J, 1991, ENVIRON RES, V56, P1, DOI 10.1017/CBO9780511563980.002; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12, DOI 10.1093/oxfordjournals.aje.a116195; SCHWARTZ J, 1991, ENVIRON RES, V56, P204, DOI 10.1016/S0013-9351(05)80009-X; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; SPEIZER FE, 1966, ARCH ENVIRON HEALTH, V12, P725, DOI 10.1080/00039896.1966.10664471; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; SPEKTOR DM, 1985, ENVIRON RES, V37, P174, DOI 10.1016/0013-9351(85)90056-8; SPENGLER JD, 1989, ENVIRON HEALTH PERSP, V79, P43; TAM E, 1983, AM REV RESPIR DIS, V127, P257; Utell M, 1989, J AEROSOL MED, V2, P141; UTELL MJ, 1985, ENVIRON HEALTH PERSP, V63, P39, DOI 10.2307/3430027; UTELL MJ, 1984, JAPCA J AIR WASTE MA, V34, P931, DOI 10.1080/00022470.1984.10465838; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; WILLIAMS PV, 1992, AM J ASTHMA ALLERGY, V5, P1; 1989, BIOMARKERS PULMONARY; 1982, EPA600882; 1992, JAMA-J AM MED ASSOC, V339, P396	108	45	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				557	566		10.1016/0091-6749(92)90128-O	http://dx.doi.org/10.1016/0091-6749(92)90128-O			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401639	Bronze			2022-12-18	WOS:A1992JT99500001
J	VANDENPLAS, O; CARTIER, A; LESAGE, J; PERRAULT, G; GRAMMER, LC; MALO, JL				VANDENPLAS, O; CARTIER, A; LESAGE, J; PERRAULT, G; GRAMMER, LC; MALO, JL			OCCUPATIONAL ASTHMA CAUSED BY A PREPOLYMER BUT NOT THE MONOMER OF TOLUENE DIISOCYANATE (TDI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; OCCUPATIONAL ASTHMA; BRONCHIAL PROVOCATION TESTS; ISOCYANATES	ISOCYANATE-INDUCED ASTHMA; TOLUENE DIISOCYANATE; ANTIBODIES; HISTAMINE; REACTIVITY; DIAGNOSIS; DISEASE; VOLUME; TESTS; MDI	Isocyanates are the most common cause of occupational asthma. Isocyanate monomers and prepolymers are widely used in the manufacture of polyurethane compounds. However, prepolymers are generating increasing interest because of their lower volatility. No distinction has yet been made between asthmatic reactions caused by the monomers and the prepolymers of isocyanates, and asthmatic reactions caused by one type of isocyanate but not the other type have not been reported. We describe two wood-roof maintenance workers who developed asthma after being exposed to a varnish containing a prepolymer of toluene diisocyanate (TDI) with only small amounts of the monomer. Specific inhalation-challenge tests with the TDI monomer did not elicit significant airway obstruction, whereas exposure to the varnish and to the purified TDI prepolymer induced late asthmatic reactions. Specific antibodies against TDI monomer human serum albumin and TDI prepolymer human serum albumin conjugates could not be demonstrated. These observations demonstrate that isocyanate prepolymers can cause occupational asthma and that asthmatic reactions caused by isocyanate prepolymers, but not to the corresponding monomer, can occur in some exposed workers.	SACRE COEUR HOSP, DEPT CHEST MED, 5400 GOUIN W, MONTREAL H4J 1C5, QUEBEC, CANADA; INST RECH SANTE & SECUR TRAVAIL, MONTREAL, QUEBEC, CANADA; NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, OCCUPAT MED SECT, CHICAGO, IL 60611 USA	Universite de Montreal; Northwestern University; Northwestern University				Grammer, Leslie/0000-0001-6860-2014				AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; BANKS DE, 1989, CHEST, V95, P414, DOI 10.1378/chest.95.2.414; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BELIN L, 1981, SCAND J WORK ENV HEA, V7, P310, DOI 10.5271/sjweh.2543; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; GERBLICH AA, 1979, J ALLERGY CLIN IMMUN, V64, P658, DOI 10.1016/0091-6749(79)90032-0; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; HARDY DL, 1979, ANN OCCUP HYG, V22, P421; INNOCENTI A, 1988, CLIN ALLERGY, V18, P323, DOI 10.1111/j.1365-2222.1988.tb02879.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAGIER F, 1990, REV MAL RESPIR, V7, P337; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MAPP CE, 1988, EUR RESPIR J, V1, P273; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MUSK AW, 1988, AM J IND MED, V13, P331, DOI 10.1002/ajim.4700130304; NIELSEN J, 1985, SCAND J WORK ENV HEA, V11, P51, DOI 10.5271/sjweh.2253; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V72, P676, DOI 10.1016/0091-6749(83)90628-0; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; SCHAUERTE K, 1985, SONDERDRUCK OERTEL P, P41; SEGUIN P, 1987, J OCCUP ENVIRON MED, V29, P340; 1987, AM REV REPSIR DIS, V136, P1285	29	45	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1183	1188		10.1016/0091-6749(92)90303-J	http://dx.doi.org/10.1016/0091-6749(92)90303-J			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1318888				2022-12-18	WOS:A1992HZ74800014
J	LAUBE, BL; NORMAN, PS; ADAMS, GK				LAUBE, BL; NORMAN, PS; ADAMS, GK			THE EFFECT OF AEROSOL DISTRIBUTION ON AIRWAY RESPONSIVENESS TO INHALED METHACHOLINE IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AEROSOL DISTRIBUTION; AIRWAY REACTIVITY; METHACHOLINE; ASTHMA	HEALTHY-SUBJECTS; SALINE AEROSOL; DEPOSITION; OBSTRUCTION; HISTAMINE	It has been demonstrated that airway deposition of inhaled aerosols is more heterogeneous in patients with asthma than in normal subjects. Nevertheless, the influence of abnormal airway deposition on responses to bronchoactive aerosols is poorly understood. We altered bronchopulmonary deposition heterogeneity of methacholine aerosol in nine asymptomatic patients with asthma by controlling inspiratory flow at high (approximately 60 L/min) versus low (approximately 12 L/min) rates on 2 study days and determined the effect on the provocative dose of methacholine causing a 20% fall in FEV1 (PD20) (often used as a measure of airway responsiveness). Deposition uniformity was quantified from gamma-camera scans of the lungs in terms of the distribution of a technetium-labeled aerosol that was inhaled rapidly or slowly before the inhalation of methacholine. Increased deposition in an inner (large, central airways) versus an outer (peripheral airways and alveoli) zone of the right lung (inner/outer ratio, > 1) and higher values of skew (an index of deposition asymmetry) and kurtosis (an index of deposition range) indicated enhanced heterogeneity of deposition. Mean (+/- SD) inner/outer ratio was significantly higher during rapid inspiration compared to slow inspiration with 2.91 +/- 0.51 and 1.84 +/- 0.30, respectively (p < 0.01). Mean skew and kurtosis were also significantly higher after rapid inspiration, with 1.12 +/- 0.35 and 3.86 +/- 1.25, respectively, compared to 0.74 +/- 0.36 and 2.64 +/- 0.77 after slow inhalation (p < 0.01). Geometric mean PD20 methacholine was significantly reduced when the aerosol was inhaled rapidly, with 5.9 cumulative methacholine units compared to 15.7 units after slow inhalation (p < 0.02). A Spearman's rank-correlation test demonstrated that values of skew and kurtosis were inversely correlated with PD20 methacholine (p < 0.02; r(s) = -0.55 and -0.60, respectively). Results from these studies indicate that increased heterogeneity in aerosol deposition significantly decreases PD20 methacholine in patients with asthma.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University	LAUBE, BL (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,615 N WOLFE ST,ROOM 2001,BALTIMORE,MD 21205, USA.				PHS HHS [A120136] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGNEW JE, 1984, CLIN SCI, V66, P525, DOI 10.1042/cs0660525; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1988, EUR RESPIR J, V1, P890; COATES G, 1985, CLIN NUCL MED, V10, P835, DOI 10.1097/00003072-198512000-00001; DOLOVICH MB, 1976, J APPL PHYSIOL, V40, P468, DOI 10.1152/jappl.1976.40.3.468; DONNA E, 1989, J ALLERGY CLIN IMMUN, V83, P456, DOI 10.1016/0091-6749(89)90133-4; GILLETT MK, 1989, AM REV RESPIR DIS, V140, P1727, DOI 10.1164/ajrccm/140.6.1727; JAMES AL, 1987, AM REV RESPIR DIS, V135, P87; LAUBE BL, 1984, AEROSOL SCI TECH, V3, P97, DOI 10.1080/02786828408958997; LAUBE BL, 1988, J NUCL MED, V29, P1057; LAUBE BL, 1986, AM REV RESPIR DIS, V133, P740; LIPPMANN M, 1971, INHALED PARTICLES, V13, P105; MACEY DJ, 1982, J NUCL MED, V23, P731; MERCER TT, 1973, ARCH INTERN MED, V131, P39, DOI 10.1001/archinte.131.1.39; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; SMALDONE GC, 1988, J AEROSOL MED, V1, P113; STROHL KP, 1981, J APPL PHYSIOL, V50, P575, DOI 10.1152/jappl.1981.50.3.575; THOMSON ML, 1974, ARCH ENVIRON HEALTH, V29, P214, DOI 10.1080/00039896.1974.10666571; WANNER A, 1985, AM REV RESPIR DIS, V131, P3; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3	20	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					510	518		10.1016/0091-6749(92)90317-U	http://dx.doi.org/10.1016/0091-6749(92)90317-U			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740581				2022-12-18	WOS:A1992HD75300002
J	BOCHNER, BS; FRIEDMAN, B; KRISHNASWAMI, G; SCHLEIMER, RP; LICHTENSTEIN, LM; KROEGEL, C				BOCHNER, BS; FRIEDMAN, B; KRISHNASWAMI, G; SCHLEIMER, RP; LICHTENSTEIN, LM; KROEGEL, C			EPISODIC EOSINOPHILIA-MYALGIA LIKE SYNDROME IN A PATIENT WITHOUT L-TRYPTOPHAN USE - ASSOCIATION WITH EOSINOPHIL ACTIVATION AND INCREASED SERUM LEVELS OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL ACTIVATION; MYALGIA; GM-CSF	INTERLEUKIN-5; INGESTION; CYTOKINES; DENSITY; INJURY; CELLS; BLOOD	We have studied a patient with recurrent bouts of angioedema, myalgia, and eosinophilia that was not due to L-tryptophan ingestion. Peripheral blood eosinophils (EOSs) during exacerbations of his illness displayed characteristics of "activation," including hypodense phenotype and increased responsiveness to platelet-activating factor (PAF) in vitro with respect to expression of CD11b surface adhesion proteins. Elevated serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) bioactivity were also detected, whereas interleukin-3 and interleukin-5 levels were not increased. During treatment with glucocorticoids, all clinical symptoms resolved, EOSs decreased in number and became normodense, PAF responsiveness diminished, and GM-CSF levels returned to normal. During glucocorticoid tapering, a subsequent clinical relapse was again associated with EOS hypodensity, increased PAF responsiveness, and increased serum GM-CSF levels. Although this patient satisfies the diagnostic criteria for eosinophilia-myalgia syndrome, the episodic and profound nature of exacerbations and response to therapy in the absence of L-tryptophan usage suggests a possible overlap with the syndrome of episodic angioedema and eosinophilia. In vitro studies suggest that GM-CSF may play a role in the eosinophilia, EOS activation, and pathophysiology of disease in this patient and demonstrate resolution of these abnormalities during glucocorticoid therapy. The efficacy of glucocorticoid therapy in some hypereosinophilic states may therefore be mediated, at least in part, via reduction of GM-CSF production and/or EOS activation.			BOCHNER, BS (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,UNIT OFF 3,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.				NIAID NIH HHS [AI20136, AI27429, AI08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI008270, R29AI027429, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; DONAHUE RE, 1986, NATURE, V321, P872, DOI 10.1038/321872a0; FRIEDMAN B, 1990, J ALLERGY CLIN IMMUN, V85, P223; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GLEICH G J, 1990, Journal of Allergy and Clinical Immunology, V85, P253; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HARTNELL A, 1990, IMMUNOLOGY, V69, P264; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KITA H, 1991, FASEB J, V5, P641; LAMAS AM, 1991, J IMMUNOL, V147, P254; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; RUGHAVACHER A, 1987, J IMMUNOL, V139, P3753; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLADEK GD, 1983, J RHEUMATOL, V10, P467; SPRY CJF, 1988, EOSINOPHILS COMPREHE, P263; TOMIOKA K, 1991, FASEB J, V5, P640	27	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					629	636		10.1016/0091-6749(91)90157-J	http://dx.doi.org/10.1016/0091-6749(91)90157-J			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918729				2022-12-18	WOS:A1991GL04900012
J	STEPHAN, V; ZIMMERMANN, A; KUHR, J; URBANEK, R				STEPHAN, V; ZIMMERMANN, A; KUHR, J; URBANEK, R			DETERMINATION OF N-METHYLHISTAMINE IN URINE AS AN INDICATOR OF HISTAMINE-RELEASE IN IMMEDIATE ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TAU-METHYLHISTAMINE; COLD URTICARIA	The use of urine histamine metabolite, N-methylhistamine (N-MH), as a parameter of histamine release in immediate allergic reactions was investigated. Baseline levels were determined in 34 normal control subjects and 29 atopic patients. Increases of urine N-MH values were measured during histamine infusions and in venom-allergic patients receiving bee-sting challenges. N-MH was determined by a newly developed radioimmunoassay. Baseline levels in control subjects and atopic patients demonstrated no significant differences. With regard to challenge tests, fluctuation of N-MH levels during a 6-hour period was measured. Random 6-hour increases in health and atopic subjects ranged from 5% to 41%. Before infusion of histamine (0.25-mu-g/kg/min for 30 minutes), baseline values were 137 +/- 11.4-mu-g N-MH per gram of creatinine and 9 +/- 1.1-mu-g N-MH per hour (n = 9). Levels peaked 1 hour after infusion at 275 +/- 45-mu-g/gm of creatinine and 44 +/- 5.6-mu-g/hr and decreased to resting levels after 2 hours. Metabolization by N-MH accounted for 9.5% +/- 4.9% (range, 2.4% to 18.4%) of infused histamine in the urine of the nine subjects. Bee-sting challenges were performed in 12 patients and three control subjects. Only in three patients experiencing generalized urticaria, nausea, dyspnea, and hypotension were significant increases of urine N-MH levels (138%, 144%, and 238%) observed. All other patients and three normal control subjects demonstrated normal local reactions without increase of N-MH values. Thus, excretion of N-MH in urine reflected increased histaminemia in histamine infusions and provided a useful index of histamine release into the circulation in patients exhibiting immediate allergic reactions after bee-sting challenges. Easy accessibility, the possibility of retrospective analysis, and the high metabolization rate of histamine to N-MH suggest the use of this parameter for evaluation of histamine release in humans.	UNIV FREIBURG, TROP AGR, W-7800 FREIBURG, GERMANY	University of Freiburg								Beaven M A, 1978, Monogr Allergy, V13, P1; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DEVALIA JL, 1985, J CHROMATOGR, V343, P407, DOI 10.1016/S0378-4347(00)84610-1; GRANERUS G, 1980, ALLERGY, V35, P31, DOI 10.1111/j.1398-9995.1980.tb01714.x; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KAPELLERADLER R, 1950, Q J EXP PHYSL, V35, P281; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KEYZER JJ, 1983, J CHROMATOGR, V275, P261, DOI 10.1016/S0378-4347(00)84373-X; KEYZER JJ, 1985, AGENTS ACTIONS, V16, P76, DOI 10.1007/BF01983105; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MITCHELL RG, 1974, J ALLERGY CLIN IMMUN, V54, P111, DOI 10.1016/0091-6749(74)90039-6; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; PORTER JF, 1970, CLIN SCI, V38, P135, DOI 10.1042/cs0380135; SCHAYER RW, 1956, J APPL PHYSIOL, V9, P481, DOI 10.1152/jappl.1956.9.3.481; SCHWARTZ GJ, 1976, J PEDIATR-US, V88, P828, DOI 10.1016/S0022-3476(76)81125-0; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TIETZ NW, 1976, FUNDAMENTALS CLIN CH, P994; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	20	45	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				862	868		10.1016/S0091-6749(05)80147-2	http://dx.doi.org/10.1016/S0091-6749(05)80147-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	1702126				2022-12-18	WOS:A1990EQ04500005
J	DABROWSKI, AJ; VANDERBREMPT, X; SOLER, M; SEGURET, N; LUCCIANI, P; CHARPIN, D; VERVLOET, D				DABROWSKI, AJ; VANDERBREMPT, X; SOLER, M; SEGURET, N; LUCCIANI, P; CHARPIN, D; VERVLOET, D			CAT SKIN AS AN IMPORTANT SOURCE OF FEL D I ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,DEPT MALAD RESP,BP 29,F-13277 MARSEILLE 9,FRANCE; HOP ST MARGUERITE,IMMUNOL LAB,F-13277 MARSEILLE 9,FRANCE; CNRS,NEUROSCI FONCT LAB,SERV CHIRURG ANIM,F-13003 MARSEILLE,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS)			VAN DER BREMPT, Xavier/GLT-1646-2022					ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; MULLER GH, 1975, DERMATOLOGIE PETITS, V27, P31; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V	13	45	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				462	465		10.1016/S0091-6749(05)80200-3	http://dx.doi.org/10.1016/S0091-6749(05)80200-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229808				2022-12-18	WOS:A1990EG45400004
J	VICHYANOND, P; IRVIN, CG; LARSEN, GL; SZEFLER, SJ; HILL, MR				VICHYANOND, P; IRVIN, CG; LARSEN, GL; SZEFLER, SJ; HILL, MR			PENETRATION OF CORTICOSTEROIDS INTO THE LUNG - EVIDENCE FOR A DIFFERENCE BETWEEN METHYLPREDNISOLONE AND PREDNISOLONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,PEDIAT PULM & CRIT CARE MED SECT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005842] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NCRR NIH HHS [S07RR05842] Funding Source: Medline; NHLBI NIH HHS [HL 36577] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALABASTER VA, 1977, METABOLIC FUNCTIONS, P3; ARNOUX B, 1982, AM REV RESPIR DIS, V125, pA50; BARTOSZEK M, 1987, CLIN PHARMACOL THER, V42, P424, DOI 10.1038/clpt.1987.173; BRAUDE AC, 1982, ANN INTERN MED, V97, P59, DOI 10.7326/0003-4819-97-1-59; BRAUDE AC, 1983, LANCET, V2, P995; EBLING WF, 1986, J PHARM SCI, V75, P760, DOI 10.1002/jps.2600750807; EBLING WF, 1985, DRUG METAB DISPOS, V13, P296; EBLING WF, 1984, J CHROMATOGR, V305, P271, DOI 10.1016/S0378-4347(00)83342-3; FELS AOS, 1986, J APPL PHYSIOL, V60, P353, DOI 10.1152/jappl.1986.60.2.353; GROSS NJ, 1987, DRUG THERAPY ASTHMA, P615; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KEOGH BA, 1983, AM REV RESPIR DIS, V127, P18, DOI 10.1164/arrd.1983.127.1.18; KHALAFALLAH N, 1984, J PHARMACOL EXP THER, V229, P719; KLEIN JO, 1986, PEDIATRICS S, V78, P970; MARCY TW, 1987, AM REV RESPIR DIS, V135, P1276; MORLEY J, 1981, LYMPHOKINES, V4, P377; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; OZAKI T, 1982, CLIN EXP IMMUNOL, V47, P505; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; ROCCI ML, 1981, J PHARM SCI, V79, P1201; STUTMAN HR, 1987, J PEDIATR-US, V110, P812, DOI 10.1016/S0022-3476(87)80031-8; SZEFLER SJ, 1986, EUR J CLIN PHARMACOL, V30, P323, DOI 10.1007/BF00541537; TOUTAIN PL, 1986, J PHARMACOL EXP THER, V236, P794	25	45	47	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				867	873		10.1016/0091-6749(89)90381-3	http://dx.doi.org/10.1016/0091-6749(89)90381-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600321				2022-12-18	WOS:A1989CG29300002
J	GOETZ, DW; JACOBSON, JM; MURNANE, JE; REID, MJ; REPPERGER, DW; GOODYEAR, C; MARTIN, ME				GOETZ, DW; JACOBSON, JM; MURNANE, JE; REID, MJ; REPPERGER, DW; GOODYEAR, C; MARTIN, ME			PROLONGATION OF SIMPLE AND CHOICE REACTION-TIMES IN A DOUBLE-BLIND COMPARISON OF TWICE-DAILY HYDROXYZINE VERSUS TERFENADINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ARMSTRONG AEROSP MED RES LAB,DAYTON,OH		GOETZ, DW (corresponding author), WILFORD HALL USAF MED CTR,SGHMMA,DEPT MED,LACKLAND AFB,TX 78236, USA.							BETTS T, 1984, BRIT MED J, V288, P281, DOI 10.1136/bmj.288.6413.281; BUCKLEY CE, 1988, ANN ALLERGY, V60, P123; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; COWART V, 1985, JAMA-J AM MED ASSOC, V254, P15, DOI 10.1001/jama.254.1.15; GOETZ DW, 1988, J ALLERGY CLIN IMMUN, V81, P227, DOI 10.1016/0091-6749(88)90471-X; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; JACOBSON JM, 1986, PERCEPT MOTOR SKILL, V62, P195, DOI 10.2466/pms.1986.62.1.195; KULSHRESTHA VK, 1978, BRIT J CLIN PHARMACO, V6, P25, DOI 10.1111/j.1365-2125.1978.tb01677.x; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; NICHOLSON AN, 1979, BRIT J CLIN PHARMACO, V8, P321, DOI 10.1111/j.1365-2125.1979.tb04712.x; NICHOLSON AN, 1986, EUR J CLIN PHARMACOL, V30, P27, DOI 10.1007/BF00614191; NICHOLSON AN, 1985, AVIAT SPACE ENVIR MD, V56, P293; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; PECK AW, 1975, EUR J CLIN PHARMACOL, V8, P455, DOI 10.1007/BF00562321; REPPERGER DW, 1985, J MED ENG TECHNOL, V9, P220; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5	17	45	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					316	322		10.1016/0091-6749(89)90414-4	http://dx.doi.org/10.1016/0091-6749(89)90414-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2570798				2022-12-18	WOS:A1989AR19900007
J	LITTLE, MM; CASALE, TB				LITTLE, MM; CASALE, TB			AZELASTINE INHIBITS IGE-MEDIATED HUMAN BASOPHIL HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,IOWA CITY,IA 52242; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	LITTLE, MM (corresponding author), UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007260] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07260] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CONNELL JT, 1985, ANN ALLERGY, V55, P392; DANIELS C, 1986, EUR J PHARMACOL, V123, P463, DOI 10.1016/0014-2999(86)90725-9; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FISCHER B, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1193; KATAYAMA S, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1196; LITTLE MM, IN PRESS AGENTS ACTI; MAGNUSSEN H, 1987, CHEST, V91, P855, DOI 10.1378/chest.91.6.855; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; NACLERIO RM, 1986, CLIN ALLERGY, V16, P101, DOI 10.1111/j.1365-2222.1986.tb00753.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1983, OTORHINOLARYNGOLOGY, V26, P81; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; Patterson Jr MK, 1973, TISSUE CULTURE METHO, P406; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SKOOG WA, 1956, BLOOD, V11, P436, DOI 10.1182/blood.V11.5.436.436; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; TASAKA K, 1979, ARZNEIMITTEL-FORSCH, V29-1, P488; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	22	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					862	865		10.1016/0091-6749(89)90096-1	http://dx.doi.org/10.1016/0091-6749(89)90096-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2469707				2022-12-18	WOS:A1989U716100002
J	HAUS, M; HEESE, HD; WEINBERG, EG; POTTER, PC; HALL, JM; MALHERBE, D				HAUS, M; HEESE, HD; WEINBERG, EG; POTTER, PC; HALL, JM; MALHERBE, D			THE INFLUENCE OF ETHNICITY, AN ATOPIC FAMILY HISTORY, AND MATERNAL ASCARIASIS ON CORD BLOOD-SERUM IGE CONCENTRATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									S AFRICAN MED RES COUNCIL, INST BIOSTAT, CAPE TOWN, SOUTH AFRICA; UNIV CAPE TOWN, INST CHILD HLTH, DEPT PAEDIAT & CHILD HLTH, CAPE TOWN, SOUTH AFRICA; UNIV CAPE TOWN, DEPT CLIN SCI & IMMUNOL, CAPE TOWN, SOUTH AFRICA	South African Medical Research Council; University of Cape Town; University of Cape Town								BAHNA SL, 1980, ALLERGIES MILK, P1; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BAZARAL M, 1971, J IMMUNOL, V107, P794; BJORKSTEN B, 1983, 11 P INT C ALL CLIN, P139; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; Cooke RA, 1916, J IMMUNOL, V1, P201; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; DUBOWITZ L, 1970, J PEDIATR, V1, P77; DUCHATEAU J, 1983, LANCET, V1, P413; GANJU A, 1979, ANN ALLERGY, V43, P271; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HEESE HD, 1985, J TROP PEDIATRICS, V31, P48, DOI 10.1093/tropej/31.1.48; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; KAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P90, DOI 10.1016/0091-6749(79)90042-3; KAY AB, 1985, ADV ALLERGOLOGY APPL, P205; KJELLMAN NI, 1982, P INT ALLERGY WORKSH; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1983, SKANDIA INT S THEORE, P52; KUROUME T, 1976, ANN ALLERGY, V37, P41; LEVIN S, 1971, PEDIATR RES, V5, P87, DOI 10.1203/00006450-197102000-00028; MAGNUSSON CGM, 1984, 1984 INT S PREV ALL, P35; MANSFIELD LE, 1978, ANN ALLERGY, V41, P155; MATTHEW DJ, 1977, LANCET, V1, P321; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MICHEL FB, 1980, INT ALLERGY S, P35; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; MILNER V, 1971, S AFR MED J, V43, P683; MOLKHOU P, 1987, 1987 ANN M EUR AC AL, P185; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; OPREE W, 1972, ACTA ALLERGOL, V27, P247, DOI 10.1111/j.1398-9995.1972.tb01423.x; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; ORREN A, 1975, S AFR MED J, V49, P1387; ORREN A, 1975, INT ARCH ALLER A IMM, V48, P874; PAUWELS R, 1979, INT ARCH ALLER A IMM, V58, P351, DOI 10.1159/000232212; REED CE, 1983, ALLERGY PRINCIPLES P, V2, P811; ROUSSEAUXPREVOST R, 1977, IMMUNOLOGY, V33, P501; ROWE DS, 1972, LANCET, V2, P1232; SHULMAN G, 1976, S AFR MED J, V50, P1465; SOOTHILL JF, 1976, P ROY SOC MED, V69, P439, DOI 10.1177/003591577606900617; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; TURNER KJ, 1974, INT ARCH ALLER A IMM, V47, P650, DOI 10.1159/000231257; VANARSDEL PP, 1959, ACTA GENET, V8, P101; VANASPEREN PP, 1984, ACTA PAEDIATR SCAND, V73, P80; VANNIEKERK CH, 1979, THESIS U CAPE TOWN C; VANRIJSWIJK AW, 1985, S AFR MED J, V68, P925; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; [No title captured]	55	45	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					179	189		10.1016/0091-6749(88)90997-9	http://dx.doi.org/10.1016/0091-6749(88)90997-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403861				2022-12-18	WOS:A1988P874100007
J	SKONER, DP; DOYLE, WJ; FIREMAN, P				SKONER, DP; DOYLE, WJ; FIREMAN, P			EUSTACHIAN-TUBE OBSTRUCTION (ETO) AFTER HISTAMINE NASAL PROVOCATION - A DOUBLE-BLIND DOSE-RESPONSE STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,CHILDRENS HOSP,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016337] Funding Source: NIH RePORTER; NCRR NIH HHS [3M01 RR00084-23S1] Funding Source: Medline; NINDS NIH HHS [5 P01 NS 16337] Funding Source: Medline; PHS HHS [R01 A119262] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; BERNSTEIN JM, 1983, AM J OTOL, V5, P66; BLUESTONE CD, 1975, HDB CLIN IMPEDANCE A, P127; CASSELBRANT ML, 1985, LARYNGOSCOPE, V95, P428; DOYLE WJ, 1984, ARCH OTOLARYNGOL, V110, P508; DOYLE WJ, 1985, J ALLERGY CLIN IMMUN, V76, P551, DOI 10.1016/0091-6749(85)90774-2; FRIEDMAN PA, 1983, J ALLERGY CLIN IMMUN, V71, P442; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; TSAY YG, 1984, BOOK ABSTRACTS, pW20; WALKER SB, 1985, J ALLERGY CLIN IMMUN, V76, P158, DOI 10.1016/0091-6749(85)90694-3; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	15	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					27	31		10.1016/S0091-6749(87)80012-X	http://dx.doi.org/10.1016/S0091-6749(87)80012-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805544				2022-12-18	WOS:A1987F881000008
J	BOUSQUET, J; KJELLMAN, NIM				BOUSQUET, J; KJELLMAN, NIM			PREDICTIVE VALUE OF TESTS IN CHILDHOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN	Linkoping University	BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,F-34000 MONTPELLIER,FRANCE.							BASUYAU JP, 1977, NOUV PRESSE MED, V9, P591; BJORKSTEN B, 1983, IMMUNOL TODAY, V4, P215, DOI 10.1016/0167-5699(83)90029-4; BJORKSTEN B, 1983, ADV PEDIATRIC ALLERG, P19; BJORKSTEN B, 1983, 11 P INT C ALL CLIN, P145; BOUSQUET J, 1983, ANN ALLERGY, V51, P291; BOUSQUET J, 1983, ADV PEDIATRIC ALLERG, P55; BRATCHEL R, 1979, HUM GENET, V49, P337; BROCARD M, 1982, REV FR ALLERGOL, V22, P25, DOI 10.1016/S0335-7457(82)80044-0; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; Casimir G, 1983, Rev Med Brux, V4, P323; CASIMIR G, 1983, LANCET, V1, P413; CHANDRA RK, 1983, LANCET, V2, P1393; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; de Weck A L, 1977, Monogr Allergy, V11, P3; DEMONTIS G, 1981, ANN ALLERGY, V47, P171; DEMONTIS G, 1979, NOUV PRESSE MED, V78, P3665; DRY L, 1980, ADV ALLERGY APPL IMM, P779; DUTAU G, 1979, ARCH FR PEDIATR, V36, P795; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; GERRARD JW, 1979, ANN ALLERGY, V42, P69; GERRARD JW, 1976, ANN ALLERGY, V36, P10; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; GRUNDBACHER FJ, 1976, J ALLERGY CLIN IMMUN, V57, P218; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HESKEL N, 1983, CLIN RES, V31, P573; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; HOFFMANN JJML, 1981, CLIN ALLERGY, V11, P555, DOI 10.1111/j.1365-2222.1981.tb02174.x; JUTO P, 1980, J ALLERGY CLIN IMMUN, V66, P402, DOI 10.1016/0091-6749(80)90120-7; KATZ RM, 1976, J ALLERGY CLIN IMMUN, V57, P41, DOI 10.1016/0091-6749(76)90077-4; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KEMP AS, 1979, MED J AUSTRALIA, V1, P263, DOI 10.5694/j.1326-5377.1979.tb112072.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KJELLMAN NIM, 1982, ALLERGY, V67, P463; MAGNUSSON C, 1984, JUN INT S PREV ALL D; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MORRISONSMITH J, 1979, CLIN ALLERGY, V9, P153; Ringel KP, 1982, LABORATORIUMSBLATTER, V32, P26; ROBERT J, 1979, REV FR ALLERGOL, V19, P153, DOI 10.1016/S0335-7457(79)80021-0; ROSE R, 1976, PLANT PHYSIOL, V57, P41, DOI 10.1104/pp.57.1.41; SAARINEN UM, 1979, LANCET, V2, P163; SCHWARTZ RH, 1977, J ALLERGY CLIN IMMUN, V59, P31, DOI 10.1016/0091-6749(77)90173-7; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SOOTHILL JF, 1982, CLIN IMMUNOL ALLERGY, V2, P243; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; Souillet G, 1976, Pediatrie, V31, P57; SZCEKLIK A, 1974, AM REV RESPIR DIS, V109, P487; THOMAS J, 1979, ANN ALLERGY, V43, P144; WELIKY N, 1981, J ALLERGY CLIN IMMUN, V67, P104; YOUNG P, 1980, NIH PUBLICATION, V30, P388	56	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1019	1022		10.1016/0091-6749(86)90296-4	http://dx.doi.org/10.1016/0091-6749(86)90296-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537085	Bronze			2022-12-18	WOS:A1986E971900017
J	MCFADDEN, ER				MCFADDEN, ER			CLINICAL PHYSIOLOGICAL CORRELATES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University	MCFADDEN, ER (corresponding author), CASE WESTERN RESERVE UNIV HOSP,CTR ASTHMA & ALLERG DIS,DEPT MED,2074 ABINGTON RD,CLEVELAND,OH 44106, USA.							ADAMS F, 1856, EXTANT WORKS ARETAEU, P316; APPEL D, 1983, AM J MED, V75, P580, DOI 10.1016/0002-9343(83)90436-9; BANNER AS, 1976, JAMA-J AM MED ASSOC, V235, P1337, DOI 10.1001/jama.235.13.1337; BONDI E, 1977, NEW YORK STATE J MED, V77, P350; BRENNER BE, 1983, AM J MED, V74, P1005, DOI 10.1016/0002-9343(83)90802-1; CADE JF, 1971, CLIN SCI, V40, P381, DOI 10.1042/cs0400381; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FISCHL MA, 1981, NEW ENGL J MED, V305, P783, DOI 10.1056/NEJM198110013051402; GELB AF, 1979, J ALLERGY CLIN IMMUN, V64, P18, DOI 10.1016/0091-6749(79)90077-0; GROSSMAN J, 1976, J ALLERGY CLIN IMMUN, V57, P310, DOI 10.1016/0091-6749(76)90087-7; KELSEN SG, 1978, AM J MED, V64, P622, DOI 10.1016/0002-9343(78)90582-X; KNOWLES GK, 1973, LANCET, V2, P1356; MARTIN TG, 1982, ANN EMERG MED, V11, P466, DOI 10.1016/S0196-0644(82)80063-2; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1975, NEW ENGL J MED, V292, P555, DOI 10.1056/NEJM197503132921103; MCFADDEN ER, 1975, J ALLERGY CLIN IMMUN, V56, P18, DOI 10.1016/0091-6749(75)90030-5; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1969, J APPL PHYSIOL, V27, P452, DOI 10.1152/jappl.1969.27.4.452; MCFADDEN ER, 1983, ALLERGY PRINCIPLES P, P843; MIYAMOTO T, 1970, J ALLERGY, V45, P248, DOI 10.1016/0021-8707(70)90135-8; NOGRADY SG, 1977, THORAX, V32, P559, DOI 10.1136/thx.32.5.559; NOWAK RM, 1982, ANN EMERG MED, V11, P64, DOI 10.1016/S0196-0644(82)80298-9; NOWAK RM, 1979, JACEP-J AM COLL EMER, V8, P9, DOI 10.1016/S0361-1124(79)80439-6; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; REES HA, 1968, Q J MED, V37, P541; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; RUBINFELD AR, 1976, LANCET, V1, P882; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; TAI E, 1967, LANCET, V1, P644; WENG TR, 1970, AM REV RESPIR DIS, V101, P274; WENG TR, 1969, AM REV RESPIR DIS, V99, P719	35	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				1	5		10.1016/0091-6749(86)90313-1	http://dx.doi.org/10.1016/0091-6749(86)90313-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944367				2022-12-18	WOS:A1986AZD3600001
J	SPRINGER, C; GOLDENBERG, B; BENDOV, I; GODFREY, S				SPRINGER, C; GOLDENBERG, B; BENDOV, I; GODFREY, S			CLINICAL, PHYSIOLOGIC, AND PSYCHOLOGIC COMPARISON OF TREATMENT BY CROMOLYN OR THEOPHYLLINE IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HADASSAH UNIV HOSP,DEPT PEDIAT,POB 24035,IL-91240 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,DEPT CHILD PSYCHIAT,IL-91240 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								BENDOV I, 1982, AM REV RESPIR DIS, V125, P530, DOI 10.1164/arrd.1982.125.5.530; BENTON AL, 1963, REVISED VISUAL RETEN; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; DUNLEAVY RA, 1980, J CONSULT CLIN PSYCH, V48, P214, DOI 10.1037/0022-006X.48.2.214; DUNLEAVY RG, 1981, J CLIN NEUROPSYCHOL, V3, P9; FEUERSTEIN R, 1979, DYNAMIC ASSESSMENT R, P148; FIRESTONE P, 1979, J ABNORM CHILD PSYCH, V7, P261, DOI 10.1007/BF00916536; FURUKAWA CT, 1984, LANCET, V1, P621; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; Godfrey S, 1974, EXERCISE TESTING CHI; GOLDSTEIN A, 1965, J PHARMACOL EXP THER, V150, P146; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HAMBLETON G, 1977, LANCET, V1, P381; MCCARTHY MM, 1981, PEDIATRICS, V68, P749; MCWHIRTER JJ, 1977, LEARNING DISABLED CH; MURPHY M, 1980, BRIT MED J, V15, P281; PEPYS J, 1968, LANCET, V2, P134; PORTEUS SD, 1965, MAZE TEST CLIN PSYCH; Rall T. W., 1980, PHARMACOL BASIS THER, P592; REITAN RM, 1944, TRAIL MAKING TEST US; REY A, 1966, TROUBLES MEMOIRE EXA; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; SUESS WM, 1981, J CONSULT CLIN PSYCH, V49, P135, DOI 10.1037/0022-006X.49.1.135; WASSER WG, 1981, ANN INTERN MED, V95, P191, DOI 10.7326/0003-4819-95-2-191; Wechsler D, 1977, WECHSLER INTELLIGENC; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; YELLIN AM, 1980, RES COMMUN PSYCH PSY, V5, P137; [No title captured]	31	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					64	69		10.1016/0091-6749(85)90806-1	http://dx.doi.org/10.1016/0091-6749(85)90806-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AMV84	3924984				2022-12-18	WOS:A1985AMV8400009
J	SZCZEKLIK, A; NIZANKOWSKA, E; CZERNIAWSKAMYSIK, G; SEK, S				SZCZEKLIK, A; NIZANKOWSKA, E; CZERNIAWSKAMYSIK, G; SEK, S			HYDROCORTISONE AND AIR-FLOW IMPAIRMENT IN ASPIRIN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTI-INFLAMMATORY DRUGS; INTRAVENOUS HYDROCORTISONE; CORTICOSTEROIDS		REG CLIN PULM DIS, Krakow, POLAND		SZCZEKLIK, A (corresponding author), COPERNICUS ACAD MED, DEPT ALLERGY & CLIN IMMUNOL, SKAWINSKA 8, PL-31-066 KRAKOW, POLAND.							DAJANI BM, 1981, J ALLERGY CLIN IMMUN, V68, P201, DOI 10.1016/0091-6749(81)90184-6; Di Rosa M, 1984, Prostaglandins, V28, P441, DOI 10.1016/0090-6980(84)90232-6; DUGUE P, 1977, B EUR PHYSIOPATH RES, V13, P619; ELLULMIC.R, 1972, CLIN SCI, V43, pP15; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; FLOWER R, 1981, TRENDS PHARMACOL SCI, V2, P186, DOI 10.1016/0165-6147(81)90307-2; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KAY AB, 1983, STEROIDS ASTHMA, P46; KING RA, 1960, LANCET, V2, P1093; KOUNIS NG, 1976, ANN ALLERGY, V36, P203; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; OGARRA JA, 1962, BMJ-BRIT MED J, P615, DOI 10.1136/bmj.1.5278.615; PARTRIDGE MR, 1978, BRIT MED J, V1, P1521, DOI 10.1136/bmj.1.6126.1521; RAMSDELL JW, 1983, J ALLERGY CLIN IMMUN, V72, P69, DOI 10.1016/0091-6749(83)90054-4; SCHMITZSCHUMANN M, 1982, PRAX KLIN PNEUMOL, V36, P17; SETTIPANE GA, 1983, AM J MED, V74, P102, DOI 10.1016/0002-9343(83)90537-5; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1983, DRUGS, V25, P533, DOI 10.2165/00003495-198325060-00001; VANARSDEL PP, 1984, J ALLERGY CLIN IMMUN, V73, P431, DOI 10.1016/0091-6749(84)90351-8; WEVER AMJ, 1981, EUR J RESPIR DIS, V62, P127	25	45	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					530	536		10.1016/0091-6749(85)90771-7	http://dx.doi.org/10.1016/0091-6749(85)90771-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056240				2022-12-18	WOS:A1985ATH6600002
J	KRILIS, S; BALDO, BA; SUTTON, R; BASTEN, A				KRILIS, S; BALDO, BA; SUTTON, R; BASTEN, A			ANTIGENS AND ALLERGENS FROM THE COMMON HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS .1. DEMONSTRATION OF MULTIPLE ALLERGENS BY IMMUNOCHEMICAL AND BIOLOGIC ANALYSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SYDNEY,CLIN IMMUNOL RES CTR,SYDNEY,NSW 2006,AUSTRALIA; ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA; CSIRO,WHEAT RES UNIT,N RYDE,NSW 2113,AUSTRALIA	University of Sydney; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Sutton, Rosemary/J-3784-2014	Sutton, Rosemary/0000-0002-0188-6005				AAS K, 1972, ACTA ALLERGOL, V27, P439; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; Baldo B A, 1981, Contemp Top Mol Immunol, V8, P41; BALDO BA, 1976, EXPERIENTIA, V32, P641, DOI 10.1007/BF01990210; BALDO BA, 1982, INT ARCH ALLER A IMM, V68, P295, DOI 10.1159/000233117; BALDO BA, 1977, CLIN ALLERGY, V7, P429, DOI 10.1111/j.1365-2222.1977.tb01474.x; BALDO BA, 1979, NATURWISSENSCHAFTEN, V66, P623, DOI 10.1007/BF00405134; BALDO BA, 1980, ALLERGY, V35, P45, DOI 10.1111/j.1398-9995.1980.tb01716.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; DUCROS DL, 1979, J SCI FOOD AGR, V30, P785, DOI 10.1002/jsfa.2740300807; HOLFORDSTREVENS DV, 1970, ANALES MED, V61, P370; KABASAWA Y, 1979, JPN J EXP MED, V49, P51; KABASAWA Y, 1976, ACTA ALLERGOL, V31, P442, DOI 10.1111/j.1398-9995.1976.tb01494.x; KRILIS S, 1981, INT ARCH ALLER A IMM, V66, P252, DOI 10.1159/000232912; KRILIS S, 1979, NATURWISSENSCHAFTEN, V66, P475, DOI 10.1007/BF00399012; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MIYAMOTO T, 1969, J ALLERGY, V44, P282, DOI 10.1016/0021-8707(69)90033-1; NAKAGAWA T, 1977, INT ARCH ALLER A IMM, V55, P47, DOI 10.1159/000231907; PEPYS J, 1968, LANCET, V1, P1270; PORTER MC, 1971, CHEM TECH, V1, P440; ROMAGNANI S, 1976, INT ARCH ALLER A IMM, V50, P525, DOI 10.1159/000231557; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P275, DOI 10.1038/icb.1980.27; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; STEWART GA, 1980, CLIN ALLERGY, V10, P617, DOI 10.1111/j.1365-2222.1980.tb02144.x; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; SVENDSEN PJ, 1973, SCAND J IMMUNOL, V2, P69, DOI 10.1111/j.1365-3083.1973.tb03781.x; TAYLOR KM, 1980, INT ARCH ALLER A IMM, V61, P19, DOI 10.1159/000232410; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voorhorst R., 1964, Allergie Asthma, V10, P329; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WIDE L, 1967, LANCET, V2, P1105; WINTER A, 1975, PREPARATIVE FLATBED, P198; WRIGHT GLT, 1975, MED J AUSTRALIA, V1, P375, DOI 10.5694/j.1326-5377.1975.tb111453.x	43	45	45	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					132	141		10.1016/0091-6749(84)90275-6	http://dx.doi.org/10.1016/0091-6749(84)90275-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747134				2022-12-18	WOS:A1984TE22600003
J	DOR, PJ; VERVLOET, D; SAPENE, M; ANDRAC, L; BONERANDI, JJ; CHARPIN, J				DOR, PJ; VERVLOET, D; SAPENE, M; ANDRAC, L; BONERANDI, JJ; CHARPIN, J			INDUCTION OF LATE CUTANEOUS REACTION BY KALLIKREIN INJECTION - COMPARISON WITH ALLERGIC-LIKE LATE RESPONSE TO COMPOUND-48-80	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR HOSP RENNES,RENNES,FRANCE; HOP ST MARGUERITE,SERV DERMATOL,F-13009 MARSEILLE,FRANCE	CHU Rennes; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	DOR, PJ (corresponding author), HOP ST MARGUERITE,SERV PNEUMOPHTYSIOL ALLERGOL,F-13009 MARSEILLE,FRANCE.							BECKER CG, 1981, BLOOD, V58, P861; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; ERDOS EG, 1976, BIOCHEM PHARMACOL, V25, P1563, DOI 10.1016/0006-2952(76)90465-2; FREY EK, 1968, KALLIKREIN KININ SYS, P10; GALLIN JI, 1974, J IMMUNOL, V113, P1928; GOFFIN JC, 1970, J BELG RADIOL, V53, P300; GRIFFIN JH, 1975, MOL BIOL ASPECTS ACU, P371; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HALONEN M, 1975, J IMMUNOL, V115, P519; HAVEZ R, 1966, CR ACAD SCI PARIS, V262, P1778; JUHLIN L, 1969, ACTA DERM-VENEREOL, V48, P26; Kaplan A P, 1977, Monogr Allergy, V12, P120; KUTZBACH C, 1972, H-S Z PHYSIOL CHEM, V353, P1099, DOI 10.1515/bchm2.1972.353.2.1099; LEWIS AJ, 1976, EUR J PHARMACOL, V40, P1, DOI 10.1016/0014-2999(76)90347-2; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; NEWBALL HH, 1981, INT ARCH ALLER A IMM, V66, P165, DOI 10.1159/000232894; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PEPYS J, 1968, EXCERPTA MED INT C S, V162, P221; PINCKARD RN, 1975, J IMMUNOL, V115, P525; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; Pupil P, 1976, Ann Anesthesiol Fr, V17, P199; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VOORHORST R, 1979, ANN ALLERGY, V42, P185	32	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					363	370		10.1016/0091-6749(83)90063-5	http://dx.doi.org/10.1016/0091-6749(83)90063-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6187790				2022-12-18	WOS:A1983QL12100002
J	GEORGITIS, JW; REISMAN, RE; CLAYTON, WF; MUELLER, UR; WYPYCH, JI; ARBESMAN, CE				GEORGITIS, JW; REISMAN, RE; CLAYTON, WF; MUELLER, UR; WYPYCH, JI; ARBESMAN, CE			LOCAL INTRANASAL IMMUNOTHERAPY FOR GRASS-ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY, ALLERGY RES LAB, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [2R01 AI01303-24] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; COOK N, 1974, Journal of Laryngology and Otology, V88, P1169, DOI 10.1017/S0022215100079901; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P197, DOI 10.1016/0091-6749(72)90083-8; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P467; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V65, P191; MEHTA S B, 1975, Clinical Allergy, V5, P279; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1	11	45	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					71	76		10.1016/0091-6749(83)90549-3	http://dx.doi.org/10.1016/0091-6749(83)90549-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6337198	Bronze			2022-12-18	WOS:A1983PZ46100011
J	KOEPKE, JW; SELNER, JC; DUNHILL, AL				KOEPKE, JW; SELNER, JC; DUNHILL, AL			PRESENCE OF SULFUR-DIOXIDE IN COMMONLY USED BRONCHODILATOR SOLUTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PRESBYTERIAN ST LUKES MED CTR,DEPT MED,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								FRANK NR, 1969, ARCH ENVIRON HEALTH, V18, P315, DOI 10.1080/00039896.1969.10665414; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; PRENNER BM, 1976, ANN ALLERGY, V37, P180; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6	9	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					504	508		10.1016/0091-6749(83)90588-2	http://dx.doi.org/10.1016/0091-6749(83)90588-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6630799				2022-12-18	WOS:A1983RR91600012
J	MURRAY, AB; FERGUSON, AC				MURRAY, AB; FERGUSON, AC			DIAGNOSIS OF HOUSE DUST MITE ALLERGY IN ASTHMATIC-CHILDREN - WHAT CONSTITUTES A POSITIVE HISTORY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT PAEDIAT,DIV ALLERGY,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				BERNSTEIN L, 1978, ALLERGY PRINCIPLES P, P743; BULLOCK JD, 1972, AM J DIS CHILD, V123, P222, DOI 10.1001/archpedi.1972.02110090092010; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; CHAI H, 1976, LANCET, V1, P649; COLLINSWILLIAMS C, 1976, ANN ALLERGY, V37, P12; GERVAIS P, 1977, J ALLERGY CLIN IMMUN, V59, P207, DOI 10.1016/0091-6749(77)90151-8; GODFREY RC, 1976, CLIN ALLERGY, V6, P79, DOI 10.1111/j.1365-2222.1976.tb01415.x; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HETZEL MR, 1977, THORAX, V32, P418, DOI 10.1136/thx.32.4.418; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MITCHELL EA, 1980, LANCET, V2, P559; MORRISONSMITH J, 1970, ACTA ALLERGOL, V25, P37; MORRISONSMITH J, 1969, BRIT MED J, V2, P723; MURRAY AB, 1980, ANN ALLERGY, V45, P347; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MURRAY AB, 1981, CLIN ALLERGY, V11, P87, DOI 10.1111/j.1365-2222.1981.tb01570.x; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; MURRAY AB, 1983, PEDIATRICS; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SIEGEL SC, 1978, ALLERGY PRINCIPLES P, P708; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; TOVEY E, 1979, CLIN ALLERGY, V9, P253, DOI 10.1111/j.1365-2222.1979.tb01551.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WARNER JO, 1978, ARCH DIS CHILD, V53, P710, DOI 10.1136/adc.53.9.710; 1979, BR J DIS CHEST, V73, P260; 1974, LANCET, V2, P1492	28	45	45	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					21	28		10.1016/0091-6749(83)90542-0	http://dx.doi.org/10.1016/0091-6749(83)90542-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6822690	Bronze			2022-12-18	WOS:A1983PZ46100004
J	REBUCK, AS; GENT, M; CHAPMAN, KR				REBUCK, AS; GENT, M; CHAPMAN, KR			ANTICHOLINERGIC AND SYMPATHOMIMETIC COMBINATION THERAPY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University	REBUCK, AS (corresponding author), UNIV TORONTO,TORONTO WESTERN HOSP,DIV RESP MED,TORONTO M5T 2S8,ONTARIO,CANADA.							AJEWSKI Z, 1979, SCAND J RESP DIS S, V103, P205; BAIGELMAN W, 1977, CHEST, V71, P324, DOI 10.1378/chest.71.3.324; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; INGRAM RH, 1977, NEW ENGL J MED, V297, P596; KALINER M, 1977, J ALLERGY CLIN IMMUN, V60, P204, DOI 10.1016/0091-6749(77)90125-7; KREISMAN H, 1981, THORAX, V36, P387, DOI 10.1136/thx.36.5.387; LICHTERFELD A, 1979, SCAND J RESPIR DIS S, V103, P143; LIGHTBODY IM, 1978, BRIT J DIS CHEST, V72, P181, DOI 10.1016/0007-0971(78)90039-6; MARINI JJ, 1981, CHEST, V80, P285, DOI 10.1378/chest.80.3.285; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PAKES GE, 1980, DRUGS, V20, P237, DOI 10.2165/00003495-198020040-00001; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; RUFFIN RE, 1982, J ALLERGY CLIN IMMUN, V69, P60, DOI 10.1016/0091-6749(82)90089-6; RUFFIN RE, 1977, J ALLERGY CLIN IMMUN, V59, P136, DOI 10.1016/0091-6749(77)90215-9; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; VINCENT NJ, 1970, J APPL PHYSIOL, V29, P236, DOI 10.1152/jappl.1970.29.2.236; WEBBJOHNSON DC, 1977, NEW ENGL J MED, V297, P476; WILDBOLZ U, 1977, LUNG, V154, P141; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; 1962, AM REV RESPIR DIS, V85, P762	24	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					317	323		10.1016/0091-6749(83)90086-6	http://dx.doi.org/10.1016/0091-6749(83)90086-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6219156				2022-12-18	WOS:A1983QH18800008
J	ATKINS, PC; ZWEIMAN, B				ATKINS, PC; ZWEIMAN, B			MEDIATOR RELEASE IN LOCAL HEAT URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [AI-14322-04] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BAER RL, 1978, IMMUNOLOGIC DISEASES, P1020; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DELARINE P, 1969, J ALLERGY, V43, P284; DEMARAGAS JM, 1973, ARCH DERMATOL, V108, P684; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V67, P75, DOI 10.1016/0091-6749(81)90049-X; GREAVES MW, 1974, BRIT J DERMATOL, V90, P289, DOI 10.1111/j.1365-2133.1974.tb06404.x; LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x; LEWIS GM, 1939, ARCH DERM SYPH SOC T, V39, P365; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; STARR JC, 1980, ANN ALLERGY, V44, P164; TENNENBA.JI, 1973, J ALLERGY CLIN IMMUN, V51, P57, DOI 10.1016/0091-6749(73)90009-2; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WISE RD, 1978, ARCH DERMATOL, V114, P1079, DOI 10.1001/archderm.114.7.1079; WUTHRICH B, 1979, DERMATOLOGICA, V159, P371	20	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					286	289		10.1016/0091-6749(81)90153-6	http://dx.doi.org/10.1016/0091-6749(81)90153-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	7288047				2022-12-18	WOS:A1981ML52500007
J	DORSCH, W; RING, J				DORSCH, W; RING, J			INDUCTION OF LATE CUTANEOUS REACTIONS BY SKIN-BLISTER FLUID FROM ALLERGEN-TESTED AND NORMAL SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MUNICH,DEPT DERMATOL,D-8000 MUNICH 2,FED REP GER	University of Munich	DORSCH, W (corresponding author), UNIV MUNICH,KINDER POLIKLIN,D-8000 MUNICH 2,FED REP GER.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BORK K, 1978, ARCH DERMATOL RES, V263, P91, DOI 10.1007/BF00446858; BROCKLEHURST WE, 1971, P ROY SOC MED, V64, P4, DOI 10.1177/003591577106400102; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DEWECK A, 1974, PRAKTISCHE ALLERGIED, P71; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1980, PRAX KLIN PNEUMOL, V34, P461; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; GOLDYNE ME, 1973, PROSTAG OTH LIPID M, V4, P737, DOI 10.1016/S0090-6980(73)80058-9; GREAVES MW, 1971, BMJ-BRIT MED J, V2, P258, DOI 10.1136/bmj.2.5756.258; HADDING U, 1977, Z IMMUNITATSFORSCH S, V2, P14; PATTERSO.R, 1965, J CLIN INVEST, V44, P140, DOI 10.1172/JCI105120; PEPYS J, 1973, ALLERGOLOGY, P84; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RATNOFF OD, 1977, J ALLERGY CLIN IMMUN, V58, P438; RATNOFF OD, 1971, THROMB DIATH HAEMO, V45, P109; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P66; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1976, J INVEST DERMATOL, V67, P313, DOI 10.1111/1523-1747.ep12514349; STRANDBERG K, 1977, INT ARCH ALLER A IMM, V53, P520, DOI 10.1159/000231794; TURNERWARWICK M, 1978, IMMUNOLOGY LUNG, P53; UMEMOTO L, 1975, J ALLERGY CLIN IMMUN, V55, P112; VANE JR, 1976, ADV PROSTAG THROMB R, V2, P791; VERMEER BJ, 1979, J INVEST DERMATOL, V73, P303, DOI 10.1111/1523-1747.ep12531833; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	28	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					117	123		10.1016/0091-6749(81)90006-3	http://dx.doi.org/10.1016/0091-6749(81)90006-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451778				2022-12-18	WOS:A1981LB94700006
J	WEILERRAVELL, D; GODFREY, S				WEILERRAVELL, D; GODFREY, S			DO EXERCISE-INDUCED AND ANTIGEN-INDUCED ASTHMA UTILIZE THE SAME PATHWAYS - ANTIGEN PROVOCATION IN PATIENTS RENDERED REFRACTORY TO EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HEBREW UNIV JERUSALEM,HADASSAH HOSP & MED SCH,DEPT PEDIAT,JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BLACKHALL MI, 1969, DISODIUM CROMOGLYCAT, P63; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1972, J ALLERGY CLIN IMMUN, V50, P57, DOI 10.1016/0091-6749(72)90079-6; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1977, ASTHMA, P56; GODFREY S, 1975, ACTA ALLERGOLOGICA S, V12, P51; HARGREAVE FE, 1969, DISODIUM CROMOGLYCAT, P27; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MORSE JLC, 1976, AM REV RESPIR DIS, V113, P89; MORTON AR, 1973, ANN ALLERGY, V31, P265; MUITTARI A, 1969, BRIT MED J, V4, P170, DOI 10.1136/bmj.4.5676.170-a; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; SEALE JP, 1977, AUST NZ J MED, V7, P270, DOI 10.1111/j.1445-5994.1977.tb03685.x; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; SLY RM, 1975, ANN ALLERGY, V34, P7; SLY RM, 1971, ANN ALLERGY, V29, P362; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; [No title captured]	27	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					391	397		10.1016/0091-6749(81)90085-3	http://dx.doi.org/10.1016/0091-6749(81)90085-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7194892	Bronze			2022-12-18	WOS:A1981LQ56300010
J	ASKENASE, PW				ASKENASE, PW			BASOPHIL ARRIVAL AND FUNCTION IN TISSUE HYPERSENSITIVITY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ASKENASE, PW (corresponding author), YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510, USA.							ALLEN J R, 1973, International Journal for Parasitology, V3, P195, DOI 10.1016/0020-7519(73)90024-6; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; ASKENASE PW, 1976, J IMMUNOL, V117, P741; ASKENASE PW, 1977, AM J TROP MED HYG, V26, P96, DOI 10.4269/ajtmh.1977.26.96; ASKENASE PW, 1978, IMMUNOLOGY, V35, P741; ASKENASE PW, 1973, J EXP MED, V138, P1144, DOI 10.1084/jem.138.5.1144; ASKENASE PW, 1976, J CLIN INVEST, V58, P1145, DOI 10.1172/JCI108567; ASKENASE PW, 1975, NATURE, V256, P52, DOI 10.1038/256052a0; ASKENASE PW, 1976, CLIN EXP IMMUNOL, V23, P318; ASKENASE PW, 1978, J IMMUNOL, V120, P198; ASKENASE PW, 1979, FED PROC, V38, P1221; ASKENASE PW, 1976, J IMMUNOL, V117, P1722; ASKENASE PW, UNPUBLISHED; AVELLA J, 1978, LANCET, V1, P624; BAGNALL BG, 1975, THESIS U SYDNEY; BAST RC, 1971, J EXP MED, V133, P202, DOI 10.1084/jem.133.2.202; BENACERRAF B, 1963, J EXP MED, V117, P937, DOI 10.1084/jem.117.6.937; COLVIN RB, 1974, ANN INTERN MED, V81, P404, DOI 10.7326/0003-4819-81-3-404; COLVIN RB, 1975, J IMMUNOL, V114, P377; COLVIN RB, 1974, LANCET, V1, P212, DOI 10.1016/S0140-6736(74)92512-4; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DVORAK AM, 1976, LAB INVEST, V34, P179; DVORAK AM, 1971, J IMMUNOL, V107, P422; DVORAK HF, 1971, J IMMUNOL, V107, P138; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1976, J ALLERGY CLIN IMMUN, V58, P229, DOI 10.1016/0091-6749(76)90159-7; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; DVORAK HF, 1973, J EXP MED, V137, P751, DOI 10.1084/jem.137.3.751; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; DVORAK HF, 1971, J IMMUNOL, V106, P279; DVORAK HF, 1971, J IMMUNOL, V107, P1576; FRIEDLAENDER MH, 1977, J IMMUNOL, V118, P1558; GERSHON RK, 1975, J EXP MED, V142, P732, DOI 10.1084/jem.142.3.732; GRAZIANO FM, J IMMUNOL; HASTIE R, UNPUBLISHED; HAYNES JD, 1978, J IMMUNOL, V120, P886; HAYNES JD, 1977, J IMMUNOL, V118, P1063; HUBER B, 1976, J EXP MED, V143, P1534, DOI 10.1084/jem.143.6.1534; HURLIMANN J, 1965, J IMMUNOL, V95, P765; KATZ SI, 1974, NATURE, V251, P550, DOI 10.1038/251550a0; LEE GCS, UNPUBLISHED; LEONARD EJ, INT ARCH ALLERGY APP; LUBAROFF DM, 1968, J EXP MED, V128, P1425, DOI 10.1084/jem.128.6.1425; MARCHESI VT, 1964, PROC R SOC SER B-BIO, V159, P283, DOI 10.1098/rspb.1964.0002; MCCLUSKEY RT, 1976, J IMMUNOL, V58, P466; METZLER CM, UNPUBLISHED; MILLER HRP, 1971, LAB INVEST, V24, P339; MULLER HK, 1973, IMMUNOLOGY, V24, P1099; NETA R, 1974, J IMMUNOL, V113, P1716; NETA R, 1973, CELL IMMUNOL, V9, P242, DOI 10.1016/0008-8749(73)90075-0; OGILVIE BM, 1978, EXP PARASITOL, V46, P20, DOI 10.1016/0014-4894(78)90153-4; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; OVARY Z, 1964, IMMUNOLOGICAL METHOD, P259; PARISH WE, 1972, IMMUNOLOGY, V23, P19; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; RICHERSON HB, 1971, J EXP MED, V134, P630, DOI 10.1084/jem.134.3.630; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; ROCKLIN RE, 1978, CELL IMMUNOL, V37, P162, DOI 10.1016/0008-8749(78)90184-3; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; ROTHWELL TL, 1972, IMMUNOLOGY, V22, P733; ROTHWELL TLW, 1975, J PATHOL, V116, P15; SCHWARTZ A, 1977, J IMMUNOL, V118, P159; SISKIND GREGORY W., 1965, J IMMUNOL, V95, P436; SOHNLE PG, 1977, J ALLERGY CLIN IMMUN, V59, P171, DOI 10.1016/0091-6749(77)90221-4; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STADECKE.MJ, 1974, J IMMUNOL, V113, P496; STADECKER M, 1976, J EXP MED, V143, P206, DOI 10.1084/jem.143.1.206; STADECKER MJ, 1976, J IMMUNOL, V116, P1646; STADECKER MJ, 1973, P SOC EXP BIOL MED, V142, P150; STASHENKO PP, 1977, J IMMUNOL, V119, P1987; TURK JL, 1973, IMMUNOLOGY, V24, P751; UVNAS B, 1974, FED PROC, V33, P2172; WARD PA, 1975, J IMMUNOL, V114, P1523; WIKEL SK, 1976, IMMUNOLOGY, V30, P311; WIKEL SK, 1976, IMMUNOLOGY, V30, P479; WOLFJURGENSEN P, 1966, BASOPHILIC LEUKOCYTE	77	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					79	89		10.1016/0091-6749(79)90041-1	http://dx.doi.org/10.1016/0091-6749(79)90041-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	313413				2022-12-18	WOS:A1979HG42600001
J	MARX, JJ; EMANUEL, DA; DOVENBARGER, WV; REINECKE, ME; ROBERTS, RC; TREUHAFT, MW				MARX, JJ; EMANUEL, DA; DOVENBARGER, WV; REINECKE, ME; ROBERTS, RC; TREUHAFT, MW			FARMERS LUNG-DISEASE AMONG FARMERS WITH PRECIPITATING ANTIBODIES TO THERMOPHILIC ACTINOMYCETES - CLINICAL AND IMMUNOLOGICAL STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARSHFIELD CLIN,CARDIOL SECT,MARSHFIELD,WI 54449; MARSHFIELD CLIN,PULM DIS SECT,MARSHFIELD,WI 54449	Marshfield Clinic; Marshfield Clinic	MARX, JJ (corresponding author), MARSHFIELD MED FDN INC,510 N ST JOSEPH AVE,MARSHFIELD,WI 54449, USA.							CAMPBELL D, 1964, METHODS IMMUNOLOGY; CHMELIK F, 1975, AM REV RESPIR DIS, V111, P201; DOPICO GA, 1976, AM REV RESPIR DIS, V113, P451; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FLAHERTY DK, 1974, J LAB CLIN MED, V84, P298; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HANSEN RL, 1977, AM J DIS CHILD, V131, P518, DOI 10.1001/archpedi.1977.02120180032004; KURUP VP, 1975, INT J SYST BACTERIOL, V25, P150, DOI 10.1099/00207713-25-2-150; MADSEN D, 1976, AM REV RESPIR DIS, V113, P171; MARX JJ, 1977, J ALLERGY CLIN IMMUN, V60, P169, DOI 10.1016/0091-6749(77)90120-8; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4, P5; ROBERTS RC, 1976, J ALLERGY CLIN IMMUN, V57, P518, DOI 10.1016/0091-6749(76)90002-6; WEILL H, 1975, AM REV RESPIR DIS, V112, P1; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464	17	45	45	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					185	189		10.1016/0091-6749(78)90105-7	http://dx.doi.org/10.1016/0091-6749(78)90105-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	681631				2022-12-18	WOS:A1978FP55400010
J	LEE, TP; BUSSE, WW; REED, CE				LEE, TP; BUSSE, WW; REED, CE			EFFECT OF BETA-ADRENERGIC AGONIST, PROSTAGLANDINS, AND CORTISOL ON LYMPHOCYTE LEVELS OF CYCLIC ADENOSINE-MONOPHOSPHATE AND GLYCOGEN - ABNORMAL LYMPHOCYTIC METABOLISM IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; Boyum A., 1967, SCAND J CLIN LAB INV, V97, P77; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; HASSID WZ, 1957, METHOD ENZYMOL, V3, P34, DOI 10.1016/S0076-6879(57)03345-5; JORT J, 1971, ANN REV BIOCHEM, V40, P741; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOGSDON PJ, 1973, J ALLERGY CLIN IMMUN, V52, P148, DOI 10.1016/0091-6749(73)90031-6; MENDELSOHN J, 1973, J CLIN INVEST, V52, P2129, DOI 10.1172/JCI107397; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1974, ADV CYCLIC NUCLEOTID, V5, P812; NELSON HS, 1974, J ALLERGY CLIN IMMUN, V51, P421; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; POINTER RH, 1976, J BIOL CHEM, V251, P2987; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; SMITH JW, 1970, J LAB CLIN MED, V76, P993	20	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					408	413		10.1016/0091-6749(77)90002-1	http://dx.doi.org/10.1016/0091-6749(77)90002-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	16943				2022-12-18	WOS:A1977DJ99000001
J	GRIECO, MH; SIEGEL, I; GOEL, Z				GRIECO, MH; SIEGEL, I; GOEL, Z			MODULATION OF HUMAN T-LYMPHOCYTE ROSETTE FORMATION BY AUTONOMIC AGONISTS AND CYCLIC NUCLEOTIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10027; ROOSEVELT HOSP,RA COOKE INST ALLERGY,MED SERV,ALLERGY CLIN IMMUNOL & INFECT DIS DIV,NEW YORK,NY	Columbia University; Mount Sinai West								BACH JF, 1969, TRANSPLANT P, V1, P403; BENTWICH Z, 1973, CLIN IMMUNOL IMMUNOP, V1, P511, DOI 10.1016/0090-1229(73)90007-X; BENTWICH Z, 1973, J EXP MED, V137, P1532, DOI 10.1084/jem.137.6.1532; BOURNE HR, 1972, J IMMUNOL, V108, P695; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CHAPEL HM, 1973, TRANSPLANTATION, V15, P320, DOI 10.1097/00007890-197303000-00009; CHISARI FV, 1974, J EXP MED, V140, P512; DERUBERTIS FR, 1974, J IMMUNOL, V113, P151; ESTENSEN RD, 1973, NATURE, V245, P458, DOI 10.1038/245458a0; FRANKS DJ, 1971, BIOCHEM BIOPH RES CO, V42, P844, DOI 10.1016/0006-291X(71)90507-9; GALANT SP, 1975, J IMMUNOL, V114, P512; GALILI U, 1974, J IMMUNOL, V112, P1628; GEORGE WJ, 1970, P NATL ACAD SCI USA, V66, P398, DOI 10.1073/pnas.66.2.398; GUPTA S, 1975, ANN INTERN MED, V82, P484, DOI 10.7326/0003-4819-82-4-484; HADDEN JW, 1972, P NATL ACAD SCI USA, V69, P3024, DOI 10.1073/pnas.69.10.3024; HENNEY CS, 1972, J IMMUNOL, V108, P1526; IGNARRO LJ, 1974, J EXP MED, V140, P225, DOI 10.1084/jem.140.1.225; IGNARRO LJ, 1974, J EXP MED, V139, P1395, DOI 10.1084/jem.139.6.1395; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KEDAR E, 1974, J IMMUNOL, V113, P1544; KERSEY JH, 1974, J IMMUNOL, V112, P862; KOLATA GB, 1973, SCIENCE, V182, P149, DOI 10.1126/science.182.4108.149; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1131; MELMON KL, 1974, J CLIN INVEST, V53, P13, DOI 10.1172/JCI107530; NORDLING S, 1972, SCIENCE, V178, P1001, DOI 10.1126/science.178.4064.1001; ORANGE RP, 1971, J EXP MED          S, V134, P136; OWEN FL, 1974, J IMMUNOL, V113, P1138; PATINKIN D, 1970, CANCER RES, V30, P489; STEER ML, 1975, NEW ENGL J MED, V292, P409; STROM TB, 1973, J EXP MED, V138, P381, DOI 10.1084/jem.138.2.381; STROM TB, 1972, P NATL ACAD SCI USA, V69, P2995, DOI 10.1073/pnas.69.10.2995; TAKYANYU D, 1975, J IMMUNOL, V114, P788; Wybran J, 1971, Trans Assoc Am Physicians, V84, P239; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550	36	45	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					149	159		10.1016/0091-6749(76)90150-0	http://dx.doi.org/10.1016/0091-6749(76)90150-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	182731				2022-12-18	WOS:A1976BX74400004
J	REISMAN, RE; WYPYCH, J; ARBESMAN, CE				REISMAN, RE; WYPYCH, J; ARBESMAN, CE			STINGING INSECT ALLERGY - DETECTION AND CLINICAL SIGNIFICANCE OF VENOM IGE ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP, ALLERGY RES LAB, BUFFALO, NY 14203 USA; SUNY, DEPT MICROBIOL, BUFFALO, NY 14222 USA; SUNY, DEPT MED, BUFFALO, NY 14222 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; SUNY Maritime College								BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BUSSE W, 1974, J ALLERGY CLIN IMMUN, V53, P104; CHARAVEJ.CC, 1974, J ALLERGY CLIN IMMUN, V53, P104; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SHULMAN S, 1966, J IMMUNOL, V96, P29; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; VALENTIN.MD, 1974, J ALLERGY CLIN IMMUN, V53, P105; WIDE L, 1967, LANCET, V2, P1105; 1972, REPORT INSECT COMMIT	10	45	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	6					443	449		10.1016/0091-6749(75)90062-7	http://dx.doi.org/10.1016/0091-6749(75)90062-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ301	1206184				2022-12-18	WOS:A1975AZ30100003
J	BERMAN, SZ; MATHISON, DA; STEVENSON, DD; USSELMAN, JA; SHORE, S; TAN, EM				BERMAN, SZ; MATHISON, DA; STEVENSON, DD; USSELMAN, JA; SHORE, S; TAN, EM			MAXILLARY SINUSITIS AND BRONCHIAL-ASTHMA - CORRELATION OF ROENTGENOGRAMS, CULTURES, AND THERMOGRAMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN, DIV RADIOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, DIV OTORHINOLARYNGOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, DIV ALLERGY & IMMUNOL, 476 PROSPECT ST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								ALLIBONE EC, 1956, BRIT MED J, V1, P1457, DOI 10.1136/bmj.1.4981.1457; [Anonymous], 1965, LANCET, V1, P775; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; BALLANTYNE J C, 1949, J Laryngol Otol, V63, P337, DOI 10.1017/S0022215100046557; BERMAN SZ, 1973, J ALLERGY CLIN IMMUN, V51, P122, DOI 10.1016/S0091-6749(73)80095-8; BULLEN SS, 1932, J ALLERGY, V4, P402; CATLIN FI, 1965, SOUTHERN MED J, V58, P1497, DOI 10.1097/00007611-196512000-00006; Cooke RA, 1932, AM J MED SCI, V183, P309; Dolan K D, 1971, Otolaryngol Clin North Am, V4, P13; FASCENEL.FW, 1969, ARCH OTOLARYNGOL, V90, P198; GROVE R. CLARK, 1940, JOUR ALLERGY, V11, P271, DOI 10.1016/S0021-8707(40)90572-X; GROVE RC, 1951, J ALLERGY, V22, P550, DOI 10.1016/0021-8707(51)90114-1; Grove RC, 1933, ARCHIV OTOLARYNGOL, V18, P622; Litton W B, 1971, Otolaryngol Clin North Am, V4, P25; MATHISON DA, 1973, JAMA-J AM MED ASSOC, V224, P1134, DOI 10.1001/jama.224.8.1134; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MCNEILL R A, 1963, J Laryngol Otol, V77, P1009, DOI 10.1017/S0022215100061673; QUINTERO JM, 1966, J ALLERGY, V37, P84, DOI 10.1016/0021-8707(66)90124-9; ROSE G, 1971, IMMUNOLOGICAL DISEAS, V2; Smith J M, 1971, Otolaryngol Clin North Am, V4, P39; SPECTOR SL, 1973, AM J MED, V55, P227, DOI 10.1016/0002-9343(73)90173-3; SWINEFORD OS, 1962, ANN INTERN MED, V57, P144, DOI 10.7326/0003-4819-57-1-144; VANALYEA OE, 1963, POSTGRAD MED, V34, P473, DOI 10.1080/00325481.1963.11694910; VUORINEN P, 1962, J Laryngol Otol, V76, P359, DOI 10.1017/S0022215100059442	24	45	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	5					311	317		10.1016/0091-6749(74)90111-0	http://dx.doi.org/10.1016/0091-6749(74)90111-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S9114	4595650				2022-12-18	WOS:A1974S911400009
J	Sun, LC; Fu, JR; Lin, SH; Sun, JL; Xia, L; Lin, CH; Liu, LJ; Zhang, CY; Yang, L; Xue, P; Wang, X; Huang, SH; Han, X; Chen, HL; Huang, MS; Zhang, XB; Huang, SK; Zhou, YF				Sun, Licheng; Fu, Jinrong; Lin, Sheng-Hao; Sun, Jin-Lyu; Xia, Li; Lin, Ching-Hsiung; Liu, Lijuan; Zhang, Caiyan; Yang, Lan; Xue, Ping; Wang, Xiang; Huang, Saihua; Han, Xiao; Chen, Hua-Ling; Huang, Ming-Shyan; Zhang, Xiaobo; Huang, Shau-Ku; Zhou, Yufeng			Particulate matter of 2.5 mu m or less in diameter disturbs the balance of T-H 17/regulatory T cells by targeting glutamate oxaloacetate transaminase 1 and hypoxia-inducible factor 1 proportional to in an asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; particulate matter of 2.5 mu m or less in diameter; aryl hydrocarbon receptors; T-cell differentiation; glycolysis; DNA methylation	POLYCYCLIC AROMATIC-HYDROCARBONS; INDUCED INFLAMMATION; METABOLIC-CONTROL; DIFFERENTIATION; EXPOSURE; IMPAIRS; REG; DEMETHYLATION; T(H)17; IL-17	Background: Epidemiologic evidence suggests that exposure to particulate matter of 2.5 mu m or less in diameter (PM2.5) aggravates asthma. Objective: We sought to investigate the underlying mechanisms between PM2.5 exposure and asthma severity. Methods: The relationship between PM2.5 exposure and asthma severity was investigated in an asthma model with CD4(+ )T cell- specific aryl hydrocarbon receptor (AhR)-null mice. Effects of PM2.5 and polycyclic aromatic hydrocarbons (PAHs) on differentiation of T(H)17/regulatory T (Treg) cells were investigated by using flow cytometry and quantitative RT-PCR. Mechanisms were investigated by using mRNA sequencing, chromatin immunoprecipitation, bisulfite sequencing, and glycolysis rates. Results: PM2.5 impaired differentiation of Treg cells, promoted differentiation of T(H)17 cells, and aggravated asthma in an AhRdependent manner. PM2.5 and one of its prominent PAHs, indeno[1,2,3-cd]pyrene (IP), promoted differentiation of T(H)17 cells by upregulating hypoxia-inducible factor 1 proportional to expression and enhancing glycolysis through AhRs. Exposure to PM2.5 and IP enhanced glutamate oxaloacetate transaminase 1 (Got1) expression through AhRs and accumulation of 2-hydroxyglutarate, which inhibited ten-eleven translocation methylcytosine dioxygenase 2 activity, resulting in hypermethylation in the forkhead box P3 locus and impaired differentiation of Treg cells. A GOT1 inhibitor, (aminooxy)acetic acid, ameliorated asthma by shifting differentiation of T(H)17 cells to Treg cells. Similar regulatory effects of exposure to PM2.5 or IP on T(H)17/Treg cell imbalance were noted in human T cells, and in a case-control design PAH exposure appeared to be a potential risk factor for asthma. Conclusions: The AhR-hypoxia-inducible factor 1 proportional to and AhRGOT1 molecular pathways mediate pulmonary responses on exposure to PM2.5 through their ability to disturb the balance of T(H)17/Treg cells.	[Sun, Licheng; Fu, Jinrong; Xia, Li; Zhang, Caiyan; Yang, Lan; Xue, Ping; Wang, Xiang; Huang, Saihua; Han, Xiao; Zhou, Yufeng] Fudan Univ, Childrens Hosp, Shanghai, Peoples R China; [Sun, Licheng; Fu, Jinrong; Xia, Li; Zhang, Caiyan; Yang, Lan; Xue, Ping; Wang, Xiang; Huang, Saihua; Han, Xiao; Zhou, Yufeng] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Sun, Licheng; Xia, Li; Zhang, Caiyan; Yang, Lan; Huang, Saihua; Han, Xiao; Zhou, Yufeng] Fudan Univ, NHC Key Lab Neonatal Dis, Shanghai, Peoples R China; [Fu, Jinrong; Liu, Lijuan; Zhang, Xiaobo] Fudan Univ, Respirol Dept, Childrens Hosp, Shanghai, Peoples R China; [Lin, Sheng-Hao; Lin, Ching-Hsiung] Chang Hua Christian Hosp, Dept Internal Med, Chest Div, Changhua, Taiwan; [Sun, Jin-Lyu] Chinese Acad Med Sci, Beijing Key Lab Precis Med Diag & Treatment Aller, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Allergy, Beijing, Peoples R China; [Chen, Hua-Ling; Huang, Shau-Ku] Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, Miaoli, Taiwan; [Huang, Ming-Shyan] I Shou Univ, E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Huang, Shau-Ku] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Huang, Shau-Ku] Kaohsiung Med Univ, Kaohsiung, Taiwan; [Huang, Shau-Ku] Shen Zhen Univ, Lou Hu Hosp, Shenzhen, Guangdong, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Changhua Christian Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; National Health Research Institutes - Taiwan; E-Da Hospital; I Shou University; Johns Hopkins University; Kaohsiung Medical University; Shenzhen University	Zhou, YF (corresponding author), 399 Wanyuan Rd, Shanghai 201102, Peoples R China.	yfzhou1@fudan.edu.cn	Lin, Ching-Hsiung/AAS-3280-2021	Lin, Ching-Hsiung/0000-0003-0512-4953; wang, xiang/0000-0003-0992-8553; Lin, Ching-Hsiung/0000-0001-9407-8578; zhou, Yufeng/0000-0002-6050-4951	National Key R&D Program of China [2016YFC1305102]; National Natural Science Foundation of China [81671561, 81974248, 81900751]; 1000 Young Talents Plan Program of China; Fudan University; International Joint Laboratory Program of National Children's Medical Center [EK1125180109]; Program for Outstanding Medical Academic Leader [2019LJ19]; Shanghai Municipal Planning Commission of Science and Research Fund [201740065, 20174Y0079]; Shanghai Pujiang Program [16PJ1401600]; Shanghai Committee of Science and Technology [19ZR1406400, 18411951700]; National Health Research Institutes, Taiwan [EOPP10-014, EOSP07-014]; Shenzhen Science and Technology Peacock Team Project [KQTD20170331145453160]; Key projects of Beijing Natural Science Foundation [7191008]; Kaohsiung Medical University "The Talent Plan", Taiwan [106KMUOR04]; Fudan Children's Hospital	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1000 Young Talents Plan Program of China; Fudan University; International Joint Laboratory Program of National Children's Medical Center; Program for Outstanding Medical Academic Leader; Shanghai Municipal Planning Commission of Science and Research Fund; Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Shenzhen Science and Technology Peacock Team Project; Key projects of Beijing Natural Science Foundation; Kaohsiung Medical University "The Talent Plan", Taiwan; Fudan Children's Hospital	This work was supported by grants from the National Key R&D Program of China (2016YFC1305102 to Y.Z.); the National Natural Science Foundation of China (81671561 and 81974248 to Y.Z. and 81900751 to X.H.); the 1000 Young Talents Plan Program of China; Initial Funding for New PI, Fudan Children's Hospital and Fudan University; the International Joint Laboratory Program of National Children's Medical Center (EK1125180109 to Y.Z.); the Program for Outstanding Medical Academic Leader (2019LJ19 to Y.Z.), the Shanghai Municipal Planning Commission of Science and Research Fund (201740065 to Y.Z. and 20174Y0079 to X.H.); the Shanghai Pujiang Program 16PJ1401600 (to J.F.); the Shanghai Committee of Science and Technology (19ZR1406400 to J.F. and 18411951700 to X.Z.); the National Health Research Institutes, Taiwan (EOPP10-014 and EOSP07-014 to S.-K.H.); Kaohsiung Medical University "The Talent Plan" (106KMUOR04 to SKH), Taiwan; a Shenzhen Science and Technology Peacock Team Project (KQTD20170331145453160 to S.-K.H.); and Key projects of Beijing Natural Science Foundation (7191008 to J.S.).	Awji EG, 2015, AM J RESP CELL MOL, V52, P377, DOI 10.1165/rcmb.2014-0142OC; Buteau S, 2018, ENVIRON INT, V121, P23, DOI 10.1016/j.envint.2018.08.040; Castaneda AR, 2018, TOXICOL LETT, V292, P85, DOI 10.1016/j.toxlet.2018.04.020; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Feng SL, 2016, ECOTOX ENVIRON SAFE, V128, P67, DOI 10.1016/j.ecoenv.2016.01.030; Ferecatu I, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-18; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012; He L, 2018, IMMUNOLOGY, V153, P84, DOI 10.1111/imm.12813; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Hung CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073534; Jiang S, 2017, TOXICOL LETT, V273, P36, DOI 10.1016/j.toxlet.2017.03.015; Joller N, 2014, NAT MED, V20, P15, DOI 10.1038/nm.3439; Kawasaki H, 2014, ALLERGY, V69, P445, DOI 10.1111/all.12346; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Lee CL, 2016, J HAZARD MATER, V314, P286, DOI 10.1016/j.jhazmat.2016.04.047; Lu XX, 2018, J THORAC DIS, V10, P1449, DOI 10.21037/jtd.2018.03.02; Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nakatsukasa H, 2019, INT IMMUNOL, V31, P335, DOI 10.1093/intimm/dxz008; Nie J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00493; Oliveira M, 2019, ENVIRON INT, V124, P180, DOI 10.1016/j.envint.2018.12.052; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Prunicki M, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-017-0433-4; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Silverpil E, 2012, EXPERT REV RESP MED, V6, P173, DOI [10.1586/ERS.12.12, 10.1586/ers.12.12]; Someya K, 2017, INT IMMUNOL, V29, P365, DOI 10.1093/intimm/dxx049; Stelmaszczyk-Emmel A, 2013, INT ARCH ALLERGY IMM, V162, P16, DOI 10.1159/000350769; Su HH, 2016, TOXICOLOGY, V370, P116, DOI 10.1016/j.tox.2016.09.019; Sun LC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01632; Tsai PJ, 2004, ATMOS ENVIRON, V38, P333, DOI 10.1016/j.atmosenv.2003.08.038; Vaickus LJ, 2012, J ASTHMA, V49, P510, DOI 10.3109/02770903.2012.678958; Wang EY, 2019, ALLERGY, V74, P1675, DOI 10.1111/all.13784; Wang HT, 2017, SCI REP-UK, V7, DOI 10.1038/srep44256; Wang HC, 2019, CELL MOL IMMUNOL, V16, P783, DOI [10.1038/s41423-018-0022-2, 10.1038/s41423-018-0040-0]; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wong TH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23542-9; Xia MC, 2018, J ALLERGY CLIN IMMUN, V142, P1243, DOI 10.1016/j.jaci.2018.03.009; Xia MC, 2015, J ALLERGY CLIN IMMUN, V136, P441, DOI 10.1016/j.jaci.2015.02.014; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Xu T, 2015, J IMMUNOL, V195, P5539, DOI 10.4049/jimmunol.1501198; Yang RL, 2015, IMMUNITY, V43, P251, DOI 10.1016/j.immuni.2015.07.017; Zamali I, 2019, J LEUKOCYTE BIOL, V105, P291, DOI 10.1002/JLB.2AB0518-205RR; Zhou YF, 2013, BLOOD, V121, P3195, DOI 10.1182/blood-2012-08-453597	46	44	47	6	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					402	414		10.1016/j.jaci.2019.10.008	http://dx.doi.org/10.1016/j.jaci.2019.10.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31647966	Bronze			2022-12-18	WOS:000505590800043
J	Huff, RD; Carlsten, C; Hirota, JA				Huff, Ryan D.; Carlsten, Chris; Hirota, Jeremy A.			An update on immunologic mechanisms in the respiratory mucosa in response to air pollutants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway epithelial cells; host defense peptides; oxidative stress; antioxidants; gene-pollution interactions	BRONCHIAL EPITHELIAL-CELLS; DIESEL EXHAUST PARTICLES; FINE PARTICULATE MATTER; POLYCYCLIC AROMATIC-HYDROCARBONS; THYMIC STROMAL LYMPHOPOIETIN; OXIDATIVE STRESS; INNATE IMMUNITY; N-ACETYLCYSTEINE; GENE-EXPRESSION; CYCLE ARREST	Every day, we breathe in more than 10,000 L of air that contains a variety of air pollutants that can pose negative consequences to lung health. The respiratory mucosa formed by the airway epithelium is the first point of contact for air pollution in the lung, functioning as a mechanical and immunologic barrier. Under normal circumstances, airway epithelial cells connected by tight junctions secrete mucus, airway surface lining fluid, host defense peptides, and antioxidants and express innate immune pattern recognition receptors to respond to inhaled foreign substances and pathogens. Under conditions of air pollution exposure, the defenses of the airway epithelium are compromised by reductions in barrier function, impaired host defense to pathogens, and exaggerated inflammatory responses. Central to the mechanical and immunologic changes induced by air pollution are activation of redox-sensitive pathways and a role for antioxidants in normalizing these negative effects. Genetic variants in genes important in epithelial cell function and phenotype contribute to a diversity of responses to air pollution in the population at the individual and group levels and suggest a need for personalized approaches to attenuate the respiratory mucosal immune responses to air pollution.	[Huff, Ryan D.; Carlsten, Chris; Hirota, Jeremy A.] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada; [Hirota, Jeremy A.] McMaster Univ, Dept Med, Div Respirol, Firestone Inst Resp Hlth, 50 Charlton Ave E Luke Wing Room L314, Hamilton, ON L8N 4A6, Canada; [Hirota, Jeremy A.] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON, Canada; [Hirota, Jeremy A.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Hirota, Jeremy A.] Univ Waterloo, Dept Biol, Waterloo, ON, Canada	University of British Columbia; McMaster University; McMaster University; McMaster University; University of Waterloo	Hirota, JA (corresponding author), McMaster Univ, Dept Med, Div Respirol, Firestone Inst Resp Hlth, 50 Charlton Ave E Luke Wing Room L314, Hamilton, ON L8N 4A6, Canada.	hirotaja@mcmaster.ca		Huff, Ryan/0000-0002-6038-8217	Canada Research Chairs program	Canada Research Chairs program(Canada Research Chairs)	Supported by the Canada Research Chairs program for funding related to the manuscript.	Abbas I, 2016, ENVIRON RES, V147, P146, DOI 10.1016/j.envres.2016.01.041; Alexis NE, 2013, J ALLERGY CLIN IMMUN, V131, P610, DOI 10.1016/j.jaci.2012.07.005; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; An J, 2019, TOXICOL IN VITRO, V54, P67, DOI 10.1016/j.tiv.2018.09.008; Becker S, 2005, ENVIRON HEALTH PERSP, V113, P1032, DOI 10.1289/ehp.7996; Becker S, 2005, TOXICOL APPL PHARM, V203, P45, DOI 10.1016/j.taap.2004.07.007; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Bleck B, 2013, J IMMUNOL, V190, P3757, DOI 10.4049/jimmunol.1201165; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Blue E, 2018, ANN AM THORAC SOC, V15, P440, DOI 10.1513/AnnalsATS.201706-451OC; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bowatte G, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0664-z; Bowler RP, 2002, AM J RESP CRIT CARE, V166, pS38, DOI 10.1164/rccm.2206014; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Buonfiglio LGV, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/ehp876, 10.1289/EHP876]; Carlsten C, 2014, EMBO REP, V15, P736, DOI 10.15252/embr.201438480; Carlsten C, 2014, TOXICOL SCI, V139, P479, DOI 10.1093/toxsci/kfu040; Carlsten C, 2012, CURR OPIN ALLERGY CL, V12, P455, DOI 10.1097/ACI.0b013e328357cc55; Carlsten C, 2018, CHEST, V154, P918, DOI 10.1016/j.chest.2018.06.004; Chen XY, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0700-0; Chen Y, 2018, ECOTOX ENVIRON SAFE, V165, P505, DOI 10.1016/j.ecoenv.2018.09.034; Chowdhury PH, 2018, ENVIRON POLLUT, V235, P223, DOI [10.10, 10.1016/j.envpol.2017.12.040]; Clifford RL, 2017, J ALLERGY CLIN IMMUN, V139, P112, DOI 10.1016/j.jaci.2016.03.046; Corradi Massimo, 2008, Acta Biomed, V79 Suppl 1, P73; De Grove KC, 2018, CLIN EXP ALLERGY, V48, P773, DOI 10.1111/cea.13178; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dilger M, 2016, ARCH TOXICOL, V90, P3029, DOI 10.1007/s00204-016-1659-1; Fry RC, 2014, AM J PHYSIOL-LUNG C, V306, pL1129, DOI 10.1152/ajplung.00348.2013; Fuertes E, 2013, J ALLERGY CLIN IMMUN, V132, P342, DOI 10.1016/j.jaci.2013.03.007; Ganguly K, 2009, PHYSIOL GENOMICS, V37, P260, DOI 10.1152/physiolgenomics.90363.2008; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gold MJ, 2016, MUCOSAL IMMUNOL, V9, P809, DOI 10.1038/mi.2015.104; Guan LF, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13050483; Heijink I, 2014, THORAX, V69, P5, DOI 10.1136/thoraxjnl-2013-203520; Hiemstra PS, 2018, TOXICOL IN VITRO, V47, P137, DOI 10.1016/j.tiv.2017.11.005; Hiemstra PS, 2015, MOL IMMUNOL, V68, P28, DOI 10.1016/j.molimm.2015.07.030; Hirota JA, 2012, CURR OPIN IMMUNOL, V24, P740, DOI 10.1016/j.coi.2012.08.012; Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003; Huls A, 2018, PEDIAT ALLERG IMM-UK, V29, P596, DOI 10.1111/pai.12903; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Jiang H, 2007, CHEM RES TOXICOL, V20, P1331, DOI 10.1021/tx700107z; Kasurinen S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192453; Kasurinen S, 2017, ENVIRON TOXICOL, V32, P1487, DOI 10.1002/tox.22369; Kesic MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035108; Krapf M, 2017, ENVIRON SCI-PROC IMP, V19, P538, DOI [10.1039/c6em00586a, 10.1039/C6EM00586A]; Kumar SS, 2018, ENVIRON POLLUT, V239, P483, DOI 10.1016/j.envpol.2018.04.049; Lakey PSJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32916; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lavrich KS, 2018, TOXICOL APPL PHARM, V342, P99, DOI 10.1016/j.taap.2018.01.024; Leclercq B, 2018, ENVIRON POLLUT, V243, P1434, DOI 10.1016/j.envpol.2018.09.062; Leclercq B, 2017, ENVIRON POLLUT, V230, P163, DOI 10.1016/j.envpol.2017.06.028; Leclercq B, 2016, ENVIRON POLLUT, V218, P1074, DOI 10.1016/j.envpol.2016.08.059; Lee KW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1870-5; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Li Y, 2018, J APPL TOXICOL, V38, P1251, DOI 10.1002/jat.3636; Li ZW, 2013, J BIOCHEM MOL TOXIC, V27, P3, DOI 10.1002/jbt.21453; Libalova H, 2018, MUTAT RES-GEN TOX EN, V827, P50, DOI 10.1016/j.mrgentox.2018.01.006; Liu CW, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989-018-0240-x; MacIntyre EA, 2014, ENVIRON HEALTH PERSP, V122, P107, DOI 10.1289/ehp.1306755; McCarthy CE, 2017, TOXICOL IN VITRO, V43, P76, DOI 10.1016/j.tiv.2017.05.021; Meldrum K, 2017, TOXICOL IN VITRO, V45, P409, DOI 10.1016/j.tiv.2017.06.023; Menni C, 2015, AM J RESP CRIT CARE, V191, P1203, DOI 10.1164/rccm.201411-2059LE; Mookherjee N, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01385-2017; Natarajan K, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0455-z; Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423; Niu Y, 2018, ENVIRON SCI TECHNOL, V52, P8785, DOI 10.1021/acs.est.8b01295; Obeidat M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00657-2017; Parker D, 2011, AM J RESP CELL MOL, V45, P189, DOI 10.1165/rcmb.2011-0011RT; Pfeffer PE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200040; Pirozzi CS, 2018, ANN AM THORAC SOC, V15, P449, DOI 10.1513/AnnalsATS.201706-495OC; Pu XJ, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.04.13; Radan M, 2019, FREE RADICAL RES, P1; Raudoniute J, 2018, ENVIRON SCI POLLUT R, V25, P32277, DOI 10.1007/s11356-018-3167-8; Reyes-Zarate E, 2016, ENVIRON POLLUT, V214, P646, DOI 10.1016/j.envpol.2016.04.072; Rider CF, 2016, J ALLERGY CLIN IMMUN, V138, P1690, DOI 10.1016/j.jaci.2016.02.038; Robinson RK, 2018, J ALLERGY CLIN IMMUN, V141, P1074, DOI 10.1016/j.jaci.2017.04.038; Ru Q, 2018, INT J OCCUP MED ENV, V31, P173, DOI 10.13075/ijomeh.1896.00527; Santibanez-Andrade M, 2017, ENVIRON POLLUT, V229, P412, DOI 10.1016/j.envpol.2017.06.019; Seriani R, 2016, ENVIRON SCI POLLUT R, V23, P9862, DOI 10.1007/s11356-016-6228-x; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Silbajoris R, 2011, ENVIRON HEALTH PERSP, V119, P1379, DOI 10.1289/ehp.1103594; Skuland TS, 2017, ENVIRON TOXICOL PHAR, V52, P138, DOI 10.1016/j.etap.2017.04.004; Smit LAM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-26; Song YY, 2019, SCI TOTAL ENVIRON, V651, P3139, DOI 10.1016/j.scitotenv.2018.10.171; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665, DOI 10.1289/ehp.02110665; Tomasek I, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0178-9; Van Den Heuvel R, 2016, ENVIRON RES, V149, P48, DOI 10.1016/j.envres.2016.04.029; van der Vlugt LEPM, 2018, J ALLERGY CLIN IMMUN, V141, P1949, DOI 10.1016/j.jaci.2018.01.025; Vaughan A, 2019, ENVIRON RES, V170, P194, DOI 10.1016/j.envres.2018.12.035; Wang W, 2018, J IMMUNOL, V201, P2221, DOI 10.4049/jimmunol.1800709; Welsh KG, 2017, CHEST, V152, P771, DOI 10.1016/j.chest.2017.07.001; Weng CM, 2018, ALLERGY, V73, P2192, DOI 10.1111/all.13462; Weng CM, 2018, BIOCHEM PHARMACOL, V151, P1, DOI 10.1016/j.bcp.2018.02.028; Werder RB, 2018, J ALLERGY CLIN IMMUN, V141, P1607, DOI 10.1016/j.jaci.2017.07.051; Widdicombe JH, 2002, J ANAT, V201, P313, DOI 10.1046/j.1469-7580.2002.00098.x; Wong CM, 2009, ENVIRON HEALTH PERSP, V117, P248, DOI 10.1289/ehp.11605; Wu J, 2017, ENVIRON SCI POLLUT R, V24, P25071, DOI 10.1007/s11356-017-0090-3; Xu F, 2018, TOXICOL LETT, V294, P145, DOI 10.1016/j.toxlet.2018.05.003; Xu XD, 2016, AUTOPHAGY, V12, P1832, DOI 10.1080/15548627.2016.1204496; Yang LY, 2017, SCI TOTAL ENVIRON, V574, P1649, DOI 10.1016/j.scitotenv.2016.08.211; Zarcone MC, 2018, TOXICOL IN VITRO, V48, P221, DOI 10.1016/j.tiv.2018.01.024; Zarcone MC, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0510-4; Zarcone MC, 2016, AM J PHYSIOL-LUNG C, V311, pL111, DOI 10.1152/ajplung.00064.2016; Zhang YM, 2017, ENVIRON TOXICOL PHAR, V54, P21, DOI 10.1016/j.etap.2017.06.012; Zhao JL, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000007909, 10.1097/md.0000000000007909]; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	109	44	46	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					1989	2001		10.1016/j.jaci.2019.04.012	http://dx.doi.org/10.1016/j.jaci.2019.04.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	31176381	Bronze			2022-12-18	WOS:000470113200002
J	Maric, J; Ravindran, A; Mazzurana, L; Van Acker, A; Rao, A; Kokkinou, E; Ekoff, M; Thomas, D; Fauland, A; Nilsson, G; Wheelock, CE; Dahlen, SE; Ferreiros, N; Geisslinger, G; Friberg, D; Heinemann, A; Konya, V; Mjosberg, J				Maric, Jovana; Ravindran, Avinash; Mazzurana, Luca; Van Acker, Aline; Rao, Anna; Kokkinou, Efthymia; Ekoff, Maria; Thomas, Dominique; Fauland, Alexander; Nilsson, Gunnar; Wheelock, Craig E.; Dahlen, Sven-Erik; Ferreiros, Nerea; Geisslinger, Gerd; Friberg, Danielle; Heinemann, Akos; Konya, Viktoria; Mjosberg, Jenny			Cytokine-induced endogenous production of prostaglandin D-2 is essential for human group 2 innate lymphoid cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; prostaglandin D-2; chemoattractant receptor-homologous molecule expressed on T(H)2 cells; allergy	HUMAN MAST-CELLS; HUMAN EOSINOPHILS; D SYNTHASE; RECEPTOR; CRTH2; EXPRESSION; MEDIATORS; CHEMOTAXIS; METABOLITE; J(2)	Objective: We set out to examine PG production in human ILC2s and the implications of such endogenous production on ILC2 function. Methods: The effects of the COX-1/2 inhibitor flurbiprofen, the hematopoietic prostaglandin D2 synthase (HPGDS) inhibitor KMN698, and the CRTH2 antagonist CAY10471 on human ILC2s were determined by assessing receptor and transcription factor expression, cytokine production, and gene expression with flow cytometry, ELISA, and quantitative RT-PCR, respectively. Concentrations of lipid mediators were measured by using liquid chromatography-tandem mass spectrometry and ELISA. Results: We show that ILC2s constitutively express HPGDS and upregulate COX-2 upon IL-2, IL-25, and IL-33 plus thymic stromal lymphopoietin stimulation. Consequently, PGD2 and its metabolites can be detected in ILC2 supernatants. We reveal that endogenously produced PGD2 is essential in cytokine-induced ILC2 activation because blocking of the COX-1/2 or HPGDS enzymes or the CRTH2 receptor abolishes ILC2 responses. Conclusion: PGD2 produced by ILC2s is, in a paracrine/autocrine manner, essential in cytokine-induced ILC2 activation. Hence we provide the detailed mechanism behind how CRTH2 antagonists represent promising therapeutic tools for allergic diseases by controlling ILC2 function.	[Maric, Jovana; Heinemann, Akos; Konya, Viktoria] Med Univ Graz, Otto Loewi Res Ctr, Pharmacol Sect, Graz, Austria; [Maric, Jovana; Heinemann, Akos; Konya, Viktoria] BioTechMed, Graz, Austria; [Maric, Jovana; Mazzurana, Luca; Van Acker, Aline; Rao, Anna; Kokkinou, Efthymia; Konya, Viktoria; Mjosberg, Jenny] Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden; [Fauland, Alexander; Wheelock, Craig E.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res, Stockholm, Sweden; [Friberg, Danielle] Karolinska Inst, Dept Clin Sci Intervent & Technol, CLINTEC, Stockholm, Sweden; [Ravindran, Avinash; Ekoff, Maria; Nilsson, Gunnar] Karolinska Inst, Dept Med, Immunol & Allergy Unit, Solna, Sweden; [Ravindran, Avinash; Ekoff, Maria; Nilsson, Gunnar] Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden; [Thomas, Dominique; Ferreiros, Nerea; Geisslinger, Gerd] Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany; [Nilsson, Gunnar] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Geisslinger, Gerd] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol TMP, Frankfurt, Germany; [Friberg, Danielle] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden; [Mjosberg, Jenny] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden	Medical University of Graz; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Goethe University Frankfurt; Uppsala University; Fraunhofer Gesellschaft; Uppsala University; Linkoping University	Konya, V (corresponding author), Med Univ Graz, Otto Loewi Res Ctr, Pharmacol Sect, Graz, Austria.; Mjosberg, J (corresponding author), Karolinska Inst, Ctr Infect Med, F59, S-14186 Stockholm, Sweden.	viktoria.konya@medunigraz.at; jenny.mjosberg@ki.se		Friberg, Danielle/0000-0001-8327-1292; Ravindran, Avinash/0000-0002-1599-1658	Swedish Research Council [521-2013-2791]; Swedish Cancer Society [130396]; Foundation for Strategic Research [ICA120023]; Swedish Society for Medical Research; Austrian Science Fund FWF [P25531-B23]; PhD Program DK-MOLIN [FWF-W1241]; Deutsche Forschungsgemeinschaft DFG [SFB 1039]; Swedish Research Council; Swedish Heart-Lung Foundation [HLF 20150640, HLF 20140469]; Swedish Heart-Lung Foundation; Karolinska Institutet; Vardal Foundation; Science for Life Laboratory Joint Research Collaboration; Karin and Sten Morstedt Initiative on Anaphylaxis; Swedish Foundation for Strategic Research	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Foundation for Strategic Research; Swedish Society for Medical Research; Austrian Science Fund FWF(Austrian Science Fund (FWF)); PhD Program DK-MOLIN; Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Karolinska Institutet(Karolinska Institutet); Vardal Foundation; Science for Life Laboratory Joint Research Collaboration; Karin and Sten Morstedt Initiative on Anaphylaxis; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	This project received funding from the Swedish Research Council (521-2013-2791), the Swedish Cancer Society (130396), the Foundation for Strategic Research (ICA120023), and the Swedish Society for Medical Research (to J. Mjosberg); the Austrian Science Fund FWF (grant P25531-B23; to V.K.); PhD Program DK-MOLIN (FWF-W1241; to J. Maric); Deutsche Forschungsgemeinschaft DFG (SFB 1039, Z01; to G.G.); the Swedish Research Council, and the Swedish Heart-Lung Foundation (to G.N.). A.F. was funded by the Karin and Sten Morstedt Initiative on Anaphylaxis. C.E.W. was supported by the Swedish Heart-Lung Foundation (HLF 20150640 and HLF 20140469). S.-E.D. acknowledges the ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium, which is funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, AstraZeneca & the Science for Life Laboratory Joint Research Collaboration, and the Vardal Foundation.	Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bjorklund AK, 2016, NAT IMMUNOL, V17, P740, DOI 10.1038/ni0616-740a; Bohm E, 2004, J BIOL CHEM, V279, P7663, DOI 10.1074/jbc.M310270200; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Chen T, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal5196; Dhariwal J, 2017, AM J RESP CRIT CARE, V195, P1586, DOI 10.1164/rccm.201609-1846OC; Dichlberger A, 2014, J LIPID RES, V55, P2471, DOI 10.1194/jlr.M048553; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Duerr CU, 2016, CYTOKINE, V87, P1, DOI 10.1016/j.cyto.2016.01.018; Forkel M, 2017, EUR J IMMUNOL, V47, P1280, DOI 10.1002/eji.201646890; Frandsen PM, 2013, ALLERGY ASTHMA IMMUN, V5, P409, DOI 10.4168/aair.2013.5.6.409; Gallant MA, 2007, EUR J PHARMACOL, V557, P115, DOI 10.1016/j.ejphar.2006.11.058; Gela A, 2015, ALLERGY, V70, P161, DOI 10.1111/all.12542; Gheorghe KR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3851; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Huang T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86689; Jandl K, 2016, J ALLERGY CLIN IMMUN, V137, P833, DOI 10.1016/j.jaci.2015.11.012; Kobayashi Y, 2005, J IMMUNOL, V175, P5744, DOI 10.4049/jimmunol.175.9.5744; Konya V, 2018, J ALLERGY CLIN IMMUN, V141, P279, DOI 10.1016/j.jaci.2017.01.045; Konya V, 2016, IMMUNOL LETT, V179, P36, DOI 10.1016/j.imlet.2016.07.006; Liu XJ, 2011, CHEM RES TOXICOL, V24, P2227, DOI 10.1021/tx200336f; Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Okayama Y, 2001, J IMMUNOL, V166, P4705, DOI 10.4049/jimmunol.166.7.4705; Peinhaupt M, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00104; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Salimi M, 2017, J ALLERGY CLIN IMMUN, V140, P1090, DOI 10.1016/j.jaci.2016.12.958; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836; Sedej M, 2012, J ALLERGY CLIN IMMUN, V129, P492, DOI 10.1016/j.jaci.2011.08.015; Seo MJ, 2017, PROG LIPID RES, V66, P50, DOI 10.1016/j.plipres.2017.04.003; Shimura C, 2010, AM J PATHOL, V176, P227, DOI 10.2353/ajpath.2010.090111; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Vichai V, 2005, INFLAMM RES, V54, P163, DOI 10.1007/s00011-004-1338-1; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Xiang Z, 2006, ALLERGY, V61, P1040, DOI 10.1111/j.1398-9995.2006.01024.x; Xue L, 2009, CLIN EXP IMMUNOL, V156, P126, DOI 10.1111/j.1365-2249.2008.03871.x; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Zayed N, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2581	48	44	45	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2202	+		10.1016/j.jaci.2018.10.069	http://dx.doi.org/10.1016/j.jaci.2018.10.069			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578872	Bronze			2022-12-18	WOS:000470113200024
J	Biedermann, T; Kuna, P; Panzner, P; Valovirta, E; Andersson, M; de Blay, F; Thrane, D; Jacobsen, SH; Stage, BS; Winther, L				Biedermann, Tilo; Kuna, Piotr; Panzner, Petr; Valovirta, Erkka; Andersson, Morgan; de Blay, Frederic; Thrane, Dorthe; Jacobsen, Sanja Hald; Stage, Brian Sonne; Winther, Lone			The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinoconjunctivitis; allergy immunotherapy; birch pollen; clinical efficacy; clinical trial; safety; sublingual immunotherapy tablet; total combined score; tree pollen	ALLERGY IMMUNOTHERAPY TABLET; QUALITY-OF-LIFE; SUBLINGUAL IMMUNOTHERAPY; NORTH-AMERICAN; CLINICAL-TRIALS; GRASS; RHINOCONJUNCTIVITIS; EFFICACY; SAFETY; ADOLESCENTS	Background: The SQ tree sublingual immunotherapy (SLIT)tablet (ALK-Abello, Horsholm, Denmark) is developed for treatment of tree pollen-induced allergic rhinoconjunctivitis (ARC). Objective: The aim of this pivotal phase III trial was to demonstrate the efficacy and safety of the SQ tree SLIT-tablet. Methods: This was a randomized, double-blind, placebo-controlled trial with 634 subjects (12-65 years) with moderate-to-severe ARC despite use of symptom-relieving medication. Eligible subjects were randomized 1:1 to active or placebo treatment. The primary end point was the average daily ARC total combined score (TCS) during the birch pollen season (BPS) analyzed for subjects with diary data during the BPS. Secondary end points included average daily symptom scores (DSS) during the BPS, average TCS and DSS during the tree pollen season (TPS), and average daily medication scores (DMS) in the BPS and TPS. Results: The primary and key secondary end points demonstrated statistically significant and clinically relevant effects of the SQ tree SLIT-tablet compared with placebo. For the BPS, absolute (relative) differences from placebo were 3.02 (40%) for TCS, 1.32 (37%) for DSS, and 1.58 (49%) for DMS (all P < .0001). For the TPS, absolute (relative) differences from placebo were 2.27 (37%) for TCS, 0.99 (33%) for DSS, and 1.20 (47%) for DMS (all P < .0001). Treatment was well tolerated. The most frequently reported treatment-related adverse events were mild or moderate local reactions related to sublingual administration. Conclusion: The trial demonstrated the efficacy and safety of the SQ tree SLIT-tablet compared with placebo during the BPS and TPS in adolescents and adults with birch pollen-induced ARC (EudraCT 2015-004821-15).	[Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergol, Biedersteiner Str 29, D-80802 Munich, Germany; [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Panzner, Petr] Charles Univ Prague, Fac Med Pilsen, Dept Immunol & Allergol, Prague, Czech Republic; [Valovirta, Erkka] Univ Turku, Dept Pulm Dis & Clin Allergol, Turku, Finland; [Valovirta, Erkka] Terveystalo Allergy Clin, Turku, Finland; [Andersson, Morgan] Skane Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Lund, Sweden; [de Blay, Frederic] Univ Strasbourg, Univ Hosp Strasbourg, Federat Translat Med Chest Dis Dept, Strasbourg, France; [Thrane, Dorthe; Jacobsen, Sanja Hald; Stage, Brian Sonne] ALK Abello, Global Clin Dev, Horsholm, Denmark; [Winther, Lone] Gentofte Univ Hosp, Dept Dermato Allergol, Allergy Clin, Copenhagen, Denmark	Technical University of Munich; Medical University Lodz; Charles University Prague; University of Turku; Lund University; Skane University Hospital; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; ALK-Abello AS; University of Copenhagen; Herlev & Gentofte Hospital	Biedermann, T (corresponding author), Tech Univ Munich, Dept Dermatol & Allergol, Biedersteiner Str 29, D-80802 Munich, Germany.	tilo.biedermann@tum.de		Biedermann, Tilo/0000-0002-5352-5105; Kuna, Piotr/0000-0003-2401-0070	ALK-Abello, Horsholm, Denmark	ALK-Abello, Horsholm, Denmark	This trial was funded by ALK-Abello, Horsholm, Denmark, who assumes overall responsibility of the trial and has been involved in trial design and conduct, as well as analysis and interpretation of data.	[Anonymous], 1996, ICH HARM TRIP GUID T; [Anonymous], 1994, ICH HARM TRIP GUID T; Asam C, 2015, ALLERGY, V70, P1201, DOI 10.1111/all.12696; Birk AO, 2017, CLIN THER, V39, P1858, DOI 10.1016/j.clinthera.2017.08.003; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Calderon MA, 2014, CLIN EXP ALLERGY, V44, P1228, DOI 10.1111/cea.12331; Couroux P, 2018, ALLERGY; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; Demoly P, 2017, ALLERGY, V72, P1576, DOI 10.1111/all.13155; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Ellis AK, 2018, ANN ALLERG ASTHMA IM, V120, P495, DOI 10.1016/j.anai.2018.02.003; EMEA, CHMPEWP185042006 EME; Heath MD, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0069-9; International Conference on Harmonization, 1996, ICH HARM TRIP GUID T; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lee S, 2015, AM J RHINOL ALLERGY, V29, P106, DOI 10.2500/ajra.2015.29.4148; Lorenz AR, 2009, INT ARCH ALLERGY IMM, V148, P1, DOI 10.1159/000151243; Makela MJ, 2018, CLIN THER, V40, P574, DOI 10.1016/j.clinthera.2018.02.012; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Ohashi-Doi K, 2017, INT ARCH ALLERGY IMM, V174, P26, DOI 10.1159/000479693; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Rubin DB, 2004, MULTIPLE IMPUTATION; Scadding GK, 2015, ARCH DIS CHILD, V100, P576, DOI 10.1136/archdischild-2014-306300; Smith M, 2014, ALLERGY, V69, P913, DOI 10.1111/all.12419; Thomas Mike, 2009, Prim Care Respir J, V18, P41, DOI 10.4104/pcrj.2009.00010; Valovirta E, 2018, J ALLERGY CLIN IMMUN, V141, P529, DOI 10.1016/j.jaci.2017.06.014; World Medical Association, 2013, DECL HELS ETH PRINC	36	44	44	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1058	+		10.1016/j.jaci.2018.12.1001	http://dx.doi.org/10.1016/j.jaci.2018.12.1001			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30654054	Green Published, hybrid			2022-12-18	WOS:000460272900026
J	Romberg, N; Le Coz, C; Glauzy, S; Schickel, JN; Trofa, M; Nolan, BE; Paessler, M; Xu, MNL; Lambert, MP; Lakhani, SA; Khokha, MK; Jyonouchi, S; Heimall, J; Takach, P; Maglione, PJ; Catanzaro, J; Hsu, FI; Sullivan, KE; Cunningham-Rundles, C; Meffre, E				Romberg, Neil; Le Coz, Carole; Glauzy, Salome; Schickel, Jean-Nicolas; Trofa, Melissa; Nolan, Brian E.; Paessler, Michele; Xu, Mina L.; Lambert, Michele P.; Lakhani, Saquib A.; Khokha, Mustafa K.; Jyonouchi, Soma; Heimall, Jennifer; Takach, Patricia; Maglione, Paul J.; Catanzaro, Jason; Hsu, F. Ida; Sullivan, Kathleen E.; Cunningham-Rundles, Charlotte; Meffre, Eric			Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; autoimmune cytopenias; germinal center responses; somatic hypermutation; B-cell tolerance; commensal bacteria; follicular helper T cell; regulatory T cell	B-CELLS; SOMATIC HYPERMUTATION; AUTOANTIBODIES; REDEMPTION	Background: The lack of pathogen-protective, isotype-switched antibodies in patients with common variable immunodeficiency (CVID) suggests germinal center (GC) hypoplasia, yet a subset of patients with CVID is paradoxically affected by autoantibody-mediated autoimmune cytopenias (AICs) and lymphadenopathy. Objective: We sought to compare the physical characteristics and immunologic output of GC responses in patients with CVID with AIC (CVID+AIC) and without AIC (CVID-AIC). Methods: We analyzed GC size and shape in excisional lymph node biopsy specimens from 14 patients with CVID+AIC and 4 patients with CVID-AIC. Using paired peripheral blood samples, we determined how AICs specifically affected B-and T-cell compartments and antibody responses in patients with CVID. Results: We found that patients with CVID+AIC displayed irregularly shaped hyperplastic GCs, whereas GCs were scarce and small in patients with CVID-AIC. GC hyperplasia was also evidenced by an increase in numbers of circulating follicular helper T cells, which correlated with decreased regulatory T-cell frequencies and function. In addition, patients with CVID+AIC had serum endotoxemia associated with a dearth of isotype-switched memory B cells that displayed significantly lower somatic hypermutation frequencies than their counterparts with CVID-AIC. Moreover, IgG(+) B cells from patients with CVID+AIC expressed VH4-34-encoded antibodies with unmutated Ala-Val-Tyr and Asn-His-Ser motifs, which recognize both erythrocyte I/i self-antigens and commensal bacteria. Conclusions: Patients with CVID+AIC do not contain mucosal microbiota and exhibit hyperplastic yet inefficient GC responses that favor the production of untolerized IgG(+) B-cell clones that recognize both commensal bacteria and hematopoietic I/i self-antigens.	[Romberg, Neil; Le Coz, Carole; Trofa, Melissa; Jyonouchi, Soma; Heimall, Jennifer; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Immunol & Allergy, Philadelphia, PA 19104 USA; [Nolan, Brian E.] Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA; [Paessler, Michele] Childrens Hosp Philadelphia, Div Hematopathol, Philadelphia, PA 19104 USA; [Lambert, Michele P.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Romberg, Neil; Lambert, Michele P.; Jyonouchi, Soma; Heimall, Jennifer; Sullivan, Kathleen E.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Paessler, Michele] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Takach, Patricia] Univ Penn, Dept Med, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Glauzy, Salome; Schickel, Jean-Nicolas; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Xu, Mina L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Lakhani, Saquib A.; Khokha, Mustafa K.; Catanzaro, Jason] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Khokha, Mustafa K.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Hsu, F. Ida; Meffre, Eric] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Lakhani, Saquib A.; Khokha, Mustafa K.] Yale Univ, Sch Med, Pediat Genom Discovery Program, New Haven, CT USA; [Maglione, Paul J.; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY 10029 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Icahn School of Medicine at Mount Sinai	Meffre, E (corresponding author), Yale Univ, Sch Med, 300 George St,Rm 353F, New Haven, CT 06511 USA.; Romberg, N (corresponding author), Childrens Hosp Philadelphia, Abramson Res Ctr, Rm 1216C, Philadelphia, PA 19104 USA.	rombergn@email.chop.edu; eric.meffre@yale.edu	Lambert, Michele P./AAB-9225-2021	Lambert, Michele P./0000-0003-0439-402X; Maglione, Paul J./0000-0001-6805-7271; Romberg, Neil/0000-0002-1881-5318; Hsu, F. Ida/0000-0003-2201-9442; Lakhani, Saquib/0000-0003-3235-3460; Le Coz, Carole/0000-0002-9228-5896	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [K23AI115001]; Jeffrey Modell Foundation; NIH/NIAID [AI-061093, AI-071087, AI-082713]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI115001, R01AI071087, P01AI061093, K23AI137183] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jeffrey Modell Foundation; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant number K23AI115001 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID), the Jeffrey Modell Foundation (to N.R.), and AI-061093, AI-071087, and AI-082713 from the NIH/NIAID (to E.M.).	Almejun MB, 2017, J ALLERGY CLIN IMMUN, V139, P913, DOI 10.1016/j.jaci.2016.08.030; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Cantaert T, 2016, J CLIN INVEST, V126, P4289, DOI 10.1172/JCI84645; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Potter KN, 2002, J IMMUNOL, V169, P3777, DOI 10.4049/jimmunol.169.7.3777; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Reed JH, 2016, J EXP MED, V213, P1255, DOI 10.1084/jem.20151978; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; Roskin KM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1216; Sabouri Z, 2014, P NATL ACAD SCI USA, V111, pE2567, DOI 10.1073/pnas.1406974111; Schickel JN, 2017, J EXP MED, V214, P1991, DOI 10.1084/jem.20160201; Unger S, 2014, J CLIN IMMUNOL, V34, P615, DOI 10.1007/s10875-014-0052-1; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019; Zaheen A, 2009, BLOOD, V114, P547, DOI 10.1182/blood-2009-03-211763; Zhang Y, 2013, J EXP MED, V210, P457, DOI 10.1084/jem.20120150	24	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					258	265		10.1016/j.jaci.2018.06.012	http://dx.doi.org/10.1016/j.jaci.2018.06.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29935219	Green Accepted, Bronze			2022-12-18	WOS:000454918300030
J	Alfen, JS; Larghi, P; Facciotti, F; Gagliani, N; Bosotti, R; Paroni, M; Maglie, S; Gruarin, P; Vasco, CM; Ranzani, V; Frusteri, C; Iseppon, A; Moro, M; Crosti, MC; Gatti, S; Pagani, M; Caprioli, F; Abrignani, S; Flavell, RA; Geginat, J				Alfen, Johanna Sophie; Larghi, Paola; Facciotti, Federica; Gagliani, Nicola; Bosotti, Roberto; Paroni, Moira; Maglie, Stefano; Gruarin, Paola; Vasco, Chiara Maria; Ranzani, Valeria; Frusteri, Cristina; Iseppon, Andrea; Moro, Monica; Crosti, Maria Cristina; Gatti, Stefano; Pagani, Massimiliano; Caprioli, Flavio; Abrignani, Sergio; Flavell, Richard A.; Geginat, Jens			Intestinal IFN-gamma-producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammatory bowel disease; regulatory T cells; IL-10; IL-23	TH17 CELLS; INTERLEUKIN-10 RECEPTOR; IL-23; EXPRESSION; RESPONSES; FOXP3(+); LYMPHOCYTES; ACTIVATION; GENERATION; THERAPY	Background: IL-10 is an anti-inflammatory cytokine required for intestinal immune homeostasis. It mediates suppression of T-cell responses by type 1 regulatory T (T(R)1) cells but is also produced by CD25(+) regulatory T (Treg) cells. Objective: We aimed to identify and characterize human intestinal T(R)1 cells and to investigate whether they are a relevant cellular source of IL-10 in patients with inflammatory bowel diseases (IBDs). Methods: CD4(+) T cells isolated from the intestinal lamina propria of human subjects and mice were analyzed for phenotype, cytokine production, and suppressive capacities. Intracellular IL-10 expression by CD4(+) T-cell subsets in the inflamed guts of patients with IBD (Crohn disease or ulcerative colitis) was compared with that in cells from noninflamed control subjects. Finally, the effects of proinflammatory cytokines on T-cell IL-10 expression were analyzed, and IL-1 beta and IL-23 responsiveness was assessed. Results: Intestinal T(R)1 cells could be identified by coexpression of CCR5 and programmed cell death protein 1 (PD-1) in human subjects and mice. CCR5(+) PD-1(+) T(R)1 cells expressed IFN-gamma and efficiently suppressed T-cell proliferation and transfer colitis. Intestinal IFN-gamma(+) T(R)1 cells, but not IL-7 receptor-positive T-H cells or CD25(+) Treg cells, showed lower IL-10 expression in patients with IBDs. T(R)1 cells were responsive to IL-23, and IFN-gamma(+) T(R)1 cells downregulated IL-10 with IL-1 beta and IL-23. Conversely, CD25(+) Treg cells expressed higher levels of IL-1 receptor but showed stable IL-10 expression. Conclusions: We provide the first ex vivo characterization of human intestinal T(R)1 cells. Selective downregulation of IL-10 by IFN-gamma(+) T(R)1 cells in response to proinflammatory cytokines is likely to drive excessive intestinal inflammation in patients with IBDs.	[Alfen, Johanna Sophie; Larghi, Paola; Facciotti, Federica; Bosotti, Roberto; Paroni, Moira; Maglie, Stefano; Gruarin, Paola; Vasco, Chiara Maria; Ranzani, Valeria; Moro, Monica; Crosti, Maria Cristina; Pagani, Massimiliano; Abrignani, Sergio; Geginat, Jens] INGM Natl Inst Mol Genet Romeo & Enrica Invernizz, Milan, Italy; [Larghi, Paola; Caprioli, Flavio] Univ Milan, Dept Pathophysiol & Transplantat DEPT, Milan, Italy; [Pagani, Massimiliano] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Abrignani, Sergio] Univ Milan, Dept Clin Sci & Community Hlth DISCCO, Milan, Italy; [Gagliani, Nicola] Univ Med Ctr Hamburg Eppendorf, Dept Med, Hamburg, Germany; [Gagliani, Nicola] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Gagliani, Nicola; Iseppon, Andrea; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Flavell, Richard A.] Yale Univ, Howard Hughes Med Inst, New Haven, CT USA; [Frusteri, Cristina; Caprioli, Flavio] Fdn Cagranda Osped Maggiore Policlin, Unita Operat Gastroenterol & Endoscopia, Milan, Italy; [Gatti, Stefano] Fdn Cagranda Osped Maggiore Policlin, Ctr Ric Preclin, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Milan; University of Milan; University of Milan; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Yale University; Howard Hughes Medical Institute; Yale University; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico	Geginat, J (corresponding author), Natl Inst Mol Genet, I-20122 Milan, Italy.	geginat@ingm.org	Geginat, Jens/AAA-5818-2019; Facciotti, Federica/AAA-3518-2019; Caprioli, Flavio/AAB-5176-2019; Gatti, Stefano/AAE-3281-2022; Ranzani, Valeria/AAB-8258-2019; Vasco, Chiara/C-5637-2017; Paroni, Moira/K-6470-2016	Geginat, Jens/0000-0003-4813-0384; Facciotti, Federica/0000-0002-2541-9428; Caprioli, Flavio/0000-0002-8077-8175; Gatti, Stefano/0000-0003-2209-4338; Frusteri, Cristina/0000-0002-0273-381X; Abrignani, Sergio/0000-0002-0794-3285; Pagani, Massimiliano/0000-0002-7017-9304; Vasco, Chiara/0000-0002-3788-778X; Gagliani, Nicola/0000-0001-8514-1395; Paroni, Moira/0000-0001-8199-3128	long-term EMBO fellowship; short-term EMBO fellowship; Cariplo foundation [2013-0937]; Italian Ministry of Health [RF-2011-02348920, GR-2011-02352001]; AIRC foundation [Id.17448]; Romeo ed Enrica Invernizzi foundation; Howard Hughes Medical Institute	long-term EMBO fellowship(European Molecular Biology Organization (EMBO)); short-term EMBO fellowship; Cariplo foundation(Fondazione Cariplo); Italian Ministry of Health(Ministry of Health, Italy); AIRC foundation(Fondazione AIRC per la ricerca sul cancro); Romeo ed Enrica Invernizzi foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute)	Supported by a long-term EMBO fellowship (to N.G.), and a short-term EMBO fellowship (to F.F.) and the Cariplo foundation (grant 2013-0937 to J.G., F.C. and R.A.F.). J.G., M.P., and F.C. are supported by the Italian Ministry of Health (projects RF-2011-02348920 and GR-2011-02352001). J.G. is supported by the AIRC foundation (grant IG 2015 Id.17448). INGM is supported by the Romeo ed Enrica Invernizzi foundation. R.A.F. is supported by the Howard Hughes Medical Institute. J.S.A. has attended the PhD program of Molecular Medicine of the University of Milan (UNIMI).	Abraham C, 2009, ANNU REV MED, V60, P97, DOI 10.1146/annurev.med.60.051407.123757; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allan SE, 2008, IMMUNOL REV, V223, P391, DOI 10.1111/j.1600-065X.2008.00634.x; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Awasthi A, 2009, J IMMUNOL, V182, P5904, DOI 10.4049/jimmunol.0900732; Bacchetta R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00016; Banham AH, 2006, TRENDS IMMUNOL, V27, P541, DOI 10.1016/j.it.2006.10.002; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Caprioli F, 2008, J IMMUNOL, V180, P1800, DOI 10.4049/jimmunol.180.3.1800; Caprioli F, 2013, INFLAMM BOWEL DIS, V19, P729, DOI 10.1097/MIB.0b013e318280292b; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116; Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Facciotti F, 2016, J ALLERGY CLIN IMMUN, V137, P318, DOI 10.1016/j.jaci.2015.06.044; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Geginat J, 2016, CYTOKINE GROWTH F R, V30, P87, DOI 10.1016/j.cytogfr.2016.02.003; Glocker EO, 2011, ANN NY ACAD SCI, V1246, P102, DOI 10.1111/j.1749-6632.2011.06339.x; Gocke AR, 2007, J IMMUNOL, V178, P1341, DOI 10.4049/jimmunol.178.3.1341; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Haringer B, 2009, J EXP MED, V206, P1009, DOI 10.1084/jem.20082238; Heinemann C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4770; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Izcue A, 2008, IMMUNITY, V28, P559, DOI 10.1016/j.immuni.2008.02.019; Kamanaka M, 2006, IMMUNITY, V25, P941, DOI 10.1016/j.immuni.2006.09.013; Kastirr I, 2014, J IMMUNOL, V193, P3322, DOI 10.4049/jimmunol.1400775; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuipers H, 2006, EUR J IMMUNOL, V36, P2472, DOI 10.1002/eji.200635978; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; Okamura T, 2009, P NATL ACAD SCI USA, V106, P13974, DOI 10.1073/pnas.0906872106; Paroni M, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.41; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021; Roers A, 2004, J EXP MED, V200, P1289, DOI 10.1084/jem.20041789; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Turner JE, 2007, MINI-REV MED CHEM, V7, P1089, DOI 10.2174/138955707782331768; Uhlig HH, 2006, J IMMUNOL, V177, P5852, DOI 10.4049/jimmunol.177.9.5852; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957; Zigmond E, 2014, IMMUNITY, V40, P720, DOI 10.1016/j.immuni.2014.03.012	55	44	46	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1537	+		10.1016/j.jaci.2017.12.984	http://dx.doi.org/10.1016/j.jaci.2017.12.984			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29369775	Bronze			2022-12-18	WOS:000449429800017
J	Schmidt, T; Solimani, F; Pollmann, R; Stein, R; Schmidt, A; Stulberg, I; Kuhn, K; Eming, R; Eubel, V; Kind, P; Arweiler, N; Sitaru, C; Hertl, M				Schmidt, Thomas; Solimani, Farzan; Pollmann, Robert; Stein, Ronja; Schmidt, Ansgar; Stulberg, Inna; Kuehn, Katja; Eming, Ruediger; Eubel, Verena; Kind, Peter; Arweiler, Nicole; Sitaru, Cassian; Hertl, Michael			T(H)1/T(H)17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TH1; RESPONSES; SCLEROSUS		[Schmidt, Thomas; Solimani, Farzan; Pollmann, Robert; Stein, Ronja; Stulberg, Inna; Kuehn, Katja; Eming, Ruediger; Eubel, Verena; Hertl, Michael] Philipps Univ, Dept Dermatol & Allergol, Marburg, Germany; [Schmidt, Ansgar] Philipps Univ, Dept Pathol, Marburg, Germany; [Arweiler, Nicole] Philipps Univ, Dept Periodontol, Marburg, Germany; [Kind, Peter] Hautzentrum Offenbach, Offenbach, Germany; [Sitaru, Cassian] Albert Ludwigs Univ, Dept Dermatol, Freiburg, Germany; [Sitaru, Cassian] BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Freiburg	Hertl, M (corresponding author), Philipps Univ, Dept Dermatol & Allergol, Marburg, Germany.	hertl@med.uni-marburg.de	Arweiler, Nicole/GWU-7159-2022; Solimani, Farzan/AAI-2430-2019	Solimani, Farzan/0000-0001-6507-5407; Pollmann, Robert/0000-0002-4596-516X	German Research Foundation (Deutsche Forschungsgemeinschaft) [He 1602/13-1, SI-1281/5-1, FOR 2497 PEGASUS]; Uniklinikum Giessen-Marburg (UKGM) [05/2014]	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Uniklinikum Giessen-Marburg (UKGM)	Supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft; He 1602/13-1 to M.H. and SI-1281/5-1 to C.S. and FOR 2497 PEGASUS to A.S., R.E., C.S., and M.H.) and Uniklinikum Giessen-Marburg (UKGM; project no. 05/2014 MR to N.A. and M.H.).	Baldo M, 2010, J EUR ACAD DERMATOL, V24, P186, DOI 10.1111/j.1468-3083.2009.03375.x; Budinger L, 1998, J CLIN INVEST, V102, P2082, DOI 10.1172/JCI3335; Hertl M, 2006, J CLIN INVEST, V116, P1159, DOI 10.1172/JCI28547; Piccinni MP, 2014, ORAL DIS, V20, P212, DOI 10.1111/odi.12094; Takahashi H, 2011, J CLIN INVEST, V121, P3677, DOI 10.1172/JCI57379; Terlou A, 2012, J INVEST DERMATOL, V132, P658, DOI 10.1038/jid.2011.369; Veldman C, 2003, J IMMUNOL, V170, P635, DOI 10.4049/jimmunol.170.1.635; Xie SX, 2012, J HUAZHONG U SCI-MED, V32, P451, DOI 10.1007/s11596-012-0078-7	8	44	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					669	672		10.1016/j.jaci.2018.02.044	http://dx.doi.org/10.1016/j.jaci.2018.02.044			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29626572				2022-12-18	WOS:000440664400033
J	Dressler, C; Werner, RN; Eisert, L; Zuberbier, T; Nast, A; Maurer, M				Dressler, Corinna; Werner, Ricardo Niklas; Eisert, Lisa; Zuberbier, Torsten; Nast, Alexander; Maurer, Marcus			Chronic inducible urticaria: A systematic review of treatment options	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Urticaria; angioedema; inducible urticaria; omalizumab; antihistamines; review	DELAYED PRESSURE URTICARIA; ACQUIRED COLD URTICARIA; DOUBLE-BLIND; SYMPTOMATIC DERMOGRAPHISM; CHOLINERGIC URTICARIA; CETIRIZINE; CYPROHEPTADINE; ACRIVASTINE; RUPATADINE; CHLORPHENIRAMINE	Background: Chronic inducible urticaria (CindU) is a condition characterized by the appearance of recurrent wheals, angioedema, or both as a response to specific and reproducible triggers. Objective: We sought to systematically assess evidence on the efficacy and safety of treatment options for CindU. Results were used to inform the 2017 update of "The EAACI/GA 2 LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.'' Methods: Randomized controlled trials and controlled intervention studies were searched systematically in various databases. Included studies were evaluated with the Cochrane Risk of Bias tool. Where possible, results from single studies were meta-analyzed, applying the Mantel-Haenszel approach by using a random-effects model (Der Simonian-Laird). Results: We identified 30 studies that included patients with cold urticaria, symptomatic dermographism, delayed-pressure urticaria, or cholinergic urticaria. No studies on other forms of CindU were eligible. Risk of bias was often rated as unclear or high. Overall, second-generation antihistamines were more effective than placebo, and available data indicate that updosing might be effective. Omalizumab proved effective in patients with symptomatic dermographism, who did not respond to antihistamines. Detailed results are given for each type of CindU. Conclusions: The available evidence is limited by small samples, heterogeneous efficacy outcomes, and poor reporting quality in many of the included studies. The findings are congruent with the suggested stepwise approach to treating CindUs. However, the data do not allow for drawing specific conclusions for specific subtypes of CindU.	[Dressler, Corinna; Werner, Ricardo Niklas; Eisert, Lisa; Nast, Alexander] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergy, Div Evidence Based Med dEBM, Berlin, Germany; [Zuberbier, Torsten; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergy, Berlin, Germany; [Zuberbier, Torsten; Maurer, Marcus] Free Univ Berlin, Berlin, Germany; [Zuberbier, Torsten; Maurer, Marcus] Humboldt Univ, Berlin, Germany; [Zuberbier, Torsten; Maurer, Marcus] Berlin Inst Hlth, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Werner, Ricardo Niklas/AFB-8895-2022; Maurer, Marcus/ABG-2174-2020	Werner, Ricardo Niklas/0000-0003-3209-1392; Maurer, Marcus/0000-0002-4121-481X; Dressler, Corinna/0000-0001-7075-2062; Zuberbier, Torsten/0000-0002-1466-8875; Nast, Alexander/0000-0003-3504-2203	European Academy of Allergy and Clinical Immunology (EAACI) Dermatology Section; Global Allergy and Asthma European Network (GA2LEN); European Dermatology Forum (EDF); World Allergy Organization (WAO)	European Academy of Allergy and Clinical Immunology (EAACI) Dermatology Section; Global Allergy and Asthma European Network (GA2LEN); European Dermatology Forum (EDF); World Allergy Organization (WAO)	Supported by the European Academy of Allergy and Clinical Immunology (EAACI) Dermatology Section, Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN), European Dermatology Forum (EDF), and World Allergy Organization (WAO) as part of the work Urticaria Guideline 2017-update and revision.	Abajian M, 2016, ACTA DERM-VENEREOL, V96, P56, DOI 10.2340/00015555-2150; Alsamarai AM, 2012, WORLD ALLERGY ORGAN, V5, P88, DOI 10.1097/WOX.0b013e31825a72fc; BLACK AK, 1988, ACTA DERM-VENEREOL, V68, P541; BOYLE J, 1989, J INT MED RES, V17, pB9; CAP JP, 1985, HAUTARZT, V36, P509; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dubertret L, 2003, J AM ACAD DERMATOL, V48, P578, DOI 10.1067/mjd.2003.144; Gimenez-Arnau A, 2009, ALLERGY, V64, P516; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kaplan AP, 2010, CURR ALLERGY ASTHM R, V10, P223, DOI 10.1007/s11882-010-0113-3; KONTOUFILI K, 1990, ANN ALLERGY, V65, P517; KONTOUFILI K, 1991, J AM ACAD DERMATOL, V24, P1090, DOI 10.1016/0190-9622(91)70163-V; Krause K, 2013, ALLERGY, V68, P921, DOI 10.1111/all.12171; KRAUSE LB, 1985, BRIT J DERMATOL, V112, P447, DOI 10.1111/j.1365-2133.1985.tb02319.x; Kumar Rajesh, 2002, Indian J Dermatol Venereol Leprol, V68, P88; LAWLOR F, 1989, BRIT J DERMATOL, V120, P403, DOI 10.1111/j.1365-2133.1989.tb04167.x; LAWLOR F, 1988, DERMATOLOGICA, V177, P287, DOI 10.1159/000248580; Levnadier F, 1997, J INVEST DERMATOL, V108, P823; Magerl M, 2016, ALLERGY, V71, P780, DOI 10.1111/all.12884; Magerl M, 2012, BRIT J DERMATOL, V166, P1095, DOI 10.1111/j.1365-2133.2012.10822.x; MARTINEZ FV, 1992, J INVEST ALLERG CLIN, V2, P258; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P638, DOI 10.1016/j.jaci.2017.06.032; Maurer M, 2017, J ALLERGY CLIN IMMUN, V140, P870, DOI 10.1016/j.jaci.2017.01.042; Metz M, 2016, ALLERGY, V71, P185; Metz M, 2017, J ALLERGY CLIN IMMUN, V140, P864, DOI 10.1016/j.jaci.2017.01.043; Metz M, 2010, ANN ALLERG ASTHMA IM, V104, P86, DOI 10.1016/j.anai.2009.11.013; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; NEITTAANMAKI H, 1988, DERMATOLOGICA, V177, P98, DOI 10.1159/000248523; Nettis E, 2003, J ALLERGY CLIN IMMUN, V112, P212, DOI 10.1067/mai.2003.1559; Nettis E, 2006, BRIT J DERMATOL, V155, P1279, DOI 10.1111/j.1365-2133.2006.07533.x; Nordic Cochrane Centre The Cochrane Collaboration, 2014, REV MAN REVMAN; PRISMA, TRANSP REP SYST REV; Sanchez J, 2017, J ALLER CL IMM-PRACT, V5, P464, DOI 10.1016/j.jaip.2016.09.029; Scottish Intercollegiate Guidelines Network, 2015, SEARCH FILT; SHARPE GR, 1993, BRIT J DERMATOL, V129, P580, DOI 10.1111/j.1365-2133.1993.tb00488.x; Siebenhaar F, 2009, J ALLERGY CLIN IMMUN, V123, P672, DOI 10.1016/j.jaci.2008.12.008; STPIERRE JP, 1985, ANN ALLERGY, V55, P840; Trevisonno J, 2015, POSTGRAD MED, V127, P565, DOI 10.1080/00325481.2015.1045817; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; Zuberbier T, 1996, DERMATOLOGY, V193, P324, DOI 10.1159/000246281; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313; ZUBERBIER T, 1995, ACTA DERM-VENEREOL, V75, P147	42	44	48	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1726	1734		10.1016/j.jaci.2018.01.031	http://dx.doi.org/10.1016/j.jaci.2018.01.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29438771				2022-12-18	WOS:000432148200019
J	Maazi, H; Banie, H; Muench, GRA; Patel, N; Wang, BW; Sankaranarayanan, I; Bhargava, V; Sato, T; Lewis, G; Cesaroni, M; Karras, J; Das, A; Soroosh, P; Akbari, O				Maazi, Hadi; Banie, Homayon; Muench, German R. Aleman; Patel, Nisheel; Wang, Bowen; Sankaranarayanan, Ishwarya; Bhargava, Vipul; Sato, Takahiro; Lewis, Gavin; Cesaroni, Matteo; Karras, James; Das, Anuk; Soroosh, Pejman; Akbari, Omid			Activated plasmacytoid dendritic cells regulate type 2 innate lymphoid cell-mediated airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 2 innate lymphoid cells; asthma; plasmacytoid dendritic cells; eosinophilic airway inflammation; immune regulation	LUNG INFLAMMATION; IMMUNE-RESPONSE; NUCLEIC-ACIDS; T-CELLS; RECEPTOR; INDUCTION; INTERFERON; PROLIFERATION; AGONISTS; MATURE	Background: Allergic asthma is a prevalent inflammatory disease of the airways caused by dysregulated immune balance in the lungs with incompletely understood pathogenesis. The recently identified type 2 innate lymphoid cells (ILC2s) play significant roles in the pathogenesis of asthma. Although ILC2-activating factors have been identified, the mechanisms that suppress ILC2s remain largely unknown. Plasmacytoid dendritic cells (pDCs) are important in antiviral immunity and in maintaining tolerance to inert antigens. Objective: We sought to address the role of pDCs in regulating ILC2 function and ILC2-mediated airway hyperreactivity (AHR) and lung inflammation. Methods: We used several murine models, including BDCA-2-diphtheria toxin receptor (DTR) transgenic and IFN-alpha receptor 1-deficient mice, as well as purified primary ILC2s, to reach our objective. We extended and validated our findings to human ILC2s. Results: We show that activation of pDCs through Toll-like receptor 7/8 suppresses ILC2-mediated AHR and airway inflammation and that depletion of pDCs reverses this suppression. We further show that pDCs suppress cytokine production and the proliferation rate while increasing the apoptosis rate of ILC2s through IFN-alpha production. Transcriptomic analysis of both human and murine ILC2s confirms the activation of regulatory pathways in ILC2s by IFN-alpha. Conclusion: Activation of pDCs alleviates AHR and airway inflammation by suppressing ILC2 function and survival. Our findings reveal a novel regulatory pathway in ILC2-mediated pulmonary inflammation with important clinical implications.	[Maazi, Hadi; Patel, Nisheel; Wang, Bowen; Sankaranarayanan, Ishwarya; Lewis, Gavin; Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA; [Banie, Homayon; Muench, German R. Aleman; Lewis, Gavin; Karras, James; Soroosh, Pejman] Janssen Res & Dev, San Diego, CA USA; [Bhargava, Vipul; Sato, Takahiro; Cesaroni, Matteo; Das, Anuk] Janssen Res & Dev, Spring House, PA USA	University of Southern California; Johnson & Johnson; Janssen Pharmaceuticals	Akbari, O (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	Soroosh, Pejman/AAD-8386-2021	Maazi, Hadi/0000-0002-8979-3769	National Institutes of Health public health service [R01 ES025786, R01 ES021801, R21 ES024707, R21 AI109059]; American Heart Association postdoctoral fellowship [16POST27770125]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI109059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES025786, P30ES007048, R01ES021801] Funding Source: NIH RePORTER	National Institutes of Health public health service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); American Heart Association postdoctoral fellowship(American Heart Association); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health public health service grants R01 ES025786, R01 ES021801, R21 ES024707, and R21 AI109059 (to O.A.). H.M. is supported by American Heart Association postdoctoral fellowship #16POST27770125.	Akhabir L, 2011, RESPIROLOGY, V16, P396, DOI 10.1111/j.1440-1843.2011.01939.x; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Feng ZD, 2015, J CLIN INVEST, V125, P169, DOI 10.1172/JCI77527; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Guiducci C, 2010, NATURE, V465, P937, DOI 10.1038/nature09102; Hadeiba H, 2012, IMMUNITY, V36, P438, DOI 10.1016/j.immuni.2012.01.017; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hatchwell L, 2015, THORAX, V70, P854, DOI 10.1136/thoraxjnl-2014-205465; Hu J, 2012, BIOINFORMATICS, V28, P1933, DOI 10.1093/bioinformatics/bts294; Huber JP, 2014, J IMMUNOL, V192, P5687, DOI 10.4049/jimmunol.1301908; Kerzerho J, 2013, J ALLERGY CLIN IMMUN, V131, P1048, DOI 10.1016/j.jaci.2012.09.027; Kvale EO, 2007, BLOOD, V109, P3369, DOI 10.1182/blood-2006-06-031484; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lombardi V, 2012, MUCOSAL IMMUNOL, V5, P432, DOI 10.1038/mi.2012.20; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Maazi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059599; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Mouries J, 2008, BLOOD, V112, P3713, DOI 10.1182/blood-2008-03-146290; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; O'Brien M, 2011, J CLIN INVEST, V121, P1088, DOI 10.1172/JCI44960; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Ouabed A, 2008, J IMMUNOL, V180, P5862, DOI 10.4049/jimmunol.180.9.5862; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Russo C, 2011, BLOOD, V117, P5683, DOI 10.1182/blood-2010-12-328138; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Swiecki M, 2014, J IMMUNOL, V192, P4409, DOI 10.4049/jimmunol.1303135; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Ungvari I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033573; Wang HW, 2006, J IMMUNOL, V177, P6263, DOI 10.4049/jimmunol.177.9.6263; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Zhang Z, 2015, J CLIN INVEST, V125, P3692, DOI 10.1172/JCI82124	50	44	45	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					893	+		10.1016/j.jaci.2017.04.043	http://dx.doi.org/10.1016/j.jaci.2017.04.043			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28579374				2022-12-18	WOS:000426974800010
J	Westerhof, GA; Coumou, H; de Nijs, SB; Weersink, EJ; Bel, EH				Westerhof, Guus A.; Coumou, Hanneke; de Nijs, Selma B.; Weersink, Els J.; Bel, Elizabeth H.			Clinical predictors of remission and persistence of adult-onset asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adult-onset; asthma; clinical predictors; persistence; prognosis; prospective study; remission	OBSTRUCTIVE LUNG-DISEASE; CHRONIC RHINOSINUSITIS; EOSINOPHILIC INFLAMMATION; SYSTEMIC INFLAMMATION; CHILDHOOD ASTHMA; CLUSTER-ANALYSIS; NORTHERN SWEDEN; PHENOTYPES; RHINITIS; AGE	Background: Adult-onset asthma is an important but relatively understudied asthma phenotype and little is known about its natural course and prognosis. The remission rate is believed to be low, and it is still obscure which factors predict remission or persistence of the disease. Objective: This study sought to determine the remission rate and identify predictors of persistence and remission of adult-onset asthma. Methods: Two hundred adult patients with recently diagnosed (<1 year) asthma were recruited from secondary and tertiary pulmonary clinics and prospectively followed for 5 years. Clinical, functional, and inflammatory parameters were assessed at baseline and at yearly visits. Asthma remission was defined as absence of asthma symptoms for >= 1 year and no asthma medication use for >= 1 year. Descriptive statistics and logistic regression analysis were performed. Results: Five-year follow-up data of 170 patients (85%) was available. Of these, 27 patients (15.9%) experienced asthma remission. Patients with asthma persistence were older, had worse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as compared to patients who experienced clinical remission. In a multivariable logistic regression analysis, only moderate to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persistence. Patients with these 2 characteristics had <1% chance of asthma remission. Conclusions: One in 6 patients with adult-onset asthma experiences remission within the first 5 years of the disease. In patients with moderate to severe bronchial hyperresponsiveness and nasal polyposis, the chance of remission is close to zero.	[Westerhof, Guus A.; Coumou, Hanneke; de Nijs, Selma B.; Weersink, Els J.; Bel, Elizabeth H.] Univ Amsterdam, Dept Resp Med, Acad Med Ctr, F5-260,POB 22700, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Westerhof, GA (corresponding author), Univ Amsterdam, Dept Resp Med, Acad Med Ctr, F5-260,POB 22700, NL-1100 DE Amsterdam, Netherlands.	G.A.Westerhof@amc.uva.nl			GlaxoSmithKline; Stichting Astma Bestrijding (Foundation for the Prevention of Asthma), The Netherlands	GlaxoSmithKline(GlaxoSmithKline); Stichting Astma Bestrijding (Foundation for the Prevention of Asthma), The Netherlands	Supported by an unrestricted grant from GlaxoSmithKline and a grant from Stichting Astma Bestrijding (Foundation for the Prevention of Asthma), The Netherlands. The funding sources had no role in the study design, data collection, analysis or interpretation, or in the decision to submit this article for publication.	Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Burgess JA, 2011, THORAX, V66, P508, DOI 10.1136/thx.2010.146845; Cazzoletti L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086956; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; de Nijs SB, 2013, EUR RESPIR REV, V22, P44, DOI 10.1183/09059180.00007112; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hakansson K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127228; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Holm M, 2007, EUR RESPIR J, V30, P62, DOI 10.1183/09031936.00121705; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pesce G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138570; Polosa R, 2013, EUR RESPIR J, V41, P716, DOI 10.1183/09031936.00073312; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Postma Dirkje S, 2004, Chest, V126, p96S, DOI 10.1378/chest.126.2_suppl_1.96S; POSTMA DS, 2004, CHEST S, V126, pS59; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; Ronmark E, 1999, THORAX, V54, P611, DOI 10.1136/thx.54.7.611; Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011; Scott HA, 2016, ALLERGY, V71, P1037, DOI 10.1111/all.12891; Sears MR, 2015, J ALLERGY CLIN IMMUN, V136, P829, DOI 10.1016/j.jaci.2015.04.048; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Telenga ED, 2012, ALLERGY, V67, P1060, DOI 10.1111/j.1398-9995.2012.02855.x; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Tuomisto LE, 2016, RESP MED, V117, P223, DOI 10.1016/j.rmed.2016.06.017; Van Cauwenberge P, 2007, RHINOLOGY, V45, P112; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; van Huisstede A, 2015, THORAX, V70, P659, DOI 10.1136/thoraxjnl-2014-206712; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Westerhof GA, 2014, J ALLERGY CLIN IMMUN, V134, P1051, DOI 10.1016/j.jaci.2014.05.005	50	44	46	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					104	+		10.1016/j.jaci.2017.03.034	http://dx.doi.org/10.1016/j.jaci.2017.03.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28438546	Bronze			2022-12-18	WOS:000419312200016
J	Skendros, P; Chrysanthopoulou, A; Rousset, F; Kambas, K; Arampatzioglou, A; Mitsios, A; Bocly, V; Konstantinidis, T; Pellet, P; Angelidou, I; Apostolidou, E; Ritis, D; Tsironidou, V; Galtsidis, S; Papagoras, C; Stakos, D; Kouklakis, G; Dalla, V; Koffa, M; Mitroulis, I; Theodorou, I; Ritis, K				Skendros, Panagiotis; Chrysanthopoulou, Akrivi; Rousset, Francois; Kambas, Konstantinos; Arampatzioglou, Athanasios; Mitsios, Alexandros; Bocly, Veronique; Konstantinidis, Theocharis; Pellet, Philippe; Angelidou, Iliana; Apostolidou, Eirini; Ritis, Dimitrios; Tsironidou, Victoria; Galtsidis, Sotiris; Papagoras, Charalampos; Stakos, Dimitrios; Kouklakis, Georgios; Dalla, Vasiliki; Koffa, Maria; Mitroulis, Ioannis; Theodorou, Ioannis; Ritis, Konstantinos			Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1 beta-mediated familial Mediterranean fever attack through autophagy-driven neutrophil extracellular traps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulated in development and DNA damage responses 1; familiar Mediterranean fever; autophagy; neutrophil extracellular traps; IL-1 beta; stress; inflammation	DIFFERENTIAL EXPRESSION ANALYSIS; AUTOINFLAMMATORY DISEASES; BIOCONDUCTOR PACKAGE; GENE-EXPRESSION; INNATE IMMUNITY; TISSUE FACTOR; MTOR PATHWAY; PYRIN; INFLAMMASOME; ACTIVATION	Background: Familial Mediterranean fever (FMF) is an IL-1 beta-dependent autoinflammatory disease caused by mutations of Mediterranean fever (MEFV) encoding pyrin and characterized by inflammatory attacks induced by physical or psychological stress. Objective: We investigated the underlying mechanism that links stress-induced inflammatory attacks with neutrophil activation and release of IL-1 beta-bearing neutrophil extracellular traps (NETs) in patients with FMF. Methods: RNA sequencing was performed in peripheral neutrophils from 3 patients with FMF isolated both during attacks and remission, 8 patients in remission, and 8 healthy subjects. NET formation and proteins were analyzed by using confocal immunofluorescence microscopy, immunoblotting, myeloperoxidase-DNA complex ELISA, and flow cytometry. Samples from patients with Still's disease and bacterial infections were used also. Results: The stress-related protein regulated in development and DNA damage responses 1 (REDD1) is significantly overexpressed during FMF attacks. Neutrophils from patients with FMF during remission are resistant to autophagy-mediated NET release, which can be overcome through REDD1 induction. Stress-related mediators (eg, epinephrine) decrease this threshold, leading to autophagy-driven NET release, whereas the synchronous inflammatory environment of FMF attack leads to intracellular production of IL-1 beta and its release through NETs. REDD1 in autolysosomes colocalizes with pyrin and nucleotide-binding domain, leucine-rich repeat/pyrin domain-containing 3. Mutated pyrin prohibits this colocalization, leading to higher IL-1 beta levels on NETs. Conclusions: This study provides a link between stress and initiation of inflammatory attacks in patients with FMF. REDD1 emerges as a regulator of neutrophil function upstream to pyrin, is involved in NET release and regulation of IL-1 beta, and might constitute an important piece in the IL-1b-mediated inflammation puzzle.	[Skendros, Panagiotis; Chrysanthopoulou, Akrivi; Kambas, Konstantinos; Arampatzioglou, Athanasios; Mitsios, Alexandros; Konstantinidis, Theocharis; Angelidou, Iliana; Apostolidou, Eirini; Ritis, Dimitrios; Tsironidou, Victoria; Stakos, Dimitrios; Ritis, Konstantinos] Univ Hosp Alexandroupolis, Lab Mol Hematol, Alexandroupolis, Greece; [Skendros, Panagiotis; Apostolidou, Eirini; Papagoras, Charalampos; Kouklakis, Georgios; Dalla, Vasiliki; Ritis, Konstantinos] Univ Hosp Alexandroupolis, Dept Internal Med 1, Alexandroupolis, Greece; [Galtsidis, Sotiris; Koffa, Maria] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis, Greece; [Rousset, Francois; Bocly, Veronique; Pellet, Philippe; Theodorou, Ioannis] Univ Paris 06, Dept Immunol, UF Histocompatibilite & Immunogenet, Grp Hosp Pitie Salpetriere Charle Foix, Paris, France; [Theodorou, Ioannis] Tech Univ Dresden, Fac Med, Inst Clin Chem & Lab Med, Dept Clin Pathobiochem, Dresden, Germany	Democritus University of Thrace; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Technische Universitat Dresden	Ritis, K (corresponding author), Univ Hosp Alexandroupolis, Dragana 68100, Alexandroupolis, Greece.	kritis@med.duth.gr	Mitroulis, Ioannis/AAB-7915-2021; Stakos, Dimitrios/AAO-8728-2021; Koffa, Maria/AAP-3999-2020; Papagoras, Charis/AAO-6191-2020	Mitroulis, Ioannis/0000-0002-9991-2362; Papagoras, Charis/0000-0001-6207-496X; Konstantinidis, Theocharis/0000-0003-4296-3414; Skendros, Panagiotis/0000-0003-0456-7015; Koffa, Maria (Margy)/0000-0003-2255-3426; Rousset, Francois/0000-0002-1139-192X; Chrysanthopoulou, Akrivi/0000-0002-0325-6146	Scientific Committee of Democritus University of Thrace [80895]	Scientific Committee of Democritus University of Thrace	Supported by the Scientific Committee of Democritus University of Thrace, grant no. 80895.	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099; Apostolidou E, 2016, ANN RHEUM DIS, V75, P269, DOI 10.1136/annrheumdis-2014-205958; BARAKAT MH, 1984, LANCET, V1, P656; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chae JJ, 2006, P NATL ACAD SCI USA, V103, P9982, DOI 10.1073/pnas.0602081103; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; Deng Q, 2016, BRAIN BEHAV IMMUN, V57, P243, DOI 10.1016/j.bbi.2016.04.017; Dennis MD, 2013, CELL SIGNAL, V25, P2709, DOI 10.1016/j.cellsig.2013.08.038; Desantis A, 2015, EMBO J, V34, P1214, DOI 10.15252/embj.201489920; Dinarello CA, 2013, SEMIN IMMUNOL, V25, P469, DOI 10.1016/j.smim.2013.10.008; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Gavillet M, 2015, AM J HEMATOL, V90, P1155, DOI 10.1002/ajh.24185; Grattagliano I, 2014, CLIN PHARMACOL THER, V95, P89, DOI 10.1038/clpt.2013.148; Hoffman HM, 2016, J ALLERGY CLIN IMMUN, V138, P3, DOI 10.1016/j.jaci.2016.05.001; Itakura A, 2013, AM J PHYSIOL-CELL PH, V305, pC348, DOI 10.1152/ajpcell.00108.2013; Jandeleit-Dahm KAM, 2012, CURR OPIN NEPHROL HY, V21, P66, DOI 10.1097/MNH.0b013e32834dde48; Kambas K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045427; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kimura T, 2015, J CELL BIOL, V210, P973, DOI 10.1083/jcb.201503023; Knight JS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00380; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu C, 2014, BIOCHEM BIOPH RES CO, V454, P215, DOI 10.1016/j.bbrc.2014.10.079; Manukyan G, 2013, IMMUNOBIOLOGY, V218, P892, DOI 10.1016/j.imbio.2012.10.007; Mata MA, 2011, NAT CHEM BIOL, V7, P712, DOI [10.1038/nchembio.645, 10.1038/NCHEMBIO.645]; Mitroulis I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029318; Mitroulis I, 2011, HUM IMMUNOL, V72, P135, DOI 10.1016/j.humimm.2010.11.006; Mitroulis I, 2011, EXPERT OPIN THER TAR, V15, P75, DOI 10.1517/14728222.2011.532788; Mitroulis I, 2010, EUR J INTERN MED, V21, P157, DOI 10.1016/j.ejim.2010.03.005; Molitoris JK, 2011, J BIOL CHEM, V286, P30181, DOI 10.1074/jbc.M111.245423; Morgan M, 2009, BIOINFORMATICS, V25, P2607, DOI 10.1093/bioinformatics/btp450; Ozen S, 2016, ANN RHEUM DIS, V75, P644, DOI 10.1136/annrheumdis-2015-208690; Ozen S, 2014, NAT REV RHEUMATOL, V10, P135, DOI 10.1038/nrrheum.2013.174; Papin S, 2007, CELL DEATH DIFFER, V14, P1457, DOI 10.1038/sj.cdd.4402142; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Qiao SX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8014; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Ritis K, 2004, ANN RHEUM DIS, V63, P438, DOI 10.1136/ard.2003.009258; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009; Scanzano A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00171; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stakos DA, 2015, EUR HEART J, V36, P1405, DOI 10.1093/eurheartj/ehv007; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; Yanagawa Y, 2014, IMMUNOL LETT, V158, P109, DOI 10.1016/j.imlet.2013.12.015; Yenokyan G, 2012, AM J EPIDEMIOL, V175, P1054, DOI 10.1093/aje/kwr460; Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734; Zadeh N, 2011, GENET MED, V13, P263, DOI 10.1097/GIM.0b013e31820e27b1	54	44	50	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1378	+		10.1016/j.jaci.2017.02.021	http://dx.doi.org/10.1016/j.jaci.2017.02.021			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28342915	Bronze			2022-12-18	WOS:000414304300017
J	Guttman-Yassky, E; Ungar, B; Malik, K; Dickstein, D; Suprun, M; Estrada, YD; Xu, H; Peng, XY; Oliva, M; Todd, D; Labuda, T; Suarez-Farinas, M; Bissonnette, R				Guttman-Yassky, Emma; Ungar, Benjamin; Malik, Kunal; Dickstein, Daniel; Suprun, Maria; Estrada, Yeriel D.; Xu, Hui; Peng, Xiangyu; Oliva, Margeaux; Todd, Dan; Labuda, Tord; Suarez-Farinas, Mayte; Bissonnette, Robert			Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; topical treatments; emollients; plaque model; topical calcineurin inhibitor; topical steroids; psoriasis; biomarkers	ALLERGY CLIN IMMUNOL; SKIN BARRIER; DOUBLE-BLIND; TACROLIMUS OINTMENT; CALCINEURIN INHIBITORS; LANGERHANS CELLS; PIMECROLIMUS; EFFICACY; CORTICOSTEROIDS; CREAM	Background: Atopic dermatitis (AD) presents a large unmet need for treatments with better safety and efficacy. To facilitate development of topical therapeutics, we need an efficient model for assessing different formulations and concentrations. The "plaque model'' has been successfully implemented in patients with psoriasis, another common inflammatory disease, to assess the efficacy of topical treatments. This model has not been validated for AD, which has higher placebo responses and less stable lesions than psoriasis. Objective: We aimed to assess changes in molecular signatures of intrapatient target lesions treated with topical therapeutics. Methods: We enrolled 30 patients with mild-to-moderate AD in a randomized, double-blind, intraindividual comparison of 3 approved agents applied blindly at the investigator site daily for 14 days: pimecrolimus, betamethasone dipropionate, clobetasol propionate, and a vehicle/emollient control. Changes in total sign scores (TSSs), transepidermal water loss, and tissue biomarkers (determined by using RT-PCR and immunohistochemistry) were evaluated. Results: TSSs showed improvements of 30%, 40%, 68%, and 76% at 2 weeks with vehicle, pimecrolimus, betamethasone, and clobetasol, respectively, with parallel changes in transepidermal water loss (P < .05). Significant differences versus vehicle values were limited to steroids (P < .0001). Steroids (particularly clobetasol) restored epidermal hyperplasia and terminal differentiation versus minimal changes with vehicle or pimecrolimus (P < .001). Levels of cellular infiltrates and cytokines (IL-13, IL-22, and S100As) were similarly reduced only by steroids (P < .001). TSS improvement correlated with changes in hyperplasia, infiltrates, and differentiation markers. Conclusion: We detected significant clinical and tissue differences between agents, providing a novel approach to study the differential effects of topical formulations using a limited sample size.	[Guttman-Yassky, Emma; Ungar, Benjamin; Malik, Kunal; Dickstein, Daniel; Estrada, Yeriel D.; Xu, Hui; Peng, Xiangyu; Oliva, Margeaux] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 98th St, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Immunol Inst, New York, NY 10029 USA; [Suprun, Maria; Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA; [Todd, Dan; Labuda, Tord] LEO Pharma AS, Ballerup, Denmark; [Bissonnette, Robert] Innovaderm Res, Montreal, PQ, Canada	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; LEO Pharma; Innovaderm Research Inc.	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Suprun, Maria/ABE-8323-2020; Suprun, Maria/AAE-5507-2022	Suprun, Maria/0000-0001-9161-4021; Ungar, Benjamin/0000-0003-0882-8163; Dickstein, Daniel/0000-0003-4606-5574	LEO Pharma A/S	LEO Pharma A/S	Supported by a research grant from LEO Pharma A/S.	Antonov D, 2016, CURR PROBL DERMATOL, V49, P61, DOI 10.1159/000441546; Bangert C, 2011, DERMATOLOGY, V222, P36, DOI 10.1159/000321711; Bartels NG, 2010, PEDIATR DERMATOL, V27, P1, DOI 10.1111/j.1525-1470.2009.01068.x; Bauer A, 2012, J DTSCH DERMATOL GES, V10, P426, DOI 10.1111/j.1610-0387.2011.07832.x; Brauweiler AM, 2014, J INVEST DERMATOL, V134, P2114, DOI 10.1038/jid.2014.43; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Caproni M, 2007, BRIT J DERMATOL, V156, P312, DOI 10.1111/j.1365-2133.2006.07609.x; Chong M, 2016, CLIN REV ALLERG IMMU, V51, P249, DOI 10.1007/s12016-015-8486-7; Cork MJ, 2003, BRIT J DERMATOL, V149, P582, DOI 10.1046/j.1365-2133.2003.05595.x; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; D'Auria E, 2016, ASIAN PAC J ALLERGY, V34, P98, DOI 10.12932/AP0732.34.2.2016; Doss N, 2010, PEDIAT ALLERG IMM-UK, V21, P321, DOI 10.1111/j.1399-3038.2009.00895.x; DUMAS KJ, 1972, ACTA DERM-VENEREOL, V52, P43; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Gooderham M, 2014, BRIT J DERMATOL, V171, P1470, DOI 10.1111/bjd.13235; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Hoetzenecker W, 2004, J INVEST DERMATOL, V122, P673, DOI 10.1111/j.0022-202X.2004.22324.x; Hong J, 2011, SEMIN CUTAN MED SURG, V30, P71, DOI 10.1016/j.sder.2011.05.002; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Jensen JM, 2013, ACTA DERM-VENEREOL, V93, P515, DOI 10.2340/00015555-1533; Jensen JM, 2011, EXP DERMATOL, V20, P783, DOI 10.1111/j.1600-0625.2011.01322.x; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V124, pR19, DOI 10.1016/j.jaci.2009.07.015; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kirsner RS, 2010, ACTA DERM-VENEREOL, V90, P58, DOI 10.2340/00015555-0748; Kvist PH, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-107; Lauffer F, 2016, EXPERT OPIN EMERG DR, V21, P81, DOI 10.1517/14728214.2016.1146681; Lee CS, 2009, J DRUGS DERMATOL, V8, P751; Leung DYM, 2015, J ALLERGY CLIN IMMUN, V136, P1265, DOI 10.1016/j.jaci.2015.09.011; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; Maged M, 2009, J DERMATOL SCI, V54, P76, DOI 10.1016/j.jdermsci.2009.02.002; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; Marie Loden HIM, 2012, TREATMENT DRY SKIN S, P59; Mrowietz U, 2003, ACTA DERM-VENEREOL, V83, P351, DOI 10.1080/00015550310003791; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Niwa Y, 2005, J EUR ACAD DERMATOL, V19, P387, DOI 10.1111/j.1468-3083.2004.01123.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Ong PY, 2016, CLIN REV ALLERG IMMU, V51, P329, DOI 10.1007/s12016-016-8548-5; Queille-Roussel C, 2012, CLIN DRUG INVEST, V32, P613, DOI 10.2165/11634710-000000000-00000; Reitamo S, 2005, BRIT J DERMATOL, V152, P1282, DOI 10.1111/j.1365-2133.2005.06592.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Ring J, 2008, DRUG SAFETY, V31, P185, DOI 10.2165/00002018-200831030-00001; Saeki H, 2016, J DERMATOL, V43, P1117, DOI 10.1111/1346-8138.13392; Saki N, 2013, J DERMATOL TREAT, V24, P447, DOI 10.3109/09546634.2013.782384; Schmitt J, 2011, BRIT J DERMATOL, V164, P415, DOI 10.1111/j.1365-2133.2010.10030.x; Sigurgeirsson B, 2015, PEDIATRICS, V135, P597, DOI 10.1542/peds.2014-1990; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Wiren K, 2009, J EUR ACAD DERMATOL, V23, P1267, DOI 10.1111/j.1468-3083.2009.03303.x; Wittkowski KM, 2004, STAT MED, V23, P1579, DOI 10.1002/sim.1778; Yan J, 2008, PEDIATR DERMATOL, V25, P117, DOI 10.1111/j.1525-1470.2007.00600.x	60	44	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1032	+		10.1016/j.jaci.2017.01.027	http://dx.doi.org/10.1016/j.jaci.2017.01.027			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28238742	hybrid			2022-12-18	WOS:000412172900015
J	Takeda, AJ; Zhang, Y; Dornan, GL; Siempelkamp, BD; Jenkins, ML; Matthews, HF; McElwee, JJ; Bi, WM; Seeborg, FO; Su, HC; Burke, JE; Lucas, CL				Takeda, Andrew J.; Zhang, Yu; Dornan, Gillian L.; Siempelkamp, Braden D.; Jenkins, Meredith L.; Matthews, Helen F.; McElwee, Joshua J.; Bi, Weimin; Seeborg, Filiz O.; Su, Helen C.; Burke, John E.; Lucas, Carrie L.			Novel PIK3CD mutations affecting N-terminal residues of p110d cause activated PI3Kd syndrome (APDS) in humans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HUMAN IMMUNODEFICIENCY; CANCER; GENE; PATHWAY; PI3K-DELTA; P110-ALPHA; GERMLINE; SPECTRUM; FEATURES; ALPHA		[Takeda, Andrew J.; Lucas, Carrie L.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Zhang, Yu; Su, Helen C.] NIAID, Human Immunol Dis Sect, Lab Host Def, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Zhang, Yu; Matthews, Helen F.; Su, Helen C.] NIAID, Clin Genom Program, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Matthews, Helen F.] NIAID, Mol Dev Immune Syst Sect, Lab Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Dornan, Gillian L.; Siempelkamp, Braden D.; Jenkins, Meredith L.; Burke, John E.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [McElwee, Joshua J.] Merck & Co Inc, Merck Res Labs, Boston, MA USA; [Bi, Weimin] Baylor Coll Med, Mol & Human Genet Cytogenet Lab, Houston, TX 77030 USA; [Seeborg, Filiz O.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Victoria; Merck & Company; Baylor College of Medicine; Baylor College of Medicine	Lucas, CL (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.	Carrie.Lucas@yale.edu	Su, Helen C/H-9541-2015; Burke, John/H-3922-2019	Su, Helen C/0000-0002-5582-9110; Burke, John/0000-0001-7904-9859; Lucas, Carrie/0000-0002-5754-0820; Takeda, Andrew/0000-0002-0778-0252; Jenkins, Meredith/0000-0002-0685-5048; Dornan, Gillian Leigh/0000-0002-5170-9015	National Institute of Allergy and Infectious Diseases/National Institutes of Health; Yale University from the National Heart, Lung, and Blood Institute [R00HL125668]; CIHR; Natural Sciences and Engineering Research Council of Canada [NSERC-2014-05218]; Department of Laboratory Medicine at the Clinical Center, National Institutes of Health.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL125668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001059] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Yale University from the National Heart, Lung, and Blood Institute; CIHR(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Department of Laboratory Medicine at the Clinical Center, National Institutes of Health.(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases/National Institutes of Health. C.L.L. is supported by Yale University and R00HL125668 from the National Heart, Lung, and Blood Institute. J.E.B. is supported by a new investigator grant from CIHR and a discovery research grant from the Natural Sciences and Engineering Research Council of Canada (NSERC-2014-05218).; We thank the patients and their families, as well as referring clinicians and their teams. We also thank Nisha Momin, RN, BSN, from Texas Children's Hospital and Monica Konstantino, RN, BSN, from the Yale Pediatric Genomics Discovery Program for their clinical support and assistance and Tom Fleisher, MD; Sergio Rosenzweig, MD; and Julie Niemela, MS, for support through the Department of Laboratory Medicine at the Clinical Center, National Institutes of Health.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109; Burke JE, 2011, STRUCTURE, V19, P1127, DOI 10.1016/j.str.2011.06.003; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Dornan GL, 2017, P NATL ACAD SCI USA, V114, P1982, DOI 10.1073/pnas.1617244114; Echeverria I, 2015, FEBS J, V282, P3528, DOI 10.1111/febs.13365; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Heffron TP, 2016, J MED CHEM, V59, P985, DOI 10.1021/acs.jmedchem.5b01483; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Loconte DC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123092; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Mirzaa G, 2016, JCI INSIGHT, P1; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Orloff MS, 2013, AM J HUM GENET, V92, P76, DOI 10.1016/j.ajhg.2012.10.021; Rios JJ, 2013, HUM MOL GENET, V22, P444, DOI 10.1093/hmg/dds440; Riviere JB, 2012, NAT GENET, V44, P934, DOI 10.1038/ng.2331; Ross RL, 2013, ONCOGENE, V32, P768, DOI 10.1038/onc.2012.87; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shibata T, 2009, CANCER LETT, V283, P203, DOI 10.1016/j.canlet.2009.03.038; Vadas O, 2017, METHOD ENZYMOL, V583, P143, DOI 10.1016/bs.mie.2016.09.008; Zhang XX, 2011, MOL CELL, V41, P567, DOI 10.1016/j.molcel.2011.01.026	28	44	45	3	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1152	+		10.1016/j.jaci.2017.03.026	http://dx.doi.org/10.1016/j.jaci.2017.03.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28414062	Green Accepted, Bronze			2022-12-18	WOS:000412172900029
J	Casale, TB				Casale, Thomas B.			Biologics and biomarkers for asthma, urticaria, and nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Biologics; asthma; urticaria; nasal polyps; mAbs; cytokines; IgE	SEVERE EOSINOPHILIC ASTHMA; CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA; UNCONTROLLED PERSISTENT ASTHMA; CHRONIC IDIOPATHIC URTICARIA; PLACEBO-CONTROLLED TRIAL; CONTROLLED PHASE-3 TRIAL; DOUBLE-BLIND; ALLERGIC-ASTHMA; MONOCLONAL-ANTIBODY; RANDOMIZED-TRIAL	Many patients with allergic disorders continue to have uncontrolled symptoms despite new and better pharmacologic options. Novel biologic agents that target specific and critical pathophysiologic pathways have been developed to better manage these patients. The utility of biologic agents for the management of allergic diseases has been facilitated by recent advances in better characterizing patients, including identification of relevant biomarkers that predict clinical responsiveness. This has led to the ability to phenotype and endotype patients, allowing for a more rational approach to picking a specific biologic agent for a specific patient. In this review I focus on point-of-care biomarkers that enhance the usefulness of biologics to manage uncontrolled asthma, urticaria, and nasal polyposis. I discuss biologic agents already approved for the management of allergic and respiratory disorders and biologics currently in development or recently abandoned because of a lack of efficacy or intolerable side effects. The successes and failures of biologics in clinical trials have facilitated our ability to better understand which molecules and pathways are most important in the pathogenesis of allergic diseases and in the development of symptoms and impairment in individual patients.	[Casale, Thomas B.] Univ S Florida, Morsani Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL USA	State University System of Florida; University of South Florida	Casale, TB (corresponding author), Univ S Florida, Morsani Coll Med, Dept Med, 12901 Bruce B Downs Blvd,MDC 19, Tampa, FL 33612 USA.	tbcasale@health.usf.edu						Baatjes AJ, 2015, ALLERGY, V70, P1505, DOI 10.1111/all.12708; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Berry A, 2016, J ALLERGY CLIN IMMUN, V137, P1317, DOI 10.1016/j.jaci.2016.03.009; Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Brightling CE, 2015, LANCET RESP MED, V3, P692, DOI 10.1016/S2213-2600(15)00197-6; Busse W, 2013, J ALLERGY CLIN IMMUN, V132, P485, DOI 10.1016/j.jaci.2013.02.032; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Casale TB, 2015, J ALLERGY CLIN IMMUN, V135, pAB1, DOI 10.1016/j.jaci.2014.12.937; Casale TB, 2015, J ALLER CL IMM-PRACT, V3, P743, DOI 10.1016/j.jaip.2015.04.015; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Cooke A, 2015, BIOL-TARGETS THER, V9, P25, DOI 10.2147/BTT.S63839; Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2015, J ALLERGY CLIN IMMUN, V135, P877, DOI 10.1016/j.jaci.2014.10.026; de Koning HD, 2013, ANN RHEUM DIS, V72, P1634, DOI 10.1136/annrheumdis-2012-202192; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Garcia G, 2013, CHEST, V144, P411, DOI 10.1378/chest.12-1961; Gauvreau GM, 2016, J ALLERGY CLIN IMMUN, V138, P1051, DOI 10.1016/j.jaci.2016.02.027; Gauvreau GM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008961; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gevaert P, 2003, ALLERGY, V58, P371, DOI 10.1034/j.1398-9995.2003.00110.x; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Hanania NA, 2016, LANCET RESP MED, V4, P781, DOI 10.1016/S2213-2600(16)30265-X; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Harris JM, 2016, J ALLERGY CLIN IMMUN, V138, P1730, DOI 10.1016/j.jaci.2016.06.023; Harris JM, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0347-2; Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kaplan AP, 2015, J ALLER CL IMM-PRACT, V3, P648, DOI 10.1016/j.jaip.2015.04.008; Krause K, 2013, J ALLERGY CLIN IMMUN, V132, P751, DOI 10.1016/j.jaci.2013.04.008; Kuemmerle-Deschner JB, 2015, SEMIN IMMUNOPATHOL, V37, P377, DOI 10.1007/s00281-015-0491-7; Legrand F, 2015, J ALLER CL IMM-PRACT, V3, P167, DOI 10.1016/j.jaip.2015.01.013; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Neel A, 2014, AUTOIMMUN REV, V13, P1035, DOI 10.1016/j.autrev.2014.08.031; Nowak RM, 2015, AM J EMERG MED, V33, P14, DOI 10.1016/j.ajem.2014.09.036; O'Byrne PM, 2016, LANCET RESP MED, V4, P797, DOI 10.1016/S2213-2600(16)30227-2; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pereira C, 2007, Eur Ann Allergy Clin Immunol, V39, P237; Piconi S, 2002, INT ARCH ALLERGY IMM, V128, P59, DOI 10.1159/000058004; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 2015, J INVEST DERMATOL, V135, P67, DOI 10.1038/jid.2014.306; Sand FL, 2015, DERMATOL THER, V28, P158, DOI 10.1111/dth.12222; Satoh T, 2015, IMMUNOTHERAPY-UK, V7, P243, DOI [10.2217/IMT.14.106, 10.2217/imt.14.106]; Schneider JS, 2016, JAMA OTOLARYNGOL, V142, P698, DOI 10.1001/jamaoto.2016.0678; Simon HU, 1997, J IMMUNOL, V158, P3902; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8; Stokes JR, 2016, ANN ALLERG ASTHMA IM, V117, P121, DOI 10.1016/j.anai.2016.05.016; Stokes JR, 2015, J ALLER CL IMM-PRACT, V3, P162, DOI 10.1016/j.jaip.2014.10.010; van den Berge M, 2011, CHEST, V139, P190, DOI 10.1378/chest.10-0128; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson LH, 2011, J AM ACAD DERMATOL, V64, P1221, DOI 10.1016/j.jaad.2009.10.043; Zeiger RS, 2017, J ALLER CL IMM-PRACT, V5, P144, DOI 10.1016/j.jaip.2016.07.015; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	76	44	44	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1411	+		10.1016/j.jaci.2017.03.006	http://dx.doi.org/10.1016/j.jaci.2017.03.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28477720	Bronze			2022-12-18	WOS:000400465300001
J	Dorsey, MJ; Dvorak, CC; Cowan, MJ; Puck, JM				Dorsey, Morna J.; Dvorak, Christopher C.; Cowan, Morton J.; Puck, Jennifer M.			Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; newborn screening; transplantation; T cells; T-cell lymphopenia	STEM-CELL TRANSPLANTATION; 1ST 2 YEARS; DEFICIENCY; CHILDREN; DISEASE; ENGRAFTMENT; EXPERIENCE; OUTCOMES	Severe combined immunodeficiency (SCID) is characterized by severely impaired T-cell development and is fatal without treatment. Newborn screening (NBS) for SCID permits identification of affected infants before development of opportunistic infections and other complications. Substantial variation exists between treatment centers with regard to pretransplantation care, and transplantation protocols for NBS identified infants with SCID, as well as infants with other Tlymphopenic disorders detected by using NBS. We developed approaches to management based on the study of infants identified by means of NBS for SCID who received care at the University of California, San Francisco (UCSF). From August 2010 through October 2016, 32 patients with NBS-identified SCID and leaky SCID from California and other states were treated, and 42 patients with NBS-identified non-SCID T-cell lymphopenia were followed. Our center's approach supports successful outcomes; systematic review of our practice provides a framework for diagnosis and management, recognizing that more data will continue to shape best practices.	[Dorsey, Morna J.; Dvorak, Christopher C.; Cowan, Morton J.; Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, Div Allergy Immunol & Bone Marrow Transplantat, 550 16th St,4th Floor,Box 0434, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Dorsey, MJ (corresponding author), Univ Calif San Francisco, Dept Pediat, Div Allergy Immunol & Bone Marrow Transplantat, 550 16th St,4th Floor,Box 0434, San Francisco, CA 94143 USA.	morna.dorsey@ucsf.edu	Dorsey, Morna/V-7270-2018; Dvorak, Christopher C/AAX-1630-2020	Dorsey, Morna/0000-0002-9432-3542; Dvorak, Christopher C/0000-0002-6146-3952	Primary Immunodeficiency Treatment Consortium (PIDTC) National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID); National Center for Advancing Traditional Sciences (NCATS) ORD grant [U54 AI082973, R13 AI094943]; NIH/NIAID grant [RO1 AI105776]; NIH/NCATS UCSF CTSI grant [UL1 TR000004]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI105776, U54AI082973] Funding Source: NIH RePORTER	Primary Immunodeficiency Treatment Consortium (PIDTC) National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID); National Center for Advancing Traditional Sciences (NCATS) ORD grant; NIH/NIAID grant; NIH/NCATS UCSF CTSI grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.J.C., C.C.D., and J.M.P. are supported by Primary Immunodeficiency Treatment Consortium (PIDTC) National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) and National Center for Advancing Traditional Sciences (NCATS) ORD grant U54 AI082973 and R13 AI094943. J.M.P. is supported by NIH/NIAID grant RO1 AI105776 and an NIH/NCATS UCSF CTSI grant (UL1 TR000004).	Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Cowan MJ, 2015, J ALLERGY CLIN IMMUN, V136, P1178, DOI 10.1016/j.jaci.2015.04.027; De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856; DeLuca JM, 2011, PEDIATRICS, V128, P53, DOI 10.1542/peds.2010-3413; Dimitrova D, 2014, J CLIN IMMUNOL, V34, P677, DOI 10.1007/s10875-014-0048-x; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Dvorak CC, 2014, J ALLERGY CLIN IMMUN, V134, P935, DOI 10.1016/j.jaci.2014.06.021; Dvorak CC, 2013, J CLIN IMMUNOL, V33, P1156, DOI 10.1007/s10875-013-9917-y; Etzioni A, 2014, PRIMARY IMMUNODEFICIENCY DISORDERS: A HISTORIC AND SCIENTIFIC PERSPECTIVE, P1; Fanos JH, 2001, AM J MED GENET, V98, P57, DOI 10.1002/1096-8628(20010101)98:1<57::AID-AJMG1007>3.3.CO;2-A; Griffith LM, 2016, J ALLERGY CLIN IMMUN, V138, P375, DOI 10.1016/j.jaci.2016.01.051; Grunebaum E, 2012, J ALLERGY CLIN IMMUN, V129, P1588, DOI 10.1016/j.jaci.2012.02.003; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Heller Karen, 2005, Proc (Bayl Univ Med Cent), V18, P134; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Kohn DB, 2015, BLOOD, V125, P3521, DOI 10.1182/blood-2015-04-641720; Ktuan A, 2015, SEMIN PERINATOL, V39, P194, DOI 10.1053/j.semperi.2015.03.004; Kuo CY, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0615-8; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Mezzacappa ES, 2007, ARCH WOMEN MENT HLTH, V10, P259, DOI 10.1007/s00737-007-0207-7; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Patel NC, 2012, CLIN IMMUNOL, V142, P399, DOI 10.1016/j.clim.2011.11.012; Savic RM, 2013, BIOL BLOOD MARROW TR, V19, P1608, DOI 10.1016/j.bbmt.2013.08.014; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Vogel BH, 2014, J CLIN IMMUNOL, V34, P289, DOI 10.1007/s10875-014-0006-7; Wahlstrom J, 2017, J ALLERGY CLIN IMMUN, V139, P628, DOI 10.1016/j.jaci.2016.04.049; Wu JT, 1985, SERUM AFP LEVELS NOR, P111; Ystrom E, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-36	34	44	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					733	742		10.1016/j.jaci.2017.01.005	http://dx.doi.org/10.1016/j.jaci.2017.01.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	28270365	Green Accepted, Bronze			2022-12-18	WOS:000397295800003
J	Lawrence, MG; Woodfolk, JA; Schuyler, AJ; Stillman, LC; Chapman, MD; Platts-Mills, TAE				Lawrence, Monica G.; Woodfolk, Judith A.; Schuyler, Alexander J.; Stillman, Leland C.; Chapman, Martin D.; Platts-Mills, Thomas A. E.			Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunoglobulin; IgE; half-life; metabolism; omalizumab	FC-EPSILON-RI; CELL CHYMASE GENE; MAST-CELLS; BINDING LECTIN; INHALANT ALLERGENS; ATOPIC-DERMATITIS; IMMUNOGLOBULIN-E; HUMAN BASOPHILS; B-CELLS; RECEPTOR	We present results from clinical studies on plasma infusion done in the late 1970s in patients with hypogammaglobulinemia in which we documented the short half-life of both total and allergen-specific IgE in serum. The development of specific allergic sensitization in the skin of those patients followed by the gradual decrease in sensitization over 50 days was also documented. The data are included here along with a discussion of the existing literature about the half-life of IgE in both the circulation and skin. This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms that could explain the rapid removal of IgE from the circulation. These mechanisms have clinical implications that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease.	[Lawrence, Monica G.; Woodfolk, Judith A.; Schuyler, Alexander J.; Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA; [Stillman, Leland C.; Chapman, Martin D.] Indoor Biotechnol, Charlottesville, VA USA	University of Virginia; INDOOR Biotechnologies	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X; Chapman, Martin/0000-0002-0845-3632	National Institutes of Health/National Institute of Allergy and Infectious Diseases; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases; Dupont/Danisco; National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Dupont/Danisco; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M. G. Lawrence has consultant arrangements with Merck/Faculty Connections and Regado Biosciences/Faculty Connections. J. A. Woodfolk has received grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Dupont/Danisco. M. D. Chapman has received grants from the National Institute of Allergy and Infectious Diseases, is employed by and is co-owner of Indoor Biotechnologies, has patents through the University of Virginia, and has stock/stock options as co-owner of Indoor Biotechnologies. The rest of the authors declare that they have no relevant conflicts of interest.	Abbas AK, 2015, CELLULAR MOL IMMUNOL, Vviii, P535; Abdelmotelb AM, 2014, CLIN EXP ALLERGY, V44, P822, DOI 10.1111/cea.12259; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; Asherson G, 1980, IMMUNOGLOBULIN REPLA; BACH MK, 1978, INT ARCH ALLER A IMM, V56, P1, DOI 10.1159/000231997; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; Bundhoo A, 2015, CLIN EXP ALLERGY, V45, P1085, DOI 10.1111/cea.12508; Casellas R, 2001, SAMTERS IMMUNOLOGIC; CASS RM, 1968, J ALLERGY, V42, P29, DOI 10.1016/0021-8707(68)90129-9; Cheng LE, 2013, IMMUNITY, V38, P166, DOI 10.1016/j.immuni.2012.09.022; Cheng LE, 2010, J IMMUNOL, V185, P5040, DOI 10.4049/jimmunol.1001900; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COLEMAN JW, 1981, IMMUNOLOGY, V44, P859; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Ehrlich P., 1878, THESIS; Ellinger I, 2001, EXP CELL RES, V269, P322, DOI 10.1006/excr.2001.5330; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Greer AM, 2014, J CLIN INVEST, V124, P1187, DOI 10.1172/JCI68964; Guha S, 2008, INDIAN J BIOCHEM BIO, V45, P75; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; Hamilton RG, 2008, CLIN IMMUNOLOGY PRIN; HAY FC, 1971, CLIN EXP IMMUNOL, V9, P355; IIO A, 1978, J IMMUNOL, V120, P1696; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; Iwanaga T, 2004, CLIN EXP ALLERGY, V34, P1037, DOI 10.1111/j.1365-2222.2004.02000.x; Jelinek DE, 2013, MIDDLETONS ALLERGY P; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Krzywicki HJ, 1966, 297 US ARM MED RES N; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan Donald Jr., 2003, Journal of Allergy and Clinical Immunology, V112, pS53, DOI 10.1016/S0091-6749(03)01877-3; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Mao XQ, 1998, HUM HERED, V48, P38, DOI 10.1159/000022782; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; Niki T, 2009, J BIOL CHEM, V284, P32344, DOI 10.1074/jbc.M109.035196; Platts-Mills TA, 1977, ALLERGOL IMMUNOPATH, V5, P340; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; Quinn PM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20509; Rauter I, 2008, J ALLERGY CLIN IMMUN, V121, P197, DOI 10.1016/j.jaci.2007.08.015; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; SAXON A, 1987, CELL IMMUNOL, V104, P134, DOI 10.1016/0008-8749(87)90014-1; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SMITH CH, 1995, J ALLERGY CLIN IMMUN, V96, P360, DOI 10.1016/S0091-6749(95)70055-2; Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143; WALDMANN TA, 1976, J IMMUNOL, V117, P1139; Walpole SC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-439; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	55	44	44	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					422	428		10.1016/j.jaci.2016.04.056	http://dx.doi.org/10.1016/j.jaci.2016.04.056			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27496596	Green Accepted, Bronze			2022-12-18	WOS:000397002400006
J	Selb, R; Eckl-Dorna, J; Neunkirchner, A; Schmetterer, K; Marth, K; Gamper, J; Jahn-Schmid, B; Pickl, WF; Valenta, R; Niederberger, V				Selb, Regina; Eckl-Dorna, Julia; Neunkirchner, Alina; Schmetterer, Klaus; Marth, Katharina; Gamper, Jutta; Jahn-Schmid, Beatrice; Pickl, Winfried F.; Valenta, Rudolf; Niederberger, Verena			CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD23; allergy; IgE; low-affinity IgE receptor; B cell; allergen	FC-EPSILON-RI; ANTIGEN-PRESENTING CELLS; BIRCH POLLEN ALLERGEN; BLOCKING ANTIBODIES; MONOCLONAL-ANTIBODY; NONATOPIC SUBJECTS; ATOPIC-DERMATITIS; INTERFERON-GAMMA; HUMAN BASOPHILS; RECEPTOR CD23	Background: Increasing evidence suggests that the low-affinity receptor for IgE, CD23, plays an important role in controlling the activity of allergen-specific T cells through IgE-facilitated allergen presentation. Objective: We sought to determine the number of CD23 molecules on immune cells in allergic patients and to investigate whether the number of CD23 molecules on antigen-presenting cells is associated with IgE levels and influences allergen uptake and allergen-specific T-cell activation. Methods: Numbers of CD23 molecules on immune cells of allergic patients were quantified by using flow cytometry with QuantiBRITE beads and compared with total and allergen-specific IgE levels, as well as with allergen-induced immediate skin reactivity. Allergen uptake and allergen-specific T-cell activation in relation to CD23 surface density were determined by using flow cytometry in combination with confocal microscopy and T cells transfected with the T-cell receptor specific for the birch pollen allergen Bet v 1, respectively. Defined IgE-allergen immune complexes were formed with human monoclonal allergen-specific IgE and Bet v 1. Results: In allergic patients the vast majority of CD23 molecules were expressed on naive IgD (+) B cells. The density of CD23 molecules on B cells but not the number of CD23 1 cells correlated with total IgE levels ( RS50.53, P5.03) and allergen-induced skin reactions (R-S = 0.63, P = .008). Uptake of allergen-IgE complexes into B cells and activation of allergen-specific T cells depended on IgE binding to CD23 and were associated with CD23 surface density. Addition of monoclonal IgE to cultured PBMCs significantly (P =.04) increased CD23 expression on B cells. Conclusion: CD23 surface density on B cells of allergic patients is correlated with allergen-specific IgE levels and determines allergen uptake and subsequent activation of T cells.	[Selb, Regina; Eckl-Dorna, Julia; Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, AKH 8J,Wahringer Gurtel 18-20, Vienna, Austria; [Neunkirchner, Alina; Pickl, Winfried F.] Med Univ Vienna, Christian Doppler Lab Immunomodulat, Vienna, Austria; [Schmetterer, Klaus] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Vienna, Austria; [Jahn-Schmid, Beatrice] Med Univ Vienna, Div Expt Allergol, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Neunkirchner, Alina; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Gamper, Jutta] Med Univ Vienna, Sect Med Stat, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Niederberger, V (corresponding author), Med Univ Vienna, Dept Otorhinolaryngol, AKH 8J,Wahringer Gurtel 18-20, Vienna, Austria.	verena.niederberger@meduniwien.ac.at	Eckl-Dorna, Julia/AAY-6371-2020	Selb, Regina/0000-0001-5531-5198; Valenta, Rudolf/0000-0001-5944-3365; Eckl-Dorna, Julia/0000-0001-5981-1607; Pickl, Winfried F./0000-0003-0430-4952	Austrian Science Fund [SFB 4605, SFB 4613, SFB 4609]	Austrian Science Fund(Austrian Science Fund (FWF))	Supported by the Austrian Science Fund (FWF): SFB 4605, SFB 4613, and SFB 4609.	ARMITAGE RJ, 1989, EUR J IMMUNOL, V19, P31, DOI 10.1002/eji.1830190106; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; COROMINAS M, 1993, CLIN EXP ALLERGY, V23, P612, DOI 10.1111/j.1365-2222.1993.tb00902.x; Corominas M, 1998, CLIN EXP IMMUNOL, V112, P276; Dehlink E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012204; Dombrowicz D, 2000, CHEM IMMUNOL, V76, P63; Flicker S, 2011, CURR TOP MICROBIOL, V352, P141, DOI 10.1007/82_2011_143; Gauvreau GM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008961; Gomez G, 2007, J IMMUNOL, V179, P1353, DOI 10.4049/jimmunol.179.2.1353; Griffith Q, 2015, EXP PARASITOL, V153, P139, DOI 10.1016/j.exppara.2015.03.012; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; Iyengar SR, 2013, INT ARCH ALLERGY IMM, V162, P89, DOI 10.1159/000350486; JUNG CM, 1995, J ALLERGY CLIN IMMUN, V95, P77, DOI 10.1016/S0091-6749(95)70155-9; Karagiannis SN, 2001, IMMUNOLOGY, V103, P319, DOI 10.1046/j.1365-2567.2001.01238.x; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Klouche M, 1997, J ALLERGY CLIN IMMUN, V100, P235, DOI 10.1016/S0091-6749(97)70230-6; KRAUSS S, 1993, ADV EXP MED BIOL, V329, P231; Laffer S, 1996, J IMMUNOL, V157, P4953; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; NAKAMURA K, 1991, BRIT J DERMATOL, V125, P543, DOI 10.1111/j.1365-2133.1991.tb14791.x; Neunkirchner A, 2011, J IMMUNOL, V187, P4077, DOI 10.4049/jimmunol.1003220; Niederberger V, 2015, J ALLERGY CLIN IMMUN, V136, P1101, DOI 10.1016/j.jaci.2015.03.034; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Poole JA, 2005, J ALLERGY CLIN IMMUN, V116, P780, DOI 10.1016/j.jaci.2005.07.007; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Roever AC, 2003, CLIN EXP ALLERGY, V33, P1568, DOI 10.1046/j.1365-2222.2003.01797.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; VECCHIARELLI A, 1994, CLIN EXP IMMUNOL, V97, P248; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; WANG SCT, 1995, J LEUKOCYTE BIOL, V57, P343, DOI 10.1002/jlb.57.2.343; Yamaoka KA, 1996, INT IMMUNOL, V8, P479, DOI 10.1093/intimm/8.4.479; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	45	44	45	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					290	+		10.1016/j.jaci.2016.03.042	http://dx.doi.org/10.1016/j.jaci.2016.03.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27372566	Green Accepted, Bronze			2022-12-18	WOS:000393996800030
J	Nomura, T; Kabashima, K				Nomura, Takashi; Kabashima, Kenji			Advances in atopic dermatitis in 2015	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; biologics; cytokines; chemokines; thymic stromal lymphopoietin; chemoattractant receptor-homologous molecule expressed on T(H)2 cells; petrolatum; ultraviolet B; sirtuin 1; aryl hydrocarbon receptor; Janus kinase; signal transducer and activator of transcription 3; extracellular; signal-regulated kinase; pathogenic effector T(H)2 T(H)1T(H)2 T(H)17 T(H)22; transepidermal water loss; adiposity; JTE-052	GENOME-WIDE ASSOCIATION; SKIN BARRIER; SUSCEPTIBILITY LOCI; SIGNAL TRANSDUCER; CELL SUBSETS; PSORIASIS; FILAGGRIN; EXPOSURE; MARCH; MECHANISMS	This review aims to highlight recently published articles on atopic dermatitis (AD). Updated are the insights into epidemiology, pathology, diagnostics, and therapy. Epidemiologic studies have revealed a positive correlation between AD and systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and neonatal adiposity. Pathologic findings highlight the involvement of novel barrier factors (desmoplakin and claudin), novel immune cell subsets (pathogenic effector T(H)2 cells and group 2 innate lymphoid cells), and differential skewing of helper T cells (eg, T(H)17 dominance in Asians with AD). As diagnostics, noninvasive examinations of the transepidermal water loss of neonates, the density of epidermal Staphylococcus species, and the gut flora might prognosticate the onset of AD. As for therapy, various methods are proposed, including conventional (petrolatum and UV) and molecule-oriented regimens targeting Janus kinase, signal transducer and activator of transcription 3, extracellular signal-regulated kinase, sirtuin 1, or aryl hydrocarbon receptor.	[Nomura, Takashi; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Nomura, Takashi] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci iACT, Dept Expt Therapeut, Kyoto, Japan; [Kabashima, Kenji] ASTAR, Biopolis, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Biopolis, Inst Med Biol, Singapore, Singapore; [Kabashima, Kenji] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan	Kyoto University; Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Japan Science & Technology Agency (JST)	Nomura, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	tnomura@kuhp.kyoto-u.ac.jp	Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554	Japan Society for the Promotion of Science [15H05790, 24591649, 15K09765, 15H1155, 15K15417]; Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO) [16021031300]; Japan Agency for Medical Research and Development (AMED) [16ek0410011h0003, 16he0902003h0002]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	Supported in part by the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (15H05790, 24591649, and 15K09765); Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research on Innovative Areas (15H1155); Japan Society for the Promotion of Science, Grant-in-Aid for challenging Exploratory Research (15K15417); Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO) (16021031300); and Japan Agency for Medical Research and Development (AMED; 16ek0410011h0003, 16he0902003h0002).	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Campana R, 2016, J ALLERGY CLIN IMMUN, V137, P601, DOI 10.1016/j.jaci.2015.08.042; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Fishbein AB, 2015, J ALLERGY CLIN IMMUN, V136, P1170, DOI 10.1016/j.jaci.2015.08.028; Fornasa G, 2015, J ALLERGY CLIN IMMUN, V136, P413, DOI 10.1016/j.jaci.2015.04.011; Gao L, 2015, J ALLERGY CLIN IMMUN, V136, P1591, DOI 10.1016/j.jaci.2015.06.047; Gruber C, 2015, J ALLERGY CLIN IMMUN, V136, P1696, DOI 10.1016/j.jaci.2015.07.049; Harden JL, 2016, J ALLERGY CLIN IMMUN, V137, P1830, DOI 10.1016/j.jaci.2015.09.055; Henriksen L, 2015, J ALLERGY CLIN IMMUN, V136, P360, DOI 10.1016/j.jaci.2015.02.003; Hradetzky S, 2015, J ALLERGY CLIN IMMUN, V135, P1378, DOI 10.1016/j.jaci.2014.10.038; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kim JH, 2015, J ALLERGY CLIN IMMUN, V136, P205, DOI 10.1016/j.jaci.2015.04.026; Kim KW, 2015, J ALLERGY CLIN IMMUN, V136, P678, DOI 10.1016/j.jaci.2015.03.030; Leung DYM, 2015, J ALLERGY CLIN IMMUN, V136, P1265, DOI 10.1016/j.jaci.2015.09.011; Li HG, 2016, J ALLERGY CLIN IMMUN, V137, P613, DOI 10.1016/j.jaci.2015.07.039; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; McAleer MA, 2015, J ALLERGY CLIN IMMUN, V136, P1268, DOI 10.1016/j.jaci.2015.05.002; Ming M, 2015, J ALLERGY CLIN IMMUN, V135, P936, DOI 10.1016/j.jaci.2014.09.035; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; O'Donovan SM, 2016, J ALLERGY CLIN IMMUN, V137, P108, DOI 10.1016/j.jaci.2015.05.035; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Schaarschmidt H, 2015, J ALLERGY CLIN IMMUN, V136, P802, DOI 10.1016/j.jaci.2015.01.047; Schmitt J, 2016, J ALLERGY CLIN IMMUN, V137, P130, DOI 10.1016/j.jaci.2015.06.029; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135, P1476, DOI 10.1016/j.jaci.2015.01.003; Silverberg JI, 2016, J ALLERGY CLIN IMMUN, V137, P492, DOI 10.1016/j.jaci.2015.07.020; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Song H, 2016, J ALLERGY CLIN IMMUN, V137, P852, DOI 10.1016/j.jaci.2015.08.021; Spergel JM., 2010, ANN ALLERG ASTHMA IM, V105, P107; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Tauber M, 2016, J ALLERGY CLIN IMMUN, V137, P1272, DOI 10.1016/j.jaci.2015.07.052; Taylan F, 2015, J ALLERGY CLIN IMMUN, V136, P507, DOI 10.1016/j.jaci.2015.02.010; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V136, P1163, DOI 10.1016/j.jaci.2015.06.042; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V135, P1375, DOI 10.1016/j.jaci.2015.01.001; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Wang Q, 2015, J ALLERGY CLIN IMMUN, V135, P781, DOI 10.1016/j.jaci.2014.09.015; Wawrzyniak P, 2016, J ALLERGY CLIN IMMUN, V137, P1681, DOI 10.1016/j.jaci.2016.02.010; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel Thomas, 2016, Allergo J Int, V25, P82; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Werfel T, 2015, J ALLERGY CLIN IMMUN, V136, P96, DOI 10.1016/j.jaci.2015.04.015; Yamanaka K, 2015, J ALLERGY CLIN IMMUN, V136, P823, DOI 10.1016/j.jaci.2015.06.009; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040	60	44	46	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1548	1555		10.1016/j.jaci.2016.10.004	http://dx.doi.org/10.1016/j.jaci.2016.10.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27931536	Bronze			2022-12-18	WOS:000390019300007
J	Cazzola, M; Rogliani, P				Cazzola, Mario; Rogliani, Paola			Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; chronic obstructive pulmonary disease; asthma-chronic obstructive pulmonary disease overlap syndrome; definition; prevalence	AIR-FLOW OBSTRUCTION; COPD-ASTHMA; CLINICAL PHENOTYPES; FEATURES; HEALTH; REVERSIBILITY; INFLAMMATION; POPULATION; GUIDELINES; COHORT	The association of asthma and chronic obstructive pulmonary disease (COPD) in the same patient, which is designated as mixed asthma-COPD phenotype or overlap syndrome (ACOS), remains a controversial issue. This is primarily because many conflicting aspects in the definition of ACOS remain, and it is extremely difficult to summarize the distinctive features of this syndrome. Furthermore, we are realizing that asthma, COPD, and ACOS are not single diseases but rather syndromes consisting of several endotypes and phenotypes and, consequently, comprising a spectrum of diseases. The umbrella term ACOS blurs the lines between asthma and COPD and allows an approach that simplifies therapy. However, this approach contradicts the modern concept according to which we must move toward more targeted and personalized therapies to treat patients with these diseases. Therefore we argue that the term ACOS must be abandoned and ultimately replaced when new phenotypes and underlying endotypes are identified and a new taxonomy of airway diseases is generated.	[Cazzola, Mario; Rogliani, Paola] Univ Roma Tor Vergata, Dept Syst Med, Resp Med, I-00173 Rome, Italy	University of Rome Tor Vergata	Cazzola, M (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Unit Resp Dis, Via Montpellier 1, I-00133 Rome, Italy.	mario.cazzola@uniroma2.it	Rogliani, Paola/AIB-0300-2022	Rogliani, Paola/0000-0001-7801-5040	Almirall; Boehringer Ingelheim; Novartis; Zambon; Biofutura; Chiesi Farmaceutici; GlaxoSmithKline; Menarini Group; Mundipharma; AstraZeneca; Lallemand; Almiral	Almirall(Almirall); Boehringer Ingelheim(Boehringer Ingelheim); Novartis(Novartis); Zambon; Biofutura; Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); Menarini Group(Menarini Group); Mundipharma; AstraZeneca(AstraZeneca); Lallemand(Lallemand - France); Almiral(Almirall)	M. Cazzola has served and serves on the board form Novartis, AstraZeneca, Boehringer Ingelheim, Mundipharma, GlaxoSmithKline, Pfizer, Verona Pharma, and Almirall; serves as a consultant for Chiesi Farmaceutici Lallemand, Zambon, Teva, and Skyepharma; has served as an expert witness for Ockham Biotech and Verona Pharma; has received research support from Almirall, Boehringer Ingelheim, Novartis, and Zambon; and has received payment for lectures from Almirall, AstraZeneca, BioFutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, and Novartis. P. Rogliani serves on the board for Mundipharma; has received and is receiving research support from Almiral, Boehringer Ingelheim, Novartis, and Zambon; and has received payments for lectures from Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis.	Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Barnes PJ, 2010, RESPIRATION, V80, P89, DOI 10.1159/000315416; Bateman ED, 2015, LANCET RESP MED, V3, P719, DOI 10.1016/S2213-2600(15)00254-4; Bell MC, 2015, J ALLER CL IMM-PRACT, V3, P641, DOI 10.1016/j.jaip.2014.11.003; Boulet LP, 2003, RESP MED, V97, P739, DOI 10.1053/rmed.2003.1491; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Calverley PMA, 2013, LANCET RESP MED, V1, P564, DOI 10.1016/S2213-2600(13)70086-9; Cazzola M, 2011, RESP MED, V105, P386, DOI 10.1016/j.rmed.2010.09.022; Chung JW, 2014, INT J CHRONIC OBSTR, V9, P795, DOI 10.2147/COPD.S61093; Contoli M, 2010, J ALLERGY CLIN IMMUN, V125, P830, DOI 10.1016/j.jaci.2010.01.003; Cosio BG, 2016, CHEST, V149, P45, DOI 10.1378/chest.15-1055; de Marco R, 2007, AM J RESP CRIT CARE, V175, P32, DOI 10.1164/rccm.200603-381OC; de Marco R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062985; Diaz-Guzman E, 2011, COPD, V8, P400, DOI 10.3109/15412555.2011.611200; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Fattahi F, 2015, VIRCHOWS ARCH, V467, P583, DOI 10.1007/s00428-015-1824-6; Fernandez-Villar A, 2016, ARCH BRONCONEUMOL, V52, P277, DOI 10.1016/j.arbres.2015.07.005; Fu JJ, 2014, RESPIRATION, V87, P63, DOI 10.1159/000352053; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Gibson PG, 2015, THORAX, V70, P683, DOI 10.1136/thoraxjnl-2014-206740; Global Initiative for COLD, JOINT PROJ GOLD GINA; Golpe R, 2014, ARCH BRONCONEUMOL, V50, P318, DOI 10.1016/j.arbres.2013.12.013; Hardin M, 2014, EUR RESPIR J, V44, P341, DOI 10.1183/09031936.00216013; Hardin M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-127; Iwamoto H, 2014, EUR RESPIR J, V43, P421, DOI 10.1183/09031936.00024313; Kauppi P, 2011, J ASTHMA, V48, P279, DOI 10.3109/02770903.2011.555576; Kitaguchi Y, 2012, INT J CHRONIC OBSTR, V7, P283, DOI 10.2147/COPD.S30651; Izquierdo-Alonso JL, 2013, RESP MED, V107, P724, DOI 10.1016/j.rmed.2013.01.001; Magnussen H, 2008, RESP MED, V102, P50, DOI 10.1016/j.rmed.2007.08.003; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; Menezes AMB, 2014, CHEST, V145, P297, DOI 10.1378/chest.13-0622; Milanese M, 2014, RESP MED, V108, P1091, DOI 10.1016/j.rmed.2014.05.016; Miravitlles M, 2013, RESP MED, V107, P1053, DOI 10.1016/j.rmed.2013.03.007; Tho NV, 2016, RESPIROLOGY, V21, P410, DOI 10.1111/resp.12653; Orie NGM, 1961, BRONCHITIS INT S; Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863; Reddel HK, 2015, J ALLERGY CLIN IMMUN, V136, P546, DOI 10.1016/j.jaci.2015.06.043; Segreti A, 2014, MOL DIAGN THER, V18, P381, DOI 10.1007/s40291-014-0100-9; Slats A, 2016, THER ADV RESPIR DIS, V10, P57, DOI 10.1177/1753465815617082; VERMEIRE PA, 1991, EUR RESPIR J, V4, P490; Vestbo J, 2014, RESP MED, V108, P729, DOI 10.1016/j.rmed.2014.03.002; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wurst KE, 2016, RESP MED, V110, P1, DOI 10.1016/j.rmed.2015.10.004	43	44	46	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					977	983		10.1016/j.jaci.2016.04.028	http://dx.doi.org/10.1016/j.jaci.2016.04.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27372569				2022-12-18	WOS:000385499400004
J	Labzin, LI; Lauterbach, MAR; Latz, E				Labzin, Larisa I.; Lauterbach, Mario A. R.; Latz, Eicke			Interferons and inflammasomes: Cooperation and counterregulation in disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Interferon; IL-1 beta; IL-18; gram-negative bacteria; inflammasome; NLRP3; caspase-1; caspase-11; guanylate-binding protein; pyroptosis; AIM2; tuberculosis; multiple sclerosis; experimental autoimmune encephalomyelitis	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NF-KAPPA-B; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS PATIENTS; INNATE IMMUNE RECOGNITION; IL-1 RECEPTOR ANTAGONIST; III SECRETION APPARATUS; CENTRAL-NERVOUS-SYSTEM; PYROPTOTIC CELL-DEATH; SINGLE-STRANDED RNA	Interferons and the IL-1 family of cytokines have important roles in host defense against invading viruses and bacteria. Inflammasomes, multimeric cytosolic sensors of infection, are required for IL-1 beta and IL-18 processing and release. Interferons, IL-1 beta, and IL-18 are also implicated in autoimmune disease and chronic inflammation. Although independent but complementary pathways induce these cytokine subsets during infection, in some circumstances the cross-talk between these key inflammatory mediators is a particular requirement for effective host defense. In this review we will summarize recent discoveries concerning the potentiation of inflammasome responses by type I interferons, particularly in patients with gram-negative bacterial infections, and reflect on the molecular mechanisms of IFN-beta's immunosuppressive effects through modulation of inflammasome and IL-1 beta signaling in patients with tuberculosis and multiple sclerosis.	[Labzin, Larisa I.; Lauterbach, Mario A. R.; Latz, Eicke] Univ Bonn, Univ Hosp, Inst Innate Immun, Bonn, Germany; [Latz, Eicke] Univ Massachusetts, Sch Med, Dept Infect Dis & Immunol, Worcester, MA 01605 USA; [Latz, Eicke] German Ctr Neurodegenerat Dis, Bonn, Germany; [Latz, Eicke] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway	University of Bonn; University of Massachusetts System; University of Massachusetts Worcester; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Norwegian University of Science & Technology (NTNU)	Latz, E (corresponding author), Univ Bonn, Univ Hosp, Inst Innate Immun Biomed Ctr, 1G007,Sigmund Freud Str 25, D-53127 Bonn, Germany.	eicke.latz@uni-bonn.de	Latz, Eicke/H-3951-2014; Labzin, Larisa/AAC-8618-2020	Latz, Eicke/0000-0003-1488-5666; Labzin, Larisa/0000-0001-9098-4493	German Research Foundation (DFG) [SFB 670, SFB 704, SFB 1123, SFB 645, TRR83, TRR57]; European Research Council ERC Inflammact	German Research Foundation (DFG)(German Research Foundation (DFG)); European Research Council ERC Inflammact	Supported by grants from the German Research Foundation (DFG; SFB 670, 704, 1123, 645, TRR83, and TRR57) and the European Research Council ERC Inflammact. E.L. is a member of the DFG Excellence Cluster ImmunoSensation.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Anand PK, 2012, NATURE, V488, P389, DOI 10.1038/nature11250; Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227; Ataide MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003885; Baker PJ, 2015, EUR J IMMUNOL, V45, P2918, DOI 10.1002/eji.201545655; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Benveniste Etty N, 2007, Sci STKE, V2007, ppe70, DOI 10.1126/stke.4162007pe70; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; BILLIAU A, 1988, J IMMUNOL, V140, P1506; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Broz P, 2015, NATURE, V526, P642, DOI 10.1038/nature15632; Broz P, 2012, NATURE, V490, P288, DOI 10.1038/nature11419; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen KWW, 2014, CELL REP, V8, P569, DOI 10.1016/j.celrep.2014.06.028; Cole LE, 2008, J IMMUNOL, V180, P6885, DOI 10.4049/jimmunol.180.10.6885; Collins AC, 2015, CELL HOST MICROBE, V17, P820, DOI 10.1016/j.chom.2015.05.005; de Jong BA, 2002, J NEUROIMMUNOL, V126, P172, DOI 10.1016/S0165-5728(02)00056-5; Decque A, 2016, NAT IMMUNOL, V17, P140, DOI 10.1038/ni.3342; Dempsey A, 2015, VIROLOGY, V479, P146, DOI 10.1016/j.virol.2015.03.013; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Dorhoi A, 2014, EUR J IMMUNOL, V44, P2380, DOI 10.1002/eji.201344219; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Ferber IA, 1996, J IMMUNOL, V156, P5; Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Fitzgerald KA, 2015, NAT IMMUNOL, V16, P443, DOI 10.1038/ni.3144; Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Henry T, 2007, J EXP MED, V204, P987, DOI 10.1084/jem.20062665; Hernandez-Cuellar E, 2012, J IMMUNOL, V189, P5113, DOI 10.4049/jimmunol.1202479; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Huang WX, 2004, MULT SCLER J, V10, P482, DOI 10.1191/1352458504ms1071oa; Inoue M, 2013, IMMUNOLOGY, V139, P11, DOI 10.1111/imm.12081; Inoue M, 2012, P NATL ACAD SCI USA, V109, P10480, DOI 10.1073/pnas.1201836109; Inoue M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002767; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Jakobsen MR, 2013, P NATL ACAD SCI USA, V110, pE4571, DOI 10.1073/pnas.1311669110; Jeru I, 2008, P NATL ACAD SCI USA, V105, P1614, DOI 10.1073/pnas.0708616105; Jeru I, 2011, ARTHRITIS RHEUM-US, V63, P2142, DOI 10.1002/art.30378; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Jin TC, 2012, IMMUNITY, V36, P561, DOI 10.1016/j.immuni.2012.02.014; Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107; Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130; Kantarci OH, 2000, J NEUROIMMUNOL, V106, P220, DOI 10.1016/S0165-5728(00)00202-2; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000; Labzin LI, 2015, J IMMUNOL, V195, P4446, DOI 10.4049/jimmunol.1500204; Lalor SJ, 2011, J IMMUNOL, V186, P5738, DOI 10.4049/jimmunol.1003597; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Levy M, 2015, CELL, V163, P1428, DOI 10.1016/j.cell.2015.10.048; Li T, 2012, P NATL ACAD SCI USA, V109, P10558, DOI 10.1073/pnas.1203447109; Malhotra S, 2015, BRAIN, V138, P644, DOI 10.1093/brain/awu388; Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7; Man SM, 2015, NAT IMMUNOL, V16, P467, DOI 10.1038/ni.3118; Manca C, 2005, J INTERF CYTOK RES, V25, P694, DOI 10.1089/jir.2005.25.694; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; Mayer-Barber KD, 2015, IMMUNOL REV, V264, P264, DOI 10.1111/imr.12249; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Mayer-Barber KD, 2011, IMMUNITY, V35, P1023, DOI 10.1016/j.immuni.2011.12.002; Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189; McCarthy Derrick P, 2012, Methods Mol Biol, V900, P381, DOI 10.1007/978-1-60761-720-4_19; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; MERRILL JE, 1992, P NATL ACAD SCI USA, V89, P574, DOI 10.1073/pnas.89.2.574; Meunier E, 2015, NAT IMMUNOL, V16, P476, DOI 10.1038/ni.3119; Meunier E, 2014, NATURE, V509, P366, DOI 10.1038/nature13157; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474; Monroe KM, 2014, SCIENCE, V343, P428, DOI 10.1126/science.1243640; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nath N, 2006, IMMUNOLOGY, V118, P384, DOI 10.1111/j.1365-2567.2006.02385.x; Nicoletti F, 1996, CYTOKINE, V8, P395, DOI 10.1006/cyto.1996.0054; Novikov A, 2011, J IMMUNOL, V187, P2540, DOI 10.4049/jimmunol.1100926; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; OLSSON T, 1992, J NEUROIMMUNOL, V40, P211, DOI 10.1016/0165-5728(92)90135-8; Panne D, 2007, CELL, V129, P1111, DOI 10.1016/j.cell.2007.05.019; Pilla DM, 2014, P NATL ACAD SCI USA, V111, P6046, DOI 10.1073/pnas.1321700111; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Py BF, 2013, MOL CELL, V49, P331, DOI 10.1016/j.molcel.2012.11.009; Ramgolam VS, 2009, J IMMUNOL, V183, P5418, DOI 10.4049/jimmunol.0803227; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Rudick RA, 2004, ANN NEUROL, V56, P548, DOI 10.1002/ana.20224; Ruhl S, 2015, EUR J IMMUNOL, V45, P2927, DOI 10.1002/eji.201545772; Sabatino JJ, 2008, J IMMUNOL, V180, P4451, DOI 10.4049/jimmunol.180.7.4451; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Schmid-Burgk JL, 2015, EUR J IMMUNOL, V45, P2911, DOI 10.1002/eji.201545523; Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schroder K, 2012, IMMUNOBIOLOGY, V217, P1325, DOI 10.1016/j.imbio.2012.07.020; Sciacca FL, 2000, J NEUROVIROL, V6, pS33; Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683; Stanley SA, 2007, J IMMUNOL, V178, P3143, DOI 10.4049/jimmunol.178.5.3143; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Unterholzner L, 2010, NAT IMMUNOL, V11, P997, DOI 10.1038/ni.1932; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Vance RE, 2015, CURR OPIN IMMUNOL, V32, P84, DOI 10.1016/j.coi.2015.01.010; Vladimer GI, 2012, IMMUNITY, V37, P96, DOI 10.1016/j.immuni.2012.07.006; VOORTHUIS JAC, 1990, CLIN EXP IMMUNOL, V81, P183; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang PH, 2015, SCIENCE, V350, P826, DOI 10.1126/science.aab3145; Wassermann R, 2015, CELL HOST MICROBE, V17, P799, DOI 10.1016/j.chom.2015.05.003; Watson RO, 2015, CELL HOST MICROBE, V17, P811, DOI 10.1016/j.chom.2015.05.004; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Xu H, 2014, NATURE, V513, P237, DOI 10.1038/nature13449; Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022; Zamoshnikova A, 2016, IMMUNOBIOLOGY, V221, P341, DOI 10.1016/j.imbio.2015.10.001; Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051; Zhao Y, 2015, IMMUNOL REV, V265, P85, DOI 10.1111/imr.12293; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510	146	44	47	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					37	46		10.1016/j.jaci.2016.05.010	http://dx.doi.org/10.1016/j.jaci.2016.05.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27373324	Bronze			2022-12-18	WOS:000379659100004
J	Lombardi, V; Beuraud, C; Neukirch, C; Moussu, H; Morizur, L; Horiot, S; Luce, S; Wambre, E; Linsley, P; Chollet-Martin, S; Baron-Bodo, V; Aubier, M; Moingeon, P				Lombardi, Vincent; Beuraud, Chloe; Neukirch, Catherine; Moussu, Helene; Morizur, Lise; Horiot, Stephane; Luce, Sonia; Wambre, Erik; Linsley, Peter; Chollet-Martin, Sylvie; Baron-Bodo, Veronique; Aubier, Michel; Moingeon, Philippe			Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PERIPHERAL-BLOOD		[Lombardi, Vincent; Beuraud, Chloe; Moussu, Helene; Morizur, Lise; Horiot, Stephane; Luce, Sonia; Baron-Bodo, Veronique; Moingeon, Philippe] Stallergenes, Res Dept, Antony, France; [Neukirch, Catherine; Aubier, Michel] INSERM, UMR1152, Dept Pulm Med, Paris, France; [Wambre, Erik; Linsley, Peter] Benaroya Res Inst Virginia Mason, Seattle, WA USA; [Chollet-Martin, Sylvie] Bichat Claude Bernard Hosp, INSERM, UMRS996, Dept Immunol, Paris, France	Stallergenes Greer; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Benaroya Research Institute; Virginia Mason Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Moingeon, P (corresponding author), Stallergenes, Res Dept, Antony, France.	pmoingeon@stallergenes.com		Morizur, Lise/0000-0001-7400-3018				Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	12	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					305	308		10.1016/j.jaci.2015.12.1325	http://dx.doi.org/10.1016/j.jaci.2015.12.1325			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26949057	Bronze			2022-12-18	WOS:000379659100040
J	Lee, M; Kim, DW; Yoon, H; So, D; Khalmuratova, R; Rhee, CS; Park, JW; Shin, HW				Lee, Mingyu; Kim, Dae Woo; Yoon, Haejin; So, Daeho; Khalmuratova, Roza; Rhee, Chae-Seo; Park, Jong-Wan; Shin, Hyun-Woo			Sirtuin 1 attenuates nasal polypogenesis by suppressing epithelial-to-mesenchymal transition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyposis; epithelial-to-mesenchymal transition; sirtuin 1; hypoxia-inducible factor 1; animal model	INDUCIBLE FACTOR 1-ALPHA; CHRONIC RHINOSINUSITIS; AIRWAY EPITHELIUM; CANCER-CELLS; HYPOXIA; EXPRESSION; RESPONSES; POLYPS; DISEASES; FIBROBLASTS	Background: Nasal polyps (NPs) imply a refractory clinical course in patients with chronic rhinosinusitis (CRS). Previously, we showed that hypoxia-inducible factor (HIF) 1 could mediate nasal polypogenesis through epithelial-to-mesenchymal transition (EMT). Sirtuin 1 (SIRT1), a histone deacetylase, reportedly suppresses the transcriptional activity of HIF-1. Thus we hypothesized that SIRT1 attenuates nasal polyposis by inhibiting HIF-1-induced EMT. Objective: We sought to determine the role of SIRT1 in patients with nasal polyposis. Methods: The effects of SIRT1 on nasal polypogenesis were investigated in previously developed murine models. Immunohistochemistry, immunoblotting, and immunoprecipitation were done to evaluate SIRT1, EMT, and hypoxicmarkers in human nasal epithelial cells or sinonasal tissues from the mice and the patients with CRS with or without NPs. Results: SIRT1 transgenic mice had significantly fewer mucosal lesions with epithelial disruption and fewer NPs than wild-type (WT) mice. In addition, resveratrol (a SIRT1 activator) treatment suppressed nasal polypogenesis in WT mice; however, sirtinol (a SIRT1 inhibitor) administration increased the polyp burden in SIRT1 transgenic mice. In sinonasal specimens from patients with CRS, SIRT1 was downregulated in the mucosa from patients with polyps compared with levels seen in patients without polyps. SIRT1 overexpression or activation reversed hypoxia-induced EMT in human nasal epithelial cells. The intranasal transfection of a small hairpin SIRT1 lentiviral vector induced more nasal polypoid lesions in SIRT1 transgenic mice. Finally, mucosal extracts from patients with CRS without NPs increased SIRT1 expression in nasal epithelial cells, whereas those from patients with CRS with NPs did not. Conclusion: SIRT1 suppressed NP formation, possibly because of inhibition of HIF-1-induced EMT. Thus nasal epithelium SIRT1 might be a therapeutic target for NPs.	[Lee, Mingyu; Yoon, Haejin; So, Daeho; Khalmuratova, Roza; Park, Jong-Wan; Shin, Hyun-Woo] Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul 110799, South Korea; [Park, Jong-Wan] Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul 110799, South Korea; [Lee, Mingyu; So, Daeho; Park, Jong-Wan; Shin, Hyun-Woo] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, Seoul 110799, South Korea; [Kim, Dae Woo] Boramae Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Rhee, Chae-Seo; Shin, Hyun-Woo] Seoul Natl Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea; [Shin, Hyun-Woo] Seoul Natl Univ, Canc Res Inst, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Shin, HW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul 110799, South Korea.	charlie@snu.ac.kr		Yoon, Haejin/0000-0002-7139-0419	National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning [0411-20130037]; Korean Health Technology RAMP;D Project, Ministry of health AMP; Welfare, Republic of Korea [HI14C2133]; SK Telecom Research Fund [01-2014-10]; Research Resettlement Fund for the new faculty of Seoul National University	National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning; Korean Health Technology RAMP;D Project, Ministry of health AMP; Welfare, Republic of Korea; SK Telecom Research Fund; Research Resettlement Fund for the new faculty of Seoul National University	Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (0411-20130037); a grant of the Korean Health Technology R&D Project, Ministry of health & Welfare, Republic of Korea (HI14C2133); the SK Telecom Research Fund (01-2014-10); and the Research Resettlement Fund for the new faculty of Seoul National University.	Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Banerji A, 2007, AM J RHINOL, V21, P19, DOI 10.2500/ajr.2007.21.2979; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Casale Manuele, 2011, Inflammation & Allergy Drug Targets, V10, P158; Chen IC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-254; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chien CY, 2008, OTOLARYNG HEAD NECK, V139, P206, DOI 10.1016/j.otohns.2008.04.022; Dali-Youcef N, 2007, ANN MED, V39, P335, DOI 10.1080/07853890701408194; Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x; Early SB, 2007, LARYNGOSCOPE, V117, P511, DOI 10.1097/MLG.0b013e31802e927b; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Hackett TL, 2012, CURR OPIN ALLERGY CL, V12, P53, DOI 10.1097/ACI.0b013e32834ec6eb; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hsu YC, 2007, AM J OTOLARYNG, V28, P379, DOI 10.1016/j.amjoto.2006.11.004; Hupin C, 2014, ALLERGY, V69, P1540, DOI 10.1111/all.12503; Jin J, 2014, LARYNGOSCOPE, V124, pE151, DOI 10.1002/lary.24472; Kim DW, 2011, AM J RHINOL ALLERGY, V25, pE255, DOI 10.2500/ajra.2011.25.3727; Kim SW, 2013, ALLERGY, V68, P862, DOI 10.1111/all.12132; Kong SY, 2013, J GENET GENOMICS, V40, P347, DOI 10.1016/j.jgg.2013.04.001; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee HS, 2009, AM J RESP CRIT CARE, V180, P1056, DOI 10.1164/rccm.200905-0740OC; Lee SN, 2013, EUR RESPIR J, V42, P1379, DOI 10.1183/09031936.00100412; Li J, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-4; Li P, 2012, NUCLEIC ACIDS RES, V40, P1609, DOI 10.1093/nar/gkr984; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Lin SK, 2008, ARCH OTOLARYNGOL, V134, P522, DOI 10.1001/archotol.134.5.522; Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525; Shin HW, 2014, AM J RESP CRIT CARE, V189; Shin HW, 2012, AM J RESP CRIT CARE, V185, P944, DOI 10.1164/rccm.201109-1706OC; Shin HW, 2010, BIOCHEM BIOPH RES CO, V398, P205, DOI 10.1016/j.bbrc.2010.06.060; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019; Spector S L, 1998, J Allergy Clin Immunol, V102, pS107; Sun SR, 2009, KIDNEY INT, V75, P1278, DOI 10.1038/ki.2009.62; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Wu L, 2012, FERTIL STERIL, V98, DOI 10.1016/j.fertnstert.2012.04.008; Xiaorong Zhu, 2011, IET Conference on Renewable Power Generation (RPG 2011); Xu F, 2012, ENDOCRINOLOGY, V153, P1706, DOI 10.1210/en.2011-1667; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yoon H, 2014, BIOCHEM BIOPH RES CO, V444, P36, DOI 10.1016/j.bbrc.2014.01.001	46	44	48	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					87	+		10.1016/j.jaci.2015.07.026	http://dx.doi.org/10.1016/j.jaci.2015.07.026			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26342525				2022-12-18	WOS:000367724300047
J	Rajan, J; Newbury, RO; Anilkumar, A; Dohil, R; Broide, DH; Aceves, SS				Rajan, Jessica; Newbury, Robert O.; Anilkumar, Arjun; Dohil, Ranjan; Broide, David H.; Aceves, Seema S.			Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; remodeling; fibrosis; topical corticosteroid; TGF-beta 1	FLUTICASONE; FIBROSIS; CHILDREN; DIAGNOSIS; RISK	Background: Eosinophilic esophagitis (EoE) is a chronic T(H)2 inflammatory disease characterized by tissue remodeling that leads to esophageal strictures and food impactions. Effects of therapy on long-term remodeling in patients with pediatric eosinophil-associated diseases have not been previously described. Objective: We sought to understand the long-term control of esophageal remodeling in patients with EoE. Methods: We assessed endoscopic and histologic remodeling and TGF-beta 1 expression in esophageal biopsy specimens from children (n = 32) with EoE treated with topical corticosteroids (TCSs) over 10 years (mean, 4.5 years). We used standardized EoE scoring tools to gauge endoscopic and symptom features. Results: Seven hundred thirty-eight biopsy specimens from 246 endoscopic procedures were evaluated over 10 years. Four hundred eighty-six biopsy specimens had adequate lamina propria for evaluation of subepithelial remodeling. The severity of epithelial esophageal eosinophilia correlated with epithelial remodeling (basal zone hyperplasia, desquamation, and dilated intercellular spaces; P < .0001), lamina propria eosinophilia (P < .0001), and fibrosis (P < .0001). Sixteen subjects were initial responders (<15 eosinophils/high-power field) to TCSs. Responders and nonresponders spent 54% and 97% of their total disease duration with active EoE (P < .001) and 23% and 53% (P < .02) with maximal fibrosis scores, respectively. Responders had lower endoscopy scores during their disease duration (P = .013). Having less than 15 eosinophils/high-power field at any time correlated with lower fibrosis and endoscopic severity. TGF-beta 1(+) cell counts decreased in responders at the first biopsy, but this was not sustained. Symptoms did not correlate with other disease features. Conclusions: Children with EoE have substantial esophageal remodeling, which associates with inflammation and can improve in a sustainable manner with TCSs. Although endoscopic features correspond to histologic features, symptoms did not correlate with inflammation or fibrosis.	[Rajan, Jessica; Anilkumar, Arjun; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Div Pathol, La Jolla, CA 92093 USA; [Rajan, Jessica; Anilkumar, Arjun; Aceves, Seema S.] Univ Calif San Diego, Ctr Immun Infect & Inflammat, La Jolla, CA 92093 USA; [Rajan, Jessica; Newbury, Robert O.; Anilkumar, Arjun; Aceves, Seema S.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Anilkumar, Arjun; Dohil, Ranjan; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Rady Childrens Hosp San Diego, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Aceves, SS (corresponding author), Ctr Immun Infect & Inflammat, Div Allergy & Immunol, 9500 Gilman Dr,MC-0760, La Jolla, CA 92093 USA.	saceves@ucsd.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI 092135]; ART/APFED HOPE Award; Department of Defense [FA100044]; NIH/NIAID [AI 107779, AI 70535, AI 72115]; Hearst Foundation; CEGIRS, Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS [U54AI117804]; NCATS; NIAID; NIDDK; NIH [ULRR031980]; CTSA [ULT1TR0001000]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI107779, R01AI092135, R01AI072115, U19AI070535, U54AI117804] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ART/APFED HOPE Award; Department of Defense(United States Department of Defense); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Hearst Foundation; CEGIRS, Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS; NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant AI 092135 (to S.S.A.); an ART/APFED HOPE Award (to S.S.A.); Department of Defense grant FA100044 (to D.H.B and S.S.A.); NIH/NIAID grants AI 107779, AI 70535, and AI 72115 (to D.H.B.); the Hearst Foundation (to R.D.); and CEGIRS U54AI117804 (to S.S.A.) as part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS; this consortium is funded through collaboration between NCATS, NIAID, and NIDDK. This project was also partially supported by NIH grant ULRR031980 for years 1 and 2, CTSA funding and/or ULT1TR0001000 during year 3 and beyond of CTSA funding (support of the EoE database).	Abu-Sultaneh SMA, 2011, DIGEST DIS SCI, V56, P97, DOI 10.1007/s10620-010-1259-5; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2009, ANN ALLERG ASTHMA IM, V103, P401, DOI 10.1016/S1081-1206(10)60359-6; Aceves SS, 2009, IMMUNOL ALLERGY CLIN, V29, P197, DOI 10.1016/j.iac.2008.10.003; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Butz BK, 2014, GASTROENTEROLOGY, V147, P324, DOI 10.1053/j.gastro.2014.04.019; Cortina S, 2010, CHILD HEALTH CARE, V39, P266, DOI 10.1080/02739615.2010.515927; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dellon ES, 2013, AM J GASTROENTEROL, V108, P1854, DOI 10.1038/ajg.2013.363; Dohil R, 2012, DIGEST DIS SCI, V57, P1413, DOI 10.1007/s10620-011-1991-5; Garrean Carol, 2009, Curr Gastroenterol Rep, V11, P175, DOI 10.1007/s11894-009-0028-0; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Hirano I, 2014, GASTROENTEROL CLIN N, V43, P297, DOI 10.1016/j.gtc.2014.02.015; Klion A, 2009, ANNU REV MED, V60, P293, DOI 10.1146/annurev.med.60.062107.090340; Kuchen T, 2014, ALLERGY, V69, P1248, DOI 10.1111/all.12455; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lieberman JA, 2012, ALLERGY, V67, P1299, DOI 10.1111/j.1398-9995.2012.02881.x; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P1101, DOI 10.1016/j.cgh.2013.03.020; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043	26	44	45	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					147	+		10.1016/j.jaci.2015.05.045	http://dx.doi.org/10.1016/j.jaci.2015.05.045			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26233926	Bronze, Green Accepted			2022-12-18	WOS:000367724300005
J	Petersen, A; Kull, S; Rennert, S; Becker, WM; Krause, S; Ernst, M; Gutsmann, T; Bauer, J; Lindner, B; Jappe, U				Petersen, Arnd; Kull, Skadi; Rennert, Sandra; Becker, Wolf-Meinhard; Krause, Susanne; Ernst, Martin; Gutsmann, Thomas; Bauer, Johann; Lindner, Buko; Jappe, Uta			Peanut defensins: Novel allergens isolated from lipophilic peanut extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antifungal activity; Ara h 12; Ara h 13; food allergy; lipophilic extraction; plant defensin; peanut allergy	PLANT DEFENSINS; GASTROINTESTINAL-TRACT; POLYACRYLAMIDE-GELS; MASS-SPECTROMETRY; L SEEDS; PROTEINS; PEPTIDES; IDENTIFICATION; ANTIFUNGAL; NITROCELLULOSE	Background: Peanut is one of the most hazardous sources of food allergens. Unknown allergens are still hidden in the complex lipophilic matrix. These allergens need to be discovered to allow estimation of the allergenic risk for patients with peanut allergy and to further improve diagnostic measures. Objective: We performed detection, isolation, and characterization of novel peanut allergens from lipophilic peanut extract. Methods: Extraction of roasted peanuts were performed under defined extraction conditions and examined by means of 2-dimensional PAGE. Subsequently, chromatographic methods were adapted to isolate low-molecular-weight components. Proteins were studied by using SDS-PAGE and immunoblotting with sera from patients with peanut allergy. For allergen identification protein sequencing, homology search and mass spectrometry were applied. Functional characterization for allergenicity was performed by using the basophil activation assay and for antimicrobial activity by using inhibition assays of different bacteria and fungi. Results: IgE-reactive proteins of 12, 11, and 10 kDa were first detected after chloroform/methanol extraction in the flow through of hydrophobic interaction chromatography. The proteins were able to activate basophils of patients with peanut allergy. N-terminal sequencing and homology search in the expressed sequence tag database identified the allergens as peanut defensins, which was confirmed by using mass spectrometry. On microbial cell cultures, the peanut defensins showed inhibitory effects on the mold strains of the genera Cladosporium and Alternaria but none on bacteria. Conclusions: We identified defensins as novel peanut allergens (Ara h 12 and Ara h 13) that react in particular with IgE of patients with severe peanut allergy. Their antimicrobial activity is solely antifungal.	[Petersen, Arnd; Kull, Skadi; Rennert, Sandra; Becker, Wolf-Meinhard; Krause, Susanne; Jappe, Uta] Airway Res Ctr North, Res Ctr Borstel, Div Clin & Mol Allergol, Borstel, Germany; [Ernst, Martin] Res Ctr Borstel, Div Immune Cell Analyt, D-23845 Borstel, Germany; [Gutsmann, Thomas] Res Ctr Borstel, Div Biophys, D-23845 Borstel, Germany; [Lindner, Buko] Res Ctr Borstel, Div Bioanalyt Chem, D-23845 Borstel, Germany; [Bauer, Johann] Tech Univ Munich, Anim Hyg, Freising Weihenstephan, Germany; [Jappe, Uta] Univ Lubeck, Dept Dermatol, Lubeck, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; Technical University of Munich; University of Lubeck	Kull, S (corresponding author), Res Ctr Borstel, Div Clin & Mol Allergol, Parkallee 22, D-23845 Borstel, Germany.	skull@fz-borstel.de	Gutsmann, Thomas/E-6100-2011	Rennert, Sandra/0000-0002-1001-5084	Kanert Foundation for Allergy Research; Federal Ministry of Education and Research [82DZL00101]	Kanert Foundation for Allergy Research; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	Supported in part by the Kanert Foundation for Allergy Research and the Federal Ministry of Education and Research (82DZL00101).	Almeida MS, 2000, ARCH BIOCHEM BIOPHYS, V378, P278, DOI 10.1006/abbi.2000.1824; Becker WM, 1997, INT ARCH ALLERGY IMM, V113, P118, DOI 10.1159/000237522; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; Carvalho AD, 2011, CURR PHARM DESIGN, V17, P4270, DOI 10.2174/138161211798999447; Carvalho AD, 2009, PEPTIDES, V30, P1007, DOI 10.1016/j.peptides.2009.01.018; Codina R, 1997, CLIN EXP ALLERGY, V27, P424, DOI 10.1046/j.1365-2222.1997.d01-514.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Hollemeyer K, 2002, PROTEOMICS, V2, P1524, DOI 10.1002/1615-9861(200211)2:11<1524::AID-PROT1524>3.0.CO;2-7; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Javaloyes G, 2012, J INVEST ALLERG CLIN, V22, P508; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Ladner CL, 2006, ANAL CHEM, V78, P2388, DOI 10.1021/ac051851y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lay FT, 2012, J BIOL CHEM, V287, P19961, DOI 10.1074/jbc.M111.331009; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; Leonard R, 2010, J BIOL CHEM, V285, P27192, DOI 10.1074/jbc.M110.127118; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; McGowan EC, 2013, CURR ALLERGY ASTHM R, V13, P101, DOI 10.1007/s11882-012-0324-x; Mills ENC, 2004, CRIT REV FOOD SCI, V44, P379, DOI 10.1080/10408690490489224; Moneret-Vautrin DA, 2014, ALLERGY, V69, P1701, DOI 10.1111/all.12502; Ntui VO, 2010, PLANT CELL REP, V29, P943, DOI 10.1007/s00299-010-0880-2; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Ozcan MM, 2010, J OLEO SCI, V59, P1, DOI 10.5650/jos.59.1; Petersen A, 2006, CLIN EXP ALLERGY, V36, P840, DOI 10.1111/j.1365-2222.2006.02505.x; Petersen A, 2014, BIOL CHEM, V395, P239, DOI 10.1515/hsz-2013-0206; Petersen A, 2013, J SERB CHEM SOC, V78, P321, DOI 10.2298/JSC121105007P; Sels J, 2008, PLANT PHYSIOL BIOCH, V46, P941, DOI 10.1016/j.plaphy.2008.06.011; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Spelbrink RG, 2004, PLANT PHYSIOL, V135, P2055, DOI 10.1104/pp.104.040873; Stotz HU, 2009, PLANT SIGNAL BEHAV, V4, P1010, DOI 10.4161/psb.4.11.9755; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6	38	44	51	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1295	+		10.1016/j.jaci.2015.04.010	http://dx.doi.org/10.1016/j.jaci.2015.04.010			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26037551	hybrid			2022-12-18	WOS:000364787200019
J	Wheatley, LM; Plaut, M; Schwaninger, JM; Banerji, A; Castells, M; Finkelman, FD; Gleich, GJ; Guttman-Yassky, E; Mallal, SAK; Naisbitt, DJ; Ostrov, DA; Phillips, EJ; Pichler, WJ; Platts-Mills, TAE; Roujeau, JC; Schwartz, LB; Trepanier, LA				Wheatley, Lisa M.; Plaut, Marshall; Schwaninger, Julie M.; Banerji, Aleena; Castells, Mariana; Finkelman, Fred D.; Gleich, Gerald J.; Guttman-Yassky, Emma; Mallal, Simon A. K.; Naisbitt, Dean J.; Ostrov, David A.; Phillips, Elizabeth J.; Pichler, Werner J.; Platts-Mills, Thomas A. E.; Roujeau, Jean-Claude; Schwartz, Lawrence B.; Trepanier, Lauren A.			Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; drug hypersensitivity; desensitization; pharmacogenomics; Stevens-Johnson syndrome; toxic epidermal necrolysis; hapten hypothesis; altered peptide repertoire hypothesis; pharmacologic interaction with immune receptor hypothesis	TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; BETA-LACTAM ANTIBIOTICS; RED MEAT ALLERGY; HYPERSENSITIVITY REACTIONS; PENICILLIN ALLERGY; CROSS-REACTIVITY; IGE ANTIBODIES; T-CELLS; DESENSITIZATION	Allergic reactions to drugs are a serious public health concern. In 2013, the Division of Allergy, Immunology, and Transplantation of the National Institute of Allergy and Infectious Diseases sponsored a workshop on drug allergy. International experts in the field of drug allergy with backgrounds in allergy, immunology, infectious diseases, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug allergy research. These experts were joined by representatives from several National Institutes of Health institutes and the US Food and Drug Administration. The participants identified important advances that make new research directions feasible and made suggestions for research priorities and for development of infrastructure to advance our knowledge of the mechanisms, diagnosis, management, and prevention of drug allergy. The workshop summary and recommendations are presented herein.	[Wheatley, Lisa M.; Plaut, Marshall; Schwaninger, Julie M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Rockville, MD 20852 USA; [Banerji, Aleena] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Castells, Mariana] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Drug Hypersensit & Desensitizat Ctr, Boston, MA 02115 USA; [Finkelman, Fred D.] Univ Cincinnati, Div Allergy Immunol & Rheumatol, Dept Internal Med, Coll Med,Dept Med,Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45221 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Gleich, Gerald J.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Guttman-Yassky, Emma] Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Mt Sinai Med Ctr, Inst Immunol, Icahn Sch Med, New York, NY 10029 USA; [Mallal, Simon A. K.] Vanderbilt Univ, Sch Med, Dept Med, Ctr Translat Immunol & Infect Dis, Nashville, TN 37212 USA; [Mallal, Simon A. K.; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia; [Naisbitt, Dean J.] Univ Liverpool, Dept Pharmacol, MRC, Ctr Drug Safety Sci, Liverpool L69 3BX, Merseyside, England; [Ostrov, David A.] Univ Florida, Coll Med, Div Expt Pathol, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA; [Pichler, Werner J.] ADR AC GMBH, CH-3008 Bern, Switzerland; [Platts-Mills, Thomas A. E.] Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Roujeau, Jean-Claude] Univ Paris Est Creteil, F-94010 Creteil, France; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23284 USA; [Trepanier, Lauren A.] Univ Wisconsin Madison, Sch Vet Med, Dept Med Sci, Madison, WI USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Vanderbilt University; Murdoch University; University of Liverpool; State University System of Florida; University of Florida; Vanderbilt University; University of Virginia; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Virginia Commonwealth University; University of Wisconsin System; University of Wisconsin Madison	Wheatley, LM (corresponding author), NIAID, NIH, Div Allergy Immunol & Transplantat, Rockville, MD 20852 USA.	lisa.wheatley@nih.gov	Banerji, Aleena/ABG-1245-2021; Mallal, Simon Alexander/HDM-9561-2022	Mallal, Simon Alexander/0000-0002-7036-1309; Platts-Mills, Thomas/0000-0002-1263-329X; Pichler, Werner J./0000-0002-8117-359X; Naisbitt, Dean/0000-0003-4107-7832	Merck; Sanofi; National Institutes of Health (NIH) Desensitization; National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline; Regeneron; Celgene; BMS; Janssen; NHMRC Australia; NIH; UpToDate; Roche; Lilly; Boehringer Ingelheim; AiCuris; Menarini; NIAID; AB Science; Novartis; OM-Pharma; Science Technologie; Astellas pharma; Sanofi Aventis; Dyax; ViroPharma; HELIX; CSL Behring	Merck(Merck & Company); Sanofi; National Institutes of Health (NIH) Desensitization(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); Regeneron(Regeneron); Celgene(Bristol-Myers SquibbCelgene Corporation); BMS(Bristol-Myers Squibb); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); NHMRC Australia(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UpToDate; Roche(Roche Holding); Lilly(Eli Lilly); Boehringer Ingelheim(Boehringer Ingelheim); AiCuris; Menarini(Menarini Group); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AB Science; Novartis(Novartis); OM-Pharma; Science Technologie; Astellas pharma(Astellas Pharmaceuticals); Sanofi Aventis(Sanofi-Aventis); Dyax; ViroPharma; HELIX; CSL Behring	M. Castells has received consultancy fees from Merck and Sanofi, is employed by BWH, has received research support from National Institutes of Health (NIH) Desensitization (pending), has received royalties from UpToDate, and has received travel support from the American Academy of Allergy, Asthma & Immunology (AAAAI) as a member of the Board of Directors. F. D. Finkelman has received travel support and research support from the National Institute of Allergy and Infectious Diseases (NIAID) and has a relevant patent pending with the University of Cincinnati. G. J. Gleich has received travel support from the University of Utah, has received consultancy fees from GlaxoSmithKline, and has provided expert testimony for plaintiffs' attorneys. E. Guttman-Yassky is a board member for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, Medimmune, Celgene, Anacor, and Leo Pharma; has received consultancy fees from Regeneron, Sanofi Aventis, Medimmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, and Drais; and has received research support from Regeneron, Celgene, BMS, and Janssen. S. A. K. Mallal has equity in IIID Ltd, which has a patent for HLA-B*5701 screening for abacavir hypersensitivity. D. J. Naisbitt, D. A. Ostrov, and L. A. Trepanier have received travel support from the NIH/NIAID. E. J. Phillips has received research support from NHMRC Australia and from the NIH, has received personal fees from UpToDate, and is a codirector of the company that holds the patent for HLA-B*57:01 testing for abacavir HSR; honoraria were paid to her institution by Merck Pty Ltd and ViiV. W.J. Pichler has received consultancy fees from Roche, Lilly, Boehringer Ingelheim, AiCuris, and Menarini. T. A. E. Platts-Mills has received research support from the NIAID and has received consultancy fees and travel support from Thermo Fisher/Phadia. J.-C. Roujeau has received travel support from the NIH/NIAID; is a board member for Pfizer, Menarini, Vertex, Servier, OM Pharma, and Boehringer-Ingelheim; has received consultancy fees from AB Science; has provided expert testimony for McNeil consumers (a branch of J & J); has received research support from GlaxoSmithKline, Novartis, Boehringer Ingelheim, OM-Pharma, Science & Technologie, Astellas pharma, Menarini; has received lecture fees from Menarini; and has received payment for development of educational presentations from Janssen. L. B. Schwartz has received travel support from the NIH/NIAID; has received consultancy fees from Sanofi Aventis, Dyax, ViroPharma, and HELIX; has received research support from CSL Behring and Dyax; has received royalties from VCU Tech Transfer; and is an Associate Editor of and has received an honorarium from the Journal of Clinical Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Adam J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095339; Adam J, 2011, BRIT J CLIN PHARMACO, V71, P701, DOI 10.1111/j.1365-2125.2010.03764.x; Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Barbaud A, 2013, BRIT J DERMATOL, V168, P555, DOI 10.1111/bjd.12125; Blanca M, 1999, J ALLERGY CLIN IMMUN, V103, P918, DOI 10.1016/S0091-6749(99)70439-2; Bourke J, 2015, J ALLER CL IMM-PRACT, V3, P365, DOI 10.1016/j.jaip.2014.11.002; Bousquet PJ, 2009, ALLERGY, V64, P194, DOI 10.1111/j.1398-9995.2008.01944.x; Brockow K, 2012, CHEM IMMUNOL ALLERGY, V97, P180, DOI 10.1159/000335631; Burrows JA, 2003, RESPIROLOGY, V8, P359, DOI 10.1046/j.1440-1843.2003.00461.x; Bursztejn AC, 2013, ALLERGY, V68, P1076, DOI 10.1111/all.12196; Caimmi Silvia, 2012, Clin Transl Allergy, V2, P10, DOI 10.1186/2045-7022-2-10; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2014, ANN RHEUM DIS; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; El-Ghaiesh S, 2012, J PHARMACOL EXP THER, V341, P597, DOI 10.1124/jpet.111.190900; Fox SJ, 2014, J ALLER CL IMM-PRACT, V2, P439, DOI 10.1016/j.jaip.2014.04.013; Grosen E, 2000, LANCET, V355, P288, DOI 10.1016/S0140-6736(99)04306-8; Halevy S, 2010, BRIT J DERMATOL, V163, P1245, DOI 10.1111/j.1365-2133.2010.09967.x; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Hong DI, 2012, EXPERT REV CLIN IMMU, V8, P43, DOI [10.1586/eci.11.75, 10.1586/ECI.11.75]; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Impicciatore P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/j.0306-5251.2001.01407.x; Jadotte YT, 2012, J AM ACAD DERMATOL, V66, P187, DOI 10.1016/j.jaad.2011.09.039; Kadoyama K, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-93; Kardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501; Ko TM, 2011, J ALLERGY CLIN IMMUN, V128, P1266, DOI 10.1016/j.jaci.2011.08.013; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Liu A, 2011, CLIN EXP ALLERGY, V41, P1679, DOI 10.1111/j.1365-2222.2011.03825.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Lucas A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117160; Macy E, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0476-y; Macy Eric, 2009, Perm J, V13, P12; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Matar R, 2014, PEDIAT ALLERG IMM-UK, V25, P88, DOI 10.1111/pai.12154; McGee T, 1998, PLAST RECONSTR SURG, V102, P1018, DOI 10.1097/00006534-199809040-00014; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Milpied-Homsi B, 2014, IMMUNOL ALLERGY CLIN, V34, P645, DOI 10.1016/j.iac.2014.04.011; Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077; Norcross MA, 2012, AIDS, V26, pF21, DOI 10.1097/QAD.0b013e328355fe8f; Orkin C, 2010, HIV MED, V11, P187, DOI 10.1111/j.1468-1293.2009.00762.x; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Patil SU, 2012, J ALLERGY CLIN IMMUN, V129, P443, DOI 10.1016/j.jaci.2011.10.010; Pavlos R, 2015, ANNU REV MED, V66, P439, DOI 10.1146/annurev-med-050913-022745; Pavlos R, 2014, J ALLER CL IMM-PRACT, V2, P21, DOI 10.1016/j.jaip.2013.11.005; Pereira FA, 2007, J AM ACAD DERMATOL, V56, P181, DOI 10.1016/j.jaad.2006.04.048; Phillips E, 2009, MOL DIAGN THER, V13, P1, DOI 10.2165/01250444-200913010-00001; Picard D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001116; PLEASANTS RA, 1994, CHEST, V106, P1124, DOI 10.1378/chest.106.4.1124; Saito N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008227; Sancho-Serra MD, 2011, EUR J IMMUNOL, V41, P1004, DOI 10.1002/eji.201040810; Sassolas B, 2010, CLIN PHARMACOL THER, V88, P60, DOI 10.1038/clpt.2009.252; Scherer K, 2013, ALLERGY, V68, P844, DOI 10.1111/all.12161; Schwartz RA, 2013, J AM ACAD DERMATOL, V69, pE209, DOI 10.1016/j.jaad.2013.04.064; Sekula P, 2013, J INVEST DERMATOL, V133, P1197, DOI 10.1038/jid.2012.510; Solensky R, 2013, J ALLER CL IMM-PRACT, V1, P264, DOI 10.1016/j.jaip.2013.03.010; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; STARK BJ, 1987, JAMA-J AM MED ASSOC, V257, P1474, DOI 10.1001/jama.1987.03390110050020; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; Uetrecht J, 2013, PHARMACOL REV, V65, P779, DOI 10.1124/pr.113.007450; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Veien M, 2000, ANESTHESIOLOGY, V92, P1074, DOI 10.1097/00000542-200004000-00026; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Watkins S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076211; Whitaker P, 2011, J IMMUNOL, V187, P200, DOI 10.4049/jimmunol.1100647; Wong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011; Wuillemin N, 2013, J IMMUNOL, V190, P4956, DOI 10.4049/jimmunol.1202949; Yeo SI, 2013, INT J RHEUM DIS, V16, P254, DOI 10.1111/1756-185X.12050; Yuan J, 2011, AIDS, V25, P1271, DOI 10.1097/QAD.0b013e32834779df; Zambonino MA, 2014, PEDIAT ALLERG IMM-UK, V25, P80, DOI 10.1111/pai.12155	78	44	46	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					262	+		10.1016/j.jaci.2015.05.027	http://dx.doi.org/10.1016/j.jaci.2015.05.027			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26254053	Green Accepted			2022-12-18	WOS:000359004900006
J	Lang, JE; Hossain, MJ; Lima, JJ				Lang, Jason E.; Hossain, Md Jobayer; Lima, John J.			Overweight children report qualitatively distinct asthma symptoms: Analysis of validated symptom measures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; overweight; obesity; children; dyspnea; breathlessness; shortness of breath; esophageal reflux	BODY-MASS INDEX; QUALITY-OF-LIFE; POORLY CONTROLLED ASTHMA; OBESITY; HEALTH; RISK; RESPONSIVENESS; PERCEPTION; SEVERITY; EXERCISE	Background: Past studies of asthma in overweight/obese children have been inconsistent. The reason overweight/obese children commonly report worse asthma control remains unclear. Objective: To determine qualitative differences in symptoms between lean and overweight/obese children with early-onset, atopic asthma. Methods: We conducted a cross-sectional analytic study of lean (20% to 65% body mass index) and overweight/obese (>85% body mass index) 10- to 17-year-old children with persistent, early-onset asthma. Participants completed 2 to 3 visits to provide a complete history, qualitative and quantitative asthma symptom characterization, and lung function testing. We determined associations between weight status and symptoms using multivariable linear and logistic regression methods. Results: Overweight/obese and lean asthmatic children displayed similar lung function. Despite lower fraction of exhaled nitric oxide (30.0 vs 62.6 ppb; P = .037) and reduced methacholine responsiveness (PC20FEV1 1.87 vs 0.45 mg/mL; P < .012), overweight/obese children reported more than thrice frequent rescue treatments (3.7 vs 1.1 treatments/wk; P = .0002) than did lean children. Weight status affected the child's primary symptom reported with loss of asthma control (Fisher exact test; P = .003); overweight/obese children more often reported shortness of breath (odds ratio = 11.8; 95% CI, 1.41-98.7) and less often reported cough (odds ratio = 0.26; 95% CI, 0.08-0.82). Gastroesophageal reflux scores were higher in overweight/obese children (9.6 vs 23.2; P = .003) and appear to mediate overweight/obesity-related asthma symptoms. Conclusions: Overweight/obese children with early-onset asthma display poorer asthma control and a distinct pattern of symptoms. Greater shortness of breath and beta-agonist use appears to be partially mediated via esophageal reflux symptoms. Overweight children with asthma may falsely attribute exertional dyspnea and esophageal reflux to asthma, leading to excess rescue medication use.	[Lang, Jason E.] Nemours Childrens Hosp, Div Pulm & Sleep Med, Orlando, FL 32827 USA; [Hossain, Md Jobayer] Alfred I DuPont Hosp Children, Ctr Pediat Res, Wilmington, DE USA; [Lima, John J.] Nemours Childrens Clin, Ctr Pharmacogen & Translat Res, Jacksonville, FL USA	Nemours Alfred I. duPont Hospital for Children	Lang, JE (corresponding author), Nemours Childrens Hosp, Div Pulm & Sleep Med, 13535 Nemours Pkwy, Orlando, FL 32827 USA.	jason.lang@nemours.org		Hossain, Md Jobayer/0000-0003-2609-6605	Nemours Foundation [1609110002]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104941] Funding Source: NIH RePORTER	Nemours Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The Nemours Foundation (grant no. 1609110002) funded this study.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Bajwah S, 2013, THORAX, V68, P867, DOI 10.1136/thoraxjnl-2012-202040; Bime C, 2012, J ALLERGY CLIN IMMUN, V130, P1078, DOI 10.1016/j.jaci.2012.07.058; Black MH, 2013, AM J EPIDEMIOL, V178, P1120, DOI 10.1093/aje/kwt093; Borrell LN, 2013, AM J RESP CRIT CARE, V187, P697, DOI 10.1164/rccm.201211-2116OC; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chlif M, 2007, INT J OBESITY, V31, P1456, DOI 10.1038/sj.ijo.0803546; Cloutier MM, 2012, J ALLERGY CLIN IMMUN, V129, pS24, DOI 10.1016/j.jaci.2011.12.980; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Davenport PW, 2009, RESP PHYSIOL NEUROBI, V167, P72, DOI 10.1016/j.resp.2008.10.001; Deal L, 2005, J PEDIATR GASTR NUTR, V41, P178, DOI 10.1097/01.mpg.0000172885.77795.0f; Dixon AE, 2006, J ASTHMA, V43, P553, DOI 10.1080/02770900600859123; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; Holbrook JT, 2012, JAMA-J AM MED ASSOC, V307, P373, DOI 10.1001/jama.2011.2035; Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Juniper EF, 2007, CURR ALLERGY ASTHM R, V7, P390, DOI 10.1007/s11882-007-0059-2; King GG, 2005, EUR RESPIR J, V25, P896, DOI 10.1183/09031936.05.00104504; Kress JP, 1999, AM J RESP CRIT CARE, V160, P883, DOI 10.1164/ajrccm.160.3.9902058; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Kuczmarski R.J., 2000, CDC GROWTH CHARTS US; Lang JE, 2013, PEDIATR PULM, V48, P847, DOI 10.1002/ppul.22707; Lang JE, 2011, CHEST, V140, P1524, DOI 10.1378/chest.11-0675; Laviolette L, 2014, EUR RESPIR J, V43, P1750, DOI 10.1183/09031936.00092613; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; Meng A, 2003, NURS CLIN N AM, V38, P737, DOI 10.1016/S0029-6465(03)00096-3; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; NAIMARK A, 1960, J APPL PHYSIOL, V15, P377, DOI 10.1152/jappl.1960.15.3.377; Narkiewicz K, 1999, HYPERTENSION, V33, P1153, DOI 10.1161/01.HYP.33.5.1153; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; Ofir D, 2007, J APPL PHYSIOL, V102, P2217, DOI 10.1152/japplphysiol.00898.2006; Pankow W, 1998, J APPL PHYSIOL, V85, P1236, DOI 10.1152/jappl.1998.85.4.1236; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Patterson RN, 2007, THORAX, V62, P491, DOI 10.1136/thx.2006.063982; Quinto KB, 2011, J ALLERGY CLIN IMMUN, V128, P964, DOI 10.1016/j.jaci.2011.06.031; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Richter Joel E., 2000, American Journal of Medicine, V108, p153S; Ross KR, 2009, PEDIATR PULM, V44, P877, DOI 10.1002/ppul.21065; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; Sah PK, 2013, J ALLER CL IMM-PRACT, V1, P39, DOI 10.1016/j.jaip.2012.10.006; Salome CM, 2008, INT J OBESITY, V32, P502, DOI 10.1038/sj.ijo.0803752; Scano G, 2006, CURR OPIN PULM MED, V12, P18, DOI 10.1097/01.mcp.0000199003.46038.82; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; SHARP JT, 1964, J CLIN INVEST, V43, P728, DOI 10.1172/JCI104957; Sideleva O, 2013, PULM PHARMACOL THER, V26, P455, DOI 10.1016/j.pupt.2012.05.002; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Steier J, 2009, THORAX, V64, P719, DOI 10.1136/thx.2008.109728; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; Tsai SY, 2012, NURS RES, V61, P252, DOI 10.1097/NNR.0b013e318255679c; van den Bemt L, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-5; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Wu DN, 2000, CHEST, V118, P1553, DOI 10.1378/chest.118.6.1553; Zavorsky GS, 2008, OBES REV, V9, P326, DOI 10.1111/j.1467-789X.2008.00471.x; Zutler M, 2012, PRIM CARE RESP J, V21, P194, DOI 10.4104/pcrj.2012.00028	70	44	44	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					886	+		10.1016/j.jaci.2014.08.029	http://dx.doi.org/10.1016/j.jaci.2014.08.029			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25441640	Green Accepted			2022-12-18	WOS:000352238600007
J	Davis, MF; Peng, RD; McCormack, MC; Matsui, EC				Davis, Meghan F.; Peng, Roger D.; McCormack, Meredith C.; Matsui, Elizabeth C.			Staphylococcus aureus colonization is associated with wheeze and asthma among US children and young adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UNITED-STATES; RISK-FACTORS; PREVALENCE		[Davis, Meghan F.; McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [McCormack, Meredith C.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Matsui, Elizabeth C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Davis, MF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.	mdavis65@jhu.edu	Davis, Meghan F./C-1494-2013	Davis, Meghan F./0000-0002-3475-4578; Matsui, Elizabeth/0000-0001-8134-5593; Ayers, Andrew/0000-0001-5305-7156; Koehl, Rachelle/0000-0002-7797-7456; McCormack, Meredith/0000-0003-1702-3201; Pham, Hewlett/0000-0003-0330-6104	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI083238, R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES019560, P01ES018181, P50ES015903, P50ES018176, T32ES007141, P01ES018176, R21ES024021] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05 AT002014] Funding Source: Medline; NIAID NIH HHS [R01 AI070630, U01 AI083238, U01AI083238, R01AI070630] Funding Source: Medline; NIEHS NIH HHS [P50 ES018176, P01 ES018181, R21 ES024021, T32ES7141-29, T32 ES007141, P01 ES018176, R01 ES019560, R01ES019560, P01ES018181, P50ES015903, R21ES024021, P01ES018176, P50 ES015903, R01 ES023447] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Breysse Patrick N, 2010, Proc Am Thorac Soc, V7, P102, DOI 10.1513/pats.200908-083RM; Graham PL, 2006, ANN INTERN MED, V144, P318, DOI 10.7326/0003-4819-144-5-200603070-00006; Halablab MA, 2010, EPIDEMIOL INFECT, V138, P702, DOI 10.1017/S0950268809991233; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Pastacaldi C, 2011, ALLERGY, V66, P549, DOI 10.1111/j.1398-9995.2010.02502.x; Sollid JUE, 2014, INFECT GENET EVOL, V21, P531, DOI 10.1016/j.meegid.2013.03.020; Zhang XY, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1156	9	44	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					811	813		10.1016/j.jaci.2014.10.052	http://dx.doi.org/10.1016/j.jaci.2014.10.052			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25533526	Green Accepted			2022-12-18	WOS:000351065000029
J	Bauer, RN; Manohar, M; Singh, AM; Jay, DC; Nadeau, KC				Bauer, Rebecca N.; Manohar, Monali; Singh, Anne Marie; Jay, David C.; Nadeau, Kari C.			The future of biologics: Applications for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; immunotherapy; anti-IgE; oral tolerance; allergen sensitization; anaphylaxis; biologics	THYMIC STROMAL LYMPHOPOIETIN; FC-EPSILON-RI; REGULATORY T-CELLS; INNATE LYMPHOID-CELLS; INTESTINAL EPITHELIAL-CELLS; PLATELET-ACTIVATING-FACTOR; PEANUT ORAL IMMUNOTHERAPY; TOTAL SERUM IGE; DENDRITIC CELLS; ANTI-IGE	Allergic diseases affect millions worldwide, with growing evidence of an increase in allergy occurrence over the past few decades. Current treatments for allergy include corticosteroids to reduce inflammation and allergen immunotherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to these treatments, and there are currently no approved therapeutics for the treatment of food allergy. There is a dire need for new therapeutic approaches for patients with poorly controlled atopic diseases and a need to improve the safety and effectiveness of allergen immunotherapy. Improved understanding of allergy through animal models and clinical trials has unveiled potential targets for new therapies, leading to the development of several biologics to treat allergic diseases. This review focuses on the mechanisms that contribute to allergy, with an emphasis on future targets for biologics for the treatment of food allergy. These biologics include immunotherapy with novel anti-IgE antibodies and analogs, small-molecule inhibitors of cell signaling, anti-type 2 cytokine mAbs, and TH1-promoting adjuvants.	[Bauer, Rebecca N.; Manohar, Monali; Jay, David C.; Nadeau, Kari C.] Stanford Univ, Sch Med, Dept Pediat, Div Pediat Immunol Allergy & Rheumatol, Stanford, CA 94305 USA; [Singh, Anne Marie] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Chicago, IL 60611 USA	Stanford University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Nadeau, KC (corresponding author), Stanford Univ, 269 Campus Dr,CCSR Bldg,Rm 3215, Stanford, CA 94305 USA.	knadeau@stanford.edu			National Institute of Allergy and Infectious Diseases [K23]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020926] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	A. M. Singh has received research support from the National Institute of Allergy and Infectious Diseases (K23). The rest of the authors declare that they have no relevant conflicts of interest.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Anandasabapathy N, 2014, J EXP MED, V211, P1875, DOI 10.1084/jem.20131397; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arm JP, 2014, CLIN EXP ALLERGY, V44, P1371, DOI 10.1111/cea.12400; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Bae MJ, 2013, INT J BIOL MACROMOL, V61, P164, DOI 10.1016/j.ijbiomac.2013.06.017; Bakdash G, 2014, MUCOSAL IMMUNOL; BARONE KS, 1995, CELL IMMUNOL, V163, P19, DOI 10.1006/cimm.1995.1094; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cardoso CR, 2009, AM J PHYSIOL-GASTR L, V296, pG593, DOI 10.1152/ajpgi.90431.2008; Cavkaytar O, 2014, CURR OPIN PHARMACOL, V17, P30, DOI 10.1016/j.coph.2014.07.003; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chang TW, 2012, DERMATOL SIN, V30, P147, DOI 10.1016/j.dsi.2012.10.001; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Chen JB, 2010, J IMMUNOL, V184, P1748, DOI 10.4049/jimmunol.0902437; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cooper AM, 2012, J IMMUNOL, V188, P3199, DOI 10.4049/jimmunol.1102689; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x; Eggel A, 2014, J ALLERGY CLIN IMMUN, V133, P1709, DOI 10.1016/j.jaci.2014.02.005; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gauvreau GM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008961; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grela F, 2011, J IMMUNOL, V186, P284, DOI 10.4049/jimmunol.1001348; Holgate S, 2009, ALLERGY, V64, P1728, DOI 10.1111/j.1398-9995.2009.02201.x; Ibanez AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069438; Jackman J, 2010, J BIOL CHEM, V285, P20850, DOI 10.1074/jbc.M110.113910; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Johnston LK, 2014, J IMMUNOL, V192, P2529, DOI 10.4049/jimmunol.1303026; KAISERLIAN D, 1993, IMMUNOLOGY, V80, P90; Keet CA, 2014, J CLIN INVEST, V124, P1880, DOI 10.1172/JCI72061; Kern E, 2013, EXPERT OPIN EMERG DR, V18, P353, DOI 10.1517/14728214.2013.829039; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Kim B, 2012, NATURE, V491, P613, DOI 10.1038/nature11546; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim HJ, 2006, IMMUNOLOGY, V118, P101, DOI 10.1111/j.1365-2567.2006.02346.x; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim YH, 2012, ALLERGY, V67, P183, DOI 10.1111/j.1398-9995.2011.02735.x; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kurashima Y, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.7; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lelouard H, 2012, GASTROENTEROLOGY, V142, P592, DOI 10.1053/j.gastro.2011.11.039; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Li HX, 2006, GASTROENTEROLOGY, V131, P47, DOI 10.1053/j.gastro.2006.03.044; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Liu XJ, 2009, BIOCHEM BIOPH RES CO, V386, P181, DOI 10.1016/j.bbrc.2009.06.008; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; Liu ZQ, 2013, ALLERGY, V68, P1241, DOI 10.1111/all.12218; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Maselli DJ, 2013, ANN ALLERG ASTHMA IM, V110, P457, DOI 10.1016/j.anai.2013.04.011; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; Michaud B, 2014, ALLERGY, V69, P1473, DOI 10.1111/all.12484; Mittag D, 2013, EUR J IMMUNOL, V43, P723, DOI 10.1002/eji.201242747; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Otani IM, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-25; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Pawankar R, 2013, WAO WHITE BOOK ALLER; Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; PENG C, 1992, J IMMUNOL, V148, P129; Poole JA, 2005, J ALLERGY CLIN IMMUN, V116, P780, DOI 10.1016/j.jaci.2005.07.007; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Prescott VE, 2006, J LEUKOCYTE BIOL, V80, P258, DOI 10.1189/jlb.1105637; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; Rader RA, 2008, NAT BIOTECHNOL, V26, P743, DOI 10.1038/nbt0708-743; Rafi A, 2010, ALLERGY ASTHMA PROC, V31, P76, DOI 10.2500/aap.2010.31.3304; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Roan F, 2012, J LEUKOCYTE BIOL, V91, P877, DOI 10.1189/jlb.1211622; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Rosenwasser LJ, 2005, CLIN REV ALLERG IMMU, V29, P61, DOI 10.1385/CRIAI:29:1:061; Rosewich M, 2010, CLIN EXP IMMUNOL, V160, P403, DOI 10.1111/j.1365-2249.2010.04106.x; Ruane D, 2013, J EXP MED, V210, P1871, DOI 10.1084/jem.20122762; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Saenz SA, 2013, J EXP MED, V210, P1823, DOI 10.1084/jem.20122332; Salazar F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00356; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Savilahti EM, 2013, PEDIAT ALLERG IMM-UK, V24, P114, DOI 10.1111/pai.12004; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Small Peter, 2011, Allergy Asthma Clin Immunol, V7 Suppl 1, pS3, DOI 10.1186/1710-1492-7-S1-S3; Smarr CB, 2011, J IMMUNOL, V187, P5090, DOI 10.4049/jimmunol.1100608; Smith LD, 2013, FUTURE MED CHEM, V5, P1423, DOI 10.4155/fmc.13.112; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spahn TW, 2002, EUR J IMMUNOL, V32, P1109, DOI 10.1002/1521-4141(200204)32:4<1109::AID-IMMU1109>3.3.CO;2-B; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Suarez-Fueyo A, 2014, J ALLERGY CLIN IMMUN, V133, P130, DOI 10.1016/j.jaci.2013.09.043; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Syed A, 2013, IMMUNOTHERAPY-UK, V5, P931, DOI 10.2217/imt.13.93; Terada T, 2006, CLIN IMMUNOL, V120, P45, DOI 10.1016/j.clim.2005.12.010; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Tsai YG, 2010, J IMMUNOL, V184, P7229, DOI 10.4049/jimmunol.1000083; Tu Y, 2005, GASTROENTEROLOGY, V129, P928, DOI 10.1053/j.gastro.2005.06.014; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turley DM, 2007, J IMMUNOL, V178, P2212, DOI 10.4049/jimmunol.178.4.2212; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Ventura MT, 2006, DIGEST LIVER DIS, V38, P732, DOI 10.1016/j.dld.2006.06.012; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wu LC, 2014, CURR OPIN IMMUNOL, V31, P8, DOI 10.1016/j.coi.2014.08.001; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Yang ZH, 2013, AM J PHYSIOL-GASTR L, V304, pG381, DOI 10.1152/ajpgi.00357.2012; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67; Zhou MH, 2013, J MOL HISTOL, V44, P327, DOI 10.1007/s10735-013-9484-9; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zitnik SE, 2009, PEDIAT ALLERG IMM-UK, V20, P551, DOI 10.1111/j.1399-3038.2008.00815.x	168	44	46	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					312	323		10.1016/j.jaci.2014.12.1908	http://dx.doi.org/10.1016/j.jaci.2014.12.1908			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25662303	Green Accepted			2022-12-18	WOS:000349372300002
J	Beppu, LY; Anilkumar, AA; Newbury, RO; Dohil, R; Broide, DH; Aceves, SS				Beppu, Lisa Y.; Anilkumar, Arjun A.; Newbury, Robert O.; Dohil, Ranjan; Broide, David H.; Aceves, Seema S.			TGF-beta 1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Remodeling; esophagus; eosinophils; smooth muscle; TGF-beta; phospholamban	CAM KINASE-II; DILATED CARDIOMYOPATHY; ADULT PATIENTS; CHILDREN; DYSMOTILITY; DISTURBANCES; MODULATION; MUTATION; LETHAL; MOUSE	Background: Eosinophilic esophagitis (EoE) is a chronic antigen-mediated disease characterized by esophageal eosinophilia, remodeling, and fibrosis. TGF-beta 1 is a central regulator of EoE remodeling and increases esophageal smooth muscle (ESM) cell contraction. Objective: In this study we aimed to understand the molecular mechanisms by which TGF-beta 1 could induce ESM cell contraction. Methods: We used primary human ESM cells and esophageal myofibroblasts (EMFs) to assess the mechanisms of TGF-beta 1-induced contraction. We analyzed the expression, phosphorylation, and function of phospholamban (PLN), a sarcoendoplasmic reticulum regulatory protein induced by TGF-beta 1. Expression of PLN, phospho-PLN, and its regulatory pathway was analyzed in the ESM of biopsy specimens from patients with EoE and control subjects. Gene silencing in EMFs from patients with EoE was used to understand the role of PLN in contraction. Results: TGF-beta 1 induced and phosphorylated PLN in primary human ESM cells and EMFs from patients with EoE. PLN and phospho-PLN levels were increased in smooth muscle from patients with EoE compared with that seen in smooth muscle from control subjects in vivo. PLN inhibition significantly diminished TGF-beta 1-induced EMF contraction in patients with EoE. PLN expression and ESM/EMF contraction depended on TGF-beta receptor I signals. Conclusion: We describe a previously unrecognized mechanism for ESM cell contraction that depends on TGF-beta 1, its receptors, and PLN. Because PLN levels are increased in smooth muscle from patients with EoE and PLN silencing diminishes contraction, we provide a novel potential mechanistic framework and therapeutic target for ESM dysfunction in patients with EoE.	[Beppu, Lisa Y.; Anilkumar, Arjun A.; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Beppu, Lisa Y.; Newbury, Robert O.; Dohil, Ranjan; Aceves, Seema S.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Anilkumar, Arjun A.; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Div Pathol, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Aceves, SS (corresponding author), Univ Calif San Diego, Rady Childrens Hosp, Dept Pediat, Div Allergy & Immunol, 9500 Gilman Dr,MC-0760, La Jolla, CA 92093 USA.	saceves@ucsd.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI 092135, AI 107779, AI 70535, AI 72115]; DOD [FA100044]; Hearst Foundation; NIH [ULRR031980]; CTSA [UL1TR0001000]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038425, R01AI072115, R01AI092135, U19AI070535, R01AI107779] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DOD(United States Department of Defense); Hearst Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) AI 092135 to S. S. A), DOD FA100044 (to D. H. B and S. S. A.), NIH/NIAID AI 107779 (to D. H. B.), AI 70535 (to D. H. B.), AI 72115 (to D. H. B.), and the Hearst Foundation (to R. D.). The project described was partially supported by the NIH, grant ULRR031980 for years 1 & 2 or CTSA funding and/or UL1TR0001000 during year 3 and beyond of CTSA funding (support of the EoE database).	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P1205, DOI 10.1016/j.jaci.2010.10.031; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Bassett J, 2009, DIS ESOPHAGUS, V22, P543, DOI 10.1111/j.1442-2050.2009.00949.x; Baum P, 2010, OLIGONUCLEOTIDES, V20, P17, DOI 10.1089/oli.2009.0213; Camello-Almaraz C, 2009, AM J PHYSIOL-CELL PH, V296, pC783, DOI 10.1152/ajpcell.00452.2008; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Fischer H, 2006, WORLD J GASTROENTERO, V12, P6002, DOI 10.3748/wjg.v12.i37.6002; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Haghighi K, 2006, P NATL ACAD SCI USA, V103, P1388, DOI 10.1073/pnas.0510519103; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Hejazi RA, 2010, DYSPHAGIA, V25, P231, DOI 10.1007/s00455-009-9248-6; Kim M, 2008, J PHYSIOL-LONDON, V586, P4977, DOI 10.1113/jphysiol.2008.156836; Kim MY, 2008, AM J PHYSIOL-CELL PH, V294, pC432, DOI 10.1152/ajpcell.00418.2007; Korsapati H, 2009, GUT, V58, P1056, DOI 10.1136/gut.2008.168146; Kranias EG, 2012, CIRC RES, V110, P1646, DOI 10.1161/CIRCRESAHA.111.259754; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; LANDRES RT, 1978, GASTROENTEROLOGY, V74, P1298; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2006, ALIMENT PHARM THER, V24, P1264, DOI 10.1111/j.1365-2036.2006.03109.x; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Mavi P, 2012, AM J PHYSIOL-GASTR L, V302, pG1347, DOI 10.1152/ajpgi.00013.2012; McGraw DW, 2006, PHYSIOL GENOMICS, V27, P171, DOI 10.1152/physiolgenomics.00044.2006; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Moawad FJ, 2011, DIGEST DIS SCI, V56, P1427, DOI 10.1007/s10620-011-1655-5; Nicholson AG, 1997, J PATHOL, V183, P233, DOI 10.1002/(SICI)1096-9896(199710)183:2<233::AID-PATH936>3.0.CO;2-Z; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P1101, DOI 10.1016/j.cgh.2013.03.020; Niranjan R, 2013, AM J PHYSIOL-GASTR L, V304, pG1087, DOI 10.1152/ajpgi.00070.2013; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Nurko S, 2009, AM J GASTROENTEROL, V104, P3050, DOI 10.1038/ajg.2009.543; Qureshi S, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01406.x; Ramachandran A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053430; Read AJ, 2012, J NEUROGASTROENTEROL, V18, P357, DOI 10.5056/jnm.2012.18.4.357; Remedios M, 2006, GASTROINTEST ENDOSC, V63, P3, DOI 10.1016/j.gie.2005.07.049; Rieder F, 2014, GASTROENTEROLOGY; Roman S, 2011, NEUROGASTROENT MOTIL, V23, DOI 10.1111/j.1365-2982.2010.01633.x; Saffari H, 2012, J ALLERGY CLIN IMMUN, V130, P798, DOI 10.1016/j.jaci.2012.03.009; Sathish V, 2009, AM J PHYSIOL-LUNG C, V297, pL26, DOI 10.1152/ajplung.00026.2009; Savarino E, 2011, CLIN GASTROENTEROL H, V9, P1104, DOI 10.1016/j.cgh.2011.08.002; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann Alex, 2008, Gastrointest Endosc Clin N Am, V18, P99, DOI 10.1016/j.giec.2007.09.009; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; Wang HS, 2011, PHYSIOL GENOMICS, V43, P357, DOI 10.1152/physiolgenomics.00032.2010	47	44	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1100	+		10.1016/j.jaci.2014.04.004	http://dx.doi.org/10.1016/j.jaci.2014.04.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24835503	Green Accepted			2022-12-18	WOS:000344938900015
J	Yang, G; Geng, XR; Song, JP; Wu, YY; Yan, H; Zhan, ZK; Yang, LT; He, WY; Liu, ZQ; Qiu, SQ; Liu, ZG; Yang, PC				Yang, Gui; Geng, Xiao-Rui; Song, Jiang-Ping; Wu, Yingying; Yan, Hao; Zhan, Zhengke; Yang, Litao; He, Weiyi; Liu, Zhi-Qiang; Qiu, Shuqi; Liu, Zhigang; Yang, Ping-Chang			Insulin-like growth factor 2 enhances regulatory T-cell functions and suppresses food allergy in an experimental model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cell; insulin-like growth factor; transforming growth factor; intestine; allergy	IMMUNE TOLERANCE; DIFFERENTIATION; TRANSPLANTATION; MECHANISMS; INDUCTION; STABILITY; RECEPTOR; PLAYS; MAPK	Background: The functions of regulatory T (Treg) cells are important in immunity, and the regulatory mechanisms of Treg cell activities are not fully understood yet. Objectives: We sought to investigate the role of insulin-like growth factor (IGF) 2 in the upregulation of Treg cell function. Methods: The expression of insulin-like growth factor 2 receptor (IGF2R) on T cells was assessed by using flow cytometry. Treg cell functions were evaluated by assessing the suppressor effect on proliferation of other effector T (Teff) cells. The effect of IGF2 on regulating Treg cell functions were evaluated with a cell-culture model and a food allergy mouse model. Results: Expression of IGF2R was observed in more than 90% of murine and human Treg cells but in less than 10% of effector CD4(+) T cells. Activation of IGF2R and T-cell receptor induced marked Treg cell proliferation and release of TGF-beta from Treg cells, which enhanced Treg cell immune suppressor effects on other Teff cell activities and allergic inflammation in the intestine. Conclusions: Activation of IGF2R enhances Treg cell functions in suppressing other Teff cell activities and inhibiting allergic inflammation in the intestine.	[Yang, Gui; Geng, Xiao-Rui; Yang, Litao; Liu, Zhi-Qiang; Qiu, Shuqi; Liu, Zhigang; Yang, Ping-Chang] Shenzhen Univ, ENT Inst, Shenzhen, Peoples R China; [Wu, Yingying; Yan, Hao; Zhan, Zhengke; He, Weiyi; Liu, Zhigang; Yang, Ping-Chang] Shenzhen Univ, State Key Lab Resp Dis Allergy, Shenzhen Key Lab Allergy & Immunol, Sch Med, Shenzhen, Peoples R China; [Yang, Gui; Geng, Xiao-Rui; Yang, Litao; Liu, Zhi-Qiang; Qiu, Shuqi] Shenzhen ENT Inst, Longgang Cent Hosp, Shenzhen, Peoples R China; [Song, Jiang-Ping] Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100730, Peoples R China; [Song, Jiang-Ping] Peking Union Med Coll, Beijing 100021, Peoples R China	Shenzhen University; Shenzhen University; State Key Laboratory of Respiratory Disease; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Yang, PC (corresponding author), Rm 204,Med Sch Bldg,3688 Nanhai Ave, Shenzhen, Peoples R China.	lzg@szu.edu.cn; pcy2356@szu.edu.cn	Yang, Ping-Chang/K-4669-2019		Natural Science Foundation of SZU [000004]; Innovation of Science and Technology Commission of Shenzhen Municipality [JCYJ20120613172559904]; Natural Science Foundation of China [30871752, 31101280, 81373176]; Key Laboratory Project of Shenzhen [SW201110010]; Guangdong Provincial Natural Science Foundation [S2013040014206]	Natural Science Foundation of SZU; Innovation of Science and Technology Commission of Shenzhen Municipality; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory Project of Shenzhen; Guangdong Provincial Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	Supported by grants from the Natural Science Foundation of SZU (no. 000004), the Innovation of Science and Technology Commission of Shenzhen Municipality (no. JCYJ20120613172559904), the Natural Science Foundation of China (nos. 30871752, 31101280, and 81373176), the Key Laboratory Project of Shenzhen (no. SW201110010), and the Guangdong Provincial Natural Science Foundation (no. S2013040014206).	Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Brusko TM, 2008, IMMUNOL REV, V223, P371, DOI 10.1111/j.1600-065X.2008.00637.x; Buchanan CM, 2010, GROWTH HORM IGF RES, V20, P360, DOI 10.1016/j.ghir.2010.06.003; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Chattree V, 2007, MOL IMMUNOL, V44, P2066, DOI 10.1016/j.molimm.2006.09.008; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen X, 2011, J LEUKOCYTE BIOL, V90, P751, DOI 10.1189/jlb.1210696; Feng BS, 2008, J ALLERGY CLIN IMMUN, V122, P55, DOI 10.1016/j.jaci.2008.04.036; Haase D, 2012, IMMUNOL RES, V53, P200, DOI 10.1007/s12026-012-8267-9; Hansen W, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23039; Hansenne I, 2006, J IMMUNOL, V176, P4651, DOI 10.4049/jimmunol.176.8.4651; MacDonald KG, 2012, CURR OPIN ORGAN TRAN, V17, P343, DOI 10.1097/MOT.0b013e328355aaaf; McKinnon T, 2001, J CLIN ENDOCR METAB, V86, P3665, DOI 10.1210/jc.86.8.3665; Okada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044338; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006; Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023; Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183	22	44	46	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1702	+		10.1016/j.jaci.2014.02.019	http://dx.doi.org/10.1016/j.jaci.2014.02.019			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24698315				2022-12-18	WOS:000336672500024
J	Arkwright, PD; Riley, P; Hughes, SM; Alachkar, H; Wynn, RF				Arkwright, Peter D.; Riley, Philip; Hughes, Stephen M.; Alachkar, Hana; Wynn, Robert F.			Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMPLEMENT; MICE		[Arkwright, Peter D.] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England; [Arkwright, Peter D.; Riley, Philip; Hughes, Stephen M.; Wynn, Robert F.] Royal Manchester Childrens Hosp, Dept Paediat Immunol, Manchester M27 1HA, Lancs, England; [Arkwright, Peter D.; Riley, Philip; Hughes, Stephen M.; Wynn, Robert F.] Royal Manchester Childrens Hosp, Dept Rheumatol, Manchester M27 1HA, Lancs, England; [Arkwright, Peter D.; Riley, Philip; Hughes, Stephen M.; Wynn, Robert F.] Royal Manchester Childrens Hosp, Dept Bone Marrow Transplantat, Manchester M27 1HA, Lancs, England; [Alachkar, Hana] Salford Royal Fdn Trust, Dept Immunol, Manchester, Lancs, England	University of Manchester; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; Salford Royal NHS Foundation Trust	Arkwright, PD (corresponding author), Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England.	peter.arkwright@nhs.net		Wynn, robert/0000-0002-6046-8428; Arkwright, Peter/0000-0002-7411-5375				Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029; Cortes-Hernandez J, 2004, EUR J IMMUNOL, V34, P3713, DOI 10.1002/eji.200425616; KAUL M, 1995, J IMMUNOL, V155, P5795; Petry F, 2001, J IMMUNOL, V167, P4033, DOI 10.4049/jimmunol.167.7.4033; Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225; Vassallo G, 2007, RHEUMATOLOGY, V16, P12	6	44	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					265	267		10.1016/j.jaci.2013.07.035	http://dx.doi.org/10.1016/j.jaci.2013.07.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24035158				2022-12-18	WOS:000329105700038
J	Hafkamp-de Groen, E; Lingsma, HF; Caudri, D; Levie, D; Wijga, A; Koppelman, GH; Duijts, L; Jaddoe, VWV; Smit, HA; Kerkhof, M; Moll, HA; Hofman, A; Steyerberg, EW; de Jongste, JC; Raat, H				Hafkamp-de Groen, Esther; Lingsma, Hester F.; Caudri, Daan; Levie, Deborah; Wijga, Alet; Koppelman, Gerard H.; Duijts, Liesbeth; Jaddoe, Vincent W. V.; Smit, Henriette A.; Kerkhof, Marjan; Moll, Henriette A.; Hofman, Albert; Steyerberg, Ewout W.; de Jongste, Johan C.; Raat, Hein			Predicting asthma in preschool children with asthma-like symptoms: Validating and updating the PIAMA risk score	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; birth cohort; children; external validation; Prevention and Incidence of Asthma and Mite Allergy risk score; prognosis; prediction; updating; wheeze	CHILDHOOD; DIAGNOSIS; REGRESSION; INDEX; QUESTIONNAIRE; DISEASE; VALUES; WILL; AGE	Background: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) risk score predicts the probability of having asthma at school age among preschool children with suggestive symptoms. Objective: We sought to externally validate the PIAMA risk score at different ages and in ethnic and socioeconomic subgroups of children in addition to updating it. Methods: We studied 2877 children with preschool asthma-like symptoms participating in the multiethnic, prospective, population-based cohort study Generation R. The PIAMA risk score was assessed at preschool age, and asthma was predicted at age 6 years. Discrimination (concordance index [C-index]) and calibration were calculated. The PIAMA risk score was updated, and its performance was similarly analyzed. Results: At age 6 years, 6% (168/2877) of the children had asthma. The discriminative ability of the original PIAMA risk score to predict asthma in Generation R was similar compared with that in the PIAMA cohort (C-index 5 0.74 vs 0.71). The predicted risks by using the original PIAMA risk score for having asthma at the age of 6 years tended to be slightly higher than the observed risks (8% vs 6%). No differences in discriminative ability were found at different ages or in ethnic and socioeconomic subgroups (P > .05). The updated PIAMA risk score had a C-index of 0.75. Conclusions: The PIAMA risk score showed good external validity. The discriminative ability was similar at different ages and in ethnic and socioeconomic subgroups of preschool children, which suggests good generalizability. Further studies are needed to reproduce the predictive performance of the updated PIAMA risk score in other populations and settings and to assess its clinical relevance.	[Hafkamp-de Groen, Esther; Levie, Deborah; Jaddoe, Vincent W. V.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands; [Hafkamp-de Groen, Esther; Lingsma, Hester F.; Levie, Deborah; Steyerberg, Ewout W.; Raat, Hein] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Duijts, Liesbeth; Jaddoe, Vincent W. V.; Hofman, Albert] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Caudri, Daan; Duijts, Liesbeth; de Jongste, Johan C.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat, Div Resp Med, Rotterdam, Netherlands; [Duijts, Liesbeth] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat, Div Neonatol, Rotterdam, Netherlands; [Jaddoe, Vincent W. V.; Moll, Henriette A.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat, Rotterdam, Netherlands; [Wijga, Alet] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, GRIAC Res Inst, Groningen, Netherlands; [Smit, Henriette A.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Netherlands National Institute for Public Health & the Environment; University of Groningen; University of Groningen; Utrecht University; Utrecht University Medical Center; University of Groningen	Hafkamp-de Groen, E (corresponding author), POB 2040 Room NA 2919, NL-3000 CA Rotterdam, Netherlands.	e.hafkamp@erasmusmc.nl	Steyerberg, Ewout W/C-1509-2018; Koppelman, Gerard/AAG-9187-2020	Steyerberg, Ewout W/0000-0002-7787-0122; Koppelman, Gerard/0000-0001-8567-3252	Dutch Asthma Foundation [3.4.12.015]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1226-2009, RESPIRE, PCOFUND-GA-2008-229571]; Netherlands Organization for Health Research and Development [Zonmw 90700303, 916.10159]; Dutch Lung Foundation [3.2.09.081]	Dutch Asthma Foundation; European Respiratory Society/Marie Curie Joint Research Fellowship; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Dutch Lung Foundation	E.H.-d.G. received funding by means of the Dutch Asthma Foundation (project no. 3.4.12.015). L. Duijts received funding by means of a European Respiratory Society/Marie Curie Joint Research Fellowship (MC 1226-2009) under grant agreement RESPIRE, PCOFUND-GA-2008-229571. V.W.V. Jaddoe received additional grants from the Netherlands Organization for Health Research and Development (ZonMw 90700303 and 916.10159). The Prevention and Incidence of Asthma and Mite Allergy study is supported by the Dutch Lung Foundation (grant no. 3.2.09.081).	Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Balemans WAF, 2006, J CLIN EPIDEMIOL, V59, P1207, DOI 10.1016/j.jclinepi.2006.02.011; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2011, CURR OPIN ALLERGY CL, V11, P157, DOI 10.1097/ACI.0b013e3283464c4a; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Chugh IM, 2006, ASIAN PAC J ALLERGY, V24, P135; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Hafkamp-de Groen E, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-65; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Heijmans MJWM, MONITOR ZORG EN LEEF; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jaddoe VWV, 2012, EUR J EPIDEMIOL, V27, P739, DOI 10.1007/s10654-012-9735-1; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Janssen KJM, 2009, CLIN CHEM, V55, P994, DOI 10.1373/clinchem.2008.115345; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Rodriguez-Martinez CE, 2011, PEDIATR PULM, V46, P1175, DOI 10.1002/ppul.21493; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Sole D, 1998, J INVEST ALLERG CLIN, V8, P376; Subbarao P, 2009, EXPERT REV CLIN IMMU, V5, P77, DOI 10.1586/1744666X.5.1.77; Swertz O, 2004, MIGRANTS NETHERLANDS; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; van Gent R, 2008, J ASTHMA, V45, P807, DOI 10.1080/02770900802311477; van Wonderen KE, 2010, EUR RESPIR J, V36, P48, DOI 10.1183/09031936.00154409; von Hippel PT, 2007, SOCIOL METHODOL, V37, P83, DOI 10.1111/j.1467-9531.2007.00180.x; Wang WH, 2012, EUR RESPIR J, V39, P1213, DOI 10.1183/09031936.00091311; Wever-Hess J, 1999, ACTA PAEDIATR, V88, P827, DOI 10.1080/08035259950168739	35	44	44	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1303	+		10.1016/j.jaci.2013.07.007	http://dx.doi.org/10.1016/j.jaci.2013.07.007			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23987795				2022-12-18	WOS:000327538200009
J	Maaninka, K; Lappalainen, J; Kovanen, PT				Maaninka, Katariina; Lappalainen, Jani; Kovanen, Petri T.			Human mast cells arise from a common circulating progenitor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chymase; mast cell; neutral granule protease; kit ligand; tryptase	CONNECTIVE TISSUE-TYPE; PERIPHERAL-BLOOD; CHYMASE; TRYPTASE; EXPRESSION; DIFFERENTIATION; PHENOTYPE; BASOPHILS; SURVIVAL; CD34(+)	Background: Human tissue mast cells (MCs) have the potential to express several neutral granule proteases, which are the most precise markers of the phenotypic heterogeneity of MCs. However, the full extent of such heterogeneity is limited by the fact that MCs containing either tryptase only or tryptase and chymase have long been considered to be the sole MC phenotypes. Moreover, the potential developmental relationship between human MCs of different protease phenotypes has remained a matter of dispute. Objective: We attempted to define how human MCs with different protease phenotypes relate to their circulating progenitors. Methods: MCs were generated from human peripheral blood-derived CD34(+) progenitors in the presence of kit ligand (KITLG) and the cytokines IL-3, IL-9, and IL-6 under serum-free conditions, or by KITLG alone in the presence or absence of serum. The expression of chymase, carboxypeptidase A3, cathepsin G, granzyme B, and the tryptases derived from the TPSAB1, TPSB2, TPSD1, and TPSG1/PRSS31 genes were determined weekly at the mRNA and/or protein levels. Results: Incubation of CD34(+) progenitors in the presence of KITLG and the cytokines IL-3, IL-9, and IL-6 promoted the development of a single population of MCs with a uniform tryptase(+), chymase(+), CPA3(+), cathepsin G(+), and granzyme B+ phenotype. Interestingly, the presence of KITLG alone was sufficient to induce the expression of all the above proteases. Conclusion: All circulating human MC progenitors have the potential to differentiate into MCs expressing the complete panel of neutral granule proteases, implying that human MCs originate from a common MC-committed progenitor.	[Maaninka, Katariina; Lappalainen, Jani; Kovanen, Petri T.] Wihuri Res Inst, FIN-00290 Helsinki, Finland	Wihuri Research Institute	Kovanen, PT (corresponding author), Wihuri Res Inst, Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	petri.kovanen@wri.fi		Maaninka, Katariina/0000-0001-6341-3871				Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Ahn K, 2000, J ALLERGY CLIN IMMUN, V106, P321, DOI 10.1067/mai.2000.108107; Andersen HB, 2008, J IMMUNOL METHODS, V336, P166, DOI 10.1016/j.jim.2008.04.016; Phung B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024064; Castells MC, 1996, J ALLERGY CLIN IMMUN, V98, P831, DOI 10.1016/S0091-6749(96)70133-1; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; CRAIG SS, 1989, LAB INVEST, V60, P147; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Hsieh FH, 2005, P NATL ACAD SCI USA, V102, P14380, DOI 10.1073/pnas.0503948102; Irani A M, 1990, Monogr Allergy, V27, P146; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1992, IMMUNOLOGY, V77, P136; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1991, J IMMUNOL, V147, P247; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KOBAYASHI T, 1986, J IMMUNOL, V136, P1378; Lappalainen J, 2007, CLIN EXP ALLERGY, V37, P1404, DOI 10.1111/j.1365-2222.2007.02778.x; Lee SH, 2010, EXP MOL MED, V42, P366, DOI 10.3858/emm.2010.42.5.038; Li LX, 1996, J IMMUNOL, V156, P4839; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Raymond WW, 2009, J IMMUNOL, V182, P5770, DOI 10.4049/jimmunol.0900127; Raymond WW, 2003, J BIOL CHEM, V278, P34517, DOI 10.1074/jbc.M304087200; ROTTEM M, 1994, BLOOD, V84, P2489; Saito H, 2001, INT ARCH ALLERGY IMM, V125, P1, DOI 10.1159/000053790; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SONODA S, 1986, J IMMUNOL, V137, P1319; Strik MCM, 2007, MOL IMMUNOL, V44, P3462, DOI 10.1016/j.molimm.2007.03.024; Toru H, 1998, BLOOD, V91, P187, DOI 10.1182/blood.V91.1.187.187_187_195; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Xia HZ, 1997, J IMMUNOL, V159, P2911; XIA HZ, 1995, J IMMUNOL, V154, P5472	41	44	47	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					463	+		10.1016/j.jaci.2013.02.011	http://dx.doi.org/10.1016/j.jaci.2013.02.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23582567	Bronze			2022-12-18	WOS:000322631700025
J	la Marca, G; Canessa, C; Giocaliere, E; Romano, F; Duse, M; Malvagia, S; Lippi, F; Funghini, S; Bianchi, L; Della Bona, ML; Valleriani, C; Ombrone, D; Moriondo, M; Villanelli, F; Speckmann, C; Adams, S; Gaspar, BH; Hershfield, M; Santisteban, I; Fairbanks, L; Ragusa, G; Resti, M; de Martino, M; Guerrini, R; Azzari, C				la Marca, Giancarlo; Canessa, Clementina; Giocaliere, Elisa; Romano, Francesca; Duse, Marzia; Malvagia, Sabrina; Lippi, Francesca; Funghini, Silvia; Bianchi, Leila; Della Bona, Maria Luisa; Valleriani, Claudia; Ombrone, Daniela; Moriondo, Maria; Villanelli, Fabio; Speckmann, Carsten; Adams, Stuart; Gaspar, Bobby H.; Hershfield, Michael; Santisteban, Ines; Fairbanks, Lynette; Ragusa, Giovanni; Resti, Massimo; de Martino, Maurizio; Guerrini, Renzo; Azzari, Chiara			Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adenosine deaminase; severe combined immunodeficiency; newborn screening; tandem-mass-spectrometry; late-onset; delayed-onset; Adenosine deaminase-severe combined immunodeficiency; T-cell receptor excision circle; genetics; inherited disorder	SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; ADA DEFICIENCY; EXPRESSION; MUTATIONS; ENZYME	Background: Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by genetic variants that disrupt the function of ADA. In its early-onset form, it is rapidly fatal to infants. Delayed or late-onset ADA-SCID is characterized by insidious progressive immunodeficiency that leads to permanent organ damage or death. Quantification of T-cell receptor excision circles (TRECs) or tandem mass spectrometry (tandem-MS) analysis of dried blood spots (DBSs) collected at birth can identify newborns with early-onset ADA-SCID and are used in screening programs. However, it is not clear whether these analyses can identify newborns who will have delayed or late-onset ADA-SCID before symptoms appear. Objective: We performed a retrospective study to evaluate whether tandem-MS and quantitative TREC analyses of DBSs could identify newborns who had delayed-onset ADA-SCID later in life. Methods: We tested stored DBSs collected at birth from 3 patients with delayed-onset ADA-SCID using tandem-MS (PCT EP2010/070517) to evaluate levels of adenosine and 2'-deoxyadenosine and real-time PCR to quantify TREC levels. We also analyzed DBSs from 3 newborns with early-onset ADA-SCID and 2 healthy newborn carriers of ADA deficiency. Results: The DBSs taken at birth from the 3 patients with delayed-onset ADA-SCID had adenosine levels of 10, 25, and 19 mu mol/L (normal value, <1.5 mu mol/L) and 2'-deoxyadenosine levels of 0.7, 2.7, and 2.4 mu mol/L (normal value, <0.07 mu mol/L); the mean levels of adenosine and 2'-deoxyadenosine were respectively 12.0- and 27.6-fold higher than normal values. DBSs taken at birth from all 3 patients with delayed-onset ADA deficiency had normal TREC levels, but TRECs were undetectable in blood samples taken from the same patients at the time of diagnosis. Conclusion: Tandem-MS but not TREC quantification identifies newborns with delayed-or late-onset ADA deficiency.	[la Marca, Giancarlo; Giocaliere, Elisa; Malvagia, Sabrina; Funghini, Silvia; Della Bona, Maria Luisa; Ombrone, Daniela; Villanelli, Fabio] Univ Florence, Dept Pharmacol, I-50139 Florence, Italy; [la Marca, Giancarlo; Canessa, Clementina; Giocaliere, Elisa; Romano, Francesca; Malvagia, Sabrina; Lippi, Francesca; Funghini, Silvia; Bianchi, Leila; Della Bona, Maria Luisa; Valleriani, Claudia; Ombrone, Daniela; Moriondo, Maria; Villanelli, Fabio; Resti, Massimo; de Martino, Maurizio; Azzari, Chiara] Univ Florence, Anna Meyer Childrens Univ Hosp, I-50139 Florence, Italy; [Guerrini, Renzo] Univ Florence, Clin Pediat Neurol, Dept Neurol, I-50139 Florence, Italy; [Canessa, Clementina; Romano, Francesca; Lippi, Francesca; Bianchi, Leila; Valleriani, Claudia; Moriondo, Maria; Resti, Massimo; de Martino, Maurizio; Azzari, Chiara] Univ Florence, Dept Women & Childrens Hlth, I-50139 Florence, Italy; [Duse, Marzia; Ragusa, Giovanni] Univ Roma La Sapienza, Dept Pediat & Pediat Neuropsychiat, Rome, Italy; [Speckmann, Carsten] Univ Freiburg, Ctr Chron Immundefizienz, Zentrum Kinderheilkunde & Jugendmed, Freiburg, Germany; [Adams, Stuart; Gaspar, Bobby H.; Fairbanks, Lynette] UCL Inst Child Hlth, Mol Immunol Unit, London, England; [Hershfield, Michael; Santisteban, Ines] Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA	University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; Sapienza University Rome; University of Freiburg; University of London; University College London; Duke University	Azzari, C (corresponding author), Univ Florence, Anna Meyer Childrens Univ Hosp, Dept Pediat, Viale Pieraccini 24, I-50139 Florence, Italy.	chiara.azzari@unifi.it	Villanelli, Fabio/AAC-5017-2022; la Marca, Giancarlo/A-2853-2013; Moriondo, Maria/AAB-7883-2019; Resti, Massimo/AAB-8756-2019; Lippi, francesca/AAB-8952-2019; Malvagia, Sabrina/K-3580-2018; Azzari, Chiara/AAB-8584-2019	Villanelli, Fabio/0000-0002-2462-565X; Moriondo, Maria/0000-0001-9653-8371; Resti, Massimo/0000-0001-6350-1361; Lippi, francesca/0000-0003-2533-1802; Malvagia, Sabrina/0000-0002-3968-0264; Azzari, Chiara/0000-0001-7236-1655; la marca, giancarlo/0000-0003-3319-7260; Speckmann, Carsten/0000-0002-6217-1556; Guerrini, Renzo/0000-0002-7272-7079	University of Florence; Anna Meyer Children's University Hospital; Tuscany (Italy) region; Sigma-Tau Pharmaceuticals; Great Ormond Street Hospital Childrens Charity [V1242] Funding Source: researchfish	University of Florence; Anna Meyer Children's University Hospital; Tuscany (Italy) region; Sigma-Tau Pharmaceuticals; Great Ormond Street Hospital Childrens Charity	Supported in part by a donation from Famiglia Cassigoli (C. A.) and a grant from the University of Florence (C. A. and G. l. M.), the Anna Meyer Children's University Hospital (M. R.), and the Tuscany (Italy) region (C. A., G. l. M., and M. R.). Sigma-Tau Pharmaceuticals provided grant support to M. H. and I.S.	Ariga T, 2001, J IMMUNOL, V166, P1698, DOI 10.4049/jimmunol.166.3.1698; Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; Arredondo-Vega FX, 2002, BLOOD, V99, P1005, DOI 10.1182/blood.V99.3.1005; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; Azzari C, 2011, J ALLERGY CLIN IMMUN, V127, P1394, DOI 10.1016/j.jaci.2011.03.040; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Chace DH, 2009, J MASS SPECTROM, V44, P163, DOI 10.1002/jms.1528; Comeau AM, 2010, J INHERIT METAB DIS, V33, pS273, DOI 10.1007/s10545-010-9103-9; Fairbanks LD, 2000, ADV EXP MED BIOL, V486, P51; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Gaspar HB, 2010, IMMUNOL ALLERGY CLIN, V30, P221, DOI 10.1016/j.iac.2010.01.002; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Health Resources and Services Administration, 2010, 20 M WASH DC JAN 22; HIRSCHHORN R, 1979, J CLIN INVEST, V64, P1130, DOI 10.1172/JCI109552; HIRSCHHORN R, 1986, AM J HUM GENET, V38, P13; la Marca G, 2008, RAPID COMMUN MASS SP, V22, P812, DOI 10.1002/rcm.3428; la Marca G, 2006, J MASS SPECTROM, V41, P1442, DOI 10.1002/jms.1115; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Ozsahin H, 1997, BLOOD, V89, P2849, DOI 10.1182/blood.V89.8.2849; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Sanchez JJ, 2007, ANN HUM GENET, V71, P336, DOI 10.1111/j.1469-1809.2006.00338.x; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SHOVLIN CL, 1994, J IMMUNOL, V153, P2331; Speckmann C, 2012, J ALLERGY CLIN IMMUN, V130, P991, DOI 10.1016/j.jaci.2012.04.004; Wilson JMG, 1968, 34 WHO	25	44	45	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1604	1610		10.1016/j.jaci.2012.08.054	http://dx.doi.org/10.1016/j.jaci.2012.08.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23280131	Green Submitted			2022-12-18	WOS:000320532800021
J	Carroll, KN; Gebretsadik, T; Minton, P; Woodward, K; Liu, ZW; Miller, EK; Williams, JV; Dupont, WD; Hartert, TV				Carroll, Kecia N.; Gebretsadik, Tebeb; Minton, Patricia; Woodward, Kimberly; Liu, Zhouwen; Miller, E. Kathryn; Williams, John V.; Dupont, William D.; Hartert, Tina V.			Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic predisposition; acute respiratory tract infection; rhinovirus; respiratory syncytial virus; asthma	INNATE IMMUNE-RESPONSE; SYNCYTIAL-VIRUS; VIRAL-INFECTIONS; EARLY-LIFE; RHINOVIRUS ILLNESSES; RISK-FACTORS; AGE 13; CHILDREN; BRONCHIOLITIS; EXACERBATIONS	Background: Respiratory syncytial virus (RSV) and rhinovirus infections are the most common significant infant respiratory tract illnesses and are associated with increased but differential risks of childhood asthma. Objective: We sought to determine whether maternal asthma is associated with higher odds of infant respiratory tract infection with rhinovirus versus RSV and increased infection severity. Methods: Mother-infant dyads were enrolled from 2004-2008 during an infant respiratory tract infection (104 with rhinovirus and 279 with RSV). Mothers were classified into mutually exclusive groups (atopic asthma, nonatopic asthma, and no asthma). We determined viral cause using PCR and the severity of the infant's respiratory tract infection using the bronchiolitis severity score. Adjusted relative odds of maternal asthma with viral cause were calculated by using logistic regression. Proportional odds models assessed the association of maternal asthma and infant infection severity. Results: Infants with a mother with atopic asthma compared with infants whose mothers did not have asthma were more likely to have rhinovirus versus RSV infection (adjusted odds ratio, 2.42; 95% CI, 1.19-4.90). Similarly, among infants with rhinovirus, having a mother with atopic asthma was associated with increased infection severity (adjusted odds ratio, 3.10; 95% CI, 1.21-7.98). This relationship was not seen among infants with RSV. Conclusions: Clinically significant rhinovirus infection during infancy was more strongly associated with having a mother with atopic asthma than clinically significant RSV infection. Having a mother with atopic asthma was associated with increased severity of infant rhinovirus but not RSV infections. Infants with rhinovirus were more likely to have a familial atopic predisposition, which might partly explain the subsequent increased asthma risk. (J Allergy Clin Immunol 2012;129:1236-42.)	[Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Carroll, Kecia N.; Miller, E. Kathryn; Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Gebretsadik, Tebeb; Liu, Zhouwen; Dupont, William D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Minton, Patricia; Woodward, Kimberly; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; [Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Div Gen Pediat, Nashville, TN 37232 USA; [Miller, E. Kathryn] Vanderbilt Univ, Sch Med, Div Pediat Pulm Allergy & Immunol, Nashville, TN 37232 USA; [Williams, John V.] Vanderbilt Univ, Sch Med, Div Pediat Infect Dis, Nashville, TN 37232 USA; [Carroll, Kecia N.; Gebretsadik, Tebeb; Minton, Patricia; Woodward, Kimberly; Liu, Zhouwen; Miller, E. Kathryn; Dupont, William D.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Asthma & Environm Hlth Res, Nashville, TN 37232 USA; [Hartert, Tina V.] Vanderbilt Univ, Sch Med, Gen Clin Res Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu	Dupont, William D./I-4430-2012; Williams, John/ABE-3227-2020	Williams, John/0000-0001-8377-5175	Thrasher Research Fund Clinical Research Grant; National Institutes of Health [K24 AI 077930, UL1 RR024975]; National Institutes of Health/National Institute of Allergy and Infectious Diseases; National Cancer Institute; Agency for Healthcare Research and Quality; MedImmune;  [K01 AI070808]; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024978, UL1RR024975, KL2RR024977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070808, K24AI077930] Funding Source: NIH RePORTER	Thrasher Research Fund Clinical Research Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); MedImmune(AstraZenecaMedimmune); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by K01 AI070808 (to K.N.C.), Thrasher Research Fund Clinical Research Grant (to T. V. H.), National Institutes of Health midcareer investigator award K24 AI 077930 (to T. V. H.), and UL1 RR024975 (Vanderbilt CTSA).; Disclosure of potential conflict of interest: K. N. Carroll receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. E. K Miller receives research support from the National Institutes of Health. J. V. Williams is on the scientific advisory board for Quidel, Inc. W. D. Dupont receives research support from the National Cancer Institute. T. V. Hartert receives research support from the National Institutes of Health, the Agency for Healthcare Research and Quality, and MedImmune; has provided legal consultation services or expert witness testimony for the Merck Research Advisory Board; is a member of the American Thoracic Society; and has been an invited speaker for the American Academy of Allergy, Asthma, & Immunology and for the Pediatric Academic Societies. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami Lara J, 2011, Natl Health Stat Report, P1; [Anonymous], 2006, R LANG ENV STAT COMP; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Carroll KN, 2008, IMMUNOL ALLERGY CLIN, V28, P539, DOI 10.1016/j.iac.2008.03.001; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Carroll KN, 2007, PEDIATRICS, V119, P1104, DOI 10.1542/peds.2006-2837; Carroll KN, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.04.002; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Garcia-Marcos L, 2007, PEDIAT ALLERG IMM-UK, V18, P240, DOI 10.1111/j.1399-3038.2006.00508.x; Goebel J, 2000, CLIN PEDIATR, V39, P213, DOI 10.1177/000992280003900404; GUSTAFSSON D, 1988, ALLERGY, V43, P105, DOI 10.1111/j.1398-9995.1988.tb00402.x; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Hartert TV, 2010, RESPIROLOGY, V15, P691, DOI 10.1111/j.1440-1843.2010.01743.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V118, P587, DOI 10.1016/j.jaci.2006.06.023; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kuo C, 2011, RESPIROLOGY, V16, P367, DOI 10.1111/j.1440-1843.2010.01918.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lazzaro T, 2007, J PAEDIATR CHILD H, V43, P29, DOI 10.1111/j.1440-1754.2007.00998.x; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; Noble V, 1997, ARCH DIS CHILD, V76, P315, DOI 10.1136/adc.76.4.315; Openshaw PJM, 2004, J ALLERGY CLIN IMMUN, V114, P1275, DOI 10.1016/j.jaci.2004.08.024; Peebles R. Stokes Jr., 2004, Journal of Allergy and Clinical Immunology, V113, pS15, DOI 10.1016/j.jaci.2003.10.033; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIMS DG, 1981, BRIT MED J, V282, P2086, DOI 10.1136/bmj.282.6282.2086; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; TAL A, 1983, PEDIATRICS, V71, P13; Trefny P, 2000, PEDIATR PULM, V30, P302, DOI 10.1002/1099-0496(200010)30:4<302::AID-PPUL5>3.0.CO;2-R; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	48	44	45	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1236	1242		10.1016/j.jaci.2012.01.045	http://dx.doi.org/10.1016/j.jaci.2012.01.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22336082	Green Published, Bronze, Green Accepted			2022-12-18	WOS:000303418000009
J	Romano, A; Gaeta, F; Valluzzi, RL; Caruso, C; Alonzi, C; Viola, M; Bousquet, PJ				Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Caruso, Cristiano; Alonzi, Cristiana; Viola, Marinella; Bousquet, Philippe Jean			Diagnosing nonimmediate reactions to cephalosporins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Caruso, Cristiano; Alonzi, Cristiana; Viola, Marinella] Complesso Integrato Columbus, Allergy Unit, Rome, Italy; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy; [Bousquet, Philippe Jean] GHU Caremau, BESPIM, Hop Caremeau, Dept Biostat Epidemiol Rech Clin Sante Publ & Inf, Nimes, France; [Bousquet, Philippe Jean] Hop Arnaud Villeneuve, Montpellier, France	IRCCS Oasi Maria SS; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier	Romano, A (corresponding author), Complesso Integrato Columbus, Allergy Unit, Rome, Italy.	antoninoromano@h-columbus.it	Bousquet, Philippe Jean/AAW-8608-2021; Gaeta, Francesco/AAC-7107-2020; Valluzzi, Rocco Luigi/Q-3879-2019; caruso, cristiano/AAR-9502-2020; Romano, Antonino/D-3102-2017; Bousquet, Jean/O-4221-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; Gaeta, Francesco/0000-0003-2942-7633; Valluzzi, Rocco Luigi/0000-0003-0029-6254; caruso, cristiano/0000-0001-7631-029X; Romano, Antonino/0000-0001-9742-9898; 				Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; Brockow K, 2002, ALLERGY, V57, P45; HAVERKOS HW, 1991, REV INFECT DIS, V13, P697; Lammintausta K, 2005, BRIT J DERMATOL, V152, P968, DOI 10.1111/j.1365-2133.2005.06429.x; OSAWA J, 1990, Journal of Dermatology (Tokyo), V17, P235; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Romano A, 2005, CLIN EXP ALLERGY, V35, P1234, DOI 10.1111/j.1365-2222.2005.02317.x; Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x; Romano A, 2011, J ALLERGY CLIN IMM S, V127, pS67; Romano A, 2008, PEDIATRICS, V122, P521, DOI 10.1542/peds.2007-3178	10	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1166	1169		10.1016/j.jaci.2011.12.995	http://dx.doi.org/10.1016/j.jaci.2011.12.995			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22322006				2022-12-18	WOS:000302144600042
J	Provoost, S; Maes, T; Joos, GF; Tournoy, KG				Provoost, Sharen; Maes, Tania; Joos, Guy F.; Tournoy, Kurt G.			Monocyte-derived dendritic cell recruitment and allergic T(H)2 responses after exposure to diesel particles are CCR2 dependent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCR2; CCR5; CCR6; dendritic cell; diesel exhaust particles; monocyte	INDUCED PULMONARY INFLAMMATION; CHEMOKINE RECEPTOR CCR2; AIRWAY INFLAMMATION; EXHAUST PARTICLES; EPITHELIAL-CELLS; INHALED ANTIGEN; BONE-MARROW; IN-VIVO; MICE; SUBSETS	Background: The inhalation of diesel exhaust particles (DEPs) is associated with increased sensitization toward inhaled allergens. Dendritic cells (DCs) are important mediators in immune regulation. We previously showed that the inhalation of DEPs increased the accumulation of DCs in the lung and enhanced the T(H)2 response in the mediastinal lymph node. Objective: We hypothesized that CC chemokine receptors CCR2, CCR5, and CCR6 critically mediate the DC recruitment upon exposure to DEPs and that these CC chemokine receptors are important in the DEP-induced TH2 response. Methods: We exposed CCR2 knockout, CCR5 knockout, CCR6 knockout, and wild-type mice to DEPs and examined the pulmonary monocyte and DC accumulation. By an adoptive transfer experiment, we assessed the direct involvement of CCR2 and CCR6 in the recruitment of blood monocytes toward the lung upon exposure to DEPs. We also examined the TH2 cytokine production in the mediastinal lymph nodes of DEP-exposed CCR2 knockout and CCR6 knockout mice. Results: We observed that the DEP-induced monocyte and monocyte-derived DC recruitment was completely abolished in CCR2 knockout mice. CCR6 knockout mice also showed impaired monocyte recruitment upon exposure to DEPs. In contrast, monocyte and DC recruitment was comparable between DEP-exposed wild-type and CCR5 knockout mice. The impaired monocyte-derived DC recruitment in DEP-exposed CCR2 knockout, not CCR6 knockout, mice resulted in an abolished TH2 response in the mediastinal lymph node. Conclusion: These data suggest that monocyte-derived DCs, recruited in a CCR2-dependent manner, are critical in inducing TH2 responses upon inhalation of DEPs. (J Allergy Clin Immunol 2012;129:483-91.)	[Provoost, Sharen; Maes, Tania; Joos, Guy F.; Tournoy, Kurt G.] Ghent Univ Hosp, Lab Translat Res Obstruct Pulm Dis, Dept Resp Med, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Provoost, S (corresponding author), Ghent Univ Hosp, Lab Translat Res Obstruct Pulm Dis, Dept Resp Med, Block B,4th Floor,De Pintelaan 185, B-9000 Ghent, Belgium.	sharen.provoost@UGent.be	Maes, Tania/M-8675-2016	Maes, Tania/0000-0002-3037-6928	Interuniversity Attraction Poles (IUAP) Programme, Belgian state; Belgian Science Policy [P6/35]; Fund for Scientific Research, Flanders (FWO-Vlaanderen) [G.0052.06, G.0329.11N]	Interuniversity Attraction Poles (IUAP) Programme, Belgian state; Belgian Science Policy(Belgian Federal Science Policy Office); Fund for Scientific Research, Flanders (FWO-Vlaanderen)(FWO)	This project was supported by the Interuniversity Attraction Poles (IUAP) Programme, Belgian state, Belgian Science Policy P6/35 and by the Fund for Scientific Research, Flanders (FWO-Vlaanderen-Project G.0052.06 and G.0329.11N). K.G.T. is a senior clinical investigator with a grant from FWO-Vlaanderen.	Bracke KR, 2007, CLIN EXP ALLERGY, V37, P1467, DOI 10.1111/j.1365-2222.2007.02808.x; Bracke KR, 2006, J IMMUNOL, V177, P4350, DOI 10.4049/jimmunol.177.7.4350; DeMarini DM, 2004, ENVIRON HEALTH PERSP, V112, P814, DOI 10.1289/ehp.6578; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280, DOI 10.1164/ajrccm.161.1.9904110; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Kuziel WA, 2003, ATHEROSCLEROSIS, V167, P25, DOI 10.1016/S0021-9150(02)00382-9; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, CLIN EXP ALLERGY, V30, P214; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Landsman L, 2007, J IMMUNOL, V178, P2000, DOI 10.4049/jimmunol.178.4.2000; Le Borgne M, 2006, IMMUNITY, V24, P191, DOI 10.1016/j.immuni.2006.01.005; Lin KL, 2008, J IMMUNOL, V180, P2562, DOI 10.4049/jimmunol.180.4.2562; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Osterholzer JJ, 2005, J IMMUNOL, V175, P874, DOI 10.4049/jimmunol.175.2.874; Osterholzer JJ, 2009, J IMMUNOL, V183, P8044, DOI 10.4049/jimmunol.0902823; Phadke AP, 2007, AM J RESP CRIT CARE, V175, P1165, DOI 10.1164/rccm.200602-256OC; Plantinga M, 2010, EUR J IMMUNOL, V40, P2112, DOI 10.1002/eji.201040562; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Reynolds PR, 2011, ENVIRON HEALTH PERSP, V119, P332, DOI 10.1289/ehp.1002520; Robays LJ, 2007, J IMMUNOL, V178, P5305, DOI 10.4049/jimmunol.178.8.5305; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Singh P, 2004, ENVIRON HEALTH PERSP, V112, P820, DOI 10.1289/ehp.6579; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011	31	44	46	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					483	491		10.1016/j.jaci.2011.07.051	http://dx.doi.org/10.1016/j.jaci.2011.07.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21906792				2022-12-18	WOS:000299951700028
J	Chakravarty, SD; Yee, AF; Paget, SA				Chakravarty, Soumya D.; Yee, Arthur F.; Paget, Stephen A.			Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CD203C; PATHOGENESIS; ACTIVATION; MARKER		[Chakravarty, Soumya D.] Cornell Univ, Hosp Special Surg, Div Rheumatol, New York, NY 10021 USA; Cornell Univ, New York Presbyterian Weill Cornell Med Ctr, New York, NY 10021 USA; Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA	Cornell University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cornell University	Chakravarty, SD (corresponding author), Cornell Univ, Hosp Special Surg, Div Rheumatol, New York, NY 10021 USA.	ChakravartyS@hss.edu						Arkwright PD, 2009, J ALLERGY CLIN IMMUN, V123, P510, DOI 10.1016/j.jaci.2008.11.043; Binder M, 2002, INT ARCH ALLERGY IMM, V129, P160, DOI 10.1159/000065875; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; HIDE M, 1994, CLIN EXP ALLERGY, V24, P624, DOI 10.1111/j.1365-2222.1994.tb00965.x; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Mallipeddi R, 2007, CLIN EXP DERMATOL, V32, P333, DOI 10.1111/j.1365-2230.2007.02365.x; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; Perez A, 2010, BRIT J DERMATOL, V162, P191, DOI 10.1111/j.1365-2133.2009.09538.x; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016	12	44	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1354	1355		10.1016/j.jaci.2011.08.023	http://dx.doi.org/10.1016/j.jaci.2011.08.023			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21958584				2022-12-18	WOS:000298342700030
J	Gharib, SA; Nguyen, EV; Lai, Y; Plampin, JD; Goodlett, DR; Hallstrand, TS				Gharib, Sina A.; Nguyen, Elizabeth V.; Lai, Ying; Plampin, Jessica D.; Goodlett, David R.; Hallstrand, Teal S.			Induced sputum proteome in healthy subjects and asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exercise-induced bronchoconstriction; shotgun proteomics; induced sputum; protein network	BRONCHOALVEOLAR LAVAGE FLUID; COMPLEMENT ACTIVATION; AIRWAY HYPERRESPONSIVENESS; MASS-SPECTROMETRY; SERUM-LEVELS; EXPRESSION; PROTEINS; C3A; PHASE; MODEL	Background: Asthma is a heterogeneous disease characterized by abnormal airway pathophysiology and susceptibility to different stimuli, as exemplified by a subset of patients with exercise-induced bronchoconstriction. Induced sputum provides a noninvasive method to sample airway biofluids that are enriched in proteins. Objective: We hypothesized that novel mechanisms in the pathogenesis of asthma might be revealed by studying the patterns of protein expression in induced sputum. Methods: We used shotgun proteomics to analyze induced sputum from 5 healthy subjects and 10 asthmatic patients, including 5 with exercise-induced bronchoconstriction. Differential protein expression among asthmatic patients, asthma subphenotypes, and control subjects was determined by using spectral counting and computational methods. Results: Using Gene Ontology analysis, we defined the functional landscape of the induced sputum proteome and applied network analysis to construct a protein interaction map for this airway compartment. Shotgun proteomics analysis identified a number of proteins the differential enrichment or depletion of which robustly distinguished asthmatic patients from healthy control subjects and captured the effects of exercise on induced sputum proteome. Functional and network analysis identified key processes, including proteolytic activity, that are known contributors to airway remodeling. Importantly, this approach highlighted previously unrecognized roles for differentially expressed proteins in pathways implicated in asthma, such as modulation of phospholipase A(2) by secretoglobin, a putative role for S100A8/9 in human asthma, and selective upregulation of complement component 3a in response to exercise in asthmatic patients. Conclusion: Computationally intensive analysis of induced sputum proteome is a powerful approach to understanding the pathophysiology of asthma and a promising methodology to investigating other diseases of the airways. (J Allergy Clin Immunol 2011;128:1176-84.)	[Gharib, Sina A.] Univ Washington, Ctr Lung Biol, Seattle, WA 98109 USA; [Hallstrand, Teal S.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98109 USA; [Nguyen, Elizabeth V.; Goodlett, David R.] Univ Washington, Dept Med Chem, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gharib, SA (corresponding author), Univ Washington, Ctr Lung Biol, 815 Mercer St,Box 358052, Seattle, WA 98109 USA.	sagharib@u.washington.edu; tealh@u.washington.edu		Hallstrand, Teal/0000-0002-5059-6872; GHARIB, SINA A./0000-0002-2480-4367; Nguyen, Elizabeth/0000-0002-6495-7827	Institute of Translational Health Sciences; National Institutes of Health [R01HL89215]; National Institutes of Health/National Heart, Lung, and Blood Institute; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089215] Funding Source: NIH RePORTER	Institute of Translational Health Sciences; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by an Institute of Translational Health Sciences grant (S.A.G.) and National Institutes of Health grant R01HL89215 (T.S.H.).; T. S. Hallstrand is on the speaker's bureau for Merck, Schering-Plough, and Genentech and receives research support from the National Institutes of Health/National Heart, Lung, and Blood Institute. The rest of the authors have declared that they have no conflict of interest.	Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; Ashburner M, 2001, GENOME RES, V11, P1425; Becker KG, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-61; Becker L, 2010, CELL METAB, V11, P125, DOI 10.1016/j.cmet.2010.01.003; Brightling CE, 2006, CHEST, V129, P1344, DOI 10.1378/chest.129.5.1344; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Carpe N, 2010, AM J RESP CELL MOL, V43, P720, DOI 10.1165/rcmb.2009-0412OC; Chen JZ, 2008, PROTEOM CLIN APPL, V2, P585, DOI 10.1002/prca.200780006; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Dragonieri S, 2009, Monaldi Arch Chest Dis, V71, P119; Fireman E, 1999, RESP MED, V93, P827, DOI 10.1016/S0954-6111(99)90269-X; Fu X, 2008, J PROTEOME RES, V7, P845, DOI 10.1021/pr070271+; Gharib SA, 2009, J PROTEOME RES, V8, P3020, DOI 10.1021/pr900093j; Gharib SA, 2009, PHYSIOL GENOMICS, V37, P239, DOI 10.1152/physiolgenomics.00027.2009; Gray RD, 2008, AM J RESP CRIT CARE, V178, P444, DOI 10.1164/rccm.200703-409OC; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haenen S, 2010, J PROTEOME RES, V9, P5868, DOI 10.1021/pr100638m; Hallstrand TS, 2011, CLIN EXP ALLERGY, V41, P801, DOI 10.1111/j.1365-2222.2010.03676.x; Hallstrand TS, 2007, AM J RESP CRIT CARE, V176, P1072, DOI 10.1164/rccm.200707-1088OC; Hallstrand TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008583; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Hung CH, 2004, J ALLERGY CLIN IMMUN, V114, P664, DOI 10.1016/j.jaci.2004.05.042; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kanemitsu H, 1998, BIOL PHARM BULL, V21, P129; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; Lee SK, 2010, AM J RESP CRIT CARE, V181; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Lovegrove FE, 2007, AM J PATHOL, V171, P1894, DOI 10.2353/ajpath.2007.070630; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Mizutani N, 2009, J IMMUNOL, V183, P4039, DOI 10.4049/jimmunol.0901468; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nicholas B, 2006, PROTEOMICS, V6, P4390, DOI 10.1002/pmic.200600011; Nicholas B, 2009, BIOCHEM SOC T, V37, P868, DOI 10.1042/BST0370868; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; Pedrioli PGA, 2004, NAT BIOTECHNOL, V22, P1459, DOI 10.1038/nbt1031; ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sagel SD, 2002, J PEDIATR-US, V141, P811, DOI 10.1067/mpd.2002.129847; Scherl A, 2008, ANAL CHEM, V80, P1182, DOI 10.1021/ac701680f; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P930, DOI 10.1164/ajrccm.160.3.9803113; Shima M, 1996, PREV MED, V25, P617, DOI 10.1006/pmed.1996.0097; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wang H, 2010, AM J RESP CRIT CARE, V181, P908, DOI 10.1164/rccm.200904-0597OC; Wang WX, 2003, ANAL CHEM, V75, P4818, DOI 10.1021/ac026468x; Wills-Karp Marsha, 2007, Proc Am Thorac Soc, V4, P247, DOI 10.1513/pats.200704-046AW; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273; Zhang X, 2010, EXPERT REV CLIN IMMU, V6, P269, DOI 10.1586/ECI.09.84; Zhao J, 2011, ANTIOXID REDOX SIGN, V14, P1589, DOI 10.1089/ars.2010.3583	56	44	47	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1176	U491		10.1016/j.jaci.2011.07.053	http://dx.doi.org/10.1016/j.jaci.2011.07.053			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21906793	Green Accepted			2022-12-18	WOS:000298342700004
J	Martinez, FD				Martinez, Fernando D.			New insights into the natural history of asthma: Primary prevention on the horizon	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; natural history; prevention	RESPIRATORY-SYNCYTIAL-VIRUS; 1ST 6 YEARS; OBSTRUCTIVE AIRWAYS DISEASE; EPISODIC VIRAL WHEEZE; EARLY-LIFE; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; LUNG-FUNCTION; HIGH-RISK; INHALED CORTICOSTEROIDS	Recent studies of the natural history of asthma have shifted attention toward viral respiratory tract illness in early life as a major risk factor associated with the development of the most persistent forms of the disease. Although early aeroallergen sensitization is strongly associated with chronic asthma, several trials in which single-aeroallergen exposure in pregnancy and early childhood was successfully accomplished and compared with sham avoidance have failed to show any decrease in asthma incidence. New evidence suggests that complex interactions occur between viral infection and aeroallergen sensitization in genetically susceptible subjects that trigger the immune responses and airway changes that are characteristic of persistent asthma. The finding that exposure to bacterial products among children raised on farms is associated with diminished asthma prevalence during the school years has now been replicated, and experimental studies have suggested that these effects are mediated by the activation of regulatory T cells in the airway. It is thus plausible to hypothesize that primary prevention of asthma could be attained through surrogate therapeutic interventions that activate similar mechanisms in young children at high risk for asthma. (J Allergy Clin Immunol 2011;128:939-45.)	[Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85712 USA; [Martinez, Fernando D.] Univ Arizona, Inst BIO5, Tucson, AZ 85712 USA	University of Arizona; University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85712 USA.	fernando@arc.arizona.edu			National Heart, Lung, and Blood Institute (NHLBI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177, U10HL098112] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (NHLBI).	Al-Garawi A, 2011, MUCOSAL IMMUNOL; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2011, J ALLERGY CLIN IMMUN, V127, P293, DOI 10.1016/j.jaci.2010.10.012; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2009, AM J RESP CRIT CARE, V180, P491, DOI 10.1164/rccm.200903-0327OC; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Collet JP, 1997, AM J RESP CRIT CARE, V156, P1719, DOI 10.1164/ajrccm.156.6.9612096; Corver K, 2006, PEDIAT ALLERG IMM-UK, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Del-Rio-Navarro BE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004974; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Fairchok MP, 2010, J CLIN VIROL, V49, P16, DOI 10.1016/j.jcv.2010.06.013; Garcia-Marcos L, 2010, J ALLERGY CLIN IMMUN, V126, P489, DOI 10.1016/j.jaci.2010.06.037; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Holt PG, 2011, ALLERGY, V66, P13, DOI 10.1111/j.1398-9995.2011.02623.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Maas T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006480.pub2; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Midodzi WK, 2010, J ASTHMA, V47, P7, DOI 10.3109/02770900903380996; Midulla F, 2011, EUR RESP J; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Rosenthal LA, 2010, J ALLERGY CLIN IMMUN, V125, P1212, DOI 10.1016/j.jaci.2010.04.002; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schultz A, 2010, ACTA PAEDIATR, V99, P56, DOI 10.1111/j.1651-2227.2009.01508.x; Schultz A, 2011, PAEDIATR RESPIR REV, V12, P160, DOI 10.1016/j.prrv.2011.01.008; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shadman K. A., 2011, EXPERT OPIN BIOL THE; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Silverman M, 1997, THORAX, V52, P936, DOI 10.1136/thx.52.11.936; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein Renato T, 2009, Paediatr Respir Rev, V10 Suppl 1, P29, DOI 10.1016/S1526-0542(09)70013-2; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Strachan DP, 1996, BRIT MED J, V312, P1195; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Toelle BG, 2010, J ALLERGY CLIN IMMUN, V126, P388, DOI 10.1016/j.jaci.2010.04.031; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Valkonen H, 2009, ALLERGY, V64, P1359, DOI 10.1111/j.1398-9995.2009.02022.x; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	82	44	47	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					939	945		10.1016/j.jaci.2011.09.020	http://dx.doi.org/10.1016/j.jaci.2011.09.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	22036094	Green Accepted			2022-12-18	WOS:000296578200004
J	van der Zee, T; Dubois, A; Kerkhof, M; van der Heide, S; Vlieg-Boerstra, B				van der Zee, Tjitske; Dubois, Anthony; Kerkhof, Marjan; van der Heide, Sicco; Vlieg-Boerstra, Berber			The eliciting dose of peanut in double-blind, placebo-controlled food challenges decreases with increasing age and specific IgE level in children and young adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Double-blind; placebo-controlled food challenges; DBPCFC; food allergy; eliciting dose; predicting factors; anaphylaxis	ALLERGIC REACTIONS; CLINICAL IMMUNOLOGY; ASTHMA MANAGEMENT; EUROPEAN ACADEMY; POSITION PAPER; NUT ALLERGY; ANAPHYLAXIS; ADOLESCENTS; PREDICTION; SEVERITY	Background: Several risk factors for severe anaphylactic reactions to food in daily life are known. However, to date, it is not possible to predict the severity of allergic reactions to food in the individual patient with accuracy. Some studies show that a history of severe reactions is associated with a lower eliciting dose in double-blind, placebo-controlled food challenges (DBPCFCs). Therefore, in this study, the eliciting dose was used as a measure of clinical sensitivity. Objectives: To study whether risk factors for severe allergic reactions to food in daily life such as age, degree of sensitization, and coexistent atopic disease influence the eliciting dose in DBPCFCs in children allergic to peanut. Methods: Data from children who had clinical reactions to peanut during DBPCFCs at the University Medical Center Groningen (2001-2009) were analyzed. A Cox regression model was used to analyze the association of the determinants with the eliciting dose. Results: One hundred twenty-six positive DBPCFCs with peanut were analyzed. Age older than 10 years, a specific IgE level above the lowest tertile (>= 5.6 kU/L), and the absence of atopic dermatitis were associated with reactions to lower doses: respective hazard ratios 1.89 (95% CI, 1.28-2.81; P = .001), 2.03 (95% CI, 1.37-3.00; P < .0001), and 0.45 (95% CI, 0.29-0.71; P = .001) present versus absent. No significant associations with the eliciting dose were found for sex, the presence of asthma and rhinitis, and the severity of food reactions by history. Conclusions: Using the eliciting dose as a measure of clinical sensitivity, greater clinical sensitivity in DBPCFCs to peanut was found to be associated with increasing age, higher specific IgE level, and the absence of atopic dermatitis. This finding may explain why adolescents experience severe allergic reactions in daily life to peanut more often than do younger children. (J Allergy Clin Immunol 2011;128:1031-6.)	[van der Zee, Tjitske; Dubois, Anthony; Vlieg-Boerstra, Berber] Univ Groningen, Univ Med Ctr Groningen, Dept Paediat Pulmonol & Allergy, NL-9700 RB Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [van der Heide, Sicco] Univ Groningen, Univ Med Ctr Groningen, Lab Allergy & Pulm Dis, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Dubois, A (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Div Paediat Pulmonol & Paediat Allergy, Dept Paediat, POB 30-001, NL-9700 RB Groningen, Netherlands.	a.e.j.dubois@umcg.nl	Vlieg-Boerstra, Berber/O-1922-2019	Vlieg-Boerstra, Berber/0000-0001-7962-5406				Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Benhamou AH, 2008, PEDIATR ALLERGY IMMU, V19, P173, DOI 10.1111/j.1399-3038.2007.00602.x; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; DIRVENMEIJER PC, 2007, NEDERLANDS TIJSCHRIF, V2, P33; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; SICHERER SH, 2001, J ALLERGY CLIN IMMUN, V137, P749; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Van Weel C, 2008, ALLERGY, V63, P997, DOI 10.1111/j.1398-9995.2008.01643.x; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Vlieg-Boerstra BJ, 2007, ALLERGY, V62, P905, DOI 10.1111/j.1398-9995.2007.01430.x; Vlieg-Boerstra BJ, 2004, J ALLERGY CLIN IMMUN, V113, P341, DOI 10.1016/j.jaci.2003.10.039; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	32	44	44	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1031	1036		10.1016/j.jaci.2011.07.050	http://dx.doi.org/10.1016/j.jaci.2011.07.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21885095				2022-12-18	WOS:000296578200016
J	Ruiz-Garcia, M; del Potro, MG; Fernandez-Nieto, M; Barber, D; Jimeno-Nogales, L; Sastre, J				Ruiz-Garcia, Monica; Garcia del Potro, Manuela; Fernandez-Nieto, Mar; Barber, Domingo; Jimeno-Nogales, Lucia; Sastre, Joaquin			Profilin: A relevant aeroallergen?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY; POLLEN; ALLERGEN; CHALLENGE		[Ruiz-Garcia, Monica; Garcia del Potro, Manuela; Fernandez-Nieto, Mar; Sastre, Joaquin] Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain; [Fernandez-Nieto, Mar; Sastre, Joaquin] Minist Sci & Innovat, Inst Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Barber, Domingo; Jimeno-Nogales, Lucia] ALK Abello R&D, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERES; ALK-Abello AS	Ruiz-Garcia, M (corresponding author), Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain.	jsastre@fjd.es	Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700				Asturias JA, 2005, CLIN EXP ALLERGY, V35, P374, DOI 10.1111/j.1365-2222.2005.02179.x; Barber D, 2008, ALLERGY, V63, P1550, DOI 10.1111/j.1398-9995.2008.01807.x; Barber D, 2009, CLIN EXP ALLERGY, V39, P1764, DOI 10.1111/j.1365-2222.2009.03351.x; Calabozo B, 2001, CLIN EXP ALLERGY, V31, P322, DOI 10.1046/j.1365-2222.2001.00985.x; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sastre J, 2004, ALLERGY, V59, P1181, DOI 10.1111/j.1398-9995.2004.00530.x; Sastre J, 2003, CHEST, V123, P1276, DOI 10.1378/chest.123.4.1276; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Webber CM, 2010, ANN ALLERG ASTHMA IM, V104, P101, DOI 10.1016/j.anai.2009.11.007	11	44	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					416	418		10.1016/j.jaci.2011.03.008	http://dx.doi.org/10.1016/j.jaci.2011.03.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21458043				2022-12-18	WOS:000293280800026
J	Sternthal, MJ; Coull, BA; Chiu, YHM; Cohen, S; Wright, RJ				Sternthal, Michelle J.; Coull, Brent A.; Chiu, Yueh-Hsiu Mathilda; Cohen, Sheldon; Wright, Rosalind J.			Associations among maternal childhood socioeconomic status, cord blood IgE levels, and repeated wheeze in urban children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood socioeconomic status; intergenerational; cord blood IgE; inner-city; childhood wheeze; structural equation models; life course	PROSPECTIVE BIRTH-COHORT; AIR-POLLUTION; ADULT HEALTH; YOUNG-ADULT; EARLY-LIFE; STRESS; EXPOSURE; ALLERGEN; DISEASE; ASTHMA	Background: Independent of current socioeconomic status (SES), past maternal SES might influence asthma outcomes in children. Objective: We examined associations among the mother's SES in the first 10 years of her life (maternal childhood SES), increased cord blood IgE levels (upper 20% [1.37 IU/mL]), and repeated wheeze (>= 2 episodes by age 2 years) in an urban pregnancy cohort (n = 510). Methods: Data on sociodemographics, discrimination, financial strain, community violence, interpersonal trauma, and other negative events were obtained prenatally. Prenatal household dust was assayed for cockroach and murine allergens, and traffic-related air pollution was estimated by using spatiotemporal land-use regression. Maternal childhood SES was defined by parental home ownership (birth to 10 years). Maternally reported child wheeze was ascertained at 3-month intervals from birth. Using structural equation models, we examined whether outcomes were dependent on maternal childhood SES directly versus indirect relationships operating through (1) cumulative SES-related adversities, (2) the mother's socioeconomic trajectory (adult SES), and (3) current prenatal environmental exposures. Results: Mothers were largely Hispanic (60%) or black (28%), 37% had not completed high school, and 56% reported parental home ownership. When associations between low maternal childhood SES and repeated wheeze were examined, there were significant indirect effects operating through adult SES and prenatal cumulative stress (beta = 0.28, P = .003) and pollution (beta = 0.24, P = .004; P value for total indirect effects <= .04 for both pathways). Low maternal childhood SES was directly related to increased cord blood IgE levels (beta = 0.21, P = .003). Maternal cumulative adversity (interpersonal trauma) was also associated with increased cord blood IgE levels (beta = 0.19, P = .01), although this did not explain maternal childhood SES effects. Conclusion: Lower maternal childhood SES was associated with increased cord blood IgE levels and repeated wheeze through both direct and indirect effects, providing new insights into the role of social inequalities as determinants of childhood respiratory risk. (J Allergy Clin Immunol 2011;128:337-45.)	[Sternthal, Michelle J.; Chiu, Yueh-Hsiu Mathilda] Harvard Univ, Sch Publ Hlth, Dept Environm & Occupat Med & Epidemiol, Boston, MA 02115 USA; [Coull, Brent A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Cohen, Sheldon] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; [Wright, Rosalind J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; [Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Carnegie Mellon University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Wright, RJ (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Dr, Boston, MA 02215 USA.	rerjw@channing.harvard.edu		Chiu, Yueh-Hsiu Mathilda/0000-0003-1656-660X; Cohen, Sheldon/0000-0003-2248-4600	Leaves of Grass Foundation; National Institutes of Health; US Environmental Protection Agency;  [R01 ES10932];  [U01 HL072494];  [R01 HL080674];  [T32-ES07069-29]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072494, R01HL080674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007069, R01ES010932] Funding Source: NIH RePORTER	Leaves of Grass Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The Asthma Coalition on Community, Environment, and Social Stress study is funded by grants R01 ES10932, U01 HL072494, and R01 HL080674 (R.J.W., principal investigator). M. J. Sternthal was supported by grant T32-ES07069-29 and the Leaves of Grass Foundation.; B. A. Coull receives research support from the National Institutes of Health and the US Environmental Protection Agency. R. J. Wright receives research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Agresti A., 2003, CATEGORICAL DATA ANA, V482, DOI DOI 10.1002/0471249688; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Clark C, 2010, ANN EPIDEMIOL, V20, P385, DOI 10.1016/j.annepidem.2010.02.008; Cohen S, 2004, PSYCHOSOM MED, V66, P553, DOI 10.1097/01.psy.0000126200.05189.d3; Cohen S, 2010, ANN NY ACAD SCI, V1186, P37, DOI 10.1111/j.1749-6632.2009.05334.x; Collins JW, 2009, MATERN CHILD HLTH J, V13, P326, DOI 10.1007/s10995-008-0354-0; Connelly CD, 2005, J INTERPERS VIOLENCE, V20, P1560, DOI 10.1177/0886260505280341; Graham H, 2010, SOC SCI MED, V70, P582, DOI 10.1016/j.socscimed.2009.10.041; Gryparis A, 2007, J R STAT SOC C-APPL, V56, P183, DOI 10.1111/j.1467-9876.2007.00573.x; Gustafsson PE, 2010, PSYCHONEUROENDOCRINO, V35, P613, DOI 10.1016/j.psyneuen.2009.09.019; Herr CEW, 2011, PEDIAT ALLERG IMM-UK, V22, P75, DOI 10.1111/j.1399-3038.2010.01074.x; Jackson B, 2004, INT J EPIDEMIOL, V33, P271, DOI 10.1093/ije/dyh003; Jedrychowski W, 2009, ENVIRON INT, V35, P877, DOI 10.1016/j.envint.2009.03.004; Kahn RS, 2005, PUBLIC HEALTH REP, V120, P399, DOI 10.1177/003335490512000407; KRIEGER N, 1990, SOC SCI MED, V30, P1273, DOI 10.1016/0277-9536(90)90307-E; Kuh D, 2003, J EPIDEMIOL COMMUN H, V57, P778, DOI 10.1136/jech.57.10.778; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Miller G, 2007, PSYCHOSOM MED, V69, P402, DOI 10.1097/PSY.0b013e318068fcf9; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Muthen L., 2017, STAT ANAL LATENT VAR, V8th; Myers HF, 2009, J BEHAV MED, V32, P9, DOI 10.1007/s10865-008-9181-4; Nguyen KH, 2010, J EPIDEMIOL COMMUNIT; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Parker ED, 2010, NICOTINE TOB RES, V12, P309, DOI 10.1093/ntr/ntp211; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Pinkerton KE, 2006, CLIN EXP PHARMACOL P, V33, P269, DOI 10.1111/j.1440-1681.2006.04357.x; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Power C, 1997, BRIT MED BULL, V53, P210; Prescott SL, 2006, CURR ALLERGY ASTHM R, V6, P75, DOI 10.1007/s11882-006-0014-7; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Selner-O'Hagan MB, 1998, J CHILD PSYCHOL PSYC, V39, P215, DOI 10.1017/S002196309700187X; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Sternthal MJ, 2009, J ALLERGY CLIN IMMUN, V124, P954, DOI 10.1016/j.jaci.2009.07.030; Straus Murray A, 2004, Violence Vict, V19, P507; Suglia SF, 2008, J TRAUMA STRESS, V21, P479, DOI 10.1002/jts.20362; Suglia SF, 2010, PSYCHOL TRAUMA-US, V2, P326, DOI 10.1037/a0018953; Tehranifar P, 2009, CANCER CAUSE CONTROL, V20, P867, DOI 10.1007/s10552-009-9307-1; van de Mheen H, 1998, INT J EPIDEMIOL, V27, P431, DOI 10.1093/ije/27.3.431; von Mutius E, 2002, AM J RESP CRIT CARE, V165, P1467, DOI 10.1164/rccm.2204011; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Wright RJ, 2010, BIOL PSYCHOL, V84, P46, DOI 10.1016/j.biopsycho.2010.01.007; Wright RJ, 2008, EXPERT REV CLIN IMMU, V4, P535, DOI 10.1586/1744666X.4.5.535; Wright RJ, 2008, CIENC SAUDE COLETIVA, V13, P1729, DOI 10.1590/S1413-81232008000600008	53	44	44	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					337	U349		10.1016/j.jaci.2011.05.008	http://dx.doi.org/10.1016/j.jaci.2011.05.008			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	799IQ	21704362	Green Accepted			2022-12-18	WOS:000293280800013
J	Azzari, C; La Marca, G; Resti, M				Azzari, Chiara; La Marca, Giancarlo; Resti, Massimo			Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: A reliable and inexpensive method using tandem mass spectrometry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adenosine deaminase; severe combined immunodeficiency; newborn screening; tandem mass spectrometry	NEWBORN; PURINE; DEFICIENCY; DISORDERS; MUTATIONS; URINE	Background: Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is an SCID caused by a defect in the enzyme adenosine deaminase. It is usually fatal in infancy because of severe recurrent infections. When diagnosis is made, permanent damage caused by infections or by metabolites is often present. Gene therapy, bone marrow transplantation, or enzyme therapy might be effective if performed early. ADA-SCID complies with all the criteria for inclusion in a newborn screening program. However, screening methods are still expensive or provide a non-negligible number of indeterminate results. Objective: The aim of the present study was to develop a simple, reliable, and inexpensive method for diagnosis of ADA-SCID by using dried blood spot (DBS) samples taken at birth. Cost per test was calculated, including the cost for reagents, equipment, and operators. Methods: DBS samples from 4 patients with genetically confirmed ADA-SCID and 12,020 DBS samples from healthy newborns were examined. Adenosine and 2'-deoxyadenosine were tested by using tandem mass spectrometry (PCT EP2010/070517). Results: The mean levels of adenosine and 2'-deoxyadenosine were 7.8 +/- 3.1 and 8.5 +/- 6.0 mu mol/L, respectively, in affected children; adenosine was found at 0.23 +/- 0.09 mu mol/L, whereas 2'-deoxyadenosine was never detected in healthy control subjects (adenosine: P < 10(-6) [95% confidence limit, 7.59-7.78] and 2'-deoxyadenosine: P < 10(-6) [95% confidence limit, 8.65-8.82] for control subjects vs patients with ADA-SCID). No indeterminate or false-positive results were found. Cost per test was (sic)0.01 ($0.013). A pilot population-based newborn screening for ADA-SCID has started in Tuscany, Italy. Conclusion: Tandem mass spectrometry can be used for diagnosis of one of the most frequent form of SCID at a negligible cost. (J Allergy Clin Immunol 2011;127:1394-9.)	[Azzari, Chiara] Univ Florence, Dept Pediat, Anna Meyer Childrens Univ Hosp, I-50139 Florence, Italy; [Azzari, Chiara; Resti, Massimo] Univ Florence, Dept Pediat, I-50139 Florence, Italy; [La Marca, Giancarlo] Univ Florence, Dept Pharmacol, I-50139 Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence	Azzari, C (corresponding author), Univ Florence, Dept Pediat, Anna Meyer Childrens Univ Hosp, Viale Pieraccini 24, I-50139 Florence, Italy.	chiara.azzari@unifi.it	Resti, Massimo/AAB-8756-2019; Azzari, Chiara/AAB-8584-2019; la Marca, Giancarlo/A-2853-2013	Resti, Massimo/0000-0001-6350-1361; Azzari, Chiara/0000-0001-7236-1655; la marca, giancarlo/0000-0003-3319-7260	Famiglia Cassigoli; University of Florence; Anna Meyer Children's University Hospital; Tuscany (Italy) region; Tuscany Region, Italy	Famiglia Cassigoli; University of Florence; Anna Meyer Children's University Hospital; Tuscany (Italy) region; Tuscany Region, Italy	Supported in part by a donation from Famiglia Cassigoli (C.A.) and by a grant from the University of Florence (C.A. and G.I.M.) and Anna Meyer Children's University Hospital (M.R.) and the Tuscany (Italy) region (C.A., G.I.M., and M.R.).; Disclosure of potential conflict of interest: G. La Marca receives research support from the Tuscany Region, Italy. The rest of the authors have declared that they have no conflict of interest.	Adam T, 1999, CLIN CHEM, V45, P2086; Azzari C, 2007, CURR MED RES OPIN, V23, P2945, DOI 10.1185/030079907X242610; Booth C, 2007, CLIN IMMUNOL, V123, P139, DOI 10.1016/j.clim.2006.12.009; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Chace DH, 2009, J MASS SPECTROM, V44, P163, DOI 10.1002/jms.1528; DAVIES PM, 1991, ADV EXP MED BIOL, V309, P7; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; Hirschhorn R, 1997, HUM GENET, V100, P22, DOI 10.1007/s004390050460; *HLTH RES SERV ADM, 2010, 20 M JAN 22; Howell RR, 2007, J INHERIT METAB DIS, V30, P600, DOI 10.1007/s10545-007-0674-z; ISTAT, DEM CIFR; Ito T, 2000, CLIN CHEM, V46, P445; JENKINS T, 1973, LANCET, V2, P736; la Marca G, 2008, RAPID COMMUN MASS SP, V22, P812, DOI 10.1002/rcm.3428; La Marca G, 2007, CLIN CHEM, V53, P1364, DOI 10.1373/clinchem.2007.087775; la Marca G, 2006, J MASS SPECTROM, V41, P1442, DOI 10.1002/jms.1115; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Sanchez JJ, 2007, ANN HUM GENET, V71, P336, DOI 10.1111/j.1469-1809.2006.00338.x; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; Sauer AV, 2009, CURR OPIN ALLERGY CL, V9, P496, DOI 10.1097/ACI.0b013e3283327da5	25	44	46	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1394	1399		10.1016/j.jaci.2011.03.040	http://dx.doi.org/10.1016/j.jaci.2011.03.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21624616	Bronze, Green Submitted			2022-12-18	WOS:000291048500010
J	Bougault, V; Turmel, J; Boulet, LP				Bougault, Valerie; Turmel, Julie; Boulet, Louis-Philippe			Airway hyperresponsiveness in elite swimmers: Is it a transient phenomenon?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Methacholine challenge; eucapnic voluntary hyperpnea; airway inflammation; athletes; asthma; follow-up	BRONCHIAL HYPERRESPONSIVENESS; INDUCED SPUTUM; ASTHMA; INFLAMMATION; EXERCISE; REPRODUCIBILITY; PREVALENCE; CHALLENGES; HYPERPNEA; INDEXES	Background: Airway hyperresponsiveness is highly prevalent in competitive swimmers, but it is unknown whether this is transient or persistent. Objectives: To document changes in airway responsiveness and airway inflammation in elite swimmers during intense training and rest. Methods: Nineteen swimmers and 16 healthy controls completed a standardized questionnaire, allergy skin prick tests, exhaled nitric oxide measurement, eucapnic voluntary hyperpnea testing, methacholine challenge, and induced sputum analysis. Testing was performed during intense swimming and after at least 2 weeks of rest. Results: Sixteen swimmers and 13 controls were atopic. Airway responsiveness to methacholine and eucapnic voluntary hyperpnea was significantly higher in swimmers than in controls (P < .0001). A significant decrease in airway responsiveness was observed from training to rest in swimmers only (P < .005). This occurred with both methacholine challenge-with PC20 values of 6.0 mg/mL and 12.8 mg/mL, respectively-and eucapnic voluntary hyperpnea testing-with a maximum fall in FEV1 after voluntary testing of 14.1 L and 10.1 L, respectively. Eight of 12 swimmers with airway hyperresponsiveness during intense training had normal airway responsiveness during rest. No airway inflammation occurred, and no significant change in this parameter was observed from training to rest. Conclusion: Training may contribute to the development of airway hyperresponsiveness in elite swimmers, but this seems reversible in many athletes after training cessation for at least 2 weeks. (J Allergy Clin Immunol 2011;127:892-8.)	[Bougault, Valerie; Turmel, Julie; Boulet, Louis-Philippe] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada; [Bougault, Valerie] Univ Lille Nord France, Lille, France	Laval University; Universite de Lille - ISITE; Universite de Lille	Bougault, V (corresponding author), Univ Lille 2, FSSEP, 9 Rue Univ, F-59790 Ronchin, France.	valerie.bougault@univ-lille2.fr	Bougault, Valerie/G-9904-2018	Bougault, Valerie/0000-0002-2258-6562	Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec City, Quebec, Canada; AstraZeneca; Altana; GlaxoSmithKline; Merck Frosst; Novartis; 3M	Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec City, Quebec, Canada; AstraZeneca(AstraZeneca); Altana; GlaxoSmithKline(GlaxoSmithKline); Merck Frosst; Novartis(Novartis); 3M(3M)	V.B. was supported in part by a grant from the Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec City, Quebec, Canada.; Disclosure of potential conflict of interest: L.-P. Boulet is on the advisory board for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst, and Novartis; is an advisor for the Conseil du Medicament du Quebec; is a Member of the Quebec Workmen Compensation Board Respiratory Committee; has received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst, and Novartis; has received research support from AstraZeneca, 3M, Altana, AsthmaTx, Boehringer-Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen, and Wyeth; has received support for the production of educational materials from AstraZeneca, GlaxoSmithKline, and Merck Frosst; is chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee; is co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence; holds the Laval University Chair on Knowledge Transfer, Prevention, and Education in Respiratory and Cardiovascular Health; and is a member of the Asthma Committee of the World Allergy Organization. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson SD, 2008, J ALLERGY CLIN IMMUN, V122, P225, DOI 10.1016/j.jaci.2008.05.001; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bougault V, 2010, CLIN EXP ALLERGY, V40, P1238, DOI 10.1111/j.1365-2222.2010.03551.x; Bougault V, 2009, EUR RESPIR J, V33, P740, DOI 10.1183/09031936.00117708; Bougault V, 2010, CHEST, V138, p31S, DOI 10.1378/chest.09-1689; Boulet LP, 2006, RESP MED, V100, P292, DOI 10.1016/j.rmed.2005.04.026; Boulet LP, 2003, AM J RESP CRIT CARE, V167, P371, DOI 10.1164/rccm.200111-084PP; Castricum A, 2010, BRIT J SPORT MED, V44, P736, DOI 10.1136/bjsm.2008.051169; Cockcroft D, 2009, ANN ALLERG ASTHMA IM, V103, P363, DOI 10.1016/S1081-1206(10)60353-5; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Fitch KD, 2008, J ALLERGY CLIN IMMUN, V122, P254, DOI 10.1016/j.jaci.2008.07.003; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Hemingson Howard B, 2004, Can Respir J, V11, P399; Jansen DF, 1997, RESP MED, V91, P121, DOI 10.1016/S0954-6111(97)90048-2; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kippelen P, 2010, MED SCI SPORT EXER, V42, P1853, DOI 10.1249/MSS.0b013e3181da4f7d; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; Levesque B, 2006, INT ARCH OCC ENV HEA, V80, P32, DOI 10.1007/s00420-006-0100-0; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; Pedrosa M, 2010, J ASTHMA, V47, P817, DOI 10.3109/02770903.2010.491147; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; van den Hietnwenhoff L, 2008, EUR RESPIR J, V32, P70, DOI 10.1183/09031936.00088007	32	44	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					892	898		10.1016/j.jaci.2010.11.003	http://dx.doi.org/10.1016/j.jaci.2010.11.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21167573	Bronze			2022-12-18	WOS:000289055800009
J	Hennino, A; Jean-Decoster, C; Giordano-Labadie, F; Debeer, S; Vanbervliet, B; Rozieres, A; Schmitt, AM; Nicolas, JF				Hennino, Ana; Jean-Decoster, Catherine; Giordano-Labadie, Francoise; Debeer, Sabine; Vanbervliet, Beatrice; Rozieres, Aurore; Schmitt, Anne-Marie; Nicolas, Jean-Francois			CD8(+) T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN INFLAMMATION; APOPTOSIS; DISEASES		[Hennino, Ana; Debeer, Sabine; Vanbervliet, Beatrice; Rozieres, Aurore; Nicolas, Jean-Francois] Univ Lyon, Lyon, France; [Hennino, Ana; Debeer, Sabine; Vanbervliet, Beatrice; Rozieres, Aurore; Nicolas, Jean-Francois] INSERM, U851, F-69008 Lyon, France; [Hennino, Ana; Rozieres, Aurore; Nicolas, Jean-Francois] Univ Lyon 1, IFR128, F-69622 Villeurbanne, France; [Jean-Decoster, Catherine; Schmitt, Anne-Marie] Pierre Fabre Dermocosmet, Serv Rech Clin, Toulouse, France; [Giordano-Labadie, Francoise] Ctr Univ Hosp, Serv Dermatol, Toulouse, France; [Nicolas, Jean-Francois] CH Lyon Sud, Hosp Civils Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Hennino, A (corresponding author), Univ Lyon, Lyon, France.	ana.hennino@inserm.fr	ROZIERES, Aurore/M-4447-2014; Nicolas, Jean-François/AAW-9289-2020; Hennino, Ana/I-5837-2014	ROZIERES, Aurore/0000-0003-0293-4002; NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X; Hennino, Ana/0000-0002-2619-8559				Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Hennino A, 2007, J IMMUNOL, V178, P5571, DOI 10.4049/jimmunol.178.9.5571; Holm L, 2004, ALLERGY, V59, P874, DOI 10.1111/j.1398-9995.2004.00483.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Nosbaum A, 2010, EUR J DERMATOL, V20, P563, DOI 10.1684/ejd.2010.1014; Pastore S, 2006, EUR J DERMATOL, V16, P125; Saeki H, 2006, J DERMATOL SCI, V43, P75, DOI 10.1016/j.jdermsci.2006.06.002; Simon D, 2009, ALLERGY, V64, P1681, DOI 10.1111/j.1398-9995.2009.02097.x; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x	12	44	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1064	1067		10.1016/j.jaci.2010.11.022	http://dx.doi.org/10.1016/j.jaci.2010.11.022			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21236476				2022-12-18	WOS:000289055800031
J	Gilles, S; Fekete, A; Zhang, X; Beck, I; Blume, C; Ring, J; Schmidt-Weber, C; Behrendt, H; Schmitt-Kopplin, P; Traidl-Hoffmann, C				Gilles, Stefanie; Fekete, Agnes; Zhang, Xin; Beck, Isabelle; Blume, Cornelia; Ring, Johannes; Schmidt-Weber, Carsten; Behrendt, Heidrun; Schmitt-Kopplin, Philippe; Traidl-Hoffmann, Claudia			Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell-primed T-H cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; immunomodulation; adenosine; pollen; allergy	BIRCH POLLEN; IMMUNE-RESPONSES; LIPID MEDIATORS; PETUNIA POLLEN; NADPH OXIDASE; TUBE GROWTH; EXPRESSION; RECEPTORS; CAPACITY; PHYTOPROSTANES	Background: Water-soluble components from pollen modulate dendritic cell (DC) functions, such as IL-12 secretion and 3'-5'-cyclic adenosine monophosphate (cAMP) signaling and migration, possibly contributing to the establishment of a T(H)2-dominated immune response against pollen. Because these effects could not solely be attributed to the previously identified pollen-associated lipid mediators, the pollen metabolome was analyzed for candidate immunomodulatory substances. Objective: We sought to perform an analysis of the effect of pollen-associated adenosine on DC function and T-H cell differentiation. Methods: Fractions of aqueous pollen extracts (APEs) were generated by means of ultrafiltration and were subjected simultaneously to biological tests and metabolome analysis (ultra-high-resolution mass spectrometry) and ultraperformance liquid chromatography. Effects of pollen-derived adenosine on monocyte-derived DC cAMP signaling, cytokine response, and capacity to differentiate T-H cells were studied. Results: The less than 3-kd fraction of APEs comprised thousands of substances, including adenosine in micromolar concentrations. Pollen-derived adenosine mediated A(2) receptor-dependent induction of cAMP and inhibition of IL-12p70 in DCs. APEs digested with adenosine deaminase failed to mediate IL-12 inhibition. DCs of nonatopic donors exposed to APEs showed an adenosine-dependent reduced capacity to differentiate T(H)1 cells and an enhanced capacity to induce regulatory T cells and IL-10. DCs of atopic donors failed to induce IL-10 but instead induced IL-5 and IL-13. Conclusion: This study identifies adenosine out of thousands of metabolites as a potent immunoregulatory substance in pollen. It acts on the level of the DC, with differential effects in atopic and nonatopic donors. (J Allergy Clin Immunol 2011;127:454-61.)	[Traidl-Hoffmann, Claudia] Tech Univ Munich, Dept Dermatol & Allergy, ZAUM Ctr Allergy & Environm, Helmholtz Ctr, D-80802 Munich, Germany; [Fekete, Agnes; Schmitt-Kopplin, Philippe] Helmholtz Ctr, Dept BioGeochem & Anal, Inst Ecol Chem, Munich, Germany; [Schmitt-Kopplin, Philippe] Tech Univ Munich, Dept Chem Tech Anal Res, Ctr Weihenstephan Brewing & Food Qual, D-8050 Freising Weihenstephan, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Traidl-Hoffmann, C (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, ZAUM Ctr Allergy & Environm, Helmholtz Ctr, Biedersteinerstr 29, D-80802 Munich, Germany.	Claudia.Traidl-Hoffmann@lrz.tum.de	Schmitt-Kopplin, Philippe/H-6271-2011; Ring, Johannes/GLN-4341-2022; Gilles-Stein, Stefanie/AAA-3741-2021; Schmidt-Weber, Carsten B./AAU-1621-2021; Fekete, Agnes/C-8048-2019	Schmitt-Kopplin, Philippe/0000-0003-0824-2664; Ring, Johannes/0000-0001-8236-3152; Gilles-Stein, Stefanie/0000-0002-5159-2558; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Fekete, Agnes/0000-0003-3058-7570; Blume, Cornelia/0000-0001-6133-7318; Traidl-Hoffmann, Claudia/0000-0001-5085-5179	Faculty of Medicine of the Technische Universitat Munchen; Deutsche Forschungsgemeinschaft; Christine-Kuhne-Stiftung (CK-Care); MRC [G0400473, G0900453] Funding Source: UKRI; Medical Research Council [G0900453, G0400473] Funding Source: researchfish	Faculty of Medicine of the Technische Universitat Munchen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Christine-Kuhne-Stiftung (CK-Care); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the Faculty of Medicine of the Technische Universitat Munchen (S. G. and C.T.-H.), the Deutsche Forschungsgemeinschaft (C.T.-H.), and the Christine-Kuhne-Stiftung (CK-Care).	Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Ben Addi A, 2008, EUR J IMMUNOL, V38, P1610, DOI 10.1002/eji.200737781; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Bryce M, 2010, INT ARCH ALLERGY IMM, V151, P46, DOI 10.1159/000232570; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Csillag A, 2010, J IMMUNOL, V184, P2377, DOI 10.4049/jimmunol.0803938; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Demidchik V, 2003, PLANT PHYSIOL, V133, P456, DOI 10.1104/pp.103.024091; Demidchik V, 2009, PLANT J, V58, P903, DOI 10.1111/j.1365-313X.2009.03830.x; Gilles S, 2010, CLIN EXP ALLERGY, V40, P269, DOI 10.1111/j.1365-2222.2009.03369.x; Gilles S, 2009, J IMMUNOL, V182, P6653, DOI 10.4049/jimmunol.0802613; Gougeon RD, 2009, P NATL ACAD SCI USA, V106, P9174, DOI 10.1073/pnas.0901100106; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hasko G, 2009, TRENDS IMMUNOL, V30, P263, DOI 10.1016/j.it.2009.04.001; Hofer S, 2003, J INVEST DERMATOL, V121, P300, DOI 10.1046/j.1523-1747.2003.12369.x; KAMBOJ RK, 1985, PLANT PHYSIOL, V79, P801, DOI 10.1104/pp.79.3.801; KAMBOJ RK, 1987, PLANT PHYSIOL, V84, P688, DOI 10.1104/pp.84.3.688; Leon C, 2009, J CHROMATOGR A, V1216, P7314, DOI 10.1016/j.chroma.2009.04.092; Mariani V, 2007, J IMMUNOL, V178, P7623, DOI 10.4049/jimmunol.178.12.7623; Mittag D, 2010, J IMMUNOL, V184, P4708, DOI 10.4049/jimmunol.0901036; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; Reichler SA, 2009, J EXP BOT, V60, P2129, DOI 10.1093/jxb/erp091; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Suhre K, 2008, NUCLEIC ACIDS RES, V36, pW481, DOI 10.1093/nar/gkn194; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Wu J, 2007, PLANT PHYSIOL, V144, P961, DOI 10.1104/pp.107.097568; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646	36	44	44	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					454	U1705		10.1016/j.jaci.2010.12.1082	http://dx.doi.org/10.1016/j.jaci.2010.12.1082			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281872				2022-12-18	WOS:000286808000020
J	Bottema, RWB; Kerkhof, M; Reijmerink, NE; Thijs, C; Smit, HA; van Schayck, CP; Brunekreef, B; van Oosterhout, AJ; Postma, DS; Koppelman, GH				Bottema, Renske W. B.; Kerkhof, Marjan; Reijmerink, Naomi E.; Thijs, Carel; Smit, Henriette A.; van Schayck, Constant P.; Brunekreef, Bert; van Oosterhout, Antoon J.; Postma, Dirkje S.; Koppelman, Gerard H.			Gene-gene interaction in regulatory T-cell function in atopy and asthma development in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T regulatory cells; atopy; IgE; asthma; MDR; polymorphism; interaction; birth cohort	MULTIFACTOR-DIMENSIONALITY REDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; PROMOTER POLYMORPHISMS; AIRWAY INFLAMMATION; ALLERGIC DISEASE; SERUM IGE; IMMUNOGLOBULIN-E; BIRTH COHORT; CHILDREN; ASSOCIATION	Background: Regulatory T-cell dysfunction is associated with development of the complex genetic conditions atopy and asthma. Therefore, we hypothesized that single nucleotide polymorphisms in genes involved in the development and function of regulatory T cells are associated with atopy and asthma development. Objective: To evaluate main effects and gene-gene interactions of haplotype tagging single nucleotide polymorphisms of genes involved in regulatory T-cell function-IL6, IL6R, IL10, heme-oxygenase 1 (HMOX1), IL2, Toll-like receptor 2 (TLR2), TGFB1, TGF-beta receptor (TGFBR)-1, TGFBR2, IL2RA, and forkhead box protein 3 (FOXP3)-in relation to atopy and asthma. Methods: Single-locus and multilocus associations with total IgE (3rd vs 1st tertile); specific IgE to egg, milk, and indoor allergens; and asthma were evaluated by x 2 tests and the multifactor dimensionality-reduction method in 3 birth cohorts (Allergenic study). Results: Multiple statistically significant multilocus associations existed. IL2RA rs4749926 and TLR2 rs4696480 associated with IgE in both age groups tested (1-2 and 6-8 years). TGFBR2 polymorphisms associated with total and specific IgE in both age groups and with asthma. TGFBR2 rs9831477 associated with specific IgE for milk at age 1 to 2 years and indoor allergens at age 6 to 8 years. For milk-specific IgE, interaction between TGFBR2 and FOXP3 polymorphisms was confirmed by logistic regression and consistent in 2 birth cohorts and when stratified for sex, supplying internal replications. Conclusion: Genes involved in the development and function of regulatory T cells, specifically IL2RA, TLR2, TGFBR2, and FOXP3, associate with atopy and asthma by gene-gene interaction. Modeling of multiple gene-gene interactions is important to unravel further the genetic susceptibility to atopy and asthma. (J Allergy Clin Immunol 2010;126:338-46.)	[Koppelman, Gerard H.] Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Univ Med Ctr Groningen, NL-9700 AD Groningen, Netherlands; [Bottema, Renske W. B.; Reijmerink, Naomi E.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AD Groningen, Netherlands; [Bottema, Renske W. B.; Reijmerink, Naomi E.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9700 AD Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AD Groningen, Netherlands; [van Oosterhout, Antoon J.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9700 AD Groningen, Netherlands; [Thijs, Carel] Care & Publ Hlth Res Inst, Dept Epidemiol, Maastricht, Netherlands; [Thijs, Carel] Nutr & Toxicol Res Inst Maastricht, Maastricht, Netherlands; [van Schayck, Constant P.] Maastricht Univ, Dept Gen Practice, Maastricht, Netherlands; [van Schayck, Constant P.] Maastricht Univ, Care & Publ Hlth Res Inst, Maastricht, Netherlands; [Smit, Henriette A.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University; Utrecht University Medical Center	Koppelman, GH (corresponding author), Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Univ Med Ctr Groningen, POB 196, NL-9700 AD Groningen, Netherlands.	g.h.koppelman@bkk.umcg.nl	Thijs, Carel/H-8340-2019; Koppelman, Gerard/AAG-9187-2020	Thijs, Carel/0000-0001-6646-5458; Bottema, Renske/0000-0003-0754-2147	ZonMW [912-03-031]; Netherlands Asthma Foundation; Netherlands Heart Foundation; INO Quality of Life Research Institute	ZonMW(Netherlands Organization for Health Research and Development); Netherlands Asthma Foundation; Netherlands Heart Foundation(Netherlands Heart Foundation); INO Quality of Life Research Institute	Supported by ZonMW (grant no. 912-03-031).; C. Thijs receives research support from the Netherlands Asthma Foundation, the Netherlands Heart Foundation, and the INO Quality of Life Research Institute. The rest of the authors have declared that they have no conflict of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akkerdaas JH, 2005, INT ARCH ALLERGY IMM, V138, P203, DOI 10.1159/000088720; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Bastiaanssen JM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-1; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Blakey JD, 2007, THORAX, V62, P196, DOI 10.1136/thx.2006.070649; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Bottema RWB, 2010, EUR RESPIR J, V35, P54, DOI 10.1183/09031936.00018909; BOTTEMA RW, 2009, ALLERGY          DEC, P91; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Chatterjee R, 2005, CLIN EXP ALLERGY, V35, P914, DOI 10.1111/j.1365-2222.2005.02273.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Galicia JC, 2004, GENES IMMUN, V5, P513, DOI 10.1038/sj.gene.6364120; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Immervoll T, 2001, HUM MUTAT, V18, P327, DOI 10.1002/humu.1194; Islam T, 2008, AM J RESP CRIT CARE, V177, P388, DOI 10.1164/rccm.200706-863OC; Janssens ACJW, 2008, HUM MOL GENET, V17, pR166, DOI 10.1093/hmg/ddn250; Jartti T, 2007, J ALLERGY CLIN IMMUN, V120, P177, DOI 10.1016/j.jaci.2007.03.008; Karjalainen J, 2003, CLIN EXP ALLERGY, V33, P78, DOI 10.1046/j.1365-2222.2003.01577.x; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kimman TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003665; Kuiper S, 2005, PEDIAT ALLERG IMM-UK, V16, P321, DOI 10.1111/j.1399-3038.2005.00278.x; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lemos B, 2008, SCIENCE, V319, P91, DOI 10.1126/science.1148861; Li HL, 2007, HUM GENET, V121, P529, DOI 10.1007/s00439-007-0337-z; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Matesanz F, 2004, J NEUROIMMUNOL, V148, P212, DOI 10.1016/j.jneuroim.2003.12.001; Meng JF, 2005, INT ARCH ALLERGY IMM, V138, P151, DOI 10.1159/000088437; Moore JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Negoro T, 2006, PEDIATR ALLERGY IMMU, V17, P583, DOI 10.1111/j.1399-3038.2006.00463.x; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Ono K, 2004, ATHEROSCLEROSIS, V173, P315, DOI 10.1016/j.atherosclerosis.2003.11.021; Park HW, 2007, THORAX, V62, P265, DOI 10.1136/thx.2006.065482; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60, DOI 10.1165/ajrcmb.25.1.4396; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; SAMBROOK JRD, 2001, PREPARATION PLASMID; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schonberger HJAM, 2005, EUR RESPIR J, V25, P660, DOI 10.1183/09031936.05.00067704; Shin HD, 2005, ALLERGY, V60, P1146, DOI 10.1111/j.1398-9995.2005.00839.x; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9, DOI 10.1159/000231803; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; van Oosterhout AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205; Xia ZW, 2007, AM J PATHOL, V171, P1904, DOI 10.2353/ajpath.2007.070096	64	44	46	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					338	U62		10.1016/j.jaci.2010.04.024	http://dx.doi.org/10.1016/j.jaci.2010.04.024			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20599261				2022-12-18	WOS:000281203800020
J	Dua, B; Watson, RM; Gauvreau, GM; O'Byrne, PM				Dua, Benny; Watson, Richard M.; Gauvreau, Gail M.; O'Byrne, Paul M.			Myeloid and plasmacytoid dendritic cells in induced sputum after allergen inhalation in subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; sputum; antigen presenting cells; myeloid dendritic cells; plasmacytoid dendritic cells; CCR6; CCR7	EOSINOPHILIC AIRWAY INFLAMMATION; CHEMOKINE RECEPTOR; INHALED ANTIGEN; RESPIRATORY-TRACT; ATOPIC ASTHMA; T-CELLS; RECRUITMENT; CHALLENGE; TRAFFICKING; ACTIVATION	Background: Dendritic cells are professional antigen presenting cells that mediate the response to inhaled allergens. In animal models, the induction and maintenance of allergic airway inflammation is primarily a function of myeloid dendritic cells, whereas the tolerization to inhaled allergens is likely a function of plasmacytoid dendritic cells. Objective: To investigate changes in sputum myeloid and plasmacytoid dendritic cells after allergen inhalation in subjects with asthma. Also, the number of myeloid and plasmacytoid dendritic cells expressing both CCR6 and 7 and their chemokine ligands macrophage inflammatory protein (MIP)-3 alpha and 3 beta were measured in sputum supernatants. Methods: Sputum was induced from 12 dual-responder subjects with allergic asthma before and 7 hours, 24 hours, and 72 hours after inhalation of diluent and allergen. Dendritic cells were enumerated via flow cytometry and the chemokines by using ELISAs. Results: The number of sputum myeloid dendritic cells was significantly higher 24 hours after allergen challenge compared with diluent. Similarly, sputum plasmacytoid dendritic cells increased significantly at 24 hours after allergen challenge. Also, a significant increase in CCR6(+) myeloid dendritic cells numbers occurred 72 hours after allergen challenge. In contrast, CCR7(+) myeloid dendritic cells, as well as the number of CCR6(+) and CCR7(+) plasmacytoid dendritic cells, were not different between challenges. Finally, allergen challenge increased sputum levels of MIP-3 alpha, but not MIP-3 beta, compared with baseline. Conclusions: Both myeloid and plasmacytoid dendritic cells increase in the sputum of subjects with asthma after allergen challenge, suggesting that both subsets are involved in the pathogenesis of allergen responses in asthma. (J Allergy Clin Immunol 2010;126:133-9.)	[O'Byrne, Paul M.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; St Josephs Hosp, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; McGill University; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Dept Med, HSC 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X	Canadian Institutes for Health Research [9362]; Schering-Plough; MedImmune; Genentech	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Schering-Plough(Merck & CompanySchering Plough Corporation); MedImmune(AstraZenecaMedimmune); Genentech(Roche HoldingGenentech)	Supported by Canadian Institutes for Health Research Grant #9362.; G. M. Gauvreau received research support from Schering-Plough, MedImmune, and Genentech. The rest of the authors have declared that they have no conflict of interest.	Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Chan VWF, 1999, BLOOD, V93, P3610, DOI 10.1182/blood.V93.11.3610.411a48_3610_3616; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dieu-Nosjean MC, 1999, J LEUKOCYTE BIOL, V66, P252, DOI 10.1002/jlb.66.2.252; Farrell E, 2007, ALLERGY, V62, P1139, DOI 10.1111/j.1398-9995.2007.01465.x; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Hammad H, 2003, J IMMUNOL, V171, P3936, DOI 10.4049/jimmunol.171.8.3936; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lundy SK, 2005, J IMMUNOL, V174, P2054, DOI 10.4049/jimmunol.174.4.2054; McCarthy NE, 2007, CLIN EXP ALLERGY, V37, P72, DOI 10.1111/j.1365-2222.2006.02631.x; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; Pizzichini E, 2002, EUR RESPIR J, V20, p9S, DOI 10.1183/09031936.02.00000902; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; Sozzani S, 1999, J LEUKOCYTE BIOL, V66, P1, DOI 10.1002/jlb.66.1.1; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; Upham JW, 2003, PHARMACOL THERAPEUT, V100, P75, DOI 10.1016/S0163-7258(03)00094-9; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51	28	44	45	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					133	139		10.1016/j.jaci.2010.04.006	http://dx.doi.org/10.1016/j.jaci.2010.04.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20538329				2022-12-18	WOS:000280061800024
J	Li, JT; Rank, MA; Squillace, DL; Kita, H				Li, James T.; Rank, Matthew A.; Squillace, Diane L.; Kita, Hirohito			Ovalbumin content of influenza vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EGG ALLERGY		[Li, James T.; Rank, Matthew A.; Squillace, Diane L.; Kita, Hirohito] Mayo Clin Allergy, Rochester, MN 55905 USA		Li, JT (corresponding author), Mayo Clin Allergy, Rochester, MN 55905 USA.	li.james@mayo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034486] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI034486, R01 AI034486-14] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chaloupka I, 1996, EUR J CLIN MICROBIOL, V15, P121, DOI 10.1007/BF01591484; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Rank MA, 2009, J ALLERGY CLIN IMMUN, V124, P1123, DOI 10.1016/j.jaci.2009.09.028; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	5	44	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1412	1413		10.1016/j.jaci.2010.03.009	http://dx.doi.org/10.1016/j.jaci.2010.03.009			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20451987	Green Accepted			2022-12-18	WOS:000278831000042
J	Morel, E; Escamochero, S; Cabanas, R; Diaz, R; Fiandor, A; Bellon, T				Morel, Esther; Escamochero, Salvador; Cabanas, Rosario; Diaz, Rosa; Fiandor, Ana; Bellon, Teresa			CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stevens-Johnson syndrome; toxic epidermal necrolysis; drug allergy; NK-CTLs; CD94/NKG2C; HLA-E	CYTOTOXIC T-CELLS; HLA-E; NATURAL-KILLER; MEDIATED RECOGNITION; INHIBITORY RECEPTORS; KERATINOCYTE DEATH; SURFACE EXPRESSION; BLISTER FLUID; LYMPHOCYTES; ACTIVATION	Background: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe, bullous cutaneous diseases with uncertain pathogenesis, although cytotoxic T cells seem to be involved. Natural killer (NK) like activity has been found in blister infiltrates. Cytotoxic T lymphocytes (CTLs) with NK-like activity (NK-CTLs) have been shown to express T-cell receptors restricted by the HLA-Ib molecule HLA-E. Alternatively, the HLA-E specific activating receptor CD94/NKG2C can trigger T-cell receptor independent cytotoxicity in CTLs. Objective: Our aim was to test whether HLA-E expression sensitizes keratinocytes to killing by CTLs with NK-like activity and to explore the expression of activating receptors specific for HLA-E in blister cytotoxic lymphocytes. Methods: We used flow cytometry and immunohistochemistry to analyze HLA-E expression in keratinocytes from affected skin in patients with SJS, TEN, and other less severe drug-induced exanthemas. The expression of CD94/NKG2C was analyzed by means of flow cytometry in PBMCs and blister cells from patients. PBMCs and blister cells were analyzed for their ability to kill HLA-E expressing cells. Involvement of CD94/NKG2C in triggering degranulation of cytolytic cells was explored by means of CD107a mobilization assays and standard cytotoxicity chromium release assays. Results: We found that keratinocytes from affected skin expressed HLA-E and that cell-surface HLA-E sensitizes keratinocytes to killing by CD94/NKG2C(+) CTLs. Frequencies of CD94/NKG2C(+) peripheral blood T and NK cells were increased in patients with SJS and TEN during the acute phase. Moreover, activated blister T and NK lymphocytes expressed CD94/NKG2C and were able to degranulate in response to HLA-E+ cells in an NKG2C-dependent manner. Conclusion: CD94/NKG2C might be involved in triggering cytotoxic lymphocytes in patients with SJS and TEN. (J Allergy Clin Immunol 2010;125:703-10.)	[Morel, Esther; Escamochero, Salvador; Bellon, Teresa] Hosp Univ La Paz FIBHULP, Res Unit, Madrid 28046, Spain; [Cabanas, Rosario; Fiandor, Ana] Hosp Univ La Paz, Allergy Serv, Madrid 28046, Spain; [Diaz, Rosa] Hosp Univ La Paz, Dermatol Serv, Madrid 28046, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz	Bellon, T (corresponding author), Hosp Univ La Paz, Res Unit, P Castellana 261, Madrid 28046, Spain.	tbellon.hulp@salud.madrid.org	Bellón, Teresa/ABF-4916-2020; MOREL, ESTHER/AAC-7286-2021	Bellón, Teresa/0000-0002-0138-6879; MOREL, ESTHER/0000-0002-4768-082X	Ministerio de Sanidad/ISCIII, Spain [PI 06/0441]; FIBHULP	Ministerio de Sanidad/ISCIII, Spain(Instituto de Salud Carlos IIISpanish Government); FIBHULP	Supported by grant PI 06/0441 fro, the Ministerio de Sanidad/ISCIII, Spain, to T.B.. E.M. is the recipient of a fellowship from the FIBHULP.	Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Allanore Laurence, 2007, P267, DOI 10.1159/000104206; Arlettaz L, 2004, EUR J IMMUNOL, V34, P3456, DOI 10.1002/eji.200425210; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Correia O, 2001, DERMATOLOGY, V203, P212, DOI 10.1159/000051751; Coupel S, 2007, BLOOD, V109, P2806, DOI 10.1182/blood-2006-06-030213; Derre L, 2006, J IMMUNOL, V177, P3100, DOI 10.4049/jimmunol.177.5.3100; Garcia P, 2002, EUR J IMMUNOL, V32, P936, DOI 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.0.CO;2-M; Guma M, 2005, EUR J IMMUNOL, V35, P2071, DOI 10.1002/eji.200425843; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Hunger RE, 2005, J ALLERGY CLIN IMMUN, V116, P923, DOI 10.1016/j.jaci.2005.06.029; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; Lee N, 1998, J IMMUNOL, V160, P4951; Lopez-Botet M, 2000, HUM IMMUNOL, V61, P7, DOI 10.1016/S0198-8859(99)00161-5; Mazzarino P, 2005, EUR J IMMUNOL, V35, P3240, DOI 10.1002/eji.200535343; Mela CM, 2005, AIDS, V19, P1761, DOI 10.1097/01.aids.0000183632.12418.33; Meresse B, 2006, J EXP MED, V203, P1343, DOI 10.1084/jem.20060028; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Moretta L, 2003, IMMUNOL LETT, V88, P89, DOI 10.1016/S0165-2478(03)00074-9; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2004, J INVEST DERMATOL, V123, P850, DOI 10.1111/j.0022-202X.2004.23439.x; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Pereira FA, 2007, J AM ACAD DERMATOL, V56, P181, DOI 10.1016/j.jaad.2006.04.048; Pietra G, 2001, EUR J IMMUNOL, V31, P3687, DOI 10.1002/1521-4141(200112)31:12<3687::AID-IMMU3687>3.0.CO;2-C; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Roujeau JC, 2006, M S-MED SCI, V22, P188, DOI 10.1051/medsci/2006222188; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490	34	44	49	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					703	710		10.1016/j.jaci.2009.10.030	http://dx.doi.org/10.1016/j.jaci.2009.10.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20132973	Bronze			2022-12-18	WOS:000275883200029
J	Gandhi, C; Healy, C; Wanderer, AA; Hoffman, HM				Gandhi, Chhavi; Healy, Chris; Wanderer, Alan A.; Hoffman, Hal M.			Familial atypical cold urticaria: Description of a new hereditary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cold urticaria; autosomal dominant; pedigree; questionnaire; cold stimulation time test; evaporative cooling; skin biopsy; mast cell; antihistamine; epinephrine	AUTOINFLAMMATORY SYNDROME; IDENTIFICATION; PREVENTION; MUTATION; RELEASE	Background: Acquired cold urticaria (ACU) is usually a self-limited, sporadic, cutaneous disease diagnosed based on history and a positive cold stimulation time test (CSTT) result. We describe 3 unrelated families (A, B, and C) with lifelong atypical cold urticaria distinguished from ACU and familial cold autoinflammatory syndrome. Objective: We sought to describe a new hereditary disease of cold urticaria and study its pathogenesis. Methods: Questionnaires, interviews, physical examinations, skin testing, and biopsies were performed. Absolute values, means, and prevalence percentages of data are reported. Results: Thirty-five subjects are described with familial atypical cold urticaria (FACU; family A, 17; family B, 8; and family C, 10) displaying an autosomal dominant pattern of inheritance. All tested subjects had negative CSTT results. Completed questionnaires from affected and unaffected members of families A and B (n = 35) revealed that all affected subjects had lifelong symptoms that began in early childhood with pruritus, erythema, and urticaria after cold exposure. Angioedema (family A, 23%; family B, 42%) and syncope, near syncope, or both (family A, 46%; family B, 86%) were also present. Triggers included cold atmosphere (100%), aquatic activities (family A, 92%; family B, 100%), handling cold objects (family A, 54%; family B, 71%), and ingestion of cold foods or beverages (family A, 69%,; family B, 100%). Skin biopsy specimens demonstrated a mast cell infiltrate with the appearance of degranulation after cold challenge. Conclusions: FACU is a new cold-induced inherited disease that is different than ACU in its natural history, atmospheric cold elicitation, severity of systemic reactions, and CSTT results. FACU differs from familial cold autoinflammatory syndrome in symptom timing and the absence of fever, chills, and joint pain. The cause is suspected to be mast cell related. Treatment of reactions is similar to that for ACU. Further evaluation of pathogenesis and genetics is warranted. (J Allergy Clin Immunol 2009;124:1245-50.)	[Gandhi, Chhavi; Hoffman, Hal M.] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; [Healy, Chris; Hoffman, Hal M.] Univ Wisconsin Hlth Allergy & Asthma, Madison, WI USA; [Wanderer, Alan A.] Allergy & Asthma Consultants Montana, Bozeman, MT USA; [Hoffman, Hal M.] Rady Childrens Hosp, San Diego, CA USA; [Hoffman, Hal M.] Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA USA	University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Rady Childrens Hospital San Diego; Ludwig Institute for Cancer Research	Hoffman, HM (corresponding author), 9500 Gilman Dr,Mail Code 0635, La Jolla, CA 92093 USA.	hahoffman@ucsd.edu			National Institutes of Health [T32 A 107469]; University of California, San Diego, Department of Pediatrics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California, San Diego, Department of Pediatrics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health training grant T32 A 107469 and the University of California, San Diego, Department of Pediatrics Opportunity Research Grant.	Bonadonna P, 2003, J AM ACAD DERMATOL, V49, P714, DOI 10.1067/S0190-9622(03)01590-1; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P453, DOI 10.1016/0091-6749(84)90354-3; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NEITTAANMAKI H, 1985, J AM ACAD DERMATOL, V13, P636, DOI 10.1016/S0190-9622(85)70208-3; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; Siebenhaar F, 2004, J ALLERGY CLIN IMMUN, V114, P1224, DOI 10.1016/j.jaci.2004.07.018; Siebenhaar F, 2009, J ALLERGY CLIN IMMUN, V123, P672, DOI 10.1016/j.jaci.2008.12.008; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; Wanderer AA, 2005, J ALLERGY CLIN IMMUN, V115, P1096, DOI 10.1016/j.jaci.2005.01.013; WANDERER AA, 1986, J ALLERGY CLIN IMMUN, V78, P417, DOI 10.1016/0091-6749(86)90027-8; WANDERER AA, 1995, IMMUNOL ALLERGY CLIN, V15, P701	17	44	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1245	1250		10.1016/j.jaci.2009.09.035	http://dx.doi.org/10.1016/j.jaci.2009.09.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910034	Green Accepted			2022-12-18	WOS:000273071500016
J	Trivedi, NN; Tamraz, B; Chu, C; Kwok, PY; Caughey, GH				Trivedi, Neil N.; Tamraz, Bani; Chu, Catherine; Kwok, Pui-Yan; Caughey, George H.			Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tryptase; mast cells; human genetics	SUBSTRATE-SPECIFICITY; BACTERIAL-INFECTIONS; COMPLEMENTARY-DNA; BETA-I; ALPHA; INFLAMMATION; HISTAMINE; LUNG; HYPERRESPONSIVENESS; ACTIVATION	Background: Mast cell tryptases have proposed roles in allergic inflammation and host defense against infection. Tryptase gene loci TPSAB1 and TPSB2 are known to be polymorphic, but the nature and extent of diversity at these loci have not been fully explored. Objective: We sought to compare functional and nonfunctional tryptase allele frequencies and establish haplotypes in human populations. Methods: Tryptase allele frequencies were determined by means of direct sequencing in 270 individuals from HapMap populations of European, African, Chinese, and Japanese ancestry. Haplotypes were predicted, validated in parent-child trios, and compared between populations. Results: We identify a new frame-shifted tryptase allele (beta IIIFS) carried by 23% and 19% of individuals of European and African ancestry but 0% of Asian subjects. Homology models predict that beta IIIFS is functionless. Our genotyping assay shows that allele and haplotype distributions in each population are unique. Strong linkage disequilibrium between TPSAB1 and TPSB2 (r(2) = 0.83, D' = 0.85) yields 2 major and 5 minor tryptase haplotypes. Conclusions: Tryptase deficiency alleles (alpha and the newly discovered beta IIIFS) are common, causing the number of inherited active genes to range from a minimum of 2 to a maximum of 4, with major differences between populations in the proportion of individuals inheriting 2 versus 4 active alleles. African and Asian populations are especially enriched in genes encoding functional and nonfunctional tryptases, respectively. Strong linkage of TPSAB1 and TPSB2 and pairing of deficiency alleles with functional alleles in observed haplotypes protect human subjects from "knockout" genomes and indeed from inheritance of fewer than 2 active alleles. (J Allergy Clin hnmunol 2009;124:1099-105.)	[Trivedi, Neil N.; Caughey, George H.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Trivedi, Neil N.; Tamraz, Bani; Kwok, Pui-Yan; Caughey, George H.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Trivedi, Neil N.; Caughey, George H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Chu, Catherine; Kwok, Pui-Yan] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Tamraz, Bani; Chu, Catherine; Kwok, Pui-Yan] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Caughey, George H.] Vet Hlth Res Inst, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Vet Affairs Med Ctr, 111D,4150 Clement St, San Francisco, CA 94121 USA.	George.Caughey@ucsf.edu	Kwok, Pui-Yan/F-7725-2014	Kwok, Pui-Yan/0000-0002-5087-3059	National Institutes of Health [HL024136]; Veterans Health Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Health Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL024136 and the Veterans Health Research Institute.	[Anonymous], 2003, NATURE, V426, P789; Barrios VE, 1998, LIFE SCI, V63, P2295, DOI 10.1016/S0024-3205(98)00518-9; Brown JK, 2001, AM J RESP CELL MOL, V24, P146, DOI 10.1165/ajrcmb.24.2.4165; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Costanzo MJ, 2003, J MED CHEM, V46, P3865, DOI 10.1021/jm030050p; Hallgren J, 2006, FEBS J, V273, P1871, DOI 10.1111/j.1742-4658.2006.05211.x; Hallgren J, 2005, J MOL BIOL, V345, P129, DOI 10.1016/j.jmb.2004.10.029; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; He SH, 1997, J IMMUNOL, V159, P6216; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; McNeil HP, 2007, J BIOL CHEM, V282, P20785, DOI 10.1074/jbc.R700017200; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Min HK, 2004, J ALLERGY CLIN IMMUN, V114, P48, DOI 10.1016/j.jaci.2004.04.008; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Rozen S, 2000, Methods Mol Biol, V132, P365; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; Selwood T, 2002, BIOCHEMISTRY-US, V41, P3329, DOI 10.1021/bi015662v; Shin K, 2008, J IMMUNOL, V180, P4885, DOI 10.4049/jimmunol.180.7.4885; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; Stoneking M, 1996, CURR OPIN GENET DEV, V6, P731, DOI 10.1016/S0959-437X(96)80028-1; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TAM EK, 1990, AM J RESP CELL MOL, V2, P449, DOI 10.1165/ajrcmb/2.5.449; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Thakurdas SM, 2007, J BIOL CHEM, V282, P20809, DOI 10.1074/jbc.M611842200; Trivedi NN, 2008, J ALLERGY CLIN IMMUN, V121, P1262, DOI 10.1016/j.jaci.2008.01.019; Trivedi NN, 2007, J IMMUNOL, V179, P6072, DOI 10.4049/jimmunol.179.9.6072; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Woodman L, 2008, J IMMUNOL, V181, P5001, DOI 10.4049/jimmunol.181.7.5001	41	44	47	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1099	1105		10.1016/j.jaci.2009.07.026	http://dx.doi.org/10.1016/j.jaci.2009.07.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19748655	Green Accepted			2022-12-18	WOS:000272108000033
J	Lee, TH; Woszczek, G; Farooque, SP				Lee, Tak H.; Woszczek, Grzegorz; Farooque, Sophie P.			Leukotriene E-4: Perspective on the forgotten mediator	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cysteinyl leukotriene; leukotriene E-4; asthma; aspirin-sensitive respiratory disease; cysteinyl leukotriene receptor	SLOW-REACTING SUBSTANCE; SENSITIVE ASTHMATIC SUBJECTS; GUINEA-PIG TRACHEAL; AIRWAY RESPONSIVENESS; ASPIRIN DESENSITIZATION; CYSTEINYL LEUKOTRIENES; URINARY LEUKOTRIENE-E4; RESPIRATORY-DISEASE; INFLAMMATORY CELLS; SMOOTH-MUSCLE	Leukotriene (LT) E-4 mediates many of the principal features of bronchial asthma, such as bronchial constriction, hyperresponsiveness, eosinophilia, and increased vascular permeability. Furthermore, it is the most stable of the cysteinyl leukotrienes (CysLTs) and can be active at the site of release for a prolonged time after its synthesis. There might be several reasons why LTE4 has been forgotten. LTE4 demonstrated low affinity for CysLT(1) and CysLT(2) receptors in equilibrium competition assays. It was less potent than other CysLTs in functional assays, such as calcium flux, in cells transfected with CysLT(1) and CysLT(2). The introduction of CysLT(1) antagonists into clinical practice diverted interest into CysLT(1)-related mechanisms, which were mediated mainly by LTD4. However, experiments with animal models and human studies have revealed that LTE4 has unique characteristics that cannot be explained by the current knowledge of CysLT(1) and CysLT(2). These activities include its potency relative to other CysLTs to increase airway responsiveness to histamine, to enhance eosinophilic recruitment, and to increase vascular permeability. Asthmatic airways also demonstrate marked in vivo relative hyperresponsiveness to LTE4, especially in patients with aspirin-sensitive respiratory disease. This has stimulated a search for additional LT receptors that would respond preferentially to LTE4 stimulation. (J Allergy Clin Immunol 2009;124:417-21.)	[Lee, Tak H.; Woszczek, Grzegorz; Farooque, Sophie P.] Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, London, England	University of London; King's College London	Lee, TH (corresponding author), Guys Hosp, MRC & Asthma UK Ctr Allerg Mech Asthma, 5th Floor Tower Wing, London SE1 9RT, England.	tak.lee@kcl.ac.uk	Woszczek, Grzegorz/H-5792-2012; Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059	Medical Research Council (UK); Asthma UK; National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre at Guy's; St Thomas' NHS Foundation Trust and King's College London; MRC [G0501746] Funding Source: UKRI; Medical Research Council [G0400503B, G0501746] Funding Source: researchfish	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre at Guy's(National Institute for Health Research (NIHR)); St Thomas' NHS Foundation Trust and King's College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the Medical Research Council (UK), Asthma UK, National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.	ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Farooque SP, 2009, ANNU REV PHYSIOL, V71, P465, DOI 10.1146/annurev.physiol.010908.163114; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HOLROYDE MC, 1981, LANCET, V2, P17; JACQUES CAJ, 1991, BRIT J PHARMACOL, V104, P859, DOI 10.1111/j.1476-5381.1991.tb12518.x; Laitinen A, 2005, J ALLERGY CLIN IMMUN, V115, P259, DOI 10.1016/j.jaci.2004.10.021; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; Mulder A, 1999, AM J RESP CRIT CARE, V159, P1562, DOI 10.1164/ajrccm.159.5.9810095; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052; OHICKEY SP, 1988, EUR RESPIR J, V1, P913; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; Pynaert G, 1999, MOL MED, V5, P685, DOI 10.1007/BF03401987; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WESTCOTT JY, 1993, AM REV RESPIR DIS, V148, P1244, DOI 10.1164/ajrccm/148.5.1244; Woszczek G, 2005, J IMMUNOL, V175, P5152, DOI 10.4049/jimmunol.175.8.5152; Woszczek G, 2008, J ALLERGY CLIN IMMUN, V121, P215, DOI 10.1016/j.jaci.2007.09.013; Woszczek G, 2007, J IMMUNOL, V178, P5262, DOI 10.4049/jimmunol.178.8.5262	45	44	48	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					417	421		10.1016/j.jaci.2009.04.020	http://dx.doi.org/10.1016/j.jaci.2009.04.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19482346				2022-12-18	WOS:000274315900003
J	Basinski, TM; Holzmann, D; Eiwegger, T; Zimmermann, M; Klunker, S; Meyer, N; Schmid-Grendelmeier, P; Jutel, M; Akdis, CA				Basinski, Tomasz M.; Holzmann, David; Eiwegger, Thomas; Zimmermann, Maya; Klunker, Sven; Meyer, Norbert; Schmid-Grendelmeier, Peter; Jutel, Marek; Akdis, Cezmi A.			Dual nature of T cell-epithelium interaction in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Apoptosis; chronic rhinosinusitis; epithelial cells; IFN-gamma; T cells; TNF-related apoptosis-inducing ligand	APOPTOSIS-INDUCING LIGAND; LYMPHOCYTE-ASSOCIATED ANTIGEN; IFN-GAMMA; INTERFERON-GAMMA; TRAIL RECEPTORS; EXPRESSION; KERATINOCYTES; INFLAMMATION; ACTIVATION; INDUCTION	Background: T-cell infiltration of submucosa, release of proinflammatory cytokines leading to epithelial activation, and contributions to inflammation are observed in chronic rhinosinusitis (CRS). Objectives: Molecular mechanisms and kinetics of T-cell interaction with sinus epithelium leading to activation followed by subsequent apoptosis of epithelial cells were the focus of the current study. Methods: Primary human sinus epithelial cells and T cells generated from sinus tissues of healthy individuals and patients with CRS with or without allergy and sinus tissue biopsies were characterized in terms of activation (surface marker expression, cytokine production via real-time PCR, confocal microscopy, ELISA) and apoptosis (annexin V/7-amino-actinomycin D staining, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay, receptor expression by flow cytometry, confocal microscopy) of epithelial cells. Results: Primary human sinus epithelial cells isolated from patients with CRS were at an activated state with upregulated expression of HLA-DR, IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and TNF-related apoptosis-inducing ligand (TRAIL) compared with healthy individuals. The expressions of these chemokines, HLA-DR, TRAIL, and TNF receptor 2 were significantly induced by IFN-gamma, whereas TRAIL receptor 4 was downregulated. Epithelial cells started to undergo apoptosis 48 hours after IFN-gamma stimulation when the transcription of proinflammatory cytokines and chemokines decreased to initial levels. The essential factors for sinus epithelial apoptosis were T(H)1 cells and IFN-gamma. Epithelial apoptosis was enhanced by Fas-Fas-ligand and TRAII.-TRAIL receptor 2 interactions. Remarkable apoptosis of epithelial cells and shedding was observed in CRS in situ. Conclusion: Epithelial cell interaction with activated T cells is a biphasic phenomenon in CRS. Initially activated T cells lead to activation and induction of proinflammatory functions of epithelial cells, and thereafter their apoptotic death, resulting in no more contribution to inflammation, takes place. (J Allergy Clin Immunol 2009;124:74-80.)	[Basinski, Tomasz M.; Eiwegger, Thomas; Zimmermann, Maya; Klunker, Sven; Meyer, Norbert; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Holzmann, David] Univ Zurich Hosp, Dept Otolaryngol, CH-8091 Zurich, Switzerland; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat, Vienna, Austria; [Jutel, Marek] Wroclaw Med Univ, Dept Internal Med & Allergol, Wroclaw, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Medical University of Vienna; Wroclaw Medical University	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22,7270 Davos Pl, Davos, Switzerland.	tomasz.basinski@siaf.uzh.ch; akdisac@siaf.uzh.ch	Holzmann, David/ABC-7620-2020; Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Eiwegger, Thomas/0000-0002-2914-7829; Holzmann, David/0000-0002-8176-8358	Essex Chemie AG; Swiss National Science Foundation [32-112306/1, 32-118226]; Global Allergy and Asthma European Network	Essex Chemie AG; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network	Supported by Essex Chemie AG, Swiss National Science Foundation grants 32-112306/1 and 32-118226, and the Global Allergy and Asthma European Network. T.M.B. was the recipient of a European Respiratory Society Fellowship (no. 312).	Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Begue B, 2006, GASTROENTEROLOGY, V130, P1962, DOI 10.1053/j.gastro.2006.03.022; Bolitho P, 2007, CURR OPIN IMMUNOL, V19, P339, DOI 10.1016/j.coi.2007.04.007; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Fokkens W, 2007, RHINOLOGY, P1; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jarry A, 2008, J CLIN INVEST, V118, P1132, DOI 10.1172/JCI32140; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamohara H, 2004, IMMUNOLOGY, V111, P186, DOI 10.1111/j.0019-2805.2003.01794.x; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kemp TJ, 2004, J IMMUNOL, V173, P892, DOI 10.4049/jimmunol.173.2.892; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Mirandola P, 2004, BLOOD, V104, P2418, DOI 10.1182/blood-2004-04-1294; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Robertson NM, 2002, J IMMUNOL, V169, P5986, DOI 10.4049/jimmunol.169.10.5986; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sato K, 2006, J EXP MED, V203, P239, DOI 10.1084/jem.20051062; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660	36	44	47	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					74	80		10.1016/j.jaci.2009.04.019	http://dx.doi.org/10.1016/j.jaci.2009.04.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19523671				2022-12-18	WOS:000267909700009
J	Miller, BD; Wood, BL; Lim, J; Ballow, M; Hsu, C				Miller, Bruce D.; Wood, Beatrice L.; Lim, JungHa; Ballow, Mark; Hsu, ChiunYu			Depressed children with asthma evidence increased airway resistance: "Vagal bias" as a mechanism?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; depression; children; vagal; pulmonary function; airway resistance; autonomic nervous system; dysregulation	SOCIOECONOMIC-STATUS; BEHAVIORAL-ADJUSTMENT; PSYCHOLOGICAL-FACTORS; MEDICATION ADHERENCE; CHILDHOOD ASTHMA; CHRONIC STRESS; LIFE STRESS; HEART-RATE; SYMPTOMS; REACTIVITY	Background: Depression is prevalent in pediatric asthma, and implicated in asthma morbidity and mortality. Pathways linking stress, depression, and asthma are unknown. Objectives: To examine, under controlled laboratory conditions, pathways by which depressive states affect airway function via autonomic dysregulation. Methods: Participants were 171 children with asthma, age 7 to 17 years, presenting to an emergency department for asthma exacerbation. Forty-five children with asthma and high depressive symptoms (D) were contrasted with 45 with low/no depressive symptoms (ND). Depressive symptoms, asthma disease severity, vagal and sympathetic reactivity to film stressors, airflow (FEV1), and airway resistance were compared between the groups. A subgroup with greater airway reactivity (nonmedicated FEV1<80% predicted) was also studied. Correlations among variables were examined for the entire sample. Results: Groups did not differ in demographics, disease severity, medications, or adherence. The D group with FEV1<80% predicted showed greater airway resistance throughout all conditions (P = .03), and vagal bias in the film stressors. The D group's vagal response was significant for the sad stimuli: family distress/loss (P = .03), dying (P = .003), and death (P = .03). The ND group showed sympathetic activation to sad stimuli: lonely (P = .04) and dying (P = .04). Depressive symptoms were correlated with respiratory resistance (r = .43; P = .001) and vagal bias in scene 3 (r = .24; P = .03), and vagal bias (scene 3) was correlated with postmovie airway resistance (r = 0.39; P = .004). Conclusions: Children with asthma and depressive symptoms manifest vagal bias when emotionally stressed. Those with depressive symptoms and FEV1<80% manifest greater air-way resistance. Depression, vagal bias, and airway resistance were intercorrelated for the full sample. (J Allergy Clin Immunol 2009;124:66-73.)	[Miller, Bruce D.; Wood, Beatrice L.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY 14222 USA; [Miller, Bruce D.; Wood, Beatrice L.; Ballow, Mark] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14222 USA; [Hsu, ChiunYu] SUNY Buffalo, Sch Med & Biomed Sci, Grad Program Neurosci, Buffalo, NY 14222 USA; [Lim, JungHa] Korea Univ, Dept Home Econ Educ, Seoul, South Korea	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Korea University	Miller, BD (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Womens & Childrens Hosp, Dept Psychiat,Child & Family Asthma Studies Ctr, 219 Bryant St, Buffalo, NY 14222 USA.	brumill@buffalo.edu			National Institutes of Health [5R01MH058761, 1R01MH064154]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058761, R01MH064154] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Supported in part by grants 5R01MH058761 (B.D.M.) and 1R01MH064154 (B.L.W.) from the National Institutes of Health.	Aboussafy D, 2005, INT J PSYCHOPHYSIOL, V57, P195, DOI 10.1016/j.ijpsycho.2005.02.004; Anthonisen NR, 2005, EUR RESPIR J, V26, P45, DOI 10.1183/09031936.05.00102604; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bender B, 1998, J ASTHMA, V35, P347, DOI 10.3109/02770909809075667; Bender BG, 2002, J ALLERGY CLIN IMMUN, V109, pS554, DOI 10.1067/mai.2002.124570; Bender B, 2008, J ALLERGY CLIN IMMUN, V122, P490, DOI 10.1016/j.jaci.2008.05.041; Bender BG, 2008, ANN ALLERG ASTHMA IM, V101, P382, DOI 10.1016/S1081-1206(10)60314-6; Bender BG, 2007, PEDIATRICS, V120, pE471, DOI 10.1542/peds.2006-3457; Berntson GG, 2008, PSYCHOPHYSIOLOGY, V45, P643, DOI 10.1111/j.1469-8986.2008.00652.x; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Beydon N, 2002, AM J RESP CRIT CARE, V165, P1388, DOI 10.1164/rccm.2011082; BOWERFIND M, 2003, MIDDLETONS ALLERGY P, P929; Brown ES, 2005, BIOL PSYCHIAT, V58, P865, DOI 10.1016/j.biopsych.2005.04.030; Busse WW, 2003, MIDDLETONS ALLERGY P, P1175; Butz AM, 2005, ANN ALLERG ASTHMA IM, V94, P360, DOI 10.1016/S1081-1206(10)60988-X; Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; ENGEL GL, 1978, ANN INTERN MED, V89, P403, DOI 10.7326/0003-4819-89-3-403; FREUND A, 1991, HEALTH PSYCHOL, V10, P200, DOI 10.1037/0278-6133.10.3.200; Katon W, 2007, J ADOLESCENT HEALTH, V41, P455, DOI 10.1016/j.jadohealth.2007.05.023; Kaugars AS, 2004, J PEDIATR PSYCHOL, V29, P475, DOI 10.1093/jpepsy/jsh051; Klinnert MD, 2008, FAM PROCESS, V47, P41, DOI 10.1111/j.1545-5300.2008.00238.x; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Lehrer PM, 2004, CHEST, V126, P352, DOI 10.1378/chest.126.2.352; Lim JH, 2008, J FAM PSYCHOL, V22, P264, DOI 10.1037/0893-3200.22.2.264; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430, DOI 10.1097/00004703-200112000-00011; MEARES RA, 1971, MED J AUSTRALIA, V2, P25, DOI 10.5694/j.1326-5377.1971.tb50396.x; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; Miller BD, 1997, J AM ACAD CHILD PSY, V36, P669, DOI 10.1097/00004583-199705000-00018; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; MILLER BD, 2003, SOCIAL PSYCHOL FACTO, P131; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; MOSS MH, 2003, MIDDLETONS ALLERGY P, P1225; Mrazek DA, 2003, CHILD ADOL PSYCH CL, V12, P459, DOI 10.1016/S1056-4993(03)00028-2; *NAT HEART LUNG BL, 2003, NIH PUB; PHAGOO SB, 1995, J APPL PHYSIOL, V79, P518, DOI 10.1152/jappl.1995.79.2.518; Porges S. W., 1990, PRINCIPLES PSYCHOPHY, P708; Quigley KS, 2006, PSYCHOPHYSIOLOGY, V43, P357, DOI 10.1111/j.1469-8986.2006.00405.x; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; REITE M, 1978, BIOL PSYCHIAT, V13, P91; Ritz T, 2005, PSYCHOPHYSIOLOGY, V42, P568, DOI 10.1111/j.1469-8986.2005.00312.x; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SHERWOOD A, 1993, CARDIOVASCULAR REACTIVITY TO PSYCHOLOGICAL STRESS & DISEASE, P157, DOI 10.1037/10125-007; Stoodley RG, 1999, ANN EMERG MED, V34, P8, DOI 10.1016/S0196-0644(99)70266-0; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUGIHARA H, 1965, ANN ALLERGY, V23, P422; Timonen M, 2008, BMJ-BRIT MED J, V336, P435, DOI 10.1136/bmj.39478.609097.BE; Twenge JM, 2002, J ABNORM PSYCHOL, V111, P578, DOI 10.1037//0021-843X.111.4.578; UNDEM B, 2003, MIDDLETONS ALLERGY P, P231; Waxmonsky J, 2006, J AM ACAD CHILD PSY, V45, P945, DOI 10.1097/01.chi.0000222789.34229.21; Wolf JM, 2008, BIOL PSYCHOL, V78, P20, DOI 10.1016/j.biopsycho.2007.12.004; Wood BL, 2007, J PEDIATR PSYCHOL, V32, P542, DOI 10.1093/jpepsy/jsl044; Wood BL, 2006, J AM ACAD CHILD PSY, V45, P1494, DOI 10.1097/01.chi.0000237711.81378.46; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066	62	44	46	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					66	73		10.1016/j.jaci.2009.04.038	http://dx.doi.org/10.1016/j.jaci.2009.04.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	469OR	19523670				2022-12-18	WOS:000267909700007
J	Balmes, JR; Earnest, G; Katz, PP; Yelin, EH; Eisner, MD; Chen, H; Trupin, L; Lurmann, F; Blanc, PD				Balmes, John R.; Earnest, Gillian; Katz, Patricia P.; Yelin, Edward H.; Eisner, Mark D.; Chen, Hubert; Trupin, Laura; Lurmann, Fred; Blanc, Paul D.			Exposure to traffic: Lung function and health status in adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; traffic; lung function; health status	QUALITY-OF-LIFE; AIR-POLLUTION; CHILDHOOD ASTHMA; CHILDREN; RHINITIS; OUTCOMES; IMPACT; ASSOCIATION; POPULATION; VALIDATION	Background: Exposure to traffic has been associated with asthma outcomes in children, but its effect on asthma in adults has not been well studied. Objective: To test the hypothesis that lung function and health status are associated with traffic exposures. Methods: We measured FEV(1) % predicted, general health status using the Physical Component Scale of the 12-item Short Form (SF-12 PCs), and quality of life (QoL) using the Marks Asthma Quality of Life questionnaire in a cohort of adults with asthma or rhinitis (n = 176; 145 with asthma). We assessed exposures to traffic by geocoding subjects' residential addresses and assigning distance to roadways. Associations between distance to nearest roadway and distance to nearest major roadway and FEV(1) % predicted or SF-12 PCs were studied by using linear regression. Results: FEV(1) % predicted was positively associated with distance from both nearest roadway (P = .01) and nearest major roadway (P = .02). SF-12 PCs and QoL were not significantly associated with either traffic variable. Adjustment for income, smoking, and obesity did not substantively change the associations of the traffic variables with FEV(1) % predicted (P = .04 for nearest roadway and P = .02 for nearest major roadway) and did not cause associations with either SF-12 PCS or QoL to become significant. Conclusions: Traffic exposure was associated with decreased lung function in adults with asthma. (J Allergy Clin Immunol 2009;123:626-31.)	[Balmes, John R.; Earnest, Gillian; Katz, Patricia P.; Yelin, Edward H.; Eisner, Mark D.; Chen, Hubert; Trupin, Laura; Blanc, Paul D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Katz, Patricia P.; Yelin, Edward H.; Trupin, Laura] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; [Blanc, Paul D.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Balmes, John R.] Univ Calif Berkeley, Div Environm Hlth Sci, Sch Publ Hlth, Berkeley, CA 94720 USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Balmes, JR (corresponding author), Univ Calif San Francisco, Dept Med, Box 0843, San Francisco, CA 94143 USA.	john.balmes@ucsf.edu	Balmes, John/L-6281-2019	Chen, Hubert/0000-0002-6630-239X	National Institute of Environmental Health Sciences [R01 ES 10906]; National Institutes of Health; Flight Attendants Medical Research Institute (FAMRI); California Air Resource Board; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute/National Institutes of Health; University of Califorma-Berkeley; University of California-San Francisco; California State University-Fullerton; University of Southern California; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010906] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendants Medical Research Institute (FAMRI); California Air Resource Board; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Heart, Lung, and Blood Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Califorma-Berkeley; University of California-San Francisco(University of California System); California State University-Fullerton; University of Southern California; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Disclosure of potential conflict of interest: J. R. Balmes receives grant support from the National Institutes of Health, the Flight Attendants Medical Research Institute (FAMRI), the California Air Resource Board, and the Centers for Disease Control and Prevention and has provided legal consultation on air pollution health effects for the California Department of Justice. G. Earnest has received grant support from the National Institutes of Health. P. P. Katz has received grant support from the National Institutes of Health. E. H. Yelin has received grant support from the National Institutes of Health. M. D. Eisner has received grant support from the National Heart, Lung, and Blood Institute/National Institutes of Health, the FAMRI, the National Institute of Environmental Health Sciences/National Institutes of Health, and Genentech and has provided legal consultation/expert witness testimony in cases related to pulmonary hypertension and reactive airways dysfunction syndrome. F. Lurmann has received grant support from the University of Califorma-Berkeley, the University of California-San Francisco, California State University-Fullerton, and the University of Southern California. P. D. Blanc receives grant support from the National Institutes of Health and FAMRI and has provided legal consultation/expert witness testimony in cases related to waterproofing inhalation injury. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BALMES EG, 2006, P AM THORAC SOC, V3, pA43; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Blanc PD, 1999, CHEST, V115, P1259, DOI 10.1378/chest.115.5.1259; Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; Blanc PD, 2006, EUR RESPIR J, V27, P85, DOI 10.1183/09031936.06.00061205; Blanc PD, 2005, J OCCUP ENVIRON MED, V47, P362, DOI 10.1097/01.jom.0000158708.32491.9d; Blanc PD, 2003, AM J MED, V114, P581, DOI 10.1016/S0002-9343(03)00053-6; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Eisner MD, 2002, THORAX, V57, P973, DOI 10.1136/thorax.57.11.973; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059, DOI 10.1080/10473289.2005.10464708; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Heinrich J, 2005, OCCUP ENVIRON MED, V62, P517, DOI 10.1136/oem.2004.016766; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Katz PP, 1999, J CLIN EPIDEMIOL, V52, P667, DOI 10.1016/S0895-4356(99)00026-8; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-281OC; Larsson BM, 2007, EUR RESPIR J, V29, P699, DOI 10.1183/09031936.00035706; Lwebuga-Mukasa JS, 2004, J ASTHMA, V41, P289, DOI 10.1081/JAS-120026086; MacNee W, 2007, CLIN CHEST MED, V28, P479, DOI 10.1016/j.ccm.2007.06.008; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Meng YY, 2007, ANN ALLERG ASTHMA IM, V98, P455, DOI 10.1016/S1081-1206(10)60760-0; Morris SE, 2000, J EPIDEMIOL COMMUN H, V54, P75, DOI 10.1136/jech.54.1.75; Mortimer KM, 2003, CHEST, V123, P1899, DOI 10.1378/chest.123.6.1899; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Ramos RG, 2006, J ENVIRON HEALTH, V68, P26; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; Yen IH, 2008, HEALTH PLACE, V14, P468, DOI 10.1016/j.healthplace.2007.09.003; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032, DOI 10.1080/10473289.2002.10470842; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	38	44	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					626	631		10.1016/j.jaci.2008.10.062	http://dx.doi.org/10.1016/j.jaci.2008.10.062			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19152968	Green Accepted			2022-12-18	WOS:000264731200021
J	Metcalfe, DD; Schwartz, LB				Metcalfe, Dean D.; Schwartz, Lawrence B.			Assessing anaphylactic risk? Consider mast cell clonality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Anaphylaxis; tryptase; mast cells; KIT; venom	SYSTEMIC MASTOCYTOSIS; HUMAN TRYPTASE; KIT; BLOOD		[Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Commonwealth University	Metcalfe, DD (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C-207A,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	dmetcalfe@niaid.nih.gov; lbschwar@vcu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, ZIAAI000513] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000249-27] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Iwaki S, 2008, CELL SIGNAL, V20, P195, DOI 10.1016/j.cellsig.2007.10.013; Jensen BM, 2008, J PHARMACOL EXP THER, V324, P128, DOI 10.1124/jpet.107.125237; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Muller UR, 2009, CURR ALLERGY ASTHM R, V9, P64, DOI 10.1007/s11882-009-0010-9; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005	20	44	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					687	688		10.1016/j.jaci.2009.02.003	http://dx.doi.org/10.1016/j.jaci.2009.02.003			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281912	Green Accepted			2022-12-18	WOS:000264731200031
J	Pinto, JM; Schneider, J; Perez, R; DeTineo, M; Baroody, FM; Naclerio, RM				Pinto, Jayant M.; Schneider, John; Perez, Rosanne; DeTineo, Marcella; Baroody, Fuad M.; Naclerio, Robert M.			Serum 25-hydroxyvitamin levels are lower in urban African American subjects with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-D; AGE; PREVALENCE; DEFICIENCY; PREGNANCY; ASTHMA; WOMEN		[Pinto, Jayant M.; Schneider, John; Perez, Rosanne; DeTineo, Marcella; Baroody, Fuad M.; Naclerio, Robert M.] Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	University of Chicago	Pinto, JM (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA.	jpinto@surgery.bsd.uchicago.edu						Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; GLANTZ SA, 2002, PRIMER BIOSTATISTICS, P79; GLIKLICH RE, 1994, AM J RHINOL, V8, P291, DOI 10.2500/105065894781874197; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Maggio D, 2005, J GERONTOL A-BIOL, V60, P1414, DOI 10.1093/gerona/60.11.1414; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; Shashy RG, 2004, ARCH OTOLARYNGOL, V130, P320, DOI 10.1001/archotol.130.3.320; Sigmundsdottir H, 2007, NAT IMMUNOL, V8, P285, DOI 10.1038/ni1433; Weiss ST, 2008, CLIN EXP ALLERGY, V38, P385, DOI 10.1111/j.1365-2222.2007.02920.x; Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	14	44	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					415	417		10.1016/j.jaci.2008.05.038	http://dx.doi.org/10.1016/j.jaci.2008.05.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18585770	Bronze			2022-12-18	WOS:000258426300033
J	Poole, JA; Alexis, NE; Parks, C; MacInnes, AK; Gentry-Nielsen, MJ; Fey, PD; Larsson, L; Allen-Gipson, D; Von Essen, SG; Romberger, DJ				Poole, Jill A.; Alexis, Neil E.; Parks, Conrad; MacInnes, Amy K.; Gentry-Nielsen, Martha J.; Fey, Paul D.; Larsson, Lennart; Allen-Gipson, Diane; Von Essen, Susanna G.; Romberger, Debra J.			Repetitive organic dust exposure in vitro impairs macrophage differentiation and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte; macrophage; organic dust; phagocytosis; intracellular killing; cell surface molecules; cytokines; inflammation; LPS; peptidoglycan	OBSTRUCTIVE PULMONARY-DISEASE; HUMAN ALVEOLAR MACROPHAGES; HEALTHY-VOLUNTEERS; EPITHELIAL-CELLS; MONOCYTES; FARMERS; VIVO; PHAGOCYTOSIS; INFLAMMATION; LYMPHOCYTES	Organic dust exposure in the agricultural industry results in significant airway disease and lung function decrease. Mononuclear phagocytes are key cells that mediate the inflammatory and innate immune response after dust exposure. Objective: We sought to investigate the effect of organic dust extract (ODE) from modern swine operations on monocyte-derived macrophage (MDM) phenotype and function. Methods: Peripheral blood monocytes were obtained by means of elutriation methodology (> 99% CD14(+)) and differentiated into macrophages in the presence of GM-CSF (1 week) with and without ODE (0.1 %). At 1 week, cells were analyzed by means of flow cytometry for cell-surface marker expression (HLA-DR, CD80, CD86, Toll-like receptor 2, Toll-like receptor 4, mCD14, and CD16), phagocytosis (IgG-opsonized zymosan particles), and intracellular killing of Streptococcus pneumoniae. At 1 week, MDMs were rechallenged with high-dose ODE (1%), LPS, and peptidoglycan (PGN), and cytokine levels TNF-alpha, IL-6, IL-10, and CXCL8/IL-8) were measured. Comparisons were made to MDMs conditioned with heat-inactivated dust, endotoxin-depleted dust, LPS, and PGN to elucidate ODE-associated factors. Results: Expression of HLA-DR, CD80, and CD86; phagocytosis; and intracellular bacterial killing were significantly decreased with ODE-challenged versus control MDMs. Responses were retained after marked depletion of endotoxin. PGN, LPS, and PGN plus LPS significantly reduced MDM surface marker expression and, except for LPS alone, also reduced phagocytosis. ODE-challenged MDMs had significantly diminished cytokine responses (TNF-alpha, IL-6, and IL-10) after repeat challenge with high-dose ODE. Cross-tolerant cytokine responses were also observed. Conclusion: Repetitive organic dust exposure significantly decreases markers of antigen presentation and host defense function in MDMs. Bacterial cell components appear to be driving these impaired responses.	[Poole, Jill A.; Parks, Conrad; MacInnes, Amy K.; Allen-Gipson, Diane; Von Essen, Susanna G.; Romberger, Debra J.] Univ Nebraska Med Ctr, Pulm Crit Care Sleep & Allergy Sect, Dept Internal Med, Omaha, NE 68198 USA; [Fey, Paul D.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Poole, Jill A.; Parks, Conrad; Gentry-Nielsen, Martha J.; Romberger, Debra J.] Omaha Vet Adm Med Ctr, Omaha, NE USA; [Alexis, Neil E.] Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; [Gentry-Nielsen, Martha J.] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE USA; [Larsson, Lennart] Lund Univ, Dept Med Microbiol Dermatol & Infect, Lund, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Creighton University; Lund University	Poole, JA (corresponding author), Univ Nebraska Med Ctr, Pulm Crit Care Sleep & Allergy Sect, Dept Internal Med, 985300 Nebraska Med Ctr, Omaha, NE 68198 USA.	japoole@unmc.edu	Allen-Gipson, Diane/A-9044-2012	Allen-Gipson, Diane/0000-0001-6976-3960	National Institute of Environmental Health Sciences [K08: ES015522-01: JAP]; American Academy of Allergy, Asthma & Immunology Interest Section Grant Award (JAP); National Institute for Occupational Safety and Health [1R01OH008539-01: DJR]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL084684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH008539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES015522] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Academy of Allergy, Asthma & Immunology Interest Section Grant Award (JAP); National Institute for Occupational Safety and Health(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the National Institute of Environmental Health Sciences (K08: ES015522-01: JAP): and American Academy of Allergy, Asthma & Immunology Interest Section Grant Award (JAP): and the National Institute for Occupational Safety and Health (1R01OH008539-01: DJR).	Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2006, AM J RESP CELL MOL, V34, P305, DOI 10.1165/rcmb.2005-0373OC; Arjomandi M, 2005, AM J RESP CRIT CARE, V172, P427, DOI 10.1164/rccm.200502-272OC; Balbo P, 2001, CLIN EXP ALLERGY, V31, P625, DOI 10.1046/j.1365-2222.2001.01068.x; Berenson CS, 2006, J INFECT DIS, V194, P1375, DOI 10.1086/508428; Berenson CS, 2006, AM J RESP CRIT CARE, V174, P31, DOI 10.1164/rccm.200509-1461OC; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; GENTRY MJ, 1995, J INFECT DIS, V171, P350, DOI 10.1093/infdis/171.2.350; Hashimoto S, 2001, J IMMUNOL, V167, P3619, DOI 10.4049/jimmunol.167.7.3619; Larsson BM, 1999, INFLAMMATION, V23, P217; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Lensmar C, 2006, RESP MED, V100, P918, DOI 10.1016/j.rmed.2005.08.014; LEONG PA, 1984, INFECT IMMUN, V45, P378, DOI 10.1128/IAI.45.2.378-383.1984; Lofdahl JM, 2006, CLIN EXP IMMUNOL, V145, P428, DOI 10.1111/j.1365-2249.2006.03154.x; Maus UA, 2006, AM J RESP CELL MOL, V35, P227, DOI 10.1165/rcmb.2005-0241OC; Mokart D, 2003, CHEST, V124, P644, DOI 10.1378/chest.124.2.644; Muller-Suur C, 2002, EUR RESPIR J, V20, P686, DOI 10.1183/09031936.02.02002002; Palmberg L, 2002, SCAND J WORK ENV HEA, V28, P256, DOI 10.5271/sjweh.673; Pons AR, 2005, EUR RESPIR J, V25, P647, DOI 10.1183/09031936.05.00062304; Poole JA, 2007, J ALLERGY CLIN IMMUN, V120, P366, DOI 10.1016/j.jaci.2007.04.033; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Romberger DJ, 2002, J APPL PHYSIOL, V93, P289, DOI 10.1152/japplphysiol.00815.2001; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Von Essen S, 2003, J Agric Saf Health, V9, P185; WAHL SM, 1984, CELL IMMUNOL, V85, P384, DOI 10.1016/0008-8749(84)90252-1; Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261, DOI 10.1164/ajrccm.154.5.8912733; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Yin XJJ, 2007, J TOXICOL ENV HEAL A, V70, P820, DOI 10.1080/15287390701209766; ZEJDA JE, 1993, CHEST, V103, P702, DOI 10.1378/chest.103.3.702	31	44	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					375	382		10.1016/j.jaci.2008.05.023	http://dx.doi.org/10.1016/j.jaci.2008.05.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18585769	Green Accepted, Green Submitted			2022-12-18	WOS:000258426300026
J	Davoine, F; Cao, M; Wu, Y; Ajamian, F; Ilarraza, R; Kokaji, AI; Moqbel, R; Adamko, DJ				Davoine, Francis; Cao, Min; Wu, Yingqi; Ajamian, Farnam; Ilarraza, Ramses; Kokaji, Andy I.; Moqbel, Redwan; Adamko, Darryl J.			Virus-induced eosinophil mediator release requires antigen-presenting and CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; virus infection; asthma exacerbation; eosinophil peroxidase; leukotriene; T cell; macrophage; dendritic cell	LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RESPIRATORY-TRACT; VIRAL-INFECTIONS; AIRWAY HYPERRESPONSIVENESS; ASTHMA EXACERBATIONS; IMMUNE-RESPONSE; INFLUENZA-VIRUS; RHINOVIRUS; INFLAMMATION; REINFECTION	Background: The most frequent trigger of asthma exacerbation is infection with common airway viruses; however, the precise mechanism regulating such severe reactions is not understood. The presence of airway eosinophil products is a unique feature detected in asthmatic airways. Using an animal model, we previously demonstrated that T cells play an important role in regulating an eosinophil-dependant pathway of virus-induced airway hyperreactivity. We hypothesize that human eosinophils respond to viruses, although only after interaction with T cells. Objectives: We sought to determine whether eosinophils can respond to airway, viruses in vitro and determine the mechanism of response. Methods: An in vitro coculture model of human eosinophils, antigen-presenting cells, and T cells was used with parainfluenza virus, respiratory syncytial virus, or rhinovirus. We measured release of eosinophil peroxidase (EPO) in concert with T-cell proliferation, cytokine release, and changes in T-cell phenotype. Results: The viruses induced release of EPO when coincubated in the presence of antigen-presenting cells (dendritic cells or macrophages) and T cells. Virus-mediated release was associated with proliferation of CD3(+)CD4(+) T cells and release of cytokines. UV inactivation of the virus did not prevent virus-induced EPO release or T-cell proliferation. Proliferating CD4(+) T cells show increased expression of CD25 and CD45RO. CD8(+) T cells were not activated. Conclusion: Virus-induced EPO release can occur in the context of antigen presentation to CD4(+) T cells.	[Cao, Min; Wu, Yingqi; Ilarraza, Ramses; Adamko, Darryl J.] Univ Alberta, Fac Med & Dent, Div Pediat Pulm Med, Pulm Res Grp,Dept Pediat, Edmonton, AB T6G 2S2, Canada; [Kokaji, Andy I.] Univ Alberta, Dept Med Microbiol & Immunol, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; [Davoine, Francis; Ajamian, Farnam; Moqbel, Redwan; Adamko, Darryl J.] Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; [Davoine, Francis] Univ Alberta, Campus St Jean, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Adamko, DJ (corresponding author), Univ Alberta, Fac Med & Dent, Div Pediat Pulm Med, Pulm Res Grp,Dept Pediat, 567B HMRC, Edmonton, AB T6G 2S2, Canada.	dadamko@ualberta.ca						ADA GL, 1986, CURR TOP MICROBIOL, V128, P1; Adamko D, 2003, CURR OPIN PHARMACOL, V3, P227, DOI 10.1016/S1471-4892(03)00040-7; Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; Adamko DJ, 2004, J IMMUNOL METHODS, V291, P101, DOI 10.1016/j.jim.2004.05.003; Adamko DJ, 2003, AM J RESP CRIT CARE, V167, P550, DOI 10.1164/rccm.200206-506OC; ADAMKO DJ, 2008, J ALLERGY CLIN  0501; Andreoletti L, 2000, J MED VIROL, V61, P341, DOI 10.1002/1096-9071(200007)61:3&lt;341::AID-JMV10&gt;3.0.CO;2-0; BAKER DG, 1992, AM J PHYSIOL, V263, pL142, DOI 10.1152/ajplung.1992.263.1.L142; BARDIN PG, 1995, CHEST, V107, pS157, DOI 10.1378/chest.107.3_Supplement.157S; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CARLSEN KH, 1983, ACTA PAEDIATR SCAND, V72, P53, DOI 10.1111/j.1651-2227.1983.tb09663.x; COME JM, 2002, LANCET, V359, P831; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Davoine F, 2004, INT ARCH ALLERGY IMM, V134, P165, DOI 10.1159/000078650; de Kluijver J, 2002, EUR RESPIR J, V20, P274, DOI 10.1183/09031936.02.00247202; Emonet S, 2007, EMERG INFECT DIS, V13, P472, DOI 10.3201/eid1303.061141; Fischer SA, 2006, NEW ENGL J MED, V354, P2235, DOI 10.1056/NEJMoa053240; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; Gern JE, 1996, J IMMUNOL, V156, P621; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; GLEZEN WP, 1984, J INFECT DIS, V150, P851, DOI 10.1093/infdis/150.6.851; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Granoff A., 1999, ENCY VIROLOGY; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Guerrero-Plata A, 2006, AM J RESP CELL MOL, V34, P320, DOI 10.1165/rcmb.2005-0287OC; Hargreave FE, 2007, CURR OPIN ALLERGY CL, V7, P102, DOI 10.1097/ACI.0b013e328013e3c2; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jamieson DJ, 2006, AM J OBSTET GYNECOL, V194, P1532, DOI 10.1016/j.ajog.2005.11.040; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, pS46, DOI 10.1164/ajrccm/152.4_Pt_2.S46; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lee YM, 2008, AM J RESP CRIT CARE, V177, P208, DOI 10.1164/rccm.200612-1890OC; Mansbach JM, 2008, ACAD EMERG MED, V15, P111, DOI 10.1111/j.1553-2712.2007.00034.x; Meagher LC, 1996, J IMMUNOL, V156, P4422; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; ROBERTS NJ, 1982, INFECT IMMUN, V35, P1142, DOI 10.1128/IAI.35.3.1142-1146.1982; Rowe BH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000195.pub2; Schwarze J, 1999, J IMMUNOL, V162, P4207; Sivertson KL, 2007, CELL IMMUNOL, V246, P34, DOI 10.1016/j.cellimm.2007.05.003; Stockl J, 1999, J CLIN INVEST, V104, P957, DOI 10.1172/JCI7255; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; van Elden LJR, 2008, J CLIN VIROL, V41, P116, DOI 10.1016/j.jcv.2007.10.028; Welliver RC, 1998, SEMIN PERINATOL, V22, P87, DOI 10.1016/S0146-0005(98)80010-4; WINTHER B, 1990, AM REV RESPIR DIS, V141, P839, DOI 10.1164/ajrccm/141.4_Pt_1.839; Woodhead VE, 2000, INT IMMUNOL, V12, P1051, DOI 10.1093/intimm/12.7.1051; Yamaya M, 2003, VIRAL IMMUNOL, V16, P99, DOI 10.1089/088282403322017857	53	44	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					69	77		10.1016/j.jaci.2008.03.028	http://dx.doi.org/10.1016/j.jaci.2008.03.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18472150				2022-12-18	WOS:000257605100012
J	Hua, XY; Chason, KD; Fredholm, BB; Deshpande, DA; Penn, RB; Tilley, SL				Hua, Xiaoyang; Chason, Kelly D.; Fredholm, Bertil B.; Deshpande, Deepak A.; Penn, Raymond B.; Tilley, Stephen L.			Adenosine induces airway hyperresponsiveness through activation of A(3) receptors on mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperresponsiveness; adenosine; mast cell; asthma	SMOOTH-MUSCLE; INDUCED BRONCHOCONSTRICTION; SIGNALING CONTRIBUTES; INHALED ADENOSINE; ASTHMA; INFLAMMATION; MICE; OBSTRUCTION; RELEASE; GENE	Background: The mechanisms responsible for the development of airway hyperresponsiveness in asthma are poorly understood. Adenosine levels are high in the lungs of patients with asthma, but a role for adenosine in the development of this cardinal feature of asthma has not been previously reported. Objective: To determine the capacity of adenosine to induce airway hyperresponsiveness, and to investigate the mechanisms behind these effects of adenosine on airway physiology. Methods: Wild-type C57BL/6 mice were exposed to aerosolized adenosine analog adenosine-5' N-ethylcarboxamide (NECA), and subsequent hyperresponsiveness to methacholine was investigated by measuring airway mechanics after anesthesia and tracheostomy. Similar experiments were conducted with A(1)-deficient, A(3)-deficient, and mast cell-deficient mice, as well as with mast cell-deficient mice engrafted with wild-type (wt) or A(3)(-/-) mast cells. The effect of NECA on methacholine-induced tension development in ex vivo tracheal rings was also examined. Results: Exposure of wt mice to NECA resulted in the robust induction of airway hyperresponsiveness. NECA failed to induce hyperresponsiveness to methacholine in tracheal ring preps ex vivo, and NECA-induced airway hyperresponsiveness in vivo was not affected by the genetic inactivation of the A(1) adenosine receptor. In contrast, NECA-induced airway hyperresponsiveness was abolished in A(3) adenosine receptor-deficient mice and in mice deficient in mast cells. Reconstitution of mast cell-deficient mice with wt mast cells restored hyperresponsiveness, whereas reconstitution with A3 receptor-deficient mast cells did not. Conclusion: Adenosine induces airway hyperresponsiveness indirectly by activating A(3) receptors on mast cells.	[Hua, Xiaoyang; Chason, Kelly D.; Tilley, Stephen L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; [Hua, Xiaoyang; Chason, Kelly D.; Tilley, Stephen L.] Univ N Carolina, Pulm Immunobiol Lab, Dept Med, Div Pulm & Crit Care Med, Chapel Hill, NC 27599 USA; [Fredholm, Bertil B.] Karolinska Inst, Dept Physiol & Pharmacol, Mol Pharmacol Sect, Stockholm, Sweden; [Deshpande, Deepak A.; Penn, Raymond B.] Wake Forest Univ, Ctr Human Genom, Dept Internal Med, Winston Salem, NC 27109 USA; [Hua, Xiaoyang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430074, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Karolinska Institutet; Wake Forest University; Huazhong University of Science & Technology	Tilley, SL (corresponding author), Univ N Carolina, Pulm Immunobiol Lab, Dept Med, Div Pulm & Crit Care Med, 8033 Burnett Womack,CB 7219, Chapel Hill, NC 27599 USA.	stephen_tilley@med.unc.edu	Hua, Xiaoyang/T-5252-2019	Hua, Xiaoyang/0000-0001-6414-7712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071802, K99HL087560, R01HL058506, R29HL058506] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL058506, K99-HL-087560, K99 HL087560, HL71802, R01 HL071802, HL58506, R01 HL058506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI S, 1994, AM J PHYSIOL, V266, pL271, DOI 10.1152/ajplung.1994.266.3.L271; ALI S, 1994, J PHARMACOL EXP THER, V268, P1328; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Ball HA, 2004, CLIN REV ALLERG IMMU, V27, P207, DOI 10.1385/CRIAI:27:3:207; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Csoma Z, 2005, EUR RESPIR J, V25, P873, DOI 10.1183/09031936.05.00110204; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Dvorak A M, 1992, Immunol Ser, V57, P169; DVORAK AM, 1994, BLOOD, V83, P3600; Ethier MF, 2006, AM J RESP CELL MOL, V35, P496, DOI 10.1165/rcmb.2005-0290OC; Fredholm BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GERWINS P, 1992, P NATL ACAD SCI USA, V89, P7330, DOI 10.1073/pnas.89.16.7330; HOLGATE ST, 1987, ALLERGY, V42, P481, DOI 10.1111/j.1398-9995.1987.tb00369.x; Hua XY, 2007, AM J PHYSIOL-LUNG C, V293, pL25, DOI 10.1152/ajplung.00058.2007; Hua XY, 2007, J EXP MED, V204, P117, DOI 10.1084/jem.20061372; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Keir S, 2006, BRIT J PHARMACOL, V147, P720, DOI 10.1038/sj.bjp.0706663; Liu CQ, 2006, AM J PHYSIOL-LUNG C, V291, pL1177, DOI 10.1152/ajplung.00142.2006; Lommatzsch M, 2005, AM J RESP CRIT CARE, V171, P115, DOI 10.1164/rccm.200406-758OC; Ma B, 2006, J CLIN INVEST, V116, P1274, DOI 10.1172/JCI26372; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; McNamara N, 2004, FASEB J, V18, P1770, DOI 10.1096/fj.04-1964fje; Mohsenin A, 2006, CURR OPIN PULM MED, V12, P54, DOI 10.1097/01.mcp.0000199002.46038.cb; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; PHILLIPS GD, 1989, CLIN EXP ALLERGY, V19, P405, DOI 10.1111/j.1365-2222.1989.tb02406.x; PHILLIPS GD, 1989, EUR RESPIR J, V2, P210; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; Tilley SL, 2000, J CLIN INVEST, V105, P361, DOI 10.1172/JCI8253; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Ying S, 1997, J IMMUNOL, V158, P3539; Young HWJ, 2006, AM J RESP CELL MOL, V35, P549, DOI 10.1165/rcmb.2006-0060OC; Young HWJ, 2004, J IMMUNOL, V173, P1380, DOI 10.4049/jimmunol.173.2.1380; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zhong H, 2003, J IMMUNOL, V171, P338, DOI 10.4049/jimmunol.171.1.338	45	44	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					107	113		10.1016/j.jaci.2008.03.026	http://dx.doi.org/10.1016/j.jaci.2008.03.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18472152	Green Accepted, Green Published			2022-12-18	WOS:000257605100018
J	McDonald, KL; Huq, SI; Lix, LM; Becker, AB; Kozyrskyj, AL				McDonald, Kara L.; Huq, Shamima I.; Lix, Lisa M.; Becker, Allan B.; Kozyrskyj, Anita L.			Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DPT combination vaccine; childhood asthma; retrospective birth cohort; administrative health data	RANDOMIZED CONTROLLED-TRIAL; ALLERGIC DISEASE; ATOPIC DISORDERS; ANTIBIOTIC USE; CHILDREN; IMMUNIZATION; RESPONSES; JAPAN; BIRTH; SYMPTOMS	Background: Early childhood immunizations have been viewed as promoters of asthma development by stimulating a T(H)2-type immune response or decreasing microbial pressure, which shifts the balance between T(H)1 and T(H)2 immunity. Objective: Differing time schedules for childhood immunizations may explain the discrepant findings of an association with asthma reported in observational studies. This research was undertaken to determine whether timing of diphtheria, pertussis, tetanus (DPT) immunization has an effect on the development of childhood asthma by age 7 years. Methods: This was a retrospective longitudinal study of a cohort of children born in Manitoba in 1995. The complete immunization and health care records of cohort children from birth until age 7 years were available for analysis. The adjusted odds ratio for asthma at age 7 years according to timing of DPT immunization was computed from multivariable logistic regression. Results: Among 11, 531 children who received at least 4 doses of DPT, the risk of asthma was reduced to 1/2 in children whose first dose of DPT was delayed by more than 2 months. The likelihood of asthma in children with delays in all 3 doses was 0.39 (95% Cl, 0.18-0.86). Conclusion: We found a negative association between delay in administration of the first dose of whole-cell DPT immunization in childhood and the development of asthma; the association was greater with delays in all of the first 3 doses. The mechanism for this phenomenon requires further research.	[McDonald, Kara L.; Lix, Lisa M.; Kozyrskyj, Anita L.] Univ Manitoba, Fac Med, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Huq, Shamima I.; Kozyrskyj, Anita L.] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; [Becker, Allan B.; Kozyrskyj, Anita L.] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada; [Huq, Shamima I.; Lix, Lisa M.; Kozyrskyj, Anita L.] Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Huq, Shamima I.; Kozyrskyj, Anita L.] Manitoba Inst Child Hlth, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Kozyrskyj, AL (corresponding author), Rm 210 Pharm Bldg, Winnipeg, MB R3T 2N2, Canada.	kozyrsk@cc.unnamtoba.ca						Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Anderson HR, 2001, AM J PUBLIC HEALTH, V91, P1126, DOI 10.2105/AJPH.91.7.1126; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bernsen RMD, 2006, VACCINE, V24, P2035, DOI 10.1016/j.vaccine.2005.10.056; Bernsen RMD, 2003, EUR RESPIR J, V22, P962, DOI 10.1183/09031936.03.00039803; BOBO JK, 1993, PEDIATRICS, V91, P308; Boyce TG, 2004, PEDIATR INFECT DIS J, V23, P897, DOI 10.1097/01.inf.0000141725.45280.6c; Bremner SA, 2005, ARCH DIS CHILD, V90, P567, DOI 10.1136/adc.2004.051714; Dannemann A, 1996, INT ARCH ALLERGY IMM, V111, P262, DOI 10.1159/000237376; Davis RL, 2005, EPIDEMIOLOGY, V16, P336, DOI 10.1097/01.ede.0000155506.05636.a4; Dinarello CA, 1999, J INFECT DIS, V179, pS294, DOI 10.1086/513856; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; Gruber C, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e282; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; Henderson J, 1999, BRIT MED J, V318, P1173, DOI 10.1136/bmj.318.7192.1173; *HLTH CAN, 2001, RESP DIS CAN, P33; Hurwitz EL, 2000, J MANIP PHYSIOL THER, V23, P81, DOI 10.1016/S0161-4754(00)90072-1; JOHNSTON S, 2002, ASTHMA CRITICAL DEBA; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Kozyrskyj AL, 2004, CAN MED ASSOC J, V171, P133, DOI 10.1503/cmaj.1031630; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; KOZYRSKYJ AL, 2005, ALLERGY ASTHMA CL IM, V1, P108; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Kuno-Sakai H, 2004, PEDIATR INT, V46, P650, DOI 10.1111/j.1442-200x.2004.01970.x; Laskar MS, 2005, PUBLIC HEALTH, V119, P659, DOI 10.1016/j.puhe.2004.08.019; Levy O, 2005, J ENDOTOXIN RES, V11, P113, DOI 10.1179/096805105X37376; Maher JE, 2004, PHARMACOEPIDEM DR S, V13, P1, DOI 10.1002/pds.821; Maitra A, 2004, BRIT MED J, V328, P925, DOI 10.1136/bmj.38045.858889.EB; *MAN HLTH, 1997, MAN IMM MONT SYST RE; Marodi L, 2002, CLIN EXP IMMUNOL, V128, P1, DOI 10.1046/j.1365-2249.2002.01873.x; McKeever TM, 2004, AM J PUBLIC HEALTH, V94, P985, DOI 10.2105/AJPH.94.6.985; Millar W J, 1998, Health Rep, V10, P9; Mohrenschlager M, 2007, PEDIAT ALLERG IMM-UK, V18, P5, DOI 10.1111/j.1399-3038.2006.00485.x; Mullooly JP, 2002, PHARMACOEPIDEM DR S, V11, P21, DOI 10.1002/pds.678; Nakatani H, 2002, JPN J INFECT DIS, V55, P101; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; Nilsson L, 1998, ALLERGY, V53, P1195, DOI 10.1111/j.1398-9995.1998.tb03841.x; Nilsson L, 2003, ARCH PEDIAT ADOL MED, V157, P1184, DOI 10.1001/archpedi.157.12.1184; OHKUNI H, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P51; Richards A, 1999, AUST NZ J PUBL HEAL, V23, P315, DOI 10.1111/j.1467-842X.1999.tb01263.x; Robinson JR, 1997, MED CARE, V35, P932, DOI 10.1097/00005650-199709000-00006; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Rook Graham A W, 2002, Biologist (London), V49, P145; Sato Y, 1999, BIOLOGICALS, V27, P61, DOI 10.1006/biol.1999.0181; Sporton RK, 2001, FAM PRACT, V18, P181, DOI 10.1093/fampra/18.2.181; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Williams LK, 2005, J ALLERGY CLIN IMMUN, V116, P102, DOI 10.1016/j.jaci.2005.04.021	49	44	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					626	631		10.1016/j.jaci.2007.11.034	http://dx.doi.org/10.1016/j.jaci.2007.11.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18207561				2022-12-18	WOS:000253918900013
J	Gober, LM; Sterba, PM; Eckman, JA; Saini, SS				Gober, L. M.; Sterba, P. M.; Eckman, J. A.; Saini, S. S.			Effect of Anti-IgE (Omalizumab) in chronic idiopathic urticaria (CIU) patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 14-18, 2008	Philadelphia, PA	Amer Acad Allergy, Asthma & Immunol					[Gober, L. M.; Sterba, P. M.; Eckman, J. A.; Saini, S. S.] Johns Hopkins Univ, Baltimore, MD 21218 USA	Johns Hopkins University									0	44	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		1		566	S147	S147		10.1016/j.jaci.2007.12.1121	http://dx.doi.org/10.1016/j.jaci.2007.12.1121			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266HZ					2022-12-18	WOS:000253426401030
J	Yoneyama, S; Kawai, K; Tsuno, NH; Okaji, Y; Asakage, M; Tsuchiya, T; Yamada, J; Sunami, E; Osada, T; Kitayama, J; Takahashi, K; Nagawa, H				Yoneyama, Satomi; Kawai, Kazushige; Tsuno, Nelson H.; Okaji, Yurai; Asakage, Masahiro; Tsuchiya, Takeshi; Yamada, Jun; Sunami, Eiji; Osada, Takuya; Kitayama, Joji; Takahashi, Koki; Nagawa, Hirokazu			Epigallocatechin gallate affects human dendritic cell differentiation and maturation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; EGCG; IL-10; antigen presentation; maturation; corticosteroids	GREEN-TEA; ENDOCYTIC ACTIVITY; MANNOSE RECEPTOR; IN-VITRO; INTERLEUKIN-10; IL-10; POLYPHENOL; MONOCYTES; INVOLVEMENT; ACTIVATION	Background: Epigallocatechin gallate (EGCG), a component of green tea catechin with the strongest biological activity, has been focused in recent years because of its anti-inflammatory and immunomodulatory activities. Dendritic cells (DCs) are professional antigen-presenting cells, capable of priming naive T cells, and play the key roles in the activation of T-cell-mediated immune responses. Objective: We aimed to investigate the effect of EGCG on human monocyte-derived DCs (MODCs) and, consequently, on the T-cell-mediated immune response. Methods: The induction of apoptosis, and the detailed phenotypic and functional changes of MODCs, generated by culture of peripheral blood monocytes in the presence of GM-CSF and IL-4, induced by EGCG was investigated and compared with the effects of dexamethasone. Results: Epigallocatechin gallate induced apoptosis and affected the phenotype of the developing DCs. The expressions of CD83, CD80, CD11c, and MHC class II, which are molecules essential for antigen presentation by DCs, were downregulated by EGCG. EGCG also suppressed the endocytotic ability of immature DCs, whereas dexamethasone-treated DCs had higher endocytotic ability than control DCs. Most importantly, mature DCs treated with EGCG inhibited stimulatory activity toward allogeneic T cells while secreting high amounts of IL-10. Conclusion: Epigallocatechin gallate induces immunosuppressive alterations on human MODCs, both by induction of apoptosis and suppression of cell surface molecules and antigen presentation.	[Yoneyama, Satomi; Kawai, Kazushige; Tsuno, Nelson H.; Asakage, Masahiro; Tsuchiya, Takeshi; Yamada, Jun; Sunami, Eiji; Osada, Takuya; Kitayama, Joji; Nagawa, Hirokazu] Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan; [Tsuno, Nelson H.; Takahashi, Koki] Univ Tokyo, Fac Med, Dept Transfus Med, Tokyo, Japan	University of Tokyo; University of Tokyo	Yoneyama, S (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yoneyamas-tky@umin.ac.jp	Kawai, Kazushige/AAF-4334-2020	Kawai, Kazushige/0000-0002-5881-0036				Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Bellette BM, 2003, IMMUNOLOGY, V110, P466, DOI 10.1111/j.1365-2567.2003.01759.x; Blotta MH, 1997, J IMMUNOL, V158, P5589; Bors W, 1987, Free Radic Res Commun, V2, P289, DOI 10.3109/10715768709065294; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Cippitelli M, 1998, EUR J IMMUNOL, V28, P3017, DOI 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.3.CO;2-Y; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Fujimura Y, 2006, BIOCHEM BIOPH RES CO, V348, P524, DOI 10.1016/j.bbrc.2006.07.086; Hashimoto F, 2003, BIOSCI BIOTECH BIOCH, V67, P396, DOI 10.1271/bbb.67.396; Higashi N, 2005, J LAB CLIN MED, V145, P316, DOI 10.1016/j.lab.2005.03.017; ISEMURA M, 1993, CELL BIOL INT, V17, P559, DOI 10.1006/cbir.1993.1099; Jeong YI, 2007, BIOCHEM BIOPH RES CO, V354, P1004, DOI 10.1016/j.bbrc.2007.01.076; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Kawai K, 2005, J ALLERGY CLIN IMMUN, V115, P186, DOI 10.1016/j.jaci.2004.10.005; Kawai K, 2004, J ALLERGY CLIN IMMUN, V113, P1211, DOI 10.1016/j.jaci.2004.02.044; Lambert JD, 2003, MUTAT RES-FUND MOL M, V523, P201, DOI 10.1016/S0027-5107(02)00336-6; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Longoni D, 1998, INT J CLIN LAB RES, V28, P162, DOI 10.1007/s005990050037; MOSER M, 1995, EUR J IMMUNOL, V25, P2818, DOI 10.1002/eji.1830251016; Nakagawa K, 1997, ANAL BIOCHEM, V248, P41, DOI 10.1006/abio.1997.2098; Nance CL, 2003, J ALLERGY CLIN IMMUN, V112, P851, DOI 10.1016/j.jaci.2003.08.048; Novak N, 2001, J ALLERGY CLIN IMMUN, V108, P588, DOI 10.1067/mai.2001.118597; Palucka KA, 1998, J IMMUNOL, V160, P4587; Piemonti L, 1999, J IMMUNOL, V162, P6473; Piemonti L, 1999, INT IMMUNOL, V11, P1519, DOI 10.1093/intimm/11.9.1519; Rea D, 2000, BLOOD, V95, P3162, DOI 10.1182/blood.V95.10.3162.010k18_3162_3167; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sazuka M, 1995, CANCER LETT, V98, P27; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Tang Ling-ling, 2005, J Zhejiang Univ Sci B, V6, P1176, DOI 10.1631/jzus.2005.B1176; Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205; van der Merwe PA, 2000, NAT IMMUNOL, V1, P194, DOI 10.1038/79729; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; Wolf AM, 2006, HAEMATOLOGICA, V91, P1165; Xia CQ, 2003, SCAND J IMMUNOL, V58, P23, DOI 10.1046/j.1365-3083.2003.01268.x; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	40	44	48	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					209	214		10.1016/j.jaci.2007.08.026	http://dx.doi.org/10.1016/j.jaci.2007.08.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17935769	Bronze			2022-12-18	WOS:000252372000032
J	King, EM; Vailes, LD; Tsay, A; Satinover, SM; Chapman, MD				King, Eva-Maria; Vailes, Lisa D.; Tsay, Amy; Satinover, Shama M.; Chapman, Martin D.			Simultaneous detection of total and allergenspecific IgE by using purified allergens in a fluorescent multiplex array	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						multiplex array; total IgE; allergen-specific IgE; enzyme immunoassay; allergic sensitization; allergy diagnostics; asthma	LINKED-IMMUNOSORBENT-ASSAY; FLOW-CYTOMETRIC ASSAY; DIAGNOSTIC GATEKEEPERS; RECOMBINANT ALLERGENS; RISK-FACTORS; ANTIBODIES; ASTHMA; QUANTITATION; SERUM; SENSITIZATION	Background: Testing serum samples for total and allergen-specific IgE requires separate testing for each antibody and allergen specificity. Objective: To apply fluorescent suspension array technology to allow simultaneous detection of total and allergen-specific IgE in serum in a single quantitative test. Methods: A 7-plex suspension array for the simultaneous detection of total IgE and IgE specific to Der p 1, Der p 2, Fel d 1, Can f 1, Bet v 1, and Phl p 5 was developed, using mAb or purified allergens covalently coupled to fluorescent microspheres. The multiplex array was validated by comparing total and allergen-specific IgE levels in serum from patients with allergy with results obtained by enzyme immunoassays. Results: There was a highly significant correlation between total IgE levels measured by multiplex array and fluorescent enzyme immunoassay (r = 0.97; P <.001; n = 63). Total and allergen-specific IgE levels also correlated with enzyme-linked and fluorescent enzyme immunoassay results (r = 0.44-0.94; n 95 or 106). The multiplex array was reproducible (r 0.86-0.99; mean coefficient of variance percentage, 12% to 25%). The sample volume required for a 7-plex assay was <20 mu L per sample, compared with >400 mu L in current immunoassays. Conclusion: The multiplex array is a high-throughput system that allows simultaneous quantification of allergen-specific and total IgE. Clinical implications: Our results suggest that fluorescent multiplex technology will facilitate large-scale epiderniologic studies of allergic sensitization. The reduced serum volume is an advantage for pediatric studies.	Indoor Biotechnol Inc, Charlottesville, VA 22903 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	INDOOR Biotechnologies; University of Virginia	King, EM (corresponding author), Indoor Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	eking@inbio.com		Chapman, Martin/0000-0002-0845-3632				Bernstein JA, 2003, ENVIRON HEALTH PERSP, V111, P1114; Biagini RE, 2004, CLIN DIAGN LAB IMMUN, V11, P50, DOI 10.1128/CDLI.11.1.50-55.2004; Biagini RE, 2005, ANAL BIOANAL CHEM, V382, P1027, DOI 10.1007/s00216-005-3204-6; Biagini RE, 2003, CLIN DIAGN LAB IMMUN, V10, P744, DOI 10.1128/CDLI.10.5.744-750.2003; Boquete M, 2006, J INVEST ALLERG CLIN, V16, P169; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Earle CD, 2007, J ALLERGY CLIN IMMUN, V119, P428, DOI 10.1016/j.jaci.2006.11.004; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Kellar KL, 2001, CYTOMETRY, V45, P27, DOI 10.1002/1097-0320(20010901)45:1<27::AID-CYTO1141>3.0.CO;2-I; King EM, 2007, J ALLERGY CLIN IMMUN, V119, pS265, DOI 10.1016/j.jaci.2006.12.407; Lal G, 2004, CLIN DIAGN LAB IMMUN, V11, P272, DOI 10.1128/CDLI.11.2.272-279.2004; McBride MT, 2003, ANAL CHEM, V75, P1924, DOI 10.1021/ac026379k; Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Prabhakar U, 2004, J IMMUNOL METHODS, V291, P27, DOI 10.1016/j.jim.2004.04.018; Ree R, 2004, ALLERGY, V59, P571, DOI 10.1111/j.1398-9995.2004.00499.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x; Wohrl S, 2006, ALLERGY, V61, P633, DOI 10.1111/j.1398-9995.2006.01078.x	29	44	44	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1126	1131		10.1016/j.jaci.2007.06.043	http://dx.doi.org/10.1016/j.jaci.2007.06.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17825887				2022-12-18	WOS:000250973400022
J	Rosengren, S; Mueller, JL; Anderson, JP; Niehaus, BL; Misaghi, A; Anderson, S; Boyle, DL; Hoffman, HM				Rosengren, Sanna; Mueller, James L.; Anderson, Justin P.; Niehaus, Brian L.; Misaghi, Amirhossein; Anderson, Scott; Boyle, David L.; Hoffman, Hal M.			Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cold; autoinflammatory syndrome; cryopyrin; C1AS1; interleukin-1 beta; monocytes; caspase-1; anakinra; inflammation	NF-KAPPA-B; ARTICULAR SYNDROME; GENE-EXPRESSION; RELEASE; INFLAMMASOME; MUTATIONS; CRYOPYRIN; PYRIN; CELLS; INTERLEUKIN-1-BETA	Background: Familial cold autoinflammatory syndrome (FCAS) is characterized by rash, fever, and arthralgia in response to cold exposure. CIASI, the gene that codes for cryopyrin, is mutated in FCAS. Treatment with anakinra (IL-1 receptor antagonist) prevents symptoms, indicating a crucial role for IL-1 in this disease. Objective: To study cytokine responses to cold exposure in monocytes from subjects with FCAS. Methods: Adherence-enriched monocytes were incubated at 32 degrees C or 37 degrees C. Transcription and release of IL-1 beta, IL-6, and TNF-alpha were monitored by quantitative PCR and ELISA. Results: The FCAS monocytes but not control cells responded to 4 h incubation at 32 degrees C with significant secretion of IL-1 R. At 16 h, IL-1 beta, IL-6, and TNF-alpha were all significantly elevated in FCAS monoeytes at 32 degrees C. Increased cytokine transcription was observed in all monocytes at 4 hours, but at 16 hours it was only seen in FCAS monocytes incubated at 32 degrees C. Incubation at 32 degrees C for as little as I hour sufficed to induce measurable IL-1 beta release. Caspase-1 inhibitors prevented the cold-induced IL-1 beta release, whereas a purinergic antagonist did not. Anakinra had no effect on the early IL-1 beta release but significantly reduced the latephase transcription and release of all cytokines. Conclusion: FCAS monocytes respond to mild hypothermia with IL-1 beta release, which in turn induces autocrine transcription and secretion of IL-6 and TNF-alpha as well as stimulation of further IL-1 beta production. Clinical implications: These results confirm the central role of IL-1 beta in FCAS and support the use of IL-1 targeted therapy in these patients.	Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Ludwig Inst Canc Res, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research	Hoffman, HM (corresponding author), Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, UCSD Mail Code 0635,9500 Gilman Dr, La Jolla, CA 92093 USA.	hahoffman@ucsd.edu			NCRR NIH HHS [M01 RR00827, M01 RR000827] Funding Source: Medline; NIAID NIH HHS [R01 AI52430, R01 AI052430] Funding Source: Medline; NIAMS NIH HHS [P30 AR47360, P30 AR047360] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047360] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Boyle DL, 2003, ARTHRITIS RES THER, V5, pR352, DOI 10.1186/ar1004; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Fujita Jun, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P243; Grahames CBA, 1999, BRIT J PHARMACOL, V127, P1915, DOI 10.1038/sj.bjp.0702732; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Janssen R, 2004, ARTHRITIS RHEUM, V50, P3329, DOI 10.1002/art.20494; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Lich JD, 2006, IMMUNITY, V24, P241, DOI 10.1016/j.immuni.2006.03.004; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; Sonna LA, 2006, PHYSIOL GENOMICS, V26, P91, DOI 10.1152/physiolgenomics.00296.2005; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734	30	44	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					991	996		10.1016/j.jaci.2006.12.649	http://dx.doi.org/10.1016/j.jaci.2006.12.649			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17320940	Green Accepted			2022-12-18	WOS:000245729500031
J	Wells, JW; Cowled, CJ; Giorgini, A; Kemeny, DM; Noble, A				Wells, James W.; Cowled, Christopher J.; Giorgini, Angela; Kemeny, David M.; Noble, Alistair			Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD8(+) T lymphocytes; dendritic cells; inflammation; lung; IL-12	DENDRITIC CELLS; CROSS-PRESENTATION; RESPIRATORY-TRACT; CUTTING EDGE; IFN-GAMMA; BRONCHIAL HYPERRESPONSIVENESS; INDUCED SENSITIZATION; IMMUNE-RESPONSES; INTERFERON-GAMMA; ATOPIC ASTHMA	Background: CD8 T cells are known to respond to exogenous antigens through cross-presentation. The importance of the CD8 cell response in the lung after inhalation of allergen and its effects on asthmatic inflammation are less clear. Objective: We sought to determine the dynamics, nature, and immunoregulatory activities of the class I CD8 T-cell response to inhaled allergen. Methods: We studied a murine model of respiratory allergen sensitization, adoptive transfer of transgenic T cells, and flow cytometric analysis of lung infiltrates. Results: Class I-restricted CD8 T cells responded rapidly to inhaled allergen and dominated the acute infiltration of T cells into the lung after secondary exposure. CD8 cells in the lung expressed a type I phenotype and suppressed the systemic IgE response to subsequent immunization. Dendritic cells purified from conducting airways or lung tissue were highly efficient at cross-presentation of antigen into the class I pathway after intranasal challenge. Adoptive transfer of transgenic antigen-specific CD8, but not CD4, cells resulted in increased IL-12 levels and reduced IL-13 and IL-5 levels in bronchoalveolar lavage fluid, coupled with substantially reduced airway eosinophilia after repeated allergen inhalation, a process mimicked by intranasal administration of IL-12 and inhibited by anti-IL-12 antibody. Conclusion: The data suggest that CD8 cells specific for inhaled allergens are generated in draining lymph nodes but suppress allergic airway inflammation through induction of IL-12 in the lung during interaction with respiratory dendritic cells. Clinical implications: Novel peptide immunotherapeutics targeting the class I-restricted CD8 T-cell response to allergen represent a promising strategy for extrinsic asthma.	Guys Hosp, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England; Kings Coll London, MRC, Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Noble, A (corresponding author), Guys Hosp, Dept Asthma Allergy & Resp Sci, 5th Floor Thomas Guy House, London SE1 9RT, England.	alistair.noble@kcl.ac.uk	Cowled, Christopher JE/H-5308-2013; Noble, Alistair/E-9473-2010; Wells, James W./C-7480-2011	Cowled, Christopher JE/0000-0002-1969-9371; Wells, James W./0000-0002-9618-6940	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Bannai M, 2001, EUR J IMMUNOL, V31, P3361, DOI 10.1002/1521-4141(200111)31:11<3361::AID-IMMU3361>3.0.CO;2-Z; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.0.CO;2-L; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Das G, 1999, J EXP MED, V190, P881, DOI 10.1084/jem.190.6.881; Eynott PR, 2003, J PHARMACOL EXP THER, V304, P22, DOI 10.1124/jpet.102.040295; Finkelman FD, 2004, J IMMUNOL, V172, P3808, DOI 10.4049/jimmunol.172.6.3808; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Gorak-Stolinska P, 2001, J LEUKOCYTE BIOL, V70, P756; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Joetham A, 2005, AM J RESP CELL MOL, V33, P89, DOI 10.1165/rcmb.2004-0414OC; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lloyd CM, 2001, J IMMUNOL, V166, P2033, DOI 10.4049/jimmunol.166.3.2033; Mailliard RB, 2002, J EXP MED, V195, P473, DOI 10.1084/jem.20011662; Maini MK, 2000, J IMMUNOL, V165, P5729, DOI 10.4049/jimmunol.165.10.5729; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Melief CJM, 2002, IMMUNOL REV, V188, P177, DOI 10.1034/j.1600-065X.2002.18816.x; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; Nelson D, 2000, J IMMUNOL, V165, P6123, DOI 10.4049/jimmunol.165.11.6123; Noble A, 2003, IMMUNOLOGY, V109, P476, DOI 10.1046/j.1365-2567.2003.01687.x; RENZ H, 1994, J IMMUNOL, V152, P351; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; Sawicka E, 2004, EUR J IMMUNOL, V34, P2599, DOI 10.1002/eji.200425018; Schulz O, 2002, IMMUNOLOGY, V107, P183, DOI 10.1046/j.1365-2567.2002.01513.x; Sercan O, 2006, J IMMUNOL, V176, P735, DOI 10.4049/jimmunol.176.2.735; Stock P, 2004, EUR J IMMUNOL, V34, P1817, DOI 10.1002/eji.200324623; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Ying S, 1997, J IMMUNOL, V158, P3539; Yu P, 2003, J EXP MED, V197, P985, DOI 10.1084/jem.20021804; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	52	44	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					226	234		10.1016/j.jaci.2006.09.004	http://dx.doi.org/10.1016/j.jaci.2006.09.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208606				2022-12-18	WOS:000243622200032
J	Yoshisue, H; Kirkham-Brown, J; Healy, E; Holgate, ST; Sampson, AP; Davies, DE				Yoshisue, Hajime; Kirkham-Brown, Jody; Healy, Eugene; Holgate, Stephen T.; Sampson, Anthony P.; Davies, Donna E.			Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl lenkotriene; bronchial asthma; airway remodeling; fibroblast; epidermal growth factor; G protein-coupled receptor	MUSCLE-CELL PROLIFERATION; PULMONARY-ARTERY; FACTOR RECEPTOR; UP-REGULATION; ANTAGONIST; ASTHMA; IL-13; EGF; TRANSACTIVATION; INFLAMMATION	Background: Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein-coupled,receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R). Objective: Because many G protein-coupled receptors transactivate the epidermal growth factor receptor (EGFR) through metalloprotease-mediated ligand shedding, we investigated the effects of cys-LTs on signal transduction and proliferation of bronchial fibroblasts. Methods: Human bronchial fibroblasts were grown from biopsy specimens of healthy subjects. Mitogenesis was assessed on the basis of tritiated methylthymidine incorporation. Results: Leukotriene (LT) D-4 alone did not increase mitogenesis but dose-dependently increased thymidine incorporation and cell proliferation in the presence of epidermal growth factor (EGF). The enhancement was not prevented by CysLT1R antagonists (MK-571 and montelukast) or by a dual antagonist (BAY u9773), which is consistent with the lack of detectable mRNA for CysLT1R and CysLT2R in bronchial fibroblasts. LTD4 did not cause EGFR transphosphoryiation nor was the synergism blocked by the metalloprotease inhibitor GM6001. The EGFR-selective kinase inhibitor AG1478 suppressed the synergy between LTD4 and EGF but had no effect on synergistic interactions of LTD4 with other receptor tyrosine kinase growth factors. The effect of LTD4 involved a pertussis toxin-sensitive and protein kinase C-mediated intracellular pathway, leading to sustained growth factor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 and protein kinase B (PKB/Akt). Conclusion: Cys-LTs do not transactivate EGFR but have a broader capability to synergize with receptor tyrosine kinase pathways. Clinical implications: This study implies a critical role of cys-LTs in airway fibrosis in asthma and other chronic airway diseases, which might not be blocked by therapy with current LT receptor antagonists.	Univ Southampton, Div Infect Inflammat & Repair, Sch Med, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Yoshisue, H (corresponding author), Univ Southampton, Div Infect Inflammat & Repair, Sch Med, Southampton Gen Hosp, Tremona Rd, Southampton SO16 6YD, Hants, England.	H.Yoshisue@soton.ac.uk	Sampson, Anthony/C-1112-2011; Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991; Healy, Eugene/0000-0001-5591-6970	MRC [G0800766] Funding Source: UKRI; Medical Research Council [G0800766] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Asakura T, 2004, J ALLERGY CLIN IMMUN, V114, P310, DOI 10.1016/j.jaci.2004.04.037; Back M, 2000, EUR J PHARMACOL, V401, P381, DOI 10.1016/S0014-2999(00)00452-0; BAUD L, 1987, J IMMUNOL, V138, P1190; BELLAFIORE M, 2002, AM J RESP CRIT CARE, V165, pA66; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Chibana K, 2003, J IMMUNOL, V170, P4290, DOI 10.4049/jimmunol.170.8.4290; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; LAMBRECHT G, 1992, EUR J PHARMACOL, V217, P217, DOI 10.1016/0014-2999(92)90877-7; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Lynch KR, 1999, NATURE, V399, P789; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; OLIVER MH, 1989, J CELL SCI, V92, P513; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Potter-Perigo S, 2004, AM J RESP CELL MOL, V30, P101, DOI 10.1165/rcmb.2003-0050OC; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Walch L, 2002, BRIT J PHARMACOL, V137, P1339, DOI 10.1038/sj.bjp.0704991	33	44	48	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					132	140		10.1016/j.jaci.2006.08.028	http://dx.doi.org/10.1016/j.jaci.2006.08.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208594	Bronze			2022-12-18	WOS:000243622200019
J	Gillespie, J; Wickens, K; Siebers, R; Howden-Chapman, P; Town, I; Epton, M; Fitzharris, P; Fishwick, D; Crane, J				Gillespie, Julie; Wickens, Kristin; Siebers, Rob; Howden-Chapman, Philippa; Town, Ian; Epton, Michael; Fitzharris, Penny; Fishwick, David; Crane, Julian		New Zealand Asthma Allergy Birt	Endotoxin exposure, wheezing, and rash in infancy in a New Zealand birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; atopy; wheezing; infants; rash; asthma; birth cohort; allergic disease	DIAGNOSTIC-CRITERIA; ATOPIC-DERMATITIS; DUST; ALLERGY; ASTHMA; LIPOPOLYSACCHARIDE; KERATINOCYTES; CHILDREN; LIFE	Background: Wheezing in infancy is common and is associated with small lungs, viral respiratory tract infection, and environmental tobacco smoke exposure. Recently, increased levels of endotoxin in the domestic environment have also been associated with infant wheezing, particularly among infants with a family history of atopic disease. Objective: To explore associations between exposure to endotoxin at 3 months of age and reported symptoms of wheezing, rhinitis, itchy scaly rash, and atopy at 15 months in a birth cohort of 881 New Zealand children. Methods: Using standardized methods, a 1-m(2) site from the bedroom floors of the 3-month-old infants was sampled and analyzed for endotoxin. Results: Wheezing was significantly associated with higher endotoxin levels (odds ratio [OR], 1.54; 95% CI, 1.03-2.30), particularly among infants with a parental history of allergic disease (OR, 1.67; 95% CI, 1.07-2.60). Higher endotoxin concentrations were also strongly associated with recurrent itchy rashes (OR, 1.87; 95% CI, 1.14-3.05), particularly among infants who were atopic (OR, 4.64; 95% CI, 1.56-13.77) or had a parental history of allergic disease (OR, 2.10; 95% CI, 1.22-3.61). Conclusion: Domestic endotoxin was associated with reported airway and skin symptoms in this large group of New Zealand infants. The role of endotoxin in the development of respiratory and skin disease in infancy deserves further study. Clinical implications: Reducing domestic endotoxin exposure might reduce infant wheezing and atopic dermatitis, but the long-term benefits of this remain unclear.	Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington, New Zealand; Wellington Sch Med, Dept Publ Hlth, Housing & Hlth Res Programme, Wellington, New Zealand; Univ Otago, Christchurch Sch Med, Dept Med, Canterbury Resp Ress Grp, Auckland, New Zealand; Greenlane Clin Ctr, Auckland Dist Hlth Board, Dept Immunol, Auckland, New Zealand; Univ Sheffield, Resp Dept, Sheffield S10 2TN, S Yorkshire, England	University of Otago; University of Otago; University of Otago; Auckland District Health Board; University of Sheffield	Gillespie, J (corresponding author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington, New Zealand.	gilju567@student.otago.ac.nz	Bennett, Julie/I-6757-2019; Siebers, Robert/A-4102-2009; Barnes, Phillipa/G-2669-2018	Bennett, Julie/0000-0002-3461-7223; Siebers, Robert/0000-0002-6359-3144; Barnes, Phillipa/0000-0001-7427-5371; Epton, Michael/0000-0003-4644-366X; Fishwick, David/0000-0001-5941-090X				Barber CM, 2001, ALLERGY, V56, P797, DOI 10.1034/j.1398-9995.2001.056008797.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Herr CEW, 2004, INT ARCH OCC ENV HEA, V77, P90, DOI 10.1007/s00420-003-0489-7; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; Popescu CM, 1998, BRIT J DERMATOL, V138, P436, DOI 10.1046/j.1365-2133.1998.02121.x; Rhodius R, 2002, ANN ALLERG ASTHMA IM, V88, P374, DOI 10.1016/S1081-1206(10)62367-8; RYLANDER R, 1993, ANN OCCUP HYG, V37, P57, DOI 10.1093/annhyg/37.1.57; SALMOND C, 2005, NZDEP 2001 INDEX DEP; Sawyer G, 1998, J ALLERGY CLIN IMMUN, V102, P765, DOI 10.1016/S0091-6749(98)70016-8; Silva P., 1996, CHILD ADULT DUNEDIN; Singh J, 2005, J ALLERGY CLIN IMMUN, V115, P330, DOI 10.1016/j.jaci.2004.11.021; Song PI, 2002, J INVEST DERMATOL, V119, P424, DOI 10.1046/j.1523-1747.2002.01847.x; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Tupker RA, 1998, ALLERGY, V53, P92, DOI 10.1111/j.1398-9995.1998.tb05006.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wickens K, 2004, INDOOR AIR, V14, P217, DOI 10.1111/j.1600-0668.2004.00253.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; 2001, STAT NZ	27	44	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1265	1270		10.1016/j.jaci.2006.07.051	http://dx.doi.org/10.1016/j.jaci.2006.07.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157655				2022-12-18	WOS:000242880300009
J	Kelsay, K				Kelsay, Kim			Management of sleep disturbance associated with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; eczema; sleep; sedatives; hypnotics; children	DOUBLE-BLIND; MELATONIN; INSOMNIA; CHILDREN; ANTIHISTAMINES; METAANALYSIS; ACTIGRAPHY; CLONIDINE; CROSSOVER; ITCH	Atopic dermatitis (AD) is a common childhood skin disease that also affects adults. Sleep problems are frequently associated with AD and negatively affect both patients and their families. Although this problem is well recognized, there are currently limited studies of patients with AD to guide clinical management of sleep disturbances. This targeted review will inform clinicians of the potential therapeutic agents available to manage sleep disturbances and will review literature relevant to improving the sleep of children and adults with AD. On the basis of our clinical experience and the limited data available, we provide a suggested algorithm for clinicians treating sleep problems associated with AD, but clearly more studies are needed to both further characterize the sleep of patients with AD and to test the efficacy and effectiveness of candidate agents in clinical trials.	Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Dept Psychiat, Denver, CO 80202 USA; Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Denver	Kelsay, K (corresponding author), Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	kelsayk@njc.org						Bender BG, 2005, J ALLERGY CLIN IMMUN, V116, P1200, DOI 10.1016/j.jaci.2005.09.041; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Benjamin K, 2004, J AM ACAD DERMATOL, V50, P33, DOI 10.1016/S0190-9622(03)02480-0; Boguniewiez M, 2005, IMMUNOL ALLERGY CLIN, V25, P333, DOI 10.1016/j.iac.2005.02.006; Bringhurst C, 2004, J AM ACAD DERMATOL, V51, P893, DOI 10.1016/j.jaad.2004.05.039; Brzezinski A, 2005, SLEEP MED REV, V9, P41, DOI 10.1016/j.smrv.2004.06.004; BUSCEMI N, 2004, AHRA PUBLICATION; Chamlin SL, 2005, ARCH PEDIAT ADOL MED, V159, P745, DOI 10.1001/archpedi.159.8.745; DANCHIN N, 1995, INT J CLIN PHARM TH, V33, P52; Ebata T, 1998, BRIT J DERMATOL, V138, P631; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Kapsimalis F, 2005, CURR OPIN PULM MED, V11, P481, DOI 10.1097/01.mcp.0000183062.98665.6b; Krystal AD, 2004, J CLIN PSYCHIAT, V65, P20; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; Miyazaki S, 2004, PSYCHIAT CLIN NEUROS, V58, P138, DOI 10.1111/j.1440-1819.2003.01207.x; Pelayo R, 2004, PEDIATR CLIN N AM, V51, P117, DOI 10.1016/S0031-3955(03)00179-2; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; ROSENBERG R, 2004, SLEEP, V6, P15; Roth T, 2005, SLEEP MED, V6, P487, DOI 10.1016/j.sleep.2005.06.004; Scheer FA, 2005, SLEEP MED REV, V9, P5, DOI 10.1016/j.smrv.2004.11.004; Smits MG, 2003, J AM ACAD CHILD PSY, V42, P1286, DOI 10.1097/01.chi.0000085756.71002.86; Timmerman H, 2000, ALLERGY, V55, P5, DOI 10.1034/j.1398-9995.2000.055supp60005.x; Touitou Y, 2001, EXP GERONTOL, V36, P1083, DOI 10.1016/S0531-5565(01)00120-6	25	44	45	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					198	201		10.1016/j.jaci.2006.04.038	http://dx.doi.org/10.1016/j.jaci.2006.04.038			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815155				2022-12-18	WOS:000239184800023
J	Bui, CM; Chen, H; Shyr, Y; Joos, KM				Bui, CM; Chen, H; Shyr, Y; Joos, KM			Discontinuing nasal steroids might lower intraocular pressure in glaucoma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	APR 24-29, 2004	Ft Lauderdale, FL	Assoc Res Vis & Ophthalmol		steroid nasal spray; glaucoma; intraocular pressure; eye	ALLERGIC RHINITIS; FLUID-DYNAMICS; CORTICOSTEROIDS; DEXAMETHASONE; CELLS; HYPERTENSION; MANAGEMENT; ELEVATION; PROTEINS; RISKS	Background: Topical, intraocular, oral, and parenteral steroids might increase intraocular pressure (IOP), but little is known regarding the effect of nasal steroid spray. Objective: We sought to examine the effect of discontinuing nasal steroid sprays on IOP in patients with glaucoma. Methods: A retrospective chart review of patients with glaucoma using nasal steroids was performed. Averaged IOP for each pair of eyes was determined for presteroid use, steroid use, and 2 consecutive poststeroid use (poststeroid I and poststeroid 2) examinations. Results: Twenty-four eyes of 12 patients taking nasal steroids were identified. The mean IOP for each pair of eyes was 15.4 +/- 4.3 mm Hg (range, 9-23.5 mm Hg) for the presteroid use examination, 18.0 +/- 3.8 mm Hg (range, 12-24.5 mm Hg) for the steroid use examination, 14.5 +/- 3.3 mm Hg (range, 9.5-20 mm Hg) for poststeroid use examination 1, and 14.8 +/- 3.4 mm Hg (range, 95-22.0 mm Hg) for poststeroid use examination 2. Eleven patients experienced decreased averaged IOP at poststeroid use examination 1 after steroid discontinuation at a mean of 35 +/- 14 days and continued to maintain this decrease on the poststeroid use examination 2 visit at a mean of 191 150 days. A significant increase between presteroid and steroid use examination IOPs (P =.007) and a significant decrease between steroid use and both poststeroid use I (P <.001) and 4 poststeroid use 2 (P =.011) examination IOPs were observed. No significant difference between presteroid use and either poststeroid use examination IOPs (P = 1.00) was found. Many patients met their target pressures and were able to avoid or delay additional glaucoma therapy. Conclusion: A significant reduction in IOP occurred with nasal steroid discontinuation in patients with glaucoma. Nasal steroids might contribute to IOP increase, and inquiry as to whether a patient has glaucoma before medication initiation is warranted.	Vanderbilt Univ, Inst Eye, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Joos, KM (corresponding author), Vanderbilt Univ, Inst Eye, 8017 MCE, Nashville, TN 37232 USA.	Karen.joos@vanderbilt.edu						AGGARWAL RK, 1993, EYE, V7, P664, DOI 10.1038/eye.1993.152; ALFANO JE, 1963, AM J OPHTHALMOL, V56, P245, DOI 10.1016/0002-9394(63)91858-0; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Alward WLM, 2000, EYE, V14, P429, DOI 10.1038/eye.2000.127; ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P492, DOI 10.1001/archopht.1963.00960050494011; ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P482, DOI 10.1001/archopht.1963.00960050484010; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BECKER B, 1963, JAMA-J AM MED ASSOC, V185, P884, DOI 10.1001/jama.1963.03060110088027; BERNSTEIN HN, 1963, ARCH OPHTHALMOL-CHIC, V70, P15; BERNSTEIN HN, 1962, ARCH OPHTHALMOL-CHIC, V68, P742; Bross Soriano D, 2000, Rev Alerg Mex, V47, P12; Bross-Soriano D, 2004, OTOLARYNG HEAD NECK, V130, P187, DOI 10.1016/j.otohns.2003.09.020; Buckley RJ, 1998, CLIN EXP ALLERGY, V28, P39; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; Desnoeck M, 2001, Bull Soc Belge Ophtalmol, P97; Dibildox J, 2001, J ALLERGY CLIN IMMUN, V108, pS54, DOI 10.1067/mai.2001.115567; DREYER EB, 1993, NEW ENGL J MED, V329, P1822, DOI 10.1056/NEJM199312093292420; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; FRANCOIS J, 1975, INVEST OPHTH VISUAL, V14, P173; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HERNANDEZ MR, 1983, INVEST OPHTH VIS SCI, V24, P1612; HERNANDEZ MR, 1985, INVEST OPHTH VIS SCI, V26, P1784; HERSCHLER J, 1972, AM J OPHTHALMOL, V74, P501, DOI 10.1016/0002-9394(72)90916-6; Howland WC, 1996, CLIN EXP ALLERGY, V26, P18, DOI 10.1111/j.1365-2222.1996.tb00654.x; KALINA RE, 1969, ARCH OPHTHALMOL-CHIC, V81, P788; Kayes J, 1969, Trans Am Ophthalmol Soc, V67, P339; KERSEY JP, 2005, EYE; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; LI J, 1995, ANN ALLERG ASTHMA IM, V74, P58; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; Ozturk F, 1998, Ear Nose Throat J, V77, P846; Samiy N, 1996, CAN J OPHTHALMOL, V31, P120; Settipane RA, 2001, ANN ALLERG ASTHMA IM, V86, P494, DOI 10.1016/S1081-1206(10)62896-7; Spaeth G L, 1977, Trans Am Ophthalmol Soc, V75, P353; STEELY HT, 1992, INVEST OPHTH VIS SCI, V33, P2242; SZELFER SJ, 2001, J ALLERGY CLIN IMM S, V108, pS26; Tripathi RC, 1999, DRUG AGING, V15, P439, DOI 10.2165/00002512-199915060-00004; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; YUN AJ, 1989, INVEST OPHTH VIS SCI, V30, P2012; Zhou LL, 1998, INT J MOL MED, V1, P339	43	44	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1042	1047		10.1016/j.jaci.2005.07.031	http://dx.doi.org/10.1016/j.jaci.2005.07.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	017IG	16275373				2022-12-18	WOS:000235686700014
J	Beyer, K; Jarvinen, KM; Bardina, L; Mishoe, M; Turjanmaa, K; Niggemann, B; Ahlstedt, S; Venemalm, L; Sampson, HA				Beyer, K; Jarvinen, KM; Bardina, L; Mishoe, M; Turjanmaa, K; Niggemann, B; Ahlstedt, S; Venemalm, L; Sampson, HA			IgE-binding peptides coupled to a commercial matrix as a diagnostic instrument for persistent cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; EPITOPES; IDENTIFICATION		Mt Sinai Hosp, Mt Sinai Sch Med, New York, NY 10029 USA; Humboldt Univ, Childrens Hosp, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Tampere Univ Hosp, Tampere, Finland; Karolinska Inst, Dept Environm Med, Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Pharm Diagnost AB, Uppsala, Sweden	Icahn School of Medicine at Mount Sinai; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Tampere University; Tampere University Hospital; Karolinska Institutet; Karolinska Institutet	Beyer, K (corresponding author), Mt Sinai Hosp, Mt Sinai Sch Med, New York, NY 10029 USA.				NIAID NIH HHS [AI-44236] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Wood RA, 2003, PEDIATRICS, V111, P1631	8	44	45	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					704	705		10.1016/j.jaci.2005.05.007	http://dx.doi.org/10.1016/j.jaci.2005.05.007			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159646				2022-12-18	WOS:000235686500036
J	Batista, R; Nunes, B; Carmo, M; Cardoso, C; Jose, HS; de Almeida, AB; Manique, A; Bento, L; Ricardo, CP; Oliveira, MM				Batista, R; Nunes, B; Carmo, M; Cardoso, C; Jose, HS; de Almeida, AB; Manique, A; Bento, L; Ricardo, CP; Oliveira, MM			Lack of detectable allergenicity of transgenic maize and soya samples	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transgenic food; allergenicity; immune response; public health; food safety; recombinant DNA technology	POTENTIAL ALLERGENICITY; GLYPHOSATE-TOLERANT; DOUBLE-BLIND; FOOD; PLANTS; CHILDREN; GENE	Background: The safety issues regarding foods derived from genetically modified (GM) plants are central to their acceptance into the food supply. The potential allergenicity of proteins newly introduced in GM foods is a major safety concern. Objective: We sought to monitor, in potentially sensitive human populations, the allergenicity effects of 5 GM materials obtained from sources with no allergenic potential and already under commercialization in the European Union. Methods: We have performed skin prick tests with protein extracts prepared from transgenic maize (MON810, Bt11, T25, Bt176) and soya (Roundup Ready) samples and from nontransgenic control samples in 2 sensitive groups: children with food and inhalant allergy and individuals with asthma-rhinitis. We have also tested IgE immunoblot reactivity of sera from patients with food allergy to soya (Roundup Ready) and maize (MON810, Bt11, Bt176) samples, as well as to the pure transgenic proteins (CryIA[b] and CP4 5-enolpyruvylshikimate3-phosphate synthase). Results: None of the individuals undergoing tests reacted differentially to the transgenic and nontransgenic samples under study. None of the volunteers tested presented detectable IgE antibodies against pure transgenic proteins. Conclusion: The transgenic products under testing seem to be safe in terms of allergenic potential. We propose postmarket testing as an important screening strategy for putative allergic sensitization to proteins introduced in transgenic plants.	Inst Nacl Saude Dr Ricardo Jorge, P-1649016 Lisbon, Portugal; Inst Tecnol Quim & Biol, Inst Biol Expt & Tecnol, Oeiras, Portugal; Clin Med & Diagnost Dr Joaquim Chaves, Alges, Portugal; Clin Univ Pneumol, Hosp Santa Maria, Lisbon, Portugal; Hosp Santa Maria, Dept Clin Pediat, Lisbon, Portugal; Inst Super Agron, Lisbon, Portugal; Fac Ciencias Lisboa, Dept Biol Vegetal, P-1700 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge; Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa; Universidade de Lisboa	Batista, R (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Av Padre Cruz, P-1649016 Lisbon, Portugal.	rbatista@itqb.unl.pt	Oliveira, M. Margarida/H-9318-2012; Ricardo, Cândido P P/B-7891-2008; Nunes, Baltazar/V-8903-2019	Oliveira, M. Margarida/0000-0002-0095-1952; Ricardo, Cândido P P/0000-0003-4905-1274; Nunes, Baltazar/0000-0001-6230-7209; Batista, Rita/0000-0002-2081-682X				Alam MF, 1998, PLANT SCI, V135, P25, DOI 10.1016/S0168-9452(98)00053-3; Anderson JA, 1996, CRIT REV FOOD SCI, V36, pS19, DOI 10.1080/10408399609527757; [Anonymous], 1989, ALLERGY S10, V10, P1; Bindslev-Jensen C, 1998, ALLERGY, V53, P72, DOI 10.1111/j.1398-9995.1998.tb04966.x; BLISS CI, 1967, STAT BIOL, V1; BOCK SA, 1987, PEDIATRICS, V79, P683; Burks AW, 1995, J ALLERGY CLIN IMMUN, V96, P1008, DOI 10.1016/S0091-6749(95)70243-1; Clinton WJ., 2000, OFF PRES FED REGIST, V65, P67249; delaFuente JM, 1997, SCIENCE, V276, P1566, DOI 10.1126/science.276.5318.1566; *DRAFT INT STAND, 2002, 21571 ISODIS, P25; *DRAFT INT STAND, 2002, 21569 ISODIS, P23; Ewen SWB, 1999, LANCET, V354, P1353, DOI 10.1016/S0140-6736(98)05860-7; Helm RM, 2000, CURR OPIN IMMUNOL, V12, P647, DOI 10.1016/S0952-7915(00)00157-6; Kuiper HA, 1999, LANCET, V354, P1315, DOI 10.1016/S0140-6736(99)00341-4; Lack G, 2002, CLIN EXP ALLERGY, V32, P1131, DOI 10.1046/j.1365-2222.2002.01464.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MATSUDA T, 1993, TRENDS FOOD SCI TECH, V4, P289, DOI 10.1016/0924-2244(93)90072-I; Mendieta NLR, 1997, J SCI FOOD AGR, V75, P405, DOI 10.1002/(SICI)1097-0010(199712)75:4&lt;405::AID-JSFA904&gt;3.0.CO;2-V; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; Miranda R, 2001, INSECT BIOCHEM MOLEC, V31, P1155, DOI 10.1016/S0965-1748(01)00061-3; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1992, JAMA-J AM MED ASSOC, V268, P2840, DOI 10.1001/jama.268.20.2840; Sears MK, 2001, P NATL ACAD SCI USA, V98, P11937, DOI 10.1073/pnas.211329998; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Sten E, 2004, APMIS, V112, P21, DOI 10.1111/j.1600-0463.2004.apm1120104.x; Sutton SA, 2003, J ALLERGY CLIN IMMUN, V112, P1011, DOI 10.1016/S0091-6749(03)02024-4; Taylor S. L., 1997, Nutrition Abstracts and Reviews. Series A, Human and Experimental, V67, P1163; Taylor SL, 1996, CRIT REV FOOD SCI, V36, pS91, DOI 10.1080/10408399609527761; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	37	44	46	0	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					403	410		10.1016/j.jaci.2005.04.014	http://dx.doi.org/10.1016/j.jaci.2005.04.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083797	Green Published			2022-12-18	WOS:000235686400025
J	Poole, JA; Matangkasombut, P; Rosenwasser, LJ				Poole, JA; Matangkasombut, P; Rosenwasser, LJ			Targeting the IgE molecule in allergic and asthmatic diseases: Review of the 19E molecule and clinical efficacy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FC-EPSILON-RI; QUALITY-OF-LIFE; HIGH-AFFINITY RECEPTOR; ANTIIMMUNOGLOBULIN-E ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; EPIDERMAL LANGERHANS CELLS; HUMAN-IMMUNOGLOBULIN-E; LONG-TERM CONTROL; SERUM IGE; DENDRITIC CELLS		Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Poole, JA (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	rosenwasserl@njc.org						Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BASU M, 1993, J BIOL CHEM, V268, P13118; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160, DOI 10.1016/S1081-1206(10)62171-0; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Feuchtinger T, 2003, J ALLERGY CLIN IMMUN, V111, P428, DOI 10.1067/mai.2003.56; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; *FOOD DRUG ADM, PAT SAF NEWS 1 BIOL; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; GOUNNI AS, 1994, J ALLERGY CLIN IMMUN, V94, P1214, DOI 10.1016/0091-6749(94)90334-4; *GREENT INC, XOL PROD INF; Harris MB, 1999, MOL CELL BIOL, V19, P7264; HENCHOZ S, 1994, IMMUNOLOGY, V81, P285; HERBELIN A, 1994, EUR J IMMUNOL, V24, P1869, DOI 10.1002/eji.1830240823; Holgate S, 2001, CURR MED RES OPIN, V17, P233; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JABARA HH, 1991, J IMMUNOL, V147, P1557; Jabara HH, 2001, J CLIN INVEST, V107, P371, DOI 10.1172/JCI10168; JABARA HH, 1990, J IMMUNOL, V145, P3468; Juniper E F, 1999, Curr Opin Pulm Med, V5, P105, DOI 10.1097/00063198-199903000-00005; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Kijimoto-Ochiai S, 2002, CELL MOL LIFE SCI, V59, P648, DOI 10.1007/s00018-002-8455-1; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kopp MV, 2003, PEDIAT ALLERG IMM-UK, V14, P401, DOI 10.1034/j.1399-3038.2003.00068.x; Kopp MV, 2002, J ALLERGY CLIN IMMUN, V110, P728, DOI 10.1067/mai.2002.128804; Kraft S, 2001, INT ARCH ALLERGY IMM, V124, P35, DOI 10.1159/000053662; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V90, P13, DOI 10.1016/S1081-1206(10)61654-7; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Lemanske RF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e55; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; Maizels N, 2003, NAT IMMUNOL, V4, P7, DOI 10.1038/ni0103-7; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; MAURER D, 1995, J IMMUNOL, V154, P6285; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; NISSIM A, 1993, J IMMUNOL, V150, P1365; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; Saini SS, 1999, J IMMUNOL, V162, P5624; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; White P, 1998, CLIN EXP ALLERGY, V28, P266; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5	90	44	46	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					S376	S385		10.1016/j.jaci.2004.12.1124	http://dx.doi.org/10.1016/j.jaci.2004.12.1124			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753882				2022-12-18	WOS:000227687000042
J	Pace, E; Gagliardo, R; Melis, M; La Grutta, S; Ferraro, M; Siena, L; Bonsignore, G; Gjomarkaj, M; Bousquet, J; Vignola, AM				Pace, E; Gagliardo, R; Melis, M; La Grutta, S; Ferraro, M; Siena, L; Bonsignore, G; Gjomarkaj, M; Bousquet, J; Vignola, AM			Synergistic effects of fluticasone propionate and saimeterol on in vitro T-cell activation and apoptosis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid; salmeterol; apoptosis; T cells	FACTOR-KAPPA-B; GLUCOCORTICOID-RECEPTOR; SALMETEROL; LYMPHOCYTES; DEATH; RELEASE; LIFE	Background: In asthma T cells are characterized by an increased activation state and by reduced apoptosis. Objective: Because the clinical efficacy of inhaled corticosteroids combined with long-acting beta(2)-agonists has been widely demonstrated in asthma, we studied, in vitro, the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor kappaB inhibitor (IkappaBalpha), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects. Methods: Apoptosis was evaluated on the basis of annexin V binding, whereas the expression of caspases 8 and 3 and phosphorylated IkappaBalpha, as well as the nuclear translocation of the GR, were evaluated by means of Western blot analysis. Results: FP alone increases and salmeterol alone does not affect T-cell apoptosis. The combination of FP and salmeterol significantly increases PBT apoptosis in comparison with FP alone. FP at the lower concentration, when combined with salmeterol, is equivalent to FP at the higher concentration in inducing PBT apoptosis. The synergy in the induction of cell apoptosis is associated with more efficient activation of caspases; 8 and 3. FP plus salmeterol is also able to synergistically reduce the expression of phosphorylated IkappaBalpha, thus limiting nuclear factor kappaB activation. The synergy was related to an increased nuclear translocation of the GR. Conclusion: This study shows that the combination of FP and salmeterol is able to control PBT activation in asthmatic patients more efficiently than FP alone and with a lower concentration of steroids.	CNR, Ist Biomed Immunol Mol, Sez Immunopatol Farmacol Clin & Sperimentale Dell, I-90146 Palermo, Italy; INSERM, U454, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Pace, E (corresponding author), CNR, Ist Biomed Immunol Mol, Sez Immunopatol Farmacol Clin & Sperimentale Dell, Via Ugo La Malfa 153, I-90146 Palermo, Italy.	pace@ibim.cnr.it	Bousquet, Jean/O-4221-2019; La Grutta, Stefania/N-3615-2014; Gagliardo, Rosalia/AAX-7244-2020; Ferraro, Maria/AAX-8156-2020; Pace, Elisabetta/AAL-2537-2020	La Grutta, Stefania/0000-0001-8026-0715; Pace, Elisabetta/0000-0003-1141-9010; Melis, Mario Raphael/0000-0002-5418-6301; FERRARO, MARIA/0000-0003-2533-7446; SIENA, LIBORIA/0000-0002-3182-9503				Adcock Ian M., 2002, Journal of Allergy and Clinical Immunology, V110, pS261, DOI 10.1067/mai.2002.129705; Amsterdam A, 2002, BIOCHEM PHARMACOL, V64, P843, DOI 10.1016/S0006-2952(02)01147-4; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Bremner P, 2002, J PHARM PHARMACOL, V54, P453, DOI 10.1211/0022357021778637; Cohen JJ, 1999, J ALLERGY CLIN IMMUN, V103, P548, DOI 10.1016/S0091-6749(99)70222-8; Corrigan CJ, 2000, CHEM IMMUNOL, V78, P39; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Green DR, 2003, MOL CELL, V11, P551, DOI 10.1016/S1097-2765(03)00107-2; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Ho CY, 2002, CHEST, V122, P1751, DOI 10.1378/chest.122.5.1751; ISEKI R, 1991, J IMMUNOL, V147, P4286; Jaffuel D, 2000, AM J RESP CRIT CARE, V162, P57, DOI 10.1164/ajrccm.162.1.9901006; Kagoshima M, 2003, BIOCHEM SOC T, V31, P60, DOI 10.1042/bst0310060; Kumar VHS, 2000, LIFE SCI, V66, P1639, DOI 10.1016/S0024-3205(00)00483-5; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; Marchetti MC, 2003, TOXICOL LETT, V139, P175, DOI 10.1016/S0378-4274(02)00431-9; Melis M, 2002, EUR RESPIR J, V19, P257, DOI 10.1183/09031936.02.00239202; Mohede ICM, 1996, INT J IMMUNOPHARMACO, V18, P193, DOI 10.1016/0192-0561(96)00008-2; Oddera S, 1997, PULM PHARMACOL THER, V10, P43, DOI 10.1006/pupt.1997.0073; Pace E, 1999, AM J RESP CRIT CARE, V159, P1592, DOI 10.1164/ajrccm.159.5.9806001; Roumestan C, 2002, J ALLERGY CLIN IMMUN, V109, pS240, DOI 10.1016/S0091-6749(02)81866-8; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200	30	44	51	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1216	1223		10.1016/j.jaci.2004.07.052	http://dx.doi.org/10.1016/j.jaci.2004.07.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536434				2022-12-18	WOS:000225047800033
J	Bochner, BS; Busse, WW				Bochner, BS; Busse, WW			Advances in mechanisms of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinitis; sinusitis; surrogate markers; eosinophils; basophils; mast cells; T cells; epithelial cells; chemokines; cytokines; prostaglandins; leukotrienes; animal models; smooth muscle; pathophysiology	ENDOTHELIAL GROWTH-FACTOR; PLACEBO-CONTROLLED TRIAL; AIRWAY HYPERRESPONSIVENESS; FOLLOW-UP; TGF-BETA; T-CELLS; INFLAMMATORY MARKERS; HUMAN EOSINOPHILS; NITRIC-OXIDE; 1ST YEAR	This review summarizes selected Mechanisms of Allergy articles appearing between 2002 and 2003 in the Journal of Allergy and Clinical Immunology. Articles chosen include those dealing with human airways disease pathophysiology, pharmacology, cell biology, cell recruitment, and genetics, as well as information from allergen challenge models in both human and nonhuman systems. When appropriate, articles from other journals have been included to supplement the topics being presented.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Dept Med, Baltimore, MD USA; Univ Wisconsin, Sch Med, Div Allergy & Immunol, Dept Med, Madison, WI USA	Johns Hopkins University; University of Wisconsin System; University of Wisconsin Madison	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 2B-71, Baltimore, MD 21224 USA.							Adachi T, 2003, J ALLERGY CLIN IMMUN, V111, P113, DOI 10.1067/mai.2003.27; Alam R, 2004, J ALLERGY CLIN IMMUN, V113, P38, DOI 10.1016/j.jaci.2003.10.054; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; Fritz SB, 2003, J ALLERGY CLIN IMMUN, V112, P1057, DOI 10.1016/j.jaci.2003.09.042; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Gore C, 2003, J ALLERGY CLIN IMMUN, V112, P702, DOI 10.1016/S0091-6749(03)01886-4; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Higa S, 2003, J ALLERGY CLIN IMMUN, V111, P1299, DOI 10.1067/mai.2003.1456; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; Hogan SP, 2004, CURR ALLERGY ASTHM R, V4, P74, DOI 10.1007/s11882-004-0047-8; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Isogai S, 2003, J ALLERGY CLIN IMMUN, V112, P547, DOI 10.1067/mai.2003.1682; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kessel JM, 2003, J ALLERGY CLIN IMMUN, V111, P1024, DOI 10.1067/mai.2003.1393; Koury MJ, 2003, AM J MED, V115, P587, DOI 10.1016/S0002-9343(03)00475-3; Kumar M, 2002, J ALLERGY CLIN IMMUN, V110, P879, DOI 10.1067/mai.2002.129699; Liu LY, 2003, J ALLERGY CLIN IMMUN, V111, P818, DOI 10.1067/mai.2003.1346; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; McCusker C, 2002, J ALLERGY CLIN IMMUN, V110, P891, DOI 10.1067/mai.2002.130048; Mochizuki A, 2003, J ALLERGY CLIN IMMUN, V112, P102, DOI 10.1067/mai.2003.1511; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Nakano Y, 2003, J ALLERGY CLIN IMMUN, V112, P525, DOI 10.1067/mai.2003.1710; Nakao A, 2002, J ALLERGY CLIN IMMUN, V110, P873, DOI 10.1067/mai.2002.129236; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Prosperini G, 2002, J ALLERGY CLIN IMMUN, V110, P855, DOI 10.1067/mai.2002.130050; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; Zhang XZ, 2003, J ALLERGY CLIN IMMUN, V112, P93, DOI 10.1067/mai.2003.1587; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P97, DOI 10.1067/mai.2003.3	53	44	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					868	875		10.1016/j.jaci.2004.02.016	http://dx.doi.org/10.1016/j.jaci.2004.02.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131568	Bronze			2022-12-18	WOS:000221269000008
J	Martinez-Moragon, E; Plaza, V; Serrano, J; Picado, C; Galdiz, JB; Lopez-Vina, A; Sanchis, J				Martinez-Moragon, E; Plaza, V; Serrano, J; Picado, C; Galdiz, JB; Lopez-Vina, A; Sanchis, J		Spanish High Risk Asthma Res Grp	Near-fatal asthma related to menstruation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; near-fatal asthma; asthma exacerbation; menstruation; female sex	PERIMENSTRUAL ASTHMA; CYTOKINES; CYCLE	Background: Menstruation has been suggested as a possible trigger of near-fatal asthma (NFA), but the evidence supporting this association remains weak. Objective: We sought to assess the role of menstruation as a contributing factor in the development of NFA episodes in women of reproductive age. Methods: Forty-four female patients of reproductive age with near-fatal attacks were enrolled in a multicenter study. Data on patient and clinical characteristics were collected. We also performed spirometric and allergy studies when the patients were in stable condition. Results: Significantly more NFA episodes were observed on the first day of menstruation (11 [25%] patients) than on the remaining days (33 [75 %] patients, P =.022), and patients who presented for care on the first day of menstruation used more inhaled salbutamol as rescue medication (9 [9.5] vs 1.8 [3.7] mug/d during the 7 days before the asthma exacerbation, P =.003). Conclusion: Menstruation might act as a contributing factor in the development of NFA episodes in patients with unstable asthma. Specific recommendations should be included in educational programs, and the self-management plans of asthmatic women of reproductive age should include the systematic recording of their asthma symptoms and pulmonary function in the perimenstrual phase.	Hop Santa Creu I St Pau, Dept Pneumol, Barcelona, Spain; Hop Sagunto, Secc Neumol, Valencia, Spain; Hosp Clin Barcelona, Servei Pneumol & Allergia Resp, Barcelona, Spain; Hop Cruces, Serv Neumol, Baracaldo, Spain; Hosp Univ Puerta Hierro, Serv Neumol, Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitario Cruces; Hospital Puerta de Hierro-Majadahonda	Plaza, V (corresponding author), Hop Santa Creu I St Pau, Dept Pneumol, St Antoni M Claret 167, Barcelona, Spain.		/AAL-7347-2021; Galdiz, Juan Bautista/G-4977-2012; /AFX-9519-2022	Plaza, Vicente/0000-0003-2567-5496; Serrano-Pariente, Jose/0000-0002-6583-655X				Barr RG, 2000, EUR RESPIR J, V15, P266, DOI 10.1034/j.1399-3003.2000.15b08.x; BOHM M, 1991, CHEST, V100, P1246, DOI 10.1378/chest.100.5.1246; Borger P, 2000, CLIN EXP ALLERGY, V30, P920; CHIRAY M, 1938, PRESSE MED, V38, P755; Hallsworth MP, 2001, BRIT J PHARMACOL, V132, P729, DOI 10.1038/sj.bjp.0703866; JUNIPER EF, 1984, CONN MED, V48, P777; LENOIR RJ, 1987, ANAESTHESIA, V42, P1287, DOI 10.1111/j.1365-2044.1987.tb05275.x; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; *NIH LUNG BLOOD I, 1995, NIH PUBL; PERRIN B, 1988, LANCET, V2, P843; Plaza V, 2002, EUR RESPIR J, V19, P846, DOI 10.1183/09031936.02.00241502; Shames RS, 1998, ANN ALLERG ASTHMA IM, V81, P65, DOI 10.1016/S1081-1206(10)63111-0; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Tan KS, 1997, CHEST, V111, P847, DOI 10.1378/chest.111.4.847; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676	16	44	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					242	244		10.1016/j.jaci.2003.11.002	http://dx.doi.org/10.1016/j.jaci.2003.11.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767436				2022-12-18	WOS:000188885700009
J	Leiferman, KM; Gleich, GJ				Leiferman, KM; Gleich, GJ			Hypereosinophilic syndrome: Case presentation and update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophil; hypereosinophilic syndrome; HES; skin lesions; mucosal ulcers; imatinib mesylate; FIP1L1PDGFRA gene	MAJOR BASIC-PROTEIN; EOSINOPHIL GRANULE PROTEINS; CHRONIC MYELOID-LEUKEMIA; CELL HISTAMINE-RELEASE; ABL TYROSINE KINASE; TISSUE EOSINOPHILIA; T-CELLS; DEGRANULATION; IMATINIB; ACTIVATION	Persistent peripheral blood eosinophilia can be associated with a variety of diseases, ranging from parasitic infection to gastrointestinal disease to vasculitis to the hypereosinophilic syndrome (HES). Mucosal ulcerations are a variant presentation of the HES that appear to be markers for a mutation that characterizes a subgroup of patients with HES responsive to treatment with imatinib mesylate. We present a patient with peripheral blood eosinophilia and severe recurrent mucosal ulcers and discuss his presentation in the context of new information about the evaluation, disease progression, and treatment of HES.	Univ Utah, Sch Med 4B454, Dept Dermatol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Leiferman, KM (corresponding author), Univ Utah, Sch Med 4B454, Dept Dermatol, 30 N 1900 E, Salt Lake City, UT 84132 USA.							Aractingi S, 1996, ARCH DERMATOL, V132, P535; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; BUTTERFIELD JH, 1993, CLIN EXP ALLERGY, V23, P571, DOI 10.1111/j.1365-2222.1993.tb00896.x; BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; CHEN KR, 1994, ARCH DERMATOL, V130, P1159, DOI 10.1001/archderm.130.9.1159; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DAVIS MDP, 2003, J ALLERGY CLIN IMMUN; De Cock C, 1998, J HEART VALVE DIS, V7, P668; DEMELLO DE, 1990, NEW ENGL J MED, V323, P1542, DOI 10.1056/NEJM199011293232207; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DVORAK AM, 1991, AM J PATHOL, V138, P69; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Griffin JH, 2003, P NATL ACAD SCI USA, V100, P7830, DOI 10.1073/pnas.0932698100; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; Heufelder AE, 1996, J CLIN ENDOCR METAB, V81, P977, DOI 10.1210/jc.81.3.977; KAZMIEROWSKI JA, 1978, ARCH DERMATOL, V114, P531, DOI 10.1001/archderm.114.4.531; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; KLION AD, 2003, IN PRESS BLOOD  0922; LEIFERMAN KM, 1982, JAMA-J AM MED ASSOC, V247, P1018, DOI 10.1001/jama.247.7.1018; MacGlashan DW, 1997, IMMUNOL LETT, V58, P37, DOI 10.1016/S0165-2478(97)02710-7; Marone G, 2000, CHEM IMMUNOL, V76, P118; MOY JN, 1990, J IMMUNOL, V145, P2626; NOGUCHI H, 1991, OPHTHALMOLOGY, V98, P928; NOGUCHI H, 1992, AM J PATHOL, V140, P521; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Patella V, 1996, J IMMUNOL, V157, P1219; ROHRBACH MS, 1990, J EXP MED, V172, P1271, DOI 10.1084/jem.172.4.1271; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SLUNGAARD A, 1983, NEW ENGL J MED, V309, P778, DOI 10.1056/NEJM198309293091307; SLUNGAARD A, 1993, J CLIN INVEST, V91, P1721, DOI 10.1172/JCI116382; SOLLEY GO, 1976, MAYO CLIN PROC, V51, P697; SPRY CJF, 1983, Q J MED, V52, P1; TAI PC, 1987, LANCET, V1, P643; Weiler CR, 1996, J LEUKOCYTE BIOL, V60, P493, DOI 10.1002/jlb.60.4.493; WONG DTW, 1991, BLOOD, V78, P2702; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	47	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					50	58		10.1016/j.jaci.2003.10.051	http://dx.doi.org/10.1016/j.jaci.2003.10.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713907				2022-12-18	WOS:000187837900006
J	Beezhold, DH; Hickey, VL; Sussman, GL				Beezhold, DH; Hickey, VL; Sussman, GL			Mutational analysis of the IgE epitopes in the latex allergen Hev b 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hev b 5; latex allergy; IgE antibodies; recombinant allergens; site-directed mutagenesis	SITE-DIRECTED MUTAGENESIS; NATURAL-RUBBER LATEX; HEALTH-CARE WORKERS; T-CELL EPITOPES; RECOMBINANT ALLERGENS; BINDING EPITOPES; HEV-B-5; REACTIVITY; VARIANTS; CLONING	Background: Hev b 5 is a major latex allergen and potential candidate for an immunotherapy reagent. Objective: The purpose of this study was to produce a hypoallergenic form of Hev b 5. Methods: We used SPOTs analysis with alanine substitution to identify amino acids (AAs) critical for IgE binding and used site-directed mutagenesis to produce recombinant proteins with altered IgE-binding activity. Results: Eleven epitopes were identified (5.1-5.11) in Hev b 5. Individual patients demonstrated variable epitope recognition, with the most intense reactivity to epitopes 5.4 and 5.7. IgE inhibition assays with synthetic peptides indicated that mutating a single epitope would not reduce IgE binding, but rather a combination of epitopes was required. After alanine substitutions to identify the important AAs, site-directed mutagenesis was used to replace the crucial AAs with alanine, Twenty clones with different combinations of altered epitopes were evaluated by means of IgE inhibition assays. Clones with mutations in single epitopes failed to reduce IgE binding, but changes to 8 epitopes (14 AAs) resulted in a 4500-fold reduction in IgE binding. Epitopes 5.7 and 5.9 were found to be cross-reactive, making Hev b 5 a multivalent allergen. Conclusions: We produced a recombinant Hev b 5 protein with significantly reduced IgE-binding activity. Changing a minimum of 3 immunodominant epitopes was required to cause a 100-fold reduction in IgE binding. Changes in 8 epitopes, particularly the cross-reactive epitopes 5.7 and 5.9, were needed to maximize the reduction in IgE binding. Mutants with reduced IgE-binding activity may prove to be valuable reagents for immunotherapy.	Guthrie Res Inst, Immunobiol Lab, Sayre, PA 18840 USA; Univ Toronto, Div Clin Immunol & Allergy, Toronto, ON, Canada	University of Toronto	Beezhold, DH (corresponding author), Guthrie Res Inst, Immunobiol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.			Beezhold, Donald/0000-0001-5543-5747				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; DALRYMPLE S. J., 1992, RUBBER DEV, V45, P51; de Silva HD, 2000, J ALLERGY CLIN IMMUN, V105, P1017, DOI 10.1067/mai.2000.105806; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Helm RM, 2000, J ALLERGY CLIN IMMUN, V105, P378, DOI 10.1016/S0091-6749(00)90091-5; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; LEDGER SE, 1994, PLANT MOL BIOL, V25, P877, DOI 10.1007/BF00028882; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Schramm G, 1999, J IMMUNOL, V162, P2406; Slater JE, 1999, MOL IMMUNOL, V36, P135, DOI 10.1016/S0161-5890(99)00021-8; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Slater JE, 1997, ARB P EHRLICH I BUND, V235; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342	23	44	52	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1069	1076		10.1067/mai.2001.115482	http://dx.doi.org/10.1067/mai.2001.115482			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398087				2022-12-18	WOS:000169454800021
J	Monteseirin, J; Bonilla, I; Camacho, J; Conde, J; Sobrino, F				Monteseirin, J; Bonilla, I; Camacho, J; Conde, J; Sobrino, F			Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: The effect of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; neutrophils; mechanism; IgE-dependent; allergen; myeloperoxidase; immunotherapy	INFLAMMATION; EOSINOPHILS; ACTIVATION; RADICALS; LUNG	Background: There is increasing evidence of neutrophil participation in asthma and the allergic process. After activation, neutrophils release myeloperoxidase (MPO) together with other granule enzymes, Objectives: In this study we attempted to evaluate the release of MPO in vitro by neutrophils from asthmatic patients and the relationship between neutrophil degranulation and lung function, measured as FEV1, of the patients. We also investigated the possible role of immunotherapy in the release of MPO by neutrophils, Methods: Neutrophils were stimulated with formyl-methionyl-leucyl-phenylalanine for 45 minutes at 37 degreesC. MPO released from neutrophils was assayed by using an MPO enzyme immunoassay, Results: Neutrophils released statistically significantly higher MPO levels in the asthmatic patients not receiving immunotherapy than in the healthy group. A significant inverse correlation was observed in the asthmatic group not receiving immunotherapy between MPO secretion and lung function, measured as FEV1, of the patients. Neutrophils of the asthmatic group receiving immunotherapy released significantly less MPO than did those of the asthmatic group not receiving immunotherapy, with MPO levels equal to those from nonallergic subjects. Conclusions: We conclude that neutrophils obtained from allergic asthmatic patients have an increased propensity to release MPO. The experiments described here provide evidence that there is a significant inverse relationship between levels of MPO released by neutrophils From allergic patients and lung function, as assessed by FEV1. Our study suggests that immunotherapy actively modifies the release of MPO in vitro by neutrophils from allergic asthmatic patients.	Univ Sevilla, Hosp Virgen Macarena, Serv Reg Inmunol & Alergia, Dept Med, Seville, Spain; Univ Sevilla, Fac Med, Dept Bioquim Med, Seville, Spain	Hospital Universitario Virgen Macarena; University of Sevilla; University of Sevilla	Monteseirin, J (corresponding author), Asunc 27,3 Izda, Seville 41011, Spain.			Sobrino, Francisco/0000-0002-4503-5739				BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOYUM A, 1986, SC J CLIN LAB INVE S, V97, P77; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; DANG Y, 1993, LEUKEMIA RES, V17, P1037, DOI 10.1016/0145-2126(93)90160-M; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; Jacobi HH, 1998, INT ARCH ALLERGY IMM, V116, P53, DOI 10.1159/000023925; Klebanoff S.J., 1982, ADV HOST DEFENSE MEC, P111; Monteseirin J, 1996, J EXP MED, V183, P2571, DOI 10.1084/jem.183.6.2571; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; STYRT B, 1988, J ALLERGY CLIN IMMUN, V81, P20, DOI 10.1016/0091-6749(88)90215-1; SULLIVAN GW, 1993, BLOOD, V81, P1863; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	17	44	51	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					623	626		10.1067/mai.2001.113566	http://dx.doi.org/10.1067/mai.2001.113566			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295649				2022-12-18	WOS:000168190100012
J	Hauk, PJ; Leung, DYM				Hauk, PJ; Leung, DYM			Tacrolimus (FK506): New treatment approach in superantigen-associated diseases like atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; TRIAL; EXOTOXINS; OINTMENT; CHILDREN; IGE		Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hauk, PJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.							Bieber T, 1998, J ALLERGY CLIN IMMUN, V102, P555, DOI 10.1016/S0091-6749(98)70270-2; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Tsytsykova AV, 2000, J EXP MED, V192, P581, DOI 10.1084/jem.192.4.581; WACHS GN, 1976, BRIT J DERMATOL, V95, P323, DOI 10.1111/j.1365-2133.1976.tb07021.x	10	44	47	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					391	392		10.1067/mai.2001.112848	http://dx.doi.org/10.1067/mai.2001.112848			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174211				2022-12-18	WOS:000167071400031
J	Goldberg, A; Confino-Cohen, R				Goldberg, A; Confino-Cohen, R			Insect sting-inflicted systemic reactions: Attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						insect allergy; epinephrine; after-sting behavior	ANAPHYLAXIS; ADRENALINE	Background: Patients with insect venom allergy are at higher risk for development of a recurrent systemic reaction after resting This risk significantly decreases with venom immunotherapy, Patients with insect venom allergy should be able to distinguish a life-threatening systemic reaction from all other various reactions after an insect sting. Accidental epinephrine injection by EpiPen has been reported in the past. Therefore patients with venom allergy should also be web trained in self-administration of their epinephrine when needed Objective: Our objective was to assess patients' attitudes regarding after-sting behavior and their capability to correctly self-administer the epinephrine autoinjector, Methods: All patients with venom allergy attending our allergy unit either before commencement of or during venom immunotherapy answered a questionnaire addressing various aspects of their intended after-sting behavior. Using an EpiPen trainer device, patients' performance of EpiPen self-administration was evaluated. Results: Ninety-six patients participated in the study, Seventy-six of them were equipped with an EpiPen device. Less than 30% of these patients carried it at all times. After re-sting 50 (54%) patients planned to wait for the development of other symptoms before taking any further action. Twenty-two percent of the patients said that after re-sting they mould immediately administer their EpiPen. Proper EpiPen administration technique was demonstrated by 44% of the patients. Having not reached the maintenance dose correlated with a better compliance with carrying of the EpiPen, EpiPen instruction provided by an allergist correlated with a better EpiPen administration technique by the patients. Conclusion: Many patients with venom allergy hold wrong ideas about after-sting behavior. Compliance with carrying EpiPen at all times and the ability to correctly administer it are both poor in most patients. Thorough and probably repeated instruction, both written and oral provided by knowledgeable physicians is mandatory.	Meir Hosp, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine	Goldberg, A (corresponding author), Meir Hosp, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel.							[Anonymous], 1994, J ALLERGY CLIN IMMUN, V94, P666; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; HUTCHESON PS, 1990, ANN ALLERGY, V64, P306; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; McGovern SJ, 1997, J ACCID EMERG MED, V14, P379; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1995, ALLERGY, V50, P783; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; YUNGINGER JW, 1998, ALLERGY PRINCIPLES P	11	44	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1184	1189		10.1067/mai.2000.110927	http://dx.doi.org/10.1067/mai.2000.110927			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112904				2022-12-18	WOS:000165930300023
J	Nakamura, Y; Christodoulopoulos, P; Cameron, L; Wright, E; Lavigne, F; Toda, M; Muro, S; Ray, A; Eidelman, DH; Minshall, E; Hamid, Q				Nakamura, Y; Christodoulopoulos, P; Cameron, L; Wright, E; Lavigne, F; Toda, M; Muro, S; Ray, A; Eidelman, DH; Minshall, E; Hamid, Q			Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; IL-5; GATA-3; transcription factors; allergen	MESSENGER-RNA EXPRESSION; HUMAN NASAL-MUCOSA; INDUCED RHINITIS; TOPICAL CORTICOSTEROIDS; INTERLEUKIN-5 PROMOTER; TISSUE EOSINOPHILIA; GENE-EXPRESSION; T-CELLS; ASTHMA; IL-13	Background: Allergic rhinitis is a complex upper airways disorder characterized by the infiltration of eosinophils and T-H2-type T lymphocytes. GATA-3 is a novel transcription factor recently shown to regulate IL-5 and, possibly, IL-4 gene expression. We previously reported that GATA-3 is increased within the bronchial mucosa of allergic asthmatic subjects compared with control subjects. Objective: In the present study we set out to determine whether there is also an increased number of cells expressing GATA-3 messenger (m)RNA within the nasal mucosa of patients with allergic rhinitis. Methods: Inferior turbinate biopsy specimens mere obtained from patients with allergic rhinitis and nonatopic control subjects before and after local allergen provocation in vivo. To assess the contribution of resident cells expressing GATA-3 mRNA, we also performed isolated explant studies in which nasal mucosal tissue from subjects with allergic rhinitis and nonatopic control subjects was cultured in allergen-treated medium The presence of mRNA coding for GATA-3, IL-5, IL-4, IL-13, and GM-CSF was assessed by using in situ hybridization. Results: The number of GATA-3 mRNA(+) cells was increased after local allergen provocation in vivo (increase in GATA-3 mRNA(+) cells [mean +/- SEM]: subjects,vith allergic rhinitis, 11.3 +/- 8.7; control subjects, 1.2 +/- 4.1; P < .05) and in explanted nasal mucosa in vitro (subjects with allergic rhinitis, 10.2 +/- 3.8; control subjects, 2.7 +/- 4.4; P < .05). The gene expression of GATA-3 was significantly correlated to the numbers of IL-5 (r = 0.87) and GM-CSF (r = 0.79) mRNA(+) cells but not with IL-4 or IL-13 mRNA(+) cells. Conclusion: In summary, the expression of the transcription factor GATA-3 was increased after allergen challenge, and this was evident in the absence of de novo inflammatory cell recruitment. GATA-3 may be a potential target in the treat ment of allergic diseases, such as rhinitis.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Jewish Gen Hosp, SMBD, Dept Otolaryngol Head & Neck Surg, Montreal, PQ H3T 1E2, Canada; Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Sect, New Haven, CT 06510 USA	McGill University; McGill University; Universite de Montreal; Yale University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Ghaffar O, 2000, CLIN EXP ALLERGY, V30, P86; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Simon HU, 1997, J IMMUNOL, V158, P3902; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	27	44	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1146	1152		10.1067/mai.2000.107045	http://dx.doi.org/10.1067/mai.2000.107045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856149				2022-12-18	WOS:000087781800016
J	Pandjaitan, B; Swoboda, I; Brandejsky-Pichler, F; Rumpold, H; Valenta, R; Spitzauer, S				Pandjaitan, B; Swoboda, I; Brandejsky-Pichler, F; Rumpold, H; Valenta, R; Spitzauer, S			Escherichia coli expression and purification of recombinant dog albumin, a cross-reactive animal allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						animal allergy; recombinant allergen; dog albumin; cross-reactivity	HUMAN-SERUM-ALBUMIN; GROUP-SPECIFIC COMPONENT; AMINO-ACID-SEQUENCE; ALPHA-FETOPROTEIN; IMMUNOLOGICAL CHARACTERIZATION; HUMAN IGE; CAT; PROTEIN; BINDING; ANTIBODIES	Background: Animal hair-dander represents an important source of indoor allergens. Diagnosis and therapy of animal allergy would benefit from the availability of defined recombinant allergens. They may be preferred to animal-derived proteins, particularly for in vivo application in patients. Objective: The purpose of this study was to express and purify recombinant dog albumin, an important cross-reactive animal allergen. Methods: Complementary (c)DNA sequences coding for dog albumin were obtained by reverse transcription and subsequent PCR amplification from dog liver RNA. Dog albumin-encoding cDNA sequences were inserted into phage lambda gt11, and IgE-reactive phage clones were isolated by immunoscreening with serum IgE from a patient with dog allergy. Dog albumin was expressed as IgE-reactive recombinant protein in Escherichia coli and purified by inclusion body preparation, resolubilization, and diethylaminoethyl cellulose chromatography. Cross-reactivity of dog albumin with cat and human albumin was examined by immunoblot, as well as ELISA inhibition experiments. Results: A cDNA sequence coding for complete dog albumin was obtained by reverse transcription and subsequent PCR amplification from dog liver. The cDNA and deduced amino acid sequence of dog albumin was highly homologous to the sequences of albumins from animals to human subjects, thus explaining the extensive cross-reactivities among albumins. Recombinant dog albumin was expressed in E coli and purified, It reacted with serum IgE from patients allergic to dog albumin and a monoclonal anti-human albumin antibody. Immunologic competition experiments performed with serum IgE from patients allergic to dog albumin and a mouse monoclonal antihuman albumin antibody indicated the presence of similar epitopes on dog, cat, and human albumin. Conclusion: Recombinant dog albumin may be used for diagnostic purposes to identify patients who are cross-sensitized to many animal species and perhaps for specific immunotherapy of sensitized individuals.	AKH, Inst Med & Chem Lab Diagnost, Vienna, Austria; Univ Vet Med, Dept Internal Med, Vienna, Austria; Univ Vienna, AKH, Inst Gen & Expt Pathol, Vienna, Austria	University of Veterinary Medicine Vienna; University of Vienna	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, Inst Gen & Expt Pathol, Mol Immunopathol Grp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Valenta, Rudolf/0000-0001-5944-3365; Swoboda, Ines/0000-0002-9164-1721				Battey, 1986, BASIC METHODS MOL BI; BENJAMIN DC, 1987, HYBRIDOMA, V6, P183, DOI 10.1089/hyb.1987.6.183; Botros HG, 1996, IMMUNOLOGY, V88, P340, DOI 10.1046/j.1365-2567.1996.d01-669.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; GOETZL EJ, 1972, J IMMUNOL, V108, P785; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HAEFLIGER DN, 1989, J MOL EVOL, V29, P344, DOI 10.1007/BF02103621; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Heidelberger M, 1938, J AM CHEM SOC, V60, P242, DOI 10.1021/ja01269a006; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Hilger C, 1996, GENE, V169, P295, DOI 10.1016/0378-1119(95)00851-9; HO JX, 1993, EUR J BIOCHEM, V215, P205, DOI 10.1111/j.1432-1033.1993.tb18024.x; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, J IMMUNOL, V157, P4953; MOREL GA, 1988, MOL IMMUNOL, V25, P7, DOI 10.1016/0161-5890(88)90085-5; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; PETERS JH, 1969, J BIOL CHEM, V244, P2068; Peters T., 1996, ALL ALBUMIN; Restani P, 1998, INT ARCH ALLERGY IMM, V117, P113, DOI 10.1159/000023997; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SCHOENTGEN F, 1985, FEBS LETT, V185, P47, DOI 10.1016/0014-5793(85)80738-9; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)70306-3; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; WUTHRICH B, 1985, CLIN ALLERGY, P1587	38	44	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				279	285		10.1016/S0091-6749(00)90077-0	http://dx.doi.org/10.1016/S0091-6749(00)90077-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669848				2022-12-18	WOS:000085402200012
J	Goldman, M; Rachmiel, M; Gendler, L; Katz, Y				Goldman, M; Rachmiel, M; Gendler, L; Katz, Y			Decrease in asthma mortality rate in Israel from 1991-1995: Is it related to increased use of inhaled corticosteroids?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; mortality; Israel; inhaled corticosteroids	NEW-ZEALAND; RISK; TRENDS; DEATHS; CHILDREN; SALES; DRUGS; TERM	Background: Asthma mortality rates (AMRs) during the last several decades increased in many countries with developed medical services, including Israel. The reasons for this trend were never established. Recent data suggested that this trend is changing. Objectives: We sought to compare the AMR in Israel during 1991-1995 with that of the previous decade and to investigate a possible correlation between mortality rates and use of inhaled corticosteroids (ICSs) and beta(2)-agonists. Methods: Statistical data on the AMR in Israel during 1981-1995 were extracted. Data were analyzed for 5- and 10-year periods (1981-1990) and compared with a 5-year period (1991-1995). Data on ICS and beta(2)-agonist sales were extracted from the marketing companies' official reports. Results: The mean AMR per 100,000 population per year during 1981-1990 in the 5- to 34-year-old group was 0.393 +/- 0.055 and decreased to 0.202 +/- 0.046 during the 1991-1995 period (P = .03). There was no significant difference between changes in mean AMR in the 35- to 64-year-old or in the 5- to 64-year-old group during the same periods (4.568 vs 4.063 and 2.480 vs 2.133). The mean ICS unit sales rates (per 100,000 population per year) between 1982-1990 and 1991-1995 were 21.70 and 190.45, respectively (P < .05). The correlation between ICS sales and AMR was -0.631 (P = .016). Sales of beta(2)-agonists did not change significantly during the study period. Conclusions: We identified a trend of decreased AMRs in Israel during 1991-1995. The decline in AMRs paralleled the increase in ICS sales, whereas the sales of inhaled beta(2)-agonists did not change significantly. One may speculate that the decrease in AMR may be the result of better anti-inflammatory treatment, as reflected by the increased use of ICSs, The feasibility of reducing AMRs in a country such as Israel, with low AMRs to start with, by improving medical treatment is encouraging.	Assaf Harofeh Med Ctr, Pulm & Allergy Inst, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Pediat, IL-70300 Zerifin, Israel; Sackler Fac Med, Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Katz, Y (corresponding author), Assaf Harofeh Med Ctr, Pulm & Allergy Inst, IL-70300 Zerifin, Israel.			Rachmiel, Marianna/0000-0002-0852-0831				Anthonisen NR, 1999, CHEST, V115, P3, DOI 10.1378/chest.115.1.3; *BRIT THOR ASS, 1982, BMJ-BRIT MED J, V285, P1251; *BRIT THOR SOC, 1984, THORAX, V39, P505; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; Hanania NA, 1997, CHEST, V111, P290, DOI 10.1378/chest.111.2.290; ISHIHARA K, 1995, INTERNAL MED, V34, P77, DOI 10.2169/internalmedicine.34.77; KALINER MA, 1993, JAMA-J AM MED ASSOC, V269, P1994, DOI 10.1001/jama.269.15.1994; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; Livne M, 1996, ANN ALLERG ASTHMA IM, V76, P261, DOI 10.1016/S1081-1206(10)63438-2; Mayor S, 1999, BRIT MED J, V318, P8; McLoone P, 1997, BRIT MED J, V315, P1013; MELISSINOS CG, 1995, CHEST, V107, P1771, DOI 10.1378/chest.107.6.1771-b; Mormile F, 1996, J CLIN EPIDEMIOL, V49, P1459, DOI 10.1016/S0895-4356(96)00188-6; Nishimura K, 1999, CHEST, V115, P31, DOI 10.1378/chest.115.1.31; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SLY RM, 1994, ANN ALLERGY, V73, P439; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P347, DOI 10.1016/S1081-1206(10)63195-X; Smyth ET, 1996, THORAX, V51, P293, DOI 10.1136/thx.51.3.293; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Strunk RC, 1998, LUNG BIOL HEALTH DIS, V115, P31; Vergara C, 1998, ANN ALLERG ASTHMA IM, V80, P55, DOI 10.1016/S1081-1206(10)62940-7; VOLLMER WM, 1992, J CLIN EPIDEMIOL, V45, P999, DOI 10.1016/0895-4356(92)90115-4	29	44	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				71	74		10.1016/S0091-6749(00)90180-5	http://dx.doi.org/10.1016/S0091-6749(00)90180-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629455				2022-12-18	WOS:000084992100010
J	Fleischer, AB				Fleischer, AB			Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NY			eczema; corticosteroid; FK-506; atopy	CONTACT-DERMATITIS; FK506 OINTMENT; CYCLOSPORINE-A; CHILDREN; TRIAL; TRANSPLANTATION; EFFICACY; UPDATE; CELLS	Atopic dermatitis is a chronic, relapsing form of eczema characterized by scaling, itchy, inflamed skin that can be triggered by an interplay of genetic, immunologic, and environmental factors. Immune dysregulation appears to play an important role in the cause of atopic dermatitis, Topical corticosteroid agents have been the mainstay of therapy for atopic dermatitis because of their broad immunomodulatory effects. However, topical corticosteroid agents are not ideal agents because when used over the long term, they may cause cutaneous atrophy and immunosuppression. Systemic corticosteroidal agents, certain antihistiminic agents, systemic cyclosporin, and phototherapy have proven value in treating patients with atopic dermatitis, In the search for a noncorticosteroidal topical agent, tacrolimus stands out as being uniquely suited for this condition. Tacrolimus affects a broad spectrum of inflammatory mediators and processes known to be relevant to atopic dermatitis pathogenesis, Tacrolimus demonstrates good percutaneous penetration and appears to have no potential to cause cutaneous atrophy, There are multiple double-blind controlled studies demonstrating the safety and efficacy of this agent in treating atopic dermatitis, The agent may be of particular benefit in children, among whom an alternative to the chronic use of corticosteroid agents, either topically or systemically is highly desirable.	Wake Forest Univ, Sch Med, Dept Dermatol, Winston Salem, NC 27157 USA	Wake Forest University	Fleischer, AB (corresponding author), Wake Forest Univ, Sch Med, Dept Dermatol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	afleisch@wfubmc.edu						Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; AOYAMA H, 1995, BRIT J DERMATOL, V133, P494, DOI 10.1111/j.1365-2133.1995.tb02691.x; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; de Prost Y, 1989, Acta Derm Venereol Suppl (Stockh), V144, P136; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; EberleinKonig B, 1997, ARCH DERMATOL RES, V289, P606, DOI 10.1007/s004030050248; Hanifin JM, 1996, ARCH DERMATOL, V132, P1230, DOI 10.1001/archderm.132.10.1230; Jordan ML, 1996, WORLD J UROL, V14, P239; Kawashima M, 1996, LANCET, V348, P1240, DOI 10.1016/S0140-6736(05)65512-2; KELLY PA, 1995, AM J HEALTH-SYST PH, V52, P1521, DOI 10.1093/ajhp/52.14.1521; LANGELAND T, 1994, ALLERGY, V49, P22, DOI 10.1111/j.1398-9995.1994.tb00768.x; LAROSA M, 1994, ANN ALLERGY, V73, P117; Larsen FS, 1996, PEDIAT ALLERG IMM-UK, V7, P51, DOI 10.1111/j.1399-3038.1996.tb00395.x; LAWRENCE ID, 1998, DERMATOL THER, V5, P74; LINDE YW, 1992, ACTA DERM-VENEREOL, P9; LUBACH D, 1995, DERMATOLOGY, V190, P51, DOI 10.1159/000246635; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; PIERARD GE, 1989, ACTA DERM-VENEREOL, P26; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Rothe MJ, 1996, J AM ACAD DERMATOL, V35, P1, DOI 10.1016/S0190-9622(96)90486-7; Rudikoff D, 1998, LANCET, V351, P1715, DOI 10.1016/S0140-6736(97)12082-7; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SAMPSON HA, 1992, ANN ALLERGY, V69, P469; SAWADA S, 1987, J IMMUNOL, V139, P1797; SMITH EW, 1995, CURR PROBL DERMATOL, V22, P124; Spencer CM, 1997, DRUGS, V54, P925, DOI 10.2165/00003495-199754060-00009; THOMSON AW, 1986, LANCET, V2, P971; UMEKI S, 1994, J ASTHMA, V31, P19, DOI 10.3109/02770909409056765	30	44	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S126	S130		10.1016/S0091-6749(99)70055-2	http://dx.doi.org/10.1016/S0091-6749(99)70055-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	242FP	10482864				2022-12-18	WOS:000082928500007
J	Hanifin, JM; Tofte, SJ				Hanifin, JM; Tofte, SJ			Update on therapy of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NY			atopic dermatitis; bathing/moisturizing; trigger factors	TACROLIMUS OINTMENT; INHIBITORS; CHILDREN; TRIAL	Atopic dermatitis (AD) is complicated and often difficult to manage. Effective therapy is commonly impeded by 3 ambivalencies: (1) prioritization of skin care versus allergy treatment; (2) uncertainty about optimal bathing and moisturizing, and (3) hesitation about the use of adequate topical corticosteroid therapies. With a confident, well-planned approach, effective therapy management may be achieved. On initial assessment, an evaluation form is a tool to keep the focus on important history and physical features critical for the diagnosis and to review trigger factors and past therapies. Patients and parents must be educated to become more aware of the trigger factors that may lead to an exacerbation of their disease. Errors in bathing and moisturizing are the major cause of persistent AD, and the confusing parades that water is both good and bad for the skin must be resolved to achieve therapeutic success, Avoidance/approach conflicts regarding recommendations of topical steroid use has a detrimental effect on patient outcomes, With the proper use of mid-strength topical agents and with the recent development of topical macrolides for use in AD, effective management for this disease can be realized.	Oregon Hlth & Sci Univ, Dept Dermatol L468, Portland, OR 97201 USA	Oregon Health & Science University	Hanifin, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol L468, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Christensen SB, 1998, J MED CHEM, V41, P821, DOI 10.1021/jm970090r; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; HANIFIN JM, 1995, J INVEST DERMATOL, V105, pS84, DOI 10.1111/1523-1747.ep12316116; HANIFIN JM, 1986, CLIN REV ALLERG, V4, P43; HANIFIN JM, 1992, MAST CELL HLTH DIS, P639; HANIFIN JM, 1993, ALLERGY PRINCIPLES P, P1581; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; LAPIDUS CS, 1993, J AM ACAD DERMATOL, V28, P699, DOI 10.1016/0190-9622(93)70096-C; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Stevens SR, 1998, ARCH DERMATOL, V134, P799, DOI 10.1001/archderm.134.7.799; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; WHITMORE SE, 1994, DERMATOL CLIN, V12, P491, DOI 10.1016/S0733-8635(18)30153-0	15	44	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S123	S125		10.1016/S0091-6749(99)70054-0	http://dx.doi.org/10.1016/S0091-6749(99)70054-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	242FP	10482863				2022-12-18	WOS:000082928500006
J	Page, CP; Morley, J				Page, CP; Morley, J			Contrasting properties of albuterol stereoisomers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						racemic albuterol; levalbuterol; enantiomers; asthma; bronchodilation; bronchoprotection; airway hyperreactivity; eosinophils; beta-adrenoceptor; calcium ions	AIRWAY SMOOTH-MUSCLE; STEREOSELECTIVE SULFATE CONJUGATION; GUINEA-PIGS; ADRENERGIC-RECEPTORS; REGULAR SALBUTAMOL; ASTHMATIC SUBJECTS; INHALED ALBUTEROL; IN-VITRO; HYPERREACTIVITY; INCREASES	Racemic albuterol is composed of an equimolar mixture of stereoisomers, For asthma therapy, (R)-albuterol is the eutomer and (S)-albuterol is the distomer, By interacting with beta(2)-adrenoceptors, (R)-albuterol has bronchodilator, bronchoprotective, anti-edematous properties and inhibits activation of mast cells and eosinophils, (S)-albuterol does not activate beta(2)-adrenoceptors and does not modify activation of beta(2)-adrenoceptors by (R)-albuterol so that for many Sears it was presumed to be biologically inert. Recently, it has been established that regular and excessive use of racemic albuterol induces paradoxical reactions in some subjects with asthma, Because such effects cannot be accounted for by activation of beta(2)-adrenoceptors, the pharmacologic profile of (S)-albuterol has been more carefully defined. (S)-albuterol has distinctive pharmacologic properties that are unrelated to activation of beta(2)-adrenoceptors. Thus, (S)-albuterol intensifies bronchoconstrictor responses of sensitized guinea pigs and induces hypersensitivity of asthmatic airways; it also promotes the activation of human eosinophils in vitro. These actions of (S)-albuterol may explain why racemic albuterol can intensify allergic bronchospasm and promote eosinophil activation in asthmatic airways. The capacity of (S)-albuterol to elevate intracellular Ca2+ would account for the paradox because this action will oppose, or even nullify, the consequences of adenylyl cyclase activation by (R)-albuterol, Because (S)-albuterol is metabolized more slowly than (R)-albuterol and is retained preferentially within the airways, paradoxical effects become more prominent during regular and excessive use of racemic albuterol, Because (S)-albuterol has detrimental effects in asthmatic airways, levalbuterol [homochiral (R)-albuterol] should have advantages over racemic albuterol in therapy for asthma.	Guys Kings & St Thomas Sch Biomed Sci, Sackler Inst Pulm Pharmacol, Div Pharmacol & Therapeut, London, England; Guys Kings & St Thomas Sch Med, Dept Resp Med & Allergy, London, England	University of London; King's College London; University of London; King's College London	Morley, J (corresponding author), Mill House,60 Green, St Neots PE19 4TQ, Cambs, England.							ANDERSON GP, 1994, EUR RESPIR J, V7, P569, DOI 10.1183/09031936.94.07030569; ARIENS EJ, 1993, TRENDS PHARMACOL SCI, V14, P68, DOI 10.1016/0165-6147(93)90033-G; BAI TR, 1992, LUNG, V170, P125; BARLOW RB, 1972, J PHARM PHARMACOL, V24, P753, DOI 10.1111/j.2042-7158.1972.tb08879.x; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BERENBAUM MC, 1989, ASTHMA REV, V2, P27; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; BRITTAIN RT, 1973, BRIT J PHARMACOL, V48, P144, DOI 10.1111/j.1476-5381.1973.tb08232.x; BUCHHEIT KH, 1995, EUR J PHARMACOL, V287, P85, DOI 10.1016/0014-2999(95)00613-3; Buchheit KH, 1997, N-S ARCH PHARMACOL, V355, P217, DOI 10.1007/PL00004935; Buchheit KH, 1996, N-S ARCH PHARMACOL, V354, P355; BUCKNER CK, 1974, J PHARMACOL EXP THER, V189, P616; CONNOLLY ME, 1976, J CLIN INVEST, V58, P1307; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; Crowther SD, 1997, LANCET, V350, P1450, DOI 10.1016/S0140-6736(05)64212-2; Crowther SD, 1997, CLIN EXP ALLERGY, V27, P606; CUTRER FM, 1995, NEUROSCIENCE, V64, P741, DOI 10.1016/0306-4522(94)00428-8; Easson LH, 1933, BIOCHEM J, V27, P1257, DOI 10.1042/bj0271257; Eaton EA, 1996, BRIT J CLIN PHARMACO, V41, P201, DOI 10.1111/j.1365-2125.1996.tb00183.x; FOSTER A, 1992, BRIT J PHARMACOL, V106, pP3; Fried KM, 1998, CHIRALITY, V10, P484, DOI 10.1002/(SICI)1520-636X(1998)10:5<484::AID-CHIR11>3.0.CO;2-W; GALLANT SP, 1978, NEW ENGL J MED, V299, P933; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Handley D A, 1998, Expert Opin Investig Drugs, V7, P1601, DOI 10.1517/13543784.7.10.1601; Handley DA, 1997, SYMPATHOMIMETIC ENANTIOMERS IN THE TREATMENT OF ASTHMA, P61; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P151, DOI 10.1254/jjp.63.151; JANSON C, 1991, EUR RESPIR J, V4, P544; JENNE JW, 1987, DRUG THERAPY ASTHMA, P213; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; Kallos P, 1937, ACTA MED SCAND, V91, P292; KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441; Kallstrom BL, 1996, CHIRALITY, V8, P567; KAUMANN AJ, 1984, J PHYSL, V348; Keir SD, 1999, AM J RESP CRIT CARE, V159, pA875; KERREBIJN KF, 1991, ASTHMA ITS PATHOLOGY, P523; KOCH P, 1997, AM J RESP CRIT CARE, V173, pA279; Kotlikoff MI, 1996, ANNU REV PHYSIOL, V58, P115, DOI 10.1146/annurev.ph.58.030196.000555; LEMOINE H, 1992, LUNG, V170, P163; LIBRETTO SE, 1994, ARCH TOXICOL, V68, P213, DOI 10.1007/s002040050059; MASSON P, 1996, AM J RESP CRIT CARE, V153, pA627; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; MAZZONI L, 1985, BRIT J PHARMACOL, V86, P571; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; MORGAN DJ, 1986, BRIT J CLIN PHARMACO, V22, P587, DOI 10.1111/j.1365-2125.1986.tb02939.x; Morley J, 1996, CLIN REV ALLERG IMMU, V14, P65, DOI 10.1007/BF02772204; MURAKI K, 1994, BRIT J PHARMACOL, V111, P1154, DOI 10.1111/j.1476-5381.1994.tb14866.x; MURAKI K, 1993, J PHYSIOL-LONDON, V471, P563, DOI 10.1113/jphysiol.1993.sp019916; MURUGAIAH KD, 1994, RES COMMUN MOL PATH, V86, P311; NEY UM, 1983, BRIT J PHARMACOL, V79, P1003, DOI 10.1111/j.1476-5381.1983.tb10548.x; OCONNOR BJ, 1999, TRENDS PHARMACOL SCI, V20, P527; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; PESOLA GR, 1992, RES COMMUN CHEM PATH, V75, P125; POTTER DE, 1983, CURR EYE RES, V2, P711; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; SANJAR S, 1990, J PHYSIOL-LONDON, V425, P43, DOI 10.1113/jphysiol.1990.sp018091; SANJAR S, 1988, LANCET, V2, P1601; SHEPPARD D, 1988, AM REV RESPIR DIS, V138, P547, DOI 10.1164/ajrccm/138.3.547; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; TAKUWA Y, 1988, J BIOL CHEM, V263, P762; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749, DOI 10.1164/ajrccm.154.3.8810615; VIAU C, 1998, ACAAI ANN M PHIL PA; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; WALDECK B, 1993, CHIRALITY, V5, P350, DOI 10.1002/chir.530050514; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; WANG ZL, 1994, AM J RESP CRIT CARE, V149, P960, DOI 10.1164/ajrccm.149.4.8143062; WARNER JO, 1994, EUR RESPIR REV, V4, P21; WILLIAMS JC, 1983, EUR J PHARMACOL, V88, P347, DOI 10.1016/0014-2999(83)90585-X; WITTENDERBY PA, 1993, EUR J PHARMACOL, V241, P121, DOI 10.1016/0014-2999(93)90942-B; YATES DH, 1995, EUR RESPIR J, V8, P1847, DOI 10.1183/09031936.95.08111847; YEH CK, 1988, FEBS LETT, V240, P118, DOI 10.1016/0014-5793(88)80351-X; YUKAWA T, 1990, AM REV RESPIR DIS, V141, P1446, DOI 10.1164/ajrccm/141.6.1446	74	44	46	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S31	S41		10.1016/S0091-6749(99)70271-X	http://dx.doi.org/10.1016/S0091-6749(99)70271-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452786	Bronze			2022-12-18	WOS:000082419400004
J	Bayram, H; Devalia, JL; Khair, OA; Abdelaziz, MM; Sapsford, RJ; Czarlewski, W; Campbell, AM; Bousquet, J; Davies, RJ				Bayram, H; Devalia, JL; Khair, OA; Abdelaziz, MM; Sapsford, RJ; Czarlewski, W; Campbell, AM; Bousquet, J; Davies, RJ			Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						loratadine; nitrogen dioxide electrical resistance; inflammatory mediators; bronchial epithelial cells	IN-VITRO; ANTIALLERGIC ACTIVITY; INHIBITORY ACTIVITY; ALLERGIC RHINITIS; POLLEN ALLERGY; NITRIC-OXIDE; HISTAMINE; ACTIVATION; EXPRESSION; ANTIHISTAMINE	Background: Recent studies have demonstrated that some antihistamines can attenuate histamine-induced release of inflammatory mediators from bronchial epithelial cells. Objective: The purpose of study was to test the hypothesis that Loratadine may influence pollution-induced inflammation of the airways by modulating epithelial membrane integrity and the synthesis and/or release of inflammatory mediators from airway epithelial cells. Methods: We have cultured human bronchial epithelial cell (HBEC) cultures from surgical explants and investigated the effect of loratadine on NO2-induced changes in both electrical resistance of HBEC cultures and release of IL-8, RANTES, and soluble intercellular adhesion molecule-1 (sICAM-1) from these cells after exposure for 6 hours to either air or 400 ppb NO2. Results: Exposure for 6 hours to NO2 significantly decreased the electrical resistance of HBEC cultures by 18.1% from baseline (P <.05). Incubation with 0.25 to 25 mu mol/L loratadine did not alter the NO2-induced decrease in the electrical resistance of HBEC cultures. NO2 also significantly increased the release of IL-8 from a control value of 52.5 pg/mu g cellular protein to 81.9 pg/mu g cellular protein (P <.05), RANTES from a control value of 0.023 pg/mu g cellular protein to 0.062 pg/mu g cellular protein (P <.05), and sICAM-1 from a control value of 7.7 pg/mu g cellular protein to 16.3 pg/mu g cellular protein (P <.05), The NO2-induced release of all 3 mediators was significantly attenuated by incubation of HBECs with 25 mu mol/L loratadine. Incubation with 2.5 mu mol/L loratadine also significantly attenuated the NO2-induced release of RANTES and sICAM-1, but not IL-8. Conclusions: These results suggest that loratadine has the potential to reduce airway inflammation by modulating the release of inflammatory cytokines from airway epithelial cells.	London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, London E2 9JX, England; Schering Plough France Ltd, Levallois Perret, France; City Hosp Univ, Hop Arnaud Villeneuve, INSERM, U454, Montpellier, France	University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Devalia, JL (corresponding author), London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, Bonner Rd, London E2 9JX, England.		Bousquet, Jean/O-4221-2019; Bayram, Hasan/ABE-5094-2021	Bayram, Hasan/0000-0002-5236-766X				Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Amsellem C, 1996, GEN PHARMACOL-VASC S, V27, P269, DOI 10.1016/0306-3623(95)02009-8; ARAI K, 1992, ALLERGY CLIN IMMUNOL, V4, P110; BAGNASCO M, 1995, ALLERGY, V50, P17, DOI 10.1111/j.1398-9995.1995.tb04259.x; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; Baroody FM, 1996, ARCH OTOLARYNGOL, V122, P309; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUSQUET J, 1995, ADV THER, V12, P283; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; CARTER JD, 1994, AM J RESP CRIT CARE, V149, pA319; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1175; CIPRANDI G, 1995, CLIN EXP ALLERGY, V25, P871, DOI 10.1111/j.1365-2222.1995.tb00030.x; Ciprandi G, 1996, J ALLERGY CLIN IMMUN, V98, P1088, DOI 10.1016/S0091-6749(96)80196-5; *DEP HLTH ADV GROU, 1991, 1 DEP HLTH ADV GROUP; *DEP HLTH ADV GROU, 1993, 3 DEP HLTH ADV GROUP; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, RESP MED, V87, P405, DOI 10.1016/0954-6111(93)90064-7; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DuBuske LM, 1996, J ALLERGY CLIN IMMUN, V98, pS307, DOI 10.1016/S0091-6749(96)80116-3; EDA R, 1993, ANN ALLERGY, V71, P373; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1111/j.1365-2222.1997.tb00745.x; GREIFF L, 1995, J ALLERGY CLIN IMMUN, V96, P97, DOI 10.1016/S0091-6749(95)70038-2; HARIA M, 1994, DRUGS, V48, P617, DOI 10.2165/00003495-199448040-00009; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KENNEDY JP, 1993, J BIOMAT SCI-POLYM E, V4, P1; KLEINETEBBE J, 1994, J ALLERGY CLIN IMMUN, V93, P494, DOI 10.1016/0091-6749(94)90359-X; LETARI O, 1994, EUR J PHARM-MOLEC PH, V266, P219, DOI 10.1016/0922-4106(94)90130-9; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARONE G, 1994, J ALLERGY CLIN IMMUN, V93, P258; MIADONNA A, 1994, CLIN EXP ALLERGY, V25, P364; Molet S, 1997, CLIN EXP ALLERGY, V27, P1167; MUEGGE K, 1989, New Biologist, V1, P239; NICOTERA P, 1987, MECHANISMS CELL INJU, P115; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; RUSZNAK C, 1996, EUR RESPIR J, V9, P2296; VIGNOLA AM, 1993, AM J RESP CELL MOL, V9, P411, DOI 10.1165/ajrcmb/9.4.411; VIGNOLA AM, 1995, ALLERGY, V50, P200, DOI 10.1111/j.1398-9995.1995.tb01133.x; Wang JH, 1999, CLIN EXP ALLERGY, V29, P234; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145	43	44	58	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					93	99		10.1016/S0091-6749(99)70119-3	http://dx.doi.org/10.1016/S0091-6749(99)70119-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400845				2022-12-18	WOS:000081738900014
J	Fahy, O; Tsicopoulos, A; Hammad, H; Pestel, J; Tonnel, AB; Wallaert, B				Fahy, O; Tsicopoulos, A; Hammad, H; Pestel, J; Tonnel, AB; Wallaert, B			Effects of diesel organic extracts on chemokine production by peripheral blood mononuclear cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel; chemokines; PBMC; inflammation; air pollution	ARYL-HYDROCARBON RECEPTOR; HUMAN B-CELLS; EXHAUST PARTICLES; IGE PRODUCTION; AH-RECEPTOR; HUMAN EOSINOPHILS; EPITHELIAL-CELLS; GENE-EXPRESSION; IN-VITRO; RANTES	Background: Polyaromatic hydrocarbons (PAHs) associated with diesel exhaust particles (DEPs) are found in the atmospheric urban pollution. Such compounds have been shown to favor IgE production, bronchial hyperresponsiveness, and airway inflammation. Chemokines are a group of chemotactic cytokines involved in the recruitment of inflammatory cells. Objective: We investigated the effect of DEP-PAHs on the release and mRNA expression of IL-8, MCP-1, and RANTES by PBMCs obtained from healthy subjects. Methods: Protein production in supernatants was assessed by ELISA, and mRNA expression was evaluated by semiquantitative RT-PCR. Results: Secretion of IL-8 and RANTES increased in a dose-dependent manner with increasing concentrations of DEP-PAHs (range, 0.5 ng to 50 ng/mL). On the contrary, the release of MCP-1 was significantly inhibited, also in a dose-dependent manner. Messenger RNA production coding for IL-8, RANTES, and MCP-1 showed parallel variations to the production of the correspondent proteins. Effects of DEP-PAHs became significant at 7 hours and up to 48 hours time culture for MCP-1, and up to 24 hours time culture for IL-8 and RANTES. Moreover, supernatants from DEP-PAH-activated cells, compared with those of controls, exhibited a significantly enhanced chemotactic activity for neutrophils and eosinophils, which was significantly inhibited by pretreatment with anti-IL-8 and anti-RANTES neutralizing antibodies, respectively. Conclusion: These findings suggest that the chemokine pathways are modulated by DEP-PAHs at the transcriptional level, reinforcing the idea that the development of inflammatory reactions might be affected by diesel exhaust emission.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; CHRU, Hop A Calmette, Dept Pneumol, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	Tonnel, AB (corresponding author), Inst Pasteur, INSERM, U416, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.		Hammad, Hamida/J-9391-2015; Tsicopoulos, Anne/C-2260-2019	Hammad, Hamida/0000-0003-3762-8603; Tsicopoulos, Anne/0000-0002-1579-2763				Akoum H, 1998, CYTOKINE, V10, P706, DOI 10.1006/cyto.1998.0348; ALAM R, 1993, J IMMUNOL, V150, P3442; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHAN WK, 1994, J BIOL CHEM, V269, P26464; DEL PG, 1988, J IMMUNOL, V140, P4193; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gebremichael A, 1996, TOXICOL APPL PHARM, V141, P76; GRANT GFM, 1994, ENV HLTH PERSPECT, V102, P111; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kanemitsu H, 1998, BIOL PHARM BULL, V21, P129; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; Kimata H, 1996, J EXP MED, V183, P2397, DOI 10.1084/jem.183.5.2397; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; Molet S, 1998, J LEUKOCYTE BIOL, V63, P351, DOI 10.1002/jlb.63.3.351; Morgan WKC, 1997, ANN OCCUP HYG, V41, P643, DOI 10.1093/annhyg/41.6.643; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Saneyoshi K, 1997, INT ARCH ALLERGY IMM, V114, P237, DOI 10.1159/000237674; Shi HZ, 1997, AM J RESP CELL MOL, V16, P220, DOI 10.1165/ajrcmb.16.3.9070605; *SOC FRANC SANT PU, 1996, COLL SANT SOC, V4; Sogawa K, 1997, J BIOCHEM, V122, P1075; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167, DOI 10.1159/000237663; Teran LM, 1996, CLIN EXP ALLERGY, V26, P1005, DOI 10.1111/j.1365-2222.1996.tb00640.x; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; WELLER PF, 1994, CURR OPIN IMMUNOL, V6, P85, DOI 10.1016/0952-7915(94)90038-8	36	44	46	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1115	1124		10.1016/S0091-6749(99)70187-9	http://dx.doi.org/10.1016/S0091-6749(99)70187-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359894				2022-12-18	WOS:000080929500021
J	Terrien, MH; Rahm, F; Fellrath, JM; Spertini, F				Terrien, MH; Rahm, F; Fellrath, JM; Spertini, F			Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fexofenadine; terfenadine; nasal provocation lest; acoustic rhinometry; antihistamine; allergen challenge; allergic rhinitis	EFFICACY; HYDROCHLORIDE; CHALLENGE; SAFETY	Background: Fexofenadine, the hydrochloride salt of terfenadine active metabolite, is a nonsedative, noncardiotoxic antihistamine derivative for the treatment of allergic rhinitis. Objective: We sought to compare the effects of terfenadine and fexofenadine on nasal provocation tests with allergen. Methods: A preliminary provocation test (screening phase) was performed in 25 patients with a history of seasonal allergic rhinitis to grass pollen to determine the combined nasal reaction threshold, which was defined as 2 of the 3 following criteria: (1) at least a 40% decrease in peak nasal inspiratory now and/or a 30% decrease in minimal cross-sectional area as measured by acoustic rhinometry, nasal secretions of 0.5 g, and 5 to 10 sneezes per minute. Patients were then included into a double-blind, randomized, 2-way crossover study to receive terfenadine or fexofenadine 120 mg 2 hours before provocation, Rhinorrhea, sneezing, peak nasal flow, and minimal nasal cross-sectional area, as well as symptom scores for nasal congestion and itchiness, were recorded at each allergen concentration up to the reaction threshold. The whole study was performed out of allergy season. Results: Fexofenadine was as potent as terfenadine in limiting pruritus and nasal congestion. Rhinorrhea and sneezing were better controlled by fexofenadine than by terfenadine. Overall, the allergen concentration necessary to reach the combined reaction threshold was increased after treatment with both drugs. Comparison between screening and each treatment phase indicated that the shift in allergen concentration to reach the reaction threshold was significantly greater after fexofenadine than after terfenadine (P = .033). Conclusion: After oral administration, fexofenadine provided better protection than terfenadine against the immediate allergic reaction.	CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; CHU Vaudois, ENT Serv, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Spertini, F (corresponding author), CHU Vaudois, Div Immunol & Allergy, BH-18, CH-1011 Lausanne, Switzerland.							Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533, DOI 10.1016/S1081-1206(10)63062-1; DRUCE HM, 1990, J ALLERGY CLIN IMMUN, V86, P261; DRUCE HM, 1988, ANN ALLERGY, V60, P191; ELLER MG, 1992, J CLIN PHARMACOL, V32, P267, DOI 10.1002/j.1552-4604.1992.tb03835.x; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389, DOI 10.1111/j.1365-2125.1986.tb02907.x; Lippert Christina, 1995, Pharmaceutical Research (New York), V12, pS390; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MYGIND N, 1986, EUR J RESPIR DIS, V68, P31; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; Pratt CM, 1997, ALLERGY S37, V52, P67; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; STERN M, 1996, BRIT SOC ALLERGY CLI, P10; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; Tinkeliman D., 1996, Journal of Allergy and Clinical Immunology, V97, P435, DOI 10.1016/S0091-6749(96)81227-9; Vermeeren A, 1998, J ALLERGY CLIN IMMUN, V101, P306, DOI 10.1016/S0091-6749(98)70240-4; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313; Youlten L J, 1983, Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M, P111; YOULTEN LFJ, 1983, ARB P EHRLICH I, V78, P111; ZENICH AD, 1996, W J MED, V164, P68; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P624, DOI 10.1016/S0091-6749(97)70166-0	26	44	44	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1025	1030		10.1016/S0091-6749(99)70174-0	http://dx.doi.org/10.1016/S0091-6749(99)70174-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359881				2022-12-18	WOS:000080929500008
J	Day, J; Carrillo, T				Day, J; Carrillo, T			Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; glucocorticoids; intranasal administration; birch pollen; aqueous spray; fluticasone propionate; onset of action; placebo-controlled; randomized; double-blind	ADULT PATIENTS; ASTHMA; PRETREATMENT; SAFETY; CELLS	Background: Intranasal corticosteroids, such as budesonide and fluticasone propionate, are widely prescribed in the treatment of perennial allergic rhinitis, Once daily budesonide dry powder and fluticasone propionate aqueous suspension have been found to provide similar efficacy in controlling symptoms of perennial allergic rhinitis. Objective: The purpose of this study was to assess the efficacy and safety of treatment with once daily budesonide aqueous nasal spray. Methods: This study involved a multicenter, blinded, randomized, parallel-group, placebo-controlled trial of adults with perrenial allergic rhinitis.Patients (n = 273) recorded daily nasal symptoms for 8 to 14 days (baseline) and 6 weeks (treatment). Results: Budesonide decreased combined symptoms to a significantly greater extent than did fluticasone (P = .03); both treatments significantly decreased mean combined nasal symptoms scores compared with placebo. Of the 3 nasal symptoms assessed (ie, nasal blockage, runny nose, and sneezing), nasal blockage was significantly (P = .009) more decreased with budesonide compared with fluticasone. Both treatments also significantly improved runny nose and sneezing compared with placebo, Improvement in combined nasal symptom scores of the budesonide-treated group reached statistical significance within 36 hours compared with placebo (P = .01); in those patients treated with fluticasone, significant improvement compared with placebo was first observed within 60 hours. Adverse events were mild and transient. Conclusions: Once daily budesonide aqueous nasal spray, 256 mu g, was significantly better in controlling the symptoms of perrenial allergic rhinitis than once daily fluticasone propionate, 200 mu g, especially nasal blockage. Both treatments were superior to placebo. Budesonide may have a faster onset of action than fluticasone.	Kingston Gen Hosp, Div Allergy, Kingston, ON K7L 2V7, Canada; Hosp Nuestra Senora Del Pino, Las Palmas Gran Canaria, Spain	Queens University - Canada	Day, J (corresponding author), Kingston Gen Hosp, Div Allergy, 76 Stuart St, Kingston, ON K7L 2V7, Canada.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ANDERSSON M, 1995, RHINOLOGY, V33, P19; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; Brattsand R, 1997, EUR RESPIR REV, V7, P356; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; Day J, 1997, AM J RHINOL, V11, P77, DOI 10.2500/105065897781446847; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; DAY JH, 1990, ANN ALLERGY, V64, P445; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; FRANKISH CW, 1995, J ALLERGY CLIN IMMUN, V95, P195; *INT RHIN MAN WORK, 1994, ALLERGY, V19, P2; JACKSON RT, 1991, OTOLARYNG HEAD NECK, V104, P433, DOI 10.1177/019459989110400403; MILLERLARSSON A, 1997, AM J RESP CRIT CARE, V155, pA353; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; PIPKORN U, 1988, CLIN ALLERGY, V18, P253, DOI 10.1111/j.1365-2222.1988.tb02867.x; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60, DOI 10.1177/140349489502300111; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Stern MA, 1997, AM J RHINOL, V11, P323, DOI 10.2500/105065897781446658; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; Swanson K A, 1996, J Am Pharm Assoc (Wash), VNS36, P300; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9	24	44	46	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				902	908		10.1016/S0091-6749(98)70326-4	http://dx.doi.org/10.1016/S0091-6749(98)70326-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847429				2022-12-18	WOS:000077690700005
J	Boushey, HA				Boushey, HA			Effects of inhaled corticosteroids on the consequences of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; inflammation; irreversible obstruction; chronic airflow obstruction; remodeling; glucocorticoids; inhalation drug administration; risk-benefit assessment; remission	LONG-TERM TREATMENT; QUALITY-OF-LIFE; BECLOMETHASONE DIPROPIONATE AEROSOL; HIGH-DOSE BECLOMETHASONE; TRIAMCINOLONE ACETONIDE AEROSOL; FLUTICASONE PROPIONATE AEROSOL; TO-MODERATE ASTHMA; CHILDHOOD ASTHMA; AIRWAY INFLAMMATION; MILD ASTHMA	Asthma is a chronic inflammatory disease of the airways involving a characteristic pattern of airway infiltration with lymphocytes, eosinophils, and mast cells, subepithelial deposition of collagen, and hypertrophy and hyperplasia of smooth muscle and of goblet cells and submucosal glands. The consequences of this chronic process include episodic or persistent symptoms, bronchial hyperreactivity, attacks of bronchoconstriction that may require emergency care or hospitalization and can lead to death, impairment in quality of life, and the development of irreversible airflow obstruction, Careful pathologic studies have shown that inhaled corticosteroid therapy can reverse or suppress airway inflammation, and prospective controlled clinical trials have proven that it can also improve symptoms, reduce bronchial hyperreactivity, and reduce the frequency and severity of attacks. It is also highly likely, although it is not yet proven, that inhaled corticosteroid therapy reduces the risk of asthma fatality and prevents or retards airway wall remodeling. These beneficial effects are easily shown in patients with moderate or severe asthma, Although inhaled corticosteroid therapy also benefits patients with mild asthma, it is less certain that the costs and risks of continuous therapy are justified. For these patients, the most important issues that remain to be resolved are the nature of the risk of development of permanent airflow obstruction and the effects of early, sustained treatment on the chances of sustained remission of asthma after all therapy has been stopped.	Univ Calif San Francisco, Asthma Clin Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Pulm Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Allergy & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Boushey, HA (corresponding author), Univ Calif San Francisco, Asthma Clin Res Ctr, 505 Parnassus Ave,Room M-1292, San Francisco, CA 94143 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; BAILEY WC, 1992, J ASTHMA, V29, P21, DOI 10.3109/02770909209110637; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; Beasley R, 1997, CIBA F SYMP, V206, P140; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BERNSTEIN IL, 1982, CHEST, V81, P20, DOI 10.1378/chest.81.1.20; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; Boushey HA, 1998, LUNG BIOL HEALTH DIS, V115, P363; BOUSHEY HA, 1997, ASTHMA, V2, P1391; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; *BROMPT HOSP MED R, 1979, BR J DIS CHEST, V73, P121; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77, DOI 10.1164/ajrccm/150.5_Pt_2.S77; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; DAWOOD AG, 1977, CLIN ALLERGY, V7, P161, DOI 10.1111/j.1365-2222.1977.tb01437.x; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DRAZEN JM, 1994, NEW ENGL J MED, V331, P737, DOI 10.1056/NEJM199409153311110; DRAZEN JM, 1987, J ALLERGY CLIN IMMUN, V80, P428, DOI 10.1016/0091-6749(87)90069-8; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FALLIERS CJ, 1982, J ASTHMA, V19, P241, DOI 10.3109/02770908209104767; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GADDIE J, 1973, LANCET, V1, P691; GADDIE J, 1973, LANCET, V2, P280; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HATOUM HT, 1994, ANN PHARMACOTHER, V28, P1285; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; Hoekstra MO, 1996, AM J RESP CRIT CARE, V154, P1039, DOI 10.1164/ajrccm.154.4.8887604; HUMMEL S, 1992, LANCET, V340, P1483, DOI 10.1016/0140-6736(92)92750-A; JAAKKOLA MS, 1993, AM REV RESPIR DIS, V147, P359, DOI 10.1164/ajrccm/147.2.359; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JOHNSON CE, 1987, DRUG INTEL CLIN PHAR, V21, P784, DOI 10.1177/106002808702101002; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1997, CLIN EXP ALLERGY, V27, P7, DOI 10.1111/j.1365-2222.1997.tb00666.x; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KLEIN R, 1977, PEDIATRICS, V60, P7; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; KUZEMKO JA, 1974, POSTGRAD MED J, V50, P53; LACRONIQUE J, 1991, EUR RESPIR J, V4, P807; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LI D, 1995, AM J RESP CRIT CARE, V151, P647; MAGNUSSEN H, 1992, American Review of Respiratory Disease, V145, pA498; Mahajan P, 1997, J ASTHMA, V34, P227, DOI 10.3109/02770909709068193; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MATSUSE H, 1995, ANN ALLERG ASTHMA IM, V75, P267; MELTZER EO, 1982, PEDIATRICS, V69, P340; MITCHELL RW, 1997, ASTHMA, V1, P733; MOLEMA J, 1989, EUR RESPIR J, V2, P308; Murray JJ, 1998, J ALLERGY CLIN IMMUN, V101, pS232; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; *NAT ASTHM ED PROG, 1991, NIH PUBL, P71; *NAT ASTHM ED PROG, 1991, NIH NAT HEART LUNG B; NG SH, 1977, POSTGRAD MED J, V53, P315, DOI 10.1136/pgmj.53.620.315; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Osterman K, 1997, EUR RESPIR J, V10, P2210, DOI 10.1183/09031936.97.10102210; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1996, AM J RESP CRIT CARE, V153, pS31, DOI 10.1164/ajrccm/153.6_Pt_2.S31; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; ROBERTS CR, 1997, ASTHMA, V1, P925; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; ROBERTSON CF, 1990, MED J AUSTRALIA, V152, P511, DOI 10.5694/j.1326-5377.1990.tb125350.x; ROCHE WR, 1977, ASTHMA, V1, P953; ROISMAN GL, 1995, J CLIN INVEST, V96, P12, DOI 10.1172/JCI118011; RUFFIN RE, 1991, CHEST, V99, P77, DOI 10.1378/chest.99.1.77; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; SHAPIRO GG, 1981, CHEST, V80, P671, DOI 10.1378/chest.80.6.671; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; SMITH MJ, 1987, DRUGS, V33, P423, DOI 10.2165/00003495-198733050-00001; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; Welch MJ, 1997, CHEST, V112, P597, DOI 10.1378/chest.112.3.597; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; [No title captured]	136	44	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S5	S16		10.1016/S0091-6749(98)70001-6	http://dx.doi.org/10.1016/S0091-6749(98)70001-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798719				2022-12-18	WOS:000076669400003
J	Joseph, CLM; Havstad, SL; Ownby, DR; Johnson, CC; Tilley, BC				Joseph, CLM; Havstad, SL; Ownby, DR; Johnson, CC; Tilley, BC			Racial differences in emergency department use persist despite allergist visits and prescriptions filled for antiinflammatory medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; African-American; emergency department; specialist; utilization; antiinflammatory medication	INNER-CITY; ASTHMA MORBIDITY; CHILDREN; PREVALENCE; MORTALITY; CARE; RACE; POPULATION; PATTERNS; DISEASE	Background: African-American children use the emergency department (ED) for asthma care more than their Caucasian counterparts. Objective: We sought to compare ED utilization for asthma care by race, adjusting for prescriptions filled for antiinflammatory medications, type of index visit (specialist vs nonspecialist), and demographic variables. Methods: An index asthma visit was identified for a cohort of managed care enrollees aged 4 to 11 years. Information on asthma encounters and drug claims data was evaluated during a prospective observation period of 12 months. Results: African-American race was associated with one or more ED visits during the observation period (relative risk [RR] = 1.8, 95% CI = 1.3 to 2.5, p < 0.01). After adjusting for index visit type, prescriptions filled, and selected demographic variables, African-American race remained associated with post-index ED utilization (adjusted RR = 1.6, 95% CI = 1.0 to 2.4, p = 0.05). Additional findings included an inverse relationship between African-American race and anti-inflammatory medications among children with nonspecialist index visits (RR = 0.5, 95% CI = 0.3 to 0.9, p = 0.02) and a positive relationship between African-American race and hospitalization after an ED visit for asthma care (RR = 10.2, 95% CI = 1.4 to 74.8, p < 0.01). Conclusion: African-American children were more likely to use ED asthma care even after adjusting for the type of index visit, prescriptions filled for autiinflammatory medications, and selected demographic variables. Racial differences in ED utilization for asthma care could he caused by a higher prevalence of uncontrolled or undertreated disease among African-American children not receiving specialty care.	Henry Ford Hlth Syst, Div Biostat & Res Epidemiol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Joseph, CLM (corresponding author), Henry Ford Hlth Syst, Div Biostat & Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.			Johnson, Christine Cole/0000-0002-6864-6604	AHRQ HHS [U01 HS07386] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; CORN B, 1995, J ASTHMA, V32, P405, DOI 10.3109/02770909409077751; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HOLMES MD, 1989, JAMA-J AM MED ASSOC, V261, P3242, DOI 10.1001/jama.261.22.3242; KALINER M, 1995, ANN ALLERG ASTHMA IM, V75, P169; LANG DM, 1994, J ALLERGY CLIN IMMUN, V93, P246; LEVY DR, 1985, PEDIATRICS, V75, P639; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; MAHR TA, 1993, ANN ALLERGY, V71, P115; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751; McCarthy BD, 1996, AM J PREV MED, V12, P91, DOI 10.1016/S0749-3797(18)30350-7; Michalski TA, 1997, CANCER-AM CANCER SOC, V79, P314; *NIH NAT HEART LUN, 1995, PUB NIH NAT HEART LU; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; SPERBER K, 1995, J ASTHMA, V32, P335, DOI 10.3109/02770909509082758; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; Thomas EJ, 1996, ANN EMERG MED, V27, P49, DOI 10.1016/S0196-0644(96)70296-2; Wagener Jeff S., 1995, Current Opinion in Pediatrics, V7, P262, DOI 10.1097/00008480-199506000-00004; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907	28	44	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				484	490		10.1016/S0091-6749(98)70355-0	http://dx.doi.org/10.1016/S0091-6749(98)70355-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564801	Bronze			2022-12-18	WOS:000073113500010
J	Banerjee, B; Kurup, VP; Greenberger, PA; Hoffman, DR; Nair, DS; Fink, JN				Banerjee, B; Kurup, VP; Greenberger, PA; Hoffman, DR; Nair, DS; Fink, JN			Purification of a major allergen, Asp f 2 binding to IgE in allergic bronchopulmonary aspergillosis, from culture filtrate of Aspergillus fumigatus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspergillus fumigatus; allergic bronchopulmonary aspergillosis; monoclonal antibody; allergen; RAST; ELISA	MURINE MONOCLONAL-ANTIBODIES; CONCANAVALIN-A; T-CELL; ANTIGENS	Background: Most cases of allergic bronchopulmonary aspergillosis (ABPA) are caused by the fungus Aspergillus fumigatus. Successful treatment of this disease depends on early diagnosis with the use of well-characterized and relevant antigens/allergens of the organism. Objective: The aim of this study was to purify and characterize relevant proteins from A, fumigatus that could be used in the reliable diagnosis of ABPA. Methods: Monoclonal antibodies were raised against A. fumigatus culture filtrate antigens. A Concanavalin A nonbinding protein fraction was purified with use of one of the monoclonal antibody immunoaffinity columns. The purified protein was analyzed on sodium dodecylsulfate-polyacrylamide gel electrophoresis gel and Western blots. The sensitivity and specificity of the purified protein were evaluated by RAST and ELISA with sera from 25 patients with ABPA, from 10 with allergic asthma, and from 10 normal control subjects. Results: The 37 kD Concanavalin A nonbinding protein reacted specifically with IgE antibodies in patients with ABPA. Among the 25 patients with ABPA studied, 96% had IgE antibody against the allergen, whereas none of the subjects with allergic asthma who had positive results on the skin prick test or normal control subjects had a reaction. Both RAST and ELISA results exhibited strong correlation with IgE binding. This allergen exhibited N-terminal sequence identity to a recombinant allergen Asp f 2. Conclusions: A 37 kD protein with complete N-terminal homology to Asp f 2 is a major allergen of A. fumigatus that significantly reacts with IgE antibody in patients with ABPA, but does not elicit reaction in Aspergillus-sensitive subjects with asthma and normal control subjects.	VET AFFAIRS MED CTR,RES SERV 151I,MILWAUKEE,WI 53295; NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,CHICAGO,IL 60611; E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858	US Department of Veterans Affairs; Veterans Health Administration (VHA); Northwestern University; University of North Carolina; East Carolina University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1992, J ALLERGY CLIN IMMUN, V89, P1166, DOI 10.1016/0091-6749(92)90301-H; Banerjee B, 1996, J LAB CLIN MED, V127, P253, DOI 10.1016/S0022-2143(96)90093-1; BARDANA EJ, 1985, ASPERGILLOSIS, P43; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FRATAMICO PM, 1991, INFECT IMMUN, V59, P316, DOI 10.1128/IAI.59.1.316-322.1991; GREENBERGER PA, 1988, CLIN CHEST MED, V9, P599; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; KNUTSEN AP, 1990, CLIN IMMUNOL IMMUNOP, V55, P129, DOI 10.1016/0090-1229(90)90074-Z; KNUTSEN AP, 1994, J ALLERGY CLIN IMMUN, V94, P215, DOI 10.1016/0091-6749(94)90043-4; KUMAR A, 1993, J LAB CLIN MED, V121, P431; KURUP VP, 1977, MICROBIOS, V19, P191; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; KURUP VP, 1989, J CLIN MICROBIOL, V27, P1312, DOI 10.1128/JCM.27.6.1312-1316.1989; KURUP VP, 1994, J LAB CLIN MED, V123, P749; KURUP VP, 1986, ZBL BAKT-INT J MED M, V261, P509; KURUP VP, 1989, J CLIN LAB ANAL, V3, P116, DOI 10.1002/jcla.1860030209; KURUP VP, 1991, HYBRIDOMA, V10, P387, DOI 10.1089/hyb.1991.10.387; KURUP VP, 1994, J ALLERGY CLIN IMMUN, V93, P1013, DOI 10.1016/S0091-6749(94)70050-8; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; MURALI PS, 1992, J LAB CLIN MED, V119, P377; PEREZ M, 1990, J BIOL CHEM, V265, P16210; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SLAVIN RG, 1987, INT ARCH ALLER A IMM, V83, P337, DOI 10.1159/000234365; SLAVIN RG, 1983, ALLERGY PRINCIPLES P, P1067; WALKER CA, 1989, CLIN EXP IMMUNOL, V76, P34	30	44	48	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				821	827		10.1016/S0091-6749(97)80017-6	http://dx.doi.org/10.1016/S0091-6749(97)80017-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215251	Bronze			2022-12-18	WOS:A1997XH19300016
J	Alton, EWFW; Norris, AA				Alton, EWFW; Norris, AA			Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chloride channel; cromolyn sodium; epithelial cell; mast cell; nedocromil sodium; neuronal activity	MAST-CELL PROTEIN; HISTAMINE-SECRETION; ANTIALLERGIC DRUGS; ENDOTHELIAL-CELLS; CROMOGLYCATE; PHOSPHORYLATION; ACTIVATION; INHIBITION; CHANNELS; INVITRO	Nedocromil sodium has been shown to be capable of inhibiting chloride ion flux in mast cells, epithelial cells, and neurons. This feature may explain how ii can prevent responses such as mast-cell degranulation, the effects of osmolarity changes in the airways, and neuronal activation This mechanism may also provide a unifying hypothesis to explain the effects of nedocromil sodium on a range of cell types involved in asthma, such as sensory and efferent neurons and cells involved in inflammation.	FISONS PLC,LOUGHBOROUGH,LEICS,ENGLAND		Alton, EWFW (corresponding author), NATL HEART & LUNG INST,ION TRANSPORT UNIT,MANRESA RD,LONDON SW3 6LR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; Alton EWFW, 1996, AM J RESP CELL MOL, V14, P380, DOI 10.1165/ajrcmb.14.4.8600943; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; ARMOUR CL, 1991, J AUTON PHARMACOL, V11, P167, DOI 10.1111/j.1474-8673.1991.tb00316.x; BOGGS DF, 1982, J APPL PHYSIOL, V53, P455, DOI 10.1152/jappl.1982.53.2.455; EDWARDS AM, 1994, CLIN EXP ALLERGY, V24, P612, DOI 10.1111/j.1365-2222.1994.tb00964.x; FOREMAN JC, 1977, BRIT J PHARMACOL, V59, pP473; FRIIS UG, 1994, BRIT J PHARMACOL, V111, P1179, DOI 10.1111/j.1476-5381.1994.tb14869.x; HEINKE S, 1995, BRIT J PHARMACOL, V115, P1393, DOI 10.1111/j.1476-5381.1995.tb16629.x; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACKSON DM, 1992, EUR J PHARMACOL, V221, P175, DOI 10.1016/0014-2999(92)90790-B; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KUNZELMANN K, 1993, PFLUG ARCH, V421, P238; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LOWRY RH, 1988, THORAX, V43, pP256; MACKAY GA, 1993, BRIT J PHARMACOL, V109, pP65; MATHEWS G, 1989, J PHYSL, V418, P105; MATHEWS G, 1989, J PHYSL, V418, P131; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; PAULMICHL M, 1995, INT ARCH ALLERGY IMM, V107, P416, DOI 10.1159/000237060; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; RAINEY DK, 1992, CLIN EXP ALLERGY, V22, P976, DOI 10.1111/j.1365-2222.1992.tb03023.x; REES PJ, 1991, THORAX, V46, pP761; REINSPRECHT M, 1992, BIOCHEM BIOPH RES CO, V188, P957, DOI 10.1016/0006-291X(92)91325-K; ROCCHICCIOLI KMS, 1989, DRUGS, V37, P123, DOI 10.2165/00003495-198900371-00022; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149, DOI 10.1164/ajrccm/146.5_Pt_1.1149; ROMANIN C, 1991, EMBO J, V10, P3606; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VERLEDEN GM, 1991, AM REV RESPIR DIS, V143, P114, DOI 10.1164/ajrccm/143.1.114; WELLS E, 1986, J IMMUNOL, V137, P3941; WELLS E, 1983, BIOCHEM PHARMACOL, V32, P837, DOI 10.1016/0006-2952(83)90585-3; WILLUMSEN NJ, 1994, J CLIN INVEST, V94, P779, DOI 10.1172/JCI117397	36	44	45	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S102	S105		10.1016/S0091-6749(96)80136-9	http://dx.doi.org/10.1016/S0091-6749(96)80136-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939184				2022-12-18	WOS:A1996VW14000022
J	Mari, A; DiFelice, G; Afferni, C; Barletta, B; Tinghino, R; Sallusto, F; Pini, C				Mari, A; DiFelice, G; Afferni, C; Barletta, B; Tinghino, R; Sallusto, F; Pini, C			Assessment of skin prick test and serum specific IgE detection in the diagnosis of Cupressaceae pollinosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cupressaceae; cypress; diagnosis; skin prick test; specific IgE; Taxodiaceae; winter pollinosis	CROSS-REACTIVITY; CYPRESS POLLEN; ALLERGY; IDENTIFICATION; SEMPERVIRENS; ANTIBODIES; CEDAR; ASSAY	Background: There is increasing evidence for the relevance of Cupressaceae pollinosis among persons living in geographic areas where theses species are native or imported. Objective: Previously reported problems in obtaining valid allergenic extracts to be used in the diagnosis of this winter pollinosis prompted us to assess the value of available Cupressaceae pollen extracts for in vivo and in vitro diagnosis. Methods: Commercial and in-house allergenic extracts from Cupressaceae and Taxodiaceae families were used for skin prick testing and specific IgE detection in six groups of subjects exposed to a high concentration of Cupressaceae pollen. Results: Four commercial and two in-house Cupressus sempervirens pollen extracts showed low cutaneous reactivity. Positive test results were recorded in 26% of the 713 subjects tested. C. arizonica in-house pollen extracts gave rise to larger cutaneous reactions. Furthermore, the skin prick test response was positive in a greater number of subjects (38%) of the same group. Six commercial immunoassays were able to detect specific IgE to C. sempervirens in rates ranging from 8.1% to 82.1%. Specific IgE to C. arizonica was detected by means of an inhouse immunoenzymatic method in 70.3% of 54 patients with suspected ''cypress'' allergy, and specific IgE to C. sempervirens was detected in 75.9% of these patients by using a commercial system. High rates of cross-reactivity within the Cupressaceae family and with species of the Taxodiaceae family were recorded with both in vivo and in vitro tests. Conclusions: The use of C. sempervirens in vivo diagnostics should be carefully evaluated until better characterized extracts are developed. In-house-characterized extracts of C. arizonica seem to be more reliable in the diagnosis of Cupressaceae allergy by means of skin prick testing. The sensitivity of commercially available in vitro methods to detect specific IgE to C. sempervirens should be carefully evaluated; nevertheless, valid results can be obtained with some already available immunoassays.	NATL HLTH SERV,DEPT ALLERGY,CITTA CASTELLO,ITALY		Mari, A (corresponding author), IST SUPER SANITA,DEPT IMMUNOL,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		BARLETTA, BIANCA/B-9980-2016; AFFERNI, CLAUDIA/B-9978-2016; Di Felice, Gabriella/B-9985-2016	AFFERNI, CLAUDIA/0000-0002-8567-7365; Di Felice, Gabriella/0000-0001-7387-9683				ACCORSI CA, 1990, AEROBIOLOGIA, V6, P9; AUTERI P, 1989, MODERN TRENDS IMMUNO, P388; BASS D, 1991, MED J AUSTRALIA, V155, P572, DOI 10.5694/j.1326-5377.1991.tb93901.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIAFFA MF, 1993, ANN ALLERGY, V71, P45; CHARPIN D, 1990, REV FR ALLERGOL, V30, P21, DOI 10.1016/S0335-7457(05)80141-8; CHARPIN D, 1993, CLIN EXP ALLERGY, V23, P435, DOI 10.1111/j.1365-2222.1993.tb00350.x; Cimignoli E., 1992, Aerobiologia, V8, P465, DOI 10.1007/BF02272917; DAMATO G, 1991, ALLERGENIC POLLEN PO, P176; DIFELICE G, 1994, J ALLERGY CLIN IMMUN, V94, P547, DOI 10.1016/0091-6749(94)90212-7; FERRANNINI A, 1991, Giornale Italiano di Allergologia e Immunologia Clinica, V1, P597; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; KAUFMAN HS, 1988, ANN ALLERGY, V60, P53; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Malling HJ., 2003, ALLERGY, V48, P55; MERRETT J, 1993, J CLIN IMMUNOASSAY, V16, P164; OLIVIERI V, 1993, J IMMUNOL METHODS, V157, P65, DOI 10.1016/0022-1759(93)90071-E; ORDMAN D, 1945, S AFR MED J, V19, P142; PANZANI R, 1986, ANN ALLERGY, V56, P460; PANZANI R, 1986, ANN ALLERGY, V57, P26; Panzani R., 1991, ALLERGENIC POLLEN PO, P81; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PIGNATTI S, 1982, FLORA ITALIA, P81; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; SALKIE ML, 1994, CLIN BIOCHEM, V27, P343, DOI 10.1016/0009-9120(94)90038-8; Spieksma F., 1991, ALLERGENIC POLLEN PO, P49; SPINOZZI F, 1993, LANCET, V341, P386, DOI 10.1016/0140-6736(93)90201-Q; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TAS J, 1965, ACTA ALLERGOL, V20, P405, DOI 10.1111/j.1398-9995.1965.tb03073.x; YOO TJ, 1975, ANN ALLERGY, V34, P87; 1994, PHARMEUROPA, P109	35	44	46	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					21	31		10.1016/S0091-6749(96)70222-1	http://dx.doi.org/10.1016/S0091-6749(96)70222-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765814				2022-12-18	WOS:A1996VA69200003
J	Bronsky, EA; Dockhorn, RJ; Meltzer, EO; Shapiro, G; Boltansky, H; LaForce, C; Ransom, J; Weiler, JM; Blumenthal, M; Weakley, S; Wisniewski, M; Field, E; Rogenes, P				Bronsky, EA; Dockhorn, RJ; Meltzer, EO; Shapiro, G; Boltansky, H; LaForce, C; Ransom, J; Weiler, JM; Blumenthal, M; Weakley, S; Wisniewski, M; Field, E; Rogenes, P			Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; terfenadine; seasonal allergic rhinitis; antihistamine; glucocorticosteroid; comparative study		Background: Comparative studies with topical corticosteroids and antihistamines for treatment of allergic rhinitis have not always demonstrated clear distinctions between the two on the basis of therapeutic efficacy. Objective: This study was designed to compare the efficacy and tolerability of fluticasone propionate aqueous nasal spray with those of terfenadine in the treatment of seasonal allergic rhinitis. Methods: Three hundred forty-eight patients with allergic rhinitis were given fluticasone propionate aqueous nasal spray (200 mu g once daily), terfenadine tablets (60 mg twice daily), or placebo for 4 weeks in a multicenter, randomized, double-blind, double-dummy, parallel-group study. Results: Clinician-rated total nasal symptom scores after 1, 2, 3, and 4 weeks of therapy and patient-rated total nasal symptom scores throughout treatment were significantly (p < 0.05) lower in the fluticasone propionate group compared with the terfenadine group or the placebo group. Terfenadine was not statistically different from placebo on the basis of clinician-rated nasal symptom scores, except for sneezing. Total nasal airflow, measured by rhinomanometry, significantly (p < 0.05) improved in the fluticasone propionate group compared with the terfenadine group or the placebo group. More fluticasone propionate-treated patients compared with the place-treated patients has reduced nasal mucosal eosinophil counts after 4 weeks of therapy (p < 0.05). No serious or unusual drug-related adverse events were reported. Morning plasma cortisol concentrations after 4 weeks of therapy did not differ among groups. Conclusion: Fluticasone propionate aqueous nasal spray is more effective than terfenadine tablets for treatment of seasonal allergic rhinitis.	IMTCI,LENEXA,KS; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA 92123; ASTHMA INC,SEATTLE,WA; ASTHMA INC,WASHINGTON,DC; CAROLINA ALLERGY & ASTHMA CONSULTANTS,RALEIGH,NC; TOPEKA ALLERGY & ASTHMA,TOPEKA,KS; UNIV IOWA,IOWA CITY,IA; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; GLAXO INC,RES INST,RES TRIANGLE PK,NC	University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; GlaxoSmithKline	Bronsky, EA (corresponding author), AAAA MED RES GRP,150 SOUTH 1000 EAST,SALT LAKE CITY,UT 84102, USA.							BANOV CH, 1994, ANN ALLERGY, V73, P240; BOUSQUET J, 1990, RESP MED, V84, P11, DOI 10.1016/S0954-6111(08)80002-9; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; CONNELL JR, 1992, ANN ALLERGY, V49, P179; DELAFUENTE JC, 1989, CLIN PHARMACY, V8, P474; FINDLAY SR, 1986, J ALLERGY CLIN IMMUN, V77, P116, DOI 10.1016/0091-6749(86)90333-7; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P613, DOI 10.1016/S0091-6749(05)80225-8; MELTZER EO, 1992, AM J ASTHMA ALLERGY, V6, P13; MELTZER EO, 1987, IMMUNOL ALLERGY CLIN, V7, P57; Naito K., 1989, AM J RHINOL, V3, P93; VANAS A, 1991, ANN ALLERGY, V67, P156; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010	15	44	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					915	921		10.1016/S0091-6749(96)80065-0	http://dx.doi.org/10.1016/S0091-6749(96)80065-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655886				2022-12-18	WOS:A1996UG08600005
J	KUNAS, RC; MCRAE, A; KESSELRING, J; VILLIGER, PM				KUNAS, RC; MCRAE, A; KESSELRING, J; VILLIGER, PM			ANTIDOPAMINERGIC ANTIBODIES IN A PATIENT WITH A COMPLEX AUTOIMMUNE DISORDER AND RAPIDLY PROGRESSING PARKINSONS-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									KLIN VALENS, RHEUMA & REHABIL ZENTRUM, VALENS, ITALY; UNIV GOTHENBURG, INST NEUROBIOL, GOTHENBURG, SWEDEN; KANTONSSPITAL, INNERE MED KLIN B, ST GALLEN, SWITZERLAND	University of Gothenburg; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen			Villiger, Peter/AAV-8132-2021					BLUESTEIN HG, 1981, AM J MED, V70, P240, DOI 10.1016/0002-9343(81)90756-7; BOKOR M, 1993, J NEUROL SCI, V115, P47, DOI 10.1016/0022-510X(93)90065-7; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DEGUEURCE AM, 1986, ACTA PHYSIOL SCAND, V126, P313, DOI 10.1111/j.1748-1716.1986.tb07821.x; ITAGAKI S, 1987, J NEUROIMMUNOL, V16, P81, DOI 10.1016/0165-5728(87)90252-9	5	44	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				688	690		10.1016/S0091-6749(95)70268-7	http://dx.doi.org/10.1016/S0091-6749(95)70268-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499686				2022-12-18	WOS:A1995TG52800015
J	CAFFARELLI, C; CAVAGNI, G; GIORDANO, S; STAPANE, I; ROSSI, C				CAFFARELLI, C; CAVAGNI, G; GIORDANO, S; STAPANE, I; ROSSI, C			RELATIONSHIP BETWEEN ORAL CHALLENGES WITH PREVIOUSLY UNINGESTED EGG AND EGG-SPECIFIC IGE ANTIBODIES AND SKIN PRICK TESTS IN INFANTS WITH FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INFANTS; FOOD ALLERGY; ORAL FOOD CHALLENGE; UNINGESTED EGG; SKIN PRICK TEST; RAST	BREAST-FED INFANTS; COWS MILK ALLERGY; DOUBLE-BLIND; HYPERSENSITIVITY REACTIONS; ATOPIC-DERMATITIS; NATURAL-HISTORY; CHILDREN; CHILDHOOD; ECZEMA; DIET	Background: Positive skin prick test (SPT) and RAST reactions to egg that had never previously been ingested have been observed in infants with food allergy. The likelihood of having clinical hypersensitivity reactions when egg is first ingested and the predictive value of SPT and PAST remain to be elucidated. Objective: We investigated the relationship between egg-specific IgE antibodies and positive SPT reaction to egg, and the development of clinical hypersensitivity on the first exposure, in infants with food allergy. Methods: The patient group consisted of 21 infants with food allergy and positive SPT and/or RAST reaction to egg, which they had never previously ingested; the control group of 12 infants had food allergy and negative test results. All subjects underwent double-blind placebo-controlled food challenges with egg. Results: Thirteen of 21 patients (61%) and one of 12 control subjects (8%) had positive reactions to challenges (p < 0.01). Thirteen positive reactions to challenges (93%) elicited immediate symptoms. Late-onset eczema occurred in two children. SPT results showed a high sensitivity (0.92) and negative predictive accuracy (0.92), whereas specificity (0.57) and positive predictive accuracy (0.61) were poor. RAST did nor have any diagnostic advantage over SPT. Conclusions: In infants with food allergy SPT with egg may be helpful in predicting which patients will react to the first exposure.	UNIV BRESCIA,DEPT PEDIAT,BRESCIA,ITALY	University of Brescia	CAFFARELLI, C (corresponding author), UNIV PARMA,DEPT PEDIAT,PEDIAT CLIN,VIA GRAMSCI 14,I-43100 PARMA,ITALY.		Caffarelli, Carlo/AAC-2488-2022					AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ATHERTON DJ, 1978, LANCET, V1, P401; AXELSSON I, 1986, ACTA PAEDIATR SCAND, V75, P702, DOI 10.1111/j.1651-2227.1986.tb10277.x; BAHNA SL, 1991, IMMUNOL ALLERGY CLIN, V11, P843; BAHNA SL, 1987, RELIABILITY SKIN TES, P139; BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; BUSINCO L, 1989, RIV IMMUNOL ALLERGOL, V2, P37; CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; CAVAGNI G, 1988, ANN ALLERGY, V61, P361; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; Galen RS, 1975, PREDICT VALUE EFFIC; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HILL DJ, 1989, FOOD INTOLERANCE INF, P203; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; KJELLMAN NM, 1988, ANN ALLERGY, V61, P83; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LILJA G, 1991, PEDIATR ALLERGY IMMU, V2, P6; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V64, P422; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3	37	44	44	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1215	1220		10.1016/S0091-6749(95)70078-1	http://dx.doi.org/10.1016/S0091-6749(95)70078-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797790				2022-12-18	WOS:A1995RD30900009
J	LEDFORD, DK				LEDFORD, DK			INDOOR ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				SKIN-TEST REACTIVITY; LABORATORY-ANIMAL ALLERGY; FEL-D-I; AIRBORNE CONCENTRATIONS; FORMALDEHYDE ASTHMA; POPULATION-SAMPLE; CANDIDA-ALBICANS; MAJOR ALLERGEN; RISK-FACTORS; PURIFICATION		JAMES A HALEY VET AFFAIRS HOSP,TAMPA,FL	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	LEDFORD, DK (corresponding author), UNIV S FLORIDA,13000 BRUCE B DOWNS BLVD,VAR 111D,TAMPA,FL 33612, USA.							AUKRUST L, 1992, CLIN REV ALLERG, V10, P147; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; AXELSSON IGK, 1991, ALLERGY, V46, P92, DOI 10.1111/j.1398-9995.1991.tb00550.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BEAUMONT F, 1985, ANN ALLERGY, V55, P740; BERNSTEIN DI, 1988, ALLERGY PRINCIPLES P, P1369; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BURGE HA, 1989, MYCOTAXON, V34, P55; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; DINICOLO R, 1991, J ALLERGY CLIN IMMUN, V87, P234; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; FERNANDEZCALDAS E, 1991, ALLERGEN IMMUNOTHERA, P69; FINNEGAN MJ, 1987, CLIN ALLERGY, V17, P235, DOI 10.1111/j.1365-2222.1987.tb02008.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GELFAND HH, 1983, J ALLERGY, V34, P374; Gell PGH., 1975, CLIN ASPECTS IMMUNOL, V3; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GRAMMER LC, 1992, J ALLERGY CLIN IMMUN, V89, P203; HAUSEN BM, 1988, ALLERGOLOGIE, V11, P47; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HORNER WE, 1989, J ALLERGY CLIN IMMUN, V83, P784, DOI 10.1016/0091-6749(89)90015-8; HORNER WE, 1988, J ALLERGY CLIN IMMUN, V82, P787; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; KIRKPATRICK CH, 1987, FUNDAMENTALS IMMUNOL, P153; KNYSAK D, 1989, IMMUNOL ALLERGY CLIN, P357; KOZAK PP, 1990, INDOOR AIR HUMAN HLT, P149; LAM S, 1980, AM REV RESPIR DIS, V121, P151; LIENGSWANGWONG V, 1987, CLIN ALLERGY, V17, P191, DOI 10.1111/j.1365-2222.1987.tb02003.x; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P242, DOI 10.1016/0091-6749(89)90331-X; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161, DOI 10.1159/000234496; OROURKE MK, 1984, GRANA, V23, P55, DOI 10.1080/00173138409428877; OROURKE MK, 1990, INDOOR AIR 90, V2, P9; PAZUR JH, 1990, BIOTECHNOL APPL BIOC, V12, P63; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POPE AM, 1993, INDOOR ALLERGENS ASS, P86; POPE AM, 1993, INDOOR ALLERGENS ASS, P44; ROITT IM, 1991, ESSENTIAL IMMUNOLOGY, P253; SAVOLAINEN J, 1989, INT ARCH ALLER A IMM, V90, P61, DOI 10.1159/000235001; SAVOLAINEN J, 1990, ALLERGY, V45, P40, DOI 10.1111/j.1398-9995.1990.tb01082.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; SJOSTEDT L, 1989, AM J IND MED, V16, P199, DOI 10.1002/ajim.4700160211; SLOVAK AJM, 1987, NEW ENGL REG ALLERGY, V8, P189; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	59	44	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				327	334		10.1053/ai.1994.v94.a56012	http://dx.doi.org/10.1053/ai.1994.v94.a56012			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077586				2022-12-18	WOS:A1994PG77000008
J	HOFFMAN, DR; COLLINSWILLIAMS, C				HOFFMAN, DR; COLLINSWILLIAMS, C			COLD-PRESSED PEANUT OILS MAY CONTAIN PEANUT ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							SENSITIVE INDIVIDUALS				HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH RK, 1985, J ALLERGY CLIN IMMUN, V76, P242, DOI 10.1016/0091-6749(85)90709-2; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4	5	44	45	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					801	802		10.1016/0091-6749(94)90262-3	http://dx.doi.org/10.1016/0091-6749(94)90262-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163791				2022-12-18	WOS:A1994NH49700015
J	PASTORELLO, EA; RIARIOSFORZA, GG; INCORVAIA, C; SEGALA, M; FUMAGALLI, M; GANDINI, R				PASTORELLO, EA; RIARIOSFORZA, GG; INCORVAIA, C; SEGALA, M; FUMAGALLI, M; GANDINI, R			COMPARISON OF RHINOMANOMETRY, SYMPTOM SCORE, AND INFLAMMATORY CELL COUNTS IN ASSESSING THE NASAL LATE-PHASE REACTION TO ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINOMANOMETRY; SYMPTOM SCORE; NASAL CYTOLOGY; NOSE; LATE-PHASE REACTION; ALLERGEN CHALLENGE; ALLERGIC RHINITIS	ANTIGEN CHALLENGE; DOUBLE-BLIND; HAY-FEVER; SECRETIONS; RESPONSES; MEDIATORS; RHINITIS; INFLUX; PRETREATMENT; EOSINOPHILS	Inspiratory nasal resistance symptom score, and influx of inflammatory cells into the nose were evaluated before and after a nasal challenge in 15 patients with grass pollen rhinitis and in sir nonallergic control subjects, to study the nasal late-phase reaction and its relationship with nasal cytology. All patients had an immediate positive reaction to specific nasal challenge. In seven allergic subjects we observed a late inspiratory nasal resistance increase, but only two had a significant late symptom score. Inflammatory cells increased by 8 hours in all the patients; the higher the cell influx, the higher the symptom score. Close correlations were found between the inspiratory nasal resistance increase, nasal obstruction at hours 8 and 24, and all cell counts. In control challenges there were no significant increases of symptom score or inspiratory nasal resistance either during the challenge or in the next 24 hours. A weakly significant increase was found only for neutrophil counts at 8 hours. These results indicate that an inflammatory reaction constantly occurs after a specific nasal challenge; its extent is closely related to inspiratory nasal resistance and to the intensity of nasal obstruction. Moreover, our data outline the pivotal role played by eosinophils and basophils in the genesis of an allergic late-phase reaction in the nose.	UNIV MILAN, DEPT INTERNAL MED 1, MILAN, ITALY; OSPED BAMBINI V BUZZI, ALLERGY IMMUNOL UNIT, MILAN, ITALY; OSPED MAGGIORE, MILAN, ITALY	University of Milan			PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; COLE P, 1984, AM REV RESPIR DIS, V129, P351; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DREBORG S, 1989, ALLERGY S10, V44, P27; DRUCE HM, 1990, J ALLERGY CLIN IMMUN, V86, P261; DURHAM SR, 1991, CLIN EXP ALLERGY, V21, P3, DOI 10.1111/j.1365-2222.1991.tb00797.x; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; HANSEL FRENCH K., 1934, JOUR ALLERGY, V5, P357, DOI 10.1016/S0021-8707(34)90159-3; HASEGAWA M, 1982, ANN OTO RHINOL LARYN, V91, P112, DOI 10.1177/000348948209100125; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LEMANSKE RF, 1988, J CLIN IMMUNOL, V8, P1, DOI 10.1007/BF00915151; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MELTZER EO, 1988, ALLERGY PRINCIPLES P, P1267; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1988, 5TH INT P EHRL SEM, P45; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1983, J ALLERGY CLIN IMMUN, V72, P657, DOI 10.1016/0091-6749(83)90625-5; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; PELIKAN Z, 1981, 12TH P ANN M EUR AC, P634; PRINCIPATO JJ, 1979, ARCH OTOLARYNGOL, V91, P71; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; 1972, HAEMATOLOGISCHE TAFE, P32	35	44	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				85	92		10.1016/0091-6749(94)90236-4	http://dx.doi.org/10.1016/0091-6749(94)90236-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308185				2022-12-18	WOS:A1994MT78100010
J	LISS, GM; BERNSTEIN, D; GENESOVE, L; ROOS, JO; LIM, J				LISS, GM; BERNSTEIN, D; GENESOVE, L; ROOS, JO; LIM, J			ASSESSMENT OF RISK-FACTORS FOR IGE-MEDIATED SENSITIZATION TO TETRACHLOROPHTHALIC ANHYDRIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACID ANHYDRIDES; TETRACHLOROPHTHALIC ANHYDRIDE; OCCUPATIONAL ASTHMA; SENSITIZATION; CROSS-SECTIONAL STUDIES; SMOKING	OCCUPATIONAL ASTHMA; WORKERS; ANTIBODY; EXPOSURE; REFINERY; SMOKING; PROTEIN	Two groups of workers with occupational asthma caused by tetrachlorophthalic anhydride (TCPA) have been reported on; in only one report was specific anti-TCPA antibody demonstrated. We received a request to investigate respiratory problems among workers at a plant where solenoid coils are manufactured with the use of epoxy resin and where a new TCPA hardener had been introduced in 1988. In response, we conducted a cross-sectional evaluation of 52 current workers and assayed serum samples from 49 workers for TCPA-human serum albumin-specific IgE and IgG by ELISA. Mean airborne TCPA concentrations ranged from 0.21 to 0.39 mg/m3 in 1989 and May 1990 but were considerably lower (less than 0. 009 to 0. 13 mg/m3) by July 1990 when ventilation was introduced. Workers were classified in four departments as molders (most directly working with TCPA), those intermittently exposed to TCPA, coil assemblers, and office workers. There was a high prevalence of reported work-related respiratory symptoms (from 27% to 39%). The mean decline in FEV1 over the shift in the molders (down 4. 1 %) was significantly different from the change in the office group (increased 2.5%). Intrashift change in FEV1 was inversely correlated with log personal TCPA concentration (r = - 0. 47). Of 49 current workers, 15 (31 %) had elevated serum TCPA-human serum albumin-specific IgE antibody levels and 19 (39%) had elevated specific IgG levels. The prevalence of specific IgE was highest in the mold and intermittent groups (54%), in comparison with the coil assembly (25%) and office (0%) groups. Those workers who were IgE positive were significantly less likely to be current smokers and had worked significantly longer since 1988. Of those hired in 1988 or after, the proportion of workers who were IgE positive increased with duration of employment category (p value for trend 0. 022). Since ventilation was installed and TCPA exposures reduced to less than 0.1 mg/m3, there has been a marked decrease in symptoms and no new cases of occupational asthma among newly hired workers at the plant.	ONTARIO MINIST LAB,PROFESS & SPECIALIZED SERV PROGRAM,TORONTO,ON,CANADA; UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	LISS, GM (corresponding author), ONTARIO MINIST LAB,HLTH & SAFETY STUDIES UNIT,7TH FLOOR,HOO UNIV AVE,TORONTO M7A 1T7,ON,CANADA.							BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; GARDNER RM, 1987, AM REV RESPIR DIS, V136, P1285; GHIO AJ, 1991, AM REV RESPIR DIS, V143, P1231, DOI 10.1164/ajrccm/143.6.1231; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; SARLO K, 1990, J ALLERGY CLIN IMMUN, V86, P393, DOI 10.1016/S0091-6749(05)80103-4; SCHLUETER DP, 1978, J OCCUP ENVIRON MED, V20, P183, DOI 10.1097/00043764-197803000-00006; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; VENABLES KM, 1990, J ALLERGY CLIN IMMUN, V85, P55, DOI 10.1016/0091-6749(90)90221-O; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; VENABLES KM, 1989, BRIT J IND MED, V46, P222; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; WATERS MA, 1991, AM IND HYG ASSOC J, V52, P493, DOI 10.1202/0002-8894(1991)052<0493:AMOGFT>2.0.CO;2; Wegman D. H., 1988, OCCUPATIONAL HLTH RE, P55; WERNFORS M, 1986, INT ARCH ALLER A IMM, V79, P77, DOI 10.1159/000233946	19	44	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					237	247		10.1016/0091-6749(93)90167-E	http://dx.doi.org/10.1016/0091-6749(93)90167-E			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349934	Bronze			2022-12-18	WOS:A1993LT46900004
J	ZINREICH, SJ				ZINREICH, SJ			IMAGING OF CHRONIC SINUSITIS IN ADULTS - X-RAY, COMPUTED-TOMOGRAPHY, AND MAGNETIC-RESONANCE-IMAGING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS			SURGERY; SINUSES; CT		JOHNS HOPKINS MED INST,RUSSELL H MORGAN DEPT RADIOL,DIV NEURORADIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine								BABBEL R, 1991, AM J ROENTGENOL, V157, P1093; Caldwell G.W., 1893, NEW J MED J, V58, P526; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; Messerklinger W, 1967, Acta Otolaryngol, V63, P176, DOI 10.3109/00016486709128748; Messerklinger W., 1978, ENDOSCOPY NOSE; Proctor DF, 1966, LEWISWALTERS PRACTIC, P1; SOM PM, 1984, HEAD NECK IMAGING EX, P5; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	9	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			445	451		10.1016/0091-6749(92)90167-Z	http://dx.doi.org/10.1016/0091-6749(92)90167-Z			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527335				2022-12-18	WOS:A1992JP52100008
J	KNOL, EF; MUL, FPJ; KUIJPERS, TW; VERHOEVEN, AJ; ROOS, D				KNOL, EF; MUL, FPJ; KUIJPERS, TW; VERHOEVEN, AJ; ROOS, D			INTRACELLULAR EVENTS IN ANTI-IGE NONRELEASING HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BASOPHILS; HISTAMINE RELEASE; AGGREGATION; ANTI-IGE; RELEASABILITY	HISTAMINE-RELEASE; MEDIATOR RELEASE; PHOSPHOLIPASE-D; ACTIVATION; PATHWAY; CA-2+	Histamine release (HR) after activation of human basophils with anti-IgE demonstrates a great variability among different donors. To elucidate the biochemical basis of this phenomenon, we studied the activation of purified basophils from donors that barely demonstrated HR (< 7%) after stimulation by anti-IgE, although IgE was present on these cells and formyl-methionyl-leucyl-phenylalanine (fMLP)-induced HR was normal. Basophils from anti-IgE "nonreleasers" demonstrated, in contrast to cells from "releasers," hardly any changes in cytosolic-free Ca++ concentration after addition of anti-IgE. However, anti-IgE treatment of basophils from these anti-IgE nonreleasers resulted in at least two intracellular changes. First, a profound inhibition (54.2% +/- 4.2%) of a subsequent fMLP-induced HR was observed. This inhibition caused by anti-IgE was also observed in basophils from anti-IgE releasers treated with wortmannin, an inhibitor of the anti-IgE-induced HR. The time course of the inhibition induced by wortmannin plus anti-IgE on the fMLP-induced HR (half-life maximum, 4 minutes; time of maximum concentration, 10 minutes) was comparable to the time course of the anti-IgE-induced HR. Second, anti-IgE did induce homotypic aggregation in these anti-IgE-nonreleasing basophils, like in anti-IgE-releasing basophils. These studies indicate that basophils not responding to anti-IgE with HR or cytosolic-free Ca++ concentration changes do generate intracellular signals that inhibit the subsequent response to a heterologous stimulus and induce homotypic aggregation.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, POB 9406, 1006 AK AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS	University of Amsterdam				Mul, FPJ/0000-0002-8234-9972; Knol, Edward/0000-0001-7368-9820				BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COLUMBO M, 1992, J ALLERGY CLIN IMMUN, V89, P243; CONROY MC, 1977, J IMMUNOL, V118, P1317; DEBOER M, 1986, J IMMUNOL, V136, P3447; GILBERT HS, 1975, BLOOD, V46, P279; GOMPERTS BD, 1990, J EXP PATHOL, V71, P423; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO C-B, 1990, Journal of Allergy and Clinical Immunology, V85, P172; HARLAN JM, 1985, BLOOD, V65, P513; KEIJ JF, 1989, CYTOMETRY, V10, P814, DOI 10.1002/cyto.990100623; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KNOL EF, 1901, J ALLERGY CLIN IMMUN, V8, P328; KNOL EF, UNPUB HOMOTYPIC AGGR; KNOL EF, UNPUB CHARACTERIZATI; KUIJPERS TW, 1990, EUR J IMMUNOL, V20, P501; LUCE G G, 1985, Biotechniques, V3, P270; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; NOLTE H, 1990, ALLERGY, V45, P427, DOI 10.1111/j.1398-9995.1990.tb01093.x; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; STELLATO C, 1991, Journal of Allergy and Clinical Immunology, V87, P172, DOI 10.1016/0091-6749(91)91416-Q; WARNER JA, 1987, J IMMUNOL, V139, P161; WARNER JA, 1990, J IMMUNOL, V145, P1897	27	44	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					92	103		10.1016/S0091-6749(06)80015-1	http://dx.doi.org/10.1016/S0091-6749(06)80015-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1378461				2022-12-18	WOS:A1992JE25500011
J	JENEY, EVM; RAPHAEL, GD; MEREDITH, SD; KALINER, MA				JENEY, EVM; RAPHAEL, GD; MEREDITH, SD; KALINER, MA			ABNORMAL NASAL GLANDULAR SECRETION IN RECURRENT SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,9000 ROCKVILLE PIKE,BLDG 10,11C205,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ABRAHAM SN, 1985, ADV HOST DEFENSE MEC, V4, P63; BALLOW M, 1987, INVEST OPHTH VIS SCI, V28, P543; CARENFELT C, 1976, ACTA OTO-LARYNGOL, V82, P123, DOI 10.3109/00016487609120871; CARENFELT C, 1978, ACTA OTO-LARYNGOL, V85, P116, DOI 10.3109/00016487809121431; CARENFELT C, 1977, ACTA OTO-LARYNGOL, V84, P440, DOI 10.3109/00016487709123989; CARSON JL, 1985, NEW ENGL J MED, V312, P463, DOI 10.1056/NEJM198502213120802; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; JOHANSSON P, 1988, ACTA OTO-LARYNGOL, V105, P357, DOI 10.3109/00016488809097019; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJIMA Y, 1988, ARCH OTO-RHINO-LARYN, V244, P355, DOI 10.1007/BF00497464; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; METCALF JA, 1986, LABORATORY MANUAL NE, P149; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P11; OHASHI Y, 1983, ACTA OTOLARYNGOL S S, V397, P3; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; PAVIA D, 1988, RESPIRATION, V53, P187, DOI 10.1159/000195412; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; REIMER A, 1978, ACTA OTO-LARYNGOL, V355, P3; ROIFFMAN CM, 1988, PEDIATR INFECT DIS J, V7, P92; SAKURA Y, 1985, CLIN OTOLARYNGOL, V10, P79; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P1028, DOI 10.1016/0091-6749(88)90174-1; TOS M, 1984, ACTA OTO-LARYNGOL, V97, P151, DOI 10.3109/00016488409130975; VANNOSTRAND AWP, 1976, OTOLARYNG CLIN N AM, V9, P21; WALD ER, 1985, PEDIATR INFECT DI S6, V4, P51; 1984, NIH DATA BOOK, P54	29	44	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					10	18		10.1016/S0091-6749(05)80117-4	http://dx.doi.org/10.1016/S0091-6749(05)80117-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370381				2022-12-18	WOS:A1990DQ68800003
J	GERRITSEN, J; KOETER, GH; DEMONCHY, JG; KNOL, K				GERRITSEN, J; KOETER, GH; DEMONCHY, JG; KNOL, K			ALLERGY IN SUBJECTS WITH ASTHMA FROM CHILDHOOD TO ADULTHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP GRONINGEN,DEPT PEDIAT,DIV PEDIAT PULMONOL,GRONINGEN,NETHERLANDS; UNIV HOSP GRONINGEN,DEPT INTERNAL MED,DIV PULMONOL,GRONINGEN,NETHERLANDS; UNIV HOSP GRONINGEN,DEPT ALLERGY,GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen; University of Groningen								BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BLYTHE SA, 1988, PEDIATR PULM, V4, P173, DOI 10.1002/ppul.1950040310; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; CAMPAGNE JG, 1969, SCAND J RESPIR DIS, V50, P76; CAMPAGNE JGV, 1972, THESIS NETHERLANDS; CURRAN WS, 1965, ANN INTERN MED, V55, P777; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIEGES PH, 1983, THESIS ERASMUS U ROT; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GODFREY RC, 1976, CLIN ALLERGY, V6, P79, DOI 10.1111/j.1365-2222.1976.tb01415.x; GODFREY S, 1983, ASTHMA; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HANIFIN JF, 1985, J ALLERGY CLIN IMMUN, V73, P211; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; JACOBS RL, 1981, J RESPIR DIS, V2, P20; KAUFFMAN J, 1986, AM REV RESPIR DIS, V134, P117; KERREBIJN KF, 1977, ACTA PAEDIATR SCAND, V61, P1; KJELLMAN B, 1986, ALLERGY, V41, P351, DOI 10.1111/j.1398-9995.1986.tb00312.x; KRAFCHIK BR, 1983, PEDIATR CLIN N AM, V30, P669; MARTIN AJ, 1981, MED J AUSTRALIA, V2, P470, DOI 10.5694/j.1326-5377.1981.tb112942.x; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MIDDLETON E, 1988, J ALLERGY CLIN IMMUN, V81, P971, DOI 10.1016/0091-6749(88)90163-7; PEARLMAN DS, 1988, J ALLERGY CLIN IMMUN, V81, P962, DOI 10.1016/0091-6749(88)90161-3; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P858, DOI 10.1056/NEJM195205292462204; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; ROTH HL, 1964, ARCH DERMATOL, V89, P97; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Szalai A., 1972, USE TIME; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VEENING GJJ, 1958, THESIS GRONINGEN; VICKERS CFH, 1980, ACTA DERM-VENEREOL, V92, P113; WALKER RB, 1956, BRIT J DERMATOL, V68, P182, DOI 10.1111/j.1365-2133.1956.tb12805.x; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	44	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				116	125		10.1016/0091-6749(90)90232-S	http://dx.doi.org/10.1016/0091-6749(90)90232-S			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299097	Bronze			2022-12-18	WOS:A1990CM37800020
J	MEREDITH, SD; RAPHAEL, GD; BARANIUK, JN; BANKS, SM; KALINER, MA				MEREDITH, SD; RAPHAEL, GD; BARANIUK, JN; BANKS, SM; KALINER, MA			THE PATHO-PHYSIOLOGY OF RHINITIS .3. THE CONTROL OF IGG SECRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,9000 ROCKVILLE PIKE,BLDG 10,11C207,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Baraniuk, James Nicholas/0000-0002-1866-4177				BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BORUM P, 1979, ACTA OTOLARYNGOL S S, V360, P35; BRANDTZAEG P, 1974, J IMMUNOL, V112, P1553; Brandtzaeg P., 1984, IMMUNOLOGY LUNG UPPE, P28; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BUTLER WT, 1967, J CLIN INVEST, V46, P1883, DOI 10.1172/JCI105678; BUTLER WT, 1970, J IMMUNOL, V105, P584; CAUNA N, 1970, ANN OTO RHINOL LARYN, V79, P443, DOI 10.1177/000348947007900303; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; CLEMENTS ML, 1986, J CLIN MICROBIOL, V23, P66, DOI 10.1128/JCM.23.1.66-72.1986; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; ECCLES R, 1985, CLIN REV ALLERG, V3, P501; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KIRKEGAARD J, 1982, ALLERGY, V37, P203, DOI 10.1111/j.1398-9995.1982.tb01897.x; KIRKEGAARD J, 1983, BRIT J DIS CHEST, V77, P113, DOI 10.1016/0007-0971(83)90017-7; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MYGIND N, 1982, J ALLERGY CLIN IMMUN, V70, P149, DOI 10.1016/0091-6749(82)90036-7; MYGIND N, 1975, INT ARCH ALLER A IMM, V49, P99, DOI 10.1159/000231383; MYGIND N, 1978, NASAL ALLERGY, P199; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; REASOR MJ, 1978, J APPL PHYSIOL, V45, P190, DOI 10.1152/jappl.1978.45.2.190; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SHELHAMER J, 1984, EAR NOSE THROAT J, V63, P82; WANATABE N, 1977, B YAMAGUCI MED SCH, V24, P25; WIDDICOMBE JG, 1982, NOSE UPPER AIRWAY PH, P215	31	44	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				920	930		10.1016/0091-6749(89)90390-4	http://dx.doi.org/10.1016/0091-6749(89)90390-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2480970	Bronze			2022-12-18	WOS:A1989CG29300011
J	MEADOR, KJ; LORING, DW; THOMPSON, EE; THOMPSON, WO				MEADOR, KJ; LORING, DW; THOMPSON, EE; THOMPSON, WO			DIFFERENTIAL COGNITIVE EFFECTS OF TERFENADINE AND CHLORPHENIRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL GEORGIA, OFF RES COMP & STAT, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University	MEADOR, KJ (corresponding author), MED COLL GEORGIA, DEPT NEUROL, BEHAV NEUROL SECT, AUGUSTA, GA 30912 USA.			Thompson, Elaine/0000-0001-8633-2417				BETTS T, 1984, BRIT MED J, V288, P281, DOI 10.1136/bmj.288.6413.281; BRANDON ML, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1204; BREWSTER BS, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1213; CALLAWAY E, 1985, PSYCHOPHARMACOLOGY, V85, P133, DOI 10.1007/BF00428401; CALLAWAY E, 1984, BIOL PSYCHIAT, V19, P649; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; CONNELL JT, 1985, PHARMACOTHERAPY, V5, P201; DESMEDT JE, 1981, ORG CEREBRAL CORTEX, P441; DONCHIN E, 1977, PROGR CLIN NEUROPHYS, P1; DUGUE P, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1206; FINK M, 1979, PHARMAKOPSYCH NEURO, V12, P35, DOI 10.1055/s-0028-1094592; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; HAMMOND EJ, 1987, NEUROLOGY, V37, P346, DOI 10.1212/WNL.37.2.346; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; KARRER R, 1984, BRAIN INFORMATION EV; KEMP JP, 1985, ANN ALLERGY, V54, P502; KULSHRESTHA VK, 1978, BRIT J CLIN PHARMACO, V6, P25, DOI 10.1111/j.1365-2125.1978.tb01677.x; LEESON GA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1173; MEADOR KJ, 1987, INT J NEUROSCI, V33, P199, DOI 10.3109/00207458708987404; MEADOR KJ, 1989, J CLIN EXP NEUROPSYC, V11, P252, DOI 10.1080/01688638908400887; MEADOR KJ, 1988, J GERONTOL, V43, pM158, DOI 10.1093/geronj/43.6.M158; MELILLO G, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1202; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; NICHOLSON AN, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1191; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V14, P683, DOI 10.1111/j.1365-2125.1982.tb04957.x; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; WOODWARD JK, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1154; N8303 MERR PHARM INC; N8302 MERR PHARM INC	34	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					322	325		10.1016/0091-6749(89)90415-6	http://dx.doi.org/10.1016/0091-6749(89)90415-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2570799				2022-12-18	WOS:A1989AR19900008
J	AKAGI, K; TOWNLEY, RG				AKAGI, K; TOWNLEY, RG			SPONTANEOUS HISTAMINE-RELEASE AND HISTAMINE CONTENT IN NORMAL SUBJECTS AND SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,CTR ALLERG DIS,SCH MED,DEPT MED,DIV ALLERGY,OMAHA,NE 68178	Creighton University					PHS HHS [2P50A1-1229] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKAGI K, 1984, Journal of Allergy and Clinical Immunology, V73, P166; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CONROY MC, 1977, J IMMUNOL, V118, P1317; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; FANTOZZI R, 1978, AGENTS ACTIONS, V8, P347, DOI 10.1007/BF01968614; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V81, P224, DOI 10.1016/0091-6749(88)90460-5; HIRATANI M, 1987, American Review of Respiratory Disease, V135, pA224; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LICHTENSTEIN LM, 1986, J ALLERGY CLIN IMMUN, V77, P291, DOI 10.1016/S0091-6749(86)80106-3; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACDONALD SM, 1988, J ALLERGY CLIN IMMUN, V81, P301, DOI 10.1016/0091-6749(88)90767-1; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; MONGAR JL, 1958, J PHYSIOL-LONDON, V140, P272, DOI 10.1113/jphysiol.1958.sp005933; NEIJENS HJ, 1980, CLIN ALLERGY, V10, P535, DOI 10.1111/j.1365-2222.1980.tb02134.x; PARKER C W, 1972, Clinical Research, V20, P418; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; THUESON DO, 1979, J IMMUNOL, V123, P626; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TUNG R, 1982, J IMMUNOL, V128, P2067; WEISS M, 1988, J ALLERGY CLIN IMMUN, V81, P224, DOI 10.1016/0091-6749(88)90459-9	35	44	45	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					742	749		10.1016/0091-6749(89)90009-2	http://dx.doi.org/10.1016/0091-6749(89)90009-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2468701				2022-12-18	WOS:A1989U342000006
J	HARGREAVE, FE				HARGREAVE, FE			LATE-PHASE ASTHMATIC RESPONSES AND AIRWAY INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	HARGREAVE, FE (corresponding author), ST JOSEPHS HOSP, FIRESTONE REG CHEST & ALLERGY UNIT, 50 CHARLTON AVE E, HAMILTON L8N 4A6, ONTARIO, CANADA.							BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HARGREAVE FE, 1987, ALLERGY INT TXB, P289; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; SEARS MR, 1986, EUR J RESPIR DIS, V69, P175; TURNER KJ, 1985, INT ARCH ALLER A IMM, V77, P158, DOI 10.1159/000233772; WOOLCOCK AJ, 1986, EUR J RESPIR DIS, V69, P166; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361	18	44	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				525	527		10.1016/0091-6749(89)90033-X	http://dx.doi.org/10.1016/0091-6749(89)90033-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645349	Bronze			2022-12-18	WOS:A1989T449100004
J	SCHUMACHER, MJ; GRIFFITH, RD; OROURKE, MK				SCHUMACHER, MJ; GRIFFITH, RD; OROURKE, MK			RECOGNITION OF POLLEN AND OTHER PARTICULATE AEROANTIGENS BY IMMUNOBLOT MICROSCOPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,ARIZONA HLTH SCI CTR,DIV RESP SCI,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,COLL MED,DEPT PEDIAT,TUCSON,AZ 85724, USA.							AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; MARTIN BG, 1985, ANN ALLERGY, V54, P99; PELTRE G, 1987, GRANA, V26, P158, DOI 10.1080/00173138709429945; Rantio-Lehtimaki A, 1987, Experientia Suppl, V51, P382; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SINGH MB, 1985, INT ARCH ALLER A IMM, V78, P300, DOI 10.1159/000233901; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x	11	44	46	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					608	616		10.1016/0091-6749(88)90972-4	http://dx.doi.org/10.1016/0091-6749(88)90972-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3049747				2022-12-18	WOS:A1988Q639900012
J	LARSEN, JN; FORD, A; GJESING, B; LEVY, D; PETRUNOV, B; SILVESTRI, L; LOWENSTEIN, H				LARSEN, JN; FORD, A; GJESING, B; LEVY, D; PETRUNOV, B; SILVESTRI, L; LOWENSTEIN, H			THE COLLABORATIVE STUDY OF THE INTERNATIONAL STANDARD OF DOG, CANIS-DOMESTICUS, HAIR DANDER EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; NATL INST BIOL STAND & CONTROL,IMMUNOL SECT,LONDON NW3 6RB,ENGLAND; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM & EPIDEMIOL,BALTIMORE,MD 21218; ACAD MED SOFIA,INFECT & PARASIT DIS RES INST,ALLERGY LAB,SOFIA,BULGARIA; KEY PHARMACEUT INC,IMMUNOL RES & DEV,MIAMI,FL	University of Copenhagen; National Institute for Biological Standards & Control; Johns Hopkins University; Medical University Sofia; Military Medical Academy Sofia				Petrunov, Bogdan/0000-0001-8435-6175				Baily JL, 1962, TECHNIQUES PROTEIN C, P73; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P337, DOI 10.1159/000230849; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; CAMPBELL PJ, 1974, J BIOL STAND, V2, P259, DOI 10.1016/0092-1157(74)90034-1; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PETRUNOV B, 1977, ALLERGOL IMMUNOPATHO, V5, P319; SCHWARTZ J, 1966, INT ARCH ALLER A IMM, V30, P67, DOI 10.1159/000229794; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; UHLIN T, 1984, ALLERGY, V39, P125, DOI 10.1111/j.1398-9995.1984.tb01944.x; Yman L, 1975, Dev Biol Stand, V29, P151; 1978, WHO TECHNICAL REPORT, V626	17	44	45	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				318	330		10.1016/0091-6749(88)90002-4	http://dx.doi.org/10.1016/0091-6749(88)90002-4			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170981				2022-12-18	WOS:A1988Q322900002
J	TAYLOR, SL; BUSH, RK; SELNER, JC; NORDLEE, JA; WIENER, MB; HOLDEN, K; KOEPKE, JW; BUSSE, WW				TAYLOR, SL; BUSH, RK; SELNER, JC; NORDLEE, JA; WIENER, MB; HOLDEN, K; KOEPKE, JW; BUSSE, WW			SENSITIVITY TO SULFITED FOODS AMONG SULFITE-SENSITIVE SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,FOOD RES INST,DEPT FOOD,MADISON,WI 53792; UNIV WISCONSIN,FOOD RES INST,DEPT MICROBIOL,MADISON,WI 53792; UNIV WISCONSIN,FOOD RES INST,DEPT TOXICOL & FOOD SCI,MADISON,WI 53792; UNIV WISCONSIN,DEPT MED,MADISON,WI 53792; WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53705; ALLERGY RESP INST COLORADO,DENVER,CO	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital								[Anonymous], 1986, FED REGISTER, V51, P25012; BAKER GJ, 1981, MED J AUSTRALIA, V2, P644; BEELMAN RB, 1986, 46TH ANN I FOOD TECH, P110; BUSH RK, 1986, J ALLERGY CLIN IMMUN, V78, P191, DOI 10.1016/0091-6749(86)90012-6; BUSH RK, 1986, AM J MED, V81, P816, DOI 10.1016/0002-9343(86)90351-7; DELOHERY J, 1984, AM REV RESPIR DIS, V130, P1027; FINNE G, 1986, J FOOD SCI, V51, P231, DOI 10.1111/j.1365-2621.1986.tb10879.x; Green L. F., 1976, FOOD CHEM, V1, P103, DOI [10.1016/0308-8146(76)90003-0, DOI 10.1016/0308-8146(76)90003-0]; HOWLAND WC, 1985, J ALLERGY CLIN IMMUN, V75, P145, DOI 10.1016/0091-6749(85)90296-9; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; LEE RJ, 1986, J ALLERGY CLIN IMMUN, V77, P157; MARTIN LB, 1986, J FOOD PROTECT, V49, P126, DOI 10.4315/0362-028X-49.2.126; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V76, P840, DOI 10.1016/0091-6749(85)90758-4; SELNER J, 1987, J ALLERGY CLIN IMMUN, V79, P241; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; Taylor S L, 1986, Adv Food Res, V30, P1, DOI 10.1016/S0065-2628(08)60347-X; U.S. Food and Drug Administration, 1986, FED REG, V51, P25; WILLIAMS S, 1984, OFFICIAL METHODS ANA, P391; 1985, REEXAMINATION GRAS S, P96	19	44	44	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1159	1167		10.1016/0091-6749(88)90885-8	http://dx.doi.org/10.1016/0091-6749(88)90885-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379229	Green Published			2022-12-18	WOS:A1988P002300015
J	CASTELLS, MC; PASCUAL, C; ESTEBAN, MM; OJEDA, JA				CASTELLS, MC; PASCUAL, C; ESTEBAN, MM; OJEDA, JA			ALLERGY TO WHITE POTATO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP INFANTIL LA PAZ,SERV ALERGIA,CASTELLANA 261,E-28016 MADRID,SPAIN	Hospital Universitario La Paz								ASPEREN PP, 1983, ARCH DIS CHILD, V58, P253; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CESKA M, 1977, BIOL BIOMEDICAL APPL, P57; Donnally HH, 1930, J IMMUNOL, V19, P15; ERLICH HA, 1978, CELL, V13, P681, DOI 10.1016/0092-8674(78)90218-0; ESTEBAN MM, 1983, AN ESP PEDIATR, V19, P359; GERRARD JW, 1980, INT C SERIES, V58, P170; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINESTEBAN M, 1977, ACTA ALLERGOL, V32, P413, DOI 10.1111/j.1398-9995.1977.tb01365.x; MATSUMURA T, 1975, ANN ALLERGY, V35, P221; NATER JP, 1967, J ALLERGY, V40, P201; PEARSON RSB, 1966, ACTA ALLERGOL, V21, P507, DOI 10.1111/j.1398-9995.1966.tb03170.x; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TAYLOR KM, 1980, INT ARCH ALLER A IMM, V61, P19, DOI 10.1159/000232410; 1984, NIH8424428 PUBL, P18	18	44	45	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1110	1114		10.1016/0091-6749(86)90258-7	http://dx.doi.org/10.1016/0091-6749(86)90258-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782675				2022-12-18	WOS:A1986F302600004
J	NACLERIO, RM; BARTENFELDER, D; PROUD, D; TOGIAS, AG; MEYERS, DA; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM				NACLERIO, RM; BARTENFELDER, D; PROUD, D; TOGIAS, AG; MEYERS, DA; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM			THEOPHYLLINE REDUCES HISTAMINE-RELEASE DURING POLLEN-INDUCED RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL32272] Funding Source: Medline; NIAID NIH HHS [AI8270, AI07290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GK, 1979, J IMMUNOL, V122, P555; BRISSON GR, 1972, J CLIN INVEST, V51, P232, DOI 10.1172/JCI106808; CHIPPS BE, 1980, J ALLERGY CLIN IMMUN, V65, P61, DOI 10.1016/0091-6749(80)90178-5; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; FALLIERS CJ, 1979, J ALLERGY CLIN IMMUN, V64, P685, DOI 10.1016/0091-6749(79)90039-3; HENDELES L, 1983, ALLERGY PRINCIPLES P, P535; HOLGATE ST, 1980, J IMMUNOL, V129, P2122; HORROBIN DF, 1977, PROSTAGLANDINS, V13, P33, DOI 10.1016/0090-6980(77)90040-5; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NISSIM JE, 1980, J ALLERGY CLIN IMMUN, V65, P180; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TUNG RS, 1981, J PHARMACOL EXP THER, V218, P642; 1981, BMDP STATISTICAL SOF	20	44	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				874	876		10.1016/0091-6749(86)90233-2	http://dx.doi.org/10.1016/0091-6749(86)90233-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	2431021				2022-12-18	WOS:A1986E971300008
J	WASSERMAN, SI				WASSERMAN, SI			THE HEART IN ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											WASSERMAN, SI (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DIV ALLERGY,225 W DICKINSON ST,SAN DIEGO,CA 92103, USA.							AUSTIN SM, 1984, AM J MED, V77, P729, DOI 10.1016/0002-9343(84)90374-7; AVER J, 1910, J EXP MED, V12, P151; BOOTH BH, 1970, J AMER MED ASSOC, V211, P627, DOI 10.1001/jama.211.4.627; BRASHER GW, 1974, JAMA-J AM MED ASSOC, V229, P1210, DOI 10.1001/jama.229.9.1210; BURKE JA, 1982, J PHARMACOL EXP THER, V221, P235; CAPURRO N, 1975, CIRC RES, V36, P520, DOI 10.1161/01.RES.36.4.520; CAPURRO N, 1973, BRIT J PHARMACOL, V48, P620, DOI 10.1111/j.1476-5381.1973.tb08249.x; CRIEP LH, 1971, ANN ALLERGY, V29, P399; DRUCK MN, 1981, CAN MED ASSOC J, V125, P1131; FEIGEN GA, 1969, AM J CARDIOL, V24, P474, DOI 10.1016/0002-9149(69)90490-1; FORMAN MB, 1985, NEW ENGL J MED, V313, P1138, DOI 10.1056/NEJM198510313131807; GRAVER LM, 1986, J ALLERGY CLIN IMMUN, V77, P709, DOI 10.1016/0091-6749(86)90415-X; GUO ZG, 1984, J CARDIOVASC PHARM, V6, P1210; HALONEN M, 1980, AM REV RESPIR DIS, V122, P915; HOUKI S, 1973, ARCH INT PHARMACOD T, V206, P113; KALSNER S, 1984, SCIENCE, V223, P1435, DOI 10.1126/science.6701530; LEDDA F, 1976, BRIT J PHARMACOL, V57, P247, DOI 10.1111/j.1476-5381.1976.tb07474.x; LEVI R, 1982, KLIN WOCHENSCHR, V60, P965, DOI 10.1007/BF01716956; LEVI R, 1984, CIRC RES, V54, P117, DOI 10.1161/01.RES.54.2.117; Levi R, 1980, DRUG INDUCED HEART D, P377; LEVI R, 1985, PROSTAGLANDINS LEUKO, P275; LEVI R, 1982, ADV HISTAMINE RES, P213; LEVINE HD, 1976, AM HEART J, V91, P365, DOI 10.1016/S0002-8703(76)80222-0; MULLANE K, 1985, P127; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PATTERSON R, 1966, J ALLERGY, V37, P295, DOI 10.1016/S0021-8707(96)90013-1; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; POMERANCE A, 1958, J PATHOL BACTERIOL, V76, P55, DOI 10.1002/path.1700760106; STEIN I, 1970, J ALLERGY, V45, P48, DOI 10.1016/0021-8707(70)90016-X; SULLIVAN TJ, 1982, JAMA-J AM MED ASSOC, V248, P2161, DOI 10.1001/jama.248.17.2161; TRZECIAKOWSKI JP, 1981, FED P, V40, P692; ZAVECZ JH, 1977, CIRC RES, V40, P15, DOI 10.1161/01.RES.40.1.15; ZAVECZ JH, 1976, PHARMACOLOGIST, V18, P168	33	44	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					663	666		10.1016/0091-6749(86)90405-7	http://dx.doi.org/10.1016/0091-6749(86)90405-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700887				2022-12-18	WOS:A1986C390300003
J	STORMS, W; MIDDLETON, E; DVORIN, D; KEMP, J; SPECTOR, S; NEWTON, J; PERHACH, JL				STORMS, W; MIDDLETON, E; DVORIN, D; KEMP, J; SPECTOR, S; NEWTON, J; PERHACH, JL			AZELASTINE (AZEL) IN THE TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					167	167		10.1016/0091-6749(85)90386-0	http://dx.doi.org/10.1016/0091-6749(85)90386-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22		Bronze			2022-12-18	WOS:A1985ACF2200251
J	GEHA, RS				GEHA, RS			HUMAN IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,BOSTON,MA 02115	Harvard University; Boston Children's Hospital					NIADDK NIH HHS [AM31925-01] Funding Source: Medline; NIAID NIH HHS [K07 AI0440-01, AI20373-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020373] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMLOT PL, 1978, BRIT MED J, V1, P327, DOI 10.1136/bmj.1.6109.327; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BENNICH H, 1969, J IMMUNOL, V102, P826; BLASER K, 1980, J IMMUNOL, V125, P24; BROSTOFF J, 1979, LANCET, V1, P1268; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON M, 1981, J IMMUNOL, V126, P1764; CAPRON M, 1984, J IMMUNOL, V132, P462; CONRAD DH, 1976, J IMMUNOL, V116, P319; DESSAINT JP, 1975, IMMUNOLOGY, V29, P813; DESSEIN AJ, 1981, J EXP MED, V153, P423, DOI 10.1084/jem.153.2.423; ETTLIN R, 1981, INT ARCH ALLER A IMM, V66, P93, DOI 10.1159/000232878; GEHA RS, 1982, J IMMUNOL, V129, P139; GEHA RS, 1983, J IMMUNOL, V130, P1634; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V59, P377, DOI 10.1016/0091-6749(77)90022-7; HIRASHIMA M, 1980, J IMMUNOL, V125, P2154; HOGARTHSCOTT RS, 1973, MED J AUSTRALIA, V1, P1293, DOI 10.5694/j.1326-5377.1973.tb111120.x; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; ISHIZAKA K, 1981, J IMMUNOL, V126, P1692; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1967, J ALLERGY, V39, P254, DOI 10.1016/0021-8707(67)90019-6; ISHIZAKA K, 1973, P55; ISHIZAKA K, 1968, J IMMUNOL, V100, P554; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1975, PROG ALLERGY, V19, P60, DOI 10.1159/000313384; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; ISHIZAKA T, 1977, J IMMUNOL, V119, P1589; ISHIZAKA T, 1970, J IMMUNOL, V104, P335; ISHIZAKA T, 1974, J IMMUNOL, V112, P1781; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; KISHIMOTO T, 1973, J IMMUNOL, V111, P720; KISHIMOTO T, 1976, J IMMUNOL, V117, P396; LAWTON AR, 1975, FED PROC, V34, P33; LEE WY, 1978, INT ARCH ALLERGY APP, V56, P183; LEUNG D Y M, 1984, Journal of Allergy and Clinical Immunology, V73, P176; LEUNG DYM, 1984, CLIN IMMUNOL IMMUNOP; LEUNG DYM, 1984, CLIN RES, V32, P538; LEVINE BB, 1968, J CLIN INVEST, V47, P556, DOI 10.1172/JCI105752; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARCH DG, 1982, J EXP MED, V155, P1439; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1981, INT ARCH ALLER A IMM, V66, P48, DOI 10.1159/000232866; MARSH DG, 1975, ANTIGENS, V3, P271; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MICHAEL JG, 1973, J IMMUNOL, V111, P1600; MITSUYA H, 1983, CLIN IMMUNOL IMMUNOP, V26, P171, DOI 10.1016/0090-1229(83)90135-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; OOI BS, 1974, LANCET, V1, P1254; ORANGE RP, 1971, J EXP MED, V134, pS136; ORGEL HA, 1975, PEDIATRIC CLIN N AM; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PERERA MG, 1975, AM REV RESPIR DIS, V111, P605; POLMAR SH, 1972, AM J PATHOL, V69, P499; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; REEVES W G, 1975, Clinical Allergy, V5, P121, DOI 10.1111/j.1365-2222.1975.tb01845.x; RICCI M, 1983, J ALLERGY CLIN IMMUN, V71, P913; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; RUBENSTEIN E, 1975, J ALLERGY CLIN IMMUN, V55, P115; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARYAN F, 1983, J CLIN INVEST, V71, P556; SARYAN JA, 1983, J IMMUNOL, V130, P242; SETSUKO I, 1983, CLIN EXP IMMUNOL, V51, P407; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; STONE SP, 1976, ARCH DERMATOL, V112, P1254, DOI 10.1001/archderm.112.9.1254; TADA T, 1970, Journal of Immunology, V104, P377; UBER CL, 1980, NATURE, V287, P226, DOI 10.1038/287226a0; URBAN JF, 1977, J IMMUNOL, V118, P1982; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; YODOI J, 1981, J IMMUNOL, V126, P877; YOUNG MC, EUR J IMMUNOL; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	81	44	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					109	120		10.1016/0091-6749(84)90270-7	http://dx.doi.org/10.1016/0091-6749(84)90270-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6205033				2022-12-18	WOS:A1984TE22600001
J	GUILLOT, C; FORNARIS, M; BADIER, M; OREHEK, J				GUILLOT, C; FORNARIS, M; BADIER, M; OREHEK, J			SPONTANEOUS AND PROVOKED RESISTANCE TO ISOPROTERENOL IN ISOLATED HUMAN BRONCHI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SALVATOR,EXPLORAT FONCTIONNELLES RESP LAB,F-13009 MARSEILLE,FRANCE; INSERM,U174,F-13258 MARSEILLE 09,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)								AVNER BP, 1981, J ALLERGY CLIN IMMUN, V68, P51, DOI 10.1016/0091-6749(81)90123-8; BOUHUYS A, 1976, PNEUMONOLOGIE, V153, P185, DOI 10.1007/BF02095884; BRINK C, 1981, BRIT J PHARMACOL, V73, P13, DOI 10.1111/j.1476-5381.1981.tb16765.x; BRINK C, 1980, BRIT J PHARMACOL, V69, P383, DOI 10.1111/j.1476-5381.1980.tb07026.x; DAVIS C, 1980, BRIT J CLIN PHARMACO, V10, P417, DOI 10.1111/j.1365-2125.1980.tb01782.x; DOUGLAS JS, 1977, EUR J PHARMACOL, V42, P195, DOI 10.1016/0014-2999(77)90285-0; DULL WL, 1982, AM REV RESPIR DIS, V126, P656; EATON ML, 1980, ANN INTERN MED, V92, P758, DOI 10.7326/0003-4819-92-6-758; GEDDES BA, 1974, AM REV RESPIR DIS, V110, P420; HOLGATE ST, 1977, LANCET, V2, P373; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; KARLSSON JA, 1981, BRIT J PHARMACOL, V74, P73, DOI 10.1111/j.1476-5381.1981.tb09956.x; MARINI JJ, 1980, CHEST, V77, P591, DOI 10.1378/chest.77.5.591; MORRIS HG, 1980, J ALLERGY CLIN IMMUN, V65, P83, DOI 10.1016/0091-6749(80)90190-6; PATERSON JW, 1979, AM REV RESPIR DIS, V120, P1149; POPPIUS H, 1973, BMJ-BRIT MED J, V4, P134, DOI 10.1136/bmj.4.5885.134; SCHREURS AJM, 1980, J PHARMACOL EXP THER, V215, P691; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; WILLIAMS LT, 1978, RECEPTOR BINDING STU, P127	20	44	45	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					713	718		10.1016/0091-6749(84)90235-5	http://dx.doi.org/10.1016/0091-6749(84)90235-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6501744				2022-12-18	WOS:A1984TT16900010
J	DESHAZO, RD; BOEHM, TM; KUMAR, D; GALLOWAY, JA; DVORAK, HF				DESHAZO, RD; BOEHM, TM; KUMAR, D; GALLOWAY, JA; DVORAK, HF			DERMAL HYPERSENSITIVITY REACTIONS TO INSULIN - CORRELATIONS OF 3 PATTERNS TO THEIR HISTOPATHOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR, CLIN INVEST SERV, WASHINGTON, DC 20012 USA; UNIV SO CALIF, SCH MED, DIABET SECT, LOS ANGELES, CA 90007 USA; INDIANA UNIV, SCH MED, DEPT MED, LILLY LAB CLIN RES, INDIANAPOLIS, IN 46204 USA; HARVARD UNIV, SCH MED,BETH ISRAEL HOSP,CHARLES A DANA RES INST, DEPT PATHOL, BOSTON, MA 02115 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Southern California; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	DESHAZO, RD (corresponding author), TULANE UNIV, SCH MED, CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA.							ARKINS JA, 1962, J ALLERGY, V33, P69, DOI 10.1016/0021-8707(62)90065-5; BERTRAMS J, 1976, TISSUE ANTIGENS, V8, P13; BLOOM SR, 1979, LANCET, V1, P14; CHANCE RE, 1976, ACTA ENDOCRINOL-COP, V83, P185; DESHAZO RD, 1977, J ALLERGY CLIN IMMUN, V59, P161, DOI 10.1016/0091-6749(77)90219-6; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DESHAZO RD, 1977, POSTGRAD MED, V63, P85; DESHAZO RD, 1981, NATIONAL EYE I S IMM; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORAK AM, 1976, LAB INVEST, V34, P179; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; DVORAK HF, 1978, IMMEDIATE HYPERSENSI, P659; FAULK WP, 1975, INT ARCH ALLER A IMM, V48, P364; FEINGLOS MN, 1979, LANCET, V1, P122; FISHER AA, 1973, CONTACT DERMATITIS, P121; GALLOWAY JA, 1980, DIABETES CARE, V3, P615, DOI 10.2337/diacare.3.5.615; GALLOWAY JA, 1975, ENDOCRINOLOGY DIABET; Kahn C R, 1979, Diabetes Care, V2, P283; KEYSTONE EC, 1980, CLIN EXP IMMUNOL, V40, P202; KUMAR D, 1977, J CLIN ENDOCR METAB, V45, P1159, DOI 10.1210/jcem-45-6-1159; KUMAR D, 1977, DIABETES, V26, P296, DOI 10.2337/diab.26.4.296; KUMAR D, 1981, DIABETES CARE, V4, P104, DOI 10.2337/diacare.4.1.104; LAMPKIN M, 1976, J ALLERGY CLIN IMMUN, V58, P213; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; LYNFIELD Y, 1979, ARCH DERMATOL, V115, P591, DOI 10.1001/archderm.115.5.591; MINARS N, 1975, J ALLERGY CLIN IMMUN, V56, P411, DOI 10.1016/0091-6749(75)90135-9; PALEY RG, 1952, DIABETES, V1, P22, DOI 10.2337/diab.1.1.22; PATTERSON R, 1969, J IMMUNOL, V103, P1061; POLAK L, 1968, IMMUNOLOGY, V14, P707; SHELDON RM, 1967, MANUAL CLIN ALLERGY, P59; SHORE RN, 1975, ARCH DERMATOL, V111, P94; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WENTWORTH SM, 1976, DIABETES, V25, P326; YAGI Y, 1963, J IMMUNOL, V90, P760; YALOW RS, 1961, AM J MED, V31, P882, DOI 10.1016/0002-9343(61)90030-4; YUE DK, 1977, DIABETES, V26, P341, DOI 10.2337/diab.26.4.341	38	44	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					229	237		10.1016/0091-6749(82)90104-X	http://dx.doi.org/10.1016/0091-6749(82)90104-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7035526	Bronze			2022-12-18	WOS:A1982NC58100010
J	ELWOOD, RK; ABBOUD, RT				ELWOOD, RK; ABBOUD, RT			THE SHORT-TERM BRONCHODILATOR EFFECTS OF FENOTEROL AND IPRATROPIUM IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,VANCOUVER V5Z 1M9,BC,CANADA	University of British Columbia								CHANYEUNG M, 1977, CHEST, V71, P320, DOI 10.1378/chest.71.3.320; CHERNIACK RM, 1972, AM REV RESPIR DIS, V106, P38, DOI 10.1164/arrd.1972.106.1.38; DETROYER A, 1978, AM REV RESPIR DIS, V118, P987; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; GOLDBERG R, 1975, POSTGRAD MED J, V51, P53, DOI 10.1136/pgmj.51.592.53; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; GUTERSOHN J, 1975, POST GRAD MED J, V5, P113; HENSLEY MJ, 1978, J APPL PHYSIOL, V45, P778, DOI 10.1152/jappl.1978.45.5.778; LIGHTBODY IM, 1978, BRIT J DIS CHEST, V72, P181, DOI 10.1016/0007-0971(78)90039-6; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NADEL J A, 1973, P29; OFFERMEYER G, 1975, POSTGRADUATE MED J S, V51, P117; POPPIUS H, 1972, B PHYSIO-PATHOL RESP, V8, P643; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; Steel RGD, 1960, PRINCIPLES PROCEDURE, P107; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TWEEL HK, 1971, ANN ALLERGY, V29, P142; WETTENGEL R, 1971, INT J CLIN PHARM T S, V4, P96; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823; 1962, AM REV RESPIR DIS, V85, P762	23	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					467	473		10.1016/0091-6749(82)90123-3	http://dx.doi.org/10.1016/0091-6749(82)90123-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	6210726				2022-12-18	WOS:A1982NP93400010
J	WELSH, PW; ZIMMERMANN, EM; YUNGINGER, JW; KERN, EB; GLEICH, GJ				WELSH, PW; ZIMMERMANN, EM; YUNGINGER, JW; KERN, EB; GLEICH, GJ			PRESEASONAL INTRANASAL IMMUNOTHERAPY WITH NEBULIZED SHORT RAGWEED EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT PEDIAT, ROCHESTER, MN 55901 USA; MAYO MED SCH, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT OTORHINOLARYNGOL, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT MED, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT IMMUNOL, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOK N, 1974, Journal of Laryngology and Otology, V88, P1169, DOI 10.1017/S0022215100079901; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; DIXON WJ, 1969, INTRO STATISTICAL AN, P341; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, J IMMUNOL; GLEICH GJ, 1975, CLIN ALLERGY, V1, P79; GUERCIO J, 1979, AM REV RESPIR DIS, V119, P69; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MCLEAN JA, 1979, J ALLERGY CLIN IMMUN, V63, P166; MEHTA S B, 1975, Clinical Allergy, V5, P279; NICKELSEN JA, 1979, J ALLERGY CLIN IMMUN, V63, P166; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; Sheldon JM, 1967, MANUAL CLINICAL ALLE, P98; SWINEFORD O, 1955, J ALLERGY, V26, P305, DOI 10.1016/0021-8707(55)90060-5; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; WELSH PW, 1979, J ALLERGY CLIN IMMUN, V64, P209, DOI 10.1016/0091-6749(79)90097-6; WELSH PW, 1977, J ALLERGY CLIN IMMUN, V60, P104, DOI 10.1016/0091-6749(77)90034-3; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	20	44	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					237	242		10.1016/0091-6749(81)90067-1	http://dx.doi.org/10.1016/0091-6749(81)90067-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7007474				2022-12-18	WOS:A1981LG77800012
J	WONG, L; HENDELES, L; WEINBERGER, M				WONG, L; HENDELES, L; WEINBERGER, M			PHARMACOLOGIC PROPHYLAXIS OF ALLERGIC RHINITIS - RELATIVE EFFICACY OF HYDROXYZINE AND CHLORPHENIRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL PHARM,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PEDIAT,DIV CLIN PHARMACOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007035] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-59, RR-07035] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CONNELL JT, 1979, ANN ALLERGY, V42, P278; CONNELL JT, 1977, CP5362 ROSS LAB REP; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; EMPEY DW, 1975, ANN ALLERGY, V34, P41; ORANGE RP, 1971, BIOCHEMISTRY ACUTE A, P189; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; SCHAAF L, 1979, J ALLERGY CLIN IMMUN, V63, P129, DOI 10.1016/0091-6749(79)90203-3; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P902	8	44	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					223	228		10.1016/0091-6749(81)90065-8	http://dx.doi.org/10.1016/0091-6749(81)90065-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7007473				2022-12-18	WOS:A1981LG77800010
J	PATTERSON, R; HARRIS, KE; GREENBERGER, PA				PATTERSON, R; HARRIS, KE; GREENBERGER, PA			EFFECT OF PROSTAGLANDIN-D2 AND PROSTAGLANDIN-I2 ON THE AIRWAYS OF RHESUS-MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,INFECT DIS SECT,CHICAGO,IL 60611	Northwestern University	PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; JAKSCHIK BA, 1978, FED P, V37, P906; KELLY JF, 1974, J LAB CLIN MED, V83, P738; MILLER MM, 1976, J LAB CLIN MED, V88, P995; MONOCADA S, 1976, NATURE LOND, V263, P663; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P261, DOI 10.1016/0091-6749(78)90201-4; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; PATTERSON R, 1978, LIFE SCI, V22, P389, DOI 10.1016/0024-3205(78)90285-0; PATTERSON R, 1976, J LAB CLIN MED, V87, P65; PATTERSON R, 1974, ANNU REV MED, V25, P53, DOI 10.1146/annurev.me.25.020174.000413; ROBERTS LJ, 1978, FED P, V37, P908; SNEDECOR GW, 1973, STATISTICAL METHODS, P59	14	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					269	273		10.1016/0091-6749(80)90154-2	http://dx.doi.org/10.1016/0091-6749(80)90154-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JN548	6766962				2022-12-18	WOS:A1980JN54800005
J	SLAVIN, RG; IZU, AE; BERNSTEIN, IL; BLUMENTHAL, MN; BOLIN, JF; OUELLETTE, JJ; REED, CE; OREN, J				SLAVIN, RG; IZU, AE; BERNSTEIN, IL; BLUMENTHAL, MN; BOLIN, JF; OUELLETTE, JJ; REED, CE; OREN, J			MULTI-CENTER STUDY OF FLUNISOLIDE AEROSOL IN ADULT PATIENTS WITH STEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,DEPT INTERNAL MED,CINCINNATI,OH 45221; UNIV WISCONSIN,DEPT INTERNAL MED,MADISON,WI 53706; UNIV MINNESOTA,DEPT INTERNAL MED,MINNEAPOLIS,MN 55455; SYNTEX RES CORP,PALO ALTO,CA 94304	University System of Ohio; University of Cincinnati; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities; Syntex Corporation	SLAVIN, RG (corresponding author), ST LOUIS UNIV,MED CTR,SCH MED,DEPT INTERNAL MED,ALLERGY & IMMUNOL SECT,ST LOUIS,MO 63104, USA.							CHERVINSKY P, 1977, ANN ALLERGY, V38, P192; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; FALLIERS CJ, 1975, J ALLERGY CLIN IMMUN, V57, P1; GODFREY S, 1963, ARCH DIS CHILD, V48, P665; HORAN JD, 1978, CAN MED ASSOC J, V119, P334; KASS I, 1977, CHEST, V71, P703, DOI 10.1378/chest.71.6.703; KRIZ RJ, 1977, CHEST, V72, P36, DOI 10.1378/chest.72.1.36; LOWELL FC, 1976, J ALLERGY CLIN IMMUN, V57, P257; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; SCHULZ JI, 1978, CLIN ALLERGY, V8, P313, DOI 10.1111/j.1365-2222.1978.tb00466.x; SIGEL SC, 1964, PEDIATRICS, V33, P245; SLY RM, 1978, J ALLERGY CLIN IMMUN, V62, P76, DOI 10.1016/0091-6749(78)90082-9; SPANGLER DL, 1977, ANN ALLERGY, V39, P70; STRAND LJ, 1977, CUTIS, V19, P689; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; VOGT F, 1976, J ALLERGY CLIN IMMUN, V58, P316, DOI 10.1016/0091-6749(76)90137-8; WEBB DR, 1979, ANN ALLERGY, V42, P80; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; ZEITZ H, 1977, ANN ALLERGY, V39, P70; 1976, BRIT J DIS CHEST, V70, P95; 1975, LANCET, V2, P469	22	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					379	385		10.1016/0091-6749(80)90117-7	http://dx.doi.org/10.1016/0091-6749(80)90117-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7440855				2022-12-18	WOS:A1980KQ96500006
J	WAHN, U; SIRAGANIAN, RP				WAHN, U; SIRAGANIAN, RP			EFFICACY AND SPECIFICITY OF IMMUNOTHERAPY WITH LABORATORY-ANIMAL ALLERGEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIDR,MICROBIOL & IMMUNOL LAB,CLIN IMMUNOL SECT,BLDG 10 2B12,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BERRENS L, 1974, ACTA ALLERGOL, V29, P10, DOI 10.1111/j.1398-9995.1974.tb01990.x; BROWN FR, 1968, ANN ALLERGY, V26, P305; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; GIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LUTSKY II, 1975, ANN ALLERGY, V35, P201; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; SHIMIZU M, 1978, J IMMUNOL METHODS, V19, P317, DOI 10.1016/0022-1759(78)90016-9; SIRAGANIAN RP, 1977, J ALLERGY CLIN IMMUN, V59, P214, DOI 10.1016/0091-6749(77)90152-X; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P393; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; TAYLOR AN, 1977, LANCET, V2, P847; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUFT L, 1967, AM J MED SCI, V253, P19, DOI 10.1097/00000441-196701000-00005; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	26	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					413	421		10.1016/0091-6749(80)90233-X	http://dx.doi.org/10.1016/0091-6749(80)90233-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	7372963				2022-12-18	WOS:A1980JV76400003
J	GLEICH, GJ				GLEICH, GJ			EOSINOPHIL - NEW ASPECTS OF STRUCTURE AND FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO GRAD SCH MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic								BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CLARK RAF, 1975, CLIN HAEMATOL, V4, P635; ELHASHIMI W, 1971, AM J PATHOL, V65, P311; GAUDERER CA, TO BE PUBLISHED; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1973, J EXP MED, V137, P1459, DOI 10.1084/jem.137.6.1459; GLEICH GJ, 1975, J IMMUNOL, V115, P950; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GLEICH GJ, 1973, J LAB CLIN MED, V82, P522; GLEICH GJ, UNPUBLISHED OBSERVAT; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; HUBSCHER T, 1975, J IMMUNOL, V114, P1379; LEWIS DM, 1976, IMMUNOCHEMISTRY, V13, P743, DOI 10.1016/0019-2791(76)90194-4; MAHMOUD AAF, 1975, J EXP MED, V142, P805, DOI 10.1084/jem.142.4.805; MAHMOUD AAF, 1975, J EXP MED, V142, P560, DOI 10.1084/jem.142.3.560; MAHMOUD AAF, 1973, J EXP MED, V137, P1526, DOI 10.1084/jem.137.6.1526; MILLER F, 1966, J CELL BIOL, V31, P349, DOI 10.1083/jcb.31.2.349; PARMLEY RT, 1974, LAB INVEST, V30, P557; PEASE DC, 1956, BLOOD, V11, P501, DOI 10.1182/blood.V11.6.501.501; SOLLEY GO, 1976, MAYO CLIN PROC, V51, P697; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; WELSH RA, 1959, AM J PATHOL, V35, P1091; WILHELM J A, 1971, Subcellular Biochemistry, V1, P39; ZEIGER RS, 1976, J ALLERGY CLIN IMMUN, V58, P172, DOI 10.1016/0091-6749(76)90152-4; ZUCKER-FRANKLIN D, 1971, Hospital Practice, V6, P119; Zucker-Franklin D, 1974, Adv Intern Med, V19, P1	26	44	44	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					73	82		10.1016/0091-6749(77)90086-0	http://dx.doi.org/10.1016/0091-6749(77)90086-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	326849	Bronze			2022-12-18	WOS:A1977DN22400011
J	JAMES, L; FACIANE, J; SLY, RM				JAMES, L; FACIANE, J; SLY, RM			EFFECT OF TREADMILL EXERCISE ON ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUISIANA STATE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112	Louisiana State University System								Adams F, 1856, EXTANT WORKS ARETAEU; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; HEIMLICH EM, 1966, J ALLERGY, V37, P103; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; MCNEILL RS, 1966, Q J MED, V35, P55; PIERSON WE, 1972, J ALLERGY CLIN IMMUN, V49, P129; REBUCK AS, 1968, LANCET, V2, P429; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1972, BMJ-BRIT MED J, V1, P207, DOI 10.1136/bmj.1.5794.207; SLY RM, 1970, ANN ALLERGY, V28, P1; SLY RM, 1972, PEDIATR DIG, V14, P42	13	44	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					408	416		10.1016/0091-6749(76)90055-5	http://dx.doi.org/10.1016/0091-6749(76)90055-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	1262613				2022-12-18	WOS:A1976BR20100003
J	KRELL, RD; CHAKRIN, LW				KRELL, RD; CHAKRIN, LW			CANINE AIRWAY RESPONSES TO ACETYLCHOLINE, PROSTAGLANDIN-F2ALPHA, HISTAMINE, AND SEROTONIN AFTER CHRONIC ANTIGEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SK&F LABS,DEPT BIOL RES,RESP DIS SECT,PHILADELPHIA,PA 19101	GlaxoSmithKline								CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; CHURCH MK, 1975, BRIT J PHARMACOL, V55, P423, DOI 10.1111/j.1476-5381.1975.tb06947.x; COLEBATCH HJ, 1966, J APPL PHYSIOL, V21, P217, DOI 10.1152/jappl.1966.21.1.217; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; GILES RE, 1971, ARCH INT PHARMACOD T, V194, P213; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; HOGARTHS.RS, 1967, IMMUNOLOGY, V13, P535; ISLAM MS, 1974, RESPIRATION, V31, P47, DOI 10.1159/000193098; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; KRELL R, IN PRESS; KRELL RD, 1976, J ALLERGY CLIN IMMUN, V58, P19, DOI 10.1016/0091-6749(76)90103-2; KRELL RD, 1975, IMMUNOPHARMACOLOGY, P125; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MICHELSON AL, 1958, J LAB CLIN MED, V51, P57; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; NADEL JA, 1968, ARCH ENVIRON HEALTH, V16, P171, DOI 10.1080/00039896.1968.10665039; PIPER PJ, 1973, INT ARCH ALLER A IMM, V45, P87, DOI 10.1159/000231008; SANDERS R, 1959, SURG GYNECOL OBSTET, V109, P455; SANYAL RK, 1958, J PHYSIOL-LONDON, V144, P525, DOI 10.1113/jphysiol.1958.sp006117; SHEARD P, 1967, NATURE, V216, P283, DOI 10.1038/216283a0; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; WASSERMAN MA, 1975, EUR J PHARMACOL, V32, P146, DOI 10.1016/0014-2999(75)90277-0	25	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					664	675		10.1016/0091-6749(76)90178-0	http://dx.doi.org/10.1016/0091-6749(76)90178-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	993481				2022-12-18	WOS:A1976CP07700005
J	RHOADES, RB; LEIFER, KN; COHAN, R; WITTIG, HJ				RHOADES, RB; LEIFER, KN; COHAN, R; WITTIG, HJ			SUPPRESSION OF HISTAMINE-INDUCED PRURITUS BY 3 ANTIHISTAMINIC DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida								AYD F J Jr, 1959, South Med J, V52, P1554; CALLAWAY J L, 1957, N C Med J, V18, P320; COLLINS J, 1960, J ALLERGY, V31, P387, DOI 10.1016/0021-8707(60)90001-0; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; CORMIA FE, 1953, J INVEST DERMATOL, V20, P429, DOI 10.1038/jid.1953.54; CORMIA FE, 1959, ARCH DERMATOL, V79, P172, DOI 10.1001/archderm.1959.01560140034005; CORMIA FE, 1952, J INVEST DERMATOL, V19, P21, DOI 10.1038/jid.1952.62; CORMIA FE, 1954, AMA ARCH DERM SYPH, V69, P206, DOI 10.1001/archderm.1954.01540140074006; GALANT SP, 1972, J ALLERGY CLIN IMMUN, V49, P119; JOGLEKAR GV, 1963, CLIN PHARMACOL THER, V4, P197; JUHLIN L, 1954, ACTA DERM-VENEREOL, V69, P206; LONDON I D, 1959, J Med Assoc State Ala, V28, P342; MOSKO MM, 1950, J ALLERGY, V21, P242, DOI 10.1016/0021-8707(50)90132-8; RAJKA G, 1967, ACTA DERM-VENEREOL, V47, P154; RAJKA G, 1968, ACTA DERM-VENEREOL, V48, P93; RAJKA VE, 1965, DERMATOLOGICA, V130, P113; SCHWARTZ E, 1949, J ALLERGY, V20, P32, DOI 10.1016/0021-8707(49)90081-7; SHELLEY WB, 1950, J INVEST DERMATOL, V15, P299, DOI 10.1038/jid.1950.103; SMITH P, 1962, SOUTHERN MED J, V55, P643, DOI 10.1097/00007611-196206000-00022; ZIPPIN C, 1971, J ALLERGY, V47, P94	20	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					180	185		10.1016/0091-6749(75)90014-7	http://dx.doi.org/10.1016/0091-6749(75)90014-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	234488				2022-12-18	WOS:A1975V844800005
J	ZEITZ, SJ; OSTROW, JH; VANARSDE.PP				ZEITZ, SJ; OSTROW, JH; VANARSDE.PP			HUMORAL AND CELLULAR IMMUNITY IN ANERGIC TUBERCULOSIS PATIENT - PROSPECTIVE STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA; FIRLAND HOSP,SEATTLE,WA	University of Washington; University of Washington Seattle								BOVORNKITTI S, 1960, DIS CHEST, V38, P51, DOI 10.1378/chest.38.1.51; BRODY JA, 1964, NEW ENGL J MED, V271, P1294, DOI 10.1056/NEJM196412172712505; BROWN RS, 1967, ANN INTERN MED, V67, P291, DOI 10.7326/0003-4819-67-2-291; CHESNOW GJ, 1967, DIS CHEST, V51, P635; DAVID JR, 1973, NEW ENGL J MED, V288, P143; DWYER JM, 1973, J EXP MED, V137, P32, DOI 10.1084/jem.137.1.32; EDWARDS PQ, 1972, NEW ENGL J MED, V286, P373, DOI 10.1056/NEJM197202172860712; FRIEDMAN RM, 1964, P SOC EXP BIOL MED, V116, P471, DOI 10.3181/00379727-116-29282; FURCOLOW ML, 1948, PUBLIC HEALTH REP, V63, P1290, DOI 10.2307/4586715; GRZYBOWSKI S, 1970, AM REV RESP DIS, V100, P87; HERSH GM, 1965, N ENGL J MED, V273, P1006; HORLAND PS, 1965, LANCET, V2, P719; HUGHES LE, 1965, BMJ-BRIT MED J, V2, P1346, DOI 10.1136/bmj.2.5474.1346; JOHNSON RN, 1963, BRIT MED J, V1, P720; KENT DC, 1967, AM REV RESPIR DIS, V95, P411; LAMB D, 1962, J IMMUNOL, V89, P555; LESTER CF, 1958, AM REV TUBERC PULM, V78, P399; Nelson WE, 1937, J AMER MED ASSOC, V108, P2179, DOI 10.1001/jama.1937.02780260007002; SHARMA OP, 1970, INDIAN J MED RES, V58, P1551; SOLOMON H, 1961, AM REV RESPIR DIS, V83, P235; STARR S, 1964, N ENGL J MED, V270, P388; WARD JR, 1964, ARTHRITIS RHEUM, V7, P654, DOI 10.1002/art.1780070605; WIER JA, 1959, AM REV RESPIR DIS, V80, P569; WOODRUFF CE, 1970, IND J MED REV, V58, P1551; ZACK MB, 1970, AM REV RESPIR DIS, V102, P91	25	44	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	1					20	26		10.1016/0091-6749(74)90095-5	http://dx.doi.org/10.1016/0091-6749(74)90095-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R8075	4202828				2022-12-18	WOS:A1974R807500003
J	Brough, HA; Caubet, JC; Mazon, A; Haddad, D; Bergmann, MM; Wassenberg, J; Panetta, V; Gourgey, R; Radulovic, S; Nieto, M; Santos, AF; Nieto, A; Lack, G; Eigenmann, PA				Brough, Helen A.; Caubet, Jean-Christoph; Mazon, Angel; Haddad, Diab; Bergmann, Marcel M.; Wassenberg, Jacqueline; Panetta, Valentina; Gourgey, Rosalynd; Radulovic, Suzana; Nieto, Maria; Santos, Alexandra F.; Nieto, Antonio; Lack, Gideon; Eigenmann, Philippe A.			Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; tree nut allergy; sesame seed allergy; multiple nut allergies; predictor; age; London; Geneva; Valencia	QUALITY-OF-LIFE; FOOD ALLERGY; PEANUT ALLERGY; SKIN PRICK; TREE NUT; QUESTIONNAIRE SURVEY; NATURAL-HISTORY; CHILDREN; SENSITIZATION; ANAPHYLAXIS	Background: Peanut, tree nut, and sesame allergies are responsible for most life-threatening food-induced allergic reactions. Rates of coexistent allergy between these foods have been from mostly retrospective studies that include only a limited number of tree nuts or were not based on oral food challenges. Objective: The Pronuts study is a multicenter European study (London, Geneva, and Valencia) assessing the challenge-proven rate of coexistent peanut, tree nut, and/or sesame seed allergy. Methods: Children aged 0 to 16 years with at least 1 confirmed nut or sesame seed allergy underwent sequential diagnostic food challenges to all other nuts and sesame seed. Results: Overall, the rate of coexistent peanut, tree nut, and sesame seed allergy was 60.7% (n = 74/122; 95% CI, 51.4% to 69.4%). Peanut allergy was more common in London, cashew and pistachio nut allergies were more common in Geneva, and walnut and pecan allergies were more common in Valencia. Strong correlations were found between cashew-pistachio, walnut-pecan, and walnut-pecan-hazelnut-macadamia clusters. Age (>36 months) and center (Valencia > Geneva > London) were associated with an increased odds of multiple nut allergies. By pursuing the diagnostic protocol to demonstrate tolerance to other nuts, participants were able to introduce a median of 9 nuts. Conclusion: We found a higher rate of coexistent nut and sesame seed allergies than previously reported. Performing sequential food challenges was labor intensive and could result in severe allergic reactions; however, it reduced dietary restrictions. Age was a significant predictor of multiple nut allergies, and thus the secondary spread of nut allergies occurred in older children.	[Brough, Helen A.; Gourgey, Rosalynd; Radulovic, Suzana; Santos, Alexandra F.; Lack, Gideon] Kings Coll London, Dept Women & Childrens Hlth, Paediat Allergy Grp, London, England; [Brough, Helen A.; Gourgey, Rosalynd; Radulovic, Suzana; Santos, Alexandra F.; Lack, Gideon] Kings Coll London, Sch Immunol & Microbial Sci, Guys Hosp, Paediat Allergy Grp,Peter Gorer Dept Immunobiol, London, England; [Brough, Helen A.; Gourgey, Rosalynd; Radulovic, Suzana; Santos, Alexandra F.; Lack, Gideon] Guys & St Thomas Hosp NHS Fdn Trust, Evelina Childrens Hosp, Childrens Allergy Serv, London, England; [Caubet, Jean-Christoph; Bergmann, Marcel M.; Eigenmann, Philippe A.] Univ Geneva, Univ Hosp Geneva, Dept Pediat Gynecol & Obstet, Med Sch, Geneva, Switzerland; [Mazon, Angel; Nieto, Maria; Nieto, Antonio] Childrens Hosp La Fe, Inst Hlth Res La Fe, Unit Pediat Allergy & Pneumol, Valencia, Spain; [Haddad, Diab] St Peters Hosp, Chertsey, England; [Wassenberg, Jacqueline] Univ Hosp Lausanne, Dept Pediat, Unit Pediat Allergy & Rheumatol, Lausanne, Switzerland; [Panetta, Valentina] Laltrastatist Srl, Consultancy & Training Biostat Off, Rome, Italy; [Santos, Alexandra F.] Asthma UK Ctr Allerg Mech Asthma, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of London; King's College London	Brough, HA (corresponding author), Guys & St Thomas Hosp, Childrens Allergy Serv, Evelina London, Paediat Allergy, South Wing,Stairwell B,Level 2, London SE1 7EH, England.	Helen.Brough@gstt.nhs.uk	Mazon, Angel/ABG-8016-2020	Mazon, Angel/0000-0001-5639-1037; Bergmann, Marcel/0000-0002-1905-5162; Brough, Helen/0000-0001-7203-0813; Santos, Alexandra/0000-0002-7805-1436; Nieto, Maria/0000-0003-3968-510X	Food Allergy Research & Education (FARE); Ulrich Muller-Gierock Foundation; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; MRC [G0902018, MR/M008517/1] Funding Source: UKRI	Food Allergy Research & Education (FARE); Ulrich Muller-Gierock Foundation; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Food Allergy Research & Education (FARE) provided funding for the London arm of the study, and the Ulrich Muller-Gierock Foundation provided funding for the Geneva arm of the study. Thermo Scientific, Stallergenes, and Meridian Foods provided research supplies for all centers.; This research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London and/or the NIHR Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Andorf S, 2017, J ALLER CL IMM-PRACT, V5, P1325, DOI 10.1016/j.jaip.2017.01.016; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Ball H, 2011, PEDIAT ALLERG IMM-UK, V22, P808, DOI 10.1111/j.1399-3038.2011.01191.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Brough HA, 2011, J ALLERGY CLIN IMMUN, V127, pAB186, DOI 10.1016/j.jaci.2010.12.741; Burney PGJ, 2014, ALLERGY, V69, P365, DOI 10.1111/all.12341; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Cohen A, 2007, PEDIAT ALLERG IMM-UK, V18, P217, DOI 10.1111/j.1399-3038.2006.00506.x; Couch C, 2017, ANN ALLERG ASTHMA IM, V118, P591, DOI 10.1016/j.anai.2017.02.010; Derby CJ, 2005, PEDIAT ALLERG IMM-UK, V16, P171, DOI 10.1111/j.1399-3038.2005.00232.x; Deschildre A, 2017, CLIN EXP ALLERGY, V47, P1125, DOI 10.1111/cea.12984; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; DunnGalvin A, 2017, J ALLER CL IMM-PRACT, V5, P363, DOI 10.1016/j.jaip.2016.09.049; Eigenmann PA, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2008.00762.x; Elizur A, 2018, ALLERGY, V73, P593, DOI 10.1111/all.13353; Ewan PW, 1996, BRIT MED J, V312, P1074; Fernandez-Rivas M, 2015, ALLERGY, V70, P576, DOI 10.1111/all.12585; Foong RX, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00089; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Kapoor S, 2004, ALLERGY, V59, P185, DOI 10.1046/j.1398-9995.2003.00365.x; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; McWilliam V, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0555-8; MULLER U, 1989, WIEN MED WOCHENSCHR, V139, P150; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2015, J ALLER CL IMM-PRACT, V3, P429, DOI 10.1016/j.jaip.2014.12.009; Savage J, 2016, J ALLER CL IMM-PRACT, V4, P196, DOI 10.1016/j.jaip.2015.11.024; Schroeder A, 2009, CLIN EXP ALLERGY, V39, P261, DOI 10.1111/j.1365-2222.2008.03160.x; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vogel NM, 2008, J ASTHMA, V45, P862, DOI 10.1080/02770900802444195	45	43	45	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1231	1239		10.1016/j.jaci.2019.09.036	http://dx.doi.org/10.1016/j.jaci.2019.09.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31866098	Green Published, hybrid			2022-12-18	WOS:000523633400019
J	Weiler, CR; Austen, KF; Akin, C; Barkoff, MS; Bernstein, JA; Bonadonna, P; Butterfield, JH; Carter, M; Fox, CC; Maitland, A; Pongdee, T; Mustafa, SS; Ravi, A; Tobin, MC; Vliagoftis, H; Schwartz, LB				Weiler, Catherine R.; Austen, K. Frank; Akin, Cem; Barkoff, Marla S.; Bernstein, Jonathan A.; Bonadonna, Patrizia; Butterfield, Joseph H.; Carter, Melody; Fox, Charity C.; Maitland, Anne; Pongdee, Thanai; Mustafa, S. Shahzad; Ravi, Anupama; Tobin, Mary C.; Vliagoftis, Harissios; Schwartz, Lawrence B.			AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell activation syndrome; tryptase; hereditary alpha-tryptasemia; mastocytosis; anaphylaxis; histamine; prostaglandin D-2; leukotriene C-4; c-kit	KIT D816V MUTATION; EXACERBATED RESPIRATORY-DISEASE; INDOLENT SYSTEMIC MASTOCYTOSIS; PROSTAGLANDIN-D SYNTHASE; SERUM TRYPTASE; CUTANEOUS MASTOCYTOSIS; DIFFERENTIAL-DIAGNOSIS; RECEPTOR ANTAGONISTS; COGNITIVE IMPAIRMENT; VENOM IMMUNOTHERAPY	Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and consensus guidelines for clinically recognizing systemic anaphylaxis in real time, regardless of whether allergen-triggered or other pathways are involved; our current understanding of the biomarkers secreted by activated MCs that best discriminate this disorder from other conditions; and the therapeutic drugs that might selectively affect those mediators or MCs themselves. Finding familial or somatic mutations of genes that cause MCs to be hyperactivatable would extend our diagnostic tools and potentially indicate new therapeutic interventions, targeting either the mutated gene product or the associated molecular pathway. In conclusion, we trust that the clinical, laboratory, and therapeutic criteria for primary MC activation syndromes described herein will provide clinicians with practical criteria of sufficient sensitivity and specificity to diagnose most cases without overdiagnosing the disorder in patients who likely have other conditions.	[Weiler, Catherine R.; Butterfield, Joseph H.; Pongdee, Thanai] Mayo Clin, Dept Internal Med, Div Allergy, Rochester, MN USA; [Ravi, Anupama] Mayo Clin, Dept Pediat, Div Pediat Allergy & Immunol, Rochester, MN USA; [Austen, K. Frank] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Akin, Cem] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA; [Barkoff, Marla S.] Endocrinol, Chicago, IL USA; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Internal Med Immunol & Allergy, Cincinnati, OH USA; [Bernstein, Jonathan A.] Bernstein Allergy Grp, Cincinnati, OH USA; [Bernstein, Jonathan A.] Bernstein Clin Res Ctr, Cincinnati, OH USA; [Bonadonna, Patrizia] Azienda Osped Univ Integrata Verona, Multidisciplinary Mastocytosis Clin, Allergy Unit, Verona, Italy; [Carter, Melody] Natl Inst Hlth Clin Ctr, Bethesda, MD USA; [Fox, Charity C.] Ohio State Univ, Dept Otolaryngol, Wexner Med Ctr, Div Allergy & Immunol, Columbus, OH 43210 USA; [Maitland, Anne] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Mustafa, S. Shahzad] Univ Rochester, Sch Med & Dent, Rochester Reg Hlth Syst, Allergy & Clin Immunol, Rochester, NY USA; [Tobin, Mary C.] Rush Univ, Med Ctr, Immunol Div, Dept Internal Med Allergy, Chicago, IL 60612 USA; [Vliagoftis, Harissios] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	Mayo Clinic; Mayo Clinic; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University System of Ohio; Ohio State University; Icahn School of Medicine at Mount Sinai; University of Rochester; Rush University; University of Alberta; Virginia Commonwealth University	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, POB 980263, Richmond, VA 23298 USA.	lawrence.schwartz@vcuhealth.org		Bernstein, Jonathan/0000-0002-3476-1196				Aberer E, 2015, AUSTRALAS J DERMATOL, V56, P7, DOI 10.1111/ajd.12146; Afrin LB, 2017, EUR J HAEMATOL, V99, P190, DOI 10.1111/ejh.12893; Afrin LB, 2017, AM J MED SCI, V353, P207, DOI 10.1016/j.amjms.2016.12.013; Afrin LB, 2016, TRANSL RES, V174, P33, DOI 10.1016/j.trsl.2016.01.003; Afrin LB, 2016, TRANSL RES, V174, P1, DOI 10.1016/j.trsl.2016.03.003; Afrin LB, 2016, ANN MED, V48, P190, DOI 10.3109/07853890.2016.1161231; Afrin LB, 2015, EUR J HAEMATOL, V95, P595, DOI 10.1111/ejh.12606; Afrin LB, 2015, BRAIN BEHAV IMMUN, V50, P314, DOI 10.1016/j.bbi.2015.07.002; Afrin LB, 2014, AM J MED SCI, V348, P460, DOI 10.1097/MAJ.0000000000000325; Afrin LB, 2014, ONCOLOGY-NY, V28, P129; Afrin LB, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-28; Afrin LB, 2012, PATHOL RES PRACT, V208, P181, DOI 10.1016/j.prp.2011.12.005; Afrin LB, 2012, MIL MED, V177, P113, DOI 10.7205/MILMED-D-11-00111; Afrin LB, 2011, AM J MED SCI, V342, P44, DOI 10.1097/MAJ.0b013e31821d41dd; Afrin LB, 2011, ORAL SURG ORAL MED O, V111, P465, DOI 10.1016/j.tripleo.2010.11.030; Akin C, 2004, J ALLERGY CLIN IMMUN, V114, P13, DOI 10.1016/j.jaci.2004.04.046; Akin C, 2002, INT ARCH ALLERGY IMM, V127, P133, DOI 10.1159/000048184; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2017, J ALLERGY CLIN IMMUN, V140, P349, DOI 10.1016/j.jaci.2017.06.007; Akin C, 2014, J ALLER CL IMM-PRACT, V2, P252, DOI 10.1016/j.jaip.2014.03.007; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alcaniz L, 2013, FASEB J, V27, P2902, DOI 10.1096/fj.12-223867; Alvarez-Twose I, 2012, INT ARCH ALLERGY IMM, V157, P275, DOI 10.1159/000329856; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Angelidou A, 2011, J AUTISM DEV DISORD, V41, P1579, DOI 10.1007/s10803-010-1171-z; Arock M, 2015, LEUKEMIA, V29, P1223, DOI 10.1038/leu.2015.24; Baird JH, 2018, CURR HEMATOL MALIG R, V13, P407, DOI 10.1007/s11899-018-0469-3; Barete S, 2015, BLOOD, V126, P1009, DOI 10.1182/blood-2014-12-614743; Baretto RL, 2017, ALLERGY, V72, P2031, DOI 10.1111/all.13226; Bell MC, 2012, ANN ALLERG ASTHMA IM, V108, P383, DOI 10.1016/j.anai.2012.02.021; Bencsath M, 1998, Pathol Oncol Res, V4, P121; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BENYON RC, 1987, BRIT J PHARMACOL, V92, P635, DOI 10.1111/j.1476-5381.1987.tb11366.x; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Bonadonna P, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0550-0; Bonamichi-Santos R, 2018, IMMUNOL ALLERGY CLIN, V38, P497, DOI 10.1016/j.iac.2018.04.004; BOSRON WF, 1988, MOL ASPECTS MED, V10, P147, DOI 10.1016/0098-2997(88)90019-2; Boushey Robin P, 2002, Curr Treat Options Oncol, V3, P319, DOI 10.1007/s11864-002-0031-2; Boustani M, 2007, J AM GERIATR SOC, V55, P1248, DOI 10.1111/j.1532-5415.2007.01270.x; Boutzios G, 2015, FRONT HORM RES, V44, P40, DOI 10.1159/000382053; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2014, IMMUNOL ALLERGY CLIN, V34, P283, DOI 10.1016/j.iac.2014.01.003; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; BUTTERFIELD JH, 1995, MAYO CLIN PROC, V70, P481, DOI 10.4065/70.5.481; Butterfield JH, 2008, INT ARCH ALLERGY IMM, V147, P338, DOI 10.1159/000144042; Butterfield JH, 2018, IMMUNOL ALLERGY CLIN, V38, P397, DOI 10.1016/j.iac.2018.04.011; Butterfield JH, 2010, PROSTAG OTH LIPID M, V92, P73, DOI 10.1016/j.prostaglandins.2010.03.003; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; Cardet JC, 2013, EXPERT OPIN PHARMACO, V14, P2033, DOI 10.1517/14656566.2013.824424; Cardet JC, 2013, CURR ALLERGY ASTHM R, V13, P10, DOI 10.1007/s11882-012-0326-8; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Carter MC, 2018, BRIT J HAEMATOL, V183, P775, DOI 10.1111/bjh.15624; Carter MC, 2018, J ALLERGY CLIN IMMUN, V141, P180, DOI 10.1016/j.jaci.2017.05.036; Carvalhosa AB, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001414; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Castells M, 2011, AM J CLIN DERMATOL, V12, P259, DOI 10.2165/11588890-000000000-00000; Castells MC, 2015, J ALLER CL IMM-PRACT, V3, P350, DOI 10.1016/j.jaip.2015.03.015; Celejewska-Wojcik N, 2012, POL ARCH MED WEWN, V122, P422, DOI 10.20452/pamw.1379; Chomchai S, 2018, CLIN TOXICOL, V56, P126, DOI 10.1080/15563650.2017.1349320; Colachis S C 3rd, 1992, J Am Paraplegia Soc, V15, P171; Corless CL, 2006, J MOL DIAGN, V8, P604, DOI 10.2353/jmoldx.2006.060089; da Silva EN, 2013, J ALLER CL IMM-PRACT, V1, P687, DOI 10.1016/j.jaip.2013.07.004; Daens S, 2018, Rev Med Liege, V73, P61; De Gennaro L, 2017, ACTA CLIN BELG, V72, P142, DOI 10.1080/17843286.2016.1265756; De Schryver S, 2016, J ALLERGY CLIN IMMUN, V137, P1138, DOI 10.1016/j.jaci.2015.09.001; DeAngelo DJ, 2018, LEUKEMIA, V32, P470, DOI 10.1038/leu.2017.234; Divekar R, 2015, ALLERGY, V70, P1230, DOI 10.1111/all.12668; Douglass JA, 2010, ALLERGY, V65, P926, DOI 10.1111/j.1398-9995.2009.02259.x; Dugas-Breit S, 2010, CLIN EXP ALLERGY, V40, P643, DOI 10.1111/j.1365-2222.2009.03436.x; EGGLESTON PA, 1990, AM REV RESPIR DIS, V141, P960, DOI 10.1164/ajrccm/141.4_Pt_1.960; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Evans JD, 2015, PATIENT PREFER ADHER, V9, P1159, DOI 10.2147/PPA.S56002; Fellinger C, 2014, ALLERGOL IMMUNOPATH, V42, P544, DOI 10.1016/j.aller.2014.05.002; Feng C, 2016, CLIN REV ALLERG IMMU, V50, P64, DOI 10.1007/s12016-015-8467-x; Fletcher L, 2019, CURR OPIN HEMATOL, V26, P112, DOI 10.1097/MOH.0000000000000486; Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211; Garland EM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0583-8; Gonzalo-Garijo MA, 2010, J INVEST ALLERG CLIN, V20, P540; Goodman BP, 2018, AUTON NEUROSCI-BASIC, V215, P12, DOI 10.1016/j.autneu.2018.04.004; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; GrahamBrown R, 1997, CLIN DERMATOL, V15, P143, DOI 10.1016/S0738-081X(96)00116-2; Gray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663; Gulen T, 2017, CURR OPIN ALLERGY CL, V17, P295, DOI 10.1097/ACI.0000000000000377; Gulen T, 2014, CLIN EXP ALLERGY, V44, P121, DOI 10.1111/cea.12225; Haenisch B, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0143-5; Hamilton MJ, 2018, IMMUNOL ALLERGY CLIN, V38, P469, DOI 10.1016/j.iac.2018.04.002; Hamilton MJ, 2011, J ALLERGY CLIN IMMUN, V128, P147, DOI 10.1016/j.jaci.2011.04.037; Hanjra P, 2018, J ALLER CL IMM-PRACT, V6, P687, DOI 10.1016/j.jaip.2017.08.022; Hannah-Shmouni F, 2016, REV ENDOCR METAB DIS, V17, P373, DOI 10.1007/s11154-016-9394-8; Hedlund PO, 2000, PROSTATE, P32; Heymann WR, 2006, J AM ACAD DERMATOL, V55, P1075, DOI 10.1016/j.jaad.2006.07.008; HIRSCHOWITZ BI, 1979, ANN INTERN MED, V90, P769, DOI 10.7326/0003-4819-90-5-769; HORAN RF, 1990, J ALLERGY CLIN IMMUN, V85, P852, DOI 10.1016/0091-6749(90)90067-E; Huguet I, 2017, EUR J ENDOCRINOL, V177, pR219, DOI 10.1530/EJE-17-0295; Ikizoglu G, 2014, CLIN DERMATOL, V32, P800, DOI 10.1016/j.clindermatol.2014.02.019; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; IRANI AMA, 1994, ALLERGY PROC, V15, P303, DOI 10.2500/108854194778816472; Izikson L, 2006, J AM ACAD DERMATOL, V55, P193, DOI 10.1016/j.jaad.2005.07.057; Janson EMT, 1996, BAILLIERE CLIN GASTR, V10, P589, DOI 10.1016/S0950-3528(96)90015-9; Jawhar M, 2017, BLOOD, V130, P137, DOI 10.1182/blood-2017-01-764423; Jennings S, 2014, J ALLER CL IMM-PRACT, V2, P70, DOI 10.1016/j.jaip.2013.09.004; Jennings SV, 2018, IMMUNOL ALLERGY CLIN, V38, P505, DOI 10.1016/j.iac.2018.04.006; Jogie-Brahim S, 2004, J ALLERGY CLIN IMMUN, V113, P1086, DOI 10.1016/j.jaci.2004.02.032; Jones BL, 2011, CLIN PHARMACOL THER, V89, P189, DOI 10.1038/clpt.2010.256; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Kasamon YL, 2018, ONCOLOGIST, V23, P1511, DOI 10.1634/theoncologist.2018-0222; KEYZER JJ, 1984, ANAL BIOCHEM, V139, P474, DOI 10.1016/0003-2697(84)90037-X; Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; KNAPP TRF, 1991, DICP ANN PHARMAC, V25, P253; Ko K, 2018, J MED CHEM, V61, P2949, DOI 10.1021/acs.jmedchem.7b01855; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; Kounis NG, 2015, INT J CARDIOL, V193, P39, DOI 10.1016/j.ijcard.2015.05.038; Kristensen T, 2014, AM J HEMATOL, V89, P493, DOI 10.1002/ajh.23672; Kristensen T, 2013, EUR J HAEMATOL, V91, P106, DOI 10.1111/ejh.12128; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; LAM BK, 1989, J BIOL CHEM, V264, P12885; Le QT, 2019, J EXP MED; Legrand F, 2019, J ALLERGY CLIN IMMUN, V143, P2227, DOI 10.1016/j.jaci.2018.10.066; Lim KH, 2009, AM J HEMATOL, V84, P790, DOI 10.1002/ajh.21561; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200; LORCERIE B, 1989, LANCET, V2, P1155; Lortholary O, 2017, LANCET, V389, P612, DOI 10.1016/S0140-6736(16)31403-9; Lueke AJ, 2016, CLIN BIOCHEM, V49, P979, DOI 10.1016/j.clinbiochem.2016.02.007; Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806; Lyons JJ, 2018, IMMUNOL ALLERGY CLIN, V38, P483, DOI 10.1016/j.iac.2018.04.003; Lyons JJ, 2018, GENET MED, V20, P503, DOI 10.1038/gim.2017.136; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Marotta V, 2018, ENDOCR-RELAT CANCER, V25, pR11, DOI 10.1530/ERC-17-0269; Matito A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076116; Mohri I, 2007, J NEUROPATH EXP NEUR, V66, P469, DOI 10.1097/01.jnen.0000240472.43038.27; Molderings GJ, 2018, CLIN BREAST CANCER, V18, pE271, DOI 10.1016/j.clbc.2017.12.004; Molderings Gerhard J, 2017, F1000Res, V6, P1889, DOI 10.12688/f1000research.12730.1; Molderings GJ, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-10; Molderings GJ, 2011, J ALLERGY CLIN IMMUN, V127, P1311, DOI 10.1016/j.jaci.2010.12.1113; MOONEY E, 1985, INT J DERMATOL, V24, P549, DOI 10.1111/j.1365-4362.1985.tb05565.x; Moore AR, 1999, DRUG AGING, V15, P15, DOI 10.2165/00002512-199915010-00002; MORROW JD, 1995, J INVEST DERMATOL, V104, P937, DOI 10.1111/1523-1747.ep12606209; Nassiri M, 2016, J ALLERGY CLIN IMMUN, V137, P312, DOI 10.1016/j.jaci.2015.07.001; Nittner-Marszalska M, 2015, ARCH IMMUNOL THER EX, V63, P317, DOI 10.1007/s00005-015-0334-1; Nurmatov UB, 2015, ALLERGY, V70, P1052, DOI 10.1111/all.12672; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Oranje AP, 2002, CLIN EXP DERMATOL, V27, P502, DOI 10.1046/j.1365-2230.2002.01072.x; Pardanani A, 2013, LEUKEMIA, V27, P2091, DOI 10.1038/leu.2013.227; Pardanani A, 2010, EUR J HAEMATOL, V84, P371, DOI 10.1111/j.1600-0609.2010.01407.x; Pardanani A, 2019, AM J HEMATOL, V94, P363, DOI 10.1002/ajh.25371; Pardanani A, 2010, CURR OPIN HEMATOL, V17, P125, DOI 10.1097/MOH.0b013e3283366c59; Penrose JF, 1999, CLIN REV ALLERG IMMU, V17, P133, DOI 10.1007/BF02737601; Peter B, 2016, LEUKEMIA, V30, P464, DOI 10.1038/leu.2015.242; Picard M, 2013, CLIN THER, V35, P548, DOI 10.1016/j.clinthera.2013.04.001; Poli C, 2016, J PHARMACEUT BIOMED, V118, P307, DOI 10.1016/j.jpba.2015.11.001; QUAK SH, 1988, AUST PAEDIATR J, V24, P55; Quintas-Cardama A, 2013, LEUKEMIA LYMPHOMA, V54, P1959, DOI 10.3109/10428194.2012.763121; Rabinovitch N, 2007, IMMUNOL ALLERGY CLIN, V27, P651, DOI 10.1016/j.iac.2007.09.004; Rajan JP, 2014, J ALLER CL IMM-PRACT, V2, P168, DOI 10.1016/j.jaip.2013.10.002; Ravi A, 2014, J ALLER CL IMM-PRACT, V2, P775, DOI 10.1016/j.jaip.2014.06.011; Regan JA, 2017, J ALLERGY CLIN IMMUN, V140, P875, DOI 10.1016/j.jaci.2017.03.013; Richardson K, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1315; Ridolo E, 2016, CURR OPIN ALLERGY CL, V16, P516, DOI 10.1097/ACI.0000000000000297; Roberts L J 2nd, 1982, Adv Shock Res, V8, P145; ROBERTS LJ, 1985, PROSTAGLANDINS, V30, P383, DOI 10.1016/0090-6980(85)90114-5; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBINSON C, 1989, J INVEST DERMATOL, V93, P397, DOI 10.1111/1523-1747.ep12280290; Sabato V, 2018, J CLIN IMMUNOL, V38, P457, DOI 10.1007/s10875-018-0506-y; Sabato V, 2014, J ALLERGY CLIN IMMUN, V134, P1448, DOI 10.1016/j.jaci.2014.06.007; Sadeghian A, 2017, J AM ACAD DERMATOL, V77, P405, DOI 10.1016/j.jaad.2016.12.032; Sadeghian A, 2017, J AM ACAD DERMATOL, V77, P391, DOI 10.1016/j.jaad.2016.12.031; Sahiner UM, 2014, ALLERGY ASTHMA PROC, V35, P404, DOI 10.2500/aap.2014.35.3769; Salem A, 2017, BRIT J DERMATOL, V176, P1213, DOI 10.1111/bjd.14995; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sasaguri Yasuyuki, 2004, J Atheroscler Thromb, V11, P122; Schumacher JA, 2008, J CLIN PATHOL, V61, P109, DOI 10.1136/jcp.2007.047928; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; Seidel H, 2011, THROMB HAEMOSTASIS, V106, P987, DOI 10.1160/TH11-05-0351; Seneviratne SL, 2017, AM J MED GENET C, V175, P226, DOI 10.1002/ajmg.c.31555; Shimura C, 2010, AM J PATHOL, V176, P227, DOI 10.2353/ajpath.2010.090111; Siebenhaar F, 2013, ALLERGY, V68, P949, DOI 10.1111/all.12159; Smith J A Jr, 1996, Oncology (Williston Park), V10, P1319; SOLCIA E, 1993, ENDOCRIN METAB CLIN, V22, P795, DOI 10.1016/S0889-8529(18)30136-1; SOLCIA E, 1995, PATHOL RES PRACT, V191, P366, DOI 10.1016/S0344-0338(11)80890-3; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Tannenbaum C, 2012, DRUG AGING, V29, P639, DOI 10.2165/11633250-000000000-00000; Tascilar N, 2007, AUTON NEUROSCI-BASIC, V137, P1, DOI 10.1016/j.autneu.2007.05.004; Tefferi A, 2001, NEW ENGL J MED, V344, P307, DOI 10.1056/NEJM200101253440415; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; TING S, 1990, J ALLERGY CLIN IMMUN, V85, P818, DOI 10.1016/0091-6749(90)90205-I; Tolar J, 2004, NEW ENGL J MED, V350, P735, DOI 10.1056/NEJM200402123500723; Triggiani M, 2014, CURR OPIN ALLERGY CL, V14, P309, DOI 10.1097/ACI.0000000000000071; Trivedi NN, 2008, J ALLERGY CLIN IMMUN, V121, P1262, DOI 10.1016/j.jaci.2008.01.019; Trivedi NN, 2007, J IMMUNOL, V179, P6072, DOI 10.4049/jimmunol.179.9.6072; Trivedi NN, 2010, AM J RESP CELL MOL, V42, P257, DOI 10.1165/rcmb.2009-0324RT; Trivedi NN, 2009, J ALLERGY CLIN IMMUN, V124, P1099, DOI 10.1016/j.jaci.2009.07.026; Turner PJ, 2012, PEDIATR DERMATOL, V29, P223, DOI 10.1111/j.1525-1470.2011.01598.x; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Valent P, 2017, ANN ONCOL, V28, P2367, DOI 10.1093/annonc/mdx290; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2019, J ALLER CL IMM-PRACT, V7, P1125, DOI 10.1016/j.jaip.2019.01.006; Valent P, 2014, EXPERT REV HEMATOL, V7, P683, DOI 10.1586/17474086.2014.955008; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; van Anrooij B, 2018, J ALLERGY CLIN IMMUN, V142, P1006, DOI 10.1016/j.jaci.2018.06.003; Van den Poel B, 2017, ACTA CLIN BELG, V72, P123, DOI 10.1080/17843286.2017.1293312; van Doormaal JJ, 2012, ALLERGY, V67, P683, DOI 10.1111/j.1398-9995.2012.02809.x; van Toorenenbergen AW, 2005, CLIN CHIM ACTA, V359, P72, DOI 10.1016/j.cccn.2005.03.041; VANDERDONK EMM, 1991, PROSTAG LEUKOTR ESS, V44, P11, DOI 10.1016/0952-3278(91)90138-U; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; Vitte J, 2019, ALLERGY, V74, P1157, DOI 10.1111/all.13752; Vitte J, 2015, MOL IMMUNOL, V63, P18, DOI 10.1016/j.molimm.2014.04.001; Vitte J, 2013, J ALLERGY CLIN IMMUN, V131, P1714, DOI 10.1016/j.jaci.2013.03.028; Vysniauskaite M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124912; WELCH EA, 1983, J AM ACAD DERMATOL, V9, P349, DOI 10.1016/S0190-9622(83)70140-4; Welsh O, 2014, CLIN DERMATOL, V32, P734, DOI 10.1016/j.clindermatol.2014.02.011; WILKIN JK, 1981, ANN INTERN MED, V95, P468, DOI 10.7326/0003-4819-95-4-468; Wu YH, 2017, GERIATR GERONTOL INT, V17, P57, DOI 10.1111/ggi.13032; Youngblood BA, 2019, INT ARCH ALLERGY IMM	227	43	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					883	896		10.1016/j.jaci.2019.08.023	http://dx.doi.org/10.1016/j.jaci.2019.08.023			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31476322	Bronze			2022-12-18	WOS:000488803900002
J	Alosaimi, MF; Hoenig, M; Jaber, F; Platt, CD; Jones, J; Wallace, J; Debatin, KM; Schulz, A; Jacobsen, E; Moller, P; Shamseldin, HE; Abdulwahab, F; Ibrahim, N; Alardati, H; Almuhizi, F; Abosoudah, IF; Basha, TA; Chou, J; Alkuraya, FS; Geha, RS				Alosaimi, Mohammed F.; Hoenig, Manfred; Jaber, Faris; Platt, Craig D.; Jones, Jennifer; Wallace, Jacqueline; Debatin, Klaus-Michael; Schulz, Ansgar; Jacobsen, Eva; Moller, Peter; Shamseldin, Hanan E.; Abdulwahab, Ferdous; Ibrahim, Niema; Alardati, Hosam; Almuhizi, Faisal; Abosoudah, Ibraheem F.; Basha, Talal A.; Chou, Janet; Alkuraya, Fowzan S.; Geha, Raif S.			Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						4-1BB; CD137; immunodeficiency; EBV; Hodgkin lymphoma	CD137 PROMOTES; NK CELLS; T-CELLS; PROLIFERATION; COSTIMULATION; MUTATIONS; EXPANSION; RESPONSES; PERFORIN; SURVIVAL	Background: The tumor TNF receptor family member 4-1BB (CD137) is encoded by TNFRSF9 and expressed on activated Tcells. 4-1BB provides a costimulatory signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors. The ligand for 4-1BB is expressed on antigen-presenting cells and EBV-transformed B cells. Objective: We investigated the genetic basis of recurrent sinopulmonary infections, persistent EBV viremia, and EBV-induced lymphoproliferation in 2 unrelated patients. Methods: Whole-exome sequencing, immunoblotting, immunophenotyping, and in vitro assays of lymphocyte and mitochondrial function were performed. Results: The 2 patients shared a homozygous G109S missense mutation in 4-1BB that abolished protein expression and ligand binding. The patients' CD8(+) T cells had reduced proliferation, impaired expression of IFN-gamma and perforin, and diminished cytotoxicity against allogeneic and HLA-matched EBV-B cells. Mitochondrial biogenesis, membrane potential, and function were significantly reduced in the patients' activated T cells. An inhibitory antibody against 4-1BB recapitulated the patients' defective CD8(+) T-cell activation and cytotoxicity against EBV-infected B cells in vitro. Conclusion: This novel immunodeficiency demonstrates the critical role of 4-1BB costimulation in host immunity against EBV infection.	[Alosaimi, Mohammed F.; Jaber, Faris; Platt, Craig D.; Jones, Jennifer; Wallace, Jacqueline; Chou, Janet; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, 1 Blackfan Circle,Karp Bldg 10th Floor, Boston, MA 02115 USA; [Alosaimi, Mohammed F.; Jaber, Faris; Platt, Craig D.; Jones, Jennifer; Wallace, Jacqueline; Chou, Janet; Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Alosaimi, Mohammed F.] King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; [Hoenig, Manfred; Debatin, Klaus-Michael; Schulz, Ansgar; Jacobsen, Eva] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Moller, Peter] Univ Ulm, Inst Pathol, Ulm, Germany; [Shamseldin, Hanan E.; Abdulwahab, Ferdous; Ibrahim, Niema; Alkuraya, Fowzan S.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh, Saudi Arabia; [Alardati, Hosam] King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Jeddah, Saudi Arabia; [Abosoudah, Ibraheem F.] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Jeddah, Saudi Arabia; [Basha, Talal A.] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Jeddah, Saudi Arabia; [Almuhizi, Faisal] Secur Force Hosp, Dept Med, Riyadh, Saudi Arabia	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; King Saud University; Ulm University; Ulm University; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Security Forces Hospital - Saudi Arabia	Geha, RS (corresponding author), Boston Childrens Hosp, Div Immunol, 1 Blackfan Circle,Karp Bldg 10th Floor, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Alosaimi, Mohammed F/AAY-5814-2021; Debatin, Klaus-Michael/J-9704-2014	Alosaimi, Mohammed F/0000-0002-8025-3491; Debatin, Klaus-Michael/0000-0002-8397-1886; Jaber, Faris/0000-0002-8483-6934; Wallace, Jacqueline/0000-0001-6565-2534	National Institutes of Health [5K08AI116979-04, 1R01AI139633-01]; Perkin Fund; King Salman Center for Disability Research; Saudi Human Genome Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI116979, R01AI139633] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Perkin Fund; King Salman Center for Disability Research; Saudi Human Genome Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 5K08AI116979-04 (to J.C.) and 1R01AI139633-01 (to R.S.G.) and the Perkin Fund (to R.S.G.). This work was supported in part by King Salman Center for Disability Research and the Saudi Human Genome Program.	Abolhassani H, 2017, J EXP MED, V214, P91, DOI 10.1084/jem.20160849; Alkuraya FS, 2016, HUM GENET, V135, P615, DOI 10.1007/s00439-016-1664-8; Baessler T, 2010, BLOOD, V115, P3058, DOI 10.1182/blood-2009-06-227934; Bartkowiak T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00117; Bitra A, 2018, J BIOL CHEM, V293, P9958, DOI 10.1074/jbc.RA118.003176; Chacon JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060031; Chester C, 2018, BLOOD, V131, P49, DOI 10.1182/blood-2017-06-741041; Chester C, 2016, CANCER IMMUNOL IMMUN, V65, P1243, DOI 10.1007/s00262-016-1829-2; Choi IK, 2018, P NATL ACAD SCI USA, V115, pE686, DOI 10.1073/pnas.1713607115; Geltink RIK, 2017, CELL, V171, P385, DOI 10.1016/j.cell.2017.08.018; Harfuddin Z, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26859; Hui-Yuen J, 2011, J VIS EXP, V57; Izawa K, 2017, J EXP MED, V214, P73, DOI 10.1084/jem.20160784; Jabara HH, 2016, NAT GENET, V48, P74, DOI 10.1038/ng.3465; Jang IK, 1998, BIOCHEM BIOPH RES CO, V242, P613, DOI 10.1006/bbrc.1997.8016; Katano H, 2004, BLOOD, V103, P1244, DOI 10.1182/blood-2003-06-2171; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Kwon BS, 2002, J IMMUNOL, V168, P5483, DOI 10.4049/jimmunol.168.11.5483; Laderach D, 2002, INT IMMUNOL, V14, P1155, DOI 10.1093/intimm/dxf080; Latour S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01103; Li GB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121322; Li XM, 2015, INT J ONCOL, V47, P335, DOI 10.3892/ijo.2015.3005; Menk AV, 2018, J EXP MED, V215, P1091, DOI 10.1084/jem.20171068; Monies D, 2017, HUM GENET, V136, P921, DOI 10.1007/s00439-017-1821-8; Navabi SS, 2015, INFLAMMATION, V38, P1181, DOI 10.1007/s10753-014-0082-0; Noto A, 2013, JOVE-J VIS EXP, V82; Palendira U, 2015, ANN NY ACAD SCI, V1356, P22, DOI 10.1111/nyas.12937; Ryffel B, 1997, J IMMUNOL, V158, P2126; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Stephan MT, 2007, NAT MED, V13, P1440, DOI 10.1038/nm1676; Teijeira A, 2018, CANCER IMMUNOL RES, V6, P798, DOI 10.1158/2326-6066.CIR-17-0767; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; Vinay DS, 2004, J IMMUNOL, V173, P4218, DOI 10.4049/jimmunol.173.6.4218; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897; Wilcox RA, 2002, J IMMUNOL, V169, P4230, DOI 10.4049/jimmunol.169.8.4230; Yamada S, 2002, CLIN EXP IMMUNOL, V130, P424, DOI 10.1046/j.1365-2249.2002.02012.x; Zhang XY, 2010, J IMMUNOL, V184, P787, DOI 10.4049/jimmunol.0901619	39	43	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					574	+		10.1016/j.jaci.2019.03.002	http://dx.doi.org/10.1016/j.jaci.2019.03.002			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30872117	Bronze, Green Accepted			2022-12-18	WOS:000478789300024
J	Luksch, H; Stinson, WA; Platt, DJ; Qian, W; Kalugotla, G; Miner, CA; Bennion, BG; Gerbaulet, A; Rosen-Wolff, A; Miner, JJ				Luksch, Hella; Stinson, W. Alexander; Platt, Derek J.; Qian, Wei; Kalugotla, Gowri; Miner, Cathrine A.; Bennion, Brock G.; Gerbaulet, Alexander; Roesen-Wolff, Angela; Miner, Jonathan J.			STING-associated lung disease in mice relies on T cells but not type I interferon	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stimulator of interferon genes; vasculopathy; interferonopathy; innate immunity; STING-associated vasculopathy with onset in infancy; cyclic GMP-AMP synthase	NF-KAPPA-B; MUTATIONS; SENSOR; ALPHA; CGAS; ACTIVATION; PATHWAY; MOUSE; BETA	Background: Monogenic interferonopathies are thought to be mediated by type I interferon. For example, a gain-of-function mutation in stimulator of interferon genes (STING; N1535) upregulates type I interferon stimulated genes and causes perivascular inflammatory lung disease in mice. The equivalent mutation in human subjects also causes lung disease, which is thought to require signaling through the cyclic GMP-AMP synthase (cGAS) STING pathway and subsequent activation of interferon regulatory factors (IRFs) 3 and 7, type I interferon, and interferon-stimulated genes. Objective: We set out to define the roles of cGAS, IRF3, IRF7, the type I interferon receptor (IFN-alpha and IFN-beta receptor subunit 1 [IFNAR1]), T cells, and B cells in spontaneous lung disease in STING N153S mice. Methods: STING N153S mice were crossed to animals lacking cGAS, IRF3/IRF7, IFNAR1, adaptive immunity, alpha beta T cells, and mature B cells. Mice were evaluated for spontaneous lung disease. Additionally, bone marrow chimeric mice were assessed for lung disease severity and survival. Results: Lung disease in STING N153S mice developed independently of cGAS, IRF3/IRF7, and IFNAR1. Bone marrow transplantation revealed that certain features of STING N153S-associated disease are intrinsic to the hematopoietic compartment. Recombination-activating gene 1 (Rag1)(-/-) STING N153S mice that lack adaptive immunity had no lung disease, and T-cell receptor beta chain (Tcrb)(-/-) STING N153S animals only had mild disease. STING N153S led to a reduction in percentages and numbers of naive and regulatory T cells, as well as an increased frequency of cytokine-producing effector T cells. Conclusion: Spontaneous lung disease in STING N153S mice develops independently of type I interferon signaling and cGAS. STING N153S relies primarily on T cells to promote lung disease in mice.	[Luksch, Hella; Roesen-Wolff, Angela] Univ Hosp Carl Gustav Carus, Dept Pediat, Dresden, Germany; [Gerbaulet, Alexander] Tech Univ Dresden, Inst Immunol, Dresden, Germany; [Qian, Wei; Kalugotla, Gowri; Miner, Cathrine A.; Miner, Jonathan J.] Washington Univ, Sch Med, Dept Med, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA; [Stinson, W. Alexander; Bennion, Brock G.; Miner, Jonathan J.] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA; [Platt, Derek J.; Miner, Jonathan J.] Washington Univ, Sch Med, Dept Mol Microbiol, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Miner, JJ (corresponding author), Washington Univ, Sch Med, Dept Med, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA.; Miner, JJ (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA.; Miner, JJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 South Euclid Ave,Box 8045, St Louis, MO 63110 USA.; Rosen-Wolff, A (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Pediat, Fetscherstr 74, D-01307 Dresden, Germany.	Angela.Roesen-Wolff@uniklinikum-dresden.de; jonathan.miner@wustl.edu		Platt, Derek/0000-0003-0766-4590	National Institutes of Health [K08 AR070918]; German Research Foundation [TRR237]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI143982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR070918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM103757] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The Miner laboratory is supported by National Institutes of Health grant K08 AR070918.	Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14; Bouis D, 2019, J ALLERGY CLIN IMMUN, V143, P712, DOI 10.1016/j.jaci.2018.04.034; Brownell J, 2014, J VIROL, V88, P1582, DOI 10.1128/JVI.02007-13; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cerboni S, 2017, J EXP MED, V214, P1769, DOI 10.1084/jem.20161674; Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Fremond ML, 2016, J ALLERGY CLIN IMMUN, V138, P1752, DOI 10.1016/j.jaci.2016.07.015; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Heise N, 2014, J EXP MED, V211, P2103, DOI 10.1084/jem.20132613; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Lazear HM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003118; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Ma Z, 2016, CELL HOST MICROBE, V19, P150, DOI 10.1016/j.chom.2016.01.010; Melki I, 2017, J ALLERGY CLIN IMMUN, V140, P543, DOI 10.1016/j.jaci.2016.10.031; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORSE HC, 1992, J IMMUNOL, V149, P3129; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Sharma S, 2011, IMMUNITY, V35, P194, DOI 10.1016/j.immuni.2011.05.016; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Uggenti C, 2019, ANN REV IMMUNOL; Van Dis E, 2018, CELL REP, V23, P1435, DOI 10.1016/j.celrep.2018.04.003; Warner JD, 2017, J EXP MED, V214, P3279, DOI 10.1084/jem.20171351; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114	32	43	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					254	+		10.1016/j.jaci.2019.01.044	http://dx.doi.org/10.1016/j.jaci.2019.01.044			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30772497	Green Accepted, Bronze			2022-12-18	WOS:000473432800027
J	Kim, J; Chang, Y; Bae, B; Sohn, KH; Cho, SH; Chung, DH; Kang, HR; Kim, HY				Kim, Jihyun; Chang, Yuna; Bae, Boram; Sohn, Kyoung-Hee; Cho, Sang-Heon; Chung, Doo Hyun; Kang, Hye Ryun; Kim, Hye Young			Innate immune crosstalk in asthmatic airways: Innate lymphoid cells coordinate polarization of lung macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; innate lymphoid cells; macrophage; polarization; induced sputum; asthma phenotype	PERIPHERAL-BLOOD; DENDRITIC CELLS; T-BET; PLASTICITY; ACTIVATION; PHENOTYPES; DIFFERENTIATION; INFLAMMATION; ALVEOLAR; SPUTUM	Background: Recent studies have emphasized the role of innate lymphoid cells (ILCs) in the development of asthma. The involvement of group 2 innate lymphoid cells (ILC2s) in asthma is well studied: however, the participation of other types of ILCs in the development of asthma remains unclear. Objective: This study aims to understand the role of various ILCs in patients with asthma, especially their effect on macrophage polarization. Methods: Each subset of ILCs and macrophages in induced sputum from 51 steroid-naive patients with asthma and 18 healthy donors was analyzed by using flow cytometry. Alveolar macrophages (AM) were sorted and cocultured with each subset of ILCs to determine whether the polarization of macrophages could be regulated by ILCs. Results: In addition to ILC2s, numbers of group 1 innate lymphoid cells (ILC1s) and group 3 innate lymphoid cells (ILC3s) were increased in induced sputum from asthmatic patients when compared with those in healthy control subjects. The dominance of macrophages in induced sputum was more prominent in asthmatic patients than in healthy control subjects. A positive correlation between numbers of ILC2s and numbers of M2 macrophages and those of ILC1s/ILC3s and M1 macrophages was observed. Coculture of ILC2s with AMs induced expression of M2 macrophage-related genes, whereas coculture of ILC1s and ILC3s with AMs induced expression of M1 macrophage-related genes through cytokine secretion, as well as cell-cell contact. According to the inflammatory signature, patients with eosinophilic asthma have more ILC2s and M2 macrophages, and those with noneosinophilic asthma have an M1 macrophage-dominant profile. Conclusion: A different subset of ILCs regulates macrophage polarization, contributing to developing the distinct phenotype of asthma.	[Kim, Jihyun; Chang, Yuna; Kim, Hye Young] Seoul Natl Univ, Coll Med, Lab Mucosal Immunol, Dept Biomed Sci, 103 Daehak Ro, Seoul 03080, South Korea; [Sohn, Kyoung-Hee; Cho, Sang-Heon; Kang, Hye Ryun] Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea; [Chung, Doo Hyun] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Chung, Doo Hyun] Seoul Natl Univ, Coll Med, Lab Immune Regulat, Dept Biomed Sci, Seoul, South Korea; [Bae, Boram; Sohn, Kyoung-Hee; Cho, Sang-Heon; Kang, Hye Ryun; Kim, Hye Young] Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, HY (corresponding author), Seoul Natl Univ, Coll Med, Lab Mucosal Immunol, Dept Biomed Sci, 103 Daehak Ro, Seoul 03080, South Korea.; Kang, HR (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea.	helenmed@snu.ac.kr; hykim11@snu.ac.kr	Kim, Hye Young/AAF-7609-2020	Kim, Hye Young/0000-0001-5978-512X; Sohn, Kyoung-Hee/0000-0001-8407-8080; Chang, Yuna/0000-0002-4068-3171	Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea [HI15C3083, HI15C1736]; National Research Foundation of Korea; BK21-plus Education Program	Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea; National Research Foundation of Korea(National Research Foundation of Korea); BK21-plus Education Program	Supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (HI15C3083 and HI15C1736), and grants from the National Research Foundation of Korea (SRC 2017R1A5A1014560). J.K. received a scholarship from the BK21-plus Education Program provided by the National Research Foundation of Korea.	Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013; Arora S, 2018, IMMUNOBIOLOGY, V223, P383, DOI 10.1016/j.imbio.2017.11.001; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Barlow JL, 2014, CURR OPIN ALLERGY CL, V14, P397, DOI 10.1097/ACI.0000000000000090; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Boulet LP, 2009, EUR RESPIR J, V33, P897, DOI 10.1183/09031936.00121308; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cai YH, 2014, J IMMUNOL, V192, P2821, DOI 10.4049/jimmunol.1302269; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chapman DG, 2015, CLIN EXP ALLERGY, V45, P706, DOI 10.1111/cea.12506; Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI 10.1164/rccm.201612-2427OC; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Dong L, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/852571; Dupasquier M, 2006, J LEUKOCYTE BIOL, V80, P838, DOI 10.1189/jlb.1005564; Ebbo M, 2017, NAT REV IMMUNOL, V17, P665, DOI 10.1038/nri.2017.86; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Gershon AS, 2010, THORAX, V65, P612, DOI 10.1136/thx.2009.131078; Guilliams M, 2013, MUCOSAL IMMUNOL, V6, P464, DOI 10.1038/mi.2013.14; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Jiang ZL, 2016, J ASTHMA ALLERGY, V9, P101, DOI 10.2147/JAA.S104508; Kim HY, 2016, EUR J IMMUNOL, V46, P795, DOI 10.1002/eji.201444557; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Komlosi ZI, 2018, J ALLERGY CLIN IMMUN, V142, P178, DOI 10.1016/j.jaci.2017.07.046; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kumagai K, 2016, AM J RESP CELL MOL, V54, P782, DOI 10.1165/rcmb.2015-0118OC; Ledford DK, 2013, CURR OPIN ALLERGY CL, V13, P78, DOI 10.1097/ACI.0b013e32835c16b6; Maggi L, 2017, J ALLERGY CLIN IMMUN, V139, P964, DOI 10.1016/j.jaci.2016.06.032; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; McKenzie Andrew N J, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS263, DOI 10.1513/AnnalsATS.201403-097AW; Montaldo E, 2015, EUR J IMMUNOL, V45, P2171, DOI 10.1002/eji.201545598; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Morrell ED, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99281; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Paclik D, 2015, EUR J IMMUNOL, V45, P2766, DOI 10.1002/eji.201545635; Rankin LC, 2013, NAT IMMUNOL, V14, P389, DOI 10.1038/ni.2545; Robbe P, 2015, AM J PHYSIOL-LUNG C, V308, pL358, DOI 10.1152/ajplung.00341.2014; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002; Shirai T, 2003, CLIN EXP ALLERGY, V33, P84, DOI 10.1046/j.1365-2222.2003.01578.x; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Sohn SW, 2008, ALLERGY, V63, P268, DOI 10.1111/j.1398-9995.2007.01550.x; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Taylor S, 2017, J EXP MED, V214, P1663, DOI 10.1084/jem.20161653; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Yang Q, 2016, J ALLERGY CLIN IMMUN, V137, P571, DOI 10.1016/j.jaci.2015.06.037; Zhu M, 2016, ALLERGY ASTHMA PROC, V37, P148, DOI 10.2500/aap.2016.37.3928	67	43	44	5	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1769	+		10.1016/j.jaci.2018.10.040	http://dx.doi.org/10.1016/j.jaci.2018.10.040			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30414858	Bronze			2022-12-18	WOS:000466784600013
J	Edwards, ESJ; Bier, J; Cole, TS; Wong, M; Hsu, P; Berglund, LJ; Boztug, K; Lau, A; Gostick, E; Price, DA; O'Sullivan, M; Meyts, I; Choo, S; Gray, P; Holland, SM; Deenick, EK; Uzel, G; Tangye, SG				Edwards, Emily S. J.; Bier, Julia; Cole, Theresa S.; Wong, Melanie; Hsu, Peter; Berglund, Lucinda J.; Boztug, Kaan; Lau, Anthony; Gostick, Emma; Price, David A.; O'Sullivan, Michael; Meyts, Isabelle; Choo, Sharon; Gray, Paul; Holland, Steven M.; Deenick, Elissa K.; Uzel, Gulbu; Tangye, Stuart G.			Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PIK3CD; CD8(+) T cells; memory; exhaustion/senescence; EBV	T-CELL EXHAUSTION; 3-KINASE DELTA SYNDROME; NATURAL-KILLER-CELLS; PHOSPHOINOSITIDE 3-KINASE; B-CELL; P110 DELTA; EXPRESSION; PI3K-DELTA; INFECTION; SURVIVAL	Background: Germline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110 delta subunit of phosphoinositide 3-kinase (PI3K), result in hyperactivation of the PI3K-AKT-mechanistic target of rapamycin pathway and underlie a novel inborn error of immunity. Affected subjects exhibit perturbed humoral and cellular immunity, manifesting as recurrent infections, autoimmunity, hepatosplenomegaly, uncontrolled EBV and/or cytomegalovirus infection, and increased incidence of B-cell lymphoproliferation, lymphoma, or both. Mechanisms underlying disease pathogenesis remain unknown. Objective: Understanding the cellular and molecular mechanisms underpinning inefficient surveillance of EBV-infected B cells is required to understand disease in patients with PIK3CD GOF mutations, identify key molecules required for cell-mediated immunity against EBV, and develop immunotherapeutic interventions for the treatment of this and other EBV-opathies. Methods: We studied the consequences of PIK3CD GOF mutations on the generation, differentiation, and function of CD8(+) T cells and natural killer (NK) cells, which are implicated in host defense against infection with herpesviruses, including EBV. Results: PIK3CD GOF total and EBV-specific CD8(+) T cells were skewed toward an effector phenotype, with exaggerated expression of markers associated with premature immunosenescence/exhaustion and increased susceptibility to reactivation-induced cell death. These findings were recapitulated in a novel mouse model of PI3K GOF mutations. NK cells in patients with PIK3CD GOF mutations also exhibited perturbed expression of differentiation-associated molecules. Both CD8(+) T and NK cells had reduced capacity to kill EBV-infected B cells. PIK3CD GOF B cells had increased expression of CD48, programmed death ligand 1/2, and CD70. Conclusions: PIK3CD GOF mutations aberrantly induce exhaustion, senescence, or both and impair cytotoxicity of CD8(+) T and NK cells. These defects might contribute to clinical features of affected subjects, such as impaired immunity to herpesviruses and tumor surveillance.	[Edwards, Emily S. J.; Bier, Julia; Lau, Anthony; Deenick, Elissa K.; Tangye, Stuart G.] Garvan Inst Med Res, Div Immunol, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Edwards, Emily S. J.; Bier, Julia; Lau, Anthony; Deenick, Elissa K.; Tangye, Stuart G.] Univ New South Wales Sydney, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Cole, Theresa S.; Choo, Sharon] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Choo, Sharon] Royal Childrens Hosp, Lab Serv, Immunol Lab, Melbourne, Vic, Australia; [Wong, Melanie; Hsu, Peter] Childrens Hosp, Westmead, NSW, Australia; [Wong, Melanie; Hsu, Peter; Berglund, Lucinda J.; Gray, Paul; Deenick, Elissa K.; Tangye, Stuart G.] CIRCA Clin Immunogen Consortia Australia, Sydney, NSW, Australia; [Berglund, Lucinda J.] Westmead Hosp, Immunopathol Dept, Westmead, NSW, Australia; [Hsu, Peter] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia; [Berglund, Lucinda J.] Univ Sydney, Fac Med, Sydney, NSW, Australia; [Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Childrens Canc Res Inst, Dept Paediat & Adolescent Med, Vienna, Austria; [Boztug, Kaan] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Gostick, Emma; Price, David A.] Cardiff Univ, Sch Med, Div Infect & Immun, Cardiff, S Glam, Wales; [Price, David A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [O'Sullivan, Michael] Perth Childrens Hosp, Nedlands, WA, Australia; [Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Meyts, Isabelle] Katholieke Univ Leuven, Dept Microbiol & Immunol, Childhood Immunol, Leuven, Belgium; [Gray, Paul] Univ New South Wales, Sch Womens & Childrens Hlth, Randwick, NSW, Australia; [Holland, Steven M.; Uzel, Gulbu] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Edwards, Emily S. J.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Melbourne, Vic, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Sydney; University of Sydney; University of Sydney; University of Sydney; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Saint Anna Children's Hospital; Cardiff University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); KU Leuven; University Hospital Leuven; KU Leuven; University of New South Wales Sydney; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Monash University	Tangye, SG (corresponding author), Garvan Inst Med Res, Div Immunol, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.tangye@garvan.org.au	Cole, Theresa/AAX-7893-2021; Meyts, Isabelle/Z-3295-2019; Deenick, Elissa/AAY-8998-2020; Boztug, Kaan/AAM-4161-2021; Berglund, Lucinda/S-7921-2019; O'Sullivan, Michael/AAZ-5853-2021; Edwards, Emily S.J./AAI-6037-2020; Price, David A/C-7876-2013	Cole, Theresa/0000-0002-8272-4074; Deenick, Elissa/0000-0002-9271-0004; Boztug, Kaan/0000-0001-8387-9185; O'Sullivan, Michael/0000-0001-7896-2697; Edwards, Emily S.J./0000-0002-0240-4370; Price, David A/0000-0001-9416-2737; Gray, Paul/0000-0003-2057-3968; Lau, Anthony/0000-0002-7338-7176; Berglund, Lucinda/0000-0002-6595-9947; Bier, Julia/0000-0001-7727-1149	Susan and John Freeman Cancer Research Grant from Cancer Council NSW(Australia); Office of Health and Medical Research of the NSW Government; Jeffrey Modell Foundation; John Cook Brown Foundation; National Health and Medical Research Council of Australia [1088215, 1127157]; NHMRC [1042925]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, ZIAAI000647] Funding Source: NIH RePORTER	Susan and John Freeman Cancer Research Grant from Cancer Council NSW(Australia); Office of Health and Medical Research of the NSW Government; Jeffrey Modell Foundation; John Cook Brown Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Susan and John Freeman Cancer Research Grant from Cancer Council NSW(Australia), the Office of Health and Medical Research of the NSW Government, the Jeffrey Modell Foundation, the John Cook Brown Foundation, and the National Health and Medical Research Council of Australia (1088215; 1127157). D.A.P. is a Wellcome Trust Senior Investigator. S.G.T. is a Principal Research Fellow of the NHMRC (1042925).	Abolhassani H, 2017, J EXP MED, V214, P91, DOI 10.1084/jem.20160849; Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Azzi T, 2014, BLOOD, V124, P2533, DOI 10.1182/blood-2014-01-553024; Bengsch B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000947; Beziat V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011966; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Bucciol G, 2017, J CLIN IMMUNOL, V37, P422, DOI 10.1007/s10875-017-0407-5; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Carpier JM, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02005; Chaigne-Delalande B, 2013, SCIENCE, V341, P186, DOI 10.1126/science.1240094; Chan TD, 2009, J IMMUNOL, V183, P3139, DOI 10.4049/jimmunol.0901690; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chijioke O, 2013, CELL REP, V5, P1489, DOI 10.1016/j.celrep.2013.11.041; Chlewicki LK, 2008, J IMMUNOL, V180, P8159, DOI 10.4049/jimmunol.180.12.8159; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Finlay DK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00247; Florea AED, 2017, J ALLERGY CLIN IMMUN, V139, P1032, DOI 10.1016/j.jaci.2016.08.028; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gubser PM, 2013, NAT IMMUNOL, V14, P1064, DOI 10.1038/ni.2687; Guo HL, 2008, J EXP MED, V205, P2419, DOI 10.1084/jem.20072327; Hislop AD, 2002, J EXP MED, V195, P893, DOI 10.1084/jem.20011692; Hislop AD, 2010, BLOOD, V116, P3249, DOI 10.1182/blood-2009-09-238832; Jentsch-Ullrich K, 2005, CLIN IMMUNOL, V116, P192, DOI 10.1016/j.clim.2005.03.020; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; KESTENS L, 1992, AIDS, V6, P793, DOI 10.1097/00002030-199208000-00004; Kim EH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00020; Kim N, 2007, BLOOD, V110, P3202, DOI 10.1182/blood-2007-02-075366; Larsen SE, 2017, J IMMUNOL, V198, P147, DOI 10.4049/jimmunol.1601218; Lens SMA, 1999, BRIT J HAEMATOL, V106, P491, DOI 10.1046/j.1365-2141.1999.01573.x; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Martin AL, 2008, J IMMUNOL, V180, P2081, DOI 10.4049/jimmunol.180.4.2081; Nielsen CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00422; Oak JS, 2007, AUTOIMMUNITY, V40, P433, DOI 10.1080/08916930701464780; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okoye IS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01215; Palendira U, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001187; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; Pearce VQ, 2015, J IMMUNOL, V195, P3206, DOI 10.4049/jimmunol.1501227; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Petrovas C, 2009, J IMMUNOL, V183, P1120, DOI 10.4049/jimmunol.0900182; Price DA, 2005, J EXP MED, V202, P1349, DOI 10.1084/jem.20051357; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood-2017-08-801191; Raziorrouh B, 2010, HEPATOLOGY, V52, P1934, DOI 10.1002/hep.23936; Ruiz-Garcia R, 2018, J ALLERGY CLIN IMMUN, V142, P605, DOI 10.1016/j.jaci.2017.11.042; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Snow AL, 2009, J CLIN INVEST, V119, P2976, DOI 10.1172/JCI39518; Stepensky P, 2015, BLOOD, V125, P753, DOI 10.1182/blood-2014-08-593202; Takeda AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1152, DOI 10.1016/j.jaci.2017.03.026; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Tu WJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02111; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Xu XJ, 2012, SEMIN IMMUNOL, V24, P429, DOI 10.1016/j.smim.2012.12.005; Yamamoto T, 2011, BLOOD, V117, P4805, DOI 10.1182/blood-2010-11-317297; Yang K, 2012, SEMIN IMMUNOL, V24, P421, DOI 10.1016/j.smim.2012.12.004	62	43	43	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					276	+		10.1016/j.jaci.2018.04.030	http://dx.doi.org/10.1016/j.jaci.2018.04.030			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29800648	Green Accepted, Bronze			2022-12-18	WOS:000454918300032
J	Pfajfer, L; Mair, NK; Jimenez-Heredia, R; Genel, F; Gulez, N; Ardeniz, O; Hoeger, B; Kostel, S; Madritsch, C; Kalinichenko, A; Ardy, RC; Gerceker, B; Rey-Barroso, J; Ijspeert, H; Tangye, SG; Simonitsch-Klupp, I; Huppa, JB; van der Burg, M; Dupre, L; Bortug, K				Pfajfer, Laurene; Mair, Nina K.; Jimenez-Heredia, Raul; Genel, Ferah; Gulez, Nesrin; Ardeniz, Omur; Hoeger, Birgit; Kostel, Sevgi; Madritsch, Christoph; Kalinichenko, Artem; Ardy, Rico Chandra; Gerceker, Bengu; Rey-Barroso, Javier; Ijspeert, Hanna; Tangye, Stuart G.; Simonitsch-Klupp, Ingrid; Huppa, Johannes B.; van der Burg, Mirjam; Dupre, Loic; Bortug, Kaan			Mutations affecting the actin regulator WD repeat-containing protein 1 lead to aberrant lymphoid immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						WD repeat-containing protein 1; actin cytoskeleton; immunodeficiency; lymphocytes; immunologic synapse	WISKOTT-ALDRICH-SYNDROME; INTERACTING PROTEIN-1; REFERENCE VALUES; COFILIN; DYNAMICS; AIP1; IMMUNODEFICIENCY; DEFICIENCY; CORONIN; CELLS	Background: The actin-interacting protein WD repeat-containing protein 1 (WDR1) promotes cofilin-dependent actin filament turnover. Biallelic WDR1 mutations have been identified recently in an immunodeficiency/autoinflammatory syndrome with aberrant morphology and function of myeloid cells. Objective: Given the pleiotropic expression of WDR1, here we investigated to what extent it might control the lymphoid arm of the immune system in human subjects. Methods: Histologic and detailed immunologic analyses were performed to elucidate the role of WDR1 in the development and function of B and T lymphocytes. Results: Here we identified novel homozygous and compound heterozygous WDR1 missense mutations in 6 patients belonging to 3 kindreds who presented with respiratory tract infections, skin ulceration, and stomatitis. In addition to defective adhesion and motility of neutrophils and monocytes, WDR1 deficiency was associated with aberrant T-cell activation and B-cell development. T lymphocytes appeared to develop normally in the patients, except for the follicular helper T-cell subset. However, peripheral T cells from the patients accumulated atypical actin structures at the immunologic synapse and displayed reduced calcium flux and mildly impaired proliferation on T-cell receptor stimulation. WDR1 deficiency was associated with even more severe abnormalities of the B-cell compartment, including peripheral B-cell lymphopenia, paucity of B-cell progenitors in the bone marrow, lack of switched memory B cells, reduced clonal diversity, abnormal B-cell spreading, and increased apoptosis on B-cell receptor/Toll-like receptor stimulation. Conclusion: Our study identifies a novel role for WDR1 in adaptive immunity, highlighting WDR1 as a central regulator of actin turnover during formation of the B-cell and T-cell immunologic synapses.	[Pfajfer, Laurene; Mair, Nina K.; Jimenez-Heredia, Raul; Hoeger, Birgit; Kostel, Sevgi; Kalinichenko, Artem; Ardy, Rico Chandra; Dupre, Loic; Bortug, Kaan] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria; [Pfajfer, Laurene; Mair, Nina K.; Jimenez-Heredia, Raul; Hoeger, Birgit; Kostel, Sevgi; Kalinichenko, Artem; Ardy, Rico Chandra; Dupre, Loic; Bortug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Pfajfer, Laurene; Rey-Barroso, Javier; Dupre, Loic] Ctr Physiopathol Toulouse Purpan, UMR1043, INSERM, Toulouse, France; [Pfajfer, Laurene; Rey-Barroso, Javier; Dupre, Loic] Univ Toulouse III Paul Sabatier, Toulouse, France; [Pfajfer, Laurene; Rey-Barroso, Javier; Dupre, Loic] CNRS, UMR 5282, Toulouse, France; [Genel, Ferah; Gulez, Nesrin] Dr Behcet Uz Childrens Hosp, Dept Pediat, Izmir, Turkey; [Ardeniz, Omur] EUTF Internal Med, Div Allergy & Clin Immunol, Izmir, Turkey; [Kostel, Sevgi] Ankara Univ, Dept Pediat Allergy & Immunol, Sch Med, Ankara, Turkey; [Madritsch, Christoph; Huppa, Johannes B.] Med Univ Vienna, Inst Hyg & Appl Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Simonitsch-Klupp, Ingrid] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Bortug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria; [Bortug, Kaan] Med Univ Vienna, Dept Pediat, St Anna Kinderspital & Childrens Canc Res Inst, Vienna, Austria; [Gerceker, Bengu] EUTF Internal Med, Div Dermatol, Izmir, Turkey; [Ijspeert, Hanna; van der Burg, Mirjam] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Tangye, Stuart G.] Garvan Inst Med Res, Immunol Div, Darlinghurst, NSW, Australia; [Tangye, Stuart G.] Univ New South Wales, St Vincents Clin Sch, Darlinghurst, NSW, Australia	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Izmir Dr Behcet Uz Children's Disease & Surgery Training & Research Hospital; Ankara University; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Garvan Institute of Medical Research; University of New South Wales Sydney	Bortug, K (corresponding author), Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria.; Dupre, L (corresponding author), CHU Purpan, INSERM UMR1043, Ctr Physiopathol Toulouse Purpan, 1 Pl Dr Baylac, F-31300 Toulouse, France.	loic.dupre@inserm.fr; kaan.boztug@rud.lbg.ac.at	gulez, nesrin/ABF-5609-2020; dupre, loic/L-8174-2014; Huppa, Johannes Bernhard/AAY-9471-2021; IJspeert, Hanna/U-9479-2019; Boztug, Kaan/AAM-4161-2021; Pfajfer, Laurene/GRO-2420-2022	gulez, nesrin/0000-0002-3343-6949; dupre, loic/0000-0002-7278-6503; Huppa, Johannes Bernhard/0000-0003-2634-8198; Boztug, Kaan/0000-0001-8387-9185; Pfajfer, Laurene/0000-0002-1281-9342; Jimenez Heredia, Raul/0000-0002-1406-0608; Kalinichenko, Artem/0000-0002-7020-7256; Madritsch, Christoph/0000-0001-7044-7420; Mair, Nina K/0000-0003-1119-5432; Hoeger, Birgit/0000-0001-7491-9405; Ardy, Rico Chandra/0000-0003-4975-2177	Vienna Science and Technology Fund [WWTF-LS16-060, WWTF-LS14-31]; Austrian Science Fund [I2250-B28]; French National Agency for Research [ANR-13-BSV1-0031]; ZonMW Vidi grant [91712323]; National Health and Medical Research Council of Australia	Vienna Science and Technology Fund; Austrian Science Fund(Austrian Science Fund (FWF)); French National Agency for Research(French National Research Agency (ANR)); ZonMW Vidi grant; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the Vienna Science and Technology Fund (WWTF-LS16-060 to K.B. and L.D. and WWTF-LS14-31 to J.B.H.), the Austrian Science Fund (I2250-B28 to K.B.), the French National Agency for Research (ANR-13-BSV1-0031 to L.D.), a ZonMW Vidi grant (no. 91712323 to M.v.d.B.), and grants from the National Health and Medical Research Council of Australia (to O.A. and S.G.T.).	Axmann M, 2015, JOVE-J VIS EXP, DOI 10.3791/53158; Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013; Brieher WM, 2006, J CELL BIOL, V175, P315, DOI 10.1083/jcb.200603149; Candotti F, 2018, J CLIN IMMUNOL, V38, P13, DOI 10.1007/s10875-017-0453-z; Castiello MC, 2014, J AUTOIMMUN, V50, P42, DOI 10.1016/j.jaut.2013.10.006; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; de Jong BG, 2017, IMMUNOL CELL BIOL, V95, P744, DOI 10.1038/icb.2017.43; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Freeman SN, 2011, J IMMUNOL, V187, P5887, DOI 10.4049/jimmunol.1102233; Hao SL, 2005, MOL BIOL CELL, V16, P2275, DOI 10.1091/mbc.e04-10-0881; Hauck F, 2018, J ALLERGY CLIN IMMUN, V141, P59, DOI 10.1016/j.jaci.2017.06.009; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; Ikinciogullari A, 2004, TURKISH J PEDIATR, V46, P125; Jansen S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8202; Kile BT, 2007, BLOOD, V110, P2371, DOI 10.1182/blood-2006-10-055087; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kueh HY, 2008, J CELL BIOL, V182, P341, DOI 10.1083/jcb.200801027; Kuhns DB, 2016, BLOOD, V128, P2135, DOI 10.1182/blood-2016-03-706028; Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Liu LD, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15016050; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Mace EM, 2014, P NATL ACAD SCI USA, V111, P6708, DOI 10.1073/pnas.1314975111; Magi A, 2014, BIOINFORMATICS, V30, P2852, DOI 10.1093/bioinformatics/btu401; Mattila PK, 2016, J CELL BIOL, V212, P267, DOI 10.1083/jcb.201504137; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; Moulding DA, 2013, IMMUNOL REV, V256, P282, DOI 10.1111/imr.12114; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 2002, J BIOL CHEM, V277, P43011, DOI 10.1074/jbc.M203111200; Okada K, 2006, MOL BIOL CELL, V17, P2855, DOI 10.1091/mbc.e06-02-0135; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887; Pollard TD, 2016, COLD SPRING HARB PER, P8; Puissant-Lubrano B, 2015, CLIN CHEM LAB MED, V53, pE359, DOI 10.1515/cclm-2014-1186; Qi DC, 2015, MOL MED REP, V12, P2570, DOI 10.3892/mmr.2015.3773; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Salzer E, 2016, NAT IMMUNOL, V17, P1352, DOI 10.1038/ni.3575; Schiefer AI, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002388; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; STIEHM ER, 1966, PEDIATRICS, V37, P715; Vandenberghe P, 2011, PEDIATRIC REP, V3, P21, DOI 10.4081/pr.2011.s2.e9; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200; Xu HC, 2016, AM J TRANSL RES, V8, P1253	45	43	44	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1589	+		10.1016/j.jaci.2018.04.023	http://dx.doi.org/10.1016/j.jaci.2018.04.023			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29751004	Green Published, hybrid			2022-12-18	WOS:000449429800021
J	Kinaciyan, T; Nagl, B; Faustmann, S; Frommlet, F; Kopp, S; Wolkersdorfer, M; Wohrl, S; Bastl, K; Huber, H; Berger, U; Bohle, B				Kinaciyan, Tamar; Nagl, Birgit; Faustmann, Sandra; Frommlet, Florian; Kopp, Stephan; Wolkersdorfer, Martin; Woehrl, Stefan; Bastl, Katharina; Huber, Hans; Berger, Uwe; Bohle, Barbara			Efficacy and safety of 4 months of sublingual immunotherapy with recombinantMal d 1 and Bet v 1 in patients with birch pollen-related apple allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; birch pollen allergy; birch pollen-related food allergy; IgE; allergen-specific immunotherapy; recombinant allergens; Bet v 1; Mal d 1	FOOD ALLERGY; DOUBLE-BLIND; IMMUNE-RESPONSE; PEANUT ALLERGY; CHALLENGE; TOLERANCE; HAZELNUT; LEVEL; TESTS; SIT	Background: Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy. Objective: We sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy. Methods: Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n = 20) or 25 mu g of rMal d 1 (n = 20) or rBet v 1 (n = 20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick tests with recombinant allergens, and measurements of allergen-specific IgE and IgG(4) antibodies were performed before and after treatment. Results: Both formulations caused comparable, mainly local adverse events. No systemic reactions occurred. Compared with the placebo and rBet v 1-treated groups, SLIT with rMal d 1 reduced rMal d 1-induced oral symptoms (P = .001 and P = .038) accompanied by longitudinally reduced rMal d 1-specific cutaneous reactions (P = .022) and enhanced IgG(4)/IgE ratios (P = .012). SLIT with rBet v 1 neither improved the clinical reactivity to rMal d 1 nor enhanced rMal d 1-specific IgG(4)/IgE ratios. Participants receiving placebo showed no allergen-specific changes. Conclusion: Sublingual treatment with a recombinant food allergen was safe and clinically effective, as determined by using standardized challenges. We present a promising approach for the effective treatment of birch pollen-related apple allergy.	[Kinaciyan, Tamar] Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria; [Nagl, Birgit; Faustmann, Sandra; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria; [Nagl, Birgit; Faustmann, Sandra; Bohle, Barbara] Med Univ Vienna, Christian Doppler Lab Immunomodulat, Vienna, Austria; [Frommlet, Florian] Med Univ Vienna, Dept Med Stat CEMSIIS, Vienna, Austria; [Bastl, Katharina; Berger, Uwe] Med Univ Vienna, Dept Otorhinolaryngol, Aerobiol & Pollen Informat Res Unit, Vienna, Austria; [Kopp, Stephan; Huber, Hans] Biomay AG, Vienna, Austria; [Wolkersdorfer, Martin] Landesapotheke, Dept Prod, Salzburg, Austria; [Woehrl, Stefan] FAZ, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Bohle, B (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Frommlet, Florian/H-7097-2019; Wöhrl, Stefan/B-6954-2013	Frommlet, Florian/0000-0003-4104-1768; Wöhrl, Stefan/0000-0002-6324-0007; Bastl, Katharina/0000-0002-8200-9708; Kinaciyan, Tamar/0000-0002-8238-2561; Bohle, Barbara/0000-0002-5105-7985	Austrian Science Fund [KLI96, SFBF4610]; Biomay AG; Christian Doppler Research Association, Vienna, Austria	Austrian Science Fund(Austrian Science Fund (FWF)); Biomay AG; Christian Doppler Research Association, Vienna, Austria	Supported by the Austrian Science Fund (projects KLI96 and SFBF4610), Biomay AG, and the Christian Doppler Research Association, Vienna, Austria.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Asero R, 2004, ALLERGY, V59, P1269, DOI 10.1111/j.1398-9995.2004.00561.x; Asero R, 1998, CLIN EXP ALLERGY, V28, P1368, DOI 10.1046/j.1365-2222.1998.00399.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Geroldinger-Simic M, 2013, J ALLERGY CLIN IMMUN, V131, P94, DOI 10.1016/j.jaci.2012.06.039; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Gomez F, 2017, CLIN EXP ALLERGY, V47, P339, DOI 10.1111/cea.12901; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Hansen KS, 2001, ALLERGY, V56, P109, DOI 10.1034/j.1398-9995.2001.056002109.x; HERRMANN D, 1995, J INVEST ALLERG CLIN, V5, P259; KELSO JM, 1995, ANN ALLERG ASTHMA IM, V74, P391; Kinaciyan T, 2016, ALLERGY, V71, P272, DOI 10.1111/all.12781; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Kollmann D, 2013, J ALLERGY CLIN IMMUN, V132, P1008, DOI 10.1016/j.jaci.2013.05.030; Kopac P, 2012, ALLERGY, V67, P280, DOI 10.1111/j.1398-9995.2011.02744.x; Matthes A, 2009, J AGR FOOD CHEM, V57, P10548, DOI 10.1021/jf901938q; Mauro M, 2011, INT ARCH ALLERGY IMM, V156, P416, DOI 10.1159/000323909; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Modrzynski Marek, 2002, Przegl Lek, V59, P1007; Nony E, 2015, ALLERGY, V70, P795, DOI 10.1111/all.12622; Radauer C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-286; Sancho AI, 2006, J AGR FOOD CHEM, V54, P5917, DOI 10.1021/jf060880m; van Hoffen E, 2011, J ALLERGY CLIN IMMUN, V127, P100, DOI 10.1016/j.jaci.2010.08.021; Werfel T, 2015, ALLERGY, V70, P1079, DOI 10.1111/all.12666	31	43	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1002	1008		10.1016/j.jaci.2017.07.036	http://dx.doi.org/10.1016/j.jaci.2017.07.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28870463				2022-12-18	WOS:000426974800020
J	Cruz, AA; Cooper, PJ; Figueiredo, CA; Alcantara-Neves, NM; Rodrigues, LC; Barreto, ML				Cruz, Alvaro A.; Cooper, Philip J.; Figueiredo, Camila A.; Alcantara-Neves, Neuza M.; Rodrigues, Laura C.; Barreto, Mauricio L.			Global issues in allergy and immunology: Parasitic infections and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; asthma; parasite infection; helminths; epidemiology; pathogenesis	SCHISTOSOMA-MANSONI INFECTION; MORPHOGENETIC PROTEIN HOMOLOG; PLACEBO-CONTROLLED TRIAL; SKIN-TEST REACTIVITY; REGULATORY T-CELLS; HELMINTH INFECTION; PROMOTER POLYMORPHISM; CHILDHOOD ASTHMA; IMMUNE-SYSTEM; THERAPY	Allergic diseases are on the increase globally in parallel with a decrease in parasitic infection. The inverse association between parasitic infections and allergy at an ecological level suggests a causal association. Studies in human subjects have generated a large knowledge base on the complexity of the interrelationship between parasitic infection and allergy. There is evidence for causal links, but the data from animal models are the most compelling: despite the strong type 2 immune responses they induce, helminth infections can suppress allergy through regulatory pathways. Conversely, many helminths can cause allergic-type inflammation, including symptoms of "classical'' allergic disease. From an evolutionary perspective, subjects with an effective immune response against helminths can be more susceptible to allergy. This narrative review aims to inform readers of the most relevant up-to-date evidence on the relationship between parasites and allergy. Experiments in animal models have demonstrated the potential benefits of helminth infection or administration of helminth-derived molecules on chronic inflammatory diseases, but thus far, clinical trials in human subjects have not demonstrated unequivocal clinical benefits. Nevertheless, there is sufficiently strong evidence to support continued investigation of the potential benefits of helminth-derived therapies for the prevention or treatment of allergic and other inflammatory diseases.	[Cruz, Alvaro A.] Univ Fed Bahia, Fac Med, ProAR, Rua Carlos Gomes 270,7 Andar, BR-40060330 Salvador, BA, Brazil; [Cruz, Alvaro A.; Cooper, Philip J.; Figueiredo, Camila A.; Alcantara-Neves, Neuza M.; Rodrigues, Laura C.; Barreto, Mauricio L.] Social Change Asthma & Allergy Latin Amer SCAALA, Salvador, BA, Brazil; [Cruz, Alvaro A.; Cooper, Philip J.; Figueiredo, Camila A.; Alcantara-Neves, Neuza M.; Rodrigues, Laura C.; Barreto, Mauricio L.] Social Change Asthma & Allergy Latin Amer SCAALA, Quito, Ecuador; [Cruz, Alvaro A.; Cooper, Philip J.; Figueiredo, Camila A.; Alcantara-Neves, Neuza M.; Rodrigues, Laura C.; Barreto, Mauricio L.] Social Change Asthma & Allergy Latin Amer SCAALA, London, England; [Cooper, Philip J.] St Georges Univ London, Inst Infect & Immun, London, England; [Cooper, Philip J.] Univ Internac Ecuador, Fac Ciencias Med Salud & Vida, Quito, Ecuador; [Figueiredo, Camila A.; Alcantara-Neves, Neuza M.] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil; [Rodrigues, Laura C.] London Sch Hyg & Trop Med, London, England; [Barreto, Mauricio L.] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil	Universidade Federal da Bahia; St Georges University London; Universidade Federal da Bahia; University of London; London School of Hygiene & Tropical Medicine; Fundacao Oswaldo Cruz	Cruz, AA (corresponding author), Univ Fed Bahia, Fac Med, ProAR, Rua Carlos Gomes 270,7 Andar, BR-40060330 Salvador, BA, Brazil.	cruz.proar@gmail.com	Figueiredo, Camila Alexandrina/H-3525-2015; RODRIGUES, LAURA CUNHA/AAO-4130-2021; Barreto, Mauricio L/B-1752-2008	Figueiredo, Camila Alexandrina/0000-0003-1356-6188; Barreto, Mauricio L/0000-0002-0215-4930; Cooper, Philip/0000-0002-6770-6871	Brazilian Research Council (CNPq)	Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	C.A.F., N.M.A.-N., M.L.B., and A.A.C. receive investigator grants from the Brazilian Research Council (CNPq).	Ahumada V, 2015, CLIN EXP ALLERGY, V45, P1189, DOI 10.1111/cea.12513; Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Alvarado R, 2017, FASEB J, V31, P85, DOI 10.1096/fj.201500093R; Amberbir A, 2011, CLIN EXP ALLERGY, V41, P1422, DOI 10.1111/j.1365-2222.2011.03831.x; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Aravindhan V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000707; ASHFORD RW, 1998, PARASITES HOMO SAPIE; Babu S, 2016, TRENDS IMMUNOL, V37, P597, DOI 10.1016/j.it.2016.07.005; Barnes KC, 2005, CURR OPIN ALLERGY CL, V5, P379, DOI 10.1097/01.all.0000182543.37724.7b; Beeton C, 2006, P NATL ACAD SCI USA, V103, P17414, DOI 10.1073/pnas.0605136103; Bottema RWB, 2010, J ALLERGY CLIN IMMUN, V126, P338, DOI 10.1016/j.jaci.2010.04.024; Bottema RW, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Bouchery T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7970; Bourke CD, 2012, CLIN EXP ALLERGY, V42, P1582, DOI 10.1111/j.1365-2222.2012.04063.x; Briggs N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004944; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Caraballo L, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0110-7; Carvalho L, 2009, IMMUNOLOGY, V126, P28, DOI 10.1111/j.1365-2567.2008.03008.x; Cattadori IM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159770; Chen YH, 2013, J CLIN ENDOCR METAB, V98, pE283, DOI 10.1210/jc.2012-2517; Cho MK, 2011, PARASITE IMMUNOL, V33, P265, DOI 10.1111/j.1365-3024.2010.01276.x; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Cook PC, 2012, P NATL ACAD SCI USA, V109, P9977, DOI 10.1073/pnas.1121231109; Cooper PJ, 2016, J ALLERGY CLIN IMMUN, V137, P899, DOI 10.1016/j.jaci.2015.07.044; Cooper PJ, 2015, INT J EPIDEMIOL, V44, P1517, DOI 10.1093/ije/dyu128; Correale J, 2011, J NEUROIMMUNOL, V233, P6, DOI 10.1016/j.jneuroim.2011.01.002; Costa RD, 2017, ANN ALLERG ASTHMA IM, V118, P483, DOI 10.1016/j.anai.2017.01.028; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; Cruz AA, 2007, CLIN EXP ALLERGY, V37, P197, DOI 10.1111/j.1365-2222.2007.02650.x; Daveson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017366; Esen M, 2012, VACCINE, V30, P7621, DOI 10.1016/j.vaccine.2012.10.026; Feary J, 2011, ALLERGY, V66, P569, DOI 10.1111/j.1398-9995.2010.02512.x; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Figueiredo CA, 2013, J ALLERGY CLIN IMMUN, V131, P1683, DOI 10.1016/j.jaci.2012.10.043; Fincham JE, 2007, T ROY SOC TROP MED H, V101, P680, DOI 10.1016/j.trstmh.2006.11.006; Finlay CM, 2014, IMMUNOL REV, V259, P206, DOI 10.1111/imr.12164; Flohr C, 2010, CLIN EXP ALLERGY, V40, P131, DOI 10.1111/j.1365-2222.2009.03346.x; Forno E, 2017, AM J RESP CELL MOL, V57, P439, DOI 10.1165/rcmb.2017-0002OC; Freitas TC, 2009, INT J PARASITOL, V39, P281, DOI 10.1016/j.ijpara.2008.08.001; Garg SK, 2014, COCHRANE DB SYST REV, V20; Gazzinelli-Guimaraes PH, 2016, J IMMUNOL, V197, P2772, DOI 10.4049/jimmunol.1600829; GELPI AP, 1967, AM J TROP MED HYG, V16, P646, DOI 10.4269/ajtmh.1967.16.646; Geri G, 2015, INFECTION, V43, P691, DOI 10.1007/s15010-015-0799-1; Gordon ED, 2016, P NATL ACAD SCI USA, V113, P8765, DOI 10.1073/pnas.1601914113; Grant AV, 2008, J INFECT DIS, V198, P1227, DOI 10.1086/591946; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; He YX, 2002, EXP PARASITOL, V102, P99, DOI 10.1016/S0014-4894(03)00024-9; Helmby H, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0074-3; Hopkin J, 2009, PARASITE IMMUNOL, V31, P267, DOI 10.1111/j.1365-3024.2009.01104.x; House JS, 2017, J ALLERGY CLIN IMMUN, V140, P249, DOI 10.1016/j.jaci.2016.09.036; Huang ZY, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028320; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Karimabad MN, 2013, INFLAMMATION, V36, P35, DOI 10.1007/s10753-012-9517-7; Kouriba B, 2005, J IMMUNOL, V174, P6274, DOI 10.4049/jimmunol.174.10.6274; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Krams M, 2003, STROKE, V34, P2543, DOI 10.1161/01.STR.0000092527.33910.89; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; LaBeaud AD, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000442; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Liu R, 2013, EXP PARASITOL, V135, P64, DOI 10.1016/j.exppara.2013.05.016; Long X, 2017, J ALLERGY CLIN IMMUN, V140, P1416, DOI 10.1016/j.jaci.2016.12.969; Long X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135360; Maizels RM, 2016, CLIN MICROBIOL INFEC, V22, P481, DOI 10.1016/j.cmi.2016.04.024; Maizels RM, 2016, J ALLERGY CLIN IMMUN, V138, P666, DOI 10.1016/j.jaci.2016.07.007; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Matricardi PM, 2014, GLOBAL ATLAS ALLERGY, P112; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Mpairwe H, 2014, PEDIAT ALLERG IMM-UK, V25, P481, DOI 10.1111/pai.12251; Navarro S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8807; Nawras M, 2015, J COAST LIFE MED, V3, P914; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Park JE, 2009, J IMMUNOL, V182, P6316, DOI 10.4049/jimmunol.0804239; Ponte EV, 2014, J ASTHMA, V51, P1022, DOI 10.3109/02770903.2014.936454; Porto AF, 2001, PARASITE IMMUNOL, V23, P503, DOI 10.1046/j.1365-3024.2001.00407.x; Robinson D, 2017, CLIN EXP ALLERGY, V47, P161, DOI 10.1111/cea.12880; Rodgers DT, 2015, LUPUS, V24, P1437, DOI 10.1177/0961203315591031; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Rodriguez A, 2011, THORAX, V66, P1043, DOI 10.1136/thoraxjnl-2011-200225; Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269; Santiago HD, 2016, CRIT REV IMMUNOL, V36, P1, DOI 10.1615/CritRevImmunol.2016016545; Santos LN, 2017, ACTA TROP, V166, P202, DOI 10.1016/j.actatropica.2016.11.016; Sawant DV, 2014, J IMMUNOL, V192, P2904, DOI 10.4049/jimmunol.1202502; Schnyder-Candrian Silvia, 2012, J Allergy (Cairo), V2012, P245909, DOI 10.1155/2012/245909; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Smith KA, 2012, INFECT IMMUN, V80, P3481, DOI 10.1128/IAI.00436-12; Steinfelder S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005480; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Timmann C, 2004, GENES IMMUN, V5, P256, DOI 10.1038/sj.gene.6364094; Tyagi N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004546; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Veenstra AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078405; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Wammes LJ, 2016, P NATL ACAD SCI USA, V113, P12526, DOI 10.1073/pnas.1604570113; Weinstock JV, 2013, INT J PARASITOL, V43, P245, DOI 10.1016/j.ijpara.2012.10.016; Wen XY, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001399; Whelan RA, 2014, MOL THER, V22, P1730, DOI 10.1038/mt.2014.125; Wiria AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054855; Wiria AE, 2012, SEMIN IMMUNOPATHOL, V34, P889, DOI 10.1007/s00281-012-0358-0; World Health Organization, SOIL TRANSM HELM INF	111	43	44	2	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1217	1228		10.1016/j.jaci.2017.09.005	http://dx.doi.org/10.1016/j.jaci.2017.09.005			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	29108604	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000414304300001
J	Kurowska-Stolarska, M; Hasoo, MK; Welsh, DJ; Stewart, L; McIntyre, D; Morton, BE; Johnstone, S; Miller, AM; Asquith, DL; Millar, NL; Millar, AB; Feghali-Bostwick, CA; Hirani, N; Crick, PJ; Wang, YQ; Griffiths, WJ; McInnes, IB; McSharry, C				Kurowska-Stolarska, Mariola; Hasoo, Manhl K.; Welsh, David J.; Stewart, Lynn; McIntyre, Donna; Morton, Brian E.; Johnstone, Steven; Miller, Ashley M.; Asquith, Darren L.; Millar, Neal L.; Millar, Ann B.; Feghali-Bostwick, Carol A.; Hirani, Nikhil; Crick, Peter J.; Wang, Yuqin; Griffiths, William J.; McInnes, Iain B.; McSharry, Charles			The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MicroRNA-155; lung fibrosis; liver X receptor; fibroblasts; alternatively activated macrophages	INNATE LYMPHOID-CELLS; LUNG FIBROSIS; GROWTH-FACTOR; SYSTEMIC-SCLEROSIS; MACROPHAGES; EXPRESSION; DISEASE; ALPHA; RNA; MICRORNAS	Background: Idiopathic pulmonary fibrosis (IPF) is progressive and rapidly fatal. Improved understanding of pathogenesis is required to prosper novel therapeutics. Epigenetic changes contribute to IPF; therefore, microRNAs may reveal novel pathogenic pathways. Objectives: We sought to determine the regulatory role of microRNA (miR)-155 in the profibrotic function of murine lung macrophages and fibroblasts, IPF lung fibroblasts, and its contribution to experimental pulmonary fibrosis. Methods: Bleomycin-induced lung fibrosis in wild-type and miR-155(-/-) mice was analyzed by histology, collagen, and profibrotic gene expression. Mechanisms were identified by in silico and molecular approaches and validated in mouse lung fibroblasts and macrophages, and in IPF lung fibroblasts, using loss-and-gain of function assays, and in vivo using specific inhibitors. Results: miR-155(-/-) mice developed exacerbated lung fibrosis, increased collagen deposition, collagen 1 and 3 mRNA expression, TGF-beta production, and activation of alternatively activated macrophages, contributed by deregulation of the miR-155 target gene the liver X receptor (LXR)alpha in lung fibroblasts and macrophages. Inhibition of LXR alpha in experimental lung fibrosis and in IPF lung fibroblasts reduced the exacerbated fibrotic response. Similarly, enforced expression of miR-155 reduced the profibrotic phenotype of IPF and miR-155(-/-) fibroblasts. Conclusions: We describe herein a molecular pathway comprising miR-155 and its epigenetic LXRa target that when deregulated enables pathogenic pulmonary fibrosis. Manipulation of the miR-155/LXR pathway may have therapeutic potential for IPF.	[Kurowska-Stolarska, Mariola; Hasoo, Manhl K.; Stewart, Lynn; McIntyre, Donna; Morton, Brian E.; Johnstone, Steven; Asquith, Darren L.; Millar, Neal L.; McInnes, Iain B.; McSharry, Charles] Univ Glasgow, Inst Infect Immun & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland; [Welsh, David J.] Univ Glasgow, Scottish Pulm Vasc Unit, Glasgow, Lanark, Scotland; [Miller, Ashley M.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Millar, Ann B.] Univ Bristol, Acad Resp Unit, Learning & Res, Bristol, Avon, England; [Feghali-Bostwick, Carol A.] Med Univ South Carolina, Div Rheumatol & Immunol, Charleston, SC USA; [Hirani, Nikhil] Univ Edinburgh, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh, Midlothian, Scotland; [Crick, Peter J.; Wang, Yuqin; Griffiths, William J.] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [McSharry, Charles] Yorkhill Hosp, Greater Glasgow & Clyde Clin Res & Dev, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Bristol; Medical University of South Carolina; University of Edinburgh; Swansea University	Kurowska-Stolarska, M; McSharry, C (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	Kurowska-Stolarska@glasgow.ac.uk; Charles.McSharry@glasgow.ac.uk	Griffiths, William/N-4641-2016; Kurowska-Stolarska, Mariola/AAD-1683-2019	Griffiths, William/0000-0002-4129-6616; McSharry, Charles/0000-0003-4758-9038; Welsh, David/0000-0002-2843-4623; wang, yuqin/0000-0002-3063-3066	Arthritis Research UK [19213]; British Heart Foundation [FS/08/035/25309]; Ministry of Higher Education and Scientific Research, Republic of Iraq; Medical Research Scotland [657-2012]; Lamellar Biomedical Ltd, Bellshill, United Kingdom; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P30 AR061271, K24 AR060297]; British Pigeon Fanciers' Medical Research Trust; Biotechnology & Biological Sciences Research Council [BB/I001735/1, BB/L001942/1]; Biotechnology and Biological Sciences Research Council [BB/I001735/1] Funding Source: researchfish; Medical Research Council [G0901697, MR/K015206/1] Funding Source: researchfish; Versus Arthritis [19213] Funding Source: researchfish; Chief Scientist Office [ETM/153, ETM/330] Funding Source: researchfish; British Lung Foundation [MRCPHD07-1] Funding Source: researchfish; BBSRC [BB/I001735/1] Funding Source: UKRI; MRC [MR/K015206/1, G0901697] Funding Source: UKRI; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR060297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072506] Funding Source: NIH RePORTER	Arthritis Research UK(Versus Arthritis); British Heart Foundation(British Heart Foundation); Ministry of Higher Education and Scientific Research, Republic of Iraq; Medical Research Scotland; Lamellar Biomedical Ltd, Bellshill, United Kingdom; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); British Pigeon Fanciers' Medical Research Trust; Biotechnology & Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Versus Arthritis(Versus Arthritis); Chief Scientist Office; British Lung Foundation; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	M.K.-S. was supported by Arthritis Research UK (grant no. 19213); A.M.M. was supported by the British Heart Foundation (grant no. FS/08/035/25309). M.K.H. was supported by the Ministry of Higher Education and Scientific Research, Republic of Iraq. B.E.M. was supported by a joint grant (grant no. 657-2012) from Medical Research Scotland and Lamellar Biomedical Ltd, Bellshill, United Kingdom. C.A.F.-B. was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant nos. P30 AR061271 and K24 AR060297). S.J. was supported by British Pigeon Fanciers' Medical Research Trust. Oxysterol measurement was supported by Biotechnology & Biological Sciences Research Council (grant nos. BB/I001735/1 and BB/L001942/1).	Albers M, 2006, J BIOL CHEM, V281, P4920, DOI 10.1074/jbc.M510101200; Beyer C, 2015, ANN RHEUM DIS, V74, P1317, DOI 10.1136/annrheumdis-2013-204401; Cho JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-8; Christmann RB, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1054-6; Endo M, 2003, AM J PHYSIOL-LUNG C, V285, pL313, DOI 10.1152/ajplung.00434.2002; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Griffiths WJ, 2013, FREE RADICAL BIO MED, V59, P69, DOI 10.1016/j.freeradbiomed.2012.07.027; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Hasty AH, 2013, CIRC RES, V113, P1182, DOI 10.1161/CIRCRESAHA.113.302613; Herzog EL, 2014, ARTHRITIS RHEUMATOL, V66, P1967, DOI 10.1002/art.38702; Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kikuchi T, 2012, CHEST, V142, P329, DOI 10.1378/chest.11-2091; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Li P, 2013, J ASTHMA, V50, P960, DOI 10.3109/02770903.2013.822080; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Marathe C, 2006, J BIOL CHEM, V281, P32197, DOI 10.1074/jbc.M605237200; Meltzer EB, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-70; Miller AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072324; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Moore BB, 2013, AM J RESP CELL MOL, V49, P167, DOI 10.1165/rcmb.2013-0094TR; Navaratnam V, 2013, CHEST, V143, P1078, DOI 10.1378/chest.12-0803; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8; Pottier N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006718; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Rowe SM, 2008, AM J RESP CRIT CARE, V178, P822, DOI 10.1164/rccm.200712-1894OC; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Schwartz YS, 2009, B EXP BIOL MED+, V148, P406, DOI 10.1007/s10517-010-0724-7; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; Steffensen KR, 2013, EXPERT OPIN THER TAR, V17, P977, DOI 10.1517/14728222.2013.806490; Suwara MI, 2014, MUCOSAL IMMUNOL, V7, P684, DOI 10.1038/mi.2013.87; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tranheim K.E., 2012, LIPIDS, V47, P483; Tzouvelekis A, 2007, AM J RESP CRIT CARE, V176, P1108, DOI 10.1164/rccm.200705-683OC; Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Yan QR, 2016, SCI REP-UK, V6, DOI 10.1038/srep20314; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004	50	43	43	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1946	1956		10.1016/j.jaci.2016.09.021	http://dx.doi.org/10.1016/j.jaci.2016.09.021			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27746237	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000402724600025
J	Haahtela, T; Herse, F; Karjalainen, J; Klaukka, T; Linna, M; Leskela, RL; Selroos, O; Reissell, E				Haahtela, Tari; Herse, Fredrik; Karjalainen, Jussi; Klaukka, Timo; Linna, Miika; Leskela, Riikka-Leena; Selroos, Olof; Reissell, Eeva			The Finnish experience to save asthma costs by improving care in 1987-2013	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; direct costs; indirect costs; national asthma program; public health	ECONOMIC-EVALUATION; MANAGEMENT PROGRAM; SELF-MANAGEMENT; ADULT ASTHMA; HEALTH-CARE; FINLAND; BUDESONIDE; REDUCTION; BURDEN; RISK	The Finnish National Asthma Program 1994-2004 markedly improved asthma care in the 1990s. We evaluated the changes in costs during 26 years from 1987 to 2013. Direct and indirect costs were calculated by using data from national registries. Costs from both the societal and patient perspectives were included. The costs were based on patients with persistent, physician-diagnosed asthma verified by lung function measurements. We constructed minimum and maximum scenarios to assess the effect of improved asthma care on total costs. The number of patients with persistent asthma in the national drug reimbursement register increased from 83,000 to 247,583. Improved asthma control reduced health care use and disability, resulting in major cost savings. Despite a 3-fold increase in patients, the total costs decreased by 14%, from (SIC)222 million to (SIC)191 million. Costs for medication and primary care visits increased, but overall annual costs per patient decreased by 72%, from (SIC)2656 to (SIC)749. The theoretical total cost savings for 2013, comparing actual with predicted costs, were between (SIC)120 and (SIC)475 million, depending on the scenario used. The Finnish Asthma Program resulted in significant cost savings at both the societal and patient levels during a 26-year period.	[Haahtela, Tari] Univ Helsinki Hosp, Skin & Allergy Hosp, POB 160, FIN-00029 Helsinki, Finland; [Herse, Fredrik; Leskela, Riikka-Leena] Finland Nord Healthcare Grp, Helsinki, Finland; [Karjalainen, Jussi] Tampere Univ Hosp, Allergy Ctr, Tampere, Finland; [Klaukka, Timo] Social Insurance Inst, Dept Res, Helsinki, Finland; [Linna, Miika] Aalto Univ, Espoo, Finland; [Selroos, Olof] Univ Helsinki, Helsinki, Finland; [Reissell, Eeva] Natl Inst Hlth andWelfare, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; Aalto University; University of Helsinki	Haahtela, T (corresponding author), Univ Helsinki Hosp, Skin & Allergy Hosp, POB 160, FIN-00029 Helsinki, Finland.	tari.haahtela@haahtela.fi			European Commission's 7th Framework Programme (MeDALL-project) [261357]; Helsinki University Hospital grant.	European Commission's 7th Framework Programme (MeDALL-project); Helsinki University Hospital grant.	The basis of the present report of asthma care costs in Finland is derived from the governmental, public health care asthma programme 1994-2004 (main results published in Thorax 2001 and 2006). The cost analyses were further developed in a project concerning several common diseases of public health concern commissioned by the Pharma Industry Finland (PIF) with the help of Nordic Healthcare Group (NHG). PIF published a report of the study findings of the selected chronic diseases, asthma among them. PIF did not participate in the design of the present, extended asthma study or in the collection, analysis, and interpretation of data. The final stage of this work was supported by the European Commission's 7th Framework Programme under grant agreement 261357 (MeDALL-project) and a Helsinki University Hospital grant.	AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bedouch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050949; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Byford S, 2000, BRIT MED J, V320, P1335, DOI 10.1136/bmj.320.7245.1335; CLARK TJH, 1972, LANCET, V1, P1361; Drummond M, 2005, METHODS ECONOMICEVAL, P7; Drummond M, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1204; Foliaki S, 2009, INT J TUBERC LUNG D, V13, P142; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haahtela T, 2001, THORAX, V56, P806, DOI 10.1136/thorax.56.10.806; Haahtela T, 1996, CLIN EXP ALLERGY, V26, pR1, DOI 10.1111/j.1365-2222.1996.tb02572.x; Heijink R, INT COMPARISON COSTS; Hujanen T., 2003, UNIT COSTS HLTH CARE; Jarvala T, 2010, COSTS DIABETES FINLA; Jousilahti P, 2016, EUR RESPIR J, V47, P985, DOI 10.1183/13993003.01702-2015; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565, DOI 10.1164/ajrccm.164.4.2012146; Kauppi P, 1998, RESP MED, V92, P1281, DOI 10.1016/S0954-6111(98)90229-3; Kauppi P, 2015, ASIA PAC ALLERGY, V5, P32, DOI 10.5415/apallergy.2015.5.1.32; Kauppi P, 2013, THORAX, V68, P292, DOI 10.1136/thoraxjnl-2011-201028; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Kotaniemi JT, 2001, ALLERGY, V56, P169, DOI 10.1034/j.1398-9995.2001.056002169.x; Kupczyk M, 2010, ALLERGY, V65, P415, DOI 10.1111/j.1398-9995.2009.02265.x; Lahdensuo A, 1998, BRIT MED J, V316, P1138, DOI 10.1136/bmj.316.7138.1138; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lalloo UG, 2011, INT J TUBERC LUNG D, V15, P1574, DOI 10.5588/ijtld.11.0289; Liljas B, 1998, PHARMACOECONOMICS, V13, P1, DOI 10.2165/00019053-199813010-00001; Ng TP, 2006, ANN ALLERG ASTHMA IM, V97, P784, DOI 10.1016/S1081-1206(10)60970-2; Pallasaho P, 2011, RESP MED, V105, P1449, DOI 10.1016/j.rmed.2011.04.013; Pallasaho P, 2002, RESP MED, V96, P759, DOI 10.1053/rmed.2002.1308; Petro W, 2005, Pneumologie, V59, P101, DOI 10.1055/s-2004-830137; Plaza V, 2005, MED CLIN-BARCELONA, V124, P201, DOI 10.1157/13071758; Reissell E, 2008, DOSIS, V24, P311; Schermer TR, 2002, AM J RESP CRIT CARE, V166, P1062, DOI 10.1164/rccm.2105116; Selroos O, 2015, EUR RESPIR REV, V24, P474, DOI 10.1183/16000617.00008114; Steuten L, 2007, INT J TECHNOL ASSESS, V23, P184, DOI 10.1017/S0266462307070298; Tavakoli H, 2016, ALLERGY	44	43	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					408	414		10.1016/j.jaci.2016.12.001	http://dx.doi.org/10.1016/j.jaci.2016.12.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27979429	Green Published, Bronze			2022-12-18	WOS:000397002400004
J	Siroux, V; Lupinek, C; Resch, Y; Curin, M; Just, J; Keil, T; Kiss, R; Carlsen, KL; Melen, E; Nadif, R; Pin, I; Skrindo, I; Vrtala, S; Wickman, M; Anto, JM; Valenta, R; Bousquet, J				Siroux, Valerie; Lupinek, Christian; Resch, Yvonne; Curin, Mirela; Just, Jocelyne; Keil, Thomas; Kiss, Renata; Carlsen, Karin Lodrup; Melen, Erik; Nadif, Rachel; Pin, Isabelle; Skrindo, Ingebjorg; Vrtala, Susanne; Wickman, Magnus; Anto, Josep Maria; Valenta, Rudolf; Bousquet, Jean			Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; IgG; allergen components; respiratory allergens; food allergens; EGEA; cohort; epidemiology; MeDALL; microarray	BRONCHIAL HYPERRESPONSIVENESS; POLLEN ALLERGENS; IMMUNOGLOBULIN-G; MAJOR ALLERGEN; SENSITIZATION; ASTHMA; IMMUNOTHERAPY; BIRCH; CAT; ENVIRONMENT	Background: The nature of allergens and route and dose of exposure may affect the natural development of IgE and IgG responses. Objective: We sought to investigate the natural IgE and IgG responses toward a large panel of respiratory and food allergens in subjects exposed to different respiratory allergen loads. Methods: A cross-sectional analysis was conducted in 340 adults of the EGEA(Epidemiological study of the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy) (170 with and 170 without asthma) cohort. IgE and IgG responses to 47 inhalant and food allergen components were analyzed in sera using allergen microarray and compared between 5 French regions according to the route of allergen exposure (inhaled vs food allergens). Results: Overall 48.8% of the population had allergen-specific IgE levels of 0.3 ISAC standardized units (ISU) or more to at least 1 of the 47 allergens with no significant differences across the regions. For ubiquitous respiratory allergens (ie, grass, olive/ash pollen, house dust mites), specific IgE did not show marked differences between regions and specific IgG (>= 0.5 ISU) was present in most subjects everywhere. For regionally occurring pollen allergens (ragweed, birch, cypress), IgE sensitization was significantly associated with regional pollen exposure. For airborne allergens cross-reacting with food allergens, frequent IgG recognition was observed even in regions with low allergen prevalence (Bet v 1) or for allergens less frequently recognized by IgE (profilins). Conclusions: The variability in allergen-specific IgE and IgG frequencies depends on exposure, route of exposure, and overall immunogenicity of the allergen. Allergen contact by the oral route might preferentially induce IgG responses.	[Siroux, Valerie] Univ Grenoble Alpes, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France; [Siroux, Valerie; Pin, Isabelle] Team Environm Epidemiol Appl Reprod & Resp Hlth, IAB, INSERM, Grenoble, France; [Siroux, Valerie; Pin, Isabelle] CHU Grenoble, Team Environm Epidemiol Appl Reprod & Resp Hlth, IAB, Grenoble, France; [Lupinek, Christian; Resch, Yvonne; Curin, Mirela; Kiss, Renata; Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Just, Jocelyne] Hop Armand Trousseau, AP HP, Dept Allergol, Paris, France; [Just, Jocelyne] Univ Paris 6 Pierre & Marie Curie, Paris, France; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Carlsen, Karin Lodrup; Melen, Erik] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Karin Lodrup; Skrindo, Ingebjorg] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Wickman, Magnus] Sachs Children & Youth Hosp, Stockholm, Sweden; [Nadif, Rachel; Wickman, Magnus; Bousquet, Jean] VIMA, INSERM U1168, Villejuif, France; [Nadif, Rachel; Bousquet, Jean] Univ Versailles St Quentin En Yvelines, Montigny Le Bretonneux;, France; [Skrindo, Ingebjorg] Akershus Univ Hosp, Dept Otorhinolaryngol, Lorenskog, Denmark; [Vrtala, Susanne] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Dev Allergen Chips, Vienna, Austria; [Anto, Josep Maria] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, Josep Maria] Hosp del Mar Med Res Inst IMIM, Barcelona, Spain; [Anto, Josep Maria] Univ Pompeu Fabra UPF, Barcelona, Spain; [Anto, Josep Maria] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Bousquet, Jean] Univ Hosp, Montpellier, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Medical University of Vienna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Oslo; University of Oslo; Karolinska Institutet; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Medical University of Vienna; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universite de Montpellier; CHU de Montpellier	Siroux, V (corresponding author), Ctr Rech UGA, Inst Adv Biosci, Inserm U1209, CNRS UMR 5309, Site Sante,Allee Alpes, F-38700 La Tronche, France.	Valerie.siroux@univ-grenoble-alpes.fr	PIN, Isabelle/N-3020-2013; siroux, valerie/N-1865-2013; Bousquet, Jean/O-4221-2019; Nadif, Rachel/R-2876-2016; Anto, J M/H-2676-2014; Lupinek, Christian/I-3311-2019	siroux, valerie/0000-0001-7329-7237; Nadif, Rachel/0000-0003-4938-9339; Anto, J M/0000-0002-4736-8529; Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365; Resch, Yvonne/0000-0002-7933-2547; Vrtala, Susanne/0000-0003-4250-8243; Bousquet, Jean/0000-0002-4061-4766; Curin, Mirela/0000-0003-2575-4127	Inserm Aviesan Itmo sante publique; Scientific committee "AGIR for chronic diseases,'' of the Austrian Science Fund (FWF [Fonds zur Forderung der wissenschaftlichen Forschung]) [F4605]; European Commission [261357]	Inserm Aviesan Itmo sante publique; Scientific committee "AGIR for chronic diseases,'' of the Austrian Science Fund (FWF [Fonds zur Forderung der wissenschaftlichen Forschung])(Austrian Science Fund (FWF)); European Commission(European CommissionEuropean Commission Joint Research Centre)	The study was supported in part by Inserm Aviesan Itmo sante publique, the Scientific committee "AGIR for chronic diseases,'' grant F4605 of the Austrian Science Fund (FWF [Fonds zur Forderung der wissenschaftlichen Forschung]) to R.V. and by the European Commission's Seventh Framework 29 Program MeDALL under grant agreement no. 261357.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Armstrong BG, 1998, OCCUP ENVIRON MED, V55, P651, DOI 10.1136/oem.55.10.651; Banerjee S, 2015, J INVEST DERMATOL, V135, P102, DOI 10.1038/jid.2014.271; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Braza F, 2014, ALLERGY, V69, P1454, DOI 10.1111/all.12490; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Castro L, 2014, INT ARCH ALLERGY IMM, V163, P142, DOI 10.1159/000356345; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Douladiris N, 2013, INT ARCH ALLERGY IMM, V162, P65, DOI 10.1159/000353113; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Erwin EA, 2014, ANN ALLERG ASTHMA IM, V112, P545, DOI 10.1016/j.anai.2014.03.007; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hofmaier S, 2014, EUR ANN ALLERGY CLIN, V46, P6; Hofmaier S, 2015, J ALLERGY CLIN IMMUN, V135, P1367, DOI 10.1016/j.jaci.2014.09.048; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; KAUFFMANN F, 1995, CLIN EXP ALLERGY, V25, P19, DOI 10.1111/j.1365-2222.1995.tb00413.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Palomares O, 2006, INT ARCH ALLERGY IMM, V141, P110, DOI 10.1159/000094713; Panzner P, 2014, INT ARCH ALLERGY IMM, V164, P74, DOI 10.1159/000362760; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Siroux V, 2009, J ALLERGY CLIN IMMUN, V124, P681, DOI 10.1016/j.jaci.2009.06.010; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Thibaudon M, 2002, Allerg Immunol (Paris), V34, P154; Thibaudon M., 2003, ALLERG IMMUNOL PARIS, V35, P170; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vrtala S, 1998, J IMMUNOL, V160, P6137; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Wollmann E, 2015, ALLERGY, V70, P638, DOI 10.1111/all.12592; Yamagiwa M, 2002, AURIS NASUS LARYNX, V29, P261, DOI 10.1016/S0385-8146(02)00007-X	40	43	44	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					643	+		10.1016/j.jaci.2016.05.023	http://dx.doi.org/10.1016/j.jaci.2016.05.023			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27464960	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000397002400030
J	Perkin, MR; Craven, J; Logan, K; Strachan, D; Marrs, T; Radulovic, S; Campbell, LE; MacCallum, SF; McLean, WHI; Lack, G; Flohr, C				Perkin, Michael R.; Craven, Joanna; Logan, Kirsty; Strachan, David; Marrs, Tom; Radulovic, Suzana; Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin; Lack, Gideon; Flohr, Carsten		Enquiring About Tolerance Study Te	Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A population-based cross-sectional study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Filaggrin; eczema; atopic dermatitis; transepidermal water loss; water hardness	ECZEMA; DISEASE; SKIN; PREVALENCE; FILAGGRIN; SEVERITY; BARRIER	Background: Domestic water hardness and chlorine have been suggested as important risk factors for atopic dermatitis (AD). Objective: We sought to examine the link between domestic water calcium carbonate (CaCO3) and chlorine concentrations, skin barrier dysfunction (increased transepidermal water loss), and AD in infancy. Methods: We recruited 1303 three-month-old infants from the general population and gathered data on domestic water CaCO3 (in milligrams per liter) and chlorine (Cl-2; in milligrams per liter) concentrations from local water suppliers. At enrollment, infants were examined for AD and screened for filaggrin (FLG) skin barrier gene mutation status. Transepidermal water loss was measured on unaffected forearm skin. Results: CaCO3 and chlorine levels were strongly correlated. A hybrid variable of greater than and less than median levels of CaCO3 and total chlorine was constructed: a baseline group of low CaCO3/low total chlorine (CaL/ClL), high CaCO3/low total chlorine (CaH/ClL), low CaCO3/high total chlorine (CaL/ClH) and high CaCO3/high total chlorine (CaH/ClH). Visible AD was more common in all 3 groups versus the baseline group: adjusted odds ratio (AOR) of 1.87 (95% CI, 1.25-2.80; P = .002) for the CaH/ClL group, AOR of 1.46 (95% CI, 0.97-2.21; P = .07) for the CaL/ClH, and AOR of 1.61 (95% CI, 1.09-2.38; P = .02) for the CaH/ClH group. The effect estimates were greater in children carrying FLG mutations, but formal interaction testing between water quality groups and filaggrin status was not statistically significant. Conclusions: High domestic water CaCO3 levels are associated with an increased risk of AD in infancy. The influence of increased total chlorine levels remains uncertain. An intervention trial is required to see whether installation of a domestic device to decrease CaCO3 levels around the time of birth can reduce this risk.	[Perkin, Michael R.; Strachan, David] St Georges Univ London, Populat Hlth Res Inst, London, England; [Craven, Joanna; Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Lack, Gideon; Flohr, Carsten] Kings Coll London, Childrens Allergies Dept, Div Asthma Allergy & Lung Biol, London, England; [Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin] Univ Dundee, Ctr Dermatol & Genet Med, Div Mol Med, Dundee, Scotland; [Flohr, Carsten] Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England	St Georges University London; University of London; King's College London; University of Dundee; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Flohr, C (corresponding author), Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, Unit Populat Based Dermatol Res, London, England.; Flohr, C (corresponding author), Kings Coll London, London, England.	carsten.flohr@kcl.ac.uk	Perkin, Michael/AID-7491-2022	Lack, Gideon/0000-0001-7350-4021; Tonner, Sharon/0000-0002-7775-9926; Perkin, Michael/0000-0001-9272-2585	UK Food Standards Agency (FSA) [T07051]; Medical Research Council (MRC); UK National Institute for Health Research (NIHR); NIHR Clinician Scientist Award [NIHRCS/01/2008/009]; MRC [MC_G1001205, G0700314] Funding Source: UKRI; Medical Research Council [MC_G1001205, MC_PC_15020, G0700314] Funding Source: researchfish; National Institute for Health Research [CS/08/08/09] Funding Source: researchfish; British Skin Foundation [5047i] Funding Source: researchfish	UK Food Standards Agency (FSA); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Clinician Scientist Award; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); British Skin Foundation	The main components of the Enquiring About Tolerance (EAT) Study are jointly funded by the UK Food Standards Agency (FSA; grant code T07051) and the Medical Research Council (MRC). The skin-related aspects of the study are supported by the UK National Institute for Health Research (NIHR). C.F. holds a NIHR Clinician Scientist Award (NIHRCS/01/2008/009). The views expressed in this publication are those of the authors and not necessarily those of the FSA, MRC, the NHS, the NIHR, the Wellcome Trust, or the UK Department of Health.	Arnedo-Pena A, 2007, SALUD PUBLICA MEXICO, V49, P295, DOI 10.1590/S0036-36342007000400009; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Danby S, 2011, HARPERS TXB PEDIAT D; Ewence A, 2011, REV SKIN IRRITATION; Farahmand S, 2009, SKIN RES TECHNOL, V15, P392, DOI 10.1111/j.1600-0846.2009.00376.x; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Getis A, 1997, DEV SPATIAL ANAL SPA; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; McNally NJ, 1998, LANCET, V352, P527, DOI 10.1016/S0140-6736(98)01402-0; Miyake Y, 2004, ENVIRON RES, V94, P33, DOI 10.1016/S0013-9351(03)00068-9; Office for National Statistics, 2011, 2011 CENS AGGR DAT E; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V137, P1477, DOI 10.1016/j.jaci.2015.12.1322; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Taylor-Robinson DC, 2016, BRIT J DERMATOL, V174, P569, DOI 10.1111/bjd.14310; Thomas KS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000395; Tu CL, 2013, BEST PRACT RES CL EN, V27, P415, DOI 10.1016/j.beem.2013.03.002; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WILSON D, 1988, BRIT J DERMATOL, V119, P647, DOI 10.1111/j.1365-2133.1988.tb03478.x	21	43	46	9	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					509	516		10.1016/j.jaci.2016.03.031	http://dx.doi.org/10.1016/j.jaci.2016.03.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27241890	Green Submitted, Bronze, Green Accepted			2022-12-18	WOS:000380835800022
J	Bunyavanich, S; Rifas-Shiman, SL; Platts-Mills, TA; Workman, L; Sordillo, JE; Camargo, CA; Gillman, MW; Gold, DR; Litonjua, AA				Bunyavanich, Supinda; Rifas-Shiman, Sheryl L.; Platts-Mills, Thomas A.; Workman, Lisa; Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.			Prenatal, perinatal, and childhood vitamin D exposure and their association with childhood allergic rhinitis and allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; vitamin D; atopy; prenatal; perinatal; childhood; sensitization; food; supplement; allergy	25-HYDROXYVITAMIN D; PREGNANT-WOMEN; MID-PREGNANCY; ASTHMA; DISEASE; DIETARY; CHILDREN; BIRTH; RISK; AGE	Background: The role of early-life vitamin D in childhood allergy is controversial. Objective: We sought to assess vitamin D exposure in early life by multiple modalities and ascertain its association with childhood allergic rhinitis and allergic sensitization. Methods: One thousand two hundred forty-eight mother-child pairs from a US prebirth cohort unselected for any disease were studied. Vitamin D exposure was assessed by measures of maternal intake during the first and second trimesters of pregnancy and serum 25-hydroxyvitamin D (25[OH]D) levels in mothers during pregnancy, cord blood, and children at school age (median age, 7.7 years; interquartile range, 1.0 years). Tests for associations between vitamin D exposure with ever allergic rhinitis, serum total IgE level, and allergen sensitization at school age were conducted. Results: The correlations between maternal intake of vitamin D during pregnancy and serum 25(OH)D levels in pregnant mothers, cord blood, and children at school age were weak to moderate (r = -0.03 to 0.53). Each 100 IU/d of food-based vitamin D intake during the first and second trimesters (equivalent to the amount of vitamin D in an 8-ounce serving of milk) was associated with 21% and 20% reduced odds of ever allergic rhinitis at school age (odds ratios of 0.79 [95% CI, 0.67-0.92] and 0.80 [95% CI, 0.68-0.93]), respectively. There were no associations between maternal supplemental vitamin D intake or serum 25(OH)D levels at any time point with ever allergic rhinitis. There were no associations between any vitamin D exposure and serum total IgE level or allergen sensitization at school age. Conclusions: Inclusion of foods containing vitamin D in maternal diets during pregnancy may have beneficial effects on childhood allergic rhinitis.	[Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, One Gustave L Levy Pl 1198, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, One Gustave L Levy Pl 1198, New York, NY 10029 USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Platts-Mills, Thomas A.; Workman, Lisa] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Sordillo, Joanne E.; Camargo, Carlos A., Jr.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl 1198, New York, NY 10029 USA.	supinda@post.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [AI093538, AI118833, HL61907, HL64925, HD34568, AI35786, HL68041, HL007427]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R37HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL089990, R01HL064925, R01HL061907, T32HL007427, K24HL068041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960, R56AI035786, R01AI118833, R01AI020565, K08AI093538, R01AI035786] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (AI093538, AI118833, HL61907, HL64925, HD34568, AI35786, HL68041, and HL007427).	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bacharier LB, 2014, J ALLERGY CLIN IMMUN, V133, P154, DOI 10.1016/j.jaci.2013.07.034; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Burris HH, 2014, ANN EPIDEMIOL, V24, P399, DOI 10.1016/j.annepidem.2014.02.001; Burris HH, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.05.022; Burris HH, 2012, ANN EPIDEMIOL, V22, P581, DOI 10.1016/j.annepidem.2012.04.015; Centers for Disease Control and Prevention, 2011, LIF ASTHM PREV PERC; Chawes BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099856; Cheng HM, 2014, J ALLERGY CLIN IMMUN, V133, P1048, DOI 10.1016/j.jaci.2013.10.055; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Ersfeld DL, 2004, CLIN BIOCHEM, V37, P867, DOI 10.1016/j.clinbiochem.2004.06.006; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Hollis BW, 2013, J CLIN ENDOCR METAB, V98, P4619, DOI 10.1210/jc.2013-2653; HOLLIS BW, 1993, CLIN CHEM, V39, P529; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Jacobs DR, 2013, P NUTR SOC, V72, P200, DOI 10.1017/S0029665112003011; Maslova E, 2014, PEDIAT ALLERG IMM-UK, V25, P706, DOI 10.1111/pai.12295; Maslova E, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-199; Mirzakhani H, 2015, CLIN EXP ALLERGY, V45, P114, DOI 10.1111/cea.12430; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Oken E, 2003, OBSTET GYNECOL, V102, P346, DOI 10.1016/S0029-7844(03)00484-8; Rifas-Shiman SL, 2006, PAEDIATR PERINAT EP, V20, P35, DOI 10.1111/j.1365-3016.2006.00691.x; Rogers I, 1998, EUR J CLIN NUTR, V52, P246, DOI 10.1038/sj.ejcn.1600543; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1016/J.JACI.2011.07.015; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Taylor CL, 2014, J NUTR, V144, P654, DOI 10.3945/jn.113.189811; Tricon S., 2006, Clinical and Experimental Allergy Reviews, V6, P117, DOI 10.1111/j.1365-2222.2006.00114.x; U.S. Bureau of the Census, 2013, CURR POP SURV; Vitamin D, 2014, FACT SHEET HLTH PROF; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Wawro N, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0286-3; Willett W., 2013, NUTR EPIDEMIOLOGY, DOI DOI 10.1093/ACPROF:OSO/9780199754038.001.0001; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x; Yao TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099105	43	43	44	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1063	+		10.1016/j.jaci.2015.11.031	http://dx.doi.org/10.1016/j.jaci.2015.11.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26874366	Green Accepted			2022-12-18	WOS:000373351200012
J	Fellmann, F; Angelini, F; Wassenberg, J; Perreau, M; Ramirez, NA; Simon, G; Boyman, O; Demaria, O; Christen-Zaech, S; Hohl, D; Belfiore, M; von Scheven-Gete, A; Gilliet, M; Bochud, PY; Perrin, Y; Popovic, MB; Bart, PA; Beckmann, JS; Martinet, D; Hofer, M				Fellmann, Florence; Angelini, Federica; Wassenberg, Jacqueline; Perreau, Matthieu; Ramirez, Natalia Arenas; Simon, Gregoire; Boyman, Onur; Demaria, Olivier; Christen-Zaech, Stephanie; Hohl, Daniel; Belfiore, Marco; von Scheven-Gete, Annette; Gilliet, Michel; Bochud, Pierre-Yves; Perrin, Yannick; Popovic, Maya Beck; Bart, Pierre-Alexandre; Beckmann, Jacques S.; Martinet, Danielle; Hofer, Michael			IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adenosine deaminase 2; chronic inflammation; chronic mucocutaneous candidiasis; CECR1; immunodeficiency; IL17RA; vasculitis; whole-genome analyses	T-HELPER-CELLS; TH17 CELLS; FAMILY; ADA2; INTERLEUKIN-1-BETA; DIFFERENTIATION; VASCULOPATHY; CANDIDIASIS	Background: Data on patients affected by chronic mucocutaneous candidiasis underscore the preponderant role of IL-17 receptor A (IL-17RA) in preserving mucocutaneous immunity. Little is known about the role of adenosine deaminase (ADA) 2 in regulation of immune responses, although recent reports linked ADA2 deficiency with inflammation and vasculitis. Objective: We sought to investigate the mechanisms of chronic inflammation and vasculitis in a child lacking IL-17RA and ADA2 to identify therapeutic targets. Methods: We report a family with 2 siblings who have had recurrent mucocutaneous infections with Candida albicans and Staphylococcus aureus and chronic inflammatory disease and vasculitis since early childhood, which were refractory to classical treatments. Array-based comparative genomic hybridization analysis showed that both siblings are homozygous for a 770-kb deletion on chr22q11.1 encompassing both IL17RA and cat eye critical region 1 (CECR1). Immunologic studies were carried out by means of flow cytometry, ELISA, and RIA. Results: As expected, in the affected child we found a lack of IL-17RA expression, which implies a severe malfunction in the IL-17 signaling pathway, conferring susceptibility to recurrent mucocutaneous infections. Surprisingly, we detected an in vitro and in vivo upregulation of proinflammatory cytokines, notably IL-1 beta and TNF-alpha, which is consistent with the persistent systemic inflammation. Conclusions: This work emphasizes the utility of whole-genome analyses combined with immunologic investigation in patients with unresolved immunodeficiency. This approach is likely to provide an insight into immunologic pathways and mechanisms of disease. It also provides molecular evidence for more targeted therapies. In addition, our report further corroborates a potential role of ADA2 in modulating immunity and inflammation.	[Fellmann, Florence; Belfiore, Marco; Beckmann, Jacques S.; Martinet, Danielle] Univ Lausanne Hosp, Serv Med Genet, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Angelini, Federica; Wassenberg, Jacqueline; von Scheven-Gete, Annette; Perrin, Yannick; Hofer, Michael] Univ Lausanne Hosp, Dept Pediat, Immunol Allergol & Rheumatol Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Perreau, Matthieu; Bart, Pierre-Alexandre] Univ Lausanne Hosp, Dept Med, Immunol & Allergy Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Simon, Gregoire] Univ Lausanne Hosp, Rheumatol Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Demaria, Olivier; Christen-Zaech, Stephanie; Hohl, Daniel; Gilliet, Michel] Univ Lausanne Hosp, Dept Dermatol, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Bochud, Pierre-Yves] Univ Lausanne Hosp, Dept Med, Infect Dis Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Popovic, Maya Beck] Univ Lausanne Hosp, Dept Pediat, Hematol Oncol Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland; [Ramirez, Natalia Arenas; Boyman, Onur] Univ Zurich Hosp, Dept Immunol, CH-8091 Zurich, Switzerland; [Beckmann, Jacques S.] Swiss Inst Bioinformat, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich; University Zurich Hospital; Swiss Institute of Bioinformatics	Hofer, M (corresponding author), Univ Lausanne Hosp, Dept Pediat, Immunol Allergol & Rheumatol Unit, Rue Bugnon 21, CH-1011 Lausanne, Switzerland.	Michael.Hofer@chuv.ch	Beckmann, Jacques S/A-9772-2008; Hohl, Daniel M/N-7554-2016; Perreau, Matthieu/D-6309-2017; Bochud, Pierre-Yves/ABE-5979-2020	Beckmann, Jacques S/0000-0002-9741-1900; Bochud, Pierre-Yves/0000-0002-2208-4757; Arenas-Ramirez, Natalia/0000-0003-4415-5605; Boyman, Onur/0000-0001-8279-5545; Fellmann, Florence/0000-0003-3156-4768	SNF [PP00P3-128421]; Zurich Integrative Human Physiology (ZIHP) cooperative project grant	SNF; Zurich Integrative Human Physiology (ZIHP) cooperative project grant	Supported by SNF grant PP00P3-128421 and a Zurich Integrative Human Physiology (ZIHP) cooperative project grant (both to O.B.).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Alcais A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/j.1749-6632.2010.05834.x; Bouchaud G, 2013, J EXP MED, V210, P2105, DOI 10.1084/jem.20130291; Calenda G, 2006, GENE, V370, P6, DOI 10.1016/j.gene.2005.10.037; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; Hershfield M, 1993, GENEREVIEWS R; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kolly L, 2013, J ALLERGY CLIN IMMUN, V131, P1635, DOI 10.1016/j.jaci.2012.07.043; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Lasiglie D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020014; Leipe J, 2010, ARTHRITIS RHEUM-US, V62, P2876, DOI 10.1002/art.27622; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; NOTARANGELO LD, 1992, EUR J PEDIATR, V151, P811, DOI 10.1007/BF01957930; Ozsahin H, 1997, BLOOD, V89, P2849, DOI 10.1182/blood.V89.8.2849; Perreau M, 2011, J VIROL, V85, P9854, DOI 10.1128/JVI.00788-11; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Sauer AV, 2009, BLOOD, V114, P3216, DOI 10.1182/blood-2009-03-209221; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zavialov AV, 2010, J LEUKOCYTE BIOL, V88, P279, DOI 10.1189/jlb.1109764; Zavialov AV, 2010, J BIOL CHEM, V285, P12367, DOI 10.1074/jbc.M109.083527; Zavialov AV, 2005, BIOCHEM J, V391, P51, DOI 10.1042/BJ20050683; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	27	43	46	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1189	+		10.1016/j.jaci.2015.07.053	http://dx.doi.org/10.1016/j.jaci.2015.07.053			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26607704	Bronze			2022-12-18	WOS:000373351200026
J	Lerondeau, B; Trechot, P; Waton, J; Poreaux, C; Luc, A; Schmutz, JL; Paris, C; Barbaud, A				Lerondeau, Berangere; Trechot, Philippe; Waton, Julie; Poreaux, Claire; Luc, Amandine; Schmutz, Jean-Luc; Paris, Christophe; Barbaud, Annick			Analysis of cross-reactivity among radiocontrast media in 97 hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONTRAST-MEDIA; SKIN-TESTS; IODIXANOL		[Lerondeau, Berangere; Waton, Julie; Poreaux, Claire; Schmutz, Jean-Luc; Barbaud, Annick] Univ Hosp Nancy, Brabois Hosp, Dermatol & Allergy Dept, Vandoeuvre Les Nancy, France; [Trechot, Philippe] Univ Hosp Nancy, Pharmacol Toxicol Unit, Rue Lionnois, Nancy, France; [Waton, Julie; Luc, Amandine; Schmutz, Jean-Luc; Paris, Christophe; Barbaud, Annick] Lorraine Univ, Res Unit EA INGRES 72 98, Nancy, France	CHU de Nancy; Universite de Lorraine; CHU de Nancy; Universite de Lorraine; Universite de Lorraine	Barbaud, A (corresponding author), Univ Hosp Nancy, Brabois Hosp, Dermatol & Allergy Dept, Vandoeuvre Les Nancy, France.; Barbaud, A (corresponding author), Lorraine Univ, Res Unit EA INGRES 72 98, Nancy, France.	a.barbaud@chu-nancy.fr	, barbaud/AAZ-7250-2021					Akiyama M, 1998, ACAD RADIOL, V5, pS159, DOI 10.1016/S1076-6332(98)80092-5; Antunez C, 2011, CLIN EXP ALLERGY, V41, P657, DOI 10.1111/j.1365-2222.2010.03693.x; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Brockow K, 2005, TOXICOLOGY, V209, P189, DOI 10.1016/j.tox.2004.12.032; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Hasdenteufel F, 2011, J ALLERGY CLIN IMMUN, V128, P1356, DOI 10.1016/j.jaci.2011.05.034; Lebart L, 1984, MULTIVARIATE DESCRIP, pxvi; Pasternak JJ, 2012, MAYO CLIN PROC, V87, P390, DOI 10.1016/j.mayocp.2012.01.012; Scherer K, 2010, CLIN EXP ALLERGY, V40, P468, DOI 10.1111/j.1365-2222.2009.03361.x; Torres MJ, 2012, ALLERGY, V67, P929, DOI 10.1111/j.1398-9995.2012.02840.x; Vernassiere C, 2004, CONTACT DERMATITIS, V50, P359, DOI 10.1111/j.0105-1873.2004.00367.x	11	43	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					633	+		10.1016/j.jaci.2015.07.035	http://dx.doi.org/10.1016/j.jaci.2015.07.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26428955	Bronze			2022-12-18	WOS:000369235500041
J	de Diego, RP; Sanchez-Ramon, S; Lopez-Collazo, E; Martinez-Barricarte, R; Cubillos-Zapata, C; Cerdan, AF; Casanova, JL; Puel, A				Perez de Diego, Rebeca; Sanchez-Ramon, Silvia; Lopez-Collazo, Eduardo; Martinez-Barricarte, Ruben; Cubillos-Zapata, Carolina; Ferreira Cerdan, Antonio; Casanova, Jean-Laurent; Puel, Anne			Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primaryimmunodeficiency; combined immunodeficiency; B-cell lymphoma 10; mucosa-associated lymphoid tissue lymphoma-translocation gene 1; CARMA1; caspase recruitment domain 9	NF-KAPPA-B; INHERITED CARD9 DEFICIENCY; COMBINED IMMUNODEFICIENCY; INDUCED ACTIVATION; IMMUNE-RESPONSES; RECEPTORS ENGAGE; MALT LYMPHOMA; T-CELL; BCL10; MUTATIONS	Three members of the caspase recruitment domain (CARD) family of adaptors (CARD9, CARD10, and CARD11) are known to form heterotrimers with B-cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (MALT1). These 3 CARD-BCL10-MALT1 (CBM) complexes activate nuclear factor kappa B in both the innate and adaptive arms of immunity. Human inherited defects of the 3 components of the CBM complex, including the 2 adaptors CARD9 and CARD11 and the 2 core components BCL10 and MALT1, have recently been reported. Biallelic loss-of-function mutant alleles underlie several different immunologic and clinical phenotypes, which can be assigned to 2 distinct categories. Isolated invasive fungal infections of unclear cellular basis are associated with CARD9 deficiency, whereas a broad range of clinical manifestations, including those characteristic of T-and B-lymphocyte defects, are associated with CARD11, MALT1, and BCL10 deficiencies. Interestingly, human subjects corresponding knockout mice, but other features are different between human subjects and mice. Moreover, germline and somatic gain-of-function mutations of MALT1, BCL10, and CARD11 have also been found in patients with other lymphoproliferative disorders. This broad range of germline and somatic CBM lesions, including loss-of-function and gain-of-function mutations, highlights the contribution of each of the components of the CBM complex to human immunity.	[Perez de Diego, Rebeca] La Paz Univ Hosp, IdiPAZ Inst Hlth Res, Lab Immunogenet Dis, Paseo Castellana 261, Madrid 28046, Spain; [Perez de Diego, Rebeca; Lopez-Collazo, Eduardo; Cubillos-Zapata, Carolina] La Paz Univ Hosp, IdiPAZ Inst Hlth Res, Innate Immun Grp, Madrid 28046, Spain; [Lopez-Collazo, Eduardo; Cubillos-Zapata, Carolina] La Paz Univ Hosp, IdiPAZ Inst Hlth Res, Lab Tumor Immunol, Madrid 28046, Spain; [Sanchez-Ramon, Silvia] San Carlos Clin Hosp, Dept Clin Immunol, Madrid, Spain; [Martinez-Barricarte, Ruben; Casanova, Jean-Laurent; Puel, Anne] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Ferreira Cerdan, Antonio] La Paz Univ Hosp, Immunol Unit, Madrid 28046, Spain; [Casanova, Jean-Laurent; Puel, Anne] Necker Hosp Sick Children, AP HP, INSERM, Lab Human Genet Infect Dis,Necker Branch,U1163, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol Immunol Unit, Paris, France; [Casanova, Jean-Laurent; Puel, Anne] Univ Paris 05, Imagine Inst, Paris, France	Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz; Rockefeller University; Howard Hughes Medical Institute; Hospital Universitario La Paz; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	de Diego, RP (corresponding author), La Paz Univ Hosp, IdiPAZ Inst Hlth Res, Lab Immunogenet Dis, Paseo Castellana 261, Madrid 28046, Spain.	rebeca.perez@idipaz.es	Sanchez-Ramon, Silvia/I-8242-2019; Barricarte, Ruben Martinez/W-8695-2019; Zapata, Carolina Cubillos/H-3058-2017; Casanova, Jean-Laurent/I-3418-2017; Sanchez-Ramon, Silvia/AAZ-7670-2020; Puel, Anne/H-7305-2017; Lopez-Collazo, Eduardo/U-6634-2018	Sanchez-Ramon, Silvia/0000-0001-9585-6167; Barricarte, Ruben Martinez/0000-0001-7925-449X; Zapata, Carolina Cubillos/0000-0002-1948-4514; Sanchez-Ramon, Silvia/0000-0001-9585-6167; Puel, Anne/0000-0003-2603-0323; Sanchez, Silvia/0000-0002-6405-1443; Perez de Diego, Rebeca/0000-0001-8426-8765; Casanova, Jean-Laurent/0000-0002-7782-4169; Lopez-Collazo, Eduardo/0000-0003-1957-877X	Ramon Areces Foundation, grant XVII Concurso Nacional de Ayudas a la Investigacion; FIS grant [PI14/00616]; St. Giles Foundation; Rockefeller University; Jeffrey Modell Foundation; Institut National de la Sante et de la Recherche Medicale, University Paris Descartes; French National Research Agency (ANR) under the "Investments for the future'' program [ANR-10-IAHU-01]; National Center for Research Resources [8 UL1 TR000043]; National Center for Advancing Sciences (NCATS), National Institutes of Health; EMBO long-term fellowship; "Ramon y Cajal'' program (MINECO, Spain) [RYC-2011-07597]; EMBO short-term fellowship ASTF [119-2013]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089970, R01AI088364, P01AI061093] Funding Source: NIH RePORTER	Ramon Areces Foundation, grant XVII Concurso Nacional de Ayudas a la Investigacion; FIS grant; St. Giles Foundation; Rockefeller University; Jeffrey Modell Foundation; Institut National de la Sante et de la Recherche Medicale, University Paris Descartes(Institut National de la Sante et de la Recherche Medicale (Inserm)); French National Research Agency (ANR) under the "Investments for the future'' program(French National Research Agency (ANR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Sciences (NCATS), National Institutes of Health; EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); "Ramon y Cajal'' program (MINECO, Spain); EMBO short-term fellowship ASTF(European Molecular Biology Organization (EMBO)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Ramon Areces Foundation, grant XVII Concurso Nacional de Ayudas a la Investigacion; FIS grant reference PI14/00616; the St. Giles Foundation, Rockefeller University; the Jeffrey Modell Foundation; Institut National de la Sante et de la Recherche Medicale, University Paris Descartes, the French National Research Agency (ANR) under the "Investments for the future'' program (grant no. ANR-10-IAHU-01); and grant 8 UL1 TR000043 from the National Center for Research Resources and the National Center for Advancing Sciences (NCATS), National Institutes of Health. R.M.B. is supported by an EMBO long-term fellowship. R.P.D. is supported by the "Ramon y Cajal'' program (MINECO, Spain; no. RYC-2011-07597) and EMBO short-term fellowship ASTF no. 119-2013.	Bhattacharyya S, 2008, AM J PHYSIOL-GASTR L, V295, pG784, DOI 10.1152/ajpgi.90434.2008; Bhattacharyya S, 2008, J BIOL CHEM, V283, P10550, DOI 10.1074/jbc.M708833200; Bhattacharyya S, 2007, AM J PHYSIOL-GASTR L, V293, pG429, DOI 10.1152/ajpgi.00149.2007; Bhattacharyya S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/397642; Bhattacharyya S, 2010, J BIOL CHEM, V285, P39511, DOI 10.1074/jbc.M110.159681; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Borthakur A, 2007, AM J PHYSIOL-GASTR L, V292, pG829, DOI 10.1152/ajpgi.00380.2006; Boyle RJ, 2006, CLIN EXP IMMUNOL, V146, P486, DOI 10.1111/j.1365-2249.2006.03242.x; Brohl AS, 2015, J CLIN IMMUNOL, V35, P32, DOI 10.1007/s10875-014-0106-4; Caruana G, 2002, INT J DEV BIOL, V46, P511; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Casanova JL, 2013, ANNU REV GENOM HUM G, V14, P215, DOI 10.1146/annurev-genom-091212-153448; Chan WP, 2013, MOL CELL BIOL, V33, P429, DOI 10.1128/MCB.00850-12; Dong GH, 2011, CLIN CANCER RES, V17, P1440, DOI 10.1158/1078-0432.CCR-10-1859; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Ferch U, 2009, J EXP MED, V206, P2313, DOI 10.1084/jem.20091167; Fischer KD, 2004, TRENDS IMMUNOL, V25, P113, DOI 10.1016/j.it.2003.12.007; Gavino C, 2014, CLIN INFECT DIS, V59, P81, DOI 10.1093/cid/ciu215; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Gringhuis SI, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001259; Gross O, 2008, BLOOD, V112, P2421, DOI 10.1182/blood-2007-11-123513; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hara H, 2009, TRENDS IMMUNOL, V30, P234, DOI 10.1016/j.it.2009.03.002; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jachiet M, 2015, JAMA DERMATOL, V151, P192, DOI 10.1001/jamadermatol.2014.2154; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Lamason RL, 2010, MOL CELL, V40, P798, DOI 10.1016/j.molcel.2010.11.007; Lanternier F, 2015, J ALLERGY CLIN IMMUN, V135, P1558, DOI 10.1016/j.jaci.2014.12.1930; Lanternier F, 2015, J INFECT DIS, V211, P1241, DOI 10.1093/infdis/jiu412; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Liu YL, 2004, J BIOL CHEM, V279, P37436, DOI 10.1074/jbc.M400241200; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Malarkannan S, 2007, J IMMUNOL, V179, P3752, DOI 10.4049/jimmunol.179.6.3752; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; Marion S, 2012, DEV CELL, V23, P954, DOI 10.1016/j.devcel.2012.09.021; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; McAllister-Lucas LM, 2010, J BIOL CHEM, V285, P25880, DOI 10.1074/jbc.C110.109421; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; Montesinos-Rongen M, 2010, ACTA NEUROPATHOL, V120, P529, DOI 10.1007/s00401-010-0709-7; Nakagawa M, 2006, LEUKEMIA, V20, P929, DOI 10.1038/sj.leu.2404192; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Shen LJ, 2003, BLOOD, V102, P1553, DOI 10.1182/blood-2003-04-1286; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Spencer J, 1999, GUT, V44, P778, DOI 10.1136/gut.44.6.778; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Strasser D, 2012, IMMUNITY, V36, P32, DOI 10.1016/j.immuni.2011.11.015; Tada R, 2009, IMMUNOL LETT, V123, P144, DOI 10.1016/j.imlet.2009.03.005; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Thome M, 2008, NAT REV IMMUNOL, V8, P495, DOI 10.1038/nri2338; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015; Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang XW, 2014, J ALLERGY CLIN IMMUN, V133, P905, DOI 10.1016/j.jaci.2013.09.033; Wegener Elmar, 2007, Sci STKE, V2007, ppe21, DOI 10.1126/stke.3842007pe21; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Xie CY, 2014, TUMOR BIOL, V35, P7957, DOI 10.1007/s13277-014-2070-2; Xu S, 2009, J BIOL CHEM, V284, P7038, DOI 10.1074/jbc.M806650200; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Ye Hongtao, 2006, Haematologica, V91, pECR28; Yu M, 2012, J IMMUNOL, V189, P5185, DOI 10.4049/jimmunol.1102952; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	76	43	44	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1139	1149		10.1016/j.jaci.2015.06.031	http://dx.doi.org/10.1016/j.jaci.2015.06.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26277595	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000364787200001
J	Bin, LH; Edwards, MG; Heiser, R; Streib, JE; Richers, B; Hall, CF; Leung, DYM				Bin, Lianghua; Edwards, Michael G.; Heiser, Ryan; Streib, Joanne E.; Richers, Brittany; Hall, Clifton F.; Leung, Donald Y. M.			Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema herpeticum; herpes simplex virus; interferon regulatory factor 3; interferon regulatory factor 7; type I interferon; type III interferon	SIMPLEX-VIRUS ENCEPHALITIS; TOLL-LIKE RECEPTOR-3; STAPHYLOCOCCUS-AUREUS; RNA-SEQ; INNATE; INTERFERONS; DEFICIENCY; ALPHA/BETA; IMMUNITY; REVEALS	Background: A subset of patients with atopic dermatitis (AD) is prone to disseminated herpes simplex virus (HSV) infection (ie, atopic dermatitis with a history of eczema herpeticum [ADEH+]). Biomarkers that identify ADEH+ are lacking. Objective: We sought to search for novel ADEH+ gene signatures in PBMCs. Methods: An RNA-sequencing approach was applied to evaluate global transcriptional changes by using PBMCs from patients with ADEH+ and patients with atopic dermatitis without a history of eczema herpeticum (ADEH-). Candidate genes were confirmed by means of quantitative PCR or ELISA. Results: PBMCs from patients with ADEH+ had distinct changes to the transcriptome when compared with those from patients with ADEH- after HSV-1 stimulation: 792 genes were differentially expressed at a false discovery rate of less than 0.05 (ANOVA), and 15 type I and type III interferon genes were among the top 20 most downregulated genes in patients with ADEH+. We further validated that IFN-alpha and IL-29 mRNA and protein levels were significantly decreased in HSV-1-stimulated PBMCs from patients with ADEH+ compared with those from patients with ADEH- and healthy subjects. Ingenuity Pathway Analysis demonstrated that the upstream regulators of type I and type III interferons, interferon regulatory factor (IRF) 3 and IRF7, were significantly inhibited in patients with ADEH+ based on the downregulation of their target genes. Furthermore, we found that gene expression of IRF3 and IRF7 was significantly decreased in HSV-1-stimulated PBMCs from patients with ADEH+. Conclusions: PBMCs from patients with ADEH+ have a distinct immune response after HSV-1 exposure compared with those from patients with ADEH-. Inhibition of the IRF3 and IRF7 innate immune pathways in patients with ADEH+ might be an important mechanism for increased susceptibility to disseminated viral infection.	[Bin, Lianghua; Heiser, Ryan; Streib, Joanne E.; Richers, Brittany; Hall, Clifton F.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Edwards, Michael G.] Univ Colorado Denver, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Leung, Donald Y. M.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA.	leungd@njhealth.org			National Institutes of Health/National Institute of Allergy and Infectious Disease Atopic Dermatitis Research Network [HHSN272 201000020C]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Disease Atopic Dermatitis Research Network; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was funded by National Institutes of Health/National Institute of Allergy and Infectious Disease Atopic Dermatitis Research Network contract HHSN272 201000020C.	Ank N, 2009, BIOFACTORS, V35, P82, DOI 10.1002/biof.19; Averbuch D, 2011, PEDIATR INFECT DIS J, V30, P352, DOI 10.1097/INF.0b013e3181fdff4a; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin L, 2011, J ALLERGY CLIN IMMUN, V127, pAB148, DOI 10.1016/j.jaci.2010.12.587; Bin LH, 2012, J ALLERGY CLIN IMMUN, V130, P683, DOI 10.1016/j.jaci.2012.06.019; Bin LH, 2011, J ALLERGY CLIN IMMUN, V127, P430, DOI 10.1016/j.jaci.2010.11.013; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Coleman JL, 2013, HUM VACC IMMUNOTHER, V9, P729, DOI 10.4161/hv.23289; de Diego RP, 2010, IMMUNITY, V33, P400, DOI 10.1016/j.immuni.2010.08.014; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Fensterl V, 2009, BIOFACTORS, V35, P14, DOI 10.1002/biof.6; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Halford WP, 1997, VIROLOGY, V236, P328, DOI 10.1006/viro.1997.8738; Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Keles S, 2014, J ALLERGY CLIN IMMUN, V133, P1753, DOI 10.1016/j.jaci.2014.03.032; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Leung DYM, 2013, ANTIVIR RES, V98, P153, DOI 10.1016/j.antiviral.2013.02.010; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Liesegang TJ, 1999, CORNEA, V18, P127, DOI 10.1097/00003226-199903000-00001; Lopusna K, 2013, ACTA VIROL, V57, P171, DOI 10.4149/av_2013_02_171; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Nagalakshmi Ugrappa, 2010, Curr Protoc Mol Biol, VChapter 4, DOI 10.1002/0471142727.mb0411s89; Nie Y, 2013, PROTEIN CELL, V4, P1, DOI 10.1007/s13238-012-2122-6; Papan C, 2014, J ALLERGY CLIN IMMUN, V133, P1456, DOI 10.1016/j.jaci.2014.02.008; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Sili U, 2014, J CLIN VIROL, V60, P112, DOI 10.1016/j.jcv.2014.03.010; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vollstedt S, 2004, J VIROL, V78, P3846, DOI 10.1128/JVI.78.8.3846-3850.2004; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Whitley RJ, 2002, J CLIN INVEST, V110, P145, DOI [10.1172/JCI200216126, 10.1172/JCI0216126]; Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9; Xiao TS, 2013, MOL CELL, V51, P135, DOI 10.1016/j.molcel.2013.07.004; Xing Y, 2006, NUCLEIC ACIDS RES, V34, P3150, DOI 10.1093/nar/gkl396; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhou L, 2011, J NEUROVIROL, V17, P212, DOI 10.1007/s13365-011-0031-8	51	43	44	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					848	855		10.1016/j.jaci.2014.07.018	http://dx.doi.org/10.1016/j.jaci.2014.07.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25159465	Green Accepted			2022-12-18	WOS:000343155700010
J	Melum, GR; Farkas, L; Scheel, C; Van Dieren, B; Gran, E; Liu, YJ; Johansen, FE; Jahnsen, FL; Baekkevold, ES				Melum, Guro R.; Farkas, Lorant; Scheel, Cecilie; Van Dieren, Brenda; Gran, Einar; Liu, Yong-Jun; Johansen, Finn-Eirik; Jahnsen, Frode L.; Baekkevold, Espen S.			A thymic stromal lymphopoietin-responsive dendritic cell subset mediates allergic responses in the upper airway mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; airway allergy; human airway mucosa; dendritic cells; CCR7	ANTIGEN-PRESENTING CELLS; MEMORY T-CELLS; EPITHELIAL-CELLS; NONALLERGIC INDIVIDUALS; FUNCTIONAL PLASTICITY; CUTTING EDGE; NASAL-MUCOSA; DISTINCT; INDUCE; T(H)2	Background: Thymic stromal lymphopoietin (TSLP) controls allergic T(H)2 inflammatory responses through induction of distinct activation programs in dendritic cells (DCs). However, knowledge about TSLP receptor expression and functional consequences of receptor activation by DCs residing in the human respiratory tract is limited. Objective: We wanted to identify TSLP-responding DC populations in the human upper airway mucosa and assess the TSLP-mediated effects on such DCs in allergic airway responses. Results: We found that the TSLP receptor was constitutively and preferentially expressed by myeloid CD1c(+) DCs in the human airway mucosa and that the density of this DC subset in nasal mucosa increased significantly after in vivo allergen challenge of patients with allergic rhinitis. In vitro, TSLP strongly enhanced the capacity of CD1c(+) DCs to activate allergen-specific memory CD4(+) T cells. Moreover, TSLP rapidly induced CCR7 expression on CD1c(+) DCs. However, T(H)2 cytokines attenuated TSLP-mediated CCR7 induction, thus inhibiting the TSLP-induced DC migration potential to the draining lymph nodes. Conclusion: Our results suggest that TSLP-mediated activation of human nasal mucosal CD1c(+) DCs triggers CCR7-dependent migration to the draining lymph nodes and enhances their capacity to initiate T(H)2 responses. However, the observation that T(H)2 cytokines abrogate the induction of CCR7 implies that during a T(H)2-mediated inflammatory reaction, TLSP-activated CD1c(+) DCs are retained in the inflamed tissue to further exacerbate local inflammation by activating local antigen-specific memory T(H)2 cells.	[Melum, Guro R.; Farkas, Lorant; Scheel, Cecilie; Van Dieren, Brenda; Johansen, Finn-Eirik; Jahnsen, Frode L.; Baekkevold, Espen S.] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Melum, Guro R.; Farkas, Lorant; Scheel, Cecilie; Van Dieren, Brenda; Johansen, Finn-Eirik; Jahnsen, Frode L.; Baekkevold, Espen S.] Univ Oslo, Dept Pathol, N-0316 Oslo, Norway; [Melum, Guro R.; Van Dieren, Brenda; Johansen, Finn-Eirik; Jahnsen, Frode L.; Baekkevold, Espen S.] Oslo Univ Hosp, Ctr Immune Regulat, Oslo, Norway; [Melum, Guro R.; Van Dieren, Brenda; Johansen, Finn-Eirik; Jahnsen, Frode L.; Baekkevold, Espen S.] Univ Oslo, Ctr Immune Regulat, N-0316 Oslo, Norway; [Gran, Einar] Lovisenberg Diakonale Hosp, Dept Otolaryngol, Oslo, Norway; [Liu, Yong-Jun] Baylor Res Inst, Baylor Inst Immunol Res, Dallas, TX USA	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Baylor Scott & White Health; Baylor University Medical Center	Melum, GR (corresponding author), Univ Oslo, Oslo Univ Hosp, Ctr Immune Regulat, N-0027 Oslo, Norway.	guro.reinholt.melum@rr-research.no			Research Council of Norway through its Centres of Excellence [179573]; South Eastern Norway Regional Health Authority [39186]	Research Council of Norway through its Centres of Excellence(Research Council of Norway); South Eastern Norway Regional Health Authority	This work was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 179573 and grants from the South Eastern Norway Regional Health Authority, project number 39186.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Bertorelli G, 2000, ALLERGY, V55, P449, DOI 10.1034/j.1398-9995.2000.055005449.x; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Faith A, 2005, J ALLERGY CLIN IMMUN, V116, P1136, DOI 10.1016/j.jaci.2005.08.002; Farkas L, 2006, SCAND J IMMUNOL, V64, P404, DOI 10.1111/j.1365-3083.2006.01792.x; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; Hammad H, 2011, ALLERGY, V66, P579, DOI 10.1111/j.1398-9995.2010.02528.x; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Helft J, 2010, IMMUNOL REV, V234, P55, DOI 10.1111/j.0105-2896.2009.00885.x; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2004, AM J RESP CELL MOL, V30, P31, DOI 10.1165/rcmb.2002-0230OC; Kamekura R, 2009, CELL TISSUE RES, V338, P283, DOI 10.1007/s00441-009-0855-1; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kitajima M, 2013, J IMMUNOL, V191, P4903, DOI 10.4049/jimmunol.1302175; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; Lu N, 2009, J EXP MED, V206, P2111, DOI 10.1084/jem.20090153; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Patterson S, 2005, J IMMUNOL, V174, P8200, DOI 10.4049/jimmunol.174.12.8200; Piccioli D, 2007, BLOOD, V109, P5371, DOI 10.1182/blood-2006-08-038422; Robbins SH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r17; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Rochman Y, 2010, P NATL ACAD SCI USA, V107, P19455, DOI 10.1073/pnas.1008271107; Skrindo I, 2011, CLIN EXP ALLERGY, V41, P954, DOI 10.1111/j.1365-2222.2011.03710.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Ueno-Yamanouchi A, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-6; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Watchmaker PB, 2014, NAT IMMUNOL, V15, P98, DOI 10.1038/ni.2768; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	43	43	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					613	+		10.1016/j.jaci.2014.05.010	http://dx.doi.org/10.1016/j.jaci.2014.05.010			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24958565	Green Published			2022-12-18	WOS:000341372400014
J	Ekoff, M; Choi, JH; James, A; Dahlen, B; Nilsson, G; Dahlen, SE				Ekoff, Maria; Choi, Jeong-Hee; James, Anna; Dahlen, Barbro; Nilsson, Gunnar; Dahlen, Sven-Erik			Bitter taste receptor (TAS2R) agonists inhibit IgE-dependent mast cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY SMOOTH-MUSCLE		[Ekoff, Maria; Choi, Jeong-Hee; James, Anna; Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med Expt Asthma & Allergy Res, Stockholm, Sweden; [Ekoff, Maria; Choi, Jeong-Hee; James, Anna; Dahlen, Barbro; Nilsson, Gunnar; Dahlen, Sven-Erik] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Choi, Jeong-Hee; Nilsson, Gunnar] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Med, Stockholm, Sweden; [Dahlen, Barbro] Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Ekoff, M (corresponding author), Karolinska Inst, Inst Environm Med Expt Asthma & Allergy Res, Stockholm, Sweden.	Sven-Erik.Dahlen@ki.se	James, Anna/AAY-9937-2021	Nilsson, Gunnar/0000-0001-6795-5512				Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Charous BL, 1998, J ALLERGY CLIN IMMUN, V102, P198, DOI 10.1016/S0091-6749(98)70086-7; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Gonzalez EM, 2006, MOL IMMUNOL, V43, P570, DOI 10.1016/j.molimm.2005.04.015; GREEN K B, 1989, Skin Pharmacology, V2, P77; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; NOSAL R, 1991, AGENTS ACTIONS, V33, P37, DOI 10.1007/BF01993121; Orsmark-Pietrast C, 2013, EUR RESPIR J, V42, P65, DOI 10.1183/09031936.00077712; Pulkkinen V, 2012, AM J PHYSIOL-LUNG C, V303, pL956, DOI 10.1152/ajplung.00205.2012; Sigrist CJA, 2010, NUCLEIC ACIDS RES, V38, pD161, DOI 10.1093/nar/gkp885	10	43	48	3	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					475	478		10.1016/j.jaci.2014.02.029	http://dx.doi.org/10.1016/j.jaci.2014.02.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24755408				2022-12-18	WOS:000341370800030
J	Lai, Y; Altemeier, WA; Vandree, J; Piliponsky, AM; Johnson, B; Appel, CL; Frevert, CW; Hyde, DM; Ziegler, SF; Smith, DE; Henderson, WR; Gelb, MH; Hallstrand, TS				Lai, Ying; Altemeier, William A.; Vandree, John; Piliponsky, Adrian M.; Johnson, Brian; Appel, Cara L.; Frevert, Charles W.; Hyde, Dallas M.; Ziegler, Steven F.; Smith, Dirk E.; Henderson, William R., Jr.; Gelb, Michael H.; Hallstrand, Teal S.			Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperresponsiveness; eicosanoid; epithelial cell; leukotriene	GENOME-WIDE ASSOCIATION; AIRWAY HYPERRESPONSIVENESS; CYTOKINE PRODUCTION; HUMAN LUNG; ASTHMA; EXPRESSION; INFLAMMATION; PHENOTYPE; STANDARDS; RESPONSES	Background: Exercise-induced bronchoconstriction (EIB) is a prototypical feature of indirect airway hyperresponsiveness. Mast cells are implicated in EIB, but the characteristics, regulation, and function of mast cells in patients with EIB are poorly understood. Objectives: We sought to examine mast cell infiltration of the airway epithelium in patients with EIB and the regulation of mast cell phenotype and function by epithelially derived cytokines. Methods: Endobronchial biopsy specimens, epithelial brushings, and induced sputum were obtained from asthmatic patients with and without EIB and healthy control subjects. Mast cell proteases were quantified by using quantitative PCR, and mast cell density was quantified by using design-based stereology. Airway epithelial responses to wounding and osmotic stress were assessed in primary airway epithelial cells and ex vivo murine lung tissue. Mast cell granule development and function were examined in cord blood-derived mast cells. Results: Tryptase and carboxypeptidase A3 expression in epithelial brushings and epithelial mast cell density were selectively increased in the asthma group with EIB. An in vitro scratch wound initiated the release of thymic stromal lymphopoietin, which was greater in epithelial cells derived from asthmatic patients. Osmotic stress induced the release of IL-33 from explanted murine lungs, which was increased in allergen-treated mice. Thymic stromal lymphopoietin combined with IL-33 increased tryptase and carboxypeptidase A3 immunostaining in mast cell precursors and selectively increased cysteinyl leukotriene formation by mast cells in a manner that was independent of in vitro sensitization. Conclusions: Mast cell infiltration of the epithelium is a critical determinant of indirect airway hyperresponsiveness, and the airway epithelium might serve as an important regulator of thedevelopment and function of this mast cell population.	[Lai, Ying; Altemeier, William A.; Vandree, John; Hallstrand, Teal S.] Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98195 USA; [Henderson, William R., Jr.] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA; [Gelb, Michael H.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Gelb, Michael H.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Johnson, Brian; Appel, Cara L.; Frevert, Charles W.] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; [Piliponsky, Adrian M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA; [Hyde, Dallas M.] Univ Calif Davis, Sch Vet Med, Davis, CA USA; [Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA USA; [Smith, Dirk E.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of California System; University of California Davis; Benaroya Research Institute; Amgen	Hallstrand, TS (corresponding author), Univ Washington, Dept Med, Div Pulm & Crit Care, Box 356522, Seattle, WA 98195 USA.	tealh@u.washington.edu		Appel, Cara/0000-0002-4761-606X; Altemeier, William/0000-0001-8860-405X; Hallstrand, Teal/0000-0002-5059-6872; gelb, michael/0000-0001-7000-5219	National Institutes of Health [R01HL089215, R37HL036235]; American Lung Association Career Investigator Award [CI-22138-N]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113351, R37HL036235, R01HL089215] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association Career Investigator Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants R01HL089215 to T. S. H.), R37HL036235 (to M. H. G.), and an American Lung Association Career Investigator Award CI-22138-N (T. S. H.).	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Anderson SD, 2010, CHEST, V138, p25S, DOI 10.1378/chest.10-0116; Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; Bae S, 2012, J BIOL CHEM, V287, P8205, DOI 10.1074/jbc.M111.295055; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Cao J, 2011, CYTOKINE, V56, P823, DOI 10.1016/j.cyto.2011.09.016; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dhanasekaran S, 2010, J IMMUNOL METHODS, V354, P34, DOI 10.1016/j.jim.2010.01.004; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Hallstrand TS, 2013, AM J RESP CRIT CARE, V188, P42, DOI 10.1164/rccm.201301-0084OC; Hallstrand TS, 2012, CURR OPIN ALLERGY CL, V12, P42, DOI 10.1097/ACI.0b013e32834ecc67; Hallstrand TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008583; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kippelen P, 2012, BRIT J SPORT MED, V46, P471, DOI 10.1136/bjsports-2012-091056; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; MATIN R, 1992, J HISTOCHEM CYTOCHEM, V40, P781, DOI 10.1177/40.6.1588024; Mickleborough TD, 2005, MED SCI SPORT EXER, V37, P904, DOI 10.1249/01.mss.0000166949.11296.2b; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Nagarkar DR, 2012, J ALLERGY CLIN IMMUN, V130, P225, DOI 10.1016/j.jaci.2012.04.019; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Reuter S, 2008, EUR RESPIR J, V31, P773, DOI 10.1183/09031936.00058907; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Sugimoto K, 2012, J CLIN INVEST, V122, P748, DOI 10.1172/JCI58815; Suzukawa M, 2005, INT IMMUNOL, V17, P1249, DOI 10.1093/intimm/dxh301; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598	42	43	43	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1448	1455		10.1016/j.jaci.2013.08.052	http://dx.doi.org/10.1016/j.jaci.2013.08.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24220317	Green Accepted			2022-12-18	WOS:000335450700028
J	Sozanska, B; Blaszczyk, M; Pearce, N; Cullinan, P				Sozanska, Barbara; Blaszczyk, Mateusz; Pearce, Neil; Cullinan, Paul			Atopy and allergic respiratory disease in rural Poland before and after accession to the European Union	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; asthma; farming exposures; changes in farming practices	FARM MILK CONSUMPTION; HYGIENE HYPOTHESIS; CHILDHOOD ASTHMA; HAY-FEVER; CHILDREN; PREVALENCE; LIFE	Background: In 2003, we recorded a striking difference in the prevalence of atopy between village and small-town populations in southwest Poland. Nine years later, we undertook a second survey of the same area. Objective: We sought to assess whether rapid changes in farming practices, driven by accession to the European Union in 2004, were accompanied by an increase in atopy, asthma, and hay fever in these villages. Methods: In 2012, we surveyed 1730 inhabitants older than 5 years (response rate, 85%); 560 villagers and 348 town inhabitants who had taken part in the earlier survey. Participants completed a questionnaire on farm-related exposures and symptoms of asthma and hay fever. Atopy was assessed by using skin prick tests. Results: In 2012, far fewer villagers had contact with cows (4% vs 24.3% in 2003) or pigs (14% vs 33.5%), milked cows (2.7% vs 12.7%), or drank unpasteurized milk (9% vs 35%). Among the villagers, there was a significant increase at all ages in the prevalence of atopy between 2003 and 2012 both in the total population (7.3% vs 19.6%, P<.0001) and among those who took part in both surveys (7.9% vs 17.8%, P<.0001). Among the townspeople, the prevalence of atopy did not change substantially (20% vs 19.9% and 21.7% vs 18.5%, respectively). Hay fever increased 2-fold in the villages (3.0% vs 7.7%) but not in the town (7.1% vs 7.2%); there was little or no change in asthma prevalence in the villages (5.0% vs 4.3%) or town (4.3% vs 5.0%). Conclusions: We report a substantial increase in atopy at all ages and in a remarkably short period of time in a Polish population whose farm-related exposures were dramatically reduced after their country's accession to the European Union.	[Sozanska, Barbara] Wroclaw Med Univ, Dept Pediat Allergol & Cardiol 1, Wroclaw, Poland; [Blaszczyk, Mateusz] Univ Wroclaw, Fac Sociol, PL-50138 Wroclaw, Poland; [Pearce, Neil] London Sch Hyg & Trop Med, London, England; [Pearce, Neil] Massey Univ, Wellington, New Zealand; [Cullinan, Paul] Imperial Coll NHLI, London SW3 6LR, England; [Cullinan, Paul] Royal Brompton Hosp, London SW3 6LR, England	Wroclaw Medical University; University of Wroclaw; University of London; London School of Hygiene & Tropical Medicine; Massey University; Imperial College London; Royal Brompton Hospital	Cullinan, P (corresponding author), Imperial Coll NHLI, 1b Manresa Rd, London SW3 6LR, England.	cullinan@imperial.ac.uk	Błaszczyk, Mateusz/AAO-1104-2020	Błaszczyk, Mateusz/0000-0002-5778-2723; Pearce, Neil/0000-0002-9938-7852; Cullinan, Paul/0000-0002-9314-6468; Sozanska, Barbara/0000-0002-9161-706X	National Science Centre, Poland [DEC-2011/01/B/NZ7/05464]	National Science Centre, Poland(National Science Centre, Poland)	Supported by a grant from the National Science Centre, Poland (DEC-2011/01/B/NZ7/05464).	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Davies N., 2002, MICROCOSM PORTRAIT C; Douwes J., 2009, Oxford textbook of public health, Volume 3: the practice of public health, P1021; Douwes J, 2008, INT J EPIDEMIOL, V37, P570, DOI 10.1093/ije/dyn077; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Nicholson PJ, 2010, OCCUPATIONAL ASTHMA; Pearce N, 2004, ENVIRON HEALTH PERSP, V112, P1047, DOI 10.1289/ehp.6927; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pearce N, 2013, LANCET RESP MED, V1, P96, DOI 10.1016/S2213-2600(13)70023-7; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Preston P J, 1970, J R Nav Med Serv, V56, P229; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rottem M, 2005, INT ARCH ALLERGY IMM, V136, P198, DOI 10.1159/000083894; Sozanska B, 2007, ALLERGY, V62, P394, DOI 10.1111/j.1398-9995.2007.01346.x; Sozanska B, 2013, ALLERGY, V68, P644, DOI 10.1111/all.12147; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; von Mutius E, 2010, CLIN EXP IMMUNOL, V160, P130, DOI 10.1111/j.1365-2249.2010.04138.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x	24	43	44	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1347	1353		10.1016/j.jaci.2013.10.035	http://dx.doi.org/10.1016/j.jaci.2013.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24342546	Bronze, Green Submitted			2022-12-18	WOS:000335450700016
J	Tey, D; Allen, KJ; Peters, RL; Koplin, JJ; Tang, MLK; Gurrin, LC; Ponsonby, AL; Lowe, AJ; Wake, M; Dharmage, SC				Tey, Dean; Allen, Katrina J.; Peters, Rachel L.; Koplin, Jennifer J.; Tang, Mimi L. K.; Gurrin, Lyle C.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Wake, Melissa; Dharmage, Shyamali C.		HealthNuts Study Investigators	Population response to change in infant feeding guidelines for allergy prevention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; infant feeding; solids; egg; peanut; formula; weaning; family history; guidelines	1ST YEAR; ATOPIC-DERMATITIS; SOLID FOODS; PREVALENCE; DISEASE; RISK; SENSITIZATION; CONSUMPTION; CHILDREN; LIFE	Background: It is unknown whether population infant feeding practices have changed since recently revised Australian allergy guidelines removed recommendations to delay allergenic solids. Objectives: We sought to determine whether updated 2008 guidelines were associated with changes in feeding practice and to determine whether sociodemographic factors influenced this response. Methods: In a population-based, cross-sectional study (HealthNuts) of 5276 infants recruited between 2007 and 2011 in Melbourne, Australia, parents reported on infant feeding practices. Multinomial logistic regression was used to investigate the associations between recruitment year and feeding practices and whether these associations were modified by sociodemographic factors. Results: Compared with participants recruited in 2007-2009, those recruited in 2009-2011 were more likely to introduce solids at age 4 months (adjusted multinomial odds ratio [aMOR], 1.21; 95% CI, 1.02-1.45; P=.032) and less likely to introduce solids at age 6 months (aMOR, 0.80; 95% CI, 0.69-0.92; P=.002), egg after 6 months (aMOR, 0.82; 95% CI, 0.71-0.94; P=.004), and peanut after 12 months (aMOR, 0.70; 95% CI, 0.49-0.98; P=.037). Although parents recruited in 2009-2011 were less likely to formula feed (aMOR, 0.84; 95% CI, 0.72-0.98; P=.023), formula-fed infants were more likely to be given a partially hydrolyzed formula (aMOR, 1.37; 95% CI, 1.12-1.70; P=.003). These changes were significantly stronger among families with a higher socioeconomic status and those without a family history of allergies. Conclusion: Updated national allergy guidelines are associated with reduced delay in introduction of solids, egg, and peanut and an increase in partially hydrolyzed formula use among formula-fed infants. Higher socioeconomic status and absence of family history of allergies were associated with better uptake of feeding guidelines.	[Tey, Dean; Allen, Katrina J.; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Tey, Dean; Allen, Katrina J.; Peters, Rachel L.; Koplin, Jennifer J.; Tang, Mimi L. K.; Gurrin, Lyle C.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Wake, Melissa; Dharmage, Shyamali C.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Tey, Dean; Allen, Katrina J.; Peters, Rachel L.; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Wake, Melissa] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Koplin, Jennifer J.; Gurrin, Lyle C.; Lowe, Adrian J.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia; [Allen, Katrina J.] Univ Manchester, Manchester M13 9PL, Lancs, England	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Ponsonby, Anne-Louise/AAE-4351-2019; Tang, Mimi/ABD-8350-2020; Wake, Melissa/J-1396-2012; Allen, Katrina/I-4361-2018	Tang, Mimi/0000-0002-3839-5293; Koplin, Jennifer/0000-0002-7576-5142; Lowe, Adrian/0000-0002-4691-8162; Peters, Rachel/0000-0002-2411-6628; Wake, Melissa/0000-0001-7501-9257; Gurrin, Lyle/0000-0001-7052-1969; Ponsonby, Anne-Louise/0000-0002-6581-3657; Allen, Katrina/0000-0002-1921-4493	National Health & Medical Research Council (NHMRC) of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government; NHMRC	National Health & Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by funding from the National Health & Medical Research Council (NHMRC) of Australia, the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program. K.J.A. is a Viertel Senior Medical Research Fellow. J.J.K., M.W., A.J.L., and S.C.D. are supported by the NHMRC. R.L.P. is an Australian Postgraduate Award PhD scholar. ALK-Abello S.A., Madrid, Spain, supplied the skin prick testing reagents.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; [Anonymous], 2008, FOODS 1 YEAR LIF; [Anonymous], IND REL SOC DIS; [Anonymous], 1998, FOOD 1 YEAR LIF; Chuang CH, 2011, PEDIAT ALLERG IMM-UK, V22, P43, DOI 10.1111/j.1399-3038.2010.01007.x; Clayton HB, 2013, PEDIATRICS, V131, pE1108, DOI 10.1542/peds.2012-2265; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; Giovannini M, 2004, ACTA PAEDIATR, V93, P492, DOI 10.1080/08035250410025591; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grummer-Strawn LM, 2008, PEDIATRICS, V122, pS36, DOI 10.1542/peds.2008-1315d; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; Koplin JJ, 2013, CLIN EXP ALLERGY, V43, P826, DOI 10.1111/cea.12090; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; National Health and Medical Research Council, 2005, NSW PUBLIC HLTH B, V16, P41; Norris JM, 2005, JAMA-J AM MED ASSOC, V293, P2343, DOI 10.1001/jama.293.19.2343; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott S, 2007, MJA PRACTICE ESSENTI; Schiess S, 2010, J PEDIATR GASTR NUTR, V50, P92, DOI 10.1097/MPG.0b013e31819f1ddc; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Venter C, 2009, PEDIAT ALLERG IMM-UK, V20, P320, DOI 10.1111/j.1399-3038.2008.00832.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	30	43	43	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					476	484		10.1016/j.jaci.2013.11.019	http://dx.doi.org/10.1016/j.jaci.2013.11.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24388636				2022-12-18	WOS:000332397100023
J	Pfefferle, PI; Prescott, SL; Kopp, M				Pfefferle, Petra Ina; Prescott, Susan L.; Kopp, Matthias			Microbial influence on tolerance and opportunities for intervention with prebiotics/probiotics and bacterial lysates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; probiotics; prebiotics; allergy; prevention; immune tolerance; bacterial lysates; allergic disease; Developmental Origins of Health and Disease	PLACEBO-CONTROLLED TRIAL; RESPIRATORY-TRACT INFECTIONS; 1ST 6 MONTHS; RANDOMIZED CONTROLLED-TRIAL; LACTOBACILLUS GG TREATMENT; SCHOOL-AGE-CHILDREN; DOUBLE-BLIND; ATOPIC-DERMATITIS; PROBIOTIC SUPPLEMENTATION; BIFIDOBACTERIUM-LACTIS	Epidemiologic studies indicate that microbes and microbial components are associated with protection against chronic inflammatory disease. Consequently, a plethora of clinical approaches have been used to investigate the benefits of a range of microbial products on inflammatory conditions in human trials. Centered particularly on the use of prebiotics, probiotic bacteria, and bacterial lysates in early life, this review provides an overview on clinical approaches aimed at reducing the global burden of allergic disease through primary prevention. Microbial interventions beginning before birth and in early infancy are discussed in the context of underlying mechanisms of oral tolerance and the establishment of gut colonization as a critical early homeostatic influence. We explore both the findings and challenges faced in existing studies with a view toward improving future clinical studies of the application of microbial compounds for the prevention of allergic disease and other inflammatory diseases.	[Pfefferle, Petra Ina] Univ Marburg, Inst Lab Med & Pathobiochem, D-35043 Marburg, Germany; [Pfefferle, Petra Ina; Prescott, Susan L.] Univ Giessen, Marburg, Germany; [Pfefferle, Petra Ina; Prescott, Susan L.] Marburg Lung Ctr UGMLC, Marburg, Germany; [Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Prescott, Susan L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Kopp, Matthias] Univ Lubeck, Childrens Hosp, Dept Pediat Allergy & Pulmonol, Lubeck, Germany	Philipps University Marburg; Justus Liebig University Giessen; University of Western Australia; University of Western Australia; University of Lubeck	Pfefferle, PI (corresponding author), Univ Marburg, Mol Diagnost Biomed Res Ctr, Inst Lab Med & Pathobiochem, Hans Meerweinstr 2, D-35043 Marburg, Germany.	pfefferl@med.uni-marburg.de	Prescott, Susan/H-5665-2014					Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Bercik P, 2012, NEUROGASTROENT MOTIL, V24, P405, DOI 10.1111/j.1365-2982.2012.01906.x; Bercik P, 2011, GASTROENTEROLOGY, V141, P599, DOI 10.1053/j.gastro.2011.04.052; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Boerner BP, 2011, ANN NY ACAD SCI, V1243, P103, DOI 10.1111/j.1749-6632.2011.06340.x; Bowman LM, 2001, INFECT IMMUN, V69, P3719, DOI 10.1128/IAI.69.6.3719-3727.2001; Boyle P, 2000, BIODRUGS, V14, P389, DOI 10.2165/00063030-200014060-00004; Boyle RJ, 2008, CLIN EXP ALLERGY, V38, P1882, DOI 10.1111/j.1365-2222.2008.03100.x; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brunetti L, 2005, BIODRUGS, V19, P393, DOI 10.2165/00063030-200519060-00006; Cazzola M, 2008, RESP MED, V102, P321, DOI 10.1016/j.rmed.2007.11.002; Cazzola M, 2012, CURR OPIN PHARMACOL, V12, P300, DOI 10.1016/j.coph.2012.01.019; Cazzola M, 2012, PULM PHARMACOL THER, V25, P62, DOI 10.1016/j.pupt.2011.11.002; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Doege K, 2012, BRIT J NUTR, V107, P1, DOI 10.1017/S0007114511003400; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FAURE GC, 1990, INT J IMMUNOPHARMACO, V12, P315, DOI 10.1016/0192-0561(90)90087-4; Fujiwara R, 2010, BRIT J NUTR, V103, P530, DOI 10.1017/S000711450999198X; Gonzalez A, 2011, EMBO REP, V12, P775, DOI 10.1038/embor.2011.137; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Grzeskowiak L, 2012, ANAEROBE, V18, P7, DOI 10.1016/j.anaerobe.2011.09.006; Harris JK, 2012, J ALLERGY CLIN IMMUN, V129, P441, DOI 10.1016/j.jaci.2011.12.969; Hatzler L, 2012, PEDIAT ALLERG IMM-UK, V23, P616, DOI 10.1111/pai.12022; Huber M, 2005, EUR J MED RES, V10, P209; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jarchum I, 2011, CURR OPIN IMMUNOL, V23, P353, DOI 10.1016/j.coi.2011.03.001; Jongmans W, 2005, J IMMUNOTHER, V28, P480, DOI 10.1097/01.cji.0000171290.78495.66; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kim JY, 2010, PEDIAT ALLERG IMM-UK, V21, pE386, DOI 10.1111/j.1399-3038.2009.00958.x; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lisciandro JG, 2012, J ALLERGY CLIN IMMUN, V130, P1167, DOI 10.1016/j.jaci.2012.06.005; Lisciandro JG, 2012, PEDIAT ALLERG IMM-UK, V23, P173, DOI 10.1111/j.1399-3038.2011.01242.x; Lodinova-Zadnikova R, 2010, INT ARCH ALLERGY IMM, V153, P201, DOI 10.1159/000312638; Maurer AD, 2011, BRIT J NUTR, V105, P329, DOI 10.1017/S0007114510003533; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Metchnikoff E, 1907, PROLONGATION LIFE OP; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x; Nissle, 1918, MED KLIN, V2, P29; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub2; Ou CY, 2012, CLIN EXP ALLERGY, V42, P1386, DOI 10.1111/j.1365-2222.2012.04037.x; Ouwehand AC, 2000, LETT APPL MICROBIOL, V30, P10, DOI [10.1046/j.1472-765x.2000.00590.x, 10.1046/j.1472-765X.2000.00590.x]; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; PODLESKI WK, 1985, INT J IMMUNOPHARMACO, V7, P713, DOI 10.1016/0192-0561(85)90156-0; Prescott SL, 2008, CLIN EXP ALLERGY, V38, P1606, DOI 10.1111/j.1365-2222.2008.03061.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 2011, J ALLERGY CLIN IMMUN, V128, P886, DOI 10.1016/j.jaci.2011.05.017; PUIGDOLLERS JM, 1980, RESPIRATION, V40, P142, DOI 10.1159/000194264; Rautava S, 2006, PEDIATR RES, V60, P221, DOI 10.1203/01.pdr.0000228317.72933.db; Rautava S, 2012, J ALLERGY CLIN IMMUN, V130, P1355, DOI 10.1016/j.jaci.2012.09.003; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rogosch T, 2012, J IMMUNOL, V189, P5449, DOI 10.4049/jimmunol.1103347; Rose MA, 2010, CLIN EXP ALLERGY, V40, P1398, DOI 10.1111/j.1365-2222.2010.03560.x; Rossi GA, 2003, IMMUNOL LETT, V86, P85, DOI 10.1016/S0165-2478(02)00290-0; Rozy Adriana, 2008, Pneumonol Alergol Pol, V76, P353; Ruah SB, 2001, ADV THER, V18, P151, DOI 10.1007/BF02850109; RUEDL C, 1994, CLIN DIAGN LAB IMMUN, V1, P150, DOI 10.1128/CDLI.1.2.150-154.1994; Rutishauser M, 1998, ADV THER, V15, P330; Schaad UB, 2010, WORLD J PEDIATR, V6, P5, DOI 10.1007/s12519-010-0001-x; Schaub B, 2009, J ALLERGY CLIN IMMUN, V123; Schrezenmeir J, 2001, AM J CLIN NUTR, V73, p361S, DOI 10.1093/ajcn/73.2.361s; Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x; Stephens C, 2000, CURR BIOL, V10, pR272, DOI 10.1016/S0960-9822(00)00405-X; Steurer-Stey C, 2007, EUR J PEDIATR, V166, P365, DOI 10.1007/s00431-006-0248-3; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Sudo N, 1997, J IMMUNOL, V159, P1739; Tang MLK, 2010, CURR OPIN PEDIATR, V22, P626, DOI 10.1097/MOP.0b013e32833d9728; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Thrusfield MV, 1985, VET EPIDEMIOLOGY; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ursell LK, 2012, J ALLERGY CLIN IMMUN, V129, P1204, DOI 10.1016/j.jaci.2012.03.010; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 2010, CLIN EXP IMMUNOL, V160, P130, DOI 10.1111/j.1365-2249.2010.04138.x; Weinberger M, 2010, J ALLERGY CLIN IMMUN, V126, P770, DOI 10.1016/j.jaci.2010.08.019; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x; Wickens K, 2012, CLIN EXP ALLERGY, V42, P1071, DOI 10.1111/j.1365-2222.2012.03975.x; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Willing BP, 2011, BIOESSAYS, V33, P414, DOI 10.1002/bies.201100030	98	43	48	1	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1453	1463		10.1016/j.jaci.2013.03.020	http://dx.doi.org/10.1016/j.jaci.2013.03.020			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23643095				2022-12-18	WOS:000320532800001
J	Kim, WK; Kwon, JW; Seo, JH; Kim, HY; Yu, J; Kim, BJ; Kim, HB; Lee, SY; Kim, KW; Kang, MJ; Shin, YJ; Hong, SJ				Kim, Woo Kyung; Kwon, Ji-Won; Seo, Ju-Hee; Kim, Hyung Young; Yu, Jinho; Kim, Byoung-Ju; Kim, Hyo-Bin; Lee, So Yeon; Kim, Kyung Won; Kang, Mi-Jin; Shin, Yee-Jin; Hong, Soo-Jong			Interaction between IL13 genotype and environmental factors in the risk for allergic rhinitis in Korean children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; prevalence; risk factor; IL-13 polymorphism; gene-environment interaction; infancy	INCREASING PREVALENCE; GENETIC-VARIANTS; EARLY-CHILDHOOD; ASTHMA; ATOPY; EXPOSURE; DISEASES; CD14; AGE; POLYMORPHISMS	Background: The prevalence of allergic rhinitis (AR) is increasing worldwide. Allergic diseases develop in susceptible subjects when they are exposed to specific environmental factors. Objective: We analyzed changes in the prevalence of AR and identified genetic and environmental factors in early childhood that affect risk. Methods: We used the International Study of Asthma and Allergies in Childhood questionnaire to collect data on AR, allergies, and environmental exposures from 4554 elementary school students from 5 areas of Seoul, Korea, in 2008. We also obtained DNA from 1050 subjects from 1 area of Seoul for genotype analysis of IL13. Results: We identified genetic and environmental factors during infancy and early childhood that increased the risk for current AR (resulting in a diagnosis of AR and AR symptoms in the past 12 months) in elementary school-aged children. These included allergic disease in parents and antibiotic use in infants, allergic disease in parents and exposure of infants to mold, and allergic disease in parents and moving an infant to a newly built house. The risk of current AR also increased in subjects with GA or AA at nucleotide 2044 in IL13 who had been exposed to mold in the home during infancy (adjusted odds ratio, 3.27; 95% CI, 1.75-6.11) compared with subjects who had GG at this position and had not been exposed to mold (adjusted odds ratio, 3.27; 95% CI, 1.75-6.11). Conclusion: The prevalence of AR is increasing in Korean children. Children with a family history of allergic disease and exposure to specific environmental risk factors during infancy are more likely to have AR. Children with GA or AA at IL13(+2044) are at increased risk for AR when exposed to mold in the home during the first year of life. (J Allergy Clin Immunol 2012;130:421-6.)	[Seo, Ju-Hee; Kim, Hyung Young; Yu, Jinho; Hong, Soo-Jong] Univ Ulsan, Coll Med, Res Ctr Standardizat Allerg Dis, Dept Pediat,Childhood Asthma Atopy Ctr,Asan Med C, Seoul 138736, South Korea; [Kim, Woo Kyung] Inje Univ, Seoul Paik Hosp, Dept Pediat, Seoul, South Korea; [Kim, Woo Kyung] Inje Univ, Seoul Paik Hosp, Allergy & Resp Res Lab, Seoul, South Korea; [Kwon, Ji-Won] Seoul Natl Univ, Bundang Hosp, Dept Pediat, Seoul, South Korea; [Kim, Byoung-Ju] Inje Univ, Haeundae Paik Hosp, Dept Pediat, Seoul, South Korea; [Kim, Hyo-Bin] Inje Univ, Sanggye Paik Hosp, Dept Pediat, Seoul, South Korea; [Lee, So Yeon] Hallym Univ, Sacred Heart Hosp, Dept Pediat, Seoul, South Korea; [Kim, Kyung Won] Yonsei Univ, Coll Med, Dept Pediat, Severance Childrens Hosp, Seoul, South Korea; [Kang, Mi-Jin] Asan Inst Life Sci, Seoul, South Korea; [Shin, Yee-Jin] Yonsei Univ, Coll Med, Severance Hosp, Dept Psychiat, Seoul, South Korea	University of Ulsan; Inje University; Inje University; Seoul National University (SNU); Seoul National University Hospital; Inje University; Inje University; Hallym University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Hong, SJ (corresponding author), Univ Ulsan, Coll Med, Res Ctr Standardizat Allerg Dis, Dept Pediat,Childhood Asthma Atopy Ctr,Asan Med C, Pungnap 2 Dong, Seoul 138736, South Korea.	sjhong@amc.seoul.kr	Hong, Soo-Jong/AAR-1788-2020; Yu, Jinho/P-4293-2014	Hong, Soo-Jong/0000-0003-1409-2113; Yu, Jinho/0000-0002-1226-8077; Kim, Woo Kyung/0000-0001-8730-010X; Kim, Kyung Won/0000-0003-4529-6135; Shin, Yee Jin/0000-0001-8573-4342; Kim, Byoung-Ju/0000-0003-0271-9417	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [A092076]	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea	Supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A092076).	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barragaan-Meijueiro MM, 2006, J INVEST ALLERG CLIN, V16, P247; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; de Marco R, 2010, INT ARCH ALLERGY IMM, V152, P255, DOI 10.1159/000283034; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Halmerbauer G, 2002, PEDIAT ALLERG IMM-UK, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hong SJ, 2007, PEDIAT ALLERGY RE S1, V17, pS55; Huebner M, 2008, J ALLERGY CLIN IMMUN, V121, P408, DOI 10.1016/j.jaci.2007.09.020; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Kim HB, 2006, J HUM GENET, V51, P1055, DOI 10.1007/s10038-006-0061-x; Kim JJ, 2007, EUR ARCH OTO-RHINO-L, V264, P395, DOI 10.1007/s00405-006-0204-x; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev.med.56.062904.144908; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Le Souef PN, 2006, CURR OPIN ALLERGY CL, V6, P317, DOI 10.1097/01.all.0000244790.18486.be; Lee SI, 2010, ALLERGY ASTHMA IMMUN, V2, P61, DOI 10.4168/aair.2010.2.2.61; Lee SL, 2004, PEDIAT ALLERG IMM-UK, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Matsuwaki Y, 2009, J IMMUNOL, V183, P6708, DOI 10.4049/jimmunol.0901220; Montefort S, 2009, PEDIAT ALLERG IMM-UK, V20, P67, DOI 10.1111/j.1399-3038.2008.00746.x; Monteil MA, 2004, REV PANAM SALUD PUBL, V16, P193, DOI 10.1590/S1020-49892004000900006; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Piau JP, 2010, INT J TUBERC LUNG D, V14, P506; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Tamay Z, 2007, INT J PEDIATR OTORHI, V71, P463, DOI 10.1016/j.ijporl.2006.11.013; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zhang G, 2009, ALLERGY, V64, P1333, DOI 10.1111/j.1398-9995.2009.02006.x; Zhao J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-551; 홍수종, 2008, Clinical and Experimental Pediatrics, V51, P343	40	43	44	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					421	+		10.1016/j.jaci.2012.04.052	http://dx.doi.org/10.1016/j.jaci.2012.04.052			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846750				2022-12-18	WOS:000307002200023
J	Santiago, HC; LeeVan, E; Bennuru, S; Ribeiro-Gomes, F; Mueller, E; Wilson, M; Wynn, T; Garboczi, D; Urban, J; Mitre, E; Nutman, TB				Santiago, Helton C.; LeeVan, Elyse; Bennuru, Sasisekhar; Ribeiro-Gomes, Flavia; Mueller, Ellen; Wilson, Mark; Wynn, Thomas; Garboczi, David; Urban, Joseph; Mitre, Edward; Nutman, Thomas B.			Molecular mimicry between cockroach and helminth glutathione S-transferases promotes cross-reactivity and cross-sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GST; cockroach; allergy; hygiene hypothesis; cross-reactivity; filariasis	IGE ANTIBODY-RESPONSES; REGULATORY T-CELLS; ASCARIS-LUMBRICOIDES; ALLERGIC SENSITIZATION; AIRWAY INFLAMMATION; PARASITE INFECTION; CHILDHOOD ASTHMA; GERMAN-COCKROACH; SCHOOL-CHILDREN; MAJOR ALLERGEN	Background: The extensive similarities between helminth proteins and allergens are thought to contribute to helminth-driven allergic sensitization. Objective: The objective of this study was to investigate the cross-reactivity between a major glutathione-S transferase allergen of cockroach (Bla g 5) and the glutathione-S transferase of Wuchereria bancrofti (WbGST), a major lymphatic filarial pathogen of humans. Methods: We compared the molecular and structural similarities between Bla g 5 and WbGST by in silico analysis and by linear epitope mapping. The levels of IgE, IgG, and IgG(4) antibodies were measured in filarial-infected and filarial-uninfected patients. Mice were infected with Heligmosomoides bakeri, and their skin was tested for cross-reactive allergic responses. Results: These 2 proteins are 30% identical at the amino acid level with remarkable similarity in the N-terminal region and overall structural conservation based on predicted 3-dimensional models. Filarial infection was associated with IgE, IgG, and IgG(4) anti-Bla g 5 antibody production, with a significant correlation between antibodies (irrespective of isotype) to Bla g 5 and WbGST (P < .0003). Preincubation of sera from cockroach-allergic subjects with WbGST partially depleted (by 50%-70%) anti-Bla g 5 IgE, IgG, and IgG(4) antibodies. IgE epitope mapping of Bla g 5 revealed that 2 linear N-terminal epitopes are highly conserved in WbGST corresponding to Bla g 5 peptides partially involved in the inhibition of WbGST binding. Finally, mice infected with H bakeri developed anti-HbGST IgE and showed immediate-type skin test reactivity to Bla g 5. Conclusion: These data demonstrate that helminth glutathione-S transferase and the aeroallergen Bla g 5 share epitopes that can induce allergic cross-sensitization. (J Allergy Clin Immunol 2012; 130:248-56.)	[Santiago, Helton C.; LeeVan, Elyse; Bennuru, Sasisekhar; Ribeiro-Gomes, Flavia; Wilson, Mark; Wynn, Thomas; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Mueller, Ellen; Mitre, Edward] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; [Garboczi, David] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; [Urban, Joseph] Agr Res Serv, Diet Genom & Immunol Lab, Beltsville Human Nutr Res Ctr, USDA, Beltsville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Agriculture (USDA)	Santiago, HC (corresponding author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Bldg 4,Rm B1-05, Bethesda, MD 20892 USA.	helton.santiago@nih.gov	Wynn, Thomas A/AAO-3523-2021; Santiago, Helton/F-8704-2012; Santiago, Helton/AAA-8558-2021; Ribeiro-Gomes, Flávia L/F-7609-2015	Wynn, Thomas A/0000-0002-7244-8731; Santiago, Helton/0000-0002-5695-8256; Ribeiro-Gomes, Flávia L/0000-0003-0297-6341; Urban, Joseph/0000-0002-1590-8869	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; National Institute of Allergy and Infectious Diseases/National Institutes of Health; MRC [MC_UP_A253_1028] Funding Source: UKRI; Medical Research Council [MC_UP_A253_1028] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000805, ZICAI001051, ZIAAI000829] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the Intramural Research Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.; Disclosure of potential conflict of interest: T. B. Nutman received research support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Acevedo N, 2009, ALLERGY, V64, P1635, DOI 10.1111/j.1398-9995.2009.02084.x; Agianian B, 2003, J MOL BIOL, V326, P151, DOI 10.1016/S0022-2836(02)01327-X; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Arnold Konstantin, 2009, Journal of Structural and Functional Genomics, V10, P1, DOI 10.1007/s10969-008-9048-5; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Benicio MHD, 2004, B WORLD HEALTH ORGAN, V82, P516; Capron A, 2002, BRIT MED BULL, V62, P139, DOI 10.1093/bmb/62.1.139; Caraballo Luis, 2011, Front Biosci (Elite Ed), V3, P51, DOI 10.2741/e219; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Dittrich AM, 2008, J IMMUNOL, V180, P1792, DOI 10.4049/jimmunol.180.3.1792; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; [FAO/WHO] Food and Agriculture Organization/World Health Organization, 2001, ALL GEN MOD FOODS; Fitzsimmons CM, 2009, TRENDS PARASITOL, V25, P447, DOI 10.1016/j.pt.2009.07.004; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Gore JC, 2007, ANNU REV ENTOMOL, V52, P439, DOI 10.1146/annurev.ento.52.110405.091313; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Hagel I, 2007, ACTA TROP, V103, P231, DOI 10.1016/j.actatropica.2007.06.010; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; HAYES JD, 1986, BIOCHEM J, V233, P779, DOI 10.1042/bj2330779; Hotez PJ, 2010, NAT REV MICROBIOL, V8, P814, DOI 10.1038/nrmicro2438; Huang CH, 2006, CLIN EXP ALLERGY, V36, P369, DOI 10.1111/j.1365-2222.2006.02447.x; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; Jeong KY, 2009, INT ARCH ALLERGY IMM, V148, P59, DOI 10.1159/000151506; Kim JS, 2008, J ALLERGY CLIN IMMUN, V122, P929, DOI 10.1016/j.jaci.2008.08.009; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Metenou S, 2010, J IMMUNOL, V184, P5375, DOI 10.4049/jimmunol.0904067; Mitre E, 2008, J INFECT DIS, V197, P94, DOI 10.1086/524301; ONeill GM, 1995, IMMUNOL LETT, V48, P103, DOI 10.1016/0165-2478(95)02452-2; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Perbandt M, 2005, J BIOL CHEM, V280, P12630, DOI 10.1074/jbc.M413551200; Pomes A, 2010, INT ARCH ALLERGY IMM, V152, P1, DOI 10.1159/000260078; Proust B, 2008, INT ARCH ALLERGY IMM, V146, P212, DOI 10.1159/000115889; Santiago HC, 2011, J ALLERGY CLIN IMMUN, V127, P479, DOI 10.1016/j.jaci.2010.11.007; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Schuller DJ, 2005, PROTEINS, V61, P1024, DOI 10.1002/prot.20649; Sereda MJ, 2008, TRENDS PARASITOL, V24, P272, DOI 10.1016/j.pt.2008.03.006; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Takeuchi H, 2008, CLIN EXP ALLERGY, V38, P276, DOI 10.1111/j.1365-2222.2007.02890.x; URBAN JF, 1982, VET PARASITOL, V10, P131, DOI 10.1016/0304-4017(82)90019-X; Veerapathran A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000457; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yadav M, 2011, VACCINE, V29, P1297, DOI 10.1016/j.vaccine.2010.11.078; Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb; Zhan B, 2005, INFECT IMMUN, V73, P6903, DOI 10.1128/IAI.73.10.6903-6911.2005	49	43	43	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					248	+		10.1016/j.jaci.2012.02.045	http://dx.doi.org/10.1016/j.jaci.2012.02.045			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22541242	Green Accepted, Bronze			2022-12-18	WOS:000306644800034
J	Vasiadi, M; Therianou, A; Sideri, K; Smyrnioti, M; Sismanopoulos, N; Delivanis, DA; Asadi, S; Katsarou-Katsari, A; Petrakopoulou, T; Theoharides, A; Antoniou, C; Papadavid, E; Stavrianeas, N; Kalogeromitros, D; Theoharides, TC				Vasiadi, Magdalini; Therianou, Anastasia; Sideri, Kyriaki; Smyrnioti, Marilena; Sismanopoulos, Nikolaos; Delivanis, Danae A.; Asadi, Shahrzad; Katsarou-Katsari, Alexandra; Petrakopoulou, Theodora; Theoharides, Athanasios; Antoniou, Christina; Papadavid, Evaggelia; Stavrianeas, Nikolaos; Kalogeromitros, Dimitrios; Theoharides, Theoharis C.			Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELLS		[Vasiadi, Magdalini; Sismanopoulos, Nikolaos; Delivanis, Danae A.; Asadi, Shahrzad; Theoharides, Theoharis C.] Tufts Univ, Sch Med, Mol Immunopharmacol & Drug Discovery Lab, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Vasiadi, Magdalini; Theoharides, Theoharis C.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA; [Vasiadi, Magdalini; Sideri, Kyriaki; Sismanopoulos, Nikolaos; Kalogeromitros, Dimitrios] Univ Athens, Sch Med, Allergy Clin Res Ctr, GR-11527 Athens, Greece; [Smyrnioti, Marilena] Univ Athens, Sch Med, Pain Relief Clin, Dept Anesthesiol 2, GR-11527 Athens, Greece; [Papadavid, Evaggelia; Stavrianeas, Nikolaos] Univ Athens, Sch Med, Dept Dermatol 2, Attikon Hosp, GR-11527 Athens, Greece; [Therianou, Anastasia; Katsarou-Katsari, Alexandra; Antoniou, Christina] Univ Athens, Sch Med, Dept Dermatol 1, A Sygros Hosp, GR-11527 Athens, Greece; [Asadi, Shahrzad] Tufts Univ, Sch Med, Dept Pharm, Tufts Med Ctr, Boston, MA 02111 USA; [Petrakopoulou, Theodora] IKA, Oncol Hosp, Athens, Greece; [Theoharides, Athanasios] IKA, Ano Toumba Polyclin, Thessaloniki, Greece; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA; [Delivanis, Danae A.] Univ Connecticut, Dept Internal Med, Med Ctr, Hartford, CT 06112 USA	Tufts University; Tufts University; Tufts University; Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; Athens Medical School; National & Kapodistrian University of Athens; Tufts Medical Center; Tufts University; Tufts University; University of Connecticut	Vasiadi, M (corresponding author), Tufts Univ, Sch Med, Mol Immunopharmacol & Drug Discovery Lab, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA.	theoharis.theoharides@tufts.edu	Smyrnioti, Maria Eleni/ABD-6086-2021	Smyrnioti, Maria Eleni/0000-0002-4971-1984	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047652] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR047652, AR47652, R01 AR047652-10] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asadi S, 2012, J INVEST DERMATOL, V132, P324, DOI 10.1038/jid.2011.334; Crompton R, 2003, J CLIN ENDOCR METAB, V88, P5427, DOI 10.1210/jc.2003-030377; Fountoulakis Konstantinos N, 2006, Ann Gen Psychiatry, V5, P2, DOI 10.1186/1744-859X-5-2; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 2009, BRIT J DERMATOL, V160, P229, DOI 10.1111/j.1365-2133.2008.08958.x; Theoharides TC, 2004, J NEUROIMMUNOL, V146, P1, DOI 10.1016/j.jneuroim.2003.10.041; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403	9	43	44	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1410	1413		10.1016/j.jaci.2012.01.041	http://dx.doi.org/10.1016/j.jaci.2012.01.041			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22360979	Green Accepted			2022-12-18	WOS:000303418000037
J	Wu, Q; Jiang, D; Smith, S; Thaikoottathil, J; Martin, RJ; Bowler, RP; Chu, HW				Wu, Qun; Jiang, Di; Smith, Sean; Thaikoottathil, Jyoti; Martin, Richard J.; Bowler, Russell P.; Chu, Hong Wei			IL-13 dampens human airway epithelial innate immunity through induction of IL-1 receptor-associated kinase M	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; IL-1 receptor-associated kinase M; Toll-like receptor 2; airway epithelial cells	NF-KAPPA-B; HUMAN-BETA DEFENSIN-2; TOLL-LIKE-RECEPTORS; IRAK-M EXPRESSION; NEGATIVE REGULATOR; HUMAN BETA-DEFENSIN-2; SIGNALING PATHWAY; ATOPIC-DERMATITIS; SPLUNC1 PROTEIN; CHROMOSOME 12Q	Background: Impaired airway mucosal immunity can contribute to increased respiratory tract infections in asthmatic patients, but the involved molecular mechanisms have not been fully clarified. Airway epithelial cells serve as the first line of respiratory mucosal defense to eliminate inhaled pathogens through various mechanisms, including Toll-like receptor (TLR) pathways. Our previous studies suggest that impaired TLR2 function in T(H)2 cytokine-exposed airways might decrease immune responses to pathogens and subsequently exacerbate allergic inflammation. IL-1 receptor-associated kinase M (IRAK-M) negatively regulates TLR signaling. However, IRAK-M expression in airway epithelium from asthmatic patients and its functions under a T(H)2 cytokine milieu remain unclear. Objectives: We sought to evaluate the role of IRAK-M in IL-13-inhibited TLR2 signaling in human airway epithelial cells. Methods: We examined IRAK-M protein expression in epithelia from asthmatic patients versus that in normal airway epithelia. Moreover, IRAK-M regulation and function in modulating innate immunity (eg, TLR2 signaling) were investigated in cultured human airway epithelial cells with or without IL-13 stimulation. Results: IRAK-M protein levels were increased in asthmatic airway epithelium. Furthermore, in primary human airway epithelial cells, IL-13 consistently upregulated IRAK-M expression, largely through activation of phosphoinositide 3-kinase pathway. Specifically, phosphoinositide 3-kinase activation led to c-Jun binding to human IRAK-M gene promoter and IRAK-M upregulation. Functionally, IL-13-induced IRAK-M suppressed airway epithelial TLR2 signaling activation (eg, TLR2 and human beta-defensin 2), partly through inhibiting activation of nuclear factor kappa B. Conclusions: Our data indicate that epithelial IRAK-M overexpression in T(H)2 cytokine-exposed airways inhibits TLR2 signaling, providing a novel mechanism for the increased susceptibility of infections in asthmatic patients. (J Allergy Clin Immunol 2012;129:825-33.)	[Wu, Qun; Jiang, Di; Smith, Sean; Thaikoottathil, Jyoti; Martin, Richard J.; Bowler, Russell P.; Chu, Hong Wei] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA; [Chu, Hong Wei] Natl Jewish Hlth, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Denver, CO 80202 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Denver	Chu, HW (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St,Room A639, Denver, CO 80206 USA.	chuhw@njhealth.org			National Institutes of Health [R01 AI070175, R01 HL088264]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070175] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R01 AI070175 and R01 HL088264.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Atochina-Vasserman EN, 2011, AM J RESP CRIT CARE, V183, P856, DOI 10.1164/rccm.201004-0654OC; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Birchler T, 2001, EUR J IMMUNOL, V31, P3131, DOI 10.1002/1521-4141(200111)31:11<3131::AID-IMMU3131>3.0.CO;2-G; Booth BW, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-51; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chen HT, 2011, J CELL BIOCHEM, V112, P1219, DOI 10.1002/jcb.23043; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Escoll P, 2003, BIOCHEM BIOPH RES CO, V311, P465, DOI 10.1016/j.bbrc.2003.10.019; Farghaly HSM, 2008, MOL PHARMACOL, V73, P1530, DOI 10.1124/mol.108.045419; Flannery S, 2010, BIOCHEM PHARMACOL, V80, P1981, DOI 10.1016/j.bcp.2010.06.020; Gross CA, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-30; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; He YY, 2004, J INVEST DERMATOL, V122, P533, DOI 10.1046/j.0022-202X.2003.22123.x; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Hubbard L. L., 2010, INFECT DIS REP, V2; Hwang-Verslues WW, 2008, MOL ENDOCRINOL, V22, P78, DOI 10.1210/me.2007-0298; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jayapal KP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002097; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lankford SM, 2005, IN VITRO CELL DEV-AN, V41, P217; Mendez-Samperio P, 2008, CELL IMMUNOL, V251, P37, DOI 10.1016/j.cellimm.2008.03.002; Mueller T, 2006, J IMMUNOL, V176, P5805, DOI 10.4049/jimmunol.176.10.5805; Nakashima K, 2006, J HUM GENET, V51, P284, DOI 10.1007/s10038-005-0358-1; Nasso M, 2009, J IMMUNOL, V183, P1892, DOI 10.4049/jimmunol.0901071; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Oshima N, 2010, CLIN EXP IMMUNOL, V159, P185, DOI 10.1111/j.1365-2249.2009.04048.x; Park GY, 2007, CLIN EXP IMMUNOL, V150, P245, DOI 10.1111/j.1365-2249.2007.03478.x; Pilette Charles, 2004, Proc Am Thorac Soc, V1, P125, DOI 10.1513/pats.2306032; Prescott SL, 2003, J PAEDIATR CHILD H, V39, P575, DOI 10.1046/j.1440-1754.2003.00237.x; Raby BA, 2003, HUM MOL GENET, V12, P1973, DOI 10.1093/hmg/ddg208; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Refaeli Y, 2005, P NATL ACAD SCI USA, V102, P4097, DOI 10.1073/pnas.0409832102; Sanak M, 2011, J ALLERGY CLIN IMMUN, V127, P1141, DOI 10.1016/j.jaci.2010.12.1108; Scotton CJ, 2005, J IMMUNOL, V174, P834, DOI 10.4049/jimmunol.174.2.834; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sevin CM, 2010, CLIN EXP ALLERGY, V40, P1142, DOI 10.1111/j.1365-2222.2010.03563.x; Shahabuddin S, 2006, AM J PHYSIOL-CELL PH, V291, pC34, DOI 10.1152/ajpcell.00441.2005; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Shen Q, 2011, J BIOL CHEM, V286, P14554, DOI 10.1074/jbc.M110.165704; Smith SM, 2011, J IMMUNOL, V186, P2462, DOI 10.4049/jimmunol.1000864; Su JM, 2007, CELL SIGNAL, V19, P1596, DOI 10.1016/j.cellsig.2007.02.009; Tomita T, 2002, RESPIROLOGY, V7, P305, DOI 10.1046/j.1440-1843.2002.00415.x; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wu Q, 2008, AM J RESP CRIT CARE, V177, P720, DOI 10.1164/rccm.200709-1387OC; Wu Q, 2011, AM J PHYSIOL-LUNG C, V300, pL579, DOI 10.1152/ajplung.00336.2010; Xiang LL, 2008, AM J RESP CELL MOL, V38, P310, DOI 10.1165/rcmb.2007-0078OC; Yeh TH, 2010, AMJ RHINOL ALLERGY, V24, P17, DOI 10.2500/ajra.2010.24.3381; Zacharioudaki V, 2009, J IMMUNOL, V182, P6444, DOI 10.4049/jimmunol.0803694	64	43	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					825	U330		10.1016/j.jaci.2011.10.043	http://dx.doi.org/10.1016/j.jaci.2011.10.043			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22154382	Green Accepted			2022-12-18	WOS:000301189300031
J	Omland, O; Hjort, C; Pedersen, OF; Miller, MR; Sigsgaard, T				Omland, Oyvind; Hjort, Charlotte; Pedersen, Ole Find; Miller, Martin R.; Sigsgaard, Torben			New-onset asthma and the effect of environment and occupation among farming and nonfarming rural subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Farming; bronchial hyperresponsiveness; smoking; welding; hygiene hypothesis	RESPIRATORY HEALTH; DAIRY FARMERS; WELDING FUMES; PREVALENCE; EXPOSURE; DETERMINANTS; SYMPTOMS; CHILDREN; SMOKING; DISEASE	Background: Many factors, including environmental exposures, have been related to the increase in the prevalence of asthma, but only few have been tested for in longitudinal studies. Objective: We studied farming students to determine whether their environment during childhood and as adults was a factor determining subsequent onset of asthma. Methods: From 1994 to 1998, new cases of asthma were identified by means of an annual posted questionnaire followed by a telephone interview in a prospective cohort consisting of 1964 farming-school students and 407 nonfarming subjects aged 16 to 26 years. For each case, we selected a control subject from the cohort with no asthma in a case-based design, and all underwent an interview and a clinical examination. Results: We found 122 new cases of asthma. In a multiple regression model the odds ratio for new asthma was 3.3 (95% CI, 1.7-6.3) for smoking; 3.4 (95% CI, 1.6-7.0), 2.5 (95% CI, 1.1-5.3), and 7.0 (95% CI, 1.2-41.6) for exposure to swine, dairy production, and welding, respectively; and 11.7 (95% CI, 2.4-56.4) for bronchial hyperresponsiveness at baseline. Being born and raised on a farm significantly reduced the risk odds ratio (0.5 [95% CI, 0.3-0.98]), whereas atopy had no influence. Conclusion: Exposure to swine and dairy confinements, welding, smoking, and bronchial hyperresponsiveness are risk factors for nonallergic asthma, and being born and raised on a farm reduces the subsequent risk. These findings support the theory that immune and inflammatory responses can be influenced by environmental exposure to early childhood, reducing the risk of asthma later in life. (J Allergy Clin Immunol 2011;128:761-5.)	[Omland, Oyvind] Aarhus Univ Hosp, Aalborg Hosp, Dept Occupat Med, DK-9100 Aalborg, Denmark; [Omland, Oyvind; Hjort, Charlotte; Pedersen, Ole Find; Sigsgaard, Torben] Univ Aarhus, Inst Publ Hlth, Dept Occupat & Environm Med, Aarhus, Denmark; [Miller, Martin R.] Univ Hosp Birmingham NHS Trust, Dept Med, Selly Oak Hosp, Birmingham, AL USA	Aalborg University; Aalborg University Hospital; Aarhus University; Aarhus University	Omland, O (corresponding author), Aarhus Univ Hosp, Aalborg Hosp, Dept Occupat Med, Havrevangen 1 PB 561, DK-9100 Aalborg, Denmark.	oo@rn.dk	Sigsgaard, Torben/AAC-1292-2020	Sigsgaard, Torben/0000-0002-2043-7571	Danish Medical Research Council; Danish Agricultural Research Council, Helsefonden; P.C. Petersens foundation; GM Electronics Kilwinning, United Kingdom; Danish Work Environment Research Fund; Danish Medical Research Fund	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Agricultural Research Council, Helsefonden; P.C. Petersens foundation; GM Electronics Kilwinning, United Kingdom; Danish Work Environment Research Fund; Danish Medical Research Fund	Supported by the Danish Medical Research Council, the Danish Agricultural Research Council, Helsefonden, and the P.C. Petersens foundation.; O. F. Pedersen has received royalties from GM Electronics Kilwinning, United Kingdom. T. Sigsgaard has received research support from the Danish Work Environment Research Fund and the Danish Medical Research Fund. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Backer V, 2002, ANN ALLERG ASTHMA IM, V89, P148, DOI 10.1016/S1081-1206(10)61930-8; Bakerly ND, 2008, OCCUP MED-OXFORD, V58, P169, DOI 10.1093/occmed/kqn007; Basagana X, 2001, AM J RESP CRIT CARE, V164, P1133, DOI 10.1164/ajrccm.164.7.2012143; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; Dalphin JC, 1998, AM J RESP CRIT CARE, V158, P1493, DOI 10.1164/ajrccm.158.5.9709108; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eduard W, 2004, AM J IND MED, V46, P396, DOI 10.1002/ajim.20088; Eisner MD, 2002, AM J RESP CRIT CARE, V165, P1566, DOI 10.1164/ajrccm.165.11.165112; Hammond SK, 2005, J OCCUP ENVIRON MED, V47, P728, DOI 10.1097/01.jom.0000165748.31326.e8; Hannu T, 2007, EUR RESPIR J, V29, P85, DOI 10.1183/09031936.00058106; Hannu T, 2005, EUR RESPIR J, V26, P736, DOI 10.1183/09031936.05.00130504; Jafari AJ, 2004, ARCH ENVIRON HEALTH, V59, P116, DOI 10.3200/AEOH.59.3.116-120; Jenkins PL, 2005, AM J IND MED, V47, P20, DOI 10.1002/ajim.20110; Kronqvist M, 1999, CLIN EXP ALLERGY, V29, P35, DOI 10.1046/j.1365-2222.1999.00452.x; Lillienberg L, 2008, ANN OCCUP HYG, V52, P107, DOI 10.1093/annhyg/mem063; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262, DOI 10.5271/sjweh.319; MILLER MR, 1994, EUR RESPIR J, V7, P198, DOI 10.1183/09031936.94.07010198; Munoz X, 2009, RESPIRATION, V78, P455, DOI 10.1159/000235817; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Omland O, 2002, ANN AGR ENV MED, V9, P119; Omland O, 2003, AM J RESP CRIT CARE, V167, pA160; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2002, ANN AGR ENV MED, V9, P207; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sigsgaard T., 1997, J AGROMEDICINE, V4, P63, DOI DOI 10.1300/J096V04N; Svanes C, 1998, RESP MED, V92, P1003, DOI 10.1016/S0954-6111(98)90345-6; Thomsen SF, 2005, CHEST, V127, P1928, DOI 10.1378/chest.127.6.1928; Toren K, 2004, EUR RESPIR J, V24, P942, DOI 10.1183/09031936.04.00044804; Ulrik C S, 1998, Ugeskr Laeger, V160, P2243; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Wang XB, 2004, AM J RESP CRIT CARE, V169, P941, DOI 10.1164/rccm.2201011; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	37	43	43	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					761	765		10.1016/j.jaci.2011.06.006	http://dx.doi.org/10.1016/j.jaci.2011.06.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21752438				2022-12-18	WOS:000296538100009
J	Fujita, H; Chalubinski, M; Rhyner, C; Indermitte, P; Meyer, N; Ferstl, R; Treis, A; Gomez, E; Akkaya, A; O'Mahony, L; Akdis, M; Akdis, CA				Fujita, Hiroyuki; Chalubinski, Maciej; Rhyner, Claudio; Indermitte, Philippe; Meyer, Norbert; Ferstl, Ruth; Treis, Angela; Gomez, Enrique; Akkaya, Ahmet; O'Mahony, Liam; Akdis, Muebeccel; Akdis, Cezmi A.			Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; airway smooth muscle; asthma; claudin-1; cytokine; IFN-gamma-induced protein 10; proliferation; tight junction; treatment; vascular endothelial growth factor	GAMMA-INDUCIBLE PROTEIN-10; ENDOTHELIAL GROWTH-FACTOR; IFN-GAMMA; TIGHT JUNCTIONS; T-CELLS; ANGIOGENESIS; MECHANISMS; DISEASE; CANCER; IP-10	Background: Increased airway smooth muscle (ASM) mass is an essential component of airway remodeling and asthma development, and there is no medication specifically against it. Tight junction (TJ) proteins, which are expressed in endothelial and epithelial cells and affect tissue integrity, might exist in other types of cells and display additional functions in the asthmatic lung. Objective: The aim of this study was to investigate the existence, regulation, and function of TJ proteins in ASM in asthmatic patients. Methods: The expression and function of TJ proteins in primary ASM cell lines, human bronchial biopsy specimens, and a murine model of asthma were analyzed by means of RT-PCR, multispectral imaging flow cytometry, immunohistochemistry, Western blotting, 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester staining, tritiated thymidine incorporation, wound-healing assay, and luminometric bead array. Results: Increased claudin-1 expression was observed in ASM of asthmatic patients, as well as in a murine model of asthma-like airway inflammation. Whereas IL-1 beta and TNF-alpha upregulated claudin-1 expression, it was downregulated by the T(H)2 cytokines IL-4 and IL-13 in primary human ASM cells. Claudin-1 was localized to the nucleus and cytoplasm but not to the cell surface in ASM cells. Claudin-1 played a central role in ASM cell proliferation, as demonstrated by increased ASM cell proliferation seen with overexpression and decreased proliferation seen with small interfering RNA knockdown of claudin-1. Overexpression of claudin-1 induced vascular endothelial growth factor and downregulated IL-6, IL-8, and IFN-gamma-induced protein 10 production by ASM cells. Claudin-1 upregulation by IL-1 beta or TNF-alpha was suppressed by dexamethasone but not by rapamycin, FK506, or salbutamol. Conclusion: These results demonstrate that claudin-1 might play a role in airway remodeling in asthmatic patients by means of regulation of ASM cell proliferation, angiogenesis, and inflammation. (J Allergy Clin Immunol 2011;127:1612-21.)	[Fujita, Hiroyuki; Chalubinski, Maciej; Rhyner, Claudio; Indermitte, Philippe; Meyer, Norbert; Ferstl, Ruth; Treis, Angela; Gomez, Enrique; O'Mahony, Liam; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Fujita, Hiroyuki; Chalubinski, Maciej] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland; [Akkaya, Ahmet] Suleyman Demirel Univ, Sch Med, TR-32200 Isparta, Turkey	Swiss Institute of Allergy & Asthma Research; University of Zurich; Suleyman Demirel University	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	fujita@siaf.uzh.ch; akdisac@siaf.uzh.ch	O'Mahony, Liam/AAG-5838-2019; Akdis, Cezmi/AAV-4844-2020; Ferstl, Ruth/ABB-9679-2021	O'Mahony, Liam/0000-0003-4705-3583; Akdis, Cezmi/0000-0001-8020-019X; Gomez Alcaide, Enrique/0000-0003-0542-303X; Chalubinski, Maciej/0000-0001-8311-9530	Swiss National Science Foundation [320030-132899]; European Asthma and Allergy Center Davos (EACD); Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Commission	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Asthma and Allergy Center Davos (EACD); Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Commission(European CommissionEuropean Commission Joint Research Centre)	The authors' laboratory is supported by Swiss National Science Foundation grants 320030-132899, the European Asthma and Allergy Center Davos (EACD), and the Christine Kuhne Center for Allergy Research and Education (CK-CARE).; L. O'Mahony has collaborated with Alimentary Health Ltd and has received research support from the Swiss National Science Foundation. M. Akdis has received research support from the Swiss National Science Foundation and the European Commission. The rest of the authors have declared that they have no conflict of interest.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Bujak M, 2009, CIRC RES, V105, P973, DOI 10.1161/CIRCRESAHA.109.199471; Camoretti-Mercado B, 2009, TRANSL RES, V154, P165, DOI 10.1016/j.trsl.2009.06.008; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Keane MP, 1999, J IMMUNOL, V163, P5686; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kusch A, 2009, CARDIOVASC RES, V83, P115, DOI 10.1093/cvr/cvp117; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155; Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Pace TWW, 2009, ANN NY ACAD SCI, V1179, P86, DOI 10.1111/j.1749-6632.2009.04984.x; Pascual RM, 2009, J ALLERGY CLIN IMMUN, V124, P883, DOI 10.1016/j.jaci.2009.09.047; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Tang YM, 2010, AM J PATHOL, V176, P158, DOI 10.2353/ajpath.2010.090548; Taylor A, 2007, J ALLERGY CLIN IMMUN, V120, P76, DOI 10.1016/j.jaci.2007.04.004; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Weber CR, 2008, LAB INVEST, V88, P1110, DOI 10.1038/labinvest.2008.78; Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015; Zimmerli SC, 2007, J INVEST DERMATOL, V127, P2381, DOI 10.1038/sj.jid.5700882	41	43	45	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1612	U458		10.1016/j.jaci.2011.03.039	http://dx.doi.org/10.1016/j.jaci.2011.03.039			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21624620				2022-12-18	WOS:000291048500044
J	Laidlaw, TM; Steinke, JW; Tinana, AM; Feng, CL; Xing, W; Lam, BK; Paruchuri, S; Boyce, JA; Borish, L				Laidlaw, Tanya M.; Steinke, John W.; Tinana, Adrienne M.; Feng, Chunli; Xing, Wei; Lam, Bing K.; Paruchuri, Sailaja; Boyce, Joshua A.; Borish, Larry			Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional Fc is an element of RI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; stem cell factor; Fc is an element of RI; c-kit; tryptase; carboxypeptidase A3	GASTROINTESTINAL STROMAL TUMORS; LEUKOTRIENE C-4 SYNTHASE; BLOOD MONONUCLEAR-CELLS; PROTOONCOGENE C-KIT; EPSILON-RI; IN-VITRO; CATALYTIC DOMAIN; IMMUNOGLOBULIN-E; GAMMA-RI; ACTIVATION	Background: Studies of human mast cells (MCs) are constrained by the paucity of functional cell lines, the expense of maintaining MCs in culture, and technical complexities. Objective: We derived and characterized a human MC line that arose spontaneously from a culture of nontransformed hematopoietic progenitor cells. Methods: CD34(+) enriched mononuclear cells derived from a donor with aspirin-exacerbated respiratory disease were cultured for 8 weeks with stem cell factor and IL-6 and with IL-3 for the first week only. The cells (termed LUVA cells) survived and proliferated without further addition of any growth factors and have been maintained in culture for approximately 2 years. Results: LUVA cells possess metachromatic cytoplasmic granules that are immunoreactive for tryptase, cathepsin G, and carboxypeptidase A3. They express transcripts encoding Fc is an element of RI, c-kit, chymase, tryptase, histidine decarboxylase, carboxypeptidase A3, and the type 1 receptor for cysteinyl leukotrienes. Flow cytometry confirmed uniform expression of Fc is an element of RI, c-kit, and Fc gamma RII. Fc is an element of RI cross-linkage induced the release of beta-hexosaminidase, prostaglandin D-2, thromboxane A(2), and macrophage inflammatory protein 1 beta. Immortalization was not associated with either a known genomic mutation of c-kit in the donor or a somatic mutation of c-kit within the cells, and it was not associated with c-kit autophosphorylation. Conclusions: LUVA cells are an immortalized human MC line that can be maintained without stem cell factor and display high levels of normally signaling c-kit and Fc is an element of RI. These cells will prove valuable for functional human MC studies. (J Allergy Clin Immunol 2011;127:815-22.)	[Laidlaw, Tanya M.; Feng, Chunli; Xing, Wei; Lam, Bing K.; Paruchuri, Sailaja; Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Laidlaw, Tanya M.; Feng, Chunli; Xing, Wei; Lam, Bing K.; Paruchuri, Sailaja; Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Laidlaw, Tanya M.; Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA; [Steinke, John W.; Borish, Larry] Univ Virginia, Dept Med, Charlottesville, VA USA; [Steinke, John W.; Tinana, Adrienne M.; Borish, Larry] Univ Virginia, Div Allergy & Immunol, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Virginia; University of Virginia	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Room 638,1 Jimmy Fund Way, Boston, MA 02115 USA.	Jboyce@rics.bwh.harvard.edu			National Institutes of Health [AI-57438, AI-50989, AI-52353, AI-31599, AI 07306, HL-36110]; Charles A. Dana Foundation; American Academy of Allergy, Asthma Immunology; Merck; Genentech; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, P01AI050989, R01AI078908, T32AI007306, R01AI052353, R21AI082369, R01AI057438, U01AI031599, R56AI052353] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles A. Dana Foundation; American Academy of Allergy, Asthma Immunology; Merck(Merck & Company); Genentech(Roche HoldingGenentech); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI-57438, AI-50989, AI-52353, AI-31599, AI 07306, and HL-36110; by a grant from the Charles A. Dana Foundation; and by generous contributions from the Vinik Family. T.M.L. was supported by an American Academy of Allergy, Asthma & Immunology third-and fourth-year Fellow's Award.; J. W. Steinke has received research support from the National Institutes of Health. J. A. Boyce has received research support from the National Institutes of Health and Merck. L. Borish has consulted for Hoffman LaRoche, Cephalon, Regeneron, and Pfizer; has received honoraria and research support from Merck; and has received research support from Genentech. The rest of the authors have declared that they have no conflict of interest.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Boyce JA, 1996, BLOOD, V88, P4338; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Fajt ML, 2009, J ALLERGY CLIN IMMUN, V123, pS214, DOI 10.1016/j.jaci.2008.12.819; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Guhl S, 2010, EXP DERMATOL, V19, P845, DOI 10.1111/j.1600-0625.2010.01103.x; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; HUMPHRIES DE, 1992, J BIOL CHEM, V267, P13558; IRANI AMA, 1991, J IMMUNOL, V147, P247; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Saito H, 1996, J IMMUNOL, V157, P343; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; Schernthaner GH, 2005, ALLERGY, V60, P1248, DOI 10.1111/j.1398-9995.2005.00865.x; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Tanaka A, 2005, BLOOD, V105, P2324, DOI 10.1182/blood-2004-08-3247; Thienemann F, 2004, ARCH DERMATOL RES, V296, P134, DOI 10.1007/s00403-004-0486-z; Toru H, 1996, INT IMMUNOL, V8, P1367; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	34	43	46	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					815	U499		10.1016/j.jaci.2010.12.1101	http://dx.doi.org/10.1016/j.jaci.2010.12.1101			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21281958	Green Accepted			2022-12-18	WOS:000288018400037
J	Durham, SR; Leung, DYM				Durham, Stephen R.; Leung, Donald Y. M.			One hundred years of allergen immunotherapy: Time to ring the changes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; TERM CLINICAL-EFFICACY; SUBLINGUAL IMMUNOTHERAPY; DERMATOPHAGOIDES-PTERONYSSINUS; HAY-FEVER; ASTHMA; MECHANISMS; CHILDREN; SAFETY; RHINITIS		[Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Durham, Stephen R.] Royal Brompton Hosp, London SW3 6LY, England; [Leung, Donald Y. M.] Natl Jewish Heath, Denver, CO USA	Imperial College London; Royal Brompton Hospital	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk						Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bousquet PJ, 2011, J ALLERGY CLIN IMMUN, V127, P49, DOI 10.1016/j.jaci.2010.09.017; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Canonica GW, 2011, J ALLERGY CLIN IMMUN, V127, P44, DOI 10.1016/j.jaci.2010.09.037; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2010, CURR MED RES OPIN, V26, P2723, DOI 10.1185/03007995.2010.528647; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; FRANKLAND AW, 1954, LANCET, V1, P1055; Frankland AW, 2011, J ALLERGY CLIN IMMUN, V127, P160; Freeman J, 1930, LANCET, V1, P744; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Hankin CS, 2011, J ALLERGY CLIN IMMUN, V127, P46, DOI 10.1016/j.jaci.2010.10.014; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Johansson SGO, 1967, NOB S 3 GAMM GLOB ST, P193; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larche M, 2010, J ALLERGY CLIN IMMUN, V126, P646, DOI 10.1016/j.jaci.2010.07.027; Lockey RF, 2011, J ALLERGY CLIN IMMUN, V127, P39, DOI 10.1016/j.jaci.2010.09.033; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Prausnitz C., 1921, CENT BAKTERIO, V86, P160; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; Ree R, 2004, ALLERGY, V59, P571, DOI 10.1111/j.1398-9995.2004.00499.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Tabar AI, 2011, J ALLERGY CLIN IMMUN, V127, P57, DOI 10.1016/j.jaci.2010.10.025; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; WARNER JO, 1978, LANCET, V2, P912; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Yamanaka K, 2009, J ALLERGY CLIN IMMUN, V124, P842, DOI 10.1016/j.jaci.2009.06.020; Zielen S, 2010, J ALLERGY CLIN IMMUN, V126, P942, DOI 10.1016/j.jaci.2010.06.002	85	43	47	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					3	7		10.1016/j.jaci.2010.11.032	http://dx.doi.org/10.1016/j.jaci.2010.11.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211638				2022-12-18	WOS:000285917300001
J	Zhang, ZM; Lai, HCJ; Roberg, KA; Gangnon, RE; Evans, MD; Anderson, EL; Pappas, TE; DaSilva, DF; Tisler, CJ; Salazar, LP; Gern, JE; Lemanske, RF				Zhang, Zhumin; Lai, HuiChuan J.; Roberg, Kathy A.; Gangnon, Ronald E.; Evans, Michael D.; Anderson, Elizabeth L.; Pappas, Tressa E.; DaSilva, Douglas F.; Tisler, Christopher J.; Salazar, Lisa P.; Gern, James E.; Lemanske, Robert F., Jr.			Early childhood weight status in relation to asthma development in high-risk children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; overweight; children; high-risk birth cohort	LOW-BIRTH-WEIGHT; ADULT RESPIRATORY-FUNCTION; EARLY-LIFE ORIGINS; HUMAN-LUNG; POSTNATAL-DEVELOPMENT; RHINOVIRUS ILLNESSES; BODY-SIZE; GROWTH; OBESITY; OVERWEIGHT	Background: Obesity has been proposed to be a risk factor for the development of childhood asthma. Objective: We sought to examine weight status from birth to age 5 years in relation to the occurrence of asthma at ages 6 and 8 years. Methods: Two hundred eighty-five full-term high-risk newborns with at least 1 asthmatic/atopic parent enrolled in the Childhood Origin of Asthma project were studied from birth to age 8 years. Overweight was defined by weight-for-length percentiles of greater than the 85th percentile before the age of 2 years and a body mass index percentile of greater than the 85th percentile at ages 2 to 5 years. Results: No significant concurrent association was found between overweight status and wheezing/asthma occurrence at each year of age. In contrast, longitudinal analyses revealed complex relationships between being overweight and asthma. Being overweight at age 1 year was associated with a decreased risk of asthma at age 6 (odds ratio [OR], 0.32; P=.02) and 8 (OR, 0.35; P=.04) years, as well as better lung function. However, being overweight beyond infancy was not associated with asthma occurrence. In fact, only children who were overweight at age 5 years but not at age 1 year had an increased risk of asthma at age 6 years (OR, 5.78; P=.05). Conclusion: In children genetically at high risk of asthma, being overweight at age 1 year was associated with a decreased risk of asthma and better lung function at ages 6 and 8 years. However, being overweight beyond infancy did not have any protective effect and even could confer a higher risk for asthma. (J Allergy Clin Immunol 2010;126:1157-62.)	[Zhang, Zhumin; Lai, HuiChuan J.] Univ Wisconsin, Dept Nutr Sci, Coll Agr & Life Sci, Madison, WI 53706 USA; [Lai, HuiChuan J.; Gangnon, Ronald E.; Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Lai, HuiChuan J.; Roberg, Kathy A.; Anderson, Elizabeth L.; Pappas, Tressa E.; DaSilva, Douglas F.; Tisler, Christopher J.; Salazar, Lisa P.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Zhang, ZM (corresponding author), Univ Wisconsin, Dept Nutr Sci, Coll Agr & Life Sci, 1415 Linden Dr, Madison, WI 53706 USA.	zhuminzhang@wisc.edu		Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714	National Institutes of Health [R01 HL61879, P01 HL70831]; US Department of Agriculture [WIS01228]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD061879] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, R01HL061879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061879] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Agriculture(United States Department of Agriculture (USDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Supported by National Institutes of Health grants R01 HL61879 and P01 HL70831 and US Department of Agriculture Hatch Multi-State Grant WIS01228.	Baird J, 2005, BMJ-BRIT MED J, V331, P929, DOI 10.1136/bmj.38586.411273.E0; Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Brooks AM, 2001, ARCH PEDIAT ADOL MED, V155, P401, DOI 10.1001/archpedi.155.3.401; Canoy D, 2007, THORAX, V62, P396, DOI 10.1136/thx.2006.066241; Chinn S, 2006, PAEDIATR RESPIR REV, V7, P223, DOI 10.1016/j.prrv.2006.04.007; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Desai M, 1997, BIOL REV, V72, P329, DOI 10.1017/S0006323196005026; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Hancox RJ, 2009, THORAX, V64, P228, DOI 10.1136/thx.2008.103978; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kuczmarski R.J., 2000, CDC GROWTH CHARTS US; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lucas SR, 2006, PAEDIATR RESPIR REV, V7, P233, DOI 10.1016/j.prrv.2006.08.001; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL715, DOI 10.1152/ajplung.00166.2004; Mei ZG, 2002, AM J CLIN NUTR, V75, P978, DOI 10.1093/ajcn/75.6.978; Merkus PJFM, 1996, PEDIATR PULM, V21, P383, DOI 10.1002/(SICI)1099-0496(199606)21:6<383::AID-PPUL6>3.0.CO;2-M; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Newnham JP, 2009, OBSTET GYN CLIN N AM, V36, P227, DOI 10.1016/j.ogc.2009.03.004; Ong KK, 2006, HORM RES, V65, P65, DOI 10.1159/000091508; Orfei L, 2008, ARCH DIS CHILD, V93, P570, DOI 10.1136/adc.2006.112201; Peroni DG, 2010, INT J OBESITY, V34, P599, DOI 10.1038/ijo.2009.273; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; Steffensen FH, 2000, EPIDEMIOLOGY, V11, P185, DOI 10.1097/00001648-200003000-00018; Stunkard AJ, 2004, INT J OBESITY, V28, P503, DOI 10.1038/sj.ijo.0802517; Stunkard AJ, 1999, AM J CLIN NUTR, V69, P524; Tantisira KG, 2001, THORAX, V56, P64; Tennant PWG, 2008, THORAX, V63, P823, DOI 10.1136/thx.2008.096388; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240; ZELTNER TB, 1987, RESP PHYSIOL, V67, P269, DOI 10.1016/0034-5687(87)90058-2; ZELTNER TB, 1987, RESP PHYSIOL, V67, P247, DOI 10.1016/0034-5687(87)90057-0	41	43	45	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1157	1162		10.1016/j.jaci.2010.09.011	http://dx.doi.org/10.1016/j.jaci.2010.09.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21051081	Green Accepted, Bronze			2022-12-18	WOS:000284947800011
J	Ng, WF; von Delwig, A; Carmichael, AJ; Arkwright, PD; Abinun, M; Cant, AJ; Jolles, S; Lilic, D				Ng, Wan-Fai; von Delwig, Alexei; Carmichael, Andrew J.; Arkwright, Peter D.; Abinun, Mario; Cant, Andrew J.; Jolles, Stephen; Lilic, Desa			Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Candida species; chronic mucocutaneous candidiasis; autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; autoimmune polyendocrinopathy type 1; autoimmune regulator; primary immunodeficiency; T(H)17; IL-22; IFN-gamma; cytokines	PRIMARY IMMUNODEFICIENCIES; CELL-DIFFERENTIATION; HOST-DEFENSE; TH17 CELLS; AUTOANTIBODIES; MUTATIONS; IL-22; IL-17; DEFICIENCY; EXPRESSION	Background: Accumulating evidence implicates T(H)17 cytokines in protection against Candida species infections, but the clinical relevance is not clear. Chronic mucocutaneous candidiasis (CMC) is a heterogeneous syndrome with the unifying feature of selective susceptibility to chronic candidiasis. Different subgroups with distinct clinical features are recognized, including autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), CMC with hypothyroidism, and isolated CMC. Understanding immune defects in patients with CMC will define cellular and molecular mechanisms crucial for protection against Candida species in human subjects. Objectives: We sought to determine whether impaired T(H)17 responses underlie susceptibility to Candida species infections and whether the same defect is present in different CMC subgroups. Methods: We assessed T(H)17 responses of PBMCs to Candida and non-Candida species stimuli by measuring IL-17, IL-22, IL-21, IL-6, IL-23, and IFN-gamma cytokine production using cytokine arrays and intracellular cytokine-producing cell numbers and proliferation with flow cytometry. PBMCs from healthy subjects and unaffected family members served as controls. Results: In patients with CMC with hypothyroidism, TH17 cells demonstrated decreased proliferation and IL-17 production in response to Candida species. In contrast, in patients with APECED, TH17 cell proliferation and IL-17 production were normal unless exposed to APECED plasma, which inhibited both functions in both APECED and normal PBMCs. Candida species-stimulated IL-22 production was impaired in all patients with CMC, whereas IL-6 and IL-23 responses were unaltered. Conclusion: An impaired T(H)17 response to Candida species, although mediated by different mechanisms, was present in all CMC subgroups studied and might be a common factor predisposing to chronic candidiasis. (J Allergy Clin Immunol 2010;126:1006-15.)	[Ng, Wan-Fai; von Delwig, Alexei; Lilic, Desa] Newcastle Univ, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Carmichael, Andrew J.] James Cook Univ Hosp, Dept Dermatol, Middlesbrough, Cleveland, England; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Dept Child Hlth, Manchester M13 9PL, Lancs, England; [Abinun, Mario; Cant, Andrew J.] Newcastle Gen Hosp, Dept Paediat Immunol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Jolles, Stephen] Univ Wales Hosp, Dept Med Biochem & Immunol, Cardiff CF4 4XW, S Glam, Wales	Newcastle University - UK; James Cook University Hospital; Royal Manchester Children's Hospital; University of Manchester; Newcastle General Hospital; Cardiff University	Lilic, D (corresponding author), Newcastle Univ, Inst Cellular Med, Musculoskeletal Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Desa.Lilic@ncl.ac.uk	Arkwright, Peter/C-5149-2012; Ng, Wan-Fai/R-8083-2016	von Delwig, Alexei/0000-0003-2978-4761; Jolles, Stephen/0000-0002-7394-6804; Arkwright, Peter/0000-0002-7411-5375; Ng, Wan-Fai/0000-0002-5539-388X	Primary Immunodeficiency Association; JGW Patterson Foundation Trust; Faculty of Medical Sciences, Newcastle University; Arthritis Research Campaign; CSL Behring	Primary Immunodeficiency Association; JGW Patterson Foundation Trust; Faculty of Medical Sciences, Newcastle University; Arthritis Research Campaign(Versus Arthritis); CSL Behring	Supported by the Primary Immunodeficiency Association, the JGW Patterson Foundation Trust, and the Faculty of Medical Sciences, Newcastle University. Salary support for W. F. N. was provided by the Arthritis Research Campaign.; S. Jolles has received research support from the Primary Immunodeficiency Association and CSL Behring. The rest of the authors have declared that they have no conflict of interest.	ABINUN M, 1995, PROGR IMMUNE DEFICIE, P255; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lilic D, 1996, CLIN EXP IMMUNOL, V105, P205, DOI 10.1046/j.1365-2249.1996.d01-764.x; Lilic D, 2003, INFECT IMMUN, V71, P5690, DOI 10.1128/IAI.71.10.5690-5699.2003; LILIC D, 2007, IMMUNOLOGY FUNGAL IN, P361; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Meloni A, 2008, J CLIN ENDOCR METAB, V93, P4389, DOI 10.1210/jc.2008-0935; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Moschen AR, 2008, IMMUNOBIOLOGY, V213, P779, DOI 10.1016/j.imbio.2008.07.022; Pessach I, 2009, PEDIATR RES, V65, p3R, DOI 10.1203/PDR.0b013e31819dbe1e; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Ryan KR, 2008, CLIN EXP IMMUNOL, V154, P406, DOI 10.1111/j.1365-2249.2008.03778.x; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Wolff ASB, 2010, SCAND J IMMUNOL, V71, P459, DOI 10.1111/j.1365-3083.2010.02397.x; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007	30	43	44	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1006	U171		10.1016/j.jaci.2010.08.027	http://dx.doi.org/10.1016/j.jaci.2010.08.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20934207				2022-12-18	WOS:000283727100017
J	Meyers, DA				Meyers, Deborah A.			Genetics of asthma and allergy: What have we learned?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; genetics; asthma genetics; genomics; genome-wide association study; IgE	GENOME-WIDE ASSOCIATION; LUNG-FUNCTION DECLINE; ADAM33 GENE; POLYMORPHISMS; VARIANTS; RISK; SUSCEPTIBILITY; GENOTYPE; ORMDL3; COPD	The overall purpose of this review is to present an update on genetic approaches to understanding the susceptibility and expression (severity) of common diseases, such as asthma and allergy. Five key questions are addressed in this review: (1) What phenotypes are being studied? Multiple disease phenotypes in carefully characterized patients are required. (2) Are the same genes that are important in disease susceptibility important in disease severity? (3) Are there racial differences in disease expression and genetic susceptibility? (4) Are the genes important in normal variation in lung function important in asthma severity? (5) Are the genes important in other common diseases, such as chronic inflammatory diseases or chronic obstructive pulmonary disease, important in asthma or allergy? In addition, a discussion of some of current areas of research is presented, including the issue that current genome-wide association study results do not account for a significant portion of trait variability, the potential role of rare variants and large genome-sequencing studies, and pharmacogenetics: is there a role for basing treatment decisions on the results of genetic testing? Finally, the potential usefulness of DNA, personalized medicine, is discussed. (J Allergy Clin Immunol 2010;126:439-46.)	[Meyers, Deborah A.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Meyers, DA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wfubmc.edu			Aerovance; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101487] Funding Source: NIH RePORTER	Aerovance; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	D. A. Meyers has received research support from Aerovance and the National Heart, Lung, and Blood Institute.	Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]; Celedon JC, 2004, HUM MOL GENET, V13, P1649, DOI 10.1093/hmg/ddh171; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Demeo DL, 2008, AM J RESP CELL MOL, V38, P114, DOI 10.1165/rcmb.2007-0107OC; Feero WG, 2010, NEW ENGL J MED, V362, P2001, DOI 10.1056/NEJMra0907175; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; He JQ, 2009, THORAX, V64, P698, DOI 10.1136/thx.2008.111278; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Johnson AD, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-6; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; *NAT ASTHM ED PREV, 2007, NAT HEART LUNG BLOOD; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Sadeghnejad A, 2007, AM J RESP CRIT CARE, V176, P748, DOI 10.1164/rccm.200704-543OC; Sadeghnejad A, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-21; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vercelli D, 2010, J ALLERGY CLIN IMMUN, V125, P347, DOI 10.1016/j.jaci.2009.12.976; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weiss ST, 2010, AM J RESP CRIT CARE, V181, P1170, DOI 10.1164/rccm.201001-0069PP; Wjst M, 2008, CLIN EXP ALLERGY, V38, P1579, DOI 10.1111/j.1365-2222.2008.03086.x; WU H, 2010, J ALLERGY CLIN IMMUN, V125, pE13; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Wu L, 2004, THORAX, V59, P126, DOI 10.1136/thorax.2003.005769; Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819	39	43	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					439	446		10.1016/j.jaci.2010.07.012	http://dx.doi.org/10.1016/j.jaci.2010.07.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816180	Green Accepted			2022-12-18	WOS:000281512500004
J	Nyenhuis, SM; Schwantes, EA; Evans, MD; Mathur, SK				Nyenhuis, Sharmilee M.; Schwantes, Elizabeth A.; Evans, Michael D.; Mathur, Sameer K.			Airway neutrophil inflammatory phenotype in older subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Nyenhuis, Sharmilee M.; Schwantes, Elizabeth A.; Evans, Michael D.; Mathur, Sameer K.] Univ Wisconsin, Dept Med, Sect Allergy Pulm & Crit Care, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Nyenhuis, Sharmilee M.] Univ Illinois, Dept Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL 60680 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nyenhuis, SM (corresponding author), Univ Wisconsin, Dept Med, Sect Allergy Pulm & Crit Care, Madison, WI 53706 USA.	sm4@medicine.wisc.edu		Nyenhuis, Sharmilee/0000-0002-7381-9733; Evans, Michael/0000-0001-7449-3993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL088594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL088594-02, P01 HL088594] Funding Source: Medline; NIAID NIH HHS [T32 AI007635-11, T32 AI007635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerji A, 2006, J AM GERIATR SOC, V54, P48, DOI 10.1111/j.1532-5415.2005.00563.x; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Mathur SK, 2008, CHEST, V133, P412, DOI 10.1378/chest.07-2114; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	9	43	45	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1163	1165		10.1016/j.jaci.2010.02.015	http://dx.doi.org/10.1016/j.jaci.2010.02.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20381851	Green Accepted			2022-12-18	WOS:000277686700031
J	Vale, AM; Schroeder, HW				Vale, Andre M.; Schroeder, Harry W., Jr.			Clinical consequences of defects in B-cell development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B-cell development; human; B-cell immune deficiencies; review	BRUTONS TYROSINE KINASE; CYTIDINE DEAMINASE AID; GERMINAL-CENTERS; RHEUMATOID-ARTHRITIS; GENE MUTATION; HYPER-IGM; AGAMMAGLOBULINEMIA; ACTIVATION; LYMPHOCYTE; EXPRESSION	Abnormalities in humoral immunity typically reflect a generalized or selective failure of effective B-cell development. The developmental processes can be followed through analysis of cell-surface markers, such as IgM, IgD, CD10, CD19, CD20, CD21, and CD38. Early phases of B-cell development are devoted to the creation of immunoglobulin and testing of B-cell antigen receptor signaling. Failure leads to the absence of B cells and immunoglobulin in the blood from birth. As the developing B cells begin to express a surface B-cell receptor, they become subject to negative and positive selection pressures and increasingly depend on survival signals. Defective signaling can lead to selective or generalized hypogammaglobulinemia, even in the presence of normal numbers of B cells. In the secondary lymphoid organs some B cells enter the splenic marginal zone, where preactivated cells lie ready to rapidly respond to T-independent antigens, such as the polysaccharides that coat some microorganisms. Other cells enter the follicle and, with the aid of cognate follicular T cells, divide to help form a germinal center (GC) after their interaction with antigen. In the GC B cells can undergo the processes of class switching and somatic hypermutation. Failure to properly receive T-cell signals can lead to hyper-IgM syndrome. B cells that leave the GC can develop into memory B cells, short-lived plasma cells, or long-lived plasma cells. The latter ultimately migrate back to the bone marrow, where they can continue to produce protective antigen-specific antibodies for decades. (J Allergy Clin Immunol 2010;125:778-87.)	[Vale, Andre M.; Schroeder, Harry W., Jr.] Univ Alabama, Div Clin Immunol & Rheumatol, Dept Med, Birmingham, AL 35294 USA; [Schroeder, Harry W., Jr.] Univ Alabama, Div Clin Immunol & Rheumatol, Dept Microbiol, Birmingham, AL 35294 USA; [Schroeder, Harry W., Jr.] Univ Alabama, Div Clin Immunol & Rheumatol, Dept Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Schroeder, HW (corresponding author), Univ Alabama, Div Clin Immunol & Rheumatol, Dept Med, SHEL 176,1530 3rd Ave S, Birmingham, AL 35294 USA.	hwsj@uab.edu		Schroeder, Harry/0000-0002-3767-6878; Vale, Andre/0000-0001-7501-2370	National Institutes of Health [AI48115, AI078449, AI079741]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078449, R21AI079741, R56AI048115, U01AI090902, R21AI088498, R01AI090742, R01AI048115] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants AI48115, AI078449, and AI079741.	AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; Camacho SA, 1998, IMMUNOL TODAY, V19, P511, DOI 10.1016/S0167-5699(98)01327-9; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Castigli E, 2006, J ALLERGY CLIN IMMUN, V117, P740, DOI 10.1016/j.jaci.2006.01.038; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X; Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Durandy A, 2005, IMMUNOL REV, V203, P67, DOI 10.1111/j.0105-2896.2005.00222.x; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Ehrhardt GRA, 2008, J EXP MED, V205, P1807, DOI 10.1084/jem.20072682; Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879; FACCHETTI F, 1995, J IMMUNOL, V154, P6624; Fagarasan S, 2004, CURR OPIN IMMUNOL, V16, P277, DOI 10.1016/j.coi.2004.03.005; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Ferrari S, 2007, J EXP MED, V204, P2047, DOI 10.1084/jem.20070264; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Haas KM, 2005, ADV EXP MED BIOL, V560, P125; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Ishiai M, 1999, J IMMUNOL, V163, P1746; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kim HJ, 2000, ARTHRITIS RES, V2, P126, DOI 10.1186/ar77; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; LEBIEN TW, 1989, BLOOD, V73, P625; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; Lopes-Carvalho T, 2005, CURR OPIN IMMUNOL, V17, P244, DOI 10.1016/j.coi.2005.04.009; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Milne CD, 2006, SEMIN IMMUNOL, V18, P20, DOI 10.1016/j.smim.2005.10.003; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Nunez C, 1996, J IMMUNOL, V156, P866; Popoff IJ, 1998, MOL IMMUNOL, V35, P207, DOI 10.1016/S0161-5890(98)00042-X; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rothenberg EV, 1999, BIOESSAYS, V21, P726, DOI 10.1002/(SICI)1521-1878(199909)21:9<726::AID-BIES4>3.0.CO;2-S; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Sun J, 2003, J IMMUNOL, V170, P1699, DOI 10.4049/jimmunol.170.4.1699; Tavian M, 2001, IMMUNITY, V15, P487, DOI 10.1016/S1074-7613(01)00193-5; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; Wagner SD, 1996, ANNU REV IMMUNOL, V14, P441, DOI 10.1146/annurev.immunol.14.1.441; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; Wang Y, 2002, AM J MED GENET, V108, P333, DOI 10.1002/ajmg.10296; Wardemann H, 2007, ADV IMMUNOL, V95, P83, DOI 10.1016/S0065-2776(07)95003-8; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Weyand CM, 1998, SPRINGER SEMIN IMMUN, V20, P5, DOI 10.1007/BF00831996; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003	67	43	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					778	787		10.1016/j.jaci.2010.02.018	http://dx.doi.org/10.1016/j.jaci.2010.02.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371392	Green Accepted			2022-12-18	WOS:000276787900001
J	Pacciani, V; Gregori, S; Chini, L; Corrente, S; Chianca, M; Moschese, V; Rossi, P; Roncarolo, MG; Angelini, F				Pacciani, Valentina; Gregori, Silvia; Chini, Loredana; Corrente, Stefania; Chianca, Marco; Moschese, Viviana; Rossi, Paolo; Roncarolo, Maria Grazia; Angelini, Federica			Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; dendritic cells; Der p 2; house dust mites; IL-10; T(H)2 cells; Tr1 cells	REGULATORY CELLS; SUBLINGUAL IMMUNOTHERAPY; CYTOKINE PRODUCTION; IN-VITRO; DERMATOPHAGOIDES-PTERONYSSINUS; AIRWAY HYPERRESPONSIVENESS; AUTOIMMUNE-DISEASE; NONATOPIC CHILDREN; MONONUCLEAR-CELLS; IMMUNE-RESPONSES	Background: Dendritic cells (DCs) regulate the immune response to allergens in the lung; they induce either effector or regulatory T cells, which promote or suppress, respectively, the development of allergy. IL-10 is a potent immunosuppressive cytokine that induces type 1 regulatory (Tr1) T cells. Objective: To generate allergen-specific Tr1 cells in vitro from children with allergy. Methods: Monocyte-derived DCs from children with allergy to house dust mites (HDM) were generated by incubating the cells with IL-10 and pulsing them with Der p 2, a major HDM allergen, or by pulsing them with Der p 2 and incubating them with IL-10 during their last 2 days of differentiation. Results: Der p 2 specific T-cell proliferation and T(H)2 cytokine production were significantly reduced when T cells from patients with allergy to HDM were activated with autologous Der p 2 pulsed DCs that had been differentiated or incubated with IL-10. T-cell lines generated with Der p 2 pulsed DCs that were differentiated with IL-10 were hyporesponsive to reactivation with Der p 2 and able to suppress Der p 2 specific T(H)2 effector cells. Conclusion: Dendritic cells differentiated in the presence of IL-10 and pulsed with allergen gave rise to a population of tolerogenic DCs that induced allergen-specific Tr1 cells. This finding represents an important step forward to the prospective clinical application of tolerogenic DCs to modulate allergen-specific T-cell responses. (J Allergy Clin Immunol 2010;125:727-36.)	[Chini, Loredana; Corrente, Stefania; Chianca, Marco; Moschese, Viviana; Rossi, Paolo; Angelini, Federica] Univ Roma Tor Vergata, Div Pediat, I-00133 Rome, Italy; [Pacciani, Valentina; Rossi, Paolo; Angelini, Federica] Bambino Gesu Pediat Hosp, Dept Pediat Med, Immuno Infectivol Unit, Rome, Italy; [Pacciani, Valentina; Gregori, Silvia; Roncarolo, Maria Grazia] San Raffaele Telethon Inst Gene Therapy, HSR TIGET, Milan, Italy; [Roncarolo, Maria Grazia] Univ Vita Salute San Raffaele, Milan, Italy	University of Rome Tor Vergata; IRCCS Bambino Gesu; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University	Angelini, F (corresponding author), Univ Roma Tor Vergata, Div Pediat, Via Montpellier 1, I-00133 Rome, Italy.	angelini@med.uniroma2.it	Rossi, Paolo/K-5746-2016; rossi, paolo/D-6504-2012; SILVIA, GREGORI/J-7718-2016; MOSCHESE, VIVIANA/AHE-8931-2022	Rossi, Paolo/0000-0003-2620-7918; SILVIA, GREGORI/0000-0002-3517-9683; MOSCHESE, VIVIANA/0000-0001-7650-0632; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Bambino Gesu' Children's Hospital of Rome, Italy; Telethon Foundation	Bambino Gesu' Children's Hospital of Rome, Italy; Telethon Foundation(Fondazione Telethon)	Supported in part by a grant from the Bambino Gesu' Children's Hospital of Rome, Italy. V.P. was supported in part by a fellowship provided by the Telethon Foundation.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2008, EXPERT OPIN BIOL TH, V8, P769, DOI 10.1517/14712598.8.6.769 ; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bellinghausen I, 2006, CLIN EXP ALLERGY, V36, P1546, DOI 10.1111/j.1365-2222.2006.02601.x; Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Borgonovo B, 1997, J ALLERGY CLIN IMMUN, V100, P669, DOI 10.1016/S0091-6749(97)70172-6; Bullens DMA, 2005, CLIN EXP ALLERGY, V35, P1535, DOI 10.1111/j.1365-2222.2005.02352.x; CHANG CH, 1995, EUR J IMMUNOL, V25, P394, DOI 10.1002/eji.1830250213; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Haczku A, 1999, AM J RESP CRIT CARE, V159, P1638, DOI 10.1164/ajrccm.159.5.9711040; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153, DOI 10.1165/ajrcmb.20.1.3255; Jiang Shuiping, 2006, Inflammation & Allergy Drug Targets, V5, P239, DOI 10.2174/187152806779010981; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jung T, 1996, EUR J IMMUNOL, V26, P571, DOI 10.1002/eji.1830260311; Kimura M, 2000, J ALLERGY CLIN IMMUN, V105, P327, DOI 10.1016/S0091-6749(00)90083-6; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; LOONEY RJ, 1994, J ALLERGY CLIN IMMUN, V93, P476, DOI 10.1016/0091-6749(94)90357-3; MALEFYT RD, 1991, J EXP MED, V174, P915; Manavalan JS, 2003, TRANSPL IMMUNOL, V11, P245, DOI 10.1016/S0966-3274(03)00058-3; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Nurse B, 2000, J ALLERGY CLIN IMMUN, V106, P84, DOI 10.1067/mai.2000.107397; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; Ohki O, 1997, BRIT J DERMATOL, V136, P838, DOI 10.1111/j.1365-2133.1997.tb03922.x; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; Sato K, 1999, J IMMUNOL, V162, P3865; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Steinbrink K, 1999, BLOOD, V93, P1634, DOI 10.1182/blood.V93.5.1634.405k11_1634_1642; Taketomi EA, 2006, J INVEST ALLERG CLIN, V16, P104; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsai Jaw-Ji, 2002, Journal of Microbiology Immunology and Infection, V35, P152; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435; Wurtzen PA, 1998, J ALLERGY CLIN IMMUN, V101, P241, DOI 10.1016/S0091-6749(98)70389-6; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Xystrakis E, 2007, CURR OPIN ALLERGY CL, V7, P535, DOI 10.1097/ACI.0b013e3282f14d7c; Zheng ZY, 2004, COMP IMMUNOL MICROB, V27, P93, DOI 10.1016/S0147-9571(03)00054-7; Zhou YH, 2001, RESP RES, V2, P80, DOI 10.1186/rr42; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	58	43	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					727	736		10.1016/j.jaci.2009.12.004	http://dx.doi.org/10.1016/j.jaci.2009.12.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153036				2022-12-18	WOS:000275883200032
J	Dreger, LC; Kozyrskyj, AL; HayGlass, KT; Becker, AB; MacNeil, BJ				Dreger, Lisa C.; Kozyrskyj, Anita L.; HayGlass, Kent T.; Becker, Allan B.; MacNeil, Brian J.			Lower cortisol levels in children with asthma exposed to recurrent maternal distress from birth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; cortisol; maternal distress; stress response	STRESS HORMONE LEVELS; SALIVARY CORTISOL; PRENATAL STRESS; EARLY-LIFE; RESPONSES; EXPRESSION; CHILDHOOD; DISORDER; DISEASE; HEALTH	Background: Existing evidence supports associations between exposure to maternal distress and the development of childhood asthma, between exposure to maternal distress and an increased cortisol response in children, and between childhood asthma and an attenuated cortisol response. Objective: To investigate the association between children's cortisol levels and the combined predictors of exposure to maternal distress and childhood asthma. Methods: Serum cortisol levels were examined at age 7 to 10 years in relation to asthma status and exposure to maternal distress in a representative sample of children (n = 503) born in 1995. Data from health care and prescription databases were linked with additional data collected in this longitudinal study. Maternal distress was defined as a physician diagnosis of a depressive or anxiety disorder or a prescription history of related medications as reported in the mothers' health care records. Children's asthma status was determined via examination by 2 pediatric allergists. Results: A multiple linear regression analysis revealed that exposure to maternal distress restricted to the first year of life predicted elevated cortisol levels in children, regardless of asthma status (>40% increase). A significant interaction was discovered in the group of children exposed to maternal distress extending beyond the postnatal period such that no asthma predicted a 25.9% increase in cortisol and a diagnosis of asthma predicted a 5.2% decrease in cortisol. Cortisol levels were further lowered in atopic and bronchial hyperresponsive asthma. Conclusion: Among children exposed to recurrent maternal distress, an elevation in cortisol levels occurs in response to an acute stressor when there is no-accompanying diagnosis of asthma, whereas, in comparison, children with asthma tend to exhibit lower cortisol levels. (J Allergy Clin Immunol 2010;125:116-22.)	[Dreger, Lisa C.] Univ Manitoba, Dept Psychol, Fac Arts, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.; Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [HayGlass, Kent T.] Univ Manitoba, Dept Immunol, Fac Med, Winnipeg, MB R3T 2N2, Canada; [MacNeil, Brian J.] Univ Manitoba, Sch Med Rehabil, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB T6G 2M7, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Alberta	Dreger, LC (corresponding author), P404 Duff Roblin Bldg,190 Dysart Rd, Winnipeg, MB R3T 2N2, Canada.	umdrege9@cc.umanitoba.ca		HayGlass, Kent/0000-0002-4621-7737; MacNeil, Brian/0000-0002-2897-8049	AllerGen NCE Inc; Manitoba NCE; Canadian Institutes of Health Research; Social Sciences and Humanities Research Council	AllerGen NCE Inc; Manitoba NCE; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Social Sciences and Humanities Research Council(Social Sciences and Humanities Research Council of Canada (SSHRC))	Supported by AllerGen NCE Inc and province of Manitoba NCE support, the Canadian Institutes of Health Research (New Emerging Team Program, Study of Asthma, Genes, and the Environment), and the Social Sciences and Humanities Research Council (Canada Graduate Scholarship).	Ashman SB, 2002, DEV PSYCHOPATHOL, V14, P333, DOI 10.1017/S0954579402002080; Azar R, 2007, BIOL PSYCHIAT, V62, P573, DOI 10.1016/j.biopsych.2006.11.009; Ball TM, 2006, J ALLERGY CLIN IMMUN, V117, P306, DOI 10.1016/j.jaci.2005.11.009; Becker A, 2005, CAN MED ASSOC J, V173, pS3; Braarud HC, 2006, INFANT BEHAV DEV, V29, P70, DOI 10.1016/j.infbeh.2005.08.008; Bugental DB, 2003, HORM BEHAV, V43, P237, DOI 10.1016/S0018-506X(02)00008-9; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; Gutteling BM, 2004, STRESS, V7, P257, DOI 10.1080/10253890500044521; Gutteling BM, 2005, PSYCHONEUROENDOCRINO, V30, P541, DOI 10.1016/j.psyneuen.2005.01.002; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Halligan SL, 2004, BIOL PSYCHIAT, V55, P376, DOI 10.1016/j.biopsych.2003.09.013; Hastings PD, 2009, J ABNORM CHILD PSYCH, V37, P565, DOI 10.1007/s10802-008-9292-y; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Hruschka DJ, 2005, PSYCHONEUROENDOCRINO, V30, P698, DOI 10.1016/j.psyneuen.2005.03.002; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; Jessop DS, 2008, STRESS, V11, P1, DOI 10.1080/10253890701365527; Jones A, 2006, J CLIN ENDOCR METAB, V91, P1868, DOI 10.1210/jc.2005-2077; Juniper E, 1994, HISTAMINE METHACHOLI; Kajantie E, 2006, PSYCHONEUROENDOCRINO, V31, P151, DOI 10.1016/j.psyneuen.2005.07.002; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Lupien SJ, 2000, BIOL PSYCHIAT, V48, P976, DOI 10.1016/S0006-3223(00)00965-3; Maguire AM, 2007, PEDIATRICS, V120, pE164, DOI 10.1542/peds.2006-2558; Mai XM, 2007, J ALLERGY CLIN IMMUN, V120, P551, DOI 10.1016/j.jaci.2007.05.004; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; Pescollderungg L, 2003, THORAX, V58, P227, DOI 10.1136/thorax.58.3.227; Power C, 2006, J CLIN ENDOCR METAB, V91, P4264, DOI 10.1210/jc.2006-0625; Priftis KN, 2008, TRENDS ENDOCRIN MET, V19, P32, DOI 10.1016/j.tem.2007.10.005; Priftis KN, 2006, NEUROIMMUNOMODULAT, V13, P56, DOI 10.1159/000094645; Rosmalen JGM, 2005, PSYCHONEUROENDOCRINO, V30, P483, DOI 10.1016/j.psyneuen.2004.12.007; Seckl JR, 2007, NAT CLIN PRACT ENDOC, V3, P479, DOI 10.1038/ncpendmet0515; Smith SL, 2002, J COMMUN, V52, P84, DOI 10.1111/j.1460-2466.2002.tb02534.x; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009; Wolf JM, 2008, BIOL PSYCHOL, V78, P20, DOI 10.1016/j.biopsycho.2007.12.004; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2009, J ALLERGY CLIN IMMUN, V123, P831, DOI 10.1016/j.jaci.2009.02.017; Wust S, 2000, PSYCHONEUROENDOCRINO, V25, P707, DOI 10.1016/s0306-4530(00)00021-4; YALLOP L, 2006, ALLERGY ASTHMA CLIN, V3, P150; Yehuda R, 2005, J CLIN ENDOCR METAB, V90, P4115, DOI 10.1210/jc.2005-0550	47	43	44	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					116	122		10.1016/j.jaci.2009.09.051	http://dx.doi.org/10.1016/j.jaci.2009.09.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19962747				2022-12-18	WOS:000273660500013
J	Lopez-Exposito, I; Song, Y; Jarvinen, KM; Srivastava, K; Li, XM				Lopez-Exposito, Ivan; Song, Ying; Jaervinen, Kirsi M.; Srivastava, Kamal; Li, Xiu-Min			Maternal peanut exposure during pregnancy and lactation reduces peanut allergy risk in offspring	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Murine model; maternal peanut allergy; IgG(1) and IgG(2a); PAF; maternal peanut exposure	FOOD ALLERGY; INDUCED ANAPHYLAXIS; MURINE MODEL; TOLERANCE INDUCTION; HERBAL FORMULA-2; CHILDREN; SENSITIZATION; AVOIDANCE; ASTHMA; SUSCEPTIBILITY	Background: Maternal allergy is believed to be a risk factor for peanut allergy (PNA) in children. However, there is no direct evidence of maternal transmission of PNA susceptibility, and it is unknown whether maternal peanut exposure affects the development of PNA in offspring. Objective: To investigate the influence of maternal PNA on offspring reactions to the first peanut exposure, and whether maternal low-dose peanut exposure during pregnancy and lactation influences these reactions and peanut sensitization in a murine model. Methods: Five-week-old offspring of PNA C3H/HeJ mothers (PNA-Ms) were challenged intragastrically with peanut (first exposure), and reactions were determined. In a subset of the experiment, PNA-Ms were fed a low dose of peanut (PNA-M/PN) or not fed peanut (PNA-M/none) during pregnancy and lactation. Their 5-week-old offspring were challenged intragastrically with peanut, and reactions were determined. In another subset of the experiment, offspring of PNA-M/PN or PNA-M/none were sensitized with peanut intragastrically for 6 weeks, and serum peanut-specific antibodies were determined. Results: PNA-M offspring exhibited anaphylactic reactions at first exposure to peanut that were associated with peanut-specific IgG(1) levels and prevented by a platelet activation factor antagonist. In a subset experiment, PNA-M/PN offspring showed significantly reduced first-exposure peanut reactions, increased IgG(2a), and reduced mitogen-stimulated splenocyte cytokine production compared with PNA-M/none offspring. In an additional experiment, PNA-M/PN offspring showed reduction of peanut-specific IgE to active peanut sensitization. Conclusion: We show for the first time maternal transmission of susceptibility to first-exposure peanut reactions and active peanut sensitization. Low-dose peanut exposure during pregnancy and lactation reduced this risk. (J Allergy Clin Immunol 2009;124:1039-46.)	[Lopez-Exposito, Ivan; Song, Ying; Jaervinen, Kirsi M.; Srivastava, Kamal; Li, Xiu-Min] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.	xiu-min.li@mssm.edu	li, xiu/GXV-1745-2022; López-Expósito, Iván/M-1150-2014; Song, Ying/C-9949-2013	López-Expósito, Iván/0000-0003-3011-3527; Song, Ying/0000-0001-7735-4008	Food Allergy Initiative, National Institutes of Health [AT001495-01A1]; Ministerio de Ciencia e Innovacion (MICINN)/Fulbright Postdoctoral; American Academy of Allergy, Asthma Immunology; National Institutes of Health; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER	Food Allergy Initiative, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministerio de Ciencia e Innovacion (MICINN)/Fulbright Postdoctoral(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); American Academy of Allergy, Asthma Immunology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the Food Allergy Initiative, National Institutes of Health grant no. AT001495-01A1 to X-M.L., and the Ministerio de Ciencia e Innovacion (MICINN)/Fulbright Postdoctoral Grant to I.L.-E.; Disclosure of potential conflict of interest: K. M. Jarvinen receives grant support from the American Academy of Allergy, Asthma & Immunology and the National Institutes of Health.	Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BOCK SA, 1987, PEDIATRICS, V79, P683; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; BURKS AW, 1991, ADV EXP MED BIOL, V289, P295; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Hamada K, 2003, J IMMUNOL, V170, P1683, DOI 10.4049/jimmunol.170.4.1683; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; Herz U, 2001, INT ARCH ALLERGY IMM, V124, P193, DOI 10.1159/000053708; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2005, CURR OPIN ALLERGY CL, V5, P287, DOI 10.1097/01.all.0000168796.20324.bd; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Lim RH, 2009, AM J REPROD IMMUNOL, V61, P1, DOI 10.1111/j.1600-0897.2008.00671.x; Mahnke K, 2002, IMMUNOL CELL BIOL, V80, P477, DOI 10.1046/j.1440-1711.2002.01115.x; Melkild I, 2002, CLIN EXP ALLERGY, V32, P1370, DOI 10.1046/j.1365-2745.2002.01458.x; Morales JF, 2003, J HIGH ENERGY PHYS; Niggemann B, 2001, J ALLERGY CLIN IMMUN, V108, P1053, DOI 10.1067/mai.2001.120192; OH M, 2009, FOOD ALLERGY ADVERSE; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2008, J ALLERGY CLIN IMMUN, V121, P1351, DOI 10.1016/j.jaci.2008.01.032; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; van Wijk F, 2007, J IMMUNOL, V178, P6894, DOI 10.4049/jimmunol.178.11.6894; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Wennergren G, 2009, ACTA PAEDIATR, V98, P1085, DOI 10.1111/j.1651-2227.2009.01342.x	38	43	46	3	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1039	1046		10.1016/j.jaci.2009.08.024	http://dx.doi.org/10.1016/j.jaci.2009.08.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895992	Green Accepted			2022-12-18	WOS:000272108000026
J	Leung, DYM				Leung, Donald Y. M.			Our evolving understanding of the functional role of filaggrin in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; filaggrin; barrier	MUTATIONS; ECZEMA; RISK; METAANALYSIS		Natl Jewish Hlth, Dept Pediat Allergy Immunol, Denver, CO 80206 USA	National Jewish Health	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat Allergy Immunol, 1400 Jackson St, Denver, CO 80206 USA.	leungd@njhealth.org			NIAID NIH HHS [#N01-AI-40029] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline; PHS HHS [HHSN26620040029C] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Scott JE, 2007, J ALLERGY CLIN IMMUN, V120, P1382, DOI 10.1016/j.jaci.2007.08.004; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743	14	43	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					494	495		10.1016/j.jaci.2009.07.041	http://dx.doi.org/10.1016/j.jaci.2009.07.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733296				2022-12-18	WOS:000274315900014
J	Atanaskovic-Markovic, M; Gaeta, F; Gavrovic-Jankulovic, M; Velickovic, TC; Valluzzi, RL; Romano, A				Atanaskovic-Markovic, Marina; Gaeta, Francesco; Gavrovic-Jankulovic, Marija; Velickovic, Tanja Cirkovic; Valluzzi, Rocco Luigi; Romano, Antonino			Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMEDIATE HYPERSENSITIVITY; CROSS-REACTIVITY; ALLERGY; MEROPENEM; HISTORY		[Gaeta, Francesco; Valluzzi, Rocco Luigi; Romano, Antonino] UCSC, Allergy Unit, Dept Internal Med & Geriatr, Rome, Italy; [Atanaskovic-Markovic, Marina] Univ Childrens Hosp, Dept Allergol & Pulmonol, Belgrade, Serbia; [Gavrovic-Jankulovic, Marija; Velickovic, Tanja Cirkovic] Univ Belgrade, Fac Chem, Dept Biochem, Belgrade, Serbia; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy	Catholic University of the Sacred Heart; University of Belgrade; University of Belgrade; IRCCS Oasi Maria SS	Romano, A (corresponding author), UCSC, Allergy Unit, Dept Internal Med & Geriatr, Complesso Integrato Columbus, Rome, Italy.	antoninoromano@h-columbus.it	Cirkovic Velickovic, Tanja/R-6751-2016; Romano, Antonino/D-3102-2017; Gaeta, Francesco/AAC-7107-2020; Gavrovic-Jankulovic, Marija/AAE-4077-2022; Valluzzi, Rocco Luigi/Q-3879-2019	Cirkovic Velickovic, Tanja/0000-0003-2559-5234; Romano, Antonino/0000-0001-9742-9898; Gaeta, Francesco/0000-0003-2942-7633; Gavrovic-Jankulovic, Marija/0000-0002-8591-4391; Valluzzi, Rocco Luigi/0000-0003-0029-6254				Atanaskovic-Markovic M, 2008, ALLERGY, V63, P237, DOI 10.1111/j.1398-9995.2007.01532.x; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; McConnell SA, 2000, CLIN INFECT DIS, V31, P1512, DOI 10.1086/317507; Prescott WA, 2004, CLIN INFECT DIS, V38, P1102, DOI 10.1086/382880; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2007, ANN INTERN MED, V146, P266, DOI 10.7326/0003-4819-146-4-200702200-00005; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; SAXON A, 1988, J ALLERGY CLIN IMMUN, V82, P213, DOI 10.1016/0091-6749(88)91001-9; Sodhi M, 2004, J ANTIMICROB CHEMOTH, V54, P1155, DOI 10.1093/jac/dkh454	10	43	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					167	169		10.1016/j.jaci.2009.02.031	http://dx.doi.org/10.1016/j.jaci.2009.02.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19368966				2022-12-18	WOS:000267909700024
J	Ozcan, E; Garibyan, L; Lee, JJY; Bram, RJ; Lam, KP; Geha, RS				Ozcan, Esra; Garibyan, Lilit; Lee, John Jhe-Yun; Bram, Richard J.; Lam, Kong-Peng; Geha, Raif S.			Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; Toll-like receptor; LPS; transmembrane activator; calcium modulator; cyclophilin ligand interactor; a proliferation-inducing ligand; immunoglobin	FAMILY-MEMBERS BAFF; IMMUNE-RESPONSES; DEFICIENT MICE; APRIL; TACI; RECEPTORS; SURVIVAL; BLYS; RECOMBINATION; AUTOIMMUNITY	Background: Transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) expression on B cells is upregulated by Toll-like receptor (TLR) 4. Objective: We sought to examine whether TACI synergizes with TLR4 in driving immunoglobulin production by B cells and to examine the mechanism of this synergy. Methods: Purified mouse naive B cells were stimulated with the TACI ligand a proliferation-inducing ligand (APRIL) and with suboptimal concentrations of the TLR4 ligand LPS in the presence or absence of IL-4. Immunoglobulin secretion was measured by means of ELISA. Surface IgG1-positive B cells and CD138(+) plasmacytoid cells were enumerated by means of FACS. Expression of gamma 1 and is an element of germline transcripts, activation-induced cytidine deaminase, and gamma 1 and E mature transcripts was measured by means of RT-PCR. Results: APRIL synergized with LPS in driving B-cell proliferation and IgM, IgG1, IgG3, IgE, and IgA production. This was mediated by TACI because it was preserved in B-cell maturation antigen(-/-), but not TACI(-/-), B cells. APRIL and LPS synergized to promote isotype switching, as evidenced by increased expression of activation-induced cytidine deaminase and gamma 1 and is an element of mature transcripts and generation of surface IgG1-positive cells. More importantly, APRIL and LPS strongly synergized to drive the plasma cell differentiation program, as evidenced by an increase in CD138(+) cells and expression of B lymphocyte induced maturation protein-1 (Blimp-1), interferon regulatory factor-4 (IRF-4), and the spliced form of X-box binding protein-1 (XBP-1).TACI(-/-) mice had impaired IgM and IgG1 antibody responses to immunization, with a suboptimal dose of the type I T cell-independent antigen 2, 4, 6- Trinitrophenol (TNP)-LPS. Conclusions: These observations suggest that TACI cooperates with TLR4 to drive B-cell differentiation and immunoglobulin production in vitro and in vivo. (J Allergy Clin Immunol 2009; 123:1277-86.)	[Ozcan, Esra; Garibyan, Lilit; Lee, John Jhe-Yun; Geha, Raif S.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Ozcan, Esra; Garibyan, Lilit; Lee, John Jhe-Yun; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Bram, Richard J.] Mayo Clin, Dept Immunol Pediat & Adolescent Med, Rochester, MN USA; [Bram, Richard J.] Mayo Clin, Dept Surg, Rochester, MN USA; [Lam, Kong-Peng] ASTAR, BTI, Immunol Lab, Singapore, Singapore	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Mayo Clinic; Mayo Clinic; Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI)	Geha, RS (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	Raif.Geha@childrens.harvard.edu	Garibyan, Lilit/AAR-1638-2020; Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333	March of Duties [6-FY07-285]; National Institutes of Health [Al-031541]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031541, U01AI031541, U19AI031541] Funding Source: NIH RePORTER	March of Duties; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by March of Duties grant no. 6-FY07-285 and National Institutes of Health grant Al-031541.	Acosta-Rodriguez EV, 2007, EUR J IMMUNOL, V37, P990, DOI 10.1002/eji.200636698; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Bossen C, 2006, SEMIN IMMUNOL, V18, P263, DOI 10.1016/j.smim.2006.04.006; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood-2006-04-015958; Deenick EK, 1999, J IMMUNOL, V163, P4707; Endo T, 2007, BLOOD, V109, P703, DOI 10.1182/blood-2006-06-027755; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; He B, 2004, J IMMUNOL, V172, P3268, DOI 10.4049/jimmunol.172.5.3268; Igarashi K, 2007, J BIOCHEM, V141, P783, DOI 10.1093/jb/mvm106; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Katsenelson N, 2007, EUR J IMMUNOL, V37, P1785, DOI 10.1002/eji.200636800; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; King C, 2008, ANNU REV IMMUNOL, V26, P741, DOI 10.1146/annurev.immunol.26.021607.090344; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Mongini PKA, 2006, J IMMUNOL, V176, P6736, DOI 10.4049/jimmunol.176.11.6736; PHIPPS RP, 1990, IMMUNOL REV, V117, P135, DOI 10.1111/j.1600-065X.1990.tb00571.x; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Seyler TM, 2005, J CLIN INVEST, V115, P3083, DOI 10.1172/JCI25265; Sousa CR, 2003, PATHOL BIOL, V51, P67, DOI 10.1016/S0369-8114(03)00099-3; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wang H, 2001, NAT IMMUNOL, V2, P632, DOI 10.1038/89782; Woodland RT, 2008, BLOOD, V111, P750, DOI 10.1182/blood-2007-03-077222; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Zhang X, 2005, INT IMMUNOL, V17, P779, DOI 10.1093/intimm/dxh259	37	43	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1277	1286		10.1016/j.jaci.2009.03.019	http://dx.doi.org/10.1016/j.jaci.2009.03.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19427685	Green Accepted			2022-12-18	WOS:000266799100018
J	Arkwright, PD				Arkwright, Peter D.			Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RITUXIMAB		Univ Manchester, Booth Hall Childrens Hosp, Manchester, Lancs, England	Royal Manchester Children's Hospital; University of Manchester	Arkwright, PD (corresponding author), Univ Manchester, Booth Hall Childrens Hosp, Manchester, Lancs, England.	peter_arkwright@lineone.net		Arkwright, Peter/0000-0002-7411-5375				Alachkar H, 2006, CLIN IMMUNOL, V120, P310, DOI 10.1016/j.clim.2006.05.003; Carr DR, 2007, DERMATOL THER, V20, P277, DOI 10.1111/j.1529-8019.2007.00141.x; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Mallipeddi R, 2007, CLIN EXP DERMATOL, V32, P333, DOI 10.1111/j.1365-2230.2007.02365.x; Mease PJ, 2008, J RHEUMATOL, V35, P1245	5	43	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					510	511		10.1016/j.jaci.2008.11.043	http://dx.doi.org/10.1016/j.jaci.2008.11.043			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203667				2022-12-18	WOS:000263495000038
J	Macsali, F; Real, FG; Omenaas, ER; Bjorge, L; Janson, C; Franklin, K; Svanes, C				Macsali, Ferenc; Real, Francisco Gomez; Omenaas, Ernst Reidar; Bjorge, Line; Janson, Christer; Franklin, Karl; Svanes, Cecilie			Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; oral contraceptives; body mass index; RHINE; ECRHS	HORMONE REPLACEMENT THERAPY; SEX STEROID-HORMONES; ADULT-ONSET ASTHMA; LUNG-FUNCTION; INSULIN-RESISTANCE; RESPIRATORY SYMPTOMS; WEIGHT CHANGE; YOUNG-ADULTS; WOMEN; OBESITY	Background: Emerging evidence suggests that sex steroid hormones may influence airways obstruction, and that metabolic status may modify potential effects. Objective: This study investigated the association between use of oral contraceptive pills (OCPs) and asthma in a Nordic-Baltic population-based study, while taking into account possible interplay with body mass index (BMI). Methods: Postal questionnaires were sent to subjects in Denmark, Estonia, Iceland, Norway, and Sweden from 1999 to 2001 (response rate in women, 77%). Pregnant women, women using hormone replacement therapy, and women >45 years were excluded. Analyses included 5791 women 25 to 44 years old, of whom 961 (17%) used OCP Logistic regression analyses included adjustment for smoking, irregular menstruation, BMI, age, type of dwelling, and center. Results: Oral contraceptive pills were associated with increased risk for asthma (odds ratio, 1.42; 95% CI, 1.09-1.86), asthma with hay fever (1.48; 1.08-2.03), wheeze with shortness of breath (1.27; 1.02-1.60), hay fever (1.25; 1.06-1.48), and >= 3 asthma symptoms (1.29; 1.05-1.58). The findings were consistent between centers. The associations were present only among normal weight women (BMI 20-25 kg/m(2), asthma: 1.45; 1.02-2.05) and overweight women (BMI >25kg/m(2): 1.91; 1.20-3.02), but not among lean women (BMI <20 kg/m(2): 0.41; 0.12-1.40). Interaction between BMI and OCP in association with asthma was significant (P-interaction < .05). Conclusions: Women using oral contraceptive pills had more asthma. This was found only in normal weight and overweight women, indicating interplay between sex hormones and metabolic status in effect on the airways. The findings originate from a cross-sectional postal survey and should be interpreted with caution; it is recommended that asthma symptoms are included in clinical trials of oral contraception. (J Allergy Clin Immunol 2009;123:391-7.)	[Macsali, Ferenc; Real, Francisco Gomez; Bjorge, Line] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway; [Svanes, Cecilie] Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; [Omenaas, Ernst Reidar] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; [Macsali, Ferenc; Real, Francisco Gomez; Omenaas, Ernst Reidar; Svanes, Cecilie] Univ Bergen, Inst Med, Bergen Resp Res Grp, N-5020 Bergen, Norway; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Franklin, Karl] Umea Univ Hosp, Dept Resp Med, S-90185 Umea, Sweden	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Uppsala University; Umea University	Macsali, F (corresponding author), Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway.	ferenc.macsali@med.uib.no	Svanes, Cecilie/N-7556-2017; Bjorge, Line/AAD-6179-2021; Bjorge, Line/C-1307-2017	Svanes, Cecilie/0000-0001-8512-5192; Bjorge, Line/0000-0002-0240-2770; Bjorge, Line/0000-0002-0240-2770; Franklin, Karl/0000-0002-5306-1697; Gomez Real, Francisco/0000-0001-5407-3270	Icelandic Research Council; Swedish Heart and Lung Foundation; Vardal Foundation for Health Care Science and Allergy Research; Swedish Association Against Asthma and Allergy; Norwegian Research Council [135773/130]; Norwegian Asthma and Allergy Association; Danish Lung Association; Estonian Science Foundation [4350]; Regional Health Authority of Western Norway; Norwegian Foundation for Health and Rehabilitation	Icelandic Research Council; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Vardal Foundation for Health Care Science and Allergy Research; Swedish Association Against Asthma and Allergy; Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Asthma and Allergy Association; Danish Lung Association; Estonian Science Foundation; Regional Health Authority of Western Norway; Norwegian Foundation for Health and Rehabilitation	Supported by the Icelandic Research Council, the Swedish Heart and Lung Foundation, the Vardal Foundation for Health Care Science and Allergy Research, the Swedish Association Against Asthma and Allergy, the Norwegian Research Council project 135773/130, the Norwegian Asthma and Allergy Association, the Danish Lung Association, and the Estonian Science Foundation grant no. 4350. F.M. was supported by a grant from the Regional Health Authority of Western Norway and from the Norwegian Foundation for Health and Rehabilitation.	Barr R Graham, 2004, Treat Respir Med, V3, P1, DOI 10.2165/00151829-200403010-00001; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BEYNON HLC, 1988, LANCET, V2, P370; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Derimanov GS, 1998, ANN ALLERG ASTHMA IM, V81, P243, DOI 10.1016/S1081-1206(10)62820-7; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Engstrom G, 2003, J INTERN MED, V253, P574, DOI 10.1046/j.1365-2796.2003.01138.x; ESCHWEGE E, 1990, INT J GYNECOL OBSTET, V31, P263, DOI 10.1016/0020-7292(90)91021-H; Fernandez-Real JM, 2003, J CLIN ENDOCR METAB, V88, P1780, DOI 10.1210/jc.2002-020173; Field AE, 2007, OBESITY, V15, P2357, DOI 10.1038/oby.2007.279; Forbes L, 1999, EUR RESPIR J, V14, P1028, DOI 10.1183/09031936.99.14510289; Garamszegi C, 1998, J PSYCHOSOM OBST GYN, V19, P165, DOI 10.3109/01674829809025694; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; Jarvis D, 2008, ALLERGY, V63, P95, DOI 10.1111/j.1398-9995.2007.01530.x; Jenkins MA, 2006, CLIN EXP ALLERGY, V36, P609, DOI 10.1111/j.1365-2222.2006.02475.x; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Keller AC, 2005, MEM I OSWALDO CRUZ, V100, P19, DOI 10.1590/S0074-02762005000900005; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658, DOI 10.1165/ajrcmb.20.4.3241; Kluft C, 2002, VASC PHARMACOL, V39, P149, DOI 10.1016/S1537-1891(02)00304-X; KORYTKOWSKI MT, 1995, J CLIN ENDOCR METAB, V80, P3327, DOI 10.1210/jc.80.11.3327; Lange P, 2001, THORAX, V56, P613, DOI 10.1136/thorax.56.8.613; LEYNAERT B, 2007, EUR RESP SOC ANN M S; Lin WY, 2006, OBESITY, V14, P1654, DOI 10.1038/oby.2006.190; Must A, 2002, AM J EPIDEMIOL, V155, P672, DOI 10.1093/aje/155.7.672; *NORW I PUBL HLTH, 2007, DRUG CONS NORW; Pasquali R, 2006, FERTIL STERIL, V85, P1319, DOI 10.1016/j.fertnstert.2005.10.054; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; Real FG, 2006, THORAX, V61, P34, DOI 10.1136/thx.2005.040881; Real FG, 2008, J ALLERGY CLIN IMMUN, V121, P72, DOI 10.1016/j.jaci.2007.08.057; Real FG, 2007, J ALLERGY CLIN IMMUN, V120, P557, DOI 10.1016/j.jaci.2007.04.041; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; Svanes C, 2005, THORAX, V60, P445, DOI 10.1136/thx.2004.032615; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; Tan KS, 2000, AM J MED, V109, P727, DOI 10.1016/S0002-9343(00)00615-X; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Zimmerman JL, 2000, AM J RESP CRIT CARE, V162, P512, DOI 10.1164/ajrccm.162.2.9910105	44	43	43	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					391	397		10.1016/j.jaci.2008.10.041	http://dx.doi.org/10.1016/j.jaci.2008.10.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19121863				2022-12-18	WOS:000263495000015
J	Thomas, M; von Ziegenweidt, J; Lee, AJ; Price, D				Thomas, Mike; von Ziegenweidt, Julie; Lee, Amanda J.; Price, David			High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: An observational study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; long-acting beta-agonist; inhaled corticosteroid; safety; inflammation; observational study	ADULTS; INFLAMMATION; METAANALYSIS; PERSPECTIVE; POPULATION; SALMETEROL; SEVERITY; RISKS	Background: Guidelines recommend that for patients uncontrolled on inhaled corticosteroids (ICSs), step-up options include an increase in ICS dosage or addition of a long-acting beta-agonist (LABA). Controversy persists about the best option in routine practice. Objective: To compare asthma outcomes in patients whose first step-up from ICS monotherapy was by addition of LABA (LABA cohort) or increase in ICS dosage or formulation (ICS cohort). Methods: Observational study using the General Practice Research Database, comparing outcomes in the following 12 months with regression modeling allowing for baseline cohort differences: age, sex, socioeconomic status, body mass index, comorbidity (rhinitis, heart disease), smoking status, short-acting beta-agonist (SABA) use, oral corticosteroid use, and use of asthma complicating medication. Results: We found 46,930 patients in the ICS and 17,418 in the LABA cohort. In adjusted analysis, the odds ratio (95% CI) of successful treatment (no hospitalization, no oral corticosteroid use, average daily SABA use <1 dose/d) was lower in the ICS cohort (0.75; 0.72-0.79). The adjusted odds ratio of needing rescue SABA prescriptions was higher in the ICS cohort (1.67; 1.59-1.76). However, the adjusted odds of using any oral corticosteroids were lower (0.75; 0.71-0.78), particularly of using 3 or more courses (0.50, 0.46-0.55), and the adjusted odds of respiratory hospitalization were lower (0.69; 0.59-0.81). Conclusion: Although symptomatic control and rescue bronchodilator use may be improved by the addition of a LABA to ICS, there may be a lower risk of severe exacerbations and hospitalizations from ICS dose increase. (J Allergy Clin Immunol 2009;123:116-21.)	[von Ziegenweidt, Julie; Price, David] Resp Res Ltd, Norfolk, VA USA; [Thomas, Mike; Lee, Amanda J.; Price, David] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland	University of Aberdeen		mikethomas@doctors.org.uk	Price, David/H-2837-2019	Price, David/0000-0002-9728-9992				[Anonymous], 1990, BRIT MED J, V301, P651; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beasley R, 2006, J ALLERGY CLIN IMMUN, V117, P225, DOI 10.1016/j.jaci.2005.10.029; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; CASTLE W, 2007, BMJ-BRIT MED J, V306, P1034; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; *FDA, 2003, FDA SAF INF ADV EV R; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenfield JR, 2006, THORAX, V61, P272, DOI 10.1136/thx.2005.049643; Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026; Holgate Stephen T, 2006, BMC Pulm Med, V6 Suppl 1, pS2, DOI 10.1186/1471-2466-6-S1-S2; Hubbard RB, 2002, AM J RESP CRIT CARE, V166, P1563, DOI 10.1164/rccm.200206-606OC; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; *NAT HEART LUNG BL, 2002, GUID DIAGN MAN ASTHM; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Naureckas ET, 2005, CHEST, V128, P602, DOI 10.1378/chest.128.2.602; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P3, DOI 10.1016/j.jaci.2005.10.013; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Pearson MG, 1997, THORAX, V52, pS1; Price David, 2002, Prim Care Respir J, V11, P30, DOI 10.1038/pcrj.2002.13; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2006, J ALLERGY CLIN IMMUN, V117, P26, DOI 10.1016/j.jaci.2005.11.006; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	34	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					116	121		10.1016/j.jaci.2008.09.035	http://dx.doi.org/10.1016/j.jaci.2008.09.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18986690				2022-12-18	WOS:000262793900019
J	McLean, WHI; Palmer, CNA; Henderson, J; Kabesch, M; Weidinger, S; Irvine, AD				McLean, W. H. Irwin; Palmer, Colin N. A.; Henderson, John; Kabesch, Michael; Weidinger, Stephan; Irvine, Alan D.			Filaggrin variants confer susceptibility to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; MUTATIONS; BIRTH		[McLean, W. H. Irwin] Univ Dundee, Div Pathol & Neurosci, Human Genet Unit, Epithelial Genet Grp, Dundee, Scotland; [Palmer, Colin N. A.] Univ Dundee, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee, Scotland; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol, Avon, England; [Kabesch, Michael] Univ Munich, Childrens Hosp, D-8000 Munich, Germany; [Weidinger, Stephan] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Weidinger, Stephan] Tech Univ Munich, German Res Ctr, Helmholtz Zentrum Munich, Div Environm Dermatol & Allergy, Munich, Germany; [Weidinger, Stephan] Tech Univ Munich, Ctr Allergy & Environm, ZAUM, Munich, Germany; [Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Pediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland	University of Dundee; University of Dundee; University of Bristol; University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin	McLean, WHI (corresponding author), Univ Dundee, Div Pathol & Neurosci, Human Genet Unit, Epithelial Genet Grp, Dundee, Scotland.	irvinea@tcd.ie	Kabesch, Michael/GZM-1583-2022; Palmer, Colin NA/C-7053-2008; McLean, William HI/C-6352-2009; Weidinger, Stephan/C-8461-2011; Irvine, Alan D/A-3982-2008; Kabesch, Michael/AAB-5701-2020	Palmer, Colin NA/0000-0002-6415-6560; Weidinger, Stephan/0000-0003-3944-252X; Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757				Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; WEIRLINGER S, 2008, IN PRESS J ALLERGY C	10	43	45	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1294	1295		10.1016/j.jaci.2008.02.039	http://dx.doi.org/10.1016/j.jaci.2008.02.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18395783				2022-12-18	WOS:000255961700040
J	Salamon, P; Shoham, NG; Puxeddu, I; Paitan, Y; Levi-Schaffer, F; Mekori, YA				Salamon, Pazit; Shoham, Nitza G.; Puxeddu, Ilaria; Paitan, Yosef; Levi-Schaffer, Francesca; Mekori, Yoseph A.			Human mast cells release oncostatin M on contact with activated T cells: Possible biologic relevance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oncostatin M; mast cells; T cells	AIRWAY SMOOTH-MUSCLE; FC-EPSILON-RI; MATRIX-METALLOPROTEINASE; EXPRESSION; PROLIFERATION; INTERLEUKIN-1; CHONDROCYTES; LYMPHOCYTES; COMBINATION; MECHANISMS	Background: We have recently demonstrated that mast cells can be activated by heterotypic adhesion to activated T cells. Objective: We sought to perform gene expression profiling on human mast cells activated by either IgE cross-linking or by T cells and to characterize one of the cytokines, oncostatin M (OSM). Methods: Gene expression profiling was done by means of microarray analysis, OSM expression was validated by means of RT-PCR, and the product was measured by means of ELISA in both the LAD 2 human mast cell line and in cord blood-derived human mast cells. Immunocytochemistry was used to localize OSM in human mast cells, and its biologic activity was verified by its effect on the proliferation of human lung fibroblasts. Results: OSM was expressed and released specifically on T cell-induced mast cell activation but not on IgE cross-linking. OSM was localized to the cytoplasm, and its expression was inhibited by dexamethasone and mitogen-activated protein kinase inhibitors. OSM was also found to be biologically active in inducing lung fibroblast proliferation that was partially but significantly inhibited by anti-OSM mAb. In vivo mast cells were found to express OSM in both biopsy specimens and bronchoalveolar lavage fluid from patients with sarcoidosis. Conclusion: The production of OSM by human mast cells might represent one link between T cell-induced mast cell activation and the development of a spectrum of structural changes in T cell-mediated inflammatory processes in which mast cells have been found to be involved.	[Salamon, Pazit; Shoham, Nitza G.; Mekori, Yoseph A.] Tel Aviv Univ, Meir Gen Hosp, Sackler Sch Med, Allergy & Clin Immunol Lab, Jerusalem, Israel; [Paitan, Yosef] Tel Aviv Univ, Meir Gen Hosp, Sackler Sch Med, Microbiol Lab, Jerusalem, Israel; [Puxeddu, Ilaria; Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, Jerusalem, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	Salamon, P (corresponding author), Tel Aviv Univ, Meir Gen Hosp, Sackler Sch Med, Allergy & Clin Immunol Lab, Jerusalem, Israel.		Puxeddu, Ilaria/AAB-3263-2019	Levi-Schaffer, Francesca/0000-0003-0620-2810				Amano H, 2000, J DERMATOL SCI, V24, P60, DOI 10.1016/S0923-1811(00)00085-2; Atamas SP, 2003, CYTOKINE GROWTH F R, V14, P537, DOI 10.1016/S1359-6101(03)00060-1; Baram D, 2001, J IMMUNOL, V167, P4008, DOI 10.4049/jimmunol.167.7.4008; Barksby HE, 2006, ARTHRITIS RHEUM-US, V54, P540, DOI 10.1002/art.21574; Brill A, 2004, CLIN EXP ALLERGY, V34, P1725, DOI 10.1111/j.1365-2222.2004.02093.x; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Edwards ST, 2005, J PATHOL, V206, P279, DOI 10.1002/path.1780; Faffe DS, 2005, AM J PHYSIOL-LUNG C, V288, pL1040, DOI 10.1152/ajplung.00333.2004; Faffe DS, 2005, J ALLERGY CLIN IMMUN, V115, P514, DOI 10.1016/j.jaci.2004.11.033; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Hui W, 2003, ARTHRITIS RHEUM-US, V48, P3404, DOI 10.1002/art.11333; Ihn H, 2000, J IMMUNOL, V165, P2149, DOI 10.4049/jimmunol.165.4.2149; Inamura N, 1998, J IMMUNOL, V160, P4026; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; Maruotti N, 2007, CLIN RHEUMATOL, V26, P1, DOI 10.1007/s10067-006-0305-3; Mekori YA, 2004, J ALLERGY CLIN IMMUN, V114, P52, DOI 10.1016/j.jaci.2004.04.015; Nakae S, 2005, P NATL ACAD SCI USA, V102, P6467, DOI 10.1073/pnas.0501912102; O'Hara KA, 2003, CLIN EXP ALLERGY, V33, P1026, DOI 10.1046/j.1365-2222.2003.01714.x; Oh CK, 1996, BIOCHEM BIOPH RES CO, V221, P510, DOI 10.1006/bbrc.1996.0627; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P3301, DOI 10.1002/art.11348; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Repovic P, 2002, J NEUROSCI, V22, P5334; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Salamon P, 2005, ALLERGY, V60, P1316, DOI 10.1111/j.1398-9995.2005.00886.x; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Stopfer P, 2004, J IMMUNOL, V172, P7459, DOI 10.4049/jimmunol.172.12.7459; Suda T, 2002, CYTOKINE, V17, P335, DOI 10.1006/cyto.2002.1023; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wang SW, 2005, J ALLERGY CLIN IMMUN, V115, P287, DOI 10.1016/j.jaci.2004.11.037; Wittmann M, 2004, J ALLERGY CLIN IMMUN, V114, P965, DOI 10.1016/j.jaci.2004.06.033; Wong CK, 2006, ALLERGY, V61, P289, DOI 10.1111/j.1398-9995.2006.00972.x	35	43	44	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					448	455		10.1016/j.jaci.2007.08.054	http://dx.doi.org/10.1016/j.jaci.2007.08.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18028996				2022-12-18	WOS:000253337800026
J	Stellato, C				Stellato, Cristiana			Glucocorticoid actions on airway epithelial responses in immunity: Functional outcomes and molecular targets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway epithelium; asthma; glucocorticoids; immunity; inflammation; inhaled corticosteroid therapy	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; GOBLET CELL HYPERPLASIA; INDUCED LEUCINE-ZIPPER; THYMIC STROMAL LYMPHOPOIETIN; NITRIC-OXIDE SYNTHASE; ASTHMATIC BRONCHIAL EPITHELIUM; MESSENGER-RNA TURNOVER; RECEPTOR-BETA; GENE-EXPRESSION	Research on the biology of airway epithelium in the last decades has progressively uncovered the many roles of this cell type during the immune response. Far from the early view of the epithelial layer simply as a passive barrier, the airway epithelium is now considered a central player in mucosal immunity, providing innate mechanisms of first-line host defense as well as facilitating adaptive immune responses. Alterations of the epithelial phenotype are primarily involved in the pathogenesis of allergic airways disease, particularly in severe asthma. Appreciation of the epithelium as target of glucocorticoid therapy has also grown, because of studies defining the pathways and mediators affected by glucocorticoids, and studies illustrating the relevance of the control of the response from epithelium in the overall efficacy of topical and systemic therapy with glucocorticoids. Studies of the mechanism of action of glucocorticoids within the biology of the immune response of the epithelium have uncovered mechanisms of gene regulation involving both transcriptional and posttranscriptional events. The view of epithelium as therapeutic target therefore has plenty of room to evolve, as new knowledge on the role of epithelium in immunity is established and novel pathways mediating glucocorticoid regulation are elucidated.	[Stellato, Cristiana] Johns Hopkins Univ, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA	Johns Hopkins University	Stellato, C (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 1A-12A, Baltimore, MD 21224 USA.	stellato@jhmi.edu	Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355	NIAID NIH HHS [R01 AI060990-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060990] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham SM, 2006, BIOCHEM SOC T, V34, P1018, DOI 10.1042/BST0341018; Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Adkins KK, 1998, AM J PHYSIOL-LUNG C, V275, pL372, DOI 10.1152/ajplung.1998.275.2.L372; Adriaensen D, 2003, ANAT REC PART A, V270A, P25, DOI 10.1002/ar.a.10007; AGNEW JE, 1984, B EUR PHYSIOPATH RES, V20, P295; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Aksoy MO, 1999, J ALLERGY CLIN IMMUN, V103, P1081, DOI 10.1016/S0091-6749(99)70183-1; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; BAMES PJ, 2005, BRIT J PHARMACOL, V148, P245; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Bergeron C, 2006, J ALLERGY CLIN IMMUN, V117, P703, DOI 10.1016/j.jaci.2005.12.1344; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38, DOI 10.1165/ajrcmb.19.1.2930; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; Boers JE, 1996, AM J RESP CRIT CARE, V154, P758, DOI 10.1164/ajrccm.154.3.8810616; Bornstein SR, 2006, ANN NY ACAD SCI, V1088, P307, DOI 10.1196/annals.1366.027; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Calverley Peter M A, 2004, Proc Am Thorac Soc, V1, P161, DOI 10.1513/pats.200402-008MS; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carrick DM, 2004, ARTHRITIS RES THER, V6, P248, DOI 10.1186/ar1441; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chanez P, 2005, EUR RESPIR J, V25, P945, DOI 10.1183/09031936.05.00038605; Chen YJ, 2006, AM J RESP CELL MOL, V34, P338, DOI 10.1165/rcmb.2005-0176OC; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chinenov Y, 2007, MOL CELL ENDOCRINOL, V275, P30, DOI 10.1016/j.mce.2007.04.014; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Clark AR, 2007, MOL CELL ENDOCRINOL, V275, P79, DOI 10.1016/j.mce.2007.04.013; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; DAYER AM, 1985, CELL TISSUE RES, V239, P703, DOI 10.1007/BF00219252; Del Donno M, 2000, CHEST, V118, P1142, DOI 10.1378/chest.118.4.1142; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Dulkerian SJ, 1996, AM J RESP CELL MOL, V15, P781, DOI 10.1165/ajrcmb.15.6.8969273; Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027; Edwards MR, 2007, J BIOL CHEM, V282, P15366, DOI 10.1074/jbc.M701325200; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115; Evans MJ, 2001, EXP LUNG RES, V27, P401, DOI 10.1080/019021401300317125; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fan J, 2005, EUR RESPIR J, V26, P933, DOI 10.1183/09031936.05.00120204; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Gibson A, 2005, J BIOL CHEM, V280, P27205, DOI 10.1074/jbc.M504654200; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Grunberg K, 2000, CLIN EXP ALLERGY, V30, P1015; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Hancox RJ, 1999, THORAX, V54, P488, DOI 10.1136/thx.54.6.488; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; HEINO M, 1988, BRIT J DIS CHEST, V82, P175, DOI 10.1016/0007-0971(88)90040-X; Heller NM, 2004, CLIN EXP ALLERGY, V34, P1690, DOI 10.1111/j.1365-2222.2004.02091.x; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hippenstiel S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-97; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; Holtzman MJ, 2002, PHYSIOL REV, V82, P19, DOI 10.1152/physrev.00020.2001; Homer RJ, 2006, AM J PHYSIOL-LUNG C, V291, pL502, DOI 10.1152/ajplung.00364.2005; Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC; Hong KU, 2001, AM J RESP CELL MOL, V24, P671, DOI 10.1165/ajrcmb.24.6.4498; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Ishmael FT, 2007, J ALLERGY CLIN IMMUN, V119, pS134, DOI 10.1016/j.jaci.2006.11.653; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; KARIN M, 1997, INHALED GLUCOCORTICO, P29; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kouznetsova I, 2007, AM J RESP CELL MOL, V36, P286, DOI 10.1165/rcmb.2006-0008OC; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Laitinen A, 2000, J ALLERGY CLIN IMMUN, V105, pS509, DOI 10.1016/S0091-6749(00)90052-6; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lambrecht BN, 2003, CURR OPIN PULM MED, V9, P34, DOI 10.1097/00063198-200301000-00006; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Leung DYM, 2000, AM J RESP CRIT CARE, V162, P1; LeVan TD, 1999, BIOCHEM PHARMACOL, V57, P1003, DOI 10.1016/S0006-2952(99)00008-8; Lewis-Tuffin LJ, 2007, MOL CELL BIOL, V27, P2266, DOI 10.1128/MCB.01439-06; Lewis-Tuffin LJ, 2006, ANN NY ACAD SCI, V1069, P1, DOI 10.1196/annals.1351.001; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025; Lu WJ, 2005, AM J PHYSIOL-LUNG C, V288, pL52, DOI 10.1152/ajplung.00104.2004; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Mathieu M, 2001, AM J RESP CRIT CARE, V163, P585, DOI 10.1164/ajrccm.163.2.16310b; Matsukura S, 2004, INT ARCH ALLERGY IMM, V134, P12, DOI 10.1159/000077787; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Mellow TE, 2004, EXP LUNG RES, V30, P43, DOI 10.1080/01902140490252812; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Nadel JA, 2007, CURR OPIN ALLERGY CL, V7, P57, DOI 10.1097/ACI.0b013e328012ce22; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; O'Riordan TG, 1998, J APPL PHYSIOL, V85, P1086, DOI 10.1152/jappl.1998.85.3.1086; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Pawliczak R, 2005, PHYSIOL GENOMICS, V23, P28, DOI 10.1152/physiolgenomics.00011.2005; Perretti M, 2007, BLOOD, V109, P852, DOI 10.1182/blood-2006-11-056853; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Pichavant M, 2006, J IMMUNOL, V177, P5912, DOI 10.4049/jimmunol.177.9.5912; Prosperini G, 2002, J ALLERGY CLIN IMMUN, V110, P855, DOI 10.1067/mai.2002.130050; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Pu FRR, 2001, EXP LUNG RES, V27, P689; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Redington AE, 2001, THORAX, V56, P351, DOI 10.1136/thorax.56.5.351; Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; RocaFerrer J, 1997, EUR RESPIR J, V10, P1489, DOI 10.1183/09031936.97.10071489; Rodriguez RG, 2000, PULM PHARMACOL THER, V13, P31, DOI 10.1006/pupt.2000.0228; Rogatsky I, 2006, TISSUE ANTIGENS, V68, P1, DOI 10.1111/j.1399-0039.2006.00599.x; Rogers DF, 2007, RESP CARE, V52, P1134; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014; Sansonetti PJ, 2006, NAT IMMUNOL, V7, P1237, DOI 10.1038/ni1420; Sauty A, 1999, J IMMUNOL, V162, P3549; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; SCHLEIMER RP, 1998, ALLERGY PRINCIPLES P, P638; SCHLEIMER RP, 2002, INHALED STEROIDS AST; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Shah RV, 2006, J AEROSOL MED, V19, P208, DOI 10.1089/jam.2006.19.208; Shebani E, 2005, TISSUE CELL, V37, P145, DOI 10.1016/j.tice.2004.12.002; Shirasaki H, 2004, CLIN EXP ALLERGY, V34, P945, DOI 10.1111/j.1365-2222.2004.01964.x; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Smoak K, 2006, MOL CELL BIOL, V26, P9126, DOI 10.1128/MCB.00679-06; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Stellato C, 1999, J IMMUNOL, V163, P5624; Stellato C, 2006, J ALLERGY CLIN IMMUN, V117, pS182, DOI 10.1016/j.jaci.2005.12.723; Stellato C, 2000, CHEMOKINES IN ALLERGIC DISEASE, P473; STELLATO C, 1995, J IMMUNOL, V155, P410; STELLATO C, 1997, ASTHMA, P1569; Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS; Sunday ME, 2004, ENDOCR PATHOL, V15, P91, DOI 10.1385/EP:15:2:091; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Traves SL, 2007, CURR OPIN PHARMACOL, V7, P252, DOI 10.1016/j.coph.2006.11.010; Urbach V, 2006, STEROIDS, V71, P323, DOI 10.1016/j.steroids.2005.09.014; Vachier I, 1998, AM J RESP CRIT CARE, V158, P963, DOI 10.1164/ajrccm.158.3.9710085; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; Wanner Adam, 2004, Proc Am Thorac Soc, V1, P235, DOI 10.1513/pats.200402-013MS; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047, DOI 10.1164/ajrccm.164.6.2010045; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zhang N, 2007, J IMMUNOL, V179, P578, DOI 10.4049/jimmunol.179.1.578; Zhao J, 2007, INT ARCH ALLERGY IMM, V142, P219, DOI 10.1159/000097024; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578	176	43	44	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1247	1265		10.1016/j.jaci.2007.10.041	http://dx.doi.org/10.1016/j.jaci.2007.10.041			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	18073120				2022-12-18	WOS:000251653800002
J	Dean, T; Venter, C; Pereira, B; Arshad, SH; Grundy, J; Clayton, CB; Higgins, B				Dean, Taraneh; Venter, Carina; Pereira, Brett; Arshad, S. Hasan; Grundy, Jane; Clayton, C. Bernie; Higgins, Bernie			Patterns of sensitization to food and aeroallergens in the first 3 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; food and aeroallergens; early childhood; atopy	SKIN-PRICK TEST; POPULATION BIRTH COHORT; LONGITUDINAL CHANGES; RESPIRATORY SYMPTOMS; TEST REACTIVITY; PREVALENCE; ATOPY; AGE; HYPERSENSITIVITY; ALLERGENS	Background: There is a paucity of longitudinal studies of allergen sensitization in childhood. Objective: To investigate the pattern of sensitization in early childhood. Methods: A nested cohort of children (n = 543) were followed up from birth and given a skin prick test (SPT) at 1, 2, and 3 years of age. A detailed clinical history was obtained. Results: The prevalences of sensitization to aeroallergens were 1.3%,6.4%, and 10.7% at 1, 2, and 3 years of age. The figures for food allergens were 2.8 %, 3.9 %, and 3.7 %. There was a statistically significant increase in the prevalence of sensitization to >= 1 allergen between years 1 and 2 (P <.001) and years 2 and 3 (P =.032). Among those with a positive SPTat 1 year, 29% tested positive to additional allergens at 2 years (P =.0054). Sensitization to milk or egg at 1 year was a predictor for increased sensitization to peanut at 3 years (odds ratio, 34.8; P <.0001). Sensitization to egg at 1 year was associated with increased sensitization to aeroallergens at 3 years (odds ratios, house dust mite, 27.1, P <.001; cat, 8.9, P <.01; grass, 11.8, P =.005). For peanut and cat allergens, wheal size increases with the age of the child (P =.009 and P =.017, respectively). Conclusion: Sensitization to allergens as demonstrated by positive SPT tends to increase with age, and this change can be detected in the first 3 years of life. Clinical implications: The high predictive value for early sensitization and a linear increase in SPT reactivity provide an opportunity for early intervention.	Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth PO1 2FR, Hants, England; St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Isle Wight, England	University of Portsmouth	Dean, T (corresponding author), Univ Portsmouth, Sch Hlth Sci & Social Work, James Watson W,2 King Richard 1st Rd, Portsmouth PO1 2FR, Hants, England.	tara.dean@port.ac.uk		Dean, Taraneh/0000-0002-0123-7646				Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Demoly P., 1998, ALLERGY PRINCIPLES P, V5th ed., P430; DREBORG S, 1989, ALLERGY S10, V44, P52; Epton MJ, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-26; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; JOHNSTON SL, 1992, CLIN EXP ALLERGY, V22, P948, DOI 10.1111/j.1365-2222.1992.tb02069.x; KUEHR J, 1992, CLIN EXP ALLERGY, V22, P839, DOI 10.1111/j.1365-2222.1992.tb02829.x; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; MALLING HJ, 1985, ALLERGY, V40, P400, DOI 10.1111/j.1398-9995.1985.tb02678.x; Malling HJ., 2003, ALLERGY, V48, P55; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Sandin A, 2004, PEDIATR ALLERGY IMMU, V15, P316, DOI 10.1111/j.1399-3038.2004.00166.x; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352	21	43	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1166	1171		10.1016/j.jaci.2007.06.042	http://dx.doi.org/10.1016/j.jaci.2007.06.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17825888				2022-12-18	WOS:000250973400028
J	Howell, MD; Streib, JE; Leung, DYM				Howell, Michael D.; Streib, Joanne E.; Leung, Donald Y. M.			Antiviral activity of human beta-defensin 3 against vaccinia virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; DEFICIENCY		Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Room K926,1400 Jackson St, Denver, CO 80206 USA.	leungd@njc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR051634, R01AR041256] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00051, M01 RR000051-47, M01 RR000051, M01 RR000051-360942] Funding Source: Medline; NIAID NIH HHS [HHSN266200400033C, U01 AI147462, N01AI40030, N01 AI040029] Funding Source: Medline; NIAMS NIH HHS [R01 AR041256, R21 AR051634, AR41256, R01 AR041256-17] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033	9	43	49	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					1022	1025		10.1016/j.jaci.2007.01.044	http://dx.doi.org/10.1016/j.jaci.2007.01.044			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17353034	Green Accepted			2022-12-18	WOS:000245729500040
J	Niederberger, V; Reisinger, J; Valent, P; Krauth, MT; Pauli, G; van Hage, M; Cromwell, O; Horak, F; Valenta, R				Niederberger, Verena; Reisinger, Jurgen; Valent, Peter; Krauth, Maria-Theresa; Pauli, Gabrielle; van Hage, Marianne; Cromwell, Oliver; Horak, Friedrich; Valenta, Rudolf			Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Med Univ Vienna, Vienna Gen Hosp, Dept Otolaryngol, Vienna, Austria; Med Univ Vienna, Vienna Gen Hosp, Dept Hematol & Hemostaseol, Vienna, Austria; Guys Hosp, Dept Otolaryngol, London SE1 9RT, England; Hop Univ Strasbourg, Serv Pneumol, Strasbourg, France; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Allergopharma Joachim Ganzer KG, Reinbek, Germany; Med Univ Vienna, Vienna Gen Hosp, Christian Doppler Lab Allergy Res, Div Immunopathol,Dept Pahophysiol,Ctr Physiol & P, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Guy's & St Thomas' NHS Foundation Trust; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Karolinska Institutet; Allergopharma; Medical University of Vienna	Niederberger, V (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Dept Otolaryngol, Vienna, Austria.	verena.niederberger@meduniwien.ac.at	van Hage, Marianne/A-9678-2017; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Test, PV/U-9451-2019	van Hage, Marianne/0000-0003-3091-1596; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Helm RM, 2000, CURR OPIN IMMUNOL, V12, P647, DOI 10.1016/S0952-7915(00)00157-6; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Zuidmeer L, 2006, INT ARCH ALLERGY IMM, V141, P230, DOI 10.1159/000095293	8	43	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					1013	1016		10.1016/j.jaci.2006.12.661	http://dx.doi.org/10.1016/j.jaci.2006.12.661			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17292956				2022-12-18	WOS:000245729500035
J	Kim, BE; Leung, DYM; Streib, JE; Boguniewicz, M; Hamid, QA; Howell, MD				Kim, Byung Eui; Leung, Donald Y. M.; Streib, Joanne E.; Boguniewicz, Mark; Hamid, Qutayba A.; Howell, Michael D.			Macrophage inflammatory protein 3 alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; chemokines; innate immunity; vaccinia virus; antimicrobial peptides	CYTOKINE MILIEU; EXPRESSION; CHEMOKINES; KERATINOCYTES; INTERLEUKIN-6	Background: Patients with atopic dermatitis (AD) are prone to disseminated viral skin infections and therefore are not vaccinated against smallpox because of potential complications. Macrophage inflammatory protein 3 alpha (MIP-3 alpha) is a C-C chemokine expressed by keratinocytes that exhibits antimicrobial activity against bacteria and fungi; however, its role in antiviral innate immunity is unknown. Objective: Evaluate the level of MIP-3a in AD skin and its role in the innate immune response to vaccinia virus (VV). Methods: Macrophage inflammatory protein 3a levels were evaluated using real-time RT-PCR, immunodot-blot, and immunohistochemistry. The antiviral activity of MIP-3a was determined using a standard viral plaque assay. Results: Macrophage inflammatory protein 3a gene expression was significantly (P < .01) decreased in AD skin (< .21 +/- 0.05 ng MIP-3 alpha/ng glyceraidehyde-3-phosphate dehydrogenase) compared with psoriasis skin (0.67 +/- 0.13). This was confirmed at the protein level using immunohistochemistry. We further demonstrate that T(H)2 cytokines downregulate MIP-3a expression. The importance of MIP-3 alpha in the innate immune response against VV was established by first demonstrating that MIP-3a exhibits activity against VV. Second, VV replication was significantly increased (P < .01) in keratinocytes treated with an antibody to neutralize MIP-3 alpha. Conclusion: The current study demonstrates that MIP-3 alpha exhibits antiviral activity against VV and demonstrates the importance of MIP-3 alpha in the innate immune response against VV. In addition, AD skin is deficient in MIP-3 alpha, in part because of the overexpression of T(H)2 cytokines in AD skin. Clinical implications: MIP-3 alpha deficiency in AD skin contributes to patients' increased propensity toward eczema vaccinatum. Increasing MIP-3 alpha or neutralizing T(H)2 cytokines could prevent adverse reactions in patients with AD after smallpox vaccination.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Inje Univ, Sanggye Paik Hosp, Dept Pediat, Seoul, South Korea; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	National Jewish Health; Inje University; McGill University	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.	leungd@njc.org		Kim, Byung Eui/0000-0003-4923-1814	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256, R21AR051634] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000051, M01 RR000051-360942, M01 RR00051] Funding Source: Medline; NIAID NIH HHS [N01AI40030, HHSN266200400033C, U01 AI147462, HHSN266200400033C, N01 AI040029] Funding Source: Medline; NIAMS NIH HHS [R01 AR041256, AR41256, R21 AR051634, R21 AR051634-01, R01 AR041256-17, R21 AR051634-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akahoshi T, 2003, INFECT IMMUN, V71, P524, DOI 10.1128/IAI.71.1.524-526.2003; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; AMEGADZIE BY, 1991, J BIOL CHEM, V266, P13712; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; *J WIL SONS, 2002, CURR PROT MOL BIOL; Jeong CW, 2003, CLIN EXP ALLERGY, V33, P1717, DOI 10.1111/j.1365-2222.2003.01782.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Nakayama T, 2001, INT IMMUNOL, V13, P95, DOI 10.1093/intimm/13.1.95; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1; Tukey J. W., 1977, EXPLORATORY DATA ANA; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024	27	43	47	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					457	463		10.1016/j.jaci.2006.10.005	http://dx.doi.org/10.1016/j.jaci.2006.10.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17141855	Green Accepted			2022-12-18	WOS:000244327900026
J	Ramsey, CD; Gold, DR; Litonjua, AA; Sredl, DL; Ryan, L; Celedon, JC				Ramsey, Clare D.; Gold, Diane R.; Litonjua, Augusto A.; Sredl, Diane L.; Ryan, Louise; Celedon, Juan C.			Respiratory illnesses in early life and asthma and atopy in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchiolitis; croup; ear infections; wheezing; asthma; allergy; skin tests	SYNCYTIAL-VIRUS BRONCHIOLITIS; DAY-CARE ATTENDANCE; 1ST YEAR; OTITIS-MEDIA; RECURRENT CROUP; ALLERGIC RHINITIS; RSV BRONCHIOLITIS; MATERNAL HISTORY; RISK-FACTORS; SCHOOL-AGE	Background: The relation between respiratory illnesses in early life and the development of asthma and atopy in childhood is incompletely understood. Objective: We sought to examine the relationship between respiratory illnesses in early life and atopic diseases at school age. Methods: We performed a prospective birth cohort study of the relationship between respiratory illnesses in the first year of life and asthma, atopy (sensitization to 1 allergen), and allergic rhinitis at school age in 440 children with a parental history of atopy. Logistic regression was used to examine the relationship between respiratory illnesses and asthma, atopy, and allergic rhinitis. The relationship between respiratory illnesses in early life and repeated measures of wheezing between the ages of I and 7 years was investigated by using a proportional hazards models. Results: Physician-diagnosed croup (adjusted odds ratio [OR], 0.30; 95% CI, 0.12-0.72) and having 2 or more physician-diagnosed ear infections (adjusted OR, 0.58; 95% CI, 0.35-0.98) in the first year of life were inversely associated with atopy at school age. Physician-diagnosed bronchiolitis before age 1 year was significantly associated with asthma at age 7 years (adjusted OR, 2.77; 95% CI, 1.23-6.22). Recurrent nasal catarrh (>= 3 episodes of a runny nose) in the first year of life was associated with allergic rhinitis at age 7 years (adjusted OR, 2.99; 95% CI, 1.03-8.67). Conclusion: The relationship between early-life respiratory illnesses and asthma and atopy is complex and likely dependent on the type of infection and immune response it initiates. Clinical implications: Certain respiratory illnesses in early life modify the risk of atopy and asthma at school age.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Div Pulm & Crit Care Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Celedon, JC (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Ryan, Louise M/A-4562-2009	Ryan, Louise M/0000-0001-5957-2490; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [5 T32 HL07427, HL04370, HL073373] Funding Source: Medline; PHS HHS [AIEHS35786] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, K01HL004370, R01HL073373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; BLOOM B, 2004, NATL HLTH INTERVIEW, V10; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; Caffarelli C, 1998, CLIN EXP ALLERGY, V28, P591; Castro-Rodriguez JA, 2001, PEDIATRICS, V107, P512, DOI 10.1542/peds.107.3.512; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e77; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Eldeirawi K, 2004, CHEST, V125, P1685, DOI 10.1378/chest.125.5.1685; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kilpi T, 2001, PEDIATR INFECT DIS J, V20, P654, DOI 10.1097/00006454-200107000-00004; KONIG P, 1978, ANN ALLERGY, V41, P227; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; Leung Alexander K C, 2004, J Pediatr Health Care, V18, P297, DOI 10.1016/S0891-5245(04)00268-8; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LITMANOVITCH M, 1990, ANN ALLERGY, V65, P239; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MCCONNOCHIE KM, 1989, PEDIATR PULM, V6, P138, DOI 10.1002/ppul.1950060303; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nicolai T, 1996, ACTA PAEDIATR, V85, P1295, DOI 10.1111/j.1651-2227.1996.tb13914.x; Nja F, 2003, ARCH DIS CHILD, V88, P566, DOI 10.1136/adc.88.7.566; Noble V, 1997, ARCH DIS CHILD, V76, P315, DOI 10.1136/adc.76.4.315; PORRO E, 1992, INT J PEDIATR OTORHI, V24, P111, DOI 10.1016/0165-5876(92)90137-E; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; Romagnani S, 1996, TRENDS MICROBIOL, V4, P470, DOI 10.1016/S0966-842X(97)82906-X; RYLANDER E, 1988, ACTA PAEDIATR SCAND, V77, P711, DOI 10.1111/j.1651-2227.1988.tb10735.x; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; SIMS DG, 1981, BRIT MED J, V282, P2086, DOI 10.1136/bmj.282.6282.2086; Sobol SE, 2002, J ALLERGY CLIN IMMUN, V110, P125, DOI 10.1067/mai.2002.125697; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; TAINIO VM, 1988, PEDIATR RES, V23, P509, DOI 10.1203/00006450-198805000-00015; Therneau TM, 2000, STAT BIOL HEALTH; Turner SW, 2002, ARCH DIS CHILD, V87, P417, DOI 10.1136/adc.87.5.417; Van Bever HP, 1999, EUR J PEDIATR, V158, P253, DOI 10.1007/s004310051062; Vargas PA, 2004, J ALLERGY CLIN IMMUN, V114, P499, DOI 10.1016/j.jaci.2004.05.025; WRIGHT AL, 1994, PEDIATRICS, V94, P895; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZACH M, 1981, ARCH DIS CHILD, V56, P336, DOI 10.1136/adc.56.5.336	53	43	45	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					150	156		10.1016/j.jaci.2006.09.012	http://dx.doi.org/10.1016/j.jaci.2006.09.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208596				2022-12-18	WOS:000243622200021
J	Bogdanovic, J; Koets, M; Sander, I; Wouters, I; Meijster, T; Heederik, D; van Amerongen, A; Doekes, G				Bogdanovic, Jelena; Koets, Marjo; Sander, Ingrid; Wouters, Inge; Meijster, Tim; Heederik, Dick; van Amerongen, Aart; Doekes, Gert			Rapid detection of fungal alpha-amylase in the work environment with a lateral flow immunoassay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen exposure; lateral flow immunoassay; fungal alpha-amylase; rapid detection of allergens	BAKERY WORKERS; BAKING INDUSTRY; ALLERGENS; SENSITIZATION; ANTIBODIES; ANTIGEN; DUST; HIV	Background: Occupational allergen exposure assessment usually requires airborne dust sampling at the worksite followed by dust extraction and enzyme immunoassay (EIA) analysis at the laboratory. Use of semiquantitative lateral flow immunoassays (LFIAs) may allow a more rapid detection procedure with direct on-site demonstration of a bioallergen exposure hazard. Objective: In a field study, we evaluated a recently developed LFIA for fungal alpha-amylase, an important bakery allergen. Methods: Airborne and surface dust (wipe) samples and samples from flours and baking additives used at the workplace were collected in 5 industrial bakeries and tested in the LFIA for fungal amylase. For comparison, amylase was measured in sample eluates with the reference EIA method. Results: Sensitivity of the LFIA was 1 to 10 ng/mL, and of EIA, similar to 25 pg/mL. In LFIA, most flour. samples, 84% of wipe samples, 26% of personal airborne dust, and none of the 26 ambient air dust samples produced a visible reaction. Wipe samples from dough-making areas and flour samples gave the strongest reactions. All extracts with > 5 ng allergen per milliliter showed a positive LFIA reaction. Conclusion: The LFIA for fungal amylase is an easy and rapid method to demonstrate the allergen directly at the worksite in less than 10 to 20 minutes. Similar LFIA methods may be used for other occupational allergens in other work environments. Clinical implications: Lateral flow immunoassays for occupational allergens may be of great value in occupational hygiene surveys to demonstrate directly to workers and supervisors the hazards of work-related bioallergen exposure.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Univ Wageningen & Res Ctr, Agrotechnol & Food Sci Grp, Wageningen, Netherlands; Ruhr Univ Bochum, Berufsgenossensch Forsch Inst Arbeitsmed, Bochum, Germany; Risk Assessment Work Environm, Utrecht, Netherlands; TNO Qual Life, Business Unit, Food & Chem Risk Anal, Zeist, Netherlands	Utrecht University; Wageningen University & Research; Ruhr University Bochum; Netherlands Organization Applied Science Research	Bogdanovic, J (corresponding author), Univ Utrecht, Inst Risk Assessment Sci, POB 80178, NL-3508 TD Utrecht, Netherlands.	j.bogdanovic@iras.uu.nl	Sander, Ingrid/R-8940-2017	Sander, Ingrid/0000-0002-5014-4112; Heederik, Dick/0000-0002-4550-1437; Wouters, Inge M./0000-0001-7834-9390				Aldus CF, 2003, J APPL MICROBIOL, V95, P380, DOI 10.1046/j.1365-2672.2003.01989.x; Beelaert G, 2002, J VIROL METHODS, V105, P197, DOI 10.1016/S0166-0934(02)00102-7; Brant A, 2005, EUR RESPIR J, V25, P303, DOI 10.1183/09031936.05.00054004; Cazacu AC, 2004, J CLIN MICROBIOL, V42, P3661, DOI [10.1128/JCM.42.8.3661-3664.2004, 10.1128/jcm.42.8.3661-3664.2004]; Constantine NT, 2005, INDIAN J MED RES, V121, P519; Elms J, 2003, OCCUP ENVIRON MED, V60, P802, DOI 10.1136/oem.60.10.802; Elms J, 2001, ANN OCCUP HYG, V45, P89, DOI 10.1093/annhyg/45.2.89; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;529::AID-AJIM1&gt;3.0.CO;2-I; Houba R, 1997, J ALLERGY CLIN IMMUN, V99, P286, DOI 10.1016/S0091-6749(97)70044-7; Houba R, 1996, AM J RESP CRIT CARE, V154, P130, DOI 10.1164/ajrccm.154.1.8680668; KOETS M, 2006, J ENV MONIT     0710; Korpi A, 2004, J ALLERGY CLIN IMMUN, V113, P677, DOI 10.1016/j.jaci.2003.11.039; Lillienberg L, 2000, ANN OCCUP HYG, V44, P427, DOI 10.1093/annhyg/44.6.427; Polzius R, 2002, ALLERGY, V57, P143, DOI 10.1034/j.1398-9995.2002.1s3333.x; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256, DOI 10.1016/S0091-6749(98)70109-5; Sander I, 1997, J IMMUNOL METHODS, V210, P93, DOI 10.1016/S0022-1759(97)00181-6; Slinger R, 2004, J CLIN MICROBIOL, V42, P3731, DOI [10.1128/JCM.42.8.3731-3733.2004, 10.1128/jcm.42.8.3731-3733.2004]; *STAUBF, 1973, STAUB REINHALT LUFT, V33, P1; TERKUILE WM, 1984, STAUB REINHALT LUFT, V44, P211; Tsay A., 2002, Clinical and Experimental Allergy, V32, P1596, DOI 10.1046/j.1365-2222.2002.01533.x; van Dam GJ, 2004, J CLIN MICROBIOL, V42, P5458, DOI 10.1128/JCM.42.12.5458-5461.2004	21	43	44	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1157	1163		10.1016/j.jaci.2006.07.004	http://dx.doi.org/10.1016/j.jaci.2006.07.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088143	Green Published			2022-12-18	WOS:000244282300023
J	Nahm, DH; Lee, KH; Shin, JY; Ye, YM; Kang, Y; Park, HS				Nahm, Dong-Ho; Lee, Kwang-Hoon; Shin, Jee-Young; Ye, Young-Min; Kang, Yup; Park, Hae-Sim			Identification of alpha-enolase as an autoantigen associated with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; autoantibodies; autoantigen; airway epithelial cell	RHEUMATOID-ARTHRITIS; BRONCHIAL-ASTHMA; T-CELL; DISEASES; AUTOIMMUNE; INFLAMMATION; ANTIBODIES; CRITERIA; ANTIGEN; MUCOSA	Background: Approximately 5% to 10% of patients with asthma have severe disease that is not effectively controlled by typical therapies. The existence of an autoantigen associated with severe asthma has been previously reported. Objective: We attempted to identify the autoantigen. Methods: Severe asthma was defined as patients having at least 1 severe asthmatic exacerbation requiring an emergency department visit or admission in the last year despite continuous typical therapies. Autoantibodies to airway epithelial cells (A549) were examined in sera from patients with severe asthma by immunoblot analysis. Results: IgG autoantibodies to the 52-kd airway epithelial cell antigen were detected in sera from 32 of 78 patients with severe asthma (41%), 9 of 83 patients with mild-to-moderate asthma (11%), and 2 of 58 healthy controls (3%; P < .001). The 52-kd autoantigen was identified as alpha-enolase by mass spectrometry analysis and confirmed by using recombinant human a-enolase protein. The detection of IgG autoantibodies to alpha-enolase was the most significant indicator for distinguishing severe asthma from mild-to-moderate asthma, even after adjusting for the effects of other clinical variables, including age, sex, atopy, and FEV1 (adjusted odds ratio, 5.2; 95% CI, 2.1-12.9; P < .001). Conclusion: The alpha-enolase was identified as an autoantigen associated with severe asthma. Further studies are needed to determine the significance of this autoantigen in severe asthma. Clinical implications: IgG autoantibodies to ei-enolase could be a biological marker for severe asthma.	Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon 443721, South Korea; Ajou Univ, Sch Med, Lab Endocrinol, Suwon 443721, South Korea; Yonsei Univ, Coll Med, Dept Dermatol, Seoul 120749, South Korea	Ajou University; Ajou University; Yonsei University; Yonsei University Health System	Nahm, DH (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon 443721, South Korea.	donghonahm@yahoo.co.kr	Park, Hae-Sim/S-7974-2019	Nahm, Dong-Ho/0000-0001-5253-6577; Park, Hae-Sim/0000-0003-2614-0303; Ye, Young-Min/0000-0002-7517-1715				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Abril A, 2003, SEMIN ARTHRITIS RHEU, V33, P106, DOI 10.1016/S0049-0172(03)00083-0; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; CALLERAME ML, 1971, NEW ENGL J MED, V284, P459, DOI 10.1056/NEJM197103042840902; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Holgate ST, 2004, CYTOKINE, V28, P152, DOI 10.1016/j.cyto.2004.07.010; KALSI J, 1993, INT ARCH ALLERGY IMM, V102, P209, DOI 10.1159/000236528; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Klausner JD, 2005, NEW ENGL J MED, V353, P631; Kon OM, 1999, INFLAMM RES, V48, P516, DOI 10.1007/s000110050496; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; LASSALLE P, 1993, EUR J IMMUNOL, V23, P796, DOI 10.1002/eji.1830230404; Lee KH, 2003, ARTHRITIS RHEUM, V48, P2025, DOI 10.1002/art.11074; Mahe C, 2002, INT J EPIDEMIOL, V31, P985, DOI 10.1093/ije/31.5.985; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; Nahm DH, 2002, AM J RESP CRIT CARE, V165, P1536, DOI 10.1164/rccm.200201-009OC; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; NIIMI T, 1987, AM J CLIN PATHOL, V88, P545, DOI 10.1093/ajcp/88.5.545; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; PARK HS, 1995, CLIN EXP ALLERGY, V25, P38, DOI 10.1111/j.1365-2222.1995.tb01000.x; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rottem M, 2003, INT ARCH ALLERGY IMM, V132, P210, DOI 10.1159/000074301; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Saulot V, 2002, ARTHRITIS RHEUM, V46, P1196, DOI 10.1002/art.10252; Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909; Virchow JC, 1996, J ALLERGY CLIN IMMUN, V98, pS27; WAGNER V, 1965, ACTA ALLERGOL, V20, P1, DOI 10.1111/j.1398-9995.1965.tb03350.x; WALLAERT B, 1994, AM J RESP CRIT CARE, V150, P802, DOI 10.1164/ajrccm.150.3.8087355; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897	33	43	48	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					376	381		10.1016/j.jaci.2006.04.002	http://dx.doi.org/10.1016/j.jaci.2006.04.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890761				2022-12-18	WOS:000239877700012
J	Thivierge, M; Stankova, J; Rola-Pleszczynski, M				Thivierge, Maryse; Stankova, Jana; Rola-Pleszczynski, Marek			Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; dendritic cells; lipid mediators; leukotriene; allergy; inflammation	CYSTEINYL LEUKOTRIENE-1 RECEPTOR; CYTOSOLIC PHOSPHOLIPASE A(2); DOWN-REGULATION; GENE-EXPRESSION; ACTIVATION; TLR4; MACROPHAGES; PROTEIN; INTERLEUKIN-4; RECOGNITION	Background: Dendritic cells (DCs) acquire, during their maturation, the expression of the chemokine receptor CCR7 and the ability to migrate to lymph nodes in response to CC chemokine ligand 19 (CCL19). This migration is impaired in mice lacking the leukotriene (LT) C-4 transporter and restored by addition of exogenous LTC4. Objective: To define the role of LT in human DC function, we studied the expression and function of the cysteinyl-leukotriene (CysLT) receptors during DC differentiation from monocytes and subsequent maturation. Methods: Receptor expression was measured by flow cytometry and real-time PCR. Responsiveness to LTD4 stimulation was assessed by calcium flux and chemotaxis. Results: Maturation of DC with LPS, a classic Toll-like receptor 4 agonist, reduced CysLT receptor 1 (CysLT1) expression by 50%, whereas CysLT receptor 2 expression was increased. In contrast, the Toll-like receptor 3 agonist poly inosinic and cytidylic acid (polyI:C) had no effect on receptor expression. Downregulation of CysLT1 expression by LPS could not be mimicked by TNF-alpha alone or in combination with IL-1 beta or IL-6. It was, however, prevented by inhibitors of COX and could be reproduced by a combination of TNF-alpha and prostaglandin E-2. Immature DCs and DCs matured with polyI:C, but not with LPS, responded to LTD4 with a robust cytosolic calcium flux, which was prevented by the CysLT1 antagonist montelukast. LTD4 induced DC chemotaxis and enhanced DC migration in response to CCL19 in DCs matured with polyI:C, but only weakly in DCs matured with LPS. Conclusion: Our data suggest that human DCs may differentially respond to leukotriene, depending on their maturational stimuli. Clinical implications: Our study demonstrates that some microbial agents can reduce the migration of dendritic cells in response to leukotrienes, with potential for differential involvement of these cells in allergic inflammation.	Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Rola-Pleszczynski@USherbrooke.ca						Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Lynch KR, 1999, NATURE, V399, P789; Machida I, 2004, J IMMUNOL, V172, P1833, DOI 10.4049/jimmunol.172.3.1833; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mehindate K, 1996, LAB INVEST, V75, P529; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; Okunishi K, 2004, J IMMUNOL, V173, P6393, DOI 10.4049/jimmunol.173.10.6393; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	35	43	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1155	1162		10.1016/j.jaci.2005.12.1342	http://dx.doi.org/10.1016/j.jaci.2005.12.1342			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675346				2022-12-18	WOS:000237436300030
J	Stoloff, SW; Boushey, HA				Stoloff, SW; Boushey, HA			Severity, control, and responsiveness in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma severity; control; responsiveness; assessment; monitoring	EXHALED NITRIC-OXIDE; INHALED CORTICOSTEROIDS; PREDICTIVE-VALUE; ADULTS; CHILDREN; RISK; EMERGENCY; MARKERS; SPUTUM; EXACERBATIONS	Guidelines for asthma management have proposed that initial treatment should be based on assessment of asthma severity. The treatments proposed for different degrees of asthma severity are essentially estimates of the intensity of treatment needed to achieve asthma control. Responsiveness to treatment is heterogeneous, however, even among asthmatic patients with asthma of similar severity. This heterogeneity calls attention to the importance of assessing asthma control and adjusting treatment accordingly. Application of a guidelines-based approach to asthma management thus requires general agreement on what is meant by severity, control, and responsiveness and requires further an awareness of asthma as causing symptoms and functional impairment in the present and also as causing risk of adverse events in the future.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Nevada, Sch Med, Reno, NV 89557 USA	University of California System; University of California San Francisco; Nevada System of Higher Education (NSHE); University of Nevada Reno	Boushey, HA (corresponding author), Univ Calif San Francisco, Box 0130,1292-M,505 Parnassus Ave, San Francisco, CA 94143 USA.	homer.boushey@ucsf.edu						Adams RJ, 2000, THORAX, V55, P566, DOI 10.1136/thorax.55.7.566; Ayres JG, 1998, THORAX, V53, P315, DOI 10.1136/thx.53.4.315; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Barr RG, 2000, EUR RESPIR J, V15, P266, DOI 10.1034/j.1399-3003.2000.15b08.x; Bartoli ML, 2004, RESP MED, V98, P184, DOI 10.1016/j.rmed.2003.09.012; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2001, CURR OPIN ALLERGY CL, V1, P211; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Boulet LP, 2002, CHEST, V122, P2217, DOI 10.1378/chest.122.6.2217; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Cowie RL, 2001, J ASTHMA, V38, P179, DOI 10.1081/JAS-100000037; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Fuhlbrigge AL, 2004, CURR OPIN PULM MED, V10, P1, DOI 10.1097/00063198-200401000-00002; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gibson PG, 2000, EUR RESPIR J, V16, P1008; *GLOB IN ASTM, 1998, NIH PUBL; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; *NAT ASTHM ED PREV, 1997, GUID DIAGN MAN ASTHM; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nishiyama O, 2003, J ASTHMA, V40, P281, DOI 10.1081/JAS-120018327; O'Byrne PM, 2005, AM J RESP CRIT CARE, V172, P410, DOI 10.1164/rccm.2505001; Pavord I D, 2002, Eur Respir J Suppl, V37, p40s; Phillips Robert A, 2005, Expert Rev Cardiovasc Ther, V3, P691, DOI 10.1586/14779072.3.4.691; Prieto L, 2003, CHEST, V124, P1325, DOI 10.1378/chest.124.4.1325; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rodrigo GJ, 2000, CHEST, V118, P1547, DOI 10.1378/chest.118.6.1547; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P935, DOI 10.1016/j.jaci.2005.01.054; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P466, DOI 10.1016/j.jaci.2004.12.1113; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P395, DOI 10.1067/mai.2002.127433; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Timonen KL, 2002, EUR RESPIR J, V19, P479, DOI 10.1183/09031936.02.00087802; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098	51	43	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					544	548		10.1016/j.jaci.2006.01.005	http://dx.doi.org/10.1016/j.jaci.2006.01.005			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522451				2022-12-18	WOS:000236263100007
J	Bergeron, C; Kimoff, J; Hamid, Q				Bergeron, C; Kimoff, J; Hamid, Q			Obstructive sleep apnea syndrome and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HYPOPNEA SYNDROME; INTERLEUKIN-6; ADIPONECTIN; EXPRESSION; CHILDREN; UVULA		McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Ctr Hlth, Div Resp, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						Boyd JH, 2004, AM J RESP CRIT CARE, V170, P541, DOI 10.1164/rccm.200308-1100OC; Brouillette RT, 2001, J PEDIATR-US, V138, P838, DOI 10.1067/mpd.2001.114474; Carpagnano GE, 2002, CHEST, V122, P1162, DOI 10.1378/chest.122.4.1162; Dyugovskaya L, 2002, AM J RESP CRIT CARE, V165, P934, DOI 10.1164/ajrccm.165.7.2104126; Goldbart AD, 2005, AM J RESP CRIT CARE, V172, P364, DOI 10.1164/rccm.200408-1064OC; Goldbart AD, 2004, CHEST, V126, P13, DOI 10.1378/chest.126.1.13; Hatipoglu U, 2003, RESPIRATION, V70, P665, DOI 10.1159/000075218; Imagawa S, 2001, BLOOD, V98, P1255, DOI 10.1182/blood.V98.4.1255; Kataoka T, 2004, TOHOKU J EXP MED, V204, P267, DOI 10.1620/tjem.204.267; Lavie L, 2003, SLEEP MED REV, V7, P35, DOI 10.1053/smrv.2002.0261; Paulsen FP, 2002, AM J RESP CRIT CARE, V166, P501, DOI 10.1164/rccm.2109099; Phillips BG, 2002, CURR OPIN PULM MED, V8, P516, DOI 10.1097/00063198-200211000-00006; RUBINSTEIN I, 1995, LARYNGOSCOPE, V105, P175, DOI 10.1288/00005537-199502000-00012; Salerno FG, 2004, RESP MED, V98, P25, DOI 10.1016/j.rmed.2003.08.003; Sekosan M, 1996, LARYNGOSCOPE, V106, P1018, DOI 10.1097/00005537-199608000-00021; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; Series F, 2004, AM J RESP CRIT CARE, V170, P1114, DOI 10.1164/rccm.200404-458OC; Vgontzas AN, 2005, SLEEP MED REV, V9, P211, DOI 10.1016/j.smrv.2005.01.006; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P4409, DOI 10.1210/jc.2003-031929; Wolk R, 2005, OBES RES, V13, P186, DOI 10.1038/oby.2005.24; Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zhang XL, 2004, CHINESE MED J-PEKING, V117, P1603	23	43	45	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1393	1396		10.1016/j.jaci.2005.10.008	http://dx.doi.org/10.1016/j.jaci.2005.10.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337480				2022-12-18	WOS:000235687000039
J	Henderson, WR; Banerjee, ER; Chi, EY				Henderson, WR; Banerjee, ER; Chi, EY			Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-adrenergic agonist enantiomers; airways; mucus; edema; inflammation; hyperresponsiveness	AIRWAY INFLAMMATION; GENE-EXPRESSION; IL-4; LUNG; HYPERRESPONSIVENESS; LEUKOTRIENES; RECRUITMENT; INHIBITION; SALBUTAMOL; ABSENCE	Background: (R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma. The (R)-enantiomer binds to the beta(2)-adrenergic receptor with greater affinity than the (S)-enantiomer and is responsible for albuterol's bronchodilating activity. (S)-Albuterol augments bronchospasm and has proinflarnmatory actions. Objective: The study aim was to determine whether the (S)-enantiomer, in contrast to the (R)-enantiomer, has adverse effects on allergic airway inflammation and hyperresponsiveness in a mouse asthma model. Methods: Mice sensitized to ovalbumin (OVA) intraperitoneally on days 0 and 14 were challenged with OVA intranasally on days 14, 25, and 35. On day 36, 24 hours after the final allergen challenge, the effect of the (R)- and (S)-enantiomers of albuterol (1 mg - kg(-1) - d(-1) administered by means of a miniosmotic pump from days 13-36) on airway inflammation and hyperreactivity was determined. Results: In OVA-sensitized/OVA-challenged mice, (R)-albuterol significantly reduced the influx of eosinophils into the bronchoalveolar lavage fluid and airway tissue. (R)-Albuterol also significantly decreased airway goblet cell hyperplasia and mucus occlusion and levels of IL-4 in bronchoalveolar lavage fluid and OVA-specific IgE in plasma. Although (S)-albuterol significantly reduced airway eosinophil infiltration, goblet cell hyperplasia, and mucus occlusion, it increased airway edema and responsiveness to methacholine in OVA-sensitized/OVA-challenged mice. Allergen-induced airway edema and pulmonary mechanics were unaffected by (R)-albuterol. Conclusion: Both (R)- and (S)-enantiomers of albuterol reduce airway eosinophil trafficking and mucus hypersecretion in a mouse model of asthma. However, (S)-albuterol increases allergen-induced airway edema and hyperresponsiveness. These adverse effects of the (S)-enantiomer on lung function might limit the clinical efficacy of racemic albuterol.	Univ Washington, Dept Med, Ctr Allergy & Inflammat, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Henderson, WR (corresponding author), Univ Washington, Dept Med, Ctr Allergy & Inflammat, Box 358050,815 Mercer St, Seattle, WA 98109 USA.	joangb@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073722] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073722] Funding Source: Medline; NIAID NIH HHS [AI04989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal DK, 2004, J ALLERGY CLIN IMMUN, V113, P503, DOI 10.1016/j.jaci.2003.12.039; Baramki D, 2002, J ALLERGY CLIN IMMUN, V109, P449, DOI 10.1067/mai.2002.122159; Bennett William D., 2002, Journal of Allergy and Clinical Immunology, V110, pS291, DOI 10.1067/mai.2002.129704; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; Burke TF, 2000, BIOCHEM BIOPH RES CO, V270, P1016, DOI 10.1006/bbrc.2000.2508; Cho SH, 2001, INT ARCH ALLERGY IMM, V124, P478, DOI 10.1159/000053783; Dohi M, 1999, LAB INVEST, V79, P1559; Eaton EA, 1996, BRIT J CLIN PHARMACO, V41, P201, DOI 10.1111/j.1365-2125.1996.tb00183.x; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; Frohock JI, 2002, J APPL PHYSIOL, V92, P2396, DOI 10.1152/japplphysiol.00755.2001; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; HENDERSON WR, 2003, MIDDLETONS ALLERGY P, P465; Iio J, 2002, INT ARCH ALLERGY IMM, V127, P217, DOI 10.1159/000053866; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363, DOI 10.1152/ajplung.2001.280.2.L363; Keir S, 2002, J ALLERGY CLIN IMMUN, V110, P388, DOI 10.1067/mai.2002.126661; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mitzner W, 2003, J APPL PHYSIOL, V94, P828, DOI 10.1152/japplphysiol.00815.2002; Nguyen C, 2003, P NATL ACAD SCI USA, V100, P1169, DOI 10.1073/pnas.0437889100; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Petak F, 2001, J APPL PHYSIOL, V90, P2221, DOI 10.1152/jappl.2001.90.6.2221; PETERSON BT, 2000, AM J RESP CRIT CARE, V161, pA416; Rogers DF, 2002, CURR OPIN PHARMACOL, V2, P249, DOI 10.1016/S1471-4892(02)00146-7; Roumestan C, 2002, J ALLERGY CLIN IMMUN, V109, pS240, DOI 10.1016/S0091-6749(02)81866-8; Sartori C, 2002, J APPL PHYSIOL, V93, P1875, DOI 10.1152/japplphysiol.00275.2002; Slattery D, 2002, PEDIATR PULM, V33, P151, DOI 10.1002/ppul.10027; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; Wang CH, 2003, BRIT J PHARMACOL, V138, P1147, DOI 10.1038/sj.bjp.0705131; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	33	43	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					332	340		10.1016/j.jaci.2005.04.013	http://dx.doi.org/10.1016/j.jaci.2005.04.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083788				2022-12-18	WOS:000235686400015
J	Lim, DLC; Neo, KH; Goh, DLM; Shek, LPC; Lee, BW				Lim, DLC; Neo, KH; Goh, DLM; Shek, LPC; Lee, BW			Missing parvalbumin: Implications in diagnostic testing for tuna allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FISH		Natl Univ Singapore, Dept Paediat, Singapore 119074, Singapore	National University of Singapore	Lim, DLC (corresponding author), Natl Univ Singapore, Dept Paediat, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.		Goh, Denise/D-8486-2015; Shek, Lynette/D-8016-2015	Shek, Lynette/0000-0001-9064-8983				BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Hansen TK, 1997, ANN ALLERG ASTHMA IM, V78, P187, DOI 10.1016/S1081-1206(10)63386-8; James JM, 1997, ANN ALLERG ASTHMA IM, V79, P131, DOI 10.1016/S1081-1206(10)63099-2; Thys TM, 1998, J EXP BIOL, V201, P2993; Yamada S, 1999, ANN ALLERG ASTHMA IM, V82, P395, DOI 10.1016/S1081-1206(10)63290-5	5	43	44	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					874	875		10.1016/j.jaci.2004.12.1117	http://dx.doi.org/10.1016/j.jaci.2004.12.1117			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806014				2022-12-18	WOS:000228373400033
J	Nagpal, K; Sharma, S; B-Rao, C; Nahid, S; Niphadkar, PV; Sharma, SK; Ghosh, B				Nagpal, K; Sharma, S; B-Rao, C; Nahid, S; Niphadkar, PV; Sharma, SK; Ghosh, B			TGF beta 1 haplotypes and asthma in Indian populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; case-control study; haplotype; Indian population; serum IgE; TGF beta 1	FACTOR-BETA 1; GENE-EXPRESSION; CELLS; POLYMORPHISM; ASSOCIATION; EOSINOPHILS	Background: Asthma is a complex disorder of the airways of the lungs. TGF-beta 1 plays a key role in airway remodeling and asthma by having both proinflammatory and anti-inflammatory activities, making TGF beta 1 an important candidate gene to study. Objective: To investigate the association of TGF beta 1 gene polymorphisms with asthma. Methods: A case-control study was designed for identifying polymorphisms and haplotypes associated with asthma and associated phenotypes. We have verified our results in 2 independent cohorts collected from northern (number of patients, 187; number of controls, 187) and western India (number of patients, 209; number of controls, 190). We measured the serum TGF-beta 1 levels of selected individuals and correlated them with genotypes and haplotypes. Results: A novel (CT)(n)(CA)(m) repeat polymorphism (BV209662) 24.9 kb upstream of TGF beta 1 was identified. A significant association was seen at the level of alleles and genotypes with asthma in the 2 cohorts studied independently (P < .05). Interestingly, a novel 3-locus haplotype, 23_G_T, was found to be significantly associated with asthma (P = .00001 in cohorts A and B) as well as with higher serum TGF-beta 1 level (P = .01). On the other hand, a novel haplotype, 22_G_C, was negatively associated with asthma (P = .00001 for cohorts A and B) and with lower serum TGF-beta 1 level (P = .0019). Conclusion: This is the first study identifying novel risk and protective haplotypes-23_G_T and 22_G_C, respectively-in the TGF beta 1 gene that are associated with asthma. We also demonstrate the functional significance of these haplotypes with serum TGF-beta 1 levels. These results would be valuable in elucidating the role of TGF-beta 1 in asthma pathogenesis.	Inst Genom & Integrat Biol, Immunogenet Mol Lab, Delhi 110007, India; Ctr Asthma & Allergy, Bombay, Maharashtra, India; All India Inst Med Sci, Dept Med, Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); All India Institute of Medical Sciences (AIIMS) New Delhi	Ghosh, B (corresponding author), Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India.	bghosh@igib.res.in	Ghosh, Balaram/G-1248-2010	B-RAO, CHANDRIKA/0000-0003-3848-7945; Sharma, Shilpy/0000-0001-5900-3140				ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; AUBERT JD, 1994, THORAX, V49, P225, DOI 10.1136/thx.49.3.225; Blumenthal MN, 2004, GENES IMMUN, V5, P226, DOI 10.1038/sj.gene.6364063; Buckova D, 2001, ALLERGY, V56, P1236, DOI 10.1034/j.1398-9995.2001.00373.x; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Chakraborty AK, 1998, BIOCHEM BIOPH RES CO, V252, P716, DOI 10.1006/bbrc.1998.9711; Dunning AM, 2003, CANCER RES, V63, P2610; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Holbert S, 2001, P NATL ACAD SCI USA, V98, P1811, DOI 10.1073/pnas.041566798; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nagarkatti R, 2002, J ALLERGY CLIN IMMUN, V110, P410, DOI 10.1067/mai.2002.127859; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Sharma S, 2004, CLIN GENET, V66, P417, DOI 10.1111/j.1399-0004.2004.00333.x; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Taylor A, 2004, INT ARCH ALLERGY IMM, V135, P73, DOI 10.1159/000080523; Texereau J, 2004, THORAX, V59, P156, DOI 10.1136/thorax.2003.006718; Zak NB, 2001, DRUG DISCOV TODAY, V6, P1111, DOI 10.1016/S1359-6446(01)02007-4; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	27	43	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					527	533		10.1016/j.jaci.2004.11.048	http://dx.doi.org/10.1016/j.jaci.2004.11.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753900				2022-12-18	WOS:000227687000015
J	Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Sasaki, S; Watanabe, T; Takahashi, K; Nagawa, H				Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Sasaki, S; Watanabe, T; Takahashi, K; Nagawa, H			Epigallocatechin gallate induces apoptosis of monocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte; apoptosis; catechin; EGCG; inflammation	CELL-DEATH APOPTOSIS; GREEN TEA; CANCER PREVENTION; POLYPHENOLS; CATECHINS; MECHANISMS; INDUCTION; (-)-EPIGALLOCATECHIN-3-GALLATE; ANTIOXIDANT; INHIBITION	Background: Monocytes are the main effector cells of the immune system, and the regulation of their survival and apoptosis is essential for monocyte-involved immune responses. Green tea polyphenol catechin has been reported to have antiallergic and antiinflammatory activities, but its effect on monocytes has not yet been explored. Objective: To elucidate the mechanisms of the anti-inflammatory effect of catechin, we studied the effect of catechin, especially epigallocatechin gallate (EGCG), on the apoptosis of monocytes. Methods: Isolated peripheral blood monocytes were incubated without or with catechin, and apoptosis was evaluated by annexin V and propidium iodide double-staining or terminal deoxynucleotidyl assay. The activation of caspases 3, 8, and 9 was also evaluated by flow cytometry. The influence of GMCSF or LPS, the known monocyte survival factors, on the EGCG-induced apoptosis of monocytes was investigated. Results: Among the 4 catechin derivatives tested, EGCG and epicatechin gallate induced apoptosis of monocytes. Caspases 3, 8, and 9, which play a central role in the apoptotic cascade, were dose-dependently activated by EGCG treatment. The EGCG-induced apoptosis of monocytes was not affected by GM-CSF or LPS. Conclusion: Catechin, especially EGCG, by promoting monocytic apoptosis, may be a new promising antiinflammatory agent, and should be tested in clinical trials.	Univ Tokyo, Fac Med, Dept Surg Oncol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Transfus Med, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kawai, K (corresponding author), Univ Tokyo, Fac Med, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kz-kawai@mvd.biglobe.ne.jp	Kawai, Kazushige/AAF-4334-2020	Kawai, Kazushige/0000-0002-5881-0036				Amarowicz R, 2000, NAHRUNG, V44, P60, DOI [10.1002/(SICI)1521-3803(20000101)44:1&lt;60::AID-FOOD60&gt;3.0.CO;2-L, 10.1002/(SICI)1521-3803(20000101)44:1<60::AID-FOOD60>3.3.CO;2-C]; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Estaquier J, 1997, BLOOD, V90, P1618, DOI 10.1182/blood.V90.4.1618.1618_1618_1625; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; Gabor M, 1986, Prog Clin Biol Res, V213, P471; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Kawai K, 2004, J ALLERGY CLIN IMMUN, V113, P1211, DOI 10.1016/j.jaci.2004.02.044; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Lee H, 2002, BBA-MOL CELL BIOL L, V1582, P175, DOI 10.1016/S1388-1981(02)00153-1; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Leone M, 2003, CANCER RES, V63, P8118; LOU FQ, 1989, CHINESE MED J-PEKING, V102, P579; Maeda-Yamamoto M, 1999, J AGR FOOD CHEM, V47, P2350, DOI 10.1021/jf9811525; MANGAN DF, 1992, J IMMUNOL, V148, P1812; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Matsuo N, 1997, ALLERGY, V52, P58, DOI 10.1111/j.1398-9995.1997.tb02546.x; Meuret G, 1981, Haematol Blood Transfus, V27, P11; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; Noguchi Y, 1999, J AGR FOOD CHEM, V47, P2969, DOI 10.1021/jf9812073; Sartippour MR, 2002, J NUTR, V132, P2307, DOI 10.1093/jn/132.8.2307; Sato H, 2002, J GASTROENTEROL, V37, P106, DOI 10.1007/s005350200004; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Suzuki M, 2000, J AGR FOOD CHEM, V48, P5649, DOI 10.1021/jf000313d; THOMPSON J, 1970, Journal of Experimental Medicine, V131, P429, DOI 10.1084/jem.131.3.429; Tillinger W, 1998, AM J GASTROENTEROL, V93, P1848; Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; van Furth R, 1981, Haematol Blood Transfus, V27, P3; ZHAO BL, 1992, ACTA PHARM SINIC, V13, P9	38	43	49	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					186	191		10.1016/j.jaci.2004.10.005	http://dx.doi.org/10.1016/j.jaci.2004.10.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637567				2022-12-18	WOS:000226267000027
J	McKeever, TM; Lewis, SA; Smit, H; Burney, P; Britton, J; Cassano, PA				McKeever, TM; Lewis, SA; Smit, H; Burney, P; Britton, J; Cassano, PA			Serum nutrient markers and skin prick testing using data from the Third National Health and Nutrition Examination Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergic sensitization; serum nutrients; vitamin E	FATTY-ACIDS; VITAMIN-E; ASTHMA; DIET; SUPPLEMENTATION; SENSITIZATION; CHOLESTEROL; CHILDHOOD; DISEASES; ADULTS	Background: Diet nutrients and allergic sensitization both affect the development and severity of asthma, but the interrelationship between oral intake and allergic sensitization is not well characterized, although previous work suggests that a higher vitamin E intake may be protective against allergic sensitization. Objective: To determine whether serum levels of dietary antioxidants, lipids, and other nutrients are associated with the presence of allergen skin sensitization. Methods: Cross-sectional logistic regression analysis of,30 serum nutrient levels in relation to 10 skin test allergens in adults and children in the Third National Health and Nutrition Survey. Results: In adults, allergic skin sensitization was less common in participants with higher serum levels of vitamin E: the adjusted odds ratio (OR) per SD difference in vitamin E, level was 0.93 (95% CI, 0.87-0.99). Two of the carotenoids, P-cryptoxanthin and a-carotene, were also inversely associated with allergic skin sensitization (OR, 0.89; 95% CI, 0.83-0.95; and OR, 0.95; 95% CI, 0.91-0.99, respectively). Among adults, serum lycopene had a positive association with allergen sensitization. In youths, however, vitamin A was associated with an increased risk, and high-density lipoprotein cholesterol was associated with a decreased risk of allergic sensitization. The use of vitamin or mineral supplements had little effect on the magnitude of all reported associations. Conclusion: Overall, there were no strong or consistent associations between serum levels of potentially antiallergic nutrients, and the occurrence of allergic skin sensitization in these data. However limited, findings suggest that increases in vitamin E, carotenoids, and high-density lipoprotein cholesterol may reduce the risk of allergic skin sensitization.	Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Univ London Kings Coll, London WC2R 2LS, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of Nottingham; University of Nottingham; Netherlands National Institute for Public Health & the Environment; University of London; King's College London; Cornell University	McKeever, TM (corresponding author), City Hosp, Div Epidemiol & Publ Hlth, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	Tricia.McKeever@Nottingham.ac.uk		McKeever, Tricia/0000-0003-0914-0416; Cassano, Patricia A./0000-0003-4827-5073; Burney, Peter/0000-0001-8635-5678	NHLBI NIH HHS [R03 HL066539, R03HL6659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL066539] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albers R, 2003, NUTRITION, V19, P940, DOI 10.1016/S0899-9007(03)00178-3; Bando N, 2003, BIOSCI BIOTECH BIOCH, V67, P2176, DOI 10.1271/bbb.67.2176; Cirillo DJ, 2002, AM J EPIDEMIOL, V155, P842, DOI 10.1093/aje/155.9.842; Cui DM, 2000, J NUTR, V130, P1132, DOI 10.1093/jn/130.5.1132; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; GUNTER EW, 1988, LAB PROCEDURES 3 NAT; Heinrich J, 2001, EUR RESPIR J, V17, P395, DOI 10.1183/09031936.01.17303950; National Center for Health Statistics, 1988, PLAN OP 3 NAT HLTH N; Picado C, 1999, ALLERGY, V54, P569, DOI 10.1034/j.1398-9995.1999.00024.x; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; Schafer T, 2003, CLIN EXP ALLERGY, V33, P1360, DOI 10.1046/j.1365-2222.2003.01780.x; SHENOI A, 1992, ACTA PAEDIATR, V81, P150, DOI 10.1111/j.1651-2227.1992.tb12192.x; Smit HA, 1999, P NUTR SOC, V58, P309, DOI 10.1017/S0029665199000427; Spieker Lukas E., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P51, DOI 10.2174/1568008043340044; Tsoureli-Nikita E, 2002, INT J DERMATOL, V41, P146, DOI 10.1046/j.1365-4362.2002.01423.x; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Willett W., 1990, NUTR EPIDEMIOLOGY; Woods RK, 2003, AM J CLIN NUTR, V78, P414, DOI 10.1093/ajcn/78.3.414	20	43	45	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1398	1402		10.1016/j.jaci.2004.08.006	http://dx.doi.org/10.1016/j.jaci.2004.08.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577844				2022-12-18	WOS:000225577400023
J	Nowak-Wegrzyn, A; Shapiro, GG; Beyer, K; Bardina, L; Sampson, HA				Nowak-Wegrzyn, A; Shapiro, GG; Beyer, K; Bardina, L; Sampson, HA			Contamination of dry powder inhalers for asthma with milk proteins containing lactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHALATION; CHILDREN; ALLERGY; FOOD		Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY USA; NW Asthma & Allergy Ctr PS, Seattle, WA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA.			Nowak-Wegrzyn, Anna/0000-0002-0960-9854				Anibarro B, 1997, J ALLERGY CLIN IMMUN, V100, P734, DOI 10.1016/S0091-6749(97)70266-5; Armentia A, 2002, CLIN EXP ALLERGY, V32, P1216, DOI 10.1046/j.1365-2745.2002.01456.x; Fiocchi A, 2003, PEDIATRICS, V112, P359, DOI 10.1542/peds.112.2.359; Fiocchi A, 2003, J ALLERGY CLIN IMMUN, V111, P193, DOI 10.1067/mai.2003.12; Fiocchi A, 2002, ANN ALLERG ASTHMA IM, V89, P26, DOI 10.1016/S1081-1206(10)62119-9; GENNARO AR, 1980, REMINGTONS PHARM SCI, P1322; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Mofidi S, 2000, J ALLERGY CLIN IMMUN, V105, pS138, DOI 10.1016/S0091-6749(00)90846-7; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; SPIES JR, 1971, P SOC EXP BIOL MED, V137, P211, DOI 10.3181/00379727-137-35546	10	43	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					558	560		10.1016/j.jaci.2003.11.015	http://dx.doi.org/10.1016/j.jaci.2003.11.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007361				2022-12-18	WOS:000220144200031
J	Storms, WW				Storms, William W.			Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Quality of life; polysomnography; allergic rhinitis; antihistamine; leukotriene receptor antagonist; intranasal corticosteroid; decongestant; sleep; microarousals	QUALITY-OF-LIFE; DOUBLE-BLIND; NASAL OBSTRUCTION; SLEEP; MONTELUKAST; SOMNOLENCE; EFFICACY; RHINOCONJUNCTIVITIS; CORTICOSTEROIDS; INSTRUMENT	Allergic rhinitis is associated with sleep disturbances, daytime somnolence, and fatigue. The exact relationship between rhinitis and sleep disturbance is unknown; however, both the symptoms and underlying pathology of allergic rhinitis can interfere with sleep quality. Nasal congestion, which has been shown to cause sleep-disordered breathing, is thought to be primarily responsible for rhinitis-related sleep disorders. The severity of nasal congestion follows a circadian rhythm, being worst at night and in the early morning. Chronotherapy is the study of the effects of administration time on the safety and efficacy of drug therapy based on circadian influences on the pharmacokinetics and pharmacodynamics of medications. Chronotherapy studies in allergic rhinitis suggest there are benefits to nighttime dosing of antiallergy medications. For example, the antihistamine mequitazine has shown improved efficacy when administered in the evening compared with morning dosing. More study is needed to determine whether this is a class effect. Leukotriene receptor antagonists are indicated for evening administration; these drugs significantly improve nighttime rhinitis symptoms. Intranasal corticosteroids administered in the morning have demonstrated efficacy in improving nighttime symptoms; however, it is unknown whether evening administration would improve their effects on nocturnal rhinitis symptoms. Because of the significant detrimental effects of nocturnal rhinitis symptoms on quality of life, allergic rhinitis therapies should be evaluated for efficacy in ameliorating nighttime symptoms. (J Allergy Clin Immunol 2004; 114: S146-53.)	[Storms, William W.] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Storms, WW (corresponding author), Care of Sweetman L, Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53203 USA.				AstraZeneca; A Vennis; Medpointe; Novartis; Merck; Winston; Seprencor-Investigational	AstraZeneca(AstraZeneca); A Vennis; Medpointe; Novartis(Novartis); Merck(Merck & Company); Winston; Seprencor-Investigational	W. W. Storms has consultant arrangements with AstraZeneca, Novartis, Merck, Winston, and Seprencor-Investigation. He has received financial support from AstraZeneca, A Vennis, and Medpointe. He has received grants-research support from AstraZeneca, Novartis, Merck, Winston, and Seprencor-Investigational. He has received speaker's honoraria from AstraZeneca, Novartis, Merck, Winston, and Seprencor-Investigational.	Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Casale TB, 2003, J ALLERGY CLIN IMMUN, V111, pS835, DOI 10.1067/mai.2003.1550; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144, DOI 10.1016/S0091-6749(99)70310-6; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Craig TJ, 2003, ALLERGY ASTHMA PROC, V24, P53; Ferguson BJ, 2004, OTOLARYNG HEAD NECK, V130, P617, DOI 10.1016/j.otohns.2004.02.001; FORESMAN BH, 2000, J AM OSTEOPATH ASS S, V8, pS1; Gawchik S, 2003, ANN ALLERG ASTHMA IM, V90, P416, DOI 10.1016/S1081-1206(10)61826-1; Golden S, 2000, ANN ALLERG ASTHMA IM, V85, P53, DOI 10.1016/S1081-1206(10)62434-9; Hindmarch I, 1999, CLIN EXP ALLERGY, V29, P133, DOI 10.1046/j.1365-2222.1999.0290s3133.x; Horak F, 2002, ALLERGY, V57, P25, DOI 10.1034/j.1398-9995.57.s75.5.x; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927, DOI 10.1016/S0091-6749(99)70070-9; Hughes K, 2003, ALLERGY, V58, P380, DOI 10.1034/j.1398-9995.2003.00093.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kakumanu Sujani, 2002, Am J Respir Med, V1, P195; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Martin SE, 1997, AM J RESP CRIT CARE, V155, P1596, DOI 10.1164/ajrccm.155.5.9154863; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; Meltzer E. O., 2002, Clinical and Experimental Allergy Reviews, V2, P67, DOI 10.1046/j.1472-9725.2002.00039.x; Meltzer EO, 2002, ANN ALLERG ASTHMA IM, V88, P23, DOI 10.1016/S1081-1206(10)62025-X; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Mintz M, 2004, ANN ALLERG ASTHMA IM, V92, P255, DOI 10.1016/S1081-1206(10)61557-8; Naclerio R., 2002, Clinical and Experimental Allergy Reviews, V2, P137, DOI 10.1046/j.1472-9725.2.s4.4.x; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Obal F, 2003, FRONT BIOSCI-LANDMRK, V8, pD520, DOI 10.2741/1033; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Ratner PH, 2002, MAYO CLIN PROC, V77, P350, DOI 10.4065/77.4.350; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; REINBERG A, 1989, CHRONOPHARMACOLOGY C, P115; Reinberg A, 1985, ANN REV CHRONOPHARMA, V3, P441; SMOLENSKY MH, 1995, J ALLERGY CLIN IMMUN, V95, P1084, DOI 10.1016/S0091-6749(95)70212-1; Storms W, 1997, J ALLERGY CLIN IMMUN, V99, pS825, DOI 10.1016/S0091-6749(97)80043-7; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214, DOI 10.1016/S1081-1206(10)62144-8; Weaver TE, 1997, SLEEP, V20, P835; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6	40	43	48	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	5		S			S146	S153		10.1016/j.jaci.2004.08.045	http://dx.doi.org/10.1016/j.jaci.2004.08.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V17HV	15536446				2022-12-18	WOS:000207929200004
J	Semper, AE; Heron, K; Woollard, ACS; Kochan, JP; Friedmann, PS; Church, MK; Reischl, IG				Semper, AE; Heron, K; Woollard, ACS; Kochan, JP; Friedmann, PS; Church, MK; Reischl, IG			Surface expression of Fc epsilon RI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc epsilon RI; Langerhans' cell; IgE; IgE receptor; skin; atopic dermatitis; epidermal sheet; atopic disease	ANTIGEN-PRESENTING CELLS; HIGH-AFFINITY RECEPTOR; DENDRITIC CELLS; IGE RECEPTOR; NASAL-MUCOSA; ALPHA-SUBUNIT; LESIONAL SKIN; BINDING; MICROSCOPY; ACTIVATION	Background: FcepsilonRI expressed on the surface of human epidermal Langerhans' cells facilitates uptake of IgE-associated allergens and plays a pivotal role in the pathogenesis of atopic dermatitis. Seminal results from studies investigating Langerhans' cell FcepsilonRI in skin biopsy sections or epidermal cell suspensions demonstrate the highest receptor expression in lesional skin of patients with active atopic dermatitis. Objective: We sought to investigate and localize FcepsilonRI expression on Langerhans' cells within a minimally disturbed tissue environment in clinically uninvolved skin and to compare receptor expression between healthy donors and patients with atopic dermatitis or other allergic diseases. Methods: Intact epidermal sheets from skin suction blisters, immunofluorescently stained with Langerhans' cell markers and anti-FeepsilonRIalpha (mAbs 15E5 and 22E7) or anti-IgE, were examined by means of confocal microscopy. Samples incubated with anti-FcepsilonRIalpha before or after cell fixation-permeabilization were compared to discriminate between cytoplasmic and membrane localization. Results: Cytoplasmic FcepsilonRI alpha chain was found in Langerhans' cells from all donors, irrespective of atopic status. Surface FeepsilonRI-bound IgE was detected in the skin of individuals with active atopic dermatitis and in the skin of those with active asthma or rhinitis. No surface FcepsilonRI was expressed in the skin of patients with a clinical history of atopic dermatitis, asthma, or rhinitis whose disease was in remission or in the skin of nonatopic individuals. Conclusion: In clinically uninvolved skin, Langerhans' cell-surface FcepsilonRI expression is not only linked to atopic dermatitis but is also generally associated with allergic disease. This supports the concept of a systemic regulatory mechanism associated with active allergic disease, which is further aggravated by local inflammation in atopic skin lesions.	Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton, Hants, England; Hoffmann La Roche Inc, Nutley, NJ USA	University of Southampton; Roche Holding	Reischl, IG (corresponding author), US FDA, Ctr Biol Evaluat & Res, Off Therapeut Review & Res, Div Monoclonal Antibodies, Bldg 29B,HFM 564,29 Lincoln Dr,MSC 4555, Bethesda, MD 20892 USA.		Woollard, Alex/I-3925-2019	Woollard, Alex/0000-0002-7917-6353				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; BIEBER T, 1991, J AM ACAD DERMATOL, V24, P658, DOI 10.1016/S0190-9622(08)80168-5; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; BOROFSKY MA, 1992, IMMUNOL RES, V11, P154, DOI 10.1007/BF02918620; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; BRUIJNZEELKOOME.CA, 1988, LANGERHANS CELL, P335; EMILSON A, 1993, ACTA DERM-VENEREOL, V73, P323; FRELINGER JA, 1980, J INVEST DERMATOL, V75, P68, DOI 10.1111/1523-1747.ep12521247; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; GRABBE J, 1993, BRIT J DERMATOL, V129, P120, DOI 10.1111/j.1365-2133.1993.tb03512.x; Haas N, 1997, ALLERGY, V52, P436, DOI 10.1111/j.1398-9995.1997.tb01025.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JURGENS M, 1995, J IMMUNOL, V155, P5184; KIISTALA U, 1964, LANCET, V1, P1444; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Klubal R, 1997, J INVEST DERMATOL, V108, P336, DOI 10.1111/1523-1747.ep12286482; Kraft S, 1998, J IMMUNOL, V161, P1000; Kubo S, 2001, J IMMUNOL, V167, P3427, DOI 10.4049/jimmunol.167.6.3427; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MAURER D, 1995, J INVEST DERMATOL, V104, P707, DOI 10.1111/1523-1747.ep12606958; Maurer D, 1996, J IMMUNOL, V157, P607; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MUDDE GC, 1992, J INVEST DERMATOL, V99, P103; NARAHARA H, 1995, J CLIN ENDOCR METAB, V80, P3121, DOI 10.1210/jc.80.11.3121; Reischl IG, 1996, CLIN EXP ALLERGY, V26, P630, DOI 10.1046/j.1365-2222.1996.1047408.x; Reischl IG, 2000, CLIN EXP ALLERGY, V30, P1033; RISKE F, 1991, J BIOL CHEM, V266, P11245; Steinman RM, 1999, J LEUKOCYTE BIOL, V66, P205, DOI 10.1002/jlb.66.2.205; Till SJ, 2001, ALLERGY, V56, P126, DOI 10.1034/j.1398-9995.2001.056002126.x; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yoshida A, 1997, BRIT J OPHTHALMOL, V81, P402, DOI 10.1136/bjo.81.5.402; YU RC, 1994, BRIT J DERMATOL, V131, P843, DOI 10.1111/j.1365-2133.1994.tb08587.x	39	43	45	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					411	419		10.1067/mai.2003.1626	http://dx.doi.org/10.1067/mai.2003.1626			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897750				2022-12-18	WOS:000184650600028
J	Zhang, XZ; Moilanen, E; Lahti, A; Hamalainen, M; Giembycz, MA; Barnes, PJ; Lindsay, MA; Kankaanranta, H				Zhang, XZ; Moilanen, E; Lahti, A; Hamalainen, M; Giembycz, MA; Barnes, PJ; Lindsay, MA; Kankaanranta, H			Regulation of eosinophil apoptosis by nitric oxide: Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; apoptosis; nitric oxide; c-Jun-N-terminal kinase; cGMP; STAT5; caspases	PROTEIN-KINASE; IN-VITRO; MACROPHAGES; DEATH; BCL-2; PATHOPHYSIOLOGY; MODULATION; NEUTROPHIL; EXPRESSION; INDUCTION	Background: Reduced eosinophil apoptosis is considered to be a key mechanism for eosinophilia in allergic diseases such as asthma, rhinitis, and eczema. Objective: The aim of our study was to investigate the possible modulatory effect of nitric oxide (NO) in human eosinophils. Methods: Apoptosis in isolated eosinophils was assessed by relative DNA fragmentation assay, annexin-V binding, and morphologic analysis. The activation of c-Jun-N-terminal kinase (JNK) and signal transducer and activator of transcription 5 (STAT5) was assessed by immunoblot analysis. Results: The NO donor S-nitroso-N-acetylpenicillamine (SNAP) reversed the survival-prolonging effect of IL-5 by inducing apoptosis. This effect was blocked by the NO scavenger (2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3oxide.potassium salt), indicating that reversal of IL-5-mediated eosinophil survival was due to NO. The effect of NO on IL-5-afforded cell survival was not mediated by cyclic guanosine 3':5'-monophosphate (cGMP), because neither an inhibitor of guanylyl cyclase nor inhibitors of phosphodiesterases had any effect on SNAP-induced eosinophil apoptosis in IL-5-treated cells. SNAP induced a time-dependent increase in the activity of JNK, and an inhibitor peptide specific for JNK, L-JNK11, completely reversed SNAP-induced apoptosis in IL-5-treated eosinophils. In contrast, SNAP did not inhibit IL-5-induced STAT5 activation. Inhibition of the activity of caspases by Z-Asp-CH2-DCB reversed the effect of SNAP, suggesting that NO promotes apoptosis in IL-5-treated human eosinophils in a caspase-dependent manner. However, this effect of NO was not mediated by means of activation of caspases 3, 8, or 9. Conclusions: Our results suggest that exogenous NO reverses IL-5-mediated eosinophil survival by inducing apoptosis, and this is mediated by means of activation of JNK in a cGMP-independent manner.	Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Thorac Med, London, England; AstraZeneca, EST Biol, Macclesfield, Cheshire, England; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Imperial College London; AstraZeneca; Tampere University; Tampere University Hospital	Kankaanranta, H (corresponding author), Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland.			Barnes, Peter/0000-0002-5122-4018; Hamalainen, Mari/0000-0002-6409-3758; Kankaanranta, Hannu/0000-0001-5258-0906; Lindsay, Mark/0000-0003-4807-5506				Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x; Beauvais F, 1999, FEBS LETT, V443, P37, DOI 10.1016/S0014-5793(98)01673-1; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Chae HJ, 2001, INT IMMUNOPHARMACOL, V1, P967, DOI 10.1016/S1567-5769(01)00033-9; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; Clancy R, 2001, OSTEOARTHR CARTILAGE, V9, P294, DOI 10.1053/joca.2000.0388; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; delPozo V, 1997, J IMMUNOL, V158, P859; Dewson G, 1999, AM J RESP CELL MOL, V20, P720, DOI 10.1165/ajrcmb.20.4.3453; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Hall DJ, 2001, BLOOD, V98, P2014, DOI 10.1182/blood.V98.7.2014; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Ishihara K, 2001, BBA-MOL BASIS DIS, V1536, P73, DOI 10.1016/S0925-4439(01)00035-7; Jun CD, 1999, J IMMUNOL, V162, P3395; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Kankaanranta H, 1996, BRIT J PHARMACOL, V117, P401, DOI 10.1111/j.1476-5381.1996.tb15204.x; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Kankaanranta H, 2000, METH MOLEC MED, V44, P99, DOI 10.1385/1-59259-072-1:99; Kharitonov SA, 2001, AM J RESP CRIT CARE, V164, P727, DOI 10.1164/ajrccm.164.5.2106122c; Korhonen R, 2001, INFLAMMATION, V25, P223, DOI 10.1023/A:1010971703271; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Moilanen E, 1997, AM J PATHOL, V150, P881; Moilanen E., 1999, INFLAMMATION BASIC P, P787; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Simon HU, 1998, CLIN EXP ALLERGY, V28, P1321; Taimor G, 2001, FASEB J, V15, P2518, DOI 10.1096/fj.01-0353fje; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Walsh GM, 1997, BRIT J HAEMATOL, V97, P701, DOI 10.1046/j.1365-2141.1997.00125.x; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Zangrilli J, 2000, CLIN EXP IMMUNOL, V120, P12, DOI 10.1046/j.1365-2249.2000.01173.x; Zhang JP, 2000, CLIN EXP IMMUNOL, V122, P20, DOI 10.1046/j.1365-2249.2000.01344.x; Zhang XZ, 2002, LIFE SCI, V71, P1523, DOI 10.1016/S0024-3205(02)01921-5	45	43	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					93	101		10.1067/mai.2003.1587	http://dx.doi.org/10.1067/mai.2003.1587			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847485				2022-12-18	WOS:000184010600016
J	Belay, T; Aviles, H; Vance, M; Fountain, K; Sonnenfeld, G				Belay, T; Aviles, H; Vance, M; Fountain, K; Sonnenfeld, G			Effects of the hindlimb-unloading model of spaceflight conditions on resistance of mice to infection with Klebsielia pneumoniae	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hindlimb; unloading; antiorthostatic; suspension; stress; spaceflight; resistance; mice; infection	ANTIORTHOSTATIC SUSPENSION; MACROPHAGE; STRESS; GROWTH; MICROGRAVITY; PATHOGENESIS; MODULATION; RESPONSES	Background: It has been well documented in several studies that many immunologic parameters are altered in experimental animals and human subjects who have flown in space. However, it is not fully known whether these immunologic changes could result in increased susceptibility to infection. Hindlimb (antiorthostatic) unloading of rodents has been used successfully to simulate some of the effects of spaceflight on physiologic systems. Objective: The objective of this study was to determine the effect of hindlimb unloading on the outcome of Klebsiella pneumoniae infection in mice. Methods: Hindlimb-unloaded, hindlimb-restrained, and control mice were intraperitoneally infected with one 50% lethal dose of K pneumoniae 2 days after suspension. Mortality and bacterial load in several organs were compared among the groups. Results: Unloaded mice showed significantly increased mortality: and reduced mean time to death compared with that seen in the control groups. Kinetics of bacterial growth with smaller infective doses revealed that control mice were able to clear bacteria from the organs after 30 hours. In contrast, unloaded mice had continued bacterial growth at the same time point. Conclusion: The results of this study suggest that hindlimb unloading might enhance the dissemination of K pneumoniae, leading to increased mortality. The complex physiologic changes observed during hindlimb unloading, including stress, have a key role in the pathophysiology of this infection.	Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA	Morehouse School of Medicine	Sonnenfeld, G (corresponding author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, 720 Westview Dr SW, Atlanta, GA 30310 USA.				NCRR NIH HHS [5G12 RR/AI 03034] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMIDON GL, 1991, J CLIN PHARMACOL, V31, P968, DOI 10.1002/j.1552-4604.1991.tb03658.x; Aviles H, 2001, NEUROIMMUNOMODULAT, V9, P6, DOI 10.1159/000049002; Aviles HO, 2001, EXP PARASITOL, V99, P89, DOI 10.1006/expr.2001.4658; Belay T, 2002, LIFE SCI, V71, P447, DOI 10.1016/S0024-3205(02)01683-1; BRUNNER LJ, 1995, J PHARMACOL EXP THER, V274, P345; CHAPES SK, 1993, J LEUKOCYTE BIOL, V54, P227, DOI 10.1002/jlb.54.3.227; CHRISTENSEN NJ, 1997, J GRAVITATIONAL PHYS, V4, P115; DURNOVA GN, 1976, AVIAT SPACE ENVIR MD, V47, P588; ENCKEVORT FH, 2001, EUR CYTOKINE NETW, V12, P581; Gould C L, 1987, J Biol Regul Homeost Agents, V1, P33; Greenberger MJ, 1996, J INFECT DIS, V173, P159, DOI 10.1093/infdis/173.1.159; Gregory SH, 2002, J IMMUNOL, V168, P308, DOI 10.4049/jimmunol.168.1.308; Kinney KS, 1999, MICROB PATHOGENESIS, V26, P85, DOI 10.1006/mpat.1998.0251; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; KOPYDLOWSKI KM, 1992, J LEUKOCYTE BIOL, V52, P202, DOI 10.1002/jlb.52.2.202; LYTE M, 1992, LIFE SCI, V50, P203, DOI 10.1016/0024-3205(92)90273-R; LYTE M, 1993, J ENDOCRINOL, V137, P343, DOI 10.1677/joe.0.1370343; Lyte M, 1997, J SURG RES, V70, P195, DOI 10.1006/jsre.1997.5130; MANDEL AD, 1977, AVIAT SPACE ENVIR MD, V48, P1051; Miller ES, 1999, NEUROIMMUNOMODULAT, V6, P160, DOI 10.1159/000026377; MILLER ES, 1994, J LEUKOCYTE BIOL, V55, P371, DOI 10.1002/jlb.55.3.371; MOREY E, 1999, BIOSCIENCE, V29, P168; Neal CP, 2001, FEMS MICROBIOL LETT, V194, P163, DOI 10.1016/S0378-1097(00)00523-1; Nickerson CA, 2000, INFECT IMMUN, V68, P3147, DOI 10.1128/IAI.68.6.3147-3152.2000; O'Brien AD, 1999, AM J PHYSIOL-LUNG C, V276, pL961, DOI 10.1152/ajplung.1999.276.6.L961; PETERSON PK, 1991, REV INFECT DIS, V13, P710; POLK HC, 1992, ANTIINFECTIVE APPL I, P29; REED L. J., 1938, AMER JOUR HYG, V27, P493; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Sheridan JF, 1998, ANN NY ACAD SCI, V840, P803, DOI 10.1111/j.1749-6632.1998.tb09618.x; SOLOMON GF, 1987, J NEUROSCI RES, V18, P1, DOI 10.1002/jnr.490180103; SONNENFELD G, 1990, AVIAT SPACE ENVIR MD, V61, P648; SONNENFELD G, 1982, J INTERFERON RES, V2, P467, DOI 10.1089/jir.1982.2.467; SONNENFELD G, 1993, J APPL PHYSIOL, V17, pS191; Steffen J M, 1984, Physiologist, V27, pS39; STEFFEN JM, 1984, AVIAT SPACE ENVIR MD, V55, P612; TAYLOR GR, 1986, AVIAT SPACE ENVIR MD, V57, P213; TAYLOR GR, 1983, AVIAT SPACE ENVIR MD, V54, pS55; TAYLOR PW, 1983, MICROBIOL REV, V47, P46, DOI 10.1128/MMBR.47.1.46-83.1983; Weizman R, 1999, CYTOKINES STRESS IMM, P1; Zerath E, 1998, ADV SPACE RES, V21, P1049, DOI 10.1016/S0273-1177(98)00026-X	41	43	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					262	268	UNSP 1/84/126459	10.1067/mai.2002.126459	http://dx.doi.org/10.1067/mai.2002.126459			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170267				2022-12-18	WOS:000177509800011
J	Bandeira-Melo, C; Hall, JC; Penrose, JF; Weller, PF				Bandeira-Melo, C; Hall, JC; Penrose, JF; Weller, PF			Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; IL-4; cysteinyl leukotrienes; leukotriene receptors; leukotriene C-4; leukotriene D-4; leukotriene E-4	IN-VITRO; BASOPHIL GRANULOCYTES; CD34(+) PROGENITORS; MOLECULAR-CLONING; RECEPTOR; EXPRESSION; CELLS; DIFFERENTIATION; IDENTIFICATION; INTERLEUKIN-4	Background: Eosinophils contain preformed stores of IL-4 within their cytoplasmic granules, but physiologic stimuli to release IL-4 from eosinophils are not yet defined. Objective: We evaluated whether cysteinyl leukotrienes (CysLTs) could elicit IL-4 release from eosinophils. Methods: We used a dual-antibody capture and detection assay (EliCell) for IL-4 release and used eosinophils differentiated in vitro from human cord blood-derived progenitors. Results: Leukotriene (LT) C-4, LTD4, and LTE4 each elicited the rapid, vesicular transport-mediated, dose- and time-dependent release of IL-4 from eosinophils. Both LTD4 and LTE4 evoked similar and earlier IL-4 release than LTC4. LTC4 did not act directly but only after conversion to LTD4 because an inhibitor of gamma-glutamyl transpeptidase, acivicin, blocked LTC4-induced IL-4 release. MK571 and LY171833, receptor antagonists for CysLT(1) and not CysLT(2), and pertussis toxin inhibited LTC4-, LTD4-, and LTE4-indticed IL-4 release. Cord blood-differentiated eosinophils contained CysLT(1) protein detectable by means of immunoblotting. Conclusion: CysLTs acting through G(i) protein-coupled and MK571- and LY171833-inhibitable receptors on cord blood-derived human eosinophils can act as autocrine or paracrine mediators to stimulate the rapid, nonexocytotic release of preformed IL-4.	Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Weller, PF (corresponding author), Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, DA-617,330 Brookline Ave, Boston, MA 02215 USA.		de Melo, Christianne Bandeira/B-7724-2009; Bandeira-Melo, Christianne/X-5619-2019	de Melo, Christianne Bandeira/0000-0003-3305-3865; Bandeira-Melo, Christianne/0000-0003-3305-3865	NHLBI NIH HHS [HL56386] Funding Source: Medline; NIAID NIH HHS [AI22571, AI20241, AI41995] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022571, U19AI041995, R01AI020241, R37AI020241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bandeira-Melo C, 2000, J IMMUNOL METHODS, V244, P105, DOI 10.1016/S0022-1759(00)00264-7; Bandeira-Melo C, 2001, J IMMUNOL, V166, P4813, DOI 10.4049/jimmunol.166.8.4813; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; BOYCE JA, 1995, J EXP MED, V182, P49, DOI 10.1084/jem.182.1.49; Boyce JA, 1996, BLOOD, V88, P4338; Boyce JA, 1996, P NATL ACAD SCI USA, V93, P2436, DOI 10.1073/pnas.93.6.2436; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Cohn L, 1999, J IMMUNOL, V162, P6178; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Lacy P, 2000, CHEM IMMUNOL, V76, P134; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lynch KR, 1999, NATURE, V399, P789; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Mahmudi-Azer S, 2000, J ALLERGY CLIN IMMUN, V105, P1178, DOI 10.1067/mai.2000.106930; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Mochizuki M, 1998, J IMMUNOL, V160, P60; Moller GM, 1996, AM J RESP CELL MOL, V14, P439; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Noben-Trauth N, 2000, J IMMUNOL, V165, P3620, DOI 10.4049/jimmunol.165.7.3620; NONAKA M, 1995, J IMMUNOL, V155, P3234; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Velazquez JR, 2000, IMMUNOLOGY, V101, P419, DOI 10.1046/j.1365-2567.2000.00104.x	32	43	43	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					975	979		10.1067/mai.2002.124269	http://dx.doi.org/10.1067/mai.2002.124269			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063527	Bronze			2022-12-18	WOS:000176442700013
J	Jones, CA; Vance, GHS; Power, LL; Pender, SLF; MacDonald, TT; Warner, JO				Jones, CA; Vance, GHS; Power, LL; Pender, SLF; MacDonald, TT; Warner, JO			Costimulatory molecules in the developing human gastrointestinal tract: A pathway for fetal allergen priming	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; costimulation; atopy; antigen priming; fetal gut; amniotic fluid	DENDRITIC CELLS; CORD-BLOOD; AMNIOTIC-FLUID; T-CELLS; RESPONSES; MACROPHAGES; MATURATION; ACTIVATION; CYTOKINES; ANTIGENS	Background: Antigen-specific responses can be detected in umbilical cord blood mononuclear cells. The fetal immune system must therefore attain a level of maturity compatible with the initiation of such responses as well as be exposed to antigen. Objective: We sought to assess the expression of costimulatory molecules in fetal gut and the presence of cytokines in amniotic fluid at this time as a preliminary analysis of the suitability of the fetal gut as a site of antigen priming during intrauterine life. Methods: Human fetal gut was analyzed for cells expressing costimulatory molecules through use of immunohistochemistry. Amniotic fluid was studied by ELISA, for cytokines regulating the nature of the response, and as a source of the common dietary antigen ovalbumin. Results: MHC class II-positive cells were abundant over the period examined (11-24 weeks of gestation), other sin-face antigens showing spatial and temporal variation in expression. From 11 to 14 weeks of gestation, CD68-positive and CD40-positive cells, like MHC class II-positive cells, were present throughout the lamina propria; few CD3-positive cells (T cells) were observed. With the emergence of lymphoid aggregates (14-16 weeks), CD83-positive cells (dendritic cells) and CD20-positive cells (B cells) could be detected in fetal gut; however, expression was restricted to the lymphoid aggregates. In contrast, MHC class II, CD40, and CD68 continued to be expressed in the lamina propria. CD28-positive cells were also evident from 14 weeks of gestation, occurring throughout the lamina propria and lymphoid aggregates; this corresponded to the increasing numbers of CD3-positive cells. The occasional CD86-positive, CD40L-positive, or CTLA4-positive cell could be seen in or around lymphoid aggregates after 14 weeks of gestation. Lymphoid follicles forming after 16 weeks of gestation contained MHC class II-positive, CD83-positive, CD20-positive, CD40-positive, CD86-positive, CD3-positive, CD28-positive, CD40L-positive, and CTLA4-positive cells. MHC class II-positive, CD40-positive, CD68-positive, CD3-positive, and CD28-positive cells continued to be present in the lamina propria at this time. At all times studied, CD14 was not expressed in the lamina propria or lymphoid follicles. Prostaglandin E-2, TGF beta (1), and IL-10 dominated the amniotic fluid cytokine milieu, and ovalbumin was also detectable in amniotic fluid from 3 of 26 women who had detectable circulating levels. Conclusion: Of the costimulatory molecules studied, CD40 was the most abundant. However, both of the ligand families studied (CD40-CD40L and CD86-CD28/CD152) could provide the costimulatory signals required for the initiation of antigen-specific reactivity in the gastrointestinal tract of the human fetus as early as 16 weeks of gestation. The cytokine milieu would favor the development of T(H)2-type reactivity to antigens, such as ovalbumin, that are present at this time.	Univ Southampton, Sch Med, Southampton, Hants, England	University of Southampton	Jones, CA (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061858] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bloomfield FH, 1998, FETAL MAT MED REV, V10, P91, DOI DOI 10.1017/S0965539597000235; Brunner MC, 1999, J IMMUNOL, V162, P5813; Casas R, 2001, PEDIATR ALLERGY IMMU, V12, P59, DOI 10.1034/j.1399-3038.2001.012002059.x; DAFFOS F, 1984, LANCET, V2, P1; DAHL GMK, 1984, COMP BIOCHEM PHYS A, V77, P199, DOI 10.1016/0300-9629(84)90046-X; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Ellis JH, 1996, J IMMUNOL, V156, P2700; Geissmann F, 1999, J IMMUNOL, V162, P4567; GITLIN D, 1973, AM J OBSTET GYNECOL, P632; Guilbert LJ, 1996, J REPROD IMMUNOL, V32, P105, DOI 10.1016/S0165-0378(96)00996-5; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1997, J IMMUNOL, V159, P28; KELLY PMA, 1988, J CLIN PATHOL, V41, P510, DOI 10.1136/jcp.41.5.510; King CL, 1998, J IMMUNOL, V160, P3578; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; LIN H, 1993, J IMMUNOL, V151, P4562; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; McLellan AD, 1998, J INVEST DERMATOL, V111, P841, DOI 10.1046/j.1523-1747.1998.00375.x; NOVATOSILVA E, 1992, SCAND J IMMUNOL, V35, P429, DOI 10.1111/j.1365-3083.1992.tb02878.x; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; PITKIN RM, 1975, AM J OBSTET GYNECOL, V123, P356, DOI 10.1016/S0002-9378(16)33436-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; RUGTVEIT J, 1995, GUT, V37, P367, DOI 10.1136/gut.37.3.367; SCHMIDT KV, 1997, PEDIATR RES, V41, P128; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; SPENCER J, 1987, CLIN EXP IMMUNOL, V67, P415; SPENCER J, 1986, CLIN EXP IMMUNOL, V65, P553; Steed Helen, 2001, Obstetrics and Gynecology, V97, p42S, DOI 10.1016/S0029-7844(01)01245-5; Strobl H, 1998, J IMMUNOL, V161, P740; Sudo N, 2000, CLIN EXP ALLERGY, V30, P979, DOI 10.1046/j.1365-2222.2000.00811.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JO, 1999, THORAX, V54, pS46, DOI 10.1136/thx.54.2008.S46; YU M, 1995, CLIN EXP IMMUNOL, V101, P190; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	40	43	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					235	241		10.1067/mai.2001.117178	http://dx.doi.org/10.1067/mai.2001.117178			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496240				2022-12-18	WOS:000170584600012
J	Goldberg, A; Confino-Cohen, R				Goldberg, A; Confino-Cohen, R			Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom allergy; immunotherapy; maintenance interval; sting challenge	STING CHALLENGE; ADVERSE REACTIONS; HONEYBEE VENOM; RUSH-IMMUNOTHERAPY; HYMENOPTERA VENOMS; ALLERGY; BEE; PRETREATMENT	Background: Maintenance venom immunotherapy (MVIT) is usually administered to patients with venom allergy at 4- to 6-week intervals for at least 3 to 5 years, The small number of studies assessing the possibility of extending the maintenance interval (MI) included either too small a population and patients with only vespid and not bee venom (BV) allergy or relied on reaction to field stings only Objective: We sought to assess the safety and efficacy of MVIT given at 3-month intervals to a large population of patients allergic to both yellow jacket venom and BV, Methods: In all patients undergoing venom immunotherapy, MI was gradually extended to 3 months, Systemic reactions (SRs) to immunotherapy injections or to field stings were regularly recorded. Some of the patients were also deliberately sting challenged during the 3-month interval. Patients discontinuing MVIT were interviewed regarding their responses to field re-stings, and in some of them, an in-hospital sting challenge was performed, Results: One hundred sixty patients mostly allergic to BV were enrolled in the study, Failure to reach the 3-month interval was observed in 6 (3.8%) patients, originating in failure to reach the full maintenance dose in most of them. SRs to MVIT administered at 3-month intervals were observed in 2.6% of the patients. One of 36 patients who experienced a field sting during the 3-month interval had an objective mild SR (2.8%). Two (4.5%) of 44 patients who were deliberately stung during the 3-month interval had mild SRs, After discontinuation of MVIT, 2 (8.3%) of 24 patients who experienced a field sting had an SR. Both were allergic to yellow jacket venom, Three to 82 months after discontinuation of MVIT, 22 patients allergic to BV were sting challenged. Only one (4.5%) patient had a mild objective SR, Conclusions: The conventional 4- to 6-week MI can easily be extended to 3 months in most patients without any adverse events. MVIT given at a 3-month interval is safe and effective while being administered, as well as after its discontinuation. This fact should be applied to almost every patient allergic to insect venom,	Meir Hosp, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine	Goldberg, A (corresponding author), Meir Hosp, Allergy & Clin Immunol Unit, IL-44281 Kefar Sava, Israel.							BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; GOLDBERG A, 1991, NEW ENGL J MED, V324, P1220; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P139, DOI 10.1016/S0091-6749(97)70207-0; GOLDBERG A, 1994, J ALLERGY CLIN IMMUN, V93, P997, DOI 10.1016/S0091-6749(94)70047-8; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; KOCHUYT AM, 1994, CLIN EXP ALLERGY, V24, P35, DOI 10.1111/j.1365-2222.1994.tb00914.x; Laurent J, 1997, ALLERGY, V52, P94, DOI 10.1111/j.1398-9995.1997.tb02551.x; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; MULLER U, 1987, J ALLERGY CLIN IMMUN, V80, P252, DOI 10.1016/0091-6749(87)90027-3; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; RZANY B, 1991, ALLERGY, V46, P251, DOI 10.1111/j.1398-9995.1991.tb00582.x; TAMIR R, 1992, ALLERGY, V47, P260, DOI 10.1111/j.1398-9995.1992.tb00660.x; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; YOULTEN LJF, 1995, CLIN EXP ALLERGY, V25, P159, DOI 10.1111/j.1365-2222.1995.tb01021.x; YUNGINGER JW, 1998, ALLERGY PRINCIPLES P; 1992, CLIN EXP ALLERGY S3, V23, P11; 1988, J ALLERGY CLIN IMMUN, V101, P573	26	43	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					902	906		10.1067/mai.2001.114986	http://dx.doi.org/10.1067/mai.2001.114986			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344360				2022-12-18	WOS:000168812300021
J	Siegmund, R; Vogelsang, H; Machnik, A; Herrmann, D				Siegmund, R; Vogelsang, H; Machnik, A; Herrmann, D			Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wasp venom allergy; basophils; immunotherapy; cytokine receptors; HLA-DR	MAST-CELLS; IL-4 RECEPTOR; UP-REGULATION; BONE-MARROW; B-CELLS; EXPRESSION; INTERLEUKIN-4; PHENOTYPE; HYPOSENSITIZATION; EOSINOPHILS	Background: Venom immunotherapy (VIT) pro,ides widespread protection against systemic anaphylactic reactions after a sting of the respective insect. This effect is attributed to a shift from T(H)2 to T(H)1. However, because basophils also produce and release cytokines, such as IL-4 and IL-13, they may he part of the cytokine network. The cytokines may regulate basophilic granulocytes, as suggested by the presence of cytokine receptors IL-2R alpha, GM-CSFR alpha, IL-1RII, IL-3R, IL-4R, IL-5R, and IL-6R on basophils from nonallergic donors. Objective: The purpose of this study was to demonstrate that human basophils from subjects allergic to wasp venom undergoing VIT are regulated by cytokines, as shown by the alteration of the expression of cytokine receptors land other markers). Methods: The expression of the surface interleukin receptors and activation antigens on basophils from 19 nonallergic subjects and 48 patients with wasp venom allergy was investigated before, immediately after, and 1 week after VIT (20 patients only). Results: Basophilic granulocytes in allergic subjects, compared with those in healthy. persons, showed elevated expression of CD32 (Fc gamma RII), CD122 (IL-2R beta), CD124 (IL-4R alpha), CD130 (IL-6 and 11R beta), CD154 (CD40L), and HLA-DR. Activation of basophils clearly increased during VIT indicated by increased expression of CD32, CD33, CD35 (CR1), CD63, CD116 (GM-CSFR alpha), CD122, CD124, CD130, and CD154. HLA-DR expression also tended to increase. The expression of IL-5R (CD125) decreased. A significant decrease of the basophilic surface antigens CD11c, CD32 CD35, CD63, CD116, (SD122, CD124, CD130, and CD132 (interleukin receptor gamma) was detected 1 week after the end of rush VIT. Conclusion: The rise in CD63 during VIT indicates a partial basophil degranulation with release of stored protein mediators, including IL-4. IL-4 may muse a transient upregulation of different surface antigens in an autocrine manner. Thereafter, cytokines released by T cells, which as a result of VIT have changed from a T(H)2 type to a more T(H)1 type, downregulate the activation of the basophilic granulocytes.	Klinikum Univ Jena, Inst Klin Immunol, D-07740 Jena, Germany	Friedrich Schiller University of Jena	Herrmann, D (corresponding author), Klinikum Univ Jena, Inst Klin Immunol, D-07740 Jena, Germany.							BANOVAC K, 1989, IMMUNOL INVEST, V18, P901, DOI 10.3109/08820138909050768; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P1157, DOI 10.1016/0091-6749(94)90326-3; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Dahinden CA, 1997, INT ARCH ALLERGY IMM, V113, P134, DOI 10.1159/000237527; FRANDJI P, 1993, J IMMUNOL, V151, P6318; FRANDJI P, 1995, CELL IMMUNOL, V163, P37, DOI 10.1006/cimm.1995.1096; FUREDER W, 1994, ALLERGY, V49, P861, DOI 10.1111/j.1398-9995.1994.tb00788.x; GANE P, 1993, CYTOMETRY, V14, P344, DOI 10.1002/cyto.990140316; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; HERRMANN D, 1995, J INVEST ALLERG CLIN, V5, P259; KNOL EF, 1995, LEUKOCYTE TYPING, V1, P1049; KOCH KC, 1992, EUR J IMMUNOL, V22, P153, DOI 10.1002/eji.1830220123; Kon OM, 1998, ALLERGY, V53, P891, DOI 10.1111/j.1398-9995.1998.tb03997.x; LAUDY JS, 1998, INFLAMM RES, V47, P401; Leveque C, 1998, CYTOKINE, V10, P487, DOI 10.1006/cyto.1997.0324; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Monneret G, 1999, CLIN EXP IMMUNOL, V115, P393; Mueller H.L., 1990, INSECT STING ALLERGY; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; RENZ H, 1991, J IMMUNOL, V146, P3049; Romagnani S, 1997, INT ARCH ALLERGY IMM, V113, P153, DOI 10.1159/000237532; SCHUERWEGH AJ, 1999, ALLERGY S52, V54, P5; Toba K, 1999, CYTOMETRY, V35, P249, DOI 10.1002/(SICI)1097-0320(19990301)35:3<249::AID-CYTO8>3.0.CO;2-O; VALENT P, 1994, J ALLERGY CLIN IMMUN, V94, P1177, DOI 10.1016/0091-6749(94)90329-8; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; ZOLA H, 1993, CELL IMMUNOL, V150, P149, DOI 10.1006/cimm.1993.1186	27	43	45	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1190	1195						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112905				2022-12-18	WOS:000165930300024
J	Nelson, HS				Nelson, HS			The use of standardized extracts in allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypersensitivity; allergy; immunotherapy; allergy extracts; allergy vaccines; major allergens; standardized extracts; allergy treatment	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; PARTIALLY PURIFIED EXTRACT; DOUBLE-BLIND PLACEBO; CLINICAL EFFICACY; INTERFERON-GAMMA; NASAL CHALLENGE; RAGWEED-POLLEN; CAT-DANDER; T-CELLS	Background: Double-blind, placebo-controlled studies have established that injection allergen immunotherapy is clinically effective. However, it is not known to what extent the doses of allergen extract commonly used in clinical practice match those that have been used in these controlled studies. Objective: The aim of this study was to determine by questionnaire the doses of standardized allergen extracts commonly used by board-certified allergists in the United States and to compare these with doses that have proven effective in double-blind, placebo-controlled studies. Methods: A questionnaire containing a hypothetical case and asking for a recommended allergen prescription for maintenance immunotherapy was mailed to 500 randomly selected board-certified members of the American Academy of Allergy, Asthma and Immunology living in the United States. The recommended doses were compared with those doses of the extracts that had been proven effective by using major allergen content figures for representative standardized US allergen extracts provided by an allergy extract laboratory. Results: Responses were received from 118 (23%) of the addressees. Eighty (16%) contained interpretable data on maintenance dosing for extracts. The median doses of pollen recommended were comparable with those that have been demonstrated to be clinically effective. Median doses of house dust mites were only slightly Lower than those that have proven effective. Median doses of animal dander, on the other hand, were well below those used effectively in controlled studies. Although the median doses used were often in the range of proven doses, the range of doses recommended by allergists included some that were one tenth to one five hundredth those of the median doses. Conclusion: In the absence of useful guidance from the federal regulatory authorities, American allergists, for the most part, use doses of pollens and house dust mites that are within the proven range. Their dosing of animal dander is generally below proven effective doses. There is, however, a wide range of dosing of all extracts used, and there is use of mixes that have no botanical basis. Therefore there is need For studies defining what are effective and ineffective allergen extract doses.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; CARREIRA J, 1994, ARB PEI GSH, V87, P155; Chanez P, 1996, ALLERGY, V51, P850; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; EBNER C, 1994, ALLERGY, V49, P38, DOI 10.1111/j.1398-9995.1994.tb00771.x; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HORN N, 1987, INT ARCH ALLER A IMM, V83, P404, DOI 10.1159/000234376; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATTHIESEN F, 1990, Clinical and Experimental Allergy, V20, P47; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Ramirez J, 1997, ALLERGY, V52, P806, DOI 10.1111/j.1398-9995.1997.tb02151.x; ROSS RN, IN PRESS CLIN THER; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TURKELTAUB PC, 1986, CLIN REV ALLERG, V4, P371; *US FDA CBER DAPP, US FDA CBER DAPP PUB; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997	37	43	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				41	45		10.1067/mai.2000.107197	http://dx.doi.org/10.1067/mai.2000.107197			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887303				2022-12-18	WOS:000088393300005
J	Fagiolo, U; Cancian, M; Bertollo, L; Peserico, A; Amadori, A				Fagiolo, U; Cancian, M; Bertollo, L; Peserico, A; Amadori, A			Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; heparin; histamine; cutaneous response	FC-EPSILON-RI; HISTAMINE-RELEASE; ANTI-IGE; AUTOANTIBODIES; CELLS	Background: Most patients with chronic idiopathic urticaria (CIU) show cutaneous reactivity to intradermal injection of autologous serum. In some cases this reactivity is associated with the presence of autoantibodies directed against IgE or IgE receptors expressed on mast cells, whereas in others no autoimmune mechanisms can be documented. Objectives: The aims of this study mere to compare the cutaneous reactivity to serum and plasma samples in a series of patients with active CIU and to address the mechanisms of the inhibitory effect exerted by heparin on the cutaneous responsiveness to the histamine-releasing factors (HRFs) present in CIU serum. Methods: Fourteen patients with CIU were injected intradermally with autologous serum, plasma (anticoagulated by either heparin or EDTA), or serum samples to which heparin had been added. The effects of heparin injection on cutaneous responsiveness to allergens was tested in 5 atopic patients. Moreover, in a set of experiments sera were also adsorbed with Sepharose-conjugated heparin. Results: All the patients had positive cutaneous reactions to autologous serum injection. When heparinized plasma was injected, negative reactions were observed in 12 of 14 patients, and a sizable reduction in the wheal-and-flare reactions was recorded in the remaining 2. Compared with results obtained with serum, no substantial change was observed in 6 of 8 patients injected with EDTA-anticoagulated plasma. When heparin was added to serum, abrogation of skin reactivity was seen; nonetheless, no change in the cutaneous response to allergens was associated with locally administered heparin in 5 atopic patients with no history of CIU, Finally, adsorption of CIU sera with solid-phase heparin abrogated the ability to induce cutaneous reactions in 5 of 7 patients, whereas in the remaining 2 a sizable reduction was observed. Conclusions: These data indicate that heparin is able to profoundly inhibit the cutaneous response to HRFs present in the sera of patients with CIU. Although the precise level of action of this heparin-mediated effect is unclear from present data, preliminary evidence seems to indicate that heparin could directly interfere with HRFs present in CIU sera.	Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy; Univ Padua, Inst Internal Med, I-35128 Padua, Italy; Univ Padua, Dept Clin Dermatol, I-35128 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua; University of Padua	Amadori, A (corresponding author), Univ Padua, Dept Oncol & Surg Sci, Via Gattamelata 64, I-35128 Padua, Italy.							Ahmed T, 1997, AM J RESP CRIT CARE, V155, P1848, DOI 10.1164/ajrccm.155.6.9196085; AMADORI A, 1989, J IMMUNOL, V143, P2146; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160, DOI 10.1164/ajrccm/147.1.160; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P21; FAGIOLO U, 1991, Giornale Italiano di Allergologia e Immunologia Clinica, V1, P147; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1996, CURR OPIN IMMUNOL, V8, P784, DOI 10.1016/S0952-7915(96)80005-7; GHOSH TK, 1988, J BIOL CHEM, V263, P11705; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GREAVES MW, 1997, PROGR ALLERGY CLIN I, V4, P256; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; INASE N, 1993, AM J PHYSIOL, V264, pL387, DOI 10.1152/ajplung.1993.264.4.L387; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAQUES LB, 1991, J LAB CLIN MED, V117, P122; Kalpaklioglu AF, 1997, J ASTHMA, V34, P337, DOI 10.3109/02770909709067224; LUCIO J, 1992, J APPL PHYSIOL, V73, P1093, DOI 10.1152/jappl.1992.73.3.1093; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219	21	43	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1143	1147		10.1016/S0091-6749(99)70190-9	http://dx.doi.org/10.1016/S0091-6749(99)70190-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359897	Bronze			2022-12-18	WOS:000080929500024
J	Masuyama, K; Till, SJ; Jacobson, MR; Kamil, A; Cameron, L; Juliusson, S; Lowhagen, O; Kay, AB; Hamid, QA; Durham, SR				Masuyama, K; Till, SJ; Jacobson, MR; Kamil, A; Cameron, L; Juliusson, S; Lowhagen, O; Kay, AB; Hamid, QA; Durham, SR			Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; eosinophils; cytokines; IL-5; allergy; rhinitis; corticosteroids	CYTOKINE MESSENGER-RNA; T-CELLS; TISSUE EOSINOPHILIA; INTERLEUKIN-5; MUCOSA; IMMUNOREACTIVITY; IDENTIFICATION; NEUTROPHILS; MODULATION; ADHESION	Background: Nasal allergen provocation in patients with allergic rhinitis leads to expression of the proeosinophilic cytokines IL-5 and GM-CSF and tissue eosinophilia. Objective: We sought to examine the effect of natural seasonal allergen exposure on IL-5 and GM-CSF mRNA expression and nasal eosinophilia and to evaluate the effects of topical corticosteroid therapy on these responses. Methods: Nasal biopsy specimens were collected from 46 grass pollen-sensitive patients with seasonal rhinitis before the grass pollen season. A second biopsy specimen was collected during the pollen season, by which time patients had received 6 weeks treatment with either fluticasone propionate (200 mu g twice daily) or placebo nasal spray. Results: Fluticasone treatment was clinically effective (P < .005). Patients receiving placebo, but not fluticasone, showed increased numbers of epithelial and submucosal EG2+ eosinophils (P < .005) and IL-5 and GM-CSF mRNA-expressing cells (P < .0001) during the pollen season. Colocalization experiments showed that greater than 80% of IL-5 mRNA-expressing cells were submucosal CD3+ T cells in both groups. The numbers of submucosal CD3+ T cells did not increase during the pollen season or decrease with fluticasone treatment. Fluticasone also inhibited IL-5 secretion by grass pollen-stimulated peripheral blood T cells from patients with seasonal rhinitis (n = 5, inhibitory concentration of 50% = 10(-9) to 10(-10) mol/L). Conclusions: These results suggest that topical corticosteroids may reduce eosinophilia in seasonal rhinitis by inhibiting T cell IL-5 production.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ, Canada; McGill Univ, Meakins Christie Labs, Dept Pathol, Montreal, PQ, Canada; Sergrein Hals Net Ogeymalaekninger, Reykjavik, Iceland	Imperial College London; McGill University; McGill University	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Till, Stephen/0000-0003-4518-3093				BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; GARRELDS IM, 1995, EUR J PHARMACOL, V275, P295, DOI 10.1016/0014-2999(95)00049-Q; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WALSH GM, 1990, IMMUNOLOGY, V71, P258; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Ying S, 1997, J IMMUNOL, V158, P5050; YING S, 1997, J IMMUNOL	23	43	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				610	617		10.1016/S0091-6749(98)70277-5	http://dx.doi.org/10.1016/S0091-6749(98)70277-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802369	Green Published			2022-12-18	WOS:000076600400011
J	Miyamasu, M; Misaki, Y; Izumi, S; Takaishi, T; Morita, Y; Nakamura, H; Matsushima, K; Kasahara, T; Hirai, K				Miyamasu, M; Misaki, Y; Izumi, S; Takaishi, T; Morita, Y; Nakamura, H; Matsushima, K; Kasahara, T; Hirai, K			Glucocorticoids inhibit chemokine generation by human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; cytokine; chemokine; glucocorticoid; C5a; FMLP; IL-8; MCP-1; IL-5	BASOPHIL HISTAMINE-RELEASE; COLONY-STIMULATING FACTOR; CYTOKINE GENERATION; ACTIVATING FACTOR; KAPPA-B; DEGRANULATION; INTERLEUKIN-8; NEUTROPHILS; MECHANISMS; MODULATION	Recent identification of eosinophils as a cellular source of various cytokines suggests that eosinophil-derived cytokines contribute to allergic inflammation through either an autocrine or a paracrine fashion. The profound inhibitory effects of glucocorticoids (GCCs) on the production of various cytokines have been well recognized, however, there has been no definitive evidence that GCCs in fact inhibit cytokine generation by eosinophils. To verify the inhibitory ability of GCCs on eosinophil cytokine generation, we studied the effect of GCCs by determination of IL-8 and monocyte chemoattractant protein-1 (MCP-1) as parameters. Dexamethasone (DEX) inhibited both generation and secretion of IL-8 in a dose-dependent fashion. DEX also dampened formyl-methionyl-leucyl- phenylalanine- or ionomycin-induced eosinophil IL-8 production. Furthermore, MCP-1 production was also inhibited by DEX. The slope and the shape of the dose-response curve of DEX were similar irrespective of either the input stimuli or the output cytokines; half-maximal inhibition was observed at 10(-8) mol/L, and nearly complete abolishment was observed at 10(-7) mol/L. The competitive polymerase chain reaction for IL-8 mRNA and semiquantitative polymerase chain reaction for MCP-1 mRNA revealed that the inhibition occurred at a Level of pretranslation. These results indicate that the beneficial effect of GCCs in allergic inflammation might be related, at least in part, to a direct effect of the drugs on eosinophil cytokine synthesis.	Univ Tokyo, Sch Med, Dept Med & Phys Therapy, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Bioregulat Funct, Bunkyo Ku, Tokyo 113, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Clin Immunol, Ohita, Japan; Toray Ind Inc, Shiga Plant, Med Devices & Diagnost Res Labs, Shiga, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan; Kyoritsu Coll Pharm, Dept Biochem, Tokyo, Japan	University of Tokyo; University of Tokyo; Kyushu University; Toray Industries, Inc.; University of Tokyo; Keio University	Hirai, K (corresponding author), Univ Tokyo, Sch Med, Dept Med & Phys Therapy, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; EBISAWA M, 1994, J IMMUNOL, V152, P4590; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HALLAM C, 1982, CLIN EXP IMMUNOL, V48, P641; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; IDA N, 1994, CYTOKINE, V6, P32, DOI 10.1016/1043-4666(94)90005-1; Izumi S, 1997, EUR J IMMUNOL, V27, P816, DOI 10.1002/eji.1830270404; KAISER J, 1993, J PHARMACOL EXP THER, V267, P245; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; LAMAS AM, 1991, J IMMUNOL, V147, P254; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; Lopez A F, 1992, Immunol Ser, V57, P549; Meagher LC, 1996, J IMMUNOL, V156, P4422; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; Miyamasu M, 1997, ALLERGY, V52, P317, DOI 10.1111/j.1398-9995.1997.tb00997.x; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; TANIGUCHI A, 1994, J IMMUNOL METHODS, V169, P101; UEDA A, 1994, J IMMUNOL, V153, P2052; WALLEN N, 1991, J IMMUNOL, V147, P3490; WARRINGA RAJ, 1991, BLOOD, V77, P2694	31	43	46	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				75	83		10.1016/S0091-6749(98)70196-4	http://dx.doi.org/10.1016/S0091-6749(98)70196-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449504				2022-12-18	WOS:000071539800012
J	Nurse, B; Haus, M; Puterman, AS; Weinberg, EG; Potter, PC				Nurse, B; Haus, M; Puterman, AS; Weinberg, EG; Potter, PC			Reduced interferon-gamma but normal IL-4 and IL-5 release by peripheral blood mononuclear cells from Xhosa children with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; African; peripheral blood mononuclear cells; interferon-gamma; IL-4; IL-5; tumor necrosis factor-alpha; granulocyte-macrophage-colony stimulating factor; Ascaris	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; CD4(+) T-CELLS; IFN-GAMMA; CYTOKINE PRODUCTION; GENE-EXPRESSION; IGE PRODUCTION; LYMPHOCYTE-T; IN-VITRO; DERMATITIS	Background: Allergic asthma is increasing in black South Africans, a cohort with inherently high basal IgE levels. Atopy has been linked to an excess of the T helper 2 cytokines IL-4 and IL-5 relative to the T helper 1 cytokine interferon-gamma (IFN-gamma); however, most studies have utilized T cell clones. Studies on peripheral blood mononuclear cells (PBMC) have shown decreased IFN-gamma release in patients with atopic dermatitis. It is uncertain whether this finding extends to atopic asthma. Objectives: To characterize cytokine release by mitogen-activated PBMC from Xhosa children and to investigate whether reduced IFN-gamma release is a feature of atopic asthma and whether there is a relationship between cytokine profiles and asthma severity. Methods: Cytokine release and proliferation of phytohemagglutinin-stimulated PBMC from 10 patients with severe asthma and 14 patients with moderate asthma (highly allergic to house dust mites) and 17 healthy controls was assessed. Total serum, allergen-specific, and Ascaris-specific IgE was measured. Results: Proliferation did not differ between the groups. The release of IFN-gamma was progressively decreased (and the IL-4/ IFN-gamma ratio increased) in the groups with moderate or severe asthma. Tumor necrosis factor-alpha release was reduced, but IL-4, IL-5, and granulocyte-macrophage-colony stimulating factor release was unchanged. The presence of Ascaris-specific IgE did not influence the cytokine profiles. Conclusion: Our study extends the findings observed for other atopic disorders and suggests that defective IFN-gamma release is a generalized feature of atopic diseases. This study- the first to investigate both severe and moderate asthma, with the groups having similar atopic profiles-indicates that the extent of the defect in IFN-gamma release might be related to asthma severity.	UNIV CAPE TOWN,DEPT IMMUNOL,ALLERGOL UNIT,ZA-7925 CAPE TOWN,SOUTH AFRICA; RED CROSS CHILDRENS HOSP,ALLERGY CLIN,INST CHILD HLTH,CAPE TOWN,SOUTH AFRICA	University of Cape Town								BARNES PJ, 1995, CLIN EXP ALLERGY, V25, P771, DOI 10.1111/j.1365-2222.1995.tb00016.x; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BRADLEY LM, 1995, J IMMUNOL, V155, P1713; CHAN SC, 1993, J IMMUNOL, V151, P3345; ELGHAZALI GEB, 1993, EUR J IMMUNOL, V23, P2740, DOI 10.1002/eji.1830231103; Frew AJ, 1995, CLIN EXP ALLERGY, V25, P1143, DOI 10.1111/j.1365-2222.1995.tb03035.x; HAUS M, 1990, S AFR MED J, V77, P7; Hilkens CMU, 1996, J IMMUNOL, V156, P1722; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; Humbert M, 1996, CLIN EXP ALLERGY, V26, P123, DOI 10.1111/j.1365-2222.1996.tb00069.x; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Kay AB, 1996, AM J RESP CRIT CARE, V154, pS66, DOI 10.1164/ajrccm/154.2_Pt_2.S66; KING CL, 1993, J IMMUNOL, V150, P1873; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P138, DOI 10.1111/j.1365-2222.1996.tb00072.x; Lai CKW, 1996, J ALLERGY CLIN IMMUN, V97, P1320, DOI 10.1016/S0091-6749(96)70201-4; LESTER MR, 1995, J IMMUNOL, V154, P6174; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; LUYT DK, 1995, S AFR MED J, V85, P999; MAGGI E, 1992, J IMMUNOL, V148, P2142; MAHANTY S, 1992, J IMMUNOL, V148, P3567; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; OKAYAMA H, 1994, J ALLERGY CLIN IMMUN, V93, P1006, DOI 10.1016/S0091-6749(94)70049-4; ORREN A, 1974, THESIS U CAPE TOWN C; OSTER W, 1989, EUR J IMMUNOL, V19, P543, DOI 10.1002/eji.1830190320; Park CS, 1996, J ALLERGY CLIN IMMUN, V97, P1121, DOI 10.1016/S0091-6749(96)70267-1; Potter PC, 1996, CLIN EXP ALLERGY, V26, P132, DOI 10.1111/j.1365-2222.1996.tb00071.x; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; *S AFR CHILDH ASTH, 1994, S AFR MED J, V84, P862; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; SIMON MR, 1995, J ALLERGY CLIN IMMUN, V96, P84, DOI 10.1016/S0091-6749(95)70036-6; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; Suomalainen H, 1993, Pediatr Allergy Immunol, V4, P203, DOI 10.1111/j.1399-3038.1993.tb00092.x; SVETIC A, 1993, J IMMUNOL, V150, P3434; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG M, 1994, CLIN EXP IMMUNOL, V95, P66; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; TANG MLK, 1994, CLIN EXP IMMUNOL, V97, P491; TANG MLK, 1994, CLIN EXP IMMUNOL, V97, P483; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109	50	43	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					662	668		10.1016/S0091-6749(97)70171-4	http://dx.doi.org/10.1016/S0091-6749(97)70171-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389297				2022-12-18	WOS:A1997YG20200014
J	SanchezGuerrero, IM; Vidal, JB; Escudero, AI				SanchezGuerrero, IM; Vidal, JB; Escudero, AI			Scombroid fish poisoning: A potentially life-threatening allergic-like reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE		HOSP RAFAEL MENDEZ,INTERNAL MED SERV,MURCIA,SPAIN; HOSP RAFAEL MENDEZ,ALLERGY UNITY SERV,MURCIA,SPAIN									ARNEDO A, 1989, MED CLIN-BARCELONA, V93, P641; MORROW JD, 1991, NEW ENGL J MED, V324, P716, DOI 10.1056/NEJM199103143241102; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SMART DR, 1992, MED J AUSTRALIA, V157, P748; TAYLOR SL, 1989, J TOXICOL-CLIN TOXIC, V27, P225, DOI 10.3109/15563658908994420	5	43	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					433	434		10.1016/S0091-6749(97)70263-X	http://dx.doi.org/10.1016/S0091-6749(97)70263-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314362				2022-12-18	WOS:A1997XX47900027
J	Peng, ZK; Simons, FER				Peng, ZK; Simons, FER			Cross-reactivity of skin and serum specific IgE responses and allergen analysis for three mosquito species with worldwide distribution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; allergy; antigen; IgE; immunoblot; mosquito; Aedes vexans; Aedes aegypti; Culex quinquefaciatus	AEDES-AEGYPTI; ANTIBODIES; EXTRACTS; BITES; IMMUNOTHERAPY; PROTEINS	Background: Allergic reactions to mosquito bites are a common problem worldwide. Cross-reactive immunologic responses have not been reported. Objective: For the three most common mosquito species, Aedes (Ae.) vexans, Ae. aegypti, and Culex (Cx.) quinquefaciatus, we investigated skin and serum specific IgE responses and analyzed salivary allergens. Methods: Locally, Ae. vexans is a major pest, but Ae. aegypti and Cx. quinquefaciatus are not found, We studied 41 subjects living in Manitoba, using (1) skin bite tests, (2) ELISA to measure serum mosquito saliva-or salivary gland-specific IgE, (3) ELISA inhibition tests, and (4) sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting. Results: Twenty-nine of the 41 subjects had skin reactions to lie. vexans bites, Twenty-two of the 29 also reacted to Ae. aegvpti bites, Mean serum mosquito-IgE levels to each of the three species mere significantly higher in the reactive subjects than in the nonreactive subjects. Significant intercorrelations mere found among skin reactions and mosquito-specific IgE levels for the three species. The Ae. aegypti-IgE ELISA reaction could be inhibited by addition of each mosquito extract, The serum IgE and IgG from Manitobans reacted with the antigens of all three species. A 37 kd allergen in each of the three species was recognized by the antibody against a recombinant Ae. aegypti saliva protein. Conclusions: Strong cross-reactive skin and IgE responses and species-shared antigens exist among the three mosquito species studied.	UNIV MANITOBA,DEPT PEDIAT,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,DEPT IMMUNOL,FAC MED,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba; University of Manitoba								ALLEN JR, 1966, EXP PARASITOL, V19, P132, DOI 10.1016/0014-4894(66)90061-0; BENAIMPINTO C, 1990, INT J DERMATOL, V29, P600, DOI 10.1111/j.1365-4362.1990.tb03479.x; BOORMAN J, 1987, MED VET ENTOMOL, V1, P211, DOI 10.1111/j.1365-2915.1987.tb00346.x; BROWN Alan, 1938, Southern Medical Journal, V31, P590, DOI 10.1097/00007611-193806000-00002; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; CHRISTOPHERS SR, 1960, AEDES AEGYPTI L YELL, P739; Fan Ping-Chin, 1995, Kaohsiung Journal of Medical Sciences, V11, P420; GLUCK JC, 1986, ANN ALLERGY, V56, P492; HUDSON A, 1960, SCIENCE, V131, P1730, DOI 10.1126/science.131.3415.1730; HUDSON ANNE, 1958, MOSQUITO NEWS, V18, P249; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; KILLBY VA, 1967, AM J TROP MED HYG, V16, P374, DOI 10.4269/ajtmh.1967.16.374; Knight K.L., 1977, CATALOG MOSQUITOES W, Vxi; KONISHI E, 1990, J MED ENTOMOL, V27, P519, DOI 10.1093/jmedent/27.4.519; LELONG M, 1986, Allergie et Immunologie (Paris), V18, P25; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; MCKIEL JA, 1961, CAN J ZOOLOG, V39, P597, DOI 10.1139/z61-064; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P341; PANZANI R, 1994, J INVEST ALLERG CLIN, V4, P42; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P371, DOI 10.1016/S1081-1206(10)63335-2; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P46, DOI 10.1159/000237309; PENNEYS NS, 1989, ARCH DERMATOL, V125, P219, DOI 10.1001/archderm.125.2.219; PENNEYS NS, 1988, J AM ACAD DERMATOL, V18, P87, DOI 10.1016/S0190-9622(88)70013-4; PUYANA J, 1990, ALLERGY, V45, P126, DOI 10.1111/j.1398-9995.1990.tb00470.x; REUNALA T, 1994, J ALLERGY CLIN IMMUN, V94, P902, DOI 10.1016/0091-6749(94)90158-9; REUNALA T, 1994, ANN MED, V26, P301, DOI 10.3109/07853899409147906; ROITT IM, 1988, HYPERSENSITIVITY ESS, P193; SHEN HD, 1989, ANN ALLERGY, V63, P143; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SUZUKI S, 1976, ACTA ALLERGOL, V31, P428, DOI 10.1111/j.1398-9995.1976.tb01493.x; WOOD DM, 1979, AGR CAN PUBL, V1686, P390; WU CH, 1989, INT ARCH ALLER A IMM, V90, P271, DOI 10.1159/000235036	36	43	49	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					192	198		10.1016/S0091-6749(97)70224-0	http://dx.doi.org/10.1016/S0091-6749(97)70224-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275140	Bronze			2022-12-18	WOS:A1997XR35100009
J	Tharp, MD				Tharp, MD			Chronic urticaria: Pathophysiology and treatment approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; corticosteroids; H-1 antihistamines; cetirizine; chronic disease; drug therapy	CHRONIC IDIOPATHIC URTICARIA; LATE-PHASE; HUMAN-SKIN; HISTAMINE-RELEASE; MAST-CELLS; TERFENADINE; VASCULITIS; THERAPY; NEUROPEPTIDES; ANGIOEDEMA	Urticaria, a cutaneous reaction pattern, varies clinically and histopathologically. The origin of acute urticaria can be detected in some cases; in patients with chronic urticaria, however, the cause is rarely identified. Thus, most patients with chronic urticaria are considered to have idiopathic disease. The dermal mast cell and its mediators may play a central role in chronic idiopathic urticaria. Other inflammatory cells, including lymphocytes and polymorphonuclear cells, have also been implicated. Treatment is based on identification of the inflammatory cells within skin lesions and blockage of the effects of histamine in the skin. Urticaria in which a lymphocyte-predominant infiltrate is seen often responds to one or more H-1 antihistamines. Recently, a new generation of nonsedating or mildly sedating H-1 antihistamines has proved useful int eh management of these cases. Antihistamine use alone may be unsuccessful in urticaria in which polymorphonuclear neutrophils predominate; frequently, the addition of agents that alter polymorphonuclear neutrophil function, such as colchicine or dapsone, is required. During the introduction of antihistamine and anti-polymorphonuclear neutrophils therapy, a simultaneous brief course of systemic corticosteroid therapy may be necessary, but the extended use of systemic corticosteroids should be avoided because of significant adverse effects. As the pathophysiologic mechanisms responsible for chronic urticaria are better defined, more effective therapeutic agents should become available.			Tharp, MD (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT DERMATOL,630 S HERMITAGE,507 KIDSTON HOUSE,CHICAGO,IL 60612, USA.							ANDRI L, 1993, ALLERGY, V48, P358, DOI 10.1111/j.1398-9995.1993.tb02406.x; BRESSLER RB, 1989, J ALLERGY CLIN IMMUN, V83, P756, DOI 10.1016/0091-6749(89)90011-0; CALLEN JP, 1982, BRIT J DERMATOL, V107, P87, DOI 10.1111/j.1365-2133.1982.tb00295.x; CERIO R, 1984, CLIN ALLERGY, V14, P139, DOI 10.1111/j.1365-2222.1984.tb02644.x; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CHARLESWORTH EN, 1992, J PHARMACOL EXP THER, V262, P964; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; FOREMAN JC, 1987, ALLERGY, V42, P1, DOI 10.1111/j.1398-9995.1987.tb02180.x; FRADIN MS, 1991, J AM ACAD DERMATOL, V25, P1065, DOI 10.1016/0190-9622(91)70308-O; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; FREW AJ, 1988, J ALLERGY CLIN IMMUN, V81, P1117, DOI 10.1016/0091-6749(88)90878-0; FULLER RW, 1987, BRIT J PHARMACOL, V92, P781, DOI 10.1111/j.1476-5381.1987.tb11381.x; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; HARTO A, 1985, DERMATOLOGICA, V170, P90, DOI 10.1159/000249507; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JONES RR, 1983, BRIT J DERMATOL, V108, P695, DOI 10.1111/j.1365-2133.1983.tb01082.x; JUHLIN L, 1992, CLIN REV ALLERG, V10, P349; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; LEHACH JG, 1992, CLIN REV ALLERG, V10, P281; MATHEWS KP, 1983, J ALLERGY CLIN IMMUN, V72, P1, DOI 10.1016/0091-6749(83)90042-8; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MONROE EW, 1981, INT J DERMATOL, V20, P32, DOI 10.1111/j.1365-4362.1981.tb05282.x; MONROE EW, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1119; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; RAO KA, 1994, MAYO CLIN PROC, V69, P589, DOI 10.1016/S0025-6196(12)62252-6; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P995; SMITH SJ, 1994, OTOLARYNG HEAD NECK, V111, P348, DOI 10.1177/01945998941113P203; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; THARP MD, 1987, J ALLERGY CLIN IMMUN, V79, P646, DOI 10.1016/S0091-6749(87)80162-8; THARP MD, 1990, ATLAS ALLERGIES, V16, P2; THOMAS RHM, 1985, BRIT J CLIN PHARMACO, V20, P377, DOI 10.1111/j.1365-2125.1985.tb05080.x; VOLONAKIS M, 1992, ANN ALLERGY, V69, P61; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185; WERNI R, 1986, DERMATOLOGICA, V172, P36, DOI 10.1159/000249290; WHITE MV, 1989, J ALLERGY CLIN IMMUN, V84, P773, DOI 10.1016/0091-6749(89)90308-4; WOODWARD JK, 1988, CUTIS, V42, P5; ZAVADAK D, 1995, IMMUNOL ALLERGY CLIN, V15, P745	45	43	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	3	S			S325	S330		10.1016/S0091-6749(96)80118-7	http://dx.doi.org/10.1016/S0091-6749(96)80118-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC448	8977544				2022-12-18	WOS:A1996WC44800006
J	Lalloo, UG; Barnes, PJ; Chung, KF				Lalloo, UG; Barnes, PJ; Chung, KF			Pathophysiology and clinical presentations of cough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angiotensin-converting enzyme inhibitor cough; asthma; cough; gastroesophageal acid reflux; postnasal drip	CHRONIC PERSISTENT COUGH; INDUCED BRONCHOCONSTRICTION; GASTROESOPHAGEAL REFLUX; RECEPTOR SENSITIVITY; ASTHMATIC SUBJECTS; INHALED CAPSAICIN; BRADYKININ; THERAPY; PROSTAGLANDIN-E2; INHIBITORS	The human cough reflex is still poorly understood although it is known to occur independently of bronchoconstriction. Sensitization of the cough reflex is a unifying hypothesis for chronic dry cough in several conditions, including gastroesophageal acid reflux angiotensin-converting enzyme inhibitor cough, and cough-variant asthma. The most common cause of chronic dry cough is a group of related conditions of chronic rhinitis, sinusitis, and postnasal drip. In these cases the cough reflex may be sensitized through an action of inflammatory mediators from the nasal mucosa on the airways or a reflex sensitization of airway sensory nerves. The association of cough with gastroesophageal reflux may occur through a local esophageal-tracheobronchial reflex. Angiotensin-converting enzyme inhibitor cough is a side effect of treatment in about 10% of patients; it probably results from inhibition of the degradation of kinins, particularly bradykinin, in the airway. Why some patients with asthma have cough as the principal feature of their disease is unclear. Tachykinins are probably involved in the mechanism of sensitization of the cough reflex, and the development of neuropeptide antagonists may open new research opportunities. A study that used ambulatory recording of cough in a group of subjects with asthma confirmed the presence of significant cough, the frequency of which did not correlate with lung function or diurnal variation in peak pow. This finding highlights the problem of cough in patients with asthma, a problem that probably has been underestimated in the past.	NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London			Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				BARANIUK JN, 1995, ASTHMA RHINITIS, P652; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; CARRAO WM, 1979, NEW ENGL J MED, V300, P633; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137, DOI 10.1164/ajrccm/140.1.137; CHOUDRY NB, 1992, EUR RESPIR J, V5, P296; CHUNG KF, 1992, PULM PHARMACOL, V5, P17; Coleridge H.M., 1986, HDB PHYSL, P395, DOI [10.1002/cphy.cp030212, DOI 10.1002/CPHY.CP030212]; COLERIDGE HM, 1994, ANNU REV PHYSIOL, V56, P69, DOI 10.1146/annurev.ph.56.030194.000441; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; FUJIMURA M, 1992, THORAX, V47, P441, DOI 10.1136/thx.47.6.441; FUJIMURA M, 1992, EUR RESPIR J, V5, P291; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; FULLER RW, 1991, LUNG SCI F, P1861; FULLER RW, 1987, BRIT MED J, V16, P1432; FURUYA K, 1994, LANCET, V343, P354, DOI 10.1016/S0140-6736(94)91190-8; GILCHRIST NL, 1989, J HUM HYPERTENS, V3, P451; HARGREAVES MR, 1995, LANCET, V345, P13, DOI 10.1016/S0140-6736(95)91151-0; HSU JY, 1994, EUR RESPIR J, V7, P1246, DOI 10.1183/09031936.94.07071246; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576; ING AJ, 1991, THORAX, V46, P479, DOI 10.1136/thx.46.7.479; IRWIN R, 1994, AM J RESP CRIT CARE, V149, pA188; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; IRWIN RS, 1984, CHEST, V85, P346, DOI 10.1378/chest.85.3.346; IRWIN RS, 1991, CHEST, V6, P1477; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; KAMEI J, 1991, EUR J PHARMACOL, V203, P253; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007, DOI 10.1152/jappl.1988.65.3.1007; KATSUMATA U, 1991, TOHOKU J EXP MED, V164, P103, DOI 10.1620/tjem.164.103; OCONNELL EJ, 1991, ANN ALLERGY, V66, P279; OCONNELL F, 1995, AM J RESP CRIT CARE, V152, P2068, DOI 10.1164/ajrccm.152.6.8520777; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; OGIHARA T, 1991, AM J HYPERTENS, V4, pS46, DOI 10.1093/ajh/4.1.46S; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; REES PJ, 1991, THORAX, V46, pP761; REISIN L, 1992, J HUM HYPERTENS, V6, P333; STOCKWELL M, 1993, J APPL PHYSIOL, V75, P613, DOI 10.1152/jappl.1993.75.2.613; STONE R, 1992, J APPL PHYSIOL, V73, P649, DOI 10.1152/jappl.1992.73.2.649; STONE R, 1983, RESPIR MED, V87, P249; STONE RA, 1993, EUR RESPIR J, V6, P862; STONE RA, 1993, J APPL PHYSIOL, V74, P396, DOI 10.1152/jappl.1993.74.1.396; STONE RA, 1991, RESPIR MED, V86, P78; UJIIE Y, 1993, AM REV RESPIR DIS, V148, P1628, DOI 10.1164/ajrccm/148.6_Pt_1.1628; WIDDICOMBE JG, 1988, LUNG BIOL HLTH DIS A, V33, P187; YEO WW, 1995, BRIT J CLIN PHARMACO, V39, P271, DOI 10.1111/j.1365-2125.1995.tb04448.x	46	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S91	S96		10.1016/S0091-6749(96)80134-5	http://dx.doi.org/10.1016/S0091-6749(96)80134-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939182				2022-12-18	WOS:A1996VW14000019
J	Khoury, L; Warrington, R				Khoury, L; Warrington, R			The multiple drug allergy syndrome: A matched-control retrospective study in patients allergic to penicillin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG,MB R3A 1R9,CANADA; HLTH SCI CTR,WINNIPEG,MB,CANADA	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba								KAMADA MM, 1991, ALLERGY PROC, V12, P347, DOI 10.2500/108854191778879124; MOSELEY E K, 1991, Journal of Allergy and Clinical Immunology, V87, P226, DOI 10.1016/0091-6749(91)91631-3; SILVIUDAN F, 1993, J ALLERGY CLIN IMMUN, V91, P694, DOI 10.1016/0091-6749(93)90188-L; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; SULLIVAN TJ, 1989, J ALLERGY CLIN IMMUN, V83, P270	5	43	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					462	464		10.1016/S0091-6749(96)70172-0	http://dx.doi.org/10.1016/S0091-6749(96)70172-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757225				2022-12-18	WOS:A1996VC99500027
J	Bellia, V; Bonanno, A; Cibella, F; Cuttitta, G; Mirabella, A; Profita, M; Vignola, AM; Bonsignore, G				Bellia, V; Bonanno, A; Cibella, F; Cuttitta, G; Mirabella, A; Profita, M; Vignola, AM; Bonsignore, G			Urinary leukotriene E(4) in the assessment of nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; nocturnal asthma; leukotrienes; LTE(4); airway inflammation	PEAK EXPIRATORY FLOW; EXERCISE CHALLENGE; BRONCHIAL-ASTHMA; EXCRETION; ALLERGEN; METABOLISM; ASPIRIN; HUMANS; BRONCHOCONSTRICTION; THROMBOXANE-A2	Background: Urinary leukotriene E(4) (LTE(4)) is a marker of the body's production of cysteinyl LTs, important mediators of airway inflammation. The role of the latter in nocturnal asthma is a topic of increasing interest. Objective: his investigation was aimed at determining whether nighttime attacks are associated with increased release of LTs, expressed by urinary LTE(4), and the relationship between the two phenomena. Methods: Three groups were studied group A, seven control subjects: group B, nine asthmatic patients without nocturnal attacks; and group C, nine asthmatic patients with a comparable daytime FEV(1) but who were experiencing nocturnal exacerbations (morning dips in peak expiratory flow > 20%). Urine was collected over 24 hours in three samples (9:00 AM to 3:00 PM; 3:00 PM to 9:00 PM; and 9:00 PM to 9:00 AM). LTE(4) was measured by high-performance liquid chromatography and radioimmunoassay and expressed as nanograms per millimole of creatinine. Results: No significant difference between urinary LTE(4) were noticed groups A and B. Conversely, in group C urinary LTE4 at night (geometric mean with 95% confidence interval: 35.16 with 28.77-42.85) was significantly higher than that of the other samples (respectively 23.12 with 17.78-30.06, p < 0.05; and 25.18 with 21.03-30-13, p < 0.02); it was also significantly higher than in all samples of other groups. A significant (p < 0.02) linear correlation was observed between morning dip in peak expiratory flow and the log urinary LTE4 in the nocturnal sample. Conclusion: These results indicate the role of LTs in nocturnal asthma and suggest that urinary LTE4 may be a useful marker of this condition.	UNIV PALERMO,IST MED GEN & PNEUMOL,PALERMO,ITALY; ITALIAN NATL RES COUNCIL,IST FISIOPATOL RESP,PALERMO,ITALY; ITALIAN NATL RES COUNCIL,IST SCI & TECNOL SPORT ATTIVIA FIS,PALERMO,ITALY	University of Palermo; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			bonanno, anna/F-7613-2015; Profita, Mirella/AAY-3165-2020; Cibella, Fabio/AAH-6982-2019; Bonanno, Anna/AAV-9474-2020; Profita, Mirella/D-8957-2018	bonanno, anna/0000-0003-3448-283X; Cibella, Fabio/0000-0003-1674-2263; Profita, Mirella/0000-0002-7821-8283; Cuttitta, Giuseppina/0000-0002-9242-6935				BARNES PJ, 1988, AM J MED, V85, P64, DOI 10.1016/0002-9343(88)90245-8; BELLIA V, 1985, CHEST, V88, P89, DOI 10.1378/chest.88.1.89; BELLIA V, 1989, AM REV RESPIR DIS, V140, P363, DOI 10.1164/ajrccm/140.2.363; BELLIA V, 1988, CHEST, V94, P108, DOI 10.1378/chest.94.1.108; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; DOUGLAS NJ, 1985, CLIN CHEST MED, V6, P663; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; HENDERSON WR, 1991, AM REV RESPIR DIS, V143, pS86, DOI 10.1164/ajrccm/143.5_Pt_2.S86; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; JARJOUR NN, 1993, NOCTURNAL ASTHMA MEC, P163; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MANSO G, 1992, EUR RESPIR J, V5, P712; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; PICENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; SALA A, 1990, J BIOL CHEM, V265, P21771; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; SMITH CM, 1992, EUR RESPIR J, V5, P693; SNEDECOR GW, 1980, STATISTICAL METHODS, P233; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, J APPL PHYSIOL, V71, P1396, DOI 10.1152/jappl.1991.71.4.1396; TAYLOR IK, 1992, J APPL PHYSIOL, V73, P743, DOI 10.1152/jappl.1992.73.2.743; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; WENZEL SE, 1993, NOCTURNAL ASTHMA MEC, P199; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322; 1987, AM REV RESPIR DIS, V136, P225	31	43	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					735	741		10.1016/S0091-6749(96)80149-7	http://dx.doi.org/10.1016/S0091-6749(96)80149-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613628				2022-12-18	WOS:A1996UA97500002
J	OKAYAMA, H; FUSHIMI, T; SHIMURA, S; SASAKI, H; SHIRATO, K				OKAYAMA, H; FUSHIMI, T; SHIMURA, S; SASAKI, H; SHIRATO, K			GLUCOCORTICOIDS SUPPRESSED PRODUCTION AND GENE-EXPRESSION OF INTERLEUKIN-5 BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS IN ATOPIC PATIENTS AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTERLEUKIN-5; GLUCOCORTICOIDS; ATOPY; MONONUCLEAR CELLS; POLYMERASE CHAIN REACTION	CHRONIC ASTHMA; MESSENGER-RNA; DEXAMETHASONE; RESISTANCE; PHARMACOKINETICS; INHIBITION; INVITRO; EOSINOPHILS; LYMPHOCYTES; ACTIVATION	Background: Interleukin-5 (IL-5) is known to play a major role in regulating eosinophil function in atopic diseases, including bronchial asthma. Glucocorticoids are most effective agents for treating these diseases. However their mechanism remains unclear. We examined the effect of glucocorticoids on the production and gene expression of IL-5 in atopic patients and normal subjects. Methods: Human peripheral blood mononuclear cells (PBMCs) in five atopic and four normal subjects were cultured with phytohemagglutinin and phorbol 12-myristate 13-acetate (PMA) in the presence of dexamethasone. IL-5 secreted by PBMCs was assayed by ELISA. Gene expression of IL-5 by PBMCs was assessed semiquantitatively by sequential reverse transcription-polymerase chain reaction, and Southern blot analysis. Results: Phytohemagglutinin/PMA-stimulated PBMCs from all atopic patients and three normal subjects secreted detectable amounts of IL-5, which were suppressed by dexamethasone in a dose-dependent manner, with 85.8% suppression at 10(-6) mol/L. Gene expression of IL-5 was detected by reverse-transcription polymerase chain reaction in PBMCs from all subjects, even when not stimulated; was increased by stimulation; and was suppressed by dexamethasone. The concentration of dexamethasone resulting in 50% inhibition in IL-5 gene expression did not differ between atopic patients and normal subjects. Conclusion: These findings indicate that dexamethasone suppressed IL-5 production in atopic human PBMCs through an inhibitory action on the gene expression. These results suggest that the suppression of IL-5 production through the suppression of IL-5 gene expression is one of the most important mechanisms by which glucocoticoids inhibit eosinophil functions in the treatment of atopic diseases, including bronchial asthma.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT GERIATR MED,SENDAI,MIYAGI 982,JAPAN	Tohoku University; Tohoku University								ARYA SK, 1984, J IMMUNOL, V133, P273; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; CUTTERBUCK EJ, 1988, BLOOD, V73, P1504; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; LEW W, 1988, J IMMUNOL, V140, P1895; LOEW D, 1986, EUR J CLIN PHARMACOL, V30, P225, DOI 10.1007/BF00614309; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; PAUL RB, 1990, P NATL ACAD SCI USA, V87, P5283; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; STAYNOV DZ, 1992, IMMUNOLOGY, V75, P196; TOBLER A, 1992, BLOOD, V79, P45; TSUEI SE, 1979, J PHARMACOKINET BIOP, V7, P249, DOI 10.1007/BF01060016; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WALKER KB, 1987, CLIN EXP IMMUNOL, V68, P162; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; YOUNG MC, 1989, EUR J CLIN PHARMACOL, V37, P757	23	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1006	1012		10.1016/S0091-6749(94)70049-4	http://dx.doi.org/10.1016/S0091-6749(94)70049-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006305				2022-12-18	WOS:A1994NT17200009
J	ALENIUS, H; TURJANMAA, K; MAKINENKILJUNEN, S; REUNALA, T; PALOSUO, T				ALENIUS, H; TURJANMAA, K; MAKINENKILJUNEN, S; REUNALA, T; PALOSUO, T			IGE IMMUNE-RESPONSE TO RUBBER PROTEINS IN ADULT PATIENTS WITH LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; NATURAL RUBBER; LATEX; ALLERGY; IMMUNOBLOTTING	CONTACT URTICARIA; SURGICAL GLOVES; ANAPHYLAXIS; ANTIGENS	In the present immunoblot study we examined IgE immune responses to natural rubber latex proteins in sera from 27 adult patients with latex allergy. We demonstrated at least 30 proteins in the rubber tree sap, of which 19 bound IgE antibodies in a heterogeneous manner in patient sera. Twenty-two of the 27 patient sera (81%) showed positive immunoblot test results. IgE antibodies in the patient sera bound most frequently to a 20 kd allergen, which was recognized by 17 of the 22 (77%) patient sera with positive immunoblot test results. These results suggest chat a 20 kd rubber protein could be a major allergen in adult patients with later allergy. Immunoblotting with a representative set of allergens as antigen would offer a sensitive, confirmatory in vitro test to demonstrate hypersensitivity to latex	NATL PUBL HLTH INST, DEPT IMMUNOBIOL, SF-00300 HELSINKI, FINLAND; TAMPERE UNIV HOSP, DEPT DERMATOL, TAMPERE, FINLAND; UNIV HELSINKI, DEPT DERMATOL, HELSINKI, FINLAND; UNIV HOSP SKIN & ALLERG DIS, HELSINKI, FINLAND	Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital; University of Helsinki								ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ALENIUS H, 1992, ALLERGY PROC, V13, P75, DOI 10.2500/108854192778878863; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINENKILJUNEN S, 1992, LANCET, V339, P1608, DOI 10.1016/0140-6736(92)91872-6; MAKINENKILJUNEN S, 1992, P INT LATEX C BALT, P51; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; SLATER J E, 1991, Journal of Allergy and Clinical Immunology, V87, P268, DOI 10.1016/0091-6749(91)91799-Y; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, THESIS U TAMPERE FIN; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x	22	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					859	863		10.1016/0091-6749(94)90378-6	http://dx.doi.org/10.1016/0091-6749(94)90378-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182228				2022-12-18	WOS:A1994NL91900009
J	ALWABEL, A; ALJANADI, M; RAZIUDDIN, S				ALWABEL, A; ALJANADI, M; RAZIUDDIN, S			CYTOKINE PROFILE OF VIRAL AND AUTOIMMUNE CHRONIC ACTIVE HEPATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HEPATITIS-B VIRUS; AUTOIMMUNE-TYPE CHRONIC ACTIVE HEPATITIS; CYTOKINES; INTERLEUKINS; INTERFERON-GAMMA; TUMOR NECROSIS FACTOR-ALPHA	TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; INTERLEUKIN-6; LYMPHOKINE; BIOLOGY	Background. Patients with,hepatitis have multiple immunologic abnormalities, which may be related to cytokine production. Methods: We examined the in vitro production of interleukins (IL-2, IL-4, IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in purified peripheral blood mononuclear cells (PBMCs) of patients with hepatitis B virus positive (HBV), acute viral hepatitis (A-HBV), HBV+ chronic active hepatitis (HBV-CAH), and autoimmune-type chronic active hepatitis (AI-ACH). Results. IFN-gamma and TNF-alpha production were characteristically higher in patients with A-HBV than in healthy control subjects (p < 0.001). However, patients with AI-CAH produced highly elevated levels of IL-4 and IL-6 compared with patients with A-HBV and HBV-CAH and healthy control subjects. The cytokine profile (PBMC-induced IL-2, IL-4, IL-6, IFN-gamma, and TNF-alpha production) is different in A-HBV, HBV-CAH, and AI-CAH disease. The increased cytokine secretion (IFN-gamma and TNF-alpha in A-HBV and IL-4 and IL-6 in AI-CAH) could reflect altered relative frequencies of different cell phenotypes in these diseases. Conclusion: Specific cytokine production may be important in the pathophysiology associated with diverse inflammatory states in patients with hepatitis.	KING SAUD UNIV,COLL MED,DEPT CLIN IMMUNOL,POB 641,ABHA,SAUDI ARABIA; KING SAUD UNIV,COLL MED,DEPT INTERNAL MED,GASTROENTEROL UNIT,ABHA,SAUDI ARABIA; ASSIR CENT HOSP,ABHA,SAUDI ARABIA	King Saud University; King Saud University; Assir Central Hospital								ALWABEL AA, UNPUB TUMOR NECROSIS; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; CHILSON OP, 1989, EUR J IMMUNOL, V19, P389, DOI 10.1002/eji.1830190225; DANIELS HM, 1990, LANCET, V335, P875, DOI 10.1016/0140-6736(90)90475-K; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; Eddleston AL, 1991, GUT, V32, P540; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAUL WE, 1991, BLOOD, V77, P1859; RAZIUDDIN S, 1989, J CLIN IMMUNOL, V9, P448, DOI 10.1007/BF00918013; ROBERTSON DAF, 1987, LANCET, V1, P9; SUN YQ, 1992, J CLIN IMMUNOL, V12, P197, DOI 10.1007/BF00918089; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	16	43	44	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					902	908		10.1016/0091-6749(93)90068-Q	http://dx.doi.org/10.1016/0091-6749(93)90068-Q			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258624				2022-12-18	WOS:A1993ML89300016
J	GEHA, R; BUCKLEY, CE; GREENBERGER, P; PATTERSON, R; POLMAR, S; SAXON, A; ROHR, A; YANG, W; DROUIN, M				GEHA, R; BUCKLEY, CE; GREENBERGER, P; PATTERSON, R; POLMAR, S; SAXON, A; ROHR, A; YANG, W; DROUIN, M			ASPARTAME IS NO MORE LIKELY THAN PLACEBO TO CAUSE URTICARIA ANGIOEDEMA - RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPARTAME; FOOD ADDITIVE; DOUBLE-BLIND CHALLENGES; HYPERSENSITIVITY; ALLERGY; CLINICAL STUDY	PANNICULITIS	Background: Anecdotes and single case reports have suggested that the high-intensity sweetener, aspartame, may be associated with allergic/hypersensitivity-type reactions. Methods: We conducted a multicenter, placebo-controlled clinical study to evaluate individuals who had experienced urticaria and/or angioedema allegedly associated with ingestion of an aspartame-containing product. Despite extensive recruiting efforts over 4 years, only 21 subjects could be enrolled. After admission to clinical research units, subjects were given aspartame and placebo in a randomized, double-blind, crossover fashion. Subjects received, on different days, increasing doses (50, 300, 600 mg) of aspartame and placebo at 8.00 AM, 10.00 AM, and noon. Subjects who weighed less than 40 kg received one half of these doses. Conversion products of aspartame, aspartylphenylalanine diketopiperazine and beta-aspartame, were also included in the aspartame arm of the study. Positive reactions were defined as urticaria (hives with wheals 4 mm or more in diameter with a collective diameter of at least 15 mm or one or more hives with a wheal of 4 mm or greater with a flare of 8 mm or greater) or as angioedema. Results: According to these criteria, four reactions were observed; two followed aspartame ingestion and two followed placebo ingestion (p = 1.00). The incidence of other adverse experiences was no different after aspartame versus placebo ingestion (p = 0.289). Conclusion: These results indicate that aspartame and its conversion products are no more likely than placebo to cause urticaria and/or angioedema reactions in subjects with a history consistent with hypersensitivity to aspartame.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; DUKE UNIV,MED CTR,DURHAM,NC 27710; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110; UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024; UNIV OTTAWA,SCH MED,OTTAWA K1N 6N5,ONTARIO,CANADA	Harvard University; Harvard Medical School; Duke University; Northwestern University; Washington University (WUSTL); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Ottawa			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NCRR NIH HHS [M01-RR02172, M01-RR00048, M01-RR-30] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000048, M01RR002172] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRADSTOCK MK, 1986, AM J CLIN NUTR, V43, P464, DOI 10.1093/ajcn/43.3.464; BUTCHKO HH, 1991, J AM COLL NUTR, V10, P258; BUTCHKO HH, 1989, COMMENTS TOXICOL, V3, P253; FLEISS JL, 1981, STATISTICAL METHODS, P112; GARRIGA MM, 1991, J ALLERGY CLIN IMMUN, V87, P821, DOI 10.1016/0091-6749(91)90128-B; KULCZYCKI A, 1986, ANN INTERN MED, V104, P207, DOI 10.7326/0003-4819-104-2-207; MCCAULIFFE DP, 1991, J AM ACAD DERMATOL, V24, P298, DOI 10.1016/S0190-9622(08)80617-2; MIETTINEN OS, 1968, BIOMETRICS, V24, P339, DOI 10.2307/2528039; NOVICK NL, 1985, ANN INTERN MED, V102, P206, DOI 10.7326/0003-4819-102-2-206; RANNEY RE, 1976, J TOXICOL ENV HEALTH, V2, P441, DOI 10.1080/15287397609529445; WITT J, 1986, NOV P INT ASP WORKSH; 1984, MMWR, V33, P605	12	43	44	1	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					513	520		10.1016/0091-6749(93)90075-Q	http://dx.doi.org/10.1016/0091-6749(93)90075-Q			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409113	Bronze			2022-12-18	WOS:A1993MC59000003
J	CYPCAR, D; BUSSE, WW				CYPCAR, D; BUSSE, WW			STEROID-RESISTANT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CORTICOSTEROID-DEPENDENT ASTHMA; GLUCOCORTICOID RECEPTOR CHARACTERISTICS; BRONCHIAL-ASTHMA; DOUBLE-BLIND; GOLD SALT; METHOTREXATE; CYCLOSPORINE; INHIBITION; MONOCYTES; AURANOFIN		UNIV WISCONSIN,SCH MED,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALVAREZ J, 1990, Journal of Allergy and Clinical Immunology, V85, P195; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BLACKWELL GJ, 1983, ADV PROSTAG THROMB L, V11, P65; BOCHNER BS, 1990, FOCUS PULMONARY PHAR, V2, P121; CALDERON E, 1992, J ALLERGY CLIN IMMUN, V89, P629, DOI 10.1016/0091-6749(92)90331-U; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; CREAM JJ, 1980, BRIT J DERMATOL, V102, P557, DOI 10.1111/j.1365-2133.1980.tb07655.x; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; HIRATA F, 1981, J BIOL CHEM, V256, P7730; KAY AB, 1981, CLIN EXP IMMUNOL, V44, P576; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; LANE SJ, 1991, AM REV RESPIR DIS, V143, P1020, DOI 10.1164/ajrccm/143.5_Pt_1.1020; MALO PE, 1986, J ALLERGY CLIN IMMUN, V77, P371, DOI 10.1016/S0091-6749(86)80120-8; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; MAZER BD, 1989, CLIN IMMUNOL IMMUNOP, V53, pS156, DOI 10.1016/0090-1229(89)90081-0; MIESFELD RL, 1990, AM REV RESPIR DIS, V141, pS11; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MULLARKEY MF, 1986, ANN ALLERGY, V56, P347; MUNCK A, 1990, AM REV RESPIR DIS, V141, pS1; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NARAYFEJESTOTH A, 1988, J STEROID BIOCHEM, V30, P155, DOI 10.1016/0022-4731(88)90088-X; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SUZUKI S, 1983, J ALLERGY CLIN IMMUN, V72, P469, DOI 10.1016/0091-6749(83)90583-3; SZCZEKLIK A, 1991, ALLERGY, V46, P312, DOI 10.1111/j.1398-9995.1991.tb00590.x; TERNOWITZ T, 1987, J INVEST DERMATOL, V89, P192, DOI 10.1111/1523-1747.ep12470559; VECCHIARELLI A, 1992, CLIN EXP ALLERGY, V22, P365, DOI 10.1111/j.1365-2222.1992.tb03097.x; VENKATESH VC, 1991, AM J RESP CELL MOL, V4, P301, DOI 10.1165/ajrcmb/4.4.301; WILKINSON JRW, 1990, CLIN EXP ALLERGY, V20, P189, DOI 10.1111/j.1365-2222.1990.tb02666.x; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381	37	43	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					362	372		10.1016/0091-6749(93)90114-U	http://dx.doi.org/10.1016/0091-6749(93)90114-U			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360386				2022-12-18	WOS:A1993LX30900001
J	FREW, A; CHAN, H; DRYDEN, P; SALARI, H; LAM, S; CHANYEUNG, M				FREW, A; CHAN, H; DRYDEN, P; SALARI, H; LAM, S; CHANYEUNG, M			IMMUNOLOGICAL STUDIES OF THE MECHANISMS OF OCCUPATIONAL ASTHMA CAUSED BY WESTERN RED CEDAR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BASOPHILS; MAST CELLS; OCCUPATIONAL ASTHMA; HISTAMINE; IGE; SEROLOGY; CEDAR; IMMEDIATE HYPERSENSITIVITY	HISTAMINE-RELEASING ACTIVITY; HUMAN MONONUCLEAR-CELLS; HUMAN BASOPHILS; MAST-CELLS; IGE ANTIBODIES; ACTIVATING-FACTOR; THUJA-PLICATA; ANTIGEN; STIMULATION; ENHANCEMENT	Background: Occupational asthma caused by western red cedar (Thuja plicata) is a common problem in sawmill industries. The objective of this study was to examine the cellular and immunologic mechanisms of western red cedar asthma (WRCA) mom closely. Methods: Bronchial biopsy specimens, bronchoalveolar lavage (BAL) mast cells and peripheral blood basophils from patients with WRCA, patients with atopic asthma, and nonatopic control subjects were challenged in vitro with plicatic acid (PA), PA-human serum albumin conjugate (PA-HSA), grass pollen, or calcium ionophore. Results: PA (100 mug/ml) released histamine from the basophils of 9 of 11 patients with WRCA, 1 of 7 patients with atopic asthma, and 2 of 7 normal subjects. PA triggered histamine release from 10 of 11 bronchial biopsy specimens and 8 of 8 BAL samples from patients with WRCA. Interestingly, PA released histamine from BAL cells and bronchial biopsy specimens from 3 of 7 normal subjects but in none of the patients with atopic asthma. PA-HSA-induced histamine release from basophils and biopsy specimens was confined to patients with WRCA. PA-specific IgE was not detectable in serum from most patients with WRCA, and their serum did not transfer PA sensitivity to human lung fragments or lactate-stripped basophils. After pretreatment with anti-IgE in the absence of calcium, basophils from 14 subjects with WRCA still responded to PA (mean 64% to 67% of pretreatment response), whereas responses to grass pollen or anti-IgE were abolished. Conclusions: This study confirms that PA releases histamine from bronchial mast cells of most patients with WRCA but not from those of patients with atopic asthma. The PA response of some normal subjects suggests that PA may have both specific and nonspecific actions on mast cells and basophils, whereas the serologic studies indicate histamine release in WRCA cannot simply be attributed to PA-specific IgE.	UNIV BRITISH COLUMBIA, VANCOUVER GEN HOSP, DEPT MED, DIV RESP, VANCOUVER V5Z 1M9, BC, CANADA	University of British Columbia			Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				ALAM R, 1989, J IMMUNOL, V142, P3431; ALAM R, 1984, ANN ALLERGY, V53, P66; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BOYLE W, 1968, TRANSPLANTATION, V6, P761, DOI 10.1097/00007890-196809000-00002; BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1103; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P688; CHURCH MK, 1989, AGENTS ACTIONS, V27, P9, DOI 10.1007/BF02222185; COCKCROFT DW, 1983, LANCET, V2, P253; DURONIO V, 1990, CAN J PHYSIOL PHARM, V68, P1514, DOI 10.1139/y90-230; FINDLAY SR, 1980, J IMMUNOL, V124, P238; FINE JM, 1988, CLIN CHEST MED, V9, P577; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; HEARD BE, 1990, AM J RESP CELL MOL, V3, P71, DOI 10.1165/ajrcmb/3.1.71; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; MACGLASHAN D, 1987, J IMMUNOL, V139, P501; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MASSEY WA, 1989, J IMMUNOL, V143, P1875; MOIRA CY, 1989, J ALLERGY CLIN IMMUN, V84, P762, DOI 10.1016/0091-6749(89)90306-0; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; THUESON DO, 1979, J IMMUNOL, V123, P626; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; WARDLAW AJ, 1986, CLIN ALLERGY, V16, P163, DOI 10.1111/j.1365-2222.1986.tb00760.x; WHITE MV, 1987, J IMMUNOL, V139, P1624; YANAGIHARA Y, 1987, J ALLERGY CLIN IMMUN, V79, P448, DOI 10.1016/0091-6749(87)90362-9	37	43	43	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					466	478		10.1016/0091-6749(93)90126-Z	http://dx.doi.org/10.1016/0091-6749(93)90126-Z			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360398				2022-12-18	WOS:A1993LX30900013
J	FIREMAN, P				FIREMAN, P			DIAGNOSIS OF SINUSITIS IN CHILDREN - EMPHASIS ON THE HISTORY AND PHYSICAL-EXAMINATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		DIAGNOSIS; SINUSITIS	INFECTIONS	Sinusitis can occur as an acute, subacute, recurrent acute, or chronic clinical disease process in children. Sinusitis most often manifests as a prolongation or complication of a viral upper respiratory tract infection. Because children average six to eight upper respiratory tract infections per year, sinusitis is probably a more frequent diagnosis in the pediatric age group compared with adults who average two to three upper respiratory infections per year. Upward of 5 to 13% of children may experience sinusitis, but precise incidence data are not available because many imaging techniques currently available are inappropriate procedures for a prospective pediatric survey. Symptoms of acute sinusitis in children can vary from the more common persistent, purulent rhinorrhea and cough to the less common symptoms of fever, headache, facial pain, and swelling. Recurrent acute and chronic sinusitis may be associated with another condition such as a host-defense defect, cystic fibrosis, asthma, or a local condition that predisposes to obstruction of the sinus ostia such as nasal polyps, deviated septum, foreign body, or allergic inflammation. Diagnosis of sinusitis can be made on the basis of a careful history and physical examination with radiography reserved for confirmation of clinical impression or documentation of disease. Although fiberoptic rhinoscopy is used more frequently as an adjunct in adults for the evaluation and management of sinusitis, more studies need to be performed to document its clinical usefulness in children.	UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								DINGLE JH, 1964, ILLNESS HOME STUDY 2, P19; ELIASSON R, 1977, NEW ENGL J MED, V297, P1, DOI 10.1056/NEJM197707072970101; FIREMAN P, 1990, PEDIAT OTOLARYNGOLOG, P793; FRIDAY G, 1990, CHILDHOOD RHINITIS S, P199; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; KOGUTT MS, 1973, PEDIATRICS, V52, P121; MCLEAN DC, 1970, CLIN PEDIATR, V9, P342, DOI 10.1177/000992287000900611; RACHELEFSKY GS, 1988, PEDIATR CLIN N AM, V35, P1091; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; Stiehm E. R., 1989, IMMUNOLOGIC DISORDER, P329; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; WALD ER, 1991, PEDIATRICS, V87, P129; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302	15	43	44	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			433	436		10.1016/0091-6749(92)90164-W	http://dx.doi.org/10.1016/0091-6749(92)90164-W			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527332				2022-12-18	WOS:A1992JP52100005
J	ROSS, BD; MCCULLOUGH, J; OWNBY, DR				ROSS, BD; MCCULLOUGH, J; OWNBY, DR			PARTIAL CROSS-REACTIVITY BETWEEN LATEX AND BANANA ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									HENRY FORD HOSP,DIV ALLERGY & IMMUNOL,2799 W GRAND BLVD,CFP 413,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; ROSS B D, 1991, Journal of Allergy and Clinical Immunology, V87, P274, DOI 10.1016/0091-6749(91)91821-A	4	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				409	410		10.1016/S0091-6749(05)80023-5	http://dx.doi.org/10.1016/S0091-6749(05)80023-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527325				2022-12-18	WOS:A1992JP52000021
J	PENG, ZK; NACLERIO, RM; NORMAN, PS; ADKINSON, NF				PENG, ZK; NACLERIO, RM; NORMAN, PS; ADKINSON, NF			QUANTITATIVE IGE-SUBCLASS AND IGG-SUBCLASS RESPONSES DURING AND AFTER LONG-TERM RAGWEED IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAGWEED; IGE; IGG SUBCLASSES; IMMUNOTHERAPY; ALLERGY; HUMAN	POLLEN-ALLERGIC PATIENTS; HAY-FEVER PATIENTS; MITE-SPECIFIC IGE; ANTIBODY-RESPONSE; BLOCKING ANTIBODY; MONOCLONAL-ANTIBODIES; VENOM IMMUNOTHERAPY; PERENNIAL RHINITIS; ELUTION TECHNIQUE; SUPPRESSOR CELLS	We studied the quantitative responses of short ragweed (RW)-pollen-specific serum antibodies in 22 patients with RW immunotherapy (IT) and in a different set of 31 patients, 16 of whom stopped RW IT after more than 5 years of treatment. Serum was assayed before and after season, 1 year before and 1 and 2 years after starting IT, and 1 year and 2 years after stopping IT. RW pan-IgG, RW IgG1, and RW IgG4 were measured by ELISA, and RW IgE by RAST. Absolute quantities of RW IgG1 and RW IgG4 in reference sera were estimated by least-squares multiple regression analysis of 223 sera with the equation RW pan-IgG = RW IgG1 + RW IgG4. IgG1 is dominant in the early immune response of IT and disappears relatively slowly when IT is stopped. In contrast, IgG4 appears in significant quantities only after prolonged IT and disappears rapidly when IT is stopped. The apparent average half-life of RW IgG4 (9 months) was significantly shorter than that of RW IgG1 (29 months) (p < 0.001). Before IT, mean RW IgE rose 180% (p < 0.01) during the RW pollination season (August to November). This seasonal rise in RW IgE was ablated after IT from 1 year up to 8 years, but returned the year after IT was stopped. After 2 years of IT, the RW IgG1 and IgG4 levels were significantly correlated with RW IgE (r = 0.94 and 0.81; p = 0.0001 and 0.005).	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University								AALBERSE RC, 1983, J IMMUNOL, V130, P722; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; ADKINSON NF, 1988, NEW ENGL REG ALLERGY, V9, P23; Adkinson NF, 1986, MANUAL CLIN LABORATO, P664; ANDERSEN BR, 1968, NATURE, V217, P174, DOI 10.1038/217174a0; BERNSTEIN IL, 1979, INT ARCH ALLER A IMM, V58, P30; BOREL Y, 1976, TRANSPLANT REV, V31, P3; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; Ekins R. P., 1981, LIGAND Q, V4, P33; ETIEVANT M, 1979, ANN ALLERGY, V43, P169; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HAMILTON RG, 1987, ELECTROPHORESIS, V8, P127, DOI 10.1002/elps.1150080302; HAMILTON RG, 1980, J IMMUNOL, V124, P2966; HAMILTON RG, 1988, J CLIN IMMUNOASSAY, V11, P24; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; ISKANDER R, 1981, INT ARCH ALLER A IMM, V66, P200, DOI 10.1159/000232819; JEFFERIS R, 1985, IMMUNOL LETT, V10, P223, DOI 10.1016/0165-2478(85)90082-3; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LEE HB, 1988, J ALLERGY CLIN IMMUN, V82, P11, DOI 10.1016/0091-6749(88)90044-9; LEE HB, UNPUB RAGWEED SPECIF; LEE WY, 1978, IMMUNOL REV, V41, P200, DOI 10.1111/j.1600-065X.1978.tb01466.x; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P294, DOI 10.1016/0091-6749(88)90737-3; OHASHI Y, 1987, ANN OTO RHINOL LARYN, V96, P434, DOI 10.1177/000348948709600417; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROGERS DF, 1976, MATH ELEMENTS COMPUT, P133; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; THOMPSON PM, 1983, SCAND J IMMUNOL, V18, P123, DOI 10.1111/j.1365-3083.1983.tb00848.x; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	48	43	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					519	529		10.1016/0091-6749(92)90318-V	http://dx.doi.org/10.1016/0091-6749(92)90318-V			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740582	Bronze			2022-12-18	WOS:A1992HD75300003
J	BRUNET, C; BEDARD, PM; LAVOIE, A; JOBIN, M; HEBERT, J				BRUNET, C; BEDARD, PM; LAVOIE, A; JOBIN, M; HEBERT, J			ALLERGIC RHINITIS TO RAGWEED POLLEN .1. REASSESSMENT OF THE EFFECTS OF IMMUNOTHERAPY ON CELLULAR AND HUMORAL RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; RHINITIS; BASOPHIL; RELEASABILITY; HISTAMINE; RAGWEED; NASAL REACTIVITY; CLINICAL SYMPTOMS; IGE; IGG	NASAL AIRWAY CHALLENGE; IGE ANTIBODIES; HISTAMINE-RELEASE; INDIVIDUALS	This work presents a double-blind, placebo-controlled study of 27 patients with allergic rhinitis to ragweed who received preseasonal desensitization immunotherapy [IT] with alum-precipitated aqueous ragweed extracts. We reassessed the following parameters in relation to clinical responses: clinical scores, nasal reactivity to a provocative dose of ragweed causing a 75% fall in airflow rate (PD75), ragweed IgE and IgG, and ragweed-induced basophil histamine release (BHR). First, the nasal PD75 correlated with the severity of nasal symptoms (p < 0.05). Second, we confirmed a significant symptomatic improvement in the IT-treated group either by clinical scores (p < 0.05) or the prevention of the seasonal fall of the PD75 (p < 0.005). Also, IT reduced the seasonal rise of IgE (p < 0.02) and induced an increase in IgG (p < 0.01) and a decrease in BHR (p < 0.03). There was a significant correlation between IgE and BHR (r = 0.80; p < 0.01). After selecting out the effects of IgE, the BHR was still higher in the placebo-treated group than in the IT-treated group (p < 0.02), suggesting the involvement of other modulating factors. Symptomatic improvement after IT correlated only with the summation of both IgE and BHR (PD75; r = 0.64; p < 0.005). This observation suggests that the severity of clinical symptoms is determined by several interacting factors and not by the antibody response alone.	CHU LAVAL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,SUITE 9800,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University								BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BEAULIEU L, 1986, J IMMUNOL METHODS, V86, P131, DOI 10.1016/0022-1759(86)90276-0; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BEDARD PM, 1989, AM J RHINOL, V3, P211; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HEBERT J, 1988, ANN ALLERGY, V60, P226; HEBERT J, 1984, ANN ALLERGY, V53, P138; HEBERT J, 1988, AM J RHINOL, V2, P71; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1964, J EXP MED, V10, P50; Loveless MH, 1943, J IMMUNOL, V47, P165; MECHERI S, 1988, IMMUNOLOGY, V64, P11; MOURAD W, 1989, MOL IMMUNOL, V26, P1051, DOI 10.1016/0161-5890(89)90069-2; MOURAD W, 1987, CLIN EXP IMMUNOL, V67, P391; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SHERMAN WB, 1957, J ALLERGY, V28, P62, DOI 10.1016/0021-8707(57)90071-0; SOBOTKA KA, 1976, J IMMUNOL, V117, P84; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; [No title captured]	29	43	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				76	86		10.1016/S0091-6749(05)80043-0	http://dx.doi.org/10.1016/S0091-6749(05)80043-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1370510				2022-12-18	WOS:A1992GZ90800009
J	SNOWMAN, AM; SNYDER, SH				SNOWMAN, AM; SNYDER, SH			CETIRIZINE - ACTIONS ON NEUROTRANSMITTER RECEPTORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			BINDING-SITES; BRAIN MEMBRANES; RAT-BRAIN; <MEPYRAMINE-H-3	First-generation H1-antagonist antihistamines, such as hydroxyzine, have the ability to cross the blood-brain barrier and cause sedation, which limits their usefulness in the treatment of allergic disorders. Cetirizine, a carboxylated metabolite of hydroxyzine, possesses the parent compound's antihistaminic activity but causes less sedation. We compared the activity of cetirizine at central H1 sites with that of hydroxyzine and terfenadine. We also compared the ability of cetirizine and three antihistamines to cross the blood-brain barrier. In each case we found that the drug's potency at H1 receptors in the central nervous system was similar to its activity in displacing H1 receptors in the lung. However, the selectivity for H1 receptors varied widely from drug to drug. Cetirizine did not bind at any of the receptors investigated, except H1 sites, even at concentrations as high as 10-mu-mol/L. Hydroxyzine and dexchlorpheniramine and, to a lesser extent, terfenadine crossed the blood-brain barrier in significant amounts. Cetirizine passed into the central nervous system only half as readily as terfenadine. These findings suggest that cetirizine's low incidence of sedative effects is most likely caused by its diminished potential to cross the blood-brain barrier and also may be partly the result of its greater selectivity for H1 receptors, compared with its effect at other receptors that may be involved in sedation.			SNOWMAN, AM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							CHANG RSL, 1979, J NEUROCHEM, V32, P1653, DOI 10.1111/j.1471-4159.1979.tb02276.x; CREESE I, 1977, EUR J PHARMACOL, V46, P377, DOI 10.1016/0014-2999(77)90232-1; CREESE I, 1978, EUR J PHARMACOL, V49, P201, DOI 10.1016/0014-2999(78)90080-8; GOULD RJ, 1982, P NATL ACAD SCI-BIOL, V79, P3656, DOI 10.1073/pnas.79.11.3656; PEROUTKA SJ, 1977, NEUROPHARMACOLOGY, V16, P549, DOI 10.1016/0028-3908(77)90023-5; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; TRAN VT, 1978, P NATL ACAD SCI USA, V75, P6290, DOI 10.1073/pnas.75.12.6290; UPRICHARD DC, 1978, EUR J PHARMACOL, V50, P87, DOI 10.1016/0014-2999(78)90258-3; UPRICHARD DC, 1978, SCIENCE, V199, P197, DOI 10.1126/science.202024; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	10	43	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1025	1028		10.1016/S0091-6749(05)80248-9	http://dx.doi.org/10.1016/S0091-6749(05)80248-9			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979798				2022-12-18	WOS:A1990ER13100007
J	CHANEZ, P; MANN, C; BOUSQUET, J; CHABRIER, PE; GODARD, P; BRAQUET, P; MICHEL, FB				CHANEZ, P; MANN, C; BOUSQUET, J; CHABRIER, PE; GODARD, P; BRAQUET, P; MICHEL, FB			ATRIAL-NATRIURETIC-FACTOR (ANF) IS A POTENT BRONCHODILATOR IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST HENRI BEAUFOUR, LES ULIS, FRANCE		CHANEZ, P (corresponding author), HOP AIGUELONGUE, MALADIES RESP CLIN, F-34059 MONTPELLIER, FRANCE.		Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				ADNOT S, 1987, AM REV RESPIR DIS, V136, P951, DOI 10.1164/ajrccm/136.4.951; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1988, ASTHMA BASIC MECHANI, P415; BOITEAU R, 1988, AM REV RESPIR DIS, V137, pA484; BOUSQUET J, 1988, AIRWAYS NEURAL CONTR, P119; BURROWS B, 1977, AM REV RESPIR DIS, V115, P195; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CURRIE MG, 1984, SCIENCE, V223, P67, DOI 10.1126/science.6419347; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; ENGLEBACH IM, 1988, AM REV RESPIR DIS, V137, pA28; GUTOWSKA J, 1987, FEBS LETT, V24, P17; HAMADA M, 1988, AM REV RESPIR DIS S, V137, pA35; HAMET P, 1987, NEPHROLOGIE, V8, P7; HEFFNER J E, 1989, American Review of Respiratory Disease, V139, pA47; HUNKS G, 1989, AM REV RESPIR DIS, V139, pA609; MORICE A, 1983, LANCET, V2, P1225; OLINS GM, 1986, BIOCHEM BIOPH RES CO, V140, P302, DOI 10.1016/0006-291X(86)91090-9; RICHARDS AM, 1985, LANCET, V1, P545; SAID SI, 1982, EXP LUNG RES, V3, P343, DOI 10.3109/01902148209069662; WATANABE H, 1988, AM REV RESPIR DIS, V137, pA102	20	43	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				321	324		10.1016/S0091-6749(05)80094-6	http://dx.doi.org/10.1016/S0091-6749(05)80094-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2145347				2022-12-18	WOS:A1990EA85900005
J	BUSH, RK; KAGEN, SL				BUSH, RK; KAGEN, SL			GUIDELINES FOR THE PREPARATION AND CHARACTERIZATION OF HIGH MOLECULAR-WEIGHT ALLERGENS USED FOR THE DIAGNOSIS OF OCCUPATIONAL LUNG-DISEASE - REPORT OF THE SUBCOMMITTEE-ON-PREPARATION-AND-CHARACTERIZATION-OF-HIGH-MOLECULAR-WEIGHT-ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM MED CTR, DEPT MED, MADISON, WI 53705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	BUSH, RK (corresponding author), UNIV WISCONSIN, DEPT MED, ALLERGY SECT, H6-367 CSC, 600 HIGHLAND AVE, MADISON, WI 53706 USA.							Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; ANDERSON MC, 1986, CLIN REV ALLERG, V4, P363; AXELSEN NH, 1973, SCAND J IMMUNOL, V2, P155, DOI 10.1111/j.1365-3083.1973.tb03797.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; KABAT EA, 1967, EXPT IMMUNOCHEMISTRY, P559; KRILIS S, 1983, J ALLERGY CLIN IMMUN, V71, P261, DOI 10.1016/0091-6749(83)90079-9; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; Norman P, 1986, MANUAL CLIN LABORATO, P660; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PHILLIPS PV, 4TH P INT P EHRLICH, V187, P59; PRICE JA, 1986, ALLERGY, V41, P603, DOI 10.1111/j.1398-9995.1986.tb00353.x; RICHMAN PG, 1984, METHODS LABORATORY A; SIRIGANIAN RP, 1986, MANUAL CLIN LABORATO, P675; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, P97; TEE RD, 1988, J ALLERGY CLIN IMMUN, V81, P505, DOI 10.1016/0091-6749(88)90188-1; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X; TOVEY ER, 1987, ELECTROPHORESIS, V8, P452, DOI 10.1002/elps.1150080915; TURKELTAUB PC, 1986, CLIN REV ALLERG, V4, P371; 1983, NIAID RES RESOURCES; 1986, METHODS LABORATORY A	29	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	2	S			814	819		10.1016/0091-6749(89)90344-8	http://dx.doi.org/10.1016/0091-6749(89)90344-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CC527	2600351				2022-12-18	WOS:A1989CC52700004
J	GERSTMAN, BB; BOSCO, LA; TOMITA, DK; GROSS, TP; SHAW, MM				GERSTMAN, BB; BOSCO, LA; TOMITA, DK; GROSS, TP; SHAW, MM			PREVALENCE AND TREATMENT OF ASTHMA IN THE MICHIGAN MEDICAID PATIENT POPULATION YOUNGER THAN 45 YEARS, 1980-1986	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HLTH INFORMAT DESIGNS INC,ARLINGTON,VA		GERSTMAN, BB (corresponding author), US FDA,OFF EPIDEMIOL & BIOSTAT,5600 FISHERS LANE,ROOM 15-42,ROCKVILLE,MD 20857, USA.							ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BARBEE RA, 1987, MONOGR ALLERGY, V21, P21; BARGER LW, 1988, ANN ALLERGY, V60, P31; BOSCO LA, 1987, J ALLERGY CLIN IMMUN, V80, P398, DOI 10.1016/0091-6749(87)90058-3; BURNEY P, 1987, CHEST, V91, pS194, DOI 10.1378/chest.91.6_Supplement.194S; BURNEY PGJ, 1986, LANCET, V2, P323; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HAY IFC, 1987, LANCET, V2, P609; HOLLAND WW, 1987, CHEST, V91, pS65, DOI 10.1016/S0012-3692(15)43273-8; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; LANES SF, 1987, AM J EPIDEMIOL, V125, P755, DOI 10.1093/oxfordjournals.aje.a114592; LESSLER JT, 1984, MED DATA SOURCE POST; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MAO Y, 1987, CAN MED ASSOC J, V137, P620; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; PEDERSEN PA, 1987, CHEST, V91, pS107, DOI 10.1378/chest.91.6.107S; RUTHER M, 1987, 4CFA03247 PUB, P15; SINCLAIR BL, 1987, THORAX, V42, P670, DOI 10.1136/thx.42.9.670; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; STRIBOLT TB, 1986, MED CLIN N AM, P909; STROM BL, 1985, CLIN PHARMACOL THER, V38, P359, DOI 10.1038/clpt.1985.188; TUCHINDA M, 1987, ANN ALLERGY, V59, P207; USHERWOOD TP, 1987, FAM PRACT, V4, P318, DOI 10.1093/fampra/4.4.318; 1986, DHHS PHS861582 PUBL, P81; 1986, SUPERCALC4 USERS GUI; 1985, DHHS PHS851578 PUBL, P82	29	43	43	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1032	1039		10.1016/0091-6749(89)90444-2	http://dx.doi.org/10.1016/0091-6749(89)90444-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2659644				2022-12-18	WOS:A1989AC23500005
J	HAKANSSON, L; RAK, S; DAHL, R; VENGE, P				HAKANSSON, L; RAK, S; DAHL, R; VENGE, P			THE FORMATION OF EOSINOPHIL AND NEUTROPHIL CHEMOTACTIC ACTIVITY DURING A POLLEN SEASON AND AFTER ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP UPPSALA, DEPT CLIN CHEM, INFLAMMAT RES LAB, S-75185 UPPSALA, SWEDEN; UNIV LUND HOSP, DEPT LUNG MED, S-22185 LUND, SWEDEN; AARHUS UNIV HOSP, DEPT LUNG MED, DK-8000 AARHUS, DENMARK	Uppsala University; Uppsala University Hospital; Lund University; Skane University Hospital; Aarhus University			Dahl, Ronahl/F-8170-2013					ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1987, J LEUKOCYTE BIOL, V42, P689, DOI 10.1002/jlb.42.6.689; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, UNPUB J ALLERGY CLIN; TANNOUS R, 1981, J LAB CLIN MED, V98, P238; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; VENGE P, UNPUB J ALLERGY CLIN; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WILKINSON PC, 1974, CHEMOTAXIS INFLAMMAT	18	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					933	939		10.1016/0091-6749(89)90108-5	http://dx.doi.org/10.1016/0091-6749(89)90108-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2654257				2022-12-18	WOS:A1989U716100014
J	VANHAGEHAMSTEN, M; JOHANSSON, SGO				VANHAGEHAMSTEN, M; JOHANSSON, SGO			CLINICAL-SIGNIFICANCE AND ALLERGENIC CROSS-REACTIVITY OF EUROGLYPHUS-MAYNEI AND OTHER NONPYROGLYPHID AND PYROGLYPHID MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VANHAGEHAMSTEN, M (corresponding author), KAROLINSKA HOSP, KAROLINSKA INST, DEPT CLIN IMMUNOL, TC BERGH FDN, S-10401 STOCKHOLM 60, SWEDEN.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596				AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; BLYTHE ME, 1974, CLIN ALLERGY, V4, P25, DOI 10.1111/j.1365-2222.1974.tb01359.x; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CARSWELL F, 1982, CLIN ALLERGY, V12, P533, DOI 10.1111/j.1365-2222.1982.tb02552.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CUNNINGTON AM, 1968, NATURE, V217, P1271, DOI 10.1038/2171271a0; CUTHBERT OD, 1984, CLIN ALLERGY, V14, P197, DOI 10.1111/j.1365-2222.1984.tb02653.x; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; GRIFFITHS DA, 1976, ANN APPL BIOL, V82, P180; Hallas T. E., 1981, Journal of Agricultural Research in Iceland, V13, P61; INGRAM CG, 1979, LANCET, V2, P1330; JEFFREY IG, 1976, J STORED PROD RES, V12, P149, DOI 10.1016/0022-474X(76)90003-5; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, V85, P99; MAUNSELL K, 1968, LANCET, V1, P1267; MUMCUOGLU Y, 1977, ACTA ALLERGOL, V32, P333; MUMCUOGLU Y, 1976, J MED ENTOMOL, V13, P361, DOI 10.1093/jmedent/13.3.361; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; RAO V R M, 1975, Clinical Allergy, V5, P209, DOI 10.1111/j.1365-2222.1975.tb01854.x; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P609; SESAY H R, 1972, Acarologia (Paris), V14, P384; SINHA R. N., 1964, PROC ENTOMOL SOC MANITOBA, V20, P19; Spieksma F. Th. M., 1967, Acarologia, V9, P226; TERHO EO, 1982, ALLERGY, V37, P15, DOI 10.1111/j.1398-9995.1982.tb04112.x; TERHO EO, 1985, ALLERGY, V40, P23, DOI 10.1111/j.1398-9995.1985.tb04150.x; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANHAGEHAMSTEN M, 1988, ALLERGY, V43, P545, DOI 10.1111/j.1398-9995.1988.tb00926.x; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; Voorhorst R., 1964, Allergie Asthma, V10, P329; WALSHAW MJ, 1987, CLIN ALLERGY, V17, P7, DOI 10.1111/j.1365-2222.1987.tb02314.x; WIDE L, 1967, LANCET, V2, P1105; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	37	43	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					581	589		10.1016/0091-6749(89)90069-9	http://dx.doi.org/10.1016/0091-6749(89)90069-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2926080				2022-12-18	WOS:A1989T859600003
J	WATSON, WTA; BECKER, AB; SIMONS, FER				WATSON, WTA; BECKER, AB; SIMONS, FER			COMPARISON OF IPRATROPIUM SOLUTION, FENOTEROL SOLUTION, AND THEIR COMBINATION ADMINISTERED BY NEBULIZER AND FACE MASK TO CHILDREN WITH ACUTE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BECKER AB, 1988, AM J DIS CHILD, V138, P574; BRYANT DH, 1985, CHEST, V88, P24, DOI 10.1378/chest.88.1.24; CHERNIACK RM, 1972, AM REV RESPIR DIS, V106, P38, DOI 10.1164/arrd.1972.106.1.38; COOK JJ, 1985, PHARMATHERAPEUTICA, V4, P383; DAVIS A, 1984, J PEDIATR-US, V105, P1002, DOI 10.1016/S0022-3476(84)80099-2; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; KARPEL JP, 1986, AM REV RESPIR DIS, V133, P727; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LEAHY BC, 1983, BRIT J DIS CHEST, V77, P159, DOI 10.1016/0007-0971(83)90022-0; MANN JS, 1985, BRIT J DIS CHEST, V79, P209; MANN JS, 1984, BRIT MED J, V289, P469, DOI 10.1136/bmj.289.6443.469; PAKES GE, 1980, DRUGS, V20, P237, DOI 10.2165/00003495-198020040-00001; RAYNER RJ, 1987, ARCH DIS CHILD, V62, P840, DOI 10.1136/adc.62.8.840; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REILLY PA, 1983, J PEDIATR-US, V103, P121, DOI 10.1016/S0022-3476(83)80797-5; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; SANTAMARIA J, 1987, CHEST, V91, P86, DOI 10.1378/chest.91.1.86; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P239, DOI 10.1016/0091-6749(87)90025-X; STORR J, 1986, ARCH DIS CHILD, V61, P602, DOI 10.1136/adc.61.6.602; SVEDMYR N, 1985, PHARMACOTHERAPY, V5, P109; TWEEDDALE PM, 1985, THORAX, V40, P825, DOI 10.1136/thx.40.11.825; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WARD MJ, 1985, BRIT J DIS CHEST, V79, P374, DOI 10.1016/0007-0971(85)90071-3	25	43	43	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1012	1018		10.1016/0091-6749(88)90138-8	http://dx.doi.org/10.1016/0091-6749(88)90138-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2974463				2022-12-18	WOS:A1988R631100009
J	WEILER, JM; DONNELLY, A; CAMPBELL, BH; CONNELL, JT; DIAMOND, L; HAMILTON, LH; ROSENTHAL, RR; HEMSWORTH, GR; PERHACH, JL				WEILER, JM; DONNELLY, A; CAMPBELL, BH; CONNELL, JT; DIAMOND, L; HAMILTON, LH; ROSENTHAL, RR; HEMSWORTH, GR; PERHACH, JL			MULTICENTER, DOUBLE-BLIND, MULTIPLE-DOSE, PARALLEL-GROUPS EFFICACY AND SAFETY TRIAL OF AZELASTINE, CHLORPHENIRAMINE, AND PLACEBO IN THE TREATMENT OF SPRING ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,IOWA CITY,IA 52242; ZABLOCKI VET ADM MED CTR,MILWAUKEE,WI; NASAL DIS STUDY CTR,ENGLEWOOD,NJ; UNIV KENTUCKY,LEXINGTON,KY 40506; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; WALLACE LABS,CRANBURY,NJ 08512	University of Iowa; University of Kentucky; Johns Hopkins University								ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAND N, 1987, ANN ALLERGY, V58, P344; CHAND N, 1986, AGENTS ACTIONS, V19, P164, DOI 10.1007/BF01966201; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1987, American Review of Respiratory Disease, V135, pA318; CHAND N, 1985, INT J IMMUNOPHARMACO, V7, P833, DOI 10.1016/0192-0561(85)90045-1; CHAND N, 1986, BRIT J PHARMACOL, V87, P443, DOI 10.1111/j.1476-5381.1986.tb10835.x; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CHAND N, 1983, K BER WISS TAG NORDD, V18, P93; CONNELL JT, 1985, ANN ALLERGY, V55, P392; DIAMANTIS W, 1984, FED PROC, V43, P389; DIAMANTIS W, 1984, Journal of Allergy and Clinical Immunology, V73, P184; EMOTO K, 1983, JPN J CLIN EXP MED, V60, P308; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FISCHER B, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1193; FUKUTAKE T, 1983, OTOLARYNGOLOGY, V29, P496; GOULD CAL, 1985, ANN ALLERGY, V55, P232; Inoue Y, 1983, Nihon Ika Daigaku Zasshi, V50, P371; KAJI R, 1981, IMMUNOPHARMACOLOGY, V3, P49, DOI 10.1016/0162-3109(81)90038-2; KATAYAMA S, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1196; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KUBO N, 1987, JPN J PHARMACOL, V43, P277, DOI 10.1254/jjp.43.277; LITTLE MM, 1987, J ALLERGY CLIN IMMUN, V79, P204; MAGNUSSEN H, 1987, CHEST, V91, P855, DOI 10.1378/chest.91.6.855; MELTZER EO, 1987, J ALLERGY CLIN IMMUN, V79, P205; MELTZER EO, 1987, ANN ALLERGY, V58, P281; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PERHACH J, 1984, Journal of Allergy and Clinical Immunology, V73, P144; PERHACH JL, 1987, NEW ENGL REG ALLERGY, V8, P121; RHODES BJ, 1986, ANN ALLERGY, V56, P528; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; STORMS WW, 1987, ANN ALLERGY, V58, P281; VONSCHMUTZLER W, 1986, ATEMW LUNGENKRKH, V12, pS89; VONSCHMUTZLER W, 1981, PHARMAKOTHERAPIE, V4, P155; WINSLOW CM, 1984, FED PROC, V43, P1941; YAMANAKA T, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1203	41	43	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				801	811		10.1016/0091-6749(88)90082-6	http://dx.doi.org/10.1016/0091-6749(88)90082-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3057041	Bronze			2022-12-18	WOS:A1988R170800014
J	FREW, AJ; KAY, AB				FREW, AJ; KAY, AB			THE PATTERN OF HUMAN LATE-PHASE SKIN REACTIONS TO EXTRACTS OF AEROALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital			Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEHRENS BL, 1987, LAB INVEST, V56, P101; BLACKLEY J, 1873, EXPT RES CAUSES CATA; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SEGAL AW, 1985, INFLAMMATION BASIC M, P105; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VENGE P, 1985, INFLAMMATION, P85; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	13	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1117	1121		10.1016/0091-6749(88)90878-0	http://dx.doi.org/10.1016/0091-6749(88)90878-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379223				2022-12-18	WOS:A1988P002300008
J	SILK, HJ; GUAYWOODFORD, L; PEREZATAYDE, AR; GEHA, RS; BROFF, MD				SILK, HJ; GUAYWOODFORD, L; PEREZATAYDE, AR; GEHA, RS; BROFF, MD			FATAL VARICELLA IN STEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR, DIV ALLERGY, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DIV PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007321] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-2037] Funding Source: Medline; NICHD NIH HHS [HD-07321-01, HD T32] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASANO Y, 1985, J PEDIATR-US, V106, P69, DOI 10.1016/S0022-3476(85)80468-6; BRUNELL PA, 1975, J INFECT DIS, V132, P49, DOI 10.1093/infdis/132.1.49; CLOSE GC, 1981, LANCET, V2, P480; DOLIN R, 1978, ANN INTERN MED, V89, P375, DOI 10.7326/0003-4819-89-3-375; FALLIERS CJ, 1965, ARCH DIS CHILD, V40, P593, DOI 10.1136/adc.40.214.593; FELDHOFF CM, 1981, J PEDIATR-US, V98, P25, DOI 10.1016/S0022-3476(81)80527-6; FELDMAN S, 1975, PEDIATRICS, V56, P388; FELDMAN S, 1976, J PEDIATR-US, V88, P265, DOI 10.1016/S0022-3476(76)80995-X; FINKEL KC, 1961, PEDIATRICS, V28, P436; GERSHON A, 1972, J PEDIATR-US, V81, P1034, DOI 10.1016/S0022-3476(72)80566-3; GIRSH LS, 1966, ANN ALLERGY, V24, P690; HAGGERTY RJ, 1956, PEDIATRICS, V18, P160; MACGREGO.RR, 1969, NEW ENGL J MED, V280, P1427, DOI 10.1056/NEJM196906262802601; MORGAN ER, 1983, AM J DIS CHILD, V137, P883, DOI 10.1001/archpedi.1983.02140350057014; ORENSTEIN WA, 1981, J PEDIATR-US, V98, P368, DOI 10.1016/S0022-3476(81)80697-X; PETER G, 1986, REPORT COMMITTEE INF, P399; SHAPIRO GG, 1983, PEDIATR CLIN N AM, V30, P955; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; WELLER TH, 1983, NEW ENGL J MED, V309, P1434, DOI 10.1056/NEJM198312013092205	19	43	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					47	51		10.1016/0091-6749(88)90219-9	http://dx.doi.org/10.1016/0091-6749(88)90219-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339190				2022-12-18	WOS:A1988M027400008
J	HOWARTH, PH; DURHAM, SR; KAY, AB; HOLGATE, ST				HOWARTH, PH; DURHAM, SR; KAY, AB; HOLGATE, ST			THE RELATIONSHIP BETWEEN MAST-CELL MEDIATOR RELEASE AND BRONCHIAL REACTIVITY IN ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, LONDON SW3 6HP, ENGLAND	University of Southampton; Royal Brompton Hospital				Howarth, Peter/0000-0003-0619-7927				ALLEN DH, 1979, CHEST, V75, P235; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; BARNES PJ, 1982, CLIN SCI, V62, P661, DOI 10.1042/cs0620661; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; ENNIS M, 1983, AGENTS ACTIONS, V13, P144, DOI 10.1007/BF01967319; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; HEGARDT B, 1982, ALLERGY, V37, P407, DOI 10.1111/j.1398-9995.1982.tb02319.x; HOLGATE ST, 1983, IMMUNOLOGY MED, P79; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, 1984, CLIN SCI, V67, pP5, DOI 10.1042/cs067005Pb; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; IND PW, 1983, CLIN ALLERGY, V13, P61, DOI 10.1111/j.1365-2222.1983.tb02568.x; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; LARSON G, 1986, CLIN RESPIR PHYSL S7, V22, P35; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MANN JS, 1984, THORAX, V39, P706; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MOODLEY I, 1983, CLIN SCI, V64, pP12; NAGY L, 1981, Allergie und Immunologie (Leipzig), V27, P48; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NEIJENS HJ, 1980, CLIN ALLERGY, V10, P535, DOI 10.1111/j.1365-2222.1980.tb02134.x; ODRISCOLL BRC, 1983, J ALLERGY CLIN IMMUN, V72, P695, DOI 10.1016/0091-6749(83)90632-2; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT, P35	41	43	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					703	711		10.1016/0091-6749(87)90291-0	http://dx.doi.org/10.1016/0091-6749(87)90291-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	2445803				2022-12-18	WOS:A1987K993000011
J	HANIFIN, JM; HOMBURGER, HA				HANIFIN, JM; HOMBURGER, HA			STAPHYLOCOCCAL COLONIZATION, INFECTION, AND ATOPIC-DERMATITIS - ASSOCIATION NOT ETIOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									MAYO CLIN & MAYO FDN,LAB MED,ROCHESTER,MN 55905	Mayo Clinic	HANIFIN, JM (corresponding author), OREGON HLTH SCI UNIV,DERMATOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.							ABRAMSON JS, 1982, J AM ACAD DERMATOL, V7, P105, DOI 10.1016/S0190-9622(82)80017-0; ALY R, 1977, ARCH DERMATOL, V113, P780, DOI 10.1001/archderm.113.6.780; ANDERSEN E K, 1951, Acta Derm Venereol, V31, P679; BERGER M, 1980, J IMMUNOL, V125, P2437; BIBEL DJ, 1982, J INVEST DERMATOL, V79, P250, DOI 10.1111/1523-1747.ep12500072; Cooke RA, 1922, J IMMUNOL, V7, P147; FRIEDMAN SJ, 1985, ARCH DERMATOL, V121, P869, DOI 10.1001/archderm.121.7.869; FRIEDMAN SJ, 1984, J IMMUNOL METHODS, V66, P369, DOI 10.1016/0022-1759(84)90350-8; GABRIELSEN T, 1985, ACTA DERM-VENEREOL, V114, P61; GLOOR M, 1982, DERMATOLOGICA, V164, P258, DOI 10.1159/000250099; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HARE R, 1961, BRIT MED J, V2, P333, DOI 10.1136/bmj.2.5248.333; HAUSER C, 1985, DERMATOLOGICA, V170, P114, DOI 10.1159/000249514; HENOCQ E, 1982, CLIN ALLERGY, V12, P113, DOI 10.1111/j.1365-2222.1982.tb01629.x; HERLITZ G, 1959, INT ARCH ALLER A IMM, V8, P160; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MOTALA C, 1986, J ALLERGY CLIN IMMUN, V78, P583, DOI 10.1016/0091-6749(86)90075-8; NORRLIND R, 1946, ACTA DERM VENERE S13, V26, P9; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; RAJKA G, 1965, J PEDIATR, V66, P222; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SEYMOUR JL, PEDIATRICIAN; SHERR EH, 1986, J ALLERGY CLIN IMMUN, V77, P193; Sulzberger MB., 1955, ATOPIC DERMATITIS, P11; Walker IC, 1917, J MED RES, V36, P423; WALSH GA, 1981, J CLIN MICROBIOL, V13, P1046, DOI 10.1128/JCM.13.6.1046-1048.1981; WHITE MI, 1985, BRIT J DERMATOL, V113, P179, DOI 10.1111/j.1365-2133.1985.tb02062.x	28	43	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				563	566		10.1016/0091-6749(86)90071-0	http://dx.doi.org/10.1016/0091-6749(86)90071-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3771948				2022-12-18	WOS:A1986E568200002
J	BRICKMAN, CM; TSOKOS, GC; CHUSED, TM; BALOW, JE; LAWLEY, TJ; SANTAELLA, M; HAMMER, CH; LINTON, GF; FRANK, MM				BRICKMAN, CM; TSOKOS, GC; CHUSED, TM; BALOW, JE; LAWLEY, TJ; SANTAELLA, M; HAMMER, CH; LINTON, GF; FRANK, MM			IMMUNOREGULATORY DISORDERS ASSOCIATED WITH HEREDITARY ANGIOEDEMA .2. SEROLOGIC AND CELLULAR ABNORMALITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, CLIN INVEST LAB, BETHESDA, MD 20205 USA; NIADDKD, ARTHIRIT & RHEUMATISM BRANCH, BETHESDA, MD 20205 USA; NIAID, MICROBIAL IMMUN LAB, BETHESDA, MD 20205 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				ALSPAUGH MA, 1981, J CLIN INVEST, V67, P1134, DOI 10.1172/JCI110127; Aubert E F, 1942, Br Med J, V1, P659; BILLINGS PB, 1983, P NATL ACAD SCI-BIOL, V80, P7104, DOI 10.1073/pnas.80.23.7104; BORSOS T, 1961, J IMMUNOL, V87, P310; BORSOS T, 1963, J IMMUNOL, V91, P851; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P749, DOI 10.1016/0091-6749(86)90424-0; Cillari E, 1982, Ann Sclavo, V24, P666; COLTON T, 1974, STAT MED, P30; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; FLEISHER TA, 1984, CLIN IMMUNOL IMMUNOP, V33, P391, DOI 10.1016/0090-1229(84)90310-6; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1977, ANN INTERN MED, V87, P210, DOI 10.7326/0003-4819-87-2-210; FRANK MM, 1980, CLIN IMMUNOLOGY, P262; GAITHER TA, 1974, J IMMUNOL, V113, P574; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; GIGLI I, 1968, J IMMUNOL, V100, P1154; GOODMAN MG, 1982, J EXP MED, V156, P912, DOI 10.1084/jem.156.3.912; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; LAY WH, 1968, J EXP MED, V128, P991, DOI 10.1084/jem.128.5.991; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MORIMOTO C, 1982, CLIN IMMUNOL IMMUNOP, V22, P270, DOI 10.1016/0090-1229(82)90043-5; OCHS HD, 1983, CLIN EXP IMMUNOL, V53, P208; RUSSELL AS, 1983, CLIN RHEUM DIS, V9, P117; SMOLEN JS, 1982, AM J MED, V72, P783, DOI 10.1016/0002-9343(82)90544-7; TAKAHASHI M, 1978, J CLIN INVEST, V62, P349, DOI 10.1172/JCI109135; THEOFILOPOULOS AN, 1976, J CLIN INVEST, V57, P169, DOI 10.1172/JCI108257; TSOKOS GC, 1981, CLIN IMMUNOL IMMUNOP, V21, P172, DOI 10.1016/0090-1229(81)90206-3; TSOKOS GC, 1984, PROG ALLERGY, V35, P93; VAUGHAN JH, 1983, CLIN EXP RHEUMATOL, V1, P265; ZUBLER RH, 1976, J IMMUNOL, V116, P232	30	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					758	767		10.1016/0091-6749(86)90425-2	http://dx.doi.org/10.1016/0091-6749(86)90425-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3486201				2022-12-18	WOS:A1986C390300023
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .13. ISOLATION AND PURIFICATION OF PROTEIN-COMPONENTS FROM 3 SPECIES OF VESPID VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27834, USA.							ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HOFFMAN DR, 1978, ANN ALLERGY, V40, P171; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; Krombein K.V., 1979, CATALOG HYMENOPTERA; LITTLER S, 1983, J ALLERGY CLIN IMMUN, V71, P120, DOI 10.1016/0091-6749(83)90250-6; MERINEY D, 1981, J CLIN LAB IMMUNOL, V5, P1; MERRIL CR, 1982, ELECTROPHORESIS, V3, P17, DOI 10.1002/elps.1150030104; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; WOOD CL, 1983, TOXICON, V21, P291, DOI 10.1016/0041-0101(83)90014-4; WOOD CL, 1983, ANN ALLERGY, V51, P441	18	43	45	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					599	605		10.1016/0091-6749(85)90036-3	http://dx.doi.org/10.1016/0091-6749(85)90036-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989145				2022-12-18	WOS:A1985AHV0700010
J	BERNSTEIN, DI; GALLAGHER, JS; DSOUZA, L; BERNSTEIN, IL				BERNSTEIN, DI; GALLAGHER, JS; DSOUZA, L; BERNSTEIN, IL			HETEROGENEITY OF SPECIFIC-IGE RESPONSES IN WORKERS SENSITIZED TO ACID ANHYDRIDE COMPOUNDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267, USA.							BERNSTEI.IL, 1969, J ALLERGY, V43, P191, DOI 10.1016/0021-8707(69)90062-8; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; GALLAGHER JS, 1983, J ALLERGY CLIN IMMUN, V71, P157, DOI 10.1016/0091-6749(83)90400-1; GALLAGHER JS, 1980, J ALLERGY CLIN IMMUN, V65, P169; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MCCARTY M, 1967, CROSSREACTING ANTIGE, P8; MOLLER DR, UNPUB J ALLERGY CLIN; SANDBRIDGE RL, 1978, LABORATORY METHODS; SCHIRRMA.V, 1974, J IMMUNOL, V113, P1635; SCHLUETER DP, 1981, J OCCUP MED, V20, P183; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380	20	43	44	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					794	801		10.1016/0091-6749(84)90181-7	http://dx.doi.org/10.1016/0091-6749(84)90181-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6209323				2022-12-18	WOS:A1984TW41800006
J	HELM, RM; GAUERKE, MB; BAER, H; LOWENSTEIN, H; FORD, A; LEVY, DA; NORMAN, PS; YUNGINGER, JW				HELM, RM; GAUERKE, MB; BAER, H; LOWENSTEIN, H; FORD, A; LEVY, DA; NORMAN, PS; YUNGINGER, JW			PRODUCTION AND TESTING OF AN INTERNATIONAL REFERENCE-STANDARD OF SHORT RAGWEED POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; US FDA,BETHESDA,MD 20014; NATL INST BIOL STAND & CONTROL,LONDON NW3 6RB,ENGLAND; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Mayo Clinic; US Food & Drug Administration (FDA); National Institute for Biological Standards & Control; University of Copenhagen; Johns Hopkins University					NIAID NIH HHS [AI-12675] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI012675] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; ANDERSON MC, 1981, RAST INHIBITION PROC; CALAM DH, 1982, CHROMATOGRAPHIA, V16, P216, DOI 10.1007/BF02258905; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MAY JC, 1979, J ALLERGY CLIN IMMUN, V63, P87, DOI 10.1016/0091-6749(79)90197-0; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; REIMER CB, 1978, J BIOL STAND, V6, P133, DOI 10.1016/S0092-1157(78)80045-6; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; Voller A, 1977, ENZYME LINKED IMMUNO, P24; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; 1978, WHO TECHNICAL REPORT, V626; 1981, FED REG 39129   0731, V46	17	43	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					790	800		10.1016/0091-6749(84)90449-4	http://dx.doi.org/10.1016/0091-6749(84)90449-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6725791	Bronze			2022-12-18	WOS:A1984SV82900005
J	LEMAO, J; DANDEU, JP; RABILLON, J; LUX, M; DAVID, B				LEMAO, J; DANDEU, JP; RABILLON, J; LUX, M; DAVID, B			COMPARISON OF ANTIGENIC AND ALLERGENIC COMPOSITION OF 2 PARTIALLY PURIFIED EXTRACTS FROM DERMATOPHAGOIDES-FARINAE AND DERMATOPHAGOIDES-PTERONYSSINUS MITE CULTURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEMAO, J (corresponding author), INST PASTEUR,DEPT IMMUNOL,IMMUNO ALLERGY SECT,UNITE IMMUNO ALLERGIE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							BILIOTTI G, 1975, CLIN ALLERGY, V1, P69; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; LEMAO J, 1981, IMMUNOLOGY, V44, P239; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; LOWENSTEIN H, 1978, PROG ALLERGY, V25, P24; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; NAKAGAWA T, 1977, INT ARCH ALLER A IMM, V55, P47, DOI 10.1159/000231907; PAULI G, 1972, REV FR ALLERGOL, V12, P141, DOI 10.1016/S0035-2845(72)80014-3; PEPYS J, 1968, LANCET, V1, P1270; PRAHL P, 1978, ALLERGY, V33, P241, DOI 10.1111/j.1398-9995.1978.tb01544.x; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SPIEKSMA FT, 1969, ACTA ALLERGOL, V24, P124, DOI 10.1111/j.1398-9995.1969.tb03762.x; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x; WEEKE B, 1973, MANUAL QUANTITATIVE, P47; WIDE L, 1967, LANCET, V2, P105	21	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					588	596		10.1016/0091-6749(83)90441-4	http://dx.doi.org/10.1016/0091-6749(83)90441-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853928				2022-12-18	WOS:A1983QV13900011
J	AVNER, BP; JENNE, JW				AVNER, BP; JENNE, JW			DESENSITIZATION OF ISOLATED HUMAN BRONCHIAL SMOOTH-MUSCLE TO BETA-RECEPTOR AGONISTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,ALBUQUERQUE,NM 87108		AVNER, BP (corresponding author), UNIV NEW MEXICO,DEPT PHARMACOL,ALBUQUERQUE,NM 87131, USA.				NHLBI NIH HHS [HL 20184] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PR, 1975, PFLUG ARCH EUR J PHY, V360, P135, DOI 10.1007/BF00580536; ATLAS D, 1976, P NATL ACAD SCI USA, V73, P1921, DOI 10.1073/pnas.73.6.1921; ATLAS D, 1976, BIOCHEM BIOPH RES CO, V69, P397, DOI 10.1016/0006-291X(76)90535-0; AVNER B P, 1976, American Review of Respiratory Disease, V113, P239; AVNER BP, 1977, P W PHARMACOL SOC, V20, P25; AVNER BP, 1979, P W PHARMACOL SOC, V22, P177; AVNER BP, 1978, J PHARMACOL EXP THER, V207, P23; CHO YW, 1968, J ALLERGY, V42, P36, DOI 10.1016/0021-8707(68)90130-5; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; CONOLLY ME, 1973, CHEST S, V63, P16; DAVIS C, 1977, CLIN SCI MOL MED, V53, P28; DOUGLAS JS, 1977, EUR J PHARMACOL, V42, P195, DOI 10.1016/0014-2999(77)90285-0; DRAZEN JM, 1978, J APPL PHYSIOL, V44, P340, DOI 10.1152/jappl.1978.44.3.340; FASTIER FN, 1973, BRIT J PHARMACOL, V49, P490, DOI 10.1111/j.1476-5381.1973.tb17259.x; FLEISCH JH, 1972, J PHARMACOL EXP THER, V181, P425; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; LIN CS, 1977, J PHARMACOL EXP THER, V203, P12; MICKEY JV, 1976, MOL PHARMACOL, V12, P409; MINATOYA H, 1975, BRIT J PHARMACOL, V53, P333, DOI 10.1111/j.1476-5381.1975.tb07368.x; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PATERSON J W, 1971, British Journal of Diseases of the Chest, V65, P21, DOI 10.1016/S0007-0971(71)80015-3; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; RANG HP, 1970, MOL PHARMACOL, V6, P357; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; STEINSLAND OS, 1975, J PHARMACOL EXP THER, V193, P138; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; Straub W, 1907, ARCH GESAMTE PHYSIOL, V119, P127, DOI 10.1007/BF01680084; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TINKELMAN DG, 1977, JAMA-J AM MED ASSOC, V237, P553, DOI 10.1001/jama.237.6.553; VENTER JC, 1979, MOL PHARMACOL, V16, P429; WATANABE M, 1976, JPN J PHARMACOL, V26, P191, DOI 10.1254/jjp.26.191; WEISSINGER JL, 1977, THESIS U NEW MEXICO; WESSELS MR, 1978, J BIOL CHEM, V253, P3371	40	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					51	57		10.1016/0091-6749(81)90123-8	http://dx.doi.org/10.1016/0091-6749(81)90123-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	6113255				2022-12-18	WOS:A1981LY10100009
J	GREENBERGER, PA; PATTERSON, R; SIMON, R; LIEBERMAN, P; WALLACE, W				GREENBERGER, PA; PATTERSON, R; SIMON, R; LIEBERMAN, P; WALLACE, W			PRETREATMENT HIGH-RISK PATIENTS REQUIRING RADIOGRAPHIC CONTRAST-MEDIA STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,ALLERGY IMMUNOL SECT,LA JOLLA,CA 92037; UNIV TENNESSEE,CTR HLTH SCI,MEMPHIS,TN 38163	Scripps Research Institute; University of Tennessee System; University of Tennessee Health Science Center	GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386, P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403, AI 10386] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; LALLI AF, 1980, RADIOLOGY, V134, P1; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; WOLFROMM R, 1966, J RADIOL ELEC MED N, V47, P346; YOCUM MW, 1977, P AM C ALLERGY NEW Y; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	14	43	43	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					185	187		10.1016/0091-6749(81)90059-2	http://dx.doi.org/10.1016/0091-6749(81)90059-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462535				2022-12-18	WOS:A1981LG77800004
J	SANTRACH, PJ; PARKER, JL; JONES, RT; YUNGINGER, JW				SANTRACH, PJ; PARKER, JL; JONES, RT; YUNGINGER, JW			DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF A MODIFIED RADIOALLERGOSORBENT TEST AND COMPARISON WITH THE CONVENTIONAL RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FADAL RG, 1979, CONTINUING ED FAMILY, P37; FADAL RG, 1979, MODIFIED RAST PROCED; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; NALEBUFF DJ, 1979, OTOLARYNG HEAD NECK, V87, P351, DOI 10.1177/019459987908700313; NALEBUFF DJ, 1979, CONT ED          MAY, P64; NALEBUFF DJ, 1978, J CONT ED ORL ALLERG, V40, P47; NORMAN PS, 1978, ALLERGY PRINCIPLES P, V1, P256; PATTERSON R, 1978, ALLERGY PRINCIPLES P, V2, P877; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; 1979, J ALLERGY CLIN IMMUN, V63, pA35	14	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					97	104		10.1016/0091-6749(81)90003-8	http://dx.doi.org/10.1016/0091-6749(81)90003-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451785				2022-12-18	WOS:A1981LB94700003
J	NATHAN, RA; KINSMAN, RA; SPECTOR, SL; HORTON, DJ				NATHAN, RA; KINSMAN, RA; SPECTOR, SL; HORTON, DJ			RELATIONSHIP BETWEEN AIRWAYS RESPONSE TO ALLERGENS AND NONSPECIFIC BRONCHIAL REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT PSYCHIAT,DENVER,CO 80202	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AAS K, 1974, ANN ALLERGY, V33, P320; ALTOUNYAN REC, 1971, IDENTIFICATION ASTHM, P160; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; CURRY JJ, 1948, J ALLERGY, V19, P9, DOI 10.1016/0021-8707(48)90072-0; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DRAZEN JM, 1975, J APPL PHYSIOL, V38, P834, DOI 10.1152/jappl.1975.38.5.834; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; HUGGINS KG, 1975, LANCET, V2, P148; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; JORDE W, 1971, RESPIRATION, V28, P360, DOI 10.1159/000192824; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LAITINEN LAI, 1974, SCAND J RESPIR DIS S, V86, P9; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SIMONSSO.BG, 1967, AM REV RESPIR DIS, V95, P873; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WOENNE R, 1978, J ALLERGY CLIN IMMUN, V62, P119, DOI 10.1016/0091-6749(78)90089-1; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823; ZUIDEMA P, 1969, RESPIRATION, VS 26, P141, DOI 10.1159/000192648	35	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					491	499		10.1016/0091-6749(79)90058-7	http://dx.doi.org/10.1016/0091-6749(79)90058-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	512267				2022-12-18	WOS:A1979HX84000004
J	FORMAN, SR; FINK, JN; MOORE, VL; WANG, J; PATTERSON, R				FORMAN, SR; FINK, JN; MOORE, VL; WANG, J; PATTERSON, R			HUMORAL AND CELLULAR IMMUNE-RESPONSES IN ASPERGILLUS-FUMIGATUS PULMONARY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,IMMUNOL SECT,MILWAUKEE,WI 53226; VET ADM CTR,RES SERV,WOOD,WI 53193; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Medical College of Wisconsin; Northwestern University	FORMAN, SR (corresponding author), MED COLL WISCONSIN,ALLERGY SECT,MILWAUKEE,WI 53226, USA.							CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; GOLBERT TM, 1970, ANN INTERN MED, V72, P395, DOI 10.7326/0003-4819-72-3-395; HASLAM P, 1976, CLIN ALLERGY, V6, P277, DOI 10.1111/j.1365-2222.1976.tb01908.x; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HENSLEY GT, 1969, ARCH PATHOL, V87, P572; HENSON KFW, 1952, THORAX, V7, P317; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; McCarthy D S, 1973, Clin Allergy, V3, P57, DOI 10.1111/j.1365-2222.1973.tb01310.x; MICHAEL JG, 1973, J IMMUNOL, V111, P1600; OPPENHEIM JJ, 1975, UTILIZATION LYMPHOCY; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; Pepys J, 1969, HYPERSENSITIVITY DIS; RACHELEFSKY GS, 1976, J ALLERGY CLIN IMMUN, V57, P569, DOI 10.1016/0091-6749(76)90008-7; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SHELDON JM, 1967, MANUEL CLIN ALLERGY; SISK PP, 1974, IMMUNOLOGIC ASPECTS; WADSWORTH C, 1962, INT ARCH ALLER A IMM, V21, P131, DOI 10.1159/000229325; YOCUM MW, 1976, AM J MED, V61, P939, DOI 10.1016/0002-9343(76)90419-8; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	23	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					131	136		10.1016/0091-6749(78)90096-9	http://dx.doi.org/10.1016/0091-6749(78)90096-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	355293				2022-12-18	WOS:A1978FP55400001
J	GALANT, SP; UNDERWOOD, SB; LUNDAK, TC; GRONCY, CC; MOURATIDES, DI				GALANT, SP; UNDERWOOD, SB; LUNDAK, TC; GRONCY, CC; MOURATIDES, DI			HETEROGENEITY OF HUMAN LYMPHOCYTE SUB-POPULATIONS TO PHARMACOLOGIC STIMULATION .1. LYMPHOCYTE RESPONSIVENESS TO BETA-ADRENERGIC AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE, MED CTR, DEPT PEDIAT, IRVINE, CA 92664 USA	University of California System; University of California Irvine								ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; ATKINSON JP, 1975, J IMMUNOL, V115, P1023; BACH MA, 1975, J CLIN INVEST, V55, P1074, DOI 10.1172/JCI108008; BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; DEAN JH, 1975, J IMMUNOL, V115, P1449; GREAVES MF, 1974, J IMMUNOL, V112, P240; GUPTA S, 1975, J ALLERGY CLIN IMMUN, V55, P99; HARRIS R, 1969, LANCET, V2, P327; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; PAPAMICHAEL M, 1977, LYMPHOCYTES SUBPOPUL, P49; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; ROSZKOWSKI W, 1977, SCIENCE, V195, P683, DOI 10.1126/science.190677; SCHMALZL F, 1968, ACTA HAEMATOL-BASEL, V39, P177, DOI 10.1159/000208959; SCHWARTZ RH, 1975, P NATL ACAD SCI USA, V72, P474, DOI 10.1073/pnas.72.2.474; STEINER AL, 1969, P NATL ACAD SCI USA, V64, P367, DOI 10.1073/pnas.64.1.367; WYBRAN J, 1973, LANCET, V1, P126	18	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					349	356		10.1016/0091-6749(78)90135-5	http://dx.doi.org/10.1016/0091-6749(78)90135-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	213463				2022-12-18	WOS:A1978GA29200006
J	IMBEAU, SA; NICHOLS, D; FLAHERTY, D; DICKIE, H; REED, C				IMBEAU, SA; NICHOLS, D; FLAHERTY, D; DICKIE, H; REED, C			RELATIONSHIPS BETWEEN PREDNISONE THERAPY, DISEASE ACTIVITY, AND TOTAL SERUM IGE LEVEL IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR HLTH SCI,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ARBESMAN C E, 1974, Clinical Allergy, V4, P349, DOI 10.1111/j.1365-2222.1974.tb01396.x; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; MALO JL, 1977, THORAX, V32, P269, DOI 10.1136/thx.32.3.269; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, J PEDIATR-US, V91, P914, DOI 10.1016/S0022-3476(77)80889-5; TURNER KJ, 1974, CLIN ALLERGY, V4, P149, DOI 10.1111/j.1365-2222.1974.tb01372.x	10	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					91	95		10.1016/0091-6749(78)90084-2	http://dx.doi.org/10.1016/0091-6749(78)90084-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	670610				2022-12-18	WOS:A1978FL83500004
J	LEVINSON, AI; SUMMERS, RJ; LAWLEY, TJ; EVANS, R; FRANK, MM				LEVINSON, AI; SUMMERS, RJ; LAWLEY, TJ; EVANS, R; FRANK, MM			EVALUATION OF ADVERSE-EFFECTS OF LONG-TERM HYPOSENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NCI,BETHESDA,MD 20014; NIAID,CHAMBLEE,GA 30341	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LEVINSON, AI (corresponding author), WALTER REED ARMY INST RES,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20012, USA.							ABRUZZO JL, 1966, BRIT J EXP PATHOL, V47, P52; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BOKISCH VA, 1972, J EXP MED, V136, P799, DOI 10.1084/jem.136.4.799; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; CHRISTIAN CL, 1965, J EXP MED, V121, P309, DOI 10.1084/jem.121.2.309; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; EICHMANN K, 1971, J EXP MED, V134, P48, DOI 10.1084/jem.134.1.48; HENSON PM, 1971, J EXP MED, V133, P554, DOI 10.1084/jem.133.3.554; ISOBE T, 1971, ANN NY ACAD SCI, V190, P507, DOI 10.1111/j.1749-6632.1971.tb13560.x; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MANNIK M, 1974, PROGR IMMUNOLOGY 2, V5, P91; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MORETTA L, 1975, EUR J IMMUNOL, V5, P565, DOI 10.1002/eji.1830050812; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PENNY R, 1970, LANCET, V1, P77; POTTER M, 1971, N ENGL J MED, V284, P8831; RAPHAEL SA, 1976, J ALLERGY CLIN IMMUN, V57, P103; ROSS GD, 1973, J CLIN INVEST, V52, P377, DOI 10.1172/JCI107194; SEHON AH, 1957, J ALLERGY, V28, P229, DOI 10.1016/0021-8707(57)90127-2; SHOU L, 1976, J EXP MED, V143, P1100, DOI 10.1084/jem.143.5.1100; SOBEL AT, 1975, J EXP MED, V142, P139, DOI 10.1084/jem.142.1.139; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAKATSU K, 1975, J IMMUNOL, V115, P1469; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; WHITE CS, 1974, ANN INTERN MED, V81, P594, DOI 10.7326/0003-4819-81-5-594; ZUBLER RH, 1976, J IMMUNOL, V116, P232; ZUBLER RH, 1976, IN VITRO METHODS CEL, P565	29	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					109	114		10.1016/0091-6749(78)90087-8	http://dx.doi.org/10.1016/0091-6749(78)90087-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	149803				2022-12-18	WOS:A1978FL83500007
J	STEIN, MR; BROWN, GL; LIMA, JE; NELSON, HS; CARR, RI				STEIN, MR; BROWN, GL; LIMA, JE; NELSON, HS; CARR, RI			LABORATORY EVALUATION OF IMMUNE-COMPLEXES IN PATIENTS ON INHALANT IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERG CLIN IMMUNOL SERV,DENVER,CO 80240; FITZSIMONS ARMY MED CTR,CLIN INVEST RES LABS,DENVER,CO 80240; NATL JEWISH HOSP & RES CTR,DEPT MED,DENVER,CO 80206	National Jewish Health								AGNELLO V, 1976, J INVEST DERMATOL, V67, P339, DOI 10.1111/1523-1747.ep12514497; BAYER AS, 1976, NEW ENGL J MED, V295, P1500, DOI 10.1056/NEJM197612302952703; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; COCHRANE CG, 1976, TXB IMMUNOPATHOLOGY, P137; CREAM JJ, 1972, CLIN EXP IMMUNOL, V10, P117; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FEINBERG SM, 1960, J ALLERGY, V31, P421, DOI 10.1016/0021-8707(60)90005-8; FEINBERG SM, 1937, J ALLERGY, V6, P532; Freeman J, 1911, LANCET, V2, P814; GABRIEL A, 1977, J CLIN INVEST, V59, P990, DOI 10.1172/JCI108722; GRISWOLD WR, 1976, INT ARCH ALLER A IMM, V52, P169, DOI 10.1159/000231678; HOLLANDER M, 1973, NONPARAMETRIC STAT, P219; KOHLER PF, 1976, J ALLERGY CLIN IMMUN, V57, P232; KOHLER PF, 1973, MEDICINE, V52, P419, DOI 10.1097/00005792-197309000-00006; KUNKEL HG, 1975, ANN NY ACAD SCI, V8, P256; LEVINSON A I, 1977, Annals of Allergy, V38, P446; Loveless MH, 1940, J IMMUNOL, V38, P25; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURHUMA AZ, 1976, CLIN EXP IMMUNOL, V25, P212; MCINTOSH RM, 1975, Q J MED, V44, P285; MCINTOSH RM, 1971, INT ARCH ALLER A IMM, V41, P700, DOI 10.1159/000230562; MCINTOSH RM, 1976, Q J MED, V45, P23; MCINTOSH RM, 1976, TXB IMMUNOPATHOLOGY, P619; MINCEY EK, 1971, ANN ALLERGY, V29, P346; NOON L, 1911, LANCET, V1, P572; RAPHAEL SA, 1976, J ALLERGY CLIN IMMUN, V57, P231; STEIN MR, 1977, ANN ALLERGY, V38, P303; TACHOVSKY TG, 1976, LANCET, V2, P997; TALMAGE DW, 1953, J INFECT DIS, V93, P176, DOI 10.1093/infdis/93.2.176; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; ZUBLER RH, 1976, J IMMUNOL, V116, P232	31	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					211	216		10.1016/0091-6749(78)90209-9	http://dx.doi.org/10.1016/0091-6749(78)90209-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701654				2022-12-18	WOS:A1978FS39200003
J	GEHA, RS				GEHA, RS			CIRCULATING IMMUNE-COMPLEXES AND ACTIVATION OF COMPLEMENT SEQUENCE IN ACUTE ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR, DEPT MED, DIV ALLERGY, BOSTON, MA 02115 USA; AMER UNIV BEIRUT, DEPT PEDIAT, BEIRUT, LEBANON; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT MED, DIV IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; American University of Beirut; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital								AGNELLO V, 1970, IMMUNOLOGY, V19, P909; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; GEHA RS, 1973, J CLIN INVEST, V52, P1726, DOI 10.1172/JCI107354; HART RJ, 1976, J PEDIATR-US, V89, P38, DOI 10.1016/S0022-3476(76)80923-7; HASLAM P, 1976, CLIN ALLERGY, V6, P277, DOI 10.1111/j.1365-2222.1976.tb01908.x; JORDAN MC, 1971, ARCH INTERN MED, V128, P576, DOI 10.1001/archinte.128.4.576; LAURELL CB, 1965, ANAL BIOCHEM, V10, P358, DOI 10.1016/0003-2697(65)90278-2; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; Manchini G, 1965, IMMUNOCHEMISTRY, V2, P234; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; MAYER MM, 1961, KABAT MAYERS EXPT IM, P133; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; SLAVIN R, 1977, 1ST AM C ALL IMM NEW	16	43	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					357	359		10.1016/0091-6749(77)90066-5	http://dx.doi.org/10.1016/0091-6749(77)90066-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	144747	Bronze			2022-12-18	WOS:A1977ED83400004
J	HANSON, G; FLOD, N; WELLS, I; NOVEY, H; GALANT, S				HANSON, G; FLOD, N; WELLS, I; NOVEY, H; GALANT, S			BRONCHOCENTRIC GRANULOMATOSIS - COMPLICATION OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT PEDIAT,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PATHOL,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine								BARDANA EJ, 1974, ANN NY ACAD SCI, V221, P64, DOI 10.1111/j.1749-6632.1974.tb28200.x; BAZARAL M, 1971, J IMMUNOL, V107, P794; BERGER I, 1972, CLIN PEDIATR, V11, P178, DOI 10.1177/000992287201100312; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; COOMBS RRA, 1968, CLINICAL ASPECTS IMM; FINEGOLD SM, 1959, AM J MED, V27, P463, DOI 10.1016/0002-9343(59)90012-9; GOLDBERT TM, 1970, ANN INTERN MED, V72, P395; GOODMAN DH, 1974, ANN ALLERGY, V33, P289; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; JORDAN MC, 1971, ARCH INTERN MED, V128, P576, DOI 10.1001/archinte.128.4.576; KATZ RM, 1973, NEW ENGL J MED, V288, P233, DOI 10.1056/NEJM197302012880504; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; LIEBOW AA, 1973, AM REV RESPIR DIS, V108, P1; LINCOLN EM, 1972, AM REV RESPIR DIS, V105, P683; MCCARTHY D S, 1970, Clinical Radiology, V21, P366, DOI 10.1016/S0009-9260(70)80070-8; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PEPYS J, 1969, MONOGRAPHYS ALLERGY, V4, P70; SLAVIN R G, 1970, Journal of Pediatrics, V76, P416, DOI 10.1016/S0022-3476(70)80482-6; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; SPOTNITZ M, 1967, DIS CHEST, V52, P92; TURNERWARWICK M, 1975, CHEST, V68, P346, DOI 10.1378/chest.68.3.346; Vithayasai V, 1973, IMJ Ill Med J, V144, P564; WIDE L, 1967, LANCET, V2, P1105; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	27	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					83	90		10.1016/0091-6749(77)90182-8	http://dx.doi.org/10.1016/0091-6749(77)90182-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	319138				2022-12-18	WOS:A1977CS82800014
J	BICE, DE; SALVAGGIO, J; HOFFMAN, E				BICE, DE; SALVAGGIO, J; HOFFMAN, E			PASSIVE TRANSFER OF EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS WITH LYMPHOID-CELLS IN RABBIT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,DEPT MED,NEW ORLEANS,LA 70112	Tulane University								ANURAS J, 1975, J ALLERGY CLIN IMMUN, V55, P71; BICE DE, 1974, INT ARCH ALLER A IMM, V47, P54; BLOOM BR, 1968, FED PROC, V27, P13; BRENTJENS JR, 1974, J EXP MED, V140, P105, DOI 10.1084/jem.140.1.105; BRUGER DR, 1971, P SOC EXP BIOL MED, V136, P1385; COMROE JH, 1974, PHYSIOLOGY RESPIRATI, P185; DAVID JR, 1964, J IMMUNOL, V93, P279; DAVID JR, 1971, IN VITRO METHODS CEL, P249; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; FINK JN, 1968, J LAB CLIN MED, V71, P20; HENSLEY GT, 1974, ARCH PATHOL, V97, P33; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; KAWAI T, 1973, CHEST, V64, P420, DOI 10.1378/chest.64.4.420; KAWAI T, 1973, CLIN EXP IMMUNOL, V15, P123; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P276, DOI 10.1016/0091-6749(72)90026-7; MIYAMOTO T, 1971, J ALLERGY, V47, P181, DOI 10.1016/S0091-6749(71)80296-8; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MYRVIK QN, 1961, J IMMUNOL, V86, P128; PARRISH EW, 1961, ACTA ALLERGOL, V16, P78; PEPYS J, 1966, ANN INTERN MED, V64, P943, DOI 10.7326/0003-4819-64-4-943; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745; RICHERSON HB, 1974, ANN NY ACAD SCI, V221, P340, DOI 10.1111/j.1749-6632.1974.tb28236.x; RICHERSON HB, 1973, FED P, V33, P804; SALVAGGIO J, 1975, J ALLERGY CLIN IMMUN, V56, P364, DOI 10.1016/0091-6749(75)90130-X; WARWICK WJ, 1960, P SOC EXP BIOL MED, V105, P459, DOI 10.3181/00379727-105-26140; WENZEL F, 1966, ANN ALLERGY, V22, P533; WILKIE B, 1973, PATHOL MICROBIOL, V39, P393, DOI 10.1159/000162686	27	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					250	262		10.1016/0091-6749(76)90130-5	http://dx.doi.org/10.1016/0091-6749(76)90130-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA661	947979				2022-12-18	WOS:A1976CA66100002
J	NAKAZAWA, T; TOYODA, T; FURUKAWA, M; TAYA, T; KOBAYASHI, S				NAKAZAWA, T; TOYODA, T; FURUKAWA, M; TAYA, T; KOBAYASHI, S			INHIBITORY EFFECTS OF VARIOUS DRUGS ON DUAL ASTHMATIC RESPONSES IN WHEAT FLOUR SENSITIVE SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUNMA UNIV,SCH MED,1ST DEPT INTERN MED,MAEBASHI 371,GUNMA,JAPAN	Gunma University								ARBESMAN CE, 1971, J ALLERGY, V47, P85; AVIADO TM, 1970, J CLIN PHARMACOL, V10, P1; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOURNE H G Jr, 1959, Ind Med Surg, V28, P232; COFFEY RG, 1973, CHEST, V63, pS2; EDA A, 1973, THERAPY, V23, P657; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; FURUKAWA M, 1974, JAP J ALLERGY, V23, P46; HARGREAV.FE, 1966, LANCET, V1, P445; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; MICHEL H, 1958, OCCUPATIONAL ALLERGY, P35; MIDDLETON E, 1974, ALLERGOLOGY, P361; NAKAZAWA T, 1971, JAP J ALLERGY, V21, P13; ORIE NGM, 1973, 8TH INT C ALL TOK; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PEPYS J, 1973, ALLERGOLOGY, P84; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; RADERMECKER M, 1971, IMMUNOLOGICAL DISEAS, P878; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHILD HO, 1951, LANCET, V2, P376; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5	23	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					1	9		10.1016/0091-6749(76)90101-9	http://dx.doi.org/10.1016/0091-6749(76)90101-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	820732				2022-12-18	WOS:A1976BX74200001
J	RACHELEFSKY, GS; OPELZ, G; MICKEY, MR; LESSIN, P; KIUCHI, M; SILVERSTEIN, MJ; STIEHM, ER				RACHELEFSKY, GS; OPELZ, G; MICKEY, MR; LESSIN, P; KIUCHI, M; SILVERSTEIN, MJ; STIEHM, ER			INTACT HUMORAL AND CELL-MEDIATED-IMMUNITY IN CHRONIC MARIHUANA SMOKING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT SURG,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOMATH,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BERKOVICH S, 1966, NEW ENGL J MED, V274, P67, DOI 10.1056/NEJM196601132740203; BIANCO C, 1970, J EXP MED, V132, P702, DOI 10.1084/jem.132.4.702; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; CATALONA W J, 1972, New England Journal of Medicine, V286, P399, DOI 10.1056/NEJM197202242860804; CROUT JE, 1975, NEW ENGL J MED, V292, P221, DOI 10.1056/NEJM197501302920501; CUSHMAN P, 1973, AM J MED, V54, P320, DOI 10.1016/0002-9343(73)90026-0; DIXON W.J., 1975, BMDP BIOMEDICAL COMP; GUPTA S, 1974, NEW ENGL J MED, V291, P874, DOI 10.1056/NEJM197410242911704; HEISS LI, 1974, AM J MED, V56, P323, DOI 10.1016/0002-9343(74)90614-7; LEMBERGER L, 1973, J CLIN INVEST, V52, P2411, DOI 10.1172/JCI107431; LISKOW B, 1971, ANN INTERN MED, V75, P571, DOI 10.7326/0003-4819-75-4-571; NAHAS GG, 1974, SCIENCE, V183, P419, DOI 10.1126/science.183.4123.419; NAHAS GG, 1974, DEC INT C PHARM CANN; PERNIS B, 1970, J EXP MED, V132, P1001, DOI 10.1084/jem.132.5.1001; SENGAR DPS, 1971, TRANSPLANTATION, V11, P260, DOI 10.1097/00007890-197103000-00004; SILVERSTEIN MJ, 1974, SCIENCE, V186, P740, DOI 10.1126/science.186.4165.740; STIEHM ER, 1966, PEDIATRICS, V37, P715; WHITE SC, 1975, SCIENCE, V188, P71, DOI 10.1126/science.1078732; WYBRAN J, 1973, LANCET, V1, P126	19	43	45	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					483	490		10.1016/0091-6749(76)90192-5	http://dx.doi.org/10.1016/0091-6749(76)90192-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CH210	135011	Bronze			2022-12-18	WOS:A1976CH21000005
J	SIMONS, FER; SIMONS, KJ; BIERMAN, CW				SIMONS, FER; SIMONS, KJ; BIERMAN, CW			PHARMACOKINETICS OF DIHYDROXYPROPYLTHEOPHYLLINE - BASIS FOR RATIONAL THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH PHARM,DEPT PHARM SCI,SEATTLE,WA; UNIV WASHINGTON,SCH MED,DIV ALLERGY,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								BUTTS WC, 1974, J LAB CLIN MED, V84, P451; HUDSON LD, 1973, CURR THER RES CLIN E, V15, P367; ISAKSSON B, 1962, ACTA MED SCAND, V171, P33; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; LEVINE ER, 1965, ANN ALLERGY, V23, P403; LINDHOLM B, 1966, ACTA ALLERGOL, V21, P299, DOI 10.1111/j.1398-9995.1966.tb03127.x; MANCY PV, 1946, J AM PHARM ASS, V35, P266; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MCCOLL JD, 1956, J PHARMACOL EXP THER, V116, P343; MITENKO PA, 1973, CLIN PHARMACOL THER, V14, P509; NICHOLSON DP, 1973, AM REV RESPIR DIS, V108, P241; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; SCHLUGER J, 1957, AM J MED SCI, V233, P296; SWINTOSKY JV, 1956, J AM PHARM ASSOC, V45, P395, DOI 10.1002/jps.3030450614; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; WAGNER JG, 1967, CLIN PHARMACOL THER, V8, P201	16	43	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					347	355		10.1016/0091-6749(75)90128-1	http://dx.doi.org/10.1016/0091-6749(75)90128-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	1181352				2022-12-18	WOS:A1975AW33000004
J	KINSMAN, RA; OBANION, K; RESNIKOFF, P; LUPARELLO, TJ; SPECTOR, SL				KINSMAN, RA; OBANION, K; RESNIKOFF, P; LUPARELLO, TJ; SPECTOR, SL			SUBJECTIVE SYMPTOMS OF ACUTE ASTHMA WITHIN A HETEROGENEOUS SAMPLE OF ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR, DEPT ALLERGY CLIN IMMUNOL & CHEST, DENVER, CO 80206 USA; NATL JEWISH HOSP & RES CTR, DEPT BEHAV SCI, PSYCHOPHYSIOL RES LABS, 3800 E COLFAX AVE, DENVER, CO 80206 USA; UNIV COLORADO, MED CTR, DENVER, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ADAMS RD, 1970, HARRISONS PRINCIPLES; FARR RS, 1968, CURRENT THERAPY; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; MATHE AA, 1971, PSYCHOSOM MED, V33, P323, DOI 10.1097/00006842-197107000-00003; PHILIPP RL, 1972, J PSYCHOSOM RES, V16, P193, DOI 10.1016/0022-3999(72)90044-X; Siegel S., 1956, NONPARAMETRIC STAT B; SPECTOR SL, 1973, J ALLERGY CLIN IMMUN, V51, P87, DOI 10.1016/S0091-6749(73)80021-1; SPECTOR SL, 1973, SURGICAL PEDIATRICS; STAMPER DA, 1971, PERCEPT MOTOR SKILL, V33, P735, DOI 10.2466/pms.1971.33.3.735; TRYON RC, 1970, CLUSTER ANALYSIS	11	43	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					284	296		10.1016/0091-6749(73)90047-X	http://dx.doi.org/10.1016/0091-6749(73)90047-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4147758				2022-12-18	WOS:A1973R208700005
J	HADDAD, ZH; KOROTZER, JL				HADDAD, ZH; KOROTZER, JL			IMMEDIATE HYPERSENSITIVITY REACTIONS TO FOOD ANTIGENS - DETECTION OF HUMAN IGE ANTIBODIES IN-VITRO AND EXPLORATION OF IMMUNOLOGICAL MECHANISMS USING RAT MAST-CELL SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BARRICK RH, 1965, J ALLERGY, V36, P374, DOI 10.1016/0021-8707(65)90044-4; BOYDEN SV, 1951, J EXP MED, V93, P107, DOI 10.1084/jem.93.2.107; BULLOCK JD, 1968, ANN ALLERGY, V26, P177; COCA AF, 1943, FAMILIAL NON REAGINI, P96; DOCKHORN RJ, 1969, ANN ALLERGY, V27, P409; DREYFUSS F, 1965, ACTA ALLERGOL KBH, V21, P17; HADDAD Z H, 1971, Journal of Allergy, V47, P88; HADDAD ZH, 1971, INT ARCH ALLERGY APP, V40, P72; ISHIZAKA K, 1970, ANN ALLERGY, V28, P189; KATZ HI, 1964, JAMA-J AM MED ASSOC, V188, P351; KOROTZER J, 1970, J ALLERGY, V45, P126; KOROTZER JL, 1971, IMMUNOLOGY, V20, P545; KRAVIS LP, 1965, J PEDIATR-US, V66, P218; MATHEWS TS, 1970, LANCET, V2, P893; PERELMUTTER L, 1971, J ALLERGY, V47, P88; PERELMUTTER L, 1970, INT ARCH ALLER A IMM, V39, P27, DOI 10.1159/000230331; PETERSON RD, 1963, PEDIATRICS, V31, P209; POPA V, 1968, J ALLERGY, V42, P130, DOI 10.1016/0021-8707(68)90086-5; REYNOLDS RD, 1967, ANN ALLERGY, V25, P318; ROWE AH, 1963, BRONCHIAL ASTHMA ITS, P44; SCHWARTZ J, 1965, INT ARCH ALLER A IMM, V26, P333, DOI 10.1159/000229586; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P216; SHELLEY WB, 1962, NATURE, V195, P1181, DOI 10.1038/1951181a0; SHIODA H, 1966, J ALLERGY, V37, P321, DOI 10.1016/0021-8707(66)90131-6; STAVITSKY AB, 1955, IMMUNOLOGY, V74, P306; Vaughan WT, 1936, J LAB CLIN MED, V21, P1278	26	43	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	4					210	&		10.1016/0091-6749(72)90084-X	http://dx.doi.org/10.1016/0091-6749(72)90084-X			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M1477	5011544	Bronze			2022-12-18	WOS:A1972M147700002
J	Carriche, GM; Almeida, L; Stuve, P; Velasquez, L; Dhillon-LaBrooy, A; Roy, U; Lindenberg, M; Strowig, T; Plaza-Sirvent, C; Schmitz, I; Lochner, M; Simon, AK; Sparwasser, T				Carriche, Guilhermina M.; Almeida, Luis; Stuve, Philipp; Velasquez, Lis; Dhillon-LaBrooy, Ayesha; Roy, Urmi; Lindenberg, Marc; Strowig, Till; Plaza-Sirvent, Carlos; Schmitz, Ingo; Lochner, Matthias; Simon, Anna Katharina; Sparwasser, Tim			Regulating T-cell differentiation through the polyamine spermidine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Polyamines; spermidine; gut immunity; Treg cells; TH17 cells	PROINFLAMMATORY IL-17(+); EX-VIVO; IN-VIVO; METABOLITES; AUTOPHAGY; ARGININE; TH17; MICROBIOTA; INDUCTION; EFFECTOR	Background: The cross-talk between the host and its microbiota plays a key role in the promotion of health. The production of metabolites such as polyamines by intestinal-resident bacteria is part of this symbiosis shaping host immunity. The polyamines putrescine, spermine, and spermidine are abundant within the gastrointestinal tract and might substantially contribute to gut immunity. Objective: We aimed to characterize the polyamine spermidine as a modulator of T-cell differentiation and function. Methods: Naive T cells were isolated from wild-type mice or cord blood from healthy donors and submitted to polarizing cytokines, with and without spermidine treatment, to evaluate CD41 T-cell differentiation in vitro. Moreover, mice were subjected to oral supplementation of spermidine, or its precursor L-arginine, to assess the frequency and total numbers of regulatory T (Treg) cells in vivo. Results: Spermidine modulates CD41 T-cell differentiation in vitro, preferentially committing naive T cells to a regulatory phenotype. After spermidine treatment, activated T cells lacking the autophagy gene Atg5 fail to upregulate Foxp3 to the same extent as wild-type cells. These results indicate that spermidine's polarizing effect requires an intact autophagic machinery. Furthermore, dietary supplementation with spermidine promotes homeostatic differentiation of Treg cells within the gut and reduces pathology in a model of T-cell transfer-induced colitis. Conclusion: Altogether, our results highlight the beneficial effects of spermidine, or L-arginine, on gut immunity by promoting Treg cell development.	[Carriche, Guilhermina M.; Almeida, Luis; Stuve, Philipp; Velasquez, Lis; Dhillon-LaBrooy, Ayesha; Lindenberg, Marc; Lochner, Matthias; Sparwasser, Tim] TWINCORE, Inst Infect Immunol, Ctr Expt & Clin Infect Res, Hannover, Germany; [Carriche, Guilhermina M.; Almeida, Luis; Stuve, Philipp; Velasquez, Lis; Dhillon-LaBrooy, Ayesha; Sparwasser, Tim] Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, Univ Med Ctr, Mainz, Germany; [Roy, Urmi; Strowig, Till] Helmholtz Ctr Infect Res, Dept Microbial Immune Regulat, Braunschweig, Germany; [Strowig, Till] Hannover Med Sch, Hannover, Germany; [Plaza-Sirvent, Carlos; Schmitz, Ingo] Otto von Guericke Univ, Inst Mol & Clin Immunol, Fac Med, Magdeburg, Germany; [Schmitz, Ingo] Helmholtz Ctr Infect Res, Syst Oriented Immunol & Inflammat Res Grp, Dept Expt Immunol, Braunschweig, Germany; [Schmitz, Ingo] Ruhr Univ Bochum, Dept Mol Immunol, Bochum, Germany; [Lochner, Matthias] Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany; [Simon, Anna Katharina] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England	Helmholtz Association; Helmholtz-Center for Infection Research; Johannes Gutenberg University of Mainz; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; Otto von Guericke University; Helmholtz Association; Helmholtz-Center for Infection Research; Ruhr University Bochum; Hannover Medical School; University of Oxford	Sparwasser, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, Univ Med Ctr, Mainz, Germany.	sparwasser@uni-mainz.de	Lindenberg, Marc/AAB-1555-2022; Sparwasser, Tim D/AAA-4306-2022; Lochner, Matthias/L-6963-2015; Schmitz, Ingo/G-2093-2013	Plaza-Sirvent, Carlos/0000-0003-2767-0402; Lochner, Matthias/0000-0002-7979-5613; Schmitz, Ingo/0000-0002-5360-0419; Almeida, Luis/0000-0002-2605-4280	Ministry for Science and Culture of Lower Saxony (research consortium COALITION) grant; European Union consortium PNEUMOSPREAD [JPIAMR 2016-044]	Ministry for Science and Culture of Lower Saxony (research consortium COALITION) grant; European Union consortium PNEUMOSPREAD	This work was supported by funding of the Ministry for Science and Culture of Lower Saxony (research consortium COALITION) grant and funds from the European Union consortium PNEUMOSPREAD (JPIAMR 2016-044).	Alexander ET, 2017, ONCOTARGET, V8, P84140, DOI 10.18632/oncotarget.20493; Ali MA, 2011, FOOD NUTR RES, V55, DOI [10.3402/fnr.v55i0.5572, 10.3402/fnr.v55i0.5455]; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Berod L, 2012, MICROB BIOTECHNOL, V5, P260, DOI 10.1111/j.1751-7915.2011.00299.x; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Castro CN, 2015, MOL IMMUNOL, V68, P575, DOI 10.1016/j.molimm.2015.07.025; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Coburn LA, 2016, INFLAMM BOWEL DIS, V22, P1847, DOI 10.1097/MIB.0000000000000790; Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Fritz JH, 2013, INFECT IMMUN, V81, P3500, DOI 10.1128/IAI.00789-13; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444; Kibe R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04548; Kiechl S, 2018, AM J CLIN NUTR, V108, P371, DOI 10.1093/ajcn/nqy102; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Klinger M, 2009, J IMMUNOL, V182, P4581, DOI 10.4049/jimmunol.0900010; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kovacs JR, 2012, CELL DEATH DIFFER, V19, P144, DOI 10.1038/cdd.2011.78; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Lochner M, 2008, J EXP MED, V205, P1381, DOI 10.1084/jem.20080034; Lochner M, 2015, PROG MOL BIOL TRANSL, V136, P99, DOI 10.1016/bs.pmbts.2015.07.013; Madeo F, 2018, SCIENCE, V359, P410, DOI 10.1126/science.aan2788; Matsumoto M, 2007, MICROBIOL IMMUNOL, V51, P25, DOI 10.1111/j.1348-0421.2007.tb03887.x; Matsumoto M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00233; Matsumoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023652; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Merkley SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02914; Milovic V, 2001, EUR J GASTROEN HEPAT, V13, P1021, DOI 10.1097/00042737-200109000-00004; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167; Munoz-Esparza NC, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00108; Nowotarski SL, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.3; O'Mahony C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000112; Ostanin DV, 2009, AM J PHYSIOL-GASTR L, V296, pG135, DOI 10.1152/ajpgi.90462.2008; Pugin Benoit, 2017, Microbial Ecology in Health and Disease, V28, P1353881, DOI 10.1080/16512235.2017.1353881; Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706; Ramos-Molina B, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00024; Rhoads JM, 2009, AMINO ACIDS, V37, P111, DOI 10.1007/s00726-008-0225-4; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Ryzhakov G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06085-5; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; Uda K, 2003, J GASTROEN HEPATOL, V18, P554, DOI 10.1046/j.1440-1746.2003.03020.x; Ueno A, 2018, J AUTOIMMUN, V87, P38, DOI 10.1016/j.jaut.2017.12.004; Wan YSY, 2010, CELL MOL IMMUNOL, V7, P204, DOI 10.1038/cmi.2010.20; Wang M, 2005, FEMS MICROBIOL ECOL, V54, P219, DOI 10.1016/j.femsec.2005.03.012; Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365; Yan J, 2019, BRIT J PHARMACOL, V176, P3126, DOI 10.1111/bph.14706; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Yang Q, 2016, CELL DEATH DIFFER, V23, P1850, DOI 10.1038/cdd.2016.71; Ye C, 2016, J IMMUNOL, V196, P915, DOI 10.4049/jimmunol.1500729; Zeng H, 2017, CURR OPIN IMMUNOL, V46, P103, DOI 10.1016/j.coi.2017.04.005; Zhang HL, 2019, MOL CELL, V76, P110, DOI 10.1016/j.molcel.2019.08.005; Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183; Zhou L, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1605; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	72	42	44	13	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					335	+		10.1016/j.jaci.2020.04.037	http://dx.doi.org/10.1016/j.jaci.2020.04.037		JAN 2021	25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32407834	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000607781700007
J	Liu, J; Zheng, XB; Huang, YY; Shan, H; Huang, J				Liu, Jing; Zheng, Xiaobin; Huang, Yiying; Shan, Hong; Huang, Jin			Successful use of methylprednisolone for treating severe COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CORTICOSTEROIDS; THERAPY		[Liu, Jing; Zheng, Xiaobin; Huang, Yiying; Huang, Jin] Sun Yat Sen Univ, Dept Pulm & Crit Care Med, Zhuhai, Peoples R China; [Liu, Jing; Shan, Hong; Huang, Jin] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Provincial Key Lab Biomed Imaging, Zhuhai, Peoples R China; [Liu, Jing; Shan, Hong; Huang, Jin] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Peoples R China; [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Huang, J (corresponding author), Sun Yat Sen Univ, Dept Pulm & Crit Care Med, Zhuhai, Peoples R China.; Shan, H; Huang, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Provincial Key Lab Biomed Imaging, Zhuhai, Peoples R China.; Shan, H; Huang, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai, Peoples R China.	shanhong@mail.sysu.edu.cn; hjin@mail.sysu.edu.cn			Natural Science Foundation of Guangdong Province of China [2020A1515011147]; Scientific Research Foundation of Guangdong Province [A2020176]	Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Scientific Research Foundation of Guangdong Province	This work was supported by grants from Natural Science Foundation of Guangdong Province of China (Grant No. 2020A1515011147 to J.L.) and Scientific Research Foundation of Guangdong Province (Grant No. A2020176 to X.Z.).	Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441; Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/eri.11.56, 10.1586/ERI.11.56]; Garg S, 2020, MMWR-MORBID MORTAL W, P69; Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5; Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715	7	42	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					325	+		10.1016/j.jaci.2020.05.021	http://dx.doi.org/10.1016/j.jaci.2020.05.021			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32479759	Green Published, Bronze			2022-12-18	WOS:000558835000017
J	Manson, ML; Safholm, J; James, A; Johnsson, AK; Bergman, P; Al-Ameri, M; Orre, AC; Karrman-Mardh, C; Dahlen, SE; Adner, M				Manson, Martijn L.; Safholm, Jesper; James, Anna; Johnsson, Anna-Karin; Bergman, Per; Al-Ameri, Mamdoh; Orre, Ann-Charlotte; Karrman-Mardh, Carina; Dahlen, Sven-Erik; Adner, Mikael			IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway smooth muscle; airway hyperresponsiveness; bronchoconstriction explanted human tissue model; calcium signaling; bronchoconstrictor agents; IL-4R alpha; dupilumab; glucocorticoid; STAT6	SMOOTH-MUSCLE; CONTRACTILE RESPONSES; UP-REGULATION; DOUBLE-BLIND; INTERLEUKIN-13; RECEPTOR; ASTHMA; PROLIFERATION; INFLAMMATION; BRONCHUS	Background: Specific inflammatory pathways are indicated to contribute to severe asthma, but their individual involvement in the development of airway hyperresponsiveness remains unexplored. Objective: This experimental study in human small bronchi aimed to provide insight into which of the type 2 and type 17 cytokines cause hyperresponsiveness of airway smooth muscle. Methods: Explanted small bronchi isolated from human lung tissue and human airway smooth muscle cells were treated for 2 and 1 day(s), respectively, with 100 ng/mL of IL-4, IL-5, IL-13, or IL-17A, and contractile responses, Ca2+ mobilization, and receptor expression were Results: Treatment with IL-13 increased the potency of histamine, carbachol, and leukotriene D-4 as contractile agonists. IL-4, but not IL-5 or IL-17A, also increased the potency of histamine. In human airway smooth muscle cells, IL-13 and IL-4, but not IL-5 and IL-17A, enhanced the histamine-induced Ca2+ mobilization that was accompanied with increased mRNA expression of histamine H-1 and cysteinyl leukotriene CysLT(1) receptors. RNA sequencing of isolated bronchi confirmed the IL-13-mediated upregulation of H-1 and CysLT(1) receptors, without showing an alteration of muscarinic M3 receptors. Dexamethasone had no effects on IL-13-induced hyperresponsiveness in human bronchi, the increased Ca2+ mobilization, or the enhanced receptor expression. In contrast, antagonism of the common receptor for IL-13 and IL-4 by the biologic dupilumab prevented the effects of both IL-13 and IL-4 in human bronchi and human airway smooth muscle cells. Conclusions: The glucocorticoid-insensitive hyperrresponsiveness in isolated human airways induced by IL13 and IL-4 provides further evidence that the IL-4Ra pathway should be targeted as a new strategy for the treatment of airway hyperresponsiveness in asthma.	[Manson, Martijn L.; Safholm, Jesper; James, Anna; Johnsson, Anna-Karin; Dahlen, Sven-Erik; Adner, Mikael] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Manson, Martijn L.; Safholm, Jesper; James, Anna; Johnsson, Anna-Karin; Dahlen, Sven-Erik; Adner, Mikael] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Manson, Martijn L.; Karrman-Mardh, Carina] AstraZeneca, IMED Biotech Unit, Biosci Resp Inflammat & Autoimmun RIA, Gothenburg, Sweden; [Bergman, Per; Al-Ameri, Mamdoh; Orre, Ann-Charlotte] Karolinska Inst, Dept Mol Med & Surg MMK, Stockholm, Sweden; [Bergman, Per; Al-Ameri, Mamdoh] Karolinska Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Stockholm, Sweden; [Manson, Martijn L.] Leiden Univ, Leiden Acad Ctr Drug Res, Leiden, Netherlands	Karolinska Institutet; Karolinska Institutet; AstraZeneca; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Leiden University; Leiden University - Excl LUMC	Adner, M (corresponding author), Karolinska Inst, Inst Environm Med, Biomed 5B,Solnavagen 9, SE-17165 Solna, Sweden.	mikael.adner@ki.se	Manson, Martijn L/AAE-8606-2019; James, Anna/AAY-9937-2021; Manson, Martijn/GQI-3438-2022	Manson, Martijn L/0000-0002-5508-8615; 	Swedish Heart-Lung foundation; Swedish Research Council - Medicine and Health; Swedish Foundation for Strategic Research (SSF); Stockholm County Council Research Funds (ALF); Karolinska Institutet; Swedish Society of Medicine; Bernard Osher Initiative for Severe Asthma Research; KI-AZ joint research project on translational medicine; Centre for Allergy Research at Karolinska Institutet	Swedish Heart-Lung foundation(Swedish Heart-Lung Foundation); Swedish Research Council - Medicine and Health(Swedish Research Council); Swedish Foundation for Strategic Research (SSF)(Swedish Foundation for Strategic Research); Stockholm County Council Research Funds (ALF); Karolinska Institutet(Karolinska Institutet); Swedish Society of Medicine; Bernard Osher Initiative for Severe Asthma Research; KI-AZ joint research project on translational medicine; Centre for Allergy Research at Karolinska Institutet(Karolinska Institutet)	The Swedish Heart-Lung foundation, the Swedish Research Council - Medicine and Health, the Swedish Foundation for Strategic Research (SSF), the Stockholm County Council Research Funds (ALF), Karolinska Institutet, the Swedish Society of Medicine, the Bernard Osher Initiative for Severe Asthma Research, the KI-AZ joint research project on translational medicine, and the Centre for Allergy Research at Karolinska Institutet funded this study.	Adner M, 2002, BRIT J PHARMACOL, V137, P971, DOI 10.1038/sj.bjp.0704928; ADVENIER C, 1986, BRIT J PHARMACOL, V88, P33, DOI 10.1111/j.1476-5381.1986.tb09468.x; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Bel EH, 2017, CHEST, V152, P1276, DOI 10.1016/j.chest.2017.05.019; BLACK JL, 1989, J ALLERGY CLIN IMMUN, V84, P440, DOI 10.1016/0091-6749(89)90356-4; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Bleecker ER, 2018, EUR RESP J; Bryborn M, 2004, CLIN EXP ALLERGY, V34, P1291, DOI 10.1111/j.1365-2222.2004.02031.x; Burgel PR, 2011, EUR RESPIR REV, V20, P23, DOI 10.1183/09059180.00010410; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Chiba Y, 2009, AM J RESP CELL MOL, V40, P159, DOI 10.1165/rcmb.2008-0162OC; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Cooper PR, 2009, AM J PHYSIOL-LUNG C, V297, pL530, DOI 10.1152/ajplung.00133.2009; Danov O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207767; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; DEJONGSTE J, 1986, EUR J PHARMACOL, V125, P29, DOI 10.1016/0014-2999(86)90080-4; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Eisenmesser EZ, 2001, J MOL BIOL, V310, P231, DOI 10.1006/jmbi.2001.4765; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Farghaly HSM, 2008, MOL PHARMACOL, V73, P1530, DOI 10.1124/mol.108.045419; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520, DOI 10.1152/ajplung.00343.2001; Hanania NA, 2016, LANCET RESP MED, V4, P781, DOI 10.1016/S2213-2600(16)30265-X; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Khaddaj-Mallat R, 2015, PROSTAG OTH LIPID M, V121, P145, DOI 10.1016/j.prostaglandins.2015.04.005; KOHROGI H, 1985, AM REV RESPIR DIS, V132, P299; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Larsson OJ, 2016, AM J PHYSIOL-LUNG C, V310, pL1121, DOI 10.1152/ajplung.00288.2015; Moynihan B, 2008, AM J PHYSIOL-LUNG C, V295, pL171, DOI 10.1152/ajplung.00457.2007; Nagashima S, 2007, BIOORGAN MED CHEM, V15, P1044, DOI 10.1016/j.bmc.2006.10.015; Oh CK, 2010, EUR RESPIR REV, V19, P46, DOI 10.1183/09059180.00007609; Panettieri RA, 2018, LANCET RESP MED, V6, P511, DOI 10.1016/S2213-2600(18)30184-X; Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093; Risse PA, 2011, AM J PHYSIOL-LUNG C, V300, pL958, DOI 10.1152/ajplung.00247.2010; Rizzo CA, 2002, J ALLERGY CLIN IMMUN, V109, P404, DOI 10.1067/mai.2002.122459; Safholm J, 2019, J ALLERGY CLIN IMMUN, V144, P984, DOI 10.1016/j.jaci.2019.04.031; Safholm J, 2015, J ALLERGY CLIN IMMUN, V136, P1232, DOI 10.1016/j.jaci.2015.04.002; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Telenga ED, 2013, EUR RESPIR J, V41, P752, DOI 10.1183/09031936.00170912; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; van der Wiel E, 2013, J ALLERGY CLIN IMMUN, V131, P646, DOI 10.1016/j.jaci.2012.12.1567; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Willis CR, 2015, AM J RESP CELL MOL, V53, P810, DOI 10.1165/rcmb.2015-0038OC	46	42	44	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					808	+		10.1016/j.jaci.2019.10.037	http://dx.doi.org/10.1016/j.jaci.2019.10.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31805312	hybrid, Green Published			2022-12-18	WOS:000518756700019
J	Menzies-Gow, A; Bafadhel, M; Busse, WW; Casale, TB; Kocks, JWH; Pavord, ID; Szefler, SJ; Woodruff, PG; de Giorgio-Miller, A; Trudo, F; Fageras, M; Ambrose, CS				Menzies-Gow, Andrew; Bafadhel, Mona; Busse, William W.; Casale, Thomas B.; Kocks, Janwillem W. H.; Pavord, Ian D.; Szefler, Stanley J.; Woodruff, Prescott G.; de Giorgio-Miller, Alexander; Trudo, Frank; Fageras, Malin; Ambrose, Christopher S.			An expert consensus framework for asthma remission as a treatment goal	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; remission; treatment; consensus; lung; biomarkers; inflammation; surveys and questionnaires; exacerbation; hyperresponsiveness; airway remodeling	ADULT-ONSET ASTHMA; RHEUMATOID-ARTHRITIS; AMERICAN-COLLEGE; CROHNS-DISEASE; BIOMARKERS; PREDICTORS; RECOMMENDATIONS; PROGNOSIS; BURDEN	With novel therapies in development, there is an opportunity to consider asthma remission as a treatment goal. In this Rostrum, we present a generalized framework for clinical and complete remission in asthma, on and off treatment, developed on the basis of medical literature and expert consensus. A modified Delphi survey approach was used to ascertain expert consensus on core components of asthma remission as a treatment target. Phase 1 identified other chronic inflammatory diseases with remission definitions. Phase 2 evaluated components of those definitions as well as published definitions of spontaneous asthma remission. Phase 3 evaluated a remission framework created using consensus findings. Clinical remission comprised 12 or more months with (1) absence of significant symptoms by validated instrument, (2) lung function optimization/ stabilization, (3) patient/provider agreement regarding remission, and (4) no use of systemic corticosteroids. Complete remission was defined as clinical remission plus objective resolution of asthma-related inflammation and, if appropriate, negative bronchial hyperresponsiveness. Remission off treatment required no asthma treatment for 12 or more months. The proposed framework is a first step toward developing asthma remission as a treatment target and should be refined through future research, patient input, and clinical study.	[Menzies-Gow, Andrew] Royal Brompton Hosp, Resp Med, London, England; [Bafadhel, Mona; Pavord, Ian D.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Resp Med Unit, Oxford, England; [Bafadhel, Mona] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford Biomed Res Ctr, Oxford, England; [Busse, William W.] Univ Wisconsin, Dept Med Allergy Pulm & Crit Care Med, Madison, WI USA; [Casale, Thomas B.] Univ S Florida, Morsani Coll Med, Div Allergy & Immunol, Dept Internal Med, Tampa, FL 33620 USA; [Kocks, Janwillem W. H.] Gen Practitioners Res Inst, Groningen, Netherlands; [Kocks, Janwillem W. H.] Observat & Pragmat Res Inst, Singapore, Singapore; [Kocks, Janwillem W. H.] Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Groningen, Netherlands; [Szefler, Stanley J.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Woodruff, Prescott G.] UCSF, Div Pulm & Crit Care Med, Dept Med, San Francisco, CA USA; [Woodruff, Prescott G.] CVRI, San Francisco, CA USA; [de Giorgio-Miller, Alexander] AstraZeneca, Cambridge, England; [Trudo, Frank] AstraZeneca, Wilmington, DE USA; [Fageras, Malin] AstraZeneca, Gothenburg, Sweden; [Ambrose, Christopher S.] AstraZeneca, Gaithersburg, MD USA	Royal Brompton Hospital; University of Oxford; University of Oxford; University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of South Florida; University of Groningen; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California San Francisco; AstraZeneca; AstraZeneca; AstraZeneca	Menzies-Gow, A (corresponding author), Royal Brompton Hosp, Dept Resp Med, Sydney St, London SW3 6NP, England.	a.menzies-gow@rbht.nhs.uk	Bafadhel, Mona/ABB-1170-2021		AstraZeneca	AstraZeneca(AstraZeneca)	This research was funded by AstraZeneca.	Anderson J, 2012, ARTHRIT CARE RES, V64, P640, DOI 10.1002/acr.21649; Baker KF, 2018, ANN RHEUM DIS, V77, P73, DOI 10.1136/annrheumdis-2018-eular.2775; Boulet LP, 2012, CAN RESPIR J, V19, P19, DOI 10.1155/2012/347989; Cazzoletti L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086956; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Dejaco C, 2011, ANN RHEUM DIS, V70, P447, DOI 10.1136/ard.2010.133850; European Medicines Agency, GUID DEV NEW MED PRO; European Medicines Agency, GUID CLIN INV MED PR; Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Hamanaka S, 2018, J GASTROEN HEPATOL, V33, P1975, DOI 10.1111/jgh.14297; Holm M, 2007, EUR RESPIR J, V30, P62, DOI 10.1183/09031936.00121705; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kawashima K, 2017, INFLAMM BOWEL DIS, V23, P2027, DOI 10.1097/MIB.0000000000001202; Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27; Liu CC, 2013, THER ADV MUSCULOSKEL, V5, P210, DOI 10.1177/1759720X13485503; McGregor MC, 2019, AM J RESP CRIT CARE, V199, P433, DOI 10.1164/rccm.201810-1944CI; Nannini LJ, 2020, J ASTHMA, V57, P687, DOI 10.1080/02770903.2019.1591443; Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC; Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011; Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783; Smolen JS, 2016, ANN RHEUM DIS, V75, P3, DOI 10.1136/annrheumdis-2015-207524; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Sozener ZC, 2015, ANN ALLERG ASTHMA IM, V114, P370, DOI 10.1016/j.anai.2015.02.010; Travis SPL, 2011, ALIMENT PHARM THER, V34, P113, DOI 10.1111/j.1365-2036.2011.04701.x; Tuomisto LE, 2016, RESP MED, V117, P223, DOI 10.1016/j.rmed.2016.06.017; Upham JW, 2011, PHARMACOL THERAPEUT, V130, P38, DOI 10.1016/j.pharmthera.2011.01.002; US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), ULC COL CLIN TRIAL E; van den Toorn LM, 2003, CURR OPIN PULM MED, V9, P15, DOI 10.1097/00063198-200301000-00003; van Tuyl LHD, 2010, ARTHRIT CARE RES, V62, P108, DOI 10.1002/acr.20021; van Vollenhoven R, 2017, ANN RHEUM DIS, V76, P554, DOI 10.1136/annrheumdis-2016-209519; Volbeda F, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-106; Vuitton L, 2017, ALIMENT PHARM THER, V45, P801, DOI 10.1111/apt.13948; Westerhof GA, 2018, J ALLERGY CLIN IMMUN, V141, P104, DOI 10.1016/j.jaci.2017.03.034; Wu TJ, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0135-9	35	42	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					757	765		10.1016/j.jaci.2019.12.006	http://dx.doi.org/10.1016/j.jaci.2019.12.006			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31866436	hybrid, Green Submitted			2022-12-18	WOS:000518756700005
J	Czarnowicki, T; He, H; Canter, T; Han, J; Lefferdink, R; Erickson, T; Rangel, S; Kameyama, N; Kim, HJ; Pavel, AB; Estrada, Y; Krueger, JG; Paller, AS; Guttman-Yassky, E				Czarnowicki, Tali; He, Helen; Canter, Talia; Han, Joseph; Lefferdink, Rachel; Erickson, Taylor; Rangel, Stephanie; Kameyama, Naoya; Kim, Hyun Je; Pavel, Ana B.; Estrada, Yeriel; Krueger, James G.; Paller, Amy S.; Guttman-Yassky, Emma			Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; endotypes; T cell; cutaneous lymphocyte antigen; IL-13; IL-22; IFN-gamma; inducible costimulator molecule; HLA-DR	AGE-RELATED-CHANGES; IFN-GAMMA; CYTOKINE PRODUCTION; TYPE-2 CYTOKINES; NATURAL-HISTORY; EFFECTOR MEMORY; SKIN; CHILDREN; BLOOD; CD4(+)	Background: The circulating immune phenotype was defined in adults and young children with early atopic dermatitis (AD), but chronologic changes in the blood of infants and children with AD through adolescence have not been explored. Objective: We sought to compare immune activation and cytokine polarization in the blood of 0- to 5-year-old (n = 39), 6- to 11-yearold (n = 26), 12- to 17-year-old (n = 21) and 18-year-old or older (n = 43) patients with AD versus age-matched control subjects. Methods: Flow cytometry was used to measure IFN-gamma, IL-9, IL-13, IL-17, and IL-22 cytokine levels in CD4(+)/CD8(+) T cells, with inducible costimulator molecule and HLA-DR defining midterm and long-term T-cell activation, respectively, within skin-homing/cutaneous lymphocyte antigen (CLA)(+) versus systemic/CLA(-)T cells. Unsupervised clustering differentiated patients based on their blood biomarker frequencies. Results: Although CLA(+)T(H)1 frequencies were significantly lower in infants with AD versus all older patients (P < .01), frequencies of CLA(+)T(H)2 T cells were similarly expanded across all AD age groups compared with control subjects (P < .05). After infancy, CLA(-)T(H)2 frequencies were increased in patients with AD in all age groups, suggesting systemic immune activation with disease chronicity. IL-22 frequencies serially increased from normal levels in infants to highly significant levels in adolescents and adults compared with levels in respective control subjects (P < .01). Unsupervised clustering aligned the AD profiles along an age-related spectrum from infancy to adulthood (eg, inducible costimulator molecule and IL-22). Conclusions: The adult AD phenotype is achieved only in adulthood. Unique cytokine signatures characterizing individual pediatric endotypes might require age-specific therapies. Future longitudinal studies, comparing the profile of patients with cleared versus persistent pediatric AD, might define age-specific changes that predict AD clearance.	[Czarnowicki, Tali; He, Helen; Han, Joseph; Kameyama, Naoya; Kim, Hyun Je; Pavel, Ana B.; Estrada, Yeriel; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Czarnowicki, Tali; He, Helen; Han, Joseph; Kameyama, Naoya; Kim, Hyun Je; Pavel, Ana B.; Estrada, Yeriel; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Immunol Inst, New York, NY 10029 USA; [Canter, Talia; Lefferdink, Rachel; Erickson, Taylor; Rangel, Stephanie; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA; [Canter, Talia; Lefferdink, Rachel; Erickson, Taylor; Rangel, Stephanie; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Czarnowicki, Tali; Krueger, James G.] Rockefeller Univ, Lab Investigative Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org		, Ana Brandusa/0000-0002-8155-8553; Canter, Talia/0000-0002-9999-1013	LEO Foundation; Northwestern Skin Disease Research Center [NIAMS P30 AR057216]; Northwestern University Clinical and Translational Sciences (NUCATS) Institute [UL1TR001422]	LEO Foundation(LEO Pharma); Northwestern Skin Disease Research Center; Northwestern University Clinical and Translational Sciences (NUCATS) Institute	This study was funded by a grant from the LEO Foundation. The study was also supported by the Northwestern Skin Disease Research Center (NIAMS P30 AR057216) and the Northwestern University Clinical and Translational Sciences (NUCATS) Institute (UL1TR001422).	Abuabara K, 2013, J ALLERGY CLIN IMMUN, V132, P1139, DOI 10.1016/j.jaci.2013.08.028; Adkins B, 2000, Int Rev Immunol, V19, P157, DOI 10.3109/08830180009088503; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Black A, 2012, EUR J IMMUNOL, V42, P311, DOI 10.1002/eji.201141847; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Brunner PM, 2019, ANN ALLERG ASTHMA IM, V122, P318, DOI 10.1016/j.anai.2018.11.025; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Burr ML, 2013, BRIT J DERMATOL, V168, P1339, DOI 10.1111/bjd.12216; Carel K, 2008, ANN ALLERG ASTHMA IM, V101, P500, DOI 10.1016/S1081-1206(10)60289-X; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; Chipeta J, 1998, CELL IMMUNOL, V183, P149, DOI 10.1006/cimm.1998.1244; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Ciprandi G, 2013, PEDIATR DERMATOL, V30, P222, DOI 10.1111/j.1525-1470.2012.01766.x; Clark RA, 2017, SEMIN IMMUNOPATHOL, V39, P47, DOI 10.1007/s00281-016-0607-8; Coyle AJ, 2004, SPRINGER SEMIN IMMUN, V25, P349, DOI 10.1007/s00281-003-0154-y; Czarnowicki T, 2018, ALLERGY, V73, P713, DOI 10.1111/all.13346; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P2095, DOI 10.1016/j.jaci.2018.11.031; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Davidson WF, 2019, J ALLERGY CLIN IMMUN, V143, P894, DOI 10.1016/j.jaci.2019.01.003; Debock I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00393; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Ferenczi K, 2000, J AUTOIMMUN, V14, P63, DOI 10.1006/jaut.1999.0343; Ferran M, 2013, EXP DERMATOL, V22, P439, DOI 10.1111/exd.12154; Fujisawa Takao, 2008, Allergol Int, V57, P141, DOI 10.2332/allergolint.O-07-498; Fujita H, 2013, J DERMATOL SCI, V72, P3, DOI 10.1016/j.jdermsci.2013.04.028; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Glines KR, 2019, EXPERT OPIN PHARMACO, V20, P621, DOI 10.1080/14656566.2018.1561868; Gorski K, 2010, J IMMUNOL, V184; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hall BM, 2015, CLIN J AM SOC NEPHRO, V10, P2050, DOI 10.2215/CJN.06620714; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Hulshof L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00630; HULSTAERT F, 1994, CLIN IMMUNOL IMMUNOP, V70, P152, DOI 10.1006/clin.1994.1023; JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Katsunuma T, 2004, INT ARCH ALLERGY IMM, V134, P240, DOI 10.1159/000078772; Kawamoto N, 2006, PEDIAT ALLERG IMM-UK, V17, P125, DOI 10.1111/j.1399-3038.2005.00363.x; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Kotiranta-Ainamo A, 2004, BIOL NEONATE, V85, P55, DOI 10.1159/000074959; Laudanska H, 2003, Rocz Akad Med Bialymst, V48, P123; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Lou HF, 2017, J IMMUNOL, V198, P2543, DOI 10.4049/jimmunol.1600126; Lynch JP, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.69; Ma L, 2014, CLIN EXP IMMUNOL, V175, P25, DOI 10.1111/cei.12198; Maazi H, 2015, ONCOTARGET, V6, P24584, DOI 10.18632/oncotarget.5245; Margolis JS, 2014, JAMA DERMATOL, V150, P593, DOI 10.1001/jamadermatol.2013.10271; Marodi L, 2002, CLIN EXP IMMUNOL, V128, P1, DOI 10.1046/j.1365-2249.2002.01873.x; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Paulos CM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000448; Pennino D, 2013, J ALLERGY CLIN IMMUN, V131, P562, DOI 10.1016/j.jaci.2012.09.036; Protonotariou E, 2004, MEDIAT INFLAMM, V13, P89, DOI 10.1080/09629350410001688468; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sandmand M, 2002, CLIN EXP IMMUNOL, V127, P107, DOI 10.1046/j.1365-2249.2002.01736.x; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Schlapbach C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007828; Siegfried EC, 2019, PEDIATR DERMATOL, V36, P172, DOI 10.1111/pde.13707; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EPA, 2018, DUPILUMAB EFFICACY S; Simpson TR, 2010, CURR OPIN IMMUNOL, V22, P326, DOI 10.1016/j.coi.2010.01.001; Statescu Laura, 2011, Maedica (Bucur), V6, P277; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029; Thijs JL, 2018, J ALLERGY CLIN IMMUN, V141, P1523, DOI 10.1016/j.jaci.2017.12.991; Uwadiae FI, 2019, ALLERGY, V74, P650, DOI 10.1111/all.13602; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; Vekaria Anjali S, 2017, F1000Res, V6, P1712, DOI 10.12688/f1000research.12422.1; Vieira PL, 2004, EUR J IMMUNOL, V34, P1282, DOI 10.1002/eji.200324417; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; WALTON S, 1986, CONTACT DERMATITIS, V15, P136, DOI 10.1111/j.1600-0536.1986.tb01313.x; Weerkamp F, 2005, J ALLERGY CLIN IMMUN, V115, P834, DOI 10.1016/j.jaci.2004.10.031; Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304; Wikenheiser DJ, 2016, J IMMUNOL, V196, P778, DOI 10.4049/jimmunol.1403206; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Xie JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041502; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	88	42	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					215	228		10.1016/j.jaci.2019.09.031	http://dx.doi.org/10.1016/j.jaci.2019.09.031			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31626841	Green Accepted, Bronze			2022-12-18	WOS:000505590800028
J	Liu, T; Zhou, YT; Wang, LQ; Li, LY; Bao, Q; Tian, S; Chen, MX; Chen, HX; Cui, J; Li, CW				Liu, Tao; Zhou, Yu Tao; Wang, Li Qiu; Li, Li Yue; Bao, Qing; Tian, Shuo; Chen, Mei Xin; Chen, He Xin; Cui, Jun; Li, Chun Wei			NOD-like receptor family, pyrin domain containing 3 (NLRP3) contributes to inflammation, pyroptosis, and mucin production in human airway epithelium on rhinovirus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal epithelium; NLRP3 inflammasome; rhinovirus; inflammation; mucus; pyroptosis	INFLAMMASOMES; MECHANISMS; ASTHMA; CELLS	Background: The airway epithelium maintains mucosal homeostasis and effectively responds to pathogens. The roles of the epithelial NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in human rhinovirus (hRV) infection and its effects mediating epithelial functional changes remain poorly understood. Objective: We investigated the mechanisms and cellular functions mediated by the epithelial NLRP3 inflammasome on hRV infection. Methods: Using models of primary human nasal epithelial progenitor cells and differentiated human nasal epithelial cells (hNECs) infected by hRV, we functionally examined key factors for NLRP3 inflammasome activation, cell death, and mucus production. Furthermore, NLRP3 and IL-1 beta in human epithelium from nasal mucosal inflammation induced by hRV were evaluated. Results: The inflammasome-mediated IL-1 beta secretion and pyroptosis in human nasal epithelial progenitor cells and hNECs on hRV infection were dependent on the DDX33/DDX58-NLRP3-caspase-1-GSDMD axis. In differentiated hNECs hRV could also promote major airway epithelial mucin (MUC5AC) production through this axis. Our results further confirmed that the NLRP3 inflammasome signaling pathway was responsible for suppressing hRV replication in airway epithelium. Finally, hRV infection in chronically inflamed nasal mucosa was associated with epithelial mucus hyperproduction, whereas NLRP3 and IL-1 beta expression levels were significantly increased in hRV-infected epithelium with goblet cell hyperplasia compared with normal epithelium without viral infection. Conclusion: The current study showed that the NLRP3 inflammasome signaling axis could functionally mediate hRV-induced inflammation, pyroptosis, and mucus production in airway epithelium, which might be an essential mechanism associated with hRV-induced airway remodeling.	[Liu, Tao; Wang, Li Qiu; Tian, Shuo; Chen, Mei Xin; Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Oncol South China, 132 Waihuandong Rd, Guangzhou 510006, Guangdong, Peoples R China; [Zhou, Yu Tao; Li, Li Yue; Bao, Qing; Chen, He Xin; Li, Chun Wei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, 58 Zhong Shan 2nd St, Guangzhou 510080, Guangdong, Peoples R China; [Zhou, Yu Tao; Li, Li Yue; Bao, Qing; Chen, He Xin; Li, Chun Wei] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou Key Lab Otorhinolaryngol, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Cui, J (corresponding author), Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Oncol South China, 132 Waihuandong Rd, Guangzhou 510006, Guangdong, Peoples R China.; Li, CW (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, 58 Zhong Shan 2nd St, Guangzhou 510080, Guangdong, Peoples R China.	cuij5@mail.sysn.edu.cn; hi_chunwei@aliyun.com	chen, meixin/AAT-4971-2020		National Key Basic Research Program of China [2015CB859800]; National Natural Science Foundation of China [81770983, 31870862, 31700760]; Guangzhou Science and Technology Programme [201804010385, 201907010038]; Guangdong Natural Science Foundation [2017A030313621]; Fundamental Research Funds for the Central Universities [17ykzd19]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Programme; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Supported by grants from the National Key Basic Research Program of China (2015CB859800); the National Natural Science Foundation of China (81770983, 31870862, and 31700760); the Guangzhou Science and Technology Programme (201804010385, 201907010038); the Guangdong Natural Science Foundation (2017A030313621); and the Fundamental Research Funds for the Central Universities (17ykzd19).	Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Chen IY, 2015, TRENDS MICROBIOL, V23, P55, DOI 10.1016/j.tim.2014.09.007; De Nardo D, 2014, AM J PATHOL, V184, P42, DOI 10.1016/j.ajpath.2013.09.007; GAMA RE, 1989, J MED VIROL, V28, P73, DOI 10.1002/jmv.1890280204; Gohy ST, 2016, CLIN EXP ALLERGY, V46, P529, DOI 10.1111/cea.12712; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Hatchwell L, 2015, THORAX, V70, P854, DOI 10.1136/thoraxjnl-2014-205465; Inoue D, 2006, RESP PHYSIOL NEUROBI, V154, P484, DOI 10.1016/j.resp.2005.11.006; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Jakiela B, 2014, AM J RESP CELL MOL, V51, P229, DOI 10.1165/rcmb.2013-0395OC; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Jia XH, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007428; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; Kim RY, 2015, THORAX, V70, P1199, DOI 10.1136/thoraxjnl-2014-206736; Levy M, 2015, SEMIN IMMUNOPATHOL, V37, P39, DOI 10.1007/s00281-014-0451-7; Liu T, 2016, CELL REP, V16, P1988, DOI 10.1016/j.celrep.2016.07.019; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shil NK, 2018, J VIROL, V92, DOI 10.1128/JVI.01776-17; Tate MD, 2016, SCI REP-UK, V6, DOI 10.1038/srep27912; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Triantafilou K, 2013, AM J RESP CELL MOL, V49, P923, DOI 10.1165/rcmb.2013-0032OC; Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026; Yu XM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04619; Zaheer RS, 2014, MUCOSAL IMMUNOL, V7, P1127, DOI 10.1038/mi.2013.128; Zhao XN, 2012, AM J RHINOL ALLERGY, V26, P345, DOI 10.2500/ajra.2012.26.3794; Zhu L, 2009, AM J RESP CELL MOL, V40, P610, DOI 10.1165/rcmb.2008-0223OC	30	42	43	3	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					777	+		10.1016/j.jaci.2019.05.006	http://dx.doi.org/10.1016/j.jaci.2019.05.006			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31102698				2022-12-18	WOS:000485222300022
J	Lee-Sarwar, KA; Kelly, RS; Lasky-Su, J; Zeiger, RS; O'Connor, GT; Sandel, MT; Bacharier, LB; Beigelman, A; Laranjo, N; Gold, DR; Weiss, ST; Litonjua, AA				Lee-Sarwar, Kathleen A.; Kelly, Rachel S.; Lasky-Su, Jessica; Zeiger, Robert S.; O'Connor, George T.; Sandel, Megan T.; Bacharier, Leonard B.; Beigelman, Avraham; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.			Integrative analysis of the intestinal metabolome of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microbiome; Christensenellaceae; metabolome; vitamin E; nutrition; diet; breast-feeding	VITAMIN-D; PRETERM BIRTH; GLOBAL BURDEN; GUT; CHILDREN; PHOSPHATIDYLCHOLINE; ENDOCANNABINOIDS; SUPPLEMENTATION; INFLAMMATION; ASSOCIATION	Background: The intestinal metabolome reflects the biological consequences of diverse exposures and might provide insight into asthma pathophysiology. Objective: We sought to perform an untargeted integrative analysis of the intestinal metabolome of childhood asthma in this ancillary study of the Vitamin D Antenatal Asthma Reduction Trial. Methods: Metabolomic profiling was performed by using mass spectrometry on fecal samples collected from 361 three-year-old subjects. Adjusted logistic regression analyses identified metabolites and modules of highly correlated metabolites associated with asthma diagnosis by age 3 years. Sparse canonical correlation analysis identified associations relevant to asthma between the intestinal metabolome and other "omics'': the intestinal microbiome as measured by using 16S rRNA sequencing, the plasma metabolome as measured by using mass spectrometry, and diet as measured by using food frequency questionnaires. Results: Several intestinal metabolites were associated with asthma at age 3 years, including inverse associations between asthma and polyunsaturated fatty acids (adjusted logistic regression beta = -6.3; 95% CI, -11.3 to -1.4; P = .01) and other lipids. Asthma-associated intestinal metabolites were significant mediators of the inverse relationship between exclusive breast-feeding for the first 4 months of life and asthma (P for indirect association = .04) and the positive association between a diet rich in meats and asthma (P = .03). Specific intestinal bacterial taxa, including the family Christensenellaceae, and plasma metabolites, including gamma-tocopherol/beta-tocopherol, were positively associated with asthma and asthma-associated intestinal metabolites. Conclusion: Integrative analyses revealed significant interrelationships between the intestinal metabolome and the intestinal microbiome, plasma metabolome, and diet in association with childhood asthma. These findings require replication in future studies.	[Lee-Sarwar, Kathleen A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Lee-Sarwar, Kathleen A.; Kelly, Rachel S.; Lasky-Su, Jessica; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA; [Lee-Sarwar, Kathleen A.; Kelly, Rachel S.; Lasky-Su, Jessica; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.] Harvard Med Sch, Boston, MA 02115 USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, San Diego, CA USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, Dept Allergy, Pasadena, CA USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA; [O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Sandel, Megan T.] Boston Med Ctr, Dept Pediat, Boston, MA USA; [Bacharier, Leonard B.; Beigelman, Avraham] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.; Beigelman, Avraham] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Litonjua, Augusto A.] Univ Rochester, Med Center, Golisano Childrens Hosp Strong, Div Pediat Pulm Med, Rochester, NY 14627 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Boston University; Boston University; Boston Medical Center; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health; University of Rochester	Lee-Sarwar, KA (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.; Litonjua, AA (corresponding author), Golisano Childrens Hosp, 601 Elmwood Ave, Rochester, NY 14642 USA.	klee-sarwar@partners.org; augusto_litonjua@urmc.rochester.edu	kelly, rachel/H-4505-2017	kelly, rachel/0000-0003-3023-1822; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [U01HL091528]; National Institutes of Health [R01HL108818, R01HL123915, R01HL141826-01, 5T32AI007306-30]; ECHO [OD023268]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123915, K01HL146980, R01HL091528, R01HL141826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UH3OD023268] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ECHO; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The Vitamin D Antenatal Asthma Reduction Trial was funded by U01HL091528 from the National Heart, Lung, and Blood Institute. Additional funding came from National Institutes of Health grants R01HL108818, R01HL123915, R01HL141826-01, and 5T32AI007306-30 and ECHO grant OD023268.	Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P287, DOI 10.1016/j.jaci.2012.04.025; Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Blighe K, 2017, AM J CLIN NUTR, V106, P1092, DOI 10.3945/ajcn.117.158220; Blum R E, 1999, Matern Child Health J, V3, P167, DOI 10.1023/A:1022350023163; Bridgewater Br E. A. M, 2014, METABOLOMICS, P04, DOI [DOI 10.4172/2153-0769.1000132, 10.4172/2153-0769.1000132]; Burbank AJ, 2018, J ALLERGY CLIN IMMUN, V141, P1231, DOI 10.1016/j.jaci.2017.06.029; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cepeda AM, 2017, LUNG, V195, P683, DOI 10.1007/s00408-017-0044-z; Chernikova DA, 2018, PEDIATR RES, V84, P71, DOI 10.1038/s41390-018-0022-z; Cook-Mills J, 2016, THORAX, V71, P954, DOI 10.1136/thoraxjnl-2016-208494; Cook-Mills JM, 2013, AM J RESP CRIT CARE, V188, P279, DOI 10.1164/rccm.201303-0503ED; Delayre-Orthez C, 2008, EUR J PHARMACOL, V581, P177, DOI 10.1016/j.ejphar.2007.11.040; Dogaru CM, 2014, AM J EPIDEMIOL, V179, P1153, DOI 10.1093/aje/kwu072; Eichmann TO, 2015, CELL MOL LIFE SCI, V72, P3931, DOI 10.1007/s00018-015-1982-3; Forsgren M, 2017, ACTA PAEDIATR, V106, P1103, DOI 10.1111/apa.13837; FRIEDMAN E, 1989, CANCER RES, V49, P544; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; de Luna MDG, 2015, J ASTHMA, V52, P485, DOI 10.3109/02770903.2014.984841; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Hevia A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147809; Iannotti FA, 2016, PROG LIPID RES, V62, P107, DOI 10.1016/j.plipres.2016.02.002; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25; Kallen B, 2013, EUR RESPIR J, V41, P671, DOI 10.1183/09031936.00041912; Kishino S, 2013, P NATL ACAD SCI USA, V110, P17808, DOI 10.1073/pnas.1312937110; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee-Sarwar K, 2019, J ALLER CL IMM-PRACT, V7, P529, DOI 10.1016/j.jaip.2018.07.039; Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Lodge CJ, 2015, ACTA PAEDIATR, V104, P38, DOI 10.1111/apa.13132; Marchese ME, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-31; Marcobal A, 2013, ISME J, V7, P1933, DOI 10.1038/ismej.2013.89; McHardy IH, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-17; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Melo B, 2018, PEDIAT ALLERG IMM-UK, V29, P504, DOI 10.1111/pai.12911; Miles EA, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070784; Moi IM, 2018, APPL MICROBIOL BIOT, V102, P5811, DOI 10.1007/s00253-018-9063-9; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Peters BA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28126-1; Roviezzo F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00857; Scholtens S, 2009, THORAX, V64, P604, DOI 10.1136/thx.2007.094938; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Stiemsma LT, 2016, CLIN SCI, V130, P2199, DOI 10.1042/CS20160349; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Turcotte C, 2015, J LEUKOCYTE BIOL, V97, P1049, DOI 10.1189/jlb.3RU0115-021R; Vandeputte D, 2017, NATURE, V551, P507, DOI 10.1038/nature24460; Vulevic J, 2004, APPL ENVIRON MICROB, V70, P5659, DOI 10.1128/AEM.70.9.5659-5666.2004; Wang CS, 2018, RESPIROLOGY, V23, P901, DOI 10.1111/resp.13339; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wu H, 2018, PAEDIATR RESPIR REV, V27, P60, DOI 10.1016/j.prrv.2017.08.002; Zhong HZ, 2019, MICROBIOME, V7, DOI 10.1186/s40168-018-0608-z; Zierer J, 2018, NAT GENET, V50, P790, DOI 10.1038/s41588-018-0135-7	56	42	42	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					442	454		10.1016/j.jaci.2019.02.032	http://dx.doi.org/10.1016/j.jaci.2019.02.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30914378	Bronze, Green Accepted			2022-12-18	WOS:000478789300013
J	Tsilochristou, O; du Toit, G; Sayre, PH; Roberts, G; Lawson, K; Sever, ML; Bahnson, HT; Radulovic, S; Basting, M; Plaut, M; Lack, G				Tsilochristou, Olympia; du Toit, George; Sayre, Peter H.; Roberts, Graham; Lawson, Kaitie; Sever, Michelle L.; Bahnson, Henry T.; Radulovic, Suzana; Basting, Monica; Plaut, Marshall; Lack, Gideon		Immune Tolerance Network Learning	Association of Staphylococcus aureus colonization with food allergy occurs independently of eczema severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food sensitization; food allergy; peanut allergy; egg allergy; eczema; atopic dermatitis; Staphylococcus aureus; prevention; Learning Early About Peanut Allergy; microbiome	ATOPIC-DERMATITIS; NASAL CARRIAGE; ENTEROTOXIN-B; T-CELLS; SENSITIZATION; RISK; IGE; EXPOSURE; CHILDREN; INFANTS	Background: Staphylococcus aureus has been implicated in the pathophysiology of eczema, allergic rhinitis, asthma, and food allergy. S aureus is a marker of more severe eczema, which is a risk factor for food sensitization/allergy. Therefore it might be that the association between S aureus and food allergy in eczematous patients is related to eczema severity. Objective: We sought to investigate the association of S aureus colonization with specific IgE (sIgE) production to common food allergens and allergies in early childhood independent of eczema severity. We additionally determined the association of S aureus colonization with eczema severity and persistence. Methods: In Learning Early About Peanut Allergy (LEAP) study participants eczema severity was assessed, and skin/nasal swabs were cultured for S aureus. Sensitization was identified by measuring sIgE levels. Peanut allergy was primarily determined by means of oral food challenge, and persistent egg allergy was primarily determined by using skin prick tests. Results: Skin S aureus colonization was significantly associated with eczema severity across the LEAP study, whereas at 12 and 60 months of age, it was related to subsequent eczema deterioration. Skin S aureus colonization at any time point was associated with increased levels of hen's egg white and peanut sIgE independent of eczema severity. Participants with S aureus were more likely to have persistent egg allergy and peanut allergy at 60 and 72 months of age independent of eczema severity. All but one of the 9 LEAP study consumers with peanut allergy (9/312) were colonized at least once with S aureus. Conclusion: S aureus, independent of eczema severity, is associated with food sensitization and allergy and can impair tolerance to foods. This could be an important consideration in future interventions aimed at inducing and maintaining tolerance to food allergens in eczematous infants.	[Tsilochristou, Olympia; du Toit, George; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England; [Tsilochristou, Olympia; du Toit, George; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, Pediat Allergy Grp, London, England; [du Toit, George; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Childrens Allergy Serv, 2nd Floor,Stairwell B,South Wing, London SE1 7EH, England; [Sayre, Peter H.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA; [Roberts, Graham] Univ Southampton, Southampton, Hants, England; [Roberts, Graham] Southampton NIHR Biomed Res Ctr, Southampton, Hants, England; [Roberts, Graham] David Hide Ctr, Newport, Wight, England; [Lawson, Kaitie; Sever, Michelle L.] Rho Fed Syst Div, Chapel Hill, NC USA; [Bahnson, Henry T.] Immune Tolerance Network, San Francisco, CA USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of California System; University of California San Francisco; University of Southampton; Immune Tolerance Network; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Serv, 2nd Floor,Stairwell B,South Wing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk		Lack, Gideon/0000-0001-7350-4021; Lussier, Stephanie/0000-0001-9992-2213; Du Toit, George/0000-0002-0321-2928; Roberts, Graham/0000-0003-2252-1248; Tsilochristou, Olympia/0000-0002-4540-4602	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [NO1-AI-15416, UM1AI109565, HHSN272200800029C, UM2AI117870]; Food Allergy Research & Education (FARE); Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board (Atlanta, Ga); Davis Foundation; Clemens von Pirquet Foundation (Geneva, Switzerland)	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Research & Education (FARE); Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board (Atlanta, Ga); Davis Foundation; Clemens von Pirquet Foundation (Geneva, Switzerland)	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers NO1-AI-15416, UM1AI109565, HHSN272200800029C, and UM2AI117870. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support came from Food Allergy Research & Education (FARE; McLean, Va), the Medical Research Council & Asthma UK Centre, and the UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board (Atlanta, Ga). The UK Food Standards Agency provided additional support for the costs of phlebotomy. G.L. acknowledges the Davis Foundation for academic support. O.T. received a research fellowship from the Clemens von Pirquet Foundation (Geneva, Switzerland).	Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Davis MF, 2015, J ALLERGY CLIN IMMUN, V135, P811, DOI 10.1016/j.jaci.2014.10.052; du Toit G, 2018, J ALLERGY CLIN IMMUN, V141, P1343, DOI 10.1016/j.jaci.2017.09.034; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Forbes-Blom E, 2012, CLIN EXP ALLERGY, V42, P305, DOI 10.1111/j.1365-2222.2011.03861.x; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Lebon A, 2009, ARCH PEDIAT ADOL MED, V163, P745, DOI 10.1001/archpediatrics.2009.117; Meylan P, 2017, J INVEST DERMATOL, V137, P2497, DOI 10.1016/j.jid.2017.07.834; Okano M, 2001, AM J RHINOL, V15, P417, DOI 10.1177/194589240101500611; Riechelmann H, 2005, ALLERGY, V60, P1418, DOI 10.1111/j.1398-9995.2005.00902.x; Savinko T, 2005, J IMMUNOL, V175, P8320, DOI 10.4049/jimmunol.175.12.8320; Semic-Jusufagic A, 2007, J ALLERGY CLIN IMMUN, V119, P930, DOI 10.1016/j.jaci.2006.12.639; Shiomori T, 2000, J ALLERGY CLIN IMMUN, V105, P449, DOI 10.1067/mai.2000.104256; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Tanaka A, 2015, ANN ALLERG ASTHMA IM, V115, P191, DOI 10.1016/j.anai.2015.06.017; Totte JEE, 2016, BRIT J DERMATOL, V175, P687, DOI 10.1111/bjd.14566; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Uong P, 2017, J ALLER CL IMM-PRACT, V5, P1782, DOI 10.1016/j.jaip.2017.03.039; Xepapadaki P, 2016, ALLERGY, V71, P350, DOI 10.1111/all.12801	25	42	45	6	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					494	503		10.1016/j.jaci.2019.04.025	http://dx.doi.org/10.1016/j.jaci.2019.04.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31160034	Bronze, Green Submitted, Green Accepted			2022-12-18	WOS:000478789300017
J	Ascott, A; Mulick, A; Yu, AM; Prieto-Merino, D; Schmidt, M; Abuabara, K; Smeeth, L; Roberts, A; Langan, SM				Ascott, Anna; Mulick, Amy; Yu, Ashley M.; Prieto-Merino, David; Schmidt, Morten; Abuabara, Katrina; Smeeth, Liam; Roberts, Amanda; Langan, Sinead M.			Atopic eczema and major cardiovascular outcomes: A systematic review and meta-analysis of population-based studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic eczema; atopic dermatitis; angina; myocardial infarction; heart failure; stroke; ischemic stroke; cardiovascular death; cardiovascular outcomes; risk factors	RISK-FACTORS; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; DERMATITIS; ASSOCIATION; PREVALENCE; DISEASE; ADULTS; COMORBIDITIES; PSORIASIS	Background: Atopic eczema is a common inflammatory skin disease. Various inflammatory conditions have been linked to cardiovascular disease, a major cause of global mortality and morbidity. Objective: We sought to systematically review and meta-analyze population-based studies assessing associations between atopic eczema and specific cardiovascular outcomes. Methods: MEDLINE, Embase, and Global Health were searched from inception to December 2017. We obtained pooled estimates using random-effects meta-analyses. We used a multivariate Bayesian meta-regression model to estimate the slope of effect of increasing atopic eczema severity on cardiovascular outcomes. Results: Nineteen relevant studies were included. The effects of atopic eczema reported in cross-sectional studies were heterogeneous, with no evidence for pooled associations with angina, myocardial infarction, heart failure, or stroke. In cohort studies atopic eczema was associated with increased risk of myocardial infarction (n = 4; relative risk [RR], 1.12; 95% CI, 1.00-1.25), stroke (n = 4; RR, 1.10; 95% CI, 1.03-1.17), ischemic stroke n = 4; RR, 1.17; 95% CI, 1.14-1.20), angina (n = 2; RR, 1.18; 95% CI, 1.13-1.24), and heart failure (n = 2; RR, 1.26; 95% CI, 1.05-1.51). Prediction intervals were wide for myocardial infarction and stroke. The risk of cardiovascular outcomes appeared to increase with increasing severity (mean RR increase between severity categories, 1.15; 95% credibility interval, 1.09-1.21; uncertainty interval, 1.04-1.28). Conclusion: Significant associations with cardiovascular outcomes were more common in cohort studies but with considerable between-study heterogeneity. Increasing atopic eczema severity was associated with increased risk of cardiovascular outcomes. Improved awareness among stakeholders regarding this small but significant association is warranted.	[Ascott, Anna] Royal Sussex Cty Hosp, Eastern Rd, Brighton BN2 5BE, E Sussex, England; [Mulick, Amy; Prieto-Merino, David; Smeeth, Liam; Langan, Sinead M.] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England; [Yu, Ashley M.] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Schmidt, Morten] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark; [Schmidt, Morten] Reg Hosp West Jutland, Dept Cardiol, Herning, Denmark; [Abuabara, Katrina] Univ Calif San Francisco, Sch Med, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA; [Roberts, Amanda] Nottingham Support Grp Carers Children Eczema, Nottingham, England	University of Brighton; University of London; London School of Hygiene & Tropical Medicine; University of Ottawa; Aarhus University; University of California System; University of California San Francisco	Ascott, A (corresponding author), Royal Sussex Cty Hosp, Eastern Rd, Brighton BN2 5BE, E Sussex, England.	annaascott@doctors.org.uk	Smeeth, Liam/X-5862-2018	Smeeth, Liam/0000-0002-9168-6022; Schmidt, Morten/0000-0002-4935-4059; Mulick, Amy/0000-0002-4009-2080; Ascott, Anna/0000-0002-9426-1898; Langan, Sinead/0000-0002-7022-7441	British Association of Dermatologists; National Institutes of Health; Robert Wood Johnson Foundation; Dermatology Foundation; Wellcome Trust; Wellcome Senior Clinical Fellowship in Science [205039/Z/16/Z]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR073915] Funding Source: NIH RePORTER	British Association of Dermatologists; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Dermatology Foundation; Wellcome Trust(Wellcome Trust); Wellcome Senior Clinical Fellowship in Science; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	A.A. reports grants from the British Association of Dermatologists during the conduct of the study. K.A. reports grants from the National Institutes of Health, Robert Wood Johnson Foundation, and Dermatology Foundation during the conduct of the study. L.S. reports grants from the Wellcome Trust. S.M.L. reports grants from Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z) during the conduct of the study (A.M. is also funded on this fellowship). The Wellcome Trust and the British Association of Dermatologists played no role in the development or results of this study, and all authors carried out this research independently of the funding bodies. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders.	Andersen YMF, 2016, J ALLERGY CLIN IMMUN, V138, P310, DOI 10.1016/j.jaci.2016.01.015; Ascott A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017979; Brockwell SE, 2001, STAT MED, V20, P825, DOI 10.1002/sim.650; Cardwell CR, 2003, DIABETES CARE, V26, P2568, DOI 10.2337/diacare.26.9.2568; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Drucker AM, 2017, BRIT J DERMATOL, V177, P1043, DOI 10.1111/bjd.15727; Drucker AM, 2016, ALLERGY, V71, P1496, DOI 10.1111/all.12957; Egeberg A, 2017, ALLERGY, V72, P783, DOI 10.1111/all.13085; Furue M, 2017, INFLAMM RES, V66, P833, DOI 10.1007/s00011-017-1065-z; Guddat C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-34; Halling-Overgaard AS, 2018, J EUR ACAD DERMATOL; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Iribarren C, 2012, AM J EPIDEMIOL, V176, P1014, DOI 10.1093/aje/kws181; Kantor R, 2016, J AM ACAD DERMATOL, V75, P1119, DOI 10.1016/j.jaad.2016.07.017; Kwa MC, 2017, AM J CLIN DERMATOL, V18, P813, DOI 10.1007/s40257-017-0293-x; Marshall VD, 2016, DERMATOLOGY THER, V6, P649, DOI 10.1007/s13555-016-0144-3; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; R Core Team, R LANG ENV STAT COMP; Radtke MA, 2017, J EUR ACAD DERMATOL, V31, P151, DOI 10.1111/jdv.13813; Riis JL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011870; Roifman I, 2011, CAN J CARDIOL, V27, P174, DOI 10.1016/j.cjca.2010.12.040; Ronmark EP, 2012, BRIT J DERMATOL, V166, P1301, DOI 10.1111/j.1365-2133.2012.10904.x; Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624; Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.1007/978-3-319-21416-0; Silverberg JI, 2017, ALLERGY, V72, P2026, DOI 10.1111/all.13225; Silverberg JI, 2015, ALLERGY, V70, P1300, DOI 10.1111/all.12685; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Silverwood RJ, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1786; Standl M, 2017, J INVEST DERMATOL, V137, P1074, DOI 10.1016/j.jid.2016.11.031; Su VYF, 2014, ANN MED, V46, P84, DOI 10.3109/07853890.2013.870018; Sung YF, 2017, J MED SCI, V37, P12; Tamagawa-Mineoka R, 2009, CLIN IMMUNOL, V131, P495, DOI 10.1016/j.clim.2009.01.006; Tamagawa-Mineoka Risa, 2008, Allergol Int, V57, P391, DOI 10.2332/allergolint.O-08-537; Terrin N, 2005, J CLIN EPIDEMIOL, V58, P894, DOI 10.1016/j.jclinepi.2005.01.006; Thyssen JP, 2018, BRIT J DERMATOL, V178, P1272, DOI 10.1111/bjd.16215; Treudler R, 2018, J EUR ACAD DERMATOL, V32, pE44, DOI 10.1111/jdv.14495; Tsai KS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/543517; van de Schoot R., 2014, EUROPEAN HLTH PSYCHO, V16, P75; Varbo A, 2017, J THROMB HAEMOST, V15, P624, DOI 10.1111/jth.13644; Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Zhang A, 2015, J AM ACAD DERMATOL, V72, P606, DOI 10.1016/j.jaad.2014.12.013	44	42	42	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1821	1829		10.1016/j.jaci.2018.11.030	http://dx.doi.org/10.1016/j.jaci.2018.11.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30576754	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000466784600018
J	Boonpiyathad, T; van de Veen, W; Wirz, O; Sokolowska, M; Ruckert, B; Tan, G; Sangasapaviliya, A; Pradubpongsa, P; Fuengthong, R; Thantiworasit, P; Sirivichayakul, S; Ruxrungtham, K; Akdis, CA; Akdis, M				Boonpiyathad, Tadech; van de Veen, Willem; Wirz, Oliver; Sokolowska, Milena; Ruckert, Beate; Tan, Ge; Sangasapaviliya, Atik; Pradubpongsa, Panitan; Fuengthong, Rattanaporn; Thantiworasit, Pattarawat; Sirivichayakul, Sunee; Ruxrungtham, Kiat; Akdis, Cezmi A.; Akdis, Mubeccel			Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; house dust mite; B cells; plasmablasts; immunoglobulin isotype; IgG(4); IgA; regulatory B cells; IL-10; IL-1 receptor antagonist; immune tolerance	VISUAL ANALOG SCALE; PROTEOLYTIC ACTIVITY; ORAL IMMUNOTHERAPY; INTRALYMPHATIC IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; ANTIBODY-RESPONSE; ALLERGEN; IGE; INTERLEUKIN-1; MECHANISMS	Background: Long-term follow-up of allergen-specific B cells in terms of immunoglobulin isotype expression, plasmablast differentiation, and regulatory B (Breg) cell development during allergen-specific immunotherapy (AIT) has not been reported. Objective: Allergen-specific B-cell responses during 2 years of house dust mite AIT were compared between responder and nonresponder patients. Methods: B cells specific for Der p 1 were detected by using the fluorochrome-labeled allergen method. The frequencyof IgA-, IgG(1)-and IgG(4)-switchedDer p 1-specificBcells, plasmablasts, and IL-10- and IL-1 receptor antagonist (IL-1RA)-producing Breg cells were investigated and correlated to clinical response to AIT. Results: Sixteen of 25 patients completed the 2-year study. Eleven responder patients showed a successful response to AIT, as measured by a decrease in symptom-medication scores from 13.23 +/- 0.28 to 2.45 +/- 0.24 (P = .001) and a decrease in skin prick test reactivity to house dust mite from 7.0 +/- 1.3 to 2.7 +/- 0.5 mm (P 5.001). IgG(4) 1 and IgA 1 Der p 1-specific B cells showed a significant increase after AIT, with a significantly greater frequency in responders compared with nonresponders in the IgG(4) 1 but not the IgA 1 fraction. The frequency of plasmablasts and IL-10- and/or IL-1RA-producing Breg cells was greater among responders compared with nonresponders after 2 years. The increased frequency of Der p 1-specific IgG4 1 B cells, plasmablasts, and IL-10(+) and dual-positive IL-10 1 IL-1RA 1 Breg cells significantly correlated with improved clinical symptoms over the course of AIT. Conclusion: Allergen-specific B cells in patients responding to AIT are characterized by increased numbers of IgA- and IgG(4)-expressing Der p 1-specific B cells, plasmablasts, and IL-10(+) and/or IL-1RA 1 Breg cells.	[Boonpiyathad, Tadech; van de Veen, Willem; Wirz, Oliver; Sokolowska, Milena; Ruckert, Beate; Tan, Ge; Akdis, Cezmi A.; Akdis, Mubeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Boonpiyathad, Tadech; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Boonpiyathad, Tadech; Sangasapaviliya, Atik; Pradubpongsa, Panitan; Fuengthong, Rattanaporn] Phramongkutklao Hosp, Dept Med, Bangkok, Thailand; [Boonpiyathad, Tadech; Thantiworasit, Pattarawat; Sirivichayakul, Sunee; Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Bangkok, Thailand	Swiss Institute of Allergy & Asthma Research; University of Zurich; Phramongkutklao Hospital; Chulalongkorn University	Akdis, M (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch	Wirz, Oliver/U-7914-2019; Akdis, Cezmi/AAV-4844-2020	Wirz, Oliver/0000-0003-0377-6464; Akdis, Cezmi/0000-0001-8020-019X; van de Veen, Willem/0000-0001-9951-6688; Ruxrungtham, Kiat/0000-0001-7348-2352; Boonpiyathad, Tadech/0000-0001-8690-7647; Tan, Ge/0000-0003-0026-8739; Sokolowska, Milena/0000-0001-9710-6685	Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Germany; Swiss National Science Foundation, Switzerland [320030_159870, 310030_179428]; 90th Anniversary of Chulalongkorn University Scholarship (Ratchadaphiseksomphot Endowment Fund), Thailand	Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Germany; Swiss National Science Foundation, Switzerland(Swiss National Science Foundation (SNSF)); 90th Anniversary of Chulalongkorn University Scholarship (Ratchadaphiseksomphot Endowment Fund), Thailand	Supported by the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Germany; Swiss National Science Foundation, Switzerland grant nos. 320030_159870 and 310030_179428; and the 90th Anniversary of Chulalongkorn University Scholarship (Ratchadaphiseksomphot Endowment Fund), Thailand.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Boonpiyathad T, 2017, ALLERGY, V72, P407, DOI 10.1111/all.12966; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Calderon MA, 2014, CLIN EXP ALLERGY, V44, P1228, DOI 10.1111/cea.12331; Clark J, 2007, ALLERGY, V62, P1023, DOI 10.1111/j.1398-9995.2007.01469.x; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; Cowen EW, 2012, ARCH DERMATOL, V148, P381, DOI 10.1001/archdermatol.2011.3014; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Durham SR, 2016, J ALLERGY CLIN IMMUN, V137, P339, DOI 10.1016/j.jaci.2015.12.1298; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; Galea J, 2018, J NEUROSURG, V128, P515, DOI 10.3171/2016.9.JNS16615; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Globinska A, 2018, ANN ALLERG ASTHMA IM, V121, P306, DOI 10.1016/j.anai.2018.06.026; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Heijink IH, 2010, AM J RESP CELL MOL, V42, P69, DOI 10.1165/rcmb.2008-0449OC; Herder C, 2015, LANCET DIABETES ENDO, V3, P228, DOI 10.1016/S2213-8587(15)00035-2; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Huang HJ, 2011, MUCOSAL IMMUNOL, V4, P519, DOI 10.1038/mi.2011.17; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Kadri S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029217; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071; Luz-Crawford P, 2016, STEM CELLS, V34, P483, DOI 10.1002/stem.2254; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Ohta K, 2013, J ASTHMA, V50, P514, DOI 10.3109/02770903.2013.786726; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Reich A, 2012, ACTA DERM-VENEREOL, V92, P497, DOI 10.2340/00015555-1265; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Schmid JM, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0107-x; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Shi JB, 2010, ORL-J OTO-RHIN-LARYN, V72, P256, DOI 10.1159/000312687; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Sugimoto M, 2016, PEDIAT ALLERG IMM-UK, V27, P276, DOI 10.1111/pai.12535; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P1434, DOI 10.1016/j.jaci.2016.07.022; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Volarevic V, 2010, AUTOIMMUNITY, V43, P255, DOI 10.3109/08916930903305641; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895	55	42	43	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1077	+		10.1016/j.jaci.2018.10.061	http://dx.doi.org/10.1016/j.jaci.2018.10.061			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30529452	Bronze			2022-12-18	WOS:000460272900028
J	Botha, M; Basera, W; Facey-Thomas, HE; Gaunt, B; Gray, CL; Ramjith, J; Watkins, A; Levin, ME				Botha, Maresa; Basera, Wisdom; Facey-Thomas, Heidi E.; Gaunt, Ben; Gray, Claudia L.; Ramjith, Jordache; Watkins, Alexandra; Levin, Michael E.			Rural and urban food allergy prevalence from the South African Food Allergy (SAFFA) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Africa; allergy; egg; ethnicity; food allergy; food sensitization; peanut; prevalence; skin prick test; urban; rural	ASTHMA	Background: Food sensitization and challenge-proved food allergy (FA) have not been compared in urban and rural settings. Objective: We sought to determine and compare the prevalence of food sensitization and challenge-proved IgE-mediated FA in urban and rural South African toddlers aged 12 to 36 months. Methods: This cross-sectional study of unselected children included 1185 participants in urban Cape Town and 398 in the rural Eastern Cape. All participants completed a questionnaire and underwent skin prick tests (SPTs) to egg, peanut, cow's milk, fish, soya, wheat, and hazelnut. Participants with SPT responses of 1 mm or greater to 1 or more foods and not tolerant on history underwent an open oral food challenge. Result: The prevalence of FAwas 2.5% (95% CI, 1.6% to 3.3%) in urban children, most commonly to raw egg white (1.9%), followed by cooked egg (0.8%), peanut (0.8%), cow's milk (0.1%), and fish (0.1%). Urban sensitization (SPT response >= 1 mm) to any food was 11.4% (95% CI, 9.6% to 13.3%) and 9.0% (95% CI, 7.5% to 10.8%) at an SPT response of 3 mm or greater. Sensitization in rural cohorts was significantly lower than in the urban cohort (1-mm SPT response, 4.5% [95% CI, 2.5% to 6.6%]; 3-mm SPT response, 2.8% [95% CI, 1.4% to 4.9%]; P < .01). In the rural black African cohort 0.5% (95% CI, 0.1% to 1.8%) of children had food allergy, all to egg. This is significantly lower than the prevalence of the urban cohort overall (2.5%) and urban black African participants (2.9%; 95% CI, 1.5% to 4.3%; P = .006). Conclusion: FA prevalence in Cape Town is comparable with rates in industrialized middle-income countries and is significantly greater than in rural areas. Further analysis will describe and compare environmental exposures and other risk factors in this cohort.	[Botha, Maresa; Facey-Thomas, Heidi E.; Gray, Claudia L.; Watkins, Alexandra; Levin, Michael E.] Univ Cape Town, Dept Paediat, Div Paediat Allergy, Cape Town, South Africa; [Basera, Wisdom] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa; [Gaunt, Ben] Zithulele Hosp, Eastern Cape Dept Hlth, Zithulele, South Africa; [Gaunt, Ben] Univ Cape Town, Fac Hlth Sci, Div Primary Hlth Care, Cape Town, South Africa; [Ramjith, Jordache] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa; [Ramjith, Jordache] Radboud Univ Nijmegen, Med Ctr, Biostat Res Grp, Dept Hlth Evidence,Radboud Inst Hlth Sci, Nijmegen, Netherlands; [Levin, Michael E.] Grp Worldwide Univ Network, inVIVO Planetary Hlth, Nijmegen, Netherlands	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; Radboud University Nijmegen	Levin, ME (corresponding author), Red Cross Hosp, Rm 516,ICH Bldg,Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	michael.levin@uct.ac.za	Levin, Michael/AAT-2370-2020; Ramjith, Jordache/AAB-7339-2019; Ramjith, Jordache/N-7307-2018	Levin, Michael/0000-0003-2439-7981; Ramjith, Jordache/0000-0003-4431-7395; Ramjith, Jordache/0000-0003-4431-7395	Medical Research Council of South Africa; National Research Foundation of South Africa; Mylan; Thermo Fisher; Nestle; Cipla; Aspen; Pharma Dynamics; Astellas; Beiersdorf; Novartis; Nutricia; MSD; Takeda; AstraZeneca	Medical Research Council of South Africa(South African Medical Research Council); National Research Foundation of South Africa(National Research Foundation - South Africa); Mylan; Thermo Fisher; Nestle(Nestle SA); Cipla; Aspen; Pharma Dynamics; Astellas(Astellas Pharmaceuticals); Beiersdorf; Novartis(Novartis); Nutricia(Danone Nutricia); MSD; Takeda(Takeda Pharmaceutical Company Ltd); AstraZeneca(AstraZeneca)	Supported by the Medical Research Council of South Africa, National Research Foundation of South Africa, Mylan, Thermo Fisher, Nestle, Cipla, Aspen, Pharma Dynamics, Astellas, Beiersdorf, Novartis, Nutricia, MSD, Takeda, and AstraZeneca.	Allen KJ, 2015, PEDIATR CLIN N AM, V62, P1441, DOI 10.1016/j.pcl.2015.07.005; Basera W, 2015, ANN ALLERG ASTHMA IM, V115, P113, DOI 10.1016/j.anai.2015.06.003; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Levin ME, 2011, SAMJ S AFR MED J, V101, P472; Levin ME, 2016, CURR PEDIAT REP, V4, P129; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Matsui EC, 2017, J ALLERGY CLIN IMMUN, V139, P448, DOI 10.1016/j.jaci.2016.09.030; Walkner M, 2015, PEDIATR CLIN N AM, V62, P1453, DOI 10.1016/j.pcl.2015.07.003; Zar HJ, 2007, PEDIAT ALLERG IMM-UK, V18, P560, DOI 10.1111/j.1399-3038.2007.00554.x	9	42	42	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					662	+		10.1016/j.jaci.2018.07.023	http://dx.doi.org/10.1016/j.jaci.2018.07.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30096388	Bronze			2022-12-18	WOS:000457718700025
J	Schuyler, AJ; Wilson, JM; Tripathi, A; Commins, SP; Ogbogu, PU; Kruzsewski, PG; Barnes, BH; McGowan, EC; Workman, LJ; Lidholm, J; Rifas-Shiman, SL; Oken, E; Gold, DR; Platts-Mills, TAE; Erwin, EA				Schuyler, Alexander J.; Wilson, Jeffrey M.; Tripathi, Anubha; Commins, Scott P.; Ogbogu, Princess U.; Kruzsewski, Patrice G.; Barnes, Barrett H.; McGowan, Emily C.; Workman, Lisa J.; Lidholm, Jonas; Rifas-Shiman, Sheryl L.; Oken, Emily; Gold, Diane R.; Platts-Mills, Thomas A. E.; Erwin, Elizabeth A.			Specific IgG(4) antibodies to cow's milk proteins in pediatric patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; children; IgG(4) assays; cow's milk proteins; molecular allergens	IGE ANTIBODIES; ORAL IMMUNOTHERAPY; ELIMINATION DIET; IMMUNOGLOBULIN-E; CHILDREN; SENSITIZATION; IGG4; FOOD; IDENTIFICATION; DIAGNOSIS	Background: Allergen-specific IgG(4) (sIgG(4)) antibodies are often associated with tolerance, but sIgG(4) antibodies to causally relevant foods have been reported recently in adults with eosinophilic esophagitis (EoE). Prevalence and levels of food sIgG(4) are not well established in the general pediatric population. Objective: We sought to investigate serum food sIgG(4) with component diagnostics in children with EoE and children from an unselected birth cohort and to explore the effects of sex, age, and milk consumption on sIgG(4) levels. Methods: Sera from 71 pediatric patients with EoE and 210 early adolescent children from an unselected birth cohort (Project Viva) were assayed for sIgG(4) and specific IgE (sIgE) to major cow's milk (CM) proteins (alpha-lactalbumin, beta-lactoglobulin, and caseins) and to wheat, soy, egg, and peanut proteins. Results: In the EoE cohort high-titer sIgG(4) (>= 10 mu g/mL) to CM proteins was more common than in control sera and achieved odds ratios for EoE ranging from 5.5 to 8.4. sIgE levels to CM proteins were mostly 4 IU/mL or less in patients with EoE, such that sIgG(4)/sIgE ratios were often 10,000 or greater. When adjusted for age and milk consumption, high-titer sIgG(4) to CM proteins was strongly associated with EoE, with an odds ratio of greater than 20 to all 3 CM proteins in boys. Conclusions: sIgG(4) to CM proteins are common and high titer in children with EoE. Although it is not clear that this response is pathogenic, sIgG(4) levels imply that these antibodies are an important feature of the local immune response that gives rise to EoE.	[Schuyler, Alexander J.; Wilson, Jeffrey M.; Tripathi, Anubha; McGowan, Emily C.; Workman, Lisa J.; Platts-Mills, Thomas A. E.] Univ Virginia, Div Allergy & Clin Immunol, Charlottesville, VA USA; [Barnes, Barrett H.] Univ Virginia, Div Pediat Gastroenterol, Charlottesville, VA USA; [Commins, Scott P.] Univ N Carolina, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA; [Ogbogu, Princess U.] Ohio State Univ, Dept Otolaryngol, Wexner Med Ctr, Allergy & Immunol, Columbus, OH 43210 USA; [Kruzsewski, Patrice G.] Emory Univ, Div Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA 30322 USA; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Med Sch, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA USA; [Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Erwin, Elizabeth A.] Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, 700 Childrens Dr, Columbus, OH 43205 USA	University of Virginia; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; Emory University; Thermo Fisher Scientific; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	Erwin, EA (corresponding author), Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, 700 Childrens Dr, Columbus, OH 43205 USA.; Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu; elizabeth.erwin@nationwidechildrens.org	Wilson, JM/AAD-6421-2020	Wilson, JM/0000-0002-5975-1760; Platts-Mills, Thomas/0000-0002-1263-329X; Lidholm, Jonas/0000-0002-7779-3411	National Institutes of Health [R01-AI-20565, K23-AI-059317]; Viva [R01-AI-102960, R01-HD-034568]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960, K23AI123596, K23AI059317, T32AI007496, R21AI138227, R01AI020565, R37AI020565] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Viva; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by funding from National Institutes of Health grants R01-AI-20565 (to T.A.E.P-M.) and K23-AI-059317 (to E.A.E.). Project Viva is supported by grants R01-AI-102960 and R01-HD-034568.	Aalberse RC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0621-x; Aalberse RC, 2015, J ALLER CL IMM-PRACT, V3, P863, DOI 10.1016/j.jaip.2015.09.013; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; BJORKSTEN F, 1977, CLIN ALLERGY, V7, P473, DOI 10.1111/j.1365-2222.1977.tb01478.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Dellon ES, 2014, GASTROENTEROL CLIN N, V43, P201, DOI 10.1016/j.gtc.2014.02.002; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Erwin EA, 2017, J PEDIATR GASTR NUTR, V65, P520, DOI 10.1097/MPG.0000000000001553; Erwin EA, 2016, J ALLERGY CLIN IMMUN, V138, P625, DOI 10.1016/j.jaci.2016.01.048; Erwin EA, 2015, J ALLER CL IMM-PRACT, V3, P896, DOI 10.1016/j.jaip.2015.05.015; Erwin EA, 2010, ANN ALLERG ASTHMA IM, V104, P496, DOI 10.1016/j.anai.2010.03.018; Frischmeyer-Guerrerio PA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006448; Hill DA, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0592-3; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Krop EJM, 2007, INT ARCH ALLERGY IMM, V144, P296, DOI 10.1159/000106318; Kruszewski PG, 2016, DIS ESOPHAGUS, V29, P377, DOI 10.1111/dote.12339; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2017, UNITED EUR GASTROENT, V5, P335, DOI 10.1177/2050640616689525; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Perzanowski MS, 2016, J ALLERGY CLIN IMMUN, V138, P1582, DOI 10.1016/j.jaci.2016.05.017; Platts-Mills TAE, 2016, J ALLERGY CLIN IMMUN, V137, P1662, DOI 10.1016/j.jaci.2016.04.010; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Schmid JM, 2016, J ALLERGY CLIN IMMUN, V137, P562, DOI 10.1016/j.jaci.2015.05.023; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; SEAGROATT V, 1981, J BIOL STAND, V9, P431, DOI 10.1016/S0092-1157(81)80034-0; Simon D, 2013, ALLERGY, V68, P945, DOI 10.1111/all.12157; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Tripathi A, 2015, J ALLERGY CLIN IMMUN, V135, P985, DOI 10.1016/j.jaci.2014.11.032; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van Rhijn BD, 2015, J ALLERGY CLIN IMMUN, V136, P1095, DOI 10.1016/j.jaci.2015.02.038; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415; Varga EM, 2013, J ALLERGY CLIN IMMUN, V131, P1419, DOI 10.1016/j.jaci.2012.08.037; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Wallace ZS, 2013, MEDICINE, V92, P206, DOI 10.1097/MD.0b013e31829cce35; Wilson JM, 2018, J ALLERGY CLIN IMMUN, V141, P419, DOI 10.1016/j.jaci.2017.07.029; Wright BL, 2016, J ALLERGY CLIN IMMUN, V138, P1190, DOI 10.1016/j.jaci.2016.02.024; Zukerberg L, 2016, HISTOPATHOLOGY, V68, P968, DOI 10.1111/his.12892	55	42	44	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					139	+		10.1016/j.jaci.2018.02.049	http://dx.doi.org/10.1016/j.jaci.2018.02.049			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29678750	Green Accepted			2022-12-18	WOS:000437837500018
J	Bigley, V; Maisuria, S; Cytlak, U; Jardine, L; Care, MA; Green, K; Gunawan, M; Milne, P; Dickinson, R; Wiscombe, S; Parry, D; Doffinger, R; Laurence, A; Fonseca, C; Stoevesandt, O; Gennery, A; Cant, A; Tooze, R; Simpson, AJ; Hambleton, S; Savic, S; Doody, G; Collin, M				Bigley, Venetia; Maisuria, Sheetal; Cytlak, Urszula; Jardine, Laura; Care, Matthew A.; Green, Kile; Gunawan, Merry; Milne, Paul; Dickinson, Rachel; Wiscombe, Sarah; Parry, David; Doffinger, Rainer; Laurence, Arian; Fonseca, Claudia; Stoevesandt, Oda; Gennery, Andrew; Cant, Andrew; Tooze, Reuben; Simpson, A. John; Hambleton, Sophie; Savic, Sinisa; Doody, Gina; Collin, Matthew			Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Interferon regulatory factor 8; immunodeficiency; dendritic cell; monocyte; myeloproliferation; interferon	TRANSCRIPTION FACTOR IRF8; SEQUENCE BINDING-PROTEIN; LEUKEMIA-LIKE SYNDROME; CUTTING EDGE; T-CELLS; MYELODYSPLASTIC SYNDROMES; SIGNALING PATHWAYS; CYTOKINE RESPONSES; CRYSTAL-STRUCTURE; PROGENITOR CELLS	Background: The homozygous K108E mutation of interferon regulatory factor 8 (IRF8) is reported to cause dendritic cell (DC) and monocyte deficiency. However, more widespread immune dysfunction is predicted from the multiple roles ascribed to IRF8 in immune cell development and function. Objective: We sought to describe the effect on hematopoiesis and immunity of the compound heterozygous R83C/R291Q mutation of IRF8, which is present in a patient with recurrent viral infection, granuloproliferation, and intracerebral calcification. Methods: Variant IRF8 alleles were identified by means of exome sequencing, and their function was tested by using reporter assays. The cellular phenotype was studied in detail by using flow cytometry, functional immunologic assay transcriptional profiling, and antigen receptor profiling. Results: Both mutations affected conserved residues, and R291Q is orthologous to R294, which is mutated in the BXH2 IRF8-deficient mouse. R83C showed reduced nuclear translocation, and neither mutant was able to regulate the Ets/IRF composite element or interferon-stimulated response element, whereas R291Q retained BATF/JUN interactions. DC deficiency and monocytopenia were observed in blood, dermis, and lung lavage fluid. Granulocytes were consistently increased, dysplastic, and hypofunctional. Natural killer cell development and maturation were arrested. T(H)1, T(H)17, and CD8 1 memory T-cell differentiation was significantly reduced, and T cells did not express CXCR3. B-cell development was impaired, with fewer memory cells, reduced class-switching, and lower frequency and complexity of somatic hypermutation. Cell-specific gene expression was widely disturbed in interferonand IRF8-regulated transcripts. Conclusions: This analysis defines the clinical features of human biallelic IRF8 deficiency, revealing a complex immunodeficiency syndrome caused by DC and monocyte deficiency combined with widespread immune dysregulation.	[Bigley, Venetia; Cytlak, Urszula; Jardine, Laura; Green, Kile; Gunawan, Merry; Milne, Paul; Dickinson, Rachel; Wiscombe, Sarah; Laurence, Arian; Gennery, Andrew; Simpson, A. John; Hambleton, Sophie; Collin, Matthew] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Bigley, Venetia; Jardine, Laura; Laurence, Arian; Gennery, Andrew; Cant, Andrew; Simpson, A. John; Hambleton, Sophie; Collin, Matthew] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Maisuria, Sheetal] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Care, Matthew A.; Tooze, Reuben; Doody, Gina] Univ Leeds, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Parry, David] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England; [Savic, Sinisa] Univ Leeds, Natl Inst Hlth Res Leeds Musculoskeletal Biomed R, Leeds, W Yorkshire, England; [Savic, Sinisa] Univ Leeds, Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Doffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; [Fonseca, Claudia; Stoevesandt, Oda] Cambridge Prot Arrays, Babraham Res Campus, Cambridge, England; [Gunawan, Merry] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Parry, David] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Leeds; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of Edinburgh	Bigley, V (corresponding author), Newcastle Univ, Med Sch, Human Dendrit Cell Lab, Room M3-119,3rd Floor Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Venetia.bigley@ncl.ac.uk	Bigley, Venetia/AAU-9738-2020; Laurence, Arian/A-8770-2009; Cytlak, Urszula/Y-2382-2019; Savic, Sinisa/Q-6217-2019; Care, Matthew/P-2987-2019; Doody, Gina/AAN-8246-2021	Bigley, Venetia/0000-0002-3017-2474; Laurence, Arian/0000-0003-0942-8292; Cytlak, Urszula/0000-0002-2536-6012; Savic, Sinisa/0000-0001-7910-0554; Care, Matthew/0000-0001-6584-5889; Doody, Gina/0000-0003-0665-6759; Doffinger, R/0000-0002-9841-3617; Parry, David/0000-0003-0376-7736; Tooze, Reuben/0000-0003-2915-7119; Simpson, John/0000-0003-4731-7294; Green, Kile/0000-0002-4777-5458; Hambleton, Sophie/0000-0001-7954-3267; Milne, Paul/0000-0002-8278-0463	Wellcome Trust [101155/Z13/Z]; Bright Red; Cancer Research UK [C30484/A21025, C7845/A17723]; NIHR Newcastle Biomedical Research Centre	Wellcome Trust(Wellcome TrustEuropean Commission); Bright Red; Cancer Research UK(Cancer Research UK); NIHR Newcastle Biomedical Research Centre	Supported by Wellcome Trust (101155/Z13/Z, to V.B.), Bright Red (to V.B. and M.C.), Cancer Research UK (to M.C. [C30484/A21025] and G.D., M.A.C., and R.T. [C7845/A17723]), and the NIHR Newcastle Biomedical Research Centre (to S.W. and A.J.S.).	Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Andersen P, 2005, BLOOD, V105, P511, DOI 10.1182/blood-2003-12-4359; Berghout J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003491; BICK RL, 1993, LAB MED, V24, P712, DOI 10.1093/labmed/24.11.712; Bigley V, 2011, HAEMATOL-HEMATOL J, V96, P1081, DOI 10.3324/haematol.2011.048355; Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459; Care MA, 2014, NUCLEIC ACIDS RES, V42, P7588, DOI 10.1093/nar/gku451; Chaix J, 2014, J IMMUNOL, V193, P1013, DOI 10.4049/jimmunol.1400488; Chen W, 2008, NAT STRUCT MOL BIOL, V15, P1213, DOI 10.1038/nsmb.1496; Cho SY, 2010, CANCER RES, V70, P3402, DOI 10.1158/0008-5472.CAN-09-3977; Collin M, 2013, IMMUNOLOGY, V140, P22, DOI 10.1111/imm.12117; Dror N, 2007, MOL IMMUNOL, V44, P338, DOI 10.1016/j.molimm.2006.02.026; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Ghosh HS, 2010, IMMUNITY, V33, P905, DOI 10.1016/j.immuni.2010.11.023; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Grajales-Reyes GE, 2015, NAT IMMUNOL, V16, P708, DOI 10.1038/ni.3197; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Hagemeyer N, 2016, EMBO J, V35, P1730, DOI 10.15252/embj.201693801; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Haniff M, 2009, J EXP MED, V206, P371, DOI 10.1084/jem.20081633; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu LP, 2016, J BIOL CHEM, V291, P4107, DOI 10.1074/jbc.M115.681361; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Ingegnoli F, 2013, DIS MARKERS, V2013, P727, DOI 10.1155/2013/726598; Jackson JT, 2011, EMBO J, V30, P2690, DOI 10.1038/emboj.2011.163; Kanno Y, 2005, J INTERF CYTOK RES, V25, P770, DOI 10.1089/jir.2005.25.770; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kubosaki A, 2010, MOL IMMUNOL, V47, P2295, DOI 10.1016/j.molimm.2010.05.289; Kurotaki D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5978; Kurotaki D, 2013, BLOOD, V121, P1839, DOI 10.1182/blood-2012-06-437863; Langlais D, 2016, J EXP MED, V213, P585, DOI 10.1084/jem.20151764; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Lee W, 2016, CELL MOL IMMUNOL, V13, P785, DOI 10.1038/cmi.2015.72; Luda KM, 2016, IMMUNITY, V44, P860, DOI 10.1016/j.immuni.2016.02.008; Mace EM, 2017, J CLIN INVEST, V127, P306, DOI 10.1172/JCI86276; Mack DG, 2009, J IMMUNOL, V182, P7317, DOI 10.4049/jimmunol.0804305; Mancino A, 2015, GENE DEV, V29, P394, DOI 10.1101/gad.257592.114; Marquis JF, 2009, J IMMUNOL, V182, P3008, DOI 10.4049/jimmunol.0800680; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Miyagawa F, 2012, P NATL ACAD SCI USA, V109, P12123, DOI 10.1073/pnas.1201453109; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; MORETTI S, 1994, LEUKEMIA LYMPHOMA, V13, P471, DOI 10.3109/10428199409049637; Murphy TL, 2013, NAT REV IMMUNOL, V13, P499, DOI 10.1038/nri3470; Newman DM, 2016, IMMUNOL CELL BIOL, V94, P796, DOI 10.1038/icb.2016.33; Ouyang XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1311; Paschall AV, 2015, J IMMUNOL, V194, P2369, DOI 10.4049/jimmunol.1402412; Pathak S, 2013, J IMMUNOL, V191, P6222, DOI 10.4049/jimmunol.1301169; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Porto BN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00311; Prak ETL, 2011, ANN NY ACAD SCI, V1217, P96, DOI 10.1111/j.1749-6632.2010.05877.x; Rao SP, 1999, J IMMUNOL, V163, P2732; Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822; Roskin KM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1216; Salem S, 2014, BLOOD, V124, P1894, DOI 10.1182/blood-2014-04-570879; Sasaki H, 2015, BLOOD, V125, P358, DOI 10.1182/blood-2014-02-557983; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schiavoni G, 2004, BLOOD, V103, P2221, DOI 10.1182/blood-2003-09-3007; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Shukla Vipul, 2014, Front Biol (Beijing), V9, P269; Sichien D, 2016, IMMUNITY, V45, P626, DOI 10.1016/j.immuni.2016.08.013; Tajima F, 2010, HEPATOL RES, V40, P711, DOI 10.1111/j.1872-034X.2010.00647.x; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Tamura T, 2015, INT J HEMATOL, V101, P342, DOI 10.1007/s12185-015-1761-9; To LB, 2003, BONE MARROW TRANSPL, V31, P371, DOI 10.1038/sj.bmt.1703860; Tooze RM, 2006, J IMMUNOL, V177, P4584, DOI 10.4049/jimmunol.177.7.4584; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Turcotte K, 2005, J EXP MED, V201, P881, DOI 10.1084/jem.20042170; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; Wang HS, 2008, BLOOD, V112, P4028, DOI 10.1182/blood-2008-01-129049; Xu HP, 2015, NAT IMMUNOL, V16, P1274, DOI 10.1038/ni.3287; Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025812; Yang JN, 2011, J IMMUNOL, V187, P4426, DOI 10.4049/jimmunol.1101034	76	42	42	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2234	2248		10.1016/j.jaci.2017.08.044	http://dx.doi.org/10.1016/j.jaci.2017.08.044			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29128673	Green Published, hybrid			2022-12-18	WOS:000434701600027
J	Renand, A; Shamji, MH; Harris, KM; Qin, T; Wambre, E; Scadding, GW; Wurtzen, PA; Till, SJ; Togias, A; Nepom, GT; Kwok, WW; Durham, SR				Renand, Amedee; Shamji, Mohamed H.; Harris, Kristina M.; Qin, Tielin; Wambre, Erik; Scadding, Guy W.; Wurtzen, Peter A.; Till, Stephen J.; Togias, Alkis; Nepom, Gerald T.; Kwok, William W.; Durham, Stephen R.			Synchronous immune alterations mirror clinical response during allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; immunotherapy; immune tolerance; allergen desensitization; T(H)2 cells	GRASS-POLLEN IMMUNOTHERAPY; T-CELL RESPONSES; IMMUNOLOGICAL CHANGES; ORAL IMMUNOTHERAPY; EFFICACY; INCREASES; TABLET; NASAL; IL-10; RHINOCONJUNCTIVITIS	Background: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation. Objective: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation. Methods: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-acilitated allergen binding). Results: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific T(H)2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation. Conclusion: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-pecific T(H)2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.	[Renand, Amedee; Wambre, Erik; Nepom, Gerald T.; Kwok, William W.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA; [Shamji, Mohamed H.; Scadding, Guy W.; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, Immunomodulat & Tolerance Grp,Allergy & Clin Immu, London, England; [Harris, Kristina M.; Qin, Tielin; Nepom, Gerald T.] Immune Tolerance Network, Bethesda, MD USA; [Wurtzen, Peter A.] ALK Abello, Immunol, Horsholm, Denmark; [Till, Stephen J.] Kings Coll London, Sch Immunol & Microbial Sci, Asthma Allergy & Lung Biol, London, England; [Shamji, Mohamed H.; Till, Stephen J.] MRC & Asthma UK, Ctr Allerg Mech Asthma, London, England; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	Benaroya Research Institute; Virginia Mason Medical Center; Imperial College London; Immune Tolerance Network; ALK-Abello AS; University of London; King's College London; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Durham, SR (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk	Shamji, Mohamed/AAD-1788-2019; Qin, Tielin/H-4564-2019; Shamji, Mohamed/AAU-8811-2020; RENAND, Amedee/A-9884-2018	Shamji, Mohamed/0000-0003-3425-3463; RENAND, Amedee/0000-0003-2265-549X	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) [UM1AI109565]; NIH [R01 AI095074]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095074, UM1AI109565, R01AI108839] Funding Source: NIH RePORTER; MRC [G0601303] Funding Source: UKRI	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research reported in this publication was sponsored by the Immune Tolerance Network and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award no. UM1AI109565 and NIH grant R01 AI095074. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bonvalet M, 2012, CLIN EXP ALLERGY, V42, P1745, DOI 10.1111/cea.12015; Burbank AJ, 2016, IMMUNOL ALLERGY CLIN, V36, P55, DOI 10.1016/j.iac.2015.08.007; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007685.pub2; Campbell JD, 2010, CLIN EXP ALLERGY, V40, P1025, DOI 10.1111/j.1365-2222.2010.03505.x; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Dahl R, 2016, ALLERGY ASTHMA PROC, V37, P92, DOI 10.2500/aap.2016.37.3937; Didier A, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0057-8; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eberlein B, 2015, CYTOM PART B-CLIN CY, V88, P183, DOI 10.1002/cyto.b.21203; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; James LK, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0600-2; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1258, DOI 10.1016/j.jaci.2016.01.008; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Lissina A, 2009, J IMMUNOL METHODS, V340, P11, DOI 10.1016/j.jim.2008.09.014; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Nelson HS, 2014, CHEM IMMUNOL ALLERGY, V100, P333, DOI 10.1159/000360047; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Renand A, 2015, J ALLERGY CLIN IMMUN, V136, P1627, DOI 10.1016/j.jaci.2015.07.031; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Schulten V, 2016, CLIN EXP ALLERGY, V46, P439, DOI 10.1111/cea.12653; Senti G, 2015, ALLERGY, V70, P707, DOI 10.1111/all.12600; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Suarez-Fueyo A, 2014, J ALLERGY CLIN IMMUN, V133, P130, DOI 10.1016/j.jaci.2013.09.043; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054; Warren L, 2006, P NATL ACAD SCI USA, V103, P17807, DOI 10.1073/pnas.0608512103; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x	50	42	44	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1750	+		10.1016/j.jaci.2017.09.041	http://dx.doi.org/10.1016/j.jaci.2017.09.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29128670	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000432148200022
J	Cardet, JC; Louisias, M; King, TS; Castro, M; Codispoti, CD; Dunn, R; Engle, L; Giles, BL; Holguin, F; Lima, JJ; Long, D; Lugogo, N; Nyenhuis, S; Ortega, VE; Ramratnam, S; Wechsler, ME; Israel, E; Phipatanakul, W				Cardet, Juan Carlos; Louisias, Margee; King, Tonya S.; Castro, Mario; Codispoti, Christopher D.; Dunn, Ryan; Engle, Linda; Giles, B. Louise; Holguin, Fernando; Lima, John J.; Long, Dayna; Lugogo, Njira; Nyenhuis, Sharmilee; Ortega, Victor E.; Ramratnam, Sima; Wechsler, Michael E.; Israel, Elliot; Phipatanakul, Wanda		AsthmaNet Investigators	Income is an independent risk factor for worse asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Disparities; socioeconomic status; education; psychological stress; asthma exacerbation; Vitamin D Add-On Therapy Enhances Corticosteroid trial; low income	VITAMIN-D INSUFFICIENCY; INNER-CITY ASTHMA; SOCIOECONOMIC-STATUS; UNITED-STATES; ALLERGEN EXPOSURE; D DEFICIENCY; HEALTH; ADHERENCE; ADULTS; RACE	Background: Socioeconomic status (SES) is associated with asthma morbidity in observational studies, but the factors underlying this association are uncertain. Objective: We investigated whether 3 SES correlates-low income, low education, and high perceived stress-were independent risk factors for treatment failure and asthma exacerbations in the context of a randomized controlled trial. Methods: The effect of low SES (household income of <$50,000/y and household educational level of less than a Bachelor's degree) and high perceived stress (defined as a score of > 20 on a perceived stress scale) on asthma morbidity was analyzed in 381 participants by using Poisson regression models. The primary outcome was treatment failure (defined in the trial protocol as a significant clinical or airflow deterioration), and the secondary outcome was asthma exacerbations requiring systemic corticosteroids. Results: Fifty-four percent of participants had a low income, 40% had a low educational level, and 17% had high perceived stress levels. Even after adjusting for race and other important confounders, participants with lower income had higher rates of both treatment failures (rate ratio, 1.6; 95% CI, 1.1-2.3; P = .03) and exacerbations (rate ratio, 1.9; 95% CI, 1.1-3.3; P = .02). Adherence with inhaled corticosteroids was similarly high for both income categories. Education and perceived stress were not significantly associated with either outcome. Conclusions: In the context of a randomized controlled trial, participants with lower income were more likely to experience adverse asthma outcomes independent of education, perceived stress, race, and medication adherence.	[Cardet, Juan Carlos; Louisias, Margee; Israel, Elliot; Phipatanakul, Wanda] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Louisias, Margee; Phipatanakul, Wanda] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [King, Tonya S.; Engle, Linda; Wechsler, Michael E.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Castro, Mario] Washington Univ, Sch Med, St Louis, MO USA; [Codispoti, Christopher D.] Rush Univ, Chicago, IL 60612 USA; [Dunn, Ryan] Natl Jewish Hlth, Denver, CO USA; [Giles, B. Louise] Univ Chicago, Chicago, IL 60637 USA; [Holguin, Fernando] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Lima, John J.] Nemours Childrens Hlth Syst, Jacksonville, FL USA; [Long, Dayna] Univ Calif San Francisco, Benioff Childrens Hosp Oakland, Dept Pediat, San Francisco, CA 94143 USA; [Lugogo, Njira] Duke Univ, Durham, NC 27706 USA; [Nyenhuis, Sharmilee] Univ Illinois, Chicago, IL USA; [Nyenhuis, Sharmilee] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA; [Ortega, Victor E.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [Ramratnam, Sima] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington University (WUSTL); Rush University; National Jewish Health; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison	Phipatanakul, W (corresponding author), Harvard Med Sch, Boston Childrens Hosp, 300 Longwood Ave,Fegan Bldg,7th Floor, Boston, MA 02115 USA.	wanda.phipatanakul@childrens.harvard.edu	Wechsler, Michael/AAC-5506-2019	Codispoti, Christopher/0000-0002-4459-5048; Cardet, Juan Carlos/0000-0002-9731-4828	National Heart, Lung, and Blood Institute [HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, HL098115]; National Institute of Allergy and Infectious Disease (NIAID) [1K23AI125785-01A1, 3U19AI095219-04S1]; National Institutes of Health (NIH) [K12HS022986, 5T32 HS00063-21]; NIAID [K24AI 106822]; Agency for Healthcare Research and Quality (AHRQ) [K12HS022986]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS022986, T32HS000063] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002345, UL1TR001102, UL1TR000448, UL1TR000150, UL1TR000050, UL1TR000430, UL1TR001422, UL1TR002003, UL1TR000454, UL1TR001082, UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098103, U10HL098107, U10HL098075, U10HL098096, U10HL098177, U10HL098102, U10HL098112, U10HL098090, U10HL098115, U10HL098098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095219, U01AI110397, K23AI125785, T32AI007635, K24AI106822, T32AI007172] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115 that were awarded by the National Heart, Lung, and Blood Institute. In addition, J.C.C. received funds from a National Institute of Allergy and Infectious Disease (NIAID) 1K23AI125785-01A1 and diversity supplement 3U19AI095219-04S1. M.L. was supported by National Institutes of Health (NIH) grants K12HS022986 and 5T32 HS00063-21. W.P. received funds from NIAID grant K24AI 106822. Supported in part by grant number K12HS022986 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ.	Agresti A., 2002, WILEY SERIES PROBABI, P397; Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Belsley D.A., 1980, REGRESSION DIAGNOSTI; Boulet LP, 2012, CLIN CHEST MED, V33, P405, DOI 10.1016/j.ccm.2012.06.002; Brehm JM, 2012, AM J RESP CRIT CARE, V186, P140, DOI 10.1164/rccm.201203-0431OC; Brehm John M, 2010, J Allergy Clin Immunol, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Cauthen NK, 2008, MEASURING POVERTY US, P1; Chen E, 2006, SOC SCI MED, V62, P2161, DOI 10.1016/j.socscimed.2005.08.054; Chen E, 2006, AM J PUBLIC HEALTH, V96, P702, DOI 10.2105/AJPH.2004.048124; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen E, 2006, HEALTH PSYCHOL, V25, P704, DOI 10.1037/0278-6133.25.6.704; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2013, ANNU REV CLIN PSYCHO, V9, P723, DOI 10.1146/annurev-clinpsy-050212-185634; Chetty R, 2016, JAMA-J AM MED ASSOC, V315, P1750, DOI 10.1001/jama.2016.4226; Chong S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-422; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1988, CLAR SYMP, P31; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; Evans GW, 2010, ANN NY ACAD SCI, V1186, P174, DOI 10.1111/j.1749-6632.2009.05336.x; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Foster JM, 2011, EUR RESPIR MONOGR, P28, DOI 10.1183/1025448x.10000710; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Kallem S, 2013, OBESITY, V21, P1759, DOI 10.1002/oby.20195; Kopel LS, 2015, PEDIATR PULM, V50, P17, DOI 10.1002/ppul.22986; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Kutner MH., 2004, APPL LINEAR REGRESSI; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Manicourt DH, 2008, J CLIN ENDOCR METAB, V93, P3893, DOI 10.1210/jc.2007-2663; Massey D., 2004, DU BOIS REV, V1, P7, DOI DOI 10.1017/S1742058X04040032; Massey DS, 1999, SOC SCI RES, V28, P316, DOI 10.1006/ssre.1999.0660; Moorman JE, 2013, MMWR-MORBID MORTAL W, V62, P93; Ponieman D, 2009, ANN ALLERG ASTHMA IM, V103, P38, DOI 10.1016/S1081-1206(10)60141-X; Roberts B, 2013, LOW INCOME WORKING F; Rosser F, 2014, AM J RESP CRIT CARE, V190, P1190, DOI 10.1164/rccm.201408-1568LE; Sedaghat AR, 2016, J ALLER CL IMM-PRACT, V4, P82, DOI 10.1016/j.jaip.2015.09.006; Sheehan WJ, 2010, J ALLERGY CLIN IMMUN, V125, P575, DOI 10.1016/j.jaci.2010.01.023; Stokes ME., 2000, CATEGORICAL DATA ANA; Gonzalez-Ramirez MT, 2013, SPAN J PSYCHOL, V16, DOI 10.1017/sjp.2013.35; Wallace TC, 2013, J AM COLL NUTR, V32, P321, DOI 10.1080/07315724.2013.839905; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904	43	42	44	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					754	+		10.1016/j.jaci.2017.04.036	http://dx.doi.org/10.1016/j.jaci.2017.04.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	FV2PQ	28535964	Bronze, Green Accepted			2022-12-18	WOS:000424410800031
J	Calzetti, F; Tamassia, N; Arruda-Silva, F; Gasperini, S; Cassatella, MA				Calzetti, Federica; Tamassia, Nicola; Arruda-Silva, Fabio; Gasperini, Sara; Cassatella, Marco A.			The importance of being "pure" neutrophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOLL-LIKE RECEPTORS; 6-SULFO LACNAC; ACTIVATION; EXPRESSION; SUBSETS; ALPHA; CELLS		[Calzetti, Federica; Tamassia, Nicola; Arruda-Silva, Fabio; Gasperini, Sara; Cassatella, Marco A.] Univ Verona, Dept Med, Sect Gen Pathol, Verona, Italy	University of Verona	Cassatella, MA (corresponding author), Univ Verona, Dept Med, Sect Gen Pathol, Verona, Italy.	marco.cassatella@univr.it	Tamassia, Nicola/J-8621-2016; Cassatella, M A/B-8037-2013; Arruda-Silva, Fabio/S-9352-2019	Tamassia, Nicola/0000-0003-2990-3003; Cassatella, M A/0000-0001-7824-1806; Arruda-Silva, Fabio/0000-0001-5608-3683	Associazione Italiana per la Ricerca sul Cancro [IG-15454]; Brazilian fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Brazilian fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (grant no. IG-15454) to M.A.C. F.A.-S. is supported by a Brazilian fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior.	Dalboni TM, 2013, CYTOKINE, V61, P716, DOI 10.1016/j.cyto.2013.01.016; Gaber T, 2016, IMMUNOL RES, V64, P665, DOI 10.1007/s12026-015-8770-x; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Hofer TP, 2015, BLOOD, V126, P2601, DOI 10.1182/blood-2015-06-651331; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Lewkowicz N, 2016, MUCOSAL IMMUNOL, V9, P364, DOI 10.1038/mi.2015.66; Naegelen I, 2015, J LEUKOCYTE BIOL, V97, P557, DOI 10.1189/jlb.3A0514-254RR; Scapini P, 1999, J IMMUNOL METHODS, V232, P121, DOI 10.1016/S0022-1759(99)00170-2; Scapini P, 2014, BLOOD, V124, P710, DOI 10.1182/blood-2014-03-453217; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; Tamassia N, 2008, J IMMUNOL, V181, P6563, DOI 10.4049/jimmunol.181.9.6563; Tamassia N, 2013, J IMMUNOL, V190, P1921, DOI 10.4049/jimmunol.1203022; Zimmermann M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19674; Zimmermann M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7061	15	42	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					352	+		10.1016/j.jaci.2016.06.025	http://dx.doi.org/10.1016/j.jaci.2016.06.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27567327	Bronze			2022-12-18	WOS:000393996800037
J	van de Veen, W; Akdis, M				van de Veen, Willem; Akdis, Muebeccel			Role of IgG(4) in IgE-mediated allergic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						IgG(4); IgE; allergen-specific immunoglobulins; immune tolerance	EOSINOPHILIC ESOPHAGITIS; IGG4				Akdis, M (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; van de Veen, Willem/0000-0001-9951-6688				Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Davies AM, 2015, IMMUNOL REV, V268, P139, DOI 10.1111/imr.12349; Hofmaier S, 2015, J ALLERGY CLIN IMMUN, V135, P1367, DOI 10.1016/j.jaci.2014.09.048; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Malbec O, 2007, IMMUNOL REV, V217, P206, DOI 10.1111/j.1600-065X.2007.00510.x; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Shamji MH, 2014, J ALLERGY CLIN IMMUN, V135, P913; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Wright BL, 2016, J ALLERGY CLIN IMMUN, V138, P1190, DOI 10.1016/j.jaci.2016.02.024; Zukerberg L, 2016, HISTOPATHOLOGY, V68, P968, DOI 10.1111/his.12892	11	42	44	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1434	+		10.1016/j.jaci.2016.07.022	http://dx.doi.org/10.1016/j.jaci.2016.07.022			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27566454	Bronze			2022-12-18	WOS:000389542700024
J	Mitsui, C; Kajiwara, K; Hayashi, H; Ito, J; Mita, H; Ono, E; Higashi, N; Fukutomi, Y; Sekiya, K; Tsuburai, T; Akiyama, K; Yamamoto, K; Taniguchi, M				Mitsui, Chihiro; Kajiwara, Keiichi; Hayashi, Hiroaki; Ito, Jun; Mita, Haruhisa; Ono, Emiko; Higashi, Noritaka; Fukutomi, Yuma; Sekiya, Kiyoshi; Tsuburai, Takahiro; Akiyama, Kazuo; Yamamoto, Kazuhiko; Taniguchi, Masami			Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						P-selectin; adhesion; aspirin-exacerbated respiratory disease; asthma; cysteinyl leukotriene; platelet	ALLERGIC-ASTHMA PATIENTS; URINARY LEUKOTRIENE E-4; SOLUBLE CD40 LIGAND; LOW-DOSE ASPIRIN; TO-TREAT ASTHMA; P-SELECTIN; LEUKOCYTE RECRUITMENT; CROSS-TALK; INVOLVEMENT; INTOLERANT	Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by respiratory reactions on ingestion of COX-1 inhibitors and cysteinyl leukotriene overproduction. The hypersensitivity reaction is induced by low doses of aspirin that inhibit COX-1 in platelets. Objective: We sought to explore the role of platelets in the pathogenesis of AERD in patients under stable conditions and during an aspirin challenge test. Methods: Stable patients with AERD (n = 30), aspirin-tolerant asthma (ATA; n = 21), or idiopathic chronic eosinophilic pneumonia (n 5 10) were enrolled. Platelet activation was estimated based on expression levels of P-selectin (CD62P), CD63, CD69, andGPIIb/IIIa (PAC-1) in peripheral platelets; percentages of circulating platelet-adherent leukocytes; and plasma levels of soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L). Results: In the stable condition, expression of all surface markers on platelets, the percentage of platelet-adherent eosinophils, and the plasma levels of sP-selectin and sCD40L were significantly higher in patients with AERD compared with those in patients with ATA. P-selectin and CD63 expression on platelets and plasma sP-selectin and sCD40L levels were positively correlated with the percentage of platelet-adherent eosinophils. Among these markers, P-selectin expression and plasma sP-selectin levels positively correlated with urinary concentrations of leukotriene E-4. Additionally, plasma sP-selectin and sCD40L levels were negatively correlated with lung function. In contrast, platelet activation markers in patients with AERD did not change during the aspirin challenge test. Conclusion: Peripheral platelets were activated more in patients with stable AERD compared with those in patients with stable ATA, patients with idiopathic chronic eosinophilic pneumonia, and control subjects. Platelet activation was involved in cysteinyl leukotriene overproduction and persistent airflow limitations in patients with AERD.	[Mitsui, Chihiro; Kajiwara, Keiichi; Hayashi, Hiroaki; Ito, Jun; Mita, Haruhisa; Ono, Emiko; Higashi, Noritaka; Fukutomi, Yuma; Sekiya, Kiyoshi; Tsuburai, Takahiro; Akiyama, Kazuo; Taniguchi, Masami] Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Higashi, Noritaka] Japanese Red Cross Kumamoto Hlth Care Ctr, Kumamoto, Japan; [Mitsui, Chihiro; Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1138654, Japan	University of Tokyo	Taniguchi, M (corresponding author), Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Minami Ku, Sakuradai 18-1, Sagamihara, Kanagawa, Japan.	m-taniguchi@sagamihara-hosp.gr.jp	Fukutomi, Yuma/AFQ-4306-2022		Ministry of Health, Labour and Welfare of Japan [H26-ITAKU (MEN)-IPPAN-002]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	Supported by a Health, Labor, and Sciences research grant on allergic disease and immunology from the Ministry of Health, Labour and Welfare of Japan (grant no. H26-ITAKU (MEN)-IPPAN-002).	ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; Amison RT, 2015, J ALLERGY CLIN IMMUN, V135, P528, DOI 10.1016/j.jaci.2014.09.032; BERTELE V, 1983, SCIENCE, V220, P517, DOI 10.1126/science.6682245; Capone ML, 2004, CIRCULATION, V109, P1468, DOI 10.1161/01.CIR.0000124715.27937.78; Caron A, 2002, J CARDIOVASC PHARM, V40, P296, DOI 10.1097/00005344-200208000-00015; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Cummings HE, 2013, J IMMUNOL, V191, P5807, DOI 10.4049/jimmunol.1302187; Doyle EL, 2011, BLOOD, V118, P4265, DOI 10.1182/blood-2010-11-321489; Fruth K, 2013, ALLERGY, V68, P659, DOI 10.1111/all.12131; Fukutomi Y, 2012, CLIN EXP ALLERGY, V42, P738, DOI 10.1111/j.1365-2222.2011.03880.x; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Inwald DP, 2003, CIRC RES, V92, P1041, DOI 10.1161/01.RES.0000070111.98158.6C; Jawien J, 2005, J PHYSIOL PHARMACOL, V56, P637; John AE, 2003, FASEB J, V17, P2296, DOI 10.1096/fj.03-0166fje; Klinkhardt U, 2002, CLIN PHARMACOL THER, V71, P176, DOI 10.1067/mcp.2002.122018; Kowal K, 2006, J THROMB HAEMOST, V4, P2718, DOI 10.1111/j.1538-7836.2006.02206.x; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; KOWALSKI ML, 1984, ALLERGY, V39, P171, DOI 10.1111/j.1398-9995.1984.tb02621.x; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Li N, 2008, J LEUKOCYTE BIOL, V83, P1069, DOI 10.1189/jlb.0907615; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; MCDONALD JR, 1974, J ALLERGY CLIN IMMUN, V54, P200, DOI 10.1016/0091-6749(74)90062-1; Michelson AD, 1996, P NATL ACAD SCI USA, V93, P11877, DOI 10.1073/pnas.93.21.11877; Mita H, 1997, J CHROMATOGR B, V692, P461, DOI 10.1016/S0378-4347(97)00006-6; Mita H, 2001, ALLERGY, V56, P1061; NIZANKOWSKA E, 1986, EUR J RESPIR DIS, V69, P363; Ono E, 2008, EUR RESPIR J, V32, P437, DOI 10.1183/09031936.00093407; Page C, 2014, CLIN EXP ALLERGY, V44, P901, DOI 10.1111/cea.12322; Palikhe S, 2014, ANN ALLERG ASTHMA IM, V113, P276, DOI 10.1016/j.anai.2014.06.011; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Patrignani P, 2012, BLOOD, V119, P3649, DOI 10.1182/blood-2012-02-406769; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; SLATER D, 1985, LANCET, V1, P110; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; TAYTARD A, 1986, AM REV RESPIR DIS, V134, P983, DOI 10.1164/arrd.1986.134.5.983; Tornhamre S., 2002, Clinical and Experimental Allergy, V32, P1566, DOI 10.1046/j.1365-2222.2002.01531.x; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; Yamaguchi H, 2011, CLIN EXP ALLERGY, V41, P1711, DOI 10.1111/j.1365-2222.2011.03839.x; Zietkowski Z, 2008, J INVEST ALLERG CLIN, V18, P272	50	42	44	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					400	411		10.1016/j.jaci.2015.05.041	http://dx.doi.org/10.1016/j.jaci.2015.05.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26194538	Bronze			2022-12-18	WOS:000369235500008
J	Starkl, P; Marichal, T; Gaudenzio, N; Reber, LL; Sibilano, R; Tsai, M; Galli, SJ				Starkl, Philipp; Marichal, Thomas; Gaudenzio, Nicolas; Reber, Laurent Lionel; Sibilano, Riccardo; Tsai, Mindy; Galli, Stephen Joseph			IgE antibodies, Fc epsilon RI alpha, and IgE-mediated local anaphylaxis can limit snake venom toxicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acquired resistance; allergy; Daboia russelii; Russell viper; Fc epsilon RI alpha; honeybee; IgE; toxin hypothesis; venom; mast cells; type 2 immunity	GERMAN HEALTH INTERVIEW; MAST-CELL; HYMENOPTERA VENOMS; IMMUNOGLOBULIN-E; STING REACTIONS; SCORPION-VENOM; IN-VIVO; ALLERGY; SENSITIZATION; MOUSE	Background: Type 2 cytokine-related immune responses associated with development of antigen-specific IgE antibodies can contribute to pathology in patients with allergic diseases and to fatal anaphylaxis. However, recent findings in mice indicate that IgE also can enhance defense against honeybee venom. Objective: We tested whether IgE antibodies, IgE-dependent effector mechanisms, and a local anaphylactic reaction to an unrelated antigen can enhance defense against Russell viper venom (RVV) and determined whether such responses can be influenced by immunization protocol or mouse strain. Methods: We compared the resistance of RVV-immunized wild-type, IgE-deficient, and Fcer1a-deficient mice after injection of a potentially lethal dose of RVV. Results: A single prior exposure to RVV enhanced the ability of wild-type mice, but not mice lacking IgE or functional Fc epsilon RI, to survive challenge with a potentially lethal amount of RVV. Moreover, IgE-dependent local passive cutaneous anaphylaxis in response to challenge with an antigen not naturally present in RVV significantly enhanced resistance to the venom. Finally, we observed different effects on resistance to RVV or honeybee venomin BALB/c versus C57BL/6 mice that had received a second exposure to that venom before challenge with a high dose of that venom. Conclusion: These observations illustrate the potential benefit of IgE-dependent effector mechanisms in acquired host defense against venoms. The extent to which type 2 immune responses against venoms can decrease pathology associated with envenomation seems to be influenced by the type of venom, the frequency of venom exposure, and the genetic background of the host.	[Starkl, Philipp; Marichal, Thomas; Gaudenzio, Nicolas; Reber, Laurent Lionel; Sibilano, Riccardo; Tsai, Mindy; Galli, Stephen Joseph] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Galli, Stephen Joseph] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr L-235, Stanford, CA 94305 USA.	sgalli@stanford.edu	Reber, Laurent L/K-4148-2014	Reber, Laurent L/0000-0003-3384-6769; Starkl, Philipp/0000-0001-7521-129X; Tsai, Mindy/0000-0002-8421-4721; Gaudenzio, Nicolas/0000-0002-5648-509X	Max Kade Fellowship of the Max Kade Foundation; Austrian Academy of Sciences; Schroedinger Fellowship of the Austrian Science Fund (FWF) [J3399-B21]; Marie Curie International Outgoing Fellowship for Career Development [299954]; French "Fondation pour la Recherche Medicale FRM"; Arthritis National Research Foundation (ANRF); National Institutes of Health (NIH) [K99AI110645]; Lucile Packard Foundation for Children's Health; Stanford NIH/NCRR CTSA [UL1 RR025744]; NIH [AI023990, CA072074, AI070813]; Department of Pathology of Stanford University; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990, K99AI110645, R01AI070813] Funding Source: NIH RePORTER	Max Kade Fellowship of the Max Kade Foundation; Austrian Academy of Sciences; Schroedinger Fellowship of the Austrian Science Fund (FWF); Marie Curie International Outgoing Fellowship for Career Development; French "Fondation pour la Recherche Medicale FRM"(Fondation pour la Recherche Medicale); Arthritis National Research Foundation (ANRF); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lucile Packard Foundation for Children's Health; Stanford NIH/NCRR CTSA; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pathology of Stanford University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	P.S. was supported by a Max Kade Fellowship of the Max Kade Foundation and the Austrian Academy of Sciences and a Schroedinger Fellowship of the Austrian Science Fund (FWF): J3399-B21. T.M. was supported by a Marie Curie International Outgoing Fellowship for Career Development (grant no. 299954). N.G. was supported by fellowships from the French "Fondation pour la Recherche Medicale FRM.'' L.L.R. was supported by the Arthritis National Research Foundation (ANRF) and National Institutes of Health (NIH) grant K99AI110645. R.S. was supported by a fellowship from the Lucile Packard Foundation for Children's Health and the Stanford NIH/NCRR CTSA (award no. UL1 RR025744). This work was supported by NIH grants AI023990, CA072074, and AI070813 (to S.J.G.) and the Department of Pathology of Stanford University.	Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; AMIRI P, 1994, J EXP MED, V180, P43, DOI 10.1084/jem.180.1.43; Artis D, 2012, NATURE, V484, P458, DOI 10.1038/484458a; Arumugam M, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-14; BERGER BJ, 1989, BIOCHEM CELL BIOL, V67, P597, DOI 10.1139/o89-092; Beyer K, 2012, ALLERGY, V67, P1451, DOI 10.1111/all.12012; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Blumenthal MN, 2012, ANN ALLERG ASTHMA IM, V108, P69, DOI 10.1016/j.anai.2011.12.003; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brodie ED, 2009, CURR BIOL, V19, pR931, DOI 10.1016/j.cub.2009.08.011; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; de Medeiros CR, 2008, TOXICON, V51, P672, DOI 10.1016/j.toxicon.2007.11.022; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Haak-Frendscho M, 1998, IMMUNOLOGY, V94, P115; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1972, N-S ARCH PHARMACOL, V273, P313, DOI 10.1007/BF00499666; Haftenberger M, 2013, BUNDESGESUNDHEITSBLA, V56, P687, DOI 10.1007/s00103-012-1658-1; Hamilton RG, 2014, J ALLERGY CLIN IMMUN, V134, P360, DOI 10.1016/j.jaci.2014.02.022; Hart PH, 1998, J EXP MED, V187, P2045, DOI 10.1084/jem.187.12.2045; HIGGINBOTHAM RD, 1971, J IMMUNOL, V106, P233; HIGGINBOTHAM RD, 1965, J IMMUNOL, V95, P867; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139, DOI 10.1016/S0091-6749(99)70005-9; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KOPP P, 1993, CLIN EXP ALLERGY, V23, P231, DOI 10.1111/j.1365-2222.1993.tb00887.x; Langen U, 2013, BUNDESGESUNDHEITSBLA, V56, P698, DOI 10.1007/s00103-012-1652-7; Lee JK, 2011, CLIN EXP ALLERGY, V41, P923, DOI 10.1111/j.1365-2222.2011.03779.x; Leynadier F, 1997, J ALLERGY CLIN IMMUN, V99, P851, DOI 10.1016/S0091-6749(97)80022-X; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; LIU FT, 1980, J IMMUNOL, V124, P2728; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; McGowan EC, 2015, J ALLERGY CLIN IMMUN, V135, P171, DOI 10.1016/j.jaci.2014.06.033; Meier J., 1995, TOXICON; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ozdemir C, 2011, CLIN EXP ALLERGY, V41, P1226, DOI 10.1111/j.1365-2222.2011.03812.x; Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Perales J, 2005, TOXICON, V45, P1013, DOI 10.1016/j.toxicon.2005.02.028; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; PROFET M, 1991, Q REV BIOL, V66, P23, DOI 10.1086/417049; PROUVOSTDANON A, 1977, IMMUNOCHEMISTRY, V14, P81, DOI 10.1016/0019-2791(77)90284-1; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Reimers AR, 2000, CLIN EXP ALLERGY, V30, P276; Risch M, 2009, J PROTEOMICS, V72, P256, DOI 10.1016/j.jprot.2009.01.006; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Rowe AH, 2013, SCIENCE, V342, P441, DOI 10.1126/science.1236451; RUSSO AJ, 1983, TOXICON, V21, P475, DOI 10.1016/0041-0101(83)90125-3; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; Schafer T, 1996, ALLERGY, V51, P372; SCHMUTZ J, 1985, LANCET, V2, P1306; Schneider LA, 2007, J EXP MED, V204, P2629, DOI 10.1084/jem.20071262; Simpson ID, 2007, WILD ENVIRON MED, V18, P2, DOI 10.1580/06-WEME-CO-023R1.1; STANWORTH DR, 1993, ALLERGY, V48, P67, DOI 10.1111/j.1398-9995.1993.tb00687.x; STANWORTH DR, 1967, LANCET, V2, P330; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x; Sturm GJ, 2014, J ALLERGY CLIN IMMUN, V133, P1635, DOI 10.1016/j.jaci.2013.10.046; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; TOGIAS AG, 1985, J ALLERGY CLIN IMMUN, V75, P672, DOI 10.1016/0091-6749(85)90092-2; VAZ NM, 1977, INT ARCH ALLER A IMM, V53, P545, DOI 10.1159/000231796; Voss RS, 2012, BIOL REV, V87, P822, DOI 10.1111/j.1469-185X.2012.00222.x; WADEE AA, 1987, J ALLERGY CLIN IMMUN, V80, P695, DOI 10.1016/0091-6749(87)90289-2; Wakayama H, 1998, CLIN EXP IMMUNOL, V114, P154; WARRELL DA, 1989, T ROY SOC TROP MED H, V83, P732, DOI 10.1016/0035-9203(89)90311-8; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016	86	42	42	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					246	+		10.1016/j.jaci.2015.08.005	http://dx.doi.org/10.1016/j.jaci.2015.08.005			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26410782	Bronze, Green Accepted			2022-12-18	WOS:000367724300016
J	Wang, M; Wang, XD; Zhang, N; Wang, H; Li, Y; Fan, EZ; Zhang, L; Zhang, L; Bachert, C				Wang, Min; Wang, Xiangdong; Zhang, Nan; Wang, Hong; Li, Ying; Fan, Erzhong; Zhang, Liang; Zhang, Luo; Bachert, Claus			Association of periostin expression with eosinophilic inflammation in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC RHINOSINUSITIS; ACTIVATION; ASTHMA; ROLES		[Wang, Min; Wang, Xiangdong; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Wang, Xiangdong; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Allergy, Beijing, Peoples R China; [Wang, Min; Wang, Xiangdong; Wang, Hong; Li, Ying; Fan, Erzhong; Zhang, Liang; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Zhang, Nan; Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, Ghent, Belgium	Capital Medical University; Capital Medical University; Ghent University; Ghent University Hospital	Wang, M (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.	dr.luozhang@139.com	Bachert, Claus/J-8825-2012; Zhang, Nan/AAQ-3944-2020; wang, xiao/HGB-7081-2022; Wang, Xiangdong/AAF-9148-2020	wang, xiao/0000-0002-4088-3341; Zhang, Luo/0000-0002-0910-9884				Barthel SR, 2008, J LEUKOCYTE BIOL, V83, P1, DOI 10.1189/jlb.0607344; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Kim SW, 2013, LARYNGOSCOPE, V123, P1075, DOI 10.1002/lary.23786; Kudo A, 2011, CELL MOL LIFE SCI, V68, P3201, DOI 10.1007/s00018-011-0784-5; Li W, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0218-2; Norris RA, 2009, J CELL COMMUN SIGNAL, V3, P275, DOI 10.1007/s12079-009-0063-5; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Xiao L, 2015, CLIN EXP ALLERGY, V45, P404, DOI 10.1111/cea.12475; Zhang W, 2012, INT FORUM ALLERGY RH, V2, P471, DOI 10.1002/alr.21056	15	42	42	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1700	1703		10.1016/j.jaci.2015.09.005	http://dx.doi.org/10.1016/j.jaci.2015.09.005			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26521039	Bronze			2022-12-18	WOS:000366044300039
J	Warm, K; Hedman, L; Lindberg, A; Lotvall, J; Lundback, B; Ronmark, E				Warm, Katja; Hedman, Linnea; Lindberg, Anne; Lotvall, Jan; Lundback, Bo; Ronmark, Eva			Allergic sensitization is age-dependently associated with rhinitis, but less so with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adults; allergic rhinitis; allergic sensitization; asthma; epidemiology; specific IgE	COMMUNITY RESPIRATORY HEALTH; COMMON AIRBORNE ALLERGENS; CLINICAL-RELEVANCE; RISK-FACTORS; BRONCHIAL HYPERRESPONSIVENESS; AEROALLERGEN SENSITIZATION; NORTHERN SWEDEN; ADULTS; POPULATION; ONSET	Background: Epidemiologic data describing the association between allergic sensitization and asthma and allergic rhinitis in adults are scarce. Objective: To determine the prevalence and impact of specific sensitization to airborne allergens on asthma and allergic rhinitis among adults in relation to age. Methods: A random population sample (age 21-86 years) was examined with structured interview and analysis of specific IgE to 9 common airborne allergens. Of those invited, 692 (68%) subjects participated in blood sampling. IgE level of 0.35 U/mL or more to the specific allergen was defined as a positive test result. Results: Allergic sensitization decreased with increasing age, both in the population sample and among subjects with asthma and allergic rhinitis. In a multivariate model, sensitization to animal was significantly positively associated with asthma (odds ratio [OR], 4.80; 95% CI, 2.68-8.60), whereas sensitization to both animal (OR, 3.90; 95% CI, 2.31-6.58) and pollen (OR, 4.25; 95% CI, 2.55-7.06) was significantly associated with allergic rhinitis. The association between allergic sensitization and rhinitis was consistently strongest among the youngest age group, whereas this pattern was not found for asthma. The prevalence of allergic sensitization among patients with asthma decreased by increasing age of asthma onset, 86% with asthma onset at age 6 y or less, 56% at age 7 to 19 years, and 26% with asthma onset at age 20 years or more. Conclusions: Sensitization to animal was associated with asthma across all age groups; allergic rhinitis was associated with sensitization to both pollen and animal and consistently stronger among younger than among older adults. Early onset of asthma was associated with allergic sensitization among adults with asthma.	[Warm, Katja; Lindberg, Anne] Umea Univ, Dept Publ Hlth & Clin Med, Div Med, SE-90187 Umea, Sweden; [Warm, Katja; Hedman, Linnea; Lindberg, Anne; Ronmark, Eva] Umea Univ, OLIN Unit, SE-90187 Umea, Sweden; [Hedman, Linnea; Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med Occupat & Environm Med, SE-90187 Umea, Sweden; [Lotvall, Jan; Lundback, Bo] Univ Gothenburg, Inst Med, Krefting Res Ctr, Gothenburg, Sweden	Umea University; Umea University; Umea University; University of Gothenburg	Ronmark, E (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med Occupat & Environm Med, SE-90187 Umea, Sweden.	eva.ronmark@nll.se		Lindberg, Anne/0000-0002-3292-7471; Lotvall, Jan/0000-0001-9195-9249	Swedish Heart-Lung Foundation; Swedish Asthma-Allergy Foundation; Swedish Research Council; Umea University; Visare Norr; Norrbotten County Council; ThermoFisher Scientific, Uppsala, Sweden	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma-Allergy Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Umea University; Visare Norr; Norrbotten County Council; ThermoFisher Scientific, Uppsala, Sweden	The studies were funded by the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umea University, Visare Norr, and Norrbotten County Council. Additional funding was provided by ThermoFisher Scientific, Uppsala, Sweden.	Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Backman H, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-1; Badorrek P, 2012, ANN ALLERG ASTHMA IM, V109, P208, DOI 10.1016/j.anai.2012.06.019; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Blomme K, 2013, INT ARCH ALLERGY IMM, V160, P200, DOI 10.1159/000339853; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Craig TJ, 2008, J ALLERGY CLIN IMMUN, V121, P671, DOI 10.1016/j.jaci.2007.12.1153; Ekerljung L, 2013, CLIN RESPIR J, V7, P53, DOI 10.1111/j.1752-699X.2012.00281.x; Eriksson J, 2011, INT ARCH ALLERGY IMM, V154, P155, DOI 10.1159/000320230; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Haahtela T, 2014, CLIN EXP ALLERGY, V44, P407, DOI 10.1111/cea.12240; Lam HT, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-6; Kerkhof M, 2003, ALLERGY, V58, P1261, DOI 10.1046/j.1398-9995.2003.00020.x; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Pallasaho P, 2006, CLIN EXP ALLERGY, V36, P503, DOI 10.1111/j.1365-2222.2006.02460.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; Raukas-Kivioja A, 2007, INT ARCH ALLERGY IMM, V142, P247, DOI 10.1159/000097027; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Ronmark EP, 2009, RESP MED, V103, P1807, DOI 10.1016/j.rmed.2009.07.014; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Schoefer Y, 2008, ALLERGY, V63, P81, DOI 10.1111/j.1398-9995.2007.01517.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC; Simola M, 1999, ANN ALLERG ASTHMA IM, V82, P152, DOI 10.1016/S1081-1206(10)62589-6; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Warm K, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-20; Warm K, 2012, J ALLERGY CLIN IMMUN, V129, P136, DOI 10.1016/j.jaci.2011.08.033; Westman M, 2012, J ALLERGY CLIN IMMUN, V129, P403, DOI 10.1016/j.jaci.2011.09.036; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	41	42	43	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1559	U201		10.1016/j.jaci.2015.06.015	http://dx.doi.org/10.1016/j.jaci.2015.06.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26220530				2022-12-18	WOS:000366044300017
J	Yao, C; Zurawski, SM; Jarrett, ES; Chicoine, B; Crabtree, J; Peterson, EJ; Zurawski, G; Kaplan, DH; Igyarto, BZ				Yao, Chen; Zurawski, Sandra M.; Jarrett, Elizabeth S.; Chicoine, Brian; Crabtree, Juliet; Peterson, Erik J.; Zurawski, Gerard; Kaplan, Daniel H.; Igyarto, Botond Z.			Skin dendritic cells induce follicular helper T cells and protective humoral immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Steady-state conditions; skin dendritic cells; T follicular helper cells; protective humoral immune responses	EPIDERMAL LANGERHANS CELLS; ANTIGEN PRESENTATION; CONTACT HYPERSENSITIVITY; CUTTING EDGE; STEADY-STATE; IN-VIVO; MICE; DIFFERENTIATION; TOLERANCE; ANTIBODIES	Background: The contribution of individual subsets of dendritic cells (DCs) to generation of adaptive immunity is central to understanding immune homeostasis and protective immune responses. Objective: We sought to define functions for steady-state skin DCs. Methods: We present an approach in which we restrict antigen presentation to individual DC subsets in the skin and monitor the effects on endogenous antigen-specific CD4(+) T-and B-cell responses. Results: Presentation of foreign antigen by Langerhans cells (LC) in the absence of exogenous adjuvant led to a large expansion of T follicular helper (T-FH) cells. This was accompanied by B-cell activation, germinal center formation, and protective antibody responses against influenza. The expansion of T-FH cells and antibody responses could be elicited by both systemic and topical skin immunization. T-FH cell induction was not restricted to LCs and occurred in response to antigen presentation by CD103(+) dermal DCs. CD103(+) DCs, despite inducing similar T-FH responses as LCs, were less efficient in induction of germinal center B cells and humoral immune responses. We also found that skin DCs are sufficient to expand CXCR5(+) T-FH cells through an IL-6-and IFN-alpha/beta receptor-independent mechanism, but B cells were required for sustained Bcl-6(+) expression. Conclusions: These data demonstrate that a major unappreciated function of skin DCs is their promotion of T-FH cells and humoral immune responses that potentially represent an efficient approach for vaccination.	[Yao, Chen; Jarrett, Elizabeth S.; Chicoine, Brian; Kaplan, Daniel H.; Igyarto, Botond Z.] Univ Minnesota, Ctr Immunol, Dept Dermatol, Minneapolis, MN 55455 USA; [Crabtree, Juliet; Peterson, Erik J.] Univ Minnesota, Dept Rheumat & Autoimmune Dis, Minneapolis, MN 55455 USA; [Zurawski, Sandra M.; Zurawski, Gerard] Baylor Inst Immunol Res, Dallas, TX USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor Scott & White Health	Igyarto, BZ (corresponding author), Univ Minnesota, Ctr Immunol, Dept Dermatol, WMBB 3-260,2101 6th St SE, Minneapolis, MN 55455 USA.	botond@umn.edu	Chicoine, Brian/AAM-9970-2021	Crabtree, Juliet/0000-0003-4921-0087; Igyarto, Botond/0000-0002-9770-800X; Yao, Chen/0000-0001-6852-5661	Dermatology Foundation [00020843]; American Skin Association [00039915]; National Institutes of Health [AR056632]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056632] Funding Source: NIH RePORTER	Dermatology Foundation; American Skin Association; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by grants from the Dermatology Foundation (00020843 to B.Z.I.), American Skin Association (00039915 to B.Z.I.), and National Institutes of Health (AR056632 to D.H.K.).	Ballesteros-Tato A, 2014, IMMUNOL CELL BIOL, V92, P22, DOI 10.1038/icb.2013.62; Barnett LG, 2014, J IMMUNOL, V192, P3607, DOI 10.4049/jimmunol.1301284; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Bobr A, 2010, J IMMUNOL, V185, P4724, DOI 10.4049/jimmunol.1001802; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Cai G, 2012, J IMMUNOL, V189, P1294, DOI 10.4049/jimmunol.1102948; Choi YS, 2013, CURR OPIN IMMUNOL, V25, P366, DOI 10.1016/j.coi.2013.04.003; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; de Aguero MG, 2012, J CLIN INVEST, V122, P1700, DOI 10.1172/JCI59725; de Witte L, 2007, NAT MED, V13, P367, DOI 10.1038/nm1541; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Flacher V, 2014, EMBO MOL MED, V6, P1191, DOI 10.15252/emmm.201303283; Flacher V, 2010, J INVEST DERMATOL, V130, P755, DOI 10.1038/jid.2009.343; Flamar AL, 2012, J IMMUNOL, V189, P2645, DOI 10.4049/jimmunol.1102390; Goenka R, 2011, J IMMUNOL, V187, P1091, DOI 10.4049/jimmunol.1100853; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; Henri S, 2010, J EXP MED, V207, P189, DOI 10.1084/jem.20091964; Idoyaga J, 2008, J IMMUNOL, V180, P3647, DOI 10.4049/jimmunol.180.6.3647; Idoyaga J, 2013, J CLIN INVEST, V123, P844, DOI 10.1172/JCI65260; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; Igyarto BZ, 2009, J IMMUNOL, V183, P5085, DOI 10.4049/jimmunol.0901884; Kaplan DH, 2007, J EXP MED, V204, P2545, DOI 10.1084/jem.20071401; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kautz-Neu K, 2011, J EXP MED, V208, P885, DOI 10.1084/jem.20102318; Lahoud MH, 2011, J IMMUNOL, V187, P842, DOI 10.4049/jimmunol.1101176; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Shklovskaya E, 2011, P NATL ACAD SCI USA, V108, P18049, DOI 10.1073/pnas.1110076108; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Tubo NJ, 2013, CELL, V153, P785, DOI 10.1016/j.cell.2013.04.007	39	42	44	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1387	+		10.1016/j.jaci.2015.04.001	http://dx.doi.org/10.1016/j.jaci.2015.04.001			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25962902	Green Accepted			2022-12-18	WOS:000364787200029
J	Schedel, M; Michel, S; Gaertner, VD; Toncheva, AA; Depner, M; Binia, A; Schieck, M; Rieger, MT; Klopp, N; von Berg, A; Bufe, A; Laub, O; Rietschel, E; Heinzmann, A; Simma, B; Vogelberg, C; Genuneit, J; Illig, T; Kabesch, M				Schedel, Michaela; Michel, Sven; Gaertner, Vincent D.; Toncheva, Antoaneta A.; Depner, Martin; Binia, Aristea; Schieck, Maximilian; Rieger, Marie T.; Klopp, Norman; von Berg, Andrea; Bufe, Albrecht; Laub, Otto; Rietschel, Ernst; Heinzmann, Andrea; Simma, Burkard; Vogelberg, Christian; Genuneit, Jon; Illig, Thomas; Kabesch, Michael			Polymorphisms related to ORMDL3 are associated with asthma susceptibility, alterations in transcriptional regulation of ORMDL3, and changes in T(H)2 cytokine levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; association study; polymorphism; ORMDL3; chromosome 17q21; promoter activity; T(H)2 cytokine; upstream stimulatory factor; transcriptional regulation	ENDOPLASMIC-RETICULUM STRESS; SIGNAL TRANSDUCER; EXPRESSION; GENE; ACTIVATION; CHILDHOOD; PROMOTER; CHILDREN; VARIANTS; CELLS	Background: Chromosome 17q21, harboring the orosomucoid 1-like 3 (ORMDL3) gene, has been consistently associated with childhood asthma in genome-wide association studies. Objective: We investigated genetic variants in and around ORMDL3 that can change the function of ORMDL3 and thus contribute to asthma susceptibility. Methods: We performed haplotype analyses and fine mapping of the ORMDL3 locus in a cross-sectional (International Study of Asthma and Allergies in Childhood Phase II, n = 3557 total subjects, n = 281 asthmatic patients) and case-control (Multicenter Asthma Genetics in Childhood Study/International Study of Asthma and Allergies in Childhood Phase II, n = 1446 total subjects, n = 763 asthmatic patients) data set to identify putative causal single nucleotide polymorphisms (SNPs) in the locus. Top asthma-associated polymorphisms were analyzed for allele-specific effects on transcription factor binding and promoter activity in vitro and gene expression in PBMCs after stimulation ex vivo. Results: Two haplotypes (H1 and H2) were significantly associated with asthma in the cross-sectional (P = 9.9 x 10(-5) and P = .0035, respectively) and case-control (P = 3.15 x 10(-8) and P = .0021, respectively) populations. Polymorphisms rs8076131 and rs4065275 were identified to drive these effects. For rs4065275, a quantitative difference in transcription factor binding was found, whereas for rs8076131, changes in upstream stimulatory factor 1 and 2 transcription factor binding were observed in vitro by using different cell lines and PBMCs. This might contribute to detected alterations in luciferase activity paralleled with changes in ORMDL3 gene expression and IL-4 and IL-13 cytokine levels ex vivo in response to innate and adaptive stimuli in an allele-specific manner. Both SNPs were in strong linkage disequilibrium with asthma-associated 17q21 SNPs previously related to altered ORMDL3 gene expression. Conclusion: Polymorphisms in a putative promoter region of ORMDL3, which are associated with childhood asthma, alter transcriptional regulation of ORMDL3, correlate with changes in T(H)2 cytokines levels, and therefore might contribute to the childhood asthma susceptibility signal from 17q21.	[Michel, Sven; Gaertner, Vincent D.; Toncheva, Antoaneta A.; Binia, Aristea; Schieck, Maximilian; Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, D-93049 Regensburg, Germany; [Schedel, Michaela] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Schedel, Michaela; Michel, Sven; Toncheva, Antoaneta A.; Schieck, Maximilian; Kabesch, Michael] Hannover Med Sch, Dept Pediat Pneumol Allergy & Neonatol, Hannover, Germany; [Depner, Martin; Rieger, Marie T.; Laub, Otto] Univ Munich, Childrens Hosp, D-80539 Munich, Germany; [Klopp, Norman; Illig, Thomas] Helmholtz Ctr Munich, Res Grp Mol Epidemiol, Neuherberg, Germany; [Klopp, Norman; Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany; [von Berg, Andrea] Marien Hosp, Childrens Dept, Res Inst Prevent Allerg Dis, Wesel, Germany; [Bufe, Albrecht] Ruhr Univ Bochum, Dept Expt Pneumol, Bochum, Germany; [Rietschel, Ernst] Univ Cologne, Univ Childrens Hosp, Cologne, Germany; [Heinzmann, Andrea] Univ Freiburg, Univ Childrens Hosp, D-79106 Freiburg, Germany; [Simma, Burkard] Feldkirch Hosp, Childrens Dept, Feldkirch, Austria; [Vogelberg, Christian] Tech Univ Dresden, Univ Childrens Hosp, Dresden, Germany; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Binia, Aristea] Nestle Res Ctr, Nutr & Hlth Dept, CH-1000 Lausanne, Switzerland	National Jewish Health; Hannover Medical School; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School; St. Marien Hospital; Ruhr University Bochum; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; Nestle SA	Kabesch, M (corresponding author), Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Campus St Hedwig,Steinmetzstr 1-3, D-93049 Regensburg, Germany.	michael.kabesch@ukr.de	Genuneit, Jon/I-9323-2012; Toncheva, Antoaneta A/D-7169-2013; Schieck, Maximilian/D-4121-2013; Kabesch, Michael/GZM-1583-2022; Schedel, Michaela/B-3065-2019; Kabesch, Michael/AAB-5701-2020; Gaertner, Vincent/E-2049-2014	Genuneit, Jon/0000-0001-5764-1528; Toncheva, Antoaneta A/0000-0001-5019-5174; Schieck, Maximilian/0000-0001-5878-0546; Schedel, Michaela/0000-0001-8465-2986; Binia, Aristea/0000-0002-8327-049X; Michel, Sven/0000-0003-3604-3187; Bufe, Albrecht/0000-0001-7335-9362; Gaertner, Vincent/0000-0001-5330-652X				Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Anantharaman A, 2011, MOL CELL BIOL, V31, P1332, DOI 10.1128/MCB.01186-10; Ball WB, 2014, INT J BIOCHEM CELL B, V48, P66, DOI [10.1016/j.biocel.2014.01.004, 10.1016/j.bioce1.2014.01.004]; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berlivet S, 2012, HUM GENET, V131, P1161, DOI 10.1007/s00439-012-1142-x; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Bu Y, 2007, J BIOL CHEM, V282, P26725, DOI 10.1074/jbc.M702885200; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Carreras-Sureda A, 2013, HUM MOL GENET, V22, P519, DOI 10.1093/hmg/dds450; Clifford RL, 2012, J IMMUNOL, V189, P819, DOI 10.4049/jimmunol.1103641; Corre S, 2005, PIGM CELL RES, V18, P337, DOI 10.1111/j.1600-0749.2005.00262.x; Deng CW, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003524; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Ge YB, 2003, J BIOL CHEM, V278, P49901, DOI 10.1074/jbc.M305085200; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Hsu KJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-4; Jin R, 2012, INT J BIOCHEM CELL B, V44, P1174, DOI 10.1016/j.biocel.2012.04.007; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Michel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013894; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Potaczek DP, 2013, PEDIAT ALLERG IMM-UK, V24, P441, DOI 10.1111/pai.12083; Qiu RF, 2013, FEBS J, V280, P2014, DOI 10.1111/febs.12225; Robroeks CMHHT, 2010, CLIN EXP ALLERGY, V40, P77, DOI 10.1111/j.1365-2222.2009.03397.x; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Team RC, R LANG ENV STAT COMP; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weber KS, 2008, J IMMUNOL, V180, P1442, DOI 10.4049/jimmunol.180.3.1442; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005765; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	57	42	45	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					893	+		10.1016/j.jaci.2015.03.014	http://dx.doi.org/10.1016/j.jaci.2015.03.014			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25930191				2022-12-18	WOS:000362976300008
J	van Rhijn, BD; Vlieg-Boerstra, BJ; Versteeg, SA; Akkerdaas, JH; van Ree, R; Terreehorst, I; Sprikkelman, AB; Verheij, J; Smout, AJPM; Bredenoord, AJ				van Rhijn, Bram D.; Vlieg-Boerstra, Berber J.; Versteeg, Serge A.; Akkerdaas, Jaap H.; van Ree, Ronald; Terreehorst, Ingrid; Sprikkelman, Aline B.; Verheij, Joanne; Smout, Andreas J. P. M.; Bredenoord, Albert J.			Evaluation of allergen-microarray-guided dietary intervention as treatment of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; ADULTS		[van Rhijn, Bram D.; Smout, Andreas J. P. M.; Bredenoord, Albert J.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Vlieg-Boerstra, Berber J.; Sprikkelman, Aline B.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Resp Med & Allergy, NL-1105 AZ Amsterdam, Netherlands; [Versteeg, Serge A.; Akkerdaas, Jaap H.; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [van Ree, Ronald; Terreehorst, Ingrid] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Verheij, Joanne] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	van Rhijn, BD (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.j.bredenoord@amc.uva.nl	Vlieg-Boerstra, Berber/O-1922-2019	Vlieg-Boerstra, Berber/0000-0001-7962-5406; Verheij, Joanne/0000-0003-1283-630X; Bredenoord, Albert/0000-0001-5918-2062				Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; Armentia A, 2015, ALLERGOL IMMUNOPATH, V43, P73, DOI 10.1016/j.aller.2014.02.006; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Kummeling I, 2009, ALLERGY, V64, P1493, DOI 10.1111/j.1398-9995.2009.02046.x; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; van Rhijn BD, 2013, ALLERGY, V68, P1475, DOI 10.1111/all.12257	8	42	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1095	1097		10.1016/j.jaci.2015.02.038	http://dx.doi.org/10.1016/j.jaci.2015.02.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25935104	Bronze			2022-12-18	WOS:000362976300029
J	Ardeniz, O; Unger, S; Onay, H; Ammann, S; Keck, C; Cianga, C; Gerceker, B; Martin, B; Fuchs, I; Salzer, U; Ikinciogullari, A; Guloglu, D; Dereli, T; Thimme, R; Ehl, S; Schwarz, K; Schmitt-Graeff, A; Cianga, P; Fisch, P; Warnatz, K				Ardeniz, Omur; Unger, Susanne; Onay, Huseyin; Ammann, Sandra; Keck, Caroline; Cianga, Corina; Gerceker, Bengu; Martin, Bianca; Fuchs, Ilka; Salzer, Ulrich; Ikinciogullari, Aydan; Guloglu, Deniz; Dereli, Tugrul; Thimme, Robert; Ehl, Stephan; Schwarz, Klaus; Schmitt-Graeff, Annette; Cianga, Petru; Fisch, Paul; Warnatz, Klaus			beta(2)-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-Microglobulin deficiency; human; MHC class I; hypogammaglobulinemia; neonatal Fc receptor; CD1; gamma delta T cells; CD8 T cells	CLASS-I DEFICIENCY; FAMILIAL HYPERCATABOLIC HYPOPROTEINEMIA; COMMON VARIABLE IMMUNODEFICIENCY; CYTOTOXIC T-CELLS; BETA-2-MICROGLOBULIN-DEFICIENT MICE; NK-CELLS; HLA-B; TAP DEFICIENCY; FC-RECEPTOR; MOLECULES	Background: Most patients with MHC class I (MHC-I) deficiency carry genetic defects in transporter associated with antigen processing 1 (TAP1) or TAP2. The clinical presentation can vary, and about half of the patients have severe skin disease. Previously, one report described beta(2)-microglobulin (beta(2)m) deficiency as another monogenetic cause of MHC-I deficiency, but no further immunologic evaluation was performed. Objective: We sought to describe the molecular and immunologic features of b2m deficiency in 2 Turkish siblings with new diagnoses. Methods: Based on clinical and serologic findings, the genetic defect was detected by means of candidate gene analysis. The immunologic characterization comprises flow cytometry, ELISA, functional assays, and immunohistochemistry. Results: Here we provide the first extensive clinical and immunologic description of beta(2)m deficiency in 2 siblings. The sister had recurrent respiratory tract infections and severe skin disease, whereas the brother was fairly asymptomatic but had bronchiectasis. Not only polymorphic MHC-I but also the related CD1a, CD1b, CD1c, and neonatal Fc receptor molecules were absent from the surfaces of beta(2)m-deficient cells. Absent neonatal Fc receptor surface expression led to low serum IgG and albumin levels in both siblings, whereas the heterozygous parents had normal results for all tested parameters except beta(2)m mRNA (B2M) expression. Similar to TAP deficiency in the absence of a regular CD8 T-cell compartment, CD8(+) gamma delta T cells were strongly expanded. Natural killer cells were normal in number but not "licensed to kill." Conclusion: The clinical presentation of patients with beta(2)m deficiency resembles that of patients with other forms of MHC-I deficiency, but because of the missing stabilizing effect of beta(2)m on other members of the MHC-I family, the immunologic defect is more extensive than in patients with TAP deficiency.	[Ardeniz, Omur] Ege Univ, Fac Med, Internal Med Div Allergy & Clin Immunol, Izmir, Turkey; [Onay, Huseyin] Ege Univ, Fac Med, Dept Med Genet, Izmir, Turkey; [Gerceker, Bengu; Dereli, Tugrul] Ege Univ, Fac Med, Dept Dermatol, Izmir, Turkey; [Unger, Susanne; Ammann, Sandra; Fuchs, Ilka; Salzer, Ulrich; Ehl, Stephan; Warnatz, Klaus] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Unger, Susanne; Ammann, Sandra; Fuchs, Ilka; Salzer, Ulrich; Ehl, Stephan; Warnatz, Klaus] Univ Freiburg, Freiburg, Germany; [Keck, Caroline; Schmitt-Graeff, Annette; Fisch, Paul] Univ Med Ctr Freiburg, Inst Pathol, Freiburg, Germany; [Martin, Bianca; Thimme, Robert] Univ Med Ctr Freiburg, Dept Internal Med 2, Freiburg, Germany; [Cianga, Corina; Cianga, Petru] Grigore T Popa Univ Med & Pharm, Dept Immunol, Iasi, Romania; [Ikinciogullari, Aydan; Guloglu, Deniz] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, TR-06100 Ankara, Turkey; [Schwarz, Klaus] Univ Ulm, Inst Transfus Med, D-89069 Ulm, Germany; [Schwarz, Klaus] German Red Cross Blood Serv, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany	Ege University; Ege University; Ege University; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Grigore T Popa University of Medicine & Pharmacy; Ankara University; Ulm University	Ardeniz, O (corresponding author), Ege Univ, Fac Med, Dept Internal Med, Div Allergy & Clin Immunol, Izmir, Turkey.	tanmehomu@yahoo.com	İkinciogullari, Aydan/AAQ-3841-2020; Ehl, Stephan/AAM-6006-2020; Warnatz, Klaus/AAD-3464-2022	İkinciogullari, Aydan/0000-0003-1145-0843; Ammann, Sandra/0000-0003-0385-1890; Ehl, Stephan/0000-0002-9265-2721; Unger, Susanne/0000-0001-6916-7544; Salzer, Ulrich/0000-0002-1769-1157	German Federal Ministry of Education and Research [BMBF 01EO1303]; Deutsche Jose Carreras Leukamie Stiftung [DJCLS R10/34f]; Romanian Academy of Medical Sciences, VIASAN grant [328]; "Grigore T. Popa'' University of Medicine and Pharmacy, Iasi, Romania [7365/2010]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Deutsche Jose Carreras Leukamie Stiftung; Romanian Academy of Medical Sciences, VIASAN grant; "Grigore T. Popa'' University of Medicine and Pharmacy, Iasi, Romania	Supported by the German Federal Ministry of Education and Research (BMBF 01EO1303 to K.W., S.U., S.E., and U.S.), grant DJCLS R10/34f from the Deutsche Jose Carreras Leukamie Stiftung (to P.F.), and Romanian Academy of Medical Sciences, VIASAN grant #328 (to P.C.). C.C. and P.C. have received research support from the "Grigore T. Popa'' University of Medicine and Pharmacy, Iasi, Romania (grant 7365/2010).	Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; Blumberg RS, 1998, AM J PHYSIOL-GASTR L, V274, pG227, DOI 10.1152/ajpgi.1998.274.2.G227; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cerundolo V, 2006, SEMIN IMMUNOL, V18, P330, DOI 10.1016/j.smim.2006.07.006; CHEN BP, 1989, HUM IMMUNOL, V26, P137, DOI 10.1016/0198-8859(89)90099-2; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; De la Salle H, 2002, CLIN EXP IMMUNOL, V128, P525, DOI 10.1046/j.1365-2249.2002.01862.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; EPSTEIN SL, 1993, J IMMUNOL, V150, P5484; French JD, 2005, P NATL ACAD SCI USA, V102, P14741, DOI 10.1073/pnas.0507520102; French JD, 2009, J IMMUNOL, V182, P1892, DOI 10.4049/jimmunol.0803165; Fujiura Y, 1996, J IMMUNOL, V156, P2710; Gadola SD, 2000, CLIN EXP IMMUNOL, V121, P173, DOI 10.1046/j.1365-2249.2000.01264.x; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Koh YI, 2008, J IMMUNOL, V181, P4560, DOI 10.4049/jimmunol.181.7.4560; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Lamprecht P, 2001, THORAX, V56, P751, DOI 10.1136/thorax.56.10.751; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MANICKAN E, 1995, J VIROL, V69, P8178, DOI 10.1128/JVI.69.12.8178-8179.1995; MARUSICGALESIC S, 1993, EUR J IMMUNOL, V23, P3115, DOI 10.1002/eji.1830231211; Miranda CJ, 2004, BLOOD, V103, P2847, DOI 10.1182/blood-2003-09-3300; MULLER D, 1992, SCIENCE, V255, P1576, DOI 10.1126/science.1347959; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; Polic B, 1996, J GEN VIROL, V77, P217, DOI 10.1099/0022-1317-77-2-217; Praetor A, 2002, J CELL SCI, V115, P2389; Rath T, 2013, J CLIN IMMUNOL, V33, pS9, DOI 10.1007/s10875-012-9768-y; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; Sullivan LC, 2006, TRENDS IMMUNOL, V27, P413, DOI 10.1016/j.it.2006.07.006; TAY CH, 1995, J IMMUNOL, V154, P780; ThomaUszynski S, 1997, MICROB PATHOGENESIS, V23, P101, DOI 10.1006/mpat.1997.0133; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WALDMANN TA, 1990, J CLIN INVEST, V86, P2093, DOI 10.1172/JCI114947; Wani MA, 2006, P NATL ACAD SCI USA, V103, P5084, DOI 10.1073/pnas.0600548103; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; WU QH, 1994, J GEN VIROL, V75, P2755, DOI 10.1099/0022-1317-75-10-2755; Zeissig S, 2012, ANN NY ACAD SCI, V1250, P14, DOI 10.1111/j.1749-6632.2011.06380.x; Zimmer J, 2005, QJM-INT J MED, V98, P719, DOI 10.1093/qjmed/hci112; Zimmer J, 1998, J EXP MED, V187, P117, DOI 10.1084/jem.187.1.117; Zimmer J, 2013, THORAX, V68, P490, DOI 10.1136/thoraxjnl-2012-203052	47	42	43	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					392	401		10.1016/j.jaci.2014.12.1937	http://dx.doi.org/10.1016/j.jaci.2014.12.1937			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25702838				2022-12-18	WOS:000359004900021
J	Turner, PJ; Southern, J; Andrews, NJ; Miller, E; Erlewyn-Lajeunesse, M				Turner, Paul J.; Southern, Jo; Andrews, Nick J.; Miller, Elizabeth; Erlewyn-Lajeunesse, Michel		SNIFFLe Study Investigators	Safety of live attenuated influenza vaccine in atopic children with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; live attenuated influenza vaccine; asthma; recurrent wheezing; safety	POSTMARKETING EVALUATION; EFFICACY; IMMUNIZATION; INTRANASAL; TRIVALENT; FREQUENCY; YOUNGER; ASTHMA	Background: Live attenuated influenza vaccine (LAIV) is an intranasal vaccine recently incorporated into the United Kingdom immunization schedule. However, it contains egg protein and, in the absence of safety data, is contraindicated in patients with egg allergy. Furthermore, North American guidelines recommend against its use in asthmatic children. Objective: We sought to assess the safety of LAIV in children with egg allergy. Methods: We performed a prospective, multicenter, open-label, phase IV intervention study involving 11 secondary/tertiary centers in the United Kingdom. Children with egg allergy (defined as a convincing clinical reaction to egg within the past 12 months and/or >95% likelihood of clinical egg allergy as per published criteria) were recruited. LAIV was administered under medical supervision, with observation for 1 hour and telephone follow-up 72 hours later. Results: Four hundred thirty-three doses were administered to 282 children with egg allergy (median, 4.9 years; range, 2-17 years); 115 (41%) had experienced prior anaphylaxis to egg. A physician's diagnosis of asthma/recurrent wheezing was noted in 67%, and 51% were receiving regular preventer therapy. There were no systemic allergic reactions (upper 95% CI for population, 1.3%). Eight children experienced mild self-limiting symptoms, which might have been due an IgE-mediated allergic reaction. Twenty-six (9.4%; 95% CI for population, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, including 13 with parent-reported wheeze. None of these episodes required medical intervention beyond routine treatment. Conclusions: In contrast to current recommendations, LAIV appears to be safe for use in children with egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze.	[Turner, Paul J.] Univ London Imperial Coll Sci Technol & Med, Sect Paediat Allergy & Immunol, London W2, England; [Turner, Paul J.] Imperial Coll London, MRC, London, England; [Turner, Paul J.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Turner, Paul J.; Southern, Jo; Andrews, Nick J.; Miller, Elizabeth] Publ Hlth England, Immunisat Hepatitis & Blood Safety Dept, London, England; [Turner, Paul J.] Univ Sydney, Div Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Erlewyn-Lajeunesse, Michel] Univ Hosp Southampton NHS Fdn Trust, Dept Paediat Allergy & Immunol, Southampton, Hants, England	Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; Public Health England; University of Sydney; University of Southampton; University Hospital Southampton NHS Foundation Trust	Turner, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Paediat Allergy & Immunol, Norfolk Pl, London W2, England.	p.turner@imperial.ac.uk		Turner, Paul/0000-0001-9862-5161; Erlewyn-Lajeunesse, Michel/0000-0003-1982-1397; Snape, Matthew/0000-0003-0531-5426	Department of Health Policy Research Programme (National Vaccine Evaluation Consortium) [039/0031]; Health Protection Scotland; Department of Health; UK Medical Research Council [MR/K010468/1]; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; MRC-Asthma UK Centre in Allergic Mechanisms of Asthma; MRC [MR/K010468/1] Funding Source: UKRI; Medical Research Council [MR/K010468/1] Funding Source: researchfish	Department of Health Policy Research Programme (National Vaccine Evaluation Consortium); Health Protection Scotland; Department of Health; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; MRC-Asthma UK Centre in Allergic Mechanisms of Asthma(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This report is independent research commissioned and funded by the Department of Health Policy Research Programme (National Vaccine Evaluation Consortium, 039/0031). The views expressed in this publication are those of the authors and not necessarily those of the Department of Health. The study received additional local support through the NIHR Clinical Research Networks, with additional funding for a Scottish site from Health Protection Scotland. P.J.T. and M.E.-L had financial support from the Department of Health for the submitted work. P.J.T. is a recipient of a Clinician Scientist award from the UK Medical Research Council (grant MR/K010468/1) and is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and the MRC-Asthma UK Centre in Allergic Mechanisms of Asthma.	Ambrose CS, 2012, EUR J CLIN MICROBIOL, V31, P2549, DOI 10.1007/s10096-012-1595-9; Ambrose CS, 2012, VACCINE, V30, P886, DOI 10.1016/j.vaccine.2011.11.104; Baxter R, 2012, VACCINE, V30, P2989, DOI 10.1016/j.vaccine.2012.02.039; Belshe RB, 2008, VACCINE, V26, pD10, DOI 10.1016/j.vaccine.2008.06.083; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; British Thoracic Society, 2005, BRIT GUID MAN ASTHM; Des Roches A, 2014, J ALLERGY CLIN IMMUN, V3, P138; Des Roches A, 2012, J ALLERGY CLIN IMMUN, V130, P1213, DOI 10.1016/j.jaci.2012.07.046; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Erlewyn-Lajeunesse M, 2011, CLIN EXP ALLERGY, V41, P1367, DOI 10.1111/j.1365-2222.2011.03842.x; Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf; Gaglani MJ, 2008, PEDIATR INFECT DIS J, V27, P444, DOI 10.1097/INF.0b013e3181660c2e; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Goldis ME, 2011, PEDIAT ALLERG IMM-UK, V22, P642, DOI 10.1111/j.1399-3038.2011.01158.x; Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Izurieta HS, 2005, JAMA-J AM MED ASSOC, V294, P2720, DOI 10.1001/jama.294.21.2720; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; McKinney KK, 2011, J ALLERGY CLIN IMMUN, V127, P1629, DOI 10.1016/j.jaci.2011.02.003; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Public Health England, IMMUNISATION INFECT; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Tennis P, 2012, VACCINE, V30, P6099, DOI 10.1016/j.vaccine.2012.07.031; Tennis P, 2011, VACCINE, V29, P4947, DOI 10.1016/j.vaccine.2011.04.113; Toback SL, 2013, VACCINE, V31, P1812, DOI 10.1016/j.vaccine.2013.01.055; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V136, P376, DOI 10.1016/j.jaci.2014.12.1925	30	42	50	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					376	381		10.1016/j.jaci.2014.12.1925	http://dx.doi.org/10.1016/j.jaci.2014.12.1925			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25684279	hybrid, Green Published			2022-12-18	WOS:000359004900019
J	Felgentreff, K; Lee, YN; Frugoni, F; Du, LK; van der Burg, M; Giliani, S; Tezcan, I; Reisli, I; Mejstrikova, E; de Villartay, JP; Sleckman, BP; Manis, J; Notarangelo, LD				Felgentreff, Kerstin; Lee, Yu Nee; Frugoni, Francesco; Du, Likun; van der Burg, Mirjam; Giliani, Silvia; Tezcan, Ilhan; Reisli, Ismail; Mejstrikova, Ester; de Villartay, Jean-Pierre; Sleckman, Barry P.; Manis, John; Notarangelo, Luigi D.			Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						V(D)J recombination; nonhomologous end-joining; DNA repair; ARTEMIS deficiency; DCLRE1C mutations; severe combined immunodeficiency	SEVERE COMBINED IMMUNODEFICIENCY; B-CELL DIFFERENTIATION; V(D)J RECOMBINATION; IMMUNE-DEFICIENCY; DISEASE ALLELE; GENE-MUTATIONS; OMENN-SYNDROME; RAG MUTATIONS; PROTEIN; REPAIR	Background: The endonuclease ARTEMIS, which is encoded by the DCLRE1C gene, is a component of the nonhomologous end-joining pathway and participates in hairpin opening during the V(D)J recombination process and repair of a subset of DNA double-strand breaks. Patients with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular radiosensitivity, but hypomorphic mutations can cause milder phenotypes (leaky SCID). Objective: We sought to correlate the functional effect of human DCLRE1C mutations on phenotypic presentation in patients with ARTEMIS deficiency. Methods: We studied the recombination and DNA repair activity of 41 human DCLRE1C mutations in Dclre1c(-/-) v-abl kinase-transformed pro-B cells retrovirally engineered with a construct that allows quantification of recombination activity by means of flow cytometry. For assessment of DNA repair efficacy, resolution of gamma H2AX accumulation was studied after ionizing radiation. Results: Low or absent activity was detected for mutations causing a typical SCID phenotype. Most of the patients with leaky SCID were compound heterozygous for 1 loss-of-function and 1 hypomorphic allele, with significant residual levels of recombination and DNA repair activity. Deletions disrupting the C-terminus result in truncated but partially functional proteins and are often associated with leaky SCID. Overexpression of hypomorphic mutants might improve the functional defect. Conclusions: Correlation between the nature and location of DCLRE1C mutations, functional activity, and the clinical phenotype has been observed. Hypomorphic variants that have been reported in the general population can be disease causing if combined in trans with a loss-of-function allele. Therapeutic strategies aimed at inducing overexpression of hypomorphic alleles might be beneficial.	[Felgentreff, Kerstin; Lee, Yu Nee; Frugoni, Francesco; Du, Likun; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Manis, John] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Transfus Med, Boston, MA 02115 USA; [van der Burg, Mirjam] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Giliani, Silvia] Univ Brescia, Dept Pediat, Angelo Nocivelli Inst Mol Med, I-25121 Brescia, Italy; [Tezcan, Ilhan] Hacettepe Univ, Sch Med, Ihsan Dogramaci Childrens Hosp, Dept Immunol, Ankara, Turkey; [Reisli, Ismail] Necmettin Erbakan Univ, Meram Med Fac, Dept Pediat Immunol & Allergy, Konya, Turkey; [Mejstrikova, Ester] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Childhood Leukemia Invest Prague, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [de Villartay, Jean-Pierre] Univ Paris 05, Sorbonne Paris Cite, UMR1163, Lab Genome Dynam Immune Syst,INSERM, Paris, France; [Sleckman, Barry P.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Notarangelo, Luigi D.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Erasmus University Rotterdam; Erasmus MC; University of Brescia; Hacettepe University; Necmettin Erbakan University; Selcuk University; Charles University Prague; Charles University Prague; Motol University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Washington University (WUSTL); Harvard University	Notarangelo, LD (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Manton Ctr Orphan Dis Res, Div Immunol,Childrens Hosp Boston, Karp Res Bldg,Rm 12017,1 Blackfan Circle, Boston, MA 02115 USA.	Luigi.Notarangelo@childrens.harvard.edu	Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016; de Villartay, jean pierre/H-9353-2017; Lee, Yu Nee/T-2360-2017	Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; de Villartay, jean pierre/0000-0001-5987-0463; Frugoni, Francesco/0000-0002-1769-8121; Lee, Yu Nee/0000-0001-8648-5253; Du, Likun/0000-0002-8448-2187	National Institute of Allergy and Infectious Diseases/National Institutes of Health [P01 AI076210-05, R01AI00887]; March of Dimes grant [1-FY13-500]; German Research Foundation [FE 1253/1-1]; Ligue Nationale contre le Cancer (Equipe Labellisee La LIGUE); MZCR [00064203, CZ.2.16/3.1.00/21540]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074953, P01AI076210, R01AI100887] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); March of Dimes grant(March of Dimes); German Research Foundation(German Research Foundation (DFG)); Ligue Nationale contre le Cancer (Equipe Labellisee La LIGUE)(Institut National du Cancer (INCA) France); MZCR(Ministry of Health, Czech Republic); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants P01 AI076210-05 and R01AI00887 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (to L.D.N.) and March of Dimes grant 1-FY13-500 (to L.D.N.). K.F. received funding from the German Research Foundation (FE 1253/1-1). The JpdeV laboratory is partly funded by Ligue Nationale contre le Cancer (Equipe Labellisee La LIGUE). E.M. is supported by MZCR 00064203 and CZ.2.16/3.1.00/21540.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Bajin IY, 2013, MOL IMMUNOL, V56, P354, DOI 10.1016/j.molimm.2013.05.004; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Bredemeyer AL, 2008, NATURE, V456, P819, DOI 10.1038/nature07392; Darroudi F, 2007, MUTAT RES-FUND MOL M, V615, P111, DOI 10.1016/j.mrfmmm.2006.11.029; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; de Villartay JP, 2009, DNA REPAIR, V8, P202, DOI 10.1016/j.dnarep.2008.10.010; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Evans PM, 2006, HUM MOL GENET, V15, P1303, DOI 10.1093/hmg/ddl050; Huang Y, 2009, J EXP MED, V206, P893, DOI 10.1084/jem.20082396; Jacobs C, 2011, HUM MOL GENET, V20, P806, DOI 10.1093/hmg/ddq524; Kobayashi N, 2003, HUM GENET, V112, P348, DOI 10.1007/s00439-002-0897-x; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lagresle-Peyrou C, 2008, MOL THER, V16, P396, DOI 10.1038/sj.mt.6300353; Le Deist F, 2004, IMMUNOL REV, V200, P142, DOI 10.1111/j.0105-2896.2004.00169.x; Lee PP, 2013, CLIN IMMUNOL, V149, P464, DOI 10.1016/j.clim.2013.08.006; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Malu S, 2012, J EXP MED, V209, P955, DOI 10.1084/jem.20111437; Martin OA, 2013, DNA REPAIR, V12, P844, DOI 10.1016/j.dnarep.2013.07.002; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Multhaup M, 2010, HUM GENE THER, V21, P865, DOI 10.1089/hum.2009.162; Musio A, 2005, EUR J IMMUNOL, V35, P1250, DOI 10.1002/eji.200425555; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pannicke U, 2010, HUM MUTAT, V31, P197, DOI 10.1002/humu.21168; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Soubeyrand S, 2006, J MOL BIOL, V358, P1200, DOI 10.1016/j.jmb.2006.02.061; Van der Burg M, 2007, EUR J IMMUNOL, V37, P3522, DOI 10.1002/eji.200737624; Wang JD, 2014, GENE DEV, V28, P2693, DOI 10.1101/gad.252478.114; Woodbine L, 2010, DNA REPAIR, V9, P1003, DOI 10.1016/j.dnarep.2010.07.001	38	42	43	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					140	U276		10.1016/j.jaci.2015.03.005	http://dx.doi.org/10.1016/j.jaci.2015.03.005			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25917813	Green Accepted			2022-12-18	WOS:000357542200016
J	Jia, Y; Yu, HF; Fernandes, SM; Wei, YD; Gonzalez-Gil, A; Motari, MG; Vajn, K; Stevens, WW; Peters, AT; Bochner, BS; Kern, RC; Schleimer, RP; Schnaar, RL				Jia, Yi; Yu, Huifeng; Fernandes, Steve M.; Wei, Yadong; Gonzalez-Gil, Anabel; Motari, Mary G.; Vajn, Katarina; Stevens, Whitney W.; Peters, Anju T.; Bochner, Bruce S.; Kern, Robert C.; Schleimer, Robert P.; Schnaar, Ronald L.			Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; inflammation; submucosal gland cells; siglecs; glycobiology; mucin 5B; nuclear factor kappa B	F LIGANDS; GLYCOBIOLOGY; INFLAMMATION; RECOGNITION; ACTIVATION; DEFICIENT; RECEPTORS; SECRETION; GLYCANS; PROTEIN	Background: Balanced activation and inhibition of the immune system ensures pathogen clearance while avoiding hyperinflammation. Siglecs, sialic acid-binding proteins found on subsets of immune cells, often inhibit inflammation: Siglec-8 on eosinophils and Siglec-9 on neutrophils engage sialoglycan ligands on airways to diminish ongoing inflammation. The identities of human siglec ligands and their expression during inflammation are largely unknown. Objective: The histologic distribution, expression, and molecular characteristics of siglec ligands were explored in healthy and inflamed human upper airways and in a cellular model of airway inflammation. Methods: Normal and chronically inflamed upper airway tissues were stained for siglec ligands. The ligands were extracted from normal and inflamed tissues and from human Calu-3 cells for quantitative analysis by means of siglec blotting and isolation by means of siglec capture. Results: Siglec-8 ligands were expressed on a subpopulation of submucosal gland cells of human inferior turbinate, whereas Siglec-9 ligands were expressed more broadly (submucosal glands, epithelium, and connective tissue); both were significantly upregulated in patients with chronic rhinosinusitis. Human airway (Calu-3) cells expressed Siglec-9 ligands on mucin 5B (MUC5B) under inflammatory control through the nuclear factor kappa B pathway, and MUC5B carried sialoglycan ligands of Siglec-9 on human upper airway tissue. Conclusion: Inflammation results in upregulation of immuneinhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. Siglec-9 ligands are upregulated through the nuclear factor kappa B pathway, resulting in their enhanced expression on MUC5B. Siglec sialoglycan ligand expression in inflamed cells and tissues may contribute to the control of airway inflammation.	[Jia, Yi] Third Mil Med Univ, Dept Pharmacol, Chongqing, Peoples R China; [Jia, Yi; Yu, Huifeng; Fernandes, Steve M.; Wei, Yadong; Gonzalez-Gil, Anabel; Motari, Mary G.; Vajn, Katarina; Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Stevens, Whitney W.; Peters, Anju T.; Bochner, Bruce S.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otorhinolaryngol, Chicago, IL 60611 USA	Army Medical University; Johns Hopkins University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	JIA, YI/AAR-3337-2020; Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Alvarenga, Anabel/0000-0002-1618-8920	Lung Inflammatory Disease Program of Excellence in Glycoscience from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute [P01 HL107151]; NIH [R37 HL068546, P01 AI106683, T32 GM080189]; Ernest S. Bazley Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, P01AI106683, U19AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080189] Funding Source: NIH RePORTER	Lung Inflammatory Disease Program of Excellence in Glycoscience from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the Lung Inflammatory Disease Program of Excellence in Glycoscience from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (P01 HL107151). R.P.S. was supported by R37 HL068546 and P01 AI106683 from the NIH and by the Ernest S. Bazley Foundation. A.G.-G. was supported in part by the NIH-funded Chemistry-Biology Interface Program at Johns Hopkins University (T32 GM080189).	An HJ, 2009, CURR OPIN CHEM BIOL, V13, P421, DOI 10.1016/j.cbpa.2009.07.022; Banga A, 2014, AM J PHYSIOL-LUNG C, V306, pL937, DOI 10.1152/ajplung.00190.2013; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Bridges RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a015016; Casalino-Matsuda SM, 2004, J BIOL CHEM, V279, P21606, DOI 10.1074/jbc.M309950200; Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Cohen M, 2010, OMICS, V14, P455, DOI 10.1089/omi.2009.0148; Ernst B, 2009, NAT REV DRUG DISCOV, V8, P661, DOI 10.1038/nrd2852; Greaser Marion L, 2012, Methods Mol Biol, V869, P111, DOI 10.1007/978-1-61779-821-4_10; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Issa SMA, 2011, ELECTROPHORESIS, V32, P3554, DOI 10.1002/elps.201100374; Johnson JL, 2013, TRENDS IMMUNOL, V34, P290, DOI 10.1016/j.it.2013.01.006; Kane BA, 2014, J INNATE IMMUN, V6, P727, DOI 10.1159/000363449; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, P240, DOI 10.1016/j.jaci.2013.05.018; Kiwamoto T, 2013, CURR OPIN ALLERGY CL, V13, P106, DOI 10.1097/ACI.0b013e32835b594a; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Lillehoj EP, 2013, INT REV CEL MOL BIO, V303, P139, DOI 10.1016/B978-0-12-407697-6.00004-0; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; McMillan SJ, 2013, BLOOD, V121, P2084, DOI 10.1182/blood-2012-08-449983; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Mountney A, 2010, P NATL ACAD SCI USA, V107, P11561, DOI 10.1073/pnas.1006683107; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; O'Neill LAJ, 2009, PHARMACOL REV, V61, P177, DOI 10.1124/pr.109.001073; Patnode ML, 2013, J BIOL CHEM, V288, P26533, DOI 10.1074/jbc.M113.485409; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rabinovich GA, 2012, ANN NY ACAD SCI, V1253, P1, DOI 10.1111/j.1749-6632.2012.06492.x; Saieg A, 2015, PEDIATR RES, V77, P356, DOI 10.1038/pr.2014.187; Schnaar RL, 2015, J ALLERGY CLIN IMMUN, V135, P609, DOI 10.1016/j.jaci.2014.10.057; SOMMERHOFF CP, 1990, AM J RESP CELL MOL, V2, P41, DOI 10.1165/ajrcmb/2.1.41; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Taylor ME, 2014, CURR OPIN STRUC BIOL, V28, P14, DOI 10.1016/j.sbi.2014.07.003; Thomas SN, 2009, AM J PHYSIOL-CELL PH, V296, pC505, DOI 10.1152/ajpcell.00472.2008; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Varki A, 2012, ANN NY ACAD SCI, V1253, P16, DOI 10.1111/j.1749-6632.2012.06517.x; Viswanathan H, 2006, AM J RHINOL, V20, P554, DOI 10.2500/ajr.2006.20.2935; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	43	42	44	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					799	U339		10.1016/j.jaci.2015.01.004	http://dx.doi.org/10.1016/j.jaci.2015.01.004			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25747723	Green Accepted			2022-12-18	WOS:000351065000028
J	Broesby-Olsen, S; Oropeza, AR; Bindslev-Jensen, C; Vestergaard, H; Moller, MB; Siebenhaar, F; Kristensen, T; Mortz, CG				Broesby-Olsen, Sigurd; Oropeza, Athamaica Ruiz; Bindslev-Jensen, Carsten; Vestergaard, Hanne; Moller, Michael Boe; Siebenhaar, Frank; Kristensen, Thomas; Mortz, Charlotte G.		Mastocytosis Ctr Odense Univ Hosp; Odense Res Ctr Anaphylaxis	Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SYSTEMIC MASTOCYTOSIS		[Broesby-Olsen, Sigurd; Oropeza, Athamaica Ruiz; Bindslev-Jensen, Carsten; Mortz, Charlotte G.] Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; [Broesby-Olsen, Sigurd; Oropeza, Athamaica Ruiz; Bindslev-Jensen, Carsten; Mortz, Charlotte G.] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark; [Vestergaard, Hanne] Odense Univ Hosp, Dept Hematol, DK-5000 Odense, Denmark; [Moller, Michael Boe; Kristensen, Thomas] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark; [Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten; Vestergaard, Hanne; Moller, Michael Boe; Mortz, Charlotte G.] Univ So Denmark, Inst Clin Res, Odense, Denmark; [Siebenhaar, Frank] Charite Univ Med Berlin, Dept Dermatol & Allergy, Interdisciplinary Mastocytosis Ctr Charite, Berlin, Germany	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Broesby-Olsen, S (corresponding author), Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark.	sigurd.broesby-olsen@rsyd.dk	Bindslev-Jensen, Carsten/H-1877-2011; Møller, Michael Boe/AAD-2113-2019; Møller, Michael B/G-8340-2016	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Møller, Michael Boe/0000-0003-2041-3630; Møller, Michael B/0000-0003-2041-3630; Mortz, Charlotte G/0000-0001-8710-0829; Siebenhaar, Frank/0000-0003-4532-1644; Oropeza, Athamaica Ruiz/0000-0001-5370-6523				Alvarez-Twose I, 2012, INT ARCH ALLERGY IMM, V157, P275, DOI 10.1159/000329856; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Kristensen T, 2014, AM J HEMATOL, V89, P493, DOI 10.1002/ajh.23672; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Sampson HA, 2003, PEDIATRICS, V111, P1601; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x	9	42	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					262	+		10.1016/j.jaci.2014.06.031	http://dx.doi.org/10.1016/j.jaci.2014.06.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25091436				2022-12-18	WOS:000347298200032
J	Traister, RS; Uvalle, CE; Hawkins, GA; Meyers, DA; Bleecker, ER; Wenzel, SE				Traister, Russell S.; Uvalle, Crystal E.; Hawkins, Gregory A.; Meyers, Deborah A.; Bleecker, Eugene R.; Wenzel, Sally E.			Phenotypic and genotypic association of epithelial IL1RL1 to human T(H)2-like asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL1RL1; ST2L; sST2; T(H)2 inflammation; single nucleotide polymorphisms	INNATE LYMPHOID-CELLS; GENETIC-VARIATION; EXPRESSION; IL-33; ST2; LUNG; CYTOKINE; SUBTYPES; PROTEIN	Background: Severe asthma remains poorly characterized, although it likely consists of at least 1 phenotype with features of T(H)2-like inflammation. IL1RL1, encoding both the IL-33 receptor, ST2L, and decoy receptor, sST2, has been genetically associated with asthma, though the mechanism for susceptibility remains unknown. Objective: Given previous data supporting a role for IL1RL1 in TH2 inflammation, we hypothesized that ST2L expression might be increased in T(H)2-like asthma and that expression levels would be associated with single nucleotide polymorphisms in IL1RL1, possibly explaining its genetic relationship with asthma. We also sought to evaluate the regulation of ST2L and sST2 in vitro. Methods: Endobronchial brushings and biopsies were obtained and expression of ST2L compared by severity levels, as well as by T(H)2-like biomarkers. Subjects were genotyped and the relationship of dichotomous expression of ST2L and sST2 to single nucleotide polymorphisms in IL1RL1 were determined. Epithelial cells were grown in air-liquid interface culture, and ST2L and sST2 responses to IFN-gamma and IL-13 were evaluated. Results: ST2L expression was increased in severe asthma (P = .02) and associated with multiple indicators of T(H)2-like inflammation, including blood eosinophils (P = .001), exhaled nitric oxide (P = .003), and epithelial CLCA1 (P < .0001) and eotaxin-3 (P = .001) mRNA expression. Multiple single nucleotide polymorphisms in IL1RL1 were found in relation to dichotomous expression of both ST2L and sST2. sST2 expression was associated with IFN-gamma expression in bronchoalveolar lavage, while inducing its expression in vitro in primary human epithelial cells. Conclusion: Both pathologic and genetic approaches support a role for IL1RL1 in severe asthma, as well as T(H)2-lke asthma, suggesting that targeting this pathway may have therapeutic benefits.	[Traister, Russell S.; Uvalle, Crystal E.; Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; [Hawkins, Gregory A.; Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University	Traister, RS (corresponding author), Univ Pittsburgh, UPMC UPSOM, Asthma Inst, Dept Med,Div Pulm Allergy & Crit Care Med, NW 931 Montefiore Hosp,3459 Fifth Ave, Pittsburgh, PA 15213 USA.	traisterrs@upmc.edu		Wenzel, Sally/0000-0002-4242-0164	National Institutes of Health/National Heart, Lung, and Blood Institute [HL-69437, HL-109152-01, HL064937-10, AI-40600]; Clinical and Translational Sciences Institute [UL1 RR024153]; Sanofi-Aventis; GlaxoSmithKline (GSK); Genentech; AstraZeneca; GSK; Novartis; Teva; Amgen; Gilead; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109152, T32HL007563, R01HL064937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Clinical and Translational Sciences Institute; Sanofi-Aventis(Sanofi-Aventis); GlaxoSmithKline (GSK)(GlaxoSmithKline); Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); GSK(GlaxoSmithKline); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); Amgen(Amgen); Gilead(Gilead Sciences); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants HL-69437, HL-109152-01, HL064937-10, AI-40600, and Clinical and Translational Sciences Institute Grant UL1 RR024153.; S. E. Wenzel's institution has received grants from Sanofi-Aventis, GlaxoSmithKline (GSK), Genentech, and AstraZeneca; she has received consultancy fees from GSK, Novartis, AstraZeneca, Teva, Amgen, and Gilead, as well as compensation for travel and other meeting-related expenses from AstraZeneca and GSK. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Ho JE, 2013, J CLIN INVEST, V123, P4208, DOI 10.1172/JCI67119; Iwahana H, 1999, EUR J BIOCHEM, V264, P397, DOI 10.1046/j.1432-1327.1999.00615.x; Kurokawa M, 2011, INT ARCH ALLERGY IMM, V155, P12, DOI 10.1159/000327259; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2011, J ALLERGY CLIN IMMUN, V128, P328, DOI 10.1016/j.jaci.2011.02.042; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Oh K, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-35; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Pham NA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-8; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Silkoff P, 2005, AM J RESP CRIT CARE, V172, P931, DOI 10.1164/ajrccm.172.7.953; Suzukawa Maho, 2008, Lab Invest, V88, P1245, DOI 10.1038/labinvest.2008.82; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Voraphani N, 2014, MUCOSAL IMMUNOL, V7, P1175, DOI 10.1038/mi.2014.6; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; Yamamoto M, 2012, CLIN EXP ALLERGY, V42, P760, DOI 10.1111/j.1365-2222.2011.03860.x; Yin H, 2012, CLIN EXP IMMUNOL, V170, P1, DOI 10.1111/j.1365-2249.2012.04629.x; Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108	34	42	42	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					92	U160		10.1016/j.jaci.2014.06.023	http://dx.doi.org/10.1016/j.jaci.2014.06.023			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25091434	Green Accepted			2022-12-18	WOS:000347298200011
J	Chan, YC; Ramadani, F; Santos, AF; Pillai, P; Ohm-Laursen, L; Harper, CE; Fang, CL; Wu, SY; Ying, S; Corrigan, CJ; Gould, HJ				Chan, Yih-Chih; Ramadani, Faruk; Santos, Alexandra F.; Pillai, Prathap; Ohm-Laursen, Line; Harper, Clare E.; Fang, Cailong; Wu, Shih-Ying; Ying, Sun; Corrigan, Christopher J.; Gould, Hannah J.			"Auto-anti-IgE": Naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; autoantibodies; IgE; basophil activation; basophil inhibition	FC-EPSILON-RI; CHRONIC IDIOPATHIC URTICARIA; ALPHA AUTOANTIBODIES; ATOPIC-DERMATITIS; BRONCHIAL-ASTHMA; CROSS-LINKING; RECEPTOR; COMPLEXES; SEVERITY; CELLS	Background: Naturally occurring IgE-specific IgG autoantibodies have been identified in patients with asthma and other diseases, but their spectrum of functions is poorly understood. Objective: Address the hypothesis that: (i) IgG anti-IgE autoantibodies are detectable in the serum of all subjects but elevated in asthmatic patients regardless of atopic status as compared with controls; (ii) some activate IgE-sensitized basophils; and (iii) some inhibit allergen-induced basophil activation. Methods: IgE-specific IgG autoantibodies were detected and quantified in sera using ELISA. Sera were examined for their ability to activate IgE-sensitized human blood basophils in the presence and absence of allergen using a basophil activation test, and to inhibit allergen binding to specific IgE on a rat basophilic cell line stably expressing human FceRI. Results: IgG autoantibodies binding to both free and Fce RI-bound IgE were detected in patients with atopic and non-atopic asthma, as well as controls. While some were able to activate IgE-sensitised basophils, others inhibited allergen-induced basophil activation, at least partly by inhibiting binding of IgE to specific allergen. Conclusion: Naturally occurring IgG anti-IgE autoantibodies may inhibit, as well as induce, basophil activation. They act in a manner distinct from therapeutic IgG anti-IgE antibodies such as omalizumab. They may at least partly explain why atopic subjects who make allergen-specific IgE never develop clinical symptoms, and why omalizumab therapy is of variable clinical benefit in severe atopic asthma.	[Chan, Yih-Chih; Ramadani, Faruk; Santos, Alexandra F.; Pillai, Prathap; Ohm-Laursen, Line; Harper, Clare E.; Fang, Cailong; Wu, Shih-Ying; Ying, Sun; Corrigan, Christopher J.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Chan, Yih-Chih; Ramadani, Faruk; Santos, Alexandra F.; Pillai, Prathap; Ohm-Laursen, Line; Harper, Clare E.; Fang, Cailong; Wu, Shih-Ying; Ying, Sun; Corrigan, Christopher J.; Gould, Hannah J.] MRC, London, England; [Chan, Yih-Chih; Ramadani, Faruk; Santos, Alexandra F.; Pillai, Prathap; Ohm-Laursen, Line; Harper, Clare E.; Fang, Cailong; Wu, Shih-Ying; Ying, Sun; Corrigan, Christopher J.; Gould, Hannah J.] Asthma UK Ctr, Allerg Mechanisms, London, England; [Chan, Yih-Chih; Ramadani, Faruk; Santos, Alexandra F.; Pillai, Prathap; Ohm-Laursen, Line; Harper, Clare E.; Fang, Cailong; Wu, Shih-Ying; Ying, Sun; Corrigan, Christopher J.; Gould, Hannah J.] Guys & St Thomas Natl Hlth Serv Fdn Trust, Dept Paediat Allergy, London, England; [Santos, Alexandra F.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)	Gould, HJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House, London SE1 1UL, England.	Hannah.Gould@kcl.ac.uk	Ramadani, Faruk/HHM-9664-2022; Pillai, Prathap/ABF-7476-2021	Ramadani, Faruk/0000-0001-8228-4868; Ohm-Laursen, Line/0000-0003-3105-3888; Wu, Shih-Ying/0000-0002-9772-0877; Gould, Hannah/0000-0003-0411-688X; Corrigan, Chris/0000-0002-0706-6534; Santos, Alexandra/0000-0002-7805-1436	Wellcome Trust, United Kingdom [091449/Z/10//24]; Novartis United Kingdom; Guy's and St Thomas' Charity; Medical Research Council [G0200485, G1000758B, G0902018, G1100090, G1000758] Funding Source: researchfish; Asthma UK [AUK-PG-2013-183, MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [G0902018, G1100090, G0200485] Funding Source: UKRI	Wellcome Trust, United Kingdom(Wellcome Trust); Novartis United Kingdom(Novartis); Guy's and St Thomas' Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by research grants from Wellcome Trust, United Kingdom (grant no. 091449/Z/10//24), Novartis United Kingdom, and Guy's and St Thomas' Charity.	Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; CARINI C, 1988, ANN ALLERGY, V60, P48; Carney AS, 2001, CLIN OTOLARYNGOL, V26, P298, DOI 10.1046/j.1365-2273.2001.00474.x; Cho CB, 2013, ANN ALLERG ASTHMA IM, V110, P29, DOI 10.1016/j.anai.2012.10.020; Corrigan C, 2004, CURR OPIN ALLERGY CL, V4, P53, DOI 10.1097/01.all.0000113679.18759.71; CZECH W, 1995, ALLERGY, V50, P243, DOI 10.1111/j.1398-9995.1995.tb01141.x; Dibbern DA, 2003, J IMMUNOL METHODS, V274, P37, DOI 10.1016/S0022-1759(02)00369-1; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, ARTHRITIS RHEUM-US, V31, P1000, DOI 10.1002/art.1780310810; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Holdom MD, 2011, NAT STRUCT MOL BIOL, V18, P571, DOI 10.1038/nsmb.2044; Horn MP, 2001, FASEB J, V15, P2268, DOI 10.1096/fj.00-0890hyp; IWAMOTO I, 1989, INT ARCH ALLER A IMM, V90, P414, DOI 10.1159/000235064; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; KEMENY DM, 1990, CLIN EXP ALLERGY, V20, P67, DOI 10.1111/j.1365-2222.1990.tb02777.x; Kim B, 2012, NATURE, V491, P613, DOI 10.1038/nature11546; Koketsu R, 2013, INT ARCH ALLERGY IMM, V161, P23, DOI 10.1159/000350339; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P906, DOI 10.1016/j.jaci.2013.04.056; Marone G, 1999, CLIN EXP ALLERGY, V29, P17; Miescher Sylvia M., 2001, Human Antibodies, V10, P119; NAWATA Y, 1984, CLIN EXP IMMUNOL, V58, P348; PAGANELLI R, 1988, J CLIN LAB IMMUNOL, V26, P153; Pillai P, 2014, J ALLERGY CLIN IMMUN, V133, P1770, DOI 10.1016/j.jaci.2014.03.027; Rajan TV, 2003, TRENDS IMMUNOL, V24, P376, DOI 10.1016/S1471-4906(03)00142-X; RISKE F, 1991, J BIOL CHEM, V266, P11245; RITTER C, 1991, J ALLERGY CLIN IMMUN, V88, P793, DOI 10.1016/0091-6749(91)90187-S; Rudolf MP, 1996, J IMMUNOL, V157, P5646; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; Sato M. N., 2002, Clinical and Experimental Allergy, V32, P1667, DOI 10.1046/j.1365-2222.2002.01429.x; SHAKIB F, 1991, INT ARCH ALLER A IMM, V95, P102, DOI 10.1159/000235413; SHAKIB F, 1994, CLIN EXP ALLERGY, V24, P270, DOI 10.1111/j.1365-2222.1994.tb00230.x; SHAKIB F, 1994, ALLERGY, V49, P192, DOI 10.1111/j.1398-9995.1994.tb00825.x; STADLER BM, 1989, INT ARCH ALLER A IMM, V88, P206, DOI 10.1159/000234787; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sturm GJ, 2009, ALLERGY, V64, P1319, DOI 10.1111/j.1398-9995.2009.02004.x; SWAINSON JA, 1985, INT ARCH ALLER A IMM, V76, P237, DOI 10.1159/000233698; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; VASSELLA CC, 1990, CLIN EXP ALLERGY, V20, P295, DOI 10.1111/j.1365-2222.1990.tb02687.x; Wigginton SJ, 2008, CLIN EXP ALLERGY, V38, P313, DOI 10.1111/j.1365-2222.2007.02896.x; YU Y, 1995, ALLERGY, V50, P119, DOI 10.1111/j.1398-9995.1995.tb05067.x; Zheng L, 2008, BIOCHEM BIOPH RES CO, V375, P619, DOI 10.1016/j.bbrc.2008.08.055; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	46	42	45	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1394	+		10.1016/j.jaci.2014.06.029	http://dx.doi.org/10.1016/j.jaci.2014.06.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25112697	Green Published, hybrid			2022-12-18	WOS:000346075400023
J	Straubinger, K; Paul, S; da Costa, OP; Ritter, M; Buch, T; Busch, DH; Layland, LE; da Costa, CUP				Straubinger, Kathrin; Paul, Sabine; da Costa, Olivia Prazeres; Ritter, Manuel; Buch, Thorsten; Busch, Dirk H.; Layland, Laura E.; da Costa, Clarissa U. Prazeres			Maternal immune response to helminth infection during pregnancy determines offspring susceptibility to allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Maternal helminth infection; offspring; allergic airway inflammation; hygiene hypothesis; pregnancy; in utero programming	HEPATITIS-B-VACCINE; REGULATORY T-CELLS; SCHISTOSOMA-MANSONI; PROTECTS MICE; VITAMIN-D; EXPOSURE; MOTHERS; SENSITIZATION; CHILDREN; ANTIGENS	Background: Schistosomiasis, a chronic helminth infection, elicits distinct immune responses within the host, ranging from an initial T(H)1 and subsequent T(H)2 phase to a regulatory state, and is associated with dampened allergic reactions within the host. Objective: We sought to evaluate whether non-transplacental helminth infection during pregnancy alters the offspring's susceptibility to allergy. Methods: Ovalbumin-induced allergic airway inflammation was analyzed in offspring from Schistosoma mansoni-infected mothers mated during the T(H)1, T(H)2, or regulatory phase of infection. Embryos derived from in vitro fertilized oocytes of acutely infected females were transferred into uninfected foster mice to determine the role of placental environment. The fetomaternal unit was further characterized by helminth-specific immune responses and microarray analyses. Eventually, IFN-gamma-deficient mice were infected to evaluate the role of this predominant cytokine on the offspring's allergy phenotype. Results: We demonstrate that offspring from schistosome-infected mothers that were mated in the T(H)1 and regulatory phases, but not the T(H)2 immune phase, are protected against the onset of allergic airway inflammation. Interestingly, these effects were associated with distinctly altered schistosome-specific cytokine and gene expression profiles within the fetomaternal interface. Furthermore, we identified that it is not the transfer of helminth antigens but rather maternally derived IFN-gamma during the acute phase of infection that is essential for the progeny's protective immune phenotype. Conclusion: Overall, we present a novel immune phase-dependent coherency between the maternal immune responses during schistosomiasis and the progeny's predisposition to allergy. Therefore, we propose to include helminth-mediated transmaternal immune modulation into the expanded hygiene hypothesis.	[Straubinger, Kathrin; Paul, Sabine; da Costa, Olivia Prazeres; Ritter, Manuel; Buch, Thorsten; Busch, Dirk H.; da Costa, Clarissa U. Prazeres] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg MIH, D-81675 Munich, Germany; [Layland, Laura E.] Univ Clin Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany	Technical University of Munich; University of Bonn	da Costa, CUP (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 30, D-81675 Munich, Germany.	Clarissa.daCosta@tum.de	Buch, Thorsten/P-1659-2019; Ritter, Manuel/ABE-7747-2020	Buch, Thorsten/0000-0002-2236-9074; Ritter, Manuel/0000-0001-8667-2067	Deutsche Forschungsgemeinschaft (German Research Foundation) [SFB Tr22]; Else-Kroner-Fresenius-Stiftung (EKFS), Germany [P07/07//A94/06]	Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG)); Else-Kroner-Fresenius-Stiftung (EKFS), Germany	Supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) (SFB Tr22) and the Else-Kroner-Fresenius-Stiftung (EKFS P07/07//A94/06), Germany.	Akhiani AA, 1996, SCAND J IMMUNOL, V43, P257, DOI 10.1046/j.1365-3083.1996.d01-33.x; Santos PDA, 2010, PARASITOL RES, V107, P95, DOI 10.1007/s00436-010-1839-5; Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Attallah AM, 2006, PARASITOL RES, V99, P137, DOI 10.1007/s00436-006-0127-x; Attallah AM, 2003, AM J TROP MED HYG, V68, P647, DOI 10.4269/ajtmh.2003.68.647; Bassily S, 1997, AM J TROP MED HYG, V57, P197, DOI 10.4269/ajtmh.1997.57.197; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bobetsis YA, 2010, J REPROD IMMUNOL, V85, P140, DOI 10.1016/j.jri.2010.04.001; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GHAFFAR YA, 1989, LANCET, V2, P272; Jimenez-Chillaron JC, 2009, DIABETES, V58, P460, DOI 10.2337/db08-0490; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Kurtis JD, 2011, INFECT IMMUN, V79, P1254, DOI 10.1128/IAI.01072-10; Layland LE, 2007, EUR J IMMUNOL, V37, P2174, DOI 10.1002/eji.200737063; Layland LE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002379; Layland LE, 2010, J IMMUNOL, V184, P713, DOI 10.4049/jimmunol.0901435; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Lima C, 2005, J IMMUNOL, V175, P3554, DOI 10.4049/jimmunol.175.6.3554; Liu NQ, 2011, J IMMUNOL, V186, P5968, DOI 10.4049/jimmunol.1003332; Maizels RM, 2009, J EXP MED, V206, P2059, DOI 10.1084/jem.20091903; Mangan NE, 2006, J IMMUNOL, V176, P138, DOI 10.4049/jimmunol.176.1.138; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Mpairwe H, 2011, PEDIAT ALLERG IMM-UK, V22, P305, DOI 10.1111/j.1399-3038.2010.01122.x; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Pearce EJ, 2005, PARASITE IMMUNOL, V27, P265, DOI 10.1111/j.1365-3024.2005.00765.x; Pfefferle PI, 2010, CURR ALLERGY ASTHM R, V10, P434, DOI 10.1007/s11882-010-0147-6; Ritter M, 2010, P NATL ACAD SCI USA, V107, P20459, DOI 10.1073/pnas.1010337107; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; Smits HH, 2010, CURR ALLERGY ASTHM R, V10, P3, DOI 10.1007/s11882-009-0085-3; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Tweyongyere R, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-234; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Yazdanbakhsh M, 2001, WIEN KLIN WOCHENSCHR, V113, P899; Zaccone P, 2009, EUR J IMMUNOL, V39, P1098, DOI 10.1002/eji.200838871	43	42	43	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1271	+		10.1016/j.jaci.2014.05.034	http://dx.doi.org/10.1016/j.jaci.2014.05.034			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25042744				2022-12-18	WOS:000346075400008
J	Zafari, Z; Lynd, LD; FitzGerald, JM; Sadatsafavi, M				Zafari, Zafar; Lynd, Larry D.; FitzGerald, J. Mark; Sadatsafavi, Mohsen			Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: A simulation study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cost-effectiveness analysis; decision analysis; evidence-based treatment; adherence	RANDOMIZED CONTROLLED-TRIAL; MILD PERSISTENT ASTHMA; COST-EFFECTIVENESS; INHALED CORTICOSTEROIDS; BUDESONIDE; BECLOMETHASONE; EXACERBATIONS; METAANALYSIS; MONTELUKAST; PLACEBO	Background: Adherence to evidence-based controller treatments for asthma is disappointingly low in many jurisdictions. Quantifying the burden associated with suboptimal adherence in patients with uncontrolled asthma will help establish the priorities for policymakers. Objective: We sought to quantify the benefits in the United States of improving adherence to controller therapies in adults with uncontrolled asthma in terms of health care costs and quality-adjusted life years (QALYs). Methods: A Markov model of asthma was created to simulate the effect of treatment with controller medications on asthma control and exacerbations over a 10-year time horizon. Health care costs and QALYs associated with the current level of adherence (status quo) were compared with a hypothetical scenario in which each patient with uncontrolled asthma at baseline will be fully adherent to an evidence-based controller therapy (the full-adherence scenario). We also evaluated the cost-effectiveness of adherence interventions as a function of their costs and improvement in the adherence. Results: The status quo level of asthma management was associated with $2,786 costs and 7.55 QALYs over 10 years, whereas the corresponding values for the full-adherence scenario were $5,973 and 7.68, respectively. Consequently, the incremental cost-effectiveness ratio of the full-adherence versus the status quo was $24,515/QALY. To be cost-effective, a program that improves adherence by 50% should cost less than $130 ($450) per person annually at a willingness-to-pay value of $50,000/QALY ($100,000/QALY). Inclusion of productivity loss in the analysis resulted in the full-adherence scenario being cost-saving. Conclusion: Considering the extent of suboptimal adherence, our study shows that attempts in improving adherence to evidence-based therapies in patients with uncontrolled asthma can be associated with significant return on investment.	[Zafari, Zafar; Lynd, Larry D.] Univ British Columbia, Fac Pharmaceut Sci, Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada; [FitzGerald, J. Mark; Sadatsafavi, Mohsen] Univ British Columbia, Fac Med, Inst Heart & Lung Hlth IHLH, Vancouver, BC, Canada; [Zafari, Zafar; FitzGerald, J. Mark; Sadatsafavi, Mohsen] Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Inst, Vancouver, BC, Canada; [Lynd, Larry D.] Ctr Hlth Evaluat & Outcomes Sci, Providence Hlth Res Inst, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Sadatsafavi, M (corresponding author), 7th Floor,828 West 10th Ave,Res Pavilion, Vancouver, BC V5Z 1M9, Canada.	msafavi@mail.ubc.ca	Sadatsafayi, Mohsen/AAZ-1593-2020	Sadatsafayi, Mohsen/0000-0002-0419-7862; Lynd, Larry/0000-0002-7622-3919	Canadian Respiratory Research Network (CRRN: Institute of Cardiovascular and Respiratory Health Emerging Network Grants) [201306]; University of British Columbia; National Sanitarium Association	Canadian Respiratory Research Network (CRRN: Institute of Cardiovascular and Respiratory Health Emerging Network Grants); University of British Columbia; National Sanitarium Association	Supported in part through the Canadian Respiratory Research Network (CRRN: Institute of Cardiovascular and Respiratory Health Emerging Network Grants-#201306). Z.Z. received a 4-year fellowship award for his PhD studies from the University of British Columbia. M. S. receives salary support from the National Sanitarium Association.	Arias E., 2007, US LIFE TABLES; Axelsson M, 2012, ASIA PAC ALLERGY, V2, P67, DOI 10.5415/apallergy.2012.2.1.67; Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Briggs AH, 2006, ALLERGY, V61, P531, DOI 10.1111/j.1398-9995.2006.01038.x; Brozek JL, 2012, ARCH INTERN MED, V172, P1365, DOI 10.1001/archinternmed.2012.3250; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; Centers for Disease Control and Prevention National Center for Health Statistics, 2012, CDC WOND ONL DAT COM; Chauhan BF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009611.pub3; FitzGerald J Mark, 2006, Can Respir J, V13, P253; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Irvin CG, 2007, AM J RESP CRIT CARE, V175, P235, DOI 10.1164/rccm.200603-416OC; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lee TA, 2010, CURR MED RES OPIN, V26, P2851, DOI 10.1185/03007995.2010.531255; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Mattke S, 2010, J ASTHMA, V47, P323, DOI 10.3109/02770900903497196; MIMS, 2012, MIMS PRESCR DRUG DAT, P59; Nathan RA, 1999, ANN ALLERG ASTHMA IM, V82, P521, DOI 10.1016/S1081-1206(10)63159-6; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Ryan D, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1756; Sadatsafavi M, 2013, CHEST; Schlender A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051139; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Szefler S, 2000, NEW ENGL J MED, V343, P1054; The R Development Core Team, R LANG ENV STAT COMP; van der Meer V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027108; Viswanathan M, CLOSING QUALITY GAP; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weiss K B, 1994, Pediatr Allergy Immunol, V5, P7, DOI 10.1111/j.1399-3038.1994.tb00341.x; Wijnhoven Hanneke A H, 2004, Prim Care Respir J, V13, P89, DOI 10.1016/S1471-4418(03)00004-5; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	35	42	42	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					908	U522		10.1016/j.jaci.2014.04.009	http://dx.doi.org/10.1016/j.jaci.2014.04.009			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24875619				2022-12-18	WOS:000343155700018
J	Tillander, H; Andersson, N; Bergstroem, A; Kull, I; Melen, E; Pershagen, G; Ahlstedt, S; Lilja, G; van Hage, M				Tillander, Henrike; Andersson, Niklas; Bergstroem, Anna; Kull, Inger; Melen, Erik; Pershagen, Goeran; Ahlstedt, Staffan; Lilja, Gunnar; van Hage, Marianne		MeDALL Consortium	Childhood-to-adolescence evolution of IgE antibodies to pollens and plant foods in the BAMSE cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSITIZATION; ALLERGENS; ASTHMA; LIFE		[Tillander, Henrike; Andersson, Niklas; Bergstroem, Anna; Melen, Erik; Pershagen, Goeran; Ahlstedt, Staffan] Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; [Kull, Inger; van Hage, Marianne] Karolinska Inst, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Andersson, Niklas; Pershagen, Goeran] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [van Hage, Marianne] Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, S-10064 Stockholm, Sweden; [Kull, Inger; Melen, Erik; Ahlstedt, Staffan] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Saint Goran's Hospital; Stockholm County Council; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet	Tillander, H (corresponding author), Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden.	magnus.wickman@ki.se	van Hage, Marianne/A-9678-2017; Andersson, Niklas/AAN-1633-2020	van Hage, Marianne/0000-0003-3091-1596; Andersson, Niklas/0000-0001-9785-7462; Asarnoj, Anna/0000-0002-0797-2369; Kull, Inger/0000-0001-6096-3771; Pershagen, Goran/0000-0002-9701-1130				Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; Borres MP, 2011, PEDIAT ALLERG IMM-UK, V22, P454, DOI 10.1111/j.1399-3038.2011.01197.x; Eller E, 2009, ALLERGY, V64, P1023, DOI 10.1111/j.1398-9995.2009.01952.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030	7	42	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					580	582		10.1016/j.jaci.2013.09.009	http://dx.doi.org/10.1016/j.jaci.2013.09.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24161748				2022-12-18	WOS:000332397100037
J	Spycher, B; Silverman, M; Pescatore, AM; Beardsmore, CS; Kuehni, CE				Spycher, Ben D.; Silverman, Michael; Pescatore, Anina M.; Beardsmore, Caroline S.; Kuehni, Claudia E.			Comparison of phenotypes of childhood wheeze and cough in 2 independent cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheeze; cough; asthma; children; phenotypes; latent class analysis; cluster analysis; cohort study; allergy; bronchial responsiveness	1ST 6 YEARS; TRANSCUTANEOUS OXYGEN-TENSION; LUNG-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; METHACHOLINE CHALLENGE; YOUNG-CHILDREN; ASTHMA; RESPONSIVENESS; SATURATION; LESSONS	Background: Among children with wheeze and recurrent cough there is great variation in clinical presentation and time course of the disease. We previously distinguished 5 phenotypes of wheeze and cough in early childhood by applying latent class analysis to longitudinal data from a population-based cohort (original cohort). Objective: To validate previously identified phenotypes of childhood cough and wheeze in an independent cohort. Methods: We included 903 children reporting wheeze or recurrent cough from an independent population-based cohort (validation cohort). As in the original cohort, we used latent class analysis to identify phenotypes on the basis of symptoms of wheeze and cough at 2 time points (preschool and school age) and objective measurements of atopy, lung function, and airway responsiveness (school age). Prognostic outcomes (wheeze, bronchodilator use, cough apart from colds) 5 years later were compared across phenotypes. Results: When using a 5-phenotype model, the analysis distinguished 3 phenotypes of wheeze and 2 of cough as in the original cohort. Two phenotypes were closely similar in both cohorts: Atopic persistent wheeze (persistent multiple trigger wheeze and chronic cough, atopy and reduced lung function, poor prognosis) and transient viral wheeze (early-onset transient wheeze with viral triggers, favorable prognosis). The other phenotypes differed more between cohorts. These differences might be explained by differences in age at measurements. Conclusions: Applying the same method to 2 different cohorts, we consistently identified 2 phenotypes of wheeze (atopic persistent wheeze, transient viral wheeze), suggesting that these represent distinct disease processes. Differences found in other phenotypes suggest that the age when features are assessed is critical and should be considered carefully when defining phenotypes.	[Spycher, Ben D.; Pescatore, Anina M.; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Silverman, Michael; Beardsmore, Caroline S.] Univ Leicester, Div Child Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England	University of Bern; University of Leicester	Spycher, B (corresponding author), Univ Bern, Inst Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	bspycher@ispm.unibe.ch	Spycher, Ben D/B-3308-2008	Spycher, Ben D/0000-0002-1430-5695; Kuehni, Claudia E./0000-0001-8957-2002	Asthma UK [07/048]; Swiss National Science Foundation [PDFMP3-123162, 32003B-144068]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1614-2010]; European Respiratory Society; European Community [PCOFUND-GA-2008-229571]; UK National Asthma Campaign; University Hospitals of Leicester NHS Trust (RD); Leicestershire & Rutland Partnership Trust; Medisearch; Trent NHS Regional Health Authority; UK Department of Health	Asthma UK; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Respiratory Society/Marie Curie Joint Research Fellowship; European Respiratory Society; European Community(European Commission); UK National Asthma Campaign; University Hospitals of Leicester NHS Trust (RD); Leicestershire & Rutland Partnership Trust; Medisearch; Trent NHS Regional Health Authority; UK Department of Health	The work presented in this article was funded by Asthma UK (grant no. 07/048) and the Swiss National Science Foundation (grant no. PDFMP3-123162 and 32003B-144068). B. D. Spycher is the recipient of a European Respiratory Society/Marie Curie Joint Research Fellowship (MC 1614-2010). The research leading to these results has received funding from the European Respiratory Society and the European Community's Seventh Framework Programme FP7/2007-2013-Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571. Data collection has been funded by UK National Asthma Campaign, University Hospitals of Leicester NHS Trust (R&D), Leicestershire & Rutland Partnership Trust, Medisearch, Trent NHS Regional Health Authority, and the UK Department of Health.	Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Brodlie M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1177; Chinn S, 1998, THORAX, V53, P984, DOI 10.1136/thx.53.11.984; Edwards CA, 2003, CHEST, V124, P18, DOI 10.1378/chest.124.1.18; Goldsobel AB, 2010, J PEDIATR-US, V156, P352, DOI 10.1016/j.jpeds.2009.12.004; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Herr M, 2012, J ALLERGY CLIN IMMUN, V130, P389, DOI 10.1016/j.jaci.2012.05.054; Hunt L, 2003, COMPUT STAT DATA AN, V41, P429, DOI 10.1016/S0167-9473(02)00190-1; Hunt L, 1999, AUST NZ J STAT, V41, P153; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Kuehni CE, 2007, INT J EPIDEMIOL, V36, P977, DOI 10.1093/ije/dym090; Lazarsfeld P.F., 1968, LATENT STRUCTURE ANA; Little R. J., 2019, STAT ANAL MISSING DA, V793; Lougheed MD, 2012, LUNG, V190, P17, DOI 10.1007/s00408-011-9348-6; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McLachlan G. J., 2000, FINITE MIXTURE MODEL; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nystad W, 2002, THORAX, V57, P1021, DOI 10.1136/thorax.57.12.1021; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; Silverman M, 2002, RESP INFECT ALLERGY, P427; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Spycher BD, 2009, STAT MED, V28, P1927, DOI 10.1002/sim.3550; Spycher BD, 2012, J ALLERGY CLIN IMMUN, V130, P503, DOI 10.1016/j.jaci.2012.06.002; Stern DA, 2008, LANCET, V372, P1058, DOI DOI 10.1016/S0140-6736(08)61447-6; Turcotte SE, 2011, CURR OPIN PHARMACOL, V11, P231, DOI 10.1016/j.coph.2011.04.008; van Asperen PP, 2006, PAEDIATR RESPIR REV, V7, P26, DOI 10.1016/j.prrv.2005.11.006; Vilozni D, 2009, PEDIATR PULM, V44, P720, DOI 10.1002/ppul.20978; Wang JY, 2006, J ASTHMA, V43, P145, DOI 10.1080/02770900500498972; Wassall HJ, 2005, J ASTHMA, V42, P737, DOI 10.1080/02770900500306498; Weinmayr G, 2013, CLIN EXP ALLERGY, V43, P223, DOI 10.1111/cea.12035; WILSON NM, 1995, EUR RESPIR J, V8, P364, DOI 10.1183/09031936.95.08030364; WILSON NM, 1991, THORAX, V46, P433, DOI 10.1136/thx.46.6.433	38	42	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1058	1067		10.1016/j.jaci.2013.08.002	http://dx.doi.org/10.1016/j.jaci.2013.08.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24075230				2022-12-18	WOS:000326235600004
J	Ben-Shoshan, M; La Vieille, S; Eisman, H; Alizadehfar, R; Mill, C; Perkins, E; Joseph, L; Morris, J; Clarke, A				Ben-Shoshan, Moshe; La Vieille, Sebastian; Eisman, Harley; Alizadehfar, Reza; Mill, Christopher; Perkins, Emma; Joseph, Lawrence; Morris, Judy; Clarke, Ann			Anaphylaxis treated in a Canadian pediatric hospital: Incidence, clinical characteristics, triggers, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EMERGENCY-DEPARTMENT; ALLERGIC REACTIONS; FOOD ALLERGY; CHILDREN		[Ben-Shoshan, Moshe; Alizadehfar, Reza] McGill Univ, Dept Pediat, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada; [Eisman, Harley] McGill Univ, Dept Emergency Med, Ctr Hlth, Montreal, PQ, Canada; [Mill, Christopher; Perkins, Emma; Joseph, Lawrence; Clarke, Ann] McGill Univ, Div Clin Epidemiol, Ctr Hlth, Dept Med, Montreal, PQ, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol & Biostat, Ctr Hlth, Montreal, PQ, Canada; [Clarke, Ann] McGill Univ, Dept Med, Ctr Hlth, Div Allergy & Clin Immunol, Montreal, PQ, Canada; [La Vieille, Sebastian] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Morris, Judy] Univ Montreal, Dept Emergency Med, Hop Sacre Coeur Montreal, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; Health Canada; Universite de Montreal	Ben-Shoshan, M (corresponding author), McGill Univ, Dept Pediat, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada.	moshebenshoshan@gmail.com	La Vieille, Sébastien/AAC-5087-2019	La Vieille, Sebastien/0000-0001-5368-1266				Arroabarren E, 2011, PEDIAT ALLERG IMM-UK, V22, P708, DOI 10.1111/j.1399-3038.2011.01181.x; Ben-Shoshan M, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2010.02422.x; Ben-Shoshan M, 2012, CURR ALLERGY ASTHM R, V12, P346, DOI 10.1007/s11882-012-0274-3; Beyer K, 2012, ALLERGY, V67, P1451, DOI 10.1111/all.12012; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Roberge Daniele, 2010, Healthc Policy, V5, P27; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x	13	42	42	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					739	741		10.1016/j.jaci.2013.06.016	http://dx.doi.org/10.1016/j.jaci.2013.06.016			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23900056	Bronze			2022-12-18	WOS:000323612000028
J	Wang, CW; Chung, WH; Cheng, YF; Ying, NW; Peck, K; Chen, YT; Hung, SI				Wang, Chuang-Wei; Chung, Wen-Hung; Cheng, Yi-Fang; Ying, Nien-Wen; Peck, Konan; Chen, Yuan-Tsong; Hung, Shuen-Iu			A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alloreactivity; aptamer; CD8; drug hypersensitivity; graft-versus-host disease; granulysin; nucleic acid-based therapeutics; Stevens-Johnson syndrome; systematic evolution of ligands by exponential enrichment; toxic epidermal necrolysis	NF-KAPPA-B; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; STEM-CELL TRANSPLANTATION; CLASS-I; GRANULYSIN; CD8; EXPRESSION; MARKER; RECEPTOR	Background: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and graft-versus-host disease (GVHD) are distinct immune reactions elicited by drugs or allogeneic antigens; however, they share a pathomechanism with the activation of cytotoxic T lymphocytes (CTLs). CTLs produce cytotoxic proteins, cytokines, chemokines, or immune alarmins, such as granulysin (GNLY), leading to the extensive tissue damage and systemic inflammation seen in patients with SJS/TEN or GVHD. Currently, there is no effective therapeutic agent specific for CTL-mediated immune disorders. Objectives: By targeting GNLY(+) CTLs, we aimed to develop a nucleic acid-based agent consisting of an anti-CD8 aptamer with GNLY small interfering RNA (siRNA). Methods: We performed systematic evolution of ligands using exponential enrichment to select and identify effective anti-CD8 aptamers. We developed an aptamer-siRNA chimera using a "sticky bridge'' method by conjugating the aptamer with siRNA. We analyzed the inhibitory effects of the aptamer-siRNA chimera on CTL responses in patients with SJS/TEN or GVHD. Results: We identified a novel DNA aptamer (CD8AP17s) targeting CTLs. This aptamer could be specifically internalized into human CTLs. We generated the CD8AP17s aptamer-GNLY siRNA chimera, which showed a greater than 79% inhibitory effect on the production of GNLY by drug/alloantigen-activated T cells. The CD8AP17s aptamer-GNLY siRNA chimera decreased cytotoxicity in in vitro models of both SJS/TEN (elicited by drug-specific antigen) and GVHD (elicited by allogeneic antigens). Conclusions: Our results identified a new nucleic acid-based agent (CD8 aptamer-GNLY siRNA chimera) that can significantly inhibit CTL-mediated drug hypersensitivity, such as that seen in patients with SJS/TEN, as well as the alloreactivity seen in patients with GVHD. This study provides a novel therapeutic strategy for CTL-mediated immune disorders.	[Wang, Chuang-Wei; Hung, Shuen-Iu] Natl Yang Ming Univ, Dept & Inst Pharmacol, Sch Med, Infect & Immun Res Ctr, Taipei 11221, Taiwan; [Wang, Chuang-Wei; Hung, Shuen-Iu] Natl Yang Ming Univ, Program Mol Med, Taipei 11221, Taiwan; [Wang, Chuang-Wei; Hung, Shuen-Iu] Acad Sinica, Taipei 115, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, Keelung, Linko, Taiwan; [Chung, Wen-Hung] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Cheng, Yi-Fang; Ying, Nien-Wen; Peck, Konan; Chen, Yuan-Tsong] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Academia Sinica - Taiwan	Hung, SI (corresponding author), Natl Yang Ming Univ, Inst Pharmacol, 155 Linong St,Sec 2, Taipei 11221, Taiwan.	sihung@ym.edu.tw	Hung, Shuen-Iu/ABB-2139-2021	Hung, Shuen-Iu/0000-0001-6531-5538	National Science Council, Taiwan [NSC98-2320-B-010-002-MY3, NSC98-2314-B-182A-027-MY3, NSC101-2320-B-010-072-MY3, NSC101 2321 B 010 027, NSC101 2325 B 001 038]; Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); Academia Sinica, Taiwan [AS-99-TP-B12]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); Academia Sinica, Taiwan(Academia Sinica - Taiwan)	Supported by grants from the National Science Council, Taiwan (NSC98-2320-B-010-002-MY3, NSC98-2314-B-182A-027-MY3, NSC101-2320-B-010-072-MY3, NSC101 2321 B 010 027 , NSC101 2325 B 001 038 ), the Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University), and Academia Sinica (AS-99-TP-B12), Taiwan.	Alexander M, 2004, J VIROL, V78, P1685, DOI 10.1128/JVI.78.4.1685-1696.2004; Ashokkumar C, 2011, AM J PATHOL, V179, P1929, DOI 10.1016/j.ajpath.2011.06.040; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Chang YC, 2009, FASEB J, V23, P3078, DOI 10.1096/fj.09-129312; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Contini P, 2005, J IMMUNOL, V175, P7244, DOI 10.4049/jimmunol.175.11.7244; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Ferrara JLM, 2008, BEST PRACT RES CL HA, V21, P677, DOI 10.1016/j.beha.2008.07.003; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Fromowitz JS, 2007, INT J DERMATOL, V46, P1092, DOI 10.1111/j.1365-4632.2007.03277.x; Gao GF, 2000, IMMUNOL TODAY, V21, P630, DOI 10.1016/S0167-5699(00)01750-3; GASTON RS, 1991, KIDNEY INT, V39, P141, DOI 10.1038/ki.1991.18; Goldrath AW, 1997, IMMUNITY, V6, P633, DOI 10.1016/S1074-7613(00)80351-9; Gomes ER, 2005, CURR OPIN ALLERGY CL, V5, P309, DOI 10.1097/01.all.0000173785.81024.33; Hausmann Oliver, 2010, Handb Exp Pharmacol, P29, DOI 10.1007/978-3-642-00663-0_2; Huang CJ, 2006, J IMMUNOL, V176, P4173, DOI 10.4049/jimmunol.176.7.4173; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141; Kida Y, 2002, IMMUNOLOGY, V107, P507, DOI 10.1046/j.1365-2567.2002.01524.x; Ko TM, 2011, J ALLERGY CLIN IMMUN, V128, P1266, DOI 10.1016/j.jaci.2011.08.013; Krensky AM, 2009, TISSUE ANTIGENS, V73, P193, DOI 10.1111/j.1399-0039.2008.01218.x; Li QB, 2009, ACTA PHARMACOL SIN, V30, P1471, DOI 10.1038/aps.2009.132; Liu LX, 2011, J IMMUNOL METHODS, V372, P22, DOI 10.1016/j.jim.2011.06.026; Ma LL, 2002, J IMMUNOL, V169, P5787, DOI 10.4049/jimmunol.169.10.5787; Mallikaratchy PR, 2011, NUCLEIC ACIDS RES, V39, P2458, DOI 10.1093/nar/gkq996; Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161; McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223; Mockenhaupt M, 2011, EXPERT REV CLIN IMMU, V7, P803, DOI [10.1586/eci.11.66, 10.1586/ECI.11.66]; Nagasawa M, 2006, AM J HEMATOL, V81, P340, DOI 10.1002/ajh.20570; Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001; O'Shaughnessy MJ, 2009, AM J TRANSPLANT, V9, P452, DOI 10.1111/j.1600-6143.2008.02533.x; Olejniczak M, 2010, NUCLEIC ACIDS RES, V38, P1, DOI 10.1093/nar/gkp829; Salmasian H, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005565.pub2; Sarwal MM, 2001, HUM IMMUNOL, V62, P21, DOI 10.1016/S0198-8859(00)00228-7; Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v; Shim MS, 2010, FEBS J, V277, P4814, DOI 10.1111/j.1742-4658.2010.07904.x; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001; Stove V, 2005, J VIROL, V79, P11422, DOI 10.1128/JVI.79.17.11422-11433.2005; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Teo L, 2009, SINGAP MED J, V50, P29; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Vodanovic-Jankovic S, 2006, BLOOD, V107, P827, DOI 10.1182/blood-2005-05-1820; Wei CY, 2012, J ALLERGY CLIN IMMUN, V129, P1562, DOI 10.1016/j.jaci.2011.12.990; Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; Zhou JH, 2011, OLIGONUCLEOTIDES, V21, P1, DOI 10.1089/oli.2010.0264; Zhou Jiehua, 2010, Silence, V1, P4, DOI 10.1186/1758-907X-1-4; Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185	53	42	44	9	54	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					713	+		10.1016/j.jaci.2013.04.036	http://dx.doi.org/10.1016/j.jaci.2013.04.036			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23791505				2022-12-18	WOS:000323612000024
J	Cheng, DT; Ma, C; Niewoehner, J; Dahl, M; Tsai, A; Zhang, J; Gonsiorek, W; Apparsundaram, S; Pashine, A; Ravindran, P; Jung, J; Hang, JL; Allard, J; Bitter, H; Tribouley, C; Narula, S; Wilson, S; Fuentes, ME				Cheng, Donavan T.; Ma, Cynthia; Niewoehner, Jens; Dahl, Martin; Tsai, Angela; Zhang, Jun; Gonsiorek, Waldemar; Apparsundaram, Subbu; Pashine, Achal; Ravindran, Palanikumar; Jung, Jimmy; Hang, Julie; Allard, John; Bitter, Hans; Tribouley, Catherine; Narula, Satwant; Wilson, Stephen; Fuentes, Maria E.			Thymic stromal lymphopoietin receptor blockade reduces allergic inflammation in a cynomolgus monkey model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; dendritic cells; allergen challenge; cynomolgus monkey; gene expression profiling; eosinophilia; T(H)2 inflammation	AIRWAY SMOOTH-MUSCLE; HUMAN EPITHELIAL-CELLS; OX40 LIGAND; TSLP; EXPRESSION; DISEASE; CHEMOKINES; CLONING	Background: Thymic stromal lymphopoietin (TSLP) pathway blockade is a potential strategy for asthma treatment because the main activities of TSLP are activation of myeloid dendritic cells (mDCs) and modulation of cytokine production by mast cells. TSLP-activated mDCs prime the differentiation of naive T cells into inflammatory T(H)2 cells. Objective: We sought to investigate mechanisms underlying the development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and to assess the effect of thymic stromal lymphopoietin receptor (TSLPR) blockade in this model. Methods: An mAb against human TSLPR was generated and confirmed to be cross-reactive to cynomolgus monkey. Animals were dosed weekly with either vehicle or anti-TSLPR mAb for 6 weeks, and their responses to allergen challenge at baseline, week 2, and week 6 were assessed. Results: After 6 weeks of treatment, anti-TSLPR mAb-treated animals showed reduced bronchoalveolar lavage (BAL) fluid eosinophil counts, reduced airway resistance in response to allergen challenge, and reduced IL-13 cytokine levels in BAL fluid compared with values seen in vehicle-treated animals. Expression profiling of BAL fluid cells collected before and after challenge showed a group of genes upregulated by allergen challenge that strongly overlapped with 11 genes upregulated in dendritic cells (DCs) when in vitro stimulated by TSLP (TSLP-DC gene signature). The number of genes differentially expressed in response to challenge was reduced in antibody-treated animals after 6 weeks relative to vehicle-treated animals. Expression of the TSLP-DC gene signature was also significantly reduced in antibody-treated animals. Conclusion: These results demonstrate promising efficacy for TSLPR blockade in an allergic lung inflammation model in which TSLP activation of mDCs might play a key role.	[Niewoehner, Jens] Roche Diagnost, Penzberg, Germany; [Wilson, Stephen] Charles River Labs, Shrewsbury, England	Roche Holding	Fuentes, ME (corresponding author), Hoffmann La Roche Inc, 340 Kingsland St, Nutley, NJ 07677 USA.	mefuentes1000@gmail.com	Fuentes, Maria/HGA-8617-2022					Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hart TK, 2001, J ALLERGY CLIN IMMUN, V108, P250, DOI 10.1067/mai.2001.116576; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kaur D, 2012, CHEST, V142, P76, DOI 10.1378/chest.11-1782; Liu YJ, 2009, ADV IMMUNOL, V101, P1, DOI 10.1016/S0065-2776(08)01001-8; May RD, 2012, BRIT J PHARMACOL, V166, P177, DOI 10.1111/j.1476-5381.2011.01659.x; Omori-Miyake M, 2012, ALLERGOL INT, V61, P27, DOI 10.2332/allergolint.11-RAI-0374; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shan LY, 2010, J IMMUNOL, V184, P7134, DOI 10.4049/jimmunol.0902515; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Smelter DF, 2010, J IMMUNOL, V185, P3035, DOI 10.4049/jimmunol.1000252; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	27	42	46	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					455	462		10.1016/j.jaci.2013.05.011	http://dx.doi.org/10.1016/j.jaci.2013.05.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23810153				2022-12-18	WOS:000322631700024
J	Healy, B; Bibby, S; Steele, R; Weatherall, M; Nelson, H; Beasley, R				Healy, Bridget; Bibby, Susan; Steele, Richard; Weatherall, Mark; Nelson, Harold; Beasley, Richard			Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antineutrophil cytoplasmic autoantibodies; Churg-Strauss syndrome; clinical features; US Food and Drug Administration's Adverse Event Reporting System database; myeloperoxidase	RECEPTOR ANTAGONIST THERAPY; TERM-FOLLOW-UP; MICROSCOPIC POLYANGIITIS; ANTIBODIES; GRANULOMATOSIS; PATHOGENESIS; VASCULITIS; DISEASE; PREVALENCE	Background: The clinical significance of antineutrophil cytoplasmic antibodies (ANCAs) in the phenotypic expression of Churg-Strauss syndrome (CSS) is uncertain. Objective: We sought to investigate the relationship between ANCA status and the clinical expression of CSS in a case series derived from the US Food and Drug Administration's adverse events database. Methods: All cases of CSS reported to the US Food and Drug Administration from 1997 to April 2003 were reviewed. Information about basic demographics, suspect medication use, clinical manifestations, histologic findings, ANCA staining patterns, and the presence of antibodies to myeloperoxidase (anti-MPO) or proteinase 3 (anti-PR3) was recorded when available. Results: There were 93 case reports of CSS with sufficient documentation, including ANCA status. There were 38 (40.9%) of 93 cases with positive ANCA results, of which 15 cases reported a positive ELISA, all of which were positive for anti-MPO. ANCA negativity was associated with an increased proportion of cardiac involvement (risk difference [RD], 38.2%; 95% CI, 25.3% to 51.0%), gastrointestinal involvement (RD, 25.5%; 95% CI, 13.9% to 37.0%), pulmonary infiltrates (odds ratio, 4.9; 95% CI, 1.5-16.2), and the outcome of a life-threatening event or death (RD, 30.9%; 95% CI, 18.7% to 43.1%) when compared with anti-MPO-positive cases. ANCA negativity was associated with a decreased proportion of peripheral neuropathy (odds ratio, 0.3; 95% CI, 0.07-0.9). Conclusion: These findings support the hypothesis that the presence or absence of autoantibodies influences the clinical expression and severity of CSS. (J Allergy Clin Immunol 2013;131:571-6.)	[Healy, Bridget; Bibby, Susan; Steele, Richard; Beasley, Richard] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Steele, Richard; Weatherall, Mark; Beasley, Richard] Capital & Coast Dist Hlth Board, Div Med, Wellington, New Zealand; [Steele, Richard; Weatherall, Mark] Univ Otago, Dept Med, Wellington, New Zealand; [Nelson, Harold] Natl Jewish Hlth, Dept Med, Div Allergy & Clin Immunol, Denver, CO USA	Medical Research Institute Of New Zealand; University of Otago; National Jewish Health	Beasley, R (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	richard.beasley@mrinz.ac.nz	Weatherall, Mark/Y-6824-2019; Beasley, Richard/AAH-3908-2019	Weatherall, Mark/0000-0002-0051-9107; Beasley, Richard/0000-0003-0337-406X; Healy, Bridget/0000-0002-7159-354X	Asthma and Respiratory Foundation of New Zealand; Bowen Trust Board; Merck	Asthma and Respiratory Foundation of New Zealand; Bowen Trust Board; Merck(Merck & Company)	H. Nelson has received consultancy fees from Merck. R. Beasley has received research support from the Asthma and Respiratory Foundation of New Zealand and the Bowen Trust Board. The rest of the authors declare that they have no relevant conflicts of interest.	Afeltra A, 1996, J RHEUMATOL, V23, P10; Beasley R, 2008, THORAX, V63, P847, DOI 10.1136/thx.2007.093971; Bibby S, 2010, THORAX, V65, P132, DOI 10.1136/thx.2009.120972; CHURG J, 1951, AM J PATHOL, V27, P277; Csernok E, 2002, RHEUMATOLOGY, V41, P1313, DOI 10.1093/rheumatology/41.11.1313; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; FIENBERG R, 1993, HUM PATHOL, V24, P160, DOI 10.1016/0046-8177(93)90295-R; Green RJ, 1996, CHEST, V110, P1305, DOI 10.1378/chest.110.5.1305; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; HASLEY PB, 1990, AM HEART J, V120, P996, DOI 10.1016/0002-8703(90)90227-O; Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A; Jennette JC, 2008, CURR OPIN RHEUMATOL, V20, P55, DOI 10.1097/BOR.0b013e3282f16c0a; Jennette JC, 2006, J AM SOC NEPHROL, V17, P1235, DOI 10.1681/ASN.2005101048; Keogh KA, 2003, AM J MED, V115, P284, DOI 10.1016/S0002-9343(03)00359-0; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Merkel PA, 1997, ANN INTERN MED, V126, P866, DOI 10.7326/0003-4819-126-11-199706010-00003; Noth I, 2003, LANCET, V361, P587, DOI 10.1016/S0140-6736(03)12518-4; Robinson PC, 2009, J CLIN PATHOL, V62, P743, DOI 10.1136/jcp.2009.064485; Sable-Fourtassou G, 2005, ANN INTERN MED, V143, P632, DOI 10.7326/0003-4819-143-9-200511010-00006; Savige J, 1999, AM J CLIN PATHOL, V111, P507; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; Sinico RA, 2005, ARTHRITIS RHEUM, V52, P2926, DOI 10.1002/art.21250; Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763; Xiao H, 2007, AM J PATHOL, V170, P52, DOI 10.2353/ajpath.2007.060573	27	42	47	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					571	+		10.1016/j.jaci.2012.05.058	http://dx.doi.org/10.1016/j.jaci.2012.05.058			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22920496	Bronze			2022-12-18	WOS:000314661500037
J	Hopper, JL; Bui, QM; Erbas, B; Matheson, MC; Gurrin, LC; Burgess, JA; Lowe, AJ; Jenkins, MA; Abramson, MJ; Walters, EH; Giles, GG; Dharmage, SC				Hopper, John L.; Bui, Quang M.; Erbas, Bircan; Matheson, Melanie C.; Gurrin, Lyle C.; Burgess, John A.; Lowe, Adrian J.; Jenkins, Mark A.; Abramson, Michael J.; Walters, E. Haydn; Giles, Graham G.; Dharmage, Shyamali C.			Does eczema in infancy cause hay fever, asthma, or both in childhood? Insights from a novel regression model of sibling data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic march; infantile eczema; childhood asthma; childhood hay fever; causation; familial confounding; sibling design	1ST 6 YEARS; ATOPIC-DERMATITIS; LUNG-FUNCTION; RISK-FACTORS; FOLLOW-UP; DISEASE; TWINS; LIFE; AGE; ASSOCIATION	Background: The atopic march hypothesis proposes that eczema precedes the development of asthma and allergic rhinitis. Objective: We sought to assess the evidence for a causal effect of infantile eczema on childhood hay fever, asthma, or both. Methods: We used parental reports on infantile eczema and childhood asthma and hay fever for 3778 pairs of 7-year-olds matched to their sibling closest in age within 2 years from the Tasmanian Longitudinal Health Study. We analyzed paired sibling data using a logistic regression model that allowed inference about a causal effect of a familial predictor on a child's outcome by examining the change in association with their cosibling's predictor after adjusting for their own predictor status. Results: Siblings were concordant for infantile eczema (tetrachoric correlation, 0.40). For having both hay fever and asthma by age 7 years, the association with cosibling's eczema was an odds ratio (OR) of 1.98 (95% CI, 1.37-2.86), which reduced after adjusting for own eczema to an OR of 1.65 (95% CI, 1.17-2.34). For having hay fever only, the association with cosibling's eczema was an OR of 1.68 (95% CI, 1.22-2.31) before and an OR of 1.59 (95% CI, 1.19-2.14) after adjusting for own eczema. There was no association between having asthma only and cosibling's eczema (OR, 1.00; 95% CI, 0.77-1.30). Conclusions: Eczema in infancy might have a causal effect on hay fever in children with and perhaps without asthma. The association of infantile eczema on asthma in children without hay fever, which might be early transient wheeze, is unlikely to be causal or familial. These findings have implications for hay fever prevention. (J Allergy Clin Immunol 2012;130:1117-22.)	[Hopper, John L.; Bui, Quang M.; Matheson, Melanie C.; Gurrin, Lyle C.; Burgess, John A.; Lowe, Adrian J.; Jenkins, Mark A.; Giles, Graham G.; Dharmage, Shyamali C.] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia; [Erbas, Bircan] La Trobe Univ, Sch Publ Hlth, Bundoora, Vic, Australia; [Abramson, Michael J.] Monash Univ, Alfred Hosp, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia; [Walters, E. Haydn] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia	University of Melbourne; La Trobe University; Florey Institute of Neuroscience & Mental Health; Monash University; University of Tasmania; Menzies Institute for Medical Research; Cancer Council Victoria	Hopper, JL (corresponding author), Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Level 3,207 Bouverie St, Carlton, Vic 3053, Australia.	j.hopper@unimelb.edu.au	WALTERS, Eugene/AAL-2264-2021; Abramson, Michael/AAQ-2671-2020; Burgess, John/H-7555-2019; Jenkins, Mark/P-7803-2015; Matheson, Melanie C/O-4721-2015	Abramson, Michael/0000-0002-9954-0538; Burgess, John/0000-0001-7532-5027; Jenkins, Mark/0000-0002-8964-6160; Matheson, Melanie C/0000-0002-5822-3499; Giles, Graham/0000-0003-4946-9099; Gurrin, Lyle/0000-0001-7052-1969; Bui, Minh/0000-0002-9099-6870; Walters, Eugene/0000-0002-0993-4374; Lowe, Adrian/0000-0002-4691-8162	Tasmanian Asthma Foundation; Department of Health Services; Victorian Asthma Foundation; National Health and Medical Research Council; Pfizer	Tasmanian Asthma Foundation; Department of Health Services; Victorian Asthma Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Pfizer(Pfizer)	This study was conducted under the auspices of the Tasmanian Asthma Foundation, which is funded by the Department of Health Services and run by the school medical officers and school health nurses. Data entry of the 1968 baseline study was supported by the Victorian Asthma Foundation. M.C.M., A.J.L., L.C.G., S.C.D., and J.L.H. are currently supported by the National Health and Medical Research Council as a Career Development Award (CDA) Fellow, Post-doctoral Fellow, CDA Fellow, Senior Research Fellow, and Australia Fellow, respectively.; Disclosure of potential conflict of interest: M. J. Abramson has received research support from Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 2007, CLIN EXP ALLERGY, V37, P1296, DOI 10.1111/j.1365-2222.2007.02796.x; Burgess JA, 2008, J ALLERGY CLIN IMMUN, V122, P280, DOI 10.1016/j.jaci.2008.05.018; Burgess JA, 2009, J ASTHMA, V46, P429, DOI 10.1080/02770900902846356; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Dite GS, 2008, CANCER EPIDEM BIOMAR, V17, P3474, DOI 10.1158/1055-9965.EPI-07-2636; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EDWARDS JH, 1984, BIOMETRICS, V40, P563; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Novembre E, 2001, ALLERGY, V56, P105, DOI 10.1111/j.1398-9995.2001.00931.x; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rusconi F, 2011, INT J EPIDEMIOL, V40, P662, DOI 10.1093/ije/dyq263; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706	27	42	42	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1117	+		10.1016/j.jaci.2012.08.003	http://dx.doi.org/10.1016/j.jaci.2012.08.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021888				2022-12-18	WOS:000310571400012
J	MacGlashan, DW; Savage, JH; Wood, RA; Saini, SS				MacGlashan, Donald W., Jr.; Savage, Jessica H.; Wood, Robert A.; Saini, Sarbjit S.			Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil; anti-IgE; peanut; spleen tyrosine kinase; IgE receptor	HISTAMINE-RELEASE; CD-SENS; IGE; POPULATION; EXPRESSION; SENSITIVITY; SYK	Background: A recent study of subjects with peanut allergy treated with omalizumab generated some results that were concordant with a study of subjects with cat allergy treated with omalizumab. However, there were differences that provided additional insight into the nature of the cellular responses in allergic subjects. Objective: We sought to determine the cause for failure to suppress the allergen-induced basophil response during treatment with omalizumab. Methods: Patients with peanut allergy were treated with omalizumab. Clinical, serologic, and cellular indices relevant to the response of the subjects and their peripheral blood basophil values (specific/total IgE ratio, cell-surface FceRI expression, and histamine release responses to anti-IgE antibody or peanut allergen) were obtained at 3 times. Results: After treatment, approximately 60% of the subjects' basophil responses to peanut allergen did not significantly decrease. In 40% of cases, the in vitro basophil response to peanut allergen increased 2- to 7-fold. The increases were associated with 2 primary factors: a high (>10%) specific/total IgE ratio and an increase in the intrinsic response of the basophil to IgE-mediated stimulation. The extent to which the basophil response to peanut allergen increased was inversely correlated with improvement in the patient's ability to tolerate ingestion of peanut. Conclusion: The basophil response during treatment with omalizumab is a consequence of 2 competing factors: suppression of allergen-specific IgE on the cell surface versus increased intrinsic sensitivity to IgE-mediated stimulation. In subjects with peanut allergy, the basophil response appears to mitigate against the ability of omalizumab to improve the patient's tolerance of oral allergen. (J Allergy Clin Immunol 2012;130:1130-5.)	[MacGlashan, Donald W., Jr.] Johns Hopkins Univ, Ctr Asthma & Allergy, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; [Savage, Jessica H.; Wood, Robert A.] Johns Hopkins Univ, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University	MacGlashan, DW (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, Dept Med, Div Allergy & Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			National Institutes of Health [AI20253, AI070345]; National Institutes of Health (NIH); Asthma and Allergy Foundation of America; National Institute of Allergy and Infectious Diseases; Genentech; Novartis; Pharmacyclics; MedImmune; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253, U19AI070345] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma and Allergy Foundation of America; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Genentech(Roche HoldingGenentech); Novartis(Novartis); Pharmacyclics; MedImmune(AstraZenecaMedimmune); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI20253 and AI070345 (to D.W.M.).; Disclosure of potential conflict of interest: D. W. MacGlashan and J. Savage have received research support from the National Institutes of Health (NIH). R. Wood has received consultancy fees from the Asthma and Allergy Foundation of America; is employed by Johns Hopkins University; has provided expert testimony for the NIH; and has received royalties for UpToDate. S. Saini has received research support from the National Institute of Allergy and Infectious Diseases and Genentech; has been provided with medicines by Genentech; has received consultancy fees from Genentech, Novartis, Pharmacyclics, and MedImmune; and has received royalties from UpToDate.	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; DEMBO M, 1978, J IMMUNOL, V121, P354; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; GOLDSTEIN B, 1979, J IMMUNOL, V123, P1873; Ishmael S, 2009, J LEUKOCYTE BIOL, V86, P313, DOI 10.1189/jlb.1208724; Ishmael SS, 2010, J LEUKOCYTE BIOL, V87, P291, DOI 10.1189/jlb.0509336; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MacGlashan DW, 2008, J IMMUNOL, V180, P4208, DOI 10.4049/jimmunol.180.6.4208; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MACGLASHAN DW, 1985, J IMMUNOL, V135, P4129; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996	19	42	42	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1130	+		10.1016/j.jaci.2012.05.038	http://dx.doi.org/10.1016/j.jaci.2012.05.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22800400	Green Accepted, Bronze			2022-12-18	WOS:000310571400014
J	Chambers, ES; Nanzer, AM; Richards, DF; Ryanna, K; Freeman, AT; Timms, PM; Martineau, AR; Griffiths, CJ; Corrigan, CJ; Hawrylowicz, CM				Chambers, Emma S.; Nanzer, Alexandra M.; Richards, David F.; Ryanna, Kimuli; Freeman, Anna T.; Timms, Peter M.; Martineau, Adrian R.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.			Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOXP3		[Chambers, Emma S.; Nanzer, Alexandra M.; Richards, David F.; Ryanna, Kimuli; Freeman, Anna T.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, MRC, London WC2R 2LS, England; [Nanzer, Alexandra M.; Martineau, Adrian R.; Griffiths, Christopher J.] Queen Mary Univ London, Blizzard Inst, Ctr Primary Care & Publ Hlth, London, England; [Timms, Peter M.] Homerton Univ, NHS Fdn Trust, London, England; [Chambers, Emma S.; Nanzer, Alexandra M.; Richards, David F.; Ryanna, Kimuli; Freeman, Anna T.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England	University of London; King's College London; University of London; Queen Mary University London; Oxford University Hospitals NHS Foundation Trust; University of London; King's College London	Chambers, ES (corresponding author), Kings Coll London, MRC, London WC2R 2LS, England.	catherine.hawrylowicz@kcl.ac.uk	Chambers, Emma/AAI-3521-2021; Martineau, Adrian R/A-3083-2010; Hawrylowicz, Catherine/Q-8483-2017	Chambers, Emma/0000-0003-0990-8835; Corrigan, Chris/0000-0002-0706-6534; Hawrylowicz, Catherine/0000-0002-2337-7463	Medical Research Council [G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; Medical Research Council [G1000758] Funding Source: Medline; Department of Health Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Maunsell Z, 2005, CLIN CHEM, V51, P1683, DOI 10.1373/clinchem.2005.052936; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	9	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					542	544		10.1016/j.jaci.2012.04.022	http://dx.doi.org/10.1016/j.jaci.2012.04.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22656048				2022-12-18	WOS:000307002200042
J	McDonald, DR				McDonald, Douglas R.			T(H)17 deficiency in human disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-H cells; Candida species; fungi; T(H)17 cell; pathogen-recognition receptors; cytokines; transcription factors; differentiation; chronic mucocutaneous candidiasis	GROWTH-FACTOR-BETA; MUCOCUTANEOUS CANDIDIASIS; CELL-DIFFERENTIATION; BACTERIAL-INFECTION; STAT1 MUTATIONS; TH17 CELLS; FAMILY; DOCK8; IL-17; EXPRESSION	The differentiation of naive T cells into distinct subsets of effector T cells is critical for effective immunity against a wide variety of infectious agents in the environment. Activation of innate immune responses by Candida species through pattern-recognition receptors directs the subsequent development of naive T cells into T(H)17 cells, which are essential for effective mucosal immunity against fungi. Thorough analyses of cohorts of patients with unusual susceptibility to chronic mucocutaneous candidiasis resulting from T(H)17 deficiency have confirmed the role of T(H)17 cells and T(H)17 cytokines in human host defense against Candida species and have provided valuable insights into the complex process of T(H)17 cell development. (J Allergy Clin Immunol 2012;129:1429-35.)	[McDonald, Douglas R.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [McDonald, Douglas R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University	McDonald, DR (corresponding author), Childrens Hosp, Div Immunol, 10125 Karp Res Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	douglas.mcdonald@childrens.harvard.edu			National Institutes of Health [5K08AI76625]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI076625] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	D.R.M. is supported by National Institutes of Health grant 5K08AI76625.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Al-Salleeh F, 2008, J IMMUNOL, V181, P4523, DOI 10.4049/jimmunol.181.7.4523; Bettelli E, 2007, CURR OPIN IMMUNOL, V19, P652, DOI 10.1016/j.coi.2007.07.020; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Buckley RH, 2002, IMMUNOL REV, V185, P206, DOI 10.1034/j.1600-065X.2002.18517.x; Chen GB, 2011, J IMMUNOL, V187, P4483, DOI 10.4049/jimmunol.1101757; Chu EY, 2012, ARCH DERMATOL, V148, P79, DOI 10.1001/archdermatol.2011.262; Crow MK, 2003, AUTOIMMUNITY, V36, P481, DOI 10.1080/08916930310001625952; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Diveu C, 2009, J IMMUNOL, V182, P5748, DOI 10.4049/jimmunol.0801162; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Hirahara K, 2010, CYTOKINE GROWTH F R, V21, P425, DOI 10.1016/j.cytogfr.2010.10.006; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kisand K, 2011, EUR J IMMUNOL, V41, P1517, DOI 10.1002/eji.201041253; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Martin-Orozco N, 2009, EUR J IMMUNOL, V39, P216, DOI 10.1002/eji.200838475; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Oppenheim Y, 2004, AUTOIMMUN REV, V3, P388, DOI 10.1016/j.autrev.2004.03.003; Pedroza LA, 2012, J ALLERGY CLIN IMMUN, V129, P464, DOI 10.1016/j.jaci.2011.08.027; Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Ramgolam VS, 2009, J IMMUNOL, V183, P5418, DOI 10.4049/jimmunol.0803227; Takahashi N, 2008, J EXP MED, V205, P1755, DOI 10.1084/jem.20080588; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vautier S, 2010, CYTOKINE GROWTH F R, V21, P405, DOI 10.1016/j.cytogfr.2010.10.001; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhou L, 2009, CURR OPIN IMMUNOL, V21, P146, DOI 10.1016/j.coi.2009.03.001; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007	48	42	45	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1429	1435		10.1016/j.jaci.2012.03.034	http://dx.doi.org/10.1016/j.jaci.2012.03.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22554706	Green Accepted			2022-12-18	WOS:000304764600001
J	Nakahigashi, K; Doi, H; Otsuka, A; Hirabayashi, T; Murakami, M; Urade, Y; Tanizaki, H; Egawa, G; Miyachi, Y; Kabashima, K				Nakahigashi, Kyoko; Doi, Hiromi; Otsuka, Atsushi; Hirabayashi, Tetsuya; Murakami, Makoto; Urade, Yoshihiro; Tanizaki, Hideaki; Egawa, Gyohei; Miyachi, Yoshiki; Kabashima, Kenji			PGD(2) induces eotaxin-3 via PPAR gamma from sebocytes: A possible pathogenesis of eosinophilic pustular folliculitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin D-2; hematopoietic prostaglandin D synthase; eotaxin-3/CCL26; sebocyte; peroxisome proliferator-activated receptor gamma	PROLIFERATOR-ACTIVATED RECEPTOR; OFUJIS-DISEASE; PROSTANOID RECEPTORS; PROSTAGLANDIN E-2; INTERFERON-GAMMA; LIPOCALIN-TYPE; MESSENGER-RNA; INDOMETHACIN; EXPRESSION; LIGAND	Background: Eosinophilic pustular folliculitis (EPF) is a chronic intractable pruritic dermatosis characterized by massive eosinophil infiltrates involving the pilosebaceous units. Recently, EPF has been regarded as an important clinical marker of HIV infection, and its prevalence is increasing in number. The precise mechanism by which eosinophils infiltrate into the pilosebaceous units remains largely unknown. Given that indomethacin, a COX inhibitor, can be successfully used to treat patients with EPF, we can assume that COX metabolites such as prostaglandins (PGs) are involved in the etiology of EPF. Objective: To determine the involvement of PGs in the pathogenesis of EPF. Methods: We performed immunostaining for PG synthases in EPF skin lesions. We examined the effect of PGD(2) on induction of eotaxin, a chemoattractant for eosinophils, in human keratinocytes, fibroblasts, and sebocytes and sought to identify its responsible receptor. Results: Hematopoietic PGD synthase was detected mainly in infiltrating inflammatory cells in EPF lesions, implying that PGD(2) was produced in the lesions. In addition, PGD(2) and its immediate metabolite 15-deoxy-Delta 12,14-PGJ(2) (15d-PGJ(2)) induced sebocytes to produce eotaxin-3 via peroxisome proliferator-activated receptor gamma. Consistent with the above findings, eotaxin-3 expression was immunohistochemically intensified in sebaceous glands of the EPF lesions. Conclusion: The PG Delta(2)/PGJ(2)-peroxisome proliferator-activated receptor gamma pathway induces eotaxin production from sebocytes, which may explain the massive eosinophil infiltrates observed around pilosebaceous units in EPF. (J Allergy Clin Immunol 2012;129:536-43.)	[Nakahigashi, Kyoko; Doi, Hiromi; Otsuka, Atsushi; Tanizaki, Hideaki; Egawa, Gyohei; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto 6068507, Japan; [Hirabayashi, Tetsuya; Murakami, Makoto] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo 113, Japan; [Urade, Yoshihiro] Osaka Biosci Inst, Dept Mol Behav Biol, Osaka, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science	Kabashima, K (corresponding author), Kyoto Univ, Dept Dermatol, Grad Sch Med, 54 Shogoin Kawara, Kyoto 6068507, Japan.	kaba@kuhp.kyoto-u.ac.jp	Zouboulis, Christos C./I-4493-2013; Kabashima, Kenji/G-2521-2014	Zouboulis, Christos C./0000-0003-1646-2608; Kabashima, Kenji/0000-0002-0773-0554; Hirabayashi, Tetsuya/0000-0001-8099-5367; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X	Ministry of Education, Culture, Sports, Science and Technology, and Health; Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research [22116005] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, and Health(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and Health and from the Ministry of Health, Labour and Welfare of Japan.	Alestas T, 2006, J MOL MED, V84, P75, DOI 10.1007/s00109-005-0715-8; Amerio Paolo, 2003, Current Drug Targets - Inflammation and Allergy, V2, P81, DOI 10.2174/1568010033344480; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Chen WC, 2003, J INVEST DERMATOL, V121, P441, DOI 10.1046/j.1523-1747.2003.12411.x; Dulkys Y, 2001, J INVEST DERMATOL, V116, P498, DOI 10.1046/j.1523-1747.2001.01299.x; Fallah H, 2006, AUSTRALAS J DERMATOL, V47, P281, DOI 10.1111/j.1440-0960.2006.00296.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fukamachi S, 2009, ACTA DERM-VENEREOL, V89, P155, DOI 10.2340/00015555-0578; Fushimi M, 1996, BRIT J DERMATOL, V134, P766; Ham R G, 1980, Methods Cell Biol, V21A, P255, DOI 10.1016/S0091-679X(08)60770-0; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Honda T, 2010, CURR DRUG TARGETS, V11, P1605, DOI 10.2174/1389450111009011605; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Kabashima K, 2004, BRIT J DERMATOL, V151, P949, DOI 10.1111/j.1365-2133.2004.06240.x; Kabashima K, 2004, J DERMATOL SCI, V34, P177, DOI 10.1016/j.jdermsci.2003.11.008; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lankerani L, 2010, CUTIS, V86, P190; Makrantonaki E, 2007, BRIT J DERMATOL, V156, P428, DOI 10.1111/j.1365-2133.2006.07671.x; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Nagata K, 2003, PROSTAG LEUKOTR ESS, V69, P169, DOI 10.1016/S0952-3278(03)00078-4; Nagy I, 2006, MICROBES INFECT, V8, P2195, DOI 10.1016/j.micinf.2006.04.001; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OFUJI S, 1984, DERMATOLOGICA, V169, P125, DOI 10.1159/000249586; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Sano S, 1999, BRIT J DERMATOL, V141, P154; Satoh T, 2010, ACTA DERM-VENEREOL, V90, P18, DOI 10.2340/00015555-0759; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shimura C, 2010, AM J PATHOL, V176, P227, DOI 10.2353/ajpath.2010.090111; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Sugita K, 2006, CLIN EXP DERMATOL, V31, P709, DOI 10.1111/j.1365-2230.2006.02169.x; Takeda K, 2006, BIOCHEM BIOPH RES CO, V339, P1098, DOI 10.1016/j.bbrc.2005.11.125; Tanglertsampan Chuchai, 2007, Journal of the Medical Association of Thailand, V90, P1180; TERAKI Y, 1993, ARCH DERMATOL, V129, P1015, DOI 10.1001/archderm.129.8.1015; Urade Y, 2002, PROSTAG OTH LIPID M, V68-9, P375, DOI 10.1016/S0090-6980(02)00042-4; URADE Y, 1990, J BIOL CHEM, V265, P371	37	42	46	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					536	543		10.1016/j.jaci.2011.11.034	http://dx.doi.org/10.1016/j.jaci.2011.11.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22206772	Bronze			2022-12-18	WOS:000299951700034
J	Girard-Madoux, MJH; Kel, JM; Reizis, B; Clausen, BE				Girard-Madoux, Mathilde J. H.; Kel, Junda M.; Reizis, Boris; Clausen, Bjorn E.			IL-10 controls dendritic cell-induced T-cell reactivation in the skin to limit contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Conditional gene targeting; dendritic cells; immune regulation; IL-10 receptor signaling; Langerhans cells; skin	LANGERHANS CELLS; INTERLEUKIN-10 RECEPTOR; AND/OR NEUTROPHILS; IN-VIVO; RESPONSES; IMMUNITY; INFLAMMATION; HOMEOSTASIS; DERMATITIS; TOLERANCE	Background: IL-10 is a pleiotropic cytokine and potent negative regulator of both innate and adaptive immune responses. Consequently, IL-10-deficient (IL-10(-/-)) mice have enhanced contact hypersensitivity (CHS) to topical hapten. Objective: Although the importance of IL-10 production by (regulatory) T cells and Langerhans cells in regulating CHS has been established by cell type-specific il-10 gene targeting, it remains elusive to what extent IL-10 controls dendritic cell (DC) function in vivo. Methods: To this aim, we generated mice with a DC-specific deletion of the IL-10 receptor (IL-10R). Results: Despite the ability of IL-10 to inhibit DC maturation in vitro, DCs of restingDC-IL10R(-/-) mice retained their immature phenotype in vivo. In contrast, IL-10R(-/-) DCs produced increased levels of proinflammatory cytokines and IL-10 after in vitro stimulation. Induction of CHS was indistinguishable from that seen in control mice at 24 hours after hapten challenge but resulted in increased ear swelling at 48 hours and delayed resolution of the inflammatory reaction. Adoptive T-cell transfer experiments revealed that only T-cell reactivation and not sensitization by IL-10R(-/-) DCs leads to enhanced CHS. Accordingly, the expression of proinflammatory cytokines and IL-10 was augmented in the skin of DC-IL10R(-/-) mice after hapten challenge. Conclusion: Our data demonstrate that IL-10 signaling in DCs is dispensable during naive T-cell priming but is critical to prevent an exaggerated effector T-cell response in the skin. (J Allergy Clin Immunol 2012; 129: 143-50.)	[Girard-Madoux, Mathilde J. H.; Kel, Junda M.; Clausen, Bjorn E.] Univ Med Ctr, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Girard-Madoux, Mathilde J. H.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [Reizis, Boris] Columbia Univ, Med Ctr, Dept Microbiol, New York, NY USA	Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Columbia University	Clausen, BE (corresponding author), Univ Med Ctr, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	b.clausen@erasmusmc.nl	CLAUSEN, Björn Erik/A-8229-2010	CLAUSEN, Björn Erik/0000-0002-2484-7842; Reizis, Boris/0000-0003-1140-7853; Girard-Madoux, Mathilde/0000-0002-8840-2623	Netherlands Organization for Scientific Research (NWO) [VIDI 917-76-365]; Landsteiner Foundation for Blood Transfusion Research (LSBR) [0414F]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Landsteiner Foundation for Blood Transfusion Research (LSBR)	Supported by grants from the Netherlands Organization for Scientific Research (NWO, VIDI 917-76-365) and the Landsteiner Foundation for Blood Transfusion Research (LSBR, 0414F) to B. E. C.	BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99; Biswas PS, 2007, J IMMUNOL, V179, P4520, DOI 10.4049/jimmunol.179.7.4520; Boyman O, 2007, CURR OPIN IMMUNOL, V19, P320, DOI 10.1016/j.coi.2007.04.015; Caton ML, 2007, J EXP MED, V204, P1653, DOI 10.1084/jem.20062648; Chang WLW, 2007, J IMMUNOL, V178, P7794, DOI 10.4049/jimmunol.178.12.7794; Clausen BE, 2010, IMMUNOL CELL BIOL, V88, P351, DOI 10.1038/icb.2010.40; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Ejrnaes M, 2006, J EXP MED, V203, P2461, DOI 10.1084/jem.20061462; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; FERGUSON TA, 1994, J EXP MED, V179, P1597, DOI 10.1084/jem.179.5.1597; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Igyarto BZ, 2009, J IMMUNOL, V183, P5085, DOI 10.4049/jimmunol.0901884; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Noordegraaf M, 2010, J INVEST DERMATOL, V130, P2752, DOI 10.1038/jid.2010.223; Pils MC, 2010, EUR J IMMUNOL, V40, P443, DOI 10.1002/eji.200939592; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Ring S, 2011, J INVEST DERMATOL, V131, P1494, DOI 10.1038/jid.2011.50; Roers A, 2004, J EXP MED, V200, P1289, DOI 10.1084/jem.20041789; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; SCHWARZ A, 1994, J INVEST DERMATOL, V103, P211, DOI 10.1111/1523-1747.ep12393073; Siewe L, 2006, EUR J IMMUNOL, V36, P3248, DOI 10.1002/eji.200636012; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Toichi E, 2008, J INVEST DERMATOL, V128, P2705, DOI 10.1038/jid.2008.137; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Wang BH, 2003, CYTOKINE GROWTH F R, V14, P381, DOI 10.1016/S1359-6101(03)00050-9; Watanabe H, 2002, J INTERF CYTOK RES, V22, P407, DOI 10.1089/10799900252952181; Yoshiki R, 2009, J INVEST DERMATOL, V129, P705, DOI 10.1038/jid.2008.304; Zhang L, 2000, J INVEST DERMATOL, V115, P168, DOI 10.1046/j.1523-1747.2000.00999.x	35	42	44	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					143	U205		10.1016/j.jaci.2011.08.032	http://dx.doi.org/10.1016/j.jaci.2011.08.032			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21975175	Bronze			2022-12-18	WOS:000298634000018
J	Passerini, L; Olek, S; Di Nunzio, S; Barzaghi, F; Hambleton, S; Abinun, M; Tommasini, A; Vignola, S; Cipolli, M; Amendola, M; Naldini, L; Guidi, L; Cecconi, M; Roncarolo, MG; Bacchetta, R				Passerini, Laura; Olek, Sven; Di Nunzio, Sara; Barzaghi, Federica; Hambleton, Sophie; Abinun, Mario; Tommasini, Alberto; Vignola, Silvia; Cipolli, Marco; Amendola, Mario; Naldini, Luigi; Guidi, Luisa; Cecconi, Massimiliano; Roncarolo, Maria G.; Bacchetta, Rosa			Forkhead box protein 3 (FOXP3) mutations lead to increased T(H)17 cell numbers and regulatory T-cell instability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Passerini, Laura; Di Nunzio, Sara; Barzaghi, Federica; Amendola, Mario; Naldini, Luigi; Roncarolo, Maria G.; Bacchetta, Rosa] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy HSR TIGET, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy; [Olek, Sven] Epiontis GmbH, Berlin, Germany; [Hambleton, Sophie; Abinun, Mario] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Tommasini, Alberto] IRCCS Burlo Garofalo, Paediat Immunol Lab, Trieste, Italy; [Vignola, Silvia] G Gaslini Hosp, Genoa, Italy; [Cipolli, Marco] Cyst Fybrosis Ctr, Verona, Italy; [Naldini, Luigi; Roncarolo, Maria G.] Univ Vita Salute San Raffaele, Milan, Italy; [Guidi, Luisa] Univ Cattolica Sacro Cuore, Unit Internal Med & Gastroenterol, Rome, Italy; [Cecconi, Massimiliano] Osped Galliera, Human Genet Labs, Genoa, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Epiontis GmbH; Newcastle Upon Tyne Hospitals NHS Foundation Trust; IRCCS Burlo Garofolo; University of Genoa; IRCCS Istituto Giannina Gaslini; Vita-Salute San Raffaele University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Ente Ospedaliero Ospedali Galliera	Passerini, L (corresponding author), Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy HSR TIGET, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy.	rosa.bacchetta@hsr.it	Naldini, Luigi/E-9083-2012; Passerini, Laura/J-7791-2016; Tommasini, Alberto/AAE-3882-2020; Guidi, Luisa/F-1688-2010; Cipolli, Marco/AAL-1419-2020; Cecconi, Massimiliano/ABC-2421-2020; amendola, mario/I-1728-2017	Passerini, Laura/0000-0002-4020-7386; Tommasini, Alberto/0000-0002-6943-7927; Guidi, Luisa/0000-0003-3320-7094; Cipolli, Marco/0000-0001-5652-7248; amendola, mario/0000-0002-1188-8856; NALDINI, Luigi/0000-0002-7835-527X; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Medical Research Council [G0701897] Funding Source: Medline; Telethon [GGP07241, TGT11A04] Funding Source: Medline; MRC [G0701897] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Crome SQ, 2010, CLIN EXP IMMUNOL, V159, P109, DOI 10.1111/j.1365-2249.2009.04037.x; d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093; Gambineri E, 2008, J ALLERGY CLIN IMMUN, V122; Hori S, 2010, CURR OPIN IMMUNOL, V22, P575, DOI 10.1016/j.coi.2010.08.004; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Moes N, 2010, GASTROENTEROLOGY, V139, P770, DOI 10.1053/j.gastro.2010.06.006; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361	9	42	44	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1376	U790		10.1016/j.jaci.2011.09.010	http://dx.doi.org/10.1016/j.jaci.2011.09.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22000569				2022-12-18	WOS:000298342700040
J	Schulke, S; Burggraf, M; Waibler, Z; Wangorsch, A; Wolfheimer, S; Kalinke, U; Vieths, S; Toda, M; Scheurer, S				Schuelke, Stefan; Burggraf, Manja; Waibler, Zoe; Wangorsch, Andrea; Wolfheimer, Sonja; Kalinke, Ulrich; Vieths, Stefan; Toda, Masako; Scheurer, Stephan			A fusion protein of flagellin and ovalbumin suppresses the T(H)2 response and prevents murine intestinal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Flagellin; Toll-like receptor 5; allergen vaccine; dendritic cell; intestinal allergy	TOLL-LIKE RECEPTOR-5; DENDRITIC CELLS; INFLUENZA VACCINE; IMMUNOTHERAPY; IL-10; MECHANISMS; IMMUNITY; DISEASE; IMMUNOGENICITY; ADJUVANTS	Background: The Toll-like receptor (TLR) 5 agonist flagellin is associated with immunomodulatory functions. Objective: We sought to investigate whether Listeria monocytogenes-derived flagellin A (flaA) can modulate ovalbumin (OVA)-specific T-cell responses and prevent OVA-induced intestinal allergy. Methods: Bone marrow-derived myeloid dendritic cells from BALB/c, C57BL/6, or TLR signaling-deficient (MyD88(-/-)) mice were stimulated with rOVA, rflaA, rflaA plus rOVA, or a recombinant fusion protein consisting of rflaA and rOVA (rflaA: OVA). The immunomodulating properties of rflaA plus rOVA and rflaA: OVA were investigated by means of DC-T-cell coculture with CD4(+) T cells from OVA-T-cell receptor transgenic or OVA/alum-immunized mice. rflaA: OVA was applied as a prophylactic and therapeutic vaccine in a murine model of intestinal allergy. Results: rflaA: OVA induced upregulation of TLR5 and dose-dependent IL-6 and IL-10 secretion by myeloid dendritic cells. IL-10 contributed to repressing IL-4 and IFN-gamma secretion by OVA-T-cell receptor transgenic CD4(+) T cells. Moreover, rflaA: OVA suppressed CD4(+) T cells derived from T(H)2-biased mice on OVA/alum immunization. In a murine model of intestinal allergy, prophylactic vaccination with rflaA: OVA reduced T-cell activation. Protection from intestinal allergy included suppression of OVA-specific IgE while inducing OVA-specific IgG(2a). Equimolar amounts of rflaA or rOVA provided alone or as a mixture did not have comparable effects. Moreover, therapeutic vaccination was shown to reduce allergic symptoms and T-cell activation in the spleen. Conclusion: The rflaA: OVA fusion protein showed strong TLR-mediated immunomodulating capacities probably attributed by the proximity of adjuvant and allergen, leading to the prevention of intestinal allergy in a murine disease model. Therefore recombinant flaA: allergen fusion proteins are promising vaccine candidates for intervention in patients with IgE-mediated allergy. (J Allergy Clin Immunol 2011; 128: 1340-8.)	[Schuelke, Stefan] Paul Ehrlich Inst, Div Allergol, Sect Recombinant Allergen Therapeut, D-63225 Langen, Germany; [Burggraf, Manja; Toda, Masako] Paul Ehrlich Inst, Jr Res Grp Allergy Models, D-63225 Langen, Germany; [Waibler, Zoe] Paul Ehrlich Inst, Jr Res Grp Novel Vaccinat Strategies & Early Immu, D-63225 Langen, Germany; [Kalinke, Ulrich] Hannover Med Sch, Hannover, Germany; [Kalinke, Ulrich] TWINCORE Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Hannover, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute; Paul Ehrlich Institute; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research	Schulke, S (corresponding author), Paul Ehrlich Inst, Div Allergol, Sect Recombinant Allergen Therapeut, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	schst@pei.de	Toda, Masako/S-9810-2019; Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X; Kalinke, Ulrich/0000-0003-0503-9564	DFG [SCHE637/3]; German Federal Ministry of Health; German Research Foundation; German Food Industry; Monsanto Company; Pioneer Hi-Bred International; Food Allergy Research & Resource Program; European Directorate for the Quality of Medicines and Health Care; German Federal Ministry for Education and Research	DFG(German Research Foundation (DFG)); German Federal Ministry of Health; German Research Foundation(German Research Foundation (DFG)); German Food Industry; Monsanto Company; Pioneer Hi-Bred International; Food Allergy Research & Resource Program; European Directorate for the Quality of Medicines and Health Care; German Federal Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by the DFG (SCHE637/3).; S. Vieths is an Associate at the Institute for Product Quality, Berlin, Germany; has received honoraria from the Food Allergy Resource and Research Program (Lincoln, Neb) and Fresenius Academy (Dortmund, Germany); has received research support from the German Federal Ministry of Health, the German Research Foundation, the Research Fund of the German Food Industry, Monsanto Company, Pioneer Hi-Bred International, the Food Allergy Research & Resource Program, the European Directorate for the Quality of Medicines and Health Care, and the German Federal Ministry for Education and Research; is a member of the European Academy of Allergy and Clinical Immunology (EAACI) Executive Committee; is Chairman of the International Union of Immunological Societies (IUIS) Allergen Standardization Subcommittee; is Secretary of the International Union of Immunological Societies (IUIS) Allergen Nomenclature Subcommittee; is a registered expert with the European Agency for the Evaluation of Medicinal Products and the European Pharmacopoeia Commission; is Chairman of the CEN (European Committee for Standardization) Technical Committee 275 Working Group 12 "Food Allergens"; and is a member of the German Society for Allergy and Clinical Immunology Food Allergy Working Group. The rest of the authors have declared that they have no conflict of interest.	Adar Y, 2009, VACCINE, V27, P2099, DOI 10.1016/j.vaccine.2009.02.011; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; Allam JP, 2009, CURR OPIN ALLERGY CL, V9, P554, DOI 10.1097/ACI.0b013e32833239a9; Bates JT, 2009, J IMMUNOL, V182, P7539, DOI 10.4049/jimmunol.0804225; Ben-Yedidia T, 2007, EXPERT REV VACCINES, V6, P939, DOI 10.1586/14760584.6.6.939; Ben-Yedidia T, 2005, HUM VACCINES, V1, P95, DOI 10.4161/hv.1.3.1851; BURGGRAF M, MOL NUTR FOOD RES; Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004; Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922; Fujimoto M, 2011, J IMMUNOL, V186, P32, DOI 10.4049/jimmunol.0903314; Gupta GK, 2010, BIODRUGS, V24, P225, DOI 10.2165/11536140-000000000-00000; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013; Johansen P, 2005, CLIN EXP ALLERGY, V35, P1591, DOI 10.1111/j.1365-2222.2005.02384.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Khan S, 2007, J BIOL CHEM, V282, P21145, DOI 10.1074/jbc.M701705200; Lee SE, 2008, J CLIN IMMUNOL, V28, P157, DOI 10.1007/s10875-007-9138-3; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; O'Garra A, 2008, IMMUNOL REV, V223, P114, DOI 10.1111/j.1600-065X.2008.00635.x; Pochard P, 2010, J ALLERGY CLIN IMMUN, V126, P92, DOI 10.1016/j.jaci.2010.04.003; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Schulke S, 2010, MOL IMMUNOL, V48, P341, DOI 10.1016/j.molimm.2010.07.006; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362; Ureta G, 2007, TRANSPL P, V39, P633, DOI 10.1016/j.transproceed.2006.12.032; Waibler Z, 2007, J VIROL, V81, P12102, DOI 10.1128/JVI.01190-07	31	42	63	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1340	U728		10.1016/j.jaci.2011.07.036	http://dx.doi.org/10.1016/j.jaci.2011.07.036			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21872305				2022-12-18	WOS:000298342700026
